PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ikematsu, N; Yoshida, Y; Kawamura-Tsuzuku, J; Ohsugi, M; Onda, M; Hirai, M; Fujimoto, J; Yamamoto, T				Ikematsu, N; Yoshida, Y; Kawamura-Tsuzuku, J; Ohsugi, M; Onda, M; Hirai, M; Fujimoto, J; Yamamoto, T			Tob2, a novel anti-proliferative Tob/BTG1 family member, associates with a component of the CCR4 transcriptional regulatory complex capable of binding cyclin-dependent kinases	ONCOGENE			English	Article						Tob family; anti-proliferation; CDKs; CCR4 transcription factor; cell cycle	NERVE GROWTH-FACTOR; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MESSENGER-RNA; PROTEIN; IDENTIFICATION; OVEREXPRESSION; PRODUCT; CLONING	Human cDNAs encoding a novel member of Tob/BTG1 anti-proliferative family proteins were cloned. The putative protein product termed Tob2 consisted of 344 amino acids with high similarity to the Tob protein, The tob2 mRNA was 4.1 kb long and was ubiquitously expressed in human adult tissues, as was revealed by Northern blot hybridization, However, further in situ hybridization analysis showed a characteristic expression of the tob2 mRNA in oocytes, suggesting a unique role of Tob2 in oogenesis, Like the Tob protein, Tob2 inhibited cell cycle progression from the G0/G1 to S phases. Intriguingly, the amino-terminal half of Tob2 as well as that of Tob was associated with a human homologue of yeast Caf1, a component of the CCR4 transcription factor complex, Moreover, Caf1 was associated with cyclin dependent kinases, These data suggested that both Tob and Tob2 were involved in cell cycle regulation through their interaction with Caf1, Finally, the tob2 gene was mapped to human chromosome 22q13.1-q13.31.	Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Minato Ku, Tokyo 1088639, Japan.		Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bogdan JA, 1998, BIOCHEM J, V336, P471, DOI 10.1042/bj3360471; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; HARPER JW, 1993, CELL, V75, P805; Hirai M, 1996, GENOMICS, V34, P263, DOI 10.1006/geno.1996.0283; Iida A, 1998, GENE CHROMOSOME CANC, V21, P108, DOI 10.1002/(SICI)1098-2264(199802)21:2<108::AID-GCC5>3.0.CO;2-4; KIM M, 1999, IN PRESS GENE; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; SCHILD D, 1995, GENETICS, V140, P115; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	28	122	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7432	7441		10.1038/sj.onc.1203193	http://dx.doi.org/10.1038/sj.onc.1203193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602502				2022-12-17	WOS:000084119600004
J	Wunder, JS; Eppert, K; Burrow, SR; Gogkoz, N; Bell, RS; Andrulis, IL				Wunder, JS; Eppert, K; Burrow, SR; Gogkoz, N; Bell, RS; Andrulis, IL			Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas	ONCOGENE			English	Article						gene amplification; CDK4; SAS; osteosarcoma	SOFT-TISSUE SARCOMAS; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-MALIGNANT GLIOMAS; METASTASIS SUPPRESSOR GENE; CELL-CYCLE ARREST; RING CHROMOSOMES; RETINOBLASTOMA PROTEIN; QUANTITATIVE-ANALYSIS; MAMMALIAN-CELLS; DNA-SEQUENCES	Amplification of genes in the 12q13-15 region occurs frequently in several malignancies including osteosarcoma. The products of these amplified genes are thought to provide cancer cells with a selective growth advantage; however, the specific gene(s) driving this amplicon is unknown. We have previously shown that the SAS gene is amplified in most parosteal osteosarcomas. In this study we analysed additional putative growth regulatory genes in this chromosomal region in 24 primary osteosarcoma specimens. CDK4 and SAS were coamplified in 6/6 parosteal tumors, and MDM2 was also amplified in 4/5 parosteal cases, In comparison, amplification occurred in only 2/16 classical intramedullary osteosarcomas and involved the SAS gene. Each amplified gene had a correspondingly elevated mRNA level. Four high grade intramedullary tumors had elevated mRNA expression of SAS, but did not exhibit gene amplification, Gene amplification/overexpression was not associated with metastatic disease and did not change markedly with tumor progression, as evidenced by analysis of sequential tumor specimens from eight patients. Three other genes in the 12q13-15 region (CDK2, WNT1 and WNT10b) were not amplified in any of the tumors. The different patterns of gene amplification and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Univ Musculoskeletal Oncol Unit, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Andrulis, IL (corresponding author), Univ Toronto, Dept Surg, Toronto, ON, Canada.		Andrulis, Irene L./E-7267-2013	Eppert, Kolja/0000-0001-9061-8856				Adachi M, 1996, CANCER RES, V56, P1751; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ARHEDEN K, 1988, CYTOGENET CELL GENET, V47, P86, DOI 10.1159/000132513; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; DEMETRICK DJ, 1994, CYTOGENET CELL GENET, V66, P72, DOI 10.1159/000133669; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; Guo XZ, 1996, CANCER RES, V56, P4876; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KATO J, 1993, GENE DEV, V7, P331; KHATIB ZA, 1993, CANCER RES, V53, P5535; LADANYI M, 1993, CANCER RES, V53, P16; Latham KM, 1996, MOL CELL BIOL, V16, P4445; LEACH FS, 1993, CANCER RES, V53, P2231; Lee PD, 1996, BRIT J CANCER, V74, P1046, DOI 10.1038/bjc.1996.487; LI Y, 1994, ONCOGENE, V9, P2261; Lonardo F, 1997, CANCER, V79, P1541, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1541::AID-CNCR15>3.0.CO;2-Y; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mousses S, 1996, MODERN PATHOL, V9, P1; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; NobleTopham SE, 1996, J ORTHOPAED RES, V14, P700, DOI 10.1002/jor.1100140504; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORNDAL C, 1992, CANCER GENET CYTOGEN, V60, P170, DOI 10.1016/0165-4608(92)90011-V; RAYMOND AK, 1991, CLIN ORTHOP RELAT R, P140; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER G, 1994, CANCER RES, V54, P4299; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Sambrook J, 1989, MOL CLONING LAB MANU; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH SH, 1992, CANCER RES, V52, P3746; Souhami RL, 1997, LANCET, V350, P911, DOI 10.1016/S0140-6736(97)02307-6; SU YA, 1994, P NATL ACAD SCI USA, V91, P9121, DOI 10.1073/pnas.91.19.9121; SUIJKERBUIJK RF, 1994, GENE CHROMOSOME CANC, V9, P292, DOI 10.1002/gcc.2870090410; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Szymanska J, 1996, GENE CHROMOSOME CANC, V15, P89, DOI 10.1002/(SICI)1098-2264(199602)15:2<89::AID-GCC2>3.0.CO;2-#; TARKKANEN M, 1995, CANCER RES, V55, P1334; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TSAI LH, 1993, ONCOGENE, V8, P1593; UNNI KK, 1976, CANCER, V37, P2466, DOI 10.1002/1097-0142(197605)37:5<2466::AID-CNCR2820370540>3.0.CO;2-G; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; Wolf M, 1997, GENE CHROMOSOME CANC, V18, P66, DOI 10.1002/(SICI)1098-2264(199701)18:1<66::AID-GCC8>3.0.CO;2-#; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	65	122	125	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					783	788		10.1038/sj.onc.1202346	http://dx.doi.org/10.1038/sj.onc.1202346			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989829				2022-12-17	WOS:000078394400024
J	Mandal, M; Adam, L; Mendelsohn, J; Kumar, R				Mandal, M; Adam, L; Mendelsohn, J; Kumar, R			Nuclear targeting of Bax during apoptosis in human colorectal cancer cells	ONCOGENE			English	Article						apoptosis; Bax; colorectal cancer; growth; factor receptor	EPIDERMAL GROWTH-FACTOR; RECEPTOR MONOCLONAL-ANTIBODY; BUTYRATE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR P53; IN-VIVO PATTERNS; WILD-TYPE P53; FACTOR-ALPHA; HUMAN-COLON; ENDOPLASMIC-RETICULUM; CARCINOMA CELLS	Homeostasis in colonic epithelial cells is regulated by the balance between proliferative activity and cell loss by apoptosis. Because epithelial cells at the apex of colonic crypts undergo apoptosis and proliferative activity is usually restricted to the base of the crypts, it has been proposed that the limited availability of growth factor-signals at the upper portions of the crypts may trigger apoptosis. In the present studies, we investigate the mechanism of apoptosis mediated by growth factor deprivation in colorectal carcinoma cells by delineating the possible involvement of Bax and its subcellular localization. We report that inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase activity and downregulation of EGFR by anti-EGFR mAb 225 induces apoptosis in human colorectal carcinoma DiFi and FET cells. Induction of apoptosis was preceded by enhanced expression of newly synthesized Bax protein, and required protein synthesis. In the mAb 225-treated cells, Bax was redistributed from the cytosol to the nucleus and subsequently, to the nuclear membranes. The observed induction of Bax expression by mAb 225 was not associated with p53 induction. However, mAb 225 treatment also triggered relocalization of p53 from the cytosol to a nuclear membrane-bound form. Induction of Bax and its redistribution to the nucleus of DiFi cells during apoptosis was also demonstrated in response to butyrate, a physiological relevant molecule in colonic epithelial cells as it is the principal short-chain fatty acid produced by bacterial fermentation of dietary fiber in colonic epithelium. Using immunofluorescence and confocal microscopy, we observed that Bax is predominantly localized in the cytosol, but during apoptosis it is localized both inside and along the nuclear membrane. Taken together, these findings suggest that apoptosis induced by growth factor-deprivation or butyrate may involve the subcellular redistribution of Bax in human colorectal carcinoma cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Cell Growth Regulat Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATLAS I, 1992, CANCER RES, V52, P3335; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; BEDI A, 1995, CANCER RES, V55, P1811; Boise L H, 1995, Curr Top Microbiol Immunol, V200, P107; BOISE LH, 1993, CELL, V79, P341; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; COFFEY RJ, 1986, CANCER RES, V46, P1164; COLES HSR, 1993, DEVELOPMENT, V118, P777; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; FAN Z, 1993, J BIOL CHEM, V268, P21073; GarciaLloret MI, 1996, J CELL PHYSIOL, V167, P324, DOI 10.1002/(SICI)1097-4652(199605)167:2<324::AID-JCP17>3.0.CO;2-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1997, BLOOD, V89, P3817, DOI 10.1182/blood.V89.10.3817.3817_3817_3825; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; KUMAR R, 1995, EXP CELL RES, V216, P143, DOI 10.1006/excr.1995.1018; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LUCIANO AM, 1994, BIOL REPROD, V51, P646, DOI 10.1095/biolreprod51.4.646; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAKAJIMA M, 1994, NEUROSCI LETT, V176, P161, DOI 10.1016/0304-3940(94)90072-8; OLIVE M, 1993, IN VITRO CELL DEV-AN, V29A, P239; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; UNTAWALE S, 1993, CANCER RES, V53, P1630; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; ZHU YM, 1994, BRIT J CANCER, V69, P468, DOI 10.1038/bjc.1994.85	63	122	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					999	1007		10.1038/sj.onc.1202020	http://dx.doi.org/10.1038/sj.onc.1202020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747879				2022-12-17	WOS:000075560900008
J	Bellosta, P; Zhang, Q; Goff, SP; Basilico, C				Bellosta, P; Zhang, Q; Goff, SP; Basilico, C			Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation	ONCOGENE			English	Article						programmed cell death; gene knock-out; TWF; c-myc	PROGRAMMED CELL-DEATH; ARREST-SPECIFIC GENE-6; AXL; PROTEINS; LIGAND; GAS6; FIBROBLASTS; ACTIVATION; EXPRESSION; CLONING	ARK (AXL) is the prototype of a distinctive family of receptor tyrosine kinases which contain in their extracellular domains features reminiscent of cell adhesion molecules, ARK is capable of homophilic binding, which results in a degree of receptor activation, but can also be activated by a heterophilic ligand, Gas6, a member of the family of vitamin K dependent proteins that is preferentially expressed in quiescent cells, Since a number of tissues and cell lines express both ARK and Gas6, we studied the effect of endogenous and exogenous Gas6 on the phenotype of ARK expressing cells, Here we show that constitutive expression of Gas6 in an NIH3T3 cell line that does not spontaneously express this protein does not result in cell transformation or uncontrolled growth, but protects from apoptosis induced by serum deprivation. Recombinant exogenous Gas6 was also capable of protecting cells from apoptosis at concentrations that did not result in significant induction of DNA synthesis, Activation of ARK phosphorylation and a weak but significant induction of MAP kinase activity accompanied the increased survival of cells treated with Gas6. The antiapoptotic effect of ARK signaling was confirmed by studies using fibroblasts from ARK knock-out mice, that showed that the absence of ARK resulted in higher levels of serum deprivation-induced apoptosis, that could not be rescued by the addition of Gas6, Interestingly ARK signaling protects from apoptosis induced by serum deprivation, myc overexpression, or by TNF alpha but not from u.v. irradiation or Staurosporine. These results suggest that a major function of Gas6-ARK signaling is that of increasing cell survival under conditions which do not allow cell proliferation.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT BIOCHEM, NEW YORK, NY 10032 USA	New York University; New York University; Columbia University			Goff, Stephen P/K-6337-2014; Bellosta, Paola/AAA-3413-2020	Goff, Stephen P/0000-0003-0693-5547; Bellosta, Paola/0000-0003-1913-5661	NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER; NCI NIH HHS [CA42568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHINNAIYAN AM, 1996, J BIOL CHEM, V271, P30022; Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1995, ONCOGENE, V10, P2349; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LAI C, 1994, ONCOGENE, V9, P2567; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LING L, 1995, MOL CELL BIOL, V15, P6582; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OHASHI K, 1994, ONCOGENE, V9, P699; PESCIGNO J, 1992, ONCOGENE, V6, P1909; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; RESCIGNO J, 1991, ONCOGENE, V6, P1909; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang QK, 1996, J VIROL, V70, P8089, DOI 10.1128/JVI.70.11.8089-8097.1996	50	122	138	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2387	2397		10.1038/sj.onc.1201419	http://dx.doi.org/10.1038/sj.onc.1201419			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395235	Green Published			2022-12-17	WOS:A1997YE96300001
J	Braunger, J; Schleithoff, L; Schulz, AS; Kessler, H; Lammers, R; Ullrich, A; Bartram, CR; Janssen, JWG				Braunger, J; Schleithoff, L; Schulz, AS; Kessler, H; Lammers, R; Ullrich, A; Bartram, CR; Janssen, JWG			Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site	ONCOGENE			English	Article						Ufo/Ax1; receptor tyrosine kinase; CORT; SH2 domain; multi-substrate docking-site	GROWTH-FACTOR RECEPTOR; SCATTER FACTOR-RECEPTOR; ARREST-SPECIFIC GENE-6; PHOSPHOLIPASE-C-GAMMA; MOLECULAR-CLONING; SH2 DOMAINS; PROTEIN-S; PHOSPHATIDYLINOSITOL 3'-KINASE; EXPRESSION CLONING; ADAPTER PROTEIN	Ufo/Axl belongs to a new family of receptor tyrosine kinases with an extracellular structure similar to that of neural cell adhesion molecules, In order to elucidate intracellular signaling, the cytoplasmic moiety of Ufo/Axl was used to screen an expression library according to the CORT (cloning of receptor targets) method, Three putative Ufo substrates were identified: phospholipase C gamma 1 (PLC gamma), as well as p85 alpha and p85 beta subunits of phosphatidylinositol 3'-kinase (PI3-kinase), Subsequently, chimeric EGFR/Ufo receptors consisting of the extracellular domains of the epidermal growth factor receptor (EGFR) and the transmembrane and intracellular moiety of Ufo were engineered, Using different far-Western blot analyses and coimmunoprecipitation assays, receptor binding of PLC gamma and p85 proteins as well as GRB2, c-src and lck was examined in vitro and in vivo, Competitive inhibition of substrate binding and mutagenesis experiments with EGFR/Ufo constructs revealed C-terminal tyrosine 821 (EILpYVNMDEG) as a docking site for multiple effecters, namely PLC gamma, p85 proteins, GRB2, c-src and Ick, Tyrosine 779 (DGLpYALMSRC) demonstrated an additional, but lower binding affinity for the p85 proteins in vitro, In addition, binding of PLC gamma occurred through tyrosine 866 (AGRpYVLCPST), Moreover, our in vivo data indicate that further direct or indirect binding sites for PLC gamma, GRB2, c-src and lck on the human Ufo receptor may exist.	UNIV HEIDELBERG, INST HUMANGENET, D-69120 HEIDELBERG, GERMANY; UNIV ULM, ABT KINDERHEILKUNDE 2, D-89075 ULM, GERMANY; MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Ruprecht Karls University Heidelberg; Ulm University; Max Planck Society								ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; Biscardi JS, 1996, J BIOL CHEM, V271, P29049, DOI 10.1074/jbc.271.46.29049; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1993, J BIOL CHEM, V268, P9478; CAO Y, 1990, Technique (Philadelphia), V2, P109; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASTAGNINO P, 1995, ONCOGENE, V10, P723; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSIER KE, 1994, GROWTH FACTORS, V11, P137, DOI 10.3109/08977199409001055; DAI W, 1994, ONCOGENE, V9, P975; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; Goruppi S, 1996, ONCOGENE, V12, P471; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; HERBST R, 1991, J BIOL CHEM, V266, P19908; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAROSE L, 1993, ONCOGENE, V8, P2493; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARK MR, 1994, J BIOL CHEM, V269, P10720; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; OHASHI K, 1995, J BIOL CHEM, V270, P22681, DOI 10.1074/jbc.270.39.22681; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OOI J, 1995, ONCOGENE, V10, P1621; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PONTKINGDON G, 1994, BIOTECHNIQUES, V16, P1010; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RESCIGNO J, 1991, ONCOGENE, V6, P1909; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEEDORF K, 1992, MOL CELL BIOL, V12, P4347, DOI 10.1128/MCB.12.10.4347; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1995, J BIOL CHEM, V270, P26029, DOI 10.1074/jbc.270.44.26029; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	73	122	143	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2619	2631		10.1038/sj.onc.1201123	http://dx.doi.org/10.1038/sj.onc.1201123			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178760				2022-12-17	WOS:A1997XB97800001
J	Beauchemin, N; Kunath, T; Robitaille, J; Chow, B; Turbide, C; Daniels, E; Veillette, A				Beauchemin, N; Kunath, T; Robitaille, J; Chow, B; Turbide, C; Daniels, E; Veillette, A			Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells	ONCOGENE			English	Article						biliary glycoprotein; Bgp; C-CAM; colon carcinoma; SHP-1; PTP1C; HCP	ANTIGEN-RELATED GENE; CARCINOEMBRYONIC ANTIGEN; ADHESION MOLECULE; ECTO-ATPASE; C-CAM; PHOSPHOTYROSINE PHOSPHATASE; COLORECTAL CARCINOMAS; ENDOGENOUS SUBSTRATE; MONOCLONAL-ANTIBODY; MURINE CORONAVIRUS	Biliary glycoprotein (Bgp) is a member of the immunoglobulin superfamily and the carcinoembryonic antigen family. Previous studies have shown that Bgp functions as an intercellular adhesion molecule and a canalicular bile salt transporter. Moreover, we and others demonstrated that Bgp can inhibit colonic and prostatic tumor cell growth in vivo, through a mechanism which depends on sequences present in its cytoplasmic domain. In this study, we have examined the possibility that the cytoplasmic domain of Bgp can interact with signal transduction molecules. We showed that tyrosine phosphorylated Bgp, expressed in mouse colon carcinoma CT51 cells, could reversibly associate with protein tyrosine phosphatase SHP-1. Mutation of either of two tyrosine residues present in the cytoplasmic domain of Bgp abrogated SHP-1 binding, suggesting that this association was mediated by both tyrosine residues. Similarly, we noted that either of the two SH2 domains of SHP-1 could bind tyrosine phosphorylated Bgp in vitro. It is therefore conceivable that some of the functions of Bgp are mediated through its ability to induce intracellular protein tyrosine dephosphorylation.	MCGILL UNIV,CTR CANC,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,DEPT ANAT & CELL BIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), MCGILL UNIV,CTR CANC,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA.			Kunath, Tilo/0000-0002-8805-7356				Adachi M, 1996, CELL, V85, P15; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRUMMER J, 1995, ONCOGENE, V11, P1649; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Daniels E, 1996, DEV DYNAM, V206, P272, DOI 10.1002/(SICI)1097-0177(199607)206:3<272::AID-AJA5>3.3.CO;2-U; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; HSIEH JT, 1995, CANCER RES, V55, P190; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kunath T, 1995, ONCOGENE, V11, P2375; KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1989, J BIOL CHEM, V264, P14408; MARGOLIS RN, 1988, P NATL ACAD SCI USA, V85, P7256, DOI 10.1073/pnas.85.19.7256; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEDELLEC P, 1994, J VIROL, V68, P4525; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; SMITH AL, 1991, J INFECT DIS, V163, P879, DOI 10.1093/infdis/163.4.879; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	53	122	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					783	790		10.1038/sj.onc.1200888	http://dx.doi.org/10.1038/sj.onc.1200888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047385				2022-12-17	WOS:A1997WJ11200004
J	Crouch, DH; Fincham, VJ; Frame, MC				Crouch, DH; Fincham, VJ; Frame, MC			Targeted proteolysis of the focal adhesion kinase pp125(FAK) during c-myc-induced apoptosis is suppressed by integrin signalling	ONCOGENE			English	Article						focal adhesion kinase; c-myc; apoptosis	PROTEIN-TYROSINE KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; PHOSPHORYLATION; TRANSFORMATION; PP125FAK; DOMAIN	The product of the c-myc proto-oncogene has a central role in induction of apoptosis, a physiological form of cell death characterised in vitro by morphological rounding, detachment and nuclear disintegration. Induction of apoptosis by serum withdrawal from c-Myc-transformed chicken embryo fibroblasts (CEF) results in early proteolysis of focal adhesion kinase (pp125(FAK)), a tyrosine kinase implicated in the conversion of integrin signals into their biological responses. Proteolysis of pp125(FAK) occurs in adherent cells prior to commitment to death, suggesting that it contributes to c-Myc-induced apoptosis, rather than being a consequence of it. Furthermore, c-Myc-induced detachment, cell death and cleavage of pp125(FAK) are coordinately suppressed by treating with insulin or plating on the extracellular matrix components collagen and fibronectin. In addition, proteolysis of pp125(FAK) is suppressed by a beta 1-specific integrin antibody, which promotes cell survival in the face of the oncoprotein-induced signal for apoptosis. These results provide compelling evidence that the c-Myc-induced cell death programme in CEF requires disruption of the integrin signalling pathways which normally function when cells are spread on ECM, and that maintaining cellular pp125(FAK), which couples integrins to their downstream effecters, is closely linked to cell survival.	BEATSON INST CANC RES, CRC, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute								AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CROUCH DH, 1990, ONCOGENE, V5, P683; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Freshney RI, 1994, CULTURE ANIMAL CELLS; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LLIC D, 1995, NATURE, V377, P539; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; OWENS LV, 1995, CANCER RES, V55, P2752; ROZENGURT E, 1995, CANCER SURV, V24, P81; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	34	122	122	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2689	2696						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700528				2022-12-17	WOS:A1996UW48700023
J	Janknecht, R; Nordheim, A				Janknecht, R; Nordheim, A			Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP	ONCOGENE			English	Article						c-fos; coactivator CBP; CREB; Ets protein Sap-1a; signaling; transcription	SERUM RESPONSE ELEMENT; TRANSCRIPTION FACTOR; PROTEIN ELK-1; EXPRESSION; ACTIVATION; PHOSPHORYLATION; INHIBITION; KINASE; BINDS; SRF	The c-fos proto-oncogene is activated by a plethora of signals via the transcription factors Sap-1a and CREB. Recently, the coactivator CBP has been demonstrated to act in concert with CREB when CREB is phosphorylated by protein kinase A. We show that CBP also binds directly to Sap-1a. While phosphorylation of Sap-1a by mitogen-activated protein kinases is not necessary for CBP/Sap-1a interaction, functional cooperation between these two proteins requires Sap-1a to become phosphorylated. CBP-antagonists impair Sap-1a-mediated transactivation. Similarly, the CBP antagonist E1A suppresses c-fos upregulation by phosphorylated CREB, indicating that CBP is a central component of c-fos regulation. Furthermore, CBP is phosphorylated by protein kinase A in vitro and the transactivation potential of the carboxyterminal region of CBP is enhanced in the presence of active protein kinase A in vivo. Thus, CBP, in addition to CREB, is a target for cAMP-dependent signaling. However, combined phosphorylation of CBP by protein kinase A and mitogen-activated protein kinases appears to be non-cooperative, suggesting that CBP serves the function of a dampening integrator of two different signaling pathways.			Janknecht, R (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill M.A., 1995, INDUCIBLE GENE EXPRE, V2, P39; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JANKNECHT R, 1992, GENE, V121, P321, DOI 10.1016/0378-1119(92)90137-E; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RUTHER U, 1989, ONCOGENE, V4, P861; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	53	122	122	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1961	1969						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649857				2022-12-17	WOS:A1996UK49800015
J	CHEN, IT; SMITH, ML; OCONNOR, PM; FORNACE, AJ				CHEN, IT; SMITH, ML; OCONNOR, PM; FORNACE, AJ			DIRECT INTERACTION OF GADD45 WITH PCNA AND EVIDENCE FOR COMPETITIVE INTERACTION OF GADD45 AND P2L(WAF1/CIP1) WITH PCNA	ONCOGENE			English	Article						GADD45; PCNA; P21; WAF1; CIP1; P53; XP-A	CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; GENE-TRANSCRIPTION; AUXILIARY PROTEIN; CYCLIN PCNA; P53; REPLICATION; INHIBITOR; IRRADIATION; COMPONENT	We have previously shown (Smith et al., 1994) that antibodies raised against the growth arrest and DNA damage inducible protein Gadd45 co-precipitate proliferating cell nuclear antigen (PCNA), a protein involved in DNA replication and repair. Here we demonstrate that Gadd45 can directly bind to PCNA using a Far-western blotting approach. In this assay, a Gadd45 bacterial expression vector was modified to allow synthesis of purified P-32-labeled Gadd45 fusion protein. This protein was used to detect filter bound PCNA protein, while filter bound Gadd45 protein could also be detected by free PCNA molecules. Using recombinant proteins in conjunction with immunoprecipitation and immunoblotting, we show that Gadd45 competes with p21 for binding to PCNA and conversely, p21 blocks the ability of Gadd45 to bind PCNA. In addition, p21 appears to disrupt PCNA trimers whereas Gadd45 has a lesser effect. PCNA trimer disruption was also observed in UV-irradiated cells but not in repair-defective xeroderma pigmentosum group A (XP-A) cells.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CHEN IT, 1995, UNPUB ONCOGENE; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL PA, 1995, ONCOGENE, V10, P2427; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1995, INT J ONCOL, V6, P937	45	122	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					1931	1937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478510				2022-12-17	WOS:A1995TF29700001
J	OUCHIDA, M; OHNO, T; FUJIMURA, Y; RAO, VN; REDDY, ESP				OUCHIDA, M; OHNO, T; FUJIMURA, Y; RAO, VN; REDDY, ESP			LOSS OF TUMORIGENICITY OF EWINGS-SARCOMA CELLS EXPRESSING ANTISENSE RNA TO EWS-FUSION TRANSCRIPTS	ONCOGENE			English	Article						EWINGS SARCOMA; THERAPY; RNA BINDING; ETS; EWS	ETS-RELATED GENE; CHROMOSOMAL TRANSLOCATIONS; DNA-BINDING; FLI-1; ERG; PROTEIN; ACTIVATION; FAMILY; LIPOSARCOMA; LEUKEMIA	Cytogenetic analysis of Ewing's sarcoma, primitive neuroectodermal tumors and Askin tumors revealed characteristic translocations t(11;22) or t(21;22). Molecular analysis of these translocations revealed S-region of EWS gene (from band 22q12) is fused to the 3'-region of either Fli-1 gene (from band 11q24) or erg gene (from band 21q22). Functional characterization of the EWS-Fli-1 and EWS-erg chimeric proteins suggested that they function as transcriptional activators. In order to develop therapeutic agents, it is essential to know whether expression of the EWS-fusion gene products is coupled to tumorigenicity of Ewing's sarcoma cells and if targeting the EWS-fusion products results in loss of tumorigenicity of Ewing's sarcoma cells. For this reason, we have made stable Ewing's sarcomas expressing antisense EWS-Fli-1 or EWS-erg transcripts by transfecting the antisense EWS-Fli-1 or EWS-erg expression plasmids. Expression of antisense EWS fusion transcripts resulted in a significant loss of endogenous EWS-Fli-1 and EWS-erg proteins in Ewing's sarcoma cells. These cells expressing antisense EWS fusion transcripts showed loss of anchorage independent growth and tumorigenicity in nude mice unlike the parental Ewing's sarcoma cells. These results demonstrate the necessity of a certain threshold level of expression of EWS-fusion products in the clonogenicity and tumorigenicity of Ewing's sarcoma cells and therefore emphasizes the importance of targeting the EWS-fusion products as a therapy for Ewing family of tumors.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University					NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057157, P01CA051083] Funding Source: NIH RePORTER; NCI NIH HHS [CA58642, CA51083, CA57157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOYD JA, 1994, MOL IMMUNOLOGIC APPR; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V369, P162; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LADANYI M, 1994, CANCER RES, V54, P2837; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	122	135	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1049	1054						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566963				2022-12-17	WOS:A1995RX18000006
J	HALL, PA; KEARSEY, JM; COATES, PJ; NORMAN, DG; WARBRICK, E; COX, LS				HALL, PA; KEARSEY, JM; COATES, PJ; NORMAN, DG; WARBRICK, E; COX, LS			CHARACTERIZATION OF THE INTERACTION BETWEEN PCNA AND GADD45	ONCOGENE			English	Article						GADD45; PCNA; 2-YBRID; CYCLINS; P21(CIP1)	CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; AUXILIARY PROTEIN; ESCHERICHIA-COLI; CYCLIN PCNA; REPAIR; P53; INHIBITOR; SUBUNIT; KINASES	We have examined the interaction between the DNA replication and repair protein PCNA, and the growth arrest and DNA damage induced protein Gadd45. An anti-Gadd45 polyclonal antibody co-immunoprecipitates PCNA but in reciprocal experiments, an anti-C terminal anti-PCNA antibody failed to co-immunoprecipitate Gadd45, We used a yeast two hybrid assay to demonstrate that human Gadd45 interacts with both human and S. pombe PCNA, We have determined that the N-terminal 94 amino acids of Gadd45 bind to PCNA, and using a series of N-terminal and C-terminal deletions of human PCNA we have mapped two potential Gadd45 binding sites, Deletion of the last 6 amino acids of PCNA ablated interaction, suggesting a role in Gadd45 binding, This explains the inability of an anti-C terminal PCNA antibody to co-immunoprecipitate Gadd45, Using a peptide ELISA approach, we showed that Gadd45 protein binds strongly to three regions of PCNA (residues 1-20, 61-80, and 196-215) and weakly to residues 121-170, The crystal structure of PCNA provides insight into our genetic and immunochemical data, Our results confirm an interaction between PCNA and Gadd45, define regions of both molecules involved in this interaction, and are consistent with a potential stoichiometry of 2 Gadd45 molecules to each PCNA monomer. These data provide support for the notion that PCNA-Gadd45 interactions co-ordinate cell cycle and DNA repair.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee	HALL, PA (corresponding author), UNIV DUNDEE,DEPT PATHOL,DUNDEE DD1 9SY,SCOTLAND.		Coates, Philip J/H-6854-2019; Warbrick, Emma/C-6424-2008; Cox, Lynne/AAT-2047-2021	Coates, Philip J/0000-0003-1518-6306; Cox, Lynne/0000-0002-5306-285X				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CANMAN CE, 1994, CANCER RES, V54, P5054; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; COX LS, 1995, UNPUB; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLORES RH, 1994, P NATL ACAD SCI USA, V91, P8655; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HALL PA, 1993, ONCOGENE, V8, P203; HALL PA, 1994, EUR J CANCER, V12, P2001; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRICE BD, 1992, CANCER RES, V52, P3814; ROSE MD, 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH M, 1994, SCIENCE, V226, P1376; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; VANLAAR T, 1994, ONCOGENE, V9, P981; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1990, J CELL SCI, V96, P121; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1992, CELL, V71, P504; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	42	122	125	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2427	2433						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784094				2022-12-17	WOS:A1995RE54300021
J	WEIH, F; CARRASCO, D; BRAVO, R				WEIH, F; CARRASCO, D; BRAVO, R			CONSTITUTIVE AND INDUCIBLE REL NF-KAPPA-B ACTIVITIES IN MOUSE THYMUS AND SPLEEN	ONCOGENE			English	Article							DORSOVENTRAL PATTERN-FORMATION; C-REL; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; SIGNAL TRANSDUCTION; PROTEIN SUBUNITS; LYMPHOID-CELLS; P65 SUBUNIT; GENE; FAMILY	We have studied the expression of members of the rel family of transcription factors and ikba in mouse thymus and spleen by in situ hybridization. Our results show that the vel genes have different temporal and spatial patterns of expression suggesting distinct roles in these lymphoid tissues. The Rel/NF-kappa B proteins and I kappa B alpha in thymus and spleen were also analysed by Western blotting and electrophoretic mobility shift assays. Although RelB protein is present at significantly lower levels in thymus and spleen extracts when compared to RelA, in both tissues the predominant kappa B-binding activity consists of p50/RelB and p52/RelB heterodimers and only very little binding of RelA-containing complexes to kappa B sites was detected. Significant binding of c-Rel complexes was only found in spleen extracts. Treatment of thymus and spleen extracts with deoxycholate (DOC), however, results in a strong increase in binding to kappa B sites of both RelA and c-Rel complexes. In contrast, binding of RelB complexes is not induced after DOC treatment. Our results suggest a differential role of Rel/NF-kappa B complexes in mouse thymus and spleen with RelB heterodimers representing the constitutive kappa B-binding activity, whereas RelA and c-Rel complexes most likely are involved in inducible kappa B-binding and gene activation.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								AGGER R, 1992, J LEUKOCYTE BIOL, V52, P34, DOI 10.1002/jlb.52.1.34; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWNELL E, 1988, ONCOGENE, V3, P93; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; CARRASCO D, 1994, IN PRESS DEVELOPMENT; CARRASCO D, 1994, CELL BIOL LABORATORY; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; COLIGAN JE, 1992, CURRENT PROTOCOLS IM; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DOBRANSKI P, 1994, IN PRESS EMBO J; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; IP YT, 1992, J CELL SCI, P33; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METCALF D, 1971, FRONTIERS BIOL HEMAT, P172; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; Orkin SH, 1990, CURR OPIN CELL BIOL, V2, P1003, DOI 10.1016/0955-0674(90)90149-9; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; RYSECK RP, 1994, IN PRESS IMMEDIATE E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEWARI M, 1992, NUCLEIC ACIDS RES, V20, P607, DOI 10.1093/nar/20.3.607; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523	73	122	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3289	3297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936653				2022-12-17	WOS:A1994PM65800022
J	COFFER, P; DEJONGE, M; METTOUCHI, A; BINETRUY, B; GHYSDAEL, J; KRUIJER, W				COFFER, P; DEJONGE, M; METTOUCHI, A; BINETRUY, B; GHYSDAEL, J; KRUIJER, W			JUNB PROMOTER REGULATION - RAS MEDIATED TRANSACTIVATION BY C-ETS-1 AND C-ETS-2	ONCOGENE			English	Review							GUANINE NUCLEOTIDE-BINDING; EMBRYONAL CARCINOMA-CELLS; ACTIVATED PROTEIN-KINASE; LONG TERMINAL REPEAT; MURINE SARCOMA-VIRUS; NIH 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; DNA-BINDING; MAP KINASE	The Jun gene family encode components of the AP-1 transcription factor complex that regulate a variety of TRE-containing target promoters. Expression of family members is induced by a wide variety of extracellular stimuli and thought to be important in mediating cellular proliferation and differentiation. We have localized cis-acting; DNA sequences in the murine junB promoter capable of mediating transcriptional activation by the proto-oncogene products c-Ets-l and c-Ets-2. We show by promoter deletion analysis that multiple elements located between - 848 and - 574, and between - 196 and - 91 can mediate transactivation by ETS-family members in different cell types. In vitro DNA binding assays indicate that the elements identified can specifically interact with c-Ets-1 protein. Furthermore, we show that ETS-transactivation of a variety of reporter constructs is dramatically enhanced by introduction of oncogenic Ha-ras. The activation of Pas by extracellular stimuli invokes a phosphorylation cascade that includes the downstream mitogen-activated protein (MAP) kinase p44(ERK-1). W,further show that addition of activated p44(ERK-1) MAP kinase can also enhance ETStransactivation of junB promoter reporter constructs. Here we propose that ETS-family members play a role in the activation of junB transcription by a Ras-stimulated signal transducing pathway that includes MAP kinase(s).	CTR UNIV ORSAY,INST CURIE,F-91405 ORSAY,FRANCE; UNIV GRONINGEN,DEPT GENET,9850 AA GRONINGEN,NETHERLANDS	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Groningen	COFFER, P (corresponding author), HUBRECHT LAB,UPPSALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Binetruy, Bernard/A-6465-2009; Coffer, Paul J/A-5769-2009; Coffer, Paul/AAF-7970-2020; Binetruy, Bernard/AFL-7188-2022; GHYSDAEL, Jacques/F-3377-2013; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/S-2062-2019	Binetruy, Bernard/0000-0001-8012-7092				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V8, P148; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMPH WW, 1988, NATURE, V334, P592; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEUNG S, 1993, ONCOGENE, V8, P989; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MEDEMA RH, 1991, MOL CELL BIOL, V12, P3245; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SETH A, 1990, ONCOGENE, V5, P1761; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TYMMS M, 1993, J CELL BIOCH A S, V17, P210; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	102	122	123	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					911	921						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108135				2022-12-17	WOS:A1994MW55100028
J	Johnson, J; Thijssen, B; McDermott, U; Garnett, M; Wessels, LFA; Bernards, R				Johnson, J.; Thijssen, B.; McDermott, U.; Garnett, M.; Wessels, L. F. A.; Bernards, R.			Targeting the RB-E2F pathway in breast cancer	ONCOGENE			English	Review							GENE-EXPRESSION SIGNATURE; RETINOBLASTOMA TUMOR-SUPPRESSOR; KINASE 4/6 INHIBITOR; TRANSCRIPTION FACTORS; CELL-CYCLE; METASTASIS; TAMOXIFEN; MYC; TUMORIGENESIS; INDUCTION	Mutations of the retinoblastoma tumor-suppressor gene (RB1) or components regulating the CDK-RB-E2F pathway have been identified in nearly every human malignancy. Re-establishing cell cycle control through cyclin-dependent kinase (CDK) inhibition has therefore emerged as an attractive option in the development of targeted cancer therapy. The most successful example of this today is the use of the CDK4/6 inhibitor palbociclib combined with aromatase inhibitors for the treatment of estrogen receptorpositive breast cancers. Multiple studies have demonstrated that the CDK-RB-E2F pathway is critical for the control of cell proliferation. More recently, studies have highlighted additional roles of this pathway, especially E2F transcription factors themselves, in tumor progression, angiogenesis and metastasis. Specific E2Fs also have prognostic value in breast cancer, independent of clinical parameters. We discuss here recent advances in understanding of the RB-E2F pathway in breast cancer. We also discuss the application of genome-wide genetic screening efforts to gain insight into synthetic lethal interactions of CDK4/6 inhibitors in breast cancer for the development of more effective combination therapies.	[Johnson, J.; Thijssen, B.; Wessels, L. F. A.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherland, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands; [McDermott, U.; Garnett, M.] Wellcome Trust Sanger Inst, Cambridge, England	Netherlands Cancer Institute; Wellcome Trust Sanger Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis & Canc Genom Netherland, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	; Ford, Caroline/A-7850-2010	Bernards, Rene/0000-0001-8677-3423; Ford, Caroline/0000-0002-4438-2309; McDermott, Ultan/0000-0001-9032-4700	Dutch Cancer Society; Cancer Genomics Netherlands consortium; Wellcome Trust [102696]; Dutch Cancer Society [H1/2014-6919]; Stand Up 2 Cancer; European Research Council	Dutch Cancer Society(KWF Kankerbestrijding); Cancer Genomics Netherlands consortium; Wellcome Trust(Wellcome TrustEuropean Commission); Dutch Cancer Society(KWF Kankerbestrijding); Stand Up 2 Cancer; European Research Council(European Research Council (ERC)European Commission)	The work of RB and LFAW is supported by grants of The Dutch Cancer Society and the and by the Cancer Genomics Netherlands consortium. MG's work is supported by the Wellcome Trust (102696), the Dutch Cancer Society (H1/2014-6919), Stand Up 2 Cancer and a European Research Council Synergy grant.	Andrechek ER, 2015, ONCOGENE, V34, P217, DOI 10.1038/onc.2013.540; Arima Y, 2012, J BIOL CHEM, V287, P7896, DOI 10.1074/jbc.M111.313759; Baker Stacey J, 2012, Genes Cancer, V3, P658, DOI 10.1177/1947601913478972; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Berthet C, 2006, DEV CELL, V10, P563, DOI 10.1016/j.devcel.2006.03.004; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bose P, 2013, EXPERT OPIN INV DRUG, V22, P723, DOI 10.1517/13543784.2013.789859; Cai DP, 2006, CANCER RES, V66, P9270, DOI 10.1158/0008-5472.CAN-06-1758; Canduri F, 2008, MED CHEM, V4, P210, DOI 10.2174/157340608784325205; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; Dickson MA, 2014, CLIN CANCER RES, V20, P3379, DOI 10.1158/1078-0432.CCR-13-1551; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14; Huang L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022274; Johnson JL, 2012, CANCER RES, V72, P516, DOI 10.1158/0008-5472.CAN-11-2647; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khaleel SS, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0486-7; Lin X, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3588; Liu HY, 2015, NAT CELL BIOL, V17, P1036, DOI 10.1038/ncb3210; Loi S, 2007, CRIT REV ONCOL HEMAT, V61, P187, DOI 10.1016/j.critrevonc.2006.09.005; Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niida A, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-71; Niida A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-404; Opavsky R, 2007, P NATL ACAD SCI USA, V104, P15400, DOI 10.1073/pnas.0706307104; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pillai S, 2015, CANCER RES, V75, P1009, DOI 10.1158/0008-5472.CAN-14-0681; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Rakha EA, 2004, J PATHOL, V203, P754, DOI 10.1002/path.1573; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sage J, 2012, GENE DEV, V26, P1409, DOI 10.1101/gad.193730.112; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Singh S, 2010, BBA-GENE REGUL MECH, V1799, P788, DOI 10.1016/j.bbagrm.2010.07.004; Thomassen M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-394; Tian S, 2010, BIOMARK INSIGHTS, V5, P129, DOI 10.4137/BMI.S6184; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Trikha P, 2016, ONCOGENE, V35, P3636, DOI 10.1038/onc.2015.429; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandenbosch R, 2007, CELL CYCLE, V6, P3065, DOI 10.4161/cc.6.24.5048; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Witkiewicz AK, 2014, ONCOGENE, V33, P3980, DOI 10.1038/onc.2013.367; Wu L, 2015, ONCOGENE, V34, P119, DOI 10.1038/onc.2013.511; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Ye X, 2015, TRENDS CELL BIOL, V25, P675, DOI 10.1016/j.tcb.2015.07.012; Yoon SO, 2006, CANCER RES, V66, P6288, DOI 10.1158/0008-5472.CAN-06-0826; Yuwanita I, 2015, ONCOTARGET, V6, P38210, DOI 10.18632/oncotarget.5690; Zhu MZ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-504	66	121	128	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4829	4835		10.1038/onc.2016.32	http://dx.doi.org/10.1038/onc.2016.32			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26923330	Green Accepted			2022-12-17	WOS:000383330700001
J	Guo, G; Kang, Q; Zhu, X; Chen, Q; Wang, X; Chen, Y; Ouyang, J; Zhang, L; Tan, H; Chen, R; Huang, S; Chen, JL				Guo, G.; Kang, Q.; Zhu, X.; Chen, Q.; Wang, X.; Chen, Y.; Ouyang, J.; Zhang, L.; Tan, H.; Chen, R.; Huang, S.; Chen, J-L			A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; STEM-CELLS; NORMAL HEMATOPOIESIS; MOLECULAR PATHWAYS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; MESSENGER-RNAS; C-MYC; CANCER; PTEN	Aberrant expression of long noncoding RNAs (lncRNAs) is associated with various human cancers. However, the role of lncRNAs in Bcr-Abl-mediated chronic myeloid leukemia (CML) is unknown. In this study, we performed a comprehensive analysis of lncRNAs in human CML cells using an lncRNA cDNA microarray and identified an lncRNA termed lncRNA-BGL3 that acted as a key regulator of Bcr-Abl-mediated cellular transformation. Notably, we observed that lncRNA-BGL3 was highly induced in response to disruption of Bcr-Abl expression or by inhibiting Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Ectopic expression of lncRNA-BGL3 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-Abl-induced tumorigenesis. Furthermore, transgenic (TG) mice expressing lncRNA-BGL3 were generated. We found that TG expression of lncRNA-BGL3 alone in mice was sufficient to impair primary bone marrow transformation by Bcr-Abl. Interestingly, we identified that lncRNA-BGL3 was a target of miR-17, miR-93, miR-20a, miR-20b, miR-106a and miR-106b, microRNAs that repress mRNA of phosphatase and tensin homolog (PTEN). Further experiments demonstrated that lncRNA-BGL3 functioned as a competitive endogenous RNA for binding these microRNAs to cross-regulate PTEN expression. Additionally, our experiments have begun to address the mechanism of how lncRNA-BGL3 is regulated in the leukemic cells and showed that Bcr-Abl repressed lncRNA-BGL3 expression through c-Myc-dependent DNA methylation. Taken together, these results reveal that Bcr-Abl-mediated cellular transformation critically requires silence of tumor-suppressor lncRNA-BGL3 and suggest a potential strategy for the treatment of Bcr-Abl-positive leukemia.	[Guo, G.; Kang, Q.; Zhu, X.; Wang, X.; Chen, Y.; Ouyang, J.; Chen, J-L] Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China; [Zhu, X.] Anhui Univ, Sch Life Sci, Hefei 230039, Peoples R China; [Chen, Q.] Fujian Agr & Forestry Univ, Coll Anim Sci, Fuzhou, Peoples R China; [Zhang, L.] Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing 100730, Peoples R China; [Zhang, L.] Peking Union Med Coll, Comparat Med Ctr, Beijing 100021, Peoples R China; [Tan, H.] Guangzhou Med Univ, Affiliated Hosp 1, Ctr Oncol & Hematol, Guangzhou, Guangdong, Peoples R China; [Chen, R.] Chinese Acad Sci, Inst Biophys, Beijing 100080, Peoples R China; [Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71105 USA	Chinese Academy of Sciences; Institute of Microbiology, CAS; Anhui University; Fujian Agriculture & Forestry University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Laboratory Animal Science - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Guangzhou Medical University; Chinese Academy of Sciences; Institute of Biophysics, CAS; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chen, JL (corresponding author), Chinese Acad Sci, Inst Microbiol, Key Lab Pathogen Microbiol & Immunol, West Beichen Rd, Beijing 100101, Peoples R China.	chenjl@im.ac.cn	Chen, Ji-Long/AAJ-2134-2021; Huang, Shile/I-1632-2019; Chen, Runsheng/S-9834-2017	Chen, Ji-Long/0000-0002-4274-0563; Huang, Shile/0000-0002-3239-1072; Chen, Runsheng/0000-0001-6049-8347; Guo, Guijie/0000-0002-9031-1915; Ouyang, Jing/0000-0002-4592-2688	National Key Technologies Research and Development Program of China [2013ZX10004-611]; National Basic Research Program (973) of China [2014CB541804]; Intramural grant of the Chinese Academy of Sciences [KJZD-EW-L01-3]; Natural Science Foundation of China [81171943, U1305212]; Hundreds of Talents Program of Chinese Academy of Sciences	National Key Technologies Research and Development Program of China(National Key Technology R&D Program); National Basic Research Program (973) of China(National Basic Research Program of China); Intramural grant of the Chinese Academy of Sciences; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hundreds of Talents Program of Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank Dr Paul B Rothman from the School of Medicine, The Johns Hopkins University for valuable discussions. This work was supported by the National Key Technologies Research and Development Program of China (2013ZX10004-611), National Basic Research Program (973) of China (2014CB541804), Intramural grant of the Chinese Academy of Sciences (KJZD-EW-L01-3), Natural Science Foundation of China (81171943, U1305212) and Hundreds of Talents Program of Chinese Academy of Sciences 2009-2014 to J-LC.	Barcelona SL, 2005, PEDIATR ANESTH, V15, P716, DOI 10.1111/j.1460-9592.2005.01548.x; Bu DC, 2012, NUCLEIC ACIDS RES, V40, pD210, DOI 10.1093/nar/gkr1175; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Chan CM, 2013, NUCLEIC ACIDS RES, V41, P9663, DOI 10.1093/nar/gkt761; Chen CC, 2012, GENE DEV, V26, P2154, DOI 10.1101/gad.197343.112; Chen JL, 2008, BLOOD, V111, P1677, DOI 10.1182/blood-2007-04-083808; Chen Y, 2010, LEUKEMIA, V24, P1545, DOI 10.1038/leu.2010.143; Chen YY, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-21; Cilloni D, 2012, CLIN CANCER RES, V18, P930, DOI 10.1158/1078-0432.CCR-10-1613; de Giorgio A, 2013, MOL CELL BIOL, V33, P3976, DOI 10.1128/MCB.00683-13; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163; Guo G, 2010, ONCOGENE, V29, P3845, DOI 10.1038/onc.2010.149; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2010, NAT BIOTECHNOL, V28, P756, DOI 10.1038/nbt0710-756b; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Heuston Elisabeth F., 2011, Frontiers in Genetics, V2, P94, DOI 10.3389/fgene.2011.00094; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kiefer CM, 2011, BLOOD, V118, P6200, DOI 10.1182/blood-2011-06-363101; Klattenhoff CA, 2013, CELL, V152, P570, DOI 10.1016/j.cell.2013.01.003; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Lin MF, 2011, BIOINFORMATICS, V27, pI275, DOI 10.1093/bioinformatics/btr209; Lu D, 2012, HYPERTENSION, V60, P81, DOI 10.1161/HYPERTENSIONAHA.112.191478; Luo JH, 2006, HEPATOLOGY, V44, P1012, DOI 10.1002/hep.21328; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Mishra A, 2012, CANCER CELL, V22, P645, DOI 10.1016/j.ccr.2012.09.009; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Nishikawa T, 2000, BIOINFORMATICS, V16, P960, DOI 10.1093/bioinformatics/16.11.960; O'Hare T, 2011, CLIN CANCER RES, V17, P212, DOI 10.1158/1078-0432.CCR-09-3314; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Peng C, 2010, BLOOD, V115, P626, DOI 10.1182/blood-2009-06-228130; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Qiu XX, 2012, NEOPLASIA, V14, P547, DOI 10.1596/neo.12230; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sigova AA, 2013, P NATL ACAD SCI USA, V110, P2876, DOI 10.1073/pnas.1221904110; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Venturini L, 2007, BLOOD, V109, P4399, DOI 10.1182/blood-2006-09-045104; Wang KC, 2011, J INVEST DERMATOL, V131, pS63; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang S, 2012, J BIOL CHEM, V287, P9804, DOI 10.1074/jbc.M111.312959; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang JL, 2013, CANCER RES, V73, P4898, DOI 10.1158/0008-5472.CAN-12-4277; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027	55	121	142	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1768	1779		10.1038/onc.2014.131	http://dx.doi.org/10.1038/onc.2014.131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837367				2022-12-17	WOS:000352158000004
J	Bae, HJ; Noh, JH; Kim, JK; Eun, JW; Jung, KH; Kim, MG; Chang, YG; Shen, Q; Kim, SJ; Park, WS; Lee, JY; Nam, SW				Bae, H. J.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Jung, K. H.; Kim, M. G.; Chang, Y. G.; Shen, Q.; Kim, S-J; Park, W. S.; Lee, J. Y.; Nam, S. W.			MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma	ONCOGENE			English	Article						SIRT1; miR-29c; hepatocellular carcinoma; cell cycle; tumor suppressor	EXPRESSION; DEACETYLASE; CANCER; FAMILY; TUMORIGENESIS; INHIBITOR; PROGNOSIS; GENOMICS; MOUSE	Mammalian sirtuin 1 (SIRT1) has connected to an ever widening circle of activities that encompass cellular stress resistance, energy metabolism and tumorigenesis. However, underlying mechanisms leading to oncogenic SIRT1 overexpression are less understood. In this study, we identified SIRT1 regulatory microRNA (miRNA) and its function in hepatocellular carcinoma (HCC). Aberrant SIRT1 overexpression was demonstrated in a subset of human HCCs. SIRT1 knockdown suppressed HCC cell growth by transcriptional deregulation of cell cycle proteins. This led to hypophosphorylation of pRb, which inactivated E2F/DP1 target gene transcription, and thereby caused significant increase of HCC cells to remain in the G1/S phase. A comprehensive miRNA profiling analysis indentified five putative endogenous miRNAs that are significantly downregulated in HCC. Ectopic expression of miRNA mimics evidenced miR-29c to suppress SIRT1 in HCC cells. Notably, ectopic miR-29c expression repressed cancer cell growth and proliferation, and it recapitulated SIRT1 knockdown effects in HCC cells. In addition, miR-29c expression was downregulated in a large cohort of HCC patients, and low expression of miR-29c was significantly associated with poor prognosis of HCC patients. Taken together, we demonstrated that miR-29c suppresses oncogenic SIRT1 by way of binding to 30-untranslated region of SIRT1 mRNA causing translational inhibition in liver cancer cells. The loss or suppression of miR-29c may cause aberrant SIRT1 overexpression and promotes liver tumorigenesis. Overall, we suggest that miR-29c functions as a tumor suppressor by regulating abnormal SIRT1 activity in liver.	[Bae, H. J.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Jung, K. H.; Kim, M. G.; Chang, Y. G.; Shen, Q.; Kim, S-J; Park, W. S.; Lee, J. Y.; Nam, S. W.] Catholic Univ Korea, Coll Med, Dept Pathol, Lab Oncogen, Seoul 137701, South Korea; [Bae, H. J.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Jung, K. H.; Kim, M. G.; Chang, Y. G.; Shen, Q.; Kim, S-J; Park, W. S.; Lee, J. Y.; Nam, S. W.] Catholic Univ Korea, Funct RNom Res Ctr, Seoul 137701, South Korea; [Nam, S. W.] Catholic Univ Korea, Canc Evolut Res Ctr, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Nam, SW (corresponding author), Catholic Univ Korea, Funct RNom Res Ctr, Coll Med, Dept Pathol, Seoul 137701, South Korea.	swnam@catholic.ac.kr	Eun, Jung Woo/ABB-5127-2020	Eun, Jung Woo/0000-0002-2461-6702	National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST) [2011-0010705, 2012M3A9D1054476]; Korean Science and Engineering Foundation via the 'Cancer Evolution Research Center' at the Catholic University of Korea	National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); Korean Science and Engineering Foundation via the 'Cancer Evolution Research Center' at the Catholic University of Korea(Korea Science and Engineering Foundation)	This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST; Grant No. 2011-0010705 and No. 2012M3A9D1054476), and by the Korean Science and Engineering Foundation via the 'Cancer Evolution Research Center' at the Catholic University of Korea.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jung KH, 2012, HEPATOLOGY, V56, P644, DOI 10.1002/hep.25699; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Kriegel AJ, 2012, PHYSIOL GENOMICS, V44, P237, DOI 10.1152/physiolgenomics.00141.2011; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Niyazi M, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-4; Noh JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028103; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Saunders LR, 2010, AGING-US, V2, P415, DOI 10.18632/aging.100176; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Xie HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034265; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380	25	121	128	2	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2557	2567		10.1038/onc.2013.216	http://dx.doi.org/10.1038/onc.2013.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23728341				2022-12-17	WOS:000336502700002
J	Yamadori, T; Ishii, Y; Homma, S; Morishima, Y; Kurishima, K; Itoh, K; Yamamoto, M; Minami, Y; Noguchi, M; Hizawa, N				Yamadori, T.; Ishii, Y.; Homma, S.; Morishima, Y.; Kurishima, K.; Itoh, K.; Yamamoto, M.; Minami, Y.; Noguchi, M.; Hizawa, N.			Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers	ONCOGENE			English	Article						Nrf2; Keap1; EGFR; cell proliferation; oxidative stress	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OXIDATIVE STRESS; GEFITINIB; KEAP1; NRF2; MUTATIONS; PATHWAY; GENE	We previously demonstrated that the transcription factor NF-E2-related factor2 (Nrf2), expressed abundantly in non-small-cell lung cancer (NSCLC) cells, plays a pivotal role in the proliferation and chemoresistance of NSCLC. Here we show that Nrf2-mediated NSCLC cell proliferation is dually regulated by epidermal growth factor receptor (EGFR) signaling and an Nrf2 repressor protein Keap1 (Kelch-like ECH-associated protein-1). NSCLC cells expressing wild-type EGFR and Keap1 genes show enhanced proliferation on stimulation with EGFR ligand under non-stress conditions. Exposure to cigarette smoke extract (CSE) enhanced cell proliferation by modification of the Nrf2/Keap1 interaction. Although EGFR-tyrosine kinase inhibitor (TKI) inhibited the proliferation of these cells, exposure to CSE attenuated its efficacy. In NSCLC cells with Keap1 gene mutations, Nrf2 was constitutively activated owing to dysfunction of Keap1 and cells proliferated independently of EGFR signaling. Furthermore, EGFR-TKI was unable to inhibit their proliferation. In NSCLC cells with EGFR gene mutations, Nrf2 was constitutively activated by EGFR signaling. In these cells, proliferation was largely dependent on the EGFR signaling pathway. Although these cells were highly sensitive to EGFR-TKI, exposure to CSE or knockdown of Keap1 mRNA reduced sensitivity to EGFR-TKI. We found a case of NSCLC showing resistance to EGFR-TKI despite having EGFR-TKI-sensitive EGFR gene mutation because of dysfunctional mutation in Keap1 gene. Results indicate that oxidative stress reduces the anticancer effects of EGFR-TKI in wild-type Keap1 NSCLC cells. Analysis of Keap1 dysfunction may become a novel molecular marker to predict resistance to EGFR-TKI in NSCLC cells having EGFR-TKI-sensitive EGFR mutations. Finally, as the downstream molecule of both EGFR and Keap1 signaling, Nrf2 is an important molecular target for the treatment of NSCLC, where cells have mutations in EGFR, KRAS or Keap1 genes.	[Yamadori, T.; Ishii, Y.; Homma, S.; Morishima, Y.; Kurishima, K.; Hizawa, N.] Univ Tsukuba, Inst Clin Med, Dept Resp Med, Tsukuba, Ibaraki 305, Japan; [Itoh, K.] Hirosaki Univ, Sch Med, Ctr Adv Med Res, Hirosaki, Aomori 036, Japan; [Yamamoto, M.] Tohoku Univ, Grad Sch Med, Dept Med Biochem, Sendai, Miyagi 980, Japan; [Minami, Y.; Noguchi, M.] Univ Tsukuba, Dept Pathol, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; Hirosaki University; Tohoku University; University of Tsukuba	Ishii, Y (corresponding author), Univ Tsukuba, Inst Clin Med, Dept Resp Med, 1-1-1 Tennoudai, Tsukuba, Ibaraki 305, Japan.	ishii-y@md.tsukuba.ac.jp	Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436	Smoking Research Foundation	Smoking Research Foundation	This work was partially supported by a grant from the Smoking Research Foundation.	De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Huber RM, 2004, LUNG CANCER, V45, pS209, DOI 10.1016/j.lungcan.2004.07.973; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Janmaat ML, 2006, INT J CANCER, V118, P209, DOI 10.1002/ijc.21290; Kim KC, 2010, INT J BIOCHEM CELL B, V42, P297, DOI 10.1016/j.biocel.2009.11.009; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kode A, 2008, AM J PHYSIOL-LUNG C, V294, pL478, DOI 10.1152/ajplung.00361.2007; Kreuzer KA, 2003, ANN HEMATOL, V82, P284, DOI 10.1007/s00277-003-0644-y; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; MITCHELL CE, 1995, ANAL BIOCHEM, V224, P148, DOI 10.1006/abio.1995.1020; Muscarella LA, 2011, EPIGENETICS-US, V6, P710, DOI 10.4161/epi.6.6.15773; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Sakai K, 2006, FASEB J, V20, P311, DOI 10.1096/fj.05-4034fje; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Xu Y, 2010, CANCER BIOL THER, V9, P572, DOI 10.4161/cbt.9.8.11881; Yageta Y, 2011, J VIROL, V85, P4679, DOI 10.1128/JVI.02456-10; Yao HW, 2008, AM J PATHOL, V172, P1222, DOI 10.2353/ajpath.2008.070765; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974	33	121	129	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	45					4768	4777		10.1038/onc.2011.628	http://dx.doi.org/10.1038/onc.2011.628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036NF	22249257				2022-12-17	WOS:000311033000005
J	Singh, RR; Kunkalla, K; Qu, C; Schlette, E; Neelapu, SS; Samaniego, F; Vega, F				Singh, R. R.; Kunkalla, K.; Qu, C.; Schlette, E.; Neelapu, S. S.; Samaniego, F.; Vega, F.			ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma	ONCOGENE			English	Article						ABCG2; ATP-binding cassettes; hedgehog pathway; GLI; diffuse large B-cell lymphoma	CANCER RESISTANCE PROTEIN; MULTIDRUG-RESISTANCE; SONIC-HEDGEHOG; P-GLYCOPROTEIN; POOR RESPONSE; EXPRESSION; GENE; TRANSPORTER; SURVIVAL; PATHWAY	Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in disease relapse and high mortality. High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling pathways has been implicated in the development of chemoresistance in cancer. Previously, our studies showed that high expression of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely with disease-and failure-free survival. In this study, we have implicated activated hedgehog (Hh) signaling pathway as a key factor behind high ABCG2 expression in DLBCL through direct upregulation of ABCG2 gene transcription. We have identified a single binding site for GLI transcription factors in the ABCG2 promoter and established its functionality using luciferase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays. Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions. This suggests a role for the stromal microenvironment in maintaining high levels of ABCG2 and GLI1. Accordingly, in vitro co-culture of DLBCL cells with HS-5 stromal cells increased ABCG2 mRNA and protein levels by paracrine activation of Hh signaling. In addition to ABCG2, co-culture of DLBCL cells with HS-5 cells also resulted in increase expression of the antiapoptotic proteins BCL2, BCL-xL and BCL2A1 and in induced chemotolerance to doxorubicin and methotrexate, drugs routinely used for the treatment of DLBCL. Similarly, activation of Hh signaling in DLBCL cell lines with recombinant Shh N-terminal peptide resulted in increased expression of BCL2 and ABCG2 associated with increased chemotolerance. Finally, functional inhibition of ABCG2 drug efflux activity with fumitremorgin C or inhibition of Hh signaling with cyclopamine-KAAD abrogated the stroma-induced chemotolerance suggesting that targeting ABCG2 and Hh signaling may have therapeutic value in overcoming chemoresistance in DLBCL. Oncogene (2011) 30, 4874-4886; doi:10.1038/onc.2011.195; published online 30 May 2011	[Singh, R. R.; Kunkalla, K.; Qu, C.; Schlette, E.; Vega, F.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Neelapu, S. S.; Samaniego, F.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Singh, RR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Unit 72,1515 Holcombe Blvd, Houston, TX 77030 USA.	rsingh@mdanderson.org; fvegava@mdanderson.org	Vega, Francisco/AGY-4571-2022	Vega, Francisco/0000-0001-5956-452X	NCI/NIH [CA16672]; Leukemia and Lymphoma Society; NIH [1 K08 CA143151-01]; UT MD Anderson Cancer Center Lymphoma SPORE [1P50CA136411-01A1]; Lauri Strauss Leukemia Foundation; NATIONAL CANCER INSTITUTE [K08CA143151, P30CA016672, P50CA136411] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UT MD Anderson Cancer Center Lymphoma SPORE; Lauri Strauss Leukemia Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Susan E Bates (NIH) for providing the ABCG2 promoter luciferase constructs. We also thank Professor Michael G Rosenblum, Department of Experimental Therapeutics, MD Anderson Cancer Center for providing OCI-LY3 and OCI-LY10 cell lines. The primary tumor samples were provided by the Hematopathology and Lymphoma Tissue Banks of the UT MD Anderson Cancer Center (supported by the NCI/NIH Grant CA16672). This research was supported by funds from The Translational Grant of The Leukemia and Lymphoma Society (to RRS and FV), K08 Physician-Scientist Award 1 K08 CA143151-01 (NIH) (to FV), SPORE Lymphoma Grant UT MD Anderson Cancer Center Lymphoma SPORE 1P50CA136411-01A1 (to FV) and Lauri Strauss Leukemia Foundation Grant award (to RRS and FV).	Abbott BL, 2002, BLOOD, V100, P4594, DOI 10.1182/blood-2002-01-0271; Alexander DD, 2007, INT J CANCER, P1, DOI 10.1002/ijc.22719; Allikmets R, 1998, CANCER RES, V58, P5337; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Andreadis C, 2007, BLOOD, V109, P3409, DOI 10.1182/blood-2006-09-047621; Armitage JO, 2007, BLOOD, V110, P29, DOI 10.1182/blood-2007-01-041871; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Barnes EA, 2005, ONCOGENE, V24, P902, DOI 10.1038/sj.onc.1208240; Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664; Benderra Z, 2004, CLIN CANCER RES, V10, P7896, DOI 10.1158/1078-0432.CCR-04-0795; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bleau AM, 2009, CELL CYCLE, V8, P2936; Candeil L, 2004, INT J CANCER, V109, P848, DOI 10.1002/ijc.20032; Damiani D, 2010, LEUKEMIA RES, V34, P942, DOI 10.1016/j.leukres.2010.01.008; Dean M, 2001, J BIOENERG BIOMEMBR, V33, P475, DOI 10.1023/A:1012823120935; Desch P, 2010, ONCOGENE, V29, P4885, DOI 10.1038/onc.2010.243; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Fernandez M, 2010, J CELL BIOCHEM, V111, P130, DOI 10.1002/jcb.22676; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grigorieva I, 1998, EXP HEMATOL, V26, P597; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Honjo Y, 2001, CANCER RES, V61, P6635; Hu LL, 2007, CARCINOGENESIS, V28, P1740, DOI 10.1093/carcin/bgm113; Jerkeman M, 2004, ANN HEMATOL, V83, P414, DOI 10.1007/s00277-004-0855-x; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kawabata S, 2003, CLIN CANCER RES, V9, P3052; Kim JE, 2009, MODERN PATHOL, V22, P1312, DOI 10.1038/modpathol.2009.98; Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Lwin T, 2009, LEUKEMIA, V23, P170, DOI 10.1038/leu.2008.266; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Miyake K, 1999, CANCER RES, V59, P8; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Murone M, 1999, EXP CELL RES, V253, P25, DOI 10.1006/excr.1999.4676; Ohsawa M, 2005, ONCOLOGY-BASEL, V68, P422, DOI 10.1159/000086984; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Queiroz KCS, 2010, ONCOGENE, V29, P6314, DOI 10.1038/onc.2010.375; Rabindran SK, 2000, CANCER RES, V60, P47; Robey RW, 2003, BRIT J CANCER, V89, P1971, DOI 10.1038/sj.bjc.6601370; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; RODRIGUEZ C, 1993, LEUKEMIA RES, V17, P149, DOI 10.1016/0145-2126(93)90060-X; Sacedon R, 2005, J IMMUNOL, V174, P1456, DOI 10.4049/jimmunol.174.3.1456; Sarkadi B, 2004, FEBS LETT, V567, P116, DOI 10.1016/j.febslet.2004.03.123; Sauerbrey A, 2002, BRIT J HAEMATOL, V118, P147, DOI 10.1046/j.1365-2141.2002.03550.x; Schmittgen TD, 2001, METHODS, V25, P383, DOI 10.1006/meth.2001.1260; Sims-Mourtada J, 2007, ONCOGENE, V26, P5674, DOI 10.1038/sj.onc.1210356; Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176; Singh RR, 2010, LEUKEMIA, V24, P1025, DOI 10.1038/leu.2010.35; Singh RR, 2009, CANCER RES, V69, P2550, DOI 10.1158/0008-5472.CAN-08-1808; Stam RW, 2004, LEUKEMIA, V18, P78, DOI 10.1038/sj.leu.2403168; Steinbach D, 2002, LEUKEMIA, V16, P1443, DOI 10.1038/sj.leu.2402541; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; To KKW, 2006, MOL CELL BIOL, V26, P8572, DOI 10.1128/MCB.00650-06; Tsunoda S, 2006, ONCOLOGY-BASEL, V71, P251, DOI 10.1159/000106787; Uggla B, 2005, LEUKEMIA RES, V29, P141, DOI 10.1016/j.leukres.2004.06.004; Winklmayr M, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-2; Yasuda S, 2009, MOL BIOL REP, V36, P1889, DOI 10.1007/s11033-008-9395-0; Yoh K, 2004, CLIN CANCER RES, V10, P1691, DOI 10.1158/1078-0432.CCR-0937-3; YUEN AR, 1994, J CLIN ONCOL, V12, P2453, DOI 10.1200/JCO.1994.12.11.2453	66	121	125	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4874	4886		10.1038/onc.2011.195	http://dx.doi.org/10.1038/onc.2011.195			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21625222	Green Accepted			2022-12-17	WOS:000298346400004
J	Liu, W; Zabirnyk, O; Wang, H; Shiao, YH; Nickerson, ML; Khalil, S; Anderson, LM; Perantoni, AO; Phang, JM				Liu, W.; Zabirnyk, O.; Wang, H.; Shiao, Y-H; Nickerson, M. L.; Khalil, S.; Anderson, L. M.; Perantoni, A. O.; Phang, J. M.			miR-23b*targets proline oxidase, a novel tumor suppressor protein in renal cancer	ONCOGENE			English	Article						proline oxidase; miR-23b*; renal cancer; ROS; tumor suppressor	CELL CARCINOMA; DOWN-REGULATION; EXPRESSION; GENE; MICRORNAS; APOPTOSIS; HYPOXIA; MYC; BIOGENESIS; BINDING	Proline oxidase (POX) is a novel mitochondrial tumor suppressor that can suppress proliferation and induce apoptosis through the generation of reactive oxygen species (ROS) and decreasing hypoxia-inducible factor (HIF) signaling. Recent studies have shown the absence of expression of POX in human cancer tissues, including renal cancer. However, the mechanism for the loss of POX remains obscure. No genetic or epigenetic variation of POX gene was found. In this study, we identified the upregulated miR-23b* in renal cancer as an important regulator of POX. Ectopic overexpression of miR-23b* in normal renal cells resulted in striking downregulation of POX, whereas POX expression increased markedly when endogenous miR-23b* was knocked down by its antagomirs in renal cancer cells. Consistent with the POX-mediated tumor suppression pathway, these antagomirs induced ROS, inhibited HIF signaling and increased apoptosis. Furthermore, we confirmed the regulation of miR-23b* on POX and its function in the DLD1 Tet-off POX cell system. Using a luciferase reporter system, we verified the direct binding of miR-23b* to the POX mRNA 3'-untranslated region. In addition, pairs of human renal carcinoma and normal tissues showed a negative correlation between miR-23b* and POX protein expression, providing its clinical corroboration. Taken together, our results suggested that miR-23b*, by targeting POX, could function as an oncogene; decreasing miR-23b* expression may prove to be an effective way of inhibiting kidney tumor growth. Oncogene (2010) 29, 4914-4924; doi: 10.1038/onc.2010.237; published online 21 June 2010	[Liu, W.; Zabirnyk, O.; Shiao, Y-H; Khalil, S.; Anderson, L. M.; Phang, J. M.] NCI, Lab Comparat Carcinogenesis, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Wang, H.; Perantoni, A. O.] NCI, Lab Canc & Dev Biol, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Nickerson, M. L.] NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, W (corresponding author), NCI, Lab Comparat Carcinogenesis, Ctr Canc Res, NIH, Bldg 538,Room 144, Frederick, MD 21702 USA.	liuwei3@mail.nih.gov; phangj@mail.nih.gov	Shiao, Yih-Horng/ABC-7262-2021; liu, wei/E-7340-2012	Shiao, Yih-Horng/0000-0001-9841-7784	NIH; National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010744, ZIABC010743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Anna E Maciag for insightful comments, Dr Matthew J Fivash for statistical analysis, Dr Miriam R Anver for evaluating POX immunohistochemical staining and miR-23b* in situ hybridization, Dr Chang H Kim for his help with the miRNA microarray. This research was supported (in part) by the Intramural Research Program of the NIH, the National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Chow TFF, 2010, CLIN BIOCHEM, V43, P150, DOI 10.1016/j.clinbiochem.2009.07.020; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Donald SP, 2001, CANCER RES, V61, P1810; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Girgin C, 2001, UROL INT, V66, P78, DOI 10.1159/000056575; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guimbellot JS, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-15; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kim S, 2008, J BIOL CHEM, V283, P18158, DOI 10.1074/jbc.M800186200; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu Y, 2008, ONCOGENE, V27, P6729, DOI 10.1038/onc.2008.322; Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nakada C, 2008, J PATHOL, V216, P418, DOI 10.1002/path.2437; Nass D, 2009, BRAIN PATHOL, V19, P375, DOI 10.1111/j.1750-3639.2008.00184.x; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Phang JM, 2008, J NUTR, V138, p2008S, DOI 10.1093/jn/138.10.2008S; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Smaldone MC, 2009, UROL ONCOL-SEMIN ORI, V27, P238, DOI 10.1016/j.urolonc.2007.12.001; Sowter HM, 2003, CANCER RES, V63, P6130; SUZUKI Y, 1992, JPN J CANCER RES, V83, P233, DOI 10.1111/j.1349-7006.1992.tb00091.x; Williams AE, 2008, CELL MOL LIFE SCI, V65, P545, DOI 10.1007/s00018-007-7355-9; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	43	121	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4914	4924		10.1038/onc.2010.237	http://dx.doi.org/10.1038/onc.2010.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562915	Green Accepted			2022-12-17	WOS:000281578700006
J	Yu, JS; Koujak, S; Nagase, S; Li, CM; Su, T; Wang, X; Keniry, M; Memeo, L; Rojtman, A; Mansukhani, M; Hibshoosh, H; Tycko, B; Parsons, R				Yu, J. S.; Koujak, S.; Nagase, S.; Li, C-M; Su, T.; Wang, X.; Keniry, M.; Memeo, L.; Rojtman, A.; Mansukhani, M.; Hibshoosh, H.; Tycko, B.; Parsons, R.			PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer	ONCOGENE			English	Article						PCDH8; protocadherin; breast cancer; tumor suppressor	TRANSCRIPTION FACTOR SNAIL; PARAXIAL PROTOCADHERIN; STRUCTURAL BASIS; CELL MOVEMENTS; CHROMOSOME 13Q; CADHERIN; MORPHOGENESIS; ADHESION; GENE; PROLIFERATION	Carcinoma is an altered state of tissue differentiation in which epithelial cells no longer respond to cues that keep them in their proper position. A break down in these cues has disastrous consequences not only in cancer but also in embryonic development when cells of various lineages must organize into discrete entities to form a body plan. Paraxial protocadherin (PAPC) is an adhesion protein with six cadherin repeats that organizes the formation and polarity of developing cellular structures in frog, fish and mouse embryos. Here we show that protocadherin-8 (PCDH8), the human ortholog of PAPC, is inactivated through either mutation or epigenetic silencing in a high fraction of breast carcinomas. Loss of PCDH8 expression is associated with loss of heterozygosity, partial promoter methylation, and increased proliferation. Complementation of mutant tumor cell line HCC2218 with wild-type PCDH8 inhibited its growth. Two tumor mutants, E146K and R343H, were defective for inhibition of cell growth and migration. Sur prisingly, the E146K mutant transformed the human mammary epithelial cell line MCF10A and sustained the expression of cyclin D1 and MYC without epidermal growth factor. We propose that loss of PCDH8 promotes oncogenesis in epithelial human cancers by disrupting cell-cell communication dedicated to tissue organization and repression of mitogenic signaling.	[Parsons, R.] Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Parsons, R.] Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, 1130 St Nicholas Ave, New York, NY 10032 USA.	rep15@columbia.edu		Memeo, Lorenzo/0000-0003-4251-7203; Parsons, Ramon/0000-0002-6656-3514; Nagase, Satoru/0000-0001-5212-1128	NATIONAL CANCER INSTITUTE [R01CA082783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA082783-05, R01 CA082783-04, R01 CA082783-07, R01 CA082783, R01 CA082783-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; Kim SH, 1998, DEVELOPMENT, V125, P4681; Kim SH, 2000, CURR BIOL, V10, P821, DOI 10.1016/S0960-9822(00)00580-7; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Medina A, 2004, EMBO J, V23, P3249, DOI 10.1038/sj.emboj.7600329; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Rhee J, 2003, DEV BIOL, V254, P248, DOI 10.1016/S0012-1606(02)00085-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Unterseher F, 2004, EMBO J, V23, P3259, DOI 10.1038/sj.emboj.7600332; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351	30	121	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4657	4665		10.1038/onc.2008.101	http://dx.doi.org/10.1038/onc.2008.101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408767	Green Accepted			2022-12-17	WOS:000258236300004
J	Thorslund, T; West, SC				Thorslund, T.; West, S. C.			BRCA2: a universal recombinase regulator	ONCOGENE			English	Review						tumour suppressor; RAD51; DMC1; DNA repair; genome instability; meiotic recombination	SUSCEPTIBILITY GENE BRCA2; HOMOLOGY-DIRECTED REPAIR; DNA STRAND EXCHANGE; CANCER SUSCEPTIBILITY; CAENORHABDITIS-ELEGANS; MEIOTIC CELLS; RADIATION HYPERSENSITIVITY; SYNAPTONEMAL COMPLEXES; RAD51-DNA FILAMENTS; NUCLEAR FOCI	Homologous recombination has a dual role in eukaryotic organisms. Firstly, it is responsible for the creation of genetic variability during meiosis by directing the formation of reciprocal crossovers that result in random combinations of alleles and traits. Secondly, in mitotic cells, it maintains the integrity of the genome by promoting the faithful repair of DNA double-strand breaks (DSBs). In vertebrates, it therefore plays a key role in tumour avoidance. Mutations in the tumour suppressor protein BRCA2 are associated with predisposition to breast and ovarian cancers, and loss of BRCA2 function leads to genetic instability. BRCA2 protein interacts directly with the RAD51 recombinase and regulates recombination-mediated DSB repair, accounting for the high levels of spontaneous chromosomal aberrations seen in BRCA2-defective cells. Recent observations indicate that BRCA2 also plays a critical role in meiotic recombination, this time through direct interactions with the meiosis-specific recombinase DMC1. The interactions of BRCA2 with RAD51 and DMC1 lead us to suggest that the BRCA2 tumour suppressor is a universal regulator of recombinase actions.	[Thorslund, T.; West, S. C.] Clare Hall Labs, London Res Inst, Canc Res UK, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Clare Hall Labs, London Res Inst, Canc Res UK, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		Thorslund, Tina/0000-0001-9207-0070; West, Stephen/0000-0001-8848-9418				Atanassov BS, 2005, GENE CHROMOSOME CANC, V44, P429, DOI 10.1002/gcc.20255; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; BENNETT CB, 1993, P NATL ACAD SCI USA, V90, P5613, DOI 10.1073/pnas.90.12.5613; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Conway AB, 2004, NAT STRUCT MOL BIOL, V11, P791, DOI 10.1038/nsmb795; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Davies OR, 2007, NAT STRUCT MOL BIOL, V14, P475, DOI 10.1038/nsmb1251; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Dray E, 2006, PLANT PHYSIOL, V140, P1059, DOI 10.1104/pp.105.075838; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Esashi F, 2007, NAT STRUCT MOL BIOL, V14, P468, DOI 10.1038/nsmb1245; Galkin VE, 2005, P NATL ACAD SCI USA, V102, P8537, DOI 10.1073/pnas.0407266102; Goggins M, 1996, CANCER RES, V56, P5360; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kinebuchi T, 2004, MOL CELL, V14, P363, DOI 10.1016/S1097-2765(04)00218-7; Kojic M, 2002, MOL CELL, V10, P683, DOI 10.1016/S1097-2765(02)00632-9; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Martin JS, 2005, MOL CELL BIOL, V25, P3127, DOI 10.1128/MCB.25.8.3127-3139.2005; McAllister KA, 2002, CANCER RES, V62, P990; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Neale MJ, 2006, NATURE, V442, P153, DOI 10.1038/nature04885; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petalcorin MIR, 2007, P NATL ACAD SCI USA, V104, P8299, DOI [10.1073/pnas.0702805104, 10.1073/pnas.0702808104]; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Saeki H, 2006, P NATL ACAD SCI USA, V103, P8768, DOI 10.1073/pnas.0600298103; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sehorn MG, 2004, NATURE, V429, P433, DOI 10.1038/nature02563; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shin DS, 2003, EMBO J, V22, P4566, DOI 10.1093/emboj/cdg429; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Shivji MKK, 2006, NUCLEIC ACIDS RES, V34, P4000, DOI 10.1093/nar/gkl505; Siaud N, 2004, EMBO J, V23, P1392, DOI 10.1038/sj.emboj.7600146; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takanami T, 2000, NUCLEIC ACIDS RES, V28, P4232, DOI 10.1093/nar/28.21.4232; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Tarsounas M, 1999, J CELL BIOL, V147, P207, DOI 10.1083/jcb.147.2.207; Tarsounas M, 2004, PHILOS T R SOC B, V359, P87, DOI 10.1098/rstb.2003.1368; Thorslund T, 2007, EMBO J, V26, P2915, DOI 10.1038/sj.emboj.7601739; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; YOSHIDA N, 1998, REC RES DEV FERMEN 1, V1, P1; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547	61	121	124	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7720	7730		10.1038/sj.onc.1210870	http://dx.doi.org/10.1038/sj.onc.1210870			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066084				2022-12-17	WOS:000251537900002
J	Mangala, LS; Fok, JY; Zorrilla-Calancha, IR; Verma, A; Mehta, K				Mangala, L. S.; Fok, J. Y.; Zorrilla-Calancha, I. R.; Verma, A.; Mehta, K.			Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells	ONCOGENE			English	Article						metastasis; integrins; cell migration; invasion; transglutaminase; fibronectin	GELATIN-BINDING DOMAIN; SWISS 3T3 FIBROBLASTS; FOCAL-ADHESION KINASE; DRUG-RESISTANT; RETINOIC ACID; CROSS-LINKING; MCF-7 CELLS; IN-VITRO; FIBRONECTIN; MIGRATION	Distant metastasis is frequently observed in patients with breast cancer and is a major cause of cancer-related deaths in these patients. Currently, very little is known about the mechanisms that underlie the development of the metastatic phenotype in breast cancer cells. We previously found that metastatic breast cancer cells express high levels of tissue transglutaminase (TG2), but established no direct link between TG2 and metastasis. In this study, we hypothesized that TG2 plays a role in conferring the metastatic phenotype to breast cancer cells. The results obtained suggested that increased expression of TG2 in breast cancer cells contributes to their increased survival, invasion and motility. We further found that TG2 protein in a metastatic breast cancer MDA-MB231 cells was present on the cell surface in close association with integrins beta 1, beta 4 and beta 5. Downregulation of endogenous TG2 by small interfering RNA inhibited. bronectin (Fn)mediated cell attachment, survival and invasion. Conversely, ectopic expression of TG2 augmented invasion of breast cancer cells and attachment to Fn-coated surfaces. We conclude that TG2 expression in breast cancer cells plays an important role in the development of the metastatic phenotype.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Mehta, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 326,1515 Holcombe Blvd, Houston, TX 77030 USA.	kmehta@mdanderson.org			NCI NIH HHS [CA 16672-29, CA 092115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Akimov SS, 2001, J CELL SCI, V114, P2989; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; Belkin AM, 2005, BLOOD, V105, P3561, DOI 10.1182/blood-2004-10-4089; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen JSK, 2004, J CELL PHYSIOL, V200, P223, DOI 10.1002/jcp.20014; Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403; Cordes N, 2003, INT J RADIAT BIOL, V79, P709, DOI 10.1080/09553000310001610240; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Han JA, 1999, J CANCER RES CLIN, V125, P89, DOI 10.1007/s004320050247; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Janiak A, 2006, MOL BIOL CELL, V17, P1606, DOI 10.1091/mbc.E05-06-0549; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Jiang DF, 2003, PROTEOMICS, V3, P724, DOI 10.1002/pmic.200300411; Jiang WG, 2003, ONCOL REP, V10, P2039; Joshi S, 2006, ONCOGENE, V25, P240, DOI 10.1038/sj.onc.1209027; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Leroy P, 2004, J LEUKOCYTE BIOL, V75, P680, DOI 10.1189/jlb.0503246; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Longtin R, 2004, J NATL CANCER I, V96, P6, DOI 10.1093/jnci/96.1.6; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehta K, 2005, PROG EXP TUMOR RES, V38, P1; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2006, J BIOL CHEM, V281, P5532, DOI 10.1074/jbc.M506864200; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Parker BS, 2003, CANCER BIOL THER, V2, P14; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Yoneda T, 2000, J Orthop Sci, V5, P75, DOI 10.1007/s007760050012; Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	47	121	123	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2459	2470		10.1038/sj.onc.1210035	http://dx.doi.org/10.1038/sj.onc.1210035			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043648				2022-12-17	WOS:000245831000006
J	Bindra, RS; Glazer, PM				Bindra, R. S.; Glazer, P. M.			Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia	ONCOGENE			English	Article						Rad51; homologous recombination; hypoxia; E2F4/p130	CELL-CYCLE ARREST; DNA-REPAIR; DIFFERENTIAL REGULATION; POCKET PROTEINS; DOWN-REGULATION; STRESS; INSTABILITY; P107; DEPHOSPHORYLATION; E2F	We and others have shown that the dysregulation of DNA repair pathways can contribute to the phenomenon of hypoxia-induced genetic instability within the tumor microenvironment. Several studies have revealed that the recombinational repair genes, RAD51 and BRCA1, and the DNA mismatch repair genes, MLH1 and MSH2, are decreased in expression in response to hypoxic stress, prompting interest in elucidating the mechanistic basis for these responses. Here we report that the downregulation of RAD51 by hypoxia is specically mediated by repressive E2F4/p130 complexes that bind to a single E2F site in the proximal promoter of the gene. Intriguingly, this E2F site is conserved in the promoter of the BRCA1 gene, which is also regulated by a similar mechanism in hypoxia. Mechanistically, we have found that hypoxia induces substantial p130 dephosphorylation and nuclear accumulation, leading to the formation of E2F4/p130 complexes and increased occupancy of E2F4 and p130 at the RAD51 and BRCA1 promoters. These findings reveal a coordinated transcriptional program mediated by the formation of repressive E2F4/p130 complexes that represents an integral response to hypoxic stress. In addition, this co-regulation of key factors within the homology-dependent DNA repair pathway provides a further basis for understanding genetic instability in tumors and may guide the design of new therapeutic strategies for cancer.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Expt Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Geriatr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Glazer, PM (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	peter.glazer@yale.edu	Glazer, Peter/S-7651-2019	Bindra, Randip/0000-0003-1552-9057; Glazer, Peter/0000-0003-4525-5560	NIEHS NIH HHS [ES05775] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005775, R29ES005775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; DuPree EL, 2004, CANCER RES, V64, P4390, DOI 10.1158/0008-5472.CAN-03-3695; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Garriga J, 2004, CELL CYCLE, V3, P1320, DOI 10.4161/cc.3.10.1183; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Li CY, 2001, CANCER RES, V61, P428; Lin WC, 2001, GENE DEV, V15, P1833; Meng AX, 2005, RADIOTHER ONCOL, V76, P168, DOI 10.1016/j.radonc.2005.06.025; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; North S, 2005, CANCER LETT, V218, P1, DOI 10.1016/j.canlet.2004.08.007; PAQUETTE B, 1994, CANCER RES, V54, P3173; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Reynolds TY, 1996, CANCER RES, V56, P5754; Roth ME, 2004, NAT BIOTECHNOL, V22, P418, DOI 10.1038/nbt948; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; Yuan JL, 2000, CANCER RES, V60, P4372; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	40	121	122	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2048	2057		10.1038/sj.onc.1210001	http://dx.doi.org/10.1038/sj.onc.1210001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001309				2022-12-17	WOS:000245313400007
J	Carragher, NO; Walker, SM; Carragher, LSA; Harris, F; Sawyer, TK; Brunton, VG; Ozanne, BW; Frame, MC				Carragher, N. O.; Walker, S. M.; Carragher, L. A. Scott; Harris, F.; Sawyer, T. K.; Brunton, V. G.; Ozanne, B. W.; Frame, M. C.			Calpain 2 and Src dependence distinguishes mesenchymal and amoeboid modes of tumour cell invasion: a link to integrin function	ONCOGENE			English	Article						calpain; Src; invasion; ROCK; mesenchymal; amoeboid	FOCAL ADHESION KINASE; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; COLORECTAL-CANCER; CLINICAL-TRIALS; LUNG-CANCER; MIGRATION; DYNAMICS; PROTEOLYSIS; INHIBITOR	Cancer cells can invade three-dimensional matrices by distinct mechanisms, recently defined by their dependence on extracellular proteases, including matrix metalloproteinases. Upon treatment with protease inhibitors, some tumour cells undergo a 'mesenchymal to amoeboid' transition that allows invasion in the absence of pericellular proteolysis and matrix degradation. We show here that in HT1080 cells, this transition is associated with weakened integrin-dependent adhesion, consistently reduced cell surface expression of the alpha 2 beta 1 integrin collagen receptor and impaired signalling downstream, as judged by reduced autophosphorylation of focal adhesion kinase (FAK). On examining cancer cells that use defined invasion strategies, we show that distinct from mesenchymal invasion, amoeboid invasion is independent of intracellular calpain 2 proteolytic activity that is usually needed for turnover of integrin-linked adhesions during two-dimensional planar migration. Moreover, an inhibitor of Rho/ROCK signalling, which specifically impairs amoeboid-like invasion, restores cell surface expression of alpha 2 beta 1 integrin, downstream FAK autophosphorylation and calpain 2 sensitivity - features of mesenchymal invasion. These findings link weakened integrin function to a lack of requirement for calpain 2-mediated integrin adhesion turnover during amoeboid invasion. In keeping with the need for integrin adhesion turnover, mesenchymal invasion is uniquely sensitive to Src inhibitors. Thus, the need for a major pathway that controls integrin adhesion turnover defines and distinguishes cancer cell invasion strategies.	Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	Beatson Institute; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Frame, MC (corresponding author), Canc Res UK Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland.	m.frame@beatson.gla.ac.uk		Frame, Margaret/0000-0001-5882-1942; Carragher, Neil/0000-0001-5541-9747				Adachi Y, 2001, TUMOR BIOL, V22, P247, DOI 10.1159/000050623; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brand K, 2000, CANCER RES, V60, P5723; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Carragher NO, 2003, CURR BIOL, V13, P1442, DOI 10.1016/S0960-9822(03)00544-X; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cooke DW, 2005, MOL CELL ENDOCRINOL, V232, P37, DOI 10.1016/j.mce.2004.12.008; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Franco SJ, 2004, NAT CELL BIOL, V6, P977, DOI 10.1038/ncb1175; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Friedl P, 2001, J LEUKOCYTE BIOL, V70, P491; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goss KJH, 1998, INT J CANCER, V78, P629; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jaspars LH, 1996, J PATHOL, V178, P36, DOI 10.1002/(SICI)1096-9896(199601)178:1<36::AID-PATH426>3.0.CO;2-S; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lokuta MA, 2003, P NATL ACAD SCI USA, V100, P4006, DOI 10.1073/pnas.0636533100; Lozonschi L, 1999, CANCER RES, V59, P1252; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Mamoune A, 2003, CANCER RES, V63, P4632; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Palecek SP, 1998, J CELL SCI, V111, P929; Pavlaki M, 2003, CANCER METAST REV, V22, P177, DOI 10.1023/A:1023047431869; Petroll WM, 2003, CELL MOTIL CYTOSKEL, V55, P254, DOI 10.1002/cm.10126; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rintoul RC, 2002, CLIN SCI, V102, P417, DOI 10.1042/CS20010216; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Shepherd FA, 2002, J CLIN ONCOL, V20, P4434, DOI 10.1200/JCO.2002.02.108; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001; Zamir E, 2001, J CELL SCI, V114, P3583; Zhai JB, 2003, J BIOL CHEM, V278, P24865, DOI 10.1074/jbc.M302381200; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	54	121	126	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2006	25	42					5726	5740		10.1038/sj.onc.1209582	http://dx.doi.org/10.1038/sj.onc.1209582			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652152				2022-12-17	WOS:000240765800004
J	Fedele, M; Pentimalli, F; Baldassarre, G; Battista, S; Klein-Szanto, AJP; Kenyon, L; Visone, R; De Martino, I; Ciarmiello, A; Arra, C; Viglietto, G; Croce, CM; Fusco, A				Fedele, M; Pentimalli, F; Baldassarre, G; Battista, S; Klein-Szanto, AJP; Kenyon, L; Visone, R; De Martino, I; Ciarmiello, A; Arra, C; Viglietto, G; Croce, CM; Fusco, A			Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell	ONCOGENE			English	Article						high-mobility group proteins; pituitary adenomas; NK1.1; IL-2; IL-15; lymphomas	EXPRESS HIGH-LEVELS; GROUP PROTEIN I(Y); HMGI(Y) PROTEINS; NEOPLASTIC TRANSFORMATION; C GENE; PHENOTYPE; REARRANGEMENTS; ACTIVATION; CARCINOMA; LIPOMAS	Overexpression of HMGA1 proteins is a constant feature of human carcinomas. Moreover, rearrangements of this gene have been detected in several human benign tumors of mesenchymal origin. To de. ne the role of these proteins in cell transformation in vivo, we have generated transgenic mice overexpressing ubiquitously the HMGA1 gene. These mice developed mixed growth hormone/prolactin cell pituitary adenomas and natural killer (NK)-T/NK cell lymphomas. The HMGA1-induced expression of IL-2 and IL-15 proteins and their receptors may account for the onset of these lymphomas. At odds with mice overexpressing a wild-type or a truncated HMGA2 protein, adrenal medullar hyperplasia and pancreatic islet cell hyperplasia frequently occurred and no increase in body size and weight was observed in HMGA1 mice. Taken together, these data indicate an oncogenic role of the HMGA1 gene also in vivo.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; Ist Tumori Napoli Fdn G Pascale, I-80131 Naples, Italy; NOGEC, CEINGE, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; Jefferson University; Fox Chase Cancer Center; Jefferson University; CEINGE Biotecnologie Avanzate	Fusco, A (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Battista, Sabrina/AAY-2981-2020; Pentimalli, Francesca/K-4936-2014; Baldassarre, Gustavo/K-1350-2016; visone, rosa/K-7910-2016; Young, Richard A/F-6495-2012; Viglietto, Giuseppe/AAC-2852-2019; Fedele, Monica/C-1417-2015	Battista, Sabrina/0000-0001-5899-9759; Pentimalli, Francesca/0000-0003-4740-6801; Baldassarre, Gustavo/0000-0002-9750-8825; Young, Richard A/0000-0001-8855-8647; Viglietto, Giuseppe/0000-0003-2327-7515; Fedele, Monica/0000-0002-9171-1312; Fusco, Alfredo/0000-0003-3332-5197; Ciarmiello, Andrea/0000-0002-6579-656X; VISONE, Rosa/0000-0002-4993-0220; Arra, Claudio/0000-0003-3162-2091; Kenyon, Lawrence/0000-0002-3719-9565				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berlingieri MT, 2002, ONCOGENE, V21, P2971, DOI 10.1038/sj.onc.1205368; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Di Noto R, 2001, LEUKEMIA, V15, P1641; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Fedele M, 1996, CANCER RES, V56, P1896; Fehniger TA, 2001, J EXP MED, V193, P219, DOI 10.1084/jem.193.2.219; Finelli P, 2002, CANCER RES, V62, P2398; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; TAMIMI Y, 1993, CANCER RES, V53, P5512; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; Wood LJ, 2000, CANCER RES, V60, P4256; Xiao S, 1997, AM J PATHOL, V150, P901; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	37	121	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3427	3435		10.1038/sj.onc.1208501	http://dx.doi.org/10.1038/sj.onc.1208501			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735694				2022-12-17	WOS:000229038800005
J	Sato, N; Parker, AR; Fukushima, N; Miyagi, Y; Iacobuzio-Donahue, C; Eshleman, JR; Goggins, M				Sato, N; Parker, AR; Fukushima, N; Miyagi, Y; Iacobuzio-Donahue, C; Eshleman, JR; Goggins, M			Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						methylation; pancreatic cancer; invasion; protease inhibitor	FACTOR PATHWAY INHIBITOR-2; METHYLATION-SPECIFIC PCR; MATRIX-METALLOPROTEINASE EXPRESSION; HUMAN CANCER-CELLS; HUMAN GLIOMAS; CHORIOCARCINOMA CELLS; PROTEASE INHIBITOR; MOLECULAR-CLONING; CPG-ISLANDS; IN-VITRO	Using microarrays, we have screened for genes reactivated by drugs that modify epigenetic mechanisms in pancreatic cancer cells. One of the genes identified was tissue factor pathway inhibitor 2 (TFPI-2), which encodes for a broad-spectrum serine proteinase inhibitor that negatively regulates the extracellular matrix degradation, an essential step in tumor invasion and metastasis. We therefore investigated the expression and methylation patterns of the TFPI-2 gene in pancreatic adenocarcinoma, and determined its role in tumor growth and invasion. In contrast to its abundant expression in normal pancreas, TFPI-2 mRNA was undetectable in a high fraction of pancreatic cancer cell lines and in primary pancreatic ductal neoplasms (IPMNs). Loss of TFPI-2 expression was associated with aberrant hypermethylation of its promoter CpG island. Treatment with the phorbol ester (PMA), known to stimulate the TFPI-2 promoter activity, augmented the TFPI-2 expression in cell lines with unmethylated or partially methylated TFPI-2, but failed to induce the expression in cell lines that harbored fully methylated TFPI-2. Aberrant methylation of TFPI-2 was also detected in 73% (102/140) of pancreatic cancer xenografts and primary pancreatic adenocarcinomas, was more likely in older patients with pancreatic cancer, and significantly correlated with progression of IPMNs (P = 0.0002). Restored expression of the TFPI-2 gene in nonexpressing pancreatic cancer cells resulted in marked suppression in their proliferation, migration, and invasive potential in vitro. We thus conclude that epigenetic inactivation of TFPI-2 is a common mechanism that contributes to the aggressive phenotype of pancreatic ductal adenocarcinoma.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Kanagawa Canc Ctr, Div Tumor Pathol, Yokohama, Kanagawa 2410815, Japan	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Kanagawa Prefectural Cancer Center	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave,241-0815, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NCI NIH HHS [CA62924, CA90709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA090709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Chand HS, 2004, BLOOD, V103, P1069, DOI 10.1182/blood-2003-06-1930; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Ellenrieder V, 1999, ANN ONCOL, V10, P46, DOI 10.1023/A:1008380501633; Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3; Fukushima N, 2003, CANCER BIOL THER, V2, P78; HAHN SA, 1995, CANCER RES, V55, P4670; Harden SV, 2003, J NATL CANCER I, V95, P1634, DOI 10.1093/jnci/djg082; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hube F, 2003, BIOL CHEM, V384, P1029, DOI 10.1515/BC.2003.115; Iacobuzio-Donahue CA, 2004, CANCER RES, V64, P871, DOI 10.1158/0008-5472.CAN-03-2756; Izumi H, 2000, FEBS LETT, V481, P31, DOI 10.1016/S0014-5793(00)01902-5; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jin MS, 2001, GYNECOL ONCOL, V83, P325, DOI 10.1006/gyno.2001.6394; Kast C, 2003, J BIOL CHEM, V278, P6787, DOI 10.1074/jbc.M210935200; Kern SE, 2000, MED CLIN N AM, V84, P691, DOI 10.1016/S0025-7125(05)70251-0; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Konduri SD, 2002, ONCOGENE, V21, P921, DOI 10.1038/sj.onc.1204983; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyagi Y, 1996, GENOMICS, V35, P267, DOI 10.1006/geno.1996.0353; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Rao CN, 2003, INT J ONCOL, V22, P843; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; Shinoda E, 1999, J BIOL CHEM, V274, P5379, DOI 10.1074/jbc.274.9.5379; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tanaka Y, 2004, INVEST OPHTH VIS SCI, V45, P245, DOI 10.1167/iovs.03-0230; Tasiou A, 2001, INT J ONCOL, V19, P591; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wojtukiewicz MZ, 2003, THROMB HAEMOSTASIS, V90, P140	41	121	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					850	858		10.1038/sj.onc.1208050	http://dx.doi.org/10.1038/sj.onc.1208050			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592528				2022-12-17	WOS:000226577100011
J	Gondi, CS; Lakka, SS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Gondi, CS; Lakka, SS; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas	ONCOGENE			English	Article						gliomas; invasion; cathepsin and uPAR; RNA interference; angiogenesis	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; CYSTEINE PROTEINASE-INHIBITORS; IN-VIVO; UROKINASE RECEPTOR; CYSTATIN-C; TISSUE INHIBITORS; COLORECTAL-CANCER; MICE; LOCALIZATION	RNA interference (RNAi) provides a powerful method for gene silencing in eukaryotic cells, including proliferating mammalian cells. Here, we determined whether RNAi could be utilized to inhibit the expression of proteases implicated in the extracellular matrix degradation, which is characteristic of tumor progression. We have previously shown that antisense stable clones of uPAR and cathepsin B were less invasive and did not form tumors when injected intracranially ex vivo. Since antisense-mediated gene silencing does not completely inhibit the translation of target mRNA and high molar concentrations of antisense molecules are required to achieve gene silencing, we used the RNAi approach to silence uPAR and cathepsin B in this study. We found that the expression of double-stranded RNA leads to the efficient and specific inhibition of endogenous uPAR and cathepsin B protein expression in glioma cell lines as determined by Western blotting. We also found the RNAi of uPAR and cathepsin B reduces glioma cell invasion and angiogenesis in in vitro and in vivo models. Intratumoral injections of plasmid vectors expressing hpRNA for uPAR and cathepsin B resulted in the regression of pre-established intracranial tumors. Further, RNAi for uPAR and cathepsin B inhibited cell proliferation and reduced the levels of pERK and pFAK compared to controls. Taken together, our findings indicate for the first time that RNAi operates in human glioma cells with potential application for cancer gene therapy.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA085216, R01CA092393] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75557, CA 85216, CA 92393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Alonso DF, 1998, ANTICANCER RES, V18, P4499; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Bervar A, 2003, BIOL CHEM, V384, P447, DOI 10.1515/BC.2003.050; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Evens DM, 1998, CLIN EXP METASTAS, V16, P353; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; GLADSON CL, 1995, AM J PATHOL, V146, P1150; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hazen LGM, 2000, J HISTOCHEM CYTOCHEM, V48, P1421, DOI 10.1177/002215540004801012; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; Kisker O, 2001, CANCER RES, V61, P7669; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; KOBAYASHI H, 1993, JPN J CANCER RES, V84, P633, DOI 10.1111/j.1349-7006.1993.tb02023.x; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; Kos J, 2000, CLIN CANCER RES, V6, P505; Kostoulas G, 1999, FEBS LETT, V455, P286, DOI 10.1016/S0014-5793(99)00897-2; Kruger S, 1999, CANCER RES, V59, P6010; LEUNIG M, 1992, CANCER RES, V52, P6553; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McGuire PG, 2003, INVEST OPHTH VIS SCI, V44, P2736, DOI 10.1167/iovs.02-1160; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Min HY, 1996, CANCER RES, V56, P2428; Mohan PM, 1999, CANCER RES, V59, P3369; Mohanam S, 2002, ONCOGENE, V21, P7824, DOI 10.1038/sj.onc.1205893; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; MURPHY G, 1992, ANN NY ACAD SCI, V667, P1, DOI 10.1111/j.1749-6632.1992.tb51590.x; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Planus E, 1997, J CELL SCI, V110, P1091; REDWOOD SM, 1992, CANCER, V69, P1212; REMPEL SA, 1994, CANCER RES, V54, P6027; Reuning U, 1998, INT J ONCOL, V13, P893; Sato S, 2002, FEBS LETT, V528, P212, DOI 10.1016/S0014-5793(02)03311-2; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; SINHA AA, 1995, PROSTATE, V26, P171, DOI 10.1002/pros.2990260402; SIVAPARVATHI M, 1995, CLIN EXP METASTAS, V13, P49, DOI 10.1007/BF00144018; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Szpaderska AM, 2001, CANCER RES, V61, P3493; Vallera DA, 2002, J NATL CANCER I, V94, P597; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	57	121	138	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8486	8496		10.1038/sj.onc.1207879	http://dx.doi.org/10.1038/sj.onc.1207879			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378018				2022-12-17	WOS:000224870700009
J	Martin, GS				Martin, GS			The road to Src	ONCOGENE			English	Review						Src; Rous sarcoma virus; oncogene; cancer; tyrosine kinase	ROUS-SARCOMA-VIRUS; TEMPERATURE-SENSITIVE MUTANTS; DEPENDENT DNA-POLYMERASE; PP60C-SRC PROTEIN-KINASE; AMINO-ACID-SEQUENCE; C-SRC; NUCLEOTIDE-SEQUENCE; TRANSFORMING GENE; TYROSINE KINASE; V-SRC	More than a quarter of a century has elapsed since the identification of the c-src proto-oncogene. During that period, we have learned that cancer arises as the result of mutations in proto-oncogenes and tumor suppressor genes, and we are now seeing the first fruits of these discoveries, in the form of targeted therapies directed against activated tyrosine kinases such as Bcr-Abl, c-Kit and the EGF receptor. But the discovery of the c-src proto-oncogene was in turn based on decades of study on an avian RNA tumor virus, Rous sarcoma virus (RSV). Here I review the work that led up to the identification of the RSV transforming gene and its protein product, and how this information in turn led to the discovery of cellular Src.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Martin, GS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall 3204, Berkeley, CA 94720 USA.	smartin@socrates.berkeley.edu	Martin, Greg/B-4085-2009	Martin, Greg/0000-0002-9684-7593	NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NCI NIH HHS [CA17542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrewes C H, 1971, Biogr Mem Fellows R Soc, V17, P643, DOI 10.1098/rsbm.1971.0025; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARKER WC, 1982, P NATL ACAD SCI-BIOL, V79, P2836, DOI 10.1073/pnas.79.9.2836; BEEMON K, 1977, P NATL ACAD SCI USA, V74, P3302, DOI 10.1073/pnas.74.8.3302; BERNSTEIN A, 1976, VIROLOGY, V70, P206, DOI 10.1016/0042-6822(76)90254-3; BISHOP JM, 2003, WIN NOBEL PRIZE; BLACK PH, 1963, P NATL ACAD SCI USA, V50, P1148, DOI 10.1073/pnas.50.6.1148; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BRYAN WR, 1955, JNCI-J NATL CANCER I, V16, P317; Cairns J., 1992, PHAGE ORIGINS MOL BI; COFFIN JM, 1997, RETROVIRUSES; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CRAWFORD LV, 1960, VIROLOGY, V12, P143, DOI 10.1016/0042-6822(60)90190-2; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; CZERNILOFSKY AP, 1983, NATURE, V301, P736, DOI 10.1038/301736b0; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; DOUGHERTY RM, 1965, VIROLOGY, V27, P351, DOI 10.1016/0042-6822(65)90115-7; DUESBERG PH, 1970, P NATL ACAD SCI USA, V67, P1673, DOI 10.1073/pnas.67.4.1673; DUESBERG PH, 1968, P NATL ACAD SCI USA, V60, P1511, DOI 10.1073/pnas.60.4.1511; DULBECCO R, 1953, COLD SPRING HARB SYM, V18, P273, DOI 10.1101/SQB.1953.018.01.039; DUTTA A, 1985, J VIROL, V55, P728, DOI 10.1128/JVI.55.3.728-735.1985; ECKHART W, 1979, CELL, V18, P925, DOI 10.1016/0092-8674(79)90205-8; EDGAR RS, 1964, GENETICS, V49, P649; Ellerman V., 1908, ZBL BAKT, V46, P595; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; FRIED M, 1965, P NATL ACAD SCI USA, V53, P486, DOI 10.1073/pnas.53.3.486; Fujinami A, 1914, Z KREBSFORSCH, V14, P94, DOI DOI 10.1007/BF02137232; GOLDE A, 1966, CR ACAD SCI D NAT, V262, P329; GOLDE A, 1966, CR ACAD SCI D NAT, V262, P420; GOLDE A, 1970, VIROLOGY, V40, P1022, DOI 10.1016/0042-6822(70)90148-0; Gross L., 1983, ONCOGENIC VIRUSES; Halberstaedter L, 1941, BRIT J EXP PATHOL, V22, P179; HANAFUSA H, 1963, P NATL ACAD SCI USA, V49, P572, DOI 10.1073/pnas.49.4.572; HANAFUSA H, 1965, VIROLOGY, V25, P248, DOI 10.1016/0042-6822(65)90203-5; HUEBNER RJ, 1969, P NATL ACAD SCI USA, V64, P1087, DOI 10.1073/pnas.64.3.1087; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JACOBS C, 1983, CANCER RES, V43, P1696; KAMINE J, 1977, P NATL ACAD SCI USA, V74, P2011, DOI 10.1073/pnas.74.5.2011; Keogh EV, 1938, BRIT J EXP PATHOL, V19, P1; LERNER TL, 1984, J VIROL, V49, P549, DOI 10.1128/JVI.49.2.549-556.1984; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; MANAKER RA, 1956, VIROLOGY, V2, P838, DOI 10.1016/0042-6822(56)90064-2; MARTIN GS, 1972, VIROLOGY, V47, P494, DOI 10.1016/0042-6822(72)90287-5; MARTIN GS, 1970, NATURE, V227, P1021, DOI 10.1038/2271021a0; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; ROBINSON WS, 1965, P NATL ACAD SCI USA, V54, P137, DOI 10.1073/pnas.54.1.137; ROBINSON WS, 1967, P NATL ACAD SCI USA, V58, P825, DOI 10.1073/pnas.58.3.825; Rous P, 1911, J AMER MED ASSOC, V56, P741; Rous P, 1914, J EXP MED, V19, P52, DOI 10.1084/jem.19.1.52; Rous P, 1911, J EXP MED, V13, P397, DOI 10.1084/jem.13.4.397; Rous P, 1910, J EXP MED, V12, P696, DOI 10.1084/jem.12.5.696; RUBIN H, 1960, P NATL ACAD SCI USA, V46, P1105, DOI 10.1073/pnas.46.8.1105; RUBIN H, 1961, VIROLOGY, V13, P200, DOI 10.1016/0042-6822(61)90054-X; RUBIN H, 1955, VIROLOGY, V1, P445, DOI 10.1016/0042-6822(55)90037-4; RUBIN H, 1962, VIROLOGY, V17, P184, DOI 10.1016/0042-6822(62)90096-X; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHMIDTRUPPIN KH, 1959, SONDERBAND STRAHLENT, V41, P26; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SHALLOWAY D, 1981, CELL, V24, P531, DOI 10.1016/0092-8674(81)90344-5; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIMONS PJ, 1963, JNCI-J NATL CANCER I, V31, P1275; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STEHELIN D, 1976, J MOL BIOL, V101, P349, DOI 10.1016/0022-2836(76)90152-2; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; SVETMOLDAVSKY GJ, 1958, NATURE, V182, P1452, DOI 10.1038/1821452b0; SVETMOLDAVSKY GJ, 1957, NATURE, V180, P1299, DOI 10.1038/1801299a0; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; TEMIN HM, 1958, VIROLOGY, V6, P669, DOI 10.1016/0042-6822(58)90114-4; TEMIN HM, 1962, COLD SPRING HARB SYM, V27, P407, DOI 10.1101/SQB.1962.027.001.038; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOYOSHIMA K, 1969, VIROLOGY, V39, P930, DOI 10.1016/0042-6822(69)90030-0; TOYOSHIMA K, 1970, VIROLOGY, V42, P163, DOI 10.1016/0042-6822(70)90249-7; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; VOGT PK, 1967, P NATL ACAD SCI USA, V58, P801, DOI 10.1073/pnas.58.3.801; VOGT PK, 1971, VIROLOGY, V46, P939, DOI 10.1016/0042-6822(71)90092-4; WANG LH, 1976, P NATL ACAD SCI USA, V73, P447, DOI 10.1073/pnas.73.2.447; Waterson A. P., 1978, INTRO HIST VIROLOGY; WEISS SR, 1977, CELL, V12, P983, DOI 10.1016/0092-8674(77)90163-5; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; ZIL'BER L A, 1958, Vopr Virusol, V3, P166; ZILBER L A, 1957, Acta Virol, V1, P156	100	121	132	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					7910	7917		10.1038/sj.onc.1208077	http://dx.doi.org/10.1038/sj.onc.1208077			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489909				2022-12-17	WOS:000224558300002
J	Michels, J; O'Neill, JW; Dallman, CL; Mouzakiti, A; Habens, F; Brimmell, M; Zhang, KYJ; Craig, RW; Marcusson, EG; Johnson, PWM; Packham, G				Michels, J; O'Neill, JW; Dallman, CL; Mouzakiti, A; Habens, F; Brimmell, M; Zhang, KYJ; Craig, RW; Marcusson, EG; Johnson, PWM; Packham, G			Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage	ONCOGENE			English	Article						apoptosis; Mcl-1; antisense; non-Hodgkin's lymphoma; Bcl-2; caspase	CHRONIC LYMPHOCYTIC-LEUKEMIA; APOPTOSIS-REGULATING PROTEINS; BCL-2 FAMILY; IN-VIVO; EXPRESSION; HOMOLOG; DIFFERENTIATION; ACTIVATION; PROTECTS; MYELOMA	Enforced expression of the antiapoptotic Bcl-2 family protein Mcl-1 promotes lymphomagenesis in the mouse; however, the functional role of Mcl-1 in human B-cell lymphoma remains unclear. We demonstrate that Mcl-1 is widely expressed in malignant B-cells, and high-level expression of Mcl-1 is required for B-lymphoma cell survival, since transfection of Mcl-1-specific antisense oligodeoxynucleotides was sufficient to promote apoptosis in Akata6 lymphoma cells. Mcl-1 was efficiently cleaved by caspases at evolutionarily conserved aspartic acid residues in vitro, and during cisplatin-induced apoptosis in B-lymphoma cell lines and spontaneous apoptosis of primary malignant B-cells. Overexpression of the Mcl-1 cleavage product that accumulated during apoptosis was sufficient to kill cells. Therefore, Mcl-1 is an essential survival molecule for B-lymphoma cells and is cleaved by caspases to a death-promoting molecule during apoptosis. In contrast to Mcl-1, Bcl-2 and Bcl-X-L were relatively resistant to caspase cleavage in vitro and in intact cells. Interfering with Mcl-1 function appears to be an effective means of inducing apoptosis in Mcl-1-positive B-cell lymphoma, and the unique sensitivity of Mcl-1 to caspase-mediated cleavage suggests an attractive strategy for converting it to a proapoptotic molecule.	Univ Southampton, Sch Med, Canc Sci Div, Canc Res UK Oncol Unit, Southampton, Hants, England; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	University of Southampton; Fred Hutchinson Cancer Center; Dartmouth College; Isis Pharmaceuticals Inc	Packham, G (corresponding author), Southampton Gen Hosp, Canc Res UK Oncol Unit, Somers Canc Res Bldg MP824,Tremona Rd, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/L-2403-2018; Zhang, Kam Y. J./B-3552-2012; Johnson, Peter/O-3529-2019	Johnson, Peter/0000-0003-2306-4974; Zhang, Kam Y. J./0000-0002-9282-8045; Johnson, Peter/0000-0003-2306-4974; Marcusson, Eric/0000-0002-0504-8674; Packham, Graham/0000-0002-9232-5691	NATIONAL CANCER INSTITUTE [R01CA057359] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA57359] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Agarwal B, 2002, AM J HEMATOL, V70, P278, DOI 10.1002/ajh.10139; Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Altmeyer A, 1997, IMMUNITY, V7, P667, DOI 10.1016/S1074-7613(00)80387-8; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Bellosillo B, 1999, BLOOD, V94, P2836, DOI 10.1182/blood.V94.8.2836.420k35_2836_2843; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; Chen MC, 2001, BBA-GENE STRUCT EXPR, V1519, P127, DOI 10.1016/S0167-4781(01)00209-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRAIG RW, 1984, CANCER RES, V44, P2421; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; DALLMAN CL, 2004, IN PRESS MOL METHODS; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Drexler HG., 2001, LEUKEMIA LYMPHOMA CE, P2, DOI [10.1016/B978-012221970-2/50002-4, DOI 10.1016/B978-012221970-2/50002-4]; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Khoury JD, 2003, J PATHOL, V199, P90, DOI 10.1002/path.1254; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lenoir G M, 1985, IARC Sci Publ, P309; Lomo J, 1996, CANCER RES, V56, P40; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NIHAWAN D, 2003, GENE DEV, V17, P1475; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; OXFORD SME, 2004, IN PRESS CURRENT MED; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Packham G, 1998, APOPTOSIS, V3, P75, DOI 10.1023/A:1009688706783; Pagnano KBB, 2002, ACTA HAEMATOL-BASEL, V107, P29, DOI 10.1159/000046626; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pepper C, 2002, EUR J HAEMATOL, V69, P227, DOI 10.1034/j.1600-0609.2002.02799.x; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Soini Y, 1998, TUMOR BIOL, V19, P176, DOI 10.1159/000030005; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spets H, 2002, EUR J HAEMATOL, V69, P76, DOI 10.1034/j.1600-0609.2002.01549.x; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vrana JA, 2002, CANCER RES, V62, P892; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	51	121	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4818	4827		10.1038/sj.onc.1207648	http://dx.doi.org/10.1038/sj.onc.1207648			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122313				2022-12-17	WOS:000222104200002
J	Dai, Y; Rahmani, M; Grant, S				Dai, Y; Rahmani, M; Grant, S			Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappa B-dependent process	ONCOGENE			English	Article						apoptosis; proteasome inhibitor; flavopiridol; NF-kappa B; JNK	MULTIPLE-MYELOMA CELLS; BREAST-CARCINOMA CELLS; CYTOCHROME-C RELEASE; CANCER-THERAPY; TRANSCRIPTIONAL REPRESSION; SYNERGISTIC INDUCTION; ENDOTHELIAL-CELLS; DOWN-REGULATION; PS-341; MITOCHONDRIAL	Interactions between proteasome and cyclin-dependent kinase inhibitors have been examined in human leukemia cells in relation to induction of apoptosis. Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nm flavopiridol and 300 nm MG-132 resulted in a marked increase in mitochondrial injury ( cytochrome c, Smac/DIABLO release, loss of DeltaPsim), caspase activation, and synergistic induction of cell death, accompanied by a marked decrease in clonogenic potential. Similar effects were observed with other proteasome inhibitors (e. g., Bortezomib (VELCADE(TM) bortezomib or injection), lactacystin, LLnL) and cyclin-dependent kinase inhibitors (e. g., roscovitine), as well as other leukemia cell types (e.g., HL-60, Jurkat, Raji). In U937 cells, synergistic interactions between MG-132 and. avopiridol were associated with multiple perturbations in expression/activation of signaling- and survival-related proteins, including downregulation of XIAP and Mcl-1, activation of JNK and p34(cdc2), and diminished expression of p21(CIP1). The lethal effects of MG-132/flavopiridol were not reduced in leukemic cells ectopically expressing Bcl-2, but were partially attenuated in cells ectopically expressing dominant-negative caspase-8 or CrmA. Flavopiridol/proteasome inhibitor-mediated lethality was also significantly diminished by agents and siRNA blocking JNK activation. Lastly, coadministration of MG-132 with. avopiridol resulted in diminished DNA binding of NF-kappaB. Notably, pharmacologic interruption of the NF-kappaB pathway (e. g., by BAY 11-7082, PDTC, or SN-50) or molecular dysregulation of NF-kappaB (i.e., in cells ectopically expressing an IkappaBalpha super-repressor) mimicked the actions of proteasome inhibitors in promoting flavopiridol-induced mitochondrial injury, JNK activation, and apoptosis. Together, these findings indicate that proteasome inhibitors strikingly lower the apoptotic threshold of leukemic cells exposed to pharmacologic CDK inhibitors, and suggest that interruption of the NF-kappaB cytoprotective pathway and JNK activation both play key roles in this phenomenon. They also raise the possibility that combining proteasome and CDK inhibitors could represent a novel antileukemic strategy.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.		Dai, Yun/AAG-4040-2019	Dai, Yun/0000-0003-2285-0818; Rahmani, Mohamed/0000-0002-3992-8039	NCI NIH HHS [CA63753, CA93738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Carlson B, 1999, CANCER RES, V59, P4634; Carlson BA, 1996, CANCER RES, V56, P2973; Cartee L, 2002, MOL PHARMACOL, V61, P1313, DOI 10.1124/mol.61.6.1313; Cartee L, 2001, CANCER RES, V61, P2583; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Dai Y, 2001, CANCER RES, V61, P5106; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Decker RH, 2001, CELL DEATH DIFFER, V8, P715, DOI 10.1038/sj.cdd.4400868; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldberg AL, 2002, NAT MED, V8, P338, DOI 10.1038/nm0402-338; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Karp JE, 2003, CLIN CANCER RES, V9, P307; Kim DM, 2003, CANCER RES, V63, P621; Kitada S, 2000, BLOOD, V96, P393; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Ogiso Y, 2000, CANCER RES, V60, P2429; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Porcile C, 2002, ANN NY ACAD SCI, V973, P402, DOI 10.1111/j.1749-6632.2002.tb04673.x; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rosato RR, 2002, MOL CANCER THER, V1, P253; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tan C, 2002, CANCER RES, V62, P1083; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tang L, 2000, BIOCHEM PHARMACOL, V60, P1445, DOI 10.1016/S0006-2952(00)00463-9; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; Wittmann S, 2003, CANCER RES, V63, P93; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	65	121	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7108	7122		10.1038/sj.onc.1206863	http://dx.doi.org/10.1038/sj.onc.1206863			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562039				2022-12-17	WOS:000185955000002
J	Zhang, XD; Borrow, JM; Zhang, XY; Nguyen, T; Hersey, P				Zhang, XD; Borrow, JM; Zhang, XY; Nguyen, T; Hersey, P			Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria	ONCOGENE			English	Article						melanoma; TRAIL; Erk1/2; apoptosis; Smac/DIABLO	NF-KAPPA-B; BCL-X-L; ANTITUMOR-ACTIVITY; CYTOCHROME-C; BAX; FAMILY; LIGAND; RECEPTOR; KINASE; MEMBER	We have previously shown that Smac/DIABLO release from mitochondria appears to be the principal pathway by which TRAIL induces apoptosis of human melanoma. We report that TRAIL-induced release of Smac/DIABLO appears to be downregulated by concomitant signaling through the MEK Erk1/2 kinase pathway and that this inhibits TRAIL-induced apoptosis. Inhibition of Erk1/2 signaling by either the MEK inhibitor U0126 or a dominant-negative mutant of MKK1 markedly sensitized melanoma cells to TRAIL-induced apoptosis. The site in the apoptotic pathway acted on by U0126 appeared to be downstream of caspase-8 and Bid but upstream of caspase-3 in that the levels of proteolytic cleavage of caspase-8 and Bid by TRAIL were similar in cells with or without exposure to U0126. Caspase-3 activation and cleavage of its substrates, PARP, ICAD and XIAP, were however increased by cotreatment with U0126. This was associated with a rapid reduction in mitochondrial transmembrane potential (MMP) and increased release of Smac/DIABLO into the cytosol. Exploration of events leading to the changes in MMP revealed an increased translocation of Bax from the cytosol to mitochondria in the presence of U0126. There was also a delayed decrease in the levels of expression of Mcl-1. Bcl-2 and BCI-X-L. Over expression of Bcl-2 blocked TRAIL-induced apoptosis in the presence of U0126. Cytochrome c appeared not to play a major role in sensitization of melanoma to TRAIL in that caspase-9 activation was not detected in most of the cell lines. These results suggest that Erk1/2 signaling may protect melanoma cells against TRAIL-induced apoptosis by inhibiting the relocation of Bax from the cytosol to mitochondria and that this may reduce TRAIL-mediated release of Smac/DIABLO and induction of apoptosis.	Immunol & Oncol Unit, Newcastle, NSW 2300, Australia		Hersey, P (corresponding author), Immunol & Oncol Unit, Room 443,David Maddison Clin Sci Bldg,Cnr King &, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au	zhang, xu/GRX-9733-2022; zhang, xian/GYA-0290-2022; zhang, xu/GYE-3558-2022; Zhang, xiaoyu/GXA-3206-2022	Zhang, Xu Dong/0000-0001-9457-8003				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Bouillet P, 2002, J CELL SCI, V115, P1567; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dai Y, 2001, CANCER RES, V61, P5106; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Franco AV, 2001, J IMMUNOL, V166, P5337, DOI 10.4049/jimmunol.166.9.5337; Ganju N, 2002, BIOCHEM BIOPH RES CO, V291, P1258, DOI 10.1006/bbrc.2002.6584; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ozoren N, 2000, CANCER RES, V60, P6259; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Sabol SL, 1998, BIOCHEM BIOPH RES CO, V253, P151, DOI 10.1006/bbrc.1998.9770; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	43	121	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2869	2881		10.1038/sj.onc.1206427	http://dx.doi.org/10.1038/sj.onc.1206427			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771938				2022-12-17	WOS:000182824800002
J	Garcia-Fernandez, LF; Losada, A; Alcaide, V; Alvarez, AM; Cuadrado, A; Gonzalez, L; Nakayama, K; Nakayama, KI; Fernandez-Sousa, JM; Munoz, A; Sanchez-Puelles, JM				Garcia-Fernandez, LF; Losada, A; Alcaide, V; Alvarez, AM; Cuadrado, A; Gonzalez, L; Nakayama, K; Nakayama, KI; Fernandez-Sousa, JM; Munoz, A; Sanchez-Puelles, JM			Aplidin (TM) induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta	ONCOGENE			English	Article						Aplidin (TM); oxidative damage; JNK; p38; caspascs; PKC-delta	N-TERMINAL KINASE; SIGNAL-REGULATED KINASE; CELL-DEATH; GAMMA-RADIATION; GLUTATHIONE; CASPASES; DIDEMNIN; ALPHA; BCL-2; ERK	Aplidin(TM), a new antitumoural drug presently in phase II clinical trials, has shown both in vitro and in vivo activity against human cancer cells. Aplidin(TM) effectively inhibits cell viability by triggering a canonical apoptotic program resulting in alterations in cell morphology, caspase activation, and chromatin fragmentation. Pro-apoptotic concentrations of Aplidin(TM) induce early oxidative stress, which results in a rapid and persistent activation of both JNK and p38 MAPK and a biphasic activation of ERK. Inhibition of JNK and p38 MAPK blocks the apoptotic program induced by Aplidin(TM), demonstrating its central role in the integration of the cellular stress induced by the drug. JNK and p38 MAPK activation results in downstream cytochrome c release and activation of caspases -9 and -3 and PARP cleavage, demonstrating the mediation of the mitochondrial apoptotic pathway in this process. We also demonstrate that protein kinase C delta (PKC-delta) mediates the cytotoxic effect of Aplidin(TM), and that it is concomitantly processed and activated late in the apoptotic process by a caspase mediated mechanism. Remarkably, cells deficient in PKC-delta show enhanced survival upon drug treatment as compared to its wild type counterpart. PKC-delta thus appears as an important component necessary for full caspase cascade activation and execution of apoptosis, which most probably initiates a positive feedback loop further amplifying the apoptotic process.	PharmaMar SA, Drug Discovery Dept, E-28760 Madrid, Spain; Univ Complutense Madrid, Fac Farm, Ctr Citrometria Flujo, E-28040 Madrid, Spain; UAM, CSIC, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cell Biol, Fukuoka 8128582, Japan	PharmaMar; Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Kyushu University; Kyushu University	Sanchez-Puelles, JM (corresponding author), PharmaMar SA, Drug Discovery Dept, E-28760 Madrid, Spain.	jmspuelles@pharmamar.com	Alvarez-Barrientos, Alberto/L-9299-2014; Losada, Alejandro/AAW-8589-2021; Cuadrado, Ana/AAA-9277-2019; Munoz, Alberto/O-6393-2014; Cuadrado, Ana/HGU-4777-2022; Sanchez-Puelles, Jose Maria/E-4159-2018	Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Cuadrado, Ana/0000-0002-9752-5932; Munoz, Alberto/0000-0003-3890-4251; Sanchez-Puelles, Jose Maria/0000-0002-4283-4885				Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; ANTHONEY A, 2000, J CLIN ONCOL S, V19, pA734; ARMAND JP, 2001, P AM SOC CLIN ONCOL, V20; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BOWMAN A, 2001, P AM SOC CLIN ONCOL, V20; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BROGGINI M, 2000, P 11 NCI EORTC AACR; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CIRUELOS EM, 2002, P AM SOC CLIN ONCOL, V20; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Crews CM, 1996, P NATL ACAD SCI USA, V93, P4316, DOI 10.1073/pnas.93.9.4316; CREWS CM, 1994, J BIOL CHEM, V269, P15411; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Ding W, 2000, TOXICOL APPL PHARM, V162, P93, DOI 10.1006/taap.1999.8829; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; ERBA E, 1999, P AACR NCI EORTC INT; FAIRCLOTH G, 1999, P AM ASS CANC RES, V40; FAIRCLOTH G, 1998, P AM ASS CANC RES, V39; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Grubb DR, 2001, ONCOGENE, V20, P4085, DOI 10.1038/sj.onc.1204545; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hay E, 2001, J BIOL CHEM, V276, P29028, DOI 10.1074/jbc.M011265200; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hofmann J, 2001, REV PHYSIOL BIOCH P, V142, P1, DOI 10.1007/BFb0117491; Huang CS, 1999, CANCER RES, V59, P3053; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kang Yup, 2000, Molecular Cell Biology Research Communications, V4, P181, DOI 10.1006/mcbr.2001.0276; KOJI U, 1999, J BIOL CHEM, V274, P2234; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Krupinski J, 2000, NEUROBIOL DIS, V7, P332, DOI 10.1006/nbdi.2000.0310; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LESZCZYNSKI D, 1995, ONCOL RES, V7, P471; LUCAS M, 1995, GEN PHARMACOL, V26, P881, DOI 10.1016/0306-3623(94)00295-X; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAUROUN JA, 2001, P AM SOC CLIN ONCOL, V20; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Miyanishi K, 2001, GASTROENTEROLOGY, V121, P865, DOI 10.1053/gast.2001.27982; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Persons DL, 1999, CLIN CANCER RES, V5, P1007; POOT M, 1995, J CELL PHYSIOL, V163, P555, DOI 10.1002/jcp.1041630316; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rinehart KL, 2000, MED RES REV, V20, P1; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schnelldorfer T, 2000, CANCER-AM CANCER SOC, V89, P1440, DOI 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.3.CO;2-S; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; STEMPKA L, 1998, ASBMB S PROT KIN C C; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Whelan R D, 1989, Cancer Commun, V1, P359; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Yu WP, 2001, CANCER RES, V61, P6569; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	77	121	125	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2002	21	49					7533	7544		10.1038/sj.onc.1205972	http://dx.doi.org/10.1038/sj.onc.1205972			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386816				2022-12-17	WOS:000178618200009
J	Bahassi, EM; Conn, CW; Myer, DL; Hennigan, RF; McGowan, CH; Sanchez, Y; Stambrook, PJ				Bahassi, EM; Conn, CW; Myer, DL; Hennigan, RF; McGowan, CH; Sanchez, Y; Stambrook, PJ			Mammalian Polo-like kinase 3 (PIU) is a multifunctional protein involved in stress response pathways	ONCOGENE			English	Article						Plk3; ATM; P53; Chk2; Cdc25c; ionizing radiation	CELL-CYCLE REGULATION; DNA-DAMAGE CHECKPOINT; SERINE/THREONINE KINASE; INDUCED PHOSPHORYLATION; CYTOKINESIS; EXPRESSION; DROSOPHILA; CHK2; ATM; P53	The Polo-like kinases (Plks) are a conserved family of kinases that contribute to cell cycle regulation, particularly in G2 and mitosis. In mammals, there are at least three members of the Plk family. Here we show that Plk3 is a stress response protein that becomes phosphorylated following DNA damage or mitotic spindle disruption. Phosphorylation enhances its kinase activity and is dependent upon ataxia telangiectasia-mutated (ATM) in the former case but not the latter. Plk3 associates with complexes of multiple sizes ranging from 150 to greater then 600 kDa. In its unphosphorylated form it elutes from a sizing column at about 400 kDa whereas it associates with complexes of 150 and 600 kDa when phosphorylated. Among the proteins with which it physically associates and utilizes, as substrates are Chk2 and P53. It phosphorylates Chk2 on a residue different from threonine 68 (Thr68), the principal target for ATM. While ATM is necessary for phosphorylation and activation of Chk2 in vivo, Plk3 seems to contribute to its full activation. In its phosphorylated form it also coelutes and forms a complex with unpolymerized tubulin. In aggregate, the data argue that Plk3 is a multifunctional protein that associates with multiple complexes and that contributes to response to stress incurred by DNA damage and mitotic spindle disruption, albeit via different pathways.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; Scripps Res Inst, Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University System of Ohio; University of Cincinnati; St Jude Children's Research Hospital; Scripps Research Institute	Stambrook, PJ (corresponding author), Univ Cincinnati, Med Ctr, Dept Anat Cell Biol & Neurobiol, Vontz Ctr Mol Studies, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu						BAHASSI E, 2001, CANC RES ALERT, V12, P133; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; Conn CW, 2000, CANCER RES, V60, P6826; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; SUNKEL CE, 1988, J CELL SCI, V89, P25; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200	32	121	128	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6633	6640		10.1038/sj.onc.1205850	http://dx.doi.org/10.1038/sj.onc.1205850			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM					2022-12-17	WOS:000178202300009
J	Taylor, PM; Woodfield, RJ; Hodgkin, MN; Pettitt, TR; Martin, A; Kerr, DJ; Wakelam, MJO				Taylor, PM; Woodfield, RJ; Hodgkin, MN; Pettitt, TR; Martin, A; Kerr, DJ; Wakelam, MJO			Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway	ONCOGENE			English	Article						EMMPRIN; MMP2; phospholipase A(2); 5-lipoxygenase; breast cancer cell; fibroblast	MATRIX-METALLOPROTEINASE INDUCER; PROGELATINASE-A; COLLAGENASE; EXPRESSION; CARCINOMAS; ACTIVATION; RECEPTOR	Metalloproteinases (NIMP) produced by both cancer and normal stromal fibroblast cells play a critical role in the metastatic spread of tumours, however little is known of the regulation of their release. In this report we demonstrate that breast cancer cells in culture release apparently full length soluble EMMPRIN that promotes the release of pro-MMP2 from fibroblasts. The generation of MMP2 is mediated by activation of phospholipase A(2) and 5-lipoxygenase. These results suggest that the production of soluble EMMPRIN, phospholipase A(2) and 5-lipoxygenase activities are sites for potential therapeutic intervention.	Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	Cancer Research UK; University of Birmingham	Wakelam, MJO (corresponding author), Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	m.j.o.wakelam@bham.ac.uk		Wakelam, Michael/0000-0003-4059-9276				Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; BISWAS C, 1995, CANCER RES, V55, P434; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; DERRICO A, 1991, MODERN PATHOL, V4, P239; ELLIS SM, 1989, CANCER RES, V49, P3385; Ferry DR, 2000, ANN ONCOL, V11, P1165, DOI 10.1023/A:1008303715515; Guo HM, 1997, J BIOL CHEM, V272, P24; Huang MT, 1997, J CELL BIOCHEM, P26; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Light DB, 1997, J MEMBRANE BIOL, V158, P229, DOI 10.1007/s002329900260; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; NOMURA H, 1995, CANCER RES, V55, P3263; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sun JX, 2001, CANCER RES, V61, P2276; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Zeng ZS, 1999, CARCINOGENESIS, V20, P749, DOI 10.1093/carcin/20.5.749; Zucker S, 2001, AM J PATHOL, V158, P1921, DOI 10.1016/S0002-9440(10)64660-3	24	121	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5765	5772		10.1038/sj.onc.1205702	http://dx.doi.org/10.1038/sj.onc.1205702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173047				2022-12-17	WOS:000177463400012
J	Lee, SH; Shin, MS; Kim, HS; Lee, HK; Park, WS; Kim, SY; Lee, JH; Han, SY; Park, JY; Oh, RR; Kang, CS; Kim, KM; Jang, JJ; Nam, SW; Lee, JY; Yoo, NJ				Lee, SH; Shin, MS; Kim, HS; Lee, HK; Park, WS; Kim, SY; Lee, JH; Han, SY; Park, JY; Oh, RR; Kang, CS; Kim, KM; Jang, JJ; Nam, SW; Lee, JY; Yoo, NJ			Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma	ONCOGENE			English	Article						mutation; TRAIL-receptor 1; TRAIL-receptor 2; non-Hodgkin's lymphoma	TRAIL-INDUCED APOPTOSIS; FAS APO-1/CD95 GENE; LIGAND TRAIL; RECEPTOR; DEATH; CELLS; REGIONS; FADD; DNA	Tumor necrosis factor-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) and tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) are cell-surface receptors involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. TRAIL-RI and TRAIL-R2 genes have recently been mapped to chromosome 8p21-22, which is a frequent site of allelic deletions in many types of human tumors, including non-Hodgkin's lymphoma (NHL), Because TRAIL/TRAIL, receptor system plays an important role in lymphocyte homeostasis, we hypothesized that the mutations of TRAIL-RI and TRAIL-R2 may be involved in the development of NHL and that such mutations may be responsible for the allelic losses of 8p21-22 in NHL, In this study, we analysed the entire coding region of TRAIL-R2 gene and the death domain region of TRAIL-RI gene for the detection of the somatic mutations in a series of 117 human NHLs using polymerase chain reaction (PCR)-based single strand conformation polymorphism (SSCP) analysis. Overall, eight tumors (6.8%) were found to have two TRAIL-RI gene mutations or six TRAIL-R2 gene mutations. Interestingly, of the eight mutations, six missense mutations (two TRAIL-RI and four TRAIL-R2) were detected in the death domains and one nonsense mutation of TRAIL-R2 was detected just before the death domain. Our data suggest that somatic mutations of TRAIL-RI and TRAIL-R2 genes may play a role in the pathogenesis of some NHLs and that TRAIL-R2 and TRAIL-R2 genes might be the relevant genes to the frequent loss of chromosome 8p21-22 in human NHL.	Catholic Univ Korea, Coll Med, Dept Pathol, Socho Gu, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul 110799, South Korea; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA	Catholic University of Korea; Catholic University of Korea; Seoul National University (SNU); Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Socho Gu, 505 Banpo Dong, Seoul 137701, South Korea.		Jang, JaJune/F-6647-2011; kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022					Arai T, 1998, CANCER LETT, V133, P197, DOI 10.1016/S0304-3835(98)00230-4; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; EMI M, 1992, CANCER RES, V52, P5368; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gronbaek K, 1998, BLOOD, V92, P3018; HARRIS NL, 1994, BLOOD, V84, P1361; KAGAN J, 1995, ONCOGENE, V11, P2121; Keane MM, 1999, CANCER RES, V59, P734; Kim KH, 2000, CLIN CANCER RES, V6, P335; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 1999, CANCER RES, V59, P3068; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Mariani SM, 1998, EUR J IMMUNOL, V28, P973, DOI 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.3.CO;2-K; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martinez-Lorenzo MJ, 1998, EUR J IMMUNOL, V28, P2714, DOI 10.1002/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Monni O, 1996, BLOOD, V87, P5269, DOI 10.1182/blood.V87.12.5269.bloodjournal87125269; Mori S, 1999, J IMMUNOL, V162, P5616; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Thomas WD, 1998, J IMMUNOL, V161, P2195; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wistuba II, 1999, CANCER RES, V59, P1973; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhang XD, 1999, CANCER RES, V59, P2747	37	121	125	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					399	403		10.1038/sj.onc.1204103	http://dx.doi.org/10.1038/sj.onc.1204103			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313970				2022-12-17	WOS:000166411000015
J	Rytomaa, M; Lehmann, K; Downward, J				Rytomaa, M; Lehmann, K; Downward, J			Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling	ONCOGENE			English	Article						anoikis; apoptosis; Ras; Akt; PKB; Raf	PROTEIN-KINASE B/AKT; CELL-DEATH; EXTRACELLULAR-MATRIX; APOPTOSIS; SURVIVAL; BAX; PHOSPHORYLATION; ADHESION; PATHWAY; TRANSFORMATION	Detachment of epithelial cells from extracellular matrix results in induction of apoptosis ('anoikis') which can be blocked by expression of activated Pas or PKB/Akt. Here we show that detachment causes release of cytochrome c from mitochondria in MDCK cells, This is blocked by caspase inhibitors, suggesting a role for caspases upstream of mitochondria in the initiation of anoikis, in accord with the ability of dominant negative FADD to inhibit this form of cell death, Bulk activation of caspase-8 following detachment lags behind cytochrome c release, and is likely the result of a mitochondrial positive feed back loop. Matrix detachment also induces Bax translocation to mitochondria in a caspase-dependent manner. Expression of activated Ras or PKB/Akt blocks all the detectable events on the detachment-induced apoptosis signalling pathway, suggesting that PKB/Akt acts at an early point in the pathway, providing the signal normally generated by matrix attachment. Strong activation of Raf can also protect MDCK cells from detachment induced apoptosis, but this occurs at a point downstream of cytochrome c release from mitochondria, and is clearly distinct from the effect of PKB/Akt.	Imperial Canc Res Fund, Signal Transduct Lab, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	32	121	124	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4461	4468		10.1038/sj.onc.1203805	http://dx.doi.org/10.1038/sj.onc.1203805			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002418	Bronze			2022-12-17	WOS:000089236800002
J	Mastrangelo, T; Modena, P; Tornielli, S; Bullrich, F; Testi, MA; Mezzelani, A; Radice, P; Azzarelli, A; Pilotti, S; Croce, CM; Pierotti, MA; Sozzi, G				Mastrangelo, T; Modena, P; Tornielli, S; Bullrich, F; Testi, MA; Mezzelani, A; Radice, P; Azzarelli, A; Pilotti, S; Croce, CM; Pierotti, MA; Sozzi, G			A novel zinc finger gene is fused to EWS in small round cell tumor	ONCOGENE			English	Article						sarcoma; EWS; fusion; POZ/BTB domain; zinc finger	EWINGS-SARCOMA TRANSLOCATION; PLZF-RAR-ALPHA; CHROMOSOME-TRANSLOCATION; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; DOMAIN; PROTEINS; LEUKEMIA; SEQUENCE; ALLELE	Ewing sarcoma family of tumors share recurrent translocations that fuse EWS from 22q12 to five different members of transcription factors namely FLI-1 ERG, ETV1, E1AF and FEV. Different classes of DNA binding proteins, ATF1, WT1 and CHOP are fused to EWS generating distinct tumor phenotypes: clear cell sarcoma, desmoplastic small round cell tumor, and myxoid liposarcoma, respectively. We have cloned a novel gene located at 22q12 fused to EWS by a submicroscopic inversion of 22q in a small round cell sarcoma showing a translocation (t(1;22)(p36.1;q12), The gene, designated ZSG (Zinc finger Sarcoma Gene), is a putative Cys(2)-His(2) zinc finger protein which contains a POZ transcriptional repressor-like domain at the N-terminus. The rearrangement involves intron 8 of EWS and exon 1 of ZSG creating a chimeric sequence containing the transactivation domain of EWS fused to zinc finger domain of ZSG, This product lacks the transcriptional repressor domain at the N-terminus of ZSG, A rearrangement of the second ZSG allele was also found in tumor cells. This is the first example of an intra-chromosomal rearrangement of chromosome 22, undetectable by cytogenetics, activating EWS in soft tissue sarcoma.	Ist Nazl Tumori, I-20133 Milan, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Fondazione IRCCS Istituto Nazionale Tumori Milan; Jefferson University	Sozzi, G (corresponding author), Ist Nazl Tumori, Via Venezian 1, I-20133 Milan, Italy.		Radice, Paolo/O-3119-2013; Young, Richard A/F-6495-2012; Mezzelani, Alessandra/B-3355-2014; sozzi, gabriella/G-8259-2011; Testi, Maria Adele/D-6994-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Radice, Paolo/0000-0001-6298-4111; Young, Richard A/0000-0001-8855-8647; sozzi, gabriella/0000-0001-9360-6914; Testi, Maria Adele/0000-0002-9462-0336; Pierotti, Marco Alessandro/0000-0002-7431-8332; MEZZELANI, ALESSANDRA/0000-0001-7563-5869				Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DESMAZE C, 1994, CANCER GENET CYTOGEN, V74, P13, DOI 10.1016/0165-4608(94)90022-1; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Gerald WL, 1998, J CLIN ONCOL, V16, P3028, DOI 10.1200/JCO.1998.16.9.3028; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Katz RL, 1997, HUM PATHOL, V28, P502, DOI 10.1016/S0046-8177(97)90042-3; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; LADANYI M, 1994, CANCER RES, V54, P2837; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Ordi J, 1998, AM J SURG PATHOL, V22, P1026, DOI 10.1097/00000478-199808000-00014; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; SHISEKI M, 1994, CANCER RES, V54, P5643; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sozzi G, 1997, HUM PATHOL, V28, P134, DOI 10.1016/S0046-8177(97)90096-4; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695	28	121	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3799	3804		10.1038/sj.onc.1203762	http://dx.doi.org/10.1038/sj.onc.1203762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949935				2022-12-17	WOS:000088568400013
J	Timme, TL; Goltsov, A; Tahir, S; Li, LK; Wang, JX; Ren, CZ; Johnston, RN; Thompson, TC				Timme, TL; Goltsov, A; Tahir, S; Li, LK; Wang, JX; Ren, CZ; Johnston, RN; Thompson, TC			Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis	ONCOGENE			English	Article						caveolin; c-myc; apoptosis; prostate cancer	IN-SITU HYBRIDIZATION; ONCOGENICALLY TRANSFORMED-CELLS; PROSTATE-CANCER; UP-REGULATION; CHROMOSOMAL-ANOMALIES; BREAST-CANCER; TARGET GENES; EXPRESSION; GROWTH; TRANSCRIPTION	accent data indicating that overexpression of caveolin-1 as well as c-myc are relatively. common features of advanced prostate cancer prompted us to test for potential cooperative interactions between caveolin-1 and c-myc that would be consistent with malignant progression. We used the well-characterized Rat1AmycER(TM) cells to show that the caleolin-1 gene is down-regulated at the level of transcription by c-myc. BS maintaining relatively high levels of caveolin-1 with an adenoviral vector or in stably transfected clones we show; that caveolin-1 can suppress c-myc-induced apoptosis, Further we established human prostate cancer cell lines with the mycER(TM) construct and show that clones with increased caveolin-1 are more resistant to myc-induced apoptosis and have increased capacity for growth in soft agar when c-myc is activated.	Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Calgary	Thompson, TC (corresponding author), Baylor Coll Med, Scott Dept Urol, 6560 Fannin St,Suite 2100, Houston, TX 77030 USA.		Johnston, Randal/B-9247-2009		NCI NIH HHS [P50-CA58204, CA50588, R0-1 CA68814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204, R01CA050588, R01CA068814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bubendorf L, 1999, CANCER RES, V59, P803; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Dang CV, 1999, MOL CELL BIOL, V19, P1; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Helbing CC, 1998, ONCOGENE, V17, P1491, DOI 10.1038/sj.onc.1202241; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Jenkins RB, 1997, CANCER RES, V57, P524; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Qian JQ, 1997, MODERN PATHOL, V10, P1113; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shinoura N, 1999, CANCER RES, V59, P4119; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; THOMPSON TC, 1999, EMERGING THERAPEUTIC, V3, P337; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; Vairo G, 1996, ONCOGENE, V13, P1511; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	50	121	124	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3256	3265		10.1038/sj.onc.1203654	http://dx.doi.org/10.1038/sj.onc.1203654			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918582				2022-12-17	WOS:000088019300004
J	Neve, RM; Sutterluty, H; Pullen, N; Lane, HA; Daly, JM; Krek, W; Hynes, NE				Neve, RM; Sutterluty, H; Pullen, N; Lane, HA; Daly, JM; Krek, W; Hynes, NE			Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells	ONCOGENE			English	Article						single chain antibody; p27(kip1); c-Myc; PI3 kinase; MAP kinase	NEU DIFFERENTIATION FACTOR; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; INTRACELLULAR EXPRESSION; SIGNAL-TRANSDUCTION; INHIBITOR P27(KIP1); KINASE-ACTIVITY; OVARIAN-CANCER; CDK INHIBITOR; GROWTH	The ErbB2 receptor tyrosine kinase is overexpressed in a variety of human tumours. In order to understand the mechanism by which ErbB2 mediates tumour proliferation we have functionally inactivated the receptor using an intracellularly expressed, ER-targeted single-chain antibody (scFV-5R), Inducible expression of scFv-5R in the ErbB2-overexpressing SKBr3 breast tumour cell line leads to loss of plasma membrane localized ErbB2, Simultaneously, the activity of ErbB3, MAP kinase and PKB/Akt decreased dramatically, suggesting that active ErbB2/ErbB3 dimers are necessary for sustained activity of these kinases. Loss of functional ErbB2 caused the SKBr3 tumour cells to accumulate in the G1 phase of the cell cycle, This was a result of reduction in CDK2 activity, which was mediated by a re-distribution of p27(Kip1) from sequestering complexes to cyclin E/CDK2 complexes. The level of c-Myc and D-cyclins, proteins involved in p27(Kip1) sequestration, decreased in the absence of functional ErbB2. Ectopic expression of c-Myc led to an increase in D cyclin levels, CDK2 activity and resulted in a partial G1 rescue. We propose that c-Myc is a primary effector of ErbB2-mediated oncogenicity and functions to prevent normal p27(Kip1) control of cyclinE/CDR2.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst, R-1066-206,Maulbeerstr 66, CH-4058 Basel, Switzerland.			Pullen, Nicholas/0000-0002-4014-9278; Sutterluty-Fall, Hedwig/0000-0001-9249-9299				ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 1997, J BIOL CHEM, V272, P23247, DOI 10.1074/jbc.272.37.23247; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BERGER MS, 1988, CANCER RES, V48, P1238; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Czubayko F, 1997, GENE THER, V4, P943, DOI 10.1038/sj.gt.3300483; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; EBBINGHAUS SW, 1993, J CLIN INVEST, V92, P2433, DOI 10.1172/JCI116850; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jannot CB, 1996, ONCOGENE, V13, P275; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; SCHUURING E, 1992, ONCOGENE, V7, P355; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; Zhang K, 1996, J BIOL CHEM, V271, P3884	60	121	128	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2000	19	13					1647	1656		10.1038/sj.onc.1203470	http://dx.doi.org/10.1038/sj.onc.1203470			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763821				2022-12-17	WOS:000086083800004
J	Wang, YC; Blandino, G; Givol, D				Wang, YC; Blandino, G; Givol, D			Induced p21(waf) expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin	ONCOGENE			English	Article						inducible p21(waf); senescence; anti-cancer drugs; radiation	CYCLE ARREST; HUMAN FIBROBLASTS; WILD-TYPE; APOPTOSIS; P53; P21; INDUCTION; P21(WAF1/CIP1); INHIBITOR; WAF1/CIP1	The CDK inhibitor p21(waf) is a principal mediator of p53 function but can also be transactivated by many p53-independent stimuli leading to cell growth arrest or differentiation. In order to study the function of p21(waf) in a p53-deficient environment, we established an inducible expression of p21(waf) in the p53-null lung cancer cell line H1299, based on the muristerone-regulated system. Overexpression of p211(waf) led cells to growth arrest which after several days became irreversible and the arrested cells acquired a senescent phenotype as judged by cell shape, the senescence-associated beta-gal marker and inhibition of colony formation, The effect of p21(waf) overexpression, in the absence of p53, on the cytotoxicity caused by irradiation, doxorubicin and taxol was studied. Expression of p21(waf) provided protection against the cytotoxic effect of radiation and doxorubicin but not of taxol. These results are relevant to treatment of cancer when p53 is inactive.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Blandino, Giovanni/B-1137-2013	Blandino, Giovanni/0000-0002-6970-2241				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1993, CELL, V75, P805; Fazeli A, 1997, P NATL ACAD SCI USA, V94, P10199, DOI 10.1073/pnas.94.19.10199; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P817; Kondo Y, 1997, EXP CELL RES, V236, P51, DOI 10.1006/excr.1997.3693; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MICHIELI P, 1994, CANCER RES, V54, P3391; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Sambrook J, 1989, MOL CLONING LAB MANU; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; Wouters BG, 1997, CANCER RES, V57, P4703; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393	34	121	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2643	2649		10.1038/sj.onc.1202632	http://dx.doi.org/10.1038/sj.onc.1202632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353608				2022-12-17	WOS:000079907100012
J	Lauper, N; Beck, ARP; Cariou, S; Richman, L; Hofmann, K; Reith, W; Slingerland, JM; Amati, B				Lauper, N; Beck, ARP; Cariou, S; Richman, L; Hofmann, K; Reith, W; Slingerland, JM; Amati, B			Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle	ONCOGENE			English	Article						cyclin e2; cyclin E; CDK2; p27(Kip1)	DEPENDENT KINASE INHIBITOR; UBIQUITIN-PROTEASOME PATHWAY; GROWTH-FACTOR-BETA; PROTEIN-KINASE; C-MYC; P27(KIP1); ACTIVATION; ARREST; PROGRESSION; P21	We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin El subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Geneva, Sch Med, CMU, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland	Swiss Institute Experimental Cancer Research; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Geneva	Amati, B (corresponding author), Swiss Inst Expt Canc Res, 155 Ch Boveresses, CH-1066 Epalinges, Switzerland.		Hofmann, Kay/D-6714-2011; Amati, Bruno/AAM-3418-2020	Hofmann, Kay/0000-0002-2289-9083; Amati, Bruno/0000-0002-2958-1799				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Alevizopoulos K, 1998, EMBO J, V17, P5987, DOI 10.1093/emboj/17.20.5987; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BRAUN K, 1998, IN PRESS ONCOGENE, V16; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hancock DC, 1998, METH MOL B, V80, P15; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; LUKAS J, 1994, ONCOGENE, V9, P707; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x	49	121	128	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2637	2643		10.1038/sj.onc.1202477	http://dx.doi.org/10.1038/sj.onc.1202477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840927				2022-12-17	WOS:000077058900011
J	Candau, R; Scolnick, DM; Darpino, P; Ying, CY; Halazonetis, TD; Berger, SL				Candau, R; Scolnick, DM; Darpino, P; Ying, CY; Halazonetis, TD; Berger, SL			Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity	ONCOGENE			English	Article						adaptor; genetics; mdm-2; p53; transcription	WILD-TYPE P53; TATA-BINDING PROTEIN; PUTATIVE TRANSCRIPTIONAL ADAPTER; TUMOR-SUPPRESSOR GENE; DNA-BINDING; OLIGOMERIZATION DOMAIN; TETRAMERIZATION DOMAIN; REPRESSION FUNCTIONS; BASAL TRANSCRIPTION; OVERLAPPING DOMAINS	The ability of p53 to function as a tumor suppressor is linked to its function as a transcriptional activator, since p53 mutants that do not transactivate are unable to suppress tumor cell growth, Previous studies identified an activation domain in the amino terminal 40 residues of the protein, a region that binds to several general transcription factors and to some oncogene products, For example, mdm-2, a cellular oncoprotein, binds to this region and represses p53 transactivation, Here we describe a new activation domain within the amino terminus of p53 that maps between amino acids 40-83, and whose residues trp-53 and phe-54 are critical for function both in yeast and in mammalian cells, In vivo studies in yeast show that the new activation subdomain, unlike the previously described, is mdm-2 independent, Both p53 activation subdomains (1-40 and 40-83) require the yeast adaptor complex ADA2/ADA3/GCN5 for transcriptional activation, Moreover, since activation by p53 requires GCN5's enzymatic histone acetyltransferase domain, p53 may regulate gene expression by influencing chromatin modification.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute			Halazonetis, Thanos/D-7923-2011	Berger, Shelley/0000-0001-5398-4400				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BLAIR WS, 1994, J VIROL, V68, P3803, DOI 10.1128/JVI.68.6.3803-3808.1994; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1996, MOL CELL BIOL, V16, P593; CANDAU R, IN PRESS EMBO J; CANDAU R, 1996, J BIOL CHEM, V271, P527; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GILL G, 1988, NATURE, V334, P4721; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEONARDO AD, 1994, GENE DEV, V8, P2540; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIENHARDSCHMITZ M, 1994, J BIOL CHEM, V41, P25613; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOIDL P, 1994, CHROMOSOMA, V103, P441; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OHASHI Y, 1994, MOL CELL BIOL, V14, P2731, DOI 10.1128/MCB.14.4.2731; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROSE MD, 1988, METHODS YEAST GENETI; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; WOLFFE AP, 1994, TRENDS BIOCHEM SCI, V19, P240, DOI 10.1016/0968-0004(94)90148-1; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WU L, 1996, NATURE GENTE, V14, P429; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	91	121	125	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					807	816		10.1038/sj.onc.1201244	http://dx.doi.org/10.1038/sj.onc.1201244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266967				2022-12-17	WOS:A1997XQ11700007
J	HARTMANN, A; BLASZYK, H; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; DEVRIES, EMG; KOVACH, JS; SOMMER, SS				HARTMANN, A; BLASZYK, H; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; DEVRIES, EMG; KOVACH, JS; SOMMER, SS			P53 GENE-MUTATIONS INSIDE AND OUTSIDE OF EXONS-5-8 - THE PATTERNS DIFFER IN BREAST AND OTHER CANCERS	ONCOGENE			English	Article						P53 GENE; MUTATIONAL PATTERN; GENETIC EPIDEMIOLOGY	TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; MOLECULAR EPIDEMIOLOGY; BINDING-SITE; MUTANT P53; CELL-LINES; T-ANTIGEN; PROTEIN; INVITRO; DNA	Most studies of mutations in the p53 tumor suppressor gene in tumors have examined only exons 5-8. Our laboratory previously round 64 mutations in exons 5-8 of the p53 gene in 194 primary breast cancers. Herein, we report 18 additional mutations found outside of exons 5-8. Mutations are present in exons 4, 9 and 10, and flanking splice junctions, but not in the promotor region or in exons 1, 2, 3 and 11. No missense mutations are found outside of exons 5-8, is predominance of frameshift mutations lesser numbers of nonsense and splice site mutations. In contrast, the majority of mutations in exons 5-8 in this sample are missense changes and all of these are at amino acids that are identical in the 11 known p53 sequences that represent about 1.6 billion years of evolutionary divergence. The difference in mutational pattern between these two regions of the p53 gene is due to a lack of missense mutations and inframe microdeletions outside of exons 5-8, A review of our database of p53 mutations (De Vries et al., in preparation) shows that the patterns of mutation inside and outside of exons 5-8 differ in other types of cancers as well. The paucity of missense mutations in exons 2-4 and 9-11 in breast and other cancers (even at amino acids identical throughout p53 gene evolution) suggest that at least some missense mutations result in a phenotype other than malignant transformation. These data also illustrate the importance of examining identical exons when comparing the pattern of p53 gene mutations in different populations.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NCI NIH HHS [R01 CA56881-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA HG, 1990, ONCOGENE, V5, P1409; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BLASZYK H, 1994, HUM MUTAT, V4, P158, DOI 10.1002/humu.1380040212; BLASZYK H, 1994, IN PRESS BIOTECHNIQU; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; COLES C, 1992, CANCER RES, V52, P5291; DAMICO D, 1992, ONCOGENE, V7, P339; DANG CV, 1989, J BIOL CHEM, V264, P18019; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V56, P215; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELLEYBOSCO E, 1993, AM J HUM GENET, V53, P752; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JONES PA, 1991, CANCER RES, V51, P3617; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NISHIDA N, 1993, CANCER RES, V53, P368; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1994, CELL GROWTH DIFFER, V5, P61; OSBORNE RJ, 1991, CANCER RES, V51, P6194; PURDIE CA, 1994, ONCOGENE, V9, P603; SAITOH S, 1994, ONCOGENE, V9, P2869; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; SOUSSI T, 1990, ONCOGENE, V5, P945; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TSUDA H, 1993, JPN J CANCER RES, V84, P393; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; 1991, STATXACT VER 2 0	64	121	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					681	688						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862445				2022-12-17	WOS:A1995QH61200007
J	PAJUSOLA, K; APRELIKOVA, O; PELICCI, G; WEICH, H; CLAESSONWELSH, L; ALITALO, K				PAJUSOLA, K; APRELIKOVA, O; PELICCI, G; WEICH, H; CLAESSONWELSH, L; ALITALO, K			SIGNALING PROPERTIES OF FLT4, A PROTEOLYTICALLY PROCESSED RECEPTOR TYROSINE KINASE RELATED TO 2 VEGF RECEPTORS	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; HEPARIN-LIKE MOLECULES; PROTO-ONCOGENE; CELL-SURFACE; FACTOR GENE; SH2 DOMAIN; BINDING; EXPRESSION; ANGIOGENESIS	The FLT4, FLT1 and KDR/FLK1 genes encode, structurally similar endothelial cell receptor tyrosine kinases. Recently it has been shown that the FLT1 and KDR/FLK-1 proteins function as high-affinity receptors for vascular endothelial growth factor (VEGF). Here we show that FLT4 does not act as a receptor for VEGF, as VEGF did not show specific binding to the FLT4 tyrosine kinase or induce its autophosphorylation. Also, FLT4 did not interact with KDR in response to VEGF. However, when fused with the ligand binding domain of the colony stimulating factor-1 receptor (CSF-1R), the FLT4 tyrosine kinase was specifically activated by CSF-1. The activated FLT4 tyrosine kinase domain was found to interact with the Src homology 2 domains of the SHC and GRB2 adaptor proteins in vitro and with SHC in cells. CSF-1 stimulation of the CSF-1R/FLT4 receptor chimera induced thymidine incorporation in serum-starved NIH3T3 fibroblasts, but not in porcine aortic or murine lung capillary endothelial cells, although tyrosyl phosphorylation of the receptor and SHC occurred in these cells as well. These results suggest that the endothelial cell FLT4 receptor tyrosine kinase transmits signals for an as yet unidentified growth factor.	UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED, I-06100 PERUGIA, ITALY; GESELL BIOTECHNOL FORSCH MBH, DEPT GENE EXPRESS, W-3300 BRAUNSCHWEIG, GERMANY; LUDWIG INST CANC RES, UPPSALA BRANCH, S-75124 UPPSALA, SWEDEN	University of Helsinki; University of Perugia; Gesellschaft fur Biotechnologische Forschung mbH; Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014; Pelicci, Giuliana/AAA-8921-2022	Alitalo, Kari K/0000-0002-7331-0902; Pelicci, Giuliana/0000-0003-0986-8255				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; APRELIKOVA O, 1992, CANCER RES, V52, P746; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROWN LF, 1993, AM J PATHOL, V143, P1255; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FIEBICH BL, 1993, EUR J BIOCHEM, V211, P19, DOI 10.1111/j.1432-1033.1993.tb19865.x; GALLAND F, 1993, ONCOGENE, V8, P1233; GIORDANO S, 1989, ONCOGENE, V4, P1383; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; LAULAJAINEN T, 1993, LAB INVEST, V69, P183; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MARK MR, 1992, J BIOL CHEM, V267, P26166; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; ROBINSON DH, 1991, BLOOD, V77, P294; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WALTENBERGER J, 1994, IN PRESS J BIOL CHEM; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	121	136	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3545	3555						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970715				2022-12-17	WOS:A1994PT39200017
J	VANHAESEBROECK, B; REED, JC; DEVALCK, D; GROOTEN, J; MIYASHITA, T; TANAKA, S; BEYAERT, R; VANROY, F; FIERS, W				VANHAESEBROECK, B; REED, JC; DEVALCK, D; GROOTEN, J; MIYASHITA, T; TANAKA, S; BEYAERT, R; VANROY, F; FIERS, W			EFFECT OF BCL-2 PROTOONCOGENE EXPRESSION ON CELLULAR-SENSITIVITY TO TUMOR NECROSIS FACTOR-MEDIATED CYTOTOXICITY	ONCOGENE			English	Article							DNA FRAGMENTATION; FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; THYMOCYTE APOPTOSIS; TRANSGENIC MICE; GENE-EXPRESSION; RESISTANT CELLS; CYTO-TOXICITY; B-CELLS; DEATH	Introduction and expression of the proto-oncogene bcl-2 (B-cell lymphoma/leukemia 2) has been shown to extend the survival of certain hematopoietic cell lines after growth factor deprivation, by blocking apoptosis or programmed cell death. We investigated the effect of bcl-2 expression on cellular sensitivity to lysis by tumor necrosis factor (TNF), a cytokine capable of inducing apoptosis in several tumor cell lines. Introduction of the human bcl-2 gene in the highly TNF-sensitive L929 mouse fibrosarcoma cell fine did not result in altered TNF sensitivity. Likewise, NIH3T3 and REF cells, which are resistant to TNF cytotoxicity but become TNF sensitive upon cotreatment with actinomycin D or upon expression of the adenovirus EIA gene, did not show altered TNF sensitivity upon bcl-2 transfection. Despite constitutive expression of the endogenous bcl-2 gene, human MCF7 breast carcinoma cells, as well as HL60 promyelocytic leukemia and U937 histiocytic lymphoma cell lines were found to be TNF sensitive. bcl-2-overexpressing derivatives of these cell lines did not acquire reduced TNF sensitivity and still exhibited the characteristic pattern of internucleosomal DNA fragmentation of TNF-induced apoptosis. Moreover, bcl-2 expression in the interleukin 3 (IL-3)-dependent myeloid cell line 32D protected these cells from apoptosis resulting from growth factor deprivation, but not from apoptosis induced by TNF. These data clearly establish the absence of a correlation between bcl-2 gene expression and cellular sensitivity to TNF-induced cell lysis. These findings are discussed in the context of the hypothesis of different pathways for induction of apoptosis, only some of which are affected by bcl-2 expression.	STATE UNIV GHENT,MOLEC BIOL LAB,K L LEDEGANCKSTR 35,B-9000 GHENT,BELGIUM; UNIV PENN,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19104	Ghent University; University of Pennsylvania			van Roy, Frans M/C-6123-2009; Beyaert, Rudi/B-2589-2009	van Roy, Frans M/0000-0003-4358-1039; Beyaert, Rudi/0000-0002-5704-582X	NATIONAL CANCER INSTITUTE [R01CA047956] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1990, J BIOL CHEM, V265, P17323; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COHEN JJ, 1984, J IMMUNOL, V132, P38; DEALTRY GB, 1987, EUR J IMMUNOL, V17, P689, DOI 10.1002/eji.1830170517; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; IMAMURA K, 1988, J BIOL CHEM, V263, P10247; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; LASTER SM, 1988, J IMMUNOL, V141, P2629; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, IN PRESS CANCER RES, V52; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEALE ML, 1988, IMMUNOLOGY, V64, P81; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, MOL CELL BIOL, V10, P4370, DOI 10.1128/MCB.10.8.4370; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RUBIN BY, 1988, CANCER RES, V48, P6006; RUFF MR, 1981, LYMPHOKINES, V2, P235; SCHMID DS, 1986, P NATL ACAD SCI USA, V83, P1881, DOI 10.1073/pnas.83.6.1881; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VANHAESEBROECK B, 1991, CANCER RES, V51, P2469; VANHAESEBROECK B, 1990, VIROLOGY, V176, P362, DOI 10.1016/0042-6822(90)90006-D; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WARING P, 1990, J BIOL CHEM, V265, P14476; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAUCHI N, 1989, CANCER RES, V49, P1671; ZIMMERMAN RJ, 1989, CANCER RES, V49, P1644	55	121	123	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1075	1081						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455935				2022-12-17	WOS:A1993KT22000033
J	STEINMEYER, K; DEPPERT, W				STEINMEYER, K; DEPPERT, W			DNA-BINDING PROPERTIES OF MURINE-P53	ONCOGENE			English	Article									UNIV ULM,DEPT BIOCHEM,D-7900 ULM,FED REP GER	Ulm University								Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; Mage M G, 1980, Methods Enzymol, V70, P142; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; ROSENWIRTH B, 1975, VIROLOGY, V67, P14, DOI 10.1016/0042-6822(75)90399-2; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SEN A, 1978, P NATL ACAD SCI USA, V75, P1647, DOI 10.1073/pnas.75.4.1647; SHOHAT O, 1987, ONCOGENE, V1, P277; SPILLMAN T, 1979, J BIOL CHEM, V254, P3100; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; VANDERVLIET PC, 1973, NATURE-NEW BIOL, V246, P170, DOI 10.1038/newbio246170a0; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WEBER K, 1975, EXP CELL RES, V95, P111, DOI 10.1016/0014-4827(75)90615-1; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	25	121	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					501	507						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2978867				2022-12-17	WOS:A1988R516300003
J	Niu, N; Mercado-Uribe, I; Liu, J				Niu, N.; Mercado-Uribe, I.; Liu, J.			Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells	ONCOGENE			English	Article							CLEAVAGE-STAGE EMBRYOS; IN-VITRO; CELLULAR SENESCENCE; OVARIAN TUMORIGENESIS; TUMOR-CELLS; DIFFERENTIATION; CYTOKINESIS; THERAPY; FAILURE; ESCAPE	Our recent perplexing findings that polyploid giant cancer cells (PGCCs) acquired embryonic-like stemness and were capable of tumor initiation raised two important unanswered questions: how do PGCCs acquire such stemness, and to which stage of normal development do PGCCs correspond. Intriguingly, formation of giant cells due to failed mitosis/cytokinesis is common in the blastomere stage of the preimplantation embryo. However, the relationship between PGCCs and giant blastomeres has never been studied. Here, we tracked the fate of single PGCCs following paclitaxel-induced mitotic failure. Morphologically, early spheroids derived from PGCCs were indistinguishable from human embryos at the blastomere, polyploid blastomere, compaction, morula and blastocyst-like stages by light, scanning electron or three-dimensional confocal scanning microscopy. Formation of PGCCs was associated with activation of senescence, while budding of daughter cells was associated with senescence escape. PGCCs showed time- and space-dependent activation of expression of the embryonic stem cell markers OCT4, NANOG, SOX2 and SSEA1 and lacked expression of Xist. PGCCs acquired mesenchymal phenotype and were capable of differentiation into all three germ layers in vitro. The embryonic-like stemness of PGCCs was associated with nuclear accumulation of YAP, a key mediator of the Hippo pathway. Spheroids derived from single PGCCs grew into a wide spectrum of human neoplasms, including germ cell tumors, high-grade and low-grade carcinomas and benign tissues. Daughter cells derived from PGCCs showed attenuated capacity for invasion and increased resistance to paclitaxel. We also observed formation of PGCCs and dedifferentiation in ovarian cancer specimens from patients treated with chemotherapy. Taken together, our findings demonstrate that PGCCs represent somatic equivalents of blastomeres, the most primitive cancer stem cells reported to date. Thus, our studies reveal an evolutionarily conserved archaic embryonic program in somatic cells that can be de-repressed for oncogenesis. Our work offers a new paradigm for cancer origin and disease relapse.	[Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA; Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA.	jliu@mdanderson.org			Cancer Prevention and Research Institute of Texas; MD Anderson Cancer Center Global Academic Programs; National Cancer Institute Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; MD Anderson Cancer Center Global Academic Programs; National Cancer Institute Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by a multi-investigator grant from the Cancer Prevention and Research Institute of Texas (JL); a Sister Institution Grant from MD Anderson Cancer Center Global Academic Programs; and National Cancer Institute Cancer Center Support Grant CA016672, which supported the High Resolution Electron Microscopy Facility. We thank Kim Vu for image artwork and Stephanie Deming for editorial assistance. We thank many colleagues for helpful discussions. We apologize for many investigators who embraced embryonic origin of tumor or its variants over past two centuries whose work can not be cited and discussed due to space limitation.	Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058; BENKHALIFA M, 1993, HUM REPROD, V8, P895, DOI 10.1093/oxfordjournals.humrep.a138162; Blum B, 2008, ADV CANCER RES, V100, P133, DOI 10.1016/S0065-230X(08)00005-5; Braune EB, 2016, STEM CELL REP, V6, P643, DOI 10.1016/j.stemcr.2016.03.004; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chakradeo S, 2016, CURR DRUG TARGETS, V17, P460, DOI 10.2174/1389450116666150825113500; Chavez SL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2249; Chen HH, 2014, STEM CELL REP, V3, P892, DOI 10.1016/j.stemcr.2014.09.003; Cohnheim J., 1867, PATH ANAT PHYSL KLIN, V40, P1, DOI 10.1007/BF02968135; Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044; Erenpreisa J, 2005, CELL BIOL INT, V29, P1005, DOI 10.1016/j.cellbi.2005.10.008; Erenpreisa JA, 2000, CELL BIOL INT, V24, P635, DOI 10.1006/cbir.2000.0558; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Forsdahl S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102559; Fox DT, 2013, DEVELOPMENT, V140, P3, DOI 10.1242/dev.080531; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2014, CELL, V158, P833, DOI 10.1016/j.cell.2014.06.029; Gasser R.F., VIRTUAL HUMAN EMBRYO; GURDON JB, 1958, NATURE, V182, P64, DOI 10.1038/182064a0; HARDY K, 1993, J REPROD FERTIL, V98, P549; Iwata K, 2014, J ASSIST REPROD GEN, V31, P421, DOI 10.1007/s10815-014-0195-2; Kamiyama T, 2006, ANN SURG, V244, P451, DOI 10.1097/01.sla.0000234840.74526.2b; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Kligman I, 1996, HUM REPROD, V11, P1492; Kumar V.A., 2010, ROBBINS CONTRAN PATH, P262; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Ledbetter DH, 2009, NAT MED, V15, P490, DOI 10.1038/nm0509-490; Lee AS, 2013, NAT MED, V19, P998, DOI 10.1038/nm.3267; Leikam C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.71; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Lopez-Sanchez LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099143; Mertzanidou A, 2013, HUM REPROD, V28, P256, DOI 10.1093/humrep/des362; Mosieniak G, 2015, NEOPLASIA, V17, P882, DOI 10.1016/j.neo.2015.11.008; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Niu N, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.75; Niu N, 2011, CELL MOL LIFE SCI, V68, P2481, DOI 10.1007/s00018-010-0572-7; Ogden A, 2015, CANCER LETT, V367, P89, DOI 10.1016/j.canlet.2015.06.025; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Pierce G B, 1967, Curr Top Dev Biol, V2, P223; PIERCE GB, 1988, CANCER RES, V48, P1996; PIERCE GB, 1971, CANCER RES, V31, P127; PIERCE GB, 1983, AM J PATHOL, V113, P115; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; Sadler T.W., 2012, LANGMANS MEDICAL EMB, V12th; Salmina K, 2010, EXP CELL RES, V316, P2099, DOI 10.1016/j.yexcr.2010.04.030; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Schrode N, 2014, DEV CELL, V29, P454, DOI 10.1016/j.devcel.2014.04.011; STEVENS LC, 1954, P NATL ACAD SCI USA, V40, P1080, DOI 10.1073/pnas.40.11.1080; STEVENS LC, 1964, P NATL ACAD SCI USA, V52, P654, DOI 10.1073/pnas.52.3.654; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Szajnik Marta, 2013, Gynecol Obstet (Sunnyvale), VSuppl 4, P3; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Van Royen E, 2003, HUM REPROD, V18, P1062, DOI 10.1093/humrep/deg201; Vanneste E, 2009, NAT MED, V15, P577, DOI 10.1038/nm.1924; Walen KH, 2005, CELL BIOL INT, V29, P1057, DOI 10.1016/j.cellbi.2005.10.016; Wang Q, 2013, INT J CANCER, V132, P1505, DOI 10.1002/ijc.27810; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wirka KA, 2014, FERTIL STERIL, V101, P1637, DOI 10.1016/j.fertnstert.2014.02.050; Wutz A, 2007, TRENDS GENET, V23, P457, DOI 10.1016/j.tig.2007.07.004; Yang G, 2006, P NATL ACAD SCI USA, V103, P16472, DOI 10.1073/pnas.0605752103; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhang Shiwu, 2016, Genes Cancer, V7, P60, DOI 10.18632/genesandcancer.102; Zhang SW, 2014, INT J CANCER, V134, P508, DOI 10.1002/ijc.28319; Zhang SW, 2013, CANCER LETT, V333, P205, DOI 10.1016/j.canlet.2013.01.037; Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021; Zielke N, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012948	72	120	127	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4887	4900		10.1038/onc.2017.72	http://dx.doi.org/10.1038/onc.2017.72			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436947	Green Published, hybrid			2022-12-17	WOS:000408234400006
J	Lewis, CA; Brault, C; Peck, B; Bensaad, K; Griffiths, B; Mitter, R; Chakravarty, P; East, P; Dankworth, B; Alibhai, D; Harris, AL; Schulze, A				Lewis, C. A.; Brault, C.; Peck, B.; Bensaad, K.; Griffiths, B.; Mitter, R.; Chakravarty, P.; East, P.; Dankworth, B.; Alibhai, D.; Harris, A. L.; Schulze, A.			SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme	ONCOGENE			English	Article							ELEMENT-BINDING PROTEIN; STEAROYL-COA DESATURASE; UNSATURATED FATTY-ACIDS; SMALL-MOLECULE; TUMOR-CELLS; HYPOXIA; METABOLISM; EXPRESSION; GROWTH; LIPOGENESIS	Oxygen and nutrient limitation are common features of the tumor microenvironment and are associated with cancer progression and induction of metastasis. The inefficient vascularization of tumor tissue also limits the penetration of other serum-derived factors, such as lipids and lipoproteins, which can be rate limiting for cell proliferation and survival. Here we have investigated the effect of hypoxia and serum deprivation on sterol regulatory element-binding protein (SREBP) activity and the expression of lipid metabolism genes in human glioblastoma multiforme (GBM) cancer cells. We found that SREBP transcriptional activity was induced by serum depletion both in normoxic and hypoxic cells and that activation of SREBP was required to maintain the expression of fatty acid and cholesterol metabolism genes under hypoxic conditions. Moreover, expression of stearoyl-CoA desaturase, the enzyme required for the generation of mono-unsaturated fatty acids, and fatty acid-binding protein 7, a regulator of glioma stem cell function, was strongly dependent on SREBP function. Inhibition of SREBP function blocked lipid biosynthesis in hypoxic cancer cells and impaired cell survival under hypoxia and in a three-dimensional spheroid model. Finally, gene expression analysis revealed that SREBP defines a gene signature that is associated with poor survival in glioblastoma.	[Lewis, C. A.; Peck, B.; Griffiths, B.; Schulze, A.] Canc Res UK London Res Inst, Gene Express Anal Lab, London WC2A 3PX, England; [Brault, C.; Dankworth, B.; Schulze, A.] Theodor Boveri Inst, Bioctr, D-97074 Wurzburg, Bavaria, Germany; [Bensaad, K.; Harris, A. L.] Univ Oxford, CRUK Growth Factor Grp, Weatherall Inst Mol Med, Oxford, England; [Mitter, R.; Chakravarty, P.; East, P.] Canc Res UK London Res Inst, Bioinformat & Biostat Serv, London WC2A 3PX, England; [Alibhai, D.] Canc Res UK London Res Inst, Light Microscopy Core, London WC2A 3PX, England; [Schulze, A.] Comprehens Canc Ctr Mainfranken Wurzburg, Wurzburg, Germany	Cancer Research UK; University of Wurzburg; University of Oxford; Cancer Research UK; Cancer Research UK	Schulze, A (corresponding author), Theodor Boveri Inst, Dept Biochem & Mol Biol, Bioctr, D-97074 Wurzburg, Bavaria, Germany.	almut.schulze@uni-wuerzburg.de	Schulze, Almut/AAX-8257-2020; Harris, Adrian L/ABA-3343-2020	Schulze, Almut/0000-0002-8199-6422; Harris, Adrian L/0000-0003-1376-8409; chakravarty, probir/0000-0003-1146-8824; Peck, Barrie/0000-0002-6687-8495; Mitter, Richard/0000-0002-1279-3760	Cancer Research UK; Cancer Research UK [16466, 18974, 11359] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish; The Francis Crick Institute [10002] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); The Francis Crick Institute	We thank the LRI Research Services for help with experiments and Charles Mein and Lia Di Faveri (Genome Center Bart's and The London School of Medicine and Dentistry) for microarray analysis. We also thank Barbara Bauer (Department of Biochemistry and Molecular Biology, University of Wurzburg, Wurzburg, Germany) for histological analyses. This work was supported by Cancer Research UK.	Axelson H, 2005, SEMIN CELL DEV BIOL, V16, P554, DOI 10.1016/j.semcdb.2005.03.007; Belanger AJ, 2007, BIOCHEM BIOPH RES CO, V364, P567, DOI 10.1016/j.bbrc.2007.10.062; Bengoechea-Alonso MT, 2007, CURR OPIN CELL BIOL, V19, P215, DOI 10.1016/j.ceb.2007.02.004; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; CASCIARI JJ, 1992, J CELL PHYSIOL, V151, P386, DOI 10.1002/jcp.1041510220; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clendening JW, 2010, P NATL ACAD SCI USA, V107, P15051, DOI 10.1073/pnas.0910258107; Currie E, 2013, CELL METAB; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Espenshade PJ, 2007, ANNU REV GENET, V41, P401, DOI 10.1146/annurev.genet.41.110306.130315; Favaro E, 2011, GENOME MED, V3, DOI 10.1186/gm271; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; GORDON GB, 1977, AM J PATHOL, V88, P663; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hess D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011394; Hilvo M, 2011, CANCER RES, V71, P3236, DOI 10.1158/0008-5472.CAN-10-3894; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jung SY, 2012, J CELL BIOCHEM, V113, P3730, DOI 10.1002/jcb.24247; Kamisuki S, 2009, CHEM BIOL, V16, P882, DOI 10.1016/j.chembiol.2009.07.007; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Krycer JR, 2012, BIOCHEM J, V446, P191, DOI 10.1042/BJ20120545; Laurenti G, 2011, J CELL BIOCHEM, V112, P3891, DOI 10.1002/jcb.23323; Lee CYS, 2009, EMBO J, V28, P135, DOI 10.1038/emboj.2008.271; Li JG, 2006, PHYSIOL GENOMICS, V25, P450, DOI 10.1152/physiolgenomics.00293.2005; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu RZ, 2012, BIOCHEM BIOPH RES CO, V422, P482, DOI 10.1016/j.bbrc.2012.05.019; Liu RZ, 2010, INT J DEV BIOL, V54, P1229, DOI 10.1387/ijdb.092976rl; Mazzatti D, 2012, ARCH PHYSIOL BIOCHEM, V118, P112, DOI 10.3109/13813455.2012.654611; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mita R, 2010, J BIOL CHEM, V285, P37005, DOI 10.1074/jbc.M110.170076; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Ntambi JM, 2004, LIPIDS, V39, P1061, DOI 10.1007/s11745-004-1331-2; Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Rankin EB, 2009, MOL CELL BIOL, V29, P4527, DOI 10.1128/MCB.00200-09; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Rysman E, 2010, CANCER RES, V70, P8117, DOI 10.1158/0008-5472.CAN-09-3871; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Schonfeld P, 2008, FREE RADICAL BIO MED, V45, P231, DOI 10.1016/j.freeradbiomed.2008.04.029; Shai R, 2003, ONCOGENE, V22, P4918, DOI 10.1038/sj.onc.1206753; Storch J, 2010, J BIOL CHEM, V285, P32679, DOI 10.1074/jbc.R110.135210; Swietach P, 2008, J BIOL CHEM, V283, P20473, DOI 10.1074/jbc.M801330200; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tang JJ, 2011, CELL METAB, V13, P44, DOI 10.1016/j.cmet.2010.12.004; Therneau T.M., 2000, STAT BIOL HEALTH; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045; Ward C, 2013, CANCER TREAT REV, V39, P171, DOI 10.1016/j.ctrv.2012.08.004; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/0092-8674(93)90690-R; Yoshii Y, 2009, CANCER SCI, V100, P821, DOI 10.1111/j.1349-7006.2009.01099.x; Young RM, 2013, GENE DEV, V27, P1115, DOI 10.1101/gad.198630.112	68	120	124	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2015	34	40					5128	5140		10.1038/onc.2014.439	http://dx.doi.org/10.1038/onc.2014.439			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CS6ZP	25619842				2022-12-17	WOS:000362233400003
J	Gang, EJ; Hsieh, YT; Pham, J; Zhao, Y; Nguyen, C; Huantes, S; Park, E; Naing, K; Klemm, L; Swaminathan, S; Conway, EM; Pelus, LM; Crispino, J; Mullighan, CG; McMillan, M; Muschen, M; Kahn, M; Kim, YM				Gang, E. J.; Hsieh, Y-T; Pham, J.; Zhao, Y.; Nguyen, C.; Huantes, S.; Park, E.; Naing, K.; Klemm, L.; Swaminathan, S.; Conway, E. M.; Pelus, L. M.; Crispino, J.; Mullighan, C. G.; McMillan, M.; Mueschen, M.; Kahn, M.; Kim, Y-M			Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia	ONCOGENE			English	Article						acute lymphoblastic leukemia; drug resistance; small-molecule inhibitor; CBP; p300; ICG-001	TRANSCRIPTIONAL COACTIVATOR CBP; CREB-BINDING PROTEIN; RUBINSTEIN-TAYBI-SYNDROME; WNT/BETA-CATENIN PATHWAY; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; SELF-RENEWAL; PRE-B; HISTONE ACETYLATION; DIFFERENTIAL ROLES	Drug resistance in acute lymphoblastic leukemia (ALL) remains a major problem warranting new treatment strategies. Wnt/catenin signaling is critical for the self-renewal of normal hematopoietic progenitor cells. Deregulated Wnt signaling is evident in chronic and acute myeloid leukemia; however, little is known about ALL. Differential interaction of catenin with either the Kat3 coactivator CREBBP (CREB-binding protein (CBP)) or the highly homologous EP300 (p300) is critical to determine divergent cellular responses and provides a rationale for the regulation of both proliferation and differentiation by the Wnt signaling pathway. Usage of the coactivator CBP by catenin leads to transcriptional activation of cassettes of genes that are involved in maintenance of progenitor cell self-renewal. However, the use of the coactivator p300 leads to activation of genes involved in the initiation of differentiation. ICG-001 is a novel small-molecule modulator of Wnt/catenin signaling, which specifically binds to the N-terminus of CBP and not p300, within amino acids 1-110, thereby disrupting the interaction between CBP and catenin. Here, we report that selective disruption of the CBP/beta-and gamma-catenin interactions using ICG-001 leads to differentiation of pre-B ALL cells and loss of self-renewal capacity. Survivin, an inhibitor-of-apoptosis protein, was also downregulated in primary ALL after treatment with ICG-001. Using chromatin immunoprecipitation assay, we demonstrate occupancy of the survivin promoter by CBP that is decreased by ICG-001 in primary ALL. CBP mutations have been recently identified in a significant percentage of ALL patients, however, almost all of the identified mutations reported occur C-terminal to the binding site for ICG-001. Importantly, ICG-001, regardless of CBP mutational status and chromosomal aberration, leads to eradication of drug-resistant primary leukemia in combination with conventional therapy in vitro and significantly prolongs the survival of NOD/SCID mice engrafted with primary ALL. Therefore, specifically inhibiting CBP/catenin transcription represents a novel approach to overcome relapse in ALL.	[Gang, E. J.; Hsieh, Y-T; Pham, J.; Huantes, S.; Park, E.; Naing, K.; Kim, Y-M] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol & Oncol,Dept Pediat, Los Angeles, CA 90033 USA; [Zhao, Y.; Nguyen, C.; McMillan, M.; Kahn, M.] Univ So Calif, Ctr Mol Pathways & Drug Discovery, Dept Mol Pharmacol & Toxicol, Norris Comprehens Canc Ctr,Dept Biochem & Mol Bio, Los Angeles, CA 90033 USA; [Klemm, L.; Swaminathan, S.; Mueschen, M.] Univ Calif San Francisco, Dept Lab Med, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Conway, E. M.] Univ British Columbia, Fac Med, Div Hematol, Ctr Blood Res, Vancouver, BC, Canada; [Pelus, L. M.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Crispino, J.] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA; [Mullighan, C. G.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of British Columbia; Indiana University System; Indiana University Bloomington; Northwestern University; St Jude Children's Research Hospital	Kahn, M (corresponding author), Univ So Calif, Ctr Mol Pathways & Drug Discovery, Dept Mol Pharmacol & Toxicol, Norris Comprehens Canc Ctr,Dept Biochem & Mol Bio, 1450 Biggy St,NRT 4501, Los Angeles, CA 90033 USA.	kahnm@usc.edu	Mullighan, Charles/H-3253-2011; kim, y/AAR-6095-2020	Mullighan, Charles/0000-0002-1871-1850; Kim, Yong-Mi/0000-0003-3793-6438; Crispino, John/0000-0002-8182-8306; Conway, Edward/0000-0003-0081-0305	William Lawrence and Blanche Hughes Foundation; Concern Foundation; American Cancer Society [R01CA172896]; USC Norris Comprehensive Cancer Center [P30 CA014089, R01CA137060, R01CA139032, R01CA157644]; Canadian Institutes for Health Research (CIHR); Nautica Triathlon; NATIONAL CANCER INSTITUTE [R01CA169458, P30CA021765, R01CA166161, R01CA172558, R01CA139032, R01CA157644, P30CA014089, R01CA172896, R01CA137060] Funding Source: NIH RePORTER; Cancer Research UK [18131] Funding Source: researchfish	William Lawrence and Blanche Hughes Foundation; Concern Foundation; American Cancer Society(American Cancer Society); USC Norris Comprehensive Cancer Center; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Nautica Triathlon; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	This work was supported by Grants from: William Lawrence and Blanche Hughes Foundation, Concern Foundation, Nautica Triathlon and the American Cancer Society and R01CA172896 (YMK); and USC Norris Comprehensive Cancer Center Support Grant P30 CA014089 (MK); R01CA137060, R01CA139032, R01CA157644 (MM). EMC is supported by a CSL Behring Research Chair and a Canada Research Chair in Endothelial Cell Biology and by grants from the Canadian Institutes for Health Research (CIHR).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Blough RI, 2000, AM J MED GENET, V90, P29, DOI 10.1002/(SICI)1096-8628(20000103)90:1<29::AID-AJMG6>3.0.CO;2-Z; Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Gastaldi T, 2006, CARCINOGENESIS, V27, P1758, DOI 10.1093/carcin/bgl008; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Herzog S, 2009, NAT REV IMMUNOL, V9, P195, DOI 10.1038/nri2491; Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038/leu.2008.262; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kahn M, 2011, FUTURE MED CHEM, V3, P1745, DOI [10.4155/FMC.11.126, 10.4155/fmc.11.126]; Kawasaki H., 1999, NUCL ACIDS S SER, V42, P263; Khan NI, 2007, BRIT J HAEMATOL, V138, P338, DOI 10.1111/j.1365-2141.2007.06667.x; Kim YM, 2011, CURR CANCER DRUG TAR, V11, P213, DOI 10.2174/156800911794328420; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Koch U, 2008, BLOOD, V111, P160, DOI 10.1182/blood-2007-07-099754; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Morrison DJ, 2012, LEUKEMIA, V26, P271, DOI 10.1038/leu.2011.199; Muljo SA, 2003, NAT IMMUNOL, V4, P31, DOI 10.1038/ni870; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Ramos YFM, 2010, NUCLEIC ACIDS RES, V38, P5396, DOI 10.1093/nar/gkq184; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Teo JL, 2005, P NATL ACAD SCI USA, V102, P12171, DOI 10.1073/pnas.0504600102; Tyner JW, 2012, LEUKEMIA, V26, P623, DOI 10.1038/leu.2011.249; Verkaar F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019185; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Xu W, 2006, BLOOD, V107, P4407, DOI 10.1182/blood-2005-08-3263; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	50	120	127	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2169	2178		10.1038/onc.2013.169	http://dx.doi.org/10.1038/onc.2013.169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23728349	Green Submitted, Green Accepted			2022-12-17	WOS:000334996000003
J	Ye, Q; Cai, W; Zheng, Y; Evers, BM; She, QB				Ye, Q.; Cai, W.; Zheng, Y.; Evers, B. M.; She, Q-B			ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer	ONCOGENE			English	Article						translational regulation; metastasis; ERK; AKT; survivin; colorectal cancer	INITIATION-FACTOR 4E; INTRINSIC RESISTANCE; TUBEROUS SCLEROSIS; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; ACTIVATION; MTOR; EIF4E; PHOSPHORYLATION; INHIBITION	The mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase (MEK/ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways are often concurrently activated by separate genetic alterations in colorectal cancer (CRC), which is associated with CRC progression and poor survival. However, how activating both pathways is required for CRC metastatic progression remains unclear. Our recent study showed that both ERK and AKT signaling are required to activate eukaryotic translation initiation factor 4E (eIF4E)-initiated cap-dependent translation via convergent regulation of the translational repressor 4E-binding protein 1 (4E-BP1) for maintaining CRC transformation. Here, we identified that the activation of cap-dependent translation by cooperative ERK and AKT signaling is critical for promotion of CRC motility and metastasis. In CRC cells with coexistent mutational activation of ERK and AKT pathways, inhibition of either MEK or AKT alone showed limited activity in inhibiting cell migration and invasion, but combined inhibition resulted in profound effects. Genetic blockade of the translation initiation complex by eIF4E knockdown or expression of a dominant active 4E-BP1 mutant effectively inhibited migration, invasion and metastasis of CRC cells, whereas overexpression of eIF4E or knockdown of 4E-BP1 had the opposite effect and markedly reduced their dependence on ERK and AKT signaling for cell motility. Mechanistically, we found that these effects were largely dependent on the increase in mammalian target of rapamycin complex 1 (mTORC1)-mediated survivin translation by ERK and AKT signaling. Despite the modest effect of survivin knockdown on tumor growth, reduction of the translationally regulated survivin profoundly inhibited motility and metastasis of CRC. These findings reveal a critical mechanism underlying the translational regulation of CRC metastatic progression, and suggest that targeting cap-dependent translation may provide a promising treatment strategy for advanced CRC.	[Ye, Q.; Cai, W.; Zheng, Y.; Evers, B. M.; She, Q-B] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA; [Ye, Q.; Cai, W.; Zheng, Y.; She, Q-B] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA; [Evers, B. M.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky; University of Kentucky	She, QB (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, 741 South Limestone,B365 BBSRB, Lexington, KY 40506 USA.	qing-bai.she@uky.edu		She, Qing-Bai/0000-0002-7207-0599	NCI [R01CA175105, P30CA147886]; Gastrointestinal Cancer [SPORE P20CA150343]; ACS [IRG85-001-22]; NIH/NCATS [UL1RR033173, KL2RR0033171]; Markey Cancer Center Start-up fund; NATIONAL CANCER INSTITUTE [R01CA175105, P30CA177558, P30CA147886, P20CA150343] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000116, UL1TR000117] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR033171, UL1RR033173] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gastrointestinal Cancer; ACS(American Cancer Society); NIH/NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Markey Cancer Center Start-up fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Rina Plattner and Kathleen O'Connor and Ms Donna Gilbreath for critical reading and editing of this manuscript, Dr Ronald Blasberg for providing the SFG-FLuc-IRES2-GFP construct. Dr Piotr Rychahou for the assistance in the animal experiments, and Ms Dana Napier for the histologic tissue processing. This work was supported by grants from NCI (R01CA175105 to Q-B She, P30CA147886 and Gastrointestinal Cancer SPORE P20CA150343 to BM Evers), ACS (IRG85-001-22 to Q-B She), NIH/NCATS UL1RR033173 (KL2RR0033171 to Q-B She), and the Markey Cancer Center Start-up fund (to Q-B She).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Balmanno K, 2009, INT J CANCER, V125, P2332, DOI 10.1002/ijc.24604; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Chu XY, 2012, J SURG ONCOL, V105, P520, DOI 10.1002/jso.22134; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Floc'h N, 2012, CANCER RES, V72, P4483, DOI 10.1158/0008-5472.CAN-12-0283; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409; Hanrahan AJ, 2012, CANCER DISCOV, V2, P56, DOI 10.1158/2159-8290.CD-11-0170; Hernandez JM, 2011, CLIN COLORECTAL CANC, V10, P188, DOI 10.1016/j.clcc.2011.03.014; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Livingstone M, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/2/021001; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mazzoletti M, 2011, CANCER RES, V71, P4573, DOI 10.1158/0008-5472.CAN-10-4322; McKenzie JA, 2010, CANCER RES, V70, P7927, DOI 10.1158/0008-5472.CAN-10-0194; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Moroz E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005077; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Thomas H.E., 2012, SCI TRANSL MED, V4, pra184; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263; Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057; Zhang M, 2010, INT J RADIAT ONCOL, V78, P1095, DOI 10.1016/j.ijrobp.2009.09.007; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	51	120	122	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1828	1839		10.1038/onc.2013.122	http://dx.doi.org/10.1038/onc.2013.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624914	Green Accepted			2022-12-17	WOS:000334345500009
J	Neilsen, PM; Noll, JE; Mattiske, S; Bracken, CP; Gregory, PA; Schulz, RB; Lim, SP; Kumar, R; Suetani, RJ; Goodall, GJ; Callen, DF				Neilsen, P. M.; Noll, J. E.; Mattiske, S.; Bracken, C. P.; Gregory, P. A.; Schulz, R. B.; Lim, S. P.; Kumar, R.; Suetani, R. J.; Goodall, G. J.; Callen, D. F.			Mutant p53 drives invasion in breast tumors through up-regulation of miR-155	ONCOGENE			English	Article						breast cancer; invasion; miR-155; mutant p53; ZNF652	CANCER PATIENTS; GENE; EXPRESSION; MICRORNA-155; METASTASIS; GROWTH; TRANSITION; CARCINOMA; CELLS; PDCD4	Loss of p53 function is a critical event during tumorigenesis, with half of all cancers harboring mutations within the TP53 gene. Such events frequently result in the expression of a mutated p53 protein with gain-of-function properties that drive invasion and metastasis. Here, we show that the expression of miR-155 was up-regulated by mutant p53 to drive invasion. The miR-155 host gene was directly repressed by p63, providing the molecular basis for mutant p53 to drive miR-155 expression. Significant overlap was observed between miR-155 targets and the molecular profile of mutant p53-expressing breast tumors in vivo. A search for cancer-related target genes of miR-155 revealed ZNF652, a novel zinc-finger transcriptional repressor. ZNF652 directly repressed key drivers of invasion and metastasis, such as TGFB1, TGFB2, TGFBR2, EGFR, SMAD2 and VIM. Furthermore, silencing of ZNF652 in epithelial cancer cell lines promoted invasion into matrigel. Importantly, loss of ZNF652 expression in primary breast tumors was significantly correlated with increased local invasion and defined a population of breast cancer patients with metastatic tumors. Collectively, these findings suggest that miR-155 targeted therapies may provide an attractive approach to treat mutant p53-expressing tumors.	[Neilsen, P. M.; Noll, J. E.; Mattiske, S.; Schulz, R. B.; Lim, S. P.; Kumar, R.; Suetani, R. J.; Callen, D. F.] Univ Adelaide, Ctr Personalised Canc Med, Adelaide, SA 5005, Australia; [Neilsen, P. M.; Noll, J. E.; Mattiske, S.; Bracken, C. P.; Gregory, P. A.; Schulz, R. B.; Lim, S. P.; Kumar, R.; Suetani, R. J.; Goodall, G. J.; Callen, D. F.] Univ Adelaide, Discipline Med, Adelaide, SA 5005, Australia; [Bracken, C. P.; Gregory, P. A.; Goodall, G. J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Goodall, G. J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide; Centre for Cancer Biology; SA Pathology; University of Adelaide	Neilsen, PM (corresponding author), Univ Adelaide, Ctr Personalised Canc Med, Sarcoma Res Grp, Adelaide, SA 5005, Australia.	Paul.Neilsen@health.sa.gov.au	Callen, David F/G-1975-2012; Gregory, Philip/F-4089-2013; Kumar, Raman/AHE-0538-2022	Gregory, Philip/0000-0002-0999-0632; Kumar, Raman/0000-0001-7976-8386; Bracken, Cameron/0000-0001-7722-625X; Noll, Jacqueline/0000-0001-7375-635X; Goodall, Gregory/0000-0003-1294-0692; Neilsen, Paul/0000-0001-7937-3675; Callen, David/0000-0002-6189-9991	National Health and Medical Research Council (NHMRC) of Australia [1009447]; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); National Breast Cancer Foundation	We thank Dr Erik Flemington for his kind gift of the pMSCV-Puro-GFP-miR-155 plasmid. We also thank Dr Emily Paterson and Bee Suan Tay for technical assistance. This study was supported by the National Health and Medical Research Council (NHMRC) of Australia (project # 1009447).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brosh R, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.65; DAVIDOFF AM, 1991, J SURG ONCOL, V48, P260, DOI 10.1002/jso.2930480409; Do TV, 2008, MOL CANCER RES, V6, P695, DOI 10.1158/1541-7786.MCR-07-0294; Huang Y, 2011, CELL DEATH DIFFER, V18, P1220, DOI 10.1038/cdd.2010.188; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Kumar R, 2008, J BIOL CHEM, V283, P19026, DOI 10.1074/jbc.M709136200; Kumar R, 2006, MOL CANCER RES, V4, P655, DOI 10.1158/1541-7786.MCR-05-0249; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieves-Alicea R, 2009, BREAST CANCER RES TR, V114, P203, DOI 10.1007/s10549-008-9993-5; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pishas KI, 2011, CLIN CANCER RES, V17, P494, DOI 10.1158/1078-0432.CCR-10-1587; Santhanam AN, 2010, ONCOGENE, V29, P3921, DOI 10.1038/onc.2010.158; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Utku Y, 2006, MOL BIOSYST, V2, P312, DOI 10.1039/b603229j; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wen YH, 2007, ONCOL REP, V18, P1387; Xiang X, 2011, ONCOGENE, V30, P3440, DOI 10.1038/onc.2011.54; Xu GR, 2010, RNA, V16, P1610, DOI 10.1261/rna.2194910; Yin QY, 2008, J VIROL, V82, P5295, DOI 10.1128/JVI.02380-07; Yu Q, 2004, CLIN EXP METASTAS, V21, P235, DOI 10.1023/B:CLIN.0000037705.25256.d3	38	120	124	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2992	3000		10.1038/onc.2012.305	http://dx.doi.org/10.1038/onc.2012.305			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797073	Green Published			2022-12-17	WOS:000320369700009
J	Bian, Y; Hall, B; Sun, ZJ; Molinolo, A; Chen, W; Gutkind, JS; Waes, CV; Kulkarni, AB				Bian, Y.; Hall, B.; Sun, Z-J; Molinolo, A.; Chen, W.; Gutkind, J. S.; Waes, C. V.; Kulkarni, A. B.			Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation	ONCOGENE			English	Article						TGF-beta; PI3K/Akt; head and neck squamous cell carcinoma; conditional knockout; cancer mouse model	GROWTH-FACTOR-BETA; FACTOR-KAPPA-B; MAMMARY-CARCINOMA; TUMOR-SUPPRESSOR; COLON-CANCER; ACTIVATION; PATHWAYS; GENE; EXPRESSION; EPITHELIA	The molecular mechanisms that contribute to the initiation and progression of head and neck squamous cell carcinoma (HNSCC) have not been completely delineated. Our observations indicate that defects in the transforming growth factor-beta and PI3K/Akt signaling pathways are common in human HNSCCs. Conditional activation of the PI3K/Akt pathway due to Pten deletion in the mouse head and neck epithelia gives rise to hyperproliferation, but only a few lesions progress to HNSCC. However, Pten-deficient mice developed full-penetrance HNSCC in combination with type I TGF-beta receptor (Tgfbr1) deletion. Molecular analysis revealed enhanced cell proliferation, decreased apoptosis, and increased expression of CCND1 in the basal layer of the head and neck epithelia, as well as in the tumors of Tgfbr1/Pten double conditional knockout (2cKO) mice. Furthermore, neoplastic transformation involves senescence evasion, and is associated with an increased number of putative cancer stem cells. In addition, the nuclear factor-kappa B pathway activation, myeloid-derived suppressor cell infiltration, angiogenesis and immune suppression in the tumor microenvironment, all of which are characteristics of human HNSCCs, contribute significantly to head and neck carcinogenesis in 2cKO mice. These tumors display pathology and multiple molecular alterations resembling human HNSCCs. This suggests that the Tgfbr1/Pten 2cKO mouse model is suitable for preclinical intervention, and that it has significant implications in the development of diagnostic cancer biomarkers and effective strategies for prevention and treatment of HNSCCs. Oncogene (2012) 31, 3322-3332; doi: 10.1038/onc.2011.494; published online 31 October 2011	[Kulkarni, A. B.] Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA; [Molinolo, A.; Gutkind, J. S.] Oral & Pharyngeal Canc Branch, Bethesda, MD USA; [Chen, W.] Natl Inst Dent & Craniofacial Res, Mucosal Immun Sect, Oral Immun & Infect Branch, Bethesda, MD 20892 USA; [Bian, Y.; Waes, C. V.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Kulkarni, AB (corresponding author), Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, 30 Convent Dr,Bldg 30,Room 130, Bethesda, MD 20892 USA.	ak40m@nih.gov	Sun, Zhi-Jun/AAD-8791-2022; Gutkind, J. Silvio/J-1201-2016	Sun, Zhi-Jun/0000-0003-0932-8013; Gutkind, J. Silvio/0000-0002-5150-4482	Divisions of Intramural Research, National Institute of Dental and Craniofacial Research [Z01-DE-000698]; National Institute on Deafness and Communication Disorders, NIH [ZIA-DC-000073]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000723, ZIADE000558, ZIADE000664, ZIADE000101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073] Funding Source: NIH RePORTER	Divisions of Intramural Research, National Institute of Dental and Craniofacial Research; National Institute on Deafness and Communication Disorders, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We would like to thank Dr Stefan Karlsson for providing us with the Tgfbr1 flox mice, Drs Raj Puri and Lalage Wakefield for critical reading of the manuscript, Drs Juan Du, Ping Zhang, Zhong Chen and Anita Terse for technical help, and Shelagh Johnson for the expert editorial assistance. This work was supported by the Divisions of Intramural Research, National Institute of Dental and Craniofacial Research (Z01-DE-000698), and National Institute on Deafness and Communication Disorders (ZIA-DC-000073), NIH.	Bian YS, 2009, CANCER RES, V69, P5918, DOI 10.1158/0008-5472.CAN-08-4623; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854; Chen TP, 2001, INT J CANCER, V93, P653, DOI 10.1002/ijc.1381; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen Z, 2009, J ONCOL, V2009, DOI 10.1155/2009/894064; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Curado MP, 2009, CURR OPIN ONCOL, V21, P194, DOI 10.1097/CCO.0b013e32832a68ca; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Deshpande AM, 2008, EXPERT REV ANTICANC, V8, P799, DOI 10.1586/14737140.8.5.799; Engle SJ, 1999, CANCER RES, V59, P3379; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Henderson YC, 1998, LARYNGOSCOPE, V108, P1553, DOI 10.1097/00005537-199810000-00024; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kim JS, 2007, MOL CELL BIOL, V27, P662, DOI 10.1128/MCB.00537-06; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Lee JY, 2009, ONCOGENE, V28, P824, DOI 10.1038/onc.2008.451; Lee JI, 2001, ARCH OTOLARYNGOL, V127, P1441, DOI 10.1001/archotol.127.12.1441; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Lu SL, 2004, CANCER RES, V64, P4405, DOI 10.1158/0008-5472.CAN-04-1032; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Molinolo AA, 2009, ORAL ONCOL, V45, P324, DOI 10.1016/j.oraloncology.2008.07.011; Moral M, 2009, CANCER RES, V69, P1099, DOI 10.1158/0008-5472.CAN-08-3240; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Pasche B, 2005, JAMA-J AM MED ASSOC, V294, P1634, DOI 10.1001/jama.294.13.1634; Pedrero JMG, 2005, INT J CANCER, V114, P242, DOI 10.1002/ijc.20711; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO;2-8; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Tang B, 2007, CANCER RES, V67, P8643, DOI 10.1158/0008-5472.CAN-07-0982; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Vijayachandra K, 2009, MOL CARCINOGEN, V48, P181, DOI 10.1002/mc.20472; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 2008, CANCER RES, V68, P3152, DOI 10.1158/0008-5472.CAN-07-5348; White RA, 2010, ONCOGENE, V29, P5437, DOI 10.1038/onc.2010.306; Xie W, 2003, ONCOL RES, V14, P61, DOI 10.3727/000000003108748612; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	51	120	124	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	28					3322	3332		10.1038/onc.2011.494	http://dx.doi.org/10.1038/onc.2011.494			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22037217	Green Accepted			2022-12-17	WOS:000306367600002
J	Medema, RH; Macurek, L				Medema, R. H.; Macurek, L.			Checkpoint control and cancer	ONCOGENE			English	Review						DNA damage; checkpoint; cancer; checkpoint recovery	DNA-DAMAGE CHECKPOINT; POLO-LIKE KINASE-1; ACTIVATED PROTEIN-KINASE; CELL-CYCLE; WIP1 PHOSPHATASE; TUMOR-SUPPRESSOR; DEPENDENT DEGRADATION; IONIZING-RADIATION; CDC25A DEGRADATION; ANALYSIS REVEALS	DNA-damaging therapies represent the most frequently used non-surgical anticancer strategies in the treatment of human tumors. These therapies can kill tumor cells, but at the same time they can be particularly damaging and mutagenic to healthy tissues. The efficacy of DNA-damaging treatments can be improved if tumor cell death is selectively enhanced, and the recent application of poly-(ADP-ribose) polymerase inhibitors in BRCA1/2-deficient tumors is a successful example of this. DNA damage is known to trigger cell-cycle arrest through activation of DNA-damage checkpoints. This arrest can be reversed once the damage has been repaired, but irreparable damage can promote apoptosis or senescence. Alternatively, cells can reenter the cell cycle before repair has been completed, giving rise to mutations. In this review we discuss the mechanisms involved in the activation and inactivation of DNA-damage checkpoints, and how the transition from arrest and cell-cycle re-entry is controlled. In addition, we discuss recent attempts to target the checkpoint in anticancer strategies. Oncogene (2012) 31, 2601-2613; doi:10.1038/onc.2011.451; published online 3 October 2011	[Macurek, L.] Acad Sci Czech Republ, Inst Mol Genet, Dept Genome Integr, Prague 14200 4, Czech Republic; [Medema, R. H.] Univ Med Ctr, Dept Med Oncol, Utrecht, Netherlands	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Utrecht University; Utrecht University Medical Center	Macurek, L (corresponding author), Acad Sci Czech Republ, Inst Mol Genet, Dept Genome Integr, Videnska 1083, Prague 14200 4, Czech Republic.	libor.macurek@img.cas.cz	Medema, Rene H/E-2981-2013; Macurek, Libor/C-7865-2014	Macurek, Libor/0000-0002-0987-1238; Medema, Rene/0000-0002-6754-0381	Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research; Dutch Cancer Society [UU2009-4478]; Grant Agency of the Czech Republic [P301/10/1525, P305/10/P420]	Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research; Dutch Cancer Society(KWF Kankerbestrijding); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic)	RHM was funded by the Netherlands Genomics Initiative of the Netherlands Organization for Scientific Research and by the Dutch Cancer Society (Grant UU2009-4478). LM was supported by the Grant Agency of the Czech Republic (P301/10/1525 and P305/10/P420).	Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2000, CANCER RES, V60, P5934; Alvarez-Fernandez M, 2010, EMBO REP, V11, P452, DOI 10.1038/embor.2010.46; Anderson VE, 2011, CANCER RES, V71, P463, DOI 10.1158/0008-5472.CAN-10-1252; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Batchelor E, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.20; Batchelor E, 2009, NAT REV CANCER, V9, P371, DOI 10.1038/nrc2604; Bekker-Jensen S, 2010, DNA REPAIR, V9, P1219, DOI 10.1016/j.dnarep.2010.09.010; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Bennetzen MV, 2010, MOL CELL PROTEOMICS, V9, P1314, DOI 10.1074/mcp.M900616-MCP200; Bensimon A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001034; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carlessi L, 2010, BBA-MOL CELL RES, V1803, P1213, DOI 10.1016/j.bbamcr.2010.06.002; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chailleux C, 2010, BIOCHEM J, V426, P365, DOI 10.1042/BJ20091329; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cotta-Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430; Cuadrado M, 2009, CANCER RES, V69, P8726, DOI 10.1158/0008-5472.CAN-09-0729; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Ferguson AM, 2005, MOL CELL BIOL, V25, P2853, DOI 10.1128/MCB.25.7.2853-2860.2005; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Fracasso PM, 2011, CANCER CHEMOTH PHARM, V67, P1225, DOI 10.1007/s00280-010-1410-1; Freeman AK, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-27; Freeman AK, 2010, CELL CYCLE, V9, P736, DOI 10.4161/cc.9.4.10613; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gupta M, 2006, J BIOL CHEM, V281, P17552, DOI 10.1074/jbc.M600950200; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hirai H, 2010, CANCER BIOL THER, V9, P514, DOI 10.4161/cbt.9.7.11115; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jin J, 2008, J BIOL CHEM, V283, P19322, DOI 10.1074/jbc.M802474200; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kasahara K, 2010, EMBO J, V29, P2802, DOI 10.1038/emboj.2010.157; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Kuntz K, 2009, CANCER BIOL THER, V8, P1433, DOI 10.4161/cbt.8.15.9081; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Lara PN, 2005, CLIN CANCER RES, V11, P4444, DOI 10.1158/1078-0432.CCR-04-2602; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Lee JH, 2010, EMBO J, V29, P574, DOI 10.1038/emboj.2009.372; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Leung-Pineda V, 2006, MOL CELL BIOL, V26, P7529, DOI 10.1128/MCB.00447-06; Li HH, 2007, EMBO J, V26, P402, DOI 10.1038/sj.emboj.7601519; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Liontos M, 2010, J CELL MOL MED, V14, P2264, DOI 10.1111/j.1582-4934.2010.01145.x; Liu QH, 2000, GENE DEV, V14, P1448; Liu XS, 2010, EMBO REP, V11, P626, DOI 10.1038/embor.2010.90; Lobjois V, 2009, BBA-MOL CELL RES, V1793, P462, DOI 10.1016/j.bbamcr.2008.12.015; Loewer A, 2010, CELL, V142, P89, DOI 10.1016/j.cell.2010.05.031; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2006, MOL CELL, V23, P307, DOI 10.1016/j.molcel.2006.06.016; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Maya-Mendoza A, 2007, EMBO J, V26, P2719, DOI 10.1038/sj.emboj.7601714; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Menzel T, 2011, EMBO REP, V12, P705, DOI 10.1038/embor.2011.99; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Peng AM, 2010, CURR BIOL, V20, P387, DOI 10.1016/j.cub.2010.01.020; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Phong MS, 2010, MOL CELL BIOL, V30, P3816, DOI 10.1128/MCB.00949-09; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Satoh N, 2011, CANCER SCI, V102, P1101, DOI 10.1111/j.1349-7006.2011.01898.x; Secchiero P, 2011, CURR PHARM DESIGN, V17, P569, DOI 10.2174/138161211795222586; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shen H, 2011, CURR PHARM DESIGN, V17, P560, DOI 10.2174/138161211795222603; Shibata A, 2010, MOL CELL BIOL, V30, P3371, DOI 10.1128/MCB.01644-09; Shouse GP, 2011, ONCOGENE, V30, P3755, DOI 10.1038/onc.2011.95; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2011, CLIN CANCER RES, V17, P1521, DOI 10.1158/1078-0432.CCR-10-1688; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Tsvetkov L, 2005, CELL CYCLE, V4, P166, DOI 10.4161/cc.4.1.1348; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang P, 2011, J HUAZHONG U SCI-MED, V31, P94, DOI 10.1007/s11596-011-0157-1; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang YL, 2001, CANCER RES, V61, P8211; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhang XN, 2009, CANCER RES, V69, P7960, DOI 10.1158/0008-5472.CAN-09-0634; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	155	120	121	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2601	2613		10.1038/onc.2011.451	http://dx.doi.org/10.1038/onc.2011.451			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21963855				2022-12-17	WOS:000304523500001
J	Caron, C; Lestrat, C; Marsal, S; Escoffier, E; Curtet, S; Virolle, V; Barbry, P; Debernardi, A; Brambilla, C; Brambilla, E; Rousseaux, S; Khochbin, S				Caron, C.; Lestrat, C.; Marsal, S.; Escoffier, E.; Curtet, S.; Virolle, V.; Barbry, P.; Debernardi, A.; Brambilla, C.; Brambilla, E.; Rousseaux, S.; Khochbin, S.			Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers	ONCOGENE			English	Article						H4 K5ac; proteasome; chromatin; histone; epigenetics	GENE-EXPRESSION; HISTONE CODE; PROTEIN; BOUNDARY; COACTIVATOR; ATPASE; ROLES; ANCCA	Cancer cells frequently express genes normally active in male germ cells. ATAD2 is one of them encoding a conserved factor harbouring an AAA type ATPase domain and a bromodomain. We show here that ATAD2 is highly expressed in testis as well as in many cancers of different origins and that its high expression is a strong predictor of rapid mortality in lung and breast cancers. These observations suggest that ATAD2 acts on upstream and basic cellular processes to enhance oncogenesis in a variety of unrelated cell types. Accordingly, our functional studies show that ATAD2 controls chromatin dynamics, genome transcriptional activities and apoptotic cell response. We could also highlight some of the important intrinsic properties of its two regulatory domains, including a functional cross-talk between the AAA ATPase domain and the bromodomain. Altogether, these data indicate that ATAD2 overexpression in somatic cells, by acting on basic properties of chromatin, may contribute to malignant transformation. Oncogene (2010) 29, 5171-5181; doi:10.1038/onc.2010.259; published online 28 June 2010	[Caron, C.; Lestrat, C.; Marsal, S.; Escoffier, E.; Curtet, S.; Debernardi, A.; Brambilla, C.; Brambilla, E.; Rousseaux, S.; Khochbin, S.] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France; [Virolle, V.; Barbry, P.] CNRS, Sophia Antipolis, France; [Virolle, V.; Barbry, P.] Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Caron, C (corresponding author), INSERM, Inst Albert Bonniot, F-38706 La Tronche, Isere, France.	cecile.caron@ujf-grenoble.fr; khochbin@ujf-grenoble.fr	CURTET, Sandrine/E-8217-2019; Khochbin, Saadi/M-8090-2013; CURTET, Sandrine/N-3517-2013; Barbry, Pascal/O-5021-2016; Rousseaux, Sophie/G-1697-2013; debernardi, alexandra/N-4220-2013	CURTET, Sandrine/0000-0002-9419-8868; Khochbin, Saadi/0000-0002-0455-0857; Barbry, Pascal/0000-0001-9632-6483; Rousseaux, Sophie/0000-0001-5246-5350; 	ANR blanc-Episperm; INCa-DHOS; ARC-ARECA; Region Rhone-Alpes; INCa [AO 2006]; Nice-Sophia Antipolis Transcriptome Platform of the Marseille-Nice Genopole; Albert Bonniot Institute; Grenoble	ANR blanc-Episperm(French National Research Agency (ANR)); INCa-DHOS; ARC-ARECA; Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); INCa(Institut National du Cancer (INCA) France); Nice-Sophia Antipolis Transcriptome Platform of the Marseille-Nice Genopole; Albert Bonniot Institute; Grenoble(Region Auvergne-Rhone-Alpes)	This work was supported by the 'ANR blanc-Episperm', INCa-DHOS' and 'ARC-ARECA' research programs. CL and SM are supported by the PhD fellowship program of Region Rhone-Alpes and the post-doc fellowship program of INCa (AO 2006), respectively. AD salary is paid by the INCa-DHOS funds. Transcriptomic analyses of lung cancer patients were obtained thanks to the Ligue Contre le Cancer 'Carte d'identite des Tumeurs' (CIT) program. We acknowledge the support of the Nice-Sophia Antipolis Transcriptome Platform of the Marseille-Nice Genopole, in which the microarray experiments were carried out. Special thanks are due to Geraldine Rios for microarray production. We also acknowledge the support of the microscopy platform, Albert Bonniot Institute, Grenoble, and thank Catherine Souchier for her precious help in the FRAP experiments.	Boussouar F, 2008, CELL CYCLE, V7, P3499, DOI 10.4161/cc.7.22.6975; Ciro M, 2009, CANCER RES, V69, P8491, DOI 10.1158/0008-5472.CAN-09-2131; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022; Fillingham J, 2009, MOL CELL, V35, P340, DOI 10.1016/j.molcel.2009.06.023; Gradolatto A, 2008, GENETICS, V179, P291, DOI 10.1534/genetics.107.086520; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Jambunathan N, 2005, GENETICS, V171, P913, DOI 10.1534/genetics.105.046938; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Pivot-Pajot C, 2003, MOL CELL BIOL, V23, P5354, DOI 10.1128/MCB.23.15.5354-5365.2003; Rousseaux S, 2009, EPIGENOMICS-UK, V1, P153, DOI 10.2217/EPI.09.1; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Tackett AJ, 2005, J CELL BIOL, V169, P35, DOI 10.1083/jcb.200502104; Tseng RJ, 2007, MOL GENET GENOMICS, V278, P507, DOI 10.1007/s00438-007-0265-6; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zou JX, 2007, P NATL ACAD SCI USA, V104, P18067, DOI 10.1073/pnas.0705814104; Zou JX, 2009, CANCER RES, V69, P3339, DOI 10.1158/0008-5472.CAN-08-3440	21	120	128	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5171	5181		10.1038/onc.2010.259	http://dx.doi.org/10.1038/onc.2010.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581866				2022-12-17	WOS:000281867200006
J	Morris, MR; Ricketts, C; Gentle, D; Abdulrahman, M; Clarke, N; Brown, M; Kishida, T; Yao, M; Latif, F; Maher, ER				Morris, M. R.; Ricketts, C.; Gentle, D.; Abdulrahman, M.; Clarke, N.; Brown, M.; Kishida, T.; Yao, M.; Latif, F.; Maher, E. R.			Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; methylation; epigenetics	HIPPEL-LINDAU-DISEASE; CLEAR-CELL; PROMOTER HYPERMETHYLATION; ABERRANT METHYLATION; TARGET GENES; EPIGENETIC INACTIVATION; BASEMENT-MEMBRANE; DNA METHYLATION; POOR-PROGNOSIS; MULTIPLE GENES	Promoter region hyermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many types of human cancers. Functional epigenetic studies, in which gene expression is induced by treatment with demethylating agents, may identify novel genes with tumour-specific methylation. We used high-density gene expression microarrays in a functional epigenetic study of 11 renal cell carcinoma (RCC) cell lines. Twenty-eight genes were then selected for analysis of promoter methylation status in cell lines and primary RCC. Eight genes (BNC1, PDLIM4, RPRM, CST6, SFRP1, GREM1, COL14A1 and COL15A1) showed frequent (>30% of RCC tested) tumour-specific promoter region methylation. Hypermethylation was associated with transcriptional silencing. Re-expression of BNC1, CST6, RPRM and SFRP1 suppressed the growth of RCC cell lines and RNA interference knock-down of BNC1, SFRP1 and COL14A1 increased the growth of RCC cell lines. Methylation of BNC1 or COL14A1 was associated with a poorer prognosis independent of tumour size, stage or grade. The identification of these epigenetically inactivated candidate RCC TSGs can provide insights into renal tumourigenesis and a basis for developing novel therapies and biomarkers for prognosis and detection. Oncogene (2010) 29, 2104-2117; doi: 10.1038/onc.2009.493; published online 15 February 2010	[Morris, M. R.; Ricketts, C.; Gentle, D.; Abdulrahman, M.; Latif, F.; Maher, E. R.] Univ Birmingham, Dept Med & Mol Genet, Inst Biomedi Res W, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Morris, M. R.; Ricketts, C.; Gentle, D.; Latif, F.; Maher, E. R.] Univ Birmingham, Canc Res UK Renal Mol Oncol Grp, Birmingham B15 2TT, W Midlands, England; [Clarke, N.; Brown, M.] Univ Manchester, Genito Urinary Canc Res Grp, Paterson Inst Canc Res, Manchester, Lancs, England; [Kishida, T.; Yao, M.] Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan; [Maher, E. R.] Birmingham Womens Hosp, W Midlands Reg Gent Serv, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; Paterson Institute for Cancer Research; University of Manchester; Yokohama City University; Birmingham Women's Hospital	Maher, ER (corresponding author), Univ Birmingham, Dept Med & Mol Genet, Inst Biomedi Res W, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	MAHER, EAMONN R/A-9507-2008; Brown, Mick/A-1308-2012; Brown, Mick D/N-6521-2015; Morris, Mark/C-6413-2008; Ricketts, Christopher/AAV-9580-2020	MAHER, EAMONN R/0000-0002-6226-6918; Brown, Mick D/0000-0003-1322-4671; Morris, Mark/0000-0002-0700-355X; Clarke, Noel/0000-0001-7776-8059; Abdulrahman, Mahera/0000-0001-6271-3776	Cancer Research UK; MRC [G0900871] Funding Source: UKRI; Medical Research Council [G0900871] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Cancer Research UK for financial support.	Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Amenta PS, 2005, J HISTOCHEM CYTOCHEM, V53, P165, DOI 10.1369/jhc.4A6376.2005; Awakura Y, 2008, ONCOL REP, V20, P1257, DOI 10.3892/or_00000138; Battagli C, 2003, CANCER RES, V63, P8695; Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522; Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289; Boumber YA, 2007, CANCER RES, V67, P1997, DOI 10.1158/0008-5472.CAN-06-3093; Brandan E, 2006, J BIOL CHEM, V281, P31562, DOI 10.1074/jbc.M602919200; Breault JE, 2005, CLIN CANCER RES, V11, P557; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Chowdhury S, 2008, EUR J CANCER, V44, P2152, DOI 10.1016/j.ejca.2008.06.028; Christoph F, 2006, CLIN CANCER RES, V12, P5040, DOI 10.1158/1078-0432.CCR-06-0144; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Costa VL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-133; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Ehnis T, 1997, J BIOL CHEM, V272, P20414, DOI 10.1074/jbc.272.33.20414; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gonzalgo ML, 2004, CLIN CANCER RES, V10, P7276, DOI 10.1158/1078-0432.CCR-03-0692; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Harris A, 2007, MOL CANCER RES, V5, P1241, DOI 10.1158/1541-7786.MCR-07-0200; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799; Ibanez de Caceres I, 2006, CANCER RES, V66, P5021, DOI 10.1158/0008-5472.CAN-05-3365; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Mancini V, 2008, UROL ONCOL-SEMIN ORI, V26, P225, DOI 10.1016/j.urolonc.2007.05.017; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McRonald FE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-31; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Morrissey C, 2001, CANCER RES, V61, P7277; Nomoto S, 2007, BRIT J CANCER, V97, P1260, DOI 10.1038/sj.bjc.6604016; Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200; Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2006, CANCER-AM CANCER SOC, V107, P251, DOI 10.1002/cncr.21977; Schaefer L, 2007, AM J PATHOL, V170, P301, DOI 10.2353/ajpath.2007.060497; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340; Smits KM, 2008, CLIN CANCER RES, V14, P782, DOI 10.1158/1078-0432.CCR-07-1753; Suzuki M, 2005, BRIT J CANCER, V93, P1029, DOI 10.1038/sj.bjc.6602837; Takahashi T, 2005, INT J CANCER, V115, P503, DOI 10.1002/ijc.20910; Urakami S, 2006, CLIN CANCER RES, V12, P6989, DOI 10.1158/1078-0432.CCR-06-1194; Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198; Wistuba II, 2007, CURR MOL MED, V7, P3, DOI 10.2174/156652407779940468; Yamada D, 2006, INT J CANCER, V118, P916, DOI 10.1002/ijc.21450; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	57	120	128	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2104	2117		10.1038/onc.2009.493	http://dx.doi.org/10.1038/onc.2009.493			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20154727	Green Accepted, Green Submitted, Green Published			2022-12-17	WOS:000276402800009
J	Bauer, M; Su, G; Casper, C; He, R; Rehrauer, W; Friedl, A				Bauer, M.; Su, G.; Casper, C.; He, R.; Rehrauer, W.; Friedl, A.			Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast	ONCOGENE			English	Article						breast neoplasms; tumor stroma; fibroblasts; invasion	CANCER-ASSOCIATED FIBROBLASTS; TISSUE GROWTH-FACTOR; TUMOR-STROMA; STEM-CELLS; AUTOCRINE; TP53; MICROENVIRONMENT; TRANSFORMATION; MUTATIONS	Breast carcinoma invasion is associated with prominent alterations in stromal fibroblasts. Carcinoma-associated fibroblasts (CAF) support and promote tumorigenesis, whereas normal mammary fibroblasts (NF) are thought to suppress tumor progression. Little is known about the difference in gene expression between CAF and NF or the patient-to-patient variability in gene expression. Paired CAF and NF were isolated from six primary human breast carcinoma specimens. RNA was extracted from low-passage cultures of CAF and NF and analyzed with Affymetrix Human Genome U133 Plus 2.0 arrays. The array data were examined with an empirical Bayes model and filtered according to the posterior probability of equivalent expression and fold difference in expression. Twenty-one genes (27 probe sets) were up-regulated in CAF, as compared with NF. Known functions of these genes relate to paracrine or intracellular signaling, transcriptional regulation, extracellular matrix and cell adhesion/migration. Ten genes (14 probe sets) were down-regulated in CAF, including the pluripotency transcription factor KLF4. Quantitative RT-PCR analysis of 10 genes validated the array results. Immunohistochemical staining for three gene products confirmed stromal expression in terms of location and relative quantity. Surprisingly, the variability of gene expression was slightly higher in NF than in CAF, suggesting inter-individual heterogeneity of normal stroma. Oncogene (2010) 29, 1732-1740; doi:10.1038/onc.2009.463; published online 11 January 2010	[Bauer, M.; Su, G.; He, R.; Rehrauer, W.; Friedl, A.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; [Casper, C.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1111 Highland Ave,6051 WIMR,Mailcode 2275, Madison, WI 53706 USA.	afriedl@wisc.edu			Dr Mildred Scheel Stiftung; National Institutes of Health [RO1 CA107012]; Wisconsin Partnership program; NATIONAL CANCER INSTITUTE [R01CA107012] Funding Source: NIH RePORTER	Dr Mildred Scheel Stiftung(Deutsche Krebshilfe); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wisconsin Partnership program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Christina Kendziorski for help with the array analyses and Dr Korise Rasmusson for her assistance with the manuscript preparation. Maret Bauer was supported by a scholarship from the Dr Mildred Scheel Stiftung. This research was funded by National Institutes of Health grant RO1 CA107012 and a grant from the Wisconsin Partnership program.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Briand P, 1996, CANCER RES, V56, P2039; Campbell IG, 2008, NEW ENGL J MED, V358, P1634, DOI 10.1056/NEJMc086024; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Chang CF, 2007, FRONT BIOSCI-LANDMRK, V12, P4393, DOI 10.2741/2396; De Jong JS, 1998, J PATHOL, V184, P44; Duque JL, 2001, J UROLOGY, V165, P284, DOI 10.1097/00005392-200101000-00080; Erickson AC, 2003, EXPERT OPIN THER TAR, V7, P71, DOI 10.1517/14728222.7.1.71; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Iacobuzio-Donahue CA, 2002, CANCER RES, V62, P5351; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ji Q, 2004, CANCER RES, V64, P7610, DOI 10.1158/0008-5472.CAN-04-1608; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kendziorski CM, 2003, STAT MED, V22, P3899, DOI 10.1002/sim.1548; Kim YC, 2008, CANCER RES, V68, P10145, DOI 10.1158/0008-5472.CAN-08-2992; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; LeWitt PA, 2004, CLIN NEUROPHARMACOL, V27, P1, DOI 10.1097/00002826-200401000-00001; Massague J, 2007, NEW ENGL J MED, V356, P294, DOI 10.1056/NEJMe068292; Mercier I, 2008, CANCER BIOL THER, V7, P1212, DOI 10.4161/cbt.7.8.6220; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nakagawa H, 2004, ONCOGENE, V23, P7366, DOI 10.1038/sj.onc.1208013; Narita K, 2007, J BIOL CHEM, V282, P14413, DOI 10.1074/jbc.M611395200; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Patocs A, 2007, NEW ENGL J MED, V357, P2543, DOI 10.1056/NEJMoa071825; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; R Development Core Team, 2008, LANG ENV STAT COMP; Roukos DH, 2008, NEW ENGL J MED, V358, P1636; Singer CF, 2002, BREAST CANCER RES TR, V72, P69, DOI 10.1023/A:1014918512569; Singer CF, 2008, BREAST CANCER RES TR, V110, P273, DOI 10.1007/s10549-007-9725-2; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sutmuller M, 1997, HISTOL HISTOPATHOL, V12, P557; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tang Y, 2004, MOL CANCER RES, V2, P73; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Xie D, 2001, CANCER RES, V61, P8917; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006	45	120	131	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1732	1740		10.1038/onc.2009.463	http://dx.doi.org/10.1038/onc.2009.463			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062080	Green Accepted			2022-12-17	WOS:000276022800003
J	Ostenfeld, MS; Bramsen, JB; Lamy, P; Villadsen, SB; Fristrup, N; Sorensen, KD; Ulhoi, B; Borre, M; Kjems, J; Dyrskjot, L; Orntoft, TF				Ostenfeld, M. S.; Bramsen, J. B.; Lamy, P.; Villadsen, S. B.; Fristrup, N.; Sorensen, K. D.; Ulhoi, B.; Borre, M.; Kjems, J.; Dyrskjot, L.; Orntoft, T. F.			miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors	ONCOGENE			English	Article						miRNA; bladder cancer; cell death; caspases; microarray	BREAST-CANCER; COLON-CANCER; PROSTATE-CANCER; MICRORNAS; TRANSLATION; DIAGNOSIS; LEUKEMIA; GROWTH; GENES; P53	Downregulation of miR-145 in a variety of cancers suggests a possible tumor suppressor function for this microRNA. Here, we show that miR-145 expression is reduced in bladder cancer and urothelial carcinoma in situ, compared with normal urothelium, using transcription profiling and in situ hybridization. Ectopic expression of miR-145 induced extensive apoptosis in urothelial carcinoma cell lines (T24 and SW780) as characterized by caspase activation, nuclear condensation and fragmentation, cellular shrinkage, and detachment. However, cell death also proceeded upon caspase inhibition by the pharmacological inhibitor zVAD-fmk and ectopic expression of anti-apoptotic Bcl-2, indicating the activation of an alternative caspase-independent death pathway. Microarray analysis of transcript levels in T24 cells, before the onset of cell death, showed destabilization of mRNAs enriched for miR-145 7mer target sites. Among these, direct targeting of CBFB, PPP3CA, and CLINT1 was confirmed by a luciferase reporter assay. Notably, a 22-gene signature targeted on enforced miR-145 expression in T24 cells was significantly (P < 0.00003) upregulated in 55 Ta bladder tumors with concomitant reduction of miR-145. Our data indicate that reduction in miR-145 expression may provide bladder cancer cells with a selective advantage by inhibition of cell death otherwise triggered in malignant cells. Oncogene (2010) 29, 1073-1084; doi:10.1038/onc.2009.395; published online 16 November 2009	[Ostenfeld, M. S.; Lamy, P.; Fristrup, N.; Sorensen, K. D.; Dyrskjot, L.; Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark; [Bramsen, J. B.; Villadsen, S. B.; Kjems, J.] Univ Aarhus, Dept Mol Biol, Aarhus C, Denmark; [Lamy, P.] Univ Aarhus, Bioinformat Res Ctr, BiRC, Aarhus C, Denmark; [Ulhoi, B.] Aarhus Hosp, Inst Pathol NBG, Aarhus, Denmark; [Borre, M.] Aarhus Univ Hosp, Dept Urol, Skejby, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University	Orntoft, TF (corresponding author), Aarhus Univ Hosp, Dept Mol Med, DK-8000 Aarhus N, Denmark.	orntoft@ki.au.dk	Kjems, Jorgen/I-3490-2016; Dyrskjot, Lars/H-4922-2012	Kjems, Jorgen/0000-0003-4128-9317; Sorensen, Karina Dalsgaard/0000-0002-4902-5490; Borre, Michael/0000-0002-1519-9185	Ministry of Technology and Science; John and Birthe Meyer Foundation; Lundbeck Foundation; Danish Cancer Society; European Community [201663]	Ministry of Technology and Science; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); European Community(European Commission)	We thank Gitte Hoj, Pamela Celis, Hanne Steen, Inge-Lis Thorsen, Gitte Stougard, and Conni Sorensen for technical assistance. We are grateful to M Jaattela for providing the pCEP4 Bcl-2 vector construct and to Thomas B Hansen for methylation analysis software. We thank the staff at the Departments of Urology, Clinical Biochemistry, and Pathology at Aarhus University Hospital. This work was supported by the Ministry of Technology and Science, The John and Birthe Meyer Foundation, the Lundbeck Foundation, and the Danish Cancer Society, and the European Community's Seventh framework program (FP7/2007-2013) under grant agreement no 201663.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dyrskjot L, 2005, CLIN CANCER RES, V11, P4029, DOI 10.1158/1078-0432.CCR-04-2095; Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hart SM, 2002, HAEMATOLOGICA, V87, P1307; Horrigan SK, 1996, BLOOD, V88, P2665, DOI 10.1182/blood.V88.7.2665.bloodjournal8872665; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kagoshima H, 2007, DEVELOPMENT, V134, P3905, DOI 10.1242/dev.008276; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Kim R, 2006, J PATHOL, V208, P319, DOI 10.1002/path.1885; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Litynska A, 2000, ACTA BIOCHIM POL, V47, P427; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mitra AP, 2007, WORLD J UROL, V25, P563, DOI 10.1007/s00345-007-0197-0; Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317; Nuovo GJ, 2008, METHODS, V44, P39, DOI 10.1016/j.ymeth.2007.10.008; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269; Ow YLP, 2008, NAT REV MOL CELL BIO, V9, P532, DOI 10.1038/nrm2434; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645	40	120	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	2010	29	7					1073	1084		10.1038/onc.2009.395	http://dx.doi.org/10.1038/onc.2009.395			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19915607				2022-12-17	WOS:000274604400013
J	Wu, Y; Siadaty, MS; Berens, ME; Hampton, GM; Theodorescu, D				Wu, Y.; Siadaty, M. S.; Berens, M. E.; Hampton, G. M.; Theodorescu, D.			Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration	ONCOGENE			English	Article						mechanism of cell movement; metastasis; gene expression; transcriptional profiling	STROMAL VERSICAN EXPRESSION; METASTASIS SUPPRESSOR GENE; BREAST-CANCER; CARCINOMA; IDENTIFICATION; MICROARRAYS; DISCOVERY; RHOGD12; PATHWAY; CD24	Cell migration is essential to cancer invasion and metastasis and is spatially and temporally integrated through transcriptionally dependent and independent mechanisms. As cell migration is studied in vitro, it is important to identify genes that both drive cell migration and are biologically relevant in promoting invasion and metastasis in patients with cancer. Here, gene expression profiling and a high-throughput cell migration system answers this question in human bladder cancer. In vitro migration rates of 40 microarray-profiled human bladder cancer cell lines were measured by radial migration assay. Genes whose expression was either directly or inversely associated with cell migration rate were identified and subsequently evaluated for their association with cancer stage in 61 patients. This analysis identified genes known to be associated with cell invasion such as versican, and novel ones, including metallothionein 1E (MT1E) and nicotinamide N-methyltransferase (NNMT), whose expression correlated positively with cancer cell migration and tumor stage. Using loss of function analysis, we show that MT1E and NNMT are necessary for cancer cell migration. These studies provide a general approach to identify the clinically relevant genes in cancer cell migration and mechanistically implicate two novel genes in this process in human bladder cancer.	[Wu, Y.; Theodorescu, D.] Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Siadaty, M. S.] Univ Virginia, Hlth Sci Ctr, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA; [Berens, M. E.] Translat Genom Res Inst, Canc & Cell Biol Div, Phoenix, AZ USA; [Hampton, G. M.] Novartis Res Fdn, Genom Inst, San Diego, CA USA	University of Virginia; University of Virginia; Translational Genomics Research Institute; Novartis	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NIH [CA075115]; NATIONAL CANCER INSTITUTE [R29CA075115, R01CA075115] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Jay Fox and Dr Yongde Bao of the University of Virginia Array Core facility for their assistance with chip hybridization. We also thank Dr Martin A Schwartz and Dr Konstadinos Moissoglu of the Cardiovascular Research Center, University of Virginia for their assistance with time-lapse microscopy. Mr Christian Beaudry at TGen performed the high-throughput cell migration experiments. This work was supported by NIH grant CA075115 to DT.	Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385; AKSOY S, 1994, J BIOL CHEM, V269, P14835; AKSOY S, 1995, GENOMICS, V29, P555, DOI 10.1006/geno.1995.9966; Altevogt P, 1988, Adv Exp Med Biol, V233, P253; Berens ME, 2004, METH MOLEC MED, V88, P219; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Chung MJ, 2006, J AGR FOOD CHEM, V54, P3819, DOI 10.1021/jf060510y; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; de Rooij J, 2005, J CELL BIOL, V171, P153, DOI 10.1083/jcb.200506152; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Faried A, 2006, EUR J CANCER, V42, P1455, DOI 10.1016/j.ejca.2006.02.012; Friederichs J, 2000, CANCER RES, V60, P6714; Friedline JA, 1998, AM J PATHOL, V152, P23; Gildea JJ, 2002, CANCER RES, V62, P6418; GORDON JN, 1993, CANCER RES, V53, P4971; Grate LR, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-97; Havaleshko DM, 2007, MOL CANCER THER, V6, P578, DOI 10.1158/1535-7163.MCT-06-0497; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jin R, 2000, BRIT J CANCER, V83, P319, DOI 10.1054/bjoc.2000.1276; JONES RF, 1992, J CANCER RES CLIN, V118, P411, DOI 10.1007/BF01629423; Kodama J, 2007, ANN ONCOL, V18, P269, DOI 10.1093/annonc/mdl370; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Li CJ, 2007, FUNCT INTEGR GENOMIC, V7, P193, DOI 10.1007/s10142-006-0043-2; Lim BH, 2006, EXP MOL MED, V38, P455, DOI 10.1038/emm.2006.54; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; Margolis EJ, 1996, CANCER LETT, V100, P163, DOI 10.1016/0304-3835(95)04096-X; Mayburd AL, 2006, CLIN CANCER RES, V12, P1820, DOI 10.1158/1078-0432.CCR-05-2149; Modlich O, 2004, CLIN CANCER RES, V10, P3410, DOI 10.1158/1078-0432.CCR-03-0134; Mukai M, 2006, BIOCHEM BIOPH RES CO, V346, P74, DOI 10.1016/j.bbrc.2006.05.068; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Pukkila M, 2007, J CLIN PATHOL, V60, P267, DOI 10.1136/jcp.2005.034181; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ricciardelli C, 1999, CANCER RES, V59, P2324; Roessler M, 2005, CLIN CANCER RES, V11, P6550, DOI 10.1158/1078-0432.CCR-05-0983; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sanchez-Carbayo M, 2003, AM J PATHOL, V163, P505, DOI 10.1016/S0002-9440(10)63679-6; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Su AI, 2001, CANCER RES, V61, P7388; *TEAM RDC, 2003, R REF MAN; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Thykjaer T, 2001, CANCER RES, V61, P2492; Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008-5472.CAN-05-1403; van Delft JHM, 2005, MUTAT RES-FUND MOL M, V575, P17, DOI 10.1016/j.mrfmmm.2005.02.006; Witjes JA, 2006, EUR UROL, V49, P790, DOI 10.1016/j.eururo.2006.01.017; Xu JM, 2003, J CLIN ENDOCR METAB, V88, P4990, DOI 10.1210/jc.2002-021843; Yao M, 2005, J PATHOL, V205, P377, DOI 10.1002/path.1693; Zheng PS, 2004, FASEB J, V18, P754, DOI 10.1096/fj.03-0545fje	52	120	127	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6679	6689		10.1038/onc.2008.264	http://dx.doi.org/10.1038/onc.2008.264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18724390	Green Accepted			2022-12-17	WOS:000260638800006
J	Lukasiak, S; Schiller, C; Oehlschlaeger, P; Schmidtke, G; Krause, P; Legler, DF; Autschbach, F; Schirmacher, P; Breuhahn, K; Groettrup, M				Lukasiak, S.; Schiller, C.; Oehlschlaeger, P.; Schmidtke, G.; Krause, P.; Legler, D. F.; Autschbach, F.; Schirmacher, P.; Breuhahn, K.; Groettrup, M.			Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon	ONCOGENE			English	Article						FAT10; ubiquitin-like modifiers; hepatocellular carcinoma; colon carcinoma; interferon-gamma	UBIQUITIN-LIKE PROTEIN; HUMAN HEPATOCELLULAR-CARCINOMA; INTERFERON-GAMMA; EXPRESSION; GENE; IDENTIFICATION; DEGRADATION; APOPTOSIS	The mRNA of the ubiquitin-like modifier FAT10 has been reported to be overexpressed in 90% of hepatocellular carcinoma (HCC) and in over 80% of colon, ovary and uterus carcinomas. Elevated FAT10 expression in malignancies was attributed to transcriptional upregulation upon the loss of p53. Moreover, FAT10 induced chromosome instability in long-term in vitro culture, which led to the hypothesis that FAT10 might be involved in carcinogenesis. In this study we show that interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha synergistically upregulated FAT10 expression in liver and colon cancer cells 10- to 100-fold. Real-time RT-PCR revealed that FAT10 mRNA was significantly overexpressed in 37 of 51 (72%) of human HCC samples and in 8 of 15 (53%) of human colon carcinomas. The FAT10 cDNA sequences in HCC samples were not mutated and intact FAT10 protein was detectable. FAT10 expression in both cancer tissues correlated with expression of the IFN-gamma- and TNF-alpha-dependent proteasome subunit LMP2 strongly suggesting that proinflammatory cytokines caused the joint overexpression of FAT10 and LMP2. NIH3T3 transformation assays revealed that FAT10 had no transforming capability. Taken together, FAT10 qualifies as a marker for an interferon response in HCC and colon carcinoma but is not significantly overexpressed in cancers lacking a proinflammatory environment.	[Lukasiak, S.; Oehlschlaeger, P.; Schmidtke, G.; Groettrup, M.] Univ Constance, Div Immunol, Dept Biol, D-78457 Constance, Germany; [Schiller, C.; Autschbach, F.; Schirmacher, P.; Breuhahn, K.] Univ Heidelberg, Inst Pathol, Univ Heidelberg Hosp, D-6900 Heidelberg, Germany; [Krause, P.; Legler, D. F.; Groettrup, M.] Univ Konstanz, Biotechnol Inst Thurgau, Kreuzlingen, Switzerland	University of Konstanz; Ruprecht Karls University Heidelberg	Groettrup, M (corresponding author), Univ Constance, Div Immunol, Dept Biol, Univ Str 10, D-78457 Constance, Germany.	marcus.groettrup@uni-konstanz.de	Groettrup, Marcus/AAT-2623-2020	Legler, Daniel F./0000-0001-8610-4764; Breuhahn, Kai/0000-0002-2462-1229	Fritz Thyssen Foundation [Az 10.05.1.145, Az 10.06.2.183]	Fritz Thyssen Foundation	We thank Klaus Scherrer for the contribution of the iota antibody and Gerardo Alvarez for excellent technical assistance. Darius Moradpour is acknowledged for the contribution of HCC cell lines. This work was supported from the grants Az 10.05.1.145 and Az 10.06.2.183 of the Fritz Thyssen Foundation.	Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Breuhahn K, 2004, CANCER RES, V64, P6058, DOI 10.1158/0008-5472.CAN-04-0292; Canaan A, 2006, MOL CELL BIOL, V26, P5180, DOI 10.1128/MCB.00966-05; Chiu YH, 2007, MOL CELL, V27, P1014, DOI 10.1016/j.molcel.2007.08.020; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Kern MA, 2002, ADV CANCER RES, V86, P67, DOI 10.1016/S0065-230X(02)86003-1; Khan S, 2001, J IMMUNOL, V167, P6859, DOI 10.4049/jimmunol.167.12.6859; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Legler DF, 2006, J IMMUNOL, V176, P966, DOI 10.4049/jimmunol.176.2.966; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Oliva J, 2008, EXP MOL PATHOL, V84, P102, DOI 10.1016/j.yexmp.2007.12.003; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Ren JW, 2006, J BIOL CHEM, V281, P11413, DOI 10.1074/jbc.M507218200; Ross MJ, 2006, J AM SOC NEPHROL, V17, P996, DOI 10.1681/ASN.2005070692; Stohwasser R, 1997, EUR J IMMUNOL, V27, P1182, DOI 10.1002/eji.1830270520; Zhang DW, 2006, ONCOGENE, V25, P2318, DOI 10.1038/sj.onc.1209220; Zhu LJ, 2005, ANAL BIOCHEM, V345, P102, DOI 10.1016/j.ab.2005.07.028	21	120	127	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2008	27	46					6068	6074		10.1038/onc.2008.201	http://dx.doi.org/10.1038/onc.2008.201			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18574467	Green Submitted			2022-12-17	WOS:000259891600009
J	Shields, JD; Emmett, MS; Dunn, DBA; Joory, KD; Sage, LM; Rigby, H; Mortimer, PS; Orlando, A; Levick, JR; Bates, DO				Shields, J. D.; Emmett, M. S.; Dunn, D. B. A.; Joory, K. D.; Sage, L. M.; Rigby, H.; Mortimer, P. S.; Orlando, A.; Levick, J. R.; Bates, D. O.			Chemokine-mediated migration of melanoma cells towards lymphatics - a mechanism contributing to metastasis	ONCOGENE			English	Article						chemotactic metastasis; melanoma; chemokine; CCL21; lymphangiogenesis	BREAST-CANCER METASTASIS; MALIGNANT-MELANOMA; NODE METASTASIS; TUMOR LYMPHANGIOGENESIS; CUTANEOUS MELANOMA; RECEPTOR CCR7; EXPRESSION; PROMOTES; SPREAD; SKIN	The mechanisms that cause tumors such as melanomas to metastasize into peripheral lymphatic capillaries are poorly defined. Non-mutually-exclusive mechanisms are lymphatic endothelial cell ( LEC) chemotaxis and proliferation in response to tumor cells ( chemotaxis-lymphangiogenesis hypothesis) or LECs may secrete chemotactic agents that attract cancer cells ( chemotactic metastasis hypothesis). Using migration assays, we found evidence supporting both hypotheses. Conditioned medium ( CM) from metastatic malignant melanoma ( MMM) cell lines attracted LEC migration, consistent with the lymphangiogenesis hypothesis. Conversely, CM from mixed endothelial cells or LECs, but not blood endothelial cells, attracted MMM cells but not non-metastatic melanoma cells, consistent with the chemotactic metastasis hypothesis. MMM cell lines expressed CCR7 receptors for the lymphatic chemokine CCL21 and CCL21 neutralizing antibodies prevented MMM chemotaxis in vitro. To test for chemotactic metastasis in vivo tumor cells were xenotransplanted into nude mice similar to 1 cm from an injected LEC depot. Two different MMM grew directionally towards the LECs, whereas non-metastatic melanomas did not. These observations support the hypothesis that MMM cells grow towards regions of high LEC density owing to chemotactic LEC secretions, including CCL21. This chemotactic metastasis may contribute to the close association between metastasizing tumor cells and peritumor lymphatic density and promote lymphatic invasion.	Univ Bristol, Microvasc Res Labs, Dept Physiol, Preclin Vet Sch, Bristol BS2 8EJ, Avon, England; Frenchay Hosp, Dept Pathol, Bristol BS16 1LE, Avon, England; St George Hosp, Sch Med, Dept Cardiac & Vasc Sci, Dermatol Unit, London, England; Frenchay Hosp, Dept Plast Surg, Bristol BS16 1LE, Avon, England; St George Hosp, Sch Med, London, England	University of Bristol; St Georges University London; St Georges University London	Bates, DO (corresponding author), Univ Bristol, Microvasc Res Labs, Dept Physiol, Preclin Vet Sch, Southwell St, Bristol BS2 8EJ, Avon, England.	dave.bates@bris.ac.uk		Bates, David/0000-0003-4850-2360	Wellcome Trust [66011, 62951] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Agarwal B, 2005, AM J SURG PATHOL, V29, P1449, DOI 10.1097/01.pas.0000174269.99459.9d; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3; ELIAS EG, 1977, SURG GYNECOL OBSTET, V144, P327; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Lubach D, 1996, BRIT J DERMATOL, V135, P733; Luther SA, 2002, J IMMUNOL, V169, P424, DOI 10.4049/jimmunol.169.1.424; Mashino K, 2002, CANCER RES, V62, P2937; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; PODGRABINSKA S, 2002, P NATL ACAD SCI USA, V22, P22; Saeki H, 1999, J IMMUNOL, V162, P2472; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Shields JD, 2004, BRIT J CANCER, V90, P693, DOI 10.1038/sj.bjc.6601571; Sipos B, 2005, J PATHOL, V207, P301, DOI 10.1002/path.1840; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stanton AWB, 1999, MICROVASC RES, V57, P320, DOI 10.1006/mvre.1998.2141; Stanton AWB, 1997, MICROVASC RES, V54, P156, DOI 10.1006/mvre.1997.2035; Takanami I, 2003, INT J CANCER, V105, P186, DOI 10.1002/ijc.11063; Takeuchi H, 2004, CLIN CANCER RES, V10, P2351, DOI 10.1158/1078-0432.CCR-03-0195; Wagner JD, 2000, PLAST RECONSTR SURG, V105, P1774, DOI 10.1097/00006534-200004050-00028; Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008-5472.CAN-03-2968; White RR, 2002, ANN SURG, V235, P879, DOI 10.1097/00000658-200206000-00017; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yan C, 2004, WORLD J GASTROENTERO, V10, P783	28	120	127	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					2997	3005		10.1038/sj.onc.1210114	http://dx.doi.org/10.1038/sj.onc.1210114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130836				2022-12-17	WOS:000246395400005
J	Alirol, E; Martinou, JC				Alirol, E.; Martinou, J. C.			Mitochondria and cancer: is there a morphological connection?	ONCOGENE			English	Review						mitochondrial morphology; apoptosis; energy metabolism; cancer	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; LINKED MECHANICAL-ACTIVITY; BCL-X-L; CELL-CYCLE; SUCCINATE-DEHYDROGENASE; LACTATE-DEHYDROGENASE; ULTRASTRUCTURAL BASES; MEMBRANE; PROTEIN	Mitochondria are key players in several cellular functions including growth, division, energy metabolism, and apoptosis. The mitochondrial network undergoes constant remodelling and these morphological changes are of direct relevance for the role of this organelle in cell physiology. Mitochondrial dysfunction contributes to a number of human disorders and may aid cancer progression. Here, we summarize the recent contributions made in the field of mitochondrial dynamics and discuss their impact on our understanding of cell function and tumorigenesis.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Martinou, JC (corresponding author), Univ Geneva, Dept Cell Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	Jean-Claude.Martinou@cellbio.unige.ch		martinou, Jean-claude/0000-0002-9847-2051; Alirol, Emilie/0000-0001-8691-3991				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Barni S, 1996, BIOTECH HISTOCHEM, V71, P66, DOI 10.3109/10520299609117135; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Danino D, 2004, J STRUCT BIOL, V147, P259, DOI 10.1016/j.jsb.2004.04.005; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Epand RF, 2003, BIOCHEMISTRY-US, V42, P14576, DOI 10.1021/bi035348w; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gallop JL, 2005, NATURE, V438, P675, DOI 10.1038/nature04136; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gatenby RA, 1996, CANCER RES, V56, P5745; Gemin A, 2005, BIOCHEM BIOPH RES CO, V332, P1122, DOI 10.1016/j.bbrc.2005.05.061; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKENBROCK CR, 1968, J CELL BIOL, V37, P345, DOI 10.1083/jcb.37.2.345; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.E04-08-0697; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; King MA, 2002, CYTOMETRY, V49, P106, DOI 10.1002/cyto.10156; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kozlovsky Y, 2002, BIOPHYS J, V83, P2634, DOI 10.1016/S0006-3495(02)75274-0; Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj.cdd.4400934; Krebs H A, 1972, Essays Biochem, V8, P1; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; LEPRAT P, 1990, EXP CELL RES, V186, P130, DOI 10.1016/0014-4827(90)90219-Z; Liu JH, 2005, BIOCHEM BIOPH RES CO, V330, P865, DOI 10.1016/j.bbrc.2005.03.048; Lucken-Ardjomande S, 2005, CR BIOL, V328, P616, DOI 10.1016/j.crvi.2005.05.002; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mattenberger Y, 2003, FEBS LETT, V538, P53, DOI 10.1016/S0014-5793(03)00124-8; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Muschen M, 2000, IMMUNOLOGY, V99, P69, DOI 10.1046/j.1365-2567.2000.00921.x; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Santel A, 2001, J CELL SCI, V114, P867; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Schornack PA, 2003, NEOPLASIA, V5, P135, DOI 10.1016/S1476-5586(03)80005-2; Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200; Scorrano L, 2005, J BIOENERG BIOMEMBR, V37, P165, DOI 10.1007/s10863-005-6572-x; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDENBOGERT C, 1992, J CELL PHYSIOL, V152, P632, DOI 10.1002/jcp.1041520323; VANDENBOGERT C, 1986, CANCER LETT, V32, P41, DOI 10.1016/0304-3835(86)90037-6; VANDENBOGERT C, 1988, EXP CELL RES, V178, P143, DOI 10.1016/0014-4827(88)90385-0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Yang L, 2003, CANCER RES, V63, P6815; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu TZ, 2005, J CELL SCI, V118, P4141, DOI 10.1242/jcs.02537; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	131	120	123	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4706	4716		10.1038/sj.onc.1209600	http://dx.doi.org/10.1038/sj.onc.1209600			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892084				2022-12-17	WOS:000239687000008
J	Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC				Copland, JA; Marlow, LA; Kurakata, S; Fujiwara, K; Wong, AKC; Kreinest, PA; Williams, SF; Haugen, BR; Klopper, JP; Smallridge, RC			Novel high-affinity PPAR gamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21(WAF1/CIP1)	ONCOGENE			English	Article						peroxisome proliferator-activated receptor gamma; paclitaxel; anaplastic thyroid carcinoma; RS5444; p21(WAF1/CIP1); combinatorial therapy; thiazolidinedione	ACTIVATED-RECEPTOR-GAMMA; PANCREATIC-CANCER CELLS; IN-VITRO; DIFFERENTIATION MARKERS; INDEPENDENT GROWTH; PROSTATE-CANCER; GENE-EXPRESSION; CYCLE ARREST; APOPTOSIS; LIGANDS	Peroxisome proliferator-activated receptor gamma (PPARc) agonists demonstrate antitumor activity likely through transactivating genes that regulate cell proliferation, apoptosis, and differentiation. The PAX8/PPARc fusion oncogene, which is common in human follicular thyroid carcinomas appears to act via dominant negative suppression of wild-type PPARc, suggesting that it may be a tumor suppressor gene in thyroid cells. We have identified a novel high-affinity PPARc agonist (RS5444) that is dependent upon PPARc for its biological activity. This is the first report of this molecule and its antitumor activity. In vitro, the IC50 for growth inhibition is similar to 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three-to fourfold in nude mice. siRNA against PPARc and a pharmacological antagonist demonstrated that functional PPARc was required for growth inhibitory activity of RS5444. RS5444 upregulated the cell cycle kinase inhibitor, p21(WAF1/CIP1). Silencing p21(WAF1CIP1) rendered cells insensitive to RS5444. RS5444 plus paclitaxel demonstrated additive antiproliferative activity in cell culture and minimal ATC tumor growth in vivo. RS5444 did not induce apoptosis but combined with paclitaxel, doubled the apoptotic index compared to that of paclitaxel. Our data indicate that functional PPARc is a molecular target for therapy in ATC. We demonstrated that RS5444, a thiazolidinedione (Tzd) derivative, alone or in combination with paclitaxel, may provide therapeutic benefit to patients diagnosed with ATC.	Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 33224 USA; Sankyo Pharma Res Inst, La Jolla, CA USA; Sankyo Co Ltd, Shinagawa Ku, Tokyo 140, Japan; Sankyo Pharma Res Inst, La Jolla, CA USA; Mayo Clin, Coll Med, Dept Internal Med, Div Endocrinol, Jacksonville, FL 33224 USA; Univ Colorado, Ctr Canc, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO 80262 USA; Hlth Sci Ctr, Aurora, CO USA	Mayo Clinic; Daiichi Sankyo Company Limited; Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Copland, JA (corresponding author), Mayo Clin, Coll Med, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd, Jacksonville, FL 33224 USA.	copland.john@mayo.edu		Marlow, Laura/0000-0002-4726-9889	NCI NIH HHS [P30CA15083, CA100560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA100560] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ain KB, 1996, J CLIN ENDOCR METAB, V81, P3650, DOI 10.1210/jc.81.10.3650; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Aldred MA, 2003, ONCOGENE, V22, P3412, DOI 10.1038/sj.onc.1206400; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; Bauer AJ, 2002, THYROID, V12, P953, DOI 10.1089/105072502320908286; Belletti B, 1999, ONCOGENE, V18, P4860, DOI 10.1038/sj.onc.1202869; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Castrillo A, 2001, J BIOL CHEM, V276, P34082, DOI 10.1074/jbc.M102472200; Chang TH, 2000, CANCER RES, V60, P1129; Chang TH, 2002, CLIN CANCER RES, V8, P1206; Chen F, 2005, CELL SIGNAL, V17, P809, DOI 10.1016/j.cellsig.2004.11.002; Chung SH, 2002, JPN J CANCER RES, V93, P1358, DOI 10.1111/j.1349-7006.2002.tb01245.x; Davies GF, 2002, J PHARMACOL EXP THER, V300, P72, DOI 10.1124/jpet.300.1.72; de la Lastra CA, 2004, CURR PHARM DESIGN, V10, P3505; Debril MB, 2001, J MOL MED, V79, P30, DOI 10.1007/s001090000145; Dwight T, 2003, J CLIN ENDOCR METAB, V88, P4440, DOI 10.1210/jc.2002-021690; Eibl G, 2001, BIOCHEM BIOPH RES CO, V287, P522, DOI 10.1006/bbrc.2001.5619; Elnemr A, 2000, INT J ONCOL, V17, P1157; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fujiwara T, 2000, LIFE SCI, V67, P2405, DOI 10.1016/S0024-3205(00)00829-8; Fujiwara T, 1998, LIFE SCI, V63, P2039, DOI 10.1016/S0024-3205(98)00482-2; Galli A, 2004, GUT, V53, P1688, DOI 10.1136/gut.2003.031997; Girnun GD, 2003, GASTROENTEROLOGY, V124, P564, DOI 10.1053/gast.2003.50070; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Han SW, 2004, CLIN CANCER RES, V10, P1911, DOI 10.1158/1078-0432.CCR-03-0985; Hayashi N, 2004, INT J ONCOL, V24, P89; Hong J, 2004, ENDOCRINOLOGY, V145, P5774, DOI 10.1210/en.2004-0686; Huang JW, 2005, MOL PHARMACOL, V67, P1342, DOI 10.1124/mol.104.007732; Itami A, 2001, INT J CANCER, V94, P370, DOI 10.1002/ijc.1488; Kawa S, 2002, PANCREAS, V24, P1, DOI 10.1097/00006676-200201000-00001; Kim S, 2005, MOL CANCER THER, V4, P632, DOI 10.1158/1535-7163.MCT-04-0293; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Lovekamp-Swan T, 2005, MOL CELL ENDOCRINOL, V233, P15, DOI 10.1016/j.mce.2005.01.011; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Lui WO, 2005, ONCOGENE, V24, P1467, DOI 10.1038/sj.onc.1208135; Margeli A., 2003, Angiogenesis, V6, P165, DOI 10.1023/B:AGEN.0000021377.13669.c0; Martelli ML, 2002, J CLIN ENDOCR METAB, V87, P4728, DOI 10.1210/jc.2001-012054; McIver Bryan, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P221, DOI 10.2174/1568008043339802; Motomura W, 2000, CANCER RES, V60, P5558; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; Nakashiro K, 2001, AM J PATHOL, V159, P591, DOI 10.1016/S0002-9440(10)61730-0; Palakurthi SS, 2001, CANCER RES, V61, P6213; Panigrahy D, 2003, EXPERT OPIN INV DRUG, V12, P1925, DOI 10.1517/13543784.12.12.1925; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Perez-Ortiz JM, 2004, J BIOL CHEM, V279, P8976, DOI 10.1074/jbc.M308518200; Place AE, 2003, CLIN CANCER RES, V9, P2798; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rumi MAK, 2004, GENES CELLS, V9, P1113, DOI 10.1111/j.1365-2443.2004.00793.x; Sato K, 2001, ENDOCR J, V48, P635, DOI 10.1507/endocrj.48.635; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; TAKASHIMA T, 2001, TRENDS MOL MED, V7, P395; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Turturro F, 2004, CLIN CANCER RES, V10, P7022, DOI 10.1158/1078-0432.CCR-04-0879; Vogt T, 2003, CANCER, V98, P2251, DOI 10.1002/cncr.11775; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Xin XH, 1999, J BIOL CHEM, V274, P9116, DOI 10.1074/jbc.274.13.9116; Xu GP, 2001, J CLIN ENDOCR METAB, V86, P1769, DOI 10.1210/jc.86.4.1769; Yang HL, 2003, J CLIN ENDOCR METAB, V88, P763, DOI 10.1210/jc.2002-020992; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; Yeung SCJ, 2000, CANCER RES, V60, P650; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yin F, 2004, ONCOGENE, V23, P4614, DOI 10.1038/sj.onc.1207598; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; Yuan JY, 2005, UROLOGY, V65, P594, DOI 10.1016/j.urology.2004.10.019	77	120	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2304	2317		10.1038/sj.onc.1209267	http://dx.doi.org/10.1038/sj.onc.1209267			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331265				2022-12-17	WOS:000236764300003
J	Kasperczyk, H; La Ferla-Bruhl, K; Westhoff, MA; Behrend, L; Zwacka, RM; Debatin, KM; Fulda, S				Kasperczyk, H; La Ferla-Bruhl, K; Westhoff, MA; Behrend, L; Zwacka, RM; Debatin, KM; Fulda, S			Betulinic acid as new activator of NF-kappa B: molecular mechanisms and implications for cancer therapy	ONCOGENE			English	Article						apoptosis; betulinic acid; cancer; NF-kappa B	MELANOMA-CELLS; TUMOR-CELLS; APOPTOSIS; EXPRESSION; PATHWAY; KINASE; CHEMOTHERAPY; INHIBITION; GROWTH; POTENT	Recent evidence demonstrates that the anticancer activity of betulinic acid (BetA) can be markedly increased by combination protocols, for example with chemotherapy, ionizing radiation or TRAIL. Since nuclear factor kappaB (NF-kappa B), a key regulator of stress-induced transcriptional activation, has been implicated in mediating apoptosis resistance, we investigated the role of NF-kappa B in BetA-induced apoptosis. Here, we provide for the first time evidence that BetA activates NF-kappa B in a variety of tumor cell lines. NF-kappa B DNA-binding complexes induced by BetA consisted of p50 and p65 subunits. Nuclear translocation of p65 was also confirmed by immunofluoresence microscopy. BetA-induced NF-kappa B activation involved increased IKK activity and phosphorylation of I kappa B-alpha at serine 32/36 followed by degradation of I kappa B-alpha. Reporter assays revealed that NF-kappa B activated by BetA is transcriptionally active. Interestingly, inhibition of BetA-induced NF-kappa B activation by different chemical inhibitors ( proteasome inhibitor, antioxidant, IKK inhibitor) attenuated BetA-induced apoptosis. Importantly, specific NF-kappa B inhibition by transient or stable expression of I kappa B-alpha super-repressor inhibited BetA-induced apoptosis in SHEP neuroblastoma cells, while transient expression of I kappa B-alpha super-repressor had no influence on BetA-induced apoptosis in two other cell lines. Thus, our. ndings that activation of NF-kappa B by BetA promotes BetA-induced apoptosis in a cell type-specific fashion indicate that NF-kappa B inhibitors in combination with BetA would have no therapeutic benefit or could even be contraproductive in certain tumors, which has important implications for the design of BetA-based combination protocols.	Univ Ulm, Childrens Hosp, Dept Hematol Oncol, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, D-89081 Ulm, Germany	Ulm University; Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Dept Hematol Oncol, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Fulda, Simone/D-5864-2011; Ibrahim, Essam Hassan/G-1960-2018; Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014	Ibrahim, Essam Hassan/0000-0003-0130-2257; Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Zwacka, Ralf/0000-0003-2821-0387; Fulda, Simone/0000-0002-0459-6417				Algul H, 2002, J GASTROINTEST CANC, V31, P71, DOI 10.1385/IJGC:31:1-3:71; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fulda S, 1999, INT J CANCER, V82, P435, DOI 10.1002/(SICI)1097-0215(19990730)82:3<435::AID-IJC18>3.0.CO;2-1; Fulda S, 2004, ONCOGENE, V23, P7611, DOI 10.1038/sj.onc.1207970; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sawada N, 2004, BRIT J CANCER, V90, P1672, DOI 10.1038/sj.bjc.6601746; Selzer E, 2000, J INVEST DERMATOL, V114, P935, DOI 10.1046/j.1523-1747.2000.00972.x; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Younes A, 2003, LEUKEMIA LYMPHOMA, V44, P929, DOI 10.1080/1042819031000067558; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	31	120	124	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6945	6956		10.1038/sj.onc.1208842	http://dx.doi.org/10.1038/sj.onc.1208842			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16007147				2022-12-17	WOS:000232701700009
J	Feuer, G; Green, PL				Feuer, G; Green, PL			Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2	ONCOGENE			English	Review						HTLV-1; HTLV-2; tax; cellular transformation; immortalization; leukemia	NF-KAPPA-B; I TAX PROTEIN; HUMAN-ENDOTHELIAL-CELLS; INTRAVENOUS-DRUG-USERS; READING FRAME II; LEUKEMIA-VIRUS; PDZ DOMAIN; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; POTENTIAL MECHANISM	HTLV-1 and HTLV-2 are highly related complex retroviruses that have been studied intensely for nearly three decades because of their association with neoplasia, neuropathology, and/or their capacity to transform primary human T lymphocytes. The study of HTLV also represents an attractive model that has allowed investigators to dissect the mechanism of various cellular processes, several of which may be critical steps in HTLV-mediated pathogenesis. Both HTLV-1 and HTLV-2 can efficiently immortalize and transform T lymphocytes in cell culture and persist in infected individuals or experimental animals. However, the clinical manifestations of these two viruses differ significantly. HTLV-1 is associated with adult T-cell leukemia (ATL) and a variety of immune-mediated disorders including the chronic neurological disease termed HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). In contrast, HTLV-2 is much less pathogenic with reports of only a few cases of variant hairy cell leukemia and neurological disease associated with infection. The limited number of individuals shown to harbor HTLV-2 in association with specific diseases has, to date, precluded convincing epidemiological demonstration of a definitive etiologic role of HTLV-2 in human disease. Therefore, it has become clear that comparative studies designed to elucidate the mechanisms by which HTLV-1 and HTLV-2 determine distinct outcomes are likely to provide fundamental insights into the initiation of multistep leukemogenesis.	Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; SUNY Syracuse, Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA; Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Comprehens Canc Ctr James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Green, PL (corresponding author), Ohio State Univ, Dept Vet Biosci, 1925 Coffey Rd, Columbus, OH 43210 USA.	green.466@osu.edu			NCI NIH HHS [P01 CA100730, P01 CA100730-069003, P01 CA100730-02, CA100730] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA100730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Akagi T, 1996, ONCOGENE, V12, P1645; AKAGI T, 1992, ACTA NEUROPATHOL, V84, P147, DOI 10.1007/BF00311387; AKGI T, 1997, ONCOGENE, V14, P2071; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BOHNLEIN E, 1989, J VIROL, V63, P1578; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHEN ISY, 1983, NATURE, V305, P502, DOI 10.1038/305502a0; CHEN ISY, 1985, SCIENCE, V230, P570, DOI 10.1126/science.2996140; CHLICHLIA K, 1995, ONCOGENE, V10, P269; Cockerell GL, 1996, BLOOD, V87, P1030, DOI 10.1182/blood.V87.3.1030.bloodjournal8731030; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; DERSE D, 1995, J VIROL, V69, P1907, DOI 10.1128/JVI.69.3.1907-1912.1995; Derse D, 1997, VIROLOGY, V237, P123, DOI 10.1006/viro.1997.8781; Dooneief G, 1996, NEUROLOGY, V46, P1556, DOI 10.1212/WNL.46.6.1556; EJIMA E, 1993, BLOOD, V81, P1017; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GESSAIN A, 1993, J ACQ IMMUN DEF SYND, V6, P324; GOUBAU P, 1993, AIDS RES HUM RETROV, V9, P709, DOI 10.1089/aid.1993.9.709; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Green P. L., 2001, FIELDS VIROLOGY, P1941; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hall AP, 1998, J PATHOL, V186, P209; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harris BZ, 2001, J CELL SCI, V114, P3219; HENEINE W, 1991, NEW ENGL J MED, V324, P565, DOI 10.1056/NEJM199102213240815; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HJELLE B, 1990, BLOOD, V76, P450; HO DD, 1984, P NATL ACAD SCI-BIOL, V81, P7588, DOI 10.1073/pnas.81.23.7588; HOFFMAN PM, 1992, P NATL ACAD SCI USA, V89, P11784, DOI 10.1073/pnas.89.24.11784; IJICHI S, 1992, J EXP MED, V176, P293, DOI 10.1084/jem.176.1.293; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; KHABBAZ RF, 1991, J INFECT DIS, V163, P252, DOI 10.1093/infdis/163.2.252; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840; LAL RB, 1993, BLOOD, V81, P1827; LAL RB, 1993, LEUKEMIA RES, V17, P31, DOI 10.1016/0145-2126(93)90138-B; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LEVINE PH, 1993, AIDS RES HUM RETROV, V9, P123, DOI 10.1089/aid.1993.9.123; Lewis MJ, 2002, VIROLOGY, V295, P182, DOI 10.1006/viro.2002.1357; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; LINDHOLM P, 1991, NEW BIOL, V2, P1034; Los M, 1998, J IMMUNOL, V161, P3050; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; Mahieux R, 2000, J VIROL, V74, P6866, DOI 10.1128/JVI.74.15.6866-6874.2000; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; MIYAMOTO K, 1991, JPN J CANCER RES, V82, P1178, DOI 10.1111/j.1349-7006.1991.tb01775.x; Mori N, 1996, BLOOD, V87, P3410, DOI 10.1182/blood.V87.8.3410.bloodjournal8783410; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; Mulloy JC, 1998, J VIROL, V72, P4408, DOI 10.1128/JVI.72.5.4408-4412.1998; Murphy EL, 1997, NEUROLOGY, V48, P315, DOI 10.1212/WNL.48.2.315; Nagai M, 2001, ANN NEUROL, V50, P807, DOI 10.1002/ana.10065; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Newbound GC, 1996, J VIROL, V70, P2101, DOI 10.1128/JVI.70.4.2101-2106.1996; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Nicot C, 1997, VIROLOGY, V236, P47, DOI 10.1006/viro.1997.8720; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; NIMER S, 1991, NEW BIOL, V3, P997; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; Ohya Osamu, 1997, Leukemia (Basingstoke), V11, P255; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; Riou P, 2000, J BIOL CHEM, V275, P10551, DOI 10.1074/jbc.275.14.10551; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Ross TM, 1997, J VIROL, V71, P8912, DOI 10.1128/JVI.71.11.8912-8917.1997; Ross TM, 2000, J VIROL, V74, P2655, DOI 10.1128/JVI.74.6.2655-2662.2000; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Saggioro D, 2001, EXP CELL RES, V269, P245, DOI 10.1006/excr.2001.5310; SAXON A, 1978, J IMMUNOL, V120, P777; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sieburg M, 2004, J VIROL, V78, P10399, DOI 10.1128/JVI.78.19.10399-10409.2004; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128/JVI.78.8.3837-3845.2004; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takemoto S, 1997, P NATL ACAD SCI USA, V94, P13897, DOI 10.1073/pnas.94.25.13897; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEDDER RS, 1984, LANCET, V2, P125; Toro C, 2005, J CLIN VIROL, V33, P65, DOI 10.1016/j.jcv.2004.10.004; Tripp A, 2003, J VIROL, V77, P12152, DOI 10.1128/JVI.77.22.12152-12164.2003; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; Wilson KC, 2003, VIROLOGY, V306, P60, DOI 10.1016/S0042-6822(02)00056-9; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YAMAOKA S, 1992, ONCOGENE, V7, P433; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Ye JX, 2003, J VIROL, V77, P7728, DOI 10.1128/JVI.77.14.7728-7735.2003; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; Younis I, 2005, FRONT BIOSCI-LANDMRK, V10, P431, DOI 10.2741/1539; Zehender G, 2001, VIROLOGY, V281, P43, DOI 10.1006/viro.2000.0765; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	137	120	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5996	6004		10.1038/sj.onc.1208971	http://dx.doi.org/10.1038/sj.onc.1208971			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155606	Green Accepted			2022-12-17	WOS:000231623400009
J	Guelen, L; Paterson, H; Gaken, J; Meyers, M; Farzaneh, F; Tavassoli, M				Guelen, L; Paterson, H; Gaken, J; Meyers, M; Farzaneh, F; Tavassoli, M			TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells	ONCOGENE			English	Article						apoptin; CAV; apoptosis; TAT-PTD; protein delivery; death effector	CHICKEN ANEMIA VIRUS; PROTEIN TRANSDUCTION; TUMOR-CELLS; MAMMALIAN-CELLS; INDUCTION; INDIVIDUALS; ACTIVATION; CASPASE-3; CYCLE; DNA	Apoptin has been described to induce apoptosis in various human cancer cell lines, but not in normal cells, thus making it an interesting candidate for the development of novel therapeutic strategies. Apoptin was generated and cloned into several mammalian expression vectors. Transfection or microinjection of apoptin cDNA resulted in its expression, initially in the cytoplasm with a filamentous pattern. Subsequently, apoptin entered the nucleus and efficiently induced apoptosis in several cancer cell lines. Nuclear localization was shown to be required for induction of apoptosis. Apoptin expression level was found to be an important determinant of the efficiency of induction of apoptosis. Surprisingly, expression of apoptin or GFP-apoptin cDNA induced apoptosis in some normal cells. When fused to the HIV-TAT protein transduction domain and delivered as a protein, TAT-apoptin was transduced efficiently (>90%) into normal and tumour cells. However, TAT-apoptin remained in the cytoplasm and did not kill normal 6689 and 1BR3 fibroblasts. In contrast TAT-apoptin migrated from the cytoplasm to the nucleus of Saos-2 and HSC-3 cancer cells resulting in apoptosis after 24 h. This study shows that apoptin is a powerful apoptosis-inducing protein with a potential for cancer therapy.	Guys Kings & St Thomas Sch Med & Dent, Rayne Inst, Dept Oral Med & Pathol, Head & Neck Oncol Grp, London, England; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England; Guys Kings & St Thomas Sch Med & Dent, Rayne Inst, Dept Mol Med, London, England	University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London	Tavassoli, M (corresponding author), GKT Sch Med & Dent, Head & Neck Oncol Grp, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Gius DR, 1999, CANCER RES, V59, P2577; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MEEHAN BM, 1992, ARCH VIROL, V124, P301, DOI 10.1007/BF01309811; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oorschot AAAMD, 1999, LEUKEMIA, V13, pS75, DOI 10.1038/sj.leu.2401291; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Zhang YH, 1999, CANCER RES, V59, P3010; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939; ZHUANG SM, 1995, LEUKEMIA, V9, pS118; ZHUANG SM, 1995, CANCER RES, V55, P486	28	120	150	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1153	1165		10.1038/sj.onc.1207224	http://dx.doi.org/10.1038/sj.onc.1207224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14691460				2022-12-17	WOS:000188749900014
J	Bowers, AJ; Scully, S; Boylan, JF				Bowers, AJ; Scully, S; Boylan, JF			SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia	ONCOGENE			English	Article						SKIP3; ATF4; hypoxia; tumor; gene expression	ACTIVATING TRANSCRIPTION FACTOR-4; LEUCINE-ZIPPER PROTEINS; CAMP RESPONSE ELEMENT; DNA-BINDING; GENE; ATF4; IDENTIFICATION; MORPHOGENESIS; EXPRESSION; INTERACT	Regions of hypoxia are a hallmark of solid tumors. Tumor cells modulate the regulation of specific genes allowing adaptation and survival in the harsh hypoxic environment. We have identified SKIP3, a novel human kinase-like gene, which is overexpressed in multiple human tumors and is regulated by hypoxia. SKIP3 is an ortholog of the Drosophila tribbles, rat NIPK, dog C5FW, and human C8FW genes. Drosophila tribbles is involved in slowing cell-cycle progression during Drosophila development, but little is known regarding the function or tissue distribution of the vertebrate orthologs. We show that the normal tissue expression of SKIP3 is confined to human liver, while multiple primary human lung, colon, and breast tumors express high levels of SKIP3 transcript. Endogenous SKIP3 protein accumulates within 48 h under hypoxic growth conditions in HT-29 and PC-3 cells, with upregulation of the SKIP3 mRNA transcript by 72 h. We identified activating transcription factor 4 (ATF4) as a SKIP3-binding partner using the yeast-two-hybrid assay. Coexpression of SKIP3 and ATF4 showed that SKIP3 is associated with the proteolysis of ATF4, which can be blocked using a proteosome inhibitor. These results indicate that SKIP3 may be an important participant in tumor cell growth.	Amgen Inc, Dept Canc Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA	Amgen; Amgen	Boylan, JF (corresponding author), Amgen Inc, Dept Canc Biol, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.		Bowers, Alex J./C-1557-2013	Bowers, Alex J./0000-0002-5140-6428				AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gachon F, 2001, FEBS LETT, V502, P57, DOI 10.1016/S0014-5793(01)02646-1; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hewes RS, 2000, GENETICS, V155, P1711; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kato Y, 1999, MOL CELL ENDOCRINOL, V154, P151, DOI 10.1016/S0303-7207(99)00078-7; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Rorth P, 2000, MOL CELL, V6, P23; Saramaki OR, 2001, CANCER GENET CYTOGEN, V128, P31, DOI 10.1016/S0165-4608(01)00396-X; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Semenza GL, 2000, GENE DEV, V14, P1983; Tang KQ, 2000, BIOCHEMISTRY-US, V39, P3185, DOI 10.1021/bi992664v; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wadle A, 2001, ONCOGENE, V20, P5920, DOI 10.1038/sj.onc.1204797; WILCOX JN, 1993, J HISTOCHEM CYTOCHEM, V41, P1725, DOI 10.1177/41.12.8245419; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117	38	120	128	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2823	2835		10.1038/sj.onc.1206367	http://dx.doi.org/10.1038/sj.onc.1206367			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743605				2022-12-17	WOS:000182569300013
J	Osterod, M; Larsen, E; Le Page, F; Hengstler, JG; van der Horst, GT; Boiteux, S; Klungland, A; Epe, B				Osterod, M; Larsen, E; Le Page, F; Hengstler, JG; van der Horst, GT; Boiteux, S; Klungland, A; Epe, B			A global DNA repair mechanism involving the Cockayne syndrome B (CSB) gene product can prevent the in vivo accumulation of endogenous, oxidative DNA base damage	ONCOGENE			English	Article						OGG1; CSB; DNA repair; 7,8-dihydro-8oxoguanine (8-oxoG)	TRANSCRIPTION-COUPLED REPAIR; MAMMALIAN-CELLS; EXCISION-REPAIR; 8-OXOGUANINE; CANCER; 8-HYDROXYGUANINE; OGG1; MICE; MUTAGENESIS; GENOME	The Cockayne syndrome B (CSB) gene product is involved in the repair of various types of base modifications in actively transcribed DNA sequences. To investigate its significance for the repair of endogenous oxidative DNA damage, homozygous csb(-/-)/ogg1(-/-) double knockout mice were generated. These combine the deficiency of CSB with that of OGG1, a gene coding for the mammalian repair glycosylase that initiates the base excision repair of 7,8-dihydro-8-oxoguanine (8-oxoG). Compared to ogg1(-/-) mice, csb(-/-)/ogg1(-/-) mice were found to accumulate with age severalfold higher levels of oxidited purine modifications in hepatocytes, splenocytes and kidney cells. In contrast, the basal (steady-state) levels of oxidative DNA modifications in cells from csb(-/-) mice were not different from those in wild-type mice and did not increase with age. The analysis of the repair rates of additional oxidative DNA base modifications induced by photosensitization in immortalized embryonic fibroblasts was in accordance with these findings: compared to wild-type cells, the global repair was only slightly affected in csb(-/-) cells, more compromised in ogg1(-/-) cells, but virtually absent in csb(-/-)/ogg1(-/-) cells. An inhibition of transcription by a-amanitin did not block the Csb-dependent repair in ogg1(-/-) fibroblasts. The influence of Csb on the global repair of 8-oxoG was not detectable in assays with total protein extracts and in a shuttle vector system. The data indicate a role for Csb in the removal of 8-oxoG from the overall genome that is independent of both Ogg1-mediated base excision repair and regular transcription.	Univ Mainz, Inst Pharm, D-55099 Mainz, Germany; Univ Oslo, Ctr Mol Biol & Neurosci, Natl Hosp, N-0027 Oslo, Norway; Univ Oslo, Inst Med Microbiol, Natl Hosp, N-0027 Oslo, Norway; CEA, UMR 217 CNRS, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France; Univ Mainz, Inst Toxicol, D-55099 Mainz, Germany; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Johannes Gutenberg University of Mainz; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; CEA; Johannes Gutenberg University of Mainz; Erasmus University Rotterdam	Epe, B (corresponding author), Univ Mainz, Inst Pharm, Staudingerweg 5, D-55099 Mainz, Germany.		Klungland, Arne/X-1233-2019; van der Horst, Gijsbertus TJ/E-3661-2015; Hengstler, Jan G./O-1415-2013	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Hengstler, Jan/0000-0002-1427-5246; Klungland, Arne/0000-0001-7274-3661				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CHENG KC, 1992, J BIOL CHEM, V267, P166; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; HAZRA TK, 1998, NUCLEIC ACIDS RES, V27, P4001; Hengstler JG, 2000, DRUG METAB REV, V32, P81, DOI 10.1081/DMR-100100564; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Pflaum M, 1997, CARCINOGENESIS, V18, P2225, DOI 10.1093/carcin/18.11.2225; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sunesen M, 2002, ONCOGENE, V21, P3571, DOI 10.1038/sj.onc.1205443; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Thorslund T, 2002, DNA REPAIR, V1, P261, DOI 10.1016/S1568-7864(02)00003-4; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tomatis L., 1990, IARC SCI PUBLICATION; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Will O, 1999, MUTAT RES-DNA REPAIR, V435, P89, DOI 10.1016/S0921-8777(99)00039-7; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	44	120	124	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8232	8239		10.1038/sj.onc.1206027	http://dx.doi.org/10.1038/sj.onc.1206027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447686				2022-12-17	WOS:000179323900001
J	Shchepina, LA; Pletjushkina, OY; Avetisyan, AV; Bakeeva, LE; Fetisova, EK; Izyumov, DS; Saprunova, VB; Vyssokikh, MY; Chernyak, BV; Skulachev, VP				Shchepina, LA; Pletjushkina, OY; Avetisyan, AV; Bakeeva, LE; Fetisova, EK; Izyumov, DS; Saprunova, VB; Vyssokikh, MY; Chernyak, BV; Skulachev, VP			Oligomycin, inhibitor of the F-0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis	ONCOGENE			English	Article						apoptosis; Bcl-2; mitochondria; ultrastructure; membrane potential; permeability transition; oligomycin; tumor necrosis factor	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; OLIGOMERIZES BAK; BCL-2; ACTIVATION; INDUCTION; MECHANISM; COMPLEX; PROTEIN; PORES	The release of cytochrome c from the intermembrane space of mitochondria into the cytosol is one of the critical events in apoptotic cell death. In the present study, it is shown that release of cytochrome c and apoptosis induced by tumor necrosis factor alpha (TNF) in HeLa cells can be inhibited by (i) overexpression of an oncoprotein Bcl-2, (ii) Cyclosporin A, an inhibitor of the mitochondrial permeability transition pore (PTP) or (iii) oligomycin, an inhibitor of H+- ATP-synthase. Staurosporine-induced apoptosis is sensitive to Bcl-2 but insensitive to Cyclosporin A and oligomycin. The effect of oligomycin is not due to changes in mitochondrial membrane potential or to inhibition of ATP synthesis/hydrolysis since (a) uncouplers (CCCP, DNP) which discharge the membrane potential fail to abolish the protective action of oligomycin and (b) aurovertin B (another inhibitor of H+-ATP-synthase, affecting its F-1 component) do not affect apoptosis. A role of oligomycin-sensitive F-0 component of H+-ATP-synthase in the TNF-induced PTP opening and apoptosis is suggested.	Moscow MV Lomonosov State Univ, AN Belozersky Inst, Moscow 119992, Russia	Lomonosov Moscow State University	Chernyak, BV (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst, 4 Khokhlova Str,Bldg A, Moscow 119992, Russia.	bchernyak@yahoo.com	Avetisyan, Armine/O-2426-2014; Chernyak, Boris V/D-9917-2012; Pletjushkina, Olga G/J-8476-2012; Skulachev, Vladimir P/J-4164-2012; Fetisova, Elena/D-3250-2018; Vyssokikh, Mikhail/H-4744-2014	Chernyak, Boris V/0000-0003-1523-0864; Skulachev, Vladimir P/0000-0003-4886-2243; Fetisova, Elena/0000-0002-7305-8102; Vyssokikh, Mikhail/0000-0002-4047-6201; Skulachev, Vladimir/0000-0001-5141-7517; Avetisyan, Armine/0000-0002-3882-2013				Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Domnina LV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P737, DOI 10.1023/A:1016336421582; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ikemoto H, 2000, CELL DEATH DIFFER, V7, P511, DOI 10.1038/sj.cdd.4400682; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NOVGORODOV SA, 1989, FEBS LETT, V247, P255, DOI 10.1016/0014-5793(89)81347-X; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Peachman KK, 2001, P NATL ACAD SCI USA, V98, P1717, DOI 10.1073/pnas.98.4.1717; Salomon AR, 2000, P NATL ACAD SCI USA, V97, P14766, DOI 10.1073/pnas.97.26.14766; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shchepina LA, 2002, BIOCHEMISTRY-MOSCOW+, V67, P222, DOI 10.1023/A:1014418231692; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Skulachev Vladimir P., 1999, Molecular Aspects of Medicine, V20, P139, DOI 10.1016/S0098-2997(99)00008-4; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tafani M, 2001, CANCER RES, V61, P2459; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wei MC, 2000, GENE DEV, V14, P2060; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhuang JG, 1998, CELL DEATH DIFFER, V5, P953, DOI 10.1038/sj.cdd.4400440	38	120	130	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2002	21	53					8149	8157		10.1038/sj.onc.1206053	http://dx.doi.org/10.1038/sj.onc.1206053			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444550				2022-12-17	WOS:000179231400008
J	Shields, PG				Shields, PG			Molecular epidemiology of smoking and lung cancer	ONCOGENE			English	Review						genetic susceptibilities; polymorphisms; carcinogenesis; biomarkers; environmental tobacco smoke	DNA ADDUCT LEVELS; ENVIRONMENTAL TOBACCO-SMOKE; POLYCYCLIC AROMATIC-HYDROCARBONS; SQUAMOUS-CELL CARCINOMA; LOW-YIELD CIGARETTES; P53 GENE-MUTATIONS; WHITE BLOOD-CELLS; S-TRANSFERASE M1; PASSIVE SMOKING; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE NNK	Lung cancer is the single most common cause of death, and almost all of it is due to tobacco smoking. Before the widespread use of cigarettes in this century, lung cancer was a rare illness. Tobacco smoke is a complex mixture of numerous mutagens and carcinogens. Over the last 40 years, the type of cigarettes most frequently used has been changing, namely the increased use of low tar and nicotine cigarettes. This has been accompanied by an increased risk of lung cancer due to a smokers' need to maintain blood nicotine levels, which in turn causes the need for smoking more cigarettes per day and deeper inhalation. This phenomena has led to the increasing rates of lung adenocarcinoma, compared to squamous cell carcinoma. It also probably explains, in part, the greater risk of lung cancer in women compared to men (in addition to some biological differences). The study of lung cancer involves many types of biomarkers, including those that measure exposure, the biologically effective dose and harm. The use of these has allowed us to understand many parts of lung carcinogenesis. Genetic susceptibilities play a large role in lung cancer risk. They govern smoking behavior (affecting dopamine reward mechanisms due to nicotine and nicotine metabolism), carcinogen metabolism and detoxification, DNA repair, cell cycle control and other cellular responses. The need for the study of lung cancer is highlighted by the need to improve cessation rates and reduce exposure among persons who cannot quit smoking, for better prevention strategies for former smokers and an understanding of environmental tobacco smoke risk.	Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Shields, PG (corresponding author), Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Res Bldg,W315,3970 Reservoir Rd NW, Washington, DC 20007 USA.	pgs2@georgetown.edu	Shields, Peter G/I-1644-2012					Atawodi SE, 1998, CANCER EPIDEM BIOMAR, V7, P817; AUERBACH O, 1957, NEW ENGL J MED, V256, P97, DOI 10.1056/NEJM195701172560301; BADAWI AF, 1995, CANCER RES, V55, P5230; Bailar JC, 1999, NEW ENGL J MED, V340, P958, DOI 10.1056/NEJM199903253401211; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Benowitz NL, 1998, J PHARMACOL EXP THER, V287, P958; BENOWITZ NL, 1986, JAMA-J AM MED ASSOC, V256, P241; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104; Brockmoller J, 1998, TOXICOL LETT, V103, P173, DOI 10.1016/S0378-4274(98)00304-X; Brownson RC, 1998, EPIDEMIOL REV, V20, P218, DOI 10.1093/oxfordjournals.epirev.a017982; Brownson RC, 1997, ANNU REV PUBL HEALTH, V18, P163, DOI 10.1146/annurev.publhealth.18.1.163; BROWNSON RC, 1992, AM J PUBLIC HEALTH, V82, P1525, DOI 10.2105/AJPH.82.11.1525; Brunnemann KD, 1996, CRIT REV TOXICOL, V26, P121, DOI 10.3109/10408449609017926; BURNEY LE, 1959, JAMA-J AM MED ASSOC, V171, P1829, DOI 10.1001/jama.1959.73010310005016; Comings DE, 1996, PHARMACOGENETICS, V6, P73, DOI 10.1097/00008571-199602000-00006; CORNFIELD J, 1959, J NATL CANCER I, V22, P173; DARBY SC, 1988, BRIT J CANCER, V58, P825, DOI 10.1038/bjc.1988.319; Djordjevic MV, 2000, JNCI-J NATL CANCER I, V92, P106, DOI 10.1093/jnci/92.2.106; Djordjevic MV, 1997, PREV MED, V26, P435, DOI 10.1006/pmed.1997.0184; DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; EBERT RV, 1983, JAMA-J AM MED ASSOC, V250, P2840, DOI 10.1001/jama.250.20.2840; Ernster VL, 1996, ANNU REV PUBL HEALTH, V17, P97; FISCHER S, 1990, CARCINOGENESIS, V11, P723, DOI 10.1093/carcin/11.5.723; FISCHER S, 1989, CARCINOGENESIS, V10, P1511; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; GRITZ ER, 1983, PHARMACOL BIOCHEM BE, V18, P457, DOI 10.1016/0091-3057(83)90469-0; Haldorsen T, 1999, INT J EPIDEMIOL, V28, P1032, DOI 10.1093/ije/28.6.1032; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; HARRIS CC, 1974, NATURE, V252, P68, DOI 10.1038/252068a0; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; Hecht SS, 1999, MUTAT RES-FUND MOL M, V424, P127, DOI 10.1016/S0027-5107(99)00014-7; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; HECHT SS, 1993, NEW ENGL J MED, V329, P1543, DOI 10.1056/NEJM199311183292105; HEGMANN KT, 1993, EPIDEMIOLOGY, V4, P444, DOI 10.1097/00001648-199309000-00010; Hoffmann D, 1997, J TOXICOL ENV HEALTH, V50, P307, DOI 10.1080/009841097160393; Hou SM, 1999, CARCINOGENESIS, V20, P437, DOI 10.1093/carcin/20.3.437; IARC, 1986, IARC MON EV CARC RIS, V38; Kaiser U, 1996, INT J CANCER, V67, P357, DOI 10.1002/(SICI)1097-0215(19960729)67:3<357::AID-IJC9>3.0.CO;2-Q; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Kim JH, 1998, CARCINOGENESIS, V19, P1847, DOI 10.1093/carcin/19.10.1847; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Kondo K, 1996, J SURG ONCOL, V61, P20, DOI 10.1002/(SICI)1096-9098(199601)61:1<20::AID-JSO6>3.3.CO;2-#; Kure EH, 1996, CARCINOGENESIS, V17, P2201, DOI 10.1093/carcin/17.10.2201; Lee P N, 1998, Stat Methods Med Res, V7, P137, DOI 10.1191/096228098669795194; Lerman C, 1999, HEALTH PSYCHOL, V18, P14, DOI 10.1037/0278-6133.18.1.14; Lerman C, 1998, HEALTH PSYCHOL, V17, P56, DOI 10.1037/0278-6133.17.1.56; LEVI F, 1987, EUR J CANCER CLIN ON, V23, P1025, DOI 10.1016/0277-5379(87)90353-1; Lewis DFV, 1997, DRUG METAB REV, V29, P1055, DOI 10.3109/03602539709002243; Lodovici M, 1998, CHEM-BIOL INTERACT, V116, P199, DOI 10.1016/S0009-2797(98)00091-X; MACLURE M, 1989, AM J PUBLIC HEALTH, V79, P1381, DOI 10.2105/AJPH.79.10.1381; Mollerup S, 1999, CANCER RES, V59, P3317; MUSTONEN R, 1993, CARCINOGENESIS, V14, P151, DOI 10.1093/carcin/14.1.151; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; NOBLE EP, 1994, MED HYPOTHESES, V42, P257, DOI 10.1016/0306-9877(94)90127-9; Nyberg F, 1997, EPIDEMIOLOGY, V8, P304, DOI 10.1097/00001648-199705000-00013; OKADA T, 1994, PHARMACOGENETICS, V4, P333, DOI 10.1097/00008571-199412000-00006; Palmisano WA, 2000, CANCER RES, V60, P5954; Parsons WD, 1998, CANCER EPIDEM BIOMAR, V7, P257; Pastorelli R, 1998, CANCER EPIDEM BIOMAR, V7, P703; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P341; PERERA FP, 1987, J NATL CANCER I, V78, P887; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Poli P, 1999, TOXICOL LETT, V108, P267, DOI 10.1016/S0378-4274(99)00098-3; Prescott E, 1998, INT J EPIDEMIOL, V27, P27, DOI 10.1093/ije/27.1.27; RENNARD SI, 1990, EUR RESPIR J, V3, P752; REPACE JL, 1990, RISK ANAL, V10, P27, DOI 10.1111/j.1539-6924.1990.tb01017.x; RISCH HA, 1994, SCIENCE, V263, P1206, DOI 10.1126/science.8122096; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; ROBERTSON IGC, 1988, POLYNUCLEAR AROMATIC, P799; Rojas M, 1998, PHARMACOGENETICS, V8, P109; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; RYBERG D, 1994, CANCER RES, V54, P5801; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Sabol SZ, 1999, HEALTH PSYCHOL, V18, P7, DOI 10.1037/0278-6133.18.1.7; Schoket B, 1998, CARCINOGENESIS, V19, P841, DOI 10.1093/carcin/19.5.841; Scott FM, 1997, CLIN CANCER RES, V3, P479; SETO H, 1993, ARCH ENVIRON CON TOX, V24, P498, DOI 10.1007/BF01146169; Shields PG, 1998, CANCER EPIDEM BIOMAR, V7, P453; SHIELDS PG, 1998, MED WORKPLACE APPL B, P253; Shimada T, 1996, CANCER RES, V56, P2979; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Shriver SP, 2000, JNCI-J NATL CANCER I, V92, P24, DOI 10.1093/jnci/92.1.24; SIDNEY S, 1995, ARCH INTERN MED, V155, P727, DOI 10.1001/archinte.155.7.727; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; SMITH TJ, 1995, CANCER RES, V55, P5566; SMITH TJ, 1992, CANCER RES, V52, P1757; SORSA M, 1984, ENVIRON RES, V33, P312, DOI 10.1016/0013-9351(84)90029-X; Speit G, 1999, METH MOL B, V113, P203; Spitz MR, 1998, J NATL CANCER I, V90, P358, DOI 10.1093/jnci/90.5.358; STERN SJ, 1993, J CELL BIOCHEM, P129; STOCKWELL HG, 1992, J NATL CANCER I, V84, P1417, DOI 10.1093/jnci/84.18.1417; Sunyer J, 1996, AM J EPIDEMIOL, V144, P734; Takagi Y, 1998, BRIT J CANCER, V77, P1568, DOI 10.1038/bjc.1998.258; TANG DL, 1995, CANCER EPIDEM BIOMAR, V4, P341; Tang DL, 1998, CARCINOGENESIS, V19, P1949, DOI 10.1093/carcin/19.11.1949; Tang DL, 2001, CANCER RES, V61, P6708; Thun MJ, 1997, JNCI-J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; TIANO HF, 1994, CARCINOGENESIS, V15, P2859, DOI 10.1093/carcin/15.12.2859; TRICKER AR, 1991, CARCINOGENESIS, V12, P257, DOI 10.1093/carcin/12.2.257; TWEEDIE RL, 1992, BRIT J CANCER, V66, P700, DOI 10.1038/bjc.1992.341; *US DEP HLTH, 2000, FTC CIG TEST METH DE, P238; Valkonen M, 1998, CIRCULATION, V97, P2012, DOI 10.1161/01.CIR.97.20.2012; van Delft JHM, 1998, CRIT REV TOXICOL, V28, P477, DOI 10.1080/10408449891344254; VANSCHOOTEN FJ, 1990, CARCINOGENESIS, V11, P1677, DOI 10.1093/carcin/11.9.1677; VINEIS P, 1994, NATURE, V369, P154, DOI 10.1038/369154a0; WADA M, 1993, BLOOD, V82, P3163; WIENCKE JK, 1995, CANCER RES, V55, P4910; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; XUE KX, 1992, INT J CANCER, V50, P702, DOI 10.1002/ijc.2910500506; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611; Zang EA, 1996, JNCI-J NATL CANCER I, V88, P183, DOI 10.1093/jnci/88.3-4.183; Zaridze D.G., 1991, IARC SCI PUBL, V105, P485; ZEISE L, 1997, EPA REPORT	120	120	134	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6870	6876		10.1038/sj.onc.1205832	http://dx.doi.org/10.1038/sj.onc.1205832			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362269				2022-12-17	WOS:000178640200002
J	Zou, TT; Selaru, FM; Xu, Y; Shustova, V; Yin, J; Mori, Y; Shibata, D; Sato, F; Wang, SM; Olaru, A; Deacu, E; Liu, TC; Abraham, JM; Meltzer, SJ				Zou, TT; Selaru, FM; Xu, Y; Shustova, V; Yin, J; Mori, Y; Shibata, D; Sato, F; Wang, SM; Olaru, A; Deacu, E; Liu, TC; Abraham, JM; Meltzer, SJ			Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon	ONCOGENE			English	Article						colon cancer; cDNA microarrays; cluster analysis; gene filtering	TRANSCRIPTIONAL PROGRAM; EXPRESSION PATTERNS; RECEPTOR; BREAST; CELLS; FIBROBLASTS; CARCINOMA; SUBTYPES; MITOGEN; TUMORS	In order to discover global gene expression patterns characterizing subgroups of colon cancer, microarrays were hybridized to labeled RNAs obtained from seventeen colonic specimens (nine carcinomas and eight normal samples). Using a hierarchical agglomerative method, the samples grouped naturally into two major clusters, in perfect concordance with pathological reports (colon cancer versus normal colon). Using a variant of the unpaired t-test, selected genes were ordered according to an index of importance. In order to confirm microarray data, we performed quantitative, real-time reverse transcriptase - polymerase chain reaction (TaqMan RT-PCR) on RNAs from 13 colorectal tumors and 13 normal tissues (seven of which were matched normal-tumor pairs). RT-PCR was performed on the gro1, B-factor, adlican, and endothelin converting enzyme-1 genes and confirmed microarray findings. Two hundred and fifty genes were identified, some of which were previously reported as being involved in colon cancer. We conclude that cDNA microarraying, combined with bioinformatics tools, can accurately classify colon specimens according to current histopathological taxonomy. Moreover, this technology holds promise of providing invaluable insight into specific gene roles in the development and progression of colon cancer. Our data suggests that a large-scale approach may be undertaken with the purpose of identifying biomarkers relevant to cancer progression.	Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Surg, Div Surg Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Room N3W62,22 S Green St, Baltimore, MD 21201 USA.			Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA85069, CA95323] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085069, R01CA095323, R01CA077057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed SI, 2000, AM J RESP CELL MOL, V22, P422, DOI 10.1165/ajrcmb.22.4.3795; Alizadeh A, 1998, J CLIN IMMUNOL, V18, P373, DOI 10.1023/A:1023293621057; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; American Cancer Society, 2000, CANC FACTS FIG; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Elek J, 2000, IN VIVO, V14, P173; GRAMMATICO P, 1995, WORLD J SURG, V19, P350, DOI 10.1007/BF00299156; Ikeda Y, 2001, ONCOLOGY-BASEL, V61, P168, DOI 10.1159/000055369; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jensen JAG, 2001, PEPTIDES, V22, P689, DOI 10.1016/S0196-9781(01)00380-1; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Luo L, 1999, NAT MED, V5, P117, DOI 10.1038/4806; MELTZER SJ, 1989, EXP MOL PATHOL, V51, P264, DOI 10.1016/0014-4800(89)90024-5; Nicke B, 1999, GUT, V45, P51, DOI 10.1136/gut.45.1.51; PATEL KV, 1995, BRIT J CANCER, V71, P442, DOI 10.1038/bjc.1995.90; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Robinson S, 2001, NEUROSURGERY, V48, P864, DOI 10.1097/00006123-200104000-00035; Selaru FM, 2002, GASTROENTEROLOGY, V122, P606, DOI 10.1053/gast.2002.31904; Selaru FM, 2002, ONCOGENE, V21, P475, DOI 10.1038/sj.onc.1205111; Sogawa K, 1997, CANCER LETT, V112, P263, DOI 10.1016/S0304-3835(96)04589-2; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stewart LV, 1997, EXP CELL RES, V233, P321, DOI 10.1006/excr.1997.3569; Takakura S, 2001, INT J ONCOL, V18, P817; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wang QD, 2000, ANTICANCER RES, V20, P75	31	120	136	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4855	4862		10.1038/sj.onc.1205613	http://dx.doi.org/10.1038/sj.onc.1205613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101425				2022-12-17	WOS:000176716300016
J	Khoo, SK; Bradley, M; Wong, FK; Hedblad, MA; Nordenskjold, M; Teh, BT				Khoo, SK; Bradley, M; Wong, FK; Hedblad, MA; Nordenskjold, M; Teh, BT			Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2	ONCOGENE			English	Article						skin tumors; renal tumors; Birt-Hogg-Dube syndrome; linkage analysis	MULTIPLE; ACROCHORDONS; FIBROFOLLICULOMAS; TRICHODISCOMAS; KINASE	Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant neoplasia syndrome characterized mainly by benign skin tumors, and to a lesser extent, renal tumors and spontaneous pneumothorax. To map the BHD locus, we performed a genome-wide linkage analysis using polymorphic microsatellite markers on a large Swedish BHD family. Evidence of linkage was identified on chromosome 17p12-q11.2, with a maximum LOD score of 3.58 for marker D17S1852. Further haplotype analysis defined a similar to 35 cm candidate interval between the two flanking markers, D17S1791 and D17S798. This information will facilitate the identification of the BHD gene, leading to the understanding of its underlying molecular etiology.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA; Karolinska Inst, Karolinska Hosp, Dept Dermatol & Venereol, S-10401 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp, Dept Clin Genet, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Van Andel Institute; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Nordenskjold, M (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, S-10401 Stockholm, Sweden.			Khoo, Sok Kean/0000-0003-3836-5497; Nordenskjold, Magnus/0000-0002-4974-425X; Bradley, Maria/0000-0001-7192-5041; Teh, Bin Tean/0000-0003-1514-1124				BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; Chung JY, 1996, INT J DERMATOL, V35, P365, DOI 10.1111/j.1365-4362.1996.tb03642.x; De la Torre C, 1999, AM J DERMATOPATH, V21, P369, DOI 10.1097/00000372-199908000-00011; FOUCAR K, 1981, CUTIS, V28, P429; Haimowitz JE, 1997, ARCH DERMATOL, V133, P1163, DOI 10.1001/archderm.133.9.1163; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; LATHROP GM, 1985, AM J HUM GENET, V37, P482; MORENO A, 1985, DERMATOLOGICA, V171, P338, DOI 10.1159/000249448; RONGIOLETTI F, 1989, CLIN EXP DERMATOL, V14, P72, DOI 10.1111/j.1365-2230.1989.tb00890.x; ROTH JS, 1993, J AM ACAD DERMATOL, V29, P1055, DOI 10.1016/S0190-9622(08)82049-X; Schulz T, 1999, J CUTAN PATHOL, V26, P55, DOI 10.1111/j.1600-0560.1999.tb01792.x; STARINK TM, 1985, ARCH DERMATOL, V121, P888, DOI 10.1001/archderm.121.7.888; STARINK TM, 1987, J AM ACAD DERMATOL, V17, P493, DOI 10.1016/S0190-9622(87)70235-7; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195; WEINTRAUB R, 1977, J CUTAN PATHOL, V4, P289, DOI 10.1111/j.1600-0560.1977.tb00920.x	17	120	121	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5239	5242		10.1038/sj.onc.1204703	http://dx.doi.org/10.1038/sj.onc.1204703			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526515				2022-12-17	WOS:000170464000020
J	Tarapore, P; Horn, HF; Tokuyama, Y; Fukasawa, K				Tarapore, P; Horn, HF; Tokuyama, Y; Fukasawa, K			Direct regulation of the centrosome duplication cycle by the p53-p21(Waf1/Cip1) pathway	ONCOGENE			English	Article						centrosome duplication; Waf1; p53; CDK2; cyclin E	CELL-CYCLE; MAMMALIAN-CELLS; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; DEPENDENT KINASES; PHASE-TRANSITION; PROTEIN-KINASE; P53; EXPRESSION; INHIBITOR	The function of the centrosomes to direct mitotic spindles is critical for accurate chromosome transmission to daughter cells. Since each daughter cell inherits one centrosome, each centrosome must duplicate prior to the next mitosis, and do so only once, Thus, there are control mechanism(s) that ensure the coordinated progression of centrosome duplication and other cell cycle events (i,e, DNA synthesis), and limit centrosome duplication to once per cell cycle, Deregulation of the centrosome duplication cycle results in abnormal amplification of centrosomes, leading to aberrant mitoses and increased chromosome transmission errors, This has been found to be the case for cells lacking functional p53 tumor suppressor protein. However, it had remained to be determined whether the deregulation of the centrosome duplication cycle is the direct or indirect effect of loss/mutational inactivation of p53, Here, we found that the normal centrosome duplication cycle is almost completely restored in p53(-/-) cells by re-introduction of wild-type p53 at a physiologically relevant level, demonstrating that p,53 is directly involved in the regulation of centrosome duplication, Since cyclin dependent kinase 2 (CDK2)/cyclin E triggers DNA synthesis as well as centrosome duplication, we tested whether Waf1, a CDK inhibitor and a major target of p53's transactivation function, is an effector of p,53-mediated regulation of centrosome duplication, We found that induced expression of Waf1 in p53(-/-) cells only partially restored the centrosome duplication control, suggesting that Waf1 comprises one of the multiple effector pathways of the p53-mediated regulation of the centrosome duplication cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Vontz Ctr Mol Studies, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996				BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; BORNENS M, 1992, CENTROSOME, V6, P1; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORO F, 1995, CARCINOGENESIS, V16, P2435, DOI 10.1093/carcin/16.10.2435; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pihan GA, 1998, CANCER RES, V58, P3974; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tournier Frederic, 1994, V13, P303; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Wahl GM, 1997, CANCER SURV, V29, P183; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	52	120	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3173	3184		10.1038/sj.onc.1204424	http://dx.doi.org/10.1038/sj.onc.1204424			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423967				2022-12-17	WOS:000169163500001
J	Sanchez-Perez, I; Martinez-Gomariz, M; Williams, D; Keyse, SM; Perona, R				Sanchez-Perez, I; Martinez-Gomariz, M; Williams, D; Keyse, SM; Perona, R			CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin	ONCOGENE			English	Article						cisplatin; JNK1; CL100-MKP-1; hVH-5; apoptosis	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; KINASE KINASE KINASE; DNA-DAMAGING AGENTS; C-JUN; MAP KINASE; IN-VIVO; CELL-DEATH; CONDITIONAL EXPRESSION	Treatment of cells with cisplatin induces a sustained activation of the stress activated protein kinase SAPK/JNK and the mitogen-activated protein kinase p38, Activation of JNK by cisplatin is necessary for the induction of apoptosis, Expression of the MAPK phosphatases CL100/MKP-1 and hVH-5 selectively prevents JNK/SAPK activation by cisplatin in a dose dependent fashion and results in protection against cisplatin-induced apoptosis, In contrast, expression of the ERK-specific phosphatase Pyst1 inhibits JNK/SAPK activity only when expressed at very high levels and does not confer protection against cisplatin. Furthermore, expression of a catalytically inactive mutant of CL100 in 293 cells decreases the IC50 for cisplatin and increases the toxicity of transplatin, This effect seems to be mediated by an increase in JNK activity since p38 activity is unaffected. These results suggest that dual-specificity MAPK phosphatases may be candidate drug targets in order to optimize cisplatin based therapeutic protocols.	CSIC, Inst Invest Biomed, UAM, E-28029 Madrid, Spain; Ninewells Hosp, Biomed Res Ctr, Mol Pharmacol Unit, Imperial Canc Res Fund, Dundee DD1 9SY, Scotland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Dundee	Perona, R (corresponding author), CSIC, Inst Invest Biomed, UAM, Arturo Duperier 4, E-28029 Madrid, Spain.		Keyse, Stephen M./B-9575-2009; Sánchez-Pérez, Isabel/R-4107-2016	Keyse, Stephen M./0000-0002-5150-8221; Sánchez-Pérez, Isabel/0000-0002-4829-201X				ALESSI DR, 1993, ONCOGENE, V8, P2015; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Leav I, 1996, LAB INVEST, V75, P361; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	57	120	126	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5142	5152		10.1038/sj.onc.1203887	http://dx.doi.org/10.1038/sj.onc.1203887			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064451				2022-12-17	WOS:000090124100003
J	Mussman, JG; Horn, HF; Carroll, PE; Okuda, M; Tarapore, P; Donehower, LA; Fukasawa, K				Mussman, JG; Horn, HF; Carroll, PE; Okuda, M; Tarapore, P; Donehower, LA; Fukasawa, K			Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression	ONCOGENE			English	Article						centrosome hyperamplification; cancer; p53; Cdk2; cyclin E	HUMAN CELL-CYCLE; DEPENDENT KINASES; DNA-REPLICATION; PROTEIN-KINASE; GAMMA-TUBULIN; MAMMALIAN FIBROBLASTS; PHASE-TRANSITION; S-PHASE; EXPRESSION; AMPLIFICATION	Centrosome hyperamplification and the consequential mitotic defects contribute to chromosome instability in cancers. Loss or mutational inactivation of p53 has been shown to induce chromosome instability through centrosome hyperamplification. It has recently been found that Cdk2-cyclin E is involved in the initiation of centrosome duplication, and that constitutive activation of Cdk2-cyclin E results in the uncoupling of the centrosome duplication cycle and the DNA replication cycle. Cyclin E overexpression and p53 mutations occur frequently in tumors. Here, we show that cyclin E overexpression and loss of p53 synergistically increase the frequency of centrosome hyperamplification in cultured cells as well as in tumors developed in p53-null, heterozygous, and wildtype mice, Through examination of cells derived from Waf1-null mice, we further found that Waf1, a potent inhibitor of Cdk2-cyclin E and a major target of p53's transactivation function, is involved in coordinating the initiation of centrosome duplication and DNA replication, suggesting that Waf1 may act as a molecular link between p53 and Cdk2-cyclin E in the control of the centrosome duplication cycle.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	University System of Ohio; University of Cincinnati; Baylor College of Medicine	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.		Tarapore, Pheruza/A-8876-2013	Tarapore, Pheruza/0000-0003-0911-3661; Horn, Henning/0000-0002-5885-8996; Okuda, Masaru/0000-0003-4690-8244				Bornens Michel, 1992, P1; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; CARBONAROHALL D, 1993, ONCOGENE, V9, P71; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARLOW E, 1998, ANTIBODIES LAB MANUA, P380; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lange BMH, 1996, TRENDS CELL BIOL, V6, P348, DOI 10.1016/0962-8924(96)10033-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pihan GA, 1998, CANCER RES, V58, P3974; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RITTLING SR, 1992, ONCOGENE, V7, P935; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka T, 1999, CANCER RES, V59, P2041; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tournier Frederic, 1994, V13, P303; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Vandre D.D., 1989, MITOSIS MOL MECHANIS, P39; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	75	120	131	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2000	19	13					1635	1646		10.1038/sj.onc.1203460	http://dx.doi.org/10.1038/sj.onc.1203460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763820				2022-12-17	WOS:000086083800003
J	Imazu, T; Shimizu, S; Tagami, S; Matsushima, M; Nakamura, Y; Miki, T; Okuyama, A; Tsujimoto, Y				Imazu, T; Shimizu, S; Tagami, S; Matsushima, M; Nakamura, Y; Miki, T; Okuyama, A; Tsujimoto, Y			Bcl-2/E1B 19kDa-interacting protein 3-like protein (Bnip3L) interacts with Bcl-2/Bcl-x(L) and induces apoptosis by altering mitochondrial membrane permeability	ONCOGENE			English	Article						Bnip3L; BH3; apoptosis; Bcl-2; mitochondrial; cytochrome c	CYTOCHROME-C RELEASE; CELL-DEATH; LOCALIZATION; DYSFUNCTION; SURVIVAL; BINDING; DOMAIN; NIP3	We have previously reported on cloning of the human gene encoding Bcl-2/adenovirus E1B 19 kDa-interacting protein 3-like protein (Bnip3L) and its growth inhibitory effect on cancer cells. Here we show that Bnip3L contains a motif similar to the BH3 domain which is conserved in Bcl-2 family proteins as well as containing a membrane-anchoring domain, and that Bnip3L interacts with Bcl-2 and Bcl-x(L). Immunofluorescence microscopy revealed that Bnip3L was localized in the mitochondria, when in the presence of the membrane-anchoring domain. Transient expression of Bnip3L induced apoptosis of Rat-1 and HeLa cells and mutational analysis revealed that the BH3 domain and the membrane-anchoring domain were required for Bnip3L to induce cell death. Addition of recombinant Bnip3L to isolated mitochondria induced membrane potential loss and cytochrome c release both of which hale been suggested to be prerequisite for apoptotic cell death, These results suggest that Bnip3L is one of the BH3-containing proapoptotic proteins and that it targets the mitochondria when inducing apoptosis.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Urol, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo 1080071, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); University of Tokyo	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AKAO Y, 1994, CANCER RES, V54, P2468; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yasuda M, 1998, ONCOGENE, V17, P2525, DOI 10.1038/sj.onc.1202467; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	22	120	126	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4523	4529		10.1038/sj.onc.1202722	http://dx.doi.org/10.1038/sj.onc.1202722			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467396				2022-12-17	WOS:000082018600001
J	Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB				Billon, N; Carlisi, D; Datto, MB; van Grunsven, LA; Watt, A; Wang, XF; Rudkin, BB			Cooperation of Spl and p300 in the induction of the CDK inhibitor p21(WAF1/CIP1) during NGF-mediated neuronal differentiation	ONCOGENE			English	Article						p21WAF1/CIP1; p300; Spl; NGF; neuronal differentiation; PC12	NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR SP1; DEPENDENT PROTEIN-KINASE; DNA-BINDING ACTIVITY; CELL-CYCLE ARREST; NF-KAPPA-B; PC12 CELLS; HISTONE ACETYLTRANSFERASE; TERMINAL DIFFERENTIATION; TRANSACTIVATION DOMAIN	Addition of nerve growth factor (NGF) to PC12 cells promotes neuronal differentiation while inhibiting cell proliferation. In order to understand how NGF exerts its antimitogenic effect during differentiation, we have studied the mechanism by which this factor activates the promoter of the CDK inhibitor p21(WAF1/CIP1). The minimal region of the p21 promoter required for the NGF-induction was mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site, This GC-rich region was shown to interact specifically with the transcription factor Spl and the related protein Sp3, in either exponentially-growing or NGF-treated PC12 cells, The addition of NGF resulted in an accumulation of the transcriptional co-activator p300 in complexes associated with the NGF-responsive region, Transcriptional activity of Sp1, Sp3 and p300 was specifically induced by NGF in a Gal4-fusion assay, indicating that induction of p21 during neuronal differentiation may involve regulation of the activity of these factors by NGF, Furthermore, p300 was able to act as a co-activator for Sp1-mediated transcriptional activation in PC12 cells, suggesting that p300 and Spl may cooperate in activating p21 transcription during the withdrawal of neuronal precursors from the cell cycle. This hypothesis is supported by experiments showing that p300 and Spl form complexes in PC12 cells.	Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, CNRS,UMR 49, F-69364 Lyon 07, France; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Duke University	Rudkin, BB (corresponding author), Ecole Normale Super Lyon, Differentiat & Cell Cycle Grp, Biol Cellulaire & Mol Lab, CNRS,UMR 49, 46 Allee Italie, F-69364 Lyon 07, France.		van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; Watt, Alanna/0000-0002-6371-6220; RUDKIN, Brian B./0000-0003-3700-1982				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4790; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V28, P743; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ECKNER R, 1996, GENE DEV, V7, P1933; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; JIANG HP, 1994, ONCOGENE, V9, P3397; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERSENGIEV SP, 1995, P NATL ACAD SCI USA, V92, P9107, DOI 10.1073/pnas.92.20.9107; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAMIREZ S, 1997, J BIOL CHEM, V272, P31013; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	63	120	121	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2872	2882		10.1038/sj.onc.1202712	http://dx.doi.org/10.1038/sj.onc.1202712			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362258				2022-12-17	WOS:000080125100010
J	Leone, PE; Bello, MJ; de Campos, JM; Vaquero, J; Sarasa, JL; Pestana, A; Rey, JA				Leone, PE; Bello, MJ; de Campos, JM; Vaquero, J; Sarasa, JL; Pestana, A; Rey, JA			NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas	ONCOGENE			English	Article						meningiomas; NF2; allelic losses; tumor progression; 1p and 14q deletion mapping	TUMOR-SUPPRESSOR GENE; NEUROFIBROMATOSIS TYPE-2; HISTOPATHOLOGICAL FINDINGS; OLIGODENDROGLIAL TUMORS; MALIGNANT MENINGIOMA; CYTOGENETIC ANALYSIS; SOMATIC MUTATIONS; FREQUENT LOSS; BRAIN-TUMORS; PROGRESSION	Formation of meningiomas and their progression to malignancy may be a multi-step process, implying accumulation of genetic mutations at specific loci. To determine the relationship between early NF2 gene inactivation and the molecular mechanisms that may contribute to meningioma tumor progression, we have performed deletion mapping analysis at chromosomes 1, 14 and 22 in a series of 81 sporadic meningiomas (54 grade I(typical), 25 grade LI (atypical) and two grade III (anaplastic)), which were also studied for NF2 gene mutations. Single-strand conformational polymorphism analysis was used to identify 11 mutations in five of the eight exons of the NF2 gene studied. All 11 tumors displayed loss of heterozygosity (LOH) for chromosome 22 markers; this anomaly was also detected in 33 additional tumors. Twenty-nine and 23 cases were characterized by LOH at 1p and 14q, respectively, mostly corresponding to aggressive tumors that also generally displayed LOH 22. All three alterations were detected in association in seven grade II and two grade III meningiomas, corroborating the hypothesis that the formation of aggressive meningiomas follows a multi-step tumor progression model.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain; Clin Puerta Hierro, Dept Neurosurg, Madrid, Spain; Fdn Jimenez Diaz, Dept Pathol Anat, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital del Rio Hortega; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Rey, JA (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.		Rey, Juan A/H-5026-2013					ALSAADI A, 1987, CANCER GENET CYTOGEN, V26, P127, DOI 10.1016/0165-4608(87)90140-3; Bandera CA, 1997, CANCER RES, V57, P513; BATTERSBY RDE, 1986, J NEUROL NEUROSUR PS, V49, P362, DOI 10.1136/jnnp.49.4.362; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P296, DOI 10.1002/gcc.2870090411; BENDER B, 1994, BIOTECHNIQUES, V16, P204; BIECHE I, 1994, CANCER RES, V54, P4274; BUTTI G, 1989, SURG NEUROL, V31, P225; CASALONE R, 1990, CANCER GENET CYTOGEN, V45, P237, DOI 10.1016/0165-4608(90)90088-R; CASARTELLI C, 1989, CANCER GENET CYTOGEN, V40, P33, DOI 10.1016/0165-4608(89)90143-X; CHANG WYH, 1995, CANCER RES, V55, P3246; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DEPREZ RHL, 1995, J NEUROPATH EXP NEUR, V54, P224, DOI 10.1097/00005072-199503000-00009; DeVitis LR, 1996, HUM GENET, V97, P632; DOMENICUCCI M, 1989, J NEUROSURG, V70, P41, DOI 10.3171/jns.1989.70.1.0041; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJINO T, 1994, CANCER RES, V54, P4294; Harada T, 1996, J NEUROSURG, V84, P847, DOI 10.3171/jns.1996.84.5.0847; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; KOVACS G, 1993, HISTOPATHOLOGY, V22, P1, DOI 10.1111/j.1365-2559.1993.tb00061.x; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LINDBLOM A, 1994, INT J CANCER, V56, P354, DOI 10.1002/ijc.2910560310; LopezGines C, 1995, CANCER GENET CYTOGEN, V85, P113, DOI 10.1016/0165-4608(95)00148-4; MALTBY EL, 1988, CANCER GENET CYTOGEN, V31, P199, DOI 10.1016/0165-4608(88)90218-X; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MEMON MY, 1980, NEUROSURGERY, V7, P262, DOI 10.1227/00006123-198009000-00010; Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853; MEREL P, 1995, GENE CHROMOSOME CANC, V13, P211, DOI 10.1002/gcc.2870130311; Mertens F, 1997, CANCER RES, V57, P2765; PAPI L, 1995, HUM GENET, V95, P347, DOI 10.1007/BF00225206; Perry A, 1996, CANCER, V77, P2567, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2567::AID-CNCR21>3.0.CO;2-P; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; Poulsgard Lars, 1993, P249; Rasio D, 1997, CANCER RES, V57, P2378; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; REMPEL SA, 1993, CANCER RES, V53, P2386; REY JA, 1988, CANCER GENET CYTOGEN, V33, P275, DOI 10.1016/0165-4608(88)90036-2; REY JA, 1992, INT J CANCER, V51, P703, DOI 10.1002/ijc.2910510507; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Schneider BF, 1995, CANCER GENET CYTOGEN, V85, P101, DOI 10.1016/0165-4608(95)00154-9; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SIMON M, 1995, CANCER RES, V55, P4696; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VAGNERCAPODANO AM, 1993, NEUROSURGERY, V32, P892, DOI 10.1227/00006123-199306000-00002; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; YOUNG J, 1993, ONCOGENE, V8, P671; ZANG KD, 1982, CANCER GENET CYTOGEN, V6, P249, DOI 10.1016/0165-4608(82)90063-2	54	120	123	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	1999	18	13					2231	2239		10.1038/sj.onc.1202531	http://dx.doi.org/10.1038/sj.onc.1202531			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327069				2022-12-17	WOS:000079525100007
J	Ichimiya, S; Nimura, Y; Kageyama, H; Takada, N; Sunahara, M; Shishikura, T; Nakamura, Y; Sakiyama, S; Seki, N; Ohira, M; Kaneko, Y; McKeon, F; Caput, D; Nakagawara, A				Ichimiya, S; Nimura, Y; Kageyama, H; Takada, N; Sunahara, M; Shishikura, T; Nakamura, Y; Sakiyama, S; Seki, N; Ohira, M; Kaneko, Y; McKeon, F; Caput, D; Nakagawara, A			p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent	ONCOGENE			English	Article						p73; neuroblastoma; loss of heterozygosity; 1p36; mutation; p53	N-MYC AMPLIFICATION; P53 GENE-MUTATIONS; SHORT ARM; EXPRESSION; DELETION; PROTEIN; REGION; INSTABILITY; TUMORS; LOCI	p73, a novel p53 family member, is a recently identified candidate neuroblastoma (NBL) suppressor gene mapped at chromosome 1p36.33 and was found to inhibit growth and induce apoptosis in cell lines. To test the hypothesis that p73 is a NBL suppressor gene, we analysed the p73 gene in primary human NBLs, Loss of heterozygosity (LOH) for p73 was observed in 19% (28/151) of informative cases which included 92 mass-screening (MS) tumors. The high frequency of p73 LOH was significantly associated with sporadic NBLs (9% vs 34%, P < 0.001), N-myc amplification (10% vs 71%, P < 0.001), and advanced stage (14% vs 28%, P < 0.05), Both p73 alpha and p73 beta transcripts were detectable in only 46 of 134 (34%) NBLs at low levels by RT-PCR methods, while they were easily detectable in most breast cancers and colorectal cancers under the same conditions. They found no correlation between p73 LOH and its expression levels (P > 0.1), We found two mutations out of 140 NBLs, one somatic and one germline, which result in amino acid substitutions in the C-terminal region of p73 which may affect transactivation functions, though, in the same tumor samples, no mutation of the p53 gene was observed as reported previously. These results suggest that allelic loss of the p73 gene may be a later event in NBL tumorigenesis. However, p73 is infrequently mutated in primary NBLs and may hardly function as a tumor suppressor in a classic Knudson's manner.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Kazusa DNA Res Inst, Lab Gene Struct 1, Chiba 2920812, Japan; Saitama Canc Ctr Hosp, Dept Canc Chemotherapy, Ina, Saitama 362, Japan; Sanofi Rech, F-31676 Labege, France; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Chiba Cancer Center; Kazusa DNA Research Institute; Sanofi-Aventis; Sanofi France; Harvard University; Harvard Medical School	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							AMLER LC, 1995, ONCOGENE, V10, P1095; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CHENG JM, 1993, NAT GENET, V4, P191, DOI 10.1038/ng0693-191; CHRISTIANSEN H, 1992, GENE CHROMOSOME CANC, V5, P141, DOI 10.1002/gcc.2870050208; FONG CT, 1992, CANCER RES, V52, P1780; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kobayashi H, 1996, BRIT J HAEMATOL, V94, P105, DOI 10.1046/j.1365-2141.1996.d01-1762.x; KOMURO H, 1993, CANCER RES, V53, P5284; Mai M, 1998, CANCER RES, V58, P2347; MARTINSSON T, 1995, CANCER RES, V55, P5681; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MIHARA M, 1998, IN PRESS BR J CANC; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NIMURA Y, 1998, IN PRESS INT J CANC; Nomoto S, 1998, CANCER RES, V58, P1380; Ohira M, 1996, GENOMICS, V33, P65, DOI 10.1006/geno.1996.0160; Ohtsu K, 1997, CLIN CANCER RES, V3, P1221; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VOGAN K, 1993, CANCER RES, V53, P5269; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	31	120	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1061	1066		10.1038/sj.onc.1202390	http://dx.doi.org/10.1038/sj.onc.1202390			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023682				2022-12-17	WOS:000078510600023
J	Magdinier, F; Ribieras, S; Lenoir, GM; Frappart, L; Dante, R				Magdinier, F; Ribieras, S; Lenoir, GM; Frappart, L; Dante, R			Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region	ONCOGENE			English	Article						BRCA1; human breast cancers; mRNA; PCR; DNA methylation; prognostic factors	SUPPRESSOR GENE BRCA1; OVARIAN-CANCER; GERMLINE MUTATIONS; EXPRESSION; RNA; CARCINOMAS; FAMILIES; TISSUES; GROWTH; CELLS	Germ-line alterations of BRCA1 are responsible for about 50% of familial breast cancers. Although its biological function(s) has not yet been fully determined, it has been suggested that it may act as a tumor suppressor gene in breast and ovarian cancers. In sporadic breast cancers alterations of BRCA1 have not been detected and in vitro experiments have indicated that BRCA1 negatively regulates cellular proliferation, The present study was designed to identify and quantify, the BRCA1 mRNA levels, in normal and neoplasic human breast tissue, BRCA1 mRNA molecules were quantified using competitive reverse transcriptase PCR assays. DNA methylation patterns of this gene have been analysed by Southern blot experiments using methylation sensitive restriction enzymes. We found that BRCA1 mRNA levels were significantly lower in sporadic breast cancers (37 cases analysed, 24 cases of invasive ductal carcinomas not otherwise specified (NOS), two lobular carcinomas in situ two medullary carcinomas, four invasive lobular carcinomas, two invasive mucinous carcinomas and three invasive ductal carcinomas with predominantly in situ component) compared with normal breast tissues (P = 0.0003), This down-regulation of BRCA1 is observed in all histologic types analysed. In invasive ductal carcinomas NOS, this down-regulation does not correlate with any of the prognostic factors studied (tumor size, node status, histologic grade, hormone receptor status), In the samples analysed, alterations of DNA methylation patterns were not dectected in the vicinity of the major transcription start site, These data suggest the involvement of BRCA1 in the carcinogenesis of these histologic types.	CNRS, UMR 5641, Genet Lab, F-69373 Lyon, France	Centre National de la Recherche Scientifique (CNRS)	Dante, R (corresponding author), CNRS, UMR 5641, Genet Lab, Ave Rockefeller, F-69373 Lyon, France.		Magdinier, Frederique/I-4735-2016	Magdinier, Frederique/0000-0002-0159-9559				Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; Baylin SB, 1998, ADV CANCER RES, V72, P141; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; DANTE R, 1994, LAB INVEST, V71, P188; Dobrovic A, 1997, CANCER RES, V57, P3347; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GRAFF JR, 1995, CANCER RES, V55, P5195; GUDAS JM, 1995, CANCER RES, V55, P4561; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Huynh H, 1996, CANCER RES, V56, P4865; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; POULSEN HE, 1975, INT HISTOLOGICAL CLA, P13; Rao VN, 1996, ONCOGENE, V12, P523; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	33	120	123	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3169	3176		10.1038/sj.onc.1202248	http://dx.doi.org/10.1038/sj.onc.1202248			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872332	Green Published			2022-12-17	WOS:000077517400010
J	Komarova, EA; Diatchenko, L; Rokhlin, OW; Hill, JE; Wang, ZJ; Krivokrysenko, VI; Feinstein, E; Gudkov, AV				Komarova, EA; Diatchenko, L; Rokhlin, OW; Hill, JE; Wang, ZJ; Krivokrysenko, VI; Feinstein, E; Gudkov, AV			Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53	ONCOGENE			English	Article						p53; transcription; secretion; growth inhibition; radiation; chemotherapy	CELL-CYCLE; IN-VIVO; APOPTOSIS; FIBROBLASTS; GENE; RADIATION; ANGIOGENESIS; MICE	p53 tumor suppressor gene controls cell response to a variety of stresses inducing growth arrest or apoptosis in damaged cells. It largely determines the sensitivity of tumor and normal cells to radiation and chemotherapy, and, therefore, defines both the efficacy and limitations of anti-cancer treatment. To determine molecular mechanisms of p53-dependent stress response in normal tissues we identified and compared the spectra of radiation-responsive genes in cells of different origin and p53 status using a cDNA array hybridization technique. The majority of genes identified were p53-dependent and cell type specific, Several of the new p53 responders encode known secreted growth inhibitory factors, This suggests that p53, in addition to its intrinsic antiproliferation activity, can cause 'bystander effect' by inducing export of growth suppressive stimuli from damaged cells to neighboring cells. Consistently, a p53-dependent accumulation of factors, which causes growth inhibitory effects in a variety of cell lines, was found after gamma irradiation in the media from established and primary cell cultures and in the urine of irradiated mice. Moreover, p53-dependent factors released by normal human fibroblasts potentiated the cytotoxic effect of a chemotherapeutic drug on co-cultivated tumor cells. This suggests a previously unknown role for normal cells in chemo- and radiation therapy of cancer.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; CLONTECH Labs Inc, Palo Alto, CA 94303 USA; Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA; QBI Enterprises Ltd, IL-74106 Ness Ziona, Israel	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Iowa	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Hill, Jason/0000-0003-2512-1661	NATIONAL CANCER INSTITUTE [R01CA060730, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA60730, CA75179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolph KW, 1997, GENE, V193, P5, DOI 10.1016/S0378-1119(97)00070-X; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GULLINO PM, 1995, ACTA ONCOL, V34, P439, DOI 10.3109/02841869509094005; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERMEKING H, 1997, MOL CELL, V1, P1; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACCALLUM DE, 1996, ONCOGENE, V13, P2545; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MIYASHITA T, 1995, CELL, V80, P293; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; OBRIEN PM, 1960, CANCER, V23, P451; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Qazilbash MH, 1997, GENE THER, V4, P675, DOI 10.1038/sj.gt.3300444; Rokhlin OW, 1997, CANCER RES, V57, P1758; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	32	120	126	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1089	1096		10.1038/sj.onc.1202303	http://dx.doi.org/10.1038/sj.onc.1202303			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764819				2022-12-17	WOS:000075598400004
J	Yawata, A; Adachi, M; Okuda, H; Naishiro, Y; Takamura, T; Hareyama, M; Takayama, S; Reed, JC; Imai, K				Yawata, A; Adachi, M; Okuda, H; Naishiro, Y; Takamura, T; Hareyama, M; Takayama, S; Reed, JC; Imai, K			Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells	ONCOGENE			English	Article						Bcl-2; BAG-1; gastric adenocarcinoma; peritoneal dissemination	BCL-2 PROTEIN; HGF RECEPTOR; GENE; EXPRESSION; BAG-1; APOPTOSIS; CARCINOMA; ADHESION; MATRIX; CHAIN	Bcl-2 and a Bcl-2-binding protein BAG-1 function in protection from apoptosis induced by a variety of stimuli. Deregulated expression of Bcl-2 leads to inhibition of apoptosis and is correlated with development of various cancers, Here, we provide evidence that prolonged cell survival introduced by overproduction of Bcl-2 or BAG-1 strongly enhances peritoneal dissemination of human gastric cancer MKN74 cells. Gene transfer-mediated overexpression of Bcl-2 or BAG-1 led to prolonged cell survival of MKN74 cells against serum-starved apoptosis and anoikis, When the viable transfectants were inoculated into the intraperitoneal cavity of BALB/c nude mice, the Bcl-2-expressing MKN74 cells and the BAG-1-expressing MKN74 cells exhibited strongly enhanced peritoneal dissemination in BALB/c nude mice and whole disseminated tumor weights were increased by ii-fold and 3.3-fold, respectively, compared with the control transfectants. The enhanced peritoneal dissemination of MKN74-Bcl-2 and MKN74-BAG-1 transfectants correlated well with resistance to cell death induced by serum-starvation and anoikis, However, the overexpression of Bcl-2 or BAG-1 caused no significant difference among the transfectants in cell growth rates, either in vitro of in vivo. Taken together, these studies demonstrate that resistance to apoptosis is a crucial factor for development of peritoneal dissemination of human gastric cancer cells.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan; Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sapporo Medical University; Sanford Burnham Prebys Medical Discovery Institute	Adachi, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 060, Japan.				NCI NIH HHS [CA-67329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; Adachi M, 1996, BLOOD, V88, P4118, DOI 10.1182/blood.V88.11.4118.bloodjournal88114118; ASAO T, 1994, CANCER LETT, V78, P57, DOI 10.1016/0304-3835(94)90031-0; ASAO T, 1995, CANCER, V75, P1539, DOI 10.1002/1097-0142(19950315)75:6+<1539::AID-CNCR2820751526>3.0.CO;2-L; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRONNER MP, 1995, AM J PATHOL, V146, P20; BUCK RC, 1973, CANCER RES, V33, P3181; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LAUWERS GY, 1995, CANCER, V75, P2209, DOI 10.1002/1097-0142(19950501)75:9<2209::AID-CNCR2820750904>3.0.CO;2-M; MCDONNELL TJ, 1992, CANCER RES, V52, P6904; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1993, J CELL BIOL, V124, P1; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	20	120	123	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2681	2686		10.1038/sj.onc.1201792	http://dx.doi.org/10.1038/sj.onc.1201792			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632144				2022-12-17	WOS:000073698200012
J	Lane, TF; Philip, L				Lane, TF; Philip, L			Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice	ONCOGENE			English	Article						Wnt10b; FGF-3/int-2; oncogene; mammary adenocarcinoma; neoplasm	WNT GENE FAMILY; TRANSGENIC MICE; TUMOR VIRUS; PROVIRAL INSERTION; EPITHELIAL-CELLS; BREAST-CANCER; EXPRESSION; GROWTH; TUMORIGENESIS; ONCOGENE	Wnt-10b is expressed during the formation of the mammary rudiment in mouse embryos and its expression continues through puberty when the mammary ductal pattern is established under control of ovarian steroids, Recently, viral activation of the Wnt-10b locus has linked its overexpression to mammary tumor formation, suggesting a role for Wnt-10b in patterning and growth-regulation of the mammary gland, To test this notion, we created lines of transgenic mice that express elevated levels of Wnt-10b under the control of the MMTV promoter/enhancer. Overexpression of this gene resulted in profound developmental alterations in the mammary gland, including expanded glandular development and the precocious appearance of alveoli in virgin females, Moreover, transgenic male mice also exhibited dramatic mammary development involving highly branched mammary ducts and gynecomastia. Aberrant expression of Wnt-10b in the mammary rudiments of males evidently bypasses the normal requirement for ovarian hormonal control in stimulating mammary ductal growth and the repressive effects of androgens, In addition to these developmental effects, transgenic mice of both sexes were highly susceptible to the development of mammary adenocarcinomas, Such tumors arose in a solitary manner indicating that Wnt-10b is a proto-oncogene which provides a necessary, but insufficient signal for oncogenesis, Relevant to this, there was no evidence of amplified expression of FGF mRNAs in these tumors though the Fgf's are a class of genes often implicated as collaborators in Wilt-mediated tumor formation, Indeed, co-expression of MMTV-Wnt-10b and MMTV-FGF-3/int-2 resulted in sterile offspring with highly disorganized mammary epithelium, demonstrating a potent interaction between their respective developmental pathways, These results suggest that Wnt-10b, or other Wilt genes expressed early in mammary development, play a role in regulating sexual dimorphism and show potent transforming activity when overexpressed.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute				Lane, Timothy F./0000-0002-0210-970X				Amundadottir LT, 1996, ONCOGENE, V13, P757; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; BRADBURY JM, 1994, ONCOGENE, V9, P2579; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; CHOOI KF, 1994, CANCER RES, V54, P6434; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; DU SJ, 1995, MOL CELL BIOL, V15, P2625; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Dunn T, 1959, PHYSIOPATHOLOGY CANC, P38; FAUKLIN LV, 1960, J NATL CANCER I, V24, P953; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hardiman G, 1996, GENE, V172, P199, DOI 10.1016/0378-1119(96)00109-6; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MEDINA D, 1982, TRANSGENES MOUSE BIO; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NANDI S, 1958, J NATL CANCER I, V21, P1039; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wang JW, 1996, ONCOGENE, V13, P1537; Wang YS, 1996, J BIOL CHEM, V271, P4468; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	42	120	127	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2133	2144		10.1038/sj.onc.1201593	http://dx.doi.org/10.1038/sj.onc.1201593			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393971				2022-12-17	WOS:A1997YD01900001
J	Savelieva, E; Belair, CD; Newton, MA; DeVries, S; Gray, JW; Waldman, F; Reznikoff, CA				Savelieva, E; Belair, CD; Newton, MA; DeVries, S; Gray, JW; Waldman, F; Reznikoff, CA			20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells	ONCOGENE			English	Article						HPV16 E7; human uroepithelial cells; immortalization; 20q amplification; genome instability	RETINOBLASTOMA GENE-PRODUCT; BREAST CARCINOMAS; BLADDER-CANCER; DNA-SEQUENCES; SOLID TUMORS; COPY NUMBER; HPV16 E7; HYBRIDIZATION; KINASE; LOSSES	Breast, bladder, colon, and ovarian carcinomas show frequent low level 20q gain and less frequently high level 20q13.2 amplification, but the significance of these 20q amplifications in transformation has not been defined, Using karyotypic and comparative genomic hybridization (CGH) analyses, chromosome losses and gains were analysed in six newly immortalized human uroepithelial cell (HUC) lines transformed by Human Papillomavirus 16 (HPV16) E7. Results showed clonal chromosomes with 20q11->qter gain in all six lines. CGH revealed a peak of 20q13.2 amplification in two cell lines. FISH with whole chromosome 20 paint showed expanded chromosome regions (ECRs) and double minute chromosomes (DMs) that contained chromosome 20 material in cell lines with 20q13.2 amplification. FISH with probes from the center of the 20q13.2 human breast cancer amplicon showed as many as 24 signals in cells with 20q13.2 amplification. The acquisition of genome instability in these E7-HUCs did not correlate with TP53 mutation, as all E7-HUCs contained only wildtype TP53. These results suggest that low level 20q gain is associated with overcoming cellular senescence in E7 transformed cells (P-value=2x10(-7)), but does not confer genome instability, while high level 20q13.2 amplification is associated with chromosome instability. Loss of 10p (P-value=3x10(-5) was also important in immortalization of E7-transformed HUCs. Thus, these results have profound implications for interpreting the significance of high versus low level 20q gains in human cancers.	UNIV WISCONSIN,SCH MED,DEPT HUMAN ONCOL,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,CTR ENVIRONM TOXICOL,MADISON,WI 53792; UNIV WISCONSIN,SCH MED,COMPREHENS CLIN CANC CTR,MADISON,WI 53792; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC GENET LAB,SAN FRANCISCO,CA 94143; DIV MOL CYTOMETRY,SAN FRANCISCO,CA 94143	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [R01 CA29525-16, R01 CA7158-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELAIR CD, 1996, RADIAT ONCOL INVEST, V3, P368; Brinkmann U, 1996, GENOME RES, V6, P187, DOI 10.1101/gr.6.3.187; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EYFJORD JE, 1995, CANCER RES, V55, P646; GRAY JW, 1992, CANCER, V69, P1536, DOI 10.1002/1097-0142(19920315)69:6+<1536::AID-CNCR2820691306>3.0.CO;2-J; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Holt SE, 1996, MOL CELL BIOL, V16, P2932; IWABUCHI H, 1995, CANCER RES, V55, P6172; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; MULERIS M, 1994, GENE CHROMOSOME CANC, V10, P160, DOI 10.1002/gcc.2870100303; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; Reznikoff CA, 1996, CANCER RES, V56, P2886; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Scherf U, 1996, P NATL ACAD SCI USA, V93, P2670, DOI 10.1073/pnas.93.7.2670; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHLEGEL J, 1995, CANCER RES, V55, P6002; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; TOMMASINO M, 1993, ONCOGENE, V8, P195; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YEAGER T, 1995, CANCER RES, V55, P493; YUNIS JJ, 1982, GENE AMPLIFICATION, P297	36	120	130	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					551	560		10.1038/sj.onc.1200868	http://dx.doi.org/10.1038/sj.onc.1200868			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053853				2022-12-17	WOS:A1997WF52400006
J	CHEN, CY; FALLER, DV				CHEN, CY; FALLER, DV			DIRECTION OF P21(RAS)-GENERATED SIGNALS TOWARDS CELL-GROWTH OR APOPTOSIS IS DETERMINED BY PROTEIN-KINASE-C AND BCL-2	ONCOGENE			English	Article						PROGRAMMED CELL DEATH; T LYMPHOCYTE; ONCOGENE; PHOSPHOPROTEIN; SIGNAL TRANSDUCTION; CELL CYCLE	ANTIGEN RECEPTOR; T-CELLS; REGULATED KINASE-2; DNA FRAGMENTATION; RAS ONCOGENES; LYMPHOCYTES-T; HA-RAS; ACTIVATION; DEATH; MYC	Normal and activated Ras proteins are known to act as signal transducers, mediating mitogenic responses. Interactions of p21(ras) and protein kinase C (PKC) are required in a number of mitogenic or activation signaling pathways. The constitutive expression of activated v-Ha-ras in Jurkat cells, a human T lymphoblastoid cell line, renders the cells susceptible to apoptosis during transient down-regulation or inhibition of PKC. Similarly, the expression of v-Ki-ras in murine fibroblasts induces apoptosis during suppression of PKC activity. This Ras-specific cell death is dependent upon suppression of cellular PKC activity, and can be blocked by the survival-promoting bcl-2 gene product. In vivo phosphorylation studies indicate that Bcl-2 is a phosphoprotein, and the phosphorylation state of Bcl-2 is modulated in the setting of activated p21(Ha-ras) in response to inhibition of PKC. These findings suggest an interactive regulation of growth or apoptosis in cells which involves at least three molecules: p21(ras), PKC and Bcl-2.	BOSTON UNIV,SCH MED,CANC RES CTR,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University								ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BARBACID M, 1987, ANNU REV BIOCHEM, P779; BERRY N, 1990, EUR J BIOCHEM, V189, P204; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DEROSSI A, 1994, VIROLOGY, V198, P234, DOI 10.1006/viro.1994.1026; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUKE RC, 1994, FASEB J, V8, P237, DOI 10.1096/fasebj.8.2.8119494; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FALLER DV, 1994, J BIOL CHEM, V269, P5022; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FERNANDEZSARABI.MJ, 1995, NATURE, V10, P768; FERNANDEZSARABI.MJ, 1993, NATURE, V366, P274; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; FU T, 1991, EXP CELL RES, V203, P230; GRAVES JD, 1990, BIOCHEM J, V265, P407, DOI 10.1042/bj2650407; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOWE PH, 1993, J BIOL CHEM, V268, P21448; ILLERA VA, 1993, J IMMUNOL, V151, P2965; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOKA P, 1991, J IMMUNOL, V146, P2417; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1994, CELL GROWTH DIFFER, V5, P321; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUCAS M, 1994, BIOCHEM PHARMACOL, V47, P667, DOI 10.1016/0006-2952(94)90129-5; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARVEL J, 1994, ONCOGENE, V9, P1117; MAUMOVSKI L, 1994, BLOOD, V83, P2261; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1993, RADIAT RES, V136, P307, DOI 10.2307/3578541; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRIS JDH, 1989, ONCOGENE, V4, P27; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POLVERINO AJ, 1990, BIOCHEM J, V271, P309, DOI 10.1042/bj2710309; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RODEN RBS, 1993, CELL GROWTH DIFFER, V4, P957; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SUGIMOTO Y, 1992, EXP CELL RES, V203, P230, DOI 10.1016/0014-4827(92)90059-H; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WALTON MI, 1993, CANCER RES, V53, P1853; WANG HG, 1994, ONCOGENE, V9, P2751; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YOSHINO T, 1994, BLOOD, V83, P1856; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	95	120	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1487	1498						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478573				2022-12-17	WOS:A1995TC53500007
J	MUKHOPADHYAY, T; ROTH, JA; MAXWELL, SA				MUKHOPADHYAY, T; ROTH, JA; MAXWELL, SA			ALTERED EXPRESSION OF THE P50 SUBUNIT OF THE NF-KAPPA-B TRANSCRIPTION FACTOR COMPLEX IN NON-SMALL-CELL LUNG-CARCINOMA	ONCOGENE			English	Note						NF-KAPPA-B; P50 SUBUNIT; NSCLC; ALTERATION	ADHESION MOLECULE-1; PROTEIN SUBUNITS; GENE-EXPRESSION; INDUCTION	Recent studies have implicated a role for the p50 subunit of the NF-kappa B transcription factor complex in tumorigenesis, Therefore, we investigated the expression of the p50 subunit of the NF-kappa B transcription factor complex in paired normal and non-small cell lung carcinoma (NSCLC) tissues. Here we show that nine of 11 (81.8%) fresh NSCLC tissues expressed from two- to 20-fold higher levels of the p50 subunit than normal lung tissue. Thirteen NSCLC cell lines also exhibited high levels of p50. Alterations in the normal NF-kappa B/rel pathway of regulation may play a role in the genesis of NSCLC.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC & CARDIOVASC SURG,THORAC MOLEC ONCOL SECT,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R37CA045187, R01CA045187, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45187, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GHERSA P, 1992, J BIOL CHEM, V267, P19226; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; GRUMONT RJ, 1994, MOL CELL BIOL, V14, P8460, DOI 10.1128/MCB.14.12.8460; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; SATO H, 1993, ONCOGENE, V8, P395; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SEN R, 1986, CELL, V46, P921; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; THAKUR S, 1994, ONCOGENE, V9, P2335; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645	26	120	125	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675461				2022-12-17	WOS:A1995RU79800023
J	PELICCI, G; LANFRANCONE, L; SALCINI, AE; ROMANO, A; MELE, S; BORRELLO, MG; SEGATTO, O; DIFIORE, PP; PELICCI, PG				PELICCI, G; LANFRANCONE, L; SALCINI, AE; ROMANO, A; MELE, S; BORRELLO, MG; SEGATTO, O; DIFIORE, PP; PELICCI, PG			CONSTITUTIVE PHOSPHORYLATION OF SHC PROTEINS IN HUMAN TUMORS	ONCOGENE			English	Article						SHC PHOSPHORYLATION; HUMAN TUMORS	GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; SIGNAL TRANSDUCTION; ADAPTER PROTEIN; SEVENLESS GENE; V-SRC; RAS; GRB2; IDENTIFICATION	The She gene encodes three overlapping proteins which all contain a carboxy-terminal SH2 domain. She proteins are ubiquitously expressed and are downstream targets and effecters of activated tyrosine kinases (TK). We investigated tyrosine-phosphorylation of She proteins in normal and transformed cells. In tumor cells with known TK gene alterations She proteins were constitutively phosphorylated and complexed with the activated TK. No constitutive She phosphorylation was found in primary cell cultures and normal tissues, In 14 of 27 tumor cell lines with no reported TK alterations, She proteins were constitutively phosphorylated and formed stable complexes with novel tyrosine-phosphorylated polypeptides. Ten distinct She-associated phosphoproteins were identified with molecular weights ranging from 30 to 200 kDa. In a subset of carcinoma cell lines, phosphorylated She proteins complexed with a p175 phosphoprotein that was identified as the constitutively activated EGFR. In one glioblastoma cell line, a Shc-associated p190 was identified as the activated PDGFR. In 13 of 14 acute leukemia samples phosphorylated She proteins were constitutively complexed with a p140 phosphoprotein. Some of the She-associated phosphoproteins (EGFR, PDGFR, erbB-2, Met, bcr-abl, H4-ret) bound both the Shc- and Grb2-SH2 domains in vitro; others (p175; p70-p80) only the Shc-SH2 domain and yet others (p140) only the Grb2-SH3 domains. These results indicate that She proteins are common substrates of constitutively activated TKs and that the analysis of She phosphorylation allow the identification of tumors with constitutive TK activation.	UNIV PERUGIA,IST MED INTERNA & SCI ONCOL,I-06100 PERUGIA,ITALY; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; NCI,EXPTL CARCINOGENESIS LAB,BETHESDA,MD 20892; IST NAZL TUMORI,MILAN,ITALY; IST REGINA ELENA,ROME,ITALY; FAC MED & CHIRURG BARI,IST MICROBIOL,BARI,ITALY; EUROPEAN INST ONCOL,MILAN,ITALY	University of Perugia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro; IRCCS European Institute of Oncology (IEO)			Borrello, Maria Grazia/C-3161-2017; Pelicci, Pier Giuseppe/AAL-6572-2020; Salcini, Anna Elisabetta/G-4472-2017; Di Fiore, Pier Paolo/K-2130-2012; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Giuliana/AAA-8921-2022	Borrello, Maria Grazia/0000-0002-6854-2848; Di Fiore, Pier Paolo/0000-0002-2252-0950; Lanfrancone, Luisa/0000-0002-4523-3815; Pelicci, Giuliana/0000-0003-0986-8255; Salcini, Anna Elisabetta/0000-0001-5828-2512; Segatto, Oreste/0000-0003-2561-1142				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDARI CT, 1995, ONCOGENE, V10, P1141; BATZER LN, 1993, NATURE, V363, P85; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CROWE AJ, 1994, ONCOGENE, V9, P537; DAMEN JE, 1993, BLOOD, V82, P2996; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DILWORTH S, 1994, NATURE, V267, P87; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; JHIANG SM, 1992, ONCOGENE, V7, P1331; KAMPS MP, 1988, ONCOGENE, V2, P305; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, IN PRESS MOL CELL BI; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PELICCI G, 1995, IN PRESS ONCOGENE; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RODRIGUES CA, 1994, CURR OPIN GENE DEV, V4, P15; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEPHENS RM, 1994, NEURON, V12, P1; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	50	120	124	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					899	907						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675449				2022-12-17	WOS:A1995RU79800011
J	KIM, HA; ROSENBAUM, T; MARCHIONNI, MA; RATNER, N; DECLUE, JE				KIM, HA; ROSENBAUM, T; MARCHIONNI, MA; RATNER, N; DECLUE, JE			SCHWANN-CELLS FROM NEUROFIBROMIN DEFICIENT MICE EXHIBIT ACTIVATION OF P21(RAS), INHIBITION OF CELL-PROLIFERATION AND MORPHOLOGICAL-CHANGES	ONCOGENE			English	Article						NEUROFIBROMATOSIS TYPE 1 (NF1); NF1-TRANSGENIC MOUSE; GLIAL GROWTH FACTOR (GGF); DORSAL ROOT GANGLIA (DRG); SCHWANNOMA	TYPE-1 GENE-PRODUCT; GROWTH-FACTOR; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; CATALYTIC DOMAIN; PROTEIN PRODUCT; RAS PROTEINS; PC12 CELLS; NF1 GENE; DIFFERENTIATION; IDENTIFICATION	Schwann cells are thought to be abnormal in type 1 neurofibromatosis (NF1) and to contribute to the formation of benign and malignant tumors in this disease. To test the role of the NF1 gene product neurofibromin as a Ras-GTPase activating protein in Schwann cells, and to study the effect of the loss of neurofibromin on Schwann cell. proliferation, we isolated Schwann cells from mice with targeted disruption of NET. The properties of these neurofibromin deficient cells were strikingly similar to those of v-ras expressing rat Schwann cells with normal levels of neurofibromin. The similarities included: growth inhibition, noted as a decrease in cell division in response to glial growth factor 2 (GGF2) and of neuronal contact; morphological changes such as the appearance of elaborated processes; and elevated levels of Ras-GTP, Furthermore, Ras-GTP levels in the neurofibromin deficient Schwann cells were consistently elevated in response to GGFZ treatment. In contrast to these results, introduction of v-ras into a Schwannoma cell line (RN22) led to cell transformation. We conclude that neurofibromin functions as a major regulator of Ras-GTP in Schwann cells; however, mutation in NF1 by itself is unlikely to explain the hyperplasia observed in Schwann cell tumors in NF1 disease.	UNIV CINCINNATI,COLL MED,DEPT CELL BIOL NEUROBIOL & ANAT,CINCINNATI,OH 45267; CAMBRIDGE NEUROSCI,CAMBRIDGE,MA 02139; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892	University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				RATNER, NANCY/0000-0001-5030-9354	NCI NIH HHS [CA59268] Funding Source: Medline; NINDS NIH HHS [NS 28840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARON P, 1991, ACTA NEUROPATHOL, V81, P491, DOI 10.1007/BF00310128; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1990, EMBO J, V12, P1923; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1983, DEV REGENERATING VER, P71; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DARTSCH PC, 1994, EUR J CELL BIOL, V63, P316; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; Davis FA, 1940, ARCH OPHTHALMOL-CHIC, V23, P957, DOI 10.1001/archopht.1940.00860131081007; Davis FA, 1940, ARCH OPHTHALMOL-CHIC, V23, P735, DOI 10.1001/archopht.1940.00860130827006; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOTHI NA, 1993, DEV NEUROSCI-BASEL, V15, P10, DOI 10.1159/000111311; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; GIBBS JB, 1985, TIBS, P355; GOLUBIC M, 1992, ONCOGENE, V7, P2151; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P1300; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; HANSSON HA, 1988, SCAND J PLAST RECONS, V22, P7, DOI 10.3109/02844318809097929; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; Kleitman N, 1991, CULTURING NERVE CELL, P337; KRASNOSELSKY A, 1994, J NEUROSCI, V14, P7284; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEBLANC AC, 1992, MOL BRAIN RES, V12, P31, DOI 10.1016/0169-328X(92)90065-J; LEMKE GE, 1984, J NEUROSCI, V4, P75; LEVI ADO, 1994, IN PRESS J NERUROSCI; LONARDO F, 1990, New Biologist, V2, P992; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MUROYA K, 1992, ONCOGENE, V7, P277; NORDLUND M, 1992, GLIA, V5, P182, DOI 10.1002/glia.440050304; ORRURTREGER A, 1952, P NATL ACAD SCI USA, P1746; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELTONEN J, 1984, ACTA NEUROPATHOL, V63, P269, DOI 10.1007/BF00687332; PFEIFFER SE, 1972, P NATL ACAD SCI USA, V69, P2885, DOI 10.1073/pnas.69.10.2885; PLEASURE D, 1985, DEV NEUROSCI-BASEL, V7, P364, DOI 10.1159/000112303; PORTER S, 1987, P NATL ACAD SCI USA, V84, P7768, DOI 10.1073/pnas.84.21.7768; RAFF MC, 1978, NATURE, V273, P672, DOI 10.1038/273672a0; RATNER N, 1986, J CELL BIOL, V103, P159, DOI 10.1083/jcb.103.1.159; RATNER N, 1985, J CELL BIOL, V101, P744, DOI 10.1083/jcb.101.3.744; RATNER N, 1990, ANN NEUROL, V27, P298, DOI 10.1002/ana.410270312; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHUBERT D, 1979, NATURE, V249, P224; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; SOBUE G, 1984, SCIENCE, V224, P72, DOI 10.1126/science.6322307; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBSTER HF, 1984, PERIPHERAL NEUROPATH, P243; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WIGLER MH, 1990, NATURE, V346, P696, DOI 10.1038/346696a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WOOD PM, 1975, NATURE, V256, P662, DOI 10.1038/256662a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YAMAMOTO M, 1993, NEUROSCI LETT, V152, P37, DOI 10.1016/0304-3940(93)90477-3; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	77	120	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					325	335						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624147				2022-12-17	WOS:A1995RK95700013
J	MAJELLO, B; DELUCA, P; SUSKE, G; LANIA, L				MAJELLO, B; DELUCA, P; SUSKE, G; LANIA, L			DIFFERENTIAL TRANSCRIPTIONAL REGULATION OF C-MYC PROMOTER THROUGH THE SAME DNA-BINDING SITES TARGETED BY SP1-LIKE PROTEINS	ONCOGENE			English	Article						C-MYC TRANSCRIPTION; SP1; SP3	TRANS-ACTIVATION; FACTOR E2F; SP1; PRODUCT; DOMAINS; GENE; TRANSACTIVATION; ELEMENTS; COMPLEX; CLONING	Sp1 and Sp3 are closely related members of a gene family encoding proteins with very similar structural features. The zinc finger DNA binding domains of Sp1 and Sp3 are highly conserved and they bind to GC and GT box with comparable affinities. To begin to delineate the specific roles of these two members of the Sp1-like gene family, here we have analysed the DNA binding specificity and their effects on activation of human c-myc promoter. We found that both proteins bind to the same sites of c-myc promoter, upstream to both the P1 and P2 initiation sites. Cotransfection experiments, in mammalian and insect cells, indicated that Sp1 trans-activate c-myc promoter, whereas Sp3 did not. In addition, enforced expression of Sp3 repressed Spl-mediated activation of c-myc. Finally, we found that Sp1 and E2F-1/DP-1 cooperatively trans-activate c-myc promoter. In contrast enforced expression of Sp3 fails to repress EZF-1/DP-1-mediated activation.	UNIV NAPLES FEDERICO II, DIPARTIMENTO GENET BIOL GEN & MOLEC, I-80134 NAPLES, ITALY; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	University of Naples Federico II; Philipps University Marburg			De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Suske, Guntram/0000-0002-4807-0513; Majello, Barbara/0000-0003-2789-3585				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHANG Y, 1991, ONCOGENE, V6, P1979; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAMANTIA G, 1992, NUCLEIC ACIDS RES, V20, P4129, DOI 10.1093/nar/20.16.4129; LIPP M, 1989, ONCOGENE, V4, P535; MAJELLO B, 1990, EMBO J, V9, P457, DOI 10.1002/j.1460-2075.1990.tb08131.x; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPENCER CA, 1991, ADV CANCER RES, V56, P1; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527	33	120	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1841	1848						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753559				2022-12-17	WOS:A1995QX46900017
J	BERNARD, OA; MAUCHAUFFE, M; MECUCCI, C; VANDENBERGHE, H; BERGER, R				BERNARD, OA; MAUCHAUFFE, M; MECUCCI, C; VANDENBERGHE, H; BERGER, R			A NOVEL GENE, AF-1P, FUSED TO HRX IN T(1,11)(P32,Q23), IS NOT RELATED TO AF-4, AF-9 NOR ENL	ONCOGENE			English	Article							ACUTE LEUKEMIAS; CHROMOSOME TRANSLOCATIONS; DROSOPHILA-TRITHORAX; DIRECT CLONING; PCR PRODUCTS; 11Q23; T(11-19)(Q23-P13); BREAKPOINTS; TRANSLATION; TRANSCRIPT	Most of the translocations affecting the chromosome band 11q23, frequently seen in human acute leukemias, involve a restricted area of the HRX gene. We have characterized two t(1;11)(p32;q11) translocations which fuse the HRX gene to a novel gene, AF-1p on chromosome 1p32, in two myeloid leukemias. The der (11) chromosome expresses the 1368 N-terminal amino acids of HRX, including the AT-hook, snRNP and methyltransferase similarities, fused to almost all the AF-1p product. The predicted wild type AF-1p product is a 98 kDa acidic protein which does not exhibit similarity to the AF4, AF-9 and ENL gene products. It is highly similar to the murine eps 15 gene product, which encodes a cytoplasmic phosphoprotein. Our data indicate that AF-lp defines another class of genes fused to HRX in 11q23 abnormalities.	INST GENET MOLEC, CNRS, SDI NO 15954 I, F-75010 PARIS, FRANCE; POLICLIN MONTELUCE, INST HEMATOL, I-06100 PERUGIA, ITALY; CTR HUMAN GENET, B-3000 LOUVAIN, BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	BERNARD, OA (corresponding author), INST NATL SANTE & RECH MED, U301, 27 RUE JULIETTE DODU, F-75010 PARIS, FRANCE.		Bernard, Olivier A./E-5721-2016	Bernard, Olivier/0000-0002-0463-9747				CHEN CS, 1993, BLOOD, V81, P2386; CHERIF D, 1993, GENE CHROMOSOME CANC, V6, P107, DOI 10.1002/gcc.2870060207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1993, BLOOD, V82, P544; CIMINO G, 1991, CANCER RES, V51, P6712; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; KOBAYASHI H, 1993, GENE CHROMOSOME CANC, V7, P204, DOI 10.1002/gcc.2870070404; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LANOTTE M, 1991, BLOOD, V77, P1080; LECONIAT M, 1993, CR ACAD SCI III-VIE, V316, P692; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MATSUOKA Y, 1967, P SOC EXP BIOL MED, V125, P1246; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MITELMAN F, 1993, GENOME PRIORITY REPO, V1, P700; MORGAN GJ, 1992, BLOOD, V80, P2172; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NICHOLS J, 1992, BLOOD, V80, P2953; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROWLEY JD, 1992, GENE CHROMOSOME CANC, V5, P264, DOI 10.1002/gcc.2870050316; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SAIT SNJ, 1993, GENE CHROMOSOME CANC, V7, P28, DOI 10.1002/gcc.2870070105; Sambrook J., 1989, MOL CLONING LAB MANU; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YOUNG BD, 1992, BAILLIERE CLIN HAEM, V5, P881, DOI 10.1016/S0950-3536(11)80050-8	37	120	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1039	1045						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134107				2022-12-17	WOS:A1994NC04800005
J	Wang, X; Lang, M; Zhao, T; Feng, X; Zheng, C; Huang, C; Hao, J; Dong, J; Luo, L; Li, X; Lan, C; Yu, W; Yu, M; Yang, S; Ren, H				Wang, X.; Lang, M.; Zhao, T.; Feng, X.; Zheng, C.; Huang, C.; Hao, J.; Dong, J.; Luo, L.; Li, X.; Lan, C.; Yu, W.; Yu, M.; Yang, S.; Ren, H.			Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+) Treg cells in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							REGULATORY T-CELLS; TUMOR-CELLS; CARCINOMA CELLS; IMMUNE ESCAPE; MURINE MODEL; EXPRESSION; ANTIBODY; INFILTRATION; INHIBITION; INFECTION	Forkheadbox protein 3 (FOXP3), initially identified as a key transcription factor for regulatory T cells (Treg cells), was also expressed in many tumors including pancreatic ductal adenocarcinoma (PDAC). However, its role in PDAC progression remains elusive. In this study, we utilized 120 PDAC tissues after radical resection to detect cancer-FOXP3 and Treg cells by immunohistochemistry and evaluated clinical and pathological features of these patients. Cancer-FOXP3 was positively correlated with Treg cells accumulation in tumor tissues derived from PDAC patients. In addition, high cancer-FOXP3 expression was associated with increased tumor volumes and poor prognosis in PDAC especially combined with high levels of Treg cells. Overexpression of cancer-FOXP3 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromised or Treg cell-depleted mice. Furthermore, CCL5 was directly trans-activated by cancer-FOXP3 and promoted the recruitment of Treg cells from peripheral blood to the tumor site in vitro and in vivo. This finding has been further reinforced by the evidence that Treg cells recruitment by cancer-FOXP3 was impaired by neutralization of CCL5, thereby inhibiting the growth of PDAC. In conclusion, cancer-FOXP3 serves as a prognostic biomarker and a crucial determinant of immunosuppressive microenvironment via recruiting Treg cells by directly trans-activating CCL5. Therefore, cancer-FOXP3 could be used to select patients with better response to CCL5/CCR5 blockade immunotherapy.	[Wang, X.; Lang, M.; Zhao, T.; Zheng, C.; Huang, C.; Hao, J.; Li, X.; Lan, C.; Yu, W.; Ren, H.] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Dept Pancreat Canc, Tianjin, Peoples R China; [Feng, X.] Chinese Acad Med Sci, Inst Hematol & Hosp Blood Dis, State Key Lab Expt Hematol, Tianjin, Peoples R China; [Feng, X.] Peking Union Med Coll, Tianjin, Peoples R China; [Dong, J.; Yu, W.] Tianjin Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Tianjin, Peoples R China; [Luo, L.] Hepingqu Gynaecol & Obster Hosp, Dept Gynaecol, Tianjin, Peoples R China; [Yang, S.] Penn State Coll Med, Hershey, PA USA	Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Tianjin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ren, H (corresponding author), Tianjin Med Univ, Dept Pancreat Canc, Canc Inst & Hosp, Tianjin 300060, Peoples R China.	renhe@tjmuch.com		WANG, XIUCHAO/0000-0002-3205-8544	National Natural Science Foundation of China [81272685, 81525021, 81672431, 81672435, 81502067, 81302082, 31471340, 31470957, 81401957, 81472264]; National Key Clinical Specialist Construction Programs of China [2013-544]; Key Program of Public Health Bureau Foundation of Tianjin [15KG 144]; NATIONAL CANCER INSTITUTE [R01CA175741] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Clinical Specialist Construction Programs of China; Key Program of Public Health Bureau Foundation of Tianjin; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Natural Science Foundation of China (grants 81272685, 81525021, 81672431, 81672435, 81502067, 81302082, 31471340, 31470957, 81401957 and 81472264), the National Key Clinical Specialist Construction Programs of China (no. 2013-544) and Key Program of Public Health Bureau Foundation of Tianjin (15KG 144).	Bayry J, 2008, P NATL ACAD SCI USA, V105, P10221, DOI 10.1073/pnas.0803453105; Borczuk AC, 2008, ONCOGENE, V27, P557, DOI 10.1038/sj.onc.1210662; Cavassani KA, 2006, J IMMUNOL, V177, P5811, DOI 10.4049/jimmunol.177.9.5811; deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216; Ene-Obong A, 2013, GASTROENTEROLOGY, V145, P1121, DOI 10.1053/j.gastro.2013.07.025; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Foley K, 2016, CANCER LETT, V381, P244, DOI 10.1016/j.canlet.2015.12.020; Generali D, 2009, CLIN CANCER RES, V15, P1046, DOI 10.1158/1078-0432.CCR-08-1507; Heinze E, 2009, INT J ONCOL, V35, P167, DOI 10.3892/ijo_00000325; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Jacobs JFM, 2010, CLIN CANCER RES, V16, P5067, DOI 10.1158/1078-0432.CCR-10-1757; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; Kryczek I, 2009, CANCER RES, V69, P3995, DOI 10.1158/0008-5472.CAN-08-3804; Kurose K, 2015, CLIN CANCER RES, V21, P4327, DOI 10.1158/1078-0432.CCR-15-0357; Li X, 2007, CANCER LETT, V253, P144, DOI 10.1016/j.canlet.2007.01.024; Lin YC, 2009, J IMMUNOL, V182, P6095, DOI 10.4049/jimmunol.0803829; Lutz ER, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.962401; Ma C, 2015, BIOCHEM BIOPH RES CO, V458, P234, DOI 10.1016/j.bbrc.2015.01.067; Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Menetrier-Caux C, 2012, ONCOIMMUNOLOGY, V1, P759, DOI 10.4161/onci.19680; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Pastille E, 2014, CANCER RES, V74, P4258, DOI 10.1158/0008-5472.CAN-13-3065; Pillarisetty VG, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.950171; Qin XJ, 2009, CLIN CANCER RES, V15, P2231, DOI 10.1158/1078-0432.CCR-08-2641; Righi E, 2011, CANCER RES, V71, P5522, DOI 10.1158/0008-5472.CAN-10-3143; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Schlecker E, 2012, J IMMUNOL, V189, P5602, DOI 10.4049/jimmunol.1201018; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Strauss L, 2009, J IMMUNOL, V182, P1469, DOI 10.4049/jimmunol.182.3.1469; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tang YK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088267; Triulzi T, 2013, J CELL PHYSIOL, V228, P30, DOI 10.1002/jcp.24125; Trujillo G, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-18; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vonderheide RH, 2013, CURR OPIN IMMUNOL, V25, P200, DOI 10.1016/j.coi.2013.01.006; Wang YP, 2014, CANCER RES, V74, P2217, DOI 10.1158/0008-5472.CAN-13-2928; Ward ST, 2015, BRIT J CANCER, V112, P319, DOI 10.1038/bjc.2014.572; Yamamoto T, 2012, PANCREAS, V41, P409, DOI 10.1097/MPA.0b013e3182373a66; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yoshii M, 2012, BRIT J CANCER, V106, P1668, DOI 10.1038/bjc.2012.141; Yurchenko E, 2006, J EXP MED, V203, P2451, DOI 10.1084/jem.20060956; Zhao TS, 2015, ONCOTARGET, V6, P2250, DOI 10.18632/oncotarget.2948; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	48	119	125	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3048	3058		10.1038/onc.2016.458	http://dx.doi.org/10.1038/onc.2016.458			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27991933	Green Published, hybrid			2022-12-17	WOS:000402000400012
J	Leithner, K; Hrzenjak, A; Trotzmuller, M; Moustafa, T; Kofeler, HC; Wohlkoenig, C; Stacher, E; Lindenmann, J; Harris, AL; Olschewski, A; Olschewski, H				Leithner, K.; Hrzenjak, A.; Troetzmueller, M.; Moustafa, T.; Koefeler, H. C.; Wohlkoenig, C.; Stacher, E.; Lindenmann, J.; Harris, A. L.; Olschewski, A.; Olschewski, H.			PCK2 activation mediates an adaptive response to glucose depletion in lung cancer	ONCOGENE			English	Article							HEPATIC ENERGY-METABOLISM; FLIGHT MASS-SPECTROMETRY; PHOSPHOENOLPYRUVATE CARBOXYKINASE; CELL METABOLISM; TUMOR-CELLS; NUTRIENT DEPRIVATION; EXPRESSION; LACTATE; GROWTH; COLON	Cancer cells are reprogrammed to utilize glycolysis at high rates, which provides metabolic precursors for cell growth. Consequently, glucose levels may decrease substantially in underperfused tumor areas. Gluconeogenesis results in the generation of glucose from smaller carbon substrates such as lactate and amino acids. The key gluconeogenic enzyme, phosphoenolpyruvate carboxykinase ( PEPCK), has been shown to provide metabolites for cell growth. Still, the role of gluconeogenesis in cancer is unknown. Here we show that the mitochondrial isoform of PEPCK (PCK2) is expressed and active in three lung cancer cell lines and in non-small cell lung cancer samples. PCK2 expression and activity were enhanced under low-glucose conditions. PEPCK activity was elevated threefold in lung cancer samples over normal lungs. To track the conversion of metabolites along the gluconeogenesis pathway, lung cancer cell lines were incubated with C-13(3)-lactate and label enrichment in the phosphoenolpyruvate (PEP) pool was measured. Under low glucose, all three carbons from C-13(3)-lactate appeared in the PEP pool, further supporting a conversion of lactate to pyruvate, via pyruvate carboxylase to oxaloacetate, and via PCK2 to phosphoenolpyruvate. PCK2 small interfering RNA and the pharmacological PEPCK inhibitor 3-mercaptopicolinate significantly enhanced glucose depletion-induced apoptosis in A549 and H23 cells, but not in H1299 cells. The growth of H23 multicellular spheroids was significantly reduced by 3-mercaptopicolinate. The results of this study suggest that lung cancer cells may utilize at least some steps of gluconeogenesis to overcome the detrimental metabolic situation during glucose deprivation and that in human lung cancers this pathway is activated in vivo.	[Leithner, K.; Hrzenjak, A.; Wohlkoenig, C.; Olschewski, H.] Med Univ Graz, Dept Internal Med, Div Pulmonol, A-8036 Graz, Austria; [Hrzenjak, A.; Olschewski, A.] Ludwig Boltzmann Inst Lung Vasc Res, Graz, Austria; [Troetzmueller, M.; Koefeler, H. C.] Med Univ Graz, Core Facil Mass Spectrometry & Lipid, A-8036 Graz, Austria; [Moustafa, T.] Karl Franzens Univ Graz, Inst Mol Biosci, Graz, Austria; [Stacher, E.] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria; [Lindenmann, J.] Med Univ Graz, Dept Surg, Div Thorac & Hyperbar Surg, A-8036 Graz, Austria; [Harris, A. L.] Univ Oxford, Weatherall Inst Mol Med, Oxford, England; [Olschewski, A.] Med Univ Graz, Univ Clin Anesthesiol & Intens Care Med, A-8036 Graz, Austria	Medical University of Graz; Ludwig Boltzmann Institute; Medical University of Graz; University of Graz; Medical University of Graz; Medical University of Graz; University of Oxford; Medical University of Graz	Leithner, K (corresponding author), Med Univ Graz, Dept Internal Med, Div Pulmonol, Auenbruggerpl 15, A-8036 Graz, Austria.	katharina.leithner@medunigraz.at	Leithner, Katharina, MD, PhD/E-7662-2011; Harris, Adrian L/ABA-3343-2020; Olschewski, Horst/L-3547-2019; Moustafa, Tarek/P-9509-2016	Leithner, Katharina, MD, PhD/0000-0002-8252-9279; Harris, Adrian L/0000-0003-1376-8409; Olschewski, Horst/0000-0002-2834-7466; Moustafa, Tarek/0000-0002-6755-4687; Trotzmuller, Martin/0000-0003-0545-9892; Olschewski, Andrea/0000-0002-8189-3634; Kofeler, Harald/0000-0002-2725-9616	Oesterreichische Nationalbank (Anniversary Fund) [12713]; state government; Cancer Research UK; Inspire to Live; Cancer Research UK [11359] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10163] Funding Source: researchfish	Oesterreichische Nationalbank (Anniversary Fund); state government; Cancer Research UK(Cancer Research UK); Inspire to Live; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We are grateful to Prof. Rudolf Zechner, Karl Franzens University, Graz, Austria, for his advice and valuable discussions. The excellent technical help by Astrid Knopf, Elisabeth Pollitzer and Alexandra Bertsch, and the contribution by Anna Katschnig are highly appreciated. We are grateful to Dr Guther Fauler and Christina Haas, Medical University of Graz, for their support. The study was supported by the Oesterreichische Nationalbank (Anniversary Fund, project number 12713 to HO) and by a research grant from the state government (KL). ALH is funded by Cancer Research UK and Inspire to Live.	Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001; Chun SY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-293; Dang CV, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-3; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41; Fell DA, 2005, J EXP BOT, V56, P267, DOI 10.1093/jxb/eri011; GAUTHIER T, 1989, INT J BIOCHEM, V21, P191, DOI 10.1016/0020-711X(89)90108-0; Guenther GG, 2014, ONCOGENE, V33, P1776, DOI 10.1038/onc.2013.139; Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heist RS, 2012, J THORAC ONCOL, V7, P924, DOI 10.1097/JTO.0b013e31824cc334; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Izuishi K, 2000, CANCER RES, V60, P6201; Kalhan SC, 2012, J BIOL CHEM, V287, P19786, DOI 10.1074/jbc.R112.357194; Kami K, 2013, METABOLOMICS, V9, P444, DOI 10.1007/s11306-012-0452-2; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Koukourakis MI, 2007, CANCER BIOL THER, V6, P1476, DOI 10.4161/cbt.6.9.4635; Kung C, 2012, CHEM BIOL, V19, P1187, DOI 10.1016/j.chembiol.2012.07.021; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Lee GH, 2011, ONCOL LETT, V2, P831, DOI 10.3892/ol.2011.353; MAKINEN AL, 1983, J BIOL CHEM, V258, P1654; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Pinheiro C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/427694; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102; Roberts PJ, 2010, J CLIN ONCOL, V28, P4769, DOI 10.1200/JCO.2009.27.4365; Rocha CM, 2010, J PROTEOME RES, V9, P319, DOI 10.1021/pr9006574; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Schroeder T, 2005, CANCER RES, V65, P5163, DOI 10.1158/0008-5472.CAN-04-3900; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; SCOTT WJ, 1994, ANN THORAC SURG, V58, P698, DOI 10.1016/0003-4975(94)90730-7; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Stark R, 2009, J BIOL CHEM, V284, P26578, DOI 10.1074/jbc.M109.011775; Stryer L., 1995, BIOCHEMISTRY-US, P559; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Viollet B, 2009, ACTA PHYSIOL, V196, P81, DOI 10.1111/j.1748-1716.2009.01970.x; Walenta S, 2001, INT J RADIAT ONCOL, V51, P840, DOI 10.1016/S0360-3016(01)01700-X; WATFORD M, 1981, J BIOL CHEM, V256, P23; Xiong Y, 2011, COLD SH Q B, V76, P285, DOI 10.1101/sqb.2011.76.010942; Yang JQ, 2009, J BIOL CHEM, V284, P27031, DOI 10.1074/jbc.R109.040535; Yang JQ, 2009, J BIOL CHEM, V284, P27025, DOI 10.1074/jbc.R109.040543	51	119	123	0	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1044	1050		10.1038/onc.2014.47	http://dx.doi.org/10.1038/onc.2014.47			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632615				2022-12-17	WOS:000350121300010
J	Kao, CJ; Martiniez, A; Shi, XB; Yang, J; Evans, CP; Dobi, A; White, RWD; Kung, HJ				Kao, C-J; Martiniez, A.; Shi, X-B; Yang, J.; Evans, C. P.; Dobi, A.; White, R. W. deVere; Kung, H-J			miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT	ONCOGENE			English	Article						prostate cancer; EGF; Src; miRNA; ERG and EMT	PROSTATE-CANCER CELLS; TO-MESENCHYMAL TRANSITION; FAMILY KINASE INHIBITOR; FOCAL ADHESION KINASE; ANDROGEN RECEPTOR; TYROSINE PHOSPHORYLATION; GENE FUSIONS; SRC; EXPRESSION; PATHWAY	Src tyrosine kinase (Src) is implicated in the development of bone metastasis and castration resistance of prostate cancer. Src inhibitors are currently being tested in clinical trials for such diseases. Understanding the molecular and cellular actions of Src inhibitors holds the key to future improvement of this line of therapy. Here we describe the microRNA expression profiles modulated by two Src inhibitors and demonstrate that the miR-30 family members are the most prominently induced species. Consistent with its tumor suppressor role, miR-30 is downmodulated by oncogenic signals such as epidermal growth factor (EGF) and hepatocyte growth factor, and is generally underexpressed in prostate cancer specimens. A number of epithelial-to-mesenchymal transition (EMT)-associated genes are predicted targets of miR-30. Among these genes the Ets-related gene (ERG) is the most frequently overexpressed oncogene in prostate cancer activated by genomic fusion events between promoter upstream sequences of the TMPRSS2 and coding sequences of ERG. We showed by ERG 3' untranslated region reporter and mutagenesis assays that ERG is a direct target of miR-30. Overexpression of miR-30 in prostate cancer cells suppresses EMT phenotypes and inhibits cell migration and invasion. It also inhibits the in vitro and in vivo growth of VCaP cells, which depends on TMPRSS2-ERG for proliferation. TMPRSS2-ERG is generally regulated by androgen at the transcriptional level. Our finding reveals a new post-transcriptional mechanism of TMPRSS2-ERG regulation by Src and growth signals via miR-30 providing a rationale for targeting ERG-positive castration-resistant tumors with Src inhibitors.	[Kao, C-J; Martiniez, A.; Kung, H-J] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Shi, X-B; Yang, J.; Evans, C. P.; White, R. W. deVere] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA; [Dobi, A.] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Rockville, MD USA; [Kung, H-J] Natl Hlth Res Inst, Inst Mol & Genom Med, Maioli, Taiwan; [Kung, H-J] Taipei Med Univ, Translat Med & Integrated Lab, Taipei, Taiwan	University of California System; University of California Davis; University of California System; University of California Davis; Uniformed Services University of the Health Sciences - USA; National Health Research Institutes - Taiwan; Taipei Medical University	Kung, HJ (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, UCDMC Res 3,Room 2400,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NIH [CA150197, CA165263]; DOD [PC093350]; DOD postdoctoral fellowship [PC110744]; NATIONAL CANCER INSTITUTE [P30CA093373, R01CA165263, R01CA150197] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); DOD postdoctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH grants (CA150197 and CA165263) and DOD grant (PC093350) to HJK. CJK acknowledges the support of DOD postdoctoral fellowship (PC110744). We are grateful to M Bradnam for excellent editorial assistance of this manuscript.	Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cai HJ, 2011, CANCER RES, V71, P862, DOI 10.1158/0008-5472.CAN-10-1605; Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hebbard L, 2011, ONCOGENE, V30, P301, DOI 10.1038/onc.2010.412; Hollenhorst Peter C, 2011, Genes Cancer, V1, P1044; Joglekar MV, 2009, ISLETS, V1, P137, DOI 10.4161/isl.1.2.9578; Karni R, 2005, MOL CELL BIOL, V25, P5031, DOI 10.1128/MCB.25.12.5031-5039.2005; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Quintavalle C, 2013, ONCOGENE, V32, P4001, DOI 10.1038/onc.2012.410; Rothschild SI, 2012, ONCOGENE, V31, P4221, DOI 10.1038/onc.2011.578; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078-0432.CCR-08-1857; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Van der Auwera I, 2010, BRIT J CANCER, V103, P532, DOI 10.1038/sj.bjc.6605787; Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324; Yang JC, 2010, MOL CANCER THER, V9, P1629, DOI 10.1158/1535-7163.MCT-09-1058; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang JC, 2012, BIOCHEM BIOPH RES CO, V417, P1100, DOI 10.1016/j.bbrc.2011.12.121; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607; Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	52	119	127	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2495	2503		10.1038/onc.2013.200	http://dx.doi.org/10.1038/onc.2013.200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728339	Green Accepted			2022-12-17	WOS:000336033600009
J	Canino, C; Mori, F; Cambria, A; Diamantini, A; Germoni, S; Alessandrini, G; Borsellino, G; Galati, R; Battistini, L; Blandino, R; Facciolo, F; Citro, G; Strano, S; Muti, P; Blandino, G; Cioce, M				Canino, C.; Mori, F.; Cambria, A.; Diamantini, A.; Germoni, S.; Alessandrini, G.; Borsellino, G.; Galati, R.; Battistini, L.; Blandino, R.; Facciolo, F.; Citro, G.; Strano, S.; Muti, P.; Blandino, G.; Cioce, M.			SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells	ONCOGENE			English	Article						EMT; chemoresistance; SASP; mesothelioma	MALIGNANT PLEURAL MESOTHELIOMA; CANCER STEM-CELLS; AUTOCRINE GROWTH-FACTOR; IN-VITRO; BREAST-CANCER; MESENCHYMAL TRANSITION; TUBERCULOUS PLEURISY; CELLULAR SENESCENCE; SIGNAL TRANSDUCER; EXPRESSION	Here we show that pemetrexed-treated mesothelioma cells undergo accelerated senescence. This is characterized by the secretion of proinflammatory and mitogenic cytokines, reminiscent of an SASP (senescence-associated secretory phenotype). Conditioned media from senescent MPM (malignant pleural mesothelioma) cells trigger the emergence of EMT (epithelial-to-mesenchymal)-like, clonogenic and chemoresistant cell subpopulations, expressing high levels of ALDH (aldehyde dehydrogenase) activity (ALDH(bright) cells). We show by fluorescence-activated cell sorting of purified ALDH(bright) and ALDH(low) cells, that both cell-autonomous and cell-non-autonomous mechanisms converge to maintain the SASP-induced, EMT-like cell subpopulations. Chemoresistant ALDH(bright) cells exist within primary MPM specimens and enrichment for ALDH(bright) cells correlates with an earlier tumor onset into NOD/SCID mice. We show that RAS(v12) expression induces SASP-like changes in untransformed human mesothelial cells, and that p53 ablation increases the effect of RASv12 expression. We identify STAT3 activation as a crucial event downstream to SASP signaling. In fact, small hairpin RNA-mediated ablation of STAT3 deeply attenuates the induction of EMT genes and the increase of ALDH(bright) cells induced by SASP-cytokines. This strongly affects the chemoresistance of MPM cells in vitro and leads to anticancer effects in vivo. Oncogene (2012) 31, 3148-3163; doi:10.1038/onc.2011.485; published online 24 October 2011	[Canino, C.; Blandino, G.; Cioce, M.] Italian Natl Canc Inst Regina Elena, Translat Oncogenom Unit, Rome, Italy; [Mori, F.; Galati, R.; Strano, S.] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Rome, Italy; [Cambria, A.; Blandino, R.] S Vincenzo Hosp, Taormina, Italy; [Diamantini, A.; Borsellino, G.; Battistini, L.] IRCCS Santa Lucia Fdn, Neuroimmunol Unit, Rome, Italy; [Germoni, S.; Citro, G.] Italian Natl Canc Inst Regina Elena, SAFU Dept, Rome, Italy; [Alessandrini, G.; Facciolo, F.] Italian Natl Canc Inst, Unit Thorac Surg, Rome, Italy; [Muti, P.] Italian Natl Canc Inst Regina Elena, Sci Directors Off, Rome, Italy	IRCCS Santa Lucia	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Translat Oncogen Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	blandino@ifo.it; mcioce@ifo.it	Blandino, Giovanni/B-1137-2013; Battistini, Luca/D-6920-2014; Muti, Paola/AAD-9108-2020; Battistini, luca/ABE-1882-2021; strano, sabrina/B-6743-2013; Galati, Rossella Maria/H-8867-2017; Cioce, Mario/R-9734-2017; Galati, Rossella/ABH-6437-2020; Borsellino, Giovanna/K-3074-2016; Strano, Sabrina/K-9654-2016	Blandino, Giovanni/0000-0002-6970-2241; Battistini, Luca/0000-0002-6488-4891; strano, sabrina/0000-0002-6341-4230; Galati, Rossella Maria/0000-0003-2646-8384; Cioce, Mario/0000-0001-8129-6664; Galati, Rossella/0000-0003-2646-8384; Borsellino, Giovanna/0000-0002-4227-6481; Facciolo, Francesco/0000-0002-7137-8946; Alessandrini, Gabriele/0000-0002-4380-7627	INAIL (Italian Workers' Compensation Authority)	INAIL (Italian Workers' Compensation Authority)	We thank Ms Tania Merlino (Regina Elena Cancer Institute, Rome) for revising and proofreading the manuscript and Dr Frank Sinicrope (Rochester, MN) for the ShSTAT3 vectors available at ADDGENE (UK). We acknowledge INAIL (Italian Workers' Compensation Authority) for grant support to GB.	Achcar RDD, 2007, ARCH PATHOL LAB MED, V131, P1350; Adhikari AS, 2011, FRONT BIOSCI-LANDMRK, V16, P1927, DOI 10.2741/3831; Albonici L, 2009, INT J IMMUNOPATH PH, V22, P389, DOI 10.1177/039463200902200216; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Casarsa C, 2011, CANCER LETT, V302, P136, DOI 10.1016/j.canlet.2011.01.009; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Cioce M, 2010, CELL CYCLE, V9, P2878, DOI 10.4161/cc.9.14.12371; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Fujino S, 1996, AM J RESP CELL MOL, V14, P508, DOI 10.1165/ajrcmb.14.6.8652179; Galffy G, 1999, CANCER RES, V59, P367; Hazarika M, 2005, CLIN CANCER RES, V11, P982; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hillegass JM, 2010, ANN NY ACAD SCI, V1203, P7, DOI 10.1111/j.1749-6632.2010.05554.x; Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396; Huang C, 2011, INT J ONCOL, V38, P1637, DOI 10.3892/ijo.2011.1000; Kim C, 2011, YONSEI MED J, V52, P51, DOI 10.3349/ymj.2011.52.1.51; KRYCZEK I, 2011, INT J CANC; Kubo T, 2011, CLIN CANCER RES, V17, P4965, DOI 10.1158/1078-0432.CCR-10-3040; Laberge RM, 2011, CANC MICROENVIRON; Li Q, 2007, CLIN CANCER RES, V13, P5918, DOI 10.1158/1078-0432.CCR-07-0501; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; METCALF RA, 1992, CANCER RES, V52, P2610; Mor O, 1997, AM J RESP CELL MOL, V16, P9, DOI 10.1165/ajrcmb.16.1.8998073; Mujoomdar AA, 2010, J THORAC CARDIOV SUR, V140, P352, DOI 10.1016/j.jtcvs.2009.11.072; Oka M, 2010, EXP DERMATOL, V19, pE50, DOI 10.1111/j.1600-0625.2009.00972.x; Park JS, 2003, SCAND J IMMUNOL, V57, P463, DOI 10.1046/j.1365-3083.2003.01201.x; Pompeo E, 2009, ANN THORAC SURG, V88, P426, DOI 10.1016/j.athoracsur.2009.04.038; Rodier F, 2005, INT J BIOCHEM CELL B, V37, P977, DOI 10.1016/j.biocel.2004.10.012; Ruco LP, 1996, J PATHOL, V179, P266; Scarpa S, 2002, ONCOL REP, V9, P205; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schramm A, 2010, EUR J CARDIO-THORAC, V37, P566, DOI 10.1016/j.ejcts.2009.08.027; Sidi R, 2011, EUR J CANCER, V47, P326, DOI 10.1016/j.ejca.2010.09.044; Sivertsen S, 2006, LUNG CANCER, V54, P309, DOI 10.1016/j.lungcan.2006.08.010; Suzuki Y, 2010, INT J CANCER, V127, P1948, DOI 10.1002/ijc.25197; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108; Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22	49	119	123	3	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	26					3148	3163		10.1038/onc.2011.485	http://dx.doi.org/10.1038/onc.2011.485			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22020330	Green Published			2022-12-17	WOS:000305934400004
J	Ernst, A; Campos, B; Meier, J; Devens, F; Liesenberg, F; Wolter, M; Reifenberger, G; Herold-Mende, C; Lichter, P; Radlwimmer, B				Ernst, A.; Campos, B.; Meier, J.; Devens, F.; Liesenberg, F.; Wolter, M.; Reifenberger, G.; Herold-Mende, C.; Lichter, P.; Radlwimmer, B.			De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures	ONCOGENE			English	Article						miR-17-92; glioblastoma; retinoic acid; spheroid culture; CTGF	TUMOR-INITIATING CELLS; TRANS-RETINOIC ACID; STEM-CELLS; GROWTH-FACTOR; NEURAL PRECURSORS; PROGENITOR CELLS; GLIOMA-CELLS; IN-VITRO; EXPRESSION; MICRORNAS	All-trans retinoic acid is a potent promoter of cellular differentiation processes, which is used in cancer therapy. Glioblastoma spheroid cultures are enriched in tumor-initiating cells, and provide a model to test new treatment options in vitro. We investigated the molecular mechanisms of response to exposure to differentiation-promoting conditions in such cultures. Microarray analyses of five independent cultures showed that after induction of differentiation, inhibitors of transforming growth factor beta/bone morphogenetic protein, Wnt/beta-catenin and IGF signaling were upregulated, whereas expression of several microRNAs decreased, particularly that of the miR-17-92 cluster. In primary astrocytic gliomas (n = 82), expression of several members of miR-17-92 was significantly higher relative to those of normal brain (n = 8) and significantly increased with tumor grade progression (P < 0.05). A high-level amplification of the miR-17-92 locus was detected in one glioblastoma specimen. Transfection of inhibitors of miR-17-92 induced increased apoptosis and decreased cell proliferation in glioblastoma spheroids. Mir-17-92 inhibition was also associated with increased messenger RNA (mRNA) and/or protein expression of CDKN1A, E2F1, PTEN and CTGF. The CTGF gene was shown to be a target of miR-17-92 in glioblastoma spheroids by luciferase reporter assays. Our results suggest that miR-17-92 and its target CTGF mediate effects of differentiation-promoting treatment on glioblastoma cells through multiple regulatory pathways. Oncogene (2010) 29, 3411-3422; doi:10.1038/onc.2010.83; published online 22 March 2010	[Ernst, A.; Meier, J.; Devens, F.; Lichter, P.; Radlwimmer, B.] German Canc Res Ctr, Div Mol Genet, D-69120 Heidelberg, Germany; [Campos, B.; Herold-Mende, C.] Heidelberg Univ, Dept Neurosurg, Div Neurosurg Res, Heidelberg, Germany; [Liesenberg, F.; Wolter, M.; Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf	Radlwimmer, B (corresponding author), German Canc Res Ctr, Div Mol Genet, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	b.radlwimmer@dkfz.de	Radlwimmer, Bernhard F/I-3229-2013; Reifenberger, Guido/AAE-3599-2019	Radlwimmer, Bernhard F/0000-0002-4553-7800; 	German Bundesministerium fur Bildung und Forschung [01GS0883, 01GS0884, 01GS0886]; European Union [MRTN-CT-2006-035733]; Tumorzentrum Heidelberg-Mannheim; Sibylle Assmus Foundation; Verein zur Forderung der Krebsforschung e.V	German Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); Tumorzentrum Heidelberg-Mannheim(European Commission); Sibylle Assmus Foundation; Verein zur Forderung der Krebsforschung e.V	We thank F Engel, M Zapatka, S Anders and W Huber for bioinformatic support. We also thank S Hofmann for support with array comparative genomic hybridization, A Korshunov for support with specimen analysis and B Malzkorn for sharing data. This study was supported by Grants 01GS0883, 01GS0884 and 01GS0886 of the German Bundesministerium fur Bildung und Forschung, by Grant MRTN-CT-2006-035733 from the European Union FP6 Marie Curie Research Training Network; by a Grant from the Tumorzentrum Heidelberg-Mannheim; by the Sibylle Assmus Foundation; and by the Verein zur Forderung der Krebsforschung e.V.	Aguado T, 2007, J BIOL CHEM, V282, P6854, DOI 10.1074/jbc.M608900200; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Corsten MF, 2007, CANCER RES, V67, P8994, DOI 10.1158/0008-5472.CAN-07-1045; D'Ercole AJ, 2008, ENDOCRINOLOGY, V149, P5958, DOI 10.1210/en.2008-0920; Das A, 2008, J NEURO-ONCOL, V87, P9, DOI 10.1007/s11060-007-9485-1; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Dictus C, 2007, J NEUROSCI METH, V161, P250, DOI 10.1016/j.jneumeth.2006.11.012; Ernst A, 2009, CLIN CANCER RES, V15, P6541, DOI 10.1158/1078-0432.CCR-09-0695; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Foshay KM, 2009, DEV BIOL, V326, P431, DOI 10.1016/j.ydbio.2008.11.016; Gal H, 2008, BIOCHEM BIOPH RES CO, V376, P86, DOI 10.1016/j.bbrc.2008.08.107; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Gillies JK, 2007, CELL CYCLE, V6, P2005, DOI 10.4161/cc.6.16.4526; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Karmakar S, 2007, APOPTOSIS, V12, P2077, DOI 10.1007/s10495-007-0116-2; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lu JR, 2008, J NEURO-ONCOL, V87, P271, DOI 10.1007/s11060-008-9518-4; Lu Y, 2007, DEV BIOL, V310, P442, DOI 10.1016/j.ydbio.2007.08.007; Malaterre J, 2007, FRONT BIOSCI-LANDMRK, V12, P492, DOI 10.2741/2077; MALZKORN B, 2009, BRAIN PATHO IN PRESS; Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; Monzo M, 2008, CELL RES, V18, P823, DOI 10.1038/cr.2008.81; Navarro A, 2009, ONCOLOGY-BASEL, V76, P162, DOI 10.1159/000201569; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obayashi S, 2009, CELL MOL NEUROBIOL, V29, P423, DOI 10.1007/s10571-008-9338-2; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Ohgawara T, 2009, FEBS LETT, V583, P1006, DOI 10.1016/j.febslet.2009.02.025; Ohno R, 2003, LEUKEMIA, V17, P1454, DOI 10.1038/sj.leu.2403031; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfister S, 2007, GENE CHROMOSOME CANC, V46, P839, DOI 10.1002/gcc.20471; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; Shi L, 2008, BRAIN RES, V1236, P185, DOI 10.1016/j.brainres.2008.07.085; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Uziel T, 2009, P NATL ACAD SCI USA, V106, P2812, DOI 10.1073/pnas.0809579106; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037; Yu J, 2006, BIOCHEM BIOPH RES CO, V349, P59, DOI 10.1016/j.bbrc.2006.07.207; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zeng Y, 2009, J CLIN NEUROSCI, V16, P285, DOI 10.1016/j.jocn.2007.11.014	55	119	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3411	3422		10.1038/onc.2010.83	http://dx.doi.org/10.1038/onc.2010.83			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20305691				2022-12-17	WOS:000278622700009
J	Treins, C; Warne, PH; Magnuson, MA; Pende, M; Downward, J				Treins, C.; Warne, P. H.; Magnuson, M. A.; Pende, M.; Downward, J.			Rictor is a novel target of p70 S6 kinase-1	ONCOGENE			English	Article						Rictor; S6K; feedback; amino acids; Akt/PKB; mTORC2	CELL-GROWTH CONTROL; MTOR COMPLEX 2; PROTEIN-KINASE; CAENORHABDITIS-ELEGANS; SUBSTRATE-SPECIFICITY; MOTIF PHOSPHORYLATION; MASS-SPECTROMETRY; BINDING PARTNER; TOR COMPLEX-2; AKT	The rapamycin-insensitive companion of mammalian target of rapamycin (mTOR) (Rictor) is a key member of mTOR complex-2 (mTORC2), which phosphorylates the AGC kinases Akt/PKB, PKC and SGK1 at a C-terminal hydrophobic motif. We identified several novel sites on Rictor that are phosphorylated, including Thr1135, which is conserved across all vertebrates. Phosphorylation of this site on Rictor is stimulated by amino acids and growth factors through a rapamycin-sensitive signaling cascade. We demonstrate here that Rictor is a direct target of the ribosomal protein S6 kinase-1 (S6K1). Rictor phosphorylation at Thr1135 does not lead to major changes in mTORC2-kinase activity. However, phosphorylation of this site turns over rapidly and mediates 14-3-3 binding to Rictor and mTORC2, providing possibility for altered interactions of the complex. These findings reveal an unexpected signaling input into mTORC2, which is regulated by amino acids, growth factors and rapamycin. Oncogene (2010) 29, 1003-1016; doi:10.1038/onc.2009.401; published online 23 November 2009	[Treins, C.; Warne, P. H.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; [Magnuson, M. A.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Med Ctr, Nashville, TN 37232 USA; [Magnuson, M. A.] Vanderbilt Univ, Ctr Stem Cell Biol, Med Ctr, Nashville, TN 37232 USA; [Treins, C.; Pende, M.] Paris Descartes Univ, Sch Med, Inserm U845, Lab Cell Growth Control Nutrients, Paris, France	Cancer Research UK; Vanderbilt University; Vanderbilt University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Franche-Comte	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julian.downward@cancer.org.uk	Magnuson, Mark/AAY-7172-2021; Pende, Mario/AFR-1348-2022; Magnuson, Mark A/B-1335-2009; Downward, Julian/A-3251-2012	Magnuson, Mark/0000-0002-8824-6499; Pende, Mario/0000-0002-7864-8937; Magnuson, Mark A/0000-0002-8824-6499; Downward, Julian/0000-0002-2331-4729	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Julie Bastien, Megan Cully, David Hancock and Oliver Pardo for helpful discussions and technical advice. This work was funded by Cancer Research UK.	Akcakanat A, 2007, BIOCHEM BIOPH RES CO, V362, P330, DOI 10.1016/j.bbrc.2007.07.151; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Cantin GT, 2008, J PROTEOME RES, V7, P1346, DOI 10.1021/pr0705441; Dai J, 2007, J PROTEOME RES, V6, P250, DOI 10.1021/pr0604155; Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kumar A, 2008, MOL CELL BIOL, V28, P61, DOI 10.1128/MCB.01405-07; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Zanivan S, 2008, J PROTEOME RES, V7, P5314, DOI 10.1021/pr800599n; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	60	119	120	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1003	1016		10.1038/onc.2009.401	http://dx.doi.org/10.1038/onc.2009.401			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935711				2022-12-17	WOS:000274604400007
J	Kim, HJ; Kim, YM; Lim, S; Nam, YK; Jeong, J; Kim, HJ; Lee, KJ				Kim, H. J.; Kim, Y. M.; Lim, S.; Nam, Y. K.; Jeong, J.; Kim, H-J; Lee, K-J			Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis	ONCOGENE			English	Article						UCH-L1; deubiquitinating enzyme; metastasis; tumor invasion; lung cancer; Akt activation; proteomics	LUNG-CANCER; ENDOTHELIAL-CELLS; PGP9.5; PROTEIN; PATHWAY; KINASE; GENE; INHIBITOR; P27(KIP1); MOTILITY	Ubiquitin C-terminal hydrolase-L1 (UCH-L1) catalyses the hydrolysis of ubiquitin ester and amide mainly in neuronal cells. Recently it was proposed as a marker with a potential role in carcinogenesis. However, the molecular mechanism underlying the biological function of UCH-L1 in tumor cells is poorly understood. We found that UCH-L1 is highly expressed in non-small lung cancer cell line H157, having high invasive potential, and that the expression of UCH-L1 in tumor cells enhances their invasive potential in vitro and in vivo. UCH-L1 changes cell morphology by regulating cell adhesion through Akt-mediated pathway. Suppressing UCH-L1 expression by RNAi significantly suppressed the invasion in vitro and in vivo, and the activation of Akt and downstream mitogen activated protein kinases c-Jun N-terminal kinases and p38, but not ERK. In Akt-negative mutants, overexpression of UCH-L1 does not affect the invasion and migration capability of H157 cells. These results suggest that UCH-L1 is a key molecule to regulate tumor-cell invasion by upstream activation of Akt.	[Lee, K-J] Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Coll Pharm, Seoul 120750, South Korea; Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University	Lee, KJ (corresponding author), Ewha Womans Univ, Ctr Cell Signaling & Drug Discovery Res, Coll Pharm, Seoul 120750, South Korea.	kjl@ewha.ac.kr			KOSEF [R15-2006-002, FPR05A2-480]	KOSEF(Korea Science and Engineering Foundation)	This study was supported by SK Corp. Korea, KOSEF through the Center for Cell Signaling & Drug Discovery Research (CCS & DDR, R15-2006-002) at Ewha Womans University, by KOSEF Grant FPR05A2-480. Kim HJ, Nam YK, Kim YM, Kim HJ and Lim S were supported by the Brain Korea 21 project.	Brichory F, 2001, CANCER RES, V61, P7908; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; Gong B, 2006, CELL, V126, P775, DOI 10.1016/j.cell.2006.06.046; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Kim YM, 2007, J PROTEOME RES, V6, P3278, DOI 10.1021/pr070168k; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Liu YC, 2003, CHEM BIOL, V10, P837, DOI 10.1016/j.chembiol.2003.08.010; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Rosas SLB, 2001, CANCER LETT, V170, P73, DOI 10.1016/S0304-3835(01)00449-9; Saigoh K, 1999, NAT GENET, V23, P47, DOI 10.1038/12647; Song EJ, 2005, MOL CELL BIOL, V25, P2511, DOI 10.1128/MCB.25.6.2511-2524.2005; Tezel E, 2000, CLIN CANCER RES, V6, P4764; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wojciak-Stothard B, 2005, AM J PHYSIOL-LUNG C, V288, pL749, DOI 10.1152/ajplung.00361.2004; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561	24	119	125	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					117	127		10.1038/onc.2008.364	http://dx.doi.org/10.1038/onc.2008.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18820707				2022-12-17	WOS:000262294100012
J	Mottet, D; Pirotte, S; Lamour, V; Hagedorn, M; Javerzat, S; Bikfalvi, A; Bellahcene, A; Verdin, E; Castronovo, V				Mottet, D.; Pirotte, S.; Lamour, V.; Hagedorn, M.; Javerzat, S.; Bikfalvi, A.; Bellahcene, A.; Verdin, E.; Castronovo, V.			HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism	ONCOGENE			English	Article						histone deacetylase; p21(WAF1/Cip1); Sp1; siRNA; cancer	HISTONE DEACETYLASE INHIBITORS; TUMOR-SUPPRESSOR PROTEIN; WAF1/CIP1 GENE PROMOTER; IN-VIVO; DNA-BINDING; SP1 SITES; P53; TRANSCRIPTION; ACETYLATION; COLON	Cancer cells have complex, unique characteristics that distinguish them from normal cells, such as increased growth rates and evasion of anti-proliferative signals. Global inhibition of class I and II histone deacetylases (HDACs) stops cancer cell proliferation in vitro and has proven effective against cancer in clinical trials, at least in part, through transcriptionalreac tivation of the p21(WAF1/Cip1) gene. The HDACs that regulate p21(WAF1/Cip1) are not fully identified. Using small interfering RNAs, we found that HDAC4 participates in the repression of p21(WAF1/Cip1) through Sp1/Sp3-, but not p53-binding sites. HDAC4 interacts with Sp1, binds and reduces histone H3 acetylation at the Sp1/Sp3 binding site-rich p21(WAF1/Cip1) proximal promoter, suggesting a key role for Sp1 in HDAC4-mediated repression of p21(WAF1/Cip1). Induction of p21(WAF1/Cip1) mediated by silencing of HDAC4 arrested cancer cell growth in vitro and inhibited tumor growth in an in vivo human glioblastoma model. Thus, HDAC4 could be a useful target for new anti-cancer therapies based on selective inhibition of specific HDACs.	[Mottet, D.; Pirotte, S.; Lamour, V.; Bellahcene, A.; Castronovo, V.] Univ Liege, Metastasis Res Lab, GIGA Canc Ctr Expt Canc Res, B-4000 Liege, Belgium; [Mottet, D.; Verdin, E.] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA; [Javerzat, S.; Bikfalvi, A.] Univ Bordeaux 1, INSERM, U920, European Lab Angiogenesis & Translat Res,Ex E0113, F-33405 Talence, France	University of Liege; University of California System; University of California San Francisco; The J David Gladstone Institutes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Castronovo, V (corresponding author), Univ Liege, Metastasis Res Lab, GIGA Canc Ctr Expt Canc Res, B23, B-4000 Liege, Belgium.	everdin@gladstone.ucsf.edu; vcastronovo@ulg.ac.be	Verdin, Eric/AAB-7999-2019	Hagedorn, Martin/0000-0002-0960-5116; Verdin, Eric/0000-0003-3703-3183	European FP6 (STROMA and METABRE); National Fund for Scientific Research (Belgium); Centre Anti-Cancereux pres de l'Universite de Liege; Fonds Leon Fredericq; TELEVIE and Interuniversity Attraction Pole Program-Belgian Science Policy [IAP 5/31]	European FP6 (STROMA and METABRE)(European Commission); National Fund for Scientific Research (Belgium)(Fonds de la Recherche Scientifique - FNRS); Centre Anti-Cancereux pres de l'Universite de Liege; Fonds Leon Fredericq; TELEVIE and Interuniversity Attraction Pole Program-Belgian Science Policy	This work was supported by grants from European FP6 (STROMA and METABRE), the National Fund for Scientific Research (Belgium), the Centre Anti-Cancereux pres de l'Universite de Liege, the Fonds Leon Fredericq, TELEVIE and Interuniversity Attraction Pole Program-Belgian Science Policy (IAP 5/31). DM and AB are Research Associates at the National Fund for Scientific Research (Belgium). VL and SP are NFSR National Fund for Scientific Research fellows.	Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Duvic M, 2007, DRUG TODAY, V43, P585, DOI 10.1358/dot.2007.43.9.1112980; Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111; Enya K, 2008, J LEUKOCYTE BIOL, V83, P190, DOI 10.1189/jlb.0106008; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049; Glenisson W, 2007, BBA-MOL CELL RES, V1773, P1572, DOI 10.1016/j.bbamcr.2007.05.016; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; Halkidou K, 2004, EUR UROL, V45, P382, DOI 10.1016/j.eururo.2003.10.005; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; He SH, 2005, MOL BIOL CELL, V16, P4073, DOI 10.1091/mbc.e05-05-0388; Hildmann C, 2007, APPL MICROBIOL BIOT, V75, P487, DOI 10.1007/s00253-007-0911-2; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Huang EY, 2000, GENE DEV, V14, P45; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Huang WF, 2006, BIOCHEM BIOPH RES CO, V339, P165, DOI 10.1016/j.bbrc.2005.11.010; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kang JE, 2005, CELL PHYSIOL BIOCHEM, V16, P23, DOI 10.1159/000087728; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2000, GENE DEV, V14, P55; Kelly WK, 2005, NAT CLIN PRACT ONCOL, V2, P150, DOI 10.1038/ncponc0106; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Lleonart ME, 2006, ONCOL REP, V16, P603; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Martin-Caballero J, 2001, CANCER RES, V61, P6234; McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Rasheed WK, 2007, EXPERT OPIN INV DRUG, V16, P659, DOI 10.1517/13543784.16.5.659; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rocchi P, 2005, ONCOL REP, V13, P1139; Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sawa H, 2004, ACTA NEUROPATHOL, V107, P523, DOI 10.1007/s00401-004-0841-3; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Urban G, 2003, J BIOL CHEM, V278, P9747, DOI 10.1074/jbc.M210993200; Waltregny D, 2005, FASEB J, V19, P966, DOI 10.1096/fj.04-2303fje; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; WILSON AJ, 2008, MOL BIOL CELL; Wouters BG, 1997, CANCER RES, V57, P4703; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	73	119	127	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					243	256		10.1038/onc.2008.371	http://dx.doi.org/10.1038/onc.2008.371			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850004				2022-12-17	WOS:000262501100008
J	Li, X; Placencio, V; Iturregui, JM; Uwamariya, C; Sharif-Afshar, AR; Koyama, T; Hayward, SW; Bhowmick, NA				Li, X.; Placencio, V.; Iturregui, J. M.; Uwamariya, C.; Sharif-Afshar, A-R; Koyama, T.; Hayward, S. W.; Bhowmick, N. A.			Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis	ONCOGENE			English	Article						prostate cancer; T beta RII; prostate stroma; Tgfbr2(fspKO); Wnt3a; Stat3	GROWTH-FACTOR-BETA; TGF-BETA; INTRAEPITHELIAL NEOPLASIA; HGF TRANSCRIPTION; EPITHELIAL-CELLS; CANCER PATIENTS; UP-REGULATION; II RECEPTOR; EXPRESSION; CATENIN	Transforming growth factor (TGF)-beta is an important paracrine factor in tumorigenesis. Ligand binding of the type I and II TGF-beta receptors initiate downstream signaling. The role of stromal TGF-beta signaling in prostate cancer progression is unknown. In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months. Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n = 140, P-value <0.0001). To investigate the mechanism of paracrine TGF-beta signaling in prostate cancer progression, we compared the effect of the prostatic stromal cells from Tgfbr2(fspKO) and floxed TGF-beta type II receptor Tgfbr2(floxE2/floxE2) mice on LNCaP human prostate cancer cells in vitro and tissue recombination xenografts. Induction of LNCaP cell proliferation and tumorigenesis was observed by Tgfbr2(fspKO) prostate stroma as a result of elevated Wnt3a expression. Neutralizing antibodies to Wnt3a reversed LNCaP tumorigenesis. The TGF-beta inhibition of Wnt3a expression was in part through the suppression of Stat3 activity on the Wnt3a promoter. In conclusion, the frequent loss of stromal TGF-beta type II receptor expression in human prostate cancer can relieve the paracrine suppression of Wnt3a expression.	[Li, X.; Uwamariya, C.; Sharif-Afshar, A-R; Hayward, S. W.; Bhowmick, N. A.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Urol Surg, Nashville, TN 37232 USA; [Placencio, V.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Placencio, V.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA; [Koyama, T.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Bhowmick, NA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Urol Surg, 1161 21st Ave S,A-1302 Med Ctr, Nashville, TN 37232 USA.	neil.bhowmick@vanderbilt.edu	Bhowmick, Neil/AAA-7302-2019; Hayward, Simon/A-1688-2011	Bhowmick, Neil/0000-0001-8747-5989; Hayward, Simon/0000-0002-6059-6550; , Xiaohong/0000-0001-5074-193X; Sharif Afshar, Ali Reza/0000-0003-0949-2630	DOD; DAMD [W81XWH-04-1-0046 to NAB]; NIH [CA108646, CA126505, FGM079879A]; NATIONAL CANCER INSTITUTE [T32CA009592, U54CA126505, R01CA108646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM079879] Funding Source: NIH RePORTER	DOD(United States Department of Defense); DAMD; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Dr Xiuping Yu (Vanderbilt University) generously provided primers for the Wnt isoforms. This study was supported by the DOD through DAMD (W81XWH-04-1-0046 to NAB) as well as through NIH Grants (CA108646, CA126505 to NAB and FGM079879A to VRP).	Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Bright JJ, 1998, J IMMUNOL, V161, P1772; Buck MB, 2004, CLIN CANCER RES, V10, P491, DOI 10.1158/1078-0432.CCR-0320-03; Calin GA, 2000, INT J CANCER, V89, P230, DOI 10.1002/1097-0215(20000520)89:3<230::AID-IJC4>3.0.CO;2-J; Cardillo MR, 2000, ANAL QUANT CYTOL, V22, P1; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; DAVIDSON D, 1995, J UROLOGY, V154, P1295, DOI 10.1016/S0022-5347(01)66840-X; DONJACOUR AA, 1990, ENDOCRINOLOGY, V126, P1343, DOI 10.1210/endo-126-3-1343; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FUJII H, 1982, J UROLOGY, V128, P858, DOI 10.1016/S0022-5347(17)53221-8; Gerdes MJ, 1998, J HISTOCHEM CYTOCHEM, V46, P379, DOI 10.1177/002215549804600312; Goggins M, 1998, CANCER RES, V58, P5329; Grady WM, 1999, CANCER RES, V59, P320; Guo YP, 1999, CANCER RES, V59, P1366; Hayward SW, 2001, CANCER RES, V61, P8135; HAYWARD SW, 1992, J CELL SCI, V102, P361; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Johnson ML, 2006, REV ENDOCR METAB DIS, V7, P41, DOI 10.1007/s1154-006-9003-3; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim IY, 1998, CLIN CANCER RES, V4, P1625; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; Kwok WK, 2007, CARCINOGENESIS, V28, P2467, DOI 10.1093/carcin/bgm185; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; QIAN JQ, 1995, CANCER RES, V55, P5408; Qiao H, 2002, J CELL BIOCHEM, V86, P665, DOI 10.1002/jcb.10239; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Royuela M, 1998, GROWTH FACTORS, V16, P101, DOI 10.3109/08977199809002121; Sam MR, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-69; SCHMID P, 1995, CARCINOGENESIS, V16, P1499, DOI 10.1093/carcin/16.7.1499; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibamoto S, 1998, GENES CELLS, V3, P659; TURNER T, 1990, IN VITRO CELL DEV B, V26, P722; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang YH, 2000, CANCER RES, V60, P6008; Wojcik EJ, 2006, ONCOGENE, V25, P2773, DOI 10.1038/sj.onc.1209306; WONG YC, 1992, ACTA ANAT, V143, P139; Yardy GW, 2005, PROSTATE CANCER P D, V8, P119, DOI 10.1038/sj.pcan.4500794; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004	56	119	120	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7118	7130		10.1038/onc.2008.293	http://dx.doi.org/10.1038/onc.2008.293			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18724388	Green Accepted			2022-12-17	WOS:000261195900006
J	Bahassi, EM; Ovesen, JL; Riesenberg, AL; Bernstein, WZ; Hasty, PE; Stambrook, PJ				Bahassi, E. M.; Ovesen, J. L.; Riesenberg, A. L.; Bernstein, W. Z.; Hasty, P. E.; Stambrook, P. J.			The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage	ONCOGENE			English	Article						Rad51; DNA damage; homologous recombination; phosphorylation	CANCER SUSCEPTIBILITY GENE; HOMOLOGOUS RECOMBINATION; HUMAN BRCA2; BREAST; PROTEIN; REPAIR; HYPERSENSITIVITY; INSTABILITY; EXCHANGE; REPEATS	The cellular response to the introduction of double strand DNA breaks involves complexes of protein interactions that govern cell cycle checkpoint arrest and repair of the DNA lesions. The checkpoint kinases Chk1 and Chk2 phosphorylate the carboxy-terminal domain of hBRCA2, a protein involved in recombination-mediated DNA repair (HRR) and replication fork maintenance. Cells deficient in hBRCA2 are hypersensitive to DNA damaging agents. Phosphorylation of the residue in hBRCA2 targeted by the Chk1 and Chk2 kinases regulates its interaction with Rad51. Furthermore, the cell line lex1/lex2, which lacks the carboxy-terminal domain containing the phosphorylated residue, does not support localization of Rad51 to nuclear foci after exposure to UV or treatment with ionizing radiation (IR). The data show that either phosphorylation of Rad51 by Chk1 or phosphorylation of the carboxy-terminal domain of hBRCA2 by Chk1 or Chk2 plays a critical role in the binding of Rad51 to hBRCA2 and the subsequent recruitment of Rad51 to sites of DNA damage. While depletion of Chk1 from cells leads to loss of Rad51 localization to nuclear foci in response to replication arrest, cells lacking Chk2 also show a defect in Rad51 localization, but only in presence of double strand DNA breaks, indicating that each of these kinases may contribute somewhat differently to the formation of Rad51 nucleoprotein. laments depending on the type of DNA damage incurred by the cells.	[Bahassi, E. M.; Ovesen, J. L.; Riesenberg, A. L.; Bernstein, W. Z.; Stambrook, P. J.] Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, Cincinnati, OH 45267 USA; [Hasty, P. E.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA	University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Health San Antonio	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell & Canc Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu		Hasty, Paul/0000-0003-3046-0131	NCI NIH HHS [CA 90934] Funding Source: Medline; NIEHS NIH HHS [U02 ES011038, P30-ES06096, P39-ES06096] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011038, P30ES006096] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bahassi EM, 2007, MUTAT RES-FUND MOL M, V616, P201, DOI 10.1016/j.mrfmmm.2006.11.025; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shivji MKK, 2006, NUCLEIC ACIDS RES, V34, P4000, DOI 10.1093/nar/gkl505; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2000, PHILOS T R SOC B, V355, P191, DOI 10.1098/rstb.2000.0558; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Yu VPCC, 2000, GENE DEV, V14, P1400	19	119	129	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	28					3977	3985		10.1038/onc.2008.17	http://dx.doi.org/10.1038/onc.2008.17			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	318JZ	18317453				2022-12-17	WOS:000257089000009
J	Arden, KC				Arden, K. C.			FOXO animal models reveal a variety of diverse roles for FOXO transcription factors	ONCOGENE			English	Review						FOXO; FKHR; daf-16; dFoxo; animal models	CAENORHABDITIS-ELEGANS; INSULIN-RECEPTOR; OXIDATIVE STRESS; LIFE-SPAN; FAT-BODY; MICE; DROSOPHILA; LONGEVITY; DAF-16; CELLS	The Foxo subfamily of FOX transcription factors plays a variety of roles in a broad assortment of diverse physiological processes including cellular differentiation, tumor suppression, metabolism, cell cycle arrest, cell death and protection from stress. Animal models have proved to be invaluable tools in furthering our understanding of the role of particular genes in complex organismal processes. Multiple animal models in diverse species, including Caenorhabditis elegans, Drosophila. melanogaster and the laboratory mouse, exist for the Foxo family of transcription factors. Foxo genes are highly conserved throughout the evolution and each of these model systems has provided valuable insight into the roles of Foxo factors. Many roles are conserved among the different model organisms. Several Foxo-related animal model systems are reviewed here along with the knowledge gleaned to date from each model system.	Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med, Sch Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Arden, KC (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, Dept Med, Sch Med, 9500 Gilman Dr,0660, La Jolla, CA 92093 USA.	karden@ucsd.edu						Adachi M, 2007, GASTROENTEROLOGY, V132, P1434, DOI 10.1053/j.gastro.2007.01.033; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; GIANNAKOU ME, 2007, DROSOPHILA AGING CEL, V6, P429; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Jacobs FMJ, 2003, J BIOL CHEM, V278, P35959, DOI 10.1074/jbc.M302804200; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Mukhopadhyay A, 2007, TRENDS CELL BIOL, V17, P65, DOI 10.1016/j.tcb.2006.12.004; Murakami S, 1996, GENETICS, V143, P1207; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Puig O, 2005, GENE DEV, V19, P2435, DOI 10.1101/gad.1340505; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; RIDDLE DL, 1981, NATURE, V290, P268; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Vogel G, 2007, SCIENCE, V318, P178, DOI 10.1126/science.318.5848.178	30	119	123	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 7	2008	27	16					2345	2350		10.1038/onc.2008.27	http://dx.doi.org/10.1038/onc.2008.27			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391976				2022-12-17	WOS:000254782700009
J	Jung, H; Lee, KP; Park, SJ; Park, JH; Jang, YS; Choi, SY; Jung, JG; Jo, K; Park, DY; Yoon, JH; Park, JH; Lim, DS; Hong, GR; Choi, C; Park, YK; Lee, JW; Hong, HJ; Kim, S; Park, YW				Jung, H.; Lee, K. P.; Park, S. J.; Park, J. H.; Jang, Y-s; Choi, S-Y; Jung, J-G; Jo, K.; Park, D. Y.; Yoon, J. H.; Park, J-H; Lim, D-S; Hong, G-R; Choi, C.; Park, Y-K; Lee, J. W.; Hong, H. J.; Kim, S.; Park, Y. W.			TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial-mesenchymal transition	ONCOGENE			English	Article						TMPRSS4; invasion; metastasis; E-cadherin; EMT; serine protease	TRANSMEMBRANE SERINE PROTEASES; SURFACE PROTEOLYTIC-ENZYMES; BREAST-CANCER CELLS; MATRIX METALLOPROTEINASES; PLASMINOGEN-ACTIVATOR; E-CADHERIN; MATRIPTASE; EXPRESSION; PROSTATE; PROTEIN	TMPRSS4 is a novel type II transmembrane serine protease found at the cell surface that is highly expressed in pancreatic, colon and gastric cancer tissues. However, the biological functions of TMPRSS4 in cancer are unknown. Here we show, using reverse transcription PCR, that TMPRSS4 is highly elevated in lung cancer tissues compared with normal tissues and is also broadly expressed in a variety of human cancer cell lines. Knockdown of TMPRSS4 by small interfering RNA treatment in lung and colon cancer cell lines was associated with reduction of cell invasion and cell-matrix adhesion as well as modulation of cell proliferation. Conversely, the invasiveness, motility and adhesiveness of SW480 colon carcinoma cells were significantly enhanced by TMPRSS4 overexpression. Furthermore, overexpression of TMPRSS4 induced loss of E-cadherin-mediated cell-cell adhesion, concomitant with the induction of SIP1/ZEB2, an E-cadherin transcriptional repressor, and led to epithelial mesenchymal transition events, including morphological changes, actin reorganization and upregulation of mesenchymal markers. TMPRSS4-overexpressing cells also displayed markedly increased metastasis to the liver in nude mice upon intrasplenic injection. Taken together, these studies suggest that TMPRSS4 controls the invasive and metastatic potential of human cancer cells by facilitating an epithelial-mesenchymal transition; TMPRSS4 may be a potential therapeutic target for cancer treatment.	[Jung, H.; Lee, K. P.; Park, S. J.; Park, J. H.; Jang, Y-s; Choi, S-Y; Jung, J-G; Jo, K.; Hong, H. J.; Kim, S.; Park, Y. W.] Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, Taejon 305806, South Korea; [Lee, K. P.; Lim, D-S] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Park, D. Y.; Yoon, J. H.] Digital Genom Inc, Seoul, South Korea; [Park, J-H] Korea Canc Ctr Hosp, Dept Thorac Surg, Seoul, South Korea; [Hong, G-R; Park, Y-K] Chonnam Natl Univ, Sch Med, Dept Surg, Hwasun, South Korea; [Choi, C.] Chonnam Natl Univ, Sch Med, Dept Pathol, Hwasun, South Korea; [Lee, J. W.] Seoul Natl Univ, Coll Med, Inst Canc Res, Seoul, South Korea; [Lee, J. W.] Seoul Natl Univ, Coll Med, Dept Tumor Biol, Seoul, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); National Cancer Center - Korea (NCC); Chonnam National University; Chonnam National University; Seoul National University (SNU); Seoul National University (SNU)	Kim, S (corresponding author), Korea Res Inst Biosci & Biotechnol, Therapeut Antibody Res Ctr, 52 Eoeun Dong, Taejon 305806, South Korea.	semikim@kribb.re.kr; ywpark@kribb.re.kr	Lim, Dae-Sik/C-1599-2011; Lee, Jung Weon/AAC-1146-2020; Lee, Jung Weon/F-9149-2012	Lim, Dae-Sik/0000-0003-2356-7555; Lee, Jung Weon/0000-0003-2722-8200; Lee, Kwang-Pyo/0000-0003-0067-6898; Kim, Semi/0000-0001-8043-1465				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Aplin AE, 1998, PHARMACOL REV, V50, P197; Benaud CM, 2002, CLIN EXP METASTAS, V19, P639, DOI 10.1023/A:1020985632550; Berntzen G, 2005, J IMMUNOL METHODS, V298, P93, DOI 10.1016/j.jim.2005.01.002; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Del Rosso M, 2002, CLIN EXP METASTAS, V19, P193, DOI 10.1023/A:1015531321445; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; Duffy MJ, 1996, CLIN CANCER RES, V2, P613; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feltes CM, 2002, CANCER RES, V62, P6688; Forbs D, 2005, INT J ONCOL, V27, P1061; Galkin AV, 2004, PROSTATE, V61, P228, DOI 10.1002/pros.20094; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Huang XK, 2005, CANCER RES, V65, P3470, DOI 10.1158/0008-5472.CAN-04-2807; Kebebew E, 2005, ANN SURG, V242, P353, DOI 10.1097/sla.0000179623.87329.6b; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Laferriere J, 2002, ANN NY ACAD SCI, V973, P562, DOI 10.1111/j.1749-6632.2002.tb04702.x; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Srikantan V, 2002, CANCER RES, V62, P6812; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Szabo R, 2003, THROMB HAEMOSTASIS, V90, P185, DOI 10.1160/TH03-02-0071; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; van Hengel J, 2007, BBA-MOL CELL RES, V1773, P78, DOI 10.1016/j.bbamcr.2006.08.033; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wallrapp C, 2000, CANCER RES, V60, P2602; Xuan JA, 2006, CANCER RES, V66, P3611, DOI 10.1158/0008-5472.CAN-05-2983	44	119	132	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2008	27	18					2635	2647		10.1038/sj.onc.1210914	http://dx.doi.org/10.1038/sj.onc.1210914			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968309				2022-12-17	WOS:000255057000013
J	Carretero, J; Medina, PP; Blanco, R; Smit, L; Tang, M; Roncador, G; Maestre, L; Conde, E; Lopez-Rios, F; Clevers, HC; Sanchez-Cespedes, M				Carretero, J.; Medina, P. P.; Blanco, R.; Smit, L.; Tang, M.; Roncador, G.; Maestre, L.; Conde, E.; Lopez-Rios, F.; Clevers, H. C.; Sanchez-Cespedes, M.			Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer	ONCOGENE			English	Article						LKB1; AMPK; lung cancer; energy stress	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; MAMMALIAN TARGET; UPSTREAM KINASE; DOWN-REGULATION; LKB1; AKT; GROWTH; CELLS; RAPAMYCIN	LKB1, mutated in Peutz-Jeghers and in sporadic lung tumours, phosphorylates a group of protein kinases named AMP-activated protein kinase (AMPK)-related kinases. Among them is included the AMPK, a sensor of cellular energy status. To investigate the relevance of LKB1 in lung carcinogenesis, we study several lung cancer cells with and without LKB1-inactivating mutations. We report that LKB1-mutant cells are deficient for AMPK activity and refractory to mTOR inhibition upon glucose depletion but not growth-factor deprivation. The requirement for wild-type LKB1 to properly activate AMPK is further demonstrated in genetically modified cancer cells. In addition, LKB1-deficient lung primary tumours had diminished AMPK activity, assessed by complete absence or low level of phosphorylation of its critical substrate, acetyl-CoA carboxylase. We also demonstrate that LKB1 wild-type cells are more resistant to cell death upon glucose withdrawal than their mutant counterparts. Finally, modulation of AMPK activity did not affect PI3K/AKT signalling, an advantage for the potential use of AMPK as a target for cancer therapy in LKB1 wildtype tumours. Thus, sustained abrogation of cell energetic checkpoint control, through alterations at key genes, appear to be an obligatory step in the development of some lung tumours.	Spanish Natl Canc Ctr, Lung Canc Grp, CNIO, Madrid 28029, Spain; Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Univ Madrid, Hosp 12 Octubre, CNIO, Monoclonal Antibodies Unit, Madrid 3, Spain; Univ Madrid, Hosp 12 Octubre, Dept Pathol, Madrid 3, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr, Lung Canc Grp, CNIO, Madrid 28029, Spain.	msanchez@cnio.es	Maestre, Lorena/L-1352-2014; Roncador, Giovanna/L-1764-2014; Sanchez-Cespedes, Montse/H-8485-2012; Carretero, Julian/N-5214-2014; Blanco, Raquel/M-4290-2015; Vico, Pedro Pablo Medina/D-1688-2013	Maestre, Lorena/0000-0001-8743-0422; Roncador, Giovanna/0000-0002-9807-2875; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Carretero, Julian/0000-0001-7269-8506; Blanco, Raquel/0000-0001-5477-5379; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Smit, Linda/0000-0003-0025-269X				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Conde E, 2006, CLIN CANCER RES, V12, P710, DOI 10.1158/1078-0432.CCR-05-1362; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; MASON DY, 1983, TECHNIQUES IMMUNOCYT, P17; Nakau M, 2002, CANCER RES, V62, P4549; NELLIST M, 1993, CELL, V75, P1305; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	41	119	123	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1616	1625		10.1038/sj.onc.1209951	http://dx.doi.org/10.1038/sj.onc.1209951			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953221				2022-12-17	WOS:000244782500011
J	Klein, E; Kis, LL; Klein, G				Klein, E.; Kis, L. L.; Klein, G.			Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions	ONCOGENE			English	Review						EBV; mononucleosis; lymphomas; B-CLL; cytokines	REED-STERNBERG CELLS; CENTER B-CELLS; LATENT MEMBRANE-PROTEIN; CLASSICAL HODGKIN LYMPHOMA; REGULATORY T-CELLS; BURKITTS-LYMPHOMA; GENE-EXPRESSION; NASOPHARYNGEAL CARCINOMA; TRANSCRIPTION FACTORS; LEUKEMIC-CELLS	After the primary infection, that may or may not cause infectious mononucleosis, the ubiquitous Epstein - Barr virus (EBV) is carried for lifetime. The great majority of adult humans are virus carriers. EBV was discovered in a B-cell lymphoma (Burkitt lymphoma). EBV infection in humans is the example for the power of immune surveillance against virus transformed, potentially malignant cells. Although the virus can transform B lymphocytes in vitro into proliferating lines, it induces malignancy directly only in immunosuppressed hosts. EBV-induced growth transformation occurs only in B lymphocytes. It is the result of a complex interaction between virally encoded and cellular proteins. Different forms of the virus - cell and the cell - host interactions have evolved during a long period of coexistence between the virus and all Old World ( but not New World) primates. The asymptomatic carrier state is based on a viral-strategy that downregulates the expression of the transforming proteins in the virus-carrying cell. In addition to the silent viral-gene carriers and the expressors of the nine virus-encoded genes that drive the growth program, virus carrying cells exist that show other patterns of gene expression, depending on the differentiated state of the host cell. Certain combinations contribute to malignant transformation, but only in conjunction with additional cellular changes. These are induced by direct or cytokine-mediated interactions with normal cells of the immune system.	Karolinska Inst, Dept Microbiol Tumor & Cell Biol, MTC, Tumor & Cell Biol Ctr, S-17177 Stockholm, Sweden	Karolinska Institutet	Klein, E (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol, MTC, Tumor & Cell Biol Ctr, S-17177 Stockholm, Sweden.	eva.klein@ki.se						AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; ALTIOK E, 1992, P NATL ACAD SCI USA, V89, P905, DOI 10.1073/pnas.89.3.905; ALTIOK E, 1992, P NATL ACAD SCI USA, V89, P6225; Atayar C, 2006, J PATHOL, V208, P423, DOI 10.1002/path.1894; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bandobashi K, 2005, VIRUS GENES, V30, P323, DOI 10.1007/s11262-004-6774-z; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Bechtel D, 2005, BLOOD, V106, P4345, DOI 10.1182/blood-2005-06-2342; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; CARBONE A, 1995, AM J PATHOL, V147, P912; Chaganti S, 2005, BLOOD, V106, P4249, DOI 10.1182/blood-2005-06-2327; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Chiang AKS, 1996, INT J CANCER, V68, P285, DOI 10.1002/(SICI)1097-0215(19961104)68:3<285::AID-IJC3>3.0.CO;2-Y; ContrerasBrodin B, 1996, J GEN VIROL, V77, P1159, DOI 10.1099/0022-1317-77-6-1159; CONTRERASBRODIN BA, 1991, J GEN VIROL, V72, P3025, DOI 10.1099/0022-1317-72-12-3025; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; DOYLE MG, 1993, LEUKEMIA, V7, P1858; Dukers DF, 2000, J IMMUNOL, V165, P663, DOI 10.4049/jimmunol.165.2.663; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FALK K, 1995, J MED VIROL, V46, P349, DOI 10.1002/jmv.1890460410; FRISAN T, 1995, BLOOD, V86, P1493, DOI 10.1182/blood.V86.4.1493.bloodjournal8641493; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENLE W, 1979, SCI AM, V241, P48, DOI 10.1038/scientificamerican0779-48; Hertel CB, 2002, ONCOGENE, V21, P4908, DOI 10.1038/sj.onc.1205629; Hjalgrim H, 2003, NEW ENGL J MED, V349, P1324, DOI 10.1056/NEJMoa023141; Hochberg D, 2004, P NATL ACAD SCI USA, V101, P239, DOI 10.1073/pnas.2237267100; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Ishida T, 2006, CANCER RES, V66, P5716, DOI 10.1158/0008-5472.CAN-06-0261; Kanzler H, 2000, BLOOD, V95, P1023, DOI 10.1182/blood.V95.3.1023.003k07_1023_1031; Kanzler H, 1996, J EXP MED, V184, P1495, DOI 10.1084/jem.184.4.1495; Kennedy G, 2003, P NATL ACAD SCI USA, V100, P14269, DOI 10.1073/pnas.2336099100; Kis LL, 2006, IMMUNOL LETT, V104, P83, DOI 10.1016/j.imlet.2005.11.003; Kis LL, 2005, INT J CANCER, V113, P937, DOI 10.1002/ijc.20654; KIS LL, 2006, INT J CANCER, V107, P2928; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; Kuppers R, 2002, ADV CANCER RES, V84, P277, DOI 10.1016/S0065-230X(02)84009-X; KUPPERS R, 1994, P NATL ACAD SCI USA, V91, P10962, DOI 10.1073/pnas.91.23.10962; Kurth J, 2000, IMMUNITY, V13, P485, DOI 10.1016/S1074-7613(00)00048-0; Kurth J, 2003, P NATL ACAD SCI USA, V100, P4730, DOI 10.1073/pnas.2627966100; LENNETTE ET, 1993, EUR J CANCER, V29A, P1584, DOI 10.1016/0959-8049(93)90299-U; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; LEWIN N, 1991, INT J CANCER, V48, P62, DOI 10.1002/ijc.2910480112; Maeda A, 2001, J HUMAN VIROL, V4, P227; Mancao C, 2005, BLOOD, V106, P4339, DOI 10.1182/blood-2005-06-2341; Marshall NA, 2004, BLOOD, V103, P1755, DOI 10.1182/blood-2003-07-2594; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Nakayama T, 2004, J VIROL, V78, P1665, DOI 10.1128/JVI.78.4.1665-1674.2004; NILSSON K, 1975, INT J CANCER, V15, P321, DOI 10.1002/ijc.2910150217; OUDEJANS JJ, 1995, AM J PATHOL, V147, P923; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RICKINSON AB, 1982, CLIN EXP IMMUNOL, V50, P347; Roschke V, 1997, ONCOGENE, V14, P3011, DOI 10.1038/sj.onc.1201156; ROWE M, 1992, J VIROL, V66, P122, DOI 10.1128/JVI.66.1.122-131.1992; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SCHAEFER BC, 1995, P NATL ACAD SCI USA, V92, P10565, DOI 10.1073/pnas.92.23.10565; Schwering I, 2003, BLOOD, V101, P1505, DOI 10.1182/blood-2002-03-0839; STARATSCHEKJOX A, 2000, HUMAN CELL CULTURE, V3, P339; TAKADA K, 1980, INTERVIROLOGY, V13, P223, DOI 10.1159/000149129; Takahara M, 2006, INT J CANCER, V119, P2775, DOI 10.1002/ijc.22139; Teramoto N, 2000, J HUMAN VIROL, V3, P125; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Tierney R, 2000, J VIROL, V74, P10458, DOI 10.1128/JVI.74.22.10458-10467.2000; Tomita Y, 1998, IMMUNOL LETT, V60, P73, DOI 10.1016/S0165-2478(97)00142-9; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P827, DOI 10.1080/10428190500398856; Tsuge I, 1999, CLIN EXP IMMUNOL, V115, P385; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; Vockerodt M, 2002, BRIT J HAEMATOL, V119, P640, DOI 10.1046/j.1365-2141.2002.03894.x; WALLS EV, 1989, INT J CANCER, V44, P846, DOI 10.1002/ijc.2910440517; WANG FH, 1990, CATHAYA, V2, P1; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; Zhang Y, 2003, BRIT J HAEMATOL, V121, P805, DOI 10.1046/j.1365-2141.2003.04359.x	80	119	128	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2007	26	9					1297	1305		10.1038/sj.onc.1210240	http://dx.doi.org/10.1038/sj.onc.1210240			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DU	17322915				2022-12-17	WOS:000244558700007
J	Wendt, MK; Johanesen, PA; Kang-Decker, N; Binion, DG; Shah, V; Dwinell, MB				Wendt, M. K.; Johanesen, P. A.; Kang-Decker, N.; Binion, D. G.; Shah, V.; Dwinell, M. B.			Silencing of epithelial CXCL12 expression by DNA hypermethylation promotes colonic carcinoma metastasis	ONCOGENE			English	Article						chemokine; intestinal mucosa; epithelial cell; epigenetic	CHEMOKINE RECEPTOR CXCR4; FACTOR-I; CPG METHYLATION; BREAST-CANCER; CELLS; SDF-1; METHYLTRANSFERASES; LOCALIZATION; LACKING; GROWTH	Cellular metastasis is the most detrimental step in carcinoma disease progression, yet the mechanisms that regulate this process are poorly understood. CXCL12 and its receptor CXCR4 are co-expressed in several tissues and cell types throughout the body and play essential roles in development. Disruption of either gene causes embryonic lethality due to similar defects. Post-natally, CXCL12 signaling has a wide range of effects on CXCR4-expressing cells, including the directed migration of leukocytes, lymphocytes and hematopoietic stem cells. Recently, this signaling axis has also been described as an important regulator of directed carcinoma cell metastasis. We show herein that while CXCR4 expression remains consistent, constitutive colonic epithelial expression of CXCL12 is silenced by DNA hypermethylation in primary colorectal carcinomas as well as colorectal carcinoma-derived cell lines. Inhibition of DNA methyltransferase (Dnmt) enzymes with 5-aza-2'-deoxycytidine or genetic ablation of both Dnmt1 and Dnmt3b prevented promoter methylation and restored CXCL12 expression. Re-expression of functional, endogenous CXCL12 in colorectal carcinoma cells dramatically reduced metastatic tumor formation in mice, as well as foci formation in soft agar. Decreased metastasis was correlated with increased caspase activity in cells re-expressing CXCL12. These data constitute the unique observation that silencing CXCL12 within colonic carcinoma cells greatly enhances their metastatic potential.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Mayo Clin Fdn, GI Res Unit, Dept Med, Rochester, MN USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Mayo Clinic; Medical College of Wisconsin	Dwinell, MB (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	mdwinell@mcw.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062066, R56DK062066, K01DK002808] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56 DK062066, DK002808, DK062066, R01 DK062066] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Arya M, 2003, CURR MED RES OPIN, V19, P557, DOI 10.1185/030079903125002216; Begum NA, 1996, BIOCHEM BIOPH RES CO, V229, P864, DOI 10.1006/bbrc.1996.1893; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Derdeyn CA, 1999, AIDS RES HUM RETROV, V15, P1063, DOI 10.1089/088922299310359; Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Moruja C, 2005, J MOL BIOL, V348, P43, DOI 10.1016/j.jmb.2005.02.016; Gazitt Y, 2004, LEUKEMIA, V18, P1, DOI 10.1038/sj.leu.2403173; Haviv YS, 2004, MOL CANCER THER, V3, P687; Heidemann J, 2004, AM J PHYSIOL-GASTR L, V286, pG1059, DOI 10.1152/ajpgi.00417.2003; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710, DOI 10.1152/ajpgi.2001.280.4.G710; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Jubb AM, 2003, ANN NY ACAD SCI, V983, P251, DOI 10.1111/j.1749-6632.2003.tb05980.x; Kang H, 2005, BREAST CANCER RES, V7, pR402, DOI 10.1186/bcr1022; Kimura R, 2003, GENES IMMUN, V4, P356, DOI 10.1038/sj.gene.6363978; Lenhard K, 2005, CLIN GASTROENTEROL H, V3, P142, DOI 10.1016/S1542-3565(04)00624-X; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; PANIS Y, 1990, J HEPATOL, V11, P53, DOI 10.1016/0168-8278(90)90271-R; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj.bjc.6600221; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Smith JM, 2005, AM J PHYSIOL-GASTR L, V288, pG316, DOI 10.1152/ajpgi.00208.2004; Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	45	119	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4986	4997		10.1038/sj.onc.1209505	http://dx.doi.org/10.1038/sj.onc.1209505			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568088	Green Accepted			2022-12-17	WOS:000239921300004
J	Barber, GN				Barber, GN			VSV-tumor selective replication and protein translation	ONCOGENE			English	Review						VSV; translation; oncolytic; virus; interferon; cancer	VESICULAR STOMATITIS-VIRUS; NUCLEOTIDE EXCHANGE FACTOR; CAP-DEPENDENT TRANSLATION; MESSENGER-RNA TRANSLATION; INITIATION-FACTOR EIF2B; MATRIX PROTEIN; MALIGNANT-TRANSFORMATION; TARGETED DISRUPTION; CATALYTIC DOMAIN; INNATE IMMUNITY	The emergence of vesicular stomatatis virus ( VSV) as a potent antitumor agent has made a dissection of the molecular determinants of host-cell permissiveness to this virus an important objective. Such insight would not only enable the intelligent design of future generations of recombinant VSV vectors to combat disease, but may also resolve general features of cellular transformation that may be exploited by this virus, and perhaps other oncolytic viruses. The defective pathways underlining the oncolytic activity of VSV remain to be fully determined but recent data indicates that flaws in innate immune responses, involving the interferon ( IFN) system, may commonly occur in tumor cells and thus play a large role in facilitating oncolysis. Aside from the IFN system, however, it is almost certain that other key cellular pathways may be similarly defective and therefore cooperatively contribute towards mediating rapid oncolytic virus activity. Recent data have indicated that defects in cancer cell translational regulation could be one area that may be exploited by VSV. Certainly, all viruses require cellular protein synthesis pathways to facilitate their replication and many have devised numerous mechanisms to ensure that viral mRNAs become translated at the expense of the host. Using VSV as a model, this review will discuss some of the recent developments in the fields of innate immunity and translational regulation that may help explain mechanisms of viral oncolysis.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Sylvester Comprehens Canc Ctr, Room 511,Papanicolaou Bldg,1550 NW 10th St M710, Miami, FL 33136 USA.	gbarber@med.miami.edu						Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Balachandran S, 2000, IUBMB LIFE, V50, P135, DOI 10.1080/15216540050212169; Ball LA, 1999, J VIROL, V73, P4705, DOI 10.1128/JVI.73.6.4705-4712.1999; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Barber GN, 2004, VIRAL IMMUNOL, V17, P516, DOI 10.1089/vim.2004.17.516; Barber GN, 2000, SEMIN CANCER BIOL, V10, P103, DOI 10.1006/scbi.2000.0313; Bergman I, 2003, VIROLOGY, V316, P337, DOI 10.1016/j.virol.2003.07.010; Bergmann M, 2001, CANCER RES, V61, P8188; BI ZB, 1995, J VIROL, V69, P6466, DOI 10.1128/JVI.69.10.6466-6472.1995; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Boehme KW, 2004, J VIROL, V78, P7867, DOI 10.1128/JVI.78.15.7867-7873.2004; Carneiro FA, 2002, J VIROL, V76, P3756, DOI 10.1128/JVI.76.8.3756-3764.2002; Chiocca EA, 2002, NAT REV CANCER, V2, P938, DOI 10.1038/nrc948; Clemens MJ, 2001, PROG MOLEC, V27, P57; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Connor JH, 2005, J BIOL CHEM, V280, P13512, DOI 10.1074/jbc.M501156200; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; DEMATTOS C, 2001, RHABDOVIRIDAE VIRUSE; Desforges M, 2001, VIRUS RES, V76, P87, DOI 10.1016/S0168-1702(01)00251-9; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Ebert O, 2004, CANCER RES, V64, P3265, DOI 10.1158/0008-5472.CAN-03-3753; Enninga J, 2002, SCIENCE, V295, P1523, DOI 10.1126/science.1067861; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Fernandez M, 2002, J VIROL, V76, P895, DOI 10.1128/JVI.76.2.895-904.2002; Gomez E, 2002, EMBO J, V21, P5292, DOI 10.1093/emboj/cdf515; HAMMON WMD, 1963, J NATL CANCER I, V31, P329; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hii SI, 2004, INT J CANCER, V109, P329, DOI 10.1002/ijc.11714; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Kimball SR, 1998, J BIOL CHEM, V273, P3039, DOI 10.1074/jbc.273.5.3039; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Lamberti A, 2004, AMINO ACIDS, V26, P443, DOI 10.1007/s00726-004-0088-2; Leegwater PAJ, 2001, NAT GENET, V29, P383, DOI 10.1038/ng764; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LODISH HF, 1980, J VIROL, V36, P719, DOI 10.1128/JVI.36.3.719-733.1980; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Obuchi M, 2003, J VIROL, V77, P8843, DOI 10.1128/JVI.77.16.8843-8856.2003; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; Pandolfi PP, 2004, ONCOGENE, V23, P3134, DOI 10.1038/sj.onc.1207618; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Pitha PM, 2000, SEMIN CANCER BIOL, V10, P69, DOI 10.1006/scbi.2000.0309; PLAKHOV IV, 1995, VIROLOGY, V209, P257, DOI 10.1006/viro.1995.1252; Porosnicu M, 2003, CANCER RES, V63, P8366; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Roberts A, 1998, J VIROL, V72, P4704, DOI 10.1128/JVI.72.6.4704-4711.1998; Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Rose JKWMA., 2001, RHABDOVIRIDAE VIRUSE; Rose NF, 2000, J VIROL, V74, P10903, DOI 10.1128/JVI.74.23.10903-10910.2000; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Schnell MJ, 1996, J VIROL, V70, P2318, DOI 10.1128/JVI.70.4.2318-2323.1996; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; Thomsen AR, 1997, INT IMMUNOL, V9, P1757, DOI 10.1093/intimm/9.11.1757; Tough DF, 2004, LEUKEMIA LYMPHOMA, V45, P257, DOI 10.1080/1042819031000149368; van den Pol AN, 2002, J VIROL, V76, P1309, DOI 10.1128/JVI.76.3.1309-1327.2002; Varghese S, 2002, CANCER GENE THER, V9, P967, DOI 10.1038/sj.cgt.7700537; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; Wang ST, 1999, AM J PATHOL, V155, P247, DOI 10.1016/S0002-9440(10)65118-8; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; Williams DD, 2001, J BIOL CHEM, V276, P24697, DOI 10.1074/jbc.M011788200; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	92	119	127	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7710	7719		10.1038/sj.onc.1209042	http://dx.doi.org/10.1038/sj.onc.1209042			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299531				2022-12-17	WOS:000233372600007
J	Kashanchi, F; Brady, JN				Kashanchi, F; Brady, JN			Transcriptional and post-transcriptional gene regulation of HTLV-1	ONCOGENE			English	Review						HTLV-1; tax; transcription; p53; chromatin; Rex	T-CELL-LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; NF-KAPPA-B; ELEMENT-BINDING PROTEIN; CAMP-RESPONSIVE ELEMENT; TYPE-1 TAX PROTEIN; TROPICAL SPASTIC PARAPARESIS; NUCLEOLAR TARGETING SIGNAL; DOMINANT-NEGATIVE MUTANTS	Adult T-cell leukemia (ATL) is an aggressive hematologic malignancy caused by human T-cell leukemia virus type I (HTLV-1). Tax, encoded by the HTLV-1 pX region, has been recognized by its pleiotropic actions to play a critical role in leukemogenesis. Three highly conserved 21-bp repeat elements located within the long terminal repeat, commonly referred to as Tax-responsive element 1 (TRE-1), are critical to Tax-mediated viral transcriptional activation through complex interaction with cyclic AMP-responsive element binding protein (CREB), CBP/ p300 and PCAF. Tax has also been shown to activate transcription from a number of critical cellular genes through the NF-kappa B and serum-responsive factor pathways. Tax transactivation has been attributed to the protein's interaction with transcription factors, chromatin remodeling complexes, cell cycle and repair genes. In this review, we will discuss some of the latest findings on this fascinating viral activator and highlight its regulation of cellular factors including CREB, p300/CBP and their effect on RNA polymerase II and chromatin remodeling, as well as its role in cytoplasmic and nuclear function. W e will highlight the possible contribution of each factor, discuss Tax's critical peptide domains and highlight its post-transcriptional modi. cations. It is quite obvious that, collectively, Tax's effects on a wide variety of cellular targets cooperate in promoting cell proliferation and leukemogenesis. In addition, the post-transcriptional effects of Rex play an important role in virus replication. Understanding these interactions at a molecular level will facilitate the targeted development of drugs to effectively inhibit or treat ATL.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20299 USA; NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA	George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St,NW,Ross Hall,Room 551, Washington, DC 20299 USA.	bcmfxk@gwumc.eduz			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R29AI044357] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44357, AI43894] Funding Source: Medline; PHS HHS [13969] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADACHI Y, 1992, J BIOL CHEM, V267, P21977; ADACHI Y, 1990, BIOCHEM BIOPH RES CO, V169, P469, DOI 10.1016/0006-291X(90)90355-Q; ADACHI Y, 1993, J BIOL CHEM, V268, P13930; ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; Ariumi Y, 2003, ONCOGENE, V22, P1611, DOI 10.1038/sj.onc.1206244; Azran Inbal, 2004, Retrovirology, V1, P20; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Barnhart MK, 1997, J VIROL, V71, P337, DOI 10.1128/JVI.71.1.337-344.1997; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Bodor J, 1996, P NATL ACAD SCI USA, V93, P3536, DOI 10.1073/pnas.93.8.3536; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; Bogerd HP, 1998, J VIROL, V72, P8627, DOI 10.1128/JVI.72.11.8627-8635.1998; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BOHNLEIN S, 1991, J VIROL, V65, P81; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOSSELUT R, 1992, VIROLOGY, V186, P764, DOI 10.1016/0042-6822(92)90044-P; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Ching Yick-Pang, 2004, Retrovirology, V1, P18, DOI 10.1186/1742-4690-1-18; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; de la Fuente Cynthia, 2004, Retrovirology, V1, P19, DOI 10.1186/1742-4690-1-19; De Valck D, 1999, ONCOGENE, V18, P4182, DOI 10.1038/sj.onc.1202787; Dodon MD, 2002, J BIOL CHEM, V277, P18744, DOI 10.1074/jbc.M109087200; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038/sj.onc.1205701; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Franchini G, 2003, ADV CANCER RES, V89, P69, DOI 10.1016/S0065-230X(03)01003-0; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; Fujisawa J, 1993, Hum Cell, V6, P266; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; Gachon F, 2000, MOL CELL BIOL, V20, P3470, DOI 10.1128/MCB.20.10.3470-3481.2000; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Georges SA, 2003, MOL CELL BIOL, V23, P3392, DOI 10.1128/MCB.23.10.3392-3404.2003; Georges SA, 2002, MOL CELL BIOL, V22, P127, DOI 10.1128/MCB.22.1.127-137.2002; GESSAIN A, 1985, LANCET, V2, P407; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; GREENE WC, 1986, SCIENCE, V232, P877, DOI 10.1126/science.3010456; GREENE WC, 1986, ANN INTERN MED, V105, P560, DOI 10.7326/0003-4819-105-4-560; Grone M, 1996, VIROLOGY, V218, P316, DOI 10.1006/viro.1996.0200; Hakata Y, 1998, J VIROL, V72, P6602, DOI 10.1128/JVI.72.8.6602-6607.1998; Harrod R, 2000, J BIOL CHEM, V275, P11852, DOI 10.1074/jbc.275.16.11852; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; Hivin P, 2004, VIROLOGY, V318, P556, DOI 10.1016/j.virol.2003.10.027; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; KANNAGI M, 1993, INT J CANCER, V54, P582, DOI 10.1002/ijc.2910540411; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kehn K, 2004, FRONT BIOSCI-LANDMRK, V9, P2347, DOI 10.2741/1401; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; King JA, 1998, ONCOGENE, V16, P3309, DOI 10.1038/sj.onc.1201884; KIRA JI, 1994, MOL NEUROBIOL, V8, P139, DOI 10.1007/BF02780664; Kress E, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-8; Kuo YL, 2000, AIDS RES HUM RETROV, V16, P1607, DOI 10.1089/08892220050193038; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lemasson I, 2004, MOL CELL BIOL, V24, P6117, DOI 10.1128/MCB.24.14.6117-6126.2004; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lemasson I, 2002, J BIOL CHEM, V277, P49459, DOI 10.1074/jbc.M209566200; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Livengood JA, 2004, FRONT BIOSCI-LANDMRK, V9, P3058, DOI 10.2741/1459; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128/JVI.78.13.6735-6743.2004; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MARRIOTT SJ, 1989, MOL CELL BIOL, V9, P4152, DOI 10.1128/MCB.9.10.4152; MARRIOTT SJ, 1992, ONCOGENE, V7, P1749; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; Mori N, 2004, J VIROL, V78, P4582, DOI 10.1128/JVI.78.9.4582-4590.2004; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Newbound GC, 2000, J MED VIROL, V62, P286, DOI 10.1002/1096-9071(200010)62:2<286::AID-JMV22>3.3.CO;2-P; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; O'Mahony AM, 2004, J BIOL CHEM, V279, P18137, DOI 10.1074/jbc.M401397200; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; Osame M, 1990, Tanpakushitsu Kakusan Koso, V35, P1320; Palmeri D, 1996, J VIROL, V70, P6442, DOI 10.1128/JVI.70.9.6442-6445.1996; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pique C, 1996, J VIROL, V70, P4919, DOI 10.1128/JVI.70.8.4919-4926.1996; Pise-Masison CA, 2005, FRONT BIOSCI-LANDMRK, V10, P919, DOI 10.2741/1586; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Princler GL, 2003, VIROLOGY, V317, P136, DOI 10.1016/j.virol.2003.09.010; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Rehberger S, 1997, EXP CELL RES, V233, P363, DOI 10.1006/excr.1997.3562; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; SEIKI M, 1990, VIROLOGY, V176, P81, DOI 10.1016/0042-6822(90)90232-G; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Suzuki T, 1996, Tanpakushitsu Kakusan Koso, V41, P1249; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; Takatsuki K, 1984, Princess Takamatsu Symp, V15, P51; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TOYOSHIMA H, 1990, J VIROL, V64, P2825, DOI 10.1128/JVI.64.6.2825-2832.1990; Uchiumi F, 1996, BIOCHEM BIOPH RES CO, V220, P411, DOI 10.1006/bbrc.1996.0419; Van Orden K, 2000, GENE EXPRESSION, V9, P29; WEICHSELBRAUN I, 1992, J VIROL, V66, P4540, DOI 10.1128/JVI.66.7.4540-4545.1992; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P21; Wessner Renee, 1997, Leukemia (Basingstoke), V11, P10; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; YAMAGUCHI K, 1984, BLOOD, V63, P1235; Yan JP, 1998, J MOL BIOL, V281, P395, DOI 10.1006/jmbi.1998.1951; Ye JX, 2003, BLOOD, V102, P3963, DOI 10.1182/blood-2003-05-1490; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; YOSHIDA M, 1987, LANCET, V1, P1085; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1994, AIDS RES HUM RETROV, V10, P1193, DOI 10.1089/aid.1994.10.1193; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIZAWA H, 1994, J ADHES SCI TECHNOL, V8, P1; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	157	119	132	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5938	5951		10.1038/sj.onc.1208973	http://dx.doi.org/10.1038/sj.onc.1208973			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155601	Bronze			2022-12-17	WOS:000231623400004
J	Woodard, GE; Lin, L; Zhang, JH; Agarwal, SK; Marx, SJ; Simonds, WF				Woodard, GE; Lin, L; Zhang, JH; Agarwal, SK; Marx, SJ; Simonds, WF			Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression	ONCOGENE			English	Article						parathyroid; parafibromin; tumor suppressor; hyperparathyroidism; jaw tumor syndrome; parathyroid carcinoma; cyclin D1	FAMILIAL ISOLATED HYPERPARATHYROIDISM; HEREDITARY HYPERPARATHYROIDISM; PARATHYROID CARCINOMA; ADENOMAS; MUTATIONS; FIBROMAS; 1Q21-Q32; MAPS	Parafibromin is the 531-amino-acid protein product encoded by HRPT2, a putative tumor suppressor gene recently implicated in the autosomal dominant hyperparathyroidism-jaw tumor familial cancer syndrome, sporadic parathyroid cancer, and a minority of families with isolated hyperparathyroidism. Parafibromin contains no identified functional domains but bears sequence homology to Cdc73p, a budding yeast protein component of the RNA polymerase II-associated Paf1 complex. This study addressed the expression and functional properties of human parabromin. A survey of human and mouse tissues analysed with polyclonal antibodies to parabromin showed specific immunoreactivity in adrenal and parathyroid glands, kidney, heart, and skeletal muscle. Subcellular fractionation and laser confocal microscopy of normal human parathyroid gland demonstrated expression of parafibromin in both the cytoplasmic and nuclear compartments. Parafibromin was expressed in four parathyroid adenomas but was absent from two parathyroid carcinomas. Transient overexpression of wild-type parafibromin, but not its Leu64Pro missense mutant implicated in parathyroid cancer and familial isolated hyperparathyroidism, inhibited cell proliferation, and blocked expression of cyclin D1, a key cell cycle regulator previously implicated in parathyroid neoplasia. These results demonstrate that human parafibromin is a nucleocytoplasmic protein with functions consistent with its postulated role as a tumor suppressor protein.	NIDDKD, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simonds, WF (corresponding author), NIDDKD, Metab Dis Branch, NIH, Bldg 10,Room 8C-101,10 Ctr DR MSC 1752, Bethesda, MD 20892 USA.	wfs@helix.nih.gov	Woodard, Geoffrey/A-8608-2009; Agarwal, Sunita K/D-1428-2016	Agarwal, Sunita K/0000-0002-7557-3191	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043012, ZIADK043012] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold A, 2002, J BONE MINER RES, V17, pN30; ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; DINNEN JS, 1977, J CLIN PATHOL, V30, P966, DOI 10.1136/jcp.30.10.966; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; FIRAT D, 1968, AM J MED, V44, P421, DOI 10.1016/0002-9343(68)90112-5; Fujikawa M, 1998, EUR J ENDOCRINOL, V138, P557, DOI 10.1530/eje.0.1380557; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; INOUE H, 1995, CLIN ENDOCRINOL, V43, P225, DOI 10.1111/j.1365-2265.1995.tb01919.x; JACKSON CE, 1990, SURGERY, V108, P1006; JACKSON CE, 1958, ANN INTERN MED, V49, P829, DOI 10.7326/0003-4819-49-4-829; KAKINUMA A, 1994, INTERNAL MED, V33, P123, DOI 10.2169/internalmedicine.33.123; KENNETT S, 1971, ORAL SURG ORAL MED O, V31, P502, DOI 10.1016/0030-4220(71)90347-1; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; MALLETTE LE, 1987, ANN INTERN MED, V107, P54, DOI 10.7326/0003-4819-107-1-54; Marx SJ, 2002, GENETIC BASIS HUMAN, P475; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; ROSEN IB, 1981, AM J SURG, V142, P494, DOI 10.1016/0002-9610(81)90382-2; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; Simonds WF, 2004, J CLIN ENDOCR METAB, V89, P96, DOI 10.1210/jc.2003-030675; Simonds WF, 2002, MEDICINE, V81, P1, DOI 10.1097/00005792-200201000-00001; STREETEN EA, 1992, J CLIN ENDOCR METAB, V75, P362, DOI 10.1210/jc.75.2.362; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2114, DOI 10.1210/jc.83.6.2114; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Vasef MA, 1999, MODERN PATHOL, V12, P412; Villar JC, 2004, FILTR SEPARAT, V41, P32, DOI 10.1016/S0015-1882(04)00282-4; Visset J, 1992, Chirurgie, V118, P223; WARNAKULASURIYA S, 1985, ORAL SURG ORAL MED O, V59, P269, DOI 10.1016/0030-4220(85)90165-3; WASSIF WS, 1993, J CLIN ENDOCR METAB, V77, P1485, DOI 10.1210/jc.77.6.1485; Yoshimoto K, 1998, CLIN ENDOCRINOL, V48, P67, DOI 10.1046/j.1365-2265.1998.00354.x	33	119	127	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1272	1276		10.1038/sj.onc.1208274	http://dx.doi.org/10.1038/sj.onc.1208274			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15580289				2022-12-17	WOS:000226898700014
J	Kalia, LV; Gingrich, JR; Salter, MW				Kalia, LV; Gingrich, JR; Salter, MW			Src in synaptic transmission and plasticity	ONCOGENE			English	Review						long-term potentiation; ND2; NMDA receptor; phosphotyrosine phosphatase; protein tyrosine kinase; STEP	LONG-TERM POTENTIATION; D-ASPARTATE RECEPTOR; PROTEIN-TYROSINE KINASES; POSTSYNAPTIC DENSITY FRACTION; DOG CEREBRAL-CORTEX; NMDA-RECEPTOR; GAIN-CONTROL; PROTEOMIC ANALYSIS; COUPLED RECEPTORS; CHANNEL ACTIVITY	In the central nervous system (CNS), Src and other Src family kinases are widely expressed and are abundant in neurons. Src has been implicated in proliferation and differentiation during the development of the CNS. But Src is highly expressed in fully differentiated neurons in the developed CNS, implying additional functions of this kinase. Over the past decade, a large body of evidence has accumulated showing that a main function of Src is to upregulate the activity of N-methyl-D-aspartate (NMDA) receptors and other ion channels. NMDA receptors (NMDARs) are a principal subtype of glutamate receptors, which mediate fast excitatory transmission at most central synapses. In this review, we focus on Src as a regulator of NMDARs and on the role of Src in NMDAR-dependent synaptic plasticity. We also describe recent studies that give insights into the regulation of Src itself at glutamatergic synapses. By upregulating the function of NMDARs, Src gates the production of NMDAR-dependent synaptic potentiation and plasticity. Thus, Src may be critical for processes underlying physiological plasticity, including learning and memory, and pathological plasticity, such as pain and epilepsy.	Univ Toronto, Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON 5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON 5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Salter, MW (corresponding author), Univ Toronto, Hosp Sick Children, Programme Brain & Behav, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mike.salter@utoronto.ca		Kalia, Lorraine/0000-0002-9384-1305				Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLOMBERG F, 1977, J CELL BIOL, V74, P204, DOI 10.1083/jcb.74.1.204; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Cataldi M, 1996, J BIOL CHEM, V271, P9441, DOI 10.1074/jbc.271.16.9441; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chen SJ, 1996, J NEUROCHEM, V67, P194; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; CONTRACTOR A, 2002, SCI STKE, pRE14; COOKE M P, 1989, New Biologist, V1, P66; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dingledine R, 1999, PHARMACOL REV, V51, P7; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; Gingrich JR, 2004, P NATL ACAD SCI USA, V101, P6237, DOI 10.1073/pnas.0401413101; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Guo W, 2002, J NEUROSCI, V22, P6208; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Huang YQ, 2001, NEURON, V29, P485, DOI 10.1016/S0896-6273(01)00220-3; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Kalia LV, 2003, NEUROPHARMACOLOGY, V45, P720, DOI 10.1016/S0028-3908(03)00313-7; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Koles L, 2001, NEUROCHEM RES, V26, P925, DOI 10.1023/A:1012380416876; Lauri SE, 2000, NEUROREPORT, V11, P997, DOI 10.1097/00001756-200004070-00020; Lei G, 2002, EMBO J, V21, P2977, DOI 10.1093/emboj/cdf292; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Manabe T, 2000, J NEUROSCI, V20, P2504; Marino MJ, 1998, P NATL ACAD SCI USA, V95, P11465, DOI 10.1073/pnas.95.19.11465; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; OYAMA T, 1995, NEUROSCIENCE, V69, P869, DOI 10.1016/0306-4522(95)00278-Q; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Petrone A, 2003, EMBO J, V22, P4121, DOI 10.1093/emboj/cdg399; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Poyton Robert O., 1992, Trends in Cell Biology, V2, P369, DOI 10.1016/0962-8924(92)90049-S; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sanna PP, 2000, P NATL ACAD SCI USA, V97, P8653, DOI 10.1073/pnas.140219097; Satoh K, 2002, GENES CELLS, V7, P187, DOI 10.1046/j.1356-9597.2001.00505.x; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Soltys BJ, 2000, INT REV CYTOL, V194, P133; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V216, P582, DOI 10.1006/bbrc.1995.2662; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Thornton C, 2003, J BIOL CHEM, V278, P23823, DOI 10.1074/jbc.M302389200; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Wan Q, 1997, J NEUROSCI, V17, P5062; Wang K, 2004, J BIOL CHEM, V279, P8779, DOI 10.1074/jbc.M309652200; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xiong ZG, 1998, MOL PHARMACOL, V54, P1055, DOI 10.1124/mol.54.6.1055; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yoshimura Y, 2004, J NEUROCHEM, V88, P759, DOI 10.1046/j.1471-4159.2003.02136.x; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	77	119	127	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2004	23	48					8007	8016		10.1038/sj.onc.1208158	http://dx.doi.org/10.1038/sj.onc.1208158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863JR	15489918				2022-12-17	WOS:000224558300011
J	McCullough, ML; Giovannucci, EL				McCullough, ML; Giovannucci, EL			Diet and cancer prevention	ONCOGENE			English	Review						diet; nutrition; neoplasms; prevention	VITAMIN-D-RECEPTOR; MAJOR CHRONIC DISEASE; METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; COLORECTAL ADENOMA RECURRENCE; EPITHELIAL-CELL PROLIFERATION; BETA-CAROTENE SUPPLEMENTATION; GUIDELINES-FOR-AMERICANS; INCIDENT BREAST-CANCER; DONE MEAT INTAKE; COLON-CANCER	Dietary effects are presumed to underlie many of the large international differences in incidence seen for most cancers. Apart from alcohol and a few micronutrients, however, the role of specific nutritional factors remains ill-defined. The evidence for a role of energy balance, physical inactivity, and obesity has strengthened, while for dietary fat it has weakened. Phytochemicals such as folate, lycopene and flavonoids are still the subject of active research. As the mechanisms underlying human carcinogenesis are better understood, dietary research will focus increasingly on intermediate markers such as the insulin-like growth factors and potentially carcinogenic metabolites.	Amer Canc Soc, Epidemiol & Surveillance Res Dept, Atlanta, GA 30329 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	American Cancer Society; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	McCullough, ML (corresponding author), Amer Canc Soc, Epidemiol & Surveillance Res Dept, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.	marji.mccullough@cancer.org		McCullough, Marjorie/0000-0003-3025-6341				ALBANES D, 1988, CANCER RES, V48, P1658; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; ALDECRUETZ H, 2003, LANCET ONCOL, V3, P364; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Ambrosone CB, 1998, INT J CANCER, V75, P825, DOI 10.1002/(SICI)1097-0215(19980316)75:6&lt;825::AID-IJC2&gt;3.0.CO;2-X; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Arab L, 2001, EPIDEMIOL REV, V23, P211, DOI 10.1093/oxfordjournals.epirev.a000803; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Augustin LSA, 2001, ANN ONCOL, V12, P1533, DOI 10.1023/A:1013176129380; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; Baron JA, 2003, JNCI-J NATL CANCER I, V95, P717, DOI 10.1093/jnci/95.10.717; Barreto AM, 2000, CANCER EPIDEM BIOMAR, V9, P265; Barrett JH, 2003, CARCINOGENESIS, V24, P275, DOI 10.1093/carcin/24.2.275; Bingham S. A., 1987, Nutrition Abstracts and Reviews. Series A-Human and Experimental, V57, P705; Bingham SA, 2002, J NUTR, V132, p3522S, DOI 10.1093/jn/132.11.3522S; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Bingham SA, 2003, LANCET, V362, P212, DOI 10.1016/S0140-6736(03)13913-X; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bostick RM, 1997, CANCER EPIDEM BIOMAR, V6, P971; Branca F, 2001, BRIT J NUTR, V86, pS55, DOI 10.1079/BJN2001339; Bretherton-Watt D, 2001, BRIT J CANCER, V85, P171, DOI 10.1054/bjoc.2001.1864; Brockton N, 2000, AM J EPIDEMIOL, V151, P846; BURKITT DP, 1971, CANCER, V28, P3, DOI 10.1002/1097-0142(197107)28:1<3::AID-CNCR2820280104>3.0.CO;2-N; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Campbell IG, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr457; CARROLL KK, 1975, CANCER RES, V35, P3374; Chan JM, 1999, CANCER EPIDEM BIOMAR, V8, P893; Chan JM, 2001, EPIDEMIOL REV, V23, P87, DOI 10.1093/oxfordjournals.epirev.a000800; Chen J, 1998, CANCER RES, V58, P3307; Chen J, 1996, CANCER RES, V56, P4862; Cho E, 2003, CANCER EPIDEM BIOMAR, V12, P1153; Cho EY, 2003, JNCI-J NATL CANCER I, V95, P1079, DOI 10.1093/jnci/95.14.1079; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Clinton SK, 1998, ANNU REV NUTR, V18, P413, DOI 10.1146/annurev.nutr.18.1.413; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; Cotton SC, 2000, AM J EPIDEMIOL, V151, P7, DOI 10.1093/oxfordjournals.aje.a010124; Cramer DW, 2000, CANCER EPIDEM BIOMAR, V9, P95; Crews H, 2001, BRIT J NUTR, V86, pS5, DOI 10.1079/BJN2001337; Cross AJ, 2003, CANCER RES, V63, P2358; Cross HS, 1997, J STEROID BIOCHEM, V62, P21, DOI 10.1016/S0960-0760(97)00020-4; de Lorgeril M, 1998, ARCH INTERN MED, V158, P1181, DOI 10.1001/archinte.158.11.1181; Deitz AC, 2000, CANCER EPIDEM BIOMAR, V9, P905; Delfino RJ, 2000, CARCINOGENESIS, V21, P607, DOI 10.1093/carcin/21.4.607; *DHHS, 1996, FED REGISTER, V61, P8781; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1992, CANCER RES, V52, pS2024; Duthie SJ, 1999, BRIT MED BULL, V55, P578, DOI 10.1258/0007142991902646; Duthie SJ, 2000, NUTR CANCER, V37, P245, DOI 10.1207/S15327914NC372_18; Eichholzer M, 2001, SWISS MED WKLY, V131, P539; ENNS CW, 1997, FAM EC NUTR REV, V10, P2; FAO/WHO, 2002, HLTH IMPL ACR FOOD, V90; Feigelson HS, 2003, CANCER EPIDEM BIOMAR, V12, P161; Ferguson LR, 2001, NUTR CANCER, V39, P155, DOI 10.1207/S15327914nc392_1; Fitzgerald AL, 2002, NUTR CANCER, V43, P127, DOI 10.1207/S15327914NC432_2; Food and Nutrition Board & Institute of Medicine, 2000, DIET REF INT VIT C V; FRIEDENREICH CM, 1994, EPIDEMIOLOGY, V5, P66, DOI 10.1097/00001648-199401000-00011; Friedenreich CM, 2001, CANCER EPIDEM BIOMAR, V10, P287; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Fung T, 2003, ARCH INTERN MED, V163, P309, DOI 10.1001/archinte.163.3.309; Fung TT, 2001, AM J CLIN NUTR, V73, P61; Gann PH, 1999, CANCER RES, V59, P1225; GARLAND CF, 1980, INT J EPIDEMIOL, V9, P227, DOI 10.1093/ije/9.3.227; GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R; Gershoni-Baruch R, 2000, EUR J CANCER, V36, P2313, DOI 10.1016/S0959-8049(00)00306-3; Gertig DM, 1998, CANCER EPIDEM BIOMAR, V7, P1001; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Giovannucci E, 2004, INT J EPIDEMIOL, V33, P217, DOI 10.1093/ije/dyh020; Giovannucci E, 1998, CANCER RES, V58, P442; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GIOVANNUCCI E, 1994, CANCER RES, V54, P2390; Giovannucci E, 2000, JNCI-J NATL CANCER I, V92, P1966, DOI 10.1093/jnci/92.24.1966; Giovannucci E, 1997, AM J CLIN NUTR, V66, P1564; Giovannucci E, 1998, CANCER CAUSE CONTROL, V9, P567, DOI 10.1023/A:1008835903714; Goodlad RA, 2001, GUT, V48, P587, DOI 10.1136/gut.48.5.587; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Harnack L, 2002, AM J CLIN NUTR, V76, P889, DOI 10.1093/ajcn/76.4.889; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HEILBRUN LK, 1985, LANCET, V1, P925; Hein DW, 2000, CANCER EPIDEM BIOMAR, V9, P29; Helzlsouer KJ, 2000, J NATL CANCER I, V92, P2018, DOI 10.1093/jnci/92.24.2018; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Higginbotham S, 2004, JNCI-J NATL CANCER I, V96, P229, DOI 10.1093/jnci/djh020; HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021; Holick CN, 2002, AM J EPIDEMIOL, V156, P536, DOI 10.1093/aje/kwf072; Holt PR, 2002, CANCER EPIDEM BIOMAR, V11, P113; Holt PR, 1999, J AM COLL NUTR, V18, p379S, DOI 10.1080/07315724.1999.10718902; Hou MF, 2002, BREAST CANCER RES TR, V74, P1, DOI 10.1023/A:1016048900049; Howe GR, 1997, CANCER CAUSE CONTROL, V8, P215, DOI 10.1023/A:1018476414781; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; *IARC, 2003, FRUIT VEG; *IARC, 1999, MET POL SUSC CANC; Ingles SA, 2000, CANCER CAUSE CONTROL, V11, P25, DOI 10.1023/A:1008979417618; Ingles SA, 1997, J NATL CANCER I, V89, P166, DOI 10.1093/jnci/89.2.166; Jacob RA., 1999, MODERN NUTR HLTH DIS, V9th edn, P467; Jacobs EJ, 2001, CANCER CAUSE CONTROL, V12, P927, DOI 10.1023/A:1013716323466; John EM, 1999, CANCER EPIDEM BIOMAR, V8, P399; Jonas CR, 2003, CANCER EPIDEM BIOMAR, V12, P573; Kampman E, 1999, CANCER EPIDEM BIOMAR, V8, P15; KANT AK, 1995, J AM COLL NUTR, V14, P358; Kant AK, 2000, JAMA-J AM MED ASSOC, V283, P2109, DOI 10.1001/jama.283.16.2109; Kato I, 1997, NUTR CANCER, V28, P276, DOI 10.1080/01635589709514588; KATSOUYANNI K, 1988, CANCER-AM CANCER SOC, V61, P181, DOI 10.1002/1097-0142(19880101)61:1<181::AID-CNCR2820610130>3.0.CO;2-J; Kolonel LN, 2001, EPIDEMIOL REV, V23, P72, DOI 10.1093/oxfordjournals.epirev.a000798; Kolonel LN, 1999, JNCI-J NATL CANCER I, V91, P414, DOI 10.1093/jnci/91.5.414; Krebs-Smith SM, 2001, J NUTR, V131, p487S, DOI 10.1093/jn/131.2.487S; Kushi L, 2002, AM J MED, V113, P63, DOI 10.1016/S0002-9343(01)00994-9; Lampe JW, 2000, CANCER EPIDEM BIOMAR, V9, P787; Lampe JW, 1999, AM J CLIN NUTR, V70, p475S, DOI 10.1093/ajcn/70.3.475s; Lampe JW, 2002, J NUTR, V132, P2991, DOI 10.1093/jn/131.10.2991; Lamprecht SA, 2001, ANN NY ACAD SCI, V952, P73, DOI 10.1111/j.1749-6632.2001.tb02729.x; Le Marchand L, 2001, CANCER EPIDEM BIOMAR, V10, P1259; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; Levi F, 2001, INT J CANCER, V91, P260, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1041&gt;3.3.CO;2-R; Lin HJ, 1998, CANCER EPIDEM BIOMAR, V7, P647; Lipkin M, 1999, J AM COLL NUTR, V18, p392S, DOI 10.1080/07315724.1999.10718903; LIPKIN M, 1985, NEW ENGL J MED, V313, P1381, DOI 10.1056/NEJM198511283132203; Liu C, 2003, J NUTR, V133, P173, DOI 10.1093/jn/133.1.173; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ma J, 1998, CANCER EPIDEM BIOMAR, V7, P385; Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S; MARTIN GM, 1997, PRINCIPLES PRACTICE, P439; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; McCullough ML, 2000, AM J CLIN NUTR, V72, P1223; McCullough ML, 2000, AM J CLIN NUTR, V72, P1214; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P959, DOI 10.1023/B:CACO.0000007983.16045.a1; McCullough ML, 2003, CANCER CAUSE CONTROL, V14, P1, DOI 10.1023/A:1022591007673; McCullough ML, 2002, AM J CLIN NUTR, V76, P1261, DOI 10.1093/ajcn/76.6.1261; MCMICHAEL AJ, 1985, JNCI-J NATL CANCER I, V75, P185; Michaud DS, 2002, J NATL CANCER I, V94, P1293, DOI 10.1093/jnci/94.17.1293; Michels KB, 2002, INT J EPIDEMIOL, V31, P847, DOI 10.1093/ije/31.4.847; MILLER DK, 1994, J FOOD SCI, V59, P747, DOI 10.1111/j.1365-2621.1994.tb08118.x; Milner JA, 2001, J NUTR, V131, p1027S, DOI 10.1093/jn/131.3.1027S; Mirvish SS, 2002, J NUTR, V132, p3526S, DOI 10.1093/jn/132.11.3526S; Missmer SA, 2002, INT J EPIDEMIOL, V31, P78, DOI 10.1093/ije/31.1.78; Negri E, 1996, INT J CANCER, V65, P140, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;140::AID-IJC3&gt;3.0.CO;2-Z; Nelson M, 1997, DESIGN CONCEPTS NUTR; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; Nomura AMY, 2000, CANCER EPIDEM BIOMAR, V9, P883; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; OLSON JA, 1999, MODERN NUTR HLTH DIS; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Outwater JL, 1997, MED HYPOTHESES, V48, P453, DOI 10.1016/S0306-9877(97)90110-9; PALMER S, 1983, CANCER RES, V43, P2509; Parodi PW, 1997, J NUTR, V127, P1055, DOI 10.1093/jn/127.6.1055; Pereira MA, 2002, AM J CLIN NUTR, V75, P848, DOI 10.1093/ajcn/75.5.848; Peters U, 2001, CANCER EPIDEM BIOMAR, V10, P1267; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; PLATZ EA, 1999, NUTR ONCOLOGY, P223; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; Pollak M, 2001, EPIDEMIOL REV, V23, P59, DOI 10.1093/oxfordjournals.epirev.a000796; Potischman N, 1999, INT J CANCER, V82, P315, DOI 10.1002/(SICI)1097-0215(19990730)82:3&lt;315::AID-IJC1&gt;3.0.CO;2-N; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; PRASAD MPR, 1992, NUTR CANCER, V18, P85, DOI 10.1080/01635589209514208; Prior RL, 1999, FREE RADICAL BIO MED, V27, P1173, DOI 10.1016/S0891-5849(99)00203-8; Rodriguez C, 2003, CANCER EPIDEM BIOMAR, V12, P597; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x; Rossouw J E, 1995, J Am Med Womens Assoc (1972), V50, P50; Ruggiero M, 1998, ONCOL RES, V10, P43; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Sandhu MS, 2001, CANCER EPIDEM BIOMAR, V10, P439; Schapira Matthieu, 2002, BMC Structural Biology, V2, P1, DOI 10.1186/1472-6807-2-1; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012; Semenza JC, 2003, BREAST CANCER RES TR, V77, P217, DOI 10.1023/A:1021843019755; Serafini M, 2002, GASTROENTEROLOGY, V123, P985, DOI 10.1053/gast.2002.35957; Seymour JD, 2003, AM J EPIDEMIOL, V157, P980, DOI 10.1093/aje/kwg077; Sharp L, 2002, CANCER LETT, V181, P65, DOI 10.1016/S0304-3835(02)00030-7; Shin MH, 2002, JNCI-J NATL CANCER I, V94, P1301, DOI 10.1093/jnci/94.17.1301; Sinha R, 1997, MUTAT RES-FUND MOL M, V376, P195, DOI 10.1016/S0027-5107(97)00043-2; Slattery ML, 1997, CANCER EPIDEM BIOMAR, V6, P677; Slattery ML, 1998, AM J EPIDEMIOL, V148, P4, DOI 10.1093/aje/148.1.4-a; Slattery ML, 2001, CANCER CAUSE CONTROL, V12, P359, DOI 10.1023/A:1011280518278; Smith-Warner SA, 2001, JAMA-J AM MED ASSOC, V285, P769, DOI 10.1001/jama.285.6.769; Smith-Warner SA, 2001, INT J CANCER, V92, P767, DOI 10.1002/1097-0215(20010601)92:5&lt;767::AID-IJC1247&gt;3.0.CO;2-0; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; SUGIMURA T, 1985, MUTAT RES, V150, P33, DOI 10.1016/0027-5107(85)90098-3; Talalay P, 2001, J NUTR, V131, p3027S, DOI 10.1093/jn/131.11.3027S; Tangrea J, 1997, CANCER CAUSE CONTROL, V8, P615, DOI 10.1023/A:1018450531136; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525; Terry P, 2002, CANCER EPIDEM BIOMAR, V11, P1507; Terry P, 2001, CANCER EPIDEM BIOMAR, V10, P1281; Terry P, 2001, AM J EPIDEMIOL, V154, P1143, DOI 10.1093/aje/154.12.1143; Terry P, 2001, J INTERN MED, V250, P280, DOI 10.1046/j.1365-2796.2001.00886.x; Terry PD, 2003, AM J CLIN NUTR, V77, P532, DOI 10.1093/ajcn/77.3.532; Terry PD, 2003, JNCI-J NATL CANCER I, V95, P914, DOI 10.1093/jnci/95.12.914; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; Tiemersma EW, 2002, CANCER CAUSE CONTROL, V13, P383, DOI 10.1023/A:1015236701054; Toniolo P, 2001, AM J EPIDEMIOL, V153, P1142, DOI 10.1093/aje/153.12.1142; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Vineis P, 2001, Public Health Nutr, V4, P485; WICKRAMASINGHE SN, 1994, BLOOD, V83, P1656; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1998, NUTR EPIDEMIOL; WILLETT WC, 1999, MODERN NUTR HLTH DIS, P1243; WOLEVER TMS, 1986, AM J CLIN NUTR, V43, P167, DOI 10.1093/ajcn/43.1.167; Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P33, DOI 10.1016/S0304-4165(97)00006-8; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Wu K, 2002, JNCI-J NATL CANCER I, V94, P437, DOI 10.1093/jnci/94.6.437; Yamagata Z, 1997, AM J HUM GENET, V61, pA388; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhang SM, 2003, J NATL CANCER I, V95, P373, DOI 10.1093/jnci/95.5.373; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632; Zhang YQ, 2002, AM J MED, V113, P734, DOI 10.1016/S0002-9343(02)01382-7; Zheng W, 1999, CANCER EPIDEM BIOMAR, V8, P233; Zmuda JM, 2001, J NATL CANCER I, V93, P930, DOI 10.1093/jnci/93.12.930; Zmuda JM, 2000, EPIDEMIOL REV, V22, P203, DOI 10.1093/oxfordjournals.epirev.a018033	222	119	122	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6349	6364		10.1038/sj.onc.1207716	http://dx.doi.org/10.1038/sj.onc.1207716			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322510				2022-12-17	WOS:000223468800004
J	Furuta, S; Hidaka, E; Ogata, A; Yokota, S; Kamata, T				Furuta, S; Hidaka, E; Ogata, A; Yokota, S; Kamata, T			Ras is involved in the negative control of autophagy through the class IPI3-kinase	ONCOGENE			English	Article						autophagy; PI3-kinase; Ras	PHOSPHOINOSITIDE 3-OH KINASE; PROTEIN-DEGRADATION; HT-29 CELLS; MACROAUTOPHAGY; GROWTH; TRANSFORMATION; PROTEOLYSIS; HEPATOCYTES; INHIBITION; MECHANISMS	Ras proteins exert a pivotal regulatory function in signal transduction involved in cell proliferation and their activation mutation leads to malignant cell transformation. However, the role of Ras proteins in autophagy, an intracellular protein degradation process in cell growth control is unknown. In the present study, we demonstrate that the degradation of long-lived proteins in NIH3T3 cells in response to nutrient starvation was significantly suppressed by oncogenic RasVal12 transformation in a rapamycin ( mTOR inhibitor)-sensitive manner. Morphologic observations also show the decrease in the formation of autophagic vacuoles upon the Ras transformation. Furthermore, epidermal growth factor or serum downregulated the protein degradation induced by serum starvation and the dominant-negative RasAsn17 mutant counteracted this suppressive effect, indicating that Ras mediates the growth factor downregulation of autophagy. The suppression of protein degradation by the activated RasVal12 was mediated by the class I phosphatidyl inositol 3-kinase (PI3-kinase), but not either or Raf Ral GDS. Consistent with this, RasVal12 and class I PI3-kinase inhibited the rate of autophagic sequestration of LDH. These data suggest that Ras plays a critical role as a negative regulator for nutrient deprivation-induced autophagy through the class I PI3-kinase signaling pathway.	Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Lab Med, Nagano 3908621, Japan; Yamanashi Univ, Sch Med, Biol Lab, Tamaho, Yamanashi 4093898, Japan	Shinshu University; Shinshu University; University of Yamanashi	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, Asahi 3-1-1, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; BALLARD FJ, 1980, J CELL PHYSIOL, V105, P335, DOI 10.1002/jcp.1041050216; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Franch HA, 2001, J BIOL CHEM, V276, P19126, DOI 10.1074/jbc.M101777200; Furuta S, 2002, ONCOGENE, V21, P7060, DOI 10.1038/sj.onc.1205790; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; KAMATA T, 1988, P NATL ACAD SCI USA, V85, P5799, DOI 10.1073/pnas.85.16.5799; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; OGIERDENIS E, 2003, BIOCHIM BIOPHYS ACTA, V1366, P177; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SCHWARZE PE, 1985, EXP CELL RES, V157, P15, DOI 10.1016/0014-4827(85)90148-X; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SLUIJTERS DA, 2000, BIOCHEM J, V351, P545; YOKOTA S, 1993, EUR J CELL BIOL, V62, P372	24	119	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3898	3904		10.1038/sj.onc.1207539	http://dx.doi.org/10.1038/sj.onc.1207539			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15064741				2022-12-17	WOS:000221382000002
J	Nandan, MO; Yoon, HS; Zhao, WD; Ouko, LA; Chanchevalap, S; Yang, VW				Nandan, MO; Yoon, HS; Zhao, WD; Ouko, LA; Chanchevalap, S; Yang, VW			Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras	ONCOGENE			English	Article						IKLF; transformation; mitogen-activated protein kinase; Egr1; cyclin D1; proliferation; small interfering RNA; anchorage-independent growth	SMOOTH-MUSCLE-CELLS; BTEB2 TRANSCRIPTION FACTOR; PROTEIN-KINASE ACTIVATION; CYCLIN D1; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; PLASMA-MEMBRANE; RAF-1 PROTEIN; NIH 3T3-CELLS	Previous studies indicate that Kruppel-like factor 5 (KLF5), also known as intestinal-enriched Kruppel-like factor (IKLF), is a positive regulator of cell proliferation and gives rise to a transformed phenotype when overexpressed. Here we demonstrate that levels of KLF5 transcript and protein are significantly elevated in oncogenic H-Ras-transformed NIH3T3 cells. These cells display an accelerated rate of proliferation in both serum-containing and serum-deprived media and form anchorage-independent colonies in soft agar assays. H-Ras-transformed cells also contain elevated mitogen-activated protein kinase (MAPK) activity. When treated with inhibitors of MEK ( MAPK kinase), H-Ras-transformed cells lose their growth advantage and no longer form colonies. Significantly, levels of KLF5 transcript and protein are substantially reduced in H-Ras-transformed cells treated with MEK inhibitors. Moreover, inhibition of KLF5 expression in H-Ras-transformed cells with KLF5-specific small interfering RNA ( siRNA) leads to a decreased rate of proliferation and a significant reduction in colony formation. H-Ras-transformed cells also contain elevated levels of Egr1 that are diminished by MEK inhibitors. Inhibition of Egr1 by siRNA results in a reduced level of KLF5, indicating that Egr1 mediates the inductive action of MAPK on KLF5. Lastly, KLF5 activates expression of cyclin D1. These findings indicate that the increased expression of KLF5 in H-Ras-transformed cells is secondary to increased MAPK activity from H-Ras overexpression and that the elevated level of KLF5 is in part responsible for the proproliferative and transforming activities of oncogenic H-Ras.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu		Mandayam, Nandan/0000-0002-4061-9348	NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230, DK64399, DK52230, R24 DK064399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FILMUS J, 1994, ONCOGENE, V9, P3627; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kawai-Kowase K, 1999, CIRC RES, V85, P787, DOI 10.1161/01.RES.85.9.787; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; KUO ML, 1993, CANCER LETT, V74, P197, DOI 10.1016/0304-3835(93)90243-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Simmen RCM, 2002, FRONT BIOSCI-LANDMRK, V7, pD1556, DOI 10.2741/simmen; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Winston JT, 1996, ONCOGENE, V12, P127; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	62	119	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3404	3413		10.1038/sj.onc.1207397	http://dx.doi.org/10.1038/sj.onc.1207397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077182	Green Accepted			2022-12-17	WOS:000220975000015
J	Schmidt, EV				Schmidt, EV			The role of c-myc in regulation of translation initiation	ONCOGENE			English	Article						translational; control; eIF4E; ribosomal synthesis; rDNA transcription	HUMAN TUMOR-CELLS; ORNITHINE-DECARBOXYLASE; MESSENGER-RNA; CYCLIN D1; FACTOR 4E; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; SACCHAROMYCES-CEREVISIAE; INCREASED EXPRESSION; RIBOSOME BIOGENESIS	Translation initiation is important for the regulation of both cell growth and cell division. It is uniquely poised to coordinate overall cell proliferation by its effects on both growth and division. A number of translation initiation factors are transcriptional targets of c-myc in a variety of assays. In particular, the mRNA cap-binding protein eIF4E has a myc-binding sequence in its promoter that is myc responsive in reporter assays and contains a high-affinity myc-binding site in chromosome immunoprecipitation experiments. Several differential expression screens have demonstrated altered levels of eIF4E, along with several other translation initiation factors, in response to alterations of c-myc levels. The potential for eIF4E and other translational control elements to mediate myc's transforming functions is particularly important because eIF4E is itself a known oncogenic factor. The ability of translation initiation factors to affect both cell division control and cell growth control coincides with myc's remarkable effects on both cell growth and cell division.	Massachusetts Gen Hosp, Canc Res Ctr, Boston, MA 02114 USA; MassGen Hosp Children, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Schmidt, EV (corresponding author), Massachusetts Gen Hosp, Canc Res Ctr, 55 Fruit St, Boston, MA 02114 USA.	schmidt@helix.mgh.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA063117] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; Baserga R, 1985, BIOL CELL REPROD; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Collier JJ, 2003, J BIOL CHEM, V278, P6588, DOI 10.1074/jbc.M208011200; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANICJOYCE PJ, 1987, EXP CELL RES, V172, P134, DOI 10.1016/0014-4827(87)90100-5; HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; IVERSEN OH, 1974, EUR J CANCER, V10, P155, DOI 10.1016/0014-2964(74)90148-0; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KILLANDER D, 1965, EXP CELL RES, V40, P12, DOI 10.1016/0014-4827(65)90285-5; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lewis BC, 2000, CANCER RES, V60, P6178; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MATTHEWS MB, 2000, TRANSLATIONAL CONTRO, P1020; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Pyronnet S, 1996, CANCER RES, V56, P1742; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	66	119	131	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2004	23	18					3217	3221		10.1038/sj.onc.1207548	http://dx.doi.org/10.1038/sj.onc.1207548			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094771				2022-12-17	WOS:000220879700010
J	Peng, YH; Li, CG; Chen, LH; Sebti, S; Chen, JD				Peng, YH; Li, CG; Chen, LH; Sebti, S; Chen, JD			Rescue of mutant p53 transcription function by ellipticine	ONCOGENE			English	Article						p53; ellipticine; rescue; conformation; mutant	ELLIPTINIUM ACETATE; ACTIVATION FUNCTION; MDM2; CANCER; PHASE; DNA; RESTORATION; MUTATIONS; STABILITY; DATABASE	The p53 tumor suppressor is frequently inactivated in tumors by point mutations in the DNA-binding domain, resulting in loss of sequence-specific DNA binding and transcription function. We present evidence that ellipticine can restore the transactivation function of several transfected p53 mutants (175 H, 248W, 249S, 273 H, 281G), resulting in the induction of p53-responsive genes (p21(WAF1), MDM2) and activation of a p53-responsive luciferase reporter. Ellipticine also activates mutant p53 function in tumor cells expressing endogenous 194F, 233L, 241F, and 273C mutants. Treatment with ellipticine alters mutant p53 reactivity to conformation-sensitive Pab1620 and Pab240 antibodies and increases its sequence-specific DNA-binding activity in vivo. Finally, ellipticine activates mutant p53 and induces p21(WAF1) and MDM2 expression in nude mouse tumor xenografts. These results demonstrate that ellipticine can restore transcription function to mutant p53. This property may contribute to the selectivity of ellipticine-derived compounds against tumor cell lines expressing mutant p53.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu						ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; BUZDAR AU, 1990, ONCOLOGY, V47, P101; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GOUYETTE A, 1982, EUR J CANCER CLIN ON, V18, P1285, DOI 10.1016/0277-5379(82)90130-4; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KATTAN J, 1994, AM J CLIN ONCOL-CANC, V17, P242, DOI 10.1097/00000421-199406000-00013; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Ohnishi T, 1999, RADIAT RES, V151, P498, DOI 10.2307/3579838; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; ROUESSE J, 1993, EUR J CANCER, V29A, P856, DOI 10.1016/S0959-8049(05)80424-1; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shi LM, 1998, MOL PHARMACOL, V53, P241, DOI 10.1124/mol.53.2.241; Soong R, 1996, HUM PATHOL, V27, P1050, DOI 10.1016/S0046-8177(96)90282-8; Sugikawa E, 2001, ANTICANCER RES, V21, P2671; Sugikawa E, 1999, ANTICANCER RES, V19, P3099; VOJTESEK B, 1995, ONCOGENE, V10, P389; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	35	119	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4478	4487		10.1038/sj.onc.1206777	http://dx.doi.org/10.1038/sj.onc.1206777			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881704				2022-12-17	WOS:000184054700003
J	Ziegert, C; Wentzensen, N; Vinokurova, S; Kisseljov, F; Einenkel, J; Hoeckel, M; Doeberitz, MV				Ziegert, C; Wentzensen, N; Vinokurova, S; Kisseljov, F; Einenkel, J; Hoeckel, M; Doeberitz, MV			A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques	ONCOGENE			English	Article						human papillomavirus (HPV); E6-E7 oncogenes; integration; viral-cellular fusion transcripts; HPV splicing; homologous recombination	HUMAN-PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; PHYSICAL STATE; MOLECULAR ANALYSIS; HIGH-RISK; CANCER; SEQUENCES; CARCINOGENESIS; INSTABILITY; DNA	Persistent infections with high-risk human papillomaviruses (HPVs) induce dysplastic lesions of the lower genital tract. Some of these lesions eventually progress to invasive cancers, particularly of the uterine cervix. In many advanced preneoplastic cervical lesions and most derived carcinomas, HPV genomes are found to be integrated into the host cell chromosomes. Although HPV integration seems to play an important role in the progression of cervical dysplasia, the underlying mechanisms are still unclear. To investigate the pathogenic role of genomic integration of HPV genomes in greater detail, we analysed integration sites of HPV16 and 18 genomes in 21 anogenital precancerous and cancerous lesions using a ligation-mediated chain reaction (DIPS) and the recently described amplification of papilloma virus oncogene transcripts (APOT) assay. On the genomic level, only singular integration events were observed in individual neoplastic cell clones. At many integration sites, a short overlap between HPV and genomic sequences was observed, suggesting that the integration of HPV genomes is mediated by nonhomologous sequence-specific recombination. APOT analysis revealed that the majority of integrated HPV genomes was actively transcribed. These data suggest that in the progression of cervical preneoplasia to invasive carcinomas, integration of viral genomes occurs only at single or few chromosomal loci in a given cell clone. Disruption of cellular genes might support malignant transformation in rare cases; however, it is not a pathogenic prerequisite. The main function of HPV integration seems to be the stabilization of oncogene transcription.	Heidelberg Univ, Inst Mol Pathol, Dept Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Blokhin Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia.	mvkd@aol.com	Einenkel, Jens/B-3772-2014; Wentzensen, Nicolas/AAG-8522-2019; von Knebel Doeberitz, Magnus/D-2372-2016	Einenkel, Jens/0000-0003-4254-667X; von Knebel Doeberitz, Magnus/0000-0002-0498-6781				BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BULLOCK P, 1984, J MOL BIOL, V174, P55, DOI 10.1016/0022-2836(84)90365-6; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Choo KB, 1996, J MED VIROL, V49, P15, DOI 10.1002/(SICI)1096-9071(199605)49:1<15::AID-JMV3>3.3.CO;2-4; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Doeberitz MV, 2002, EUR J CANCER, V38, P2229, DOI 10.1016/S0959-8049(02)00462-8; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DURST M, 1986, BANBURY REPORT, V21, P273; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kalantari M, 2001, DIAGN MOL PATHOL, V10, P46, DOI 10.1097/00019606-200103000-00008; Klaes R, 1999, CANCER RES, V59, P6132; LEHN H, 1988, J GEN VIROL, V69, P187, DOI 10.1099/0022-1317-69-1-187; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mount SM, 2000, AM J HUM GENET, V67, P788, DOI 10.1086/303098; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; Van Tine B. A., 2001, V106, P381; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	29	119	127	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2003	22	25					3977	3984		10.1038/sj.onc.1206629	http://dx.doi.org/10.1038/sj.onc.1206629			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	691NH	12813471				2022-12-17	WOS:000183612000017
J	Murakami, D; Okamoto, I; Nagano, O; Kawano, Y; Tomita, T; Iwatsubo, T; De Strooper, B; Yumoto, E; Saya, H				Murakami, D; Okamoto, I; Nagano, O; Kawano, Y; Tomita, T; Iwatsubo, T; De Strooper, B; Yumoto, E; Saya, H			Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44	ONCOGENE			English	Article						CD44; gamma-secretase; presenilin; intramembranous cleavage	FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; E-CADHERIN; MISSENSE MUTATIONS; CALCIUM INFLUX; BETA-CATENIN; RHO-FAMILY; GENE; RECEPTOR	CD44 is the major adhesion molecule for the extracellular matrix components and is implicated in a wide variety of physiological and pathological processes including the regulation of tumor cell growth and metastasis. Our previous studies have shown that CD44 undergoes sequential proteolytic cleavages in the extracellular and transmembrane domains and the cleavage product derived from CD44 intramembranous cleavage acts as a signal transduction molecule. However, the underlying mechanism of the intramembranous cleavage of CD44 remains to be elucidated. In the present study, we report for the first time that CD44 is a substrate of the presenilin (PS)-dependent gamma-secretase. We demonstrate that the intramembranous cleavage of CD44 induced by 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment or mechanical scraping is blocked by gamma-secretase inhibitors in U251MG cells and that this cleavage is also inhibited in PS-deficient mouse embryonic fibroblasts. Furthermore, we showed that PSI is redistributed to ruffling areas of the plasma membrane similarly to CD44 after TPA treatment, supporting our biochemical observation that PSI is involved in the intramembranous cleavage of CD44. Our present findings suggest important implications for understanding CD44-dependent signal transduction and a potential role of PS/gamma-secretase activity in the functional regulation of adhesion molecules.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Kumamoto 8608556, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 1, Kumamoto 8608556, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB, B-3000 Louvain, Belgium	Kumamoto University; Kumamoto University; Kumamoto University; University of Tokyo; KU Leuven; Flanders Institute for Biotechnology (VIB)	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Nagano, Osamu/J-5874-2013; de+Strooper, Bart/Z-1638-2019; Tomita, Taisuke/L-5427-2015; De Strooper, Bart/F-6507-2012	Nagano, Osamu/0000-0002-7630-142X; Tomita, Taisuke/0000-0002-0075-5943; De Strooper, Bart/0000-0001-5455-5819; Murakami, Daizo/0000-0001-8668-800X				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; LESLEY J, 1998, FRONT BIOSCI, V3, P616; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Noe V, 2001, J CELL SCI, V114, P111; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Weber GF, 2002, CANCER RES, V62, P2281	34	119	124	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1511	1516		10.1038/sj.onc.1206298	http://dx.doi.org/10.1038/sj.onc.1206298			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629514				2022-12-17	WOS:000181411900008
J	Arsura, M; Panta, GR; Bilyeu, JD; Cavin, LG; Sovak, MA; Oliver, AA; Factor, V; Heuchel, R; MErcurio, F; Thorgeirsson, SS; Sonenshein, GE				Arsura, M; Panta, GR; Bilyeu, JD; Cavin, LG; Sovak, MA; Oliver, AA; Factor, V; Heuchel, R; MErcurio, F; Thorgeirsson, SS; Sonenshein, GE			Transient activation of NF-kappa B through a TAK1/IKK kinase pathway by TGF-beta 1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation	ONCOGENE			English	Article						NF-kappa B; IKK; TGF-beta 1; JNK; AP-1; apoptosis	GROWTH-FACTOR-BETA; MICE LACKING; IKK-ALPHA; EMBRYONIC LETHALITY; TRANSGENIC MICE; HEPATOCELLULAR CARCINOMAS; MEDIATED TRANSCRIPTION; TERMINAL KINASE; ADAPTER PROTEIN; JNK ACTIVATION	NF-kappaB has been implicated in the regulation of apoptosis, a key mechanism of normal and malignant growth control. Previously, we demonstrated that inhibition of NF-kappaB activity by TGF-beta1 leads directly to induction of apoptosis of murine B-cell lymphomas and hepatocytes. Thus, we were surprised to determine that NF-kappaB is transiently activated in response to TGF-beta1 treatment. Here we elucidate the mechanism of TGF-beta1-mediated regulation of NF-kappaB and induction of apoptosis in epithelial cells. We report that TGF-beta1 activates IKK kinase, which mediates IkappaB-alpha phosphorylation. In turn, the activation of IKK following TGF-beta1 treatment is mediated by the TAK1 kinase. As a result of NF-kappaB activation, IkappaB-alpha mRNA and protein levels are increased leading to postrepression of NF-kappaB and induction of cell death. Inhibition of NF-kappaB following TGF-beta1 treatment increased AP-1 complex transcriptional activity through sustained c-Jun phosphorylation, thereby potentiating AP-1/SMADs-mediated cell killing. Furthermore, TGF-beta1-mediated upregulation of Smad7 appeared independent of NF-kappaB. In hepatocellular carcinomas of TGF-beta1 or TGF-alpha/c-myc transgenic mice, we observed constitutive activation of NF-kappaB that led to inhibition of JNK signaling. Overall, our data illustrate an autocrine mechanism based on the ability of IKK/NF-kappaB/IkappaB-alpha signaling to negatively regulate NF-kappaB levels thereby permitting TGF-beta1-induced apoptosis through AP-1 activity.	Univ Tennessee, Coll Med, Dept Pharmacol, Memphis, TN 38163 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; NCI, CCR, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA; Celgene Signal Res Div, San Diego, CA 92121 USA; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	University of Tennessee System; University of Tennessee Health Science Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research	Arsura, M (corresponding author), Univ Tennessee, Coll Med, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.		Heuchel, Rainer/P-7875-2019	Heuchel, Rainer/0000-0002-2782-585X	NATIONAL CANCER INSTITUTE [R01CA036355, R01CA078616, R01CA082742, Z01BC010036] Funding Source: NIH RePORTER; NCI NIH HHS [CA78616-S1, CA82742, CA36355, CA78616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; [Anonymous], GENOME BIOL; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Azuma M, 1999, EXP CELL RES, V250, P213, DOI 10.1006/excr.1999.4503; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chang H, 2001, MOL CELL ENDOCRINOL, V180, P39, DOI 10.1016/S0303-7207(01)00513-5; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; Factor VM, 1997, CANCER RES, V57, P2089; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nagarajan RP, 2000, BIOCHEM J, V348, P591, DOI 10.1042/0264-6021:3480591; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Rudolph D, 2000, GENE DEV, V14, P854; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; WU JC, 1994, CANCER RES, V54, P5964; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	73	119	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					412	425		10.1038/sj.onc.1206132	http://dx.doi.org/10.1038/sj.onc.1206132			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545162				2022-12-17	WOS:000180379100010
J	Ford, LP; Wright, WE; Shay, JW				Ford, LP; Wright, WE; Shay, JW			A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation	ONCOGENE			English	Article						telomerase; telomere; hnRNP	IN-VITRO; CATALYTIC SUBUNIT; BINDING-PROTEIN; PREMESSENGER RNA; RAT HEPATOCYTES; HNRNP PROTEINS; EST GENES; MATRIX; DNA; SEQUENCE	The heterogeneous nuclear ribonucleoproteins (hnRNPs) are a large family of nucleic acid binding proteins that are often found in, but not restricted to, the 40S-ribonucleoprotein particle. Subsets of huRNPs are strictly nuclear while others shuttle between the nucleus and cytoplasm. Members of the hnRNP family have been implicated to have roles in many aspects of mRNA maturation/turnover and in telomere and telomerase regulation. Telomeres are repetitive DNA elements mainly found at the ends of human chromosomes. In most normal cells, telomeres shorten with each cell division. Telomere shortening can be compensated for by a ribonucleoprotein complex, called telomerase. Telomerase, consisting of an integral RNA and catalytic protein component as well as several auxiliary factors, extends the 3'-G-rich strand of the ends of the telomeres. Here we present new data and describe a model that implicates the telomerase bound hnRNPs; in promoting telomere access by interacting with telomeres. Telomere bound hnRNPs include hnRNP A1, A2-B1, D and E and telomerase bound hnRNPs including hnRNPA1 C1/C2 and D. The telomere and telomerase bound hnRNPs; may prove to be good targets for regulating telomere length.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Ambion Inc, Austin, TX 78744 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jerry.shay@utsouthwestern.edu	Shay, Jerry W/F-7878-2011		NIA NIH HHS [AG07992, AG01228] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG001228, R37AG001228, R01AG007992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aigner S, 2000, EMBO J, V19, P6230, DOI 10.1093/emboj/19.22.6230; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Erlitzki R, 1997, J BIOL CHEM, V272, P15881, DOI 10.1074/jbc.272.25.15881; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Ford LP, 2000, MOL CELL BIOL, V20, P9084, DOI 10.1128/MCB.20.23.9084-9091.2000; GALLINARO H, 1983, EMBO J, V2, P953, DOI 10.1002/j.1460-2075.1983.tb01527.x; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hinkley CS, 1998, NUCLEIC ACIDS RES, V26, P532, DOI 10.1093/nar/26.2.532; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; Johnston SD, 1999, MOL CELL BIOL, V19, P923; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Le SY, 2000, MOL BIOL CELL, V11, P999, DOI 10.1091/mbc.11.3.999; Lendvay TS, 1996, GENETICS, V144, P1399; LESTOURGEON WM, 1977, COLD SPRING HARB SYM, V42, P885, DOI 10.1101/SQB.1978.042.01.090; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; Mattern KA, 1997, J CELL BIOCHEM, V65, P42, DOI 10.1002/(SICI)1097-4644(199704)65:1<42::AID-JCB5>3.0.CO;2-Z; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; Schnapp G, 1998, NUCLEIC ACIDS RES, V26, P3311, DOI 10.1093/nar/26.13.3311; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Steiner BR, 1996, P NATL ACAD SCI USA, V93, P2817, DOI 10.1073/pnas.93.7.2817; VANEEKELEN CAG, 1981, J CELL BIOL, V88, P554, DOI 10.1083/jcb.88.3.554; Weighardt F, 1999, J CELL SCI, V112, P1465; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	50	119	130	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					580	583		10.1038/sj.onc.1205086	http://dx.doi.org/10.1038/sj.onc.1205086			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850782				2022-12-17	WOS:000173390500009
J	Wu, CJ; O'Rourke, DM; Feng, GS; Johnson, GR; Wang, Q; Greene, MI				Wu, CJ; O'Rourke, DM; Feng, GS; Johnson, GR; Wang, Q; Greene, MI			The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors	ONCOGENE			English	Article						SHP-2; phosphatidylinositol 3-kinase (PI3K); Akt; growth factors; signaling	HUMAN GLIOBLASTOMA CELLS; FACTOR RECEPTOR; PHOSPHOINOSITIDE-3-OH KINASE; PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; FOCAL ADHESION; SH2 DOMAINS; ERBB FAMILY; PROTEIN	SHP-2 is a ubiquitously expressed non-transmembrane tyrosine phosphatase with two SH2 domains. Multiple reverse-genetic studies have indicated that SHP-2 is a required component for organ and animal development. SHP-2 wild-type and homozygous mutant mouse fibroblast cells in which the N-terminal SH2 domain was target-deleted were used to examine the function of SHP-2 in regulating Phosphatidylinositol 3-Kinase (PI3K) activation by growth factors. In addition, SHP-2 and various mutants were introduced into human glioblastoma cells as well as SHP-2(-/-) mouse fibroblasts. We found that EGF stimulation and EGFR oncoprotein (Delta EGFR) expression independently induced the co-immunoprecipitation of the p85 subunit of PI3K with SHP-2. Targeted deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation. Ectopic expression of SHP-2 in U87MG gliobastoma cells elevated EGF-induced Akt phosphorylation, and the effect was abolished by mutation of its N-terminal SH2 domain. Likewise, the reconstitution of SHP-2 expression in the SHP-2(-/-) cells enhanced Akt phosphorylation induced by EGF while rescuing that induced by PDGF and IGF. Further lipid kinase activity assays confirmed that SHP-2 modulation of Akt phosphorylation correlated with its regulation of PI3K activation. Based on these results, we conclude that SHP-2 is required for mediating PI3K/Akt activation, and the N-terminal SH2 domain is critically important for a 'positive' role of SHP-2 in regulating PI3K pathway activation.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Burnham Inst, La Jolla, CA 92037 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Sanford Burnham Prebys Medical Discovery Institute; US Food & Drug Administration (FDA)	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu	O'Rourke, Donald/AAC-3376-2021; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; O'Rourke, Donald/0000-0002-8479-7314				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Oh ES, 1999, MOL CELL BIOL, V19, P3205; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	39	119	120	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6018	6025		10.1038/sj.onc.1204699	http://dx.doi.org/10.1038/sj.onc.1204699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593409				2022-12-17	WOS:000171056300009
J	Fukazawa, T; Fujiwara, T; Uno, F; Teraishi, F; Kadowaki, Y; Itoshima, T; Takata, Y; Kagawa, S; Roth, JA; Tschopp, J; Tanaka, N				Fukazawa, T; Fujiwara, T; Uno, F; Teraishi, F; Kadowaki, Y; Itoshima, T; Takata, Y; Kagawa, S; Roth, JA; Tschopp, J; Tanaka, N			Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells	ONCOGENE			English	Article						p53; apoptosis; FLIP; ubiquitin-proteasome; colon cancer	NF-KAPPA-B; DEATH RECEPTOR; P53; GENE; EXPRESSION; KILLER/DR5; SYSTEM; FADD; MODULATION; FAS	Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many different signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no effect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53- and KILLER/DR5-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a specific inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitin-proteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transfer.	Okayama Univ, Grad Sch Med & Dent, Div Surg Oncol, Dept Surg 1, Okayama 7008558, Japan; Shiga Univ Med Sci, Dept Surg 1, Otsu, Shiga 5202192, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Okayama University; Shiga University of Medical Science; University of Texas System; UTMD Anderson Cancer Center; University of Lausanne	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med & Dent, Div Surg Oncol, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Fukazawa, Takuya/GLR-7099-2022; Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kataoka T, 1998, J IMMUNOL, V161, P3936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MEDEMA JP, 1997, EMBO J, V16, P2749; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheikh MS, 1998, CANCER RES, V58, P1593; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	23	119	119	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5225	5231		10.1038/sj.onc.1204673	http://dx.doi.org/10.1038/sj.onc.1204673			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526513				2022-12-17	WOS:000170464000018
J	Zeidler, MP; Bach, EA; Perrimon, N				Zeidler, MP; Bach, EA; Perrimon, N			The roles of the Drosophila JAK/STAT pathway	ONCOGENE			English	Article						hopscotch; unpaired; stat92E; ommatidia; segmentation; polarity	SIGNAL-TRANSDUCTION; JAK; EYE; KINASE; GENE; STAT; MELANOGASTER; ACTIVATION; HOPSCOTCH; POLARITY	The JAK/STAT signal transduction pathway has been conserved throughout evolution such that true structural and functional homologues of components originally identified in vertebrate systems are also present in the model genetic system Drosophila melanogaster. In addition to roles during larval hematopoiesis reminiscent of the requirement for this pathway in mammalian systems, the JAK/STAT pathway in Drosophila is also involved in a number of other developmental events. Recent data has demonstrated further roles for the JAK/STAT pathway in the establishment of sexual identity via the early embryonic expression of Sex lethal. the segmentation of the embryo via the control of pair rule genes including even skipped and the establishment of polarity within the adult compound eye via a mechanism that includes the four jointed gene, Use of the powerful genetics in the model organism Drosophila may identify new components of the JAK/STAT pathway, define new roles for this pathway, and provide insights into the function of this signal transduction system. Here we review the roles of STAT and its associated signaling pathway during both embryonic and adult stages of Drosophila development and discuss future prospects for the identification and characterization of novel pathway components and targets.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Zeidler, Martin/E-6209-2010	Bach, Erika/0000-0002-5997-4489; Zeidler, Martin/0000-0003-2942-1135; Perrimon, Norbert/0000-0001-7542-472X				Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; Cho KO, 1998, NATURE, V396, P272, DOI 10.1038/24394; Chou TB, 1996, GENETICS, V144, P1673; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dominguez M, 1998, NATURE, V396, P276, DOI 10.1038/24402; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Harrison DA, 1998, GENE DEV, V12, P3252, DOI 10.1101/gad.12.20.3252; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Heberlein U, 1998, DEVELOPMENT, V125, P567; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Juni N, 1996, GENETICS, V143, P1257; LIU X, 1999, SCIENCE, V285, pA167; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Luo H, 1999, DEV BIOL, V213, P432, DOI 10.1006/dbio.1999.9390; Mathey-Prevot B, 1998, CELL, V92, P697, DOI 10.1016/S0092-8674(00)81396-3; Mesilaty-Gross S, 1999, GENE, V231, P173, DOI 10.1016/S0378-1119(99)00053-0; Mohr SE, 1999, GENE, V229, P109, DOI 10.1016/S0378-1119(99)00033-5; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Papayannopoulos V, 1998, SCIENCE, V281, P2031, DOI 10.1126/science.281.5385.2031; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; SWEITZER SM, 1995, J BIOL CHEM, V270, P16510, DOI 10.1074/jbc.270.28.16510; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; VENDEROSA FJ, 1954, GENETICS, V39, P999; VILLANO JL, 1995, DEVELOPMENT, V121, P2767; Wehrli M, 1998, DEVELOPMENT, V125, P1421; Williams JG, 1999, TRENDS BIOCHEM SCI, V24, P333, DOI 10.1016/S0968-0004(99)01443-7; Wolff Tanya, 1993, P1277; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zeidler MP, 1999, CURR BIOL, V9, P1363, DOI 10.1016/S0960-9822(00)80081-0; Zeidler MP, 1999, GENE DEV, V13, P1342, DOI 10.1101/gad.13.10.1342	38	119	126	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2598	2606		10.1038/sj.onc.1203482	http://dx.doi.org/10.1038/sj.onc.1203482			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851058				2022-12-17	WOS:000087459400015
J	Dai, CY; Enders, GH				Dai, CY; Enders, GH			p16(INK4a) can initiate an autonomous senescence program	ONCOGENE			English	Article						p16(INK4a); senescence; tumor suppressor; retinoblastoma protein	HUMAN-DIPLOID FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; REPLICATIVE SENESCENCE; RETINOBLASTOMA-PROTEIN; CYCLE INHIBITION; P16 EXPRESSION; GROWTH; INACTIVATION; P53; INVOLVEMENT	The tumor suppressor p16(INK4a) is a potent mediator of cell cycle arrest in transient expression studies, is induced in senescing cells, and can impose morphological features of senescence, Nonetheless, it is unclear whether p16(INK4a) can block cell proliferation irreversibly. We explored this issue using osteogenic sarcoma cell clones with inducible p16(INK4a) expression. Induction of p16(INK4a) for 1 day arrested most cells in G1 phase. If the induction was then interrupted, p16(INK4a) levels returned to baseline and robust growth resumed within 3-5 days. When p16(INK4a) was induced for 6 days DNA synthesis remained strongly inhibited and the cells acquired morphological features of senescence. Moreover, if p16(INK4a) induction was interrupted at this point and the cells were followed for 12 more days, most cells retained these morphologic features and either failed to divide or died. This occurred despite the prompt return of p16(INK4a) expression and retinoblastoma protein phosphorylation toward baseline levels. In fact, some senescing cells appeared to enter S phase. These results demonstrate that a sustained period of p16(INK4a) expression is sufficient in this setting to impose a durable block to cell proliferation and that this state becomes independent of p16(INK4a) expression, hypophosphorylation of pRB, or a strict G1 arrest.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Program, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Enders, GH (corresponding author), Penn GI Div, 600 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [K08CA061412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER; NCI NIH HHS [7-K08-CA61412] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM 07229] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Asamoto M, 1998, CANCER LETT, V127, P9, DOI 10.1016/S0304-3835(97)00447-3; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Baylin SB, 1998, ADV CANCER RES, V72, P141; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Cohen JA, 1997, HUM PATHOL, V28, P893, DOI 10.1016/S0046-8177(97)90003-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Geradts J, 1996, AM J PATHOL, V149, P15; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Higashi H, 1997, BIOCHEM BIOPH RES CO, V231, P743, DOI 10.1006/bbrc.1997.6181; Jarrard DF, 1999, CANCER RES, V59, P2957; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Reznikoff CA, 1996, CANCER RES, V56, P2886; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139	37	119	120	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1613	1622		10.1038/sj.onc.1203438	http://dx.doi.org/10.1038/sj.onc.1203438			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763818				2022-12-17	WOS:000086083800001
J	Zhang, W; Bae, I; Krishnaraju, K; Azam, N; Fan, W; Smith, K; Hoffman, B; Liebermann, DA				Zhang, W; Bae, I; Krishnaraju, K; Azam, N; Fan, W; Smith, K; Hoffman, B; Liebermann, DA			CR6: A third member in the MyD118 and Gadd45 gene family which functions in negative growth control	ONCOGENE			English	Article						CR6; MyD118; Gadd45; growth suppression	IMMEDIATE EARLY RESPONSE; MYELOID-LEUKEMIA CELLS; TRANSCRIPTION FACTOR EGR-1; TERMINAL DIFFERENTIATION; GENOTOXIC-STRESS; C-MYC; EXPRESSION; ARREST; APOPTOSIS; PATHWAYS	MyD118 and Gadd45 are two related genes which encode for proteins that play important roles in negative growth control, including both growth suppression and apoptosis, A strategy was employed to clone new members of the MyD118 and Gadd45 family of genes. Based on alignment of the deduced amino acid sequences, one cDNA clone was found to encode for the murine homologue of human CR6, originally cloned as an IL-2 immediate-early response gene. The murine and human CR6 proteins were observed to be 97% identical, indicating that CR6 is an evolutionarily conserved protein. Analysis of CR6 expression during hematopoietic cell development associated with growth arrest and apoptotic cell death, upon exposure of hematopoietic cells to a variety of growth arrest and apoptotic stimuli, and in a variety of murine tissues, has revealed that CR6 expression differs significantly from the expression of the related MyD118 and Gadd45 genes. Nevertheless, CR6, like MyD118 and Gadd45, suppressed colony formation of human lung carcinoma H1299 cells. These data suggest that CR6 plays similar, but not identical, roles to MyD118 and Gadd45 in negative control of cell growth.	Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Med, New York, NY 10021 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Cornell University; NewYork-Presbyterian Hospital	Hoffman, B (corresponding author), Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.				NCI NIH HHS [1R01CA43618, 1R01CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618, R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GRANA X, 1995, ONCOGENE, V11, P211; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; Holbrook N J, 1996, EXS, V77, P273; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 1996, ONCOGENE, V12, P2579; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	30	119	125	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	1999	18	35					4899	4907		10.1038/sj.onc.1202885	http://dx.doi.org/10.1038/sj.onc.1202885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490824				2022-12-17	WOS:000082321700002
J	Burger, AM; Zhang, X; Li, H; Ostrowski, JL; Beatty, B; Venanzoni, M; Papas, T; Seth, A				Burger, AM; Zhang, X; Li, H; Ostrowski, JL; Beatty, B; Venanzoni, M; Papas, T; Seth, A			Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas	ONCOGENE			English	Article						molecular cloning; immunohistochemistry; FISH mapping; LOH; breast cancer	EPITHELIAL-CELLS; CANCER CELLS; IDENTIFICATION; EXPRESSION; HETEROZYGOSITY; INHIBITOR	To define genes that are essential to the initiation and progression of breast cancer we utilized subtractive hybridization and differential display cloning techniques and isolated over 950 cDNAs from breast cell-lines derived from matched normal and tumor tissue, Of these, 102 cDNAs mere characterized by DNA sequencing and Northern blot analysis, GenBank searches showed that one of these genes, T1A12 is identical to mac25, an insulin-like growth factor-binding protein related gene. Antibodies generated against the C-terminal region of the T1A12/mac25 protein were used to investigate its expression in 60 primary breast tissues. Sections of 12 benign, 16 ductal carcinoma in situ and 32 infiltrating ductal carcinoma specimens were examined, Strong immunoperoxidase staining was observed in luminal epithelial cells of normal lobules and ducts, in apocrine cells of cysts and fibroadenomas, Moderate to weak protein expression was found in hyperplastic and DCIS cells, but no specific staining was detected in invasive carcinoma cells. FISH mapping using a PAC clone localized the T1A12/mac25 gene to 4q12-13, Microsatellite length polymorphism was studied using markers for 4q in paired normal and tumor breast tissues. Thirty-three per cent (10/30) of the samples mere found to be polymorphic with D4S189 and D4S231 microsatellite markers and LOH was detected in 50% (5/10) of these informative samples. Our data indicate that T1A12/mac25 expression is abrogated during breast cancer progression concomitant with loss of heterozygosity on chromosome 4q, T1A12/mac25 may therefore have a tumor suppressor-like function and its expression could indicate a disease with a more favorable status, having a better prognosis.	Univ Toronto, MRC, Dept Lab Med & Pathobiol, Periodontal Physiol Grp, Toronto, ON M5S 1B2, Canada; Univ Toronto, Womens Coll Hosp, Toronto, ON M5S 1B2, Canada; Univ Freiburg, Tumor Biol Ctr, D-79106 Freiburg, Germany; Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Leeds Gen Infirm, Dept Pathol, Leeds LS2 9JT, W Yorkshire, England; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Canc Therapy & Prevent Res Assoc, Rome, Italy	University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Freiburg; Medical University of South Carolina; Leeds General Infirmary; University of Leeds; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Seth, A (corresponding author), Univ Toronto, MRC, Dept Lab Med & Pathobiol, Periodontal Physiol Grp, Toronto, ON M5S 1B2, Canada.							Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Baserga R, 1997, ENDOCRINOLOGY, V138, P2217, DOI 10.1210/en.138.6.2217; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; BELL SM, 1991, BRIT J CANCER, V64, P174, DOI 10.1038/bjc.1991.264; BOCKER W, 1992, VIRCHOWS ARCH A, V421, P315, DOI 10.1007/BF01660978; BURGER A, IN PRESS ONCOGENE; Burger AM, 1996, INT J ONCOL, V8, P395; BURGER AM, 1996, MIANI SHORT REPORTS, V7, P65; CAWKWELL L, 1993, BRIT J CANCER, V67, P1292; CHEN JC, 1994, CELL PHYSL, V158, P69; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CULOUSCOU JM, 1991, CANCER RES, V51, P2813; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FIGUEROA JA, 1993, J CELL BIOCHEM, V52, P196, DOI 10.1002/jcb.240520211; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAMBLY RJ, 1994, THESIS U BRADFORD; KATO MV, 1996, ONCOGENE, V12, P1362; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; OH Y, 1996, J BIOL CHEM, V271, P33352; OOI GT, 1990, MOL CELL ENDOCRINOL, V71, pC39, DOI 10.1016/0303-7207(90)90243-2; PATTERSON H, 1992, EUR J CANCER, V28A, P258, DOI 10.1016/0959-8049(92)90428-5; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEKONEN F, 1992, CANCER RES, V52, P5204; Plymate SR, 1996, J CLIN ENDOCR METAB, V81, P3709, DOI 10.1210/jc.81.10.3709; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; RADFORD DM, 1995, CANCER RES, V55, P5180; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; SATO H, 1995, BIOCHEM BIOPH RES CO, V214, P468, DOI 10.1006/bbrc.1995.2310; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SOUBEYRAN I, 1995, BREAST CANCER RES TR, V34, P119, DOI 10.1007/BF00665784; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TARMIN L, 1994, CANCER RES, V54, P6094; Tripathy D, 1992, Cancer Treat Res, V63, P15; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WESTLEY BR, 1995, BRIT J CANCER, V72, P1065, DOI 10.1038/bjc.1995.465; WINQVIST R, 1993, CANCER RES, V53, P4486; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YEE D, 1994, CELL GROWTH DIFFER, V5, P73	41	119	132	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2459	2467		10.1038/sj.onc.1201772	http://dx.doi.org/10.1038/sj.onc.1201772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627112				2022-12-17	WOS:000073672300004
J	Stilgenbauer, S; Nickolenko, J; Wilhelm, J; Wolf, S; Weitz, S; Dohner, K; Boehm, T; Dohner, H; Lichter, P				Stilgenbauer, S; Nickolenko, J; Wilhelm, J; Wolf, S; Weitz, S; Dohner, K; Boehm, T; Dohner, H; Lichter, P			Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma	ONCOGENE			English	Article						deletion mapping; FISH; exon amplification; DIRVISH	RETINOBLASTOMA GENE; D13S25 LOCUS; INSITU HYBRIDIZATION; DELETIONS; AMPLIFICATION; REGION; DNA; CYTOGENETICS; CLONES	Deletions affecting the interval between the RB1 gene and marker D13S25 at band 13q14 are the most frequent genetic abnormalities of B-cell chronic lymphocytic leukemia (B-CLL) and indicate the presence of a novel tumor suppressor gene in this region. In the current study, a high resolution physical map of fragments spanning one megabasepair (Mb) of genomic DNA at the critical 13q14 segment was constructed. To define the minimal region of loss within the RB1 and D13S25 interval, we screened 322 B-CLLs for deletions at either of the two loci. Thirty mantle cell lymphomas (MCLs) were included in the analysis because we observed a 13q14 deletion pattern similar to B-CLL in this disease, The incidence of 13q14 deletions was 51% in B-CLL and 70% in MCL, respectively. No frequent loss of the BRCA2 gene at band 13q12 was found. Detailed deletion mapping at band 13q14 with probes from the RB1-D13S25 interval lead to the identification of a critical deletion region 400 kb in size. Within this region two segments were most frequently affected, one at D13S272 120 kb in size and another 240 kb distal of D13S272 80 kb in size. From these two segments expressed sequences were identified as candidates for the putative 13q14 tumor suppressor gene involved in the pathogenesis of B-CLL and MCL.	Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome, D-69120 Heidelberg, Germany; Med Klin & Poliklin 5, D-69115 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Abt Expt Therapie, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Döhner, Hartmut/C-8933-2016; Stilgenbauer, Stephan/ABE-6609-2020	Döhner, Hartmut/0000-0003-2116-5536; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOHLANDER SK, 1992, GENOMICS, V13, P1322, DOI 10.1016/0888-7543(92)90057-Y; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; Bullrich F, 1996, BLOOD, V88, P3109, DOI 10.1182/blood.V88.8.3109.bloodjournal8883109; CHAPMAN RM, 1994, ONCOGENE, V9, P1289; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; DEVILDER MC, 1995, CANCER RES, V55, P1355; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; DOHNER H, 1997, LEUKEMIA S2, V11, P19; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GarciaMarco JA, 1996, BLOOD, V88, P1568; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; LEHRACH H., 1990, GENOME ANAL, P39; LENGAUER C, 1992, GENOMICS, V13, P826, DOI 10.1016/0888-7543(92)90160-T; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIU Y, 1992, GENE CHROMOSOME CANC, V4, P250, DOI 10.1002/gcc.2870040310; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LIU Y, 1993, P NATL ACAD SCI USA, V90, P8697, DOI 10.1073/pnas.90.18.8697; NEHLS M, 1994, ONCOGENE, V9, P2169; Panayiotidis P, 1997, BRIT J HAEMATOL, V97, P844, DOI 10.1046/j.1365-2141.1997.1322949.x; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; SCHUTTE M, 1995, CANCER RES, V55, P4570; STILGENBAUER S, 1993, BLOOD, V81, P2118; STILGENBAUER S, 1995, CANCER RES, V55, P3475	27	119	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 9	1998	16	14					1891	1897		10.1038/sj.onc.1201764	http://dx.doi.org/10.1038/sj.onc.1201764			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583687				2022-12-17	WOS:000072994600013
J	Gambarotta, G; Boccaccio, C; Giordano, S; Ando, M; Stella, MC; Comoglio, PM				Gambarotta, G; Boccaccio, C; Giordano, S; Ando, M; Stella, MC; Comoglio, PM			Ets up-regulates MET transcription	ONCOGENE			English	Article						proto-oncogenes; ETS; transcription factors; HGF receptor	HEPATOCYTE GROWTH-FACTOR; DNA-BINDING MOTIF; SCATTER FACTOR; RECEPTOR EXPRESSION; MET/HGF RECEPTOR; EPITHELIAL-CELLS; PROTEIN; OVEREXPRESSION; GENE; PROTOONCOGENE	MET, a potentially harmful oncogene controlling invasive growth, is overexpressed in a significant percentage of human cancers, Since amplification of the MET gene occurs only in a fraction of these cases, we investigated the transcriptional mechanisms responsible for up-regulation of the promoter activity, The transcription driven by the 3.1 kbp DNA fragment containing the minimal promoter was studied by 5' progressive deletion analysis, The patterns of MET promoter activity suggest the presence of weak negative and positive elements in the region between 300 and 840 bp upstream to the transcription start site, The region encompassing the first 300 bp strongly upregulates the promoter, This region contains four putative binding sites for members of the Ets transcription factor family, known to be involved in invasive growth, Transient co-expression of Ets1 resulted in a strong enhancement of the MET promoter activity, Increased expression of the Met protein was observed in cells stably transfected with ETS1, Double stranded oligonucleotides with Ets consensus sequence were used as a 'decoy' to inhibit binding to DNA native sites, They dramatically reduced the amount of Met protein in a human carcinoma cell line overexpressing the oncogene, Interestingly, Met activation induces transcription of ETS1 mRNA, showing that Ets proteins act both upstream and downstream to MET, These data indicate that members of the Ets family promote MET transcription and suggest their contribution to the invasive phenotype through overexpression of MET.	UNIV TURIN,SCH MED,INST CANC RES,IRCC,I-10060 CANDIOLO,TORINO,ITALY	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin			Boccaccio, Carla/AHE-7875-2022; Giordano, Silvia/J-9858-2018; Gambarotta, Giovanna/I-8473-2012	Boccaccio, Carla/0000-0003-2620-9083; Giordano, Silvia/0000-0003-1854-1086; Gambarotta, Giovanna/0000-0002-8380-5925; Comoglio, Paolo/0000-0002-7056-5328				BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; GALANG CK, 1994, ONCOGENE, V9, P2913; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Jeffers M, 1996, MOL CELL BIOL, V16, P115; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KRAMER B, 1995, J BIOL CHEM, V270, P65787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU C, 1992, ONCOGENE, V7, P181; Mao C, 1996, ONCOGENE, V12, P863; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAPTIS L, 1990, DNA CELL BIOL, V9, P615, DOI 10.1089/dna.1990.9.615; RAPTIS LH, 1995, BIOTECHNOLOGY, V4, P129; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SACCHI N, 1991, ONCOGENE, V6, P2149; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WASYLYK B, 1993, EUR J BIOCHEM, V211, P8; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; ZHEN Z, 1994, ONCOGENE, V9, P1691	64	119	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1911	1917						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934537				2022-12-17	WOS:A1996VR79500010
J	Pelicci, G; Dente, L; DeGiuseppe, A; VerducciGalletti, B; Giuli, S; Mele, S; Vetriani, C; Giorgio, M; Pandolfi, PP; Cesareni, G; Pelicci, PG				Pelicci, G; Dente, L; DeGiuseppe, A; VerducciGalletti, B; Giuli, S; Mele, S; Vetriani, C; Giorgio, M; Pandolfi, PP; Cesareni, G; Pelicci, PG			A family of Shc related proteins with conserved PTB, CH1 and SH2 regions	ONCOGENE			English	Article						Shc related proteins; modular organization; Shc family	PHOSPHOTYROSINE INTERACTION DOMAIN; GROWTH-FACTOR RECEPTOR; GRB2 ADAPTER PROTEINS; TYROSINE KINASES; SIGNAL-TRANSDUCTION; CONSTITUTIVE PHOSPHORYLATION; NUCLEOTIDE EXCHANGE; INSULIN-RECEPTOR; BETA-RECEPTOR; ERBB-2 KINASE	Shc proteins are targets of activated tyrosine kinases and have been implicated in the transmission of activation signals to Ras. Upon phosphorylation, Shc proteins form stable complexes with cellular tyrosine-phosphorylated proteins and with the Grb2 adaptor protein, Two Shc isoforms of 52 and 46 kDa have been characterized. They share a C-terminal SH2 domain, a proline- and glycine-rich region (collagen homologous region 1; CH1) and a N-terminal phospho-tyrosine binding domain (PTB), We report here the initial characterization of two Shc related human cDNAs: ShcB and ShcC. The ShcB and ShcC cDNAs code for proteins that are highly similar and share the same modular organization as Shc. PTB and SH2 domains of ShcB and ShcC have similar binding specificities in vitro and bind to activated EGFR in a phosphotyrosine-dependent manner. Based on these findings we propose to rename Shc as ShcA. Anti-ShcB and anti-ShcC antibodies recognize specific polypeptides of 52, 47 kDa (ShcB) and 54 kDa (ShcC) in mammalian cells. Since these two genes are predominantly expressed in specific brain tissues, these Shc family members may be involved in cell type-specific signaling, in the nervous system.	UNIV ROMA TOR VERGATA, DIPARTIMENTO BIOL, I-00173 ROME, ITALY; MEM SLOAN KETTERING CANC CTR, DEPT GENET, NEW YORK, NY 10021 USA; UNIV PERUGIA, IST MED INTERNA & SCI ONCOL, I-06122 PERUGIA, ITALY	University of Rome Tor Vergata; Memorial Sloan Kettering Cancer Center; University of Perugia	Pelicci, G (corresponding author), DEPT EXPTL ONCOL, IST EUROPEO ONCOL, VIA RIPAMONTI 435, I-20141 MILAN, ITALY.		Pelicci, Pier Giuseppe/AAL-6572-2020; Giorgio, Marco/I-9425-2012; Pelicci, Giuliana/AAA-8921-2022	Giorgio, Marco/0000-0002-5842-6042; Pelicci, Giuliana/0000-0003-0986-8255; DENTE, LUCIANA/0000-0002-9617-0922				BALDARI CT, 1995, ONCOGENE, V10, P1141; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CROWE AJ, 1994, ONCOGENE, V9, P537; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOTTI LV, 1995, IN PRESS MOL CELL BI; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	119	127	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					633	641						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760305				2022-12-17	WOS:A1996VB32800021
J	Fan, GS; Ma, XM; Kren, BT; Steer, CJ				Fan, GS; Ma, XM; Kren, BT; Steer, CJ			The retinoblastoma gene product inhibits TGF-beta 1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells	ONCOGENE			English	Article						retinoblastoma; hepatocyte; apoptosis; transforming growth factor-beta 1 (TGF-beta 1); cell cycle; E2F-1	TRANSFORMING GROWTH FACTOR-BETA-1; TGF-BETA; PROTEIN PHOSPHATASES; LIVER-REGENERATION; DEATH; EXPRESSION; INDUCTION; PHOSPHORYLATION; QUANTIFICATION; PROLIFERATION	Transforming growth factor-beta 1 (TGF-beta 1) can induce rapid growth arrest and apoptosis in hepatic cells. Its growth suppressive effects appear to be linked to decreased phosphorylation of the protein product of the retinoblastoma gene, pRb. To characterize the role of pRb in apoptosis, we examined endogenous retinoblastoma gene (Rb) expression following treatment with TGF-beta 1, okadaic acid, or antisense Rb S-oligonucleotides in cultured primary rat hepatocytes acid human hepatoma HuH-7 cells. We also investigated the effects on apoptosis of Rb overexpression following transfection with vectors containing wild-type Rb in HuH-7 cells. Our results indicated that transfection with Rb antisense S-oligonucleotides blocked the expression of pRb in cultured primary hepatocytes and induced apoptosis. Treatment of HuH-7 cells with TGF-beta 1 inhibited expression and phosphorylation of pRb, and also induced apoptosis. Furthermore, 93% of viable preapoptotic cells were arrested in the G(1) phase of the cell cycle. Incubation with the phosphatase inhibitor okadaic acid maintained pRb in its phosphorylated state, and resulted in significant apoptosis. Overexpression of wild-type Rb inhibited TGF-beta 1 induced apoptosis in HuH-7 cells. In contrast, overexpression of transcription factor E2F-1, a known target for the activity of pRb, caused significant apoptosis. However, coexpression of Rb suppressed E2F-1 induced apoptosis in HuH-7 cells. Our results suggest that inhibition of pRb expression is associated with hepatocyte apoptosis. Furthermore, E2F-1 appears to be a target in the pathway through which pRb modulates the apoptotic threshold in hepatic cells. Finally, the data suggest that these cells exit the cell cycle during the G(1) phase before progressing into apoptosis and pRb may be a negative regulator of this process.	UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT CELL BIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities								ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAUPT Y, 1995, ONCOGENE, V10, P1563; HELVERING LM, 1993, CANCER LETT, V71, P133, DOI 10.1016/0304-3835(93)90108-L; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; Massague J, 1992, CURR OPIN GENET DEV, V2, P28, DOI 10.1016/S0959-437X(05)80317-X; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; SCHULTEHERMANN R, 1993, ENVIRON HEALTH PERSP, V101, P87, DOI 10.2307/3431847; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; TSUKIDATE K, 1993, AM J PATHOL, V143, P918; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAN ZF, 1992, ONCOGENE, V7, P801; YATSUNAMI J, 1993, CANCER RES, V53, P239	56	119	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1909	1919						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649852				2022-12-17	WOS:A1996UK49800010
J	TROPPMAIR, J; BRUDER, JT; APP, H; HONG, C; LIPTAK, L; SZEBERENYI, J; COOPER, GM; RAPP, UR				TROPPMAIR, J; BRUDER, JT; APP, H; HONG, C; LIPTAK, L; SZEBERENYI, J; COOPER, GM; RAPP, UR			RAS CONTROLS COUPLING OF GROWTH-FACTOR RECEPTORS AND PROTEIN-KINASE-C IN THE MEMBRANE TO RAF-1 AND B-RAF PROTEIN SERINE KINASES IN THE CYTOSOL	ONCOGENE			English	Article							STIMULATING FACTOR-I; SIGNAL TRANSDUCTION; PC12 CELLS; PHOSPHORYLATION; ONCOGENES; DIFFERENTIATION; ACTIVATION; INSULIN; TYROSINE; GENE	A dominant negative mutant of Ras, M17 Ras, was used to study the role of Ras in receptor coupling of Raf-1 and B-Raf protein serine/threonine kinases (PSKs). We found that mutant Ras blocks serum- and 12-O-tetradecanoyl phorbol 13-acetate-induced activation of Raf-1 kinase in NIH3T3 cells and Raf-1 as well as B-Raf PSK stimulation by nerve growth factor (NGF) in PC12 pheochromocytoma cells. Mitogen stimulation of Raf kinase was measured by determination of Raf hyperphosphorylation and activity towards exogenous substrates and both of these events were inhibited in cells expressing M17 Ras. In contrast, tyrosine phosphorylation of a direct substrate of activated tyrosine kinase receptors, phospholipase C-gamma-1 (PLC-gamma-1), was unaffected. These data indicate that tyrosine phosphorylation of PLC-gamma-1 is not sufficient for growth induction in NIH3T3 cells and that Ras mediates signal transfer from activated membrane receptors to Raf kinases in the cytosol. As activated Raf induced differentiation in PC12 cells expressing M17 Ras we conclude that Raf kinase activation may be sufficient to account for this aspect of NGF function.	NCI,VIRAL CARCINOGENESIS LAB,VIRAL PATHOL SECT,FREDERICK,MD 21702; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Troppmair, Jakob/0000-0002-0611-3837				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BACCARINI M, 1991, EMBO J, V11, P3649; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LEE RM, 1991, J BIOL CHEM, V266, P10351; LEE RM, 1992, J BIOL CHEM, V267, P1088; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1989, CELL, V58, P648; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	119	119	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1867	1873						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1386920				2022-12-17	WOS:A1992JJ37600024
J	NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; ONNO, M; HUEBNER, K; CANNIZZARO, LA; BOGHOSIANSELL, L; CROCE, CM; HILL, M				NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; ONNO, M; HUEBNER, K; CANNIZZARO, LA; BOGHOSIANSELL, L; CROCE, CM; HILL, M			A NOVEL TRANSCRIPTIONAL UNIT OF THE TRE ONCOGENE WIDELY EXPRESSED IN HUMAN CANCER-CELLS	ONCOGENE			English	Article							NUCLEIC-ACID; PLASMID DNA; SEQUENCES; PROTEIN; DOMAINS; AGAROSE	Tre is a recombinant gene isolated from NIH3T3 cells transfected with human Ewing's sarcoma DNA. It is composed of three major genetic elements derived, 5' to 3', from human chromosomes 5, 18 and 17. We report here on transcripts from the 3' domain of tre. The transcripts were cloned from a cDNA library of cytoplasmic poly(A)+ RNA from tre-transfected NIH3T3 tumor cells. The complete cDNA sequence, 8201 nucleotides, possessed an unusually long non-coding region and a translatable region with two open reading frames. In one cDNA clone, the presence of two insertions suggested the possibility of alternative splicing. The sequence mapped to the centromere-proximal region of 17q. Transfection-tumorigenicity assays with the open reading frames subcloned into expression vectors were positive for the reading frame adjacent to the 5' noncoding region and negative for the second, downstream, reading frame and the possible alternatively spliced versions of both reading frames. Analysis of the 786 amino acid sequence deduced from the 5' reading frame predicted a highly hydrophilic protein with two charge clusters suggesting nucleic acid-binding properties. When used as probe, the cloned sequence detected RNA transcripts in a wide variety of human cancer cells regardless of their lineage of origin from different tissues, but not in human cells from normal tissue.	INST CANC & IMMUNOGENET,CELLULAR & MOLEC BIOL LAB,14 AVE PAUL VAILLANT COUTURIER,F-94804 VILLEJUIF,FRANCE; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; INST CANC & IMMUNOGENET,CNRS,UNITE SDI 6204,F-94804 VILLEJUIF,FRANCE	Jefferson University; Centre National de la Recherche Scientifique (CNRS)			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Xie, Xinmin Simon/0000-0002-4049-6499	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P469; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILLOVA J, 1990, ANTICANCER RES, V10, P181; HILLOVA J, 1986, J NATL CANCER I, V77, P721, DOI 10.1093/jnci/77.3.721; HUEBNER K, 1991, AM J HUM GENET, V48, P726; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NAKAMURA T, 1990, DNA CELL BIOL, V9, P697, DOI 10.1089/dna.1990.9.697; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J., 1989, MOL CLONING LAB MANU; SANDBERG AA, 1988, CANCER RES, V48, P1049; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WICKS RJ, 1986, INT J BIOCHEM, V18, P277, DOI 10.1016/0020-711X(86)90118-7; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	25	119	129	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					733	741						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565468				2022-12-17	WOS:A1992HQ68200016
J	GREEN, AR; SALVARIS, E; BEGLEY, CG				GREEN, AR; SALVARIS, E; BEGLEY, CG			ERYTHROID EXPRESSION OF THE HELIX-LOOP-HELIX GENE, SCL	ONCOGENE			English	Note							ERYTHROLEUKEMIA CELL-LINE; HUMAN-LEUKEMIA; MESSENGER-RNA; DNA-BINDING; ERYTHROPOIETIN; TRANSLOCATION; PROTEINS; DIFFERENTIATION; GLYCOPROTEINS; ONCOGENES	The SCL gene encodes a member of the 'helix-loop-helix' family of DNA binding regulatory proteins. It is transcriptionally activated in some cases of T-cell acute lymphoblastic leukaemia by a reciprocal translocation involving the T cell receptor delta-locus. In order to gain insight into the normal functions of SCL we have studied SCL mRNA levels in human and murine haemopoietic cell lines and normal tissues. We have observed high levels of SCL mRNA in all human and murine erythroid cell lines examined. Foetal and adult normal haemopoietic cell populations rich in erythroid precursors also expressed high levels of SCL mRNA. Our results suggest a previously unexpected role for SCL in the regulation of erythropoiesis.	ROYAL MELBOURNE HOSP,DEPT HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital	GREEN, AR (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA.			Green, Anthony/0000-0002-9795-0218				ANDRE C, 1989, ONCOGENE, V4, P1047; APLAN PD, IN PRESS MOL CELL BI; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, IN PRESS P NATL ACAD; BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CONKIE D, 1975, EXP CELL RES, V93, P315, DOI 10.1016/0014-4827(75)90456-5; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P1863, DOI 10.1073/pnas.72.5.1863; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GEWIRTZ AM, 1982, BLOOD, V60, P785; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HARA K, 1988, EXP HEMATOL, V16, P256; HARRISON PR, 1978, EXP CELL RES, V115, P395, DOI 10.1016/0014-4827(78)90293-8; HASTHORPE S, 1981, CANCER RES, V41, P3985; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; KELSO A, 1984, J IMMUNOL, V132, P2932; KIRSCH IR, 1985, CANCER GENET CYTOGEN, V18, P159, DOI 10.1016/0165-4608(85)90066-4; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MINOWADA J, 1981, J CANCER RES CLIN, V101, P91, DOI 10.1007/BF00405069; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; PAPAYANNOPOULOU T, 1987, BLOOD, V70, P1764; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	34	119	120	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					475	479						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011404				2022-12-17	WOS:A1991FT34400020
J	EGAN, C; BAYLEY, ST; BRANTON, PE				EGAN, C; BAYLEY, ST; BRANTON, PE			BINDING OF THE RB1 PROTEIN TO E1A PRODUCTS IS REQUIRED FOR ADENOVIRUS TRANSFORMATION	ONCOGENE			English	Article									MCMASTER UNIV, MOLEC VIROL & IMMUNOL PROGRAM, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, DEPT PATHOL, HAMILTON L8N 3Z5, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DUMONT DJ, 1988, IN PRESS J VIROL; EGAN C, 1987, VIROLOGY, V160, P292, DOI 10.1016/0042-6822(87)90077-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; FLINT SJ, 1986, ADV VIRUS RES, V31, P169, DOI 10.1016/S0065-3527(08)60264-X; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HANSEN MF, 1988, TRENDS GENET, V4, P125, DOI 10.1016/0168-9525(88)90134-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; KRIPPL B, 1985, P NATL ACAD SCI USA, V82, P7480, DOI 10.1073/pnas.82.22.7480; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MCFALL RC, 1977, CANCER RES, V37, P1003; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NEVINS JR, 1987, MICROBIOL REV, V51, P419, DOI 10.1128/MMBR.51.4.419-430.1987; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TREMBLAY ML, 1989, IN PRESS VIROLOGY; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE SP, 1983, J VIROL, V46, P1003, DOI 10.1128/JVI.46.3.1003-1013.1983; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	37	119	122	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1989	4	3					383	388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2523032				2022-12-17	WOS:A1989U567600016
J	ROVERA, G; VALTIERI, M; MAVILIO, F; REDDY, EP				ROVERA, G; VALTIERI, M; MAVILIO, F; REDDY, EP			EFFECT OF ABELSON MURINE LEUKEMIA-VIRUS ON GRANULOCYTIC DIFFERENTIATION AND INTERLEUKIN-3 DEPENDENCE OF A MURINE PROGENITOR-CELL LINE	ONCOGENE			English	Article											ROVERA, G (corresponding author), WISTAR INST ANAT & BIOL,36TH ST SPRUCE,PHILADELPHIA,PA 19104, USA.		Reddy, E. Premkumar/F-6233-2011; valtieri, mauro/H-1044-2016	valtieri, mauro/0000-0002-9139-6754; Mavilio, Fulvio/0000-0003-0459-4320	NATIONAL CANCER INSTITUTE [P30CA010815, P01CA025875] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10815, CA 25875] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CAWLEY JC, 1983, ULTRASTRUCTURE HAEMI; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DAVIDSON EH, 1984, MOL BIOL DEV; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hayhoe FGJ, 1988, HAEMATOLOGICAL CYTOC; IHLE JN, 1981, J IMMUNOL, V126, P2184; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1985, CANCER CELLS GROWTH, V3, P211; IHLE JN, 1986, IN PRESS ADV IMMUNOL; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JOHNSON KR, 1987, UNPUB NUC ACID RES; KELLER JR, 1985, J IMMUNOL, V135, P1864; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEE JC, 1982, J IMMUNOL, V128, P2393; LERACH H, 1977, BIOCHEMISTRY-US, V16, P4743; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; METCALF D, 1985, BLOOD, V65, P357; MOLONEY WC, 1960, J HISTOCHEM CYTOCHEM, V8, P200, DOI 10.1177/8.3.200; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NOWELL PC, 1960, SCIENCE, V132, P1497; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; POTTER M, 1978, NATL CANCER I MONOGR, V48, P311; PREMKUMAR E, 1975, CELL, V6, P149, DOI 10.1016/0092-8674(75)90005-7; PRYSTOWSKY MB, 1982, J IMMUNOL, V129, P2337; RADO TA, 1984, BLOOD, V64, P1103; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SACHS L, 1980, P NATL ACAD SCI-BIOL, V77, P6152, DOI 10.1073/pnas.77.10.6152; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; VALTIERI M, 1987, UNPUB J IMMUNOL; WALKER F, 1985, CELL, V43, P269, DOI 10.1016/0092-8674(85)90032-7; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	49	119	120	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1987	1	1					29	35						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	2449644				2022-12-17	WOS:A1987J635100004
J	Su, R; Lin, HS; Zhang, XH; Yin, XL; Ning, HM; Liu, B; Zhai, PF; Gong, JN; Shen, C; Song, L; Chen, J; Wang, F; Zhao, HL; Ma, YN; Yu, J; Zhang, JW				Su, R.; Lin, H-S; Zhang, X-H; Yin, X-L; Ning, H-M; Liu, B.; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W			MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets	ONCOGENE			English	Article							PROTEIN-KINASE-C; RETINOIC ACID; CELL-DIFFERENTIATION; MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PKC-DELTA; CARDIAC FIBROBLASTS; DOWN-REGULATION; BREAST-CANCER	MicroRNAs have been shown to play an important role in normal hematopoisis and leukemogenesis. Here, we report function and mechanisms of miR-181 family in myeloid differentiation and acute myeloid leukemia (AML). The aberrant overexpression of all the miR-181 family members (miR-181a/b/c/d) was detected in French-American-British M1, M2 and M3 subtypes of adult AML patients. By conducting gain-and loss-of-function experiments, we demonstrated that miR-181a inhibits granulocytic and macrophage-like differentiation of HL-60 cells and CD34+ hematopoietic stem/progenitor cells (HSPCs) by directly targeting and downregulating the expression of PRKCD (which then affected the PRKCD-P38-C/EBPa pathway), CTDSPL (which then affected the phosphorylation of retinoblastoma protein) and CAMKK1. The three genes were also demonstrated to be the targets of miR-181b, miR-181c and miR-181d, respectively. Significantly decreases in the expression levels of the target proteins were detected in AML patients. Inhibition of the expression of miR-181 family members owing to Lenti-miRZip-181a infection in bone marrow blasts of AML patients increased target protein expression levels and partially reversed myeloid differentiation blockage. In the mice implanted with AML CD34+ HSPCs, expression inhibition of the miR-181 family by Lenti-miRZip-181a injection improved myeloid differentiation, inhibited engraftment and infiltration of the leukemic CD34+ cells into the bone marrow and spleen, and released leukemic symptoms. In conclusion, our findings revealed new mechanism of miR-181 family in normal hematopoiesis and AML development, and suggested that expression inhibition of the miR-181 family could provide a new strategy for AML therapy.	[Su, R.; Lin, H-S; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W] Chinese Acad Med Sci, Key State Lab Med Mol Biol, Dept Biochem & Mol Biol, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Su, R.; Lin, H-S; Zhai, P-F; Gong, J-N; Shen, C.; Song, L.; Chen, J.; Wang, F.; Zhao, H-L; Ma, Y-N; Yu, J.; Zhang, J-W] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhang, X-H; Yin, X-L] 303 Hosp, Dept Hematol, Nanning, Guangxi, Peoples R China; [Ning, H-M] Acad Mil Med Sci, Inst Mil Hemopoiet Stem Cell, Dept Stem Cell Transplantat Ctr, Hosp, Beijing, Peoples R China; [Ning, H-M] Acad Mil Med Sci, Affiliated Hosp, Lvy Translat Med Ctr 307, Lab Oncol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Academy of Military Medical Sciences - China; Academy of Military Medical Sciences - China	Zhang, JW (corresponding author), Chinese Acad Med Sci, Key State Lab Med Mol Biol, Dept Biochem & Mol Biol, Inst Basic Med Sci, Beijing 100730, Peoples R China.	junwu_zhang@pumc.edu.cn	Su, Rui/Y-8157-2018	Shen, Chao/0000-0002-9406-7075; Su, Rui/0000-0002-4807-6229	National Natural Science Foundation of China [31171311, 30970616, 81070435]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Natural Science Foundation of China grants 31171311 and 30970616 (to J-WZ) and 81070435 (to H-MN).	BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757; Careccia S, 2009, ONCOGENE, V28, P4034, DOI 10.1038/onc.2009.255; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Chen C, 2012, BRIT J PHARMACOL, V166, P676, DOI 10.1111/j.1476-5381.2011.01785.x; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Cuesta R, 2009, MOL CELL BIOL, V29, P2841, DOI 10.1128/MCB.01971-08; Debernardi S, 2007, LEUKEMIA, V21, P912, DOI 10.1038/sj.leu.2404605; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; EGELAND T, 1991, BLOOD, V78, P3192; Feng W, 2010, BRIT J PHARMACOL, V159, P1598, DOI 10.1111/j.1476-5381.2009.00558.x; Fragoso R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002855; Gan XQ, 2012, NAT CELL BIOL, V14, P686, DOI 10.1038/ncb2507; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749; Georgantas RW, 2007, P NATL ACAD SCI USA, V104, P2750, DOI 10.1073/pnas.0610983104; Guest CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001606; Hampson P, 2005, BLOOD, V106, P1362, DOI 10.1182/blood-2004-10-4117; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Ke G, 2013, ONCOGENE, V32, P3019, DOI 10.1038/onc.2012.323; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Lawson ND, 1999, EXP HEMATOL, V27, P1682, DOI 10.1016/S0301-472X(99)00108-3; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Li ZJ, 2012, BLOOD, V119, P2314, DOI 10.1182/blood-2011-10-386235; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Naguibneva I, 2006, NAT CELL BIOL, V8, P278, DOI 10.1038/ncb1373; Nitti M, 2010, CELL SIGNAL, V22, P828, DOI 10.1016/j.cellsig.2010.01.007; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ouyang YB, 2012, MITOCHONDRION, V12, P213, DOI 10.1016/j.mito.2011.09.001; Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105; Pons A, 2009, LEUKEMIA LYMPHOMA, V50, P1854, DOI 10.3109/10428190903147645; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Schwind S, 2010, J CLIN ONCOL, V28, P5257, DOI 10.1200/JCO.2010.29.2953; Senchenko VN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-75; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; Studzinski GP, 2005, J STEROID BIOCHEM, V97, P47, DOI 10.1016/j.jsbmb.2005.06.010; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Verploegen S, 2005, BLOOD, V106, P1076, DOI 10.1182/blood-2004-09-3755; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang XS, 2012, BLOOD, V119, P4992, DOI 10.1182/blood-2011-10-385716; Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870; Yendamuri S, 2009, LEUKEMIA, V23, P1257, DOI 10.1038/leu.2008.382; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630; Zheng YS, 2012, ONCOGENE, V31, P80, DOI 10.1038/onc.2011.208	50	118	120	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3226	3239		10.1038/onc.2014.274	http://dx.doi.org/10.1038/onc.2014.274			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25174404				2022-12-17	WOS:000356592300002
J	Su, H; Xu, T; Ganapathy, S; Shadfan, M; Long, M; Huang, THM; Thompson, I; Yuan, ZM				Su, H.; Xu, T.; Ganapathy, S.; Shadfan, M.; Long, M.; Huang, T. H-M; Thompson, I.; Yuan, Z-M			Elevated snoRNA biogenesis is essential in breast cancer	ONCOGENE			English	Article						breast cancer; fibrillarin; nucleolar stress; p53; snoRNA	RIBOSOMAL-PROTEIN L23; RNA-POLYMERASE-I; P53 ISOFORMS; TRANSLATION; GENES; INHIBITION; EXPRESSION; NUCLEOLUS; INDUCTION; APOPTOSIS	Hyperactive ribosomal biogenesis is widely observed in cancer, which has been partly attributed to the increased rDNA transcription by Pol I in cancer. However, whether small nucleolar RNAs (snoRNAs), a class of non-coding RNAs crucial in ribosomal RNA (rRNA) maturation and functionality, are involved in cancer remains elusive. We report that snoRNAs and fibrillarin (FBL, an enzymatic small nucleolar ribonucleoprotein, snoRNP) are frequently overexpressed in both murine and human breast cancer as well as in prostate cancers, and significantly, that this overexpression is essential for tumorigenicity in vitro and in vivo. We demonstrate that when the elevated snoRNA pathway is suppressed, the tumor suppressor p53 can act as a sentinel of snoRNP perturbation, the activation of which mediates the growth inhibitory effect. On the other hand, high level of FBL interferes with the activation of p53 by stress. We further show that p53 activation by FBL knockdown is not only regulated by the ribosomal protein-MDM2-mediated protein stabilization pathway, but also by enhanced PTB-dependent, cap-independent translation. Together, our data uncover an essential role of deregulated snoRNA biogenesis in tumors and a new mechanism of nucleolar modulation of p53.	[Su, H.; Xu, T.; Ganapathy, S.; Shadfan, M.; Long, M.; Yuan, Z-M] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, San Antonio, TX 78229 USA; [Ganapathy, S.; Long, M.; Yuan, Z-M] Harvard Univ, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Thompson, I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Harvard University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Yuan, ZM (corresponding author), Harvard Univ, Dept Genet & Complex Dis, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu			 [NIH/NCI. 2 R01 CA85679-10];  [R01 CA125144]; NATIONAL CANCER INSTITUTE [R01CA125144, R01CA085679] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by NIH/NCI. 2 R01 CA85679-10; R01 CA125144 for Zhi-Min Yuan.	Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DERENZINI M, 1991, INT REV EXP PATHOL, V32, P149; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kondrashov AV, 2005, J MOL BIOL, V353, P88, DOI 10.1016/j.jmb.2005.07.049; Krastev DB, 2011, NAT CELL BIOL, V13, P809, DOI 10.1038/ncb2264; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mahata B, 2012, ONCOGENE, V31, P3060, DOI 10.1038/onc.2011.482; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Wang WZ, 2008, FEBS LETT, V582, P2689, DOI 10.1016/j.febslet.2008.06.048; Watkins NJ, 2004, MOL CELL, V16, P789, DOI 10.1016/j.molcel.2004.11.012; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	32	118	125	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1348	1358		10.1038/onc.2013.89	http://dx.doi.org/10.1038/onc.2013.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542174				2022-12-17	WOS:000332943500002
J	Rovillain, E; Mansfield, L; Caetano, C; Alvarez-Fernandez, M; Caballero, OL; Medema, RH; Hummerich, H; Jat, PS				Rovillain, E.; Mansfield, L.; Caetano, C.; Alvarez-Fernandez, M.; Caballero, O. L.; Medema, R. H.; Hummerich, H.; Jat, P. S.			Activation of nuclear factor-kappa B signalling promotes cellular senescence	ONCOGENE			English	Article						cellular senescence; conditional immortalisation; senescence bypass; differential expression, NF-kappa B signalling	HUMAN MAMMARY FIBROBLASTS; TELOMERASE ACTIVITY; CANCER; FOXM1; CELLS; NETWORK; PROLIFERATION; PROGRESSION; PATHWAYS; GENES	Cellular senescence is a programme of irreversible cell cycle arrest that normal cells undergo in response to progressive shortening of telomeres, changes in telomeric structure, oncogene activation or oxidative stress. The underlying signalling pathways, of major clinicopathological relevance, are unknown. We combined genome-wide expression profiling with genetic complementation to identify genes that are differentially expressed when conditionally immortalised human fibroblasts undergo senescence upon activation of the p16-pRB and p53-p21 tumour suppressor pathways. This identified 816 up and 961 downregulated genes whose expression was reversed when senescence was bypassed. Overlay of this data set with the meta-signatures of genes upregulated in cancer showed that nearly 50% of them were downregulated upon senescence showing that even though overcoming senescence may only be one of the events required for malignant transformation, nearly half of the genes upregulated in cancer are related to it. Moreover 65 of the up and 26 of the downregulated genes are known downstream targets of nuclear factor (NF)-kappa B suggesting that senescence was associated with activation of the NF-kappa B pathway. Direct perturbation of this pathway bypasses growth arrest indicating that activation of NF-kappa B signalling has a causal role in promoting senescence. Oncogene (2011) 30, 2356-2366; doi: 10.1038/onc.2010.611; published online 17 January 2011	[Rovillain, E.; Mansfield, L.; Caetano, C.; Jat, P. S.] UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England; [Alvarez-Fernandez, M.; Medema, R. H.] Univ Med Ctr, Dept Med Oncol, Utrecht, Netherlands; [Caballero, O. L.] Ludwig Inst Canc Res Ltd, New York, NY USA; [Hummerich, H.] UCL Inst Neurol, MRC Prion Unit, London WC1N 3BG, England	University of London; University College London; Utrecht University; Utrecht University Medical Center; Ludwig Institute for Cancer Research; University of London; University College London	Jat, PS (corresponding author), UCL Inst Neurol, Dept Neurodegenerat Dis, London WC1N 3BG, England.	p.jat@prion.ucl.ac.uk	Medema, Rene H/E-2981-2013; Fernández, Mónica Alvarez/C-5972-2009	Fernández, Mónica Alvarez/0000-0002-6454-5128; Medema, Rene/0000-0002-6754-0381	Wellcome Trust [078305]; Brain Research Trust; Medical Research Council [MC_U123160651] Funding Source: researchfish; MRC [MC_U123160651] Funding Source: UKRI	Wellcome Trust(Wellcome TrustEuropean Commission); Brain Research Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are indebted to AM Neville, A Baldwin, P Meier, M Resnicoff and N Perkins for advice, helpful discussions and critical reading of the manuscript. We thank J Downward, X Lu, P Meier, G Towers and C King (the UCL shRNA library core facility) for providing reagents. We are grateful to E Ortenberg and J White of Biotrove Inc. for the qPCR analysis, S Shah and A Grigoriadis for bioinformatic analysis and R Young for graphics. PSJ gratefully acknowledges financial support from the Wellcome Trust (078305) and an equipment grant from the Brain Research Trust.	Adams PD, 2009, MOL CELL, V36, P2, DOI 10.1016/j.molcel.2009.09.021; Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; AGGARWAL BB, 1995, EXP CELL RES, V218, P381, DOI 10.1006/excr.1995.1169; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Batsi C, 2009, MECH AGEING DEV, V130, P409, DOI 10.1016/j.mad.2009.04.002; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Besnier C, 2003, J VIROL, V77, P13403, DOI 10.1128/JVI.77.24.13403-13406.2003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; DIMRI GP, 1994, EXP CELL RES, V212, P132, DOI 10.1006/excr.1994.1127; Dodeller F, 2008, J BIOL CHEM, V283, P21487, DOI 10.1074/jbc.M801908200; Gonos ES, 1996, MOL CELL BIOL, V16, P5127; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardy K, 2005, MOL BIOL CELL, V16, P943, DOI 10.1091/mbc.E04-05-0392; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kriete Andres, 2008, Immun Ageing, V5, P5, DOI 10.1186/1742-4933-5-5; Kriete A, 2009, EXP GERONTOL, V44, P250, DOI 10.1016/j.exger.2008.12.005; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Laoukili J, 2008, MOL CELL BIOL, V28, P3076, DOI 10.1128/MCB.01710-07; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MANSFIELD LV, 2006, THESIS U LONDON LOND; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Penzo M, 2009, J CELL PHYSIOL, V218, P215, DOI 10.1002/jcp.21596; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	54	118	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	20					2356	2366		10.1038/onc.2010.611	http://dx.doi.org/10.1038/onc.2010.611			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	766NF	21242976	Green Accepted			2022-12-17	WOS:000290789200007
J	Cooke, SL; Ng, CKY; Melnyk, N; Garcia, MJ; Hardcastle, T; Temple, J; Langdon, S; Huntsman, D; Brenton, JD				Cooke, S. L.; Ng, C. K. Y.; Melnyk, N.; Garcia, M. J.; Hardcastle, T.; Temple, J.; Langdon, S.; Huntsman, D.; Brenton, J. D.			Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma	ONCOGENE			English	Article						ovarian cancer; heterogeneity; evolution; chemotherapy	ACUTE LYMPHOBLASTIC-LEUKEMIA; CANCER CELL-LINES; BREAST-CANCER; CHROMOSOMAL INSTABILITY; TUMOR HETEROGENEITY; DISEASE PROGRESSION; COPY NUMBER; MUTATIONS; EXPRESSION; RESISTANCE	Resistance to chemotherapy in ovarian cancer is poorly understood. Evolutionary models of cancer predict that, following treatment, resistance emerges either because of outgrowth of an intrinsically resistant sub-clone or evolves in residual disease under the selective pressure of treatment. To investigate genetic evolution in high-grade serous (HGS) ovarian cancers, we first analysed cell line series derived from three cases of HGS carcinoma before and after platinum resistance had developed (PEO1, PEO4 and PEO6; PEA1 and PEA2; and PEO14 and PEO23). Analysis with 24-colour fluorescence in situ hybridisation and single nucleotide polymorphism (SNP) array comparative genomic hybridisation (CGH) showed mutually exclusive endoreduplication and loss of heterozygosity events in clones present at different time points in the same individual. This implies that platinum-sensitive and -resistant disease was not linearly related, but shared a common ancestor at an early stage of tumour development. Array CGH analysis of six paired pre- and post-neoadjuvant treatment HGS samples from the CTCR-OV01 clinical study did not show extensive copy number differences, suggesting that one clone was strongly dominant at presentation. These data show that cisplatin resistance in HGS carcinoma develops from pre-existing minor clones but that enrichment for these clones is not apparent during short-term chemotherapy treatment. Oncogene (2010) 29, 4905-4913; doi: 10.1038/onc.2010.245; published online 28 June 2010	[Cooke, S. L.; Ng, C. K. Y.; Garcia, M. J.; Hardcastle, T.; Temple, J.; Brenton, J. D.] Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Cambridge, England; [Melnyk, N.; Huntsman, D.] British Columbia Canc Agcy, Ctr Translat & Appl Genom, Vancouver, BC V5Z 4E6, Canada; [Langdon, S.] Univ Edinburgh, Div Pathol, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland	Cancer Research UK; CRUK Cambridge Institute; British Columbia Cancer Agency; University of Edinburgh	Brenton, JD (corresponding author), Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge, England.	james.brenton@cancer.org.uk	Ng, Charlotte K Y/AAA-1670-2020; Huntsman, David/ABE-6082-2020; García, María J/G-1361-2016; Ng, Charlotte K Y/AAY-3178-2021; Brenton, James D/B-3174-2008	García, María J/0000-0002-2236-9912; Ng, Charlotte K Y/0000-0002-6100-0026; Brenton, James D/0000-0002-5738-6683; Hardcastle, Thomas/0000-0002-9328-5011	Cancer Research UK; University of Cambridge; Hutchison Whampoa Ltd; Cambridge Experimental Cancer Medicine Centre; NIHR Biomedical Research Centre; Cancer Research UK [19556] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); University of Cambridge(University of Cambridge); Hutchison Whampoa Ltd; Cambridge Experimental Cancer Medicine Centre; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK)	We thank Paul Edwards for helpful discussion of the paper. We thank our patients and members of the Gynaecological Oncology Multidisciplinary Team at Cambridge University Hospitals NHS Foundation Trust for their participation in the CTCR-OV01 clinical study. This work was funded by Cancer Research UK. We acknowledge the support of the University of Cambridge, Hutchison Whampoa Ltd, the Cambridge Experimental Cancer Medicine Centre and the NIHR Biomedical Research Centre.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696; Alsop AE, 2006, CANCER GENET CYTOGEN, V164, P97, DOI 10.1016/j.cancergencyto.2005.09.011; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bayani J, 2002, CANCER RES, V62, P3466; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Curto M, 2008, BRIT J CANCER, V98, P256, DOI 10.1038/sj.bjc.6604002; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzog TJ, 2006, NAT CLIN PRACT ONCOL, V3, P604, DOI 10.1038/ncponc0637; Herzog TJ, 2004, CLIN CANCER RES, V10, P7439, DOI 10.1158/1078-0432.CCR-04-0683; Hofmann WK, 2003, BLOOD, V102, P659, DOI 10.1182/blood-2002-06-1756; KAMB A, 1994, SCIENCE, V264, P440; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khalique L, 2007, J PATHOL, V211, P286, DOI 10.1002/path.2112; Koebel Martin, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S146239940800077X; LANGDON SP, 1988, CANCER RES, V48, P6166; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; MARKMAN M, 1991, J CLIN ONCOL, V9, P389, DOI 10.1200/JCO.1991.9.3.389; McAlpine JN, 2008, GYNECOL ONCOL, V110, P360, DOI 10.1016/j.ygyno.2008.05.019; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ouellet V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-152; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; Ruijter ET, 1996, J PATHOL, V180, P295; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Schulmann K, 2005, GASTROENTEROLOGY, V129, P74, DOI 10.1053/j.gastro.2005.04.011; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shibata K, 1998, BIOCHEM BIOPH RES CO, V246, P205, DOI 10.1006/bbrc.1998.8581; Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Torres L, 2007, BREAST CANCER RES TR, V102, P143, DOI 10.1007/s10549-006-9317-6; Toyoda M, 2003, DEV CELL, V5, P85, DOI 10.1016/S1534-5807(03)00189-8; Trofatter J A, 1993, Cell, V75, P826; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Zhu YM, 1999, BRIT J CANCER, V79, P1151, DOI 10.1038/sj.bjc.6690183	41	118	122	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4905	4913		10.1038/onc.2010.245	http://dx.doi.org/10.1038/onc.2010.245			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20581869	Green Accepted			2022-12-17	WOS:000281578700005
J	Borgdorff, V; Lleonart, ME; Bishop, CL; Fessart, D; Bergin, AH; Overhoff, MG; Beach, DH				Borgdorff, V.; Lleonart, M. E.; Bishop, C. L.; Fessart, D.; Bergin, A. H.; Overhoff, M. G.; Beach, D. H.			Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1)	ONCOGENE			English	Article						oncogene-induced senescence; Ras; siRNA; miRNA; p21(Waf1/Cip1)	ONCOGENE-INDUCED SENESCENCE; ANCHORAGE-INDEPENDENT GROWTH; MAMMARY EPITHELIAL-CELLS; HUMAN-BREAST; CANCER; PROLIFERATION; FIBROBLASTS; P16(INK4A); P53	Overexpression of Ras(G12V) in primary cells induces a permanent growth arrest called oncogene-induced senescence (OIS) that serves as a fail-safe mechanism against malignant transformation. We have performed a genome-wide small interfering RNA (siRNA) screen and a microRNA (miRNA) screen to identify mediators of OIS and show that siRNA-mediated knockdown of p21(Waf1/Cip1) rescues from Ras(G12V)-induced senescence in human mammary epithelial cells (HMECs). Moreover, we isolated a total of 28 miRNAs that prevented Ras(G12V)-induced growth arrest, among which all of the miR-106b family members were present. In addition, we obtained a number of hits, miR-130b, miR-302a, miR-302b, miR302c, miR-302d, miR-512-3p and miR-515-3p with seed sequences very similar to miR-106b family members. We show that overexpression of all these miRNAs rescues HMECs from Ras(G12V)-induced senescence by prevention of Ras(G12V)-induced upregulation of p21(Waf1/Cip1). Our results establish an important role for the cell cycle inhibitor p21(Waf1/Cip1) in growth control of HMECs and extend the repertoire of miRNAs that modulate the activity of this tumour suppressor. Oncogene (2010) 29, 2262-2271; doi: 10.1038/onc.2009.497; published online 25 January 2010	[Borgdorff, V.; Bishop, C. L.; Fessart, D.; Bergin, A. H.; Overhoff, M. G.; Beach, D. H.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, London E1 2AT, England; [Lleonart, M. E.] Hosp Gen Valle Hebron, Inst Recerca, Dept Pathol, Barcelona, Spain	University of London; Queen Mary University London; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Beach, DH (corresponding author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, London E1 2AT, England.	dhbeach@btinternet.com	LLeonart, Matilde E./Q-2662-2019; FESSART, Delphine/J-2784-2014	LLeonart, Matilde E./0000-0002-6196-7405; FESSART, Delphine/0000-0001-7566-5670; Bishop, Cleo/0000-0002-6189-8163	Wellcome Programme [DERG1C3R]; Marato TV3 Grant [052130-TV3]; AGAUR [2007 BE-1 00296]; MRC [DERB1A4R]; CRUK [DERG1F2R]; MRC [G0500357] Funding Source: UKRI; Medical Research Council [G0500357] Funding Source: researchfish	Wellcome Programme; Marato TV3 Grant; AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by Wellcome Programme Grant DERG1C3R (Viola Borgdorff, Marita G Overhoff); Marato TV3 Grant 052130-TV3 (Matilde E Lleonart); AGAUR fellowship 2007 BE-1 00296 (Matilde E Lleonart); MRC Project Grant DERB1A4R (Cleo L Bishop, Ann-Marie H Bergin); CRUK Project Grant DERG1F2R (Delphine Fessart). MELL is a FIS (Fondo de Investigacion Sanitario) investigator (CP03/00101).	Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Carbone CJ, 2007, CANCER RES, V67, P4130, DOI 10.1158/0008-5472.CAN-07-0499; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gohring UJ, 2001, J CLIN PATHOL, V54, P866, DOI 10.1136/jcp.54.11.866; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002; Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666	24	118	121	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2262	2271		10.1038/onc.2009.497	http://dx.doi.org/10.1038/onc.2009.497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101223				2022-12-17	WOS:000276685200011
J	Rickman, DS; Millon, R; De Reynies, A; Thomas, E; Wasylyk, C; Muller, D; Abecassis, J; Wasylyk, B				Rickman, D. S.; Millon, R.; De Reynies, A.; Thomas, E.; Wasylyk, C.; Muller, D.; Abecassis, J.; Wasylyk, B.			Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays	ONCOGENE			English	Article						HNSCC; distant metastasis; prognosis; intrinsic groups; differentiation	LYMPH-NODE METASTASIS; HUMAN-PAPILLOMAVIRUS; BREAST-CANCER; EXPRESSION; CLASSIFICATION; IDENTIFICATION; GENES; SIGNATURE; RECEPTOR; ALCOHOL	Propensity for subsequent distant metastasis in head and neck squamous-cell carcinoma (HNSCC) was analysed using 186 primary tumours from patients initially treated by surgery that developed ( M) or did not develop (NM) metastases as the first recurrent event. Transcriptome (Affymetrix HGU133_ Plus2, QRT-PCR) and array-comparative genomic hybridization data were collected. Non-supervised hierarchical clustering based on Affymetrix data distinguished tumours differing in pathological differentiation, and identified associated functional changes. Propensity for metastasis was not associated with these subgroups. Using QRT-PCR data we identified a four-gene model (PSMD10, HSD17B12, FLOT2 and KRT17) that predicts M/NM status with 77% success in a separate 79-sample validation group of HNSCC samples. This prediction is independent of clinical criteria ( age, lymph node status, stage, differentiation and localization). The most significantlyalte red transcripts in M versus NM were significantly associated to metastasis-related functions, including adhesion, mobility and cell survival. Several genomic modi. cations were significantly associated with M/NM status ( most notably gains at 4q11-22 and Xq12-28; losses at 11q14-24 and 17q11 losses) and partly linked to transcription modi. cations. This work yields a basis for the development of prognostic molecular signatures, markers and therapeutic targets for HNSCC metastasis.	[Wasylyk, C.; Wasylyk, B.] IGBMC, CNRS, INSERM, ULP, F-67404 Illkirch Graffenstaden, France; [Rickman, D. S.; De Reynies, A.; Thomas, E.] Ligue Natl Contre Canc, Paris, France; [Millon, R.; Muller, D.; Abecassis, J.] Ctr Reg Lutte Contre Canc Paul Strauss, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	Wasylyk, B (corresponding author), IGBMC, CNRS, INSERM, ULP, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Wasylyk, Bohdan/ABG-6778-2020; de Reyniès, Aurélien/Q-8640-2017	Wasylyk, Bohdan/0000-0002-1718-1237; de Reyniès, Aurélien/0000-0002-1328-5290; Thomas, Emilie/0000-0002-8313-7218	Ligues Nationale et Regionales; CNRS; INSERM	Ligues Nationale et Regionales; CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	Financial support: Ligues Nationale et Regionales (Bas et Haut Rhin) contre le Cancer, CNRS, INSERM.	Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Babuke T, 2007, EUR J CELL BIOL, V86, P525, DOI 10.1016/j.ejcb.2007.03.003; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Braakhuis BJM, 2006, J CLIN PATHOL, V59, P1254, DOI 10.1136/jcp.2005.035451; Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dawson S, 2006, TRENDS CELL BIOL, V16, P229, DOI 10.1016/j.tcb.2006.03.001; Dupuy A, 2007, JNCI-J NATL CANCER I, V99, P147, DOI 10.1093/jnci/djk018; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Glas AM, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-278; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Gu LH, 2007, CURR OPIN CELL BIOL, V19, P13, DOI 10.1016/j.ceb.2006.12.007; Han CY, 2005, NUCLEIC ACIDS RES, V33, P6555, DOI 10.1093/nar/gki964; Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179; Ioannidis JPA, 2007, ONCOLOGIST, V12, P301, DOI 10.1634/theoncologist.12-3-301; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jarvinen AK, 2006, ONCOGENE, V25, P6997, DOI 10.1038/sj.onc.1209690; Kaklamani Virginia G, 2006, Curr Treat Options Oncol, V7, P123, DOI 10.1007/s11864-006-0047-0; Le Tourneau C, 2005, HEAD NECK-J SCI SPEC, V27, P801, DOI 10.1002/hed.20254; Ludwig JA, 2005, NAT REV CANCER, V5, P845, DOI 10.1038/nrc1739; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ragin CCR, 2006, BRIT J CANCER, V95, P1432, DOI 10.1038/sj.bjc.6603394; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Roepman P, 2006, CANCER RES, V66, P2361, DOI 10.1158/0008-5472.CAN-05-3960; Sanderson JT, 2006, TOXICOL SCI, V94, P3, DOI 10.1093/toxsci/kfl051; Schlecht NF, 2007, J PATHOL, V213, P283, DOI 10.1002/path.2227; Simonin F, 2004, J NEUROCHEM, V89, P766, DOI 10.1111/j.1471-4159.2004.02411.x; Slebos RJC, 2006, CLIN CANCER RES, V12, P701, DOI 10.1158/1078-0432.CCR-05-2017; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Song D, 2006, J STEROID BIOCHEM, V101, P136, DOI 10.1016/j.jsbmb.2006.06.015; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vilar M, 2006, EMBO J, V25, P1219, DOI 10.1038/sj.emboj.7601017; Zhou XF, 2006, NEOPLASIA, V8, P925, DOI 10.1593/neo.06430	42	118	122	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6607	6622		10.1038/onc.2008.251	http://dx.doi.org/10.1038/onc.2008.251			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679425				2022-12-17	WOS:000260501700009
J	Rankin, EB; Rha, J; Unger, TL; Wu, CH; Shutt, HP; Johnson, RS; Simon, MC; Keith, B; Haase, VH				Rankin, E. B.; Rha, J.; Unger, T. L.; Wu, C. H.; Shutt, H. P.; Johnson, R. S.; Simon, M. C.; Keith, B.; Haase, V. H.			Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice	ONCOGENE			English	Article						von Hippel-Lindau (VHL) tumor suppressor; hypoxia-inducible factor (HIF); hemangioma; liver angiogenesis; mouse model; Cre-loxP recombination	HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR; TARGET GENES; CYCLIN D1; EXPRESSION; HEMANGIOBLASTOMAS; ERYTHROPOIETIN; IDENTIFICATION; INACTIVATION; HIF-2-ALPHA	The von Hippel-Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and-2, oxygen-sensitive basic helix-loop-helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2 alpha suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment.	[Rankin, E. B.; Rha, J.; Unger, T. L.; Wu, C. H.; Shutt, H. P.; Haase, V. H.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Johnson, R. S.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [Simon, M. C.; Keith, B.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Simon, M. C.; Keith, B.] Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of California System; University of California San Diego; University of Pennsylvania; Pennsylvania Medicine; Howard Hughes Medical Institute; University of Pennsylvania	Haase, VH (corresponding author), Univ Penn, Sch Med, Dept Med, 626 Clinical Res Bldg,415 Curie Blvd, Philadelphia, PA 19104 USA.	vhaase@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021; Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013; Johnson, Randall/AAM-1189-2021	Haase, Volker Hans/0000-0002-7051-8994; Johnson, Randall/0000-0002-4084-6639; Rankin, Erinn/0000-0002-2045-2296; Rha, Jennifer/0000-0001-9653-4370	NIH [DK073467, CA100787]; Center for Molecular Studies in Digestive and Liver Disease [P30-DK50306]; Penn Diabetes and Endocrinology Research Center Functional Genomics Core [P30-DK19525]; American Heart Association; NATIONAL CANCER INSTITUTE [R01CA100787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK073467, P30DK019525, P30DK050306] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Molecular Studies in Digestive and Liver Disease; Penn Diabetes and Endocrinology Research Center Functional Genomics Core; American Heart Association(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grant DK073467 and CA100787 (both to VHH), the Center for Molecular Studies in Digestive and Liver Disease (P30-DK50306) and the Penn Diabetes and Endocrinology Research Center Functional Genomics Core (P30-DK19525). EBR was supported by a fellowship grant from the American Heart Association.	Biju MP, 2004, MOL CELL BIOL, V24, P9038, DOI 10.1128/MCB.24.20.9038-9047.2004; Bindra RS, 2002, CANCER RES, V62, P3014; Chavez JC, 2006, J NEUROSCI, V26, P9471, DOI 10.1523/JNEUROSCI.2838-06.2006; Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gijtenbeek JMM, 2005, J NEURO-ONCOL, V74, P261, DOI 10.1007/s11060-004-7326-z; Gruber M, 2007, P NATL ACAD SCI USA, V104, P2301, DOI 10.1073/pnas.0608382104; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Kapitsinou PP, 2008, CELL DEATH DIFFER, V15, P650, DOI 10.1038/sj.cdd.4402313; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MCGRATH FP, 1992, CLIN RADIOL, V45, P37, DOI 10.1016/S0009-9260(05)81467-9; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Rankin EB, 2005, MOL CELL BIOL, V25, P3163, DOI 10.1128/MCB.25.8.3163-3172.2005; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; White P, 2005, J BIOL CHEM, V280, P3715, DOI 10.1074/jbc.M410844200; Zatyka M, 2002, CANCER RES, V62, P3803	21	118	124	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5354	5358		10.1038/onc.2008.160	http://dx.doi.org/10.1038/onc.2008.160			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18490920	Green Accepted			2022-12-17	WOS:000259096100008
J	Veverka, V; Crabbe, T; Bird, I; Lennie, G; Muskett, FW; Taylor, RJ; Carr, MD				Veverka, V.; Crabbe, T.; Bird, I.; Lennie, G.; Muskett, F. W.; Taylor, R. J.; Carr, M. D.			Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR	ONCOGENE			English	Article						mTOR; FRB; rapamycin; phosphatidic acid; NMR	N-TERMINAL DOMAIN; MAMMALIAN TARGET; TISSUE INHIBITOR; BINDING PARTNER; RAPAMYCIN MTOR; PROTEIN; CANCER; TOR; PATHWAY; GROWTH	The mammalian target of rapamycin (mTOR) is a large, multidomain protein kinase, which plays a central role in the regulation of cell growth and has recently emerged as an essential target of survival signals in many types of human cancer cells. Here, we report the solution structures of complexes formed between the FKBP12-rapamycin binding (FRB) domain of mTOR and phosphatidic acid, an important cellular activator of the kinase, and between the FRB domain and a novel inhibitor (HTS-1). The overall structure of the FRB domain is very similar to that seen in the ternary complex formed with FKBP12 and the immunosuppressive drug rapamycin; however, there are significant changes within the rapamycin-binding site with important consequences for rational drug design. The surface of the FRB domain contains a number of distinctive features that have previously escaped attention, including a potential new regulatory site on the opposite face to that involved in the binding of rapamycin, which displays the features expected for a specific binding site for a small molecule. The interaction sites for phosphatidic acid and HTS-1 were found to closely match the site responsible for rapamycin binding. In addition, the structures determined for the FRB phosphatidic acid and FRB-HTS-1 complexes revealed a striking similarity between the conformations of buried portions of the ligands and that seen for the rapamycin backbone in contact with the domain. Our findings further highlight the importance of the FRB domain in small molecule-mediated regulation of mTOR, demonstrate the ability to identify novel inhibitors of mTOR that bind tightly to the rapamycin-binding site in the absence of FKBP12, and identify a potential new regulatory site that may be exploited in the design of new anticancer drugs.	[Veverka, V.; Muskett, F. W.; Carr, M. D.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Crabbe, T.; Bird, I.; Lennie, G.; Taylor, R. J.] UCB R&D, Slough, Berks, England	University of Leicester	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk	Ward, Stephen/AAE-4341-2020; Veverka, Vaclav/P-5251-2019; Veverka, Vaclav/G-9174-2014	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Annis DA, 2004, INT J MASS SPECTROM, V238, P77, DOI 10.1016/j.ijms.2003.11.022; Avila-Flores A, 2005, J BIOL CHEM, V280, P10091, DOI 10.1074/jbc.M412296200; Banaszynski LA, 2005, J AM CHEM SOC, V127, P4715, DOI 10.1021/ja043277y; Bianco RB, 2006, EUR J CANCER, V42, P290, DOI 10.1016/j.ejca.2005.07.034; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Choi Jai-Pil, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8; DELANO WL, 2002, PYMOL MOL GRAPHICS; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Hancock JF, 2007, NAT CELL BIOL, V9, P615, DOI 10.1038/ncb0607-615; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; Koharudin LMI, 2003, J MAGN RESON, V163, P228, DOI 10.1016/S1090-7807(03)00149-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leone M, 2006, BIOCHEMISTRY-US, V45, P10294, DOI 10.1021/bi060976+; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Mor A, 2007, NAT CELL BIOL, V9, P713, DOI 10.1038/ncb1592; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Thomas GV, 2006, CURR OPIN GENET DEV, V16, P78, DOI 10.1016/j.gde.2005.12.003; Veverka V, 2006, J BIOMOL NMR, V36, P3, DOI 10.1007/s10858-005-4324-1; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhao C, 2007, NAT CELL BIOL, V9, P706, DOI 10.1038/ncb1594	43	118	126	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					585	595		10.1038/sj.onc.1210693	http://dx.doi.org/10.1038/sj.onc.1210693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684489				2022-12-17	WOS:000252674900003
J	Janda, E; Nevolo, M; Lehmann, K; Downward, J; Beug, H; Grieco, M				Janda, E.; Nevolo, M.; Lehmann, K.; Downward, J.; Beug, H.; Grieco, M.			Raf plus TGF beta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin	ONCOGENE			English	Article						E-cadherin; Raf; TGFbeta; EMT; endocytosis; monoubiquitination	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; CELL-ADHESION MOLECULE; TUMOR-CELLS; EXPRESSION; PLASTICITY; MECHANISM; PROTEIN; TRANSFORMATION; PROGRESSION	Oncogenic Ras interferes with adhesive functions of epithelial cells, but requires tumor growth factor beta (TGF beta) signaling to cause epithelial-mesenchymal transition (EMT) and tumor progression in model systems. To investigate the mechanisms by which Ras and TGFb pathways cooperate in EMT induction, we introduced a tamoxifen-inducible version of Raf-1 (RafER) into fully polarized, mammary epithelial cells (EpH4). EMT characterized by loss of E-cadherin expression and upregulation of invasiveness-promoting genes was induced by TGF beta plus 4-hydroxytamoxifen (4HT) activation of RafER. Downregulation of E-cadherin by RafER plus TGF beta was detectable in total cell lysates after 48 h and much earlier in detergent-insoluble fractions of E-cadherin. Both pathways cooperated to strongly enhance endocytosis of E-cadherin, mainly via the clathrin-dependent route. Pulse-chase experiments showed decreased E-cadherin protein stability in cells stimulated with TGF beta and 4HT and increased E-cadherin half-life in the presence of monensin. Monensin and chloroquine prevented E-cadherin degradation to different extent, but only monensin effectively blocked the loss of E-cadherin from the junctional complexes. Both lysosome inhibitors caused accumulation of E-cadherin vesicles, some of which were positive for Cathepsin D and lysosome-associated membrane protein 1 (LAMP-1). In addition, TGF beta and mitogen-activated protein kinase hyperactivation synergistically induced E-cadherin ubiquitination, suggesting that the cooperation of Raf and TGF beta favors lysosomal degradation of E-cadherin instead of its recycling. Our data indicate that early stages of EMT involve cooperative, post-translational downregulation of E-cadherin, whereas loss of E-cadherin via transcriptional repression is a late event in EMT.	Univ Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Imperial Canc Res Fund, Signal Transduct Labs, London WC2A 3PX, England; Res Inst Mol Pathol, A-1030 Vienna, Austria	Magna Graecia University of Catanzaro; Cancer Research UK; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Grieco, M (corresponding author), Univ Magna Graecia, Dipartimento Med Sperimentale & Clin, Campus Germaneto Livello 7, I-88100 Catanzaro, Italy.	mgrieco@unicz.it	Downward, Julian/A-3251-2012; Janda, Elzbieta/AFQ-7061-2022; Janda, Elzbieta/AAD-5126-2022	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Downward, Julian/0000-0002-2331-4729; Grieco, Michele/0000-0002-4212-7814				Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kemler R, 1992, Semin Cell Biol, V3, P149; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; Negroiu G, 2005, BIOCHEM BIOPH RES CO, V328, P914, DOI 10.1016/j.bbrc.2005.01.040; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shen L, 2005, MOL BIOL CELL, V16, P3919, DOI 10.1091/mbc.E04-12-1089; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sun DZ, 2000, DEV BIOL, V228, P337, DOI 10.1006/dbio.2000.9946; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Viebahn C, 1995, ACTA ANAT, V154, P79; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	38	118	122	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	54					7117	7130		10.1038/sj.onc.1209701	http://dx.doi.org/10.1038/sj.onc.1209701			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16751808				2022-12-17	WOS:000242046900001
J	Lee, JW; Kim, YG; Soung, YH; Han, KJ; Kim, SY; Rhim, HS; Min, WS; Nam, SW; Park, WS; Lee, JY; Yoo, NJ; Lee, SH				Lee, JW; Kim, YG; Soung, YH; Han, KJ; Kim, SY; Rhim, HS; Min, WS; Nam, SW; Park, WS; Lee, JY; Yoo, NJ; Lee, SH			The JAK2 V617F mutation in de novo acute myelogenous leukemias	ONCOGENE			English	Article						JAK2; acute myelogenous leukemia; mutation; cancer	TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; INHIBITOR	A missense somatic mutation in JAK2 gene (JAK2 V617F) has recently been reported in chronic myeloproliferative disorders, including polycythemia vera, essential thrombocythemia and myelofibrosis with myeloid metaplasia, strongly suggesting its role in the pathogenesis of myeloid disorders. As activation of JAK2 signaling is occurred in other malignancies as well, we have analysed 558 tissues from common human cancers, including colon, breast and lung carcinomas, and 143 acute adulthood leukemias by polymerase chain reaction - single strand conformation polymorphism analysis. We found three JAK2 mutations in the 113 acute myelogenous leukemias (AMLs)(2.7%), but none in other cancers. The mutations consisted of two V617F mutations and one K607N mutation. None of the AML patients with the JAK2 V617F mutation had a history of previous hematologic disorders. This is the first report on the JAK2 gene mutation in AML, and the data indicated that the JAK2 gene mutation may not only contribute to the development of chronic myeloid disorders, but also to some AMLs.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul, South Korea; Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; Arteaga CL, 2002, SEMIN ONCOL, V29, P4, DOI 10.1053/sonc.2002.34047; Baxter EJ, 2005, LANCET, V365, P1054, DOI 10.1016/S0140-6736(05)71142-9; DAMESHEK W, 1951, BLOOD, V6, P372, DOI 10.1182/blood.V6.4.372.372; DIEZMARTIN JL, 1991, MAYO CLIN PROC, V66, P287, DOI 10.1016/S0025-6196(12)61011-8; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Pallis M, 2003, LEUKEMIA RES, V27, P803, DOI 10.1016/S0145-2126(03)00012-2; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Steensma DP, 2005, BLOOD; SWOLIN B, 1988, BLOOD, V72, P386; Verma A, 2003, CANCER METAST REV, V22, P423, DOI 10.1023/A:1023805715476; Wakeling AE, 2002, CANCER RES, V62, P5749	15	118	129	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1434	1436		10.1038/sj.onc.1209163	http://dx.doi.org/10.1038/sj.onc.1209163			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247455				2022-12-17	WOS:000235708200018
J	Chang, PC; Chi, CW; Chau, GY; Li, FY; Tsai, YH; Wu, JC; Lee, YHW				Chang, PC; Chi, CW; Chau, GY; Li, FY; Tsai, YH; Wu, JC; Lee, YHW			DDX3, a DEAD box RNA helicase, is deregulated in hepatitis virus-associated hepatocellular carcinoma and is involved in cell growth control	ONCOGENE			English	Article						DDX3; hepatocellular carcinoma; small interfering RNA; p21(WAF1); proliferation; apoptosis	CYCLIN D1 OVEREXPRESSION; CORE PROTEIN INTERACTS; C-MYC; DECREASED EXPRESSION; GENETIC ALTERATIONS; TUMOR PROGRESSION; P53 MUTATION; CANCER; PATHOGENESIS; RECEPTOR	Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide and is highly correlated with hepatitis virus infection. Our previous report shows that a DEAD box RNA helicase, DDX3, is targeted and regulated by hepatitis C virus (HCV) core protein, which implicates the involvement of DDX3 in HCV-related HCC development. In this study, the potential role of DDX3 in hepatocarcinogenesis is investigated by examining its expression in surgically excised human HCC specimens. Here we report the differential deregulation of DDX3 expression in hepatitis virus-associated HCC. A significant downregulation of DDX3 expression is found in HCCs from hepatitis B virus (HBV)-positive patients, but not from HCV-positive ones, compared to the corresponding nontumor tissues. The expression of DDX3 is differentially regulated by the gender and, moreover, there is a tendency that the downregulation of DDX3 expression in HCCs is more frequent in males than in females. Genetic knockdown of DDX3 with small interfering RNAs (siRNA) in a nontransformed mouse fibroblast cell line, NIH-3T3, results in a premature entry to S phase and an enhancement of cell growth. This enhanced cell cycle progression is linked to the upregulation of cyclin D1 and the downregulation of p21(WAF1) in the DDX3 knockdown cells. In addition, constitutive reduction of DDX3 expression increases the resistance of NIH-3T3 cells to serum depletion-induced apoptosis and enhances the ras-induced anchorage-independent growth, indicating the involvement of DDX3 in cell growth control. These findings together with the previous study suggest that the deregulation of DDX3, a DEAD box RNA helicase with cell growth-regulatory functions, is involved in HBV- and HCV-associated pathogenesis.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan; Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan; Natl Yang Ming Univ, Dept Pathol, Taipei, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	yhwulee@ym.edu.tw		Lee Wu, Yan-Hwa/0000-0001-7299-7354				Ahn J, 2004, DM-DIS MON, V50, P556, DOI 10.1016/j.disamonth.2004.10.001; Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Chen CJ, 2002, JPN J CLIN ONCOL, V32, pS66, DOI 10.1093/jjco/hye138; De Petro G, 1998, CANCER RES, V58, P2234; Deane NG, 2001, CANCER RES, V61, P5389; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Endo K, 2000, LIVER, V20, P209, DOI 10.1034/j.1600-0676.2000.020003209.x; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fukushima K, 2001, HEPATOL RES, V20, P52, DOI 10.1016/S1386-6346(00)00122-4; Furutani M, 1997, CANCER LETT, V111, P191, DOI 10.1016/S0304-3835(96)04509-0; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu HC, 1997, CANCER RES, V57, P5179; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Hui AM, 2000, CANCER LETT, V154, P93, DOI 10.1016/S0304-3835(00)00385-2; Hui AM, 1997, HEPATOLOGY, V25, P575, DOI 10.1002/hep.510250314; Huynh H, 2004, CARCINOGENESIS, V25, P1485, DOI 10.1093/carcin/bgh154; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Jung YJ, 2001, CANCER LETT, V168, P57, DOI 10.1016/S0304-3835(01)00403-7; Kahlina K, 2004, J BIOL CHEM, V279, P44872, DOI 10.1074/jbc.M402467200; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Kim YS, 2001, MOL CELLS, V12, P209; Kobayashi T, 2002, AM J GASTROENTEROL, V97, P3166; Kobayashi Y, 2000, J HEPATOL, V32, P612, DOI 10.1016/S0168-8278(00)80223-8; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lukas J, 1997, AM J PATHOL, V150, P167; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marchetti A, 1996, ONCOGENE, V12, P1319; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Matsushita K, 1996, INT J CANCER, V69, P259, DOI 10.1002/(SICI)1097-0215(19960822)69:4<259::AID-IJC3>3.3.CO;2-D; MURAKAMI Y, 1991, CANCER RES, V51, P5520; Nagano H, 2003, ONCOGENE, V22, P4656, DOI 10.1038/sj.onc.1206588; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; NISHIDA N, 1993, CANCER RES, V53, P368; OGATA N, 1991, HEPATOLOGY, V13, P31, DOI 10.1002/hep.1840130106; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Paik SY, 2003, MODERN PATHOL, V16, P86, DOI 10.1097/01.MP.0000047308.03300.9C; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; Shackelford J, 2004, MOL CELL BIOL, V24, P5089, DOI 10.1128/MCB.24.12.5089-5093.2004; Shi YZ, 2000, BRIT J CANCER, V83, P50; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; TANAKA S, 1993, CANCER RES, V53, P2884; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; Tannapfel A, 2002, VIRCHOWS ARCH, V440, P345, DOI 10.1007/s00428-002-0617-x; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Torbenson M, 2002, HUM PATHOL, V33, P871, DOI 10.1053/hupa.2002.128061; Tron VA, 1996, AM J PATHOL, V149, P1139; Ueki T, 1997, HEPATOLOGY, V25, P862, DOI 10.1002/hep.510250413; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Xie HL, 2004, WORLD J GASTROENTERO, V10, P1125; Yan J, 2004, ONCOGENE, V23, P1939, DOI 10.1038/sj.onc.1207306; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; Yuen MF, 2001, CANCER, V91, P106, DOI 10.1002/1097-0142(20010101)91:1<106::AID-CNCR14>3.0.CO;2-2; Zhang J, 2004, WORLD J GASTROENTERO, V10, P830; ZHANG XK, 1990, ONCOGENE, V5, P909; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	81	118	123	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					1991	2003		10.1038/sj.onc.1209239	http://dx.doi.org/10.1038/sj.onc.1209239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16301996				2022-12-17	WOS:000236359700002
J	Yu, M; Schreek, S; Cerni, C; Schamberger, C; Lesniewicz, K; Poreba, E; Vervoorts, J; Walsemann, G; Grotzinger, J; Kremmer, E; Mehraein, Y; Mertsching, J; Kraft, R; Austen, M; Luscher-Firzlaff, J; Luscher, B				Yu, M; Schreek, S; Cerni, C; Schamberger, C; Lesniewicz, K; Poreba, E; Vervoorts, J; Walsemann, G; Grotzinger, J; Kremmer, E; Mehraein, Y; Mertsching, J; Kraft, R; Austen, M; Luscher-Firzlaff, J; Luscher, B			PARP-10, a novel Myc-interacting protein with poly( ADP-ribose) polymerase activity, inhibits transformation	ONCOGENE			English	Article						Myc; PARP; transcription; transformation	RNA RECOGNITION MOTIFS; POLY(ADP-RIBOSE) POLYMERASE; C-MYC; MYC/MAX/MAD NETWORK; DNA-DAMAGE; HISTONE ACETYLATION; CATALYTIC DOMAIN; HUMAN TELOMERES; CELL-GROWTH; IN-VITRO	The proto-oncoprotein c-Myc functions as a transcriptional regulator that controls different aspects of cell behavior, including proliferation, differentiation, and apoptosis. In addition, Myc proteins have the potential to transform cells and are deregulated in the majority of human cancers. Several Myc-interacting factors have been described that mediate part of Myc's functions in the control of cell behavior. Here, we describe the isolation of a novel 150 kDa protein, designated PARP-10, that interacts with Myc. PARP-10 possesses domains with homology to RNA recognition motifs and to poly( ADPribose) polymerases ( PARP). Molecular modeling and biochemical analysis de. ne a PARP domain that is capable of ADP-ribosylating PARP-10 itself and core histones, but neither Myc nor Max. PARP-10 is localized to the nuclear and cytoplasmic compartments that is controlled at least in part by a Leu-rich nuclear export sequence (NES). Functionally, PARP-10 inhibits c-Myc-and E1A-mediated cotransformation of rat embryo fibroblasts, a function that is independent of PARP activity but that depends on a functional NES. Together, our findings de. ne a novel PARP enzyme involved in the control of cell proliferation.	Rhein Westfal TH Aachen, Abt Biochem & Mol Biol, Inst Biochem, Klinikum, D-52057 Aachen, Germany; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Univ Vienna, Inst Krebsforsch, A-1090 Vienna, Austria; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Univ Saarland, Inst Humangenet, D-66421 Homburg, Germany; Max Delbruck Ctr, D-13092 Berlin, Germany	RWTH Aachen University; Hannover Medical School; University of Vienna; University of Kiel; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Saarland University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luscher, B (corresponding author), Rhein Westfal TH Aachen, Abt Biochem & Mol Biol, Inst Biochem, Klinikum, Pauwelsstr 30, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	; Luscher, Bernhard/A-7330-2011	Poreba, Elzbieta/0000-0003-2410-4974; Lesniewicz, Krzysztof/0000-0003-4399-858X; Luscher, Bernhard/0000-0002-9622-8709; Vervoorts, Jorg/0000-0002-3251-6496				Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERNI C, 1995, ONCOGENE, V11, P587; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chi NW, 2000, J BIOL CHEM, V275, P38437, DOI 10.1074/jbc.M007635200; Conte MR, 2000, EMBO J, V19, P3132, DOI 10.1093/emboj/19.12.3132; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Crowder SM, 1999, P NATL ACAD SCI USA, V96, P4892, DOI 10.1073/pnas.96.9.4892; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dallaire F, 2000, J BIOL CHEM, V275, P14509, DOI 10.1074/jbc.275.19.14509; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Domingues FS, 1999, PROTEINS, P112; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; Fiset S, 2001, NUCLEIC ACIDS RES, V29, P2268, DOI 10.1093/nar/29.11.2268; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim H, 1997, BIOCHEM J, V322, P469, DOI 10.1042/bj3220469; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Lyons RJ, 2001, J BIOL CHEM, V276, P17172, DOI 10.1074/jbc.M009756200; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Michael WM, 2000, TRENDS CELL BIOL, V10, P46, DOI 10.1016/S0962-8924(99)01695-5; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; POLO S, 2003, SCI STKE, pRE17, DOI DOI 10.1126/STKE.2132003RE17; Poortinga G, 2004, EMBO J, V23, P3325, DOI 10.1038/sj.emboj.7600335; Ruf A, 1996, P NATL ACAD SCI USA, V93, P7481, DOI 10.1073/pnas.93.15.7481; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; SIMONIN F, 1990, J BIOL CHEM, V265, P19249; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; van Gunsteren WF., 1996, BIOMOLECULAR SIMULAT, V86, P1; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198	73	118	124	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2005	24	12					1982	1993		10.1038/sj.onc.1208410	http://dx.doi.org/10.1038/sj.onc.1208410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15674325				2022-12-17	WOS:000227681900003
J	Lebedeva, IV; Sarkar, D; Su, ZZ; Kitada, S; Dent, P; Stein, CA; Reed, JC; Fisher, PB				Lebedeva, IV; Sarkar, D; Su, ZZ; Kitada, S; Dent, P; Stein, CA; Reed, JC; Fisher, PB			Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24	ONCOGENE			English	Review						cancer gene therapy; prostate cancer; Bcl-2 protein family; apoptosis; mda-7/IL-24	HUMAN ADENOVIRUS TYPE-5; IN-VIVO; GROWTH ARREST; UP-REGULATION; DNA-DAMAGE; IMMUNOHISTOCHEMICAL ANALYSIS; CLONOGENIC SURVIVAL; ANDROGEN-ABLATION; CARCINOMA-CELLS; OVER-EXPRESSION	Subtraction hybridization identified melanoma differentiation associated gene-7, mda-7, in the context of terminally differentiated human melanoma cells. Based on its structure, cytokine-like properties and proposed mode of action, mda-7 has now been classified as IL-24. When expressed by means of a replication-incompetent adenovirus, Ad. mda-7 induces apoptosis in a broad range of cancer cells, without inducing harmful effects in normal fibroblast or epithelial cells. These unique properties of mda-7/IL-24 suggest that this gene will prove beneficial for cancer gene therapy. We now demonstrate that Ad. mda-7 decreases viability by induction of apoptosis in hormone-responsive (LNCaP) and hormone-independent (DU-145 and PC-3) human prostate carcinomas, without altering growth or survival in early-passage normal human prostate epithelial cells (HuPEC). Ad. mda-7 causes G(2)/M arrest and apoptosis in LNCaP (p53-wildtype), DU-145 (p53 mutant, Bax-negative) and PC-3 (p53-negative) prostate carcinomas, but not in HuPEC. Apoptosis induction correlated with changes in the ratio of pro- to antiapoptotic Bcl-2 protein family members. A potential functional role for changes in bcl-2 family gene expression in Ad. mda-7-induced apoptosis was suggested by the finding that forced overexpression of bcl-xL or bcl-2 differentially diminished the apoptotic effect of Ad. mda-7 in prostate carcinomas. These results confirm that induction of apoptosis by the mda-7/IL-24 gene in prostate cancer cells is Bax- and p53-independent and is mediated by mitochondrial pathways involving bcl-2 family gene members. The mda-7/IL-24 gene represents a new class of cancer-specific apoptosis-inducing genes with obvious potential for the targeted gene-based therapy of human prostate cancer.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA	Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University; Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.		Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA088906, R01CA097318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [BC98-0148, CA97318, CA88906, CA35675] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2002, CELL DEATH DIFFER, V9, P1240, DOI 10.1038/sj.cdd.4401097; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amundson SA, 2000, CANCER RES, V60, P6101; Bai XZ, 1999, INT J ONCOL, V14, P785; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beham AW, 1998, INT J MOL MED, V1, P953; BERCHEM GJ, 1995, CANCER RES, V55, P735; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Cao XX, 2002, MOL MED, V8, P869, DOI 10.1007/BF03402093; Chadbourne DE, 2001, POPTRONICS, V2, P3; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Curiel DT, 2000, CANCER GENE THER, V7, P1197, DOI 10.1038/sj.cgt.7700222; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; Gazdar AF, 2001, P NATL ACAD SCI USA, V98, P10028, DOI 10.1073/pnas.191379998; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; Gopalkrishnan RV, 2001, J CELL PHYSIOL, V189, P245, DOI 10.1002/jcp.10023; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Hall SJ, 1999, CANCER GENE THER, V6, P54, DOI 10.1038/sj.cgt.7700004; Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Hull GW, 2000, CLIN CANCER RES, V6, P4101; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jin RJ, 2000, CANCER GENE THER, V7, P1537, DOI 10.1038/sj.cgt.7700266; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Ko SC, 1996, HUM GENE THER, V7, P1683, DOI 10.1089/hum.1996.7.14-1683; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEON JA, 1994, PHARMACOL THERAPEUT, V61, P237, DOI 10.1016/0163-7258(94)90065-5; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Li XY, 2001, CANCER RES, V61, P1699; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lock RB, 1996, CANCER RES, V56, P4006; Lowe SL, 2001, GENE THER, V8, P1363, DOI 10.1038/sj.gt.3301531; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; Matsubara S, 2001, CANCER RES, V61, P6012; MAY WS, 1994, J BIOL CHEM, V269, P26865; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miyake H, 2001, INT J UROL, V8, P337, DOI 10.1046/j.1442-2042.2001.00311.x; Nasu Y, 1999, GENE THER, V6, P338, DOI 10.1038/sj.gt.3300834; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pataer A, 2002, CANCER RES, V62, P2239; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Pramudji C, 2001, CLIN CANCER RES, V7, P4272; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed J C, 1996, Behring Inst Mitt, P72; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodriguez R, 1997, CANCER RES, V57, P2559; Rots M G, 2000, Cancer Gene Ther, V7, P1507, DOI 10.1038/sj.cgt.7700253; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shalev M, 2000, J UROLOGY, V163, P1747, DOI 10.1016/S0022-5347(05)67534-9; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; Sweeney P, 2000, WORLD J UROL, V18, P121, DOI 10.1007/s003450050183; Tang DG, 1998, CANCER RES, V58, P3466; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; Xie XM, 2001, CANCER RES, V61, P6795; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	108	118	134	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8758	8773		10.1038/sj.onc.1206891	http://dx.doi.org/10.1038/sj.onc.1206891			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647471				2022-12-17	WOS:000186844900014
J	Lee, SH; Lee, JW; Soung, YH; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ				Lee, SH; Lee, JW; Soung, YH; Kim, HS; Park, WS; Kim, SY; Lee, JH; Park, JY; Cho, YG; Kim, CJ; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ			BRAF and KRAS mutations in stomach cancer	ONCOGENE			English	Article						mutation; BRAF; RAS; stomach cancer; stomach	RAS ONCOGENES; GENE; ACTIVATION; MELANOMA; PATHWAY; TUMORS	Ras proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. BRAF, which encodes a RAF family member in the downstream pathway of RAS, is somatically mutated in a number of human cancers. The activating mutation of BRAF is known to play a role in tumor development. As there have been no data on the BRAF mutation in stomach cancer, we analysed the genomic DNAs from 319 stomach carcinomas for the detection of somatic mutations of BRAF. Overall, we detected BRAF mutations in seven stomach carcinomas (2.2%). Five of the seven BRAF mutations involved Val 599, the previously identified hotspot, but the substituted amino acid (V599M) was different from the most common BRAF mutation (V599E). The remaining two mutations involved a conserved amino acid (D593G). One tumor had both BRAF and KRAS mutations. This is the first report on BRAF mutation in stomach cancer, and the data indicate that BRAF is occasionally mutated in stomach cancer, and suggest that alterations of RAS pathway both by RAS and BRAF mutations contribute to the pathogenesis of stomach cancer.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea	Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.		Yoo, Nam Jin/GNM-9060-2022; kim, Hong Sug/G-2731-2014					Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; BAE JM, 1999, J KOREAN CANC ASS, V30, P1175; BOS JL, 1989, CANCER RES, V49, P4682; Brose MS, 2002, CANCER RES, V62, P6997; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; JIANG W, 1989, ONCOGENE, V4, P923; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; LEE KH, 1995, CANCER, V75, P2794, DOI 10.1002/1097-0142(19950615)75:12<2794::AID-CNCR2820751203>3.0.CO;2-F; Naoki K, 2002, CANCER RES, V62, P7001; NEUBAUER A, 1994, BLOOD, V83, P1603; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Satyamoorthy K, 2003, CANCER RES, V63, P756; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Smith ML, 2003, LEUKEMIA, V17, P274, DOI 10.1038/sj.leu.2402787; Yuen ST, 2002, CANCER RES, V62, P6451	17	118	127	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6942	6945		10.1038/sj.onc.1206749	http://dx.doi.org/10.1038/sj.onc.1206749			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534542				2022-12-17	WOS:000185843400016
J	Kretschmer, A; Moepert, K; Dames, S; Sternberger, M; Kaufmann, J; Klippel, A				Kretschmer, A; Moepert, K; Dames, S; Sternberger, M; Kaufmann, J; Klippel, A			Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4	ONCOGENE			English	Article						Smad; TGF-beta; tumor suppressor; microarray	GROWTH-FACTOR-BETA; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; TARGETED DISRUPTION; DOWN-REGULATION; CELLS; EXPRESSION; REPRESSION; INHIBITOR; ARREST	Smad transcription factors mediate the growth inhibitory effect of transforming growth factor-beta (TGF-beta) in many cell types. Mutational inactivation of Smads has been correlated with loss of responsiveness to TGF-beta-mediated signal transduction. In this study, we compare the contribution of individual Smads to TGF-beta-induced growth inhibition and endogenous gene expression in isogenic cellular backgrounds. Smad2, Smad3 and Smad4 expression were selectively inhibited in differentiation-competent cells by using improved antisense molecules. We found that TGF-beta mediates its inhibitory effect on HaCaT keratinocyte cell growth predominantly through Smad3. Inhibition of Smad3 expression was sufficient to interfere with TGF-beta-induced cell cycle arrest and to induce or suppress endogenous cell cycle regulators. Inhibition of Smad4 expression exhibited a partial effect, whereas inhibition of Smad2 expression had no effect. By gene expression pro. ling, we identified TGF-beta-dependent genes that are differentially regulated by Smad2 and Smad3 under regular growth conditions on a genome-wide scale. We show that Smad2, Smad3 and Smad4 contribute to the regulation of TGF-beta responses to varying extents, and demonstrate, in addition, that these Smads exhibit distinct roles in different cell types.	Atugen AG, D-13125 Berlin, Germany		Klippel, A (corresponding author), Atugen AG, Robert Roessle Str 10,Otto Warburg Hause 80, D-13125 Berlin, Germany.	klippel@atugen.com						Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cerezo A, 2002, J CELL SCI, V115, P1305; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Correia JJ, 2001, BIOCHEMISTRY-US, V40, P1473, DOI 10.1021/bi0019343; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FRITZ HJ, 1978, BIOCHEMISTRY-US, V17, P1257, DOI 10.1021/bi00600a020; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill CS, 1999, INT J BIOCHEM CELL B, V31, P1249, DOI 10.1016/S1357-2725(99)00093-X; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Iavarone A, 1997, NATURE, V387, P417; Inman GJ, 2002, J BIOL CHEM, V277, P51008, DOI 10.1074/jbc.M208532200; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Ling MT, 2002, BBA-GEN SUBJECTS, V1570, P145, DOI 10.1016/S0304-4165(02)00189-7; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 2001, J CELL SCI, V114, P4359; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nicolas FJ, 2003, J BIOL CHEM, V278, P3251, DOI 10.1074/jbc.M209019200; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Robertson G, 2001, UASGCP REP, V2001, P43; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOULE HD, 1990, CANCER RES, V50, P6075; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Werner S, 2000, EXP CELL RES, V254, P80, DOI 10.1006/excr.1999.4726; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; WRANA JL, 2000, SCI STKE, pRE1; Wu JW, 2001, J BIOL CHEM, V276, P20688, DOI 10.1074/jbc.M100174200; Xu GX, 2003, BIOCHEM BIOPH RES CO, V300, P383, DOI 10.1016/S0006-291X(02)02845-0; Xu GX, 2001, BIOCHEM BIOPH RES CO, V287, P47, DOI 10.1006/bbrc.2001.5533; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	62	118	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2003	22	43					6748	6763		10.1038/sj.onc.1206791	http://dx.doi.org/10.1038/sj.onc.1206791			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555988				2022-12-17	WOS:000185799300010
J	Liu, JW; Shen, JJ; Tanzillo-Swarts, A; Bhatia, B; Maldonado, CM; Person, MD; Lau, SS; Tang, DG				Liu, JW; Shen, JJ; Tanzillo-Swarts, A; Bhatia, B; Maldonado, CM; Person, MD; Lau, SS; Tang, DG			Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration	ONCOGENE			English	Article						annexins; prostate cancer; cell migration; proteomics; progression	ENHANCED EXPRESSION; CARCINOMA CELLS; DOWN-REGULATION; GENE FAMILY; CALPACTIN-I; IDENTIFICATION; RECEPTOR; PROTEIN; LOCALIZATION; APOPTOSIS	While studying Bim, a BH3-only proapoptotic protein, we identified an similar to36kDa protein, which was abundantly expressed in all five strains of primary normal human prostate (NHP) epithelial cells but significantly reduced or lost in seven prostate cancer cell lines. The similar to36kDa protein was subsequently identified as annexin II by proteomic approach and confirmed by Western blotting using an annexin II-specific antibody. Conventional and 2D SDS-PAGE, together with Western blotting, also revealed reduced or lost expression of annexin I in prostate cancer cells. Subcellular localization studies revealed that in NHP cells, annexin II was distributed both in the cytosol and underneath the plasma membrane, but not on the cell surface. Prostate cancer cells showed reduced levels as well as altered expression patterns of annexin II. Since annexins play important roles in maintaining Ca2+ homeostasis and regulating the cytoskeleton and cell motility, we hypothesized that the reduced or lost expression of annexin I/II might promote certain aggressive phenotypes of prostate cancer cells. In subsequent experiments, we indeed observed that restoration of annexin II expression inhibited the migration of the transfected prostate cancer cells without affecting cell proliferation or apoptosis. Hence, our results suggest that annexin II, and, likely, annexin I, may be endogenous suppressors of prostate cancer cell migration and their reduced or lost expression may contribute to prostate cancer development and progression.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA; Univ Texas, Coll Pharm, Ctr Mol & Cellular Toxicol, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Austin	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd,1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Tanzillo-Swarts, Angela/0000-0001-9277-3761	NCI NIH HHS [CA-90297] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NIGMS NIH HHS [GM39338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039338, R01GM039338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarli A, 1997, AM J REPROD IMMUNOL, V38, P313; Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; BIANCHI R, 1995, BIOCHEM BIOPH RES CO, V208, P910, DOI 10.1006/bbrc.1995.1421; Chetcuti A, 2001, CANCER RES, V61, P6331; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; Chiang YP, 1996, BBA-MOL CELL RES, V1313, P295, DOI 10.1016/0167-4889(96)00103-6; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; ELKSO E, 1980, CELL, V21, P829; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; GUPTA S, 2002, P AACR, V43, pA5; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Liu JW, 2002, CANCER RES, V62, P2976; Ma ASP, 1996, ARCH DERMATOL RES, V288, P596, DOI 10.1007/s004030050109; MA ASP, 1994, J CELL SCI, V107, P1973; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; Morgan RO, 1997, CELL MOL LIFE SCI, V53, P508, DOI 10.1007/s000180050064; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Paweletz CP, 2000, CANCER RES, V60, P6293; Pencil SD, 1998, CLIN EXP METASTAS, V16, P113, DOI 10.1023/A:1021917017109; Pol A, 1997, BIOCHEM J, V327, P741, DOI 10.1042/bj3270741; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REEVES SA, 1992, CANCER RES, V52, P6871; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; TAKAHASHI S, 1994, J BIOL CHEM, V269, P28696; Tang DG, 1998, CANCER RES, V58, P3466; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; THIEL C, 1992, J CELL SCI, V103, P733; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; Zobiack N, 2001, FEBS LETT, V500, P137, DOI 10.1016/S0014-5793(01)02604-7; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	39	118	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1475	1485		10.1038/sj.onc.1206196	http://dx.doi.org/10.1038/sj.onc.1206196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629510				2022-12-17	WOS:000181411900004
J	Wiencke, JK				Wiencke, JK			DNA adduct burden and tobacco carcinogenesis	ONCOGENE			English	Review						DNA adducts; tobacco; risk assessment; molecular epidemiology	GLUTATHIONE-S-TRANSFERASE; LUNG-CANCER RISK; WHITE BLOOD-CELLS; POLYCYCLIC AROMATIC-HYDROCARBONS; COKE-OVEN WORKERS; BENZO<A>PYRENE DIOL-EPOXIDE; REPAIR GENE XRCC1; NUCLEOTIDE EXCISION-REPAIR; HPRT MUTANT FREQUENCY; BLADDER-CANCER	DNA adducts associated with tobacco smoking could provide a marker of biologically effective dose of tobacco carcinogens and improve individual cancer risk prediction. A significant number of clinical and epidemiologic studies have reported associations of increased DNA adduct levels with the occurrence of the prevalent tobacco related cancers including cancer of the lung, head and neck, and bladder. The inducibility of DNA adducts following in vitro treatments using blood lymphocytes also appears to be a risk factor in the development of lung and head and neck cancer. Corroborative evidence pointing to the importance of DNA adducts in tobacco carcinogenesis include numerous studies showing associations of tobacco smoke exposure with the induction of DNA adducts in humans in vivo. Further effort is necessary, however, to more fully characterize the dose - response relationship between smoking and DNA adducts in exposed target and surrogate tissues. The relationship between gene polymorphisms thought to modify tobacco-related cancer risk and DNA adduct levels is complex. Results of some DNA adduct studies (both in vitro and in vivo) appear inconsistent with the epidemiologic findings. This is evident for polymorphisms involving both carcinogen metabolism (e.g. GSTP1) and DNA repair (e.g. XRCC1). Molecular studies of human tumors suggest associations of p53 mutation with DNA adducts and have revealed correlations of DNA adduct levels with somatic alterations (e.g. 3p21 LOH) that are thought to occur at the very earliest stages of tobacco carcinogenesis. More research is needed to assess the relationship between endogenous sources of DNA adducts and tobacco smoke exposure and the relative oncogenic effects of chemically stable versus unstable DNA adducts. Many potentially fruitful new avenues of cancer research are emerging that integrate DNA adduct analyses with assessments of smoking, genetics, diet and ambient air quality. These investigations aim to understand the multifactorial nature of interindividual variability in response to tobacco carcinogens. As these trends continue a variety of innovative study designs and approaches will become important in human populations.	Univ Calif San Francisco, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wiencke, JK (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA.	wiencke@itsa.ucsf.edu			NIEHS NIH HHS [ES06717] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006717] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALEXANDROV K, 1992, CANCER RES, V52, P6248; Andreassen A, 1996, MUTAT RES-GENET TOX, V368, P275; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Arnould JP, 1999, HUM EXP TOXICOL, V18, P314, DOI 10.1191/096032799678840174; Arnould JP, 2000, PATHOL BIOL, V48, P548; Banaszewski J, 2000, EUR ARCH OTO-RHINO-L, V257, P149, DOI 10.1007/s004050050212; Bartsch H, 1998, RECENT RES CANCER, V154, P86; Bartsch H, 2001, ADV EXP MED BIOL, V500, P675; Binkova B, 1998, MUTAT RES-GEN TOX EN, V416, P67, DOI 10.1016/S1383-5718(98)00061-8; Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; BODELL WJ, 1989, CHEM RES TOXICOL, V2, P312, DOI 10.1021/tx00011a008; Bonassi S, 2001, MUTAT RES-FUND MOL M, V480, P349, DOI 10.1016/S0027-5107(01)00194-4; Bucci F, 1998, ANTICANCER RES, V18, P2669; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Butkiewicz D, 2000, ENVIRON MOL MUTAGEN, V35, P99, DOI 10.1002/(SICI)1098-2280(2000)35:2<99::AID-EM4>3.3.CO;2-U; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Carmichael P L, 1998, Arch Toxicol Suppl, V20, P199; Casale GP, 2001, CHEM RES TOXICOL, V14, P192, DOI 10.1021/tx000012y; Chakravarti D, 2001, ONCOGENE, V20, P7945, DOI 10.1038/sj.onc.1204969; Chen HJC, 1998, CHEM RES TOXICOL, V11, P1474, DOI 10.1021/tx980107o; Chen L, 1996, CHEM RES TOXICOL, V9, P897, DOI 10.1021/tx960004a; Cheng L, 2000, CARCINOGENESIS, V21, P1527, DOI 10.1093/carcin/21.8.1527; Cheng YW, 2001, ENVIRON MOL MUTAGEN, V37, P304, DOI 10.1002/em.1037; Cheng YW, 2000, EUR J CANCER, V36, P1381, DOI 10.1016/S0959-8049(00)00131-3; Coles B, 2000, CANCER LETT, V156, P167, DOI 10.1016/S0304-3835(00)00458-4; Coles BF, 2000, CANCER RES, V60, P573; CUZICK J, 1995, J NATL CANCER I, V87, P861, DOI 10.1093/jnci/87.12.861; David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2; Devanesan PD, 1996, CHEM RES TOXICOL, V9, P1113, DOI 10.1021/tx9600513; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; Duell EJ, 2002, JNCI-J NATL CANCER I, V94, P297, DOI 10.1093/jnci/94.4.297; Endo C, 2000, SURG TODAY, V30, P695, DOI 10.1007/s005950070079; Fennell TR, 2000, CANCER EPIDEM BIOMAR, V9, P705; Fields WR, 1998, MOL PHARMACOL, V54, P298, DOI 10.1124/mol.54.2.298; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; Garner RC, 1998, MUTAT RES-FUND MOL M, V402, P67; Godschalk RWL, 1998, CARCINOGENESIS, V19, P819, DOI 10.1093/carcin/19.5.819; Godschalk RWL, 2001, PHARMACOGENETICS, V11, P389, DOI 10.1097/00008571-200107000-00003; Goldman R, 2001, CANCER RES, V61, P6367; Grant DJ, 2000, MOL CARCINOGEN, V29, P198, DOI 10.1002/1098-2744(200012)29:4<198::AID-MC1001>3.0.CO;2-K; GRINBERGFUNES RA, 1994, CARCINOGENESIS, V15, P2449, DOI 10.1093/carcin/15.11.2449; GRZYBOWSKA E, 1993, CARCINOGENESIS, V14, P2523, DOI 10.1093/carcin/14.12.2523; Grzybowska E, 2000, MUTAT RES-GEN TOX EN, V469, P271, DOI 10.1016/S1383-5718(00)00090-5; Gupta RC, 1999, MUTAT RES-FUND MOL M, V424, P195, DOI 10.1016/S0027-5107(99)00019-6; Hardie LJ, 2000, CARCINOGENESIS, V21, P167, DOI 10.1093/carcin/21.2.167; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; Hecht SS, 2001, TOXICOLOGY, V166, P31, DOI 10.1016/S0300-483X(01)00436-X; HEGMANN KT, 1993, EPIDEMIOLOGY, V4, P444, DOI 10.1097/00001648-199309000-00010; Helleberg H, 2001, MUTAGENESIS, V16, P333, DOI 10.1093/mutage/16.4.333; Hemminki K, 2001, INT J CANCER, V92, P923, DOI 10.1002/ijc.1273; Hemminki K, 2000, REGUL TOXICOL PHARM, V32, P264, DOI 10.1006/rtph.2000.1431; Hirao T, 2001, CANCER RES, V61, P612; Hoque A, 2001, CANCER CAUSE CONTROL, V12, P627, DOI 10.1023/A:1011277600059; Hou SM, 2001, CANCER EPIDEM BIOMAR, V10, P133; Hu X, 1999, CANCER RES, V59, P2358; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Jacobson JS, 2000, CANCER EPIDEM BIOMAR, V9, P1303; Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020; Josyula S, 2000, INT J ONCOL, V17, P811; Kadlubar FF, 1998, MUTAT RES-FUND MOL M, V405, P125, DOI 10.1016/S0027-5107(98)00129-8; Kantarci OH, 2002, MAYO CLIN PROC, V77, P17, DOI 10.4065/77.1.17; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Kihara M, 1999, CANCER LETT, V137, P53, DOI 10.1016/S0304-3835(98)00337-1; Kriek E, 1998, MUTAT RES-FUND MOL M, V400, P215, DOI 10.1016/S0027-5107(98)00065-7; Kure EH, 1996, CARCINOGENESIS, V17, P2201, DOI 10.1093/carcin/17.10.2201; Kyrtopoulos SA, 2001, MUTAT RES-GEN TOX EN, V496, P207, DOI 10.1016/S1383-5718(01)00222-4; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; Leuratti C, 1998, CARCINOGENESIS, V19, P1919, DOI 10.1093/carcin/19.11.1919; Li DH, 2001, CANCER RES, V61, P1445; Li DH, 2002, MUTAT RES-GEN TOX EN, V513, P37, DOI 10.1016/S1383-5718(01)00291-1; Li DH, 2001, INT J CANCER, V93, P436, DOI 10.1002/ijc.1347.abs; Lodovici M, 1998, CHEM-BIOL INTERACT, V116, P199, DOI 10.1016/S0009-2797(98)00091-X; London SJ, 1997, CANCER RES, V57, P5001; Long DJ, 2000, CHEM-BIOL INTERACT, V129, P99, DOI 10.1016/S0009-2797(00)00200-3; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Martone T, 1998, INT J CANCER, V75, P512, DOI 10.1002/(SICI)1097-0215(19980209)75:4<512::AID-IJC4>3.0.CO;2-W; Marzilli LA, 2001, METH MOL B, V162, P395; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Melendez-Colon VJ, 1999, CARCINOGENESIS, V20, P1885, DOI 10.1093/carcin/20.10.1885; MelendezColon VJ, 1997, P NATL ACAD SCI USA, V94, P13542, DOI 10.1073/pnas.94.25.13542; Melikian AA, 1999, ONCOL REP, V6, P1371; Melikian AA, 1999, CANCER LETT, V146, P127, DOI 10.1016/S0304-3835(99)00203-7; Misra RR, 2001, CANCER LETT, V164, P161, DOI 10.1016/S0304-3835(01)00384-6; Mitsudomi T, 1996, CLIN CANCER RES, V2, P1185; Moller L, 1996, CARCINOGENESIS, V17, P61, DOI 10.1093/carcin/17.1.61; Moller P, 1998, MUTAT RES-REV MUTAT, V410, P271, DOI 10.1016/S1383-5742(97)00041-0; Mollerup S, 1999, CANCER RES, V59, P3317; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; MOONEY LA, 1995, CANCER EPIDEM BIOMAR, V4, P627; Motykiewicz G, 1998, TOXICOL LETT, V96-7, P195, DOI 10.1016/S0378-4274(98)00072-1; Nair J, 1998, CARCINOGENESIS, V19, P2081, DOI 10.1093/carcin/19.12.2081; Nath RG, 1998, CANCER RES, V58, P581; Nelson HH, 2002, CANCER RES, V62, P152; Nelson HH, 1998, CANCER RES, V58, P1804; Ni JS, 1998, ANAL BIOCHEM, V264, P222, DOI 10.1006/abio.1998.2835; Nia AB, 2000, ENVIRON MOL MUTAGEN, V36, P127, DOI 10.1002/1098-2280(2000)36:2<127::AID-EM7>3.0.CO;2-G; Nia AB, 2000, CARCINOGENESIS, V21, P1335, DOI 10.1093/carcin/21.7.1335; Nowell S, 2000, PHARMACOGENETICS, V10, P789, DOI 10.1097/00008571-200012000-00004; Olshan AF, 2002, CANCER LETT, V178, P181, DOI 10.1016/S0304-3835(01)00822-9; Ozawa S, 1999, CARCINOGENESIS, V20, P991, DOI 10.1093/carcin/20.6.991; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; Palli D, 2001, INT J CANCER, V94, P121, DOI 10.1002/ijc.1433; Pan G, 1998, CARCINOGENESIS, V19, P1963, DOI 10.1093/carcin/19.11.1963; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P23; Pavanello S, 1999, CARCINOGENESIS, V20, P431, DOI 10.1093/carcin/20.3.431; Pavanello S, 2000, MUTAT RES-REV MUTAT, V463, P285, DOI 10.1016/S1383-5742(00)00051-X; PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713; Peluso M, 2000, CARCINOGENESIS, V21, P183, DOI 10.1093/carcin/21.2.183; Peluso M, 1998, CANCER EPIDEM BIOMAR, V7, P341; PERERA F, 1992, ENVIRON HEALTH PERSP, V98, P133, DOI 10.2307/3431259; PERERA F, 1989, CANCER RES, V49, P4446; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; Petruzzelli S, 1998, CANCER RES, V58, P4122; Phillips DH, 2000, ENVIRON MOL MUTAGEN, V35, P222, DOI 10.1002/(SICI)1098-2280(2000)35:3<222::AID-EM9>3.0.CO;2-E; Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Piipari R, 2000, INT J CANCER, V86, P610, DOI 10.1002/(SICI)1097-0215(20000601)86:5<610::AID-IJC2>3.0.CO;2-M; Povey AC, 2000, TOXICOL PATHOL, V28, P405, DOI 10.1177/019262330002800308; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Reddy MV, 2000, REGUL TOXICOL PHARM, V32, P256, DOI 10.1006/rtph.2000.1430; Ren Q, 2000, DRUG METAB DISPOS, V28, P1352; Risch A, 2001, PHARMACOGENETICS, V11, P757, DOI 10.1097/00008571-200112000-00003; Roberts KP, 2000, ELECTROPHORESIS, V21, P799, DOI 10.1002/(SICI)1522-2683(20000301)21:4<799::AID-ELPS799>3.3.CO;2-M; Rojas M, 2000, CARCINOGENESIS, V21, P35, DOI 10.1093/carcin/21.1.35; Rojas M, 2001, CARCINOGENESIS, V22, P1015, DOI 10.1093/carcin/22.7.1015; Rojas M, 1998, PHARMACOGENETICS, V8, P109; Romano G, 1999, CANCER EPIDEM BIOMAR, V8, P91; RYBERG D, 1994, CANCER RES, V54, P5801; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Saha BK, 2001, CELL MOL LIFE SCI, V58, P1141, DOI 10.1007/PL00000928; SAVELA K, 1991, CARCINOGENESIS, V12, P503, DOI 10.1093/carcin/12.3.503; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; Schoket B, 2001, MUTAT RES-FUND MOL M, V482, P57, DOI 10.1016/S0027-5107(01)00210-X; Schoket B, 1998, CARCINOGENESIS, V19, P841, DOI 10.1093/carcin/19.5.841; SCHOKET B, 1993, IARC SCI PUBL, V124, P315; SETO H, 1993, ARCH ENVIRON CON TOX, V24, P498, DOI 10.1007/BF01146169; SHIELDS PG, 1993, CANCER RES, V53, P3486; Shinozaki R, 1999, ARCH ENVIRON HEALTH, V54, P79, DOI 10.1080/00039899909602240; Shinozaki R, 1998, CYTOMETRY, V31, P300, DOI 10.1002/(SICI)1097-0320(19980401)31:4<300::AID-CYTO10>3.0.CO;2-U; Soni M, 1998, TOXICOLOGY, V126, P155, DOI 10.1016/S0300-483X(98)00010-9; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P125; Sturgis EM, 1999, CARCINOGENESIS, V20, P2125, DOI 10.1093/carcin/20.11.2125; Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669; Sundberg K, 2002, CHEM RES TOXICOL, V15, P170, DOI 10.1021/tx015546t; Szeliga J, 1998, CHEM RES TOXICOL, V11, P1, DOI 10.1021/tx970142f; Szyfter K, 1999, MUTAT RES-GEN TOX EN, V445, P259, DOI 10.1016/S1383-5718(99)00131-X; Szyfter K, 1999, ACTA BIOCHIM POL, V46, P275, DOI 10.18388/abp.1999_4161; TALASKA G, 1994, CANCER LETT, V84, P93, DOI 10.1016/0304-3835(94)90362-X; TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350; Tan WG, 2001, J CHROMATOGR A, V924, P377, DOI 10.1016/S0021-9673(01)00987-6; TANG DL, 1995, CANCER EPIDEM BIOMAR, V4, P341; Tang DL, 1998, CARCINOGENESIS, V19, P1949, DOI 10.1093/carcin/19.11.1949; Tang DL, 2001, CANCER RES, V61, P6708; Thier R, 2001, MUTAT RES-FUND MOL M, V482, P41, DOI 10.1016/S0027-5107(01)00208-1; Thurston SW, 2000, BIOMETRICS, V56, P139, DOI 10.1111/j.0006-341X.2000.00139.x; Timbrell JA, 1998, TOXICOLOGY, V129, P1, DOI 10.1016/S0300-483X(98)00058-4; Topinka J, 2000, MUTAT RES-GEN TOX EN, V469, P83, DOI 10.1016/S1383-5718(00)00061-9; Turteltaub KW, 1998, TOXICOL LETT, V103, P435, DOI 10.1016/S0378-4274(98)00344-0; Uno S, 2001, BIOCHEM BIOPH RES CO, V289, P1049, DOI 10.1006/bbrc.2001.6110; Vainio H, 1998, TOXICOL LETT, V103, P581, DOI 10.1016/S0378-4274(98)00252-5; van Delft JHM, 1998, CRIT REV TOXICOL, V28, P477, DOI 10.1080/10408449891344254; Van Delft JHM, 1998, ANN OCCUP HYG, V42, P105, DOI 10.1016/S0003-4878(97)00055-0; Van Delft JHM, 2001, ANN OCCUP HYG, V45, P395, DOI 10.1016/S0003-4878(00)00065-X; van Lieshout EMM, 1999, CANCER RES, V59, P586; VAN SF, 1998, FASEB J, V12, P1409; Viezzer C, 1999, MUTAT RES-FUND MOL M, V431, P259, DOI 10.1016/S0027-5107(99)00169-4; VINEIS P, 1992, ENVIRON HEALTH PERSP, V98, P95, DOI 10.2307/3431253; Vineis P, 1996, Ann Ist Super Sanita, V32, P21; Vineis P, 2000, MUTAT RES-REV MUTAT, V463, P103; Vulimiri SV, 2000, MOL CARCINOGEN, V27, P34, DOI 10.1002/(SICI)1098-2744(200001)27:1<34::AID-MC6>3.0.CO;2-G; Wang MY, 1998, CANCER RES, V58, P38; Wang Y, 1998, IND HEALTH, V36, P337, DOI 10.2486/indhealth.36.337; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wei QY, 2000, J NATL CANCER I, V92, P1764; Whyatt RM, 1998, CARCINOGENESIS, V19, P1389, DOI 10.1093/carcin/19.8.1389; Whyatt RM, 2000, CANCER EPIDEM BIOMAR, V9, P207; Whyatt RM, 2001, CANCER EPIDEM BIOMAR, V10, P581; Wiencke J., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P562; Wiencke JK, 1999, J NATL CANCER I, V91, P614, DOI 10.1093/jnci/91.7.614; WIENCKE JK, 1995, CANCER RES, V55, P4910; WIENCKE JK, 2002, ENV HLTH PERSPEC JUN; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Williams M D, 2001, Cancer Treat Res, V105, P31; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Xing JZ, 2001, METH MOL B, V162, P419; Yang K, 1998, MUTAT RES-FUND MOL M, V422, P285, DOI 10.1016/S0027-5107(98)00210-3; Yang SC, 2000, CHEM RES TOXICOL, V13, P1046, DOI 10.1021/tx0000419; Yi P, 1998, CHEM RES TOXICOL, V11, P1032, DOI 10.1021/tx9800497; Yueh MF, 2001, CARCINOGENESIS, V22, P943, DOI 10.1093/carcin/22.6.943; Zhang J, 2000, INT ARCH OCC ENV HEA, V73, P127, DOI 10.1007/s004200050018; Zhou GD, 2000, MUTAT RES-FUND MOL M, V447, P137, DOI 10.1016/S0027-5107(99)00211-0; Zienolddiny S, 2001, BRIT J CANCER, V84, P226, DOI 10.1054/bjoc.2000.1528	196	118	119	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2002	21	48					7376	7391		10.1038/sj.onc.1205799	http://dx.doi.org/10.1038/sj.onc.1205799			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379880				2022-12-17	WOS:000178618000010
J	Kleer, CG; Zhang, YH; Pan, Q; van Golen, KL; Wu, ZF; Livant, D; Merajver, SD				Kleer, CG; Zhang, YH; Pan, Q; van Golen, KL; Wu, ZF; Livant, D; Merajver, SD			WISP3 is a novel tumor suppressor gene of inflammatory breast cancer	ONCOGENE			English	Article						WISP3; breast cancer; tumor suppressor gene; angiogenesis	FACTOR-BINDING PROTEIN; IMMEDIATE-EARLY GENE; MAMMARY EPITHELIAL-CELLS; TISSUE GROWTH-FACTOR; RHOC GTPASE; IGF-I; FAMILY; CYR61; EXPRESSION; SENESCENCE	Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with a 5-year disease-free survival of less than 45%. Little is known about the genetic alterations that result in IBC. In our previous work, we found that WISP3 was specifically lost in human IBC tumors when compared to stage-matched, non-IBC tumors. We hypothesize that WISP3 has tumor suppressor function in the breast and that it may be a key genetic alteration that contributes to the unique IBC phenotype. The full-length WISP3 cDNA was sequenced and cloned into an expression vector. The resulting construct was introduced in to the SUM149 cell line that was derived from a patient with IBC and lacks WISP3 expression. In soft agar, stable WISP3 transfectants formed significantly fewer colonies than the controls. Stable WISP3 transfectants lost their ability to invade and had reduced angiogenic potential. WISP3 transfection was effective in suppressing in vivo tumor growth in nude mice. Mice bearing WISP3 expressing tumors had a significantly longer survival than those with vector-control transfectant tumors. Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis.	Univ Michigan, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kleer, CG (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Univ Hosp 2G332, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	kleer@umich.edu	Pan, Quintin/E-3808-2011		NATIONAL CANCER INSTITUTE [R01CA077612, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 46592, R01 CA 77612] Funding Source: Medline; NCRR NIH HHS [M01 RR 00042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Byun D, 2001, J ENDOCRINOL, V169, P135, DOI 10.1677/joe.0.1690135; ETHIER SP, 1993, CANCER RES, V53, P627; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; JAIYESIMI IA, 1992, J CLIN ONCOL, V10, P1014, DOI 10.1200/JCO.1992.10.6.1014; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Lee BJ, 1924, SURG GYNECOL OBSTET, V39, P580; Li WX, 1996, MOL PATHOL, V49, P91; LIVANT DL, 1995, CANCER RES, V55, P5085; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Merajver SD, 1997, J CLIN ONCOL, V15, P2873, DOI 10.1200/JCO.1997.15.8.2873; NISSANOV J, 1995, LAB INVEST, V73, P734; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sprenger CC, 1999, CANCER RES, V59, P2370; SWAIN SM, 1987, CANCER RES, V47, P3889; Tsugu A, 2000, AM J PATHOL, V157, P919, DOI 10.1016/S0002-9440(10)64605-6; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Xu LF, 2000, GENE DEV, V14, P585	30	118	120	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3172	3180		10.1038/sj.onc.1205462	http://dx.doi.org/10.1038/sj.onc.1205462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082632				2022-12-17	WOS:000175373600008
J	Sheta, EA; Trout, H; Gildea, JJ; Harding, MA; Theodorescu, D				Sheta, EA; Trout, H; Gildea, JJ; Harding, MA; Theodorescu, D			Cell density mediated pericellular hypoxia leads to induction of HIF-1 alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways	ONCOGENE			English	Article						cell hypoxia; oxygen; nuclear proteins; nitric oxide; Ras proteins	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; PROTEIN-TYROSINE PHOSPHORYLATION; HUMAN ERYTHROPOIETIN GENE; COLON-CARCINOMA CELLS; HUMAN PROSTATE-CANCER; SMOOTH-MUSCLE CELLS; FACTOR EXPRESSION; DEPENDENT REGULATION; TUMOR ANGIOGENESIS	Environmental signals in the cellular milieu such as hypoxia, growth factors, extracellular matrix (ECM), or cell-surface molecules on adjacent cells can activate signaling pathways that communicate the state of the environment to the nucleus. Several groups have evaluated gene expression or signaling pathways in response to increasing cell density as an in vitro surrogate for in vivo cell-cell interactions. These studies have also perhaps assumed that cells grown at various densities in standard in vitro incubator conditions do not have different pericellular oxygen levels. However, pericellular hypoxia can be induced by increasing cell density, which can exert profound influences on the target cell lines and may explain a number of findings previously attributed to normoxic cell-cell interactions. Thus, we first sought to test the hypothesis that cell-cell interactions as evaluated by the surrogate approach of increasing in vitro cell density in routine normoxic culture conditions results in pericellular hypoxia in prostate cancer cells. Second, we sought to evaluate whether such interactions affect transcription mediated by the hypoxia response element (HRE). Thirdly, we sought to elucidate the signal transduction pathways mediating the induction of HRE in response to cell density induced pericellular hypoxia in routine normoxic culture conditions. Our results indicate that paracrine cell interactions can induce nuclear localization of HIF-1a protein and this translocation is associated with strong stimulation of the HRE-reporter activity. We also make the novel observation that cell density-induced activity of the HRE is dependent on nitric oxide production, which acts as a diffusible paracrine factor secreted by densely cultured cells. These results suggest that paracrine cell interactions associated with pericellular hypoxia lead to the physiological induction of HRE activity via the cooperative action of Ras, MEK1, HIF-1a via pericellular diffusion of nitric oxide. In addition, these results highlight the importance of examining pericellular hypoxia as a possible stimulus in experiments involving in vitro cell density manipulation even in routine normoxic culture conditions.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.		Harding, Michael/C-3438-2013	Harding, Michael/0000-0001-8636-067X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMANO F, 1995, FEBS LETT, V368, P425, DOI 10.1016/0014-5793(95)00700-J; BAIRD A, 1986, BIOCHEM BIOPH RES CO, V138, P476, DOI 10.1016/0006-291X(86)90305-0; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; Bedrin MS, 1997, J CELL PHYSIOL, V172, P126, DOI 10.1002/(SICI)1097-4652(199707)172:1<126::AID-JCP14>3.3.CO;2-N; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gioeli D, 1999, CANCER RES, V59, P279; GROEBE K, 1988, INT J RADIAT ONCOL, V15, P691, DOI 10.1016/0360-3016(88)90313-6; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kharitonov VG, 1999, BIOCHEMISTRY-US, V38, P10699, DOI 10.1021/bi990277f; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Koura AN, 1996, CANCER RES, V56, P3891; Leung LK, 1998, CANCER LETT, V124, P47, DOI 10.1016/S0304-3835(97)00430-8; Li PM, 1996, J CELL BIOCHEM, V61, P31, DOI 10.1002/(SICI)1097-4644(19960401)61:1<31::AID-JCB5>3.0.CO;2-3; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; Mazure NM, 1996, CANCER RES, V56, P3436; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; METZEN E, 1995, RESP PHYSIOL, V100, P101, DOI 10.1016/0034-5687(94)00125-J; Minamiyama Y, 1997, ARCH BIOCHEM BIOPHYS, V341, P186, DOI 10.1006/abbi.1997.9956; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; MOULDER JE, 1984, INT J RADIAT ONCOL, V10, P695, DOI 10.1016/0360-3016(84)90301-8; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Palmer LA, 1998, CHEST, V114, p33S, DOI 10.1378/chest.114.1_Supplement.33S; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Perkinson RA, 1996, J CELL BIOCHEM, V63, P74; POLK DB, 1995, J CELL PHYSIOL, V162, P427, DOI 10.1002/jcp.1041620315; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rouquette Magali, 1997, Biochemical Society Transactions, V25, p532S; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Sheta EA, 2000, J NATL CANCER I, V92, P1065, DOI 10.1093/jnci/92.13.1065; SILVERSTEIN JL, 1988, ARCH DERMATOL, V124, P1379, DOI 10.1001/archderm.124.9.1379; Singh RK, 1996, CELL GROWTH DIFFER, V7, P397; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; THEODORESCU D, 1991, J CELL PHYSIOL, V148, P380, DOI 10.1002/jcp.1041480308; Tokuda Y, 2000, J CELL PHYSIOL, V182, P414, DOI 10.1002/(SICI)1097-4652(200003)182:3<414::AID-JCP12>3.0.CO;2-5; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; WERRLEIN RJ, 1974, NATURE, V251, P317, DOI 10.1038/251317a0; YOSHIMOTO Y, 1995, J NEUROSURG, V83, P867, DOI 10.3171/jns.1995.83.5.0867; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 2000, CANCER RES, V60, P1541	62	118	121	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2001	20	52					7624	7634		10.1038/sj.onc.1204972	http://dx.doi.org/10.1038/sj.onc.1204972			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753640				2022-12-17	WOS:000172124100005
J	Dohn, M; Jiang, JY; Chen, XB				Dohn, M; Jiang, JY; Chen, XB			Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis	ONCOGENE			English	Article						EphA2; apoptosis; p53; p73; p63	FOCAL-ADHESION-KINASE; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; NEURAL DEVELOPMENT; MAMMALIAN-CELLS; HUMAN CANCERS; P73; GENE; EPHRINS	The p53 tumor suppressor protein is mutated in more than 50% of all human cancers, which makes the study of its functions and activities critical for the understanding and management of cancer. In response to cellular stresses, p53 is activated and can mediate cell cycle arrest and/or apoptosis via the upregulation of numerous target genes. Here, we have identified EphA2 as a target gene of the p53 family, that is, p53, p73, and p63. We also found that an increase of EphA2 transcript levels correlated with an increase of EphA2 protein expression, and induction of EphA2 in response to DNA damage corresponded with p53 activation. Furthermore, we identified a p53 response element located within the EphA2 promoter that is responsive to wild-type p53, p73, and p63, but not mutant p53. Interestingly, the ligand for EphA2, ephrin-A1, is also regulated by p53. EphA2 and ephrin-A1 are members of the Eph family of receptor tyrosine kinases and ligands, which are implicated in a number of developmental processes. To analyse the role of EphA2 in p53-mediated tumor suppression, we generated stable cell lines capable of expressing exogenous EphA2 in a tetracycline-repressible system. We found that EphA2 expression resulted in an increase in apoptosis. Thus, we hypothesize that the activated EphA2 may serve to impair anti-apoptotic signaling, perhaps by disrupting focal adhesions and thereby sensitize cells to pro-apoptotic stimuli.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [R01 CA81237, R29 CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HARPER JW, 1993, CELL, V75, P805; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1998, J CELL BIOL, V143, P547; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; MIYASHITA T, 1995, CELL, V80, P293; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Prives C, 1999, J PATHOL, V187, P112; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Shimada A, 1999, CANCER RES, V59, P2781; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zaika AI, 1999, CANCER RES, V59, P3257; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	64	118	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6503	6515		10.1038/sj.onc.1204816	http://dx.doi.org/10.1038/sj.onc.1204816			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641774				2022-12-17	WOS:000171404200002
J	Ahrens, T; Sleeman, JP; Schempp, CM; Howells, N; Hofmann, M; Ponta, H; Herrlich, P; Simon, JC				Ahrens, T; Sleeman, JP; Schempp, CM; Howells, N; Hofmann, M; Ponta, H; Herrlich, P; Simon, JC			Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid	ONCOGENE			English	Article						malignant melanoma; hyaluronic acid; CD44; shedding	MAMMARY-CARCINOMA CELLS; HUMAN BREAST-CANCER; MATRIX REORGANIZATION; EXTRACELLULAR DOMAIN; METASTASIS FORMATION; SPLICE VARIANTS; L-SELECTIN; ADHESION; EXPRESSION; MIGRATION	Proteolytic cleavage of the extracellular domain of CD44 from the surface of cells has been observed recently in different cell types, In cell culture supernatants of human melanoma cell lines a 70 kDa soluble CD44 protein (soICD44) was detected at concentrations of 250-300 ng/ml. Protease inhibitor studies revealed that serine proteases and metalloproteases are involved in the cleavage of CD44 from the surface of melanoma cells. To analyse a possible function of soluble CD44 a human malignant melanoma cell line was stably transfected with cDNAs encoding either wild type soluble CD44s or mutated forms with defective HA binding properties (CD44sR41A and CD44sR150A/R154A). Soluble CD44s almost completely inhibited hyaluronic acid binding by melanoma cells, whereas soluble CD44 mutated in the HA binding domain had no effect, When cultivated on hyaluronic acid, melanoma cell proliferation was induced by 30% for both the parental and the control transfected cells. This increase in proliferation was blocked completely in solCD44s-secreting transfectants, whereas solCD44sR41A and solCD44sR150A/R154A-secreting cells again showed hyaluronic acid-induced cell proliferation, These cell lines were subcutaneously injected into MF1 nu/nu mice to compare their growth as tumors in vivo. Compared to tumors derived from parental and control transfected cells, we observed a dramatic reduction of primary tumor growth with solCD44s expressing MM cells. Transfectants expressing solCD44s mutated in the HA binding domain in contrast developed fast-growing primary tumors. These results provide strong evidence that direct solCD44 interactions with hyaluronic acid interfere competively with processes induced by hyaluronic acid binding to surface CD44, Autocrine, or drug-induced secretion of solCD44 by human melanoma cells may thus exert potent antitumoral effects in vivo.	Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany; Lion Biosci AG, D-69120 Heidelberg, Germany	University of Freiburg; Helmholtz Association; Karlsruhe Institute of Technology	Simon, JC (corresponding author), Univ Freiburg, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.		Sleeman, Jonathan P/H-2515-2013; Hofmann-Apitius, Martin/E-6123-2018	Sleeman, Jonathan P/0000-0003-1718-7687; Hofmann-Apitius, Martin/0000-0001-9012-6720				Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BAZIL V, 1992, J IMMUNOL, V149, P747; BAZIL V, 1995, IMMUNOL TODAY, V16, P135, DOI 10.1016/0167-5699(95)80130-8; BAZIL V, 1994, J IMMUNOL, V152, P1314; Champagne B, 1998, J IMMUNOL, V161, P6398; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Dietrich A, 1997, EUR J CANCER, V33, P926, DOI 10.1016/S0959-8049(96)00512-6; Fichtner I, 1997, ANTICANCER RES, V17, P3633; Friedl P, 1997, CANCER RES, V57, P2061; GALANDRINI R, 1994, J IMMUNOL, V153, P21; Goebeler M, 1996, J CELL SCI, V109, P1957; Greco RM, 1998, J CELL PHYSIOL, V177, P465, DOI 10.1002/(SICI)1097-4652(199812)177:3<465::AID-JCP9>3.0.CO;2-5; Gunthert AR, 1996, J CELL BIOL, V134, P1089, DOI 10.1083/jcb.134.4.1089; GUO YJ, 1994, CANCER RES, V54, P422; HAMANN KJ, 1995, J IMMUNOL, V154, P4073; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Itano N, 1999, CANCER RES, V59, P2499; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kosaki R, 1999, CANCER RES, V59, P1141; Lackner C, 1998, BREAST CANCER RES TR, V47, P29, DOI 10.1023/A:1005913514376; LECA G, 1995, J IMMUNOL, V154, P1069; LIAO HX, 1995, J IMMUNOL, V155, P3938; Maaser K, 1999, MOL BIOL CELL, V10, P3067, DOI 10.1091/mbc.10.10.3067; Martin S, 1997, INT J CANCER, V74, P443, DOI 10.1002/(SICI)1097-0215(19970822)74:4<443::AID-IJC14>3.3.CO;2-1; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Rafi A, 1997, BLOOD, V89, P2901, DOI 10.1182/blood.V89.8.2901; Ropponen K, 1998, CANCER RES, V58, P342; Schaider H, 1997, J AM ACAD DERMATOL, V36, P209, DOI 10.1016/S0190-9622(97)70282-2; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Simon JC, 1996, EUR J CANCER, V32A, P1394, DOI 10.1016/0959-8049(96)00196-7; Sleeman JP, 1996, CANCER RES, V56, P3134; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TURLEY EA, 1987, BIOCHEMISTRY-US, V26, P2997, DOI 10.1021/bi00385a007; Victor R, 1999, INT J CANCER, V82, P77, DOI 10.1002/(SICI)1097-0215(19990702)82:1<77::AID-IJC14>3.0.CO;2-Q; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zawadzki V, 1998, INT J CANCER, V75, P919, DOI 10.1002/(SICI)1097-0215(19980316)75:6<919::AID-IJC15>3.3.CO;2-V; Zeimet AG, 1997, BRIT J CANCER, V76, P1646, DOI 10.1038/bjc.1997.611; ZHANG LR, 1995, CANCER RES, V55, P428	51	118	126	1	16	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3399	3408		10.1038/sj.onc.1204435	http://dx.doi.org/10.1038/sj.onc.1204435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423990				2022-12-17	WOS:000169248800010
J	Mahmoudi, T; Verrijzer, CP				Mahmoudi, T; Verrijzer, CP			Chromatin silencing and activation by Polycomb and trithorax group proteins	ONCOGENE			English	Review						polycomb; trithorax; chromatin; epigenetics; transcription	POSITION-EFFECT VARIEGATION; DROSOPHILA BITHORAX COMPLEX; GAGA TRANSCRIPTION FACTOR; CHROMOSOME-BINDING-SITES; HOMEOTIC GENE-EXPRESSION; MYC TRANSGENIC MICE; CELL-CYCLE ARREST; EXTRA-SEX-COMBS; DNA-BINDING; EPIGENETIC INHERITANCE	The Polycomb group (PcG) of repressors and the trithorax group (trxG) of activators maintain the correct expression of several keg developmental regulators, including the homeotic genes. PcG and trxG proteins function in distinct multiprotein complexes that are believed to control transcription by changing the structure of chromatin, organizing it into either a 'closed' or an 'open' conformation. The hallmark of gene regulation by PcG/trxG proteins is that it can lead to a mitotically stable pattern of gene expression, often referred to as epigenetic regulation. Although much remains to be learned, recent studies have provided insights into how this epigenetic switch is set, holy PcG/trxG proteins might be linked to cis-acting DNA elements and what potential mechanisms underlie stable inheritance of gene expression status over multiple cell divisions. Finally, the study of the evolutionarily conserved PcG/trxG factors has recently gained additional urgency with the realization that they play a pertinent role in certain human cancers.	Leiden Univ, Med Ctr, MGC Ctr Biomed Genet, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Verrijzer, CP (corresponding author), Leiden Univ, Med Ctr, MGC Ctr Biomed Genet, Dept Mol Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.							Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Benyajati C, 1997, NUCLEIC ACIDS RES, V25, P3345, DOI 10.1093/nar/25.16.3345; Bhat KM, 1996, DEVELOPMENT, V122, P1113; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; BREEN TR, 1993, DEVELOPMENT, V117, P119; Breen TR, 1999, GENETICS, V152, P319; Breiling A, 1999, MOL CELL BIOL, V19, P8451; Brizuela BJ, 1997, MECH DEVELOP, V65, P209, DOI 10.1016/S0925-4773(97)00081-6; BRIZUELA BJ, 1994, GENETICS, V137, P803; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Busturia A, 1997, DEVELOPMENT, V124, P4343; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Cavalli G, 1999, SCIENCE, V286, P955, DOI 10.1126/science.286.5441.955; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHEN JD, 1993, EMBO J, V12, P2075, DOI 10.1002/j.1460-2075.1993.tb05856.x; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; CHIANG A, 1995, DEVELOPMENT, V121, P1681; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Fritsch C, 1999, DEVELOPMENT, V126, P3905; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GINDHART JG, 1995, GENETICS, V139, P797; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hagstrom K, 1997, GENETICS, V146, P1365; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Horard B, 2000, MOL CELL BIOL, V20, P3187, DOI 10.1128/MCB.20.9.3187-3197.2000; INGHAM P, 1980, MOL GEN GENET, V179, P607, DOI 10.1007/BF00271751; INGHAM PW, 1983, NATURE, V306, P591, DOI 10.1038/306591a0; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; JUDD BH, 1995, GENETICS, V141, P245; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kal AJ, 2000, GENE DEV, V14, P1058; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KASSIS JA, 1994, GENETICS, V136, P1025; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; LONIE A, 1994, DEVELOPMENT, V120, P2629; Lyko F, 1999, BIOESSAYS, V21, P824; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Mihaly J, 1998, MOL CELL, V1, P1065, DOI 10.1016/S1097-2765(00)80107-0; MULLER J, 1991, EMBO J, V10, P3147, DOI 10.1002/j.1460-2075.1991.tb04876.x; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Ohtsuki S, 1998, GENE DEV, V12, P3325, DOI 10.1101/gad.12.21.3325; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Papoulas O, 1998, DEVELOPMENT, V125, P3955; Paro R, 2000, NATURE, V406, P579, DOI 10.1038/35020675; PELEGRI F, 1994, GENETICS, V136, P1341; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PHILLIPS MD, 1990, GENETICS, V125, P91; PILLUS L, 1995, CHROMATIN STRUCTURE, P123; PIRROTTA V, 1988, GENE DEV, V2, P1839, DOI 10.1101/gad.2.12b.1839; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1999, BBA-REV CANCER, V1424, pM1; Platero JS, 1998, J CELL BIOL, V140, P1297; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rosen C, 1998, GENETICS, V148, P1865; Rozenblatt-Rosen O, 1998, P NATL ACAD SCI USA, V95, P4152, DOI 10.1073/pnas.95.8.4152; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; SCHLOSSHERR J, 1994, MOL GEN GENET, V243, P453; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; SEDKOV Y, 1994, DEVELOPMENT, V120, P1907; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sharp EJ, 1997, CHROMOSOMA, V106, P70, DOI 10.1007/s004120050226; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; STJOHNSTON D, 1992, CELL, V68, P201; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; STRUHL G, 1985, EMBO J, V4, P3259, DOI 10.1002/j.1460-2075.1985.tb04075.x; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tie F, 1998, DEVELOPMENT, V125, P3483; Tillib S, 1999, MOL CELL BIOL, V19, P5189; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Vazquez M, 1999, DEVELOPMENT, V126, P733; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wade PA, 1999, CURR BIOL, V9, pR221, DOI 10.1016/S0960-9822(99)80134-1; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; WALLRATH LL, 1995, GENE DEV, V9, P1263, DOI 10.1101/gad.9.10.1263; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wilkins RC, 1997, NUCLEIC ACIDS RES, V25, P3963, DOI 10.1093/nar/25.20.3963; Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	148	118	120	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3055	3066		10.1038/sj.onc.1204330	http://dx.doi.org/10.1038/sj.onc.1204330			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420721				2022-12-17	WOS:000169308500009
J	Stepczynska, A; Lauber, K; Engels, IH; Janssen, O; Kabelitz, D; Wesselborg, S; Schulze-Osthoff, K				Stepczynska, A; Lauber, K; Engels, IH; Janssen, O; Kabelitz, D; Wesselborg, S; Schulze-Osthoff, K			Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation	ONCOGENE			English	Article						anticancer drugs; apoptosis; caspase; staurosporine; CD95	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CYTOCHROME-C; CELL-DEATH; AKT PHOSPHORYLATION; WILD-TYPE; CD95; FAS; PROTEASE; RELEASE; MITOCHONDRIA	Apoptosis can be induced by various stimuli including DNA-damaging anticancer drugs and the protein kinase inhibitor staurosporine, It is generally believed that the molecular events during execution of apoptosis are shared, as both anticancer drugs and staurosporine derivatives induce mitochondrial damage, cytochrome c release and the activation of the caspase-9 proteolytic cascade. In the present study we show that overexpression of a dominant-negative caspase-9 mutant abolished the activation of endogenous caspase-9, caspase-3 and the cleavage of the caspase substrate Bid in response to anticancer drug treatment, Surprisingly, however, only marginal effects were observed during staurosporine-induced apoptosis, Furthermore, we describe a Jurkat T-cell clone that is completely resistant towards different anticancer drugs, but remains sensitive towards staurosporine-induced apoptosis, In these cells only staurosporine, but neither anti-CD95 nor anticancer drugs were able to trigger caspase activity and the cleavage of caspase substrates. Our results therefore suggest that the mechanism of staurosporine-induced apoptosis is more complex and at least partially differs from anticancer drug-induced caspase activation. These distinct features of staurosporine may allow to bypass chemoresistance of tumor cells and may encourage further clinical trials for the use of staurosporine derivatives in antitumor therapy.	Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Tubingen, Dept Internal Med 1, D-72074 Tubingen, Germany; Univ Kiel, Inst Immunol, D-24098 Kiel, Germany	University of Munster; Eberhard Karls University of Tubingen; University of Kiel	Schulze-Osthoff, K (corresponding author), Univ Munster, Dept Immunol & Cell Biol, Rontgenstr 21, D-48149 Munster, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Kabelitz, Dieter/AAB-4199-2021; Janssen, Ottmar/E-9735-2010; Janssen, Ottmar/N-8769-2019; Kabelitz, Dieter/A-2757-2010	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Janssen, Ottmar/0000-0002-9612-8900; Janssen, Ottmar/0000-0002-9612-8900; Wesselborg, Sebastian/0000-0002-5236-942X				Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Drew L, 1998, INT IMMUNOL, V10, P877, DOI 10.1093/intimm/10.7.877; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Fulda S, 1997, CANCER RES, V57, P3823; Gamen S, 1997, FEBS LETT, V417, P360, DOI 10.1016/S0014-5793(97)01282-9; Gescher A, 1998, GEN PHARMACOL, V31, P721, DOI 10.1016/S0306-3623(98)00069-X; Han Z, 2000, CELL DEATH DIFFER, V7, P521, DOI 10.1038/sj.cdd.4400681; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Janssen O, 1996, IMMUNOL LETT, V49, P63, DOI 10.1016/0165-2478(95)02482-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Villunger A, 1997, CANCER RES, V57, P3331; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	54	118	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2001	20	10					1193	1202		10.1038/sj.onc.1204221	http://dx.doi.org/10.1038/sj.onc.1204221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313863				2022-12-17	WOS:000167570100006
J	De Valck, D; Jin, DY; Heyninck, K; Van de Craen, M; Contreras, R; Fiers, W; Jeang, KT; Beyaert, R				De Valck, D; Jin, DY; Heyninck, K; Van de Craen, M; Contreras, R; Fiers, W; Jeang, KT; Beyaert, R			The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases	ONCOGENE			English	Article						A20; TNF; tax; apoptosis; caspases	TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; HUMAN ENDOTHELIAL-CELLS; HTLV-I TAX; FACTOR-ALPHA; ICE/CED-3 PROTEASE; SIGNALING PROTEINS; COMMON MEDIATOR; EXPRESSION; INDUCTION	A20 is a Cys(2)/Cys(2) zinc finger protein which is induced by a variety of inflammatory stimuli and which has been characterized as an inhibitor of cell death by a yet unknown mechanism. In order to clarify its molecular mechanism of action, we used the yeast two-hybrid system to screen for proteins that interact with A20. A cDNA fragment was isolated which encoded a portion of a novel protein (TXBP151), which was recently found to be a human T-cell leukemia virus type-I (HTLV-I) Tax-binding protein. The full-length 2386bp TXBP151 mRNA encodes a protein of 86kDa, Like A20, overexpression of TXBP151 could inhibit apoptosis induced by tumour necrosis factor (TNF) in NIH3T3 cells, Moreover, transfection of antisense TXBP151 partially abolished the anti-apoptotic effect of A20, Furthermore, apoptosis induced by TNF or CD95 (Fas/ APO-1) was associated with proteolysis of TXBP151. This degradation could be inhibited by the broad-spectrum caspase inhibitor zVAD-fmk or by expression of the cowpox virus-derived inhibitor CrmA, suggesting that TXBP151 is a novel substrate for caspase family members. TXBP151 was indeed found to be specifically cleaved in vitro by members of the caspase-3-like subfamily, viz, caspase-3, caspase-6 and caspase-7, Thus TXBP151 appears to be a novel A20-binding protein which might mediate the anti-apoptotic activity of A20, and which can be processed by specific caspases.	Flanders Interuniv Inst Biotechnol, Dept Biol Mol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	Ghent University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Biol Mol, Ledeganckstr 35, B-9000 Ghent, Belgium.		Jeang, Kuan-Teh/A-2424-2008; Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; DeValck D, 1996, FEBS LETT, V384, P61, DOI 10.1016/0014-5793(96)00283-9; DeValck D, 1997, BIOCHEM BIOPH RES CO, V238, P590, DOI 10.1006/bbrc.1997.7343; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FEARNHEAD HO, 1995, FEBS LETT, V375, P283, DOI 10.1016/0014-5793(95)01228-7; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; HENNET T, 1993, CANCER RES, V53, P1456; Heyninck K, 1999, FEBS LETT, V442, P147, DOI 10.1016/S0014-5793(98)01645-7; Jaattela M, 1996, J IMMUNOL, V156, P1166; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; LAHERTY CD, 1993, J BIOL CHEM, V268, P5032; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MERTENS N, 1995, GENE, V164, P9, DOI 10.1016/0378-1119(95)00505-Z; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; RUBIN BY, 1988, CANCER RES, V48, P6006; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; SPORN SA, 1990, J IMMUNOL, V144, P4434; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	46	118	124	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4182	4190		10.1038/sj.onc.1202787	http://dx.doi.org/10.1038/sj.onc.1202787			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435631				2022-12-17	WOS:000081542400002
J	Kortylewski, M; Heinrich, PC; Mackiewicz, A; Schniertshauer, U; Klingmuller, U; Nakajima, K; Hirano, T; Horn, F; Behrmann, I				Kortylewski, M; Heinrich, PC; Mackiewicz, A; Schniertshauer, U; Klingmuller, U; Nakajima, K; Hirano, T; Horn, F; Behrmann, I			Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1	ONCOGENE			English	Article						melanoma; STAT; interleukin-6; oncostatin M; p27/Kip; growth arrest	SIGNAL TRANSDUCER GP130; EMBRYONIC STEM-CELLS; TUMOR-NECROSIS-FACTOR; TRANSCRIPTIONAL ACTIVATION; STRUCTURAL CHARACTERIZATION; TYROSINE PHOSPHORYLATION; TERMINAL DIFFERENTIATION; PROTEIN EXPRESSION; CYTOKINE RECEPTORS; CYTOPLASMIC REGION	Interleukin-6 (IL-6)-type cytokines lead to growth arrest of human A375 melanoma cells. The present study demonstrates that this effect depends on the activation of STAT transcription factors. We observed a correlation between the extent of growth inhibition exerted by IL-6, IL-6 plus soluble IL-6 receptor or oncostatin M (OSM) and the intensities of STAT3 and STAT1 signals. A truncated chimeric receptor retaining only the membrane-proximal region of gp130, the common signal transducer of IL-6-type cytokines, did neither activate STATs nor mediate growth arrest of stable transfectants. These functions were restored by the addition of short STAT recruitment modules comprising critical tyrosine residues from gp130 (Y767, Y814). A receptor carrying tyrosine module Y759 of gp130 effectively mediated activation of the phosphatase SHP-2 but did not alter cell growth. Overexpression of dominant negative forms of STAT3 but not STAT1 abrogated the inhibitory effect of OSM and IL-6 in A375 cells. In addition, we have identified the cyclin-dependent kinase inhibitor p27/Kip1 as a novel target to be regulated by IL-6-type cytokines. Stimulation-dependent upregulation of p27 mRNA occurred STAT3-dependently, Also p27 protein accumulated which coincided with the disappearance of hyperphosphorylated retinoblastoma protein in three human melanoma cell lines sensitive to IL-6-type cytokines.	Rhein Westfal TH Aachen, Dept Biochem, D-52074 Aachen, Germany; Poznan Univ Tech, Sch Med Sci, Dept Canc Immunol, PL-61866 Poznan, Poland; Max Planck Inst Immunobiol, Spemann Lab, D-79108 Freiburg, Germany; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Mol Oncol, Suita, Osaka 565, Japan; Univ Leipzig, Sect Mol Immmunol, Inst Clin Immunol & Transfus Med, D-04129 Leipzig, Germany	RWTH Aachen University; Poznan University of Technology; Max Planck Society; Osaka University; Leipzig University	Behrmann, I (corresponding author), Rhein Westfal TH Aachen, Dept Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.		Klingmüller, Ursula/G-8477-2013; Hirano, Toshio/C-8194-2009; Kortylewski, Marcin/H-8052-2019	Klingmüller, Ursula/0000-0001-9845-3099; Kortylewski, Marcin/0000-0002-6003-1816; Behrmann, Iris/0000-0003-3688-3645				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Ganapathi MK, 1996, CELL GROWTH DIFFER, V7, P923; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; Hirano T, 1998, Int Rev Immunol, V16, P249; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; KUMAR G, 1994, J IMMUNOL, V153, P4436; Lee IS, 1997, FEBS LETT, V401, P133, DOI 10.1016/S0014-5793(96)01456-1; Lu C, 1996, CLIN CANCER RES, V2, P1417; LU C, 1993, CANCER RES, V53, P2708; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; MACKIEWICZ A, 1992, J IMMUNOL, V149, P2021; Manenti S, 1998, CANCER RES, V58, P1429; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; May P, 1996, FEBS LETT, V394, P221, DOI 10.1016/0014-5793(96)00955-6; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MORINAGA Y, 1989, J IMMUNOL, V143, P3538; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPORENO E, 1994, CYTOKINE, V6, P255, DOI 10.1016/1043-4666(94)90021-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; Symes A, 1997, CURR BIOL, V7, P697, DOI 10.1016/S0960-9822(06)00298-3; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKIZAWA H, 1993, CANCER RES, V53, P4175; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	56	118	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3742	3753		10.1038/sj.onc.1202708	http://dx.doi.org/10.1038/sj.onc.1202708			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391682				2022-12-17	WOS:000081140200008
J	Dorkin, TJ; Robinson, MC; Marsh, C; Bjartell, A; Neal, DE; Leung, HY				Dorkin, TJ; Robinson, MC; Marsh, C; Bjartell, A; Neal, DE; Leung, HY			FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease	ONCOGENE			English	Article						FGF8; prostate cancer; patient survival; androgen independent	FIBROBLAST GROWTH-FACTORS; MOLECULAR-CLONING; CARCINOMA-CELLS; FACTOR-VIII; TISSUES; INDUCTION; FORMS	Identification of prostate cancers at high risk of progression is difficult and a better understanding of how peptide growth factors influence cellular function might be useful. Fibroblast growth factors (FGFs) have been implicated in prostate cancer development. FGF8 was identified in the Shionogi mouse mammary carcinoma SC-3 cell line as an androgen-induced mitogen. We tested if FGF8 was over-expressed in human prostate cancer and if its expression correlated with clinical data and outcome. One hundred and six cases of prostate cancer and ten cases of BPH were examined. In situ hybridization was employed to detect FGF8 mRNA expression, which,vas identified within the malignant prostatic epithelium in 85/106 (80.2%) cases, Increased expression of FGF8 correlated significantly with higher Gleason scores (P=0.0004) and advanced tumour stage (P=0.0016), Using immunohistochemistry, me confirmed over-expression of the FGF8b isoform, Men with tumours which expressed high levels of FGF8 had worse survival (P=0.034), although FGF8 mRNA was not able to provide additional prognostic information in a multivariate analysis. Additionally, FGF8 expression was shown to persist in androgen independent prostate cancer. Using a range of normal adult tissues, FGF8 expression was restricted to neurones and the germinal epithelium in addition to the prostate, in vitro studies demonstrated that in the presence of neutralizing antibody to FGF8b there was significant inhibition of prostate cancer cell growth, confirming the biological significance of FGF8 in prostate carcinogenesis.	Newcastle Univ, Sch Med, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Freeman Rd Hosp, Dept Pathol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Hosp, Dept Urol, S-20502 Malmo, Sweden	Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Lund University; Skane University Hospital	Leung, HY (corresponding author), Newcastle Univ, Sch Med, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.			Leung, Hing Y./0000-0002-3933-3975; Neal, David/0000-0002-6033-5086				Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Ghosh AK, 1996, CELL GROWTH DIFFER, V7, P1425; Ittman M, 1997, J UROLOGY, V157, P351, DOI 10.1016/S0022-5347(01)65376-X; Lee SMK, 1997, DEVELOPMENT, V124, P959; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Leung HY, 1996, ONCOGENE, V12, P1833; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MYERS RL, 1995, ONCOGENE, V11, P785; *OFF NAT STAT, 1996, DH2962 OFF NAT STAT; Payson RA, 1996, ONCOGENE, V13, P47; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Schmitt JF, 1996, J STEROID BIOCHEM, V57, P173, DOI 10.1016/0960-0760(95)00259-6; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Suzuki H, 1998, CANCER RES, V58, P204; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; YAZIDI IE, 1995, ANTICANCER, V15, P783	21	118	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2755	2761		10.1038/sj.onc.1202624	http://dx.doi.org/10.1038/sj.onc.1202624			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348350				2022-12-17	WOS:000080124900011
J	Maeda, A; Scharenberg, AM; Tsukada, S; Bolen, JB; Kinet, JP; Kurosaki, T				Maeda, A; Scharenberg, AM; Tsukada, S; Bolen, JB; Kinet, JP; Kurosaki, T			Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1	ONCOGENE			English	Article						PIR-B; ITIM; SHP-1; SHP-2; tyrosine phosphorylation	CELL ANTIGEN RECEPTOR; TYROSINE-PHOSPHATASE SHP-1; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-2; CA2+ MOBILIZATION; DISTINCT PATHWAYS; KINASE LYN; INVOLVEMENT; LYMPHOCYTES; REQUIREMENT	Coligation of paired immunoglobulin-like receptor B (PIR-B) with B cell antigen receptor (BCR) blocks antigen-induced B cell activation. This inhibition is mediated in part by recruitment of SHP-1 and SHP-2 to the phosphorylated ITIMs in the cytoplasmic domain of PIR-B; however the molecular target(s) of these phosphatases remain elusive. Here,ve show that PIR-B ligation inhibits the BCR-induced tyrosine phosphorylation of Ig alpha/Ig beta, Syk, Btk and phospholipase C (PLC)-gamma 2 Overexpression of a catalgtically inactive form of SHP-1 prevents the PIR-B-mediated inhibition: of tyrosine phosphorylation of Syk, Btk, and PLC-gamma 2. Dephosphorylation of Syk and Btk mediated by SHP-1 leads to a decrease of their kinase activity, which in turn inhibits tyrosine phosphorylation of PLC-gamma 2. Furthermore, we define a requirement for Lan in mediating tyrosine phosphorylation of PIR-B, Based on these results, we propose a model of PIR-B-mediated inhibitory signaling in which coligation of PIR-B and BCR results in phosphorylation of ITIMs by Lyn, subsequent recruitment of SHP-1, and a resulting inhibition of the BCR-induced inositol 1,4,5-trisphosphate generation by dephosphorylation of Syk and Btk.	Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 5708506, Japan; Beth Israel Hosp, Lab Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hoechst Marion Roussel, Bridgewater, NJ 08807 USA	Kansai Medical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kurosaki, T (corresponding author), Kansai Med Univ, Dept Mol Genet, Inst Liver Res, Moriguchi, Osaka 5708506, Japan.		Maeda, Akito/AAX-6252-2020; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X; Maeda, Akito/0000-0001-8776-9135				BABA Y, IN PRESS BLOOD; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gupta N, 1997, J EXP MED, V186, P473, DOI 10.1084/jem.186.3.473; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hippen KL, 1997, IMMUNITY, V7, P49, DOI 10.1016/S1074-7613(00)80509-9; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; TAKATA M, 1995, J EXP MED, V182, P907, DOI 10.1084/jem.182.4.907; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	34	118	122	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2291	2297		10.1038/sj.onc.1202552	http://dx.doi.org/10.1038/sj.onc.1202552			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327049	Bronze			2022-12-17	WOS:000079595500001
J	Hurlstone, AFL; Reid, G; Reeves, JR; Fraser, J; Strathdee, G; Rahilly, M; Parkinson, EK; Black, DM				Hurlstone, AFL; Reid, G; Reeves, JR; Fraser, J; Strathdee, G; Rahilly, M; Parkinson, EK; Black, DM			Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines	ONCOGENE			English	Article						CAVEOLIN-1; CpG island; methylation; tumour suppressor gene	ONCOGENICALLY TRANSFORMED-CELLS; PRIMARY BREAST-CANCER; ROUS-SARCOMA VIRUS; SUPPRESSOR GENE; FREQUENT LOSS; LONG ARM; TYROSINE PHOSPHORYLATION; INDEFINITE DIVISION; PROTEIN-COMPONENT; MEMBRANE-PROTEIN	We identified CAVEOLIN-1 as a candidate for a tumour suppresser gent mapping to human chromosome 7q31.1. A number of studies suggest that caveolin could function as a tumour suppressor. Expression of caveolin, and in turn the number of caveolae within a cell, are inversely correlated with the transforming ability of numerous oncoproteins, including H-ras, v-abl, and bcr-abl, and caveolin is a major transformation-dependent substrate of v-src. Heterologous expression of caveolin has been shown to abrogate anchorage-independent growth and induce apoptosis in transformed fibroblasts and also to suppress anchorage-independent growth in human mammary carcinoma cells. We have analysed the status and expression of the human CA VEOLIN-1 gene in primary tumours and tumour-derived cell lines. We found no evidence for mutation of CAVEOLIN-1 in human cancers, Additionally, we found that while the first two exons of CAVEOLIN-1 are associated with a CpG island, this is not methylated in either primary tumours or in tumour-derived cell lines in which Caveolin-1 expression is low or undetectable. The level of expression of Caveolin-1 does not correlate,vith loss of heterozygosity at the CAVEOLIN-1 locus in these same cell lines. Contrary to other published studies, we have shown that CAVEOLIN-1 is not expressed in normal breast ductal epithelial cells in vivo. CAVEOLIN-1 is however highly expressed in breast myoepithelial cells and its expression is retained in tumours derived from breast myoepithelium. Together our data refute a role for CAVEOLIN-1 as a breast tumour suppressor gene in vivo.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Dept Med Oncol, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Stobhill Gen Hosp, Dept Pathol, Glasgow G21 3UW, Lanark, Scotland; Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland	Beatson Institute; Beatson Institute; University of Glasgow; Royal Infirmary of Edinburgh; University of Glasgow	Black, DM (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			Strathdee, Gordon/0000-0001-9681-8429; Reid, George/0000-0002-0298-693X; Hurlstone, Adam/0000-0001-5260-9457				Achille A, 1996, CANCER RES, V56, P3808; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HERMAN JG, 1995, CANCER RES, V55, P4525; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Loughran O, 1996, ONCOGENE, V13, P561; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REESE MG, 1996, LARGE SCALE SEQUENCI; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHULER GD, 1996, SCIENCE, V274, P50; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 1997, ONCOGENE, V14, P109, DOI 10.1038/sj.onc.1200806; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 1996, GENOME RES, V6, P1070, DOI 10.1101/gr.6.11.1070	50	118	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1881	1890		10.1038/sj.onc.1202491	http://dx.doi.org/10.1038/sj.onc.1202491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086342				2022-12-17	WOS:000079090000011
J	Jeffers, M; Rong, S; Anver, M; VandeWoude, GF				Jeffers, M; Rong, S; Anver, M; VandeWoude, GF			Autocrine hepatocyte growth factor scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells	ONCOGENE			English	Article						hepatocyte growth factor scatter factor; Met; transformation; invasion; metastasis	FACTOR/SCATTER FACTOR; EPITHELIAL-CELLS; CARCINOMA-CELLS; TYROSINE KINASE; PROTOONCOGENE; RECEPTOR; TUMORIGENICITY; EXPRESSION; INDUCTION; INVASION	Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector of cells expressing the Met tyrosine kinase receptor. C127 is a non-tumorigenic mouse cell line which expresses negligible levels of HGF/SF and Met proteins. In the present report we have generated C127 cells which overexpress HGP/SF and/or Met proteins, and have analysed the effect of HGF/SF-Met signaling in these cells. We show that this signaling pathway stimulates the growth and invasiveness of C127 cells in vitro and that cells overexpressing both HGF/SF and Met proteins (but neither alone) are phenotypically transformed and highly tumorigenic and metastatic in vivo. Our data unequivocally demonstrates the autocrine dependency of HGF/SF-Met-induced transformation and metastasis in this system and supports the theory that the inappropriate expression of HGF/SF and Met proteins could play a role in the development and spread of human tumors. In addition, this system may be useful for identifying metastasis-associated genes that are activated by HGF/SF-Met signaling.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								BELLUSCI S, 1994, ONCOGENE, V9, P1091; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DVORETZKY I, 1980, VIROLOGY, V103, P309; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Higashio K, 1993, EXS, V65, P351; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JEFFERS M, 1996, UNPUB; KANDA H, 1993, ONCOGENE, V8, P3047; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Matsumoto K, 1993, HEPATOCYTE GROWTH FA, P225; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PORTEOUS DJ, 1986, INT J CANCER, V38, P603, DOI 10.1002/ijc.2910380422; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; ROSEN EM, 1991, CANCER RES, V51, P5315; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sambrook J, 1989, MOL CLONING LAB MANU; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SINGHKAW P, 1995, AM J PHYSIOL-LUNG C, V268, pL1012, DOI 10.1152/ajplung.1995.268.6.L1012; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT A, 1995, DEVELOPMENT, V121, P813; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG Y, 1995, J CELL BIOL, V131, P1	49	118	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					853	861						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761307				2022-12-17	WOS:A1996VD43300021
J	Theile, M; Seitz, S; Arnold, W; Jandrig, B; Frege, R; Schlag, PM; Haensch, W; Guski, H; Winzer, KJ; Barrett, JC; Scherneck, S				Theile, M; Seitz, S; Arnold, W; Jandrig, B; Frege, R; Schlag, PM; Haensch, W; Guski, H; Winzer, KJ; Barrett, JC; Scherneck, S			A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer	ONCOGENE			English	Article						breast cancer; tumor suppressor genes; chromosome 6q; LOH analysis; microcell-mediated chromosome transfer; estrogen receptor	ESTROGEN-RECEPTOR GENE; IMMORTAL HUMAN FIBROBLASTS; HUMAN OVARIAN CARCINOMAS; HUMAN-MALIGNANT MELANOMA; 2 DISTINCT REGIONS; FREQUENT LOSS; LINKAGE MAP; CELL-LINES; HUMAN GENOME; WILD-TYPE	Recent evidence obtained by cytogenetic and molecular studies indicates that in breast cancer chromosome 6q is often affected by genetic changes suggesting the existence of putative tumor suppressor genes (TSGs). However the function of gene(s) on this chromosome in breast cancer suppession is not understood. To substantiate further the presence of breast cancer related TSGs at 60 and to define their location, we first performed microcell-mediated transfer of chromosome 6 to CAL51 breast cancer cells for studying possible suppression of malignant phenotype and secondly, we analysed DNAs from 46 primary breast cancers for loss of constitutive heterozygosity (LOH) using 24 polymorphic microsatellite markers, The chromosome transfer resulted in loss of tumorigenicity and reversion of other neoplastic properties of the microcell hybrids. Polymorphism analysis of single hybrids revealed that they harbored only a small donor chromosome fragment defined by the marker D6S310 (6q23.3-q25) and flanked by D65292 and D6S311, The LOH data suggest that four tumor suppressor gene loci mapped to the central and distal portion of 6q may be independently deleted in breast cancer. One of these regions corresponds to the region identified by chromosome transfer.	MAX DELBRUCK CTR MOL MED,FORSCH GRP ONKOL & TUMORIMMUNOL,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,ROBERT ROSSLE KLIN,ABT CHIRURG & CHIRURG ONKOL,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,D-10117 BERLIN,GERMANY; NIEHS,MOL CARCINOGENESIS LAB,NIH,RES TRIANGLE PK,NC 27709	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Theile, M (corresponding author), MAX DELBRUCK CTR MOL MED,ARBEITSGRP TUMORGENET,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							ANDERSEN TI, 1994, HUM GENET, V94, P665; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CASTLES CG, 1995, BRIT J CANCER, V71, P974, DOI 10.1038/bjc.1995.188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Del Senno L., 1992, Human Molecular Genetics, V1, P354; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FUQUA SAW, 1990, J NATL CANCER I, V82, P858, DOI 10.1093/jnci/82.10.858; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; LASTOWSKA MA, 1994, CANCER GENET CYTOGEN, V77, P99, DOI 10.1016/0165-4608(94)90222-4; LEBEAU MM, 1986, BLOOD, V67, P844; LEE JH, 1990, CANCER RES, V50, P2724; LU YJ, 1993, CANCER GENET CYTOGEN, V69, P91, DOI 10.1016/0165-4608(93)90081-V; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; MILLIKIN D, 1991, CANCER RES, V51, P5449; MORITA R, 1991, CANCER RES, V51, P5817; NEGRINI M, 1994, CANCER RES, V54, P1331; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; STEINARSDOTTIR M, 1995, GENE CHROMOSOME CANC, V13, P239, DOI 10.1002/gcc.2870130403; THEILE M, 1995, ONCOGENE, V10, P439; THEILE M, 1994, INT J ONCOL, V4, P1067; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; VISAKORPI T, 1995, CANCER RES, V55, P342; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WAN MH, 1994, INT J ONCOL, V5, P1043; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELCH DR, 1994, ONCOGENE, V9, P255; YAICH L, 1992, CANCER RES, V52, P77; YAMADA H, 1990, ONCOGENE, V5, P1141; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	60	118	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					677	685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761288				2022-12-17	WOS:A1996VD43300002
J	Meyers, S; Lenny, N; Sun, WH; Hiebert, SW				Meyers, S; Lenny, N; Sun, WH; Hiebert, SW			AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia	ONCOGENE			English	Article						AML-1; translocation; leukemia; transcription	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; DNA-BINDING; GENE; EXPRESSION; IDENTIFICATION; CELLS; TRANSLOCATION; PROMOTER	AML-1B is targeted directly and indirectly in multiple chromosomal translocations in myeloid and B-cells. The AML-1/ETO and TEL/AML-1 fusion proteins, created by the t(8;21) and t(12;21) respectively, disrupt AML-1B-dependent transcription. Recently, two human members of the runt homology domain family of transcription factors have been identified, AML-2 and AML-3, which also regulate transcription through enhancer core motifs. If multiple factors regulate transcription through the same site, a dominant interfering protein may be required to promote leukemogenesis, rather than the inactivation of both AML1 alleles. To determine which AML family proteins are active in hematopoietic cells, we developed antisera specific to each family member for use in gel mobility shift assays. We have found that AML-1B is the major DNA binding activity in T-cell lines, while both AML-1B and AML-2 are expressed in myeloid and B-cell lines. AML-1B represents most of the active protein in the mouse thymus, whereas AML-1 and AML-2 are equally expressed in the mouse spleen. AML-3 is expressed at very low levels in a single myeloid cell line, 32D.3, and is the only core binding activity present in Buffalo rat liver cells. We demonstrate that AML-2-dependent transactivation mediated by enhancer core motifs is inhibited by the AML-1/ETO and TEL/AML-1 fusion proteins. This indicates that the t(8;21) and t(12;21) fusion proteins inhibit transcriptional activation by the AML-1 transcription factor family, and in so doing contributes to leukemogenesis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN USA	St Jude Children's Research Hospital			Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA064140, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765, R01 CA-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HIBERT SW, 1996, MOL CELL BIOL, V16, P1349; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; WANG S, 1993, EMBO J, V13, P3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	38	118	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					303	312						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710369				2022-12-17	WOS:A1996VA25200009
J	Akagi, T; Ono, H; Shimotohno, K				Akagi, T; Ono, H; Shimotohno, K			Expression of cell-cycle regulatory genes in HTLV-I infected T-cell lines: Possible involvement of Tax1 in the altered expression of cyclin D2, p18(Ink4) and p21(Waf1/Cip1/Sdi1)	ONCOGENE			English	Article						HTLV-I; Tax1; cyclin; cdk; cdk-inhibitor; immortalization	PRIMARY HUMAN-LYMPHOCYTES; LEUKEMIA-VIRUS TYPE-1; DEPENDENT KINASES; TRANS-ACTIVATION; PROTEIN; LEUKOCYTES	To understand how the growth of T-cells transformed by Human T-cell leukemia virus type I(HTLV-I) is deregulated, we analysed the expression of cell-cycle regulatory genes in HTLV-I infected and non-infected T-cell lines, We investigated the gene for 6 cyclins, 4 cyclin-dependent kinases, and 5 cyclin-dependent kinase inhibitors, and found the following: (1) HTLV-I infected T-cell lines preferentially expressed cyclin D2, whereas cyclin D3 was the major D-type cyclin in HTLV-I negative T-cell lines; (2) HTLV-I infected T-cell lines expressed strikingly low levels of p18(Ink4) compared with those that were HTLV-I negative; (3) HTLV-I infected T-cell lines expressed high levels of p21(Waf1/Cip1/Sdi1), whereas p21(Waf1/Cip1/Sdi1) was undetectable in HTVL-I negative T-cell lines, These features were also found in T-cells immortalized by Tax1, which we established, Therefore, it is strongly suggested that Tax1 alters the expression of these cell-cycle regulatory genes.	NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKAGI T, 1991, GENE, V106, P255, DOI 10.1016/0378-1119(91)90207-R; AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GAZDAR AF, 1980, BLOOD, V55, P409; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HIRAMA T, 1995, BLOOD, V86, P841; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JIANG HP, 1994, ONCOGENE, V9, P3397; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	48	118	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1645	1652						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622884				2022-12-17	WOS:A1996UG45800006
J	Kaya, M; Yoshida, K; Higashino, F; Mitaka, T; Ishii, S; Fujinaga, K				Kaya, M; Yoshida, K; Higashino, F; Mitaka, T; Ishii, S; Fujinaga, K			A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells	ONCOGENE			English	Article						ets-related E1AF; MMPs; invasion; motility	TUMOR-CELLS; NEGATIVE REGULATION; BASEMENT-MEMBRANE; IV COLLAGEN; EXPRESSION; METASTASIS; ONCOGENE; GENE; PEA3; METALLOPROTEINASES	Invasion of cancer cells is the first step of metastasis. The invasive activity is thought to be dependent on the production of matrix metalloproteinases (MMPs), The transcription regulatory regions of MMP genes often contain binding sites for Ets and AP-1 transcription factors and they mediate oncogene- and growth factor-induced transcription of the genes, We recently isolated the cDNA encoding human E1AF, a new member of ets oncogene family, E1AF highly stimulated transcription from three different subclasses of MMP genes in transient expression assays, Here we show that transfection of the non-invasive human breast cancer cell line MCF-7 with the E1AF expression plasmid results in induction of invasive and motile activities, accompanied by an increase of 92 kD type IV collagenase (MMP-9) gene expression, Tumors derived from the E1AF transfectant were highly invasive and produced MMP-9, Expression of E1AF and MMP-9 genes was elevated in several invasive tumor cell lines. These results provide evidence for an important role of ets-related E1AF in tumor cell invasion.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT MOLEC BIOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT PATHOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, DEPT ORTHOPED SURG, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University			Higashino, Fumihiro/F-8510-2012; Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				ALBINI A, 1987, CANCER RES, V47, P3239; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MOHLER JL, 1988, CANCER RES, V48, P4312; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, SEMIN CANCER BIOL, V1, P99; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POWELL WC, 1993, CANCER RES, V53, P417; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETH A, 1990, ADV AP BIOT, V6, P297; SHINDOH M, 1995, OBSTET GYNECOL, V85, P721, DOI 10.1016/0029-7844(95)00043-Q; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; YOSHIDA K, 1995, CURR TOP MICROBIOL, V199, P113	41	118	119	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					221	227						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570199				2022-12-17	WOS:A1996TR53800001
J	LEVIN, WJ; PRESS, MF; GAYNOR, RB; SUKHATME, VP; BOONE, TC; REISSMANN, PT; FIGLIN, RA; HOLMES, EC; SOUZA, LM; SLAMON, DJ				LEVIN, WJ; PRESS, MF; GAYNOR, RB; SUKHATME, VP; BOONE, TC; REISSMANN, PT; FIGLIN, RA; HOLMES, EC; SOUZA, LM; SLAMON, DJ			EXPRESSION PATTERNS OF IMMEDIATE-EARLY TRANSCRIPTION FACTORS IN HUMAN NONSMALL CELL LUNG-CANCER	ONCOGENE			English	Article						C-JUN; C-FOS; EGR1; NON-SMALL CELL LUNG; CANCER	C-FOS GENE; DNA-BINDING; PROTO-ONCOGENE; FACTOR EGR-1; RESPONSE ELEMENT; JUN ENCODES; 3T3 CELLS; GROWTH; DIFFERENTIATION; AP-1	In 1995, there will be 172 000 new cases of lung cancer diagnosed and 153 000 deaths from this disease in the United States. While the pathogenesis of the disease profess is poorly understood, a growing body of evidence suggests that abnormalities in cellular regulatory genes may play an important role in the induction, maintenance and/or progression of some tumor types. These genes include both growth promoting oncogenes as well as growth inhibitory or suppressor genes. Included among these genetic sequences are several cellular transcription factor. A group of these factors including c-jun, c-fos and EGR1 are members of a class of genes known as immediate early genes whose expression are inducible by a variety of stimuli including mitogenic and differentiation inducing growth factors, indicating a potential important role for these genes in normal growth processes. Since these genes are involved in early regulation of cellular growth properties and at least two (c-jun and c-fos) can act as oncogenes, we wished to determine whether their expression levels were altered in human non-small cell lung cancers (NSCLC) compared to normal lung tissue. To address this, Northern blot analyses were performed using c-fos, c-jun and EGR1 probes on RNA extracted from 101 NSCLC tumor specimens and adjacent uninvolved lung tissue. Analysis of this cohort revealed that 72% of the normal tissues demonstrate significantly greater expression of these transcription factors as compared to adjacent malignant tissue. Moreover, this expression pattern appeared to be coordinate for all three genes in the majority of cases. This differential expression pattern was confirmed at the protein level using an immunohistochemical approach with antibodies directed against the c-jun, c-fos and EGR1 gene products. Southern blot analyses demonstrated no gross alterations of these sequences at the DNA level, indicating that the observed differential expression pattern was not due to gross structural changes in the genes. These data suggest that downregulation of these genes may be involved in the pathogenesis of lung cancer.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT SURG, LOS ANGELES, CA 90024 USA; UNIV SO CALIF, SCH MED, DEPT PATHOL, LOS ANGELES, CA 90033 USA; UNIV TEXAS, SW MED CTR, DEPT MED, DALLAS, TX 75235 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Amgen			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA36827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAICHWAL VR, 1990, CELL, V59, P979; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GINSBERG RJ, 1993, CHEST S4, V104, pS356; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILBERG F, 1992, ONCOGENE, V7, P2371; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IP YT, 1990, MOL CELL BIOL, V10, P3782, DOI 10.1128/MCB.10.7.3782; JOISHY SK, 1977, ANN INTERN MED, V87, P447, DOI 10.7326/0003-4819-87-4-447; KORNUC M, 1990, J VIROL, V64, P2004, DOI 10.1128/JVI.64.5.2004-2013.1990; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINNA JD, 1989, INT J CANCER, P32; MOLINARRODE R, 1993, MOL CELL BIOL, V13, P3213, DOI 10.1128/MCB.13.6.3213; MOOLGAVKAR SH, 1989, J NATL CANCER I, V81, P415, DOI 10.1093/jnci/81.6.415; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PRESS MF, 1990, ONCOGENE, V5, P953; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOLM M, 1992, ANTICANCER RES, V12, P11; VOLM M, 1993, CLIN EXP METASTAS, V11, P325, DOI 10.1007/BF00058052; WATSON WL, 1966, CANCER, V19, P776, DOI 10.1002/1097-0142(196606)19:6<776::AID-CNCR2820190606>3.0.CO;2-J; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	67	118	125	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	1995	11	7					1261	1269						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478546				2022-12-17	WOS:A1995RY96700006
J	LIN, JY; TERESKY, AK; LEVINE, AJ				LIN, JY; TERESKY, AK; LEVINE, AJ			2 CRITICAL HYDROPHOBIC AMINO-ACIDS IN THE N-TERMINAL DOMAIN OF THE P53 PROTEIN ARE REQUIRED FOR THE GAIN OF FUNCTION PHENOTYPES OF HUMAN P53 MUTANTS	ONCOGENE			English	Note						MUTANT P53; TRANSACTIVATION; TUMORIGENICITY; GAIN OF FUNCTION PHENOTYPES	LARGE-T-ANTIGEN; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; CELLS; DNA; GENE; RAS; IMMORTALIZATION; MODULATION	Some mutant forms of the p53 protein have been shown to gain new functions that are not shared by the wildtype p53 protein; (1) mutant p53 proteins can transcriptionally transactivate the multi-drug resistance gene-1 (MDR-1) and (2) when expressed in nontumorigenic cells with no endogenous p53 protein, mutant p53 proteins can enhance the tumorigenic potential of these cells (Dittmer et at, 1993). It has recently been shown (Lin et al., 1994b) that the transcriptional activator domain of the p53 protein contains two amino acids, leu-22 and trp-23, which are required by the wild-type p53 protein for transcriptional activity. To determine whether these same amino acid residues are utilized by mutant p53 proteins for their gain of function phenotype, the triple mutant p53 protein (at residues 22 and 23 in the transactivation domain and residue 281 in the DNA binding domain-a gain of function mutant) was made. While the p53-281 mutant transcriptionally activates the MDR-1 gene and enhances the tumorigenic potential of cells it is expressed in, the 22, 23, 281 triple mutant failed to carry out either of these functions.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University			Lin, Jiayuh/E-3515-2011					BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIN J, 1994, IN PRESS COLD SPG HB, V59; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIOU G, 1990, LANCET, V335, P1171; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, ONCOGENE, V6, P2055; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	30	118	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2387	2390						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784087				2022-12-17	WOS:A1995RE54300014
J	SHAOUL, E; REICHSLOTKY, R; BERMAN, B; RON, D				SHAOUL, E; REICHSLOTKY, R; BERMAN, B; RON, D			FIBROBLAST GROWTH-FACTOR RECEPTORS DISPLAY BOTH COMMON AND DISTINCT SIGNALING PATHWAYS	ONCOGENE			English	Article						FGF RECEPTORS SIGNALING; PROLIFERATION; LIGAND DEPENDENT TRANSFORMATION; TYROSINE PHOSPHORYLATION; KGF; AFGF	HIGH-AFFINITY RECEPTOR; FGF RECEPTOR; EXPRESSION PATTERN; TYROSINE KINASE; FACTOR FAMILY; CDNA CLONING; GENE FAMILY; BINDING; HEPARIN; MOUSE	We compared the mitogenic and signaling pathways of three Fibroblast Growth Factor Receptors (FGFRs), FGFR1, KGFR and FGFR4 in the same cell line. Each receptor was expressed in L6E9 rat myoblasts that do not normally express detectable levels of FGFRs and clones that express comparable levels of each receptor were selected. Our results show that FGFs induce an effective survival and growth of FGFR1 and KGFR expressing cells. In addition, these cells exhibit a morphology that is reminiscent of that of malignantly transformed cells and display anchorage independent growth in a ligand dependent manner. Unlike KGFR and FGFR1, FGFR4 mediates a less effective growth, and cells overexpressing this receptor do not undergo any morphological changes nor do they display an anchorage independent growth in response to FGFs, All three receptors exhibit both quantitative and qualitative differences in their ability to induce tyrosine phosphorylation of cellular substrates, Both FGFR1 and KGFR induce strong phosphorylation of phospholipase C-gamma and a 90 kDa protein, while FGFR4 induces a relatively weak phosphorylation of phospholipase C-gamma and completely fails to induce phosphorylation of the 90 kDa. The three receptors also induce phosphorylation of the mitogen activated protein kinases (MAPK) but the effect of FGFR1 is far stronger than that of the other two receptors, Since FGFR4 is expressed in myoblasts in vivo, we examined whether this receptor can function in the differentiation pathway of myoblasts. Contrary to its weak mitogenic activity, FGFR4 effectively mediates the inhibition of myogenic differentiation in L6E9 cells and also suppresses the expression of the myogenic regulatory protein myogenin, Taken together, our results suggest that the signaling mechanism of FGFR4 differs from that of FGFR1 and KGFR, and that the primary role of FGFR4 in myoblasts may be the maintenance of their non differentiated state.	TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	Technion Israel Institute of Technology								ARNAUD PC, 1991, ONCOGENE, V6, P979; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GINARD BN, 1978, CELL, V15, P855; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOUHARA H, 1994, ONCOGENE, V9, P455; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, P NATL ACAD SCI USA, V89, P3315, DOI 10.1073/pnas.89.8.3315; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; REICHSLOTKY R, 1994, J BIOL CHEM, V269, P32279; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STARK KL, 1991, DEVELOPMENT, V113, P641; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	64	118	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1553	1561						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731710				2022-12-17	WOS:A1995QU68100011
J	FRACCHIOLLA, NS; LOMBARDI, L; SALINA, M; MIGLIAZZA, A; BALDINI, L; BERTI, E; CRO, L; POLLI, E; MAIOLO, AT; NERI, A				FRACCHIOLLA, NS; LOMBARDI, L; SALINA, M; MIGLIAZZA, A; BALDINI, L; BERTI, E; CRO, L; POLLI, E; MAIOLO, AT; NERI, A			STRUCTURAL ALTERATIONS OF THE NF-KAPPA-B TRANSCRIPTION FACTOR LYT-10 IN LYMPHOID MALIGNANCIES	ONCOGENE			English	Note							NON-HODGKINS-LYMPHOMA; DNA-BINDING SUBUNIT; CELL-CYCLE CONTROL; V-REL; P65 SUBUNIT; C-REL; CHROMOSOMAL TRANSLOCATION; ONCOGENIC CONVERSION; PROTOONCOGENE BCL-3; PROTO-ONCOGENE	We have previously reported the identification of a novel putative proto-oncogene involved in the breakpoint of a t(10;14)(q24;q32) chromosomal translocation in a case of B-cell lymphoma. This gene, called lyt-10 (NFKB2/p52), is a member of the NF-KB family of transcription factors and displays a high degree of homology with the NFKB1/p50. Here we describe the genomic organization of the lyt-10 gene based on the restriction analysis of genomic phage clones and the sequence determination of exon-intron boundaries. The lyt-10 gene spans a genomic region of about 8 kb on 10q24, and contains 24 exons, ranging in size between 41 and 258 base pairs. To improve the understanding of the role of lyt-10 in lymphomagenesis, we performed Southern blot analysis to detect alterations of the lyt-10 gene in a large panel of cases representative of different types of lymphoid malignancies. We found rearrangements in 5 of 228 (approximately 2%) cases analysed: two cases of B-cell lymphoma, one case of multiple myeloma and two cases of T-cell lymphoma. The use of various probes specific for different regions of the lyt-10 locus revealed that rearrangements in positive cases lead to the partial or total deletion of the carboxy-terminal region containing the ankyrin domain. Taken together, our results indicate that lyt-10 gene rearrangements represent a recurrent lesion that may be involved in the pathogenesis of both B- and T-cell malignancies, and suggest that truncation of the ankyrin domain may be a common mechanism of lesion leading to abnormal lyt-10 activation in lymphoid neoplasia.	UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,SERV EMATOL,I-20122 MILAN,ITALY; UNIV MILAN,OSPED MAGGIORE,IRCCS,DERMATOL CLIN 1,I-20122 MILAN,ITALY	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan			Fracchiolla, Nicola Stefano/K-1915-2015; Berti, Emilio/F-5256-2012; neri, antonino/I-9690-2014	Fracchiolla, Nicola Stefano/0000-0002-5356-8690; Berti, Emilio/0000-0001-6753-4910; Baldini, Luca/0000-0003-2964-9981; Cro, Lilla Marcella/0000-0002-6007-5667; neri, antonino/0000-0001-9047-5912; Critelli, Salvatore/0000-0001-7325-0228; Fracchiolla, Nicola/0000-0002-8982-8079				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROTHMAN AR, 1990, CANCER RES, V50, P3795; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DELIA D, 1989, CANCER RES, V49, P4901; FAINBERG AP, 1983, ANAL BIOCHEM, V132, P6; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GRUMONT RJ, 1988, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Maniatis T., 1982, MOL CLONING; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; VANKRIEKEN JHJM, 1990, LEUKEMIA, V4, P811; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	45	118	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2839	2845						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378093				2022-12-17	WOS:A1993LX34300027
J	MADDEN, SL; COOK, DM; RAUSCHER, FJ				MADDEN, SL; COOK, DM; RAUSCHER, FJ			A STRUCTURE-FUNCTION ANALYSIS OF TRANSCRIPTIONAL REPRESSION MEDIATED BY THE WT1, WILMS-TUMOR SUPPRESSOR PROTEIN	ONCOGENE			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; ADENOVIRUS E1A PROTEIN; ZINC FINGER PROTEIN; MAMMALIAN-CELLS; EXPRESSION; ACTIVATION; PRODUCT; BINDING; DOMAINS; GROWTH	The chromosome 11p13 Wilms' tumor locus (wt1) encodes a zinc finger-containing transcription factor (WT1). WT1 binds to the consensus sequence (5'-GCGGGGGCG3') and represses transcription when bound to this site in vivo. The mechanism of repression is not yet defined. To investigate the mechanisms of transcriptional repression and map the domains of WT1 responsible, we constructed hybrid proteins between the yeast GAL4 1-147 DNA binding domain and WT1. Fusion of a 298 amino acid glutamine-proline-rich N-terminal segment of WT1 to the GAL4 DNA binding domain created a potent transcriptional repressor. The use of N- and C-terminal truncations of this segment demonstrated that as few as 96 amino acids were required for active repression by GAL4-WT1 hybrid proteins in NIH3T3 fibroblasts. However, the truncated GAL4-WT1 fusion proteins functioned poorly as repressors in embryonic kidney-derived 293 cells, suggesting cell type-specific requirements for transcriptional repression. Site-directed mutagenesis of the WT1 repression domain revealed that deletion of homopolymeric proline and glycine regions, as well as single amino acid changes, partially inactivated the repression function. Single repressor binding sites placed upstream of the transcription start site conferred WT1-mediated repression to a heterologous promoter, whereas multiple sites resulted in additive (non-synergistic) increases in transcriptional repression. Significant repression of transcription was observed when binding sites were placed 760 base pairs upstream or 1000 base pairs downstream relative to the site of transcription initiation. We conclude that the transcriptional repression function of WT1 is contained in the N-terminal, non-DNA binding domain of the protein and that repression can be functionally transferred to a heterologous DNA binding domain.	WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA10815, CA47983, CA52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, IN PRESS P NATL ACAD; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEVINS JR, 1992, SCIENCE, V258, P424; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHARMA PM, 1992, CANCER RES, V52, P6407; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	46	118	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1713	1720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510918				2022-12-17	WOS:A1993LG68200001
J	FEINSTEIN, E; GALE, RP; REED, J; CANAANI, E				FEINSTEIN, E; GALE, RP; REED, J; CANAANI, E			EXPRESSION OF THE NORMAL P53 GENE INDUCES DIFFERENTIATION OF K562 CELLS	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; WILD-TYPE P53; CYCLE CONTROL; LINE; GROWTH; SUPPRESSION; MECHANISMS; PROTEIN	The multistep nature of human cancers is well illustrated by chronic myelogenous leukemia (CML), a clonal hematologic malignancy with two distinct phases: chronic and acute. Transition between these phases is characterized by unregulated growth and loss of differentiation of myeloid cells and their progenitors. We recently reported that loss of normal p53 expression correlates with transition from the chronic to acute phase in at least 25% of cases of CML. However, the precise relationship between this loss and biologic features of acute-phase CMI, is uncertain. To study this question, we artificially expressed normal p53 in K562, an erythroid acute-phase CML cell line lacking normal p53 expression. Biological effects were assessed by determining several growth parameters and by measuring synthesis of hemoglobin, a feature of mature erythroid cells. K562 cells expressing normal p53 had an increased proportion of cells in G1 versus S + G2, a longer doubling time and a lower growth saturation density than control K562 cells or K562 cells with antisense p53. Cells with normal p53 also expressed up to 50-fold more hemoglobin than controls. These data are consistent with the notion that loss of p53 expression may be responsible for many of the features of acute-phase CML cells. The data also demonstrate direct involvement of p53 in differentiation processes.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19103; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL,PHILADELPHIA,PA 19107	Weizmann Institute of Science; University of California System; University of California Los Angeles; University of Pennsylvania; Jefferson University								ARLINGHAUS RB, 1991, MOL APPROACHES STUDY; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EISBRUCH A, 1988, CANCER-AM CANCER SOC, V62, P1171, DOI 10.1002/1097-0142(19880915)62:6<1171::AID-CNCR2820620621>3.0.CO;2-8; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FEINSTEIN E, 1987, NATURE, V330, P386; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; LUFTIG RB, 1977, J VIROL, V23, P799, DOI 10.1128/JVI.23.3.799-810.1977; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; REED JC, 1989, ONCOGENE, V4, P1123; RICHARDSON JM, 1987, CANCER RES, V47, P4066; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410	24	118	123	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1853	1857						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501893				2022-12-17	WOS:A1992JJ37600022
J	LUO, K; HURLEY, TR; SEFTON, BM				LUO, K; HURLEY, TR; SEFTON, BM			TRANSFER OF PROTEINS TO MEMBRANES FACILITATES BOTH CYANOGEN-BROMIDE CLEAVAGE AND 2-DIMENSIONAL PROTEOLYTIC MAPPING	ONCOGENE			English	Article											LUO, K (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92138, USA.				NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195, R01CA017289] Funding Source: NIH RePORTER; NCI NIH HHS [CA 17289, CA 42350, CA 14195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOLEN JB, 1987, ONCOGENE RES, V1, P149; GIBSON W, 1974, VIROLOGY, V62, P319, DOI 10.1016/0042-6822(74)90395-X; GLYNN JP, 1964, CANCER RES, V24, P502; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LUO K, 1990, ONCOGENE, V5, P803; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; VEILLETTE A, 1988, ONCOGENE RES, V2, P385	12	118	120	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					921	923						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1688326				2022-12-17	WOS:A1990DP55300020
J	ASHTONRICKARDT, PG; DUNLOP, MG; NAKAMURA, Y; MORRIS, RG; PURDIE, CA; STEEL, CM; EVANS, HJ; BIRD, CC; WYLLIE, AH				ASHTONRICKARDT, PG; DUNLOP, MG; NAKAMURA, Y; MORRIS, RG; PURDIE, CA; STEEL, CM; EVANS, HJ; BIRD, CC; WYLLIE, AH			HIGH-FREQUENCY OF APC LOSS IN SPORADIC COLORECTAL-CARCINOMA DUE TO BREAKS CLUSTERED IN 5Q21-22	ONCOGENE			English	Article									UNIV EDINBURGH,SCH MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; MRC,HUMAN GENET UNIT,EDINBURGH,SCOTLAND; UNIV UTAH,HOWARD HUGHES MED CTR,SALT LAKE CITY,UT 84112	University of Edinburgh; University of Edinburgh; Utah System of Higher Education; University of Utah	ASHTONRICKARDT, PG (corresponding author), UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851; Purdie, Colin/0000-0002-1258-4010				ARMITAGE NC, 1985, BRIT J SURG, V72, P828, DOI 10.1002/bjs.1800721018; BAKER SJ, 1989, SCIENCE, V244, P211; BODMER WF, 1987, NATURE, V238, P1411; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; DUNLOP MG, 1989, IN PRESS GENOMICS; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERTI AD, 1988, CANCER GENET CYTOGEN, V34, P101, DOI 10.1016/0165-4608(88)90174-4; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HOLGATE CS, 1986, J PATHOL, V149, P293, DOI 10.1002/path.1711490405; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KNUDSON AG, 1983, CANCER INVEST, V1, P187; LAW DJ, 1988, SCIENCE, V241, P961, DOI 10.1126/science.2841761; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LOTHE RA, 1988, CYTOGENET CELL GENET, V48, P167, DOI 10.1159/000132617; MACKAY J, 1988, LANCET, V2, P1384; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MULERIS M, 1985, Annales de Genetique, V28, P206; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OLAISEN B, 1987, CYTOGENET CELL GENET, V46, P147, DOI 10.1159/000132475; PETERSEN SE, 1986, CYTOMETRY, V7, P307, DOI 10.1002/cyto.990070403; QUIRKE P, 1987, J PATHOL, V151, P285, DOI 10.1002/path.1711510408; REES M, 1989, BRIT J CANCER, V59, P361, DOI 10.1038/bjc.1989.72; REICHMANN A, 1981, INT J CANCER, V28, P431, DOI 10.1002/ijc.2910280407; REMVIKOS Y, 1988, INT J CANCER, V42, P539, DOI 10.1002/ijc.2910420411; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEWART GD, 1987, NUCLEIC ACIDS RES, V15, P3939, DOI 10.1093/nar/15.9.3939; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VANDERBROEK MH, 1988, ANTICANCER RES, V8, P1104; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WASMUTH J, 1988, CYTOGENET CELL GENET, V49, P55; WYLLIE AH, 1989, P ROY COLL PHYS EDIN, V19, P171; YUNIS JJ, 1987, ONCOGENE, V1, P59	39	118	119	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1169	1174						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2797819				2022-12-17	WOS:A1989AU50800002
J	Fabian, ID; Onadim, Z; Karaa, E; Duncan, C; Chowdhury, T; Scheimberg, I; Ohnuma, SI; Reddy, MA; Sagoo, MS				Fabian, Ido D.; Onadim, Zerrin; Karaa, Esin; Duncan, Catriona; Chowdhury, Tanzina; Scheimberg, Irene; Ohnuma, Shin-Ichi; Reddy, M. Ashwin; Sagoo, Mandeep S.			The management of retinoblastoma	ONCOGENE			English	Review							INTRAOCULAR RETINOBLASTOMA; INTERNATIONAL CLASSIFICATION; INTRAVENOUS CHEMOTHERAPY; INTRAVITREAL CHEMOTHERAPY; RISK; GENE; INTRAARTERIAL; MUTATIONS; RADIOTHERAPY; SURVIVAL	Retinoblastoma (Rb) is the most common primary intraocular malignancy of childhood, but an uncommon paediatric cancer, with a constant incidence worldwide of 1: 15,000-1: 20,000 live births. Despite its rarity, Rb has served as a cornerstone in the field of oncology in many of the aspects that comprise cancer management, including classification schemes, treatment modalities, genetic testing and screening. Until just over half a century ago, the major treatment for Rb was eye removal, and prognosis was poor with outcome fatal for most children. The dramatic evolution, in a short period of time across all fields of Rb management, as well as the development of specialized centres, better infrastructure and introduction of awareness campaigns, has resulted in nearly 100% survival in developed countries and allowed eye salvage in many of the cases. External beam radiotherapy was used as the main treatment choice for four decades, but replaced by chemotherapy at the turn of the century. Initially, and still in many centres, chemotherapy is administered intravenously, but recently is targeted directly into the eye by means of intra-ophthalmic artery and intravitreal chemotherapy. To date, a range of treatments is available to the Rb expert, including enucleation, but there is lack of consensus in a number of scenarios as to what to use and when. In such a rare cancer, treatment outcomes are reported usually via retrospective analyses, with few prospective randomized controlled trials. Classification schemes have also evolved following the introduction of new treatment modalities, but discrepancies exist among centres with respect to the preferred schema and its interpretation. Retinoblastoma management is a remarkable success story, but the future will require a collaborative effort in the form of multicentre randomized controlled trials in order to further improve the quality of care for this subset of young children with ocular cancer.	[Fabian, Ido D.; Reddy, M. Ashwin; Sagoo, Mandeep S.] Moorfields Eye Hosp, London, England; [Fabian, Ido D.; Onadim, Zerrin; Karaa, Esin; Duncan, Catriona; Chowdhury, Tanzina; Scheimberg, Irene; Reddy, M. Ashwin; Sagoo, Mandeep S.] Royal London Hosp, Retinoblastoma Serv, London, England; [Fabian, Ido D.] Tel Aviv Univ, Goldschleger Eye Inst, Sheba Med Ctr, Ocular Oncol Serv, Tel Aviv, Israel; [Duncan, Catriona; Chowdhury, Tanzina] Great Ormond St Hosp Sick Children, Paediat Oncol, London, England; [Ohnuma, Shin-Ichi; Sagoo, Mandeep S.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Ohnuma, Shin-Ichi; Sagoo, Mandeep S.] UCL Inst Ophthalmol, London, England	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Barts Health NHS Trust; Royal London Hospital; Chaim Sheba Medical Center; Tel Aviv University; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Sagoo, MS (corresponding author), Moorfields Eye Hosp, London, England.; Sagoo, MS (corresponding author), Royal London Hosp, Retinoblastoma Serv, London, England.; Sagoo, MS (corresponding author), Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.; Sagoo, MS (corresponding author), UCL Inst Ophthalmol, London, England.	mandeep.sagoo@moorfields.nhs.uk	Onadim, Zerrin/AAX-6490-2021	Onadim, Zerrin/0000-0002-8594-9586; Ohnuma, Shin-ichi/0000-0002-3305-5126; Sagoo, Mandeep/0000-0003-1530-3824				Abramson DH, 2008, OPHTHALMOLOGY, V115, P1398, DOI 10.1016/j.ophtha.2007.12.014; Abramson DH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146582; Abramson DH, 2015, JAMA OPHTHALMOL, V133, P1; Al-Nawaiseh I, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/5053961; Chan HSL, 1996, CLIN CANCER RES, V2, P1499; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DiMaggio C, 2011, ANESTH ANALG, V113, P1143, DOI 10.1213/ANE.0b013e3182147f42; ERICSON LA, 1961, ACTA OPHTHALMOL, V39, P569; Fabian ID, 2017, BR J OPHTHALMOL; Fabian ID, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012366.pub2; Fabian ID, 2017, OPHTHALMOLOGY, V124, P851, DOI 10.1016/j.ophtha.2017.01.048; Fabian ID, 2017, BRIT J OPHTHALMOL, V101, P82, DOI 10.1136/bjophthalmol-2016-309710; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gallie BL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1321, DOI 10.1001/archopht.1996.01100140521001; Gatta G, 2002, CANCER-AM CANCER SOC, V95, P1767, DOI 10.1002/cncr.10833; Grigorovski N, 2014, INT J OPHTHALMOL-CHI, V7, P726, DOI 10.3980/j.issn.2222-3959.2014.04.26; Kaliki S, 2015, OPHTHALMOLOGY, V122, P1165, DOI 10.1016/j.ophtha.2015.01.018; Kaliki S, 2011, ARCH OPHTHALMOL-CHIC, V129, P1422, DOI 10.1001/archophthalmol.2011.289; Kaneko A, 2003, JPN J CLIN ONCOL, V33, P601, DOI 10.1093/jjco/hyg113; Kingston JE, 1996, ARCH OPHTHALMOL-CHIC, V114, P1339, DOI 10.1001/archopht.1996.01100140539004; Kleinerman RA, 2005, J CLIN ONCOL, V23, P2272, DOI 10.1200/JCO.2005.05.054; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Leber T, 1911, A VONGRAEFES ARCH OP, V78, P381, DOI [10.1007/BF01947065, DOI 10.1007/BF01947065]; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; MacCarthy A, 2009, BRIT J OPHTHALMOL, V93, P38, DOI 10.1136/bjo.2008.139626; Mallipatna AC., 2017, AJCC CANC STAGING MA, V8th, P819; Moore R F, 1931, Br J Ophthalmol, V15, P673, DOI 10.1136/bjo.15.12.673; Munier FL, 2017, BRIT J OPHTHALMOL, V101, P1086, DOI 10.1136/bjophthalmol-2016-309298; Munier FL, 2012, BRIT J OPHTHALMOL, V96, P1078, DOI 10.1136/bjophthalmol-2011-301450; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; NORDLING CO, 1953, BRIT J CANCER, V7, P68, DOI 10.1038/bjc.1953.8; Novetsky DE, 2009, OPHTHALMIC GENET, V30, P40, DOI 10.1080/13816810802452168; ONADIM Z, 1992, BRIT J CANCER, V65, P711, DOI 10.1038/bjc.1992.150; Pawius P., 1657, OBSERVATIONES ANATOM; Price EA, 2014, J MED GENET, V51, P208, DOI 10.1136/jmedgenet-2013-101821; REESE A B, 1963, Trans Am Acad Ophthalmol Otolaryngol, V67, P164; Richter S, 2003, AM J HUM GENET, V72, P253, DOI 10.1086/345651; Rushlow DE, 2013, LANCET ONCOL, V14, P327, DOI 10.1016/S1470-2045(13)70045-7; SEREGARD S, 1995, BRIT J OPHTHALMOL, V79, P194, DOI 10.1136/bjo.79.2.194; Shields CL, 2016, ASIA-PAC J OPHTHALMO, V5, P97, DOI 10.1097/APO.0000000000000172; Shields CL, 2006, OPHTHALMOLOGY, V113, P2276, DOI 10.1016/j.ophtha.2006.06.018; Shields CL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1330, DOI 10.1001/archopht.1996.01100140530002; Shields CL, 2001, OPHTHALMOLOGY, V108, P2116, DOI 10.1016/S0161-6420(01)00797-7; Shields CL, 2015, RETINA, V36, P1184; Soliman SE, 2016, OPHTHALMOLOGY, V123, P2610, DOI 10.1016/j.ophtha.2016.08.027; STALLARD HB, 1966, OPHTHALMOLOGICA, V151, P214, DOI 10.1159/000304892; STALLARD HB, 1948, BRIT J OPHTHALMOL, V32, P618, DOI 10.1136/bjo.32.9.618; Taich P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151343; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d; Wintersteiner H, 1897, NEUROEPITHELIOMA RET; Yamane Takashi, 2004, Int J Clin Oncol, V9, P69, DOI 10.1007/s10147-004-0392-6	54	117	123	5	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1551	1560		10.1038/s41388-017-0050-x	http://dx.doi.org/10.1038/s41388-017-0050-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29321667				2022-12-17	WOS:000428626700001
J	Formosa, A; Lena, AM; Markert, EK; Cortelli, S; Miano, R; Mauriello, A; Croce, N; Vandesompele, J; Mestdagh, P; Finazzi-Agro, E; Levine, AJ; Melino, G; Bernardini, S; Candi, E				Formosa, A.; Lena, A. M.; Markert, E. K.; Cortelli, S.; Miano, R.; Mauriello, A.; Croce, N.; Vandesompele, J.; Mestdagh, P.; Finazzi-Agro, E.; Levine, A. J.; Melino, G.; Bernardini, S.; Candi, E.			DNA methylation silences miR-132 in prostate cancer	ONCOGENE			English	Article						prostate cancer; miRNAs; miR-132; methylation; methylation-specific PCR; anoikis	MICRORNA EXPRESSION; TUMOR-SUPPRESSOR; CELL-ADHESION; GROWTH-FACTOR; EPIGENETICS; METASTASIS; HYPERMETHYLATION; CARCINOMA; APOPTOSIS; PROMOTES	Silencing of microRNAs (miRNAs) by promoter CpG island methylation may be an important mechanism in prostate carcinogenesis. To screen for epigenetically silenced miRNAs in prostate cancer (PCa), we treated prostate normal epithelial and carcinoma cells with 5-aza-2'-deoxycytidine (AZA) and subsequently examined expression changes of 650 miRNAs by megaplex stemloop reverse transcription-quantitative PCR. After applying a selection strategy, we analyzed the methylation status of CpG islands upstream to a subset of miRNAs by methylation-specific PCR. The CpG islands of miR-18b, miR-132, miR-34b/c, miR-148a, miR-450a and miR-542-3p showed methylation patterns congruent with their expression modulations in response to AZA. Methylation analysis of these CpG islands in a panel of 50 human prostate carcinoma specimens and 24 normal controls revealed miR-132 to be methylated in 42% of human cancer cases in a manner positively correlated to total Gleason score and tumor stage. Expression analysis of miR-132 in our tissue panel confirmed its downregulation in methylated tumors. Re-expression of miR-132 in PC3 cells induced cell detachment followed by cell death (anoikis). Two pro-survival proteins-heparin-binding epidermal growth factor and TALIN2-were confirmed as direct targets of miR-132. The results of this study point to miR-132 as a methylation-silenced miRNA with an antimetastatic role in PCa controlling cellular adhesion. Oncogene (2013) 32, 127-134; doi:10.1038/onc.2012.14; published online 6 February 2012	[Formosa, A.; Cortelli, S.; Croce, N.; Bernardini, S.] Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy; [Lena, A. M.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; [Lena, A. M.; Melino, G.; Candi, E.] Univ Roma Tor Vergata, Biochem Lab IDI IRCCS, Rome, Italy; [Markert, E. K.] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [Miano, R.; Finazzi-Agro, E.] Univ Roma Tor Vergata, Policlin Tor Vergata, Div Urol, Dept Surg, Rome, Italy; [Mauriello, A.] Univ Roma Tor Vergata, Dept Biopathol & Image Diagnost, Rome, Italy; [Vandesompele, J.; Mestdagh, P.] Ghent Univ Hosp, Ctr Med Genet Ghent, Ghent, Belgium; [Vandesompele, J.] Biogazelle, Zwijnaarde, Belgium; [Levine, A. J.] Canc Inst New Jersey, New Brunswick, NJ USA	University of Rome Tor Vergata; University of Rome Tor Vergata; University of Rome Tor Vergata; Institute for Advanced Study - USA; University of Rome Tor Vergata; Policlin Tor Vergata; University of Rome Tor Vergata; Ghent University; Ghent University Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Bernardini, S (corresponding author), Univ Rome, Dept Internal Med, I-00133 Rome, Italy.	bernards@uniroma2.it; candi@uniroma2.it	Agrò, Enrico Finazzi/N-7969-2018; MAURIELLO, ALESSANDRO/K-4705-2016; Lena, Anna Maria/AAI-5042-2020; Vandesompele, Jo/W-3411-2018	Agrò, Enrico Finazzi/0000-0002-0308-8824; MAURIELLO, ALESSANDRO/0000-0002-7351-5676; Vandesompele, Jo/0000-0001-6274-0184; Mestdagh, Pieter/0000-0001-7821-9684; Miano, Roberto/0000-0003-2445-1204	MIUR-PRIN; Min Sal onc_ord [26/07]; ISS e Min Sal [ACC12]; RF07 [55, 57]; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	MIUR-PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Min Sal onc_ord; ISS e Min Sal; RF07; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from MIUR-PRIN08, Min Sal onc_ord 26/07, RF07#55 to GM, and ISS e Min Sal ACC12 and RF07#57 to GM and EC.	Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Bartkowiak D, 1999, CYTOMETRY, V37, P191, DOI 10.1002/(SICI)1097-0320(19991101)37:3<191::AID-CYTO5>3.0.CO;2-U; Boissier S, 1997, CANCER RES, V57, P3890; Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Cooper CS, 2009, BRIT J CANCER, V100, P240, DOI 10.1038/sj.bjc.6604771; Cooper CR, 2000, PROSTATE CANCER P D, V3, P6, DOI 10.1038/sj.pcan.4500387; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Fabbri M, 2010, ADV GENET, V70, P87, DOI [10.1016/S0065-2660(10)70004-3, 10.1016/B978-0-12-380866-0.60004-6]; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gougelet A, 2011, INT J CANCER, V129, P680, DOI 10.1002/ijc.25715; Kalimutho M, 2011, BRIT J CANCER, V104, P1770, DOI 10.1038/bjc.2011.82; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Lages E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020600; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Lujambio A, 2007, CELL CYCLE, V6, P1455; Matsunaga S, 2007, ANTICANCER RES, V27, P927; Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64; Mestdagh P, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn725; Miyamoto S, 2007, ANTICANCER RES, V27, P3713; Monkley SJ, 2001, BIOCHEM BIOPH RES CO, V286, P880, DOI 10.1006/bbrc.2001.5497; Nelson WG, 2009, ENDOCRINOLOGY, V150, P3991, DOI 10.1210/en.2009-0573; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299; Park JY, 2010, CANCER CONTROL, V17, P245, DOI 10.1177/107327481001700405; Pavicic W, 2011, MOL MED, V17, P726, DOI 10.2119/molmed.2010.00239; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Sakamoto S, 2010, CANCER RES, V70, P1885, DOI 10.1158/0008-5472.CAN-09-2833; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Torring N, 2000, ANTICANCER RES, V20, P91; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Wong TS, 2008, INT J CANCER, V123, P251, DOI 10.1002/ijc.23583; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yoon S, 2010, FEBS LETT, V584, P4048, DOI 10.1016/j.febslet.2010.08.025; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765	44	117	128	0	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					127	134		10.1038/onc.2012.14	http://dx.doi.org/10.1038/onc.2012.14			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22310291				2022-12-17	WOS:000313029500013
J	Wilting, SM; Snijders, PJF; Verlaat, W; Jaspers, A; van de Wiel, MA; van Wieringen, WN; Meijer, GA; Kenter, GG; Yi, Y; le Sage, C; Agami, R; Meijer, CJLM; Steenbergen, RDM				Wilting, S. M.; Snijders, P. J. F.; Verlaat, W.; Jaspers, A.; van de Wiel, M. A.; van Wieringen, W. N.; Meijer, G. A.; Kenter, G. G.; Yi, Y.; le Sage, C.; Agami, R.; Meijer, C. J. L. M.; Steenbergen, R. D. M.			Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis	ONCOGENE			English	Article						microRNA; squamous cell carcinoma; adenocarcinoma; CIN lesion; HPV; hsa-miR-9	TUMOR-SUPPRESSIVE MICRORNAS; HUMAN-PAPILLOMAVIRUS DNA; GENE-EXPRESSION; MIRNA EXPRESSION; CELL-LINES; HIGH-RISK; CANCER; METHYLATION; LESIONS; KERATINOCYTES	Little is known about the alterations in microRNA (miRNA) expression patterns during the consecutive stages of cervical cancer development and their association with chromosomal instability. In this study, miRNA expression in normal cervical squamous epithelium, high-grade precancerous lesions (cervical intraepithelial neoplasia (CIN2-3)), squamous cell carcinomas (SCCs) and adenocarcinomas (AdCAs) was integrated with previously generated chromosomal profiles of the same samples. Significantly differential expression during the consecutive stages of cervical SCC development was observed for 106 miRNAs. Of these differentially expressed miRNAs, 27 showed early transiently altered expression in CIN2-3 lesions only, 46 miRNAs showed late altered expression in SCCs only and 33 showed continuously altered expression in both CIN2-3 and SCCs. Altered expression of five significantly differentially expressed miRNAs, hsa-miR-9 (1q23.2), hsa-miR-15b (3q25.32), hsa-miR-28-5p (3q27.3), hsa-miR-100 and hsa-miR-125b (both 11q24.1), was directly linked to frequent chromosomal alterations. Functional analyses were performed for hsa-miR-9, representing a potential oncogene with increased expression linked to a chromosomal gain of 1q. Hsa-miR-9 overexpression was found to increase cell viability, anchorage-independent growth and migration in vitro. Upon organic raft culturing, hsa-miR-9 hampered differentiation and induced proliferation in all strata of the epithelial layer. These findings support a potential oncogenic function of hsa-miR-9 in cervical cancer. In summary, differential expression of 106 miRNAs, partly associated with chromosomal alterations, was observed during cervical SCC development. Altered expression of hsa-miR-9 associated with a chromosomal gain of chromosome 1q was shown to be functionally relevant, underlining the importance of deregulated miRNA expression in cervical carcinogenesis. Oncogene (2013) 32, 106-116; doi:10.1038/onc.2012.20; published online 13 February 2012	[Steenbergen, R. D. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Unit Mol Pathol, NL-1007 MB Amsterdam, Netherlands; [van de Wiel, M. A.; van Wieringen, W. N.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [van de Wiel, M. A.; van Wieringen, W. N.] Vrije Univ Amsterdam, Dept Math, Amsterdam, Netherlands; [Kenter, G. G.] VU Univ Med Ctr Amsterdam, Dept Obstet & Gynaecol, Amsterdam, Netherlands; [Yi, Y.] Vanderbilt Univ Sch Med, Vanderbilt Ingram Canc Ctr, Div Genet Med, Nashville, TN USA; [le Sage, C.; Agami, R.] Netherlands Canc Inst, Div Gene Regulat, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vanderbilt University; Netherlands Cancer Institute	Steenbergen, RDM (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Pathol, Unit Mol Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	r.steenbergen@vumc.nl	van de Wiel, Mark/F-6759-2013; van Wieringen, Wessel N/F-9850-2016; agami, reuven/GOG-8289-2022	van Wieringen, Wessel N/0000-0002-5100-9123; Meijer, Gerrit/0000-0003-0330-3130; Steenbergen, Renske/0000-0002-2327-9839; van de Wiel, Mark/0000-0003-4780-8472; Wilting, Saskia/0000-0002-2838-841X; Agami, Reuven/0000-0002-2848-2473	V-ICI institute of the VU University Medical Center, Amsterdam, The Netherlands [CCA20085-04]; Dutch Cancer Society (KWF) [VU2010-4668]	V-ICI institute of the VU University Medical Center, Amsterdam, The Netherlands(Netherlands Government); Dutch Cancer Society (KWF)(KWF Kankerbestrijding)	This work was supported by the V-ICI institute of the VU University Medical Center, Amsterdam, The Netherlands (grant number CCA20085-04) and the Dutch Cancer Society (KWF, grant number VU2010-4668). We are grateful to Marlon van der Plas, Suzanne Snellenberg, Nour Makazaji and Tim Schutte for excellent technical assistance.	Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Botezatu A, 2011, MOL MED REP, V4, P121, DOI 10.3892/mmr.2010.394; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chim CS, 2011, J CELL MOL MED, V15, P2760, DOI 10.1111/j.1582-4934.2011.01274.x; Fu Y, 1989, PATHOLOGY UTERINE CE, P288; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Guo LM, 2009, FEBS J, V276, P5537, DOI 10.1111/j.1742-4658.2009.07237.x; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305; Hsu PY, 2009, CANCER RES, V69, P5936, DOI 10.1158/0008-5472.CAN-08-4914; Hu XX, 2010, CANCER RES, V70, P1441, DOI 10.1158/0008-5472.CAN-09-3289; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Li BH, 2010, INT J GYNECOL CANCER, V20, P597, DOI 10.1111/IGC.0b013e3181d63170; Li Y, 2011, J PATHOL, V224, P484, DOI 10.1002/path.2873; Lionetti M, 2009, GENE CHROMOSOME CANC, V48, P521, DOI 10.1002/gcc.20660; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Manduchi E, 2000, BIOINFORMATICS, V16, P685, DOI 10.1093/bioinformatics/16.8.685; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Mascaux C, 2009, EUR RESPIR J, V33, P352, DOI 10.1183/09031936.00084108; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; McKenna DJ, 2010, J VIROL, V84, P10644, DOI 10.1128/JVI.00703-10; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Muralidhar B, 2007, J PATHOL, V212, P368, DOI 10.1002/path.2179; Muralidhar B, 2011, J PATHOL, V224, P496, DOI 10.1002/path.2898; Nuovo GJ, 2010, DIAGN MOL PATHOL, V19, P135, DOI 10.1097/PDM.0b013e3181c4daaa; Overmeer RM, 2009, J PATHOL, V219, P327, DOI 10.1002/path.2598; Pereira PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011780; Pisani P, 2002, INT J CANCER, V97, P72, DOI 10.1002/ijc.1571; Rao QX, 2012, MED ONCOL, V29, P1242, DOI 10.1007/s12032-011-9830-2; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; TASE T, 1989, INT J GYNECOL PATHOL, V8, P8, DOI 10.1097/00004347-198903000-00002; van Wieringen WN, 2009, BIOMETRICS, V65, P19, DOI 10.1111/j.1541-0420.2008.01052.x; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209; Wentzensen N, 2007, DIS MARKERS, V23, P315, DOI 10.1155/2007/678793; Wilting S, 2006, J PATHOL, V209, P220, DOI 10.1002/path.1966; Wilting SM, 2008, GENE CHROMOSOME CANC, V47, P890, DOI 10.1002/gcc.20590; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Wilting SM, 2009, CANCER RES, V69, P647, DOI 10.1158/0008-5472.CAN-08-2478; Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Yi YJ, 2005, GENOMICS, V85, P401, DOI 10.1016/j.ygeno.2004.11.011; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zielinski GD, 2001, BRIT J CANCER, V85, P398, DOI 10.1054/bjoc.2001.1926	60	117	122	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					106	116		10.1038/onc.2012.20	http://dx.doi.org/10.1038/onc.2012.20			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330141				2022-12-17	WOS:000313029500011
J	Lee, JJ; Drakaki, A; Iliopoulos, D; Struhl, K				Lee, J-J; Drakaki, A.; Iliopoulos, D.; Struhl, K.			MiR-27b targets PPAR gamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells	ONCOGENE			English	Article						miR-27b; PPAR gamma; NHE1; NF-kappa beta; inflammation; neuroblastomas	ACTIVATED-RECEPTOR-GAMMA; BREAST-CANCER; TERMINAL DIFFERENTIATION; KAPPA-B; EXPRESSION; ROSIGLITAZONE; MICRORNAS; AGONISTS; TRANSFORMATION; PROLIFERATION	The peroxisome proliferators-activated receptor (PPAR)gamma pathway is involved in cancer, but it appears to have both tumor suppressor and oncogenic functions. In neuroblastoma cells, miR-27b targets the 30 untranslated region of PPAR gamma and inhibits its mRNA and protein expression. miR-27b overexpression or PPAR gamma inhibition blocks cell growth in vitro and tumor growth in mouse xenografts. PPAR gamma activates expression of the pH regulator NHE1, which is associated with tumor progression. Lastly, miR-27b through PPAR gamma regulates nuclear factor-kappa B activity and transcription of inflammatory target genes. Thus, in neuroblastoma, miR-27b functions as a tumor suppressor by inhibiting the tumor-promoting function of PPAR gamma, which triggers an increased inflammatory response. In contrast, in breast cancer cells, PPAR gamma inhibits NHE1 expression and the inflammatory response, and it functions as a tumor suppressor. We suggest that the ability of PPAR gamma to promote or suppress tumor formation is linked to cell type-specific differences in regulation of NHE1 and other target genes. Oncogene (2012) 31, 3818-3825; doi: 10.1038/onc.2011.543; published online 28 November 2011	[Lee, J-J; Iliopoulos, D.; Struhl, K.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Drakaki, A.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; [Iliopoulos, D.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	kevin@hms.harvard.edu	Iliopoulos, Dimitrios/AAE-9106-2019		Dana Farber Cancer Institute; National Institutes of Health [CA 107486]; NATIONAL CANCER INSTITUTE [R01CA107486] Funding Source: NIH RePORTER	Dana Farber Cancer Institute; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by start-up funds to DI from the Dana Farber Cancer Institute and by a research grant to KS from the National Institutes of Health (CA 107486).	Abe A, 2002, EUR J PHARMACOL, V436, P7, DOI 10.1016/S0014-2999(01)01577-1; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161; Cellai I, 2006, BRIT J CANCER, V95, P879, DOI 10.1038/sj.bjc.6603344; Cellai I, 2010, BRIT J CANCER, V102, P685, DOI 10.1038/sj.bjc.6605506; Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO;2-7; Chung SW, 2000, J BIOL CHEM, V275, P32681, DOI 10.1074/jbc.M002577200; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cui Y, 2002, J BIOL CHEM, V277, P17830, DOI 10.1074/jbc.M200186200; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; Han S, 2007, ANTI-CANCER DRUG, V18, P237, DOI 10.1097/CAD.0b013e328011e67d; Han SW, 2001, CLIN CANCER RES, V7, P98; Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jennewein C, 2010, J BIOL CHEM, V285, P11846, DOI 10.1074/jbc.M109.066399; Karbiener M, 2009, BIOCHEM BIOPH RES CO, V390, P247, DOI 10.1016/j.bbrc.2009.09.098; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Kim SY, 2010, BIOCHEM BIOPH RES CO, V392, P323, DOI 10.1016/j.bbrc.2010.01.012; Kumar AP, 2009, CANCER RES, V69, P8636, DOI 10.1158/0008-5472.CAN-09-0219; Lecomte J, 2008, BREAST CANCER RES TR, V112, P437, DOI 10.1007/s10549-007-9886-z; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Morosetti R, 2004, INT J ONCOL, V25, P493; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Nwankwo JO, 2001, PROSTAG LEUKOTR ESS, V64, P241, DOI 10.1054/plef.2001.0266; OBER SS, 1987, P NATL ACAD SCI USA, V84, P2766, DOI 10.1073/pnas.84.9.2766; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SICZKOWSKI M, 1994, AM J PHYSIOL, V267, pC745, DOI 10.1152/ajpcell.1994.267.3.C745; SOULE HD, 1990, CANCER RES, V50, P6075; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403; Venkatachalam G, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S3-S5; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005	44	117	121	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	33					3818	3825		10.1038/onc.2011.543	http://dx.doi.org/10.1038/onc.2011.543			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IU	22120719	Green Submitted, Bronze, Green Accepted			2022-12-17	WOS:000307924900008
J	Karadedou, CT; Gomes, AR; Chen, J; Petkovic, M; Ho, KK; Zwolinska, AK; Feltes, A; Wong, SY; Chan, KYK; Cheung, YN; Tsang, JWH; Brosens, JJ; Khoo, US; Lam, EWF				Karadedou, C. T.; Gomes, A. R.; Chen, J.; Petkovic, M.; Ho, K-K; Zwolinska, A. K.; Feltes, A.; Wong, S. Y.; Chan, K. Y. K.; Cheung, Y-N; Tsang, J. W. H.; Brosens, J. J.; Khoo, U-S; Lam, E. W-F			FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer	ONCOGENE			English	Article						VEGF; FOXO3a; FOXM1; breast cancer; transcription	TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR FOXO3A; LEUKEMIC-CELLS; GROWTH-INHIBITION; GEFITINIB IRESSA; GENE-EXPRESSION; DUAL INHIBITOR; SOLID TUMORS; LUNG-CANCER; LAPATINIB	Vascular endothelial growth factor (VEGF) has a central role in breast cancer development and progression, but the mechanisms that control its expression are poorly understood. Breast cancer tissue microarrays revealed an inverse correlation between the Forkhead transcription factor Forkhead box class O (FOXO)3a and VEGF expression. Using the lapatinib-sensitive breast cancer cell lines BT474 and SKBR3 as model systems, we tested the possibility that VEGF expression is negatively regulated by FOXO3a. Lapatinib treatment of BT474 or SKBR3 cells resulted in nuclear translocation and activation of FOXO3a, followed by a reduction in VEGF expression. Transient transfection and inducible expression experiments showed that FOXO3a represses the proximal VEGF promoter, whereas another Forkhead member, FOXM1, induces VEGF expression. Chromatin immunoprecipitation and oligonucleotide pull-down assays showed that both FOXO3a and FOXM1 bind a consensus Forkhead response element (FHRE) in the VEGF promoter. Upon lapatinib stimulation, activated FOXO3a displaces FOXM1 bound to the FHRE before recruiting histone deacetylase 2 (HDAC2) to the promoter, leading to decreased histones H3 and H4 acetylation, and concomitant transcriptional inhibition of VEGF. These results show that FOXO3a-dependent repression of target genes in breast cancer cells, such as VEGF, involves competitive displacement of DNA-bound FOXM1 and active recruitment of transcriptional repressor complexes. Oncogene (2012) 31, 1845-1858; doi: 10.1038/onc.2011.368; published online 22 August 2011	[Karadedou, C. T.; Gomes, A. R.; Chen, J.; Petkovic, M.; Ho, K-K; Zwolinska, A. K.; Feltes, A.; Brosens, J. J.; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Canc Res UK Labs, London W12 0NN, England; [Chen, J.; Wong, S. Y.; Chan, K. Y. K.; Cheung, Y-N; Khoo, U-S] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, J. W. H.] Univ Hong Kong, Dept Clin Oncol, Li Ka Shing Fac Med, Hong Kong, Hong Kong, Peoples R China	Cancer Research UK; Imperial College London; University of Hong Kong; University of Hong Kong	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Canc Res UK Labs, MRC Hammersmith Hosp Campus,Cyclotron Bldg,Du Can, London W12 0NN, England.	eric.lam@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020; Khoo, Ui Soon/C-4293-2009; Khoo, Ui Soon/C-1345-2014; Chan, Kelvin/HGA-3097-2022; Khoo, Ui Soon/K-2041-2019	Lam, Eric W-F/0000-0003-1274-3576; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Brosens, Jan/0000-0003-0116-9329	Cancer Research UK; Breast Cancer Campaign; Portuguese Science and Technology Foundation (FCT); Cancer Research UK [12011] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Portuguese Science and Technology Foundation (FCT)(Portuguese Foundation for Science and Technology); Cancer Research UK(Cancer Research UK)	This study was supported by the Cancer Research UK (M Petkovic, KK Ho and EW-F Lam), Breast Cancer Campaign (EW-F Lam), the Portuguese Science and Technology Foundation (FCT; AR Gomes).	Arden KC, 2008, ONCOGENE, V27, P2345, DOI 10.1038/onc.2008.27; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Burgering B, 2008, ONCOGENE, V27, P2258, DOI 10.1038/onc.2008.29; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Ciardiello Fortunato, 2005, Future Oncol, V1, P221, DOI 10.1517/14796694.1.2.221; DAVIE JR, 1978, P NATL ACAD SCI USA, V75, P3574, DOI 10.1073/pnas.75.8.3574; Davis R, 2009, ONCOL REP, V22, P1473, DOI 10.3892/or_00000589; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Delpuech O, 2007, MOL CELL BIOL, V27, P4917, DOI 10.1128/MCB.01789-06; Diaz R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-188; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essafi Abdelkader, 2009, V462, P201, DOI 10.1007/978-1-60327-115-8_13; de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Furuyama T, 2004, J BIOL CHEM, V279, P34741, DOI 10.1074/jbc.M314214200; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Hegde PS, 2007, MOL CANCER THER, V6, P1629, DOI 10.1158/1535-7163.MCT-05-0399; Heist RS, 2008, J CLIN ONCOL, V26, P856, DOI 10.1200/JCO.2007.13.5947; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Ikezoe T, 2006, MOL CANCER THER, V5, P2522, DOI 10.1158/1535-7163.MCT-06-0071; Ikezoe T, 2006, CANCER SCI, V97, P945, DOI 10.1111/j.1349-7006.2006.00263.x; Jain L, 2009, MOL CANCER THER, V8, P2496, DOI 10.1158/1535-7163.MCT-09-0302; Kitadai Y, 2010, J ONCOL, V2010, DOI 10.1155/2010/468725; Kondo N, 2010, ONCOL REP, V23, P957, DOI 10.3892/or_00000720; Krol J, 2007, MOL CANCER THER, V6, P3169, DOI 10.1158/1535-7163.MCT-07-0507; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lee HY, 2008, ARTERIOSCL THROM VAS, V28, P112, DOI 10.1161/ATVBAHA.107.153304; Lentzsch S, 2004, LEUKEMIA, V18, P1883, DOI 10.1038/sj.leu.2403486; Littler DR, 2010, NUCLEIC ACIDS RES, V38, P4527, DOI 10.1093/nar/gkq194; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Maiese K, 2008, TRENDS MOL MED, V14, P219, DOI 10.1016/j.molmed.2008.03.002; Makrilia N, 2009, EUR J INTERN MED, V20, P663, DOI 10.1016/j.ejim.2009.07.009; Margolin Kim, 2002, Curr Oncol Rep, V4, P20, DOI 10.1007/s11912-002-0044-9; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Montemurro F, 2007, EXPERT OPIN BIOL TH, V7, P257, DOI 10.1517/14712598.7.2.257; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nelson MH, 2006, ANN PHARMACOTHER, V40, P261, DOI 10.1345/aph.1G387; Nordigarden A, 2009, BLOOD, V113, P2302, DOI 10.1182/blood-2008-07-167023; Nott A, 2008, NATURE, V455, P411, DOI 10.1038/nature07238; Park SH, 2009, BIOCHEM BIOPH RES CO, V390, P861, DOI 10.1016/j.bbrc.2009.10.063; Pytel D, 2009, ANTI-CANCER AGENT ME, V9, P66, DOI 10.2174/187152009787047752; Reedquist KA, 2006, BIOCHEM SOC T, V34, P727, DOI 10.1042/BST0340727; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Schneider BP, 2007, NAT CLIN PRACT ONCOL, V4, P181, DOI 10.1038/ncponc0740; Srivastava RK, 2010, MOL CELL BIOCHEM, V337, P201, DOI 10.1007/s11010-009-0300-5; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Wakeling AE, 2002, CURR OPIN PHARMACOL, V2, P382, DOI 10.1016/S1471-4892(02)00183-2; Yamaguchi T, 2007, CANCER SCI, V98, P405, DOI 10.1111/j.1349-7006.2007.00402.x; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278; Zhang YJ, 2008, CANCER RES, V68, P8733, DOI 10.1158/0008-5472.CAN-08-1968	59	117	130	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	14					1845	1858		10.1038/onc.2011.368	http://dx.doi.org/10.1038/onc.2011.368			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925TT	21860419	Green Accepted, Green Submitted			2022-12-17	WOS:000302785200010
J	Wang, X; Lu, H; Urvalek, AM; Li, T; Yu, L; Lamar, J; DiPersio, CM; Feustel, PJ; Zhao, J				Wang, X.; Lu, H.; Urvalek, A. M.; Li, T.; Yu, L.; Lamar, J.; DiPersio, C. M.; Feustel, P. J.; Zhao, J.			KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9	ONCOGENE			English	Article							FOCAL ADHESION KINASE; MATRIX-METALLOPROTEINASE INHIBITORS; KRUPPEL-LIKE FACTOR-8; E-CADHERIN; TUMOR-CELLS; REGULATES MMP-9; BONE METASTASIS; UP-REGULATION; CYCLIN D1; EXPRESSION	Epithelial to mesenchymal transition (EMT) and extracellular matrix degradation are critical for the initiation and progression of tumor invasion. We have recently identified Kruppel-like factor 8 (KLF8) as a critical inducer of EMT and invasion. KLF8 induces EMT primarily by repressing E-cadherin transcription. However, how KLF8 promotes invasion is unknown. Here, we report a novel KLF8-to-matrix metalloproteinase (MMP) 9 signaling that promotes human breast cancer invasion. To identify the potential KLF8 regulation of MMPs in breast cancer, we established two inducible cell lines that allow either KLF8 overexpression in MCF-10A or knockdown in MDA-MB-231 cells. KLF8 overexpression induced a strong increase in MMP9 expression and activity as determined by quantitative real-time PCR and zymography. This induction was well correlated with the MMP inhibitor-sensitive Matrigel invasion. Conversely, KLF8 knockdown caused the opposite changes that could be partially prevented by MMP9 overexpression. Promoter-reporter assays and chromatin and oligonucleotide precipitations determined that KLF8 directly bound and activated the human MMP9 gene promoter. Three-dimensional (3D) glandular culture showed that KLF8 expression disrupted the normal acinus formation, which could be prevented by the MMP inhibitor, whereas KLF8 knockdown corrected the abnormal 3D architecture, which could be protected by MMP9 overexpression. KLF8 knockdown promoted MDA-MB-231 cell aggregation in suspension culture, which could be prevented by MMP9 overexpression. KLF8 knockdown inhibited the lung metastasis of MDA-MB-231 cells in nude mice. Immunohistochemical staining strongly correlated the co-expression of KLF8 and MMP9 with the patient tumor invasion, metastasis and poor survival. Taken together, this work identified the KLF8 activation of MMP9 as a novel and critical signaling mechanism underlying human breast cancer invasion and metastasis. Oncogene (2011) 30, 1901-1911; doi: 10.1038/onc.2010.563; published online 13 December 2010	[Wang, X.; Lu, H.; Urvalek, A. M.; Li, T.; Yu, L.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Lamar, J.; DiPersio, C. M.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Feustel, P. J.] Albany Med Coll, Ctr Neuropharmacol & Neurosci, Albany, NY 12208 USA	State University System of Florida; University of Central Florida; Albany Medical College; Albany Medical College	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA.	jizhao@mail.ucf.edu	Feustel, Paul/AAW-5157-2021; Lamar, John Michael/R-5053-2019; Li, Tianshu/L-6426-2014	Feustel, Paul/0000-0002-6963-4349; Lamar, John Michael/0000-0001-5406-8391; Li, Tianshu/0000-0002-9972-4644	NCI [CA132977, CA129637]; Susan G Komen for Cure [KG090444 and KG080616]; NATIONAL CANCER INSTITUTE [R01CA129637, R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Joan Massague for kindly providing the 4175 cells and Dr Chunhong Yan and Qingfen Li and Beihai Jiang of Zhao lab for helpful comments. This work was supported by grants from NCI (CA132977) and Susan G Komen for Cure (KG090444 and KG080616) to JZ and a grant from NCI (CA129637) to CMD. XW is a Komen postdoctoral fellow.	Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Balzer EM, 2010, BREAST CANCER RES TR, V121, P65, DOI 10.1007/s10549-009-0457-3; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Cristofanilli M, 2006, SEMIN ONCOL, V33, pS9, DOI 10.1053/j.seminoncol.2006.03.016; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089; Eaton SA, 2008, J BIOL CHEM, V283, P26937, DOI 10.1074/jbc.M804831200; Evans PM, 2010, CELL CYCLE, V9, P649; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Janda E, 2006, ONCOGENE, V25, P7117, DOI 10.1038/sj.onc.1209701; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Lamar JM, 2008, CANCER RES, V68, P7371, DOI 10.1158/0008-5472.CAN-08-1080; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lloyd JA, 2010, CELL CYCLE, V9, P650; Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396; McLachlan E, 2006, CANCER RES, V66, P9886, DOI 10.1158/0008-5472.CAN-05-4302; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Rahman KMW, 2006, MOL CANCER THER, V5, P2747, DOI 10.1158/1535-7163.MCT-06-0221; Rodriguez E, 2009, CELL RES, V19, P1041, DOI 10.1038/cr.2009.103; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Whipple RA, 2008, CANCER RES, V68, P5678, DOI 10.1158/0008-5472.CAN-07-6589; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zhang P, 2005, BLOOD CELL MOL DIS, V35, P227, DOI 10.1016/j.bcmd.2005.04.009; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	45	117	130	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1901	1911		10.1038/onc.2010.563	http://dx.doi.org/10.1038/onc.2010.563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21151179	Green Accepted, hybrid			2022-12-17	WOS:000289777700006
J	Jeninga, EH; Schoonjans, K; Auwerx, J				Jeninga, E. H.; Schoonjans, K.; Auwerx, J.			Reversible acetylation of PGC-1: connecting energy sensors and effectors to guarantee metabolic flexibility	ONCOGENE			English	Review						AMPK; ATP citrate lyase; GCN5; mitochondria; PGC-1 alpha; SIRT1	CONTROLLING MITOCHONDRIAL BIOGENESIS; GLOBAL HISTONE ACETYLATION; FATTY-ACID OXIDATION; LIFE-SPAN EXTENSION; HUMAN BREAST-CANCER; TRANSCRIPTIONAL COACTIVATOR; SACCHAROMYCES-CEREVISIAE; PPAR-GAMMA; HEPATIC GLUCONEOGENESIS; CALORIE RESTRICTION	Organisms adapt their metabolism to meet ever changing environmental conditions. This metabolic adaptation involves at a cellular level the fine tuning of mitochondrial function, which is mainly under the control of the transcriptional co-activator proliferator-activated receptor gamma co-activator (PGC)-1 alpha. Changes in PGC-1 alpha activity coordinate a transcriptional response, which boosts mitochondrial activity in times of energy needs and attenuates it when energy demands are low. Reversible acetylation has emerged as a key way to alter PGC-1 alpha activity. Although it is well established that PGC-1 alpha is deacetylated and activated by Sirt1 and acetylated and inhibited by GCN5, less is known regarding how these enzymes themselves are regulated. Recently, it became clear that the energy sensor, AMP-activated kinase (AMPK) translates the effects of energy stress into altered Sirt1 activity by regulating the intracellular level of its co-substrate nicotinamide adenine dinucleotide (NAD)(+). Conversely, the enzyme ATP citrate lyase (ACL), relates energy balance to GCN5, through the control of the nuclear production of acetyl-CoA, the substrate for GCN5's acetyltransferase activity. We review here how these metabolic signaling pathways, affecting GCN5 and Sirt1 activity, allow the reversible acetylation-deacetylation of PGC-1 alpha and the adaptation of mitochondrial energy homeostasis to energy levels. Oncogene (2010) 29, 4617-4624; doi:10.1038/onc.2010.206; published online 7 June 2010	[Jeninga, E. H.; Schoonjans, K.; Auwerx, J.] Ecole Polytech Fed Lausanne, Lab Integrat & Syst Physiol, CH-1015 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Auwerx, J (corresponding author), Ecole Polytech Fed Lausanne, EPFL SV IBI1 LISP NCEM1, Batiment AI AI 1-145,Stn 15, CH-1015 Lausanne, Switzerland.	admin.auwerx@epfl.ch	Auwerx, Johan/ABE-9307-2021	Schoonjans, Kristina/0000-0003-1247-4265; Auwerx, Johan/0000-0002-5065-5393	Ecole Polytechnique Federale de Lausanne; Swiss National Science Foundation; NIH [DK59820]; European Research Council [ERC-2008-AdG23118]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059820] Funding Source: NIH RePORTER	Ecole Polytechnique Federale de Lausanne; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); European Research Council(European Research Council (ERC)European Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Ecole Polytechnique Federale de Lausanne, Swiss National Science Foundation, NIH (DK59820) and the European Research Council Ideas programme (Sirtuins; ERC-2008-AdG23118).	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Bracha AL, 2010, NAT CHEM BIOL, V6, P202, DOI 10.1038/NCHEMBIO.301; Brown WJ, 2007, AM J PREV MED, V33, P404, DOI 10.1016/j.amepre.2007.07.029; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Coste A, 2008, P NATL ACAD SCI USA, V105, P17187, DOI 10.1073/pnas.0808207105; COSTFORD SR, 2009, AM J PHYSIOL-ENDOC M, V298, P117; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Feilchenfeldt J, 2004, CANCER LETT, V203, P25, DOI 10.1016/j.canlet.2003.08.024; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Friis RMN, 2009, NUCLEIC ACIDS RES, V37, P3969, DOI 10.1093/nar/gkp270; Fujino T, 2001, J BIOL CHEM, V276, P11420, DOI 10.1074/jbc.M008782200; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Houtkooper RH, 2010, ENDOCR REV, V31, P194, DOI 10.1210/er.2009-0026; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kals M, 2005, YEAST, V22, P213, DOI 10.1002/yea.1204; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kelly TJ, 2009, J BIOL CHEM, V284, P19945, DOI 10.1074/jbc.M109.015164; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Leriche M., 1926, MEM SOC GEOL NORD, V32, P365; Li XH, 2007, NATURE, V447, P1012, DOI 10.1038/nature05861; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luong A, 2000, J BIOL CHEM, V275, P26458, DOI 10.1074/jbc.M004160200; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208; Ortolan E, 2002, CELL BIOCHEM FUNCT, V20, P309, DOI 10.1002/cbf.978; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Suwa M, 2003, J APPL PHYSIOL, V95, P960, DOI 10.1152/japplphysiol.00349.2003; SZUTOWICZ A, 1979, BRIT J CANCER, V39, P681, DOI 10.1038/bjc.1979.120; Takahashi H, 2006, MOL CELL, V23, P207, DOI 10.1016/j.molcel.2006.05.040; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Turyn J, 2003, HORM METAB RES, V35, P565, DOI 10.1055/s-2003-43500; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Watkins G, 2004, ONCOL REP, V12, P483; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yin PH, 2004, BRIT J CANCER, V90, P2390, DOI 10.1038/sj.bjc.6601838; Yoo EJ, 2006, J BIOL CHEM, V281, P6608, DOI 10.1074/jbc.M508982200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhang Y, 2007, CELL RES, V17, P363, DOI 10.1038/cr.2007.11	72	117	127	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4617	4624		10.1038/onc.2010.206	http://dx.doi.org/10.1038/onc.2010.206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20531298	Green Accepted			2022-12-17	WOS:000281127400001
J	Kalakonda, N; Fischle, W; Boccuni, P; Gurvich, N; Hoya-Arias, R; Zhao, X; Miyata, Y; MacGrogan, D; Zhang, J; Sims, JK; Rice, JC; Nimer, SD				Kalakonda, N.; Fischle, W.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; MacGrogan, D.; Zhang, J.; Sims, J. K.; Rice, J. C.; Nimer, S. D.			Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1	ONCOGENE			English	Article						cell cycle; chromatin; L3MBTL1; lysine monomethylation; PR-SET7	POLYCOMB GROUP PROTEIN; CELL-CYCLE; DROSOPHILA-MELANOGASTER; MITOTIC CHROMOSOMES; MAMMALIAN CHROMATIN; METHYLATION STATES; SILENT CHROMATIN; HORMONE-RECEPTOR; TUDOR DOMAIN; HP1 PROTEINS	Lethal 3 malignant brain tumor 1 (L3MBTL1), a homolog of the Drosophila polycomb tumor suppressor l(3) mbt, contains three tandem MBT repeats (3xMBT) that are critical for transcriptional repression. We recently reported that the 3xMBT repeats interact with mono- and dimethylated lysines in the amino termini of histones H4 and H1b to promote methylation-dependent chromatin compaction. Using a series of histone peptides, we now show that the recognition of mono- and dimethylated lysines in histones H3, H4 and H1.4 (but not their trimethylated or unmodified counterparts) by 3xMBT occurs in the context of a basic environment, requiring a conserved aspartic acid (D355) in the second MBT repeat. Despite the broad range of in vitro binding, the chromatin association of L3MBTL1 mirrors the progressive accumulation of H4K20 monomethylation during the cell cycle. Furthermore, transcriptional repression by L3MBTL1 is enhanced by the H4K20 monomethyltransferase PR-SET7 (to which it binds) but not SUV420H1 (an H4K20 trimethylase) or G9a (an H3K9 dimethylase) and knockdown of PR-SET7 decreases H4K20me1 levels and the chromatin association of L3MBTL1. Our studies identify the importance of H4K20 monomethylation and of PR-SET7 for L3MBTL1 function.	[Kalakonda, N.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; MacGrogan, D.; Zhang, J.; Nimer, S. D.] Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; [Fischle, W.] Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; [Sims, J. K.; Rice, J. C.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Memorial Sloan Kettering Cancer Center; Rockefeller University; University of Southern California	Nimer, SD (corresponding author), Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave,Box 575, New York, NY 10021 USA.	nimers@mskcc.org	MacGrogan, Donal/AAR-7392-2021; MacGrogan, Donal/E-8604-2016; Rice, Judd C/B-7806-2009	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Zhao, Xiaolan/0000-0002-8302-6905	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075094] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM075094-01A2, R01 GM075094, R01 GM075094-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Bornemann D, 1998, GENETICS, V150, P675; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Dialynas GK, 2007, J CELL SCI, V120, P3415, DOI 10.1242/jcs.012914; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huebert DJ, 2005, CURR OPIN GENET DEV, V15, P476, DOI 10.1016/j.gde.2005.08.001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jacobs SA, 2004, METHOD ENZYMOL, V376, P131; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Klymenko T, 2006, GENE DEV, V20, P1110, DOI 10.1101/gad.377406; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; MacGrogan D, 2004, GENE CHROMOSOME CANC, V41, P203, DOI 10.1002/gcc.20087; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Trojer P, 2007, CELL, V129, P915, DOI 10.1016/j.cell.2007.03.048; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Wang WK, 2003, STRUCTURE, V11, P775, DOI 10.1016/S0969-2126(03)00127-8; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Yohn CB, 2003, GENETICS, V165, P1889; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	52	117	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4293	4304		10.1038/onc.2008.67	http://dx.doi.org/10.1038/onc.2008.67			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18408754	Green Accepted			2022-12-17	WOS:000257691100004
J	Steelman, LS; Navolanic, PM; Sokolosky, ML; Taylor, JR; Lehmann, BD; Chappell, WH; Abrams, SL; Wong, EWT; Stadelman, KM; Terrian, DM; Leslie, NR; Martelli, AM; Stivala, F; Libra, M; Franklin, RA; McCubrey, JA				Steelman, L. S.; Navolanic, P. M.; Sokolosky, M. L.; Taylor, J. R.; Lehmann, B. D.; Chappell, W. H.; Abrams, S. L.; Wong, E. W. T.; Stadelman, K. M.; Terrian, D. M.; Leslie, N. R.; Martelli, A. M.; Stivala, F.; Libra, M.; Franklin, R. A.; McCubrey, J. A.			Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors	ONCOGENE			English	Article						PTEN; Akt; mTOR; rapamycin; chemotherapeutic drugs	PROTEIN-KINASE-B; INVASIVE DUCTAL CARCINOMA; COWDEN-DISEASE; REDUCED EXPRESSION; MAMMALIAN TARGET; ACTIVATION; GENE; ANGIOGENESIS; TRASTUZUMAB; MUTATIONS	Ectopic expression of mutant forms of phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) lacking lipid ( G129E) or lipid and protein ( C124S) phosphatase activity decreased sensitivity of MCF-7 breast cancer cells, which have wild-type PTEN, to doxorubicin and increased sensitivity to the mammalian target of rapamycin ( mTOR) inhibitor rapamycin. Cells transfected with a mutant PTEN gene lacking both lipid and protein phosphatase activities were more resistant to doxorubicin than cells transfected with the PTEN mutant lacking lipid phosphatase activity indicating that the protein phosphatase activity of PTEN was also important in controlling the sensitivity to doxorubicin, while no difference was observed between the lipid ( G129E) and lipid and protein ( C124S) phosphatase PTEN mutants in terms of sensitivity to rapamycin. A synergistic inhibitory interaction was observed when doxorubicin was combined with rapamycin in the phosphatase-deficient PTEN-transfected cells. Interference with the lipid phosphatase activity of PTEN was sufficient to activate Akt/mTOR/p70S6K signaling. These studies indicate that disruption of the normal activity of the PTEN phosphatase can have dramatic effects on the therapeutic sensitivity of breast cancer cells. Mutations in the key residues which control PTEN lipid and protein phosphatase may act as dominant-negative mutants to suppress endogenous PTEN and alter the sensitivity of breast cancer patients to chemo- and targeted therapies.	[Steelman, L. S.; Navolanic, P. M.; Sokolosky, M. L.; Taylor, J. R.; Chappell, W. H.; Abrams, S. L.; Wong, E. W. T.; Stadelman, K. M.; Franklin, R. A.; McCubrey, J. A.] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; [Lehmann, B. D.; Terrian, D. M.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA; [Terrian, D. M.; Franklin, R. A.; McCubrey, J. A.] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; [Stivala, F.; Libra, M.] Univ Catania, Dept Biomed Sci, Catania, Italy; [Leslie, N. R.] Univ Dundee, Sch Life Sci, Div Cell Signaling, Dundee, Scotland; [Martelli, A. M.] Univ Bologna, Dept Human Anat Sci, Bologna, Italy; [Martelli, A. M.] IOR, CNR, IGM, Bologna, Italy	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of Catania; University of Dundee; University of Bologna; Consiglio Nazionale delle Ricerche (CNR)	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA.	mccubreyj@ecu.edu	Lehmann, Brian D./H-8464-2019; Libra, Massimo/ABF-6654-2020; Leslie, Nicholas/D-2699-2009; Libra, Massimo/L-8241-2018	Lehmann, Brian D./0000-0003-0407-5248; Libra, Massimo/0000-0002-7232-7737; Libra, Massimo/0000-0002-7232-7737; McCubrey, James/0000-0001-6027-3156; LESLIE, Nicholas/0000-0001-5131-0541; Franklin, Richard A./0000-0003-0299-9578	NATIONAL CANCER INSTITUTE [R01CA098195] Funding Source: NIH RePORTER; MRC [G9403619] Funding Source: UKRI; Medical Research Council [G9403619] Funding Source: Medline; NCI NIH HHS [R01 CA098195, R01CA098195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Rahman MH, 2006, J CLIN ONCOL, V24, P288, DOI 10.1200/JCO.2005.02.2418; Agrawal S, 2006, HUM MOL GENET, V15, P777, DOI 10.1093/hmg/ddi492; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Chiang GG, 2005, J BIOL CHEM, V280, P25485, DOI 10.1074/jbc.M501707200; Clark AS, 2002, MOL CANCER THER, V1, P707; Davis JM, 2003, CLIN CANCER RES, V9, P1161; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jin J, 2005, ONCOGENE, V24, P5459, DOI 10.1038/sj.onc.1208704; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Lee JS, 2004, APPL IMMUNOHISTO M M, V12, P205, DOI 10.1097/00129039-200409000-00004; Lehmann BD, 2007, CELL CYCLE, V6, P595, DOI 10.4161/cc.6.5.3901; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862; Luo J, 2005, CELL CYCLE, V4, P1309, DOI 10.4161/cc.4.10.2062; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Martelli AM, 2007, CURR MED CHEM, V14, P2009; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Shelton JG, 2005, EXPERT OPIN THER TAR, V9, P1009, DOI 10.1517/14728222.9.5.1009; Shelton JG, 2005, CELL CYCLE, V4, P822, DOI 10.4161/cc.4.6.1724; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Steelman LS, 2004, EXPERT OPIN THER TAR, V8, P537, DOI 10.1517/14728222.8.6.537; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Tsutsui S, 2005, CANCER-AM CANCER SOC, V104, P2048, DOI 10.1002/cncr.21471; Tsutsui S, 2005, ONCOLOGY-BASEL, V68, P398, DOI 10.1159/000086981; van Nimwegen MJ, 2006, MOL PHARMACOL, V70, P1330, DOI 10.1124/mol.106.026195; Weinstein-Oppenheimer CR, 2001, CLIN CANCER RES, V7, P2898	36	117	131	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4086	4095		10.1038/onc.2008.49	http://dx.doi.org/10.1038/onc.2008.49			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332865	Green Accepted			2022-12-17	WOS:000257325100008
J	Samanta, M; Iwakiri, D; Takada, K				Samanta, M.; Iwakiri, D.; Takada, K.			Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling	ONCOGENE			English	Article						EBV; Burkitt's lymphoma; EBER; RIG-I; IRF-3; IL-10	LYMPHOMA CELL-LINE; BURKITTS-LYMPHOMA; GROWTH TRANSFORMATION; (EBV)-ENCODED RNA; T-CELLS; EBV; PROTEIN; TRANSCRIPTION; EXPRESSION; INDUCTION	Epstein-Barr virus-encoded small RNA (EBER) is nonpolyadenylated, noncoding RNA, forms stem-loop structure by intermolecular base-pairing giving rise to double-stranded RNA (dsRNA)-like molecule and exists abundantly in EBV-infected cells. EBER induces IL-10 and thus supports the growth of Burkitt's lymphoma (BL) cells. In this study, the mechanism of IL-10 induction by EBER was analysed in the context of dsRNA signaling pathway. Knockdown of retinoic acid-inducible gene I (RIG-I) by small interfering RNA (siRNA), and expression of dominant-negative RIG-I downregulated IL-10 induction in EBER(+) EBV-infected and EBER plasmid-transfected BL cells. Transfection of EBER-expressing plasmid or in vitro synthesized EBER induced IL-10 in RIG-I-expressing cell clones, and activation of IL-10 promoter by EBER was blocked by dominant-negative RIG-I. Blocking of nuclear factor (NF)-kappa B by dominant-negative I kappa B-alpha plasmid did not block IL-10 expression, whereas knockdown of IRF-3 by siRNA resulted in downregulation of IL-10 in EBER(+) BL cells. NF-kappa B is reported to function downstream of RIG-I signaling pathway and is involved in the induction of proinflammatory cytokines. Our results indicate that EBER induces an anti-inflammatory cytokine IL-10 through RIG-I-mediated IRF-3 but not NF-kappa B signaling. These findings suggest a new mechanism of dsRNA signaling pathway that triggers the expression of IL-10, which acts as an autocrine growth factor in BL cells.	[Samanta, M.; Iwakiri, D.; Takada, K.] Hokkaido Univ, Dept Tumor Virol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Takada, K (corresponding author), Hokkaido Univ, Dept Tumor Virol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan.	kentaka@igm.hokudai.ac.jp	Takada, Kenzo/A-6666-2012					AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; GLICKMAN JN, 1988, J VIROL, V62, P902, DOI 10.1128/JVI.62.3.902-911.1988; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HEITBROCK LZ, 2003, J IMMUNOL, V171, P285; Imaizumi T, 2004, LIFE SCI, V75, P1171, DOI 10.1016/j.lfs.2004.01.030; Iwakiri D, 2005, ONCOGENE, V24, P1767, DOI 10.1038/sj.onc.1208357; Iwakiri D, 2003, CANCER RES, V63, P7062; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kieff E, 2001, FIELDS VIROLOGY, V2, P2511; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; KLEIN E, 1968, CANCER RES, V28, P1300; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; Lin RT, 1999, MOL CELL BIOL, V19, P959; MALEFYT RD, 1991, J EXP MED, V174, P915; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Samanta M, 2006, EMBO J, V25, P4207, DOI 10.1038/sj.emboj.7601314; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; TOCZYSKI DP, 1994, P NATL ACAD SCI USA, V91, P3463, DOI 10.1073/pnas.91.8.3463; TOCZYSKI DPW, 1991, EMBO J, V10, P459, DOI 10.1002/j.1460-2075.1991.tb07968.x; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Wagoner J, 2007, J VIROL, V81, P309, DOI 10.1128/JVI.01411-06; Wu Y, 2007, J VIROL, V81, P11236, DOI 10.1128/JVI.00579-07; Yajima M, 2005, J VIROL, V79, P4298, DOI 10.1128/JVI.79.7.4298-4307.2005; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Yang LX, 2004, CANCER RES, V64, P5332, DOI 10.1158/0008-5472.CAN-04-0733; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	36	117	125	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4150	4160		10.1038/onc.2008.75	http://dx.doi.org/10.1038/onc.2008.75			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362887				2022-12-17	WOS:000257496800002
J	Li, X; Deng, W; Lobo-Ruppert, SM; Ruppert, JM				Li, X.; Deng, W.; Lobo-Ruppert, S. M.; Ruppert, J. M.			Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin	ONCOGENE			English	Article						Hedgehog; Snail; Gli1; E-cadherin; beta-catenin; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; BASAL-CELL CARCINOMA; STEM-CELLS; C-MYC; TUMOR-SUPPRESSOR; CANCER CELLS; WNT; TRANSFORMATION; ADHESION; EXPRESSION	The Hedgehog pathway transcription factor Gli1 induces transformation of epithelial cells via induction of Snail, a repressor of E-cadherin (E-cad). E-cad is normally complexed with beta-catenin at the cell membrane. Loss of E-cad during developmental epithelial-mesenchymal transitions can switch beta-catenin from its role at adherens junctions to its role in nuclear transcription. During tumorigenesis it is unclear which pathways trigger this switch. In the current study, gain- and loss-of-function approaches identified E-cad as a selective inhibitor of transformation by Gli1, and Snail knockdown was rescued by downregulation of E-cad. Gli1 induced relocalization of beta-catenin from the cell membrane to the nucleus. The ability of wild-type or mutant alleles of E-cad to modulate transformation by Gli1 correlated with their ability to regulate localization of beta-catenin. Inhibition of Wnt-beta-catenin signaling by dominant negative Tcf4 selectively blocked in vitro transformation by Gli1. In Gli1-transgenic mice, infiltrating skin tumor cells expressed active, unphosphorylated beta-catenin. Our studies identify E-cad as a selective suppressor of transformation by Gli1 and point to the Sonic Hedgehog-Gli1 pathway as a key regulator of the beta-catenin switch in epithelial cells and cancers.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ruppert, JM (corresponding author), Univ Alabama, Sch Med, Dept Med, Room 570 WTI, Birmingham, AL 35294 USA.	mruppert@uab.edu			NCI NIH HHS [CA094030, R01 CA094030, CA065686, R29 CA065686, R01 CA065686, R01 CA094030-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065686, R29CA065686, R01CA094030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi T, 2006, GUT, V55, P991, DOI 10.1136/gut.2005.080333; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; van de Wetering M, 2001, CANCER RES, V61, P278; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	38	117	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4489	4498		10.1038/sj.onc.1210241	http://dx.doi.org/10.1038/sj.onc.1210241			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297467	Green Accepted			2022-12-17	WOS:000247836100003
J	D'Errico, M; Parlanti, E; Teson, M; Degan, P; Lemma, T; Calcagnile, A; Iavarone, I; Jaruga, P; Ropolo, M; Pedrini, AM; Orioli, D; Frosina, G; Zambruno, G; Dizdaroglu, M; Stefanini, M; Dogliotti, E				D'Errico, M.; Parlanti, E.; Teson, M.; Degan, P.; Lemma, T.; Calcagnile, A.; Iavarone, I.; Jaruga, P.; Ropolo, M.; Pedrini, A. M.; Orioli, D.; Frosina, G.; Zambruno, G.; Dizdaroglu, M.; Stefanini, M.; Dogliotti, E.			The role of CSA in the response to oxidative DNA damage in human cells	ONCOGENE			English	Article						cockayne syndrome; DNA repair; keratinocytes; oxidative DNA damage	COCKAYNE-SYNDROME; EXCISION-REPAIR; GENE-PRODUCT; PROTEIN; TRANSCRIPTION; LESIONS; DEFICIENT; PATHWAY	Cockayne syndrome (CS) is a rare genetic disease characterized by severe growth, mental retardation and pronounced cachexia. CS is most frequently due to mutations in either of two genes, CSB and CSA. Evidence for a role of CSB protein in the repair of oxidative DNA damage has been provided recently. Here, we show that CSA is also involved in the response to oxidative stress. CS-A human primary. fibroblasts and keratinocytes showed hypersensitivity to potassium bromate, a specific inducer of oxidative damage. This was associated with inefficient repair of oxidatively induced DNA lesions, namely 8-hydroxyguanine (8-OH-Gua) and (5 ' S)-8,5 '-cyclo 2 '-deoxyadenosine. Expression of the wild-type CSA in the CS-A cell line CS3BE significantly decreased the steady-state level of 8-OH-Gua and increased its repair rate following oxidant treatment. CS-A cell extracts showed normal 8-OH-Gua cleavage activity in an in vitro assay, whereas CS-B cell extracts were con. firmed to be defective. Our data provide the. first in vivo evidence that CSA protein contributes to prevent accumulation of various oxidized DNA bases and underline specific functions of CSB not shared with CSA. These. findings support the hypothesis that defective repair of oxidative DNA damage is involved in the clinical features of CS patients.	Ist Super Sanita, Dept Environm & Primary Prevent, Consiglio Nazl Ricerche, I-00161 Rome, Italy; IRCCS, Ist Dermopat Immacolata, Lab Mol & Cell Biol, Rome, Italy; Ist Nazl Ric Canc, Dept Translat Oncol, I-16132 Genoa, Italy; Univ Maryland Baltimore Cty, Dept Chem & Biochem Engn, Baltimore, MD 21228 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Ist Genet Mol, Pavia, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Genoa; IRCCS AOU San Martino IST; University System of Maryland; University of Maryland Baltimore County; National Institute of Standards & Technology (NIST) - USA; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Dogliotti, E (corresponding author), Ist Super Sanita, Dept Environm & Primary Prevent, Consiglio Nazl Ricerche, Viale Regina Elena 299, I-00161 Rome, Italy.	dogliott@iss.it	Parlanti, Eleonora/AAC-5978-2021; Zambruno, Giavanna/K-2933-2018; degan, paolo/AAB-4093-2019; Teson, Massimo/GSE-1949-2022; Frosina, Guido/Z-2382-2019; Jaruga, Pawel/M-4378-2015; degan, paolo/AAB-6713-2019	Frosina, Guido/0000-0002-6717-5097; degan, paolo/0000-0003-0855-8896; Jaruga, Pawel/0000-0001-9192-6084; ORIOLI, DONATA/0000-0002-3830-3408; Iavarone, Ivano/0000-0001-5856-9484; Zambruno, Giovanna/0000-0002-1295-056X				Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Brooks PJ, 2002, MUTAT RES-FUND MOL M, V509, P93, DOI 10.1016/S0027-5107(02)00222-1; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; de Waard H, 2004, MOL CELL BIOL, V24, P7941, DOI 10.1128/MCB.24.18.7941-7948.2004; de Waard H, 2003, DNA REPAIR, V2, P13, DOI 10.1016/S1568-7864(02)00188-X; Degan P, 2005, J CELL BIOCHEM, V94, P460, DOI 10.1002/jcb.20302; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; ERRICO M, 2005, CANCER RES, V65, P432; ERRICO M, 2007, MUTAT RES, V614, P37; FOURSTERI M, 2006, MOL CELL, V23, P471; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; Laine JP, 2006, TRENDS GENET, V22, P430, DOI 10.1016/j.tig.2006.06.006; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Newman JC, 2006, P NATL ACAD SCI USA, V103, P9613, DOI 10.1073/pnas.0510909103; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Spivak G, 2006, DNA REPAIR, V5, P13, DOI 10.1016/j.dnarep.2005.06.017; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com; Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7	30	117	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4336	4343		10.1038/sj.onc.1210232	http://dx.doi.org/10.1038/sj.onc.1210232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297471				2022-12-17	WOS:000247620000002
J	Yuan, L; Siegel, M; Choi, K; Khosla, C; Miller, CR; Jackson, EN; Piwnica-Worms, D; Rich, KM				Yuan, L.; Siegel, M.; Choi, K.; Khosla, C.; Miller, C. R.; Jackson, E. N.; Piwnica-Worms, D.; Rich, K. M.			Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy	ONCOGENE			English	Article						apoptosis; brain tumor; tissue transglutaminase 2 inhibitors; stroma; U87MG; BCNU	TISSUE TRANSGLUTAMINASE; CELL-DEATH; BRAIN-TUMORS; IN-VIVO; ED-B; EXPRESSION; CANCER; APOPTOSIS; RESISTANCE; INDUCTION	Transglutaminase 2 (TG2, a.k.a. tissue transglutaminase) belongs to a family of transglutaminase enzymes that stabilize proteins by affecting covalent crosslinking via formation of amide bonds. Cell surface TG2 is directly involved as an adhesive receptor in cell-extracellular matrix (ECM) interactions. Here, we show that TG2 activity is elevated in glioblastomas compared with non-neoplastic brain. Immunouorescent studies showed increased staining of. bronectin colocalized with TG2 in the ECM in glioblastomas. In addition, small clusters of invading human glioblastoma cells present in non- neoplastic brain parenchyma secrete high levels of TG2 and. bronectin that distinguish them from normal brain stroma. Downregulation of TG2 in U87MG glioblastoma cells with RNAi demonstrated decreased assembly of. bronectin in the ECM. Treatment with KCC009 blocked the remodeling of. bronectin in the ECM in glioblastomas in both in vitro and in vivo studies. KCC009 treatment in mice harboring orthotopic glioblastomas (DBT-FG) sensitized the tumors to N, N-1-bis(2-chloroethyl)-N-nitrosourea chemotherapy, as measured by reduced bioluminescence, increased apoptosis and prolonged survival. The ability of KCC009 to interfere with the permissive remodeling of. bronectin in the ECM in glioblastomas suggests a novel target to enhance sensitivity to chemotherapy directed not only at the tumor mass, but also invading glioblastoma cells.	Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Washington Univ, Sch Med, Div Neuropathol, St Louis, MO 63130 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63130 USA; Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63130 USA	Washington University (WUSTL); Stanford University; Stanford University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Rich, KM (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, 660 S Euclid Ave,Box 8057, St Louis, MO 63110 USA.	richk@nsurg.wustl.edu	Miller, Ryan/B-9365-2008	Miller, Ryan/0000-0002-0096-8762; Khosla, Chaitan/0000-0001-6529-495X; Choi, Kihang/0000-0001-5196-4107	NCI NIH HHS [P50 CA94056, T32CA009547, P30 CA91842] Funding Source: Medline; NIDDK NIH HHS [R01 DK63158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA091842, T32CA009547, P50CA094056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; Castro MG, 2003, PHARMACOL THERAPEUT, V98, P71, DOI 10.1016/S0163-7258(03)00014-7; Chicoine MR, 2001, NEUROSURGERY, V48, P607, DOI 10.1097/00006123-200103000-00032; Choi K, 2005, CHEM BIOL, V12, P469, DOI 10.1016/j.chembiol.2005.02.007; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gross S, 2005, METHOD ENZYMOL, V399, P512, DOI 10.1016/S0076-6879(05)99035-6; Han JA, 1999, J CANCER RES CLIN, V125, P89, DOI 10.1007/s004320050247; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; KUMANISHI T, 1967, JPN J EXP MED, V37, P461; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; Midulla M, 2000, CANCER RES, V60, P164; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Smith MCP, 2004, CANCER RES, V64, P8604, DOI 10.1158/0008-5472.CAN-04-1844; Verderio EAM, 2003, J BIOL CHEM, V278, P42604, DOI 10.1074/jbc.M303303200; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328; Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863	30	117	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2563	2573		10.1038/sj.onc.1210048	http://dx.doi.org/10.1038/sj.onc.1210048			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17099729				2022-12-17	WOS:000245831200004
J	Bos, CL; Kodach, LL; van den Brink, GR; Diks, SH; van Santen, MM; Richel, DJ; Peppelenbosch, MP; Hardwick, JCH				Bos, C. L.; Kodach, L. L.; van den Brink, G. R.; Diks, S. H.; van Santen, M. M.; Richel, D. J.; Peppelenbosch, M. P.; Hardwick, J. C. H.			Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A	ONCOGENE			English	Article						aspirin; Wnt/beta-catenin; PP2A; colon cancer; chemoprevention	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; FAMILIAL ADENOMATOUS POLYPOSIS; NF-KAPPA-B; BETA-CATENIN; COLORECTAL-CANCER; CYCLOOXYGENASE-2 INHIBITOR; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; OKADAIC ACID	Nonsteroidal anti-inflammatory drugs show chemopreventive efficacy in colon cancer, but the mechanism behind this remains unclear. Elucidating this mechanism is seen as vital to the development of new chemopreventive agents. We studied the effects of aspirin on the oncogenic Wnt/beta-catenin pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of beta-catenin by immunoblotting. Furthermore, the ubiquitination and cytoplasmic levels of beta-catenin were assessed by immunoblotting, and also the localization of b-catenin was shown by green fluorescent protein-tagged beta-catenin and time-lapse fluorescent imaging. Importantly, aspirin treatment caused increased phosphorylation of protein phosphatase 2A (PP2A), an event associated with inhibition of PP2A enzymatic activity, which was confirmed by a reduction in enzymatic PP2A activity. Moreover, this inhibition of PP2A enzymatic activity was essential for the effects of aspirin on the Wnt/beta-catenin pathway as shown by transient transfection with PP2A constructs. The findings in this article provide a molecular explanation for the efficacy of aspirin in chemoprevention of colorectal cancer and shows biochemical evidence that PP2A is an important regulator of Wnt/beta-catenin pathway activity in these cells.	Univ Amsterdam, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands; Univ Amsterdam, Dept Oncol, Amsterdam, Netherlands; Univ Amsterdam, Lab Expt Internal Med, Amsterdam, Netherlands; Univ Amsterdam, Dept Gastroenterol, Amsterdam, Netherlands; Univ Groningen, Dept Cell Biol, Groningen, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Groningen	Hardwick, JCH (corresponding author), Acad Med Ctr, Dept Gastroenterol, C2-112,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.c.hardwick@amc.uva.nl	Hardwick, James/J-4862-2013	Hardwick, James/0000-0002-9575-5099; Kodach, Liudmila/0000-0003-2487-3204; Peppelenbosch, Maikel/0000-0001-9112-6028				Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Boon EMJ, 2002, CANCER RES, V62, P5126; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Dihlmann S, 2003, MOL CANCER THER, V2, P509; Dihlmann S, 2001, ONCOGENE, V20, P645, DOI 10.1038/sj.onc.1204123; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Green DW, 2001, J SURG RES, V101, P16, DOI 10.1006/jsre.2001.6241; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Husain SS, 2002, AM J GASTROENTEROL, V97, P542; Kishimoto Y, 2000, GUT, V47, P812, DOI 10.1136/gut.47.6.812; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marx J, 2001, SCIENCE, V291, P581, DOI 10.1126/science.291.5504.581; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Oshima H, 1997, CANCER RES, V57, P1644; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Roh H, 2001, CANCER RES, V61, P6563; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Smal C, 2004, BIOCHEM PHARMACOL, V68, P95, DOI 10.1016/j.bcp.2004.02.031; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7	42	117	122	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6447	6456		10.1038/sj.onc.1209658	http://dx.doi.org/10.1038/sj.onc.1209658			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16878161				2022-12-17	WOS:000241395100001
J	Massard, C; Zermati, Y; Pauleau, AL; Larochette, N; Wetivier, D; Sabatier, L; Kroemer, G; Soria, JC				Massard, C.; Zermati, Y.; Pauleau, A. -L; Larochette, N.; Wetivier, D.; Sabatier, L.; Kroemer, G.; Soria, J. -C			hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway	ONCOGENE			English	Article						apoptosis; Bax; Bcl-2; chemosensitization; p53	TELOMERASE REVERSE-TRANSCRIPTASE; HUMAN CANCER-CELLS; GENE-EXPRESSION; DOWN-REGULATION; APOPTOSIS; P53; GROWTH; BAX; RNA; RESPONSES	hTERT is the catalytic subunit of the telomerase and is hence required for telomerase maintenance activity and cancer cell immortalization. Here, we show that acute hTERT depletion has no adverse effects on the viability or proliferation of cervical and colon carcinoma cell lines, as evaluated within 72h after transfection with hTERT-specific small interfering RNAs (siRNAs). Within the same time frame, hTERT depletion facilitated the induction of apoptotic cell death by cisplatin, etoposide, mitomycin C and reactive oxygen species, yet failed to sensitize cells to death induction via the CD95 death receptor. Experiments performed with p53 knockout cells or chemical p53 inhibitors revealed that p53 was not involved in the chemosensitizing effect of hTERT knockdown. However, the proapoptotic Bcl-2 family protein Bax was involved in cell death induction by hTERT siRNAs. Depletion of hTERT facilitated the conformational activation of Bax induced by genotoxic agents. Moreover, Bax knockout abolished the chemosensitizing effect of hTERT siRNAs. Inhibition of mitochondrial membrane permeabilization by overexpression of Bcl-2 or expression of the cytomegalovirus-encoded protein vMIA (viral mitochondrial inhibitor of apoptosis), which acts as a specific Bax inhibitor, prevented the induction of cell death by the combination of hTERT depletion and chemotherapeutic agents. Altogether, our data indicate that hTERT inhibition may constitute a promising strategy for facilitating the induction of the mitochondrial pathway of apoptosis.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, Div Canc Med, F-94805 Villejuif, France; CEA, DSV, DRR, LRO, Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; CEA	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr; soria@igr.fr	LAROCHETTE, Nathanael/R-4298-2017; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Soria, Jean-Charles/F-3619-2014	LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; Sabatier, Laure/0000-0003-0552-6549				Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002; Goldmacher VS, 2005, APOPTOSIS, V10, P251, DOI 10.1007/s10495-005-0800-z; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Gorbunova V, 2003, J BIOL CHEM, V278, P7692, DOI 10.1074/jbc.M212944200; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Haendeler J, 2004, CIRC RES, V94, P768, DOI 10.1161/01.RES.0000121104.05977.F3; Haendeler J, 2003, FEBS LETT, V536, P180, DOI 10.1016/S0014-5793(03)00058-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harborth J, 2001, J CELL SCI, V114, P4557; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Jacob D, 2005, CANCER GENE THER, V12, P109, DOI 10.1038/sj.cgt.7700773; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Lantuejoul S, 2005, CLIN CANCER RES, V11, P2074, DOI 10.1158/1078-0432.CCR-04-1376; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Li S, 2005, J BIOL CHEM, V280, P23709, DOI 10.1074/jbc.M502782200; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Santos JH, 2004, AGING CELL, V3, P399, DOI 10.1111/j.1474-9728.2004.00124.x; Saretzki G, 2001, ANAL CELL PATHOL, V23, P39, DOI 10.1155/2001/630972; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Takakura M, 2005, MOL CELL BIOL, V25, P8037, DOI 10.1128/MCB.25.18.8037-8043.2005; Uziel O, 2005, BRIT J CANCER, V92, P1881, DOI 10.1038/sj.bjc.6602592; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wu P, 2005, BIOCHEM BIOPH RES CO, V335, P36, DOI 10.1016/j.bbrc.2005.07.039; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje; Zhou CX, 2003, MOL CANCER THER, V2, P789	58	117	132	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4505	4514		10.1038/sj.onc.1209487	http://dx.doi.org/10.1038/sj.onc.1209487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16619047				2022-12-17	WOS:000239457500001
J	Adams, KE; Medhurst, AL; Dart, DA; Lakin, ND				Adams, KE; Medhurst, AL; Dart, DA; Lakin, ND			Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex	ONCOGENE			English	Article						ataxia telangiectasia mutated and rad3-related (ATR); cell cycle checkpoints; DNA damage and repair	DOUBLE-STRAND BREAKS; EARLY EMBRYONIC LETHALITY; CHECKPOINT KINASE ATR; ATAXIA-TELANGIECTASIA; MRE11 COMPLEX; S-PHASE; DEPENDENT PHOSPHORYLATION; REPLICATION CHECKPOINT; GENOTOXIC STRESS; DEFICIENT CELLS	ATM and ATR are two related kinases essential for signalling DNA damage. Although ATM is thought to be the principle kinase responsible for signalling ionising radiation (IR)-induced DNA damage, ATR also contributes to signalling this form of genotoxic stress. However, the molecular basis of differential ATM and ATR activation in response to IR remains unclear. Here, we report that ATR is recruited to sites of IR-induced DNA damage significantly later than activation of ATM. We show that ATR is recruited to IR-induced nuclear foci in G(1) and S phase of the cell cycle, supporting a role for ATR in detecting DNA damage outside of S phase. In addition, we report that recruitment of ATR to sites of IR-induced DNA damage is concomitant with appearance of large tracts of single-stranded DNA (ssDNA) and that this event is dependent on ATM and components of the Mre11/Rad50/Nbs1 (MRN) protein complex.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Lakin, ND (corresponding author), Univ Oxford, Dept Biochem, S Pks Rd, Oxford OX1 3QU, England.	nicholas.lakin@bioch.ox.ac.uk			Cancer Research UK [A5207] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dodson GE, 2004, J BIOL CHEM, V279, P34010, DOI 10.1074/jbc.C400242200; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Downs JA, 2003, NATURE, V424, P732, DOI 10.1038/424732a; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; IVANOV EL, 1994, MOL CELL BIOL, V14, P3414, DOI 10.1128/MCB.14.5.3414; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Llorente B, 2004, MOL CELL BIOL, V24, P9682, DOI 10.1128/MCB.24.21.9682-9694.2004; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moreau S, 1999, MOL CELL BIOL, V19, P556; Nakada D, 2004, MOL CELL BIOL, V24, P10016, DOI 10.1128/MCB.24.22.10016-10025.2004; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ward IM, 2004, J BIOL CHEM, V279, P9677, DOI 10.1074/jbc.C300554200; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yuan SSF, 2002, TOXICOLOGY, V177, P123, DOI 10.1016/S0300-483X(02)00220-2; Zhong H, 2005, HUM MOL GENET, V14, P2685, DOI 10.1093/hmg/ddi302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	61	117	124	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	28					3894	3904		10.1038/sj.onc.1209426	http://dx.doi.org/10.1038/sj.onc.1209426			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474843	Green Accepted			2022-12-17	WOS:000238668800002
J	Hurst, CD; Fiegler, H; Carr, P; Williams, S; Carter, NP; Knowles, MA				Hurst, CD; Fiegler, H; Carr, P; Williams, S; Carter, NP; Knowles, MA			High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization	ONCOGENE			English	Article						bladder cancer; comparative genomic hybridization; array	TRANSITIONAL-CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE; CHROMOSOMAL IMBALANCES; IN-VITRO; DELETION; AMPLIFICATION; HETEROZYGOSITY; PROGRESSION; LOCI; REGIONS	We have screened 22 bladder tumour- derived cell lines and one normal urothelium- derived cell line for genome- wide copy number changes using array comparative genomic hybridization ( CGH). Comparison of array CGH with existing multiplex-fluorescence in situ hybridization ( M-FISH) results revealed excellent concordance. Regions of gain and loss were defined more accurately by array CGH, and several small regions of deletion were detected that were not identified by M- FISH. Numerous genetic changes were identified, many of which were compatible with previous results from conventional CGH and loss of heterozygosity analyses on bladder tumours. The most frequent changes involved complete or partial loss of 4q ( 83%) and gain of 20q ( 78%). Other frequent losses were of 18q ( 65%), 8p ( 65%), 2q ( 61%), 6q ( 61%), 3p ( 56%), 13q ( 56%), 4p ( 52%), 6p ( 52%), 10p ( 52%), 10q ( 52%) and 5p ( 43%). We have refined the localization of a region of deletion at 8p21.2- p21.3 to an interval of approximately 1 Mb. Five homozygous deletions of tumour suppressor genes were confirmed, and several potentially novel homozygous deletions were identified. In all, 15 high- level amplifications were detected, with a previously reported amplification at 6p22.3 being the most frequent. Real- time PCR analysis revealed a novel candidate gene with consistent overexpression in all cell lines with the 6p22.3 amplicon.	St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England; Wellcome Trust Sanger Inst, Sanger Inst Canc Res UK Genom Microarray Grp, Cambridge CB10 1SA, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Wellcome Trust Sanger Institute	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	margaret.knowles@cancer.org.uk		Knowles, Margaret/0000-0002-9363-8657				Aboulkassim TO, 2003, ONCOGENE, V22, P2967, DOI 10.1038/sj.onc.1206513; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Bohm M, 1997, INT J CANCER, V74, P291; Bringuier PP, 1996, ONCOGENE, V12, P1747; Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO;2-L; Bruch J, 2000, CANCER RES, V60, P4526; CAIRNS P, 1993, ONCOGENE, V8, P1083; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Choi C, 2000, INT J CANCER, V86, P501, DOI 10.1002/(SICI)1097-0215(20000515)86:4<501::AID-IJC9>3.0.CO;2-#; CHRISTIAN BJ, 1987, CANCER RES, V47, P6066; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; ELDER PA, 1994, ONCOGENE, V9, P3433; Fadl-Elmula I, 2000, GENE CHROMOSOME CANC, V29, P256, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1034>3.0.CO;2-O; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Hoque MO, 2003, CANCER RES, V63, P2216; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Hovey RM, 1998, CANCER RES, V58, P3555; Imoto I, 2001, CANCER RES, V61, P6629; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kagan J, 1998, ONCOGENE, V16, P909, DOI 10.1038/sj.onc.1201606; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Knowles MA, 1999, BJU INT, V84, P412; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Lichter P, 2000, SEMIN HEMATOL, V37, P348, DOI 10.1053/shem.2000.16594; Miyamoto H, 1996, J UROLOGY, V155, P1444, DOI 10.1016/S0022-5347(01)66304-3; Muscheck M, 2000, LAB INVEST, V80, P1089, DOI 10.1038/labinvest.3780114; Ohgaki K, 1999, GENE CHROMOSOME CANC, V25, P1, DOI 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; POLASCIK TJ, 1995, CANCER RES, V55, P5396; PRATT CI, 1992, CANCER RES, V52, P688; Primdahl H, 2002, J NATL CANCER I, V94, P216; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; Sengelov L, 2000, CANCER GENET CYTOGEN, V123, P109, DOI 10.1016/S0165-4608(00)00308-3; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 1998, J PATHOL, V185, P345; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; Takle LA, 1996, ONCOGENE, V12, P1083; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; von Knobloch R, 2000, J PATHOL, V190, P163, DOI 10.1002/(SICI)1096-9896(200002)190:2<163::AID-PATH509>3.0.CO;2-0; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wagner U, 1997, AM J PATHOL, V151, P753; WANG MR, 1994, CANCER GENET CYTOGEN, V73, P8, DOI 10.1016/0165-4608(94)90175-9; Williams SV, 2002, GENE CHROMOSOME CANC, V34, P86, DOI 10.1002/gcc.10050; WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569	58	117	122	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2250	2263		10.1038/sj.onc.1207260	http://dx.doi.org/10.1038/sj.onc.1207260			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14968109				2022-12-17	WOS:000220280900016
J	Gautam, A; Li, ZR; Bepler, G				Gautam, A; Li, ZR; Bepler, G			RRM1-induced metastasis suppression through PTEN-regulated pathways	ONCOGENE			English	Article						ribonucleotide reductase; PTEN; focal adhesion kinase; lung cancer; chromosome 11; metastasis suppression; tumor suppression	FOCAL ADHESION KINASE; MAMMALIAN RIBONUCLEOTIDE REDUCTASE; CHROMOSOME SEGMENT 11P15.5; TUMOR-SUPPRESSOR; LUNG-CANCER; CELL MOTILITY; MESSENGER-RNA; GENE; INHIBITION; PROTEIN	Lung cancer is the leading cause of cancer-related mortality in the United States. Only 15% of patients with this disease survive 5 years or longer. Early metastatic spread is the single most important reason for this poor outcome. The survival of patients with pathological stage I disease, that is, no evidence for metastatic spread, and molecular aberrations on chromosome 11p15.5 is equal to that of patients with stage II disease, that is, metastatic spread to hilar lymph nodes. RRM1 is a gene in this region, and it is haploinsufficient in at least 34% stage I patients. Here, we show that overexpression of RRM1 in human and mouse lung cancer cell lines induced PTEN expression, reduced phosphorylation of focal adhesion kinase (FAK), suppressed migration, invasion, and metastasis formation, and increased survival in an animal model. Increased PTEN expression was required for the RRM1-induced suppression of cell motility and FAK phosphorylation. We conclude that RRM1 functions as a metastasis suppressor gene through induction of PTEN expression.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program ,MRC,MOLONC, Tampa, FL 33612 USA; Roswell Pk Canc Inst, Lung Canc Program, Buffalo, NY 14263 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Roswell Park Cancer Institute	Bepler, G (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol Program ,MRC,MOLONC, Tampa, FL 33612 USA.	beplerg@moffitt.usf.edu			NCI NIH HHS [R01-CA70317, P30-CA16056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070317, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Amara FM, 1996, J BIOL CHEM, V271, P20126, DOI 10.1074/jbc.271.33.20126; Bepler G, 1998, CANCER DETECT PREV, V22, P14; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Bepler G, 2002, J CLIN ONCOL, V20, P1353, DOI 10.1200/JCO.20.5.1353; CARNEY DN, 1985, CANCER RES, V45, P2913; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CORY JG, 1983, MOL CELL BIOCHEM, V53-4, P257; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Fan HZ, 1997, P NATL ACAD SCI USA, V94, P13181, DOI 10.1073/pnas.94.24.13181; Forgacs E, 1998, ONCOGENE, V17, P1557, DOI 10.1038/sj.onc.1202070; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; Hong TM, 2000, AM J RESP CELL MOL, V23, P355, DOI 10.1165/ajrcmb.23.3.4002; ILLC D, 1995, NATURE, V377, P539; JAKLITSCH MT, 1995, LUNG CANCER, V12, pS17, DOI 10.1016/S0169-5002(10)80003-0; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; OBriant K, 1997, ANTICANCER RES, V17, P3243; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stubbe J, 1998, P NATL ACAD SCI USA, V95, P2723, DOI 10.1073/pnas.95.6.2723; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; YUHAS JM, 1975, CANCER RES, V35, P242; Zhao BH, 2001, ONCOGENE, V20, P8154, DOI 10.1038/sj.onc.1205027; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	49	117	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2135	2142		10.1038/sj.onc.1206232	http://dx.doi.org/10.1038/sj.onc.1206232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687015	Bronze			2022-12-17	WOS:000182066900007
J	Baeza, N; Masuoka, J; Kleihues, P; Ohgaki, H				Baeza, N; Masuoka, J; Kleihues, P; Ohgaki, H			AXIN1 mutations but not deletions in cerebellar medulloblastomas	ONCOGENE			English	Article						AXIN1; medulloblastoma; mutation; polymorphism; deletion	PRIMITIVE NEUROECTODERMAL TUMORS; ADENOMATOUS POLYPOSIS-COLI; CENTRAL-NERVOUS-SYSTEM; WNT SIGNALING PATHWAY; COMPARATIVE GENOMIC HYBRIDIZATION; GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN; SPORADIC MEDULLOBLASTOMAS; NEGATIVE REGULATOR; GENE-MUTATIONS	Medulloblastoma is a malignant, invasive embryonal tumour of the cerebellum which manifests preferentially in children. A subset of cases is associated with colon cancer and APC germline mutations (Turcot syndrome), and APC and beta-catenin point mutations occur in up to 10% of sporadic cases, indicating the involvement of the Wnt pathway in the development of medulloblastoma. In 39 sporadic cerebellar medulloblastomas screeened for alterations in the AXIN1 gene, another component of the Wnt pathway, we found missense AXIN1 mutations in two tumours, CCC --> TCC at codon 255 (exon 1, Pro --> Ser) and TCT --> TGT at codon 263 (exon 1, Ser --> Cys). Furthermore, the A allele at the G/A polymorphism at nucleotide 16 in intron 4 was significantly over-represented in medulloblastomas (39 cases; G 0.76 vs-A 0.24) compared to healthy individuals (86 cases; G 0.91 vs A 0.09; P = 0.0027). RT-PCR revealed large deletions in the AXIN1 gene in 5/12 (42%) medulloblastomas, consistent with a previous report. However, we observed such deletions at a similar frequency also in normal brain tissue (6/12, 50%). Since there are multiple complementary, inverted sequences present in the AXIN1 gene, these large deletions may represent RT-PCR errors due to stem-loop secondary structures.										Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; ALBRECHT S, 1994, NEUROPATH APPL NEURO, V20, P74, DOI 10.1111/j.1365-2990.1994.tb00959.x; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; BADIALI M, 1993, DIAGN MOL PATHOL, V2, P23, DOI 10.1097/00019606-199303000-00004; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; CAVENEE WK, 2000, PATHOLOGY GENETICS T, P238; Cogen PH, 1996, J NEURO-ONCOL, V29, P103, DOI 10.1007/BF00165523; Dahmen RP, 2001, CANCER RES, V61, P7039; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; GRIFFIN CA, 1988, CANCER RES, V48, P175; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JAMES CD, 1990, GENE CHROMOSOME CANC, V2, P94, DOI 10.1002/gcc.2870020204; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KUMAR R, 1990, CHILD NERV SYST, V6, P371, DOI 10.1007/BF00302220; Lantos PL, 2002, GREENFIELDS NEUROPAT, P767; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; Lin YM, 2000, J HUM GENET, V45, P254, DOI 10.1007/s100380070036; Mader RM, 2001, J LAB CLIN MED, V137, P422, DOI 10.1067/mlc.2001.115452; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Pietsch T, 1997, CANCER RES, V57, P2085; Raffel C, 1997, CANCER RES, V57, P842; Reardon DA, 1997, CANCER RES, V57, P4042; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schutz BR, 1996, GENE CHROMOSOME CANC, V16, P196; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Watanabe K, 1998, ACTA NEUROPATHOL, V95, P559, DOI 10.1007/s004010050840; Wolter M, 1997, CANCER RES, V57, P2581; Wu R, 2001, CANCER RES, V61, P8247; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zurawel RH, 1998, CANCER RES, V58, P896; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	45	117	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					632	636		10.1038/sj.onc.1206156	http://dx.doi.org/10.1038/sj.onc.1206156			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555076				2022-12-17	WOS:000180538200016
J	Mori, T; Anazawa, Y; Iiizumi, M; Fukuda, S; Nakamura, Y; Arakawa, H				Mori, T; Anazawa, Y; Iiizumi, M; Fukuda, S; Nakamura, Y; Arakawa, H			Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53	ONCOGENE			English	Article						IRF5; p53; target gene	PROTEIN; EXPRESSION; APOPTOSIS; ELEMENT; CLONING; GROWTH; BINDS	Interferon regulatory factors (IRFs) regulate transcription of interferon genes through DNA sequence-specific binding to these targets. Using a differential display method for examining gene expression in p53-defective cells infected with adenovirus containing wild-type p53, we found that expression of interferon regulatory, factor 5 (IRF-5) mRNA was increased in the presence of exogenous p53. An electrophoretic mobility-shift assay showed that a potential p53 binding site (p53BS) detected in exon 2 of the IRF-5 gene could in fact bind to p53 protein. Moreover, a heterologous reporter assay revealed that the p53BS possessed p53-dependent transcriptional activity. Expression of IRF-5 was induced in p53+/+ cells (MCF7 and NHDF), but not in p53-/- cells (H1299) when DNA was damaged by gamma-irradiation, UV-radiation, or adriamycin treatment in a wild-type p53-dependent manner. These results suggest that IRF-5 is a novel p53-target, and that it might mediate the p53-dependent immune response.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Arakawa, H (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	harakawa@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Furuhata T, 1996, ONCOGENE, V13, P1965; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARPER JW, 1993, CELL, V75, P805; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MIYASHITA T, 1995, CELL, V80, P293; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; Shiraishi K, 2000, CANCER RES, V60, P3722; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urano T, 1997, CANCER RES, V57, P3281	25	117	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2914	2918		10.1038/sj.onc.1205459	http://dx.doi.org/10.1038/sj.onc.1205459			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973653				2022-12-17	WOS:000175063700018
J	Giambartolomei, S; Covone, F; Levrero, M; Balsano, C				Giambartolomei, S; Covone, F; Levrero, M; Balsano, C			Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein	ONCOGENE			English	Article						HCV; core; Raf; Erk1/2; EGF; HCC	HUMAN HEPATOCELLULAR-CARCINOMA; B VIRUS; TRANSCRIPTION FACTORS; RNA HELICASE; HBX PROTEIN; KINASES; RAS; HEPATOCARCINOGENESIS; INTERACTS; CIRRHOSIS	Chronic hepatitis C virus (HCV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The HCV capside core is a multifunctional protein with regulatory functions that affects transcription and cell growth in vitro and in vivo. Here, we show that both HCV genotype 1a and 3 core proteins activate MEK1 and Erk1/2 MAP kinases and that the costitutive expression of the HCV core results in a high basal activity of Raf1 and MAP/kinase/ kinase, as determined by endogenous Raf1 in vitro kinase assay and immunodetection of hyperphosphorylated Erk1 and Erk2 even after a serum starvation. Moreover, the activation of both Erk1/2 and the downstream transcription factor Elk-l in response to the mitogenic stimulus EGF is significantly prolonged. The sustained response to EGF in cells expressing the HCV core occurs despite a normal induction of the MAP phosphatases MKP regulatory feedback and is likely due to the costitutive activation of Raf-l activity. The ability of HCV core proteins to directly activate the MAP kinase cascade and to prolong its activity in response to mitogenic stimuli may contribute to the neoplastic transformation of HCV infected liver cells.	Univ Rome La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy; Univ Aquila, Dept Internal Med, I-67100 Laquila, Italy; Univ Cagliari, Dept Internal Med, Cagliari, Italy	Sapienza University Rome; University of L'Aquila; University of Cagliari	Balsano, C (corresponding author), Policlin Umberto I, Med Clin 1, Fdn A Cesalpino, Viale Policlin 155, I-001612 Rome, Italy.		Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Levrero, Massimo/0000-0002-4978-0875				Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; Colombo M, 1999, J HEPATOL, V31, P25, DOI 10.1016/S0168-8278(99)80370-5; De Francesco R, 1999, J HEPATOL, V31, P47, DOI 10.1016/S0168-8278(99)80374-2; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Hayashi J, 1999, INTERVIROLOGY, V42, P205, DOI 10.1159/000024962; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kalkuhl A, 1998, HEPATOLOGY, V27, P1081, DOI 10.1002/hep.510270425; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; McKillop IH, 1997, HEPATOLOGY, V26, P1484; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NATOLI G, 1994, ONCOGENE, V9, P2837; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Shibata Y, 1999, INT J ONCOL, V14, P1153; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Tamori A, 1999, HEPATOLOGY, V29, P1429, DOI 10.1002/hep.510290520; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999	31	117	122	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2606	2610		10.1038/sj.onc.1204372	http://dx.doi.org/10.1038/sj.onc.1204372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420671				2022-12-17	WOS:000168652500012
J	Chappell, SA; LeQuesne, JPC; Paulin, FEM; deSchoolmeester, ML; Stoneley, M; Soutar, RL; Ralston, SH; Helfrich, MH; Willis, AE				Chappell, SA; LeQuesne, JPC; Paulin, FEM; deSchoolmeester, ML; Stoneley, M; Soutar, RL; Ralston, SH; Helfrich, MH; Willis, AE			A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: A novel mechanism of oncogene de-regulation	ONCOGENE			English	Article						c-myc; multiple myeloma; internal ribosome; entry segment; translation initiation	FACTOR MESSENGER-RNA; ALTERNATIVE TRANSLATION; CELL-GROWTH; SITE; PROTEIN; CONTAINS; INITIATION; SEGMENT	The 5' untranslated region of the proto-oncogene c-myc contains an internal ribosome entry segment (IRES) (Nanbru ct nl,, 1997; Stoneley ct al., 1998) and thus c-myc protein synthesis can be initiated by a cap-independent as well as a cap-dependent mechanism (Stoneley ct al., 2000), In cell lines derived from patients with multiple myeloma (RIM) there is aberrant translational regulation of c-myc and this correlates with a C-T mutation in the c-myc-IRES (Paulin ct nl,, 1996), RNA derived from the mutant IRES displays enhanced binding of protein factors (Paulin ct nl,, 1998), Here we show that the same mutation is present in 42% of bone marrow samples obtained from patients with MM, but was not present in any of 21 controls demonstrating a strong correlation between this mutation and the disease. In a tissue culture based assay, the mutant version of the c-myc-IRES was more active in all cell types tested, but showed the greatest activity in a cell line derived from a patient with MM. Our data demonstrate that a single mutation in the c-myc-IRES is sufficient to cause enhanced initiation of translation via internal ribosome entry and represents a novel mechanism of oncogenesis.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Aberdeen, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Univ Glasgow, Western Infirm, Dept Haematol, Glasgow G11 6NT, Lanark, Scotland	University of Leicester; University of Aberdeen; University of Glasgow	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Willis, Anne/0000-0002-1470-8531				AUSEBEL RM, 1987, CURRENT PROTOCOLS MO; Bernstein J, 1997, J BIOL CHEM, V272, P9356; CHOCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARTINEZSALAS E, 1993, J VIROL, V67, P3748; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paulin FEM, 1996, ONCOGENE, V13, P505; Paulin FEM, 1998, NUCLEIC ACIDS RES, V26, P3097, DOI 10.1093/nar/26.13.3097; PELICCI P, 1986, P NATL ACAD SCI USA, P2984; ROSS J, 1995, MICROBIOL REV, V59, P16; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; SUMEGI J, 1985, INT J CANCER, V36, P367; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WEST MJ, 1995, ONCOGENE, V13, P2515	29	117	123	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4437	4440		10.1038/sj.onc.1203791	http://dx.doi.org/10.1038/sj.onc.1203791			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980620				2022-12-17	WOS:000089271900015
J	Belka, C; Rudner, J; Wesselborg, S; Stepczynska, A; Marini, P; Lepple-Wienhues, A; Faltin, H; Bamberg, M; Budach, W; Schulze-Osthoff, K				Belka, C; Rudner, J; Wesselborg, S; Stepczynska, A; Marini, P; Lepple-Wienhues, A; Faltin, H; Bamberg, M; Budach, W; Schulze-Osthoff, K			Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis	ONCOGENE			English	Article						caspase-8; BID; radiation; apoptosis; mitochondria	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; DRUG-INDUCED APOPTOSIS; BCL-X-L; CELL-DEATH; ISOLATED-MITOCHONDRIA; SIGNALING COMPLEX; LYMPHOMA-CELLS; BAX; RECEPTORS	Activation of the CD95 death receptor as well as ionizing radiation induces apoptotic cell death in human lymphoma cells. The activation of caspases is a hallmark of apoptosis induction irrespective of the apoptotic trigger. In contrast to death receptor signaling, the exact mechanisms of radiation-induced caspase activation are not well understood. We provide evidence that both, radiation and CD95 stimulation, induce the rapid activation of caspase-8 and BID followed by apoptosis in Jurkat T-cells, To analyse the relative position of caspase-8 within the apoptotic cascade we studied caspase activation and apoptosis in Jurkat cells overexpressing Bcl-2 or Bcl-x(L). Caspase-8 activation, proapoptotic BID cleavage and apoptosis in response to radiation were abrogated in these cells, while the responses to CD95 stimulation were only partially attenuated by overexpression of Bcl-2 family members. In parallel, the breakdown of the mitochondrial transmembrane potential (Delta Psi(m),) in response to radiation was inhibited by overexpression of Bcl-2/Bcl-x(L) Jurkat cells genetically deficient for caspase-8 were found to be completely resistant towards CD95, However, radiation-induced apoptotic responses in caspase-8-negative cells displayed only a modest reduction. We conclude that ionizing radiation activates caspase-8 and BID downstream of mitochondrial damage suggesting that, in contrast to CD95, both events function as executioners rather than initiators of the apoptotic process.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Tubingen, Dept Physiol 1, D-72076 Tubingen, Germany; Univ Munster, Div Cell Biol & Immunol, D-4400 Munster, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Munster	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013; Rudner, Justine/ABD-1397-2021	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Steemans M, 1998, J EXP MED, V188, P2193, DOI 10.1084/jem.188.11.2193; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Vander Heiden MG, 1999, MOL CELL, V3, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	117	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2000	19	9					1181	1190		10.1038/sj.onc.1203401	http://dx.doi.org/10.1038/sj.onc.1203401			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713706				2022-12-17	WOS:000085567800008
J	Lee, SJ; Dimtchev, A; Lavin, MF; Dritschilo, A; Jung, M				Lee, SJ; Dimtchev, A; Lavin, MF; Dritschilo, A; Jung, M			A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kappa B	ONCOGENE			English	Article						ionizing radiation; NF-kappa B; I kappa B-alpha; ataxia-telangiectasia (AT); ATM	ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE; ALPHA PROTEOLYSIS; KINASE COMPLEX; C-ABL; PHOSPHORYLATION; PROTEIN; DEGRADATION; INDUCTION; GENE	The signaling pathway through which ionizing radiation induces NF-kappa B activation is not fully understood. I kappa B-alpha, an inhibitory protein of NF-kappa B mediates the activation of NF-kappa B in response to various stimuli, including cytokines, mitogens, oxidants and other stresses. We have now identified an ionizing radiation-induced signaling pathway that is independent of TNF-alpha. I kappa B-alpha degradation is rapid in response to TNF-alpha induction, but it is absent in response to ionizing radiation exposure in cells from individuals with ataxia-telangiectasia (AT). Overexpression of wild-type ATM, the product of the gene defective in AT patients, restores radiation-induced degradation of I kappa B-alpha. Furthermore, phosphorylation of I kappa B-alpha. by immunoprecipitated ATM kinase is increased in control fibroblasts and transfected AT cells following ionizing radiation exposure. These data provide support for a novel ionizing radiation-induced signaling pathway for activation of NF-kappa B and a molecular basis for the sensitivity of AT patients to oxidative stresses.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Microbiol, Washington, DC 20007 USA; Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4006, Australia	Georgetown University; Georgetown University; QIMR Berghofer Medical Research Institute	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA.		Lavin, Martin/F-5961-2014	Lavin, Martin/0000-0002-5940-4769	NCI NIH HHS [CA45408, CA74175, CA 63023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175, R29CA063023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEG A, 1998, SCIENCE, V274, P782; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUKS Z, 1993, RADIAT ONCOL INVEST, V1, P81; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jung M, 1997, CANCER RES, V57, P24; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MOHAN N, 1994, RADIAT RES, V140, P97, DOI 10.2307/3578574; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	37	117	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1821	1826		10.1038/sj.onc.1202088	http://dx.doi.org/10.1038/sj.onc.1202088			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778048				2022-12-17	WOS:000076303300008
J	Grombacher, T; Eichhorn, U; Kaina, B				Grombacher, T; Eichhorn, U; Kaina, B			P53 is involved in regulation of the DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents	ONCOGENE			English	Article						p53; alkyltransferase; MGMT; DNA repair; inducible response	WILD-TYPE P53; CELL NUCLEAR ANTIGEN; RAT HEPATOMA-CELLS; NUCLEOTIDE EXCISION-REPAIR; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; MAMMALIAN-CELLS; IONIZING-RADIATION; MESSENGER-RNA; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; TRANSGENIC MICE	The DNA repair protein O-6-methlguanine-DNA methyltransferase (MGMT) is inducible stress. MGMT induction results from activation of the MGMT gene which Is a specific response to DNA damage, A possible factor involved in triggering MGMT induction might be p53, because both p53 and MGMT are activated by DNA breaks, To study the effect of p53 on induction of the MGMT gene, we compared the presence of functional wild-type (wt) and mutant p53 with MGMT expression level in various mouse fibroblasts and rat hepatoma cell lines upon genotoxic treatment. Cells which responded to ionizing radiation (IR) by MGMT induction displayed functional p53, whereas in cells not expressing wt p53, MGMT induction was not observed. Also, the cloned MGMT promoter was inducible by IR upon transfection into p53 wt cells, but not in cells deficient for p53, Thus, expression of wt p53 appears to be required for induction of MGMT mRNA and protein by IR, On the other hand, transfection of a MGMT-promoter-CAT construct together with p53 (either wt or mutant) in cells expressing wt p53 markedly reduced the basal activity of the MGMT promoter whereas cotransfection with a p53 antisense construct slightly increased MGMT promoter activity. Furthermore, cotransfection of MGMT promoter with wt or mutant p53 in p53 wt cells reduced radiation evoked MGMT promoter induction. Thus, transfection mediated high level expression of p53 has inhibitory effect both on basal MGMT promoter activity and its activation by IR, The results give evidence for involvement of p53 in DNA damage-induced MGMT promoter activation.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							Becker K, 1996, CANCER RES, V56, P3244; Becker K, 1997, CANCER RES, V57, P3335; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN CL, 1990, CARCINOGENESIS, V11, P1217, DOI 10.1093/carcin/11.7.1217; CHAN CL, 1992, CANCER RES, V52, P1804; DINCALCI M, 1988, CANC TREAT REV, V15, P5723; Dosch J, 1996, ONCOGENE, V13, P1927; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FRITZ G, 1992, BIOCHIM BIOPHYS ACTA, V1171, P35, DOI 10.1016/0167-4781(92)90137-O; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; FUKUHARA M, 1992, JPN J CANCER RES, V83, P72, DOI 10.1111/j.1349-7006.1992.tb02354.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; GROMBACHER T, 1995, BBA-MOL BASIS DIS, V1270, P63, DOI 10.1016/0925-4439(94)00073-Y; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1992, CANCER RES, V52, P6404; Harris LC, 1996, CANCER RES, V56, P2029; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; Kaina B, 1997, CANCER RES, V57, P2721; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LAVAL F, 1991, BIOCHEM BIOPH RES CO, V176, P1086, DOI 10.1016/0006-291X(91)90395-N; LAVAL F, 1990, MUTAT RES, V233, P211, DOI 10.1016/0027-5107(90)90164-Y; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Margan U, 1996, BERL MUNCH TIERARZTL, V109, P1; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PEGG AE, 1990, CANCER RES, V50, P6119; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Rafferty JA, 1996, ONCOGENE, V12, P693; SCHMEROLD I, 1986, CANCER RES, V46, P245; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; WILSON RE, 1993, CARCINOGENESIS, V14, P679, DOI 10.1093/carcin/14.4.679; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997	48	117	121	1	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					845	851		10.1038/sj.onc.1202000	http://dx.doi.org/10.1038/sj.onc.1202000			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780001				2022-12-17	WOS:000075448800006
J	Komurasaki, T; Toyoda, H; Uchida, D; Morimoto, S				Komurasaki, T; Toyoda, H; Uchida, D; Morimoto, S			Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4	ONCOGENE			English	Article						epiregulin; EGF family; ErbB receptors; tyrosine phosphorylation	NEU DIFFERENTIATION FACTOR; HUMAN-BREAST CANCER; TUMOR-CELL-LINES; EGF RECEPTOR; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; NERVOUS-SYSTEM; GENE-PRODUCT; FACTOR-ALPHA; PROTEIN	Epiregulin is a member of the epidermal growth factor (EGF) family, and has certain characteristics that are different from that of EGF, including mitogenic responses and binding to EGF receptor (EGFR). Epiregulin may also have another cell surface receptor and/or induces different receptor heterodimerizations for intracellular signaling. We investigated the binding ability of epiregulin to four ErbB family receptors using four human breast carcinoma cell lines that expressed different subsets of receptors. Chemical cross-linking experiments showed that [I-125]epiregulin directly bound to each of EGFR and ErbB-4 but not to ErbB-2 and ErbB-3. Furthermore, although epiregulin stimulated tyrosine phosphorylation of all four ErbB receptors, the main intracellular signal was mediated by ErbB-4 and/or EGFR. The pattern of activation of ErbB family receptors was different from that of other EGF-related ligands. Our findings indicate that ErbB-4 and EGFR are receptors for epiregulin, and suggest that EGF-related ligands transduce signals for different biological responses by the hierarchical mechanism.			Komurasaki, T (corresponding author), TAISHO PHARMACEUT CO LTD, MED RES LABS, MOL BIOL LAB, 1-403 YOSHINO CHO, OHMIYASHI, SAITAMA 330, JAPAN.							ALIMANDI M, 1995, ONCOGENE, V10, P1813; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HANCOCK MC, 1991, CANCER RES, V51, P4575; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOMES WE, 1992, SCIENCE, V256, P1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE DC, 1995, PHARMACOL REV, V47, P51; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1992, ONCOGENE, V7, P1273; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	49	117	122	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	1997	15	23					2841	2848		10.1038/sj.onc.1201458	http://dx.doi.org/10.1038/sj.onc.1201458			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419975				2022-12-17	WOS:A1997YJ80300010
J	Uhrbom, L; Nister, M; Westermark, B				Uhrbom, L; Nister, M; Westermark, B			Induction of senescence in human malignant glioma cells by p16(INK4A)	ONCOGENE			English	Article						senescence; glioma cells; CDKN2; p16(INK4A); CDK6; pRb phosphorylation	WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; CYCLIN-D; CELLULAR-TRANSFORMATION; GENE; EXPRESSION; INHIBITION; APOPTOSIS; CDK4; IDENTIFICATION	p16(INK4A) is a G1-specific cell cycle inhibitor which maps to human chromosome 9p21, a region frequently mutated or deleted in cancer cell lines and primary tumors. In glioblastomas the frequency of homozygous deletions is 40-70% making it one of the most common mutations in this tumor type. We have analysed the significance of the loss of this gene in gliomas by introducing the cDNA for p16(INK4A) into the human glioma cell line U-1242 MG which has a deleted CDKN2 locus. We used the tetracycline repressable vector system and obtained two stably transfected clones that expressed p16(INK4A) upon induction. p16(INK4A) expression caused a G1 arrest and enlargement of the cells similar to that of senescent cells. When staining for Senescence-Associated beta-galactosidase activity, described to be specific for senescent cells, we could show that the enlarged cells specifically gave a positive staining reaction. This senescence phenotype was dependent on the continuous expression of p16(INK4A) since it was reversed upon reintroduction of tetracycline suppression. Thus, the induced expression of p16(INK4A) in these glioma cells reverted their immortal phenotype and caused an immediate cellular senescence.	UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital				Westermark, Bengt/0000-0001-7153-5545				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ARAP W, 1995, CANCER RES, V55, P1351; BATES S, 1994, ONCOGENE, V9, P1633; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREYLING MH, 1995, CANCER RES, V55, P984; Fueyo J, 1996, ONCOGENE, V12, P103; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hara E, 1996, MOL CELL BIOL, V16, P859; HAUPT Y, 1995, ONCOGENE, V10, P1563; HE J, 1995, CANCER RES, V55, P4833; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HEDRUM A, 1994, BIOTECHNIQUES, V17, P122; HEDRUM A, 1994, BIOTECHNIQUES, V17, P126; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HIRAMA T, 1995, BLOOD, V86, P841; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOGAN DAH, 1995, EMBO J, V14, P461; Loughran O, 1996, ONCOGENE, V13, P561; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUBITZ W, 1980, INT J CANCER, V25, P53, DOI 10.1002/ijc.2910250107; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROUACH EY, 1991, NATURE, V352, P345; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SONODA Y, 1995, ONCOGENE, V11, P2145; STEIN GH, 1982, P NATL ACAD SCI-BIOL, V79, P5287, DOI 10.1073/pnas.79.17.5287; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu Q, 1996, INT J CANCER, V65, P840, DOI 10.1002/(SICI)1097-0215(19960315)65:6<840::AID-IJC22>3.0.CO;2-6; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	53	117	122	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 31	1997	15	5					505	514		10.1038/sj.onc.1201227	http://dx.doi.org/10.1038/sj.onc.1201227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XN255	9247304				2022-12-17	WOS:A1997XN25500002
J	Schuebel, KE; Bustelo, XR; Nielsen, DA; Song, BJ; Barbacid, M; Goldman, D; Lee, IJ				Schuebel, KE; Bustelo, XR; Nielsen, DA; Song, BJ; Barbacid, M; Goldman, D; Lee, IJ			Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes	ONCOGENE			English	Article						proto-oncogene; signal transduction; gene expression	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; T-CELL; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; SH2 DOMAIN; BINDING PROTEINS; POINT MUTATIONS; STEEL FACTOR	We describe the isolation and characterization of a cDNA encoding murine vav2. vav2 shares 63% and 55% identity at the nucleic acid and amino acid levels, respectively, with vav, a proto-oncogene that plays an essential role in embryonic development and hematopoietic signal transduction. The 100 kDa Vav2 protein contains the characteristic array of structural motifs found in Vav. However, unlike vav, vav2 transcripts are widely distributed in both hematopoietic and nonhematopoietic tissues. In the adult, vav2 mRNA is found at high levels in the spleen, liver, testes and placenta. Northern blot analysis reveals two vav2 mRNA species (designated alpha and beta). The alpha species is expressed throughout development while the alpha and beta species are expressed tissue-specifically in adults. Transfection of NIH3T3 cells with expression vectors containing vav2 deletions demonstrate that elimination of 183 amino terminal residues of Vav2 is sufficient to activate its oncogenic potential. Vav2-induced transformation is characterized by the appearance of foci composed of cells in which cytokinesis and karyokinesis are uncoupled. This phenotype is comparable, but not identical, to morphological changes induced by Vav and other members of the Dbl family of oncoproteins. Our results suggest that Vav family members mediate functions important in the regulation of cell architecture and proliferation in most, if not all, tissues.	NIAAA,NEUROGENET LAB,NIH,ROCKVILLE,MD 20852; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,PRINCETON,NJ 08543	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Bristol-Myers Squibb			Nielsen, David A/B-4655-2009; Bustelo, Xose R./AAD-2081-2022; Goldman, David/F-9772-2010; Bustelo, Xose R./A-9526-2010; Majid, Salma/AAT-2616-2020	Bustelo, Xose R./0000-0001-9398-6072; Goldman, David/0000-0002-1724-5405; Bustelo, Xose R./0000-0001-9398-6072; Majid, Salma/0000-0002-1724-5405				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HIGUCHI T, 1995, BIOL REPROD, V53, P840, DOI 10.1095/biolreprod53.4.840; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WU J, 1995, MOL CELL BIOL, V15, P4337; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	51	117	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					363	371						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710375				2022-12-17	WOS:A1996VA25200015
J	Welter, JF; Eckert, RL				Welter, JF; Eckert, RL			Differential expression of the fos and jun family members c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD during human epidermal keratinocyte differentiation	ONCOGENE			English	Article						activator protein 1; AP-1; Fra-1; Fra-2; jun; fos; keratinocyte differentiation; transcription factor; epidermis	HUMAN PAPILLOMAVIRUS TYPE-18; HUMAN INVOLUCRIN GENE; PROTEIN-KINASE-C; TRANSGENIC MICE; TRANSCRIPTION FACTOR; NONSPECIFIC-BINDING; EPITHELIAL-CELLS; AP-1; PROTOONCOGENE; INDUCTION	Activator protein 1 (AP1) family proteins have been implicated in the regulation of genes expressed in the epidermis. However, no comprehensive analysis of the expression patterns of the known AP1 family proteins in the human epidermis or any other terminally differentiating tissue has been performed. In the present study we describe the localization of c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD in the normal human epidermis. Each is expressed in specific epidermal layers, c-fos is localized in the nuclei of the upper spinous and granular layer cells. FosB is present in the nuclei in all layers. Fra-1 is absent from the basal layer, but is present in all other layers. Fra-2 is detected in all layers, but staining intensity is increased in the upper spinous layer. c-jun staining is limited to the granular layer, while junB and junD are present in all layers. The differentiation-dependent pattern of expression of the AP1 family members suggest an important role for these proteins in specifying the temporal and spatial pattern of gene expression during keratinoctye differentiation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL BIOPHYS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT DERMATOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT REPROD BIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT ONCOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NIAMS NIH HHS [AR41456, AR39750] Funding Source: Medline; NIDDK NIH HHS [DK07678] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, P30AR039750, R55AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM WC, 1991, MOL NEUROBIOL, V5, P297, DOI 10.1007/BF02935553; AMSTAD P, 1990, B CANCER, V77, P501; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, ANN NY ACAD SCI, V511, P117, DOI 10.1111/j.1749-6632.1987.tb36242.x; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BERNERD F, 1992, J INVEST DERMATOL, V98, P902, DOI 10.1111/1523-1747.ep12460344; Bernerd Francoise, 1993, Gene Expression, V3, P187; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CARRASCO D, 1995, ONCOGENE, V10, P1069; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Curran T, 1988, ONCOGENE HDB, P307; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; FISHER C, 1991, DEVELOPMENT, V111, P253; GANDARILLAS A, 1995, IN PRESS ONCOGENE; GILLARDON F, 1994, ONCOGENE, V9, P3219; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; GRUBE D, 1980, HISTOCHEMISTRY, V66, P149, DOI 10.1007/BF00494642; GRUBE D, 1981, ACTA HISTOCHEM, P277; HUFF CA, 1993, J BIOL CHEM, V268, P377; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; LU B, 1994, J BIOL CHEM, V269, P7443; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RODDEY PK, 1994, J INVEST DERMATOL, V102, P296, DOI 10.1111/1523-1747.ep12371785; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; RUCK P, 1990, J HISTOCHEM CYTOCHEM, V38, P859, DOI 10.1177/38.6.2335741; RYSECK RP, 1991, ONCOGENE, V6, P533; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SHAH G, 1993, CANCER RES, V53, P38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STREEFKERK JG, 1972, J HISTOCHEM CYTOCHEM, V20, P829, DOI 10.1177/20.10.829; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	54	117	120	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2681	2687						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545126				2022-12-17	WOS:A1995TP18800025
J	TAHARA, H; SATO, E; NODA, A; IDE, T				TAHARA, H; SATO, E; NODA, A; IDE, T			INCREASE IN EXPRESSION LEVEL OF P21(SDI1/CIP1/WAF1) WITH INCREASING DIVISION AGE IN BOTH NORMAL AND SV40-TRANSFORMED HUMAN FIBROBLASTS	ONCOGENE			English	Article						P21/SDI1/CIP1/WAF1; CELLULAR SENESCENCE; P53; T-ANTIGEN; HUMAN FIBROBLAST	CYCLIN-DEPENDENT KINASES; DNA-SYNTHESIS; T-ANTIGEN; CELLS; INHIBITOR; MUTANT; P21	p21(sdil/cip1/waf1) gene, whose product inhibits Cyclin/Cdk kinase and blocks cell proliferation, is known to be upregulated by p53 and to be expressed at high levels in senescent human fibroblasts. The present paper reports that p21 expression level was much lower in SV40ts T-antigen transformed cells than in normal cells and that after inactivation of ts T-antigen it recovered to that of normal cells. However, cell division age-dependent increase in expression level of p21 occurred not only in normal human fibroblasts but also in SV40ts T-antigen transformed fibroblasts with active T-antigen. These results suggest that cell age-dependent increase in p21 occurs independently upon the function of T-antigen binding proteins including p53, while the basal expression level of p21 is up-regulated by p53 as previously reported.	HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOLEC BIOL,HIROSHIMA 734,JAPAN; MEIJI CELL TECHNOL CTR,RES DIV CELLULAR REGULAT,ODAWARA 250,JAPAN	Hiroshima University; Meiji Holdings Co., Ltd.				Noda, Asao/0000-0002-9029-9813				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; BURMER GC, 1983, EXP CELL RES, V145, P79, DOI 10.1016/S0014-4827(83)80010-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; KUCHINO T, 1975, J VIROL, V15, P1302, DOI 10.1128/JVI.15.6.1302-1307.1975; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; MATSUO M, 1982, J GERONTOL, V37, P33, DOI 10.1093/geronj/37.1.33; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; TAHARA H, 1994, BIOCHEM BIOPH RES CO, V199, P1108, DOI 10.1006/bbrc.1994.1345; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMAGUCHI N, 1975, J VIROL, V15, P1297, DOI 10.1128/JVI.15.6.1297-1301.1975; YANISHEVSKY RM, 1980, EXP CELL RES, V126, P469, DOI 10.1016/0014-4827(80)90290-6	19	117	117	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					835	840						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898925				2022-12-17	WOS:A1995QL03800004
J	KEEN, AJ; KNOWLES, MA				KEEN, AJ; KNOWLES, MA			DEFINITION OF 2 REGIONS OF DELETION ON CHROMOSOME-9 IN CARCINOMA OF THE BLADDER	ONCOGENE			English	Article							TRANSITIONAL-CELL-CARCINOMA; ALLELIC LOSSES; CANCER; GENE; MELANOMA; LOCALIZATION; INTERFERON; AMPLIFICATION; PROGRESSION; ASSIGNMENT	Loss of heterozygosity (LOH) at loci on chromosome 9 can be detected in more than 50% of bladder tumours, suggesting the presence on this chromosome of one or more suppressor genes for bladder carcinogenesis, Localisation of the target gene(s) by deletion mapping has previously proved difficult due to the uneven distribution of polymorphic loci and the finding of LOH at all these loci in the majority of tumours. We have used a panel of 22 highly informative microsatellite markers, evenly distributed along chromosome 9 to analyse LOH in 95 cases of primary transitional cell carcinoma of the bladder. Forty nine tumours (53%) showed LOH at one or more loci. Of these, 30 had LOH at all informative loci, indicating probable monosomy 9. Nineteen tumours (22%) had subchromosomal deletions, 5 of 9p only, 9 of 9q only and 5 of both 9p and 9q with a clear region of retention of heterozygosity between. The patterns of LOH in these tumours indicated a common region of deletion on 9p between D9S126 (9p21) and IFNA (9p21). A single tumour showed a second site of deletion on 9p telomeric to IFNA indicating the possible existence of 2 target genes on 9p. All deletions of 9q were large, with a common region of deletion between D9S15 (9q13-q21.1) and D9S60 (9q33-q34.1), These results indicate a much higher frequency of subchromosomal deletion than has previously been detected and provide evidence for the simultaneous involvement of distinct suppressor loci on 9p and 9q in bladder carcinoma.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BERNUES M, 1993, CANCER GENET CYTOGEN, V69, P76, DOI 10.1016/0165-4608(93)90120-B; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DELSAL G, 1994, P NATL ACAD SCI USA, V91, P1848, DOI 10.1073/pnas.91.5.1848; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DRACOPOLI NC, 1987, CANCER RES, V47, P3995; FOSS KB, 1992, CYTOGENET CELL GENET, V60, P22, DOI 10.1159/000133286; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GIBAS Z, 1984, CANCER RES, V44, P1257; GULCHER JR, 1990, GENOMICS, V6, P616, DOI 10.1016/0888-7543(90)90495-G; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P3605, DOI 10.1093/nar/17.9.3605; HUEBNER K, 1992, GENOMICS, V14, P220, DOI 10.1016/S0888-7543(05)80209-5; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAMES CD, 1991, CANCER RES, V51, P1684; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KWIATKOWSKI DJ, 1988, AM J HUM GENET, V42, P565; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, CANCER RES, V52, P2523; PEDERSEN MI, 1989, CANCER GENET CYTOGEN, V41, P185, DOI 10.1016/0165-4608(89)90245-8; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RUPPERT JM, 1993, CANCER RES, V53, P5093; SANDBERG AA, 1986, CANCER GENET CYTOGEN, V19, P335, DOI 10.1016/0165-4608(86)90063-4; SMEETS W, 1987, CANCER GENET CYTOGEN, V29, P29, DOI 10.1016/0165-4608(87)90028-8; SUNG LA, 1992, J BIOL CHEM, V267, P2616; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TSAI YC, 1990, CANCER RES, V50, P44; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; 1973, HISTOLOGICAL CLASSIF, V10; 1978, INT UNION CANCER	42	117	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2083	2088						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208555				2022-12-17	WOS:A1994NR68500035
J	MONTE, D; BAERT, JL; DEFOSSEZ, PA; DELAUNOIT, Y; STEHELIN, D				MONTE, D; BAERT, JL; DEFOSSEZ, PA; DELAUNOIT, Y; STEHELIN, D			MOLECULAR-CLONING AND CHARACTERIZATION OF HUMAN ERM, A NEW MEMBER OF THE ETS FAMILY CLOSELY-RELATED TO MOUSE PEA3 AND ER81 TRANSCRIPTION FACTORS	ONCOGENE			English	Article							DNA-BINDING MOTIF; GENE FAMILY; C-FOS; MESSENGER-RNAS; ACTIVATION; PROTEIN; ONCOGENE; DOMAIN; EXPRESSION; SEQUENCES	The ets-related transcription factors PEA3 and ER81 have recently been isolated and characterized in the mouse. They share 95% identity in a 85 amino acid (AA) domain termed the ETS domain which is responsible for DNA binding, and therefore they form an Ets family group. By screening a human testis cDNA library with a probe containing the mouse PEA3 ETS domain, we isolated a 2.2 kb clone containing a 510 AA open reading frame. Since the ETS domain, which is localized in the carboxy terminal region of the encoded protein, is 95% and 96% identical to that of PEA3 and ER81, respectively, we named this new member 'Ets Related Molecule PEA3-like' (ERM). Although the first 120 AA in the amino-terminal region of ERM share 47% identity with PEA3 and 66% with ER81, ERM contains a central region of approximate to 35 AA not found in the two mouse proteins. Gel shift analysis indicates that the full-length ERM protein is able to bind specifically to an oligonucleotide containing the consensus nucleotide core sequence GGAA recognized by the Ets proteins. Moreover, in vitro translation of 83 AA of the ERM ETS domain led to the production of a truncated protein which also binds to DNA. Though differential expression is observed in primary tumors and normal lymphocytes do not express ERM, this gene is almost ubiquitously expressed in human normal tissues. ERM mRNA is highly expressed in brain as well as in placenta and, to a lesser degree, in lung, pancreas, and heart. Moreover, almost all human cell lines tested express it at varying levels. In mouse tissues, we showed that PEA3 and ER81 mRNAs display restricted expression, whereas ERM is almost ubiquitously expressed as observed for human tissues. Altogether these results indicate that ERM is clearly a new ets family member and not the human equivalent of PEA3 or ER81.	INST PASTEUR,UNITE ONCOL MOLEC,CNRS,URA 1160,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Defossez, Pierre-Antoine/0000-0002-6463-9263; monte, didier/0000-0002-0613-6203				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; GEGONNE A, 1992, NEW BIOL, V4, P512; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAGET MP, 1993, NUCLEIC ACIDS RES, V21, P5987, DOI 10.1093/nar/21.25.5987; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1992, ONCOGENE, V7, P9; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MONTE D, 1992, BLOOD, V79, P2670; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHAO HF, 1991, J BIOL CHEM, V266, P583	36	117	119	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1397	1406						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152800				2022-12-17	WOS:A1994NH40100011
J	MUROYA, K; HATTORI, S; NAKAMURA, S				MUROYA, K; HATTORI, S; NAKAMURA, S			NERVE GROWTH-FACTOR INDUCES RAPID ACCUMULATION OF THE GTP-BOUND FORM OF P21RAS IN RAT PHEOCHROMOCYTOMA PC12 CELLS	ONCOGENE			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; NEURONAL DIFFERENTIATION; ACTIVATING PROTEIN; MOLECULAR-CLONING; GAP; INDUCTION; KINASE; PHOSPHORYLATION; MICROINJECTION; STIMULATION	The ras gene product (p21) is thought to transduce signals from various growth and differentiation factors. p21 is a GTP-binding protein, and its activity is regulated by the bound GDP/GTP ratio. We analysed p21-bound nucleotides in cell lysates of rat pheochromocytoma cell line PC12 cells stimulated with various factors. Nerve growth factors (NGF) rapidly increased the relative amount of active p21-GTP complex to as much as 20% of the total amount of p21 within 2 min. The amount of p21-GTP then declined to 8% after 10 min, and this level was sustained for at least 2h. Epidermal growth factor (EGF) also stimulated a rapid accumulation of p21-GTP to the same extent as seen with NGF, but the amount of p21-GTP declined to 5% after 10 min and gradually returned to the basal level within 60 min. In contrast basic fibroblast growth factor, interleukin 6 and dibutyryl cAMP, which induce neuronal differentiation of PC12 cells, did not stimulate the accumulation of p21-GTP at any time point examined. Phorbol 12-myristate 13-acetate also had no effect. Interestingly, the protein kinase inhibitor K-252a specifically suppressed the NGF-induced accumulation of p21-GTP, but did not suppress the EGF-induced response. These results strongly suggest that an active p21-GTP complex transduces the differentiation signal from NGF. It may also be suggested that the process of activating p21 is mediated by a K-252a-sensitive protein kinase(s).	NATL INST NEUROSCI,NATL CTR NEUROL & PSYCHIAT,DIV BIOCHEM & CELLULAR BIOL,4-1-1 OGAWAHIGASHI,KODAIRA,TOKYO 187,JAPAN	National Center for Neurology & Psychiatry - Japan								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DOHERTY P, 1988, NEUROSCI LETT, V92, P222, DOI 10.1016/0304-3940(88)90065-1; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATTORI S, 1991, BIOCHEM BIOPH RES CO, V177, P83, DOI 10.1016/0006-291X(91)91951-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUNG YK, 1990, P NATL ACAD SCI USA, V87, P8008; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LEVIMONTALCINI R, 1982, ANNU REV NEUROSCI, V5, P341, DOI 10.1146/annurev.ne.05.030182.002013; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	38	117	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					277	281						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549349				2022-12-17	WOS:A1992HG98200011
J	EISEMANN, A; AHN, JA; GRAZIANI, G; TRONICK, SR; RON, D				EISEMANN, A; AHN, JA; GRAZIANI, G; TRONICK, SR; RON, D			ALTERNATIVE SPLICING GENERATES AT LEAST 5 DIFFERENT ISOFORMS OF THE HUMAN BASIC-FGF RECEPTOR	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; MESSENGER-RNA; ENZYMATIC AMPLIFICATION; MOUSE-BRAIN; GENE; DNA; EXPRESSION; CDNA; CELLS	Fibroblast growth factors (FGFs) are polypeptide mitogens that induce the proliferation of a wide variety of cell types. Of the seven family members, the best characterized are basic and acidic FGF. In addition to their mitogenic effects, they participate in angiogenesis, differentiation and maintenance of survival of neurons, cell migration and embryonal development. Of all family members, keratinocyte growth factor (KGF) is unique in that it is a specific mitogen for epithelial cells and does not interact with the FGF receptor of fibroblasts. To study the interactions between KGF and its receptor, we isolated KGF and FGF receptors from keratinocytes and fibroblasts, respectively. In the course of this study, we isolated five different variants of the FGF receptor from human fibroblasts and showed that all were derived from a single genetic locus. Four of these variants encode transmembrane receptors and can be divided into two subgroups that differ from one another with respect to the number (two or three) of immunoglobulin (Ig)-like domains. Within each subgroup, one receptor differed from the other by the presence of a two-codon insertion. Thus, all the variations among the four isoforms are localized to their ligand binding domains. The fifth isoform encodes a molecule truncated just 3' to the first Ig-like domain and thus could be secreted from the cell. The transcripts encoding the long and short isoforms were found to be expressed in many cell types, but their reltive levels of expression varied greatly depending on the cell type. These findings indicate that alternative splicing generates diverse FGF receptor isoforms in human cells.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; GEORGETOWN UNIV HOSP,DIV MED ONCOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Technion Israel Institute of Technology; Georgetown University	RON, D (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Graziani, Grazia/G-5747-2012	Graziani, Grazia/0000-0002-0221-768X				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHANG JH, 1988, J BIOL CHEM, V263, P12824; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPADAROWICZ D, 1990, J CLIN ORTHOPED RELA, V58, P231; GOSPODAROWICZ D, 1975, J BIOL CHEM, V250, P2515; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SHAPIRO MB, 1986, NUCLEIC ACIDS RES, V14, P65, DOI 10.1093/nar/14.1.65; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGARI A, 1985, J NEUROSCI, V5, P307; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; ZHAN X, 1988, MOL CELL BIOL, V8, P4387	45	117	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1195	1202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650441				2022-12-17	WOS:A1991GV26000015
J	Wang, YN; Zeng, ZL; Lu, JH; Wang, Y; Liu, ZX; He, MM; Zhao, Q; Wang, ZX; Li, T; Lu, YX; Wu, QN; Yu, K; Wang, F; Pu, HY; Li, B; Jia, WH; Shi, M; Xie, D; Kang, TB; Huang, P; Ju, HQ; Xu, RH				Wang, Ying-nan; Zeng, Zhao-lei; Lu, Jiahuan; Wang, Yun; Liu, Ze-xian; He, Ming-ming; Zhao, Qi; Wang, Zi-xian; Li, Ting; Lu, Yun-xin; Wu, Qi-nian; Yu, Kai; Wang, Feng; Pu, Heng-Ying; Li, Bo; Jia, Wei-hua; Shi, Ming; Xie, Dan; Kang, Tie-bang; Huang, Peng; Ju, Huai-qiang; Xu, Rui-hua			CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis	ONCOGENE			English	Article							BETA-OXIDATION; LEUKEMIA-CELLS; SURVIVAL; METABOLISM; ETOMOXIR; ENERGY; AXIS; BIOCHEMISTRY; ANTIOXIDANT; HOMEOSTASIS	Anoikis is a critical obstacle to cancer metastasis. Colorectal cancer (CRC) exhibits a high rate of metastasis, leading to death, and the mechanisms involved in anoikis resistance are still unclear. We identified that the fatty acid oxidation (FAO) pathway was activated in detached CRC cells. Multiple genes in the FAO pathway, specifically the rate-limiting enzyme CPT1A, were upregulated in CRC cells grown in suspension. Reactive oxygen species elimination mediated by CPT1A in CRC cells was vital to anoikis resistance. In vivo experiments showed that CPT1A-suppressed CRC cells colonized the lung at a much lower rate than normal CRC cells, suggesting that CPT1A-mediated FAO activation increased metastatic capacity. In clinical tissue specimens from CRC patients, elevated expression of CPT1A was observed in metastatic sites compared with primary sites. Our results demonstrate that CPT1A-mediated FAO activation induces CRC cells to resist anoikis, suggesting that CPT1A is an attractive target for treating metastatic CRC.	[Wang, Ying-nan; Zeng, Zhao-lei; Lu, Jiahuan; Wang, Yun; Liu, Ze-xian; He, Ming-ming; Zhao, Qi; Wang, Zi-xian; Li, Ting; Lu, Yun-xin; Wu, Qi-nian; Yu, Kai; Wang, Feng; Pu, Heng-Ying; Jia, Wei-hua; Shi, Ming; Xie, Dan; Kang, Tie-bang; Ju, Huai-qiang; Xu, Rui-hua] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Li, Bo] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem & Mol Biol, Guangzhou 510080, Guangdong, Peoples R China; [Huang, Peng] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center	Ju, HQ; Xu, RH (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	juhq@sysucc.org.cn; xurh@sysucc.org.cn	xu, rui/GRX-5734-2022; Xu, Rui-Hua/AAW-4766-2021; Liu, Zexian/D-1153-2011; Zhao, Qi/X-7899-2019	Xu, Rui-Hua/0000-0001-9771-8534; Liu, Zexian/0000-0001-9698-0610; Zhao, Qi/0000-0002-8683-6145; Ju, Huai-Qiang/0000-0003-1713-5465; Yu, Kai/0000-0003-3343-2902	National Natural Science Foundation of China [81602137, 81572392]; Natural Science Foundation of Guangdong Province [2017A030313485, 2014A030312015]; Science and Technology Program of Guangdong [2015B020232008]; Science and Technology Program of Guangzhou [15570006, 201508020250, 201604020003]; Pearl River S&T Nova Program of Guangzhou [201806010002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; Pearl River S&T Nova Program of Guangzhou	This research was supported by the National Natural Science Foundation of China (81602137, 81572392); Natural Science Foundation of Guangdong Province (2017A030313485, 2014A030312015); Science and Technology Program of Guangdong (2015B020232008), Science and Technology Program of Guangzhou (15570006, 201508020250, 201604020003) and by grants from Pearl River S&T Nova Program of Guangzhou (201806010002).	Aslan B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8351; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Cabrero A, 2003, J LIPID RES, V44, P388, DOI 10.1194/jlr.M200294-JLR200; Casals N, 2016, PROG LIPID RES, V61, P134, DOI 10.1016/j.plipres.2015.11.004; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Conti R, 2011, DIABETES, V60, P644, DOI 10.2337/db10-0346; Cook AD, 2005, ANN SURG ONCOL, V12, P637, DOI 10.1245/ASO.2005.06.012; Cully M, 2017, NAT REV DRUG DISCOV, V16, P15, DOI 10.1038/nrd.2016.274; D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011; Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Harjes U, 2016, CRIT REV ONCOL HEMAT, V97, P15, DOI 10.1016/j.critrevonc.2015.10.011; Hernlund E, 2008, INT J CANCER, V123, P476, DOI 10.1002/ijc.23525; Hinderling VB, 2002, AM J CLIN NUTR, V76, P141, DOI 10.1093/ajcn/76.1.141; Holubarsch CJF, 2007, CLIN SCI, V113, P205, DOI 10.1042/CS20060307; Houten SM, 2016, ANNU REV PHYSIOL, V78, P23, DOI 10.1146/annurev-physiol-021115-105045; Houten SM, 2010, J INHERIT METAB DIS, V33, P469, DOI 10.1007/s10545-010-9061-2; Huang A, 2016, CANCER LETT, V377, P149, DOI 10.1016/j.canlet.2016.04.040; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6; Ju HQ, 2017, ONCOGENE, V36, P6282, DOI 10.1038/onc.2017.227; Ju HQ, 2016, THERANOSTICS, V6, P1160, DOI 10.7150/thno.14848; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Noguchi T, 2016, ONCOLOGY-BASEL, V90, P221, DOI 10.1159/000444493; Okugawa Y, 2017, GUT, V66, P107, DOI 10.1136/gutjnl-2015-309359; Pacilli A, 2013, JNCI-J NATL CANCER I, V105, P489, DOI 10.1093/jnci/djt030; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Paumen MB, 1997, BIOCHEM BIOPH RES CO, V231, P523, DOI 10.1006/bbrc.1997.6089; Pollack LA, 2006, CANCER CAUSE CONTROL, V17, P449, DOI 10.1007/s10552-005-0505-1; Qu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.132; Ricciardi MR, 2015, BLOOD, V126, P1925, DOI 10.1182/blood-2014-12-617498; Rodrigues MF, 2016, BIOCHEM J, V473, P703, DOI 10.1042/BJ20150645; Rufer AC, 2009, CELL MOL LIFE SCI, V66, P2489, DOI 10.1007/s00018-009-0035-1; Samudio I, 2010, J CLIN INVEST, V120, P142, DOI 10.1172/JCI38942; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schlaepfer IR, 2014, MOL CANCER THER, V13, P2361, DOI 10.1158/1535-7163.MCT-14-0183; Setoyama D, 2013, GENES CELLS, V18, P1107, DOI 10.1111/gtc.12098; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Strilic B, 2017, CANCER CELL, V32, P282, DOI 10.1016/j.ccell.2017.07.001; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zammit VA, 2008, IUBMB LIFE, V60, P347, DOI 10.1002/iub.78; Zhu L, 2017, J NUCL MED, V58, P533, DOI 10.2967/jnumed.116.182345; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	58	116	118	0	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6025	6040		10.1038/s41388-018-0384-z	http://dx.doi.org/10.1038/s41388-018-0384-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29995871				2022-12-17	WOS:000450175900002
J	Yan, D; Kowal, J; Akkari, L; Schuhmacher, AJ; Huse, JT; West, BL; Joyce, JA				Yan, D.; Kowal, J.; Akkari, L.; Schuhmacher, A. J.; Huse, J. T.; West, B. L.; Joyce, J. A.			Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas	ONCOGENE			English	Article							KINASE INHIBITOR; TUMOR-GROWTH; GLIOBLASTOMA; CONSORTIUM; RESPONSES; BLOCKADE; CHIR-258; CANCER	Glioblastomas represent the most aggressive glioma grade and are associated with a poor patient prognosis. The current standard of care, consisting of surgery, radiation and chemotherapy, only results in a median survival of 14 months, underscoring the importance of developing effective new therapeutic strategies. Among the challenges in treating glioblastomas are primary resistance and the rapid emergence of recurrent disease, which can result from tumor cell-intrinsic mechanisms in addition to tumor microenvironment (TME)-mediated extrinsic resistance. Using a PDGF-B-driven proneural glioma mouse model, we assessed a panel of tyrosine kinase inhibitors with different selectivity profiles. We found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks glioma progression, markedly suppresses tumor cell proliferation and reduces tumor grade. By contrast, the multi-targeted tyrosine kinase inhibitors dovitinib and vatalanib, which directly target tumor cells, exert minimal anti-tumoral effects in vivo, despite killing glioma cells in vitro, suggesting a TME-mediated resistance mechanism may be involved. Interestingly, PLX3397 interferes with tumor-mediated education of macrophages and consequently restores the sensitivity of glioma cells to tyrosine kinase inhibitors in vivo in preclinical combination trials. Our findings thus demonstrate that microenvironmental alteration by CSF-1R blockade renders tumor cells more susceptible to receptor tyrosine kinase inhibition in a preclinical glioblastoma model, which may have important translational relevance.	[Yan, D.; Akkari, L.; Schuhmacher, A. J.; Joyce, J. A.] Mem Sloan Kettering Canc Ctr, Cancer Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA; [Kowal, J.; Akkari, L.; Joyce, J. A.] Univ Lausanne, Ludwig Inst Canc Res, Lausanne, Switzerland; [Kowal, J.; Akkari, L.; Joyce, J. A.] Univ Lausanne, Dept Oncol, CH-1066 Lausanne, Switzerland; [Huse, J. T.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Huse, J. T.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [West, B. L.] Plexxikon Inc, Berkeley, CA USA	Memorial Sloan Kettering Cancer Center; Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Plexxikon	Joyce, JA (corresponding author), Univ Lausanne, Dept Oncol, CH-1066 Lausanne, Switzerland.	johanna@joycelab.org	Schuhmacher, Alberto J./R-6765-2019	Schuhmacher, Alberto J./0000-0002-0136-1049; West, Brian/0000-0002-5320-3691; Akkari, Leila/0000-0001-5479-641X; Kowal, Joanna/0000-0001-7849-6040	US National Cancer Institute (NCI) [R01CA181355]; Swiss Cancer League [KFS 3990-08-2016]; Ludwig Institute for Cancer Research; NCI Support Grant [P30 CA008748]; American Brain Tumor Association; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA181355] Funding Source: NIH RePORTER	US National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss Cancer League; Ludwig Institute for Cancer Research; NCI Support Grant; American Brain Tumor Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Florian Klemm and all members of the Joyce laboratory for insightful comments and experimental advice. We are grateful to Kenishana Simpson, Xiaoping Chen and Nisarg Shah for excellent technical support. We thank Dr Eric Holland for scientific discussion, and for generously providing the Nestin-Tv-a Ink4a/Arf<SUP>-/-</SUP> mouse line. This research was supported by the US National Cancer Institute (NCI) (R01CA181355, JAJ), the Swiss Cancer League (KFS 3990-08-2016, JAJ), the Ludwig Institute for Cancer Research (JAJ), NCI Support Grant for the MSKCC core facilities used (P30 CA008748), and the American Brain Tumor Association (LA).	Agarwal S, 2012, MOL CANCER THER, V11, P2183, DOI 10.1158/1535-7163.MCT-12-0552; Beier D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-128; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; Charles NA, 2012, GLIA, V60, P502, DOI 10.1002/glia.21264; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Engler JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043339; Geng L, 2006, INT J RADIAT ONCOL, V64, P263, DOI 10.1016/j.ijrobp.2005.08.025; Hallett Penelope J, 2008, Curr Protoc Neurosci, VChapter 1, DOI 10.1002/0471142301.ns0116s42; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Kennedy BC, 2013, J ONCOL, V2013, DOI 10.1155/2013/486912; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Lee SH, 2005, CLIN CANCER RES, V11, P3633, DOI 10.1158/1078-0432.CCR-04-2129; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mellinghoff IK, 2012, CURR TOP MICROBIOL, V355, P135, DOI 10.1007/82_2011_178; Paul Indranil, 2013, Genes Cancer, V4, P427, DOI 10.1177/1947601913503341; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018; Reardon DA, 2014, NEURO-ONCOLOGY, V16, P1441, DOI 10.1093/neuonc/nou212; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Schafer N, 2016, J CANCER RES CLIN, V142, P1581, DOI 10.1007/s00432-016-2161-0; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tap WD, 2015, NEW ENGL J MED, V373, P428, DOI 10.1056/NEJMoa1411366; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Uhrbom L, 2004, NAT MED, V10, P1257, DOI 10.1038/nm1120; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wen PY, 2006, CLIN CANCER RES, V12, P4899, DOI 10.1158/1078-0432.CCR-06-0773; Wood JM, 2000, CANCER RES, V60, P2178; Ziegler DS, 2008, J CLIN INVEST, V118, P3109, DOI 10.1172/JCI34120	38	116	117	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6049	6058		10.1038/onc.2017.261	http://dx.doi.org/10.1038/onc.2017.261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28759044	Green Published, hybrid			2022-12-17	WOS:000413841400013
J	Vervliet, T; Parys, JB; Bultynck, G				Vervliet, T.; Parys, J. B.; Bultynck, G.			Bcl-2 proteins and calcium signaling: complexity beneath the surface	ONCOGENE			English	Review							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; DEPENDENT ANION CHANNEL; SARCOPLASMIC/ENDOPLASMIC RETICULUM CA2+-ATPASE; FAMILY-MEMBER BOK; BCL-X(L)-INHIBITORY BH3 MIMETICS; CANCER-CELL-PROLIFERATION; APOPTOTIC CA2+ SIGNALS; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL CA2+; PLASMA-MEMBRANE	Antiapoptotic Bcl-2-family members are well known for their 'mitochondrial' functions as critical neutralizers of proapoptotic Bcl-2-family members, including the executioner multidomain proteins Bax and Bak and the BH3-only proteins. It has been clear for more than 20 years that Bcl-2 proteins can impact intracellular Ca2+ homeostasis and dynamics. Moreover, altered Ca2+ signaling is increasingly linked to oncogenic behavior. Specifically targeting the Ca2+-signaling machinery may thus prove to be a valuable strategy for cancer treatment. Over 10 years ago a major controversy was recognized concerning whether or not Bcl-2 proteins exerted their antiapoptotic functions via Ca2+ signaling through lowering the filling state of the endoplasmic reticulum (ER) Ca2+ stores or by suppressing Ca2+ release from the ER without affecting the filling state of this Ca2+ store. Further research from different laboratories indicated a wide variety of mechanisms by which Bcl-2-family members can impact Ca2+ signaling. In this review, we propose that antiapoptotic Bcl-2-family members are multimodal regulators of intracellular Ca2+-signaling events in cell survival and cell death. We will discuss how different Bcl-2-family members impact cell survival and cell death by regulating Ca2+ transport systems at the ER, mitochondria and plasma membrane and by impacting the organization of organelles and how these insights can be exploited for causing cell death in cancer cells. Finally, we propose that the existing controversy reflects the diversity of links between Bcl-2 proteins and Ca2+ signaling, as certainly not all targets or mechanisms will be operative in every cell type and every condition.	[Bultynck, G.] Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium; [Bultynck, G.] LKI, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium	KU Leuven	Bultynck, G (corresponding author), Katholieke Univ Leuven, Lab Mol & Cellular Signaling, Dept Cellular & Mol Med, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium.; Bultynck, G (corresponding author), LKI, Campus Gasthuisberg O-N Bus 802,Herestr 49, BE-3000 Leuven, Belgium.	geert.bultynck@med.kuleuven.be		Vervliet, Tim/0000-0002-4030-5875; Bultynck, Geert/0000-0002-5968-4828; Parys, Jan/0000-0002-3591-4967	Research Foundation-Flanders (FWO) [6.057.12, G.0819.13, G.0C91.14, G.0A34.16]; Research Council of the KU Leuven [14/101, BOF PDM/15/188]; Interuniversity Attraction Poles Program (Belgian Science Policy) [IAP-P7/13]	Research Foundation-Flanders (FWO)(FWO); Research Council of the KU Leuven(KU Leuven); Interuniversity Attraction Poles Program (Belgian Science Policy)(Belgian Federal Science Policy Office)	Work performed in the authors' laboratory was supported by grants from the Research Foundation-Flanders (FWO grants 6.057.12, G.0819.13, G.0C91.14 and G.0A34.16), by the Research Council of the KU Leuven (OT grant 14/101) and by the Interuniversity Attraction Poles Program (Belgian Science Policy; IAP-P7/13). TV is a recipient of a post-doctoral fellowship of the Research Council of the KU Leuven (BOF PDM/15/188). We thank all lab members for fruitful discussions.	Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Abu-Hamad S, 2009, J CELL SCI, V122, P1906, DOI 10.1242/jcs.040188; Ahmad S, 2009, AM J RESP CRIT CARE, V179, P816, DOI 10.1164/rccm.200807-1104OC; Ahn T, 2010, CELL CALCIUM, V47, P387, DOI 10.1016/j.ceca.2010.02.003; Akimzhanov AM, 2013, CELL CALCIUM, V53, P152, DOI 10.1016/j.ceca.2012.10.002; Akl H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.140; Akl H, 2015, INT J DEV BIOL, V59, P391, DOI 10.1387/ijdb.150213gb; Akl H, 2014, BBA-MOL CELL RES, V1843, P2240, DOI 10.1016/j.bbamcr.2014.04.017; Akl H, 2013, HAEMATOLOGICA, V98, pE49, DOI 10.3324/haematol.2012.080598; Akl H, 2013, BBA-REV CANCER, V1835, P180, DOI 10.1016/j.bbcan.2012.12.001; Alavian KN, 2011, NAT CELL BIOL, V13, P1224, DOI 10.1038/ncb2330; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Arbabian A, 2011, BIOFACTORS, V37, P139, DOI 10.1002/biof.142; Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918; Arbel N, 2010, J BIOL CHEM, V285, P6053, DOI 10.1074/jbc.M109.082990; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; Autret A, 2009, MOL CELL, V36, P355, DOI 10.1016/j.molcel.2009.10.011; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barclay LA, 2015, MOL CELL, V57, P873, DOI 10.1016/j.molcel.2015.01.014; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Baughman JM, 2011, NATURE, V476, P341, DOI 10.1038/nature10234; Berman SB, 2009, J CELL BIOL, V184, P707, DOI 10.1083/jcb.200809060; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Bittremieux M, 2016, BBA-MOL CELL RES, V1863, P1364, DOI 10.1016/j.bbamcr.2016.01.002; Bonneau B, 2013, BBA-MOL CELL RES, V1833, P1755, DOI 10.1016/j.bbamcr.2013.01.021; Bononi A, 2012, ADV EXP MED BIOL, V740, P411, DOI 10.1007/978-94-007-2888-2_17; Bonora M, 2015, PHARMACOL RES, V99, P82, DOI 10.1016/j.phrs.2015.05.008; Bonora M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00302; Bootman MD, 2001, J CELL SCI, V114, P2213; Brini M, 2013, FEBS J, V280, P5385, DOI 10.1111/febs.12193; Brooks C, 2007, P NATL ACAD SCI USA, V104, P11649, DOI 10.1073/pnas.0703976104; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Bultynck G, 2012, J BIOL CHEM, V287, P2544, DOI 10.1074/jbc.M111.275354; Burgoyne T, 2015, BBA-MOL CELL RES, V1853, P2012, DOI 10.1016/j.bbamcr.2015.01.022; Cao X, 2015, CELL CALCIUM, V58, P342, DOI 10.1016/j.ceca.2015.03.003; Cardenas C, 2012, CELL CALCIUM, V52, P44, DOI 10.1016/j.ceca.2012.03.001; Cardenas C, 2010, CELL, V142, P270, DOI 10.1016/j.cell.2010.06.007; Carpio MA, 2015, P NATL ACAD SCI USA, V112, P7201, DOI 10.1073/pnas.1421063112; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chan J, 2010, J BIOL CHEM, V285, P36092, DOI 10.1074/jbc.M110.140160; Chang MJ, 2014, P NATL ACAD SCI USA, V111, P1186, DOI 10.1073/pnas.1323098111; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Cleland MM, 2011, CELL DEATH DIFFER, V18, P235, DOI 10.1038/cdd.2010.89; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Csordas G, 2010, MOL CELL, V39, P121, DOI 10.1016/j.molcel.2010.06.029; Curry MC, 2011, BIOFACTORS, V37, P132, DOI 10.1002/biof.146; Dang D, 2016, BBA-MOL CELL RES, V1863, P1344, DOI 10.1016/j.bbamcr.2015.11.016; Davids MS, 2012, J CLIN ONCOL, V30, P3127, DOI 10.1200/JCO.2011.37.0981; de Mattia F, 2009, MOL BIOL CELL, V20, P3638, DOI 10.1091/mbc.E09-05-0385; De Stefani D, 2012, CELL DEATH DIFFER, V19, P267, DOI 10.1038/cdd.2011.92; De Stefani D, 2011, NATURE, V476, P336, DOI 10.1038/nature10230; Decuypere JP, 2011, BBA-MOL CELL RES, V1813, P1003, DOI 10.1016/j.bbamcr.2010.11.023; Dellis O, 2006, SCIENCE, V313, P229, DOI 10.1126/science.1125203; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Distelhorst CW, 2004, ONCOGENE, V23, P2875, DOI 10.1038/sj.onc.1207519; Dremina ES, 2012, BIOCHEM J, V444, P127, DOI 10.1042/BJ20111114; Dremina ES, 2006, BIOCHEMISTRY-US, V45, P175, DOI 10.1021/bi050800s; Dremina ES, 2004, BIOCHEM J, V383, P361, DOI 10.1042/BJ20040187; Dubois C, 2014, CANCER CELL, V26, P19, DOI 10.1016/j.ccr.2014.04.025; Echeverry N, 2013, CELL DEATH DIFFER, V20, P785, DOI 10.1038/cdd.2013.10; Eckenrode EF, 2010, J BIOL CHEM, V285, P13678, DOI 10.1074/jbc.M109.096040; Elkoreh G, 2012, J CELL BIOCHEM, V113, P2775, DOI 10.1002/jcb.24155; Ferdek PE, 2012, CURR BIOL, V22, P1241, DOI 10.1016/j.cub.2012.05.002; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Foskett JK, 2007, PHYSIOL REV, V87, P593, DOI 10.1152/physrev.00035.2006; Foskett JK, 2009, BIOPHYS J, V96, p391A, DOI 10.1016/j.bpj.2008.12.2917; Gandini MA, 2015, CURR TOP MED CHEM, V15, P604, DOI 10.2174/1568026615666150225112605; Gees M, 2012, COMPR PHYSIOL, V2, P563, DOI 10.1002/cphy.c110026; Giorgi C, 2015, ANTIOXID REDOX SIGN, V22, P995, DOI 10.1089/ars.2014.6223; Giorgi C, 2015, ONCOTARGET, V6, P1435, DOI 10.18632/oncotarget.2935; Giorgi C, 2012, CELL CALCIUM, V52, P36, DOI 10.1016/j.ceca.2012.02.008; Giorgi Carlotta, 2011, Commun Integr Biol, V4, P334, DOI 10.4161/cib.4.3.15021; Greenberg EF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.355; Greenberg EF, 2014, BBA-MOL CELL RES, V1843, P2205, DOI 10.1016/j.bbamcr.2014.03.008; Grimm S, 2012, BBA-MOL CELL RES, V1823, P327, DOI 10.1016/j.bbamcr.2011.11.018; Habermacher C, 2016, NEUROPHARMACOLOGY, V104, P18, DOI 10.1016/j.neuropharm.2015.07.032; Han BS, 2015, CANCER CELL, V27, P852, DOI 10.1016/j.ccell.2015.04.010; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hanson CJ, 2008, CELL CALCIUM, V44, P324, DOI 10.1016/j.ceca.2008.01.003; Hanson CJ, 2008, CELL CALCIUM, V44, P243, DOI 10.1016/j.ceca.2007.11.014; Harr MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005579; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hedgepeth SC, 2015, J BIOL CHEM, V290, P7304, DOI 10.1074/jbc.M114.611186; Henke N, 2011, CELL CALCIUM, V50, P251, DOI 10.1016/j.ceca.2011.05.005; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Hoth M, 2016, BBA-MOL CELL RES, V1863, P1408, DOI 10.1016/j.bbamcr.2015.12.009; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Huang GJ, 2006, J CELL SCI, V119, P153, DOI 10.1242/jcs.02731; Huang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.419; Huang HY, 2013, J BIOL CHEM, V288, P19870, DOI 10.1074/jbc.M112.448290; Hwang MS, 2014, CELL DEATH DIFFER, V21, P1733, DOI 10.1038/cdd.2014.84; Ishikawa T, 2011, CELL DEATH DIFFER, V18, P1271, DOI 10.1038/cdd.2011.59; Ivanova H, 2014, BBA-MOL CELL RES, V1843, P2164, DOI 10.1016/j.bbamcr.2014.03.007; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Kanekura K, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0341; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kiviluoto S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.103; Kiviluoto S, 2013, BBA-MOL CELL RES, V1833, P1612, DOI 10.1016/j.bbamcr.2013.01.026; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Kobrinsky EM, 2001, ONCOGENE, V20, P933, DOI 10.1038/sj.onc.1204153; Krebs J, 2015, BBA-MOL CELL RES, V1853, P2018, DOI 10.1016/j.bbamcr.2014.12.020; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Kvansakul M, 2008, CELL DEATH DIFFER, V15, P1564, DOI 10.1038/cdd.2008.83; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lanner JT, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003996; Lavik AR, 2015, ONCOTARGET, V6, P27388, DOI 10.18632/oncotarget.4489; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li C, 2007, P NATL ACAD SCI USA, V104, P12565, DOI 10.1073/pnas.0702489104; Li H, 2008, P NATL ACAD SCI USA, V105, P2169, DOI 10.1073/pnas.0711647105; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lisak DA, 2015, BBA-MOL CELL RES, V1853, P2104, DOI 10.1016/j.bbamcr.2015.03.002; Liu Z, 2015, DRUG DISCOV TODAY S; Llambi F, 2011, CURR OPIN GENET DEV, V21, P12, DOI 10.1016/j.gde.2010.12.001; Lopreiato R, 2014, J BIOL CHEM, V289, P10261, DOI 10.1074/jbc.O114.555565; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Malia TJ, 2007, BIOCHEMISTRY-US, V46, P514, DOI 10.1021/bi061577h; Marchi S, 2014, BBA-BIOENERGETICS, V1837, P461, DOI 10.1016/j.bbabio.2013.10.015; McAndrew D, 2011, MOL CANCER THER, V10, P448, DOI 10.1158/1535-7163.MCT-10-0923; Mekahli D, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004317; Michels Judith, 2013, Int J Cell Biol, V2013, P705294, DOI 10.1155/2013/705294; Monaco G, 2012, CELL DEATH DIFFER, V19, P295, DOI 10.1038/cdd.2011.97; Monaco G, 2015, J BIOL CHEM, V290, P9150, DOI 10.1074/jbc.M114.622514; Monaco G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073386; Monaco G, 2013, CELL MOL LIFE SCI, V70, P1171, DOI 10.1007/s00018-012-1118-y; Monaco G, 2012, BIOCHEM BIOPH RES CO, V428, P31, DOI 10.1016/j.bbrc.2012.10.002; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Morciano G, 2016, MOL BIOL CELL, V27, P20, DOI 10.1091/mbc.E15-01-0028; Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Padanyi R, 2016, BBA-MOL CELL RES, V1863, P1351, DOI 10.1016/j.bbamcr.2015.12.011; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Palty R, 2012, J BIOL CHEM, V287, P31650, DOI 10.1074/jbc.R112.355867; Parys JB, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005093; Parys JB, 2012, ADV EXP MED BIOL, V740, P255, DOI 10.1007/978-94-007-2888-2_11; Pavlov E, 2005, BBA-BIOENERGETICS, V1710, P96, DOI 10.1016/j.bbabio.2005.09.006; Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pinton P, 2006, CELL DEATH DIFFER, V13, P1409, DOI 10.1038/sj.cdd.4401960; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Prins Daniel, 2011, Cold Spring Harb Perspect Biol, V3, DOI 10.1101/cshperspect.a004069; Rajan S, 2015, SCI REP-UK, V5, DOI 10.1038/srep10609; Raphael M, 2014, P NATL ACAD SCI USA, V111, pE3870, DOI 10.1073/pnas.1413409111; Raturi A, 2013, BBA-MOL CELL RES, V1833, P213, DOI 10.1016/j.bbamcr.2012.04.013; Raynal NJM, 2016, CANCER RES, V76, P1494, DOI 10.1158/0008-5472.CAN-14-2391; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Rojas-Rivera D, 2015, ONCOGENE, V34, P269, DOI 10.1038/onc.2014.6; Rojas-Rivera D, 2012, CELL DEATH DIFFER, V19, P1013, DOI 10.1038/cdd.2011.189; Rong YP, 2008, MOL CELL, V31, P255, DOI 10.1016/j.molcel.2008.06.014; Rong YP, 2009, P NATL ACAD SCI USA, V106, P14397, DOI 10.1073/pnas.0907555106; Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852; Roome CJ, 2013, ADV EXP MED BIOL, V961, P251, DOI 10.1007/978-1-4614-4756-6_21; Rooswinkel RW, 2014, BLOOD, V123, P2806, DOI 10.1182/blood-2013-08-519470; Sammels E, 2010, CELL CALCIUM, V47, P297, DOI 10.1016/j.ceca.2010.02.001; Saraiva N, 2013, J CELL BIOL, V202, P699, DOI 10.1083/jcb.201301016; Saraiva N, 2013, J BIOL CHEM, V288, P13057, DOI 10.1074/jbc.M112.414367; Schoenwaelder SM, 2012, BLOOD, V119, P1320, DOI 10.1182/blood-2011-10-387399; Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849; Schulman JJ, 2013, J BIOL CHEM, V288, P25340, DOI 10.1074/jbc.M113.496570; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shoshan-Barmatz V, 2008, J BIOENERG BIOMEMBR, V40, P183, DOI 10.1007/s10863-008-9147-9; Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Sung PJ, 2013, P NATL ACAD SCI USA, V110, P20593, DOI 10.1073/pnas.1306431110; Szabadkai G, 2006, J CELL BIOL, V175, P901, DOI 10.1083/jcb.200608073; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Thomenius MJ, 2003, J CELL SCI, V116, P4493, DOI 10.1242/jcs.00829; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Treves S, 2004, J CELL BIOL, V166, P537, DOI 10.1083/jcb.200404079; Treves S, 2010, J CELL SCI, V123, P4170, DOI 10.1242/jcs.068387; Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024; Vandecaetsbeek Ilse, 2011, Cold Spring Harb Perspect Biol, V3, DOI 10.1101/cshperspect.a004184; Varadarajan S, 2012, CELL DEATH DIFFER, V19, P1896, DOI 10.1038/cdd.2012.108; Vashisht A, 2015, AM J PHYSIOL-CELL PH, V309, pC457, DOI 10.1152/ajpcell.00064.2015; Verbert L, 2008, BIOL CELL, V100, P39, DOI 10.1042/BC20070086; Vervliet T, 2015, BIOCHEM SOC T, V43, P396, DOI 10.1042/BST20140298; Vervliet T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09641; Vervliet T, 2014, J CELL SCI, V127, P2782, DOI 10.1242/jcs.150011; Vervloessem T, 2015, AGING-US, V7, P748, DOI 10.18632/aging.100828; Vervloessem T, 2015, BBA-MOL CELL RES, V1853, P1992, DOI 10.1016/j.bbamcr.2014.12.006; Vogler M, 2011, BLOOD, V117, P7145, DOI 10.1182/blood-2011-03-344812; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang X, 2011, CELL DEATH DIFFER, V18, P38, DOI 10.1038/cdd.2010.68; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Wiel C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4792; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zhang LN, 2011, P NATL ACAD SCI USA, V108, P13653, DOI 10.1073/pnas.1103360108; Zhong F, 2006, J CELL BIOL, V172, P127, DOI 10.1083/jcb.200506189; Zhong F, 2011, BLOOD, V117, P2924, DOI 10.1182/blood-2010-09-307405; Zhu LP, 2001, J MOL CELL CARDIOL, V33, P2135, DOI 10.1006/jmcc.2001.1476; Zorzano A, 2010, SEMIN CELL DEV BIOL, V21, P566, DOI 10.1016/j.semcdb.2010.01.002	214	116	119	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5079	5092		10.1038/onc.2016.31	http://dx.doi.org/10.1038/onc.2016.31			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	26973249	Green Published			2022-12-17	WOS:000384433000001
J	Zhu, X; Shen, H; Yin, X; Long, L; Xie, C; Liu, Y; Hui, L; Lin, X; Fang, Y; Cao, Y; Xu, Y; Li, M; Xu, W; Li, Y				Zhu, X.; Shen, H.; Yin, X.; Long, L.; Xie, C.; Liu, Y.; Hui, L.; Lin, X.; Fang, Y.; Cao, Y.; Xu, Y.; Li, M.; Xu, W.; Li, Y.			miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; DOWN-REGULATION; TUMOR-SUPPRESSOR; PROSTATE-CANCER; POOR SURVIVAL; RESISTANCE; CELLS; EXPRESSION; EMT; MODULATION	Epithelial-mesenchymal transition (EMT) has an established role in promoting tumor progression and the acquisition of therapeutic resistance. Here, the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. Furthermore, luciferase reporter and rescue assay results showed that the EMT and drug resistance reversal in response to miR-186 was mediated by Twist1. Collectively, these findings implicate miR-186 as an attractive candidate for overcoming chemoresistance in ovarian cancer therapy.	[Zhu, X.; Yin, X.; Liu, Y.; Lin, X.; Xu, Y.; Xu, W.] Jiangsu Univ, Affiliated Hosp 4, Zhenjiang, Jiangsu, Peoples R China; [Zhu, X.; Shen, H.; Xie, C.; Hui, L.; Cao, Y.] Jiangsu Univ, Zhenjiang, Jiangsu, Peoples R China; [Shen, H.; Fang, Y.] Jiangsu Univ, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China; [Long, L.; Li, M.; Li, Y.] Jiangsu Univ, Affiliated Hosp, Zhenjiang 212001, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University; Jiangsu University; Jiangsu University	Li, Y (corresponding author), Jiangsu Univ, Affiliated Hosp, Zhenjiang 212001, Jiangsu, Peoples R China.; Xu, W (corresponding author), Jiangsu Univ, Affiliated Hosp 4, Cent Lab, 20 Zhengdong Rd, Zhenjiang 212001, Jiangsu, Peoples R China.	zxl0122721@sina.com; xwl630806@126.com		ZHU, XIAOLAN/0000-0002-0499-8045; Zhu, Xiaolan/0000-0001-7034-8617	Natural Science Foundation of China [81402165/81301194]; Natural Science Foundation of Jiangsu Province [BK20131241]; Clinical Special Projects of Science and Technology Department of Jiangsu Province [BL2012059]; Research Projects of Jiangsu Provincial Health Department [H201451]; Maternal and Child Health Research Projects of Jiangsu Province [F201437/F201350/F201215]; Social Development of Zhenjiang [SH2012057/SH2013025]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Clinical Special Projects of Science and Technology Department of Jiangsu Province; Research Projects of Jiangsu Provincial Health Department; Maternal and Child Health Research Projects of Jiangsu Province; Social Development of Zhenjiang	This work was supported by the Natural Science Foundation of China (81402165/81301194), the Natural Science Foundation of Jiangsu Province (BK20131241), the Clinical Special Projects of Science and Technology Department of Jiangsu Province (BL2012059), the Research Projects of Jiangsu Provincial Health Department (H201451), the Maternal and Child Health Research Projects of Jiangsu Province (F201437/F201350/F201215) and the Social Development of Zhenjiang (SH2012057/SH2013025).	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Baribeau S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086987; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cai JC, 2013, CANCER RES, V73, P756, DOI 10.1158/0008-5472.CAN-12-2651; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Chen DH, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004177; Chen J, 2011, GYNECOL ONCOL, V121, P200, DOI 10.1016/j.ygyno.2010.12.339; Erdmann K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-82; Farrand L, 2013, J BIOL CHEM, V288, P23740, DOI 10.1074/jbc.M113.487686; Gardi NL, 2014, CLIN CANCER RES, V20, P87, DOI 10.1158/1078-0432.CCR-13-2063; Goeppert B, 2010, HEPATOLOGY, V52, P2023, DOI 10.1002/hep.23939; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hosono S, 2007, BRIT J CANCER, V96, P314, DOI 10.1038/sj.bjc.6603533; Jia LZ, 2012, CANCER LETT, V326, P176, DOI 10.1016/j.canlet.2012.08.004; Konecny GE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju249; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Li J, 2007, ONCOGENE, V26, P2860, DOI 10.1038/sj.onc.1210086; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136; Myatt SS, 2010, CANCER RES, V70, P367, DOI 10.1158/0008-5472.CAN-09-1891; Nuti SV, 2014, ONCOTARGET, V5, P7260, DOI 10.18632/oncotarget.2428; Parikh A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3977; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Ries J, 2014, ONCOL REP, V31, P1429, DOI 10.3892/or.2014.2983; Sun CY, 2013, JNCI-J NATL CANCER I, V105, P1750, DOI 10.1093/jnci/djt302; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Zhu XL, 2014, INT J CANCER, V135, P1286, DOI 10.1002/ijc.28774; Zhu XL, 2013, FEBS LETT, V587, P73, DOI 10.1016/j.febslet.2012.11.004	38	116	127	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					323	332		10.1038/onc.2015.84	http://dx.doi.org/10.1038/onc.2015.84			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25867064	Bronze			2022-12-17	WOS:000369055300006
J	Condello, S; Morgan, CA; Nagdas, S; Cao, L; Turek, J; Hurley, TD; Matei, D				Condello, S.; Morgan, C. A.; Nagdas, S.; Cao, L.; Turek, J.; Hurley, T. D.; Matei, D.			beta-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids	ONCOGENE			English	Article							STEM-CELL PHENOTYPE; PROTEIN EXPRESSION; WNT/BETA-CATENIN; GENE-EXPRESSION; IN-VITRO; ALDEHYDE DEHYDROGENASE; SIGNALING PATHWAYS; EPITHELIAL-CELLS; RESISTANCE; MONOLAYER	Cancer cells form three-dimensional (3D) multicellular aggregates (or spheroids) under non-adherent culture conditions. In ovarian cancer (OC), spheroids serve as a vehicle for cancer cell dissemination in the peritoneal cavity, protecting cells from environmental stress-induced anoikis. To identify new targetable molecules in OC spheroids, we investigated gene expression profiles and networks upregulated in 3D vs traditional monolayer culture conditions. We identified ALDH1A1, a cancer stem cell marker as being overexpressed in OC spheroids and directly connected to key elements of the beta-catenin pathway. beta-Catenin function and ALDH1A1 expression were increased in OC spheroids vs monolayers and in successive spheroid generations, suggesting that 3D aggregates are enriched in cells with stem cell characteristics. beta-Catenin knockdown decreased ALDH1A1 expression levels and beta-catenin co-immunoprecipitated with the ALDH1A1 promoter, suggesting that ALDH1A1 is a direct beta-catenin target. Both short interfering RNA-mediated beta-catenin knockdown and A37 ((ethyl-2-((4-oxo-3-(3-(pryrrolidin-1-yl) propyl)-3,4-dihydrobenzo [4,5]thioeno [3,2-d] pyrimidin-2-yl) thio) acetate)), a novel ALDH1A1 small-molecule enzymatic inhibitor described here for the first time, disrupted OC spheroid formation and cell viability (P<0.001). beta-Catenin knockdown blocked tumor growth and peritoneal metastasis in an OC xenograft model. These data strongly support the role of beta-catenin-regulated ALDH1A1 in the maintenance of OC spheroids and propose new ALDH1A1 inhibitors targeting this cell population.	[Condello, S.; Cao, L.; Matei, D.] Indiana Univ, Dept Med, Indianapolis, IN USA; [Morgan, C. A.; Hurley, T. D.; Matei, D.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Nagdas, S.] Univ Virginia, Sch Med, Indianapolis, IN USA; [Turek, J.] Purdue Univ, Coll Vet Med, Indianapolis, IN USA; [Hurley, T. D.; Matei, D.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; [Matei, D.] Indiana Univ Sch Med, VA Roudebush Hosp, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; University of Virginia; Purdue University System; Purdue University; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Hurley, TD (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, MS-4019, Indianapolis, IN 46202 USA.	thurley@iu.edu; dmatei@iu.edu	Condello, Salvatore/ABB-6743-2021	Condello, Salvatore/0000-0003-4979-3681; Matei, Daniela/0000-0003-2169-5035; HURLEY, THOMAS/0000-0002-5942-1163	US Department of Veterans Affairs; NIH [R01-AA018123, R01EB016582]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB016582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA018123] Funding Source: NIH RePORTER	US Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Dr Jeanette McClintick from the Indiana University Center for Medical Genomics, Dr Malgorzata Kamocha from IBCM and Dr Chirayu Goswami from the Bioinformatics Core for technical assistance. This work was made possible by funding from the US Department of Veterans Affairs to DM and from NIH to TDH (R01-AA018123), DM and JT (R01EB016582).	Alvero AB, 2009, CELL CYCLE, V8, P158, DOI 10.4161/cc.8.1.7533; Barbone D, 2008, J BIOL CHEM, V283, P13021, DOI 10.1074/jbc.M709698200; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Burleson KM, 2004, CLIN EXP METASTAS, V21, P685, DOI 10.1007/s10585-004-5768-5; Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802; Camper SA, 2011, P NATL ACAD SCI USA, V108, P11303, DOI 10.1073/pnas.1108275108; Cao L, 2012, ONCOGENE, V31, P2521, DOI 10.1038/onc.2011.429; Chang TT, 2009, TISSUE ENG PT A, V15, P559, DOI 10.1089/ten.tea.2007.0434; Chau WK, 2013, ONCOGENE, V32, P2767, DOI 10.1038/onc.2012.290; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cody NAL, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-34; Condello S, 2013, FASEB J, V27, P3100, DOI 10.1096/fj.12-222620; David L, 2008, ACTA BIOMATER, V4, P256, DOI 10.1016/j.actbio.2007.08.012; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Frankel A, 2000, CLIN CANCER RES, V6, P3719; Frankel A, 1997, CANCER RES, V57, P2388; Gaedtke L, 2007, J PROTEOME RES, V6, P4111, DOI 10.1021/pr0700596; Hazlehurst LA, 2003, ONCOGENE, V22, P7396, DOI 10.1038/sj.onc.1206943; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Jackson Brian, 2011, Human Genomics, V5, P283; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; L'Esperance S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-99; Lawrenson K, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-43; Lee JM, 2013, LAB INVEST, V93, P528, DOI 10.1038/labinvest.2013.41; Lengyel E, 2014, ONCOGENE, V33, P3619, DOI 10.1038/onc.2013.321; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Moss NM, 2009, CANCER RES, V69, P7121, DOI 10.1158/0008-5472.CAN-08-4151; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Parajuli B, 2011, CHEM-BIOL INTERACT, V191, P153, DOI 10.1016/j.cbi.2011.02.018; Park SH, 2008, MOL ENDOCRINOL, V22, P2085, DOI 10.1210/me.2007-0512; Pierre-Louis O, 2009, STEM CELLS, V27, P2552, DOI 10.1002/stem.186; Poland J, 2002, ELECTROPHORESIS, V23, P1174, DOI 10.1002/1522-2683(200204)23:7/8<1174::AID-ELPS1174>3.0.CO;2-O; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Ray A, 2011, INT J ONCOL, V39, P797, DOI 10.3892/ijo.2011.1093; Reuben JM, 2011, EUR J CANCER, V47, P1527, DOI 10.1016/j.ejca.2011.01.011; Serebriiskii I, 2008, MATRIX BIOL, V27, P573, DOI 10.1016/j.matbio.2008.02.008; Shank JJ, 2012, GYNECOL ONCOL, V127, P390, DOI 10.1016/j.ygyno.2012.07.115; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Song XQ, 2003, DEVELOPMENT, V130, P3259, DOI 10.1242/dev.00524; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sumi T, 2008, DEVELOPMENT, V135, P2969, DOI 10.1242/dev.021121; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Weiswald LB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-106; Yasuda K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068187; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	54	116	118	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2297	2308		10.1038/onc.2014.178	http://dx.doi.org/10.1038/onc.2014.178			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954508	Green Accepted, Green Submitted			2022-12-17	WOS:000353824800003
J	Chan, LH; Wang, W; Yeung, W; Deng, Y; Yuan, P; Mak, KK				Chan, L. H.; Wang, W.; Yeung, W.; Deng, Y.; Yuan, P.; Mak, K. K.			Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression	ONCOGENE			English	Article						osteosarcoma; yes-associated protein1; long non-coding RNA H19	YES-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR; NONCODING RNA; CANDIDATE ONCOGENE; CTCF-BINDING; CELL-CYCLE; EXPRESSION; BONE; CANCER; PATHWAY	Osteosarcoma is one of the most common bone tumors. However, the genetic basis for its pathogenesis remains elusive. Here, we investigated the roles of Hedgehog (Hh) signaling in osteosarcoma development. Genetically-engineered mice with ubiquitous upregulated Hh signaling specifically in mature osteoblasts develop focal bone overgrowth, which greatly resembles the early stage of osteosarcoma. However, these mice die within three months, which prohibits further analysis of tumor progression. We therefore generated a mouse model with partial upregulated Hh signaling in mature osteoblasts and crossed it into a p53 heterozygous background to potentiate tumor development. We found that these mutant mice developed malignant osteosarcoma with high penetrance. Isolated primary tumor cells were mainly osteoblastic and highly proliferative with many characteristics of human osteosarcomas. Allograft transplantation into immunocompromised mice displayed high tumorigenic potential. More importantly, both human and mouse tumor tissues express high level of yes-associated protein 1 (Yap1), a potent oncogene that is amplified in various cancers. We show that inhibition of Hh signaling reduces Yap1 expression and knockdown of Yap1 significantly inhibits tumor progression. Moreover, long non-coding RNA H19 is aberrantly expressed and induced by upregulated Hh signaling and Yap1 overexpression. Our results demonstrate that aberrant Hh signaling in mature osteoblasts is responsible for the pathogenesis of osteoblastic osteosarcoma through Yap1 and H19 overexpression.	[Chan, L. H.; Wang, W.; Yeung, W.; Deng, Y.; Mak, K. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Key Labs Regenerat Med,Minist Educ, Shatin, Hong Kong, Peoples R China; [Yuan, P.] Chinese Univ Hong Kong, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China; [Mak, K. K.] Chinese Univ Hong Kong, Sch Biomed Sci, Stem Cell & Regenerat Themat Res Program, Shatin, Hong Kong, Peoples R China; [Mak, K. K.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen	Mak, KK (corresponding author), Chinese Univ Hong Kong, Sch Biomed Sci, Stem Cell & Regenerat Themat Res Program, Shatin, Hong Kong, Peoples R China.	kmak@cuhk.edu.hk		Mak, Kingston King-Lun/0000-0002-4733-9146; Yuan, Ping/0000-0001-7243-3487; Deng, Youping/0000-0002-5951-8213	School of Biomedical Sciences, The Chinese University of Hong Kong [4620504]; Research Grant Council of the Hong Kong Special Administrative Region [CUHK479012]; United College, The Chinese University of Hong Kong [CA11189];  [CUHK2041745]	School of Biomedical Sciences, The Chinese University of Hong Kong; Research Grant Council of the Hong Kong Special Administrative Region(Hong Kong Research Grants Council); United College, The Chinese University of Hong Kong(Chinese University of Hong Kong); 	We thank Drs. Tin-lap Lee and David John Wilmshurst for critical comments on the manuscript. This work is supported by the Seed Fund of the School of Biomedical Sciences, The Chinese University of Hong Kong (4620504), Early Career Scheme of the Research Grant Council of the Hong Kong Special Administrative Region (CUHK479012), Direct Grant for research (CUHK2041745) and the Endowment Fund Research Grant of the United College, The Chinese University of Hong Kong (CA11189).	Andela VB, 2005, J CLIN PATHOL, V58, P328, DOI 10.1136/jcp.2004.017640; Arima T, 1997, CANCER GENET CYTOGEN, V93, P39, DOI 10.1016/S0165-4608(96)00221-X; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fults Daniel W, 2005, Neurosurg Focus, V19, pE7, DOI 10.3171/foc.2005.19.5.8; Galindo M, 2005, J BIOL CHEM, V280, P20274, DOI 10.1074/jbc.M413665200; Hibi K, 1996, CANCER RES, V56, P480; Hirotsu M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-5; Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Mak KK, 2006, DEVELOPMENT, V133, P3695, DOI 10.1242/dev.02546; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Li N, 2009, CANCER-AM CANCER SOC, V115, P4795, DOI 10.1002/cncr.24519; Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115; Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003; Matouk IJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000845; Matouk IJ, 2009, EUR J GASTROEN HEPAT, V21, P688, DOI 10.1097/MEG.0b013e328306a3a2; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603; Molyneux SD, 2010, J CLIN INVEST, V120, P3310, DOI 10.1172/JCI42391; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Mutsaers AJ, 2013, BONE, V55, P166, DOI 10.1016/j.bone.2013.02.016; Nagao H, 2011, J PATHOL, V224, P169, DOI 10.1002/path.2880; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581-8591.2005; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-202; Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac; SWEETNAM R, 1982, BRIT J HOSP MED, V28, P112; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Tanos V, 2004, INT J GYNECOL CANCER, V14, P521, DOI 10.1111/j.1048-891x.2004.014314.x; Teplyuk NM, 2008, J BIOL CHEM, V283, P27585, DOI 10.1074/jbc.M802453200; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; Ulaner GA, 2003, HUM MOL GENET, V12, P535, DOI 10.1093/hmg/ddg034; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285; Warzecha J, 2007, J CHEMOTHERAPY, V19, P554, DOI 10.1179/joc.2007.19.5.554; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Won KY, 2009, TUMORI J, V95, P311; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8	54	116	120	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4857	4866		10.1038/onc.2013.433	http://dx.doi.org/10.1038/onc.2013.433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24141783				2022-12-17	WOS:000343240100007
J	Bessede, E; Staedel, C; Amador, LAA; Nguyen, PH; Chambonnier, L; Hatakeyama, M; Belleannee, G; Megraud, F; Varon, C				Bessede, E.; Staedel, C.; Amador, L. A. Acuna; Nguyen, P. H.; Chambonnier, L.; Hatakeyama, M.; Belleannee, G.; Megraud, F.; Varon, C.			Helicobacter pylori generates cells with cancer stem cell properties via epithelial-mesenchymal transition-like changes	ONCOGENE			English	Article						gastric cancer; infection; CD44	GASTRIC-CANCER; INCREASED RISK; CAGA PROTEIN; IDENTIFICATION; EXPRESSION; INFECTION; CD44	Helicobacter pylori infection is the major risk factor for gastric adenocarcinoma. The link with gastric adenocarcinoma is partly due to the H. pylori CagA oncoprotein. CagA is responsible for a particular cell phenotype in vitro, the 'hummingbird' phenotype, that corresponds to an elongation of the cells, mimicking an epithelial-mesenchymal transition (EMT). EMT participates in the carcinogenesis process, and is involved in the generation of cancer stem cells (CSCs). However, its involvement in gastric carcinogenesis has yet not been studied. Therefore, the aim of this study was to determine the role of H. pylori in EMT and in the emergence of gastric CSCs. For this purpose, gastric epithelial cells were cocultured with a cagA-positive H. pylori strain or its isogenic-deleted mutants or were transfected with CagA expression vectors. Study of the expression of epithelial and mesenchymal markers showed that H. pylori, via CagA, is responsible for an EMT phenotype associated with an increase in mesenchymal markers as well as CD44 expression, a known gastric CSC marker. Moreover, infection led to an increased ability to migrate, to invade and to form tumorspheres. Cell sorting experiments showed that only the CD44(high) cells induced by H. pylori infection displayed the mesenchymal phenotype and CSC properties in vitro, and had higher tumorigenic properties than CD44(low) cells in xenografted mice. Immunohistochemistry analyses on human and mouse gastric mucosa tissue samples confirmed a high expression of CD44 and mesenchymal markers in H. pylori-infected cases, and in gastric dysplasia and carcinoma. All of these data suggest that H. pylori, via CagA, unveils CSC-like properties by induction of EMT-like changes in gastric epithelial cells.	[Bessede, E.; Amador, L. A. Acuna; Nguyen, P. H.; Chambonnier, L.; Megraud, F.; Varon, C.] Univ Bordeaux, Bacteriol Lab, F-33000 Bordeaux, France; [Bessede, E.; Amador, L. A. Acuna; Nguyen, P. H.; Chambonnier, L.; Megraud, F.; Varon, C.] INSERM, U853, Bordeaux, France; [Staedel, C.] Univ Bordeaux, RNA Nat & Artificial Regulat ARNA Lab, F-33000 Bordeaux, France; [Staedel, C.] INSERM, U869, Bordeaux, France; [Hatakeyama, M.] Univ Tokyo, Grad Sch Med, Div Microbiol, Tokyo, Japan; [Belleannee, G.] Univ Hosp Ctr, Haut Leveque Hosp, Dept Pathol, Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Tokyo; CHU Bordeaux	Bessede, E (corresponding author), Univ Bordeaux, INSERM, Bacteriol Lab, U853, F-33000 Bordeaux, France.	emilie.bessede@chu-bordeaux.fr	STAEDEL, Cathy/M-7284-2014	Acuna-Amador, Luis/0000-0003-1009-3020; Staedel, Cathy/0000-0003-0488-0239; Varon, Christine/0000-0003-4026-2016	French 'Association pour la Recherche contre le Cancer' [8412]; Institut du Cancer [07/3D1616/IABC-23-12/NC-NG]; Conseil Regional d'Aquitaine [20071301017, 20081302203]	French 'Association pour la Recherche contre le Cancer'(Fondation ARC pour la Recherche sur le Cancer); Institut du Cancer(Institut National du Cancer (INCA) France); Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine)	This project was supported by the French 'Association pour la Recherche contre le Cancer' (grant number 8412), 'Institut du Cancer' (grant number 07/3D1616/IABC-23-12/NC-NG), 'Conseil Regional d'Aquitaine' (grant number 20071301017 and 20081302203). We thank D Collet (Digestive Surgery of Hospital Haut-Leveque, University Hospital Center of Bordeaux, France) and Professor JP Merlio (Tumor Bank of University Hospital Center of Bordeaux, France) for providing human gastric tissue samples from consenting patients. We thank A Giese (EA2406, Bordeaux, France), B Rousseau (level 2 animal facilities, Universite de Bordeaux), V Pitard and S Gonzalez (cytometry platform, Universite de Bordeaux), A Menard, M Alibert, E Siffre and L Biguet for technical support.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2008, CELL MICROBIOL, V10, P1573, DOI 10.1111/j.1462-5822.2008.01156.x; Baud J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060315; Bellizzi A, 2013, J CELL PHYSIOL, V228, P408, DOI 10.1002/jcp.24145; BLASER MJ, 1995, CANCER RES, V55, P2111; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029007; Franco AT, 2008, CANCER RES, V68, P379, DOI 10.1158/0008-5472.CAN-07-0824; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Gwack J, 2006, BRIT J CANCER, V95, P639, DOI 10.1038/sj.bjc.6603309; Hao JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040716; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; IARC, 1994, IARC MON EV CARC RIS, V61, P177; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Kure S, 2012, INT J ONCOL, V41, P1314, DOI 10.3892/ijo.2012.1565; Li CW, 2009, METHODS MOL BIOL, V568, P161, DOI 10.1007/978-1-59745-280-9_10; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng EH, 2012, CLIN EXP METASTAS, V29, P939, DOI 10.1007/s10585-012-9482-4; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Murata-Kamiya N, 2007, ONCOGENE, V26, P4617, DOI 10.1038/sj.onc.1210251; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saito Y, 2010, J EXP MED, V207, P2157, DOI 10.1084/jem.20100602; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Varon C, 2009, GUT, V58, P629, DOI 10.1136/gut.2007.144501; Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794	33	116	125	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4123	4131		10.1038/onc.2013.380	http://dx.doi.org/10.1038/onc.2013.380			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24096479				2022-12-17	WOS:000340595700003
J	Siu, MKY; Wong, ESY; Kong, DSH; Chan, HY; Jiang, L; Wong, OGW; Lam, EWF; Chan, KKL; Ngan, HYS; Le, XF; Cheung, AN				Siu, M. K. Y.; Wong, E. S. Y.; Kong, D. S. H.; Chan, H. Y.; Jiang, L.; Wong, O. G. W.; Lam, E. W-F; Chan, K. K. L.; Ngan, H. Y. S.; Le, X-F; Cheung, A. N.			Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers	ONCOGENE			English	Article						NANOG; cell migration and invasion; prognostic marker; therapeutic molecular target; ovarian cancer	CARCINOMA CELLS; DIFFERENTIAL EXPRESSION; TUMOR-CELLS; IDENTIFICATION; OVEREXPRESSION; PLURIPOTENCY; MODULATION; ACTIVATION; PROGNOSIS	Ovarian cancer is the most lethal of all gynecological malignancies, and the identification of novel prognostic and therapeutic targets for ovarian cancer is crucial. It is believed that only a small subset of cancer cells are endowed with stem cell properties, which are responsible for tumor growth, metastatic progression and recurrence. NANOG is one of the key transcription factors essential for maintaining self-renewal and pluripotency in stem cells. This study investigated the role of NANOG in ovarian carcinogenesis and showed overexpression of NANOG mRNA and protein in the nucleus of ovarian cancers compared with benign ovarian lesions. Increased nuclear NANOG expression was significantly associated with high-grade cancers, serous histological subtypes, reduced chemosensitivity, and poor overall and disease-free survival. Further analysis showed NANOG is an independent prognostic factor for overall and disease-free survival. Moreover, NANOG was highly expressed in ovarian cancer cell lines with metastasis-associated property and in clinical samples of metastatic foci. Stable knockdown of NANOG impeded ovarian cancer cell proliferation, migration and invasion, which was accompanied by an increase in mRNA expression of E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1. Conversely, ectopic NANOG overexpression enhanced ovarian cancer cell migration and invasion along with decreased E-cadherin, caveolin-1, FOXO1, FOXO3a, FOXJ1 and FOXB1 mRNA expression. Importantly, we found Nanog-mediated cell migration and invasion involved its regulation of E-cadherin and FOXJ1. This is the first report revealing the association between NANOG expression and clinical outcome of patients with ovarian cancers, suggesting NANOG to be a potential prognostic marker and therapeutic molecular target in ovarian cancer.	[Siu, M. K. Y.; Wong, E. S. Y.; Kong, D. S. H.; Chan, H. Y.; Jiang, L.; Wong, O. G. W.; Cheung, A. N.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England; [Chan, K. K. L.; Ngan, H. Y. S.] Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Le, X-F] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA	University of Hong Kong; Imperial College London; University of Hong Kong; University of Texas System; UTMD Anderson Cancer Center	Cheung, AN (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	mkysiu@hkucc.hku.hk; anycheun@hkucc.hku.hk	Lam, Eric W-F/AAW-8566-2020; Wong, Gee Wan/C-4661-2009; Chan, Karen/E-4041-2015; Cheung, Annie Nga Yin/C-4231-2009	Lam, Eric W-F/0000-0003-1274-3576; Ngan, Hextan Y S/0000-0003-3945-159X; Chan, Karen/0000-0001-9947-4713; Cheung, Annie Nga Yin/0000-0002-1584-7568	Hong Kong Anti-Cancer Society Grant; Strategic Research Theme of Cancer Award; Conference and Research grant from the University of Hong Kong; Cancer Research UK [12011] Funding Source: researchfish	Hong Kong Anti-Cancer Society Grant; Strategic Research Theme of Cancer Award; Conference and Research grant from the University of Hong Kong; Cancer Research UK(Cancer Research UK)	We thank Dr Judy Yam for providing the anti-caveolin-1 antibody. The work was supported by funding from the Hong Kong Anti-Cancer Society Grant, Strategic Research Theme of Cancer Award and the Conference and Research grant from the University of Hong Kong.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Demircan B, 2009, GENE CHROMOSOME CANC, V48, P83, DOI 10.1002/gcc.20620; Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667; Fei M, 2009, CANCER INVEST, V27, P52, DOI 10.1080/07357900802146204; de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Huff CA, 2006, BLOOD, V107, P431, DOI 10.1182/blood-2005-06-2517; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Jiang LL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-318; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Kurman RJ, 2008, AM J OBSTET GYNECOL, V198, P351, DOI 10.1016/j.ajog.2008.01.005; Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889; MANN SC, 1991, INT J CANCER, V48, P866, DOI 10.1002/ijc.2910480613; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Miotti S, 2005, AM J PATHOL, V167, P1411, DOI 10.1016/S0002-9440(10)61228-X; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Pan YY, 2008, INT J CLIN EXP MED, V1, P260; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Seidman JD, 2003, HEMATOL ONCOL CLIN N, V17, P909, DOI 10.1016/S0889-8588(03)00061-3; Singh SK, 2003, CANCER RES, V63, P5821; Siu MKY, 2008, AM J PATHOL, V173, P1165, DOI 10.2353/ajpath.2008.080288; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Siu MKY, 2010, INT J CANCER, V127, P21, DOI 10.1002/ijc.25005; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Wilson AP, 1999, HUM CELL, P25; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	37	116	120	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3500	3509		10.1038/onc.2012.363	http://dx.doi.org/10.1038/onc.2012.363			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22945654	Green Submitted			2022-12-17	WOS:000322220800003
J	Murr, R; Vaissiere, T; Sawan, C; Shukla, V; Herceg, Z				Murr, R.; Vaissiere, T.; Sawan, C.; Shukla, V.; Herceg, Z.			Orchestration of chromatin-based processes: mind the TRRAP	ONCOGENE			English	Review						TRRAP; HATs; histone acetylation; transcription; DNA repair; cancer	STRAND BREAK REPAIR; HISTONE ACETYLTRANSFERASE COMPLEX; NUCLEAR-RECEPTOR FUNCTION; EARLY EMBRYONIC LETHALITY; CELL-CYCLE PROGRESSION; DNA-DAMAGE RESPONSE; PIK-RELATED KINASES; HAT COFACTOR TRRAP; C-MYC; TRANSCRIPTIONAL ACTIVATION	Chromatin modi. cations at core histones including acetylation, methylation, phosphorylation and ubiquitination play an important role in diverse biological processes. Acetylation of specific lysine residues within the N terminus tails of core histones is arguably the most studied histone modi. cation; however, its precise roles in different cellular processes and how it is disrupted in human diseases remain poorly understood. In the last decade, a number of histone acetyltransferases ( HATs) enzymes responsible for histone acetylation, has been identified and functional studies have begun to unravel their biological functions. The activity of many HATs is dependent on HAT complexes, the multiprotein assemblies that contain one HAT catalytic subunit, adapter proteins, several other molecules of unknown function and a large protein called TRansformation/tRanscription domain-Associated Protein ( TRRAP). As a common component of many HAT complexes, TRRAP appears to be responsible for the recruitment of these complexes to chromatin during transcription, replication and DNA repair. Recent studies have shed new light on the role of TRRAP in HAT complexes as well as mechanisms by which it mediates diverse cellular processes. Thus, TRRAP appears to be responsible for a concerted and context-dependent recruitment of HATs and coordination of distinct chromatin-based processes, suggesting that its deregulation may contribute to diseases. In this review, we summarize recent developments in our understanding of the function of TRRAP and TRRAP-containing HAT complexes in normal cellular processes and speculate on the mechanism underlying abnormal events that may lead to human diseases such as cancer.	Int Agcy Res Canc, Epigenet Team, Mol Carcinogenesis & Biomarkers Grp, F-69008 Lyon, France; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	World Health Organization; International Agency for Research on Cancer (IARC); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Herceg, Z (corresponding author), Int Agcy Res Canc, Epigenet Team, Mol Carcinogenesis & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	herceg@iarc.fr	Vaissiere, Thomas/E-1121-2011	Murr, Rabih/0000-0002-3346-6590				Abrahamsson PA, 2004, EUR UROL SUPPL, V3, P3, DOI 10.1016/j.eursup.2004.09.001; Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Bhaumik SR, 2004, GENE DEV, V18, P333, DOI 10.1101/gad.1148404; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Ceol CJ, 2004, DEV CELL, V6, P563, DOI 10.1016/S1534-5807(04)00065-6; Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de la Cruz X, 2005, BIOESSAYS, V27, P164, DOI 10.1002/bies.20176; Deleu L, 2001, ONCOGENE, V20, P8270, DOI 10.1038/sj.onc.1205159; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Dumon-Jones V, 2003, CANCER RES, V63, P7263; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; Etard C, 2005, MECH DEVELOP, V122, P545, DOI 10.1016/j.mod.2004.11.010; Fan WQ, 2004, MOL ENDOCRINOL, V18, P127, DOI 10.1210/me.2003-0110; Feng Y, 2003, CANCER RES, V63, P8726; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Frappart PO, 2005, NAT MED, V11, P538, DOI 10.1038/nm1228; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Gause M, 2006, MOL CELL BIOL, V26, P2347, DOI 10.1128/MCB.26.6.2347-2359.2006; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jazayeri A, 2004, P NATL ACAD SCI USA, V101, P1644, DOI 10.1073/pnas.0304797101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; KLUESZA CA, 2002, ONOCGENE, V21, P1411; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Lin CM, 2003, CURR BIOL, V13, P1019, DOI 10.1016/S0960-9822(03)00382-8; Lin WC, 2006, CURR OPIN GENET DEV, V16, P137, DOI 10.1016/j.gde.2006.02.002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Loizou JI, 2006, CELL CYCLE, V5, P696, DOI 10.4161/cc.5.7.2616; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Marks Paul A, 2004, Novartis Found Symp, V259, P269; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Memedula S, 2003, CURR BIOL, V13, P241, DOI 10.1016/S0960-9822(03)00048-4; MORGAN BA, 1991, MOL CELL BIOL, V11, P4111, DOI 10.1128/MCB.11.8.4111; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Myster SH, 2004, GENETICS, V166, P807, DOI 10.1534/genetics.166.2.807; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Owen DJ, 2000, EMBO J, V19, P6141, DOI 10.1093/emboj/19.22.6141; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Perry P, 2004, CELL CYCLE, V3, P1645; Peterson CL, 2004, GENE DEV, V18, P602, DOI 10.1101/gad.1182704; Polakis P, 2000, GENE DEV, V14, P1837; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; Smith CM, 2003, ANAL BIOCHEM, V316, P23, DOI 10.1016/S0003-2697(03)00032-0; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Unno A, 2005, BIOCHEM BIOPH RES CO, V327, P933, DOI 10.1016/j.bbrc.2004.12.095; Utley RT, 2005, MOL CELL BIOL, V25, P8179, DOI 10.1128/MCB.25.18.8179-8190.2005; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; van Attikum H, 2005, NAT REV MOL CELL BIO, V6, P757, DOI 10.1038/nrm1737; van Attikum H, 2005, CELL CYCLE, V4, P1011, DOI 10.4161/cc.4.8.1887; van den Bosch M, 2003, EMBO REP, V4, P844, DOI 10.1038/sj.embor.embor925; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	144	116	116	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5358	5372		10.1038/sj.onc.1210605	http://dx.doi.org/10.1038/sj.onc.1210605			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694078				2022-12-17	WOS:000248674300005
J	Hernandez-Vargas, H; Palacios, J; Moreno-Bueno, G				Hernandez-Vargas, H.; Palacios, J.; Moreno-Bueno, G.			Molecular profling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis	ONCOGENE			English	Article						docetaxel; cDNA microarrays; taxanes; aberrant mitosis; mitotic arrest	MITOTIC CATASTROPHE; GENE-EXPRESSION; HELA-CELLS; MICROTUBULE; ARREST; DEATH; P53; PROTEIN; TAXOTERE; BCL-2	Among microtubule-targeting agents, docetaxel has received recent interest owing to its good therapeutic index. Clinical trials have underlined its potential for the treatment of advanced breast cancer, although little is known about its molecular mode of action in this context. We characterized the molecular changes induced by docetaxel in two well-known human breast carcinoma cell lines. Two mechanisms of action according to drug concentration were suggested by a biphasic sensitivity curve, and were further validated by cell morphology, cell cycle and cell death changes. Two to four nanomolar docetaxel induced aberrant mitosis followed by late necrosis, and 100 nM docetaxel induced mitotic arrest followed by apoptosis. Passing through mitosis phase was a requirement for hypodiploidy to occur, as shown by functional studies in synchronized cells and by combining docetaxel with the proteasome inhibitor MG132. Transcriptional pro. ling showed differences according to cell line and docetaxel concentration, with cell cycle, cell death and structural genes commonly regulated in both cell lines. Although p53 targets were mainly induced with low concentration of drug in MCF7 cells, its relevance in the dual mechanism of docetaxel cytotoxicity was ruled out by using an isogenic shp53 cell line. Many of the genes shown in this study may contribute to the dual mechanism by which docetaxel inhibits the growth of breast cancer cells at different concentrations. These findings provide a basis for rationally enhancing docetaxel therapy, considering lower concentrations, and better drug combinations.	Spanish Natl Canc Ctr, CNIO, Mol Pathol Programme, Breast & Gynaecol Canc Grp, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Moreno-Bueno, G (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Unidad Biol Mol & Celular Canc, Arturo Duperier 4, E-28029 Madrid, Spain.	jose.palacios.sspa@juntadeand.alucia.es; gmoreno@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Palacios, Jose/AAV-3765-2020	Moreno-Bueno, Gema/0000-0002-5030-6687; Hernandez-Vargas, Hector/0000-0001-6045-2103				Aapro M, 1996, ANTI-CANCER DRUG, V7, P33, DOI 10.1097/00001813-199608002-00009; Avramis VI, 1998, ANTICANCER RES, V18, P2327; Baker SD, 2004, CLIN CANCER RES, V10, P1976, DOI 10.1158/1078-0432.CCR-0842-03; Berchem GJ, 1999, ANTICANCER RES, V19, P535; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Caraglia M, 2005, FRONT BIOSCI, V10, P2566, DOI 10.2741/1720; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen JG, 2003, CANCER RES, V63, P7891; Consolini R, 1998, J CLIN ONCOL, V16, P907, DOI 10.1200/JCO.1998.16.3.907; Dieras V, 1996, ANTI-CANCER DRUG, V7, P47, DOI 10.1097/00001813-199608002-00012; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Fabbri F, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-6; Fumoleau P, 1996, ANN ONCOL, V7, P165; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Haldar S, 1997, CANCER RES, V57, P229; Hernandez-Vargas H, 2006, INT J CANCER, V119, P1164, DOI 10.1002/ijc.21938; Jordan MA, 1996, CANCER RES, V56, P816; Li YW, 2004, NEOPLASIA, V6, P158, DOI 10.1593/neo.03391; Mansilla S, 2006, CELL CYCLE, V5, P53, DOI 10.4161/cc.5.1.2267; Montero A, 2005, LANCET ONCOL, V6, P229, DOI 10.1016/S1470-2045(05)70094-2; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Morse DL, 2005, MOL CANCER THER, V4, P1495, DOI 10.1158/1535-7163.MCT-05-0130; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Paoletti A, 1997, J CELL SCI, V110, P2403; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; Torres K, 1998, CANCER RES, V58, P3620; Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140-6736(05)66546-4; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; Wang Q, 2004, ONCOGENE, V23, P426, DOI 10.1038/sj.onc.1207040; Yoo GH, 2002, CLIN CANCER RES, V8, P3910; Zeng S, 2000, CLIN CANCER RES, V6, P3766	42	116	117	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2902	2913		10.1038/sj.onc.1210102	http://dx.doi.org/10.1038/sj.onc.1210102			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17099726				2022-12-17	WOS:000246210800010
J	Felsani, A; Mileo, AM; Paggi, MG				Felsani, A.; Mileo, A. M.; Paggi, M. G.			Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins	ONCOGENE			English	Review						pRb; p107; pRb2/p130; E1A; E7; large T-Ag	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE-T-ANTIGEN; SIMIAN-VIRUS-40 LARGE-T; SV40 LARGE T; TUMOR-SUPPRESSOR PROTEIN; PRB-RELATED PROTEINS; CELL-CYCLE CONTROL; ADENOVIRUS E1A; BK VIRUS; E7 ONCOPROTEIN	RB, the most investigated tumor suppressor gene, is the founder of the RB family of growth/tumor suppressors, which comprises also p107(RBL1) and Rb2/p130 (RBL2). The protein products of these genes, pRb, p107 and pRb2/p130, respectively, are also known as 'pocket proteins', because they share a `pocket' domain responsible for most of the functional interactions characterizing the activity of this family of cellular factors. The interest in these genes and proteins springs essentially from their ability to regulate negatively cell cycle processes and for their ability to slow down or abrogate neoplastic growth. The pocket domain of the RB family proteins is dramatically hampered in its functions by the interference of a number of proteins produced by the small DNA viruses. In the last two decades, the 'viral hypothesis' of cancer has received a considerable renewed impulse from the notion that small DNA viruses, such as Adenovirus, Human papillomavirus (HPV) and Polyomavirus, produce factors that can physically interact with major cellular regulators and alter their function. These viral proteins (oncoproteins) act as multifaceted molecular devices that have evolved to perform very specific tasks. Owing to these features, viral oncoproteins have been widely employed as invaluable experimental tools for the identification of several key families of regulators, particularly of the cell cycle homeostasis. Adenovirus early-region 1A (E1A) is the most widely investigated small DNA tumor virus oncoprotein, but relevant interest in human oncology is raised by the E1A-related E7 protein from transforming HPV strains and by Polyomavirus oncoproteins, particularly large and small T antigens from Simian virus 40, JC virus and BK virus.	Regina Elena Inst Canc Res, Dept Dev Therapeut Programs, Lab C, I-00144 Rome, Italy; CNR, Ist Neurobiol & Med Mol, Rome, Italy; Temple Univ, Ctr Biotechnol, Philadelphia, PA 19122 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Dept Dev Therapeut Programs, Lab C, Via Elio Chianesi 53, I-00144 Rome, Italy.	paggi@ifo.it	Mileo, Anna Maria/J-3667-2016; Paggi, Marco G./K-3494-2018; Felsani, Armando/D-1784-2010	Mileo, Anna Maria/0000-0002-1970-3297; Felsani, Armando/0000-0001-8851-6295				Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BANKS L, 1990, ONCOGENE, V5, P1383; Barbanti-Brodano G, 2004, VIROLOGY, V318, P1, DOI 10.1016/j.virol.2003.09.004; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Boffetta P, 2004, ONCOGENE, V23, P6392, DOI 10.1038/sj.onc.1207715; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 2000, J CELL BIOCHEM, V76, P189, DOI 10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CICCOLINI F, 1994, ONCOGENE, V9, P2633; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cole Charles N., 1996, P917; Croul S, 2003, J NEUROVIROL, V9, P173, DOI 10.1080/13550280390194055; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dang-Tan T, 2004, ONCOGENE, V23, P6535, DOI 10.1038/sj.onc.1207877; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Engels EA, 2005, EXPERT REV VACCINES, V4, P197, DOI 10.1586/14760584.4.2.197; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fioriti D, 2005, J CELL PHYSIOL, V204, P402, DOI 10.1002/jcp.20300; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU GY, 1995, CANCER GENE THER, V2, P19; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; Mal A, 2000, J CELL BIOL, V149, P281, DOI 10.1083/jcb.149.2.281; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTELLI F, 1994, ONCOGENE, V9, P3579; MAYOL X, 1993, ONCOGENE, V8, P2561; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paggi MG, 2001, CANCER RES, V61, P4651; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Reiss K, 2003, ONCOGENE, V22, P6517, DOI 10.1038/sj.onc.1206959; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rizzo P, 1999, CANCER RES, V59, P6103; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Scheffner M, 2003, SEMIN CANCER BIOL, V13, P59, DOI 10.1016/S1044-579X(02)00100-1; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Singh M, 2005, J BIOL CHEM, V280, P37868, DOI 10.1074/jbc.M504877200; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stiegler P, 1998, J CELL BIOCHEM, P30; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; Tweedale G, 2002, NAT REV CANCER, V2, P311, DOI 10.1038/nrc774; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOUSDEN KH, 1989, ONCOGENE, V4, P153; Wang JY, 2004, J EXP CLIN CANC RES, V23, P373; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang XY, 2005, J BIOL CHEM, V280, P33165, DOI 10.1074/jbc.M505124200; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1	174	116	120	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5277	5285		10.1038/sj.onc.1209621	http://dx.doi.org/10.1038/sj.onc.1209621			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936748				2022-12-17	WOS:000240064100013
J	Bhatt, KV; Spofford, LS; Aram, G; McMullen, M; Pumiglia, K; Aplin, AE				Bhatt, KV; Spofford, LS; Aram, G; McMullen, M; Pumiglia, K; Aplin, AE			Adhesion control of cyclin D1 and p27(Kip1) levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling	ONCOGENE			English	Article						BRAF; cyclin D1; integrins; melanocytes; mitogen-activated protein kinase; p27(Kip1)	ACTIVATED PROTEIN-KINASE; METASTATIC MELANOMA; GROWTH; EXPRESSION; PROGRESSION; MUTATIONS; RAS; ARREST; GENE; MAP	Mutations in BRAF, a component of extracellular signal-regulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage- and growth factor-independence. We have previously shown that effficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27(Kip1), two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, express ion of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27(Kip1) levels were downregulated in V599E BRAF-expressing melanoma cells and active BRAF was sufficient to downregulate p27(Kip1) in serum-starved NHEM. Thus, adhesion-growth factor cooperation, leading to efficient activation of ERK, regulates cyclin D1 and p27(Kip1) levels in human melanocytes and mutant BRAF overrides adhesion-growth factor control of these two G1 cell cycle proteins in melanomas. These findings provide important insight into how BRAF mutations contribute to aberrant human melanocyte proliferation.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,MC-165, Albany, NY 12208 USA.	aplina@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NCI NIH HHS [CA81419, R01 CA081419-06, R01 CA081419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NIGMS NIH HHS [GM067893] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Collisson EA, 2003, CANCER RES, V63, P5669; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Dong JL, 2003, CANCER RES, V63, P3883; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; GRINNELL F, 1992, J CELL SCI, V101, P1; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; HARA M, 1994, J CELL SCI, V107, P2739; Hedley SJ, 1997, PIGM CELL RES, V10, P54, DOI 10.1111/j.1600-0749.1997.tb00466.x; Hingorani SR, 2003, CANCER RES, V63, P5198; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JIANG HP, 1995, ONCOGENE, V10, P1855; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Lai JM, 2002, MOL CELL BIOL, V22, P7581, DOI 10.1128/MCB.22.21.7581-7592.2002; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Le Gall M, 1998, ONCOGENE, V17, P1271, DOI 10.1038/sj.onc.1202057; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; McMahon M, 2001, METHOD ENZYMOL, V332, P401; McMullen M, 2004, ONCOGENE, V23, P1275, DOI 10.1038/sj.onc.1207243; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Sauter ER, 2002, CANCER RES, V62, P3200; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; SCOTT G, 1992, J INVEST DERMATOL, V99, P787, DOI 10.1111/1523-1747.ep12614749; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takano N, 2002, PIGM CELL RES, V15, P192, DOI 10.1034/j.1600-0749.2002.01079.x; Treinies I, 1999, MOL CELL BIOL, V19, P321; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; WANTANABE G, 1996, P NATL ACAD SCI USA, V93, P12861; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	65	116	121	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3459	3471		10.1038/sj.onc.1208544	http://dx.doi.org/10.1038/sj.onc.1208544			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735667				2022-12-17	WOS:000229038800008
J	Bitomsky, N; Bohm, M; Klempnauer, KH				Bitomsky, N; Bohm, M; Klempnauer, KH			Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun	ONCOGENE			English	Article						Pdcd4; c-Jun; phosphorylation; JNK-signaling; p300	INITIATION-FACTOR 4A; NF-KAPPA-B; ACTIVATION DOMAIN; C/EBP-BETA; HA-RAS; V-MYB; AP-1 TRANSACTIVATION; DELTA-DOMAIN; MIM-1 GENE; IN-VIVO	The transformation suppressor gene Pdcd4 ( programmed cell death gene 4) inhibits the tumor-promoter mediated transformation of mouse keratinocytes and has recently been implicated as a potential tumor suppressor gene in the development of human lung cancer. Biochemical analysis has suggested that the Pdcd4 protein is involved in protein translation as well as in nuclear events. Recent work has shown that Pdcd4 suppresses the transactivation of AP-1 responsive promoters by c-Jun, suggesting that the transformation-suppressor activity of Pdcd4 might be due, at least in part, to the inhibition of c-Jun activity. Here, we have addressed how Pdcd4 inhibits c-Jun. We show that Pdcd4 interferes with the phosphorylation of c-Jun by Jun N-terminal kinase (JNK). The inhibition of c-Jun phosphorylation by Pdcd4 appears not to be due to a general suppression of JNK activity, our data rather suggest that Pdcd4 interacts with c-Jun and thereby blocks phosphorylation of c-Jun. In addition to affecting c-Jun phosphorylation, Pdcd4 blocks the recruitment of the coactivator p300 by c-Jun. Taken together, our results strongly suggest that Pdcd4 is directly involved in the regulation of c-Jun activity.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Bannister AJ, 1995, ONCOGENE, V11, P2509; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DAI TN, 1995, ONCOGENE, V10, P849; David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6	37	116	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7484	7493		10.1038/sj.onc.1208064	http://dx.doi.org/10.1038/sj.onc.1208064			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334056				2022-12-17	WOS:000224176500005
J	Wu, XF; Zhao, H; Suk, R; Christiani, DC				Wu, XF; Zhao, H; Suk, R; Christiani, DC			Genetic susceptibility to tobacco-related cancer	ONCOGENE			English	Review						genetic susceptibility; tobacco-related cancer; polymorphism; phenotype; risk assessment; clinical outcome	GLUTATHIONE-S-TRANSFERASE; MICROSOMAL EPOXIDE HYDROLASE; SQUAMOUS-CELL CARCINOMA; SINGLE-NUCLEOTIDE POLYMORPHISM; DNA-REPAIR GENES; GROWTH-FACTOR-I; CUMULATIVE CIGARETTE-SMOKING; MATRIX METALLOPROTEINASE-1 PROMOTER; HOGG1 SER326CYS POLYMORPHISM; FACTOR-BINDING PROTEIN-3	Although cigarette smoking is the dominant risk factor for several epithelial cancers, only a small fraction of individuals with tobacco exposure develop cancer. The underlying hypothesis is that genetic factors may render certain smokers more susceptible to cancer than others. Genetic alterations in critical regulatory pathways may predispose cells to carcinogenesis. These pathways include regulation of xenobiotic metabolism; control of genomic stability, including DNA repair mechanisms, cell-cycle checkpoints, apoptosis and telomere length; and control of microenvironmental factors, such as matrix metalloproteinases, inflammation and growth factors. In addition, epigenetic events, such as promoter hypermethylation and loss of imprinting, are also involved in carcinogenesis. In this review, we will summarize recent advances in genetic susceptibility to tobacco-related cancer. Emphasizing on risk assessment, we will describe how genetic variations in the above-mentioned genetic pathways modify the tobacco-related cancer risk. In addition, we will discuss how genetic variations may assist in predicting clinical outcome, such as the natural history of cancer and treatment response. The measurements of genetic susceptibility by both genotypic and phenotypic assays are covered in the text. Finally, we present a number of current concerns that need to be addressed as the exciting field of molecular cancer epidemiology advances rapidly.	Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Wu, XF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Box 189,1515 Holcombe Blvd, Houston, TX 77030 USA.	xwu@mdanderson.org						AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Abdel-Rahman SZ, 1998, CANCER DETECT PREV, V22, P129; ALEXANDRIE AK, 1994, CARCINOGENESIS, V15, P1785, DOI 10.1093/carcin/15.9.1785; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; ANTTILA S, 1994, CARCINOGENESIS, V15, P1133, DOI 10.1093/carcin/15.6.1133; Anwar WA, 1996, CARCINOGENESIS, V17, P1923, DOI 10.1093/carcin/17.9.1923; AUSTIN GE, 1993, LEUKEMIA, V7, P1445; BADAWI AF, 1995, EUR J CANCER PREV, V4, P45, DOI 10.1097/00008469-199502000-00004; Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021; Bartsch H, 2000, CANCER EPIDEM BIOMAR, V9, P3; Benhamou S, 2002, CARCINOGENESIS, V23, P1343, DOI 10.1093/carcin/23.8.1343; Benhamou S, 1998, CANCER RES, V58, P5291; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Biros E, 2002, LUNG CANCER-J IASLC, V35, P231, DOI 10.1016/S0169-5002(01)00446-9; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BONASSI S, 1995, CANCER GENET CYTOGEN, V79, P133, DOI 10.1016/0165-4608(94)00131-T; Bosken CH, 2002, JNCI-J NATL CANCER I, V94, P1091; Bouchardy C, 1998, PHARMACOGENETICS, V8, P291, DOI 10.1097/00008571-199808000-00002; Brockmoller J, 1996, CANCER RES, V56, P3915; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Cajas-Salazar N, 2003, CANCER GENET CYTOGEN, V145, P97, DOI 10.1016/S0165-4608(03)00058-X; Camps Carlos, 2003, Clin Lung Cancer, V4, P237, DOI 10.3816/CLC.2003.n.004; Cascorbi I, 1996, CANCER RES, V56, P3961; Cascorbi I, 2000, CANCER RES, V60, P644; Chan SWL, 2003, MOL CELL, V11, P1379, DOI 10.1016/S1097-2765(03)00174-6; Chen HW, 1999, CANCER RES, V59, P3045; Chen WC, 2002, UROL ONCOL, V7, P63, DOI 10.1016/S1078-1439(01)00152-1; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Choi JY, 2003, PHARMACOGENETICS, V13, P349, DOI 10.1097/00008571-200306000-00006; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Cortessis VK, 2003, CARCINOGENESIS, V24, P1645, DOI 10.1093/carcin/bgg128; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Curigliano G, 1996, CARCINOGENESIS, V17, P911, DOI 10.1093/carcin/17.5.911; David-Beabes GL, 2001, LUNG CANCER-J IASLC, V34, P333, DOI 10.1016/S0169-5002(01)00256-2; David-Beabes GL, 2001, CANCER EPIDEM BIOMAR, V10, P911; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Deal C, 2001, J CLIN ENDOCR METAB, V86, P1274, DOI 10.1210/jc.86.3.1274; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; Divine KK, 2001, MUTAT RES-DNA REPAIR, V461, P273, DOI 10.1016/S0921-8777(00)00059-8; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; Dunn SE, 1997, CANCER RES, V57, P2687; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Farker K, 1998, EXP TOXICOL PATHOL, V50, P425, DOI 10.1016/S0940-2993(98)80029-8; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Gao CM, 2002, CANCER LETT, V188, P95, DOI 10.1016/S0304-3835(02)00115-5; GarciaClosas M, 1997, CANCER CAUSE CONTROL, V8, P544, DOI 10.1023/A:1018481910663; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Ghilardi G, 2002, CLIN CANCER RES, V8, P3820; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Goto I, 1996, CANCER RES, V56, P3725; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HAGMAR L, 1994, CANCER RES, V54, P2919; HAMADA GS, 1995, CANCER EPIDEM BIOMAR, V4, P63; Harrela M, 1996, J CLIN INVEST, V98, P2612, DOI 10.1172/JCI119081; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Harris MJ, 1998, PHARMACOGENETICS, V8, P27, DOI 10.1097/00008571-199802000-00004; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; HAYASHI S, 1991, J BIOCHEM-TOKYO, V110, P407, DOI 10.1093/oxfordjournals.jbchem.a123594; HAYASHI S, 1992, JPN J CANCER RES, V83, P866, DOI 10.1111/j.1349-7006.1992.tb01992.x; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hazra A, 2003, CANCER RES, V63, P1157; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hinoda Y, 2002, INT J CANCER, V102, P526, DOI 10.1002/ijc.10750; Hirata H, 2003, INT J CANCER, V106, P372, DOI 10.1002/ijc.11229; HIRVONEN A, 1993, CARCINOGENESIS, V14, P1479, DOI 10.1093/carcin/14.7.1479; HIRVONEN A, 1992, CANCER EPIDEM BIOMAR, V1, P485; Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Holley SL, 2001, AM J PATHOL, V159, P1917, DOI 10.1016/S0002-9440(10)63038-6; Hong YL, 1996, J CLIN ENDOCR METAB, V81, P1791, DOI 10.1210/jc.81.5.1791; Houlston RS, 2000, PHARMACOGENETICS, V10, P105, DOI 10.1097/00008571-200003000-00002; HSU TC, 1989, INT J CANCER, V43, P403, DOI 10.1002/ijc.2910430310; HSU TC, 1987, IN VITRO CELL DEV B, V23, P591; Hu JJ, 1996, CANCER EPIDEM BIOMAR, V5, P263; Huang QR, 1997, MOL IMMUNOL, V34, P577, DOI 10.1016/S0161-5890(97)00081-3; Hung HC, 1997, CANCER EPIDEM BIOMAR, V6, P901; Hung RJ, 2003, CARCINOGENESIS, V24, P875, DOI 10.1093/carcin/bgg026; Inatomi H, 1999, INT J UROL, V6, P446, DOI 10.1046/j.1442-2042.1999.00096.x; Ishibe N, 1997, CANCER EPIDEM BIOMAR, V6, P1075; Jeng YL, 2003, ANTICANCER RES, V23, P5149; JENSEN RA, 1993, HUM PATHOL, V24, P455, DOI 10.1016/0046-8177(93)90155-A; Jeon HS, 2003, CARCINOGENESIS, V24, P1677, DOI 10.1093/carcin/bgg120; Jernstrom H, 2001, MOL GENET METAB, V72, P144, DOI 10.1006/mgme.2000.3130; Johns LE, 2000, ENVIRON MOL MUTAGEN, V36, P221, DOI 10.1002/1098-2280(2000)36:3<221::AID-EM5>3.0.CO;2-Q; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Kanayama H, 1998, CANCER, V82, P1359, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1359::AID-CNCR20>3.0.CO;2-4; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; Katoh T, 1999, PHARMACOGENETICS, V9, P165; KATOH T, 1995, CARCINOGENESIS, V16, P655, DOI 10.1093/carcin/16.3.655; KAWAJIRI K, 1990, FEBS LETT, V263, P131, DOI 10.1016/0014-5793(90)80721-T; Kiemeney LALM, 1996, J UROLOGY, V156, P867, DOI 10.1016/S0022-5347(01)65644-1; KIHARA M, 1993, CANCER LETT, V71, P151, DOI 10.1016/0304-3835(93)90110-U; Kihara M, 1999, CANCER LETT, V137, P53, DOI 10.1016/S0304-3835(98)00337-1; KIHARA M, 1995, CARCINOGENESIS, V16, P2331, DOI 10.1093/carcin/16.10.2331; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Landi S, 2003, CANCER RES, V63, P3560; Le Marchand L, 1998, CANCER RES, V58, P4858; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; Le Marchand L, 2002, CANCER EPIDEM BIOMAR, V11, P409; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lewis SJ, 2001, LUNG CANCER-J IASLC, V34, P177, DOI 10.1016/S0169-5002(01)00243-4; Lin DX, 1998, CANCER EPIDEM BIOMAR, V7, P1013; Lin P, 2000, BRIT J CANCER, V82, P852, DOI 10.1054/bjoc.1999.1011; Lin PP, 1999, J TOXICOL ENV HEAL A, V58, P187, DOI 10.1080/009841099157287; London SJ, 1997, CANCER RES, V57, P5001; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; Lunn RM, 2000, CARCINOGENESIS, V21, P551, DOI 10.1093/carcin/21.4.551; Mabrouk I, 2003, ANN NY ACAD SCI, V1010, P764, DOI 10.1196/annals.1299.137; Malats N, 2000, CANCER EPIDEM BIOMAR, V9, P827; Malkinson AM, 2000, CHEST, V117, p228S, DOI 10.1378/chest.117.5_suppl_1.228S; Manning CB, 2002, INT IMMUNOPHARMACOL, V2, P191, DOI 10.1016/S1567-5769(01)00172-2; Marcus PM, 2000, CANCER EPIDEM BIOMAR, V9, P461; Marcus PM, 2000, PHARMACOGENETICS, V10, P115, DOI 10.1097/00008571-200003000-00003; Marsh HP, 2003, BRIT J CANCER, V89, P1096, DOI 10.1038/sj.bjc.6601165; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MARTINEZ C, 1995, PHARMACOGENETICS, V5, P207, DOI 10.1097/00008571-199508000-00004; Matakidou A, 2003, MUTAGENESIS, V18, P377, DOI 10.1093/mutage/geg008; Matthias C, 1998, CLIN CANCER RES, V4, P2411; Matthias C, 1999, CANCER EPIDEM BIOMAR, V8, P815; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; McCann J, 1999, J NATL CANCER I, V91, P497, DOI 10.1093/jnci/91.6.497; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; Miao XP, 2003, CANCER RES, V63, P3987; Miller DG, 1998, CANCER EPIDEM BIOMAR, V7, P321; Miller DP, 2003, EPIDEMIOLOGY, V14, P545, DOI 10.1097/01.ede.0000073120.46981.24; Miller DP, 2003, INT J CANCER, V104, P758, DOI 10.1002/ijc.10989; Miller DP, 2002, CANCER RES, V62, P2819; Minematsu N, 2001, BIOCHEM BIOPH RES CO, V289, P116, DOI 10.1006/bbrc.2001.5936; Morita S, 1999, INT J CANCER, V80, P685, DOI 10.1002/(SICI)1097-0215(19990301)80:5<685::AID-IJC9>3.0.CO;2-W; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Myohanen SK, 1998, CANCER RES, V58, P591; NAKACHI K, 1991, CANCER RES, V51, P5177; NAKACHI K, 1993, CANCER RES, V53, P2994; Nazar-Stewart V, 2003, LUNG CANCER-J IASLC, V40, P247, DOI 10.1016/S0169-5002(03)00076-X; Nia AB, 2000, CARCINOGENESIS, V21, P1335, DOI 10.1093/carcin/21.7.1335; Nickerson T, 1997, BIOCHEM BIOPH RES CO, V237, P690, DOI 10.1006/bbrc.1997.7089; Nimura Y, 1997, CANCER, V80, P852, DOI 10.1002/(SICI)1097-0142(19970901)80:5<852::AID-CNCR4>3.0.CO;2-N; OKADA T, 1994, PHARMACOGENETICS, V4, P333, DOI 10.1097/00008571-199412000-00006; Oyama T, 1997, ANTICANCER RES, V17, P577; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P993; Park JY, 2002, CANCER EPIDEM BIOMAR, V11, P23; Park JY, 1997, CANCER EPIDEM BIOMAR, V6, P791; Park SJ, 2003, MUTAT RES-GEN TOX EN, V536, P131, DOI 10.1016/S1383-5718(03)00041-X; Peluso M, 2000, CARCINOGENESIS, V21, P183, DOI 10.1093/carcin/21.2.183; Perera FP, 2002, CARCINOGENESIS, V23, P1641, DOI 10.1093/carcin/23.10.1641; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; Pfeifer K, 2000, AM J HUM GENET, V67, P777, DOI 10.1086/303101; PHILIP PA, 1988, CARCINOGENESIS, V9, P491, DOI 10.1093/carcin/9.3.491; Phillips DH, 2002, CARCINOGENESIS, V23, P1979, DOI 10.1093/carcin/23.12.1979; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; Pinarbasi H, 2003, CANCER GENET CYTOGEN, V146, P125, DOI 10.1016/S0165-4608(03)00059-1; Qiao YW, 2002, CARCINOGENESIS, V23, P295, DOI 10.1093/carcin/23.2.295; Ratnasinghe D, 2001, CANCER EPIDEM BIOMAR, V10, P119; Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rojas E, 1999, J CHROMATOGR B, V722, P225, DOI 10.1016/S0378-4347(98)00313-2; Rosell R, 2003, LUNG CANCER-J IASLC, V41, pS97, DOI 10.1016/S0169-5002(03)00151-X; Rosen CJ, 1998, J CLIN ENDOCR METAB, V83, P2286, DOI 10.1210/jc.83.7.2286; Ross D, 1996, BRIT J CANCER, V74, P995, DOI 10.1038/bjc.1996.477; ROSVOLD EA, 1995, PHARMACOGENETICS, V5, P199, DOI 10.1097/00008571-199508000-00003; ROTWEIN P, 1986, J BIOL CHEM, V261, P4828; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Ruano-Ravina A, 2003, ANTICANCER RES, V23, P4333; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Saarikoski ST, 2000, PHARMACOGENETICS, V10, P183, DOI 10.1097/00008571-200003000-00010; Santella RM, 1999, CANCER EPIDEM BIOMAR, V8, P733; Sanyal S, 2004, CARCINOGENESIS, V25, P729, DOI 10.1093/carcin/bgh058; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; Schabath MB, 2003, J NATL CANCER I, V95, P540, DOI 10.1093/jnci/95.7.540; Schabath MB, 2002, LUNG CANCER-J IASLC, V37, P35, DOI 10.1016/S0169-5002(02)00034-X; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SELLERS TA, 1994, AM J MED GENET, V52, P308, DOI 10.1002/ajmg.1320520311; Seow A, 1999, CARCINOGENESIS, V20, P1877, DOI 10.1093/carcin/20.9.1877; Shen HB, 2001, CANCER RES, V61, P3321; Shen HB, 2002, CANCER RES, V62, P4992; Shen HB, 2001, CANCER EPIDEM BIOMAR, V10, P397; Shi QL, 2003, CARCINOGENESIS, V24, P1499, DOI 10.1093/carcin/bgg035; Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309; Shih CM, 2000, JPN J CANCER RES, V91, P9, DOI 10.1111/j.1349-7006.2000.tb00854.x; SHIMA I, 1992, CANCER, V70, P2747, DOI 10.1002/1097-0142(19921215)70:12<2747::AID-CNCR2820701204>3.0.CO;2-5; SHOPLAND DR, 1991, JNCI-J NATL CANCER I, V83, P1142, DOI 10.1093/jnci/83.16.1142; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; Sjalander A, 1996, HUM HERED, V46, P221, DOI 10.1159/000154357; Smith WM, 2001, HUM GENET, V109, P146, DOI 10.1007/s004390100563; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Song CY, 2001, CANCER RES, V61, P3272; Spitz MR, 2003, CANCER EPIDEM BIOMAR, V12, P689; Spitz MR, 2001, CANCER RES, V61, P1354; Stolzenberg-Solomon RZ, 2003, CANCER EPIDEM BIOMAR, V12, P1222; Stucker I, 2002, CARCINOGENESIS, V23, P1475, DOI 10.1093/carcin/23.9.1475; Su L, 2003, CANCER EPIDEM BIOMAR, V12, P174; Su T, 2000, CANCER RES, V60, P5074; Sugimura H, 1999, CANCER EPIDEM BIOMAR, V8, P669; Sweeney C, 2003, CANCER EPIDEM BIOMAR, V12, P527; TEFRE T, 1991, PHARMACOGENETICS, V1, P20, DOI 10.1097/00008571-199110000-00004; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; To-Figueras J, 1999, CANCER CAUSE CONTROL, V10, P65, DOI 10.1023/A:1008811824890; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Tsai FJ, 2001, UROL RES, V29, P412, DOI 10.1007/s002400100219; Vaessen N, 2001, DIABETES, V50, P637, DOI 10.2337/diabetes.50.3.637; Veglia F, 2003, CANCER EPIDEM BIOMAR, V12, P157; Vineis P, 2003, INT J CANCER, V104, P650, DOI 10.1002/ijc.10995; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vulimiri SV, 2000, MOL CARCINOGEN, V27, P34, DOI 10.1002/(SICI)1098-2744(200001)27:1<34::AID-MC6>3.0.CO;2-G; Wang AH, 2004, WORLD J GASTROENTERO, V10, P940; Wang HJ, 2003, CANCER RES, V63, P8057; Wang LE, 2003, LUNG CANCER-J IASLC, V42, P1, DOI 10.1016/S0169-5002(03)00276-9; Wang LI, 2001, J NATL CANCER I, V93, P1818, DOI 10.1093/jnci/93.23.1818; Wang LZ, 2002, CARCINOGENESIS, V23, P257, DOI 10.1093/carcin/23.2.257; Wang YC, 1999, EUR J CANCER, V35, P226, DOI 10.1016/S0959-8049(98)00369-4; Wang YC, 2001, J MEMBRANE SCI, V185, P193, DOI 10.1016/S0376-7388(00)00655-4; Wang YF, 2003, CANCER, V98, P1701, DOI 10.1002/cncr.11692; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; Wang YF, 2002, LUNG CANCER, V35, P137, DOI 10.1016/S0169-5002(01)00406-8; Warren AJ, 1997, P SOC EXP BIOL MED, V216, P172; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Williams JA, 1998, PHARMACOGENETICS, V8, P519, DOI 10.1097/00008571-199812000-00009; Williams MP, 1999, AM J GASTROENTEROL, V94, pS11, DOI 10.1016/S0002-9270(99)00657-7; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Woodson K, 2004, JNCI-J NATL CANCER I, V96, P407, DOI 10.1093/jnci/djh042; Wu XF, 1998, J NATL CANCER I, V90, P1393, DOI 10.1093/jnci/90.18.1393; Wu XF, 1998, CANCER-AM CANCER SOC, V83, P1118, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1118::AID-CNCR10>3.3.CO;2-1; Wu XF, 2003, J NATL CANCER I, V95, P1211, DOI 10.1093/jnci/djg011; Wu XF, 2003, CARCINOGENESIS, V24, P505, DOI 10.1093/carcin/24.3.505; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681; Wu XF, 1997, CARCINOGENESIS, V18, P967, DOI 10.1093/carcin/18.5.967; Wu XF, 1998, CANCER EPIDEM BIOMAR, V7, P13; Wu XF, 2001, CARCINOGENESIS, V22, P923, DOI 10.1093/carcin/22.6.923; Xing DY, 2001, INT J CANCER, V95, P140, DOI 10.1002/1097-0215(20010520)95:3&lt;140::AID-IJC1024&gt;3.0.CO;2-2; Xu LL, 2001, CANCER EPIDEM BIOMAR, V10, P303; Yu CY, 2003, CANCER EPIDEM BIOMAR, V12, P176; Yu CY, 2002, CANCER RES, V62, P6430; Zambon CF, 2004, GASTROENTEROLOGY, V126, P382, DOI 10.1053/j.gastro.2003.08.042; Zhang XL, 2002, J PHARMACOL EXP THER, V302, P416, DOI 10.1124/jpet.302.2.416; Zhao H, 2002, MOL CARCINOGEN, V33, P99, DOI 10.1002/mc.10023; Zhao H, 2001, CANCER RES, V61, P7819; Zheng YX, 2001, CARCINOGENESIS, V22, P1195, DOI 10.1093/carcin/22.8.1195; ZHONG S, 1991, CARCINOGENESIS, V12, P1533, DOI 10.1093/carcin/12.9.1533; Zhou W, 2002, CANCER RES, V62, P1377; Zhou W, 2002, CANCER EPIDEM BIOMAR, V11, P15; Zhou W, 2001, CANCER EPIDEM BIOMAR, V10, P461; Zhou W, 2003, CANCER EPIDEM BIOMAR, V12, P359; Zhu Y, 2001, CANCER RES, V61, P7825; Zhu Y, 2004, CANCER RES, V64, P2251, DOI 10.1158/0008-5472.CAN-03-2800	275	116	125	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6500	6523		10.1038/sj.onc.1207811	http://dx.doi.org/10.1038/sj.onc.1207811			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322521				2022-12-17	WOS:000223468800015
J	Kim, EH; Kim, SU; Shin, DY; Choi, KS				Kim, EH; Kim, SU; Shin, DY; Choi, KS			Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; roscovitine; apoptosis; glioma	X-LINKED INHIBITOR; CYCLIN-DEPENDENT KINASES; PROSTATE-CANCER CELLS; GLIAL-CELLS; PHASE-II; EXPRESSION; PROTEIN; LIGAND; CLEAVAGE; FAMILY	The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is limited in many glioma cell lines. However, treatment with TRAIL in combination with subtoxic doses of roscovitine, a specific inhibitor of Cdc2 and Cdk2, induced rapid apoptosis in TRAIL-resistant glioma cells. Roscovitine could sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells, but not human astrocytes, to TRAIL-induced apoptosis, offering an attractive strategy for safely treating resistant gliomas. Treatment with roscovitine significantly inhibited Cdc2 activity, and expression of a dominant-negative Cdc2 mutant sensitized glioma cells to TRAIL-induced apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in U87MG and T98 glioma cells, treatment with roscovitine recovered TRAIL-induced activation of caspases very efficiently in these cells. We found that treatment with roscovitine or expression of a dominant-negative Cdc2 mutant downregulated the protein levels of survivin and XIAP, two major caspase inhibitors. Overexpression of survivin or XIAP attenuated the apoptosis induced by roscovitine and TRAIL. Taken together, these results suggest that downregulation of survivin and XIAP by subtoxic doses of roscovitine contributes to the amplification of caspase cascades, thereby overcoming glioma cell resistance to TRAIL-mediated apoptosis.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; Dankook Univ Coll Med, Dept Microbiol, Cheonan 330714, South Korea	Ajou University; Ajou University; Dankook University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Asselin E, 2001, CANCER RES, V61, P1862; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gazzaniga P, 2003, ANN ONCOL, V14, P85, DOI 10.1093/annonc/mdg002; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Grant S, 2003, DRUG RESIST UPDATE, V6, P15, DOI 10.1016/S1368-7646(02)00141-3; Griffith TS, 2002, CANCER RES, V62, P3093; Hao CH, 2001, CANCER RES, V61, P1162; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Nagane M, 2000, CANCER RES, V60, P847; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Sehgal A, 1998, SEMIN SURG ONCOL, V14, P3; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Weber RG, 2001, INT J CANCER, V91, P213, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1036>3.3.CO;2-D; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	44	116	124	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					446	456		10.1038/sj.onc.1207025	http://dx.doi.org/10.1038/sj.onc.1207025			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724573				2022-12-17	WOS:000188098300015
J	Ueda, J; Kajita, M; Suenaga, N; Fujii, K; Seiki, M				Ueda, J; Kajita, M; Suenaga, N; Fujii, K; Seiki, M			Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors	ONCOGENE			English	Article						MT1-MMP; MMP-2; CD44; tumor invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; CD44 CLEAVAGE; SURFACE; CANCER; ACTIVATION; PROGELATINASE; METASTASIS; CARCINOMA; ADHESION	Membrane-type 1 matrix metalloproteinase (MT1-MMP/MMP-14) has been believed a key enzyme in tumor invasion, because it is expressed in a variety of malignant human tumors, and overexpression of the enzyme enhances the ability of cellular invasiveness. However, it has not necessarily been clarified whether the endogenously expressed MT1-MMP in human tumors plays a critical role in their invasiveness. We used RNA silencing technology to downregulate the endogenous MT1-MMP expression in human tumor cells (fibrosarcoma HT1080 and gastric carcinoma MKN-28 cell lines), and evaluated the effect on the invasion of a reconstituted basement membrane (Matrigel). Transfection of a double-stranded RNA targeted to the MT1-MMP gene decreased the level of the enzyme to less than 10-20% without affecting production of other MMPs. According to the degree of silencing, activation of proMMP-2 was inhibited. CD44 shedding was also inhibited, but only in part. Decreased MT1-MMP levels were also reflected in reduced cell motility on hyaluronan (HA) and invasion in Matrigel. Thus, specific downregulation of MT1-MMP expression was sufficient to cause significant inhibition of the migration and invasion of tumor cells, even though other MMPs continued to be expressed.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Jikei Univ, Sch Med, Dept Orthopaed Surg, Minato Ku, Tokyo, Japan	University of Tokyo; Jikei University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015					Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Goebeler M, 1996, J CELL SCI, V109, P1957; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; McCarthy M, 2001, J RENAL NUTR, V11, P115; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAOT D, 1997, ADV CANCER RES, V71, P241; NOMURA H, 1995, CANCER RES, V55, P3263; Okada Y, 2000, VERH DEUT G, V84, P33; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	36	116	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8716	8722		10.1038/sj.onc.1206962	http://dx.doi.org/10.1038/sj.onc.1206962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647466				2022-12-17	WOS:000186844900009
J	Raval, GN; Bharadwaj, S; Levine, EA; Willingham, MC; Geary, RL; Kute, T; Prasad, G				Raval, GN; Bharadwaj, S; Levine, EA; Willingham, MC; Geary, RL; Kute, T; Prasad, G			Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors	ONCOGENE			English	Article						tropomyosin; breast cancer; tumor suppressor; anoikis; biomarker	HUMAN TRK ONCOGENE; CANCER-CELLS; TRANSFORMED PHENOTYPE; EPITHELIAL-CELLS; PROSTATE-CANCER; KINASE; METHYLATION; RECEPTOR; PROTEIN; GROWTH	Suppression of tropomyosins (TMs), a family of actin-binding, microfilament-associated proteins, is a prominent feature of many transformed cells. Yet it is unclear whether downregulation of TMs occur in human tumors. We have investigated the expression of tropomyosin-1 (TM1) in human breast carcinoma tissues by in situ hybridization and immunofluorescence. TM1 mRNA and protein are readily detectable in normal mammary tissue. In contrast, TM1 expression is abolished in the primary human breast tumors. Expression of other TM isoforms, however, is variable among the tumors. The consistent and profound downregulation of TM1 suggests that TM1 may be a novel and useful biomarker of mammary neoplasms. These data also support the hypothesis that suppression of TM1 expression during the malignant conversion of mammary epithelium as a contributing factor of breast cancer. In support of this hypothesis, we show that the ability to suppress malignant growth properties of breast cancer cells is specific to TM1 isoform. Investigations into the mechanisms of TM1-induced tumor suppression reveal that TM1 induces anoikis ( detachment induced apoptosis) in breast cancer cells. Downregulation of TM1 in breast tumors may destabilize microfilament architecture and confer resistance to anoikis, which facilitates survival of neoplastic cells outside the normal microenvironment and promote malignant growth.	Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Surg Oncol Serv, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Vasc Surg Serv, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Prasad, G (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Gen Surg, Surg Oncol Serv, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.							Ahram M, 2002, MOL CARCINOGEN, V33, P9, DOI 10.1002/mc.10019; Asch HL, 1996, CANCER RES, V56, P4841; Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; Braverman RH, 1996, ONCOGENE, V13, P537; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; Darzynkiewicz Z, 2001, METHOD CELL BIOL, V66, P69; Dhar S, 2001, CLIN CANCER RES, V7, P3393; Donner K, 2002, NEUROMUSCULAR DISORD, V12, P151, DOI 10.1016/S0960-8966(01)00252-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Franzen B, 1997, ELECTROPHORESIS, V18, P582, DOI 10.1002/elps.1150180341; Franzen B, 1996, BRIT J CANCER, V73, P909, DOI 10.1038/bjc.1996.162; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Li B, 2001, CANCER RES, V61, P8014; Lin J J, 1997, Int Rev Cytol, V170, P1, DOI 10.1016/S0074-7696(08)61619-8; Lin JLC, 2002, GASTROENTEROLOGY, V123, P152, DOI 10.1053/gast.2002.34154; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Meech SJ, 2001, BLOOD, V98, P1209, DOI 10.1182/blood.V98.4.1209; Michele DE, 2000, J MOL MED, V78, P543, DOI 10.1007/s001090000161; Mielnicki LM, 1999, EXP CELL RES, V249, P161, DOI 10.1006/excr.1999.4461; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; Mondy JS, 1997, CIRC RES, V81, P320, DOI 10.1161/01.RES.81.3.320; Nass SJ, 2000, CANCER RES, V60, P4346; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Wang SC, 2001, ONCOGENE, V20, P6960, DOI 10.1038/sj.onc.1204873; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Zhu ZY, 2001, CANCER RES, V61, P1707	50	116	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6194	6203		10.1038/sj.onc.1206719	http://dx.doi.org/10.1038/sj.onc.1206719			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679858				2022-12-17	WOS:000185506200009
J	Li, H; Fredriksson, L; Li, X; Eriksson, U				Li, H; Fredriksson, L; Li, X; Eriksson, U			PDGF-D is a potent transforming and angiogenic growth factor	ONCOGENE			English	Article						PDGF; VEGF; transformation; growth factor; tumour growth; angiogenesis	BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; IN-VIVO; EXPRESSION; CANCER; TUMORS; ALPHA; MICE; ACTIVATION	Platelet-derived growth factors (PDGFs) are important for normal tissue growth and maintenance. Overexpression of the classical PDGFs, PDGF-A and PDGF-B, has been linked to several diseases, including cancer, fibrotic disease and atherosclerosis. Recently, two novel PDGFs, PDGF-C and PDGF-D, were discovered. It has not yet been established whether PDGF-C and PDGF-D are linked to disease phenotypes like the classical PDGFs. PDGF-B, the cellular homologue of the viral simian sarcoma oncogene v-sis, is known to potently induce cellular transformation through activation of PDGF receptor (PDGFR)-beta. In this work, we have determined the transformation efficacy of PDGF-D in comparison with that of PDGF-C and PDGF-B. PDGF-D is a potent transforming growth factor for NIH/3T3 cells, and the transformed cells displayed stress fibre reorganization, increased proliferation rate, anchorage-independent growth in soft agar, ability to induce tumours in nude mice, and upregulation of vascular endothelial growth factor. Morphological analyses of the vasculatures from the PDGF-isoform-expressing tumours revealed marked differences suggesting differential signalling through the two PDGF receptors in tumour vessel development and remodelling. In summary, these results suggest that PDGF-D induce cellular transformation and promote tumour growth by accelerating the proliferation rate of the tumour cells, and by stimulation of tumour neovascularization.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, Box 240, S-17177 Stockholm, Sweden.			Fredriksson, Linda/0000-0003-4952-2742				Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Eberhard A, 2000, CANCER RES, V60, P1388; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FLEMING TP, 1992, CANCER RES, V52, P4550; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HSU S, 1995, J CELL PHYSIOL, V165, P239, DOI 10.1002/jcp.1041650204; JAIN RK, 1988, CANCER RES, V48, P2641; LaRochelle WJ, 2002, CANCER RES, V62, P2468; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lokker NA, 2002, CANCER RES, V62, P3729; NISTER M, 1991, J BIOL CHEM, V266, P16755; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; Simon MP, 1997, NAT GENET, V15, P95, DOI 10.1038/ng0197-95; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Uutela M, 2001, CIRCULATION, V103, P2242; Wang DG, 1999, CANCER RES, V59, P1464; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	32	116	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1501	1510		10.1038/sj.onc.1206223	http://dx.doi.org/10.1038/sj.onc.1206223			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629513				2022-12-17	WOS:000181411900007
J	Huang, M; Dorsey, JF; Epling-Burnette, PK; Nimmanapalli, R; Landowski, TH; Mora, LB; Niu, GL; Sinibaldi, D; Bai, FQ; Kraker, A; Yu, H; Moscinski, L; Wei, S; Djeu, J; Dalton, WS; Bhalla, K; Loughran, TP; Wu, J; Jove, R				Huang, M; Dorsey, JF; Epling-Burnette, PK; Nimmanapalli, R; Landowski, TH; Mora, LB; Niu, GL; Sinibaldi, D; Bai, FQ; Kraker, A; Yu, H; Moscinski, L; Wei, S; Djeu, J; Dalton, WS; Bhalla, K; Loughran, TP; Wu, J; Jove, R			Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells	ONCOGENE			English	Article						Stat5; Bcr-Abl; CML; PD180970; apoptosis; cell cycle	DNA-BINDING ACTIVITY; MYELOGENOUS LEUKEMIA-CELLS; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCER; BCL-2 FAMILY; SH2 DOMAINS	Chronic myelogenous leukemia (CML) is a myeloproliferative disease characterized by the BCR-ABL genetic translocation and constitutive activation of the Abl tyrosine kinase. Among members of the Signal Transducers and Activators of Transcription (STAT) family of transcription factors, Stat5 is activated by the Ber-Abl kinase and is implicated in the pathogenesis of CML. We recently identified PD180970 as a new and highly potent inhibitor of Bcr-Abl kinase. In this study, we show that blocking Bcr-Abl kinase activity using PD180970 in the human K562 CML cell line resulted in inhibition of Stat5 DNA-binding activity with an IC50 of 5 nM. Furthermore, abrogation of Abl kinase-mediated Stat5 activation suppressed cell proliferation and induced apoptosis in K562 cells, but not in the Ber-Abl-negative myeloid cell lines, HEL 92.1.7 and HL-60. Dominant-negative Stat5 protein expressed from a vaccinia virus vector also induced apoptosis of K562 cells, consistent with earlier studies that demonstrated an essential role of Stat5 signaling in growth and survival of CML cells. RNA and protein analyses revealed several candidate target genes of Stat5, including Bcl-x, Mcl-1, c-Myc and cyclin D2, which were down-regulated after treatment with PD180970. In addition, PD180970 inhibited Stat5 DNA-binding activity in cultured primary leukemic cells derived from CML patients. To detect activated Stat5 in CML patient specimens, we developed an immunocytochemical assay that can be used as a molecular end-point assay to monitor inhibition of Bcr-Abl signaling. Moreover, PD180970 blocked Stat5 signaling and induced apoptosis of STI-571 (Gleevec, Imatinib)-resistant Bcr-Abl-positive cells. Together, these results suggest that the mechanism of action of PD180970 involves inhibition of Bcr-Abl-mediated Stat5 signaling and provide further evidence that compounds in this structural class may represent potential therapeutic agents for CML.	Univ S Florida, H Lee Moffitt Canc Ctr, Res Inst, Mol Oncol Program, Tampa, FL 33682 USA; Pfizer Global Res & Dev, Dept Canc Res, Ann Arbor, MI 48106 USA; Univ Arizona, Hlth Sci Ctr, Dept Med, Tucson, AZ 85724 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Pfizer; University of Arizona; University of Arizona Health Sciences; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.	richjove@moffitt.usf.edu	Wu, Jie/R-2404-2019; Herrmann, Eva/E-8215-2010	Wu, Jie/0000-0002-2864-1606; YU, Hua/0000-0003-0931-1000; Bhalla, Kapil/0000-0001-5209-5126	NATIONAL CANCER INSTITUTE [P01CA082533, R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA82533, CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Cortez D, 1996, ONCOGENE, V13, P2589; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Dorsey JF, 2000, CANCER RES, V60, P3127; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Frank DA, 1996, LEUKEMIA, V10, P1724; Gelfanov VM, 2001, BLOOD, V98, P2508, DOI 10.1182/blood.V98.8.2508; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ibrado AM, 1996, CANCER RES, V56, P4743; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Jonuleit T, 1998, BRIT J HAEMATOL, V100, P295, DOI 10.1046/j.1365-2141.1998.00564.x; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Nagar B, 2002, CANCER RES, V62, P4236; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; NIMMANAPALLI R, 2002, IN PRESS CANC RES; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Porosnicu M, 2001, LEUKEMIA, V15, P772, DOI 10.1038/sj.leu.2402104; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rhodes J, 2000, EXP HEMATOL, V28, P305, DOI 10.1016/S0301-472X(99)00148-4; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Wisniewski D, 2002, CANCER RES, V62, P4244; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	74	116	131	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8804	8816		10.1038/sj.onc.1206028	http://dx.doi.org/10.1038/sj.onc.1206028			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483533	Bronze			2022-12-17	WOS:000179734400014
J	Astrinidis, A; Cash, TP; Hunter, DS; Walker, CL; Chernoff, J; Henske, EP				Astrinidis, A; Cash, TP; Hunter, DS; Walker, CL; Chernoff, J; Henske, EP			Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration	ONCOGENE			English	Article						tuberous sclerosis complex; TSC2; tuberin; RhoA; cell migration; cell attachment	TSC1 GENE; EKER RAT; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; KINASE GENE; GTPASE-RHO; HAMARTIN; PROLIFERATION; EXPRESSION; CANCER	Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome characterized by seizures, mental retardation, autism, and tumors of the brain, kidney, heart, retina, and skin. TSC is caused by mutations in either TSC1 or TSC2, both of which are tumor suppressor genes. Hamartin, the protein product of TSC1, was found to interact with the ezrin-radixin-moesin family of cytoskeletal proteins and to activate the small GTPase Rho. To determine whether tuberin, the TSC2 product, can also activate Rho, we stably expressed full-length human tuberin in two cell types: MDCK cells and ELT3 cells. ELT3 cells lack endogenous tuberin expression. We found that expression of human tuberin in both MDCK and ELT3 cells was associated with an increase in the amount of Rho-GTP, but not in Rac1-GTP or cdc42-GTP. Tuberin expression increased cell adhesion in both cell types, and decreased chemotactic cell migration in ELT3 cells. In MDCK cells, there was a decrease in the amount of total Focal Adhesion Kinase (FAK) and an increase in the fraction of phosphorylated FAK. These findings demonstrate for the first time that tuberin activates Rho and regulates cell adhesion and migration. Pathways involving Rho activation may have relevance to the clinical manifestations of TSC, including pulmonary lymphangioleiomyomatosis.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Univ Texas, MD Anderson Canc Ctr, Smithville, TX 78957 USA	Fox Chase Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Henske, EP (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Astreinidis, Aristotelis/AAK-5137-2020; Chernoff, Jonathan/I-7631-2014; Astreinidis, Aristotelis/ABA-6715-2021; Astrinidis, Aristotelis/A-1396-2010	Chernoff, Jonathan/0000-0002-4803-7836; Astrinidis, Aristotelis/0000-0001-7098-1391	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051052, R01DK051052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60746] Funding Source: Medline; NIDDK NIH HHS [DK 51052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BONIFACINO JS, 2001, CURRENT PROTOCOLS CE; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Flinn HM, 1996, J CELL SCI, V109, P1133; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; HOWE SR, 1995, AM J PATHOL, V146, P1568; Ilic D, 1997, J CELL SCI, V110, P401; Irani C, 2002, AM J PHYSIOL-LUNG C, V282, pL854, DOI 10.1152/ajplung.00291.2001; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; NELLIST M, 1993, CELL, V75, P1305; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Sullivan EJ, 1998, CHEST, V114, P1689, DOI 10.1378/chest.114.6.1689; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107; Yu J, 2001, AM J RESP CRIT CARE, V164, P1537, DOI 10.1164/ajrccm.164.8.2104095	44	116	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8470	8476		10.1038/sj.onc.1205962	http://dx.doi.org/10.1038/sj.onc.1205962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466966				2022-12-17	WOS:000179480100009
J	Maida, Y; Kyo, S; Kanaya, T; Wang, Z; Yatabe, N; Tanaka, M; Nakamura, M; Ohmichi, M; Gotoh, N; Murakami, S; Inoue, M				Maida, Y; Kyo, S; Kanaya, T; Wang, Z; Yatabe, N; Tanaka, M; Nakamura, M; Ohmichi, M; Gotoh, N; Murakami, S; Inoue, M			Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway	ONCOGENE			English	Article						telomerase; TERT; EGF; MAP kinase	CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; GENE-EXPRESSION; C-MYC; TERMINAL DOMAIN; PROTEIN-KINASE; CELLS; PHOSPHORYLATION; JUN; TRANSDUCTION	Telomerase is a regulated enzyme and its activity is tightly associated with cell proliferation. The mechanisms of this association are unclear, but specific growth factors may regulate telomerase activity. The present study examines the effect of epidermal growth factor (EGF) on telomerase activity and identifies the signal transduction pathway involved in this process. EGF upregulated telomerase activity in EGF receptor-positive cells after the activation of telomerase reverse transcriptase (TERT) mRNA expression. This activation was rapid, peaked after 6 or 12 h and was not blocked by the concurrent exposure to cycloheximide, suggesting a direct effect of EGF on TERT transcription. Transient expression assays revealed that EGF activates the hTERT promoter and that the proximal core promoter is responsible for this regulation. The activation of hTERT mRNA expression by EGF was specifically blocked by MEK inhibitor, and in vitro kinase assays demonstrated that ERK is activated in response to EGF. Transient expression assays using mutant reporter plasmids revealed that an ETS motif located in the core promoter of hTERT is required for the EGF-induced transactivation of hTERT. Overexpression of wild type Ets in cells enhanced the EGF effect on hTERT transcription, while that of dominant negative Ets significantly repressed EGF action. These findings suggest that EGF activates telomerase through the direct activation of TERT transcription, in which the Ras/MEK/ERK pathway and Ets factor play major roles. Our data support the notion that growth factors directly regulate telomerase via specific signal transduction pathways.	Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Kanazawa, Ishikawa 9208641, Japan; Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo, Japan; Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 6560871, Japan	Kanazawa University; Kanazawa University; University of Tokyo; Osaka University	Kyo, S (corresponding author), Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.			Gotoh, Noriko/0000-0003-3733-260X				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Babu GJ, 2000, J MOL CELL CARDIOL, V32, P1447, DOI 10.1006/jmcc.2000.1185; Baselga J, 2000, DRUGS, V60, P33, DOI 10.2165/00003495-200060001-00004; Bonnet F, 1999, NUCLEIC ACIDS RES, V27, P4399, DOI 10.1093/nar/27.22.4399; BORNAR AG, 1998, SCIENCE, V279, P349; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; Haik S, 2000, ONCOGENE, V19, P2957, DOI 10.1038/sj.onc.1203596; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1992, J BIOL CHEMN, V267, P24798; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; Tsumuki H, 2000, RHEUMATOL INT, V19, P123, DOI 10.1007/s002960050115; Tu WW, 1999, BRIT J HAEMATOL, V104, P785, DOI 10.1046/j.1365-2141.1999.01272.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang Z, 2000, CANCER RES, V60, P5376; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x; Yang XY, 2000, LIFE SCI, V66, P1545, DOI 10.1016/S0024-3205(00)00472-0	38	116	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4071	4079		10.1038/sj.onc.1205509	http://dx.doi.org/10.1038/sj.onc.1205509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037663	Green Submitted			2022-12-17	WOS:000176186000001
J	Simon, R; Struckmann, K; Schraml, P; Wagner, U; Forster, T; Moch, H; Fijan, A; Bruderer, J; Wilber, K; Mihatsch, MJ; Gasser, T; Sauter, G				Simon, R; Struckmann, K; Schraml, P; Wagner, U; Forster, T; Moch, H; Fijan, A; Bruderer, J; Wilber, K; Mihatsch, MJ; Gasser, T; Sauter, G			Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; MDM2; CDK4; GLI; tissue microarray; TMA	DEPENDENT KINASE 4; CHROMOSOMAL IMBALANCES; TISSUE MICROARRAYS; CYCLIN D1; P53; EXPRESSION; OVEREXPRESSION; PROLIFERATION; P21; COAMPLIFICATION	The chromosomal region 12q13-q15 is recurrently amplified in bladder cancer. Putative target genes located in this region include MDM2, CDK4, and GLI. To evaluate the involvement of these genes in bladder cancer, we screened a tissue microarray (TMA) containing 2317 samples by fluorescence in situ hybridization (FISH). Amplification was found for MDM2 in 5.1%, for CDK4 in 1.1%, and for GLI in 0.4% of interpretable tumors. Among tumors having amplification of at least one of these 12q13-q15 genes, 76.6% had amplification of MDM2 alone and 6.4% had amplification of CDK4 alone. Coamplifications were seen of MDM2 and CDK4 in 10.6%, and of CDK4 and GLI in 6.4%. Neither coamplifications of all three genes nor isolated GLI amplifications were found. These data suggest a prominent role of MDM2 as a 12q13-q15 amplification target in bladder cancer. However, independent CDK4 amplifications do also occur suggesting either two nonoverlapping amplification sites or else a minimal overlapping region between MDM2 and CDK4 perhaps containing another yet unknown oncogene. The frequency of amplification increased significantly from stage pTa to pT1-4 (P<0.04) and from low to high grade (P<0.005). These data are consistent with a high level of genetic instability in invasively growing and high-grade bladder tumors.	Univ Basel, Inst Pathol, CH-4003 Basel, Switzerland; Univ Basel, Urol Clin, CH-4003 Basel, Switzerland; Vysis Inc, Downers Grove, IL 60515 USA; Cantonal Hosp Liestal, Urol Clin, CH-4410 Liestal, Switzerland	University of Basel; University of Basel; Kantonsspital Baselland	Sauter, G (corresponding author), Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4003 Basel, Switzerland.	Guido.Sauter@unibas.ch		Simon, Ronald/0000-0003-0158-4258				An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; Galanis E, 1998, INT J ONCOL, V13, P717; Gamberi G, 2000, CLIN ORTHOP RELAT R, P195; Gisselsson D, 2000, GENE CHROMOSOME CANC, V28, P347; HABUCHI T, 1994, J NATL CANCER I, V86, P1331, DOI 10.1093/jnci/86.17.1331; Ioachim E, 2000, HISTOL HISTOPATHOL, V15, P721, DOI 10.14670/HH-15.721; Jahnson S, 2000, CANCER, V89, P619, DOI 10.1002/1097-0142(20000801)89:3<619::AID-CNCR18>3.3.CO;2-W; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; Kanoe H, 1998, ANTICANCER RES, V18, P2317; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Korkolopoulou P, 1997, PATHOL RES PRACT, V193, P767, DOI 10.1016/S0344-0338(97)80055-6; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; Lu S, 1997, CANCER RES, V57, P4511; Masciullo V, 1997, INT J CANCER, V74, P390, DOI 10.1002/(SICI)1097-0215(19970822)74:4<390::AID-IJC5>3.0.CO;2-Q; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Mostofi FK, 1973, HISTOLOGICAL TYPING; Oya M, 1998, JPN J CANCER RES, V89, P719, DOI 10.1111/j.1349-7006.1998.tb03276.x; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pfister C, 1999, CLIN CANCER RES, V5, P4079; Pfister C, 2000, INT J CANCER, V89, P100, DOI 10.1002/(SICI)1097-0215(20000120)89:1<100::AID-IJC16>3.3.CO;2-H; Pilotti S, 2000, BRIT J CANCER, V82, P1271; Reed SI, 1997, CANCER SURV, V29, P7; Reifenberger G, 1996, CANCER RES, V56, P5141; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; Rollbrocker B, 1996, ACTA NEUROPATHOL, V92, P70, DOI 10.1007/s004010050491; SchmitzDrager BJ, 1997, EUR UROL, V32, P487; Schraml P, 1999, CLIN CANCER RES, V5, P1966; Shiina H, 1999, ONCOLOGY-BASEL, V56, P239, DOI 10.1159/000011971; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 1998, J PATHOL, V185, P345; Takano Y, 1999, J CANCER RES CLIN, V125, P505, DOI 10.1007/s004320050309; UICC/AJCC, 1997, TNM CLASS MAL TUM; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Wolf M, 1997, GENE CHROMOSOME CANC, V18, P66, DOI 10.1002/(SICI)1098-2264(199701)18:1<66::AID-GCC8>3.0.CO;2-#; Zhao JM, 1999, CANCER RES, V59, P4658	46	116	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2476	2483		10.1038/sj.onc.1205304	http://dx.doi.org/10.1038/sj.onc.1205304			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971182				2022-12-17	WOS:000174918400004
J	Causevic, M; Hislop, RG; Kernohan, NM; Carey, FA; Kay, RA; Steele, RJC; Fuller-Pace, FV				Causevic, M; Hislop, RG; Kernohan, NM; Carey, FA; Kay, RA; Steele, RJC; Fuller-Pace, FV			Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours	ONCOGENE			English	Article						p68 RNA helicase; colorectal cancer; overexpression; ubiquitylation	UBIQUITIN-PROTEASOME PATHWAY; NUCLEAR-PORE COMPLEX; PROTEIN-DEGRADATION; SUMO-1 MODIFICATION; C-MYC; GENE; P53; COAMPLIFICATION; NEUROBLASTOMA; PROTEOLYSIS	The DEAD box RNA helicase, p68, is upregulated in exponentially growing cells and shows cell cycle-dependent changes in nuclear localization. Although some other DEAD box proteins have been implicated in cancer, there have been no reports of any link between p68 status and carcinogenesis. In the present study we have analysed specimens from 50 patients with colorectal adenocarcinomas, including cases in which an adenomatous polyp was also present, by immunohistochemistry and Western blotting. Our data indicate that p68 protein is consistently overexpressed in tumours as compared with matched normal tissue. Examination of the levels of p68 mRNA from both normal and tumour tissue showed no obvious specific increase in p68 mRNA levels in tumours nor any evidence of underlying mutations in the p68 coding region. Interestingly, however, the accumulated p68 appears to be poly-ubiquitylated, suggesting a possible defect in proteasome-mediated degradation in these tumours. This overexpression/ubiquitylation is observed in both pre-invasive and invasive lesions suggesting that the dysregulation of p68 expression occurs early during tumour development. Finally, we demonstrate that ubiquitylation of p68 occurs in cultured cells, thereby providing a model for the molecular analysis of this process and its potential role in tumorigenesis.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Dent, Dept Cell & Mol Biol, Dundee DD1 4HR, Scotland	University of Dundee; University of Dundee; University of Dundee	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Causevic, Mirsada/AAM-7423-2020	Causevic, Mirsada/0000-0002-6099-6415; Steele, Robert JC/0000-0003-4248-6785				AKAO Y, 1995, CANCER RES, V55, P3444; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Desterro JMP, 2000, CELL MOL LIFE SCI, V57, P1207, DOI 10.1007/PL00000760; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; Gavioli R, 2001, NAT CELL BIOL, V3, P283, DOI 10.1038/35060076; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nakagawa Y, 1999, BRIT J CANCER, V80, P914, DOI 10.1038/sj.bjc.6690441; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; SQUIRE JA, 1995, ONCOGENE, V10, P1417; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Webster GA, 1999, MOL CELL BIOL, V19, P3485	33	116	122	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2001	20	53					7734	7743		10.1038/sj.onc.1204976	http://dx.doi.org/10.1038/sj.onc.1204976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492HE	11753651				2022-12-17	WOS:000172161700004
J	Evans, SC; Viswanathan, M; Grier, JD; Narayana, M; El-Naggar, AK; Lozano, G				Evans, SC; Viswanathan, M; Grier, JD; Narayana, M; El-Naggar, AK; Lozano, G			An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2	ONCOGENE			English	Article						splicing; MDM2; cytoplasmic relocation; tumors	WILD-TYPE P53; MDM2 ONCOGENE OVEREXPRESSION; TUMOR-SUPPRESSOR; CELL-CYCLE; ENHANCED TRANSLATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; FEEDBACK LOOP; GENE; TRANSCRIPTS	The human counterpart hdm2 of the murine double-minute 2 (mdm2) gene encodes a 90-kD protein (HDM2) that inhibits the function of the p53 tumor suppressor, Hdm2 is amplified in approximately 30% of sarcomas, leading to overproduction of HDM2 and inactivation of p53, Using immunohistochemistry to screen a panel of human tumors for HDM2 overproduction, me detected high levels of HDM2 in the cytoplasm in 25% of lung tumors as opposed to its normal localization in the nucleus, These samples contained full-length hdm2 and several alternate-splice forms of hdm2 mRNA, Sequence analysis revealed deletions in the alternate-splice forms of the p53 binding domain and absence of a nuclear localization signal. In transient transfection assays, one of the alternate-splice forms, HDM2(ALT1), bound and sequestered full-length HDM2 in the cytoplasm, In addition, the binding of HDM2(ALT1) to HDM2 inhibited the interaction of HDM2 with p53, thus enhancing p53 transcriptional activity, These data suggest the existence of another level of regulation of HDM2 which increases the activity of p53.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.				NCI NIH HHS [CA34936, CA70907, CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047296, P50CA070907, R29CA047296, P01CA034936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Capoulade C, 1998, ONCOGENE, V16, P1603, DOI 10.1038/sj.onc.1201702; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans SC, 1998, HUM GENET, V102, P681, DOI 10.1007/s004390050761; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Matsumoto R, 1998, CANCER RES, V58, P609; McMasters KM, 1996, ONCOGENE, V13, P1731; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; WATANABE T, 1994, BLOOD, V84, P3158; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	116	121	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					4041	4049		10.1038/sj.onc.1204533	http://dx.doi.org/10.1038/sj.onc.1204533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494132				2022-12-17	WOS:000169681500012
J	Campomenosi, P; Monti, P; Aprile, A; Abbondandolo, A; Frebourg, T; Gold, B; Crook, T; Inga, A; Resnick, MA; Iggo, R; Fronza, G				Campomenosi, P; Monti, P; Aprile, A; Abbondandolo, A; Frebourg, T; Gold, B; Crook, T; Inga, A; Resnick, MA; Iggo, R; Fronza, G			p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements	ONCOGENE			English	Article						p53; yeast functional assay; p53 responsive elements	YEAST FUNCTIONAL ASSAY; CELL-CYCLE ARREST; DNA-BINDING; BREAST-CANCER; MUTATIONS; PROTEIN; APOPTOSIS; TUMORS; TRANSFORMATION; IDENTIFICATION	The human p53 protein acts mainly as a stress inducible transcription factor transactivating several genes involved in cell cycle arrest (e,g, p21) or apoptosis (e,g, Bax, PIG3), Roughly half of all human tumours contains p53 missense mutations. Virtually all tumour-derived p53 mutants are unable to activate Bax transcription but some retain the ability to activate p21 transcription, Identification of these mutants may have valuable clinical implications. We have determined the transactivation ability of 77 p53 mutants using reporter yeast strains containing a p53-regulated ADE2 gene whose promoter is regulated by p53 responsive elements derived from the regulatory region of the p21, BRS and PIG3 genes, We also assessed the influence of temperature on transactivation, Our results indicate that a significant proportion of mutants [16/77 (21%); 10/64 (16%) considering only tumour-derived mutants] are transcriptionally active, especially with the p21 promoter. Discriminant mutants preferentially affect less conserved (P < 0.04, Fisher's exact test), more rarely mutated (P < 0.006, Fisher's exact test) amino acids. Temperature sensitivity is frequently observed, but is more common among discriminant than non-discriminant mutants (P < 0.003, Fisher's exact test), Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours that surprisingly were indistinguishable from wild type in standard transcription, growth suppression and apoptosis assays in human cells, but showed gain of function in transformation assays. The incidence of transcriptionally active mutations among this group was significantly higher than in the panel of mutants studied previously (P < 0.001, Fisher's exact test), Since it is not possible to predict the behaviour of a mutant from first principles, we propose that the yeast assay be used to compile a functional p53 database and fill the gap between the biophysical, pharmacological and clinical fields.	Natl Inst Canc Res, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy; IFRMP, INSERM EP19906, Fac Med & Pharm, F-76183 Rouen, France; Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, Sect Cell Biol & Expt Pathol, London W2 1PG, England; NIEHS, Chromosome Stabil Grp, NIH, Res Triangle Pk, NC 27709 USA; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Nebraska System; University of Nebraska Medical Center; Imperial College London; Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Swiss Institute Experimental Cancer Research	Fronza, G (corresponding author), Natl Inst Canc Res, Mutagenesis Lab, Largo R Benzi 10, I-16132 Genoa, Italy.		Iggo, Richard/G-3546-2014; Inga, Alberto/AAC-3815-2022; Fronza, Gilberto/AAG-8735-2019; resnick, Michael/F-1668-2019; Monti, Paola/Y-1118-2019; Frebourg, Thierry/AAK-8390-2020; Campomenosi, Paola/C-9729-2011	Inga, Alberto/0000-0002-8767-1637; Fronza, Gilberto/0000-0003-3722-553X; resnick, Michael/0000-0002-8473-7506; Monti, Paola/0000-0002-1978-4998; Campomenosi, Paola/0000-0002-8853-1134	NATIONAL CANCER INSTITUTE [R01CA029088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA29088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Campomenosi P, 1997, INT J CANCER, V73, P816, DOI 10.1002/(SICI)1097-0215(19971210)73:6&lt;816::AID-IJC8&gt;3.0.CO;2-5; Chappuis PO, 1999, INT J CANCER, V84, P587, DOI 10.1002/(SICI)1097-0215(19991222)84:6<587::AID-IJC8>3.0.CO;2-8; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Duddy PM, 2000, J MOL DIAGN, V2, P139, DOI 10.1016/S1525-1578(10)60629-0; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812	38	116	122	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3573	3579		10.1038/sj.onc.1204468	http://dx.doi.org/10.1038/sj.onc.1204468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429705				2022-12-17	WOS:000169478300014
J	Belka, C; Schmid, B; Marini, P; Durand, E; Rudner, J; Faltin, H; Bamberg, M; Schulze-Osthoff, K; Budach, W				Belka, C; Schmid, B; Marini, P; Durand, E; Rudner, J; Faltin, H; Bamberg, M; Schulze-Osthoff, K; Budach, W			Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL	ONCOGENE			English	Article						TRAIL; radiation; caspase-8; Bcl-2; apoptosis	RADIATION-INDUCED APOPTOSIS; CYTOCHROME-C; TUMOR-CELLS; EXPRESSION; GENE; CASPASE-8; RECEPTORS; SURVIVAL; RELEASE; FADD	A combination of antitumor approaches acting on different death pathways seems ideal for increasing therapeutic responses, especially when defined resistance mechanisms interfere with individual cellular processes. Apoptosis pathways triggered by ionizing radiation (XRT) and the death ligand TRAIL were analysed in Jurkat lymphoma cells. Both induced the activation of caspase-8, caspase-3, BID and mitochondrial potential loss, TRAIL induced apoptosis required caspase-8, whereas it was not essential for radiation induced apoptosis. The inhibition of mitochondrial damage by Bcl-2 abrogated XRT induced apoptosis and caspase activation, but only marginally attenuated TRAIL induced cell death. The combined treatment with TRAIL and XRT exerted additive apoptotic effects in control cells, whereas highly synergistic effects occurred in cells overexpressing Bcl-2. In addition, a strong effect of TRAIL on radiation induced clonogenic cell death was found. In conclusion, TRAIL seems to be of high potential value for a combination with ionizing radiation in tumor therapy.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Univ Munster, Inst Expt Dermatol, Dept Immunol & Cell Biol, D-48149 Muenster, Germany	Eberhard Karls University of Tubingen; University of Munster	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Rudner, Justine/ABD-1397-2021; Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				ALDRIDGE DR, 1995, BRIT J CANCER, V71, P571, DOI 10.1038/bjc.1995.111; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gong BD, 2000, CANCER RES, V60, P5754; GRECO WR, 1995, PHARMACOL REV, V47, P331; GREEN MHL, 1991, INT J RADIAT BIOL, V59, P749, DOI 10.1080/09553009114550661; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheikh MS, 1998, CANCER RES, V58, P1593; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	29	116	122	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2190	2196		10.1038/sj.onc.1204318	http://dx.doi.org/10.1038/sj.onc.1204318			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360204				2022-12-17	WOS:000168116700015
J	Luo, JL; Yang, Q; Tong, WM; Hergenhahn, M; Wang, ZQ; Hollstein, M				Luo, JL; Yang, Q; Tong, WM; Hergenhahn, M; Wang, ZQ; Hollstein, M			Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool	ONCOGENE			English	Article						p53 mouse model; gene targeting; mutagenesis	TUMOR-SUPPRESSOR GENE; MUTATIONS; RECOMBINATION; APOPTOSIS; THERAPY; PATHWAY; PROTEIN	The high prevalence and great diversity of p53 tumor suppressor gene mutations in human tumors call for development of therapeutic molecules that rescue function of aberrant p53 protein. P53 mutations also offer new approaches to the study of the origins of mutations in human cancer. An experimental mouse model with a genetically modified but normal functioning p53 gene harboring the human rather than the murine core domain, would be of considerable benefit to research on both cancer therapeutics and etiology; however, it is uncertain whether such mice would permit biological functions of p53 to be retained. Using a Cre/lox P gene-targeting approach, we have constructed a human p53 knock-in (hupki) mouse strain in which exons 4-9 of the endogenous mouse p53 allele were replaced with the homologous, normal human p53 gene sequence, The chimeric p53 allele (p53(KI)) is properly spliced, transcribed in various tissues at levels equivalent to wild-type mice, and yields cDNA with the anticipated sequence, that is, with a core domain matching that of humans. The hupki p53 protein binds to p53 consensus sequences in gel mobility shift assays and accumulates in the nucleus of hupki fibroblasts in response to UV irradiation, as is characteristic of wild-type p53, Induction of various p53-regulated genes in spleen of gamma -irradiated homozygous hupki mice (p53(KI/KI)), and the kinetics of p53-dependent apoptosis in thymocytes are similar to results with wild-type (p53(+/+)) mice, further indicating normal p53 pathway function in the hupki strain, The mice are phenotypically normal and do not develop spontaneous tumors at an early age, in contrast to knock-out (p53(-/-)) strains with a defective p53 gene. The chimeric (p53(KI)) allele thus appears to provide a biological equivalent to the endogenous murine (p53(+)) gene. This strain is a unique tool for examining in vivo spontaneous and induced mutations in human p53 gene sequences for comparison with published human tumor p53 mutation spectra, In addition, the hupki strain paves the way for mouse models in pre-clinical testing of pharmaceuticals designed to modulate DNA-binding activity of human p53.	Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Genet Alterat Carcinogenesis C0700, D-69120 Heidelberg, Germany; Int Agcy Res Canc, Unit Gene Environm Interact, F-69008 Lyon, France	Helmholtz Association; German Cancer Research Center (DKFZ); World Health Organization; International Agency for Research on Cancer (IARC)	Hollstein, M (corresponding author), Deutsch Krebsforschungszentrum, German Canc Res Ctr, Dept Genet Alterat Carcinogenesis C0700, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.				NCI NIH HHS [R01CA79493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BAKER SJ, 1990, CANCER RES, V50, P7717; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Hainaut P, 2000, ADV CANCER RES, V77, P81; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hollstein M, 1998, MUTAT RES-FUND MOL M, V405, P145, DOI 10.1016/S0027-5107(98)00131-6; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HURSTING SD, 1995, CANCER RES, V55, P3949; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kleihues P, 1997, AM J PATHOL, V150, P1; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lane DP, 1996, ONCOGENE, V12, P2461; Lane DP, 1999, BRIT J CANCER, V80, P1; LEHMAN TA, 1991, CANCER RES, V51, P4090; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shamsher M, 1996, GENE, V176, P259, DOI 10.1016/0378-1119(96)00000-5; USHIJIMA T, 1995, MOL CARCINOGEN, V12, P23, DOI 10.1002/mc.2940120105; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang ZQ, 2000, CANCER RES, V60, P901; Zhao RB, 2000, GENE DEV, V14, P981	38	116	124	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					320	328		10.1038/sj.onc.1204080	http://dx.doi.org/10.1038/sj.onc.1204080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313961				2022-12-17	WOS:000166411000006
J	Shao, J; Fujiwara, T; Kadowaki, Y; Fukazawa, T; Waku, T; Itoshima, T; Yamatsuji, T; Nishizaki, M; Roth, JA; Tanaka, N				Shao, J; Fujiwara, T; Kadowaki, Y; Fukazawa, T; Waku, T; Itoshima, T; Yamatsuji, T; Nishizaki, M; Roth, JA; Tanaka, N			Overexpression of the wild-type p53 gene inhibits NF-kappa B activity and synergizes with aspirin to induce apoptosis in human colon cancer cells	ONCOGENE			English	Article						adenovirus vector; p53; NF-kappa B; aspirin; colon cancer	TUMOR-NECROSIS-FACTOR; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; SODIUM-SALICYLATE; EXPRESSION; ALPHA; IMMUNOSUPPRESSION; GLUCOCORTICOIDS; RESISTANCE; PROTEINS	The tumor suppressor gene p53 is a potent transcriptional regulator of genes which are involved in many cellular activities including cell cycle arrest, apoptosis, and angiogenesis, Recent studies have demonstrated that the activation of the transcriptional factor nuclear factor kappa B (NF-kappa B) plays an essential role in preventing apoptotic cell death. In this study, to better understand the mechanism reponsible for the p53-mediated apoptosis, the effect of wild-type p53 (wt-p53) gene transfer on nuclear expression of NF-kappa B was determined in human colon cancer cell lines, A Western blot analysis of nuclear extracts demonstrated that NF-kappa B protein levels in the nuclei were suppressed by the transient expression of the wt-p53 in a dose-dependent manner. Transduced wt-p53 expression increased the cytoplasmic expression of I kappa B alpha as well as its binding ability to NF-kappa B, thus markedly reducing the amount of NF-kappa B that translocated to the nucleus, The decrease in nuclear NF-kappa B protein correlated with the decreased NF-kappa B constitutive activity measured by electrophoretic mobility shift assay. Furthermore, parental cells transfected with NF-kappa B were better protected from cell death induced by the wt-p53 gene transfer. We also found that the wt-p53 gene transfer was synergistic with aspirin (acetylsalicylic acid) in inhibiting NF-kappa B constitutive activity, resulting in enhanced apoptotic cell death. These results suggest that the inhibition of NF-kappa B activity is a plausible mechanism for apoptosis induced by the wt-p53 gene transfer in human colon cancer cells and that anti-NF-kappa B reagent aspirin could make these cells more susceptible to apoptosis.	Okayama Univ, Sch Med, Dept Surg 1, Okayama 7008558, Japan; Okayama Univ, Sch Med, Sect Mol Oncol, Okayama 7008558, Japan; Shiga Univ Med Sci, Dept Surg 1, Shiga 5202192, Japan; Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	Okayama University; Okayama University; Shiga University of Medical Science; University of Texas System; UTMD Anderson Cancer Center	Fujiwara, T (corresponding author), Okayama Univ, Sch Med, Dept Surg 1, 2-5-1 Shikata Cho, Okayama 7008558, Japan.		Fukazawa, Takuya/GLR-7099-2022					AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Bellas RE, 1997, AM J PATHOL, V151, P891; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; FUJIWARA T, 1994, CANCER RES, V54, P2287; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; INSEL PA, 1990, PHARMACOL BASIS THER, P638; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kochetkova M, 1997, J CLIN INVEST, V99, P3000, DOI 10.1172/JCI119495; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ogawa N, 1997, INT J CANCER, V73, P367, DOI 10.1002/(SICI)1097-0215(19971104)73:3<367::AID-IJC11>3.0.CO;2-A; Ravi R, 1998, CANCER RES, V58, P4531; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shiff SJ, 1997, GASTROENTEROLOGY, V113, P1992, DOI 10.1016/S0016-5085(97)99999-6; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374	38	116	121	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					726	736		10.1038/sj.onc.1203383	http://dx.doi.org/10.1038/sj.onc.1203383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698490				2022-12-17	WOS:000085192100002
J	Theodosiou, A; Smith, A; Gillieron, C; Arkinstall, S; Ashworth, A				Theodosiou, A; Smith, A; Gillieron, C; Arkinstall, S; Ashworth, A			MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases	ONCOGENE			English	Article						dual-specificity phosphatase; JNK/SAPK beta; p38 MAP kinase	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; CHROMOSOMAL LOCALIZATION; IN-VIVO; INFLAMMATORY CYTOKINES; GENOMIC ORGANIZATION; MAMMALIAN-CELLS; HEAT-SHOCK; EXPRESSION	Dual-specificity protein tyrosine phosphatases are a burgeoning family of enzymes, some of which, the MKPs, are implicated in the regulation of mitogen-activated protein (MAP) kinases. MKPs have been shown to reverse the activation of the MAP kinases by hydrolyzing phosphothreonine and phosphotyrosine residues present in the substrates. Here we describe the characterization of a novel member of the MKP family, MKP5. The MKP5 gene, which maps to human chromosome lq32, is expressed tissue-specifically as two transcripts of approximately 3.4 and 2.4kb in human liver and skeletal muscle. When expressed in mammalian cells, MKP5 blocks the enzymatic activation of MAP kinases with the selectivity p38 approximate to JNK/SAPK>>ERK. Immunoprecipitation of endogenous MAP kinases by the catalytically inactive transfected MKP5 demonstrates that it preferentially binds to the p38 and JNK/SAPK kinases. These findings suggest that the selectivity of this phosphatase may be determined at least in part at the level of substrate binding.	Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, London SW3 6JB, England; Serona Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Gene Funct & Regulat, 237 Fulham Rd, London SW3 6JB, England.							Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Benitez J, 1997, CANCER RES, V57, P4217; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Loda M, 1996, AM J PATHOL, V149, P1553; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martell KJ, 1998, MOL CELLS, V8, P2; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nesbit MA, 1997, GENOMICS, V42, P284, DOI 10.1006/geno.1997.4737; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Smith A, 1997, GENOMICS, V42, P524, DOI 10.1006/geno.1997.4756; Steiner G, 1996, CANCER RES, V56, P5044; SUHAI S, 1994, COMPUTATIONAL METHOD; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YI HF, 1995, GENOMICS, V28, P92, DOI 10.1006/geno.1995.1110; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547	58	116	126	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					6981	6988		10.1038/sj.onc.1203185	http://dx.doi.org/10.1038/sj.onc.1203185			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597297				2022-12-17	WOS:000083901900003
J	Kirch, HC; Flaswinkel, S; Rumpf, H; Brockmann, D; Esche, H				Kirch, HC; Flaswinkel, S; Rumpf, H; Brockmann, D; Esche, H			Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappa B and Myc/Max	ONCOGENE			English	Article						p53; promoter; transcription; AP-1; NF-kappa B; Myc/Max	HUMAN HEPATOCELLULAR-CARCINOMA; INDUCIBLE ENHANCER ELEMENTS; CYCLE CHECKPOINT PATHWAY; TUMOR-SUPPRESSOR GENE; NECROSIS-FACTOR-ALPHA; HELIX-LOOP-HELIX; WILD-TYPE P53; BINDING PROTEIN; CANCER-CELLS; DNA-BINDING	Transcriptional control of p53 expression participates in the generation of appropriate le, els of active p53 in response to mitogenic stimulation, This prompted us to study the role of a putative AP-1 and a NF-kappa B motif in the human p53 promoter for transcriptional regulation, We show that mutation of the AP-1 or the NF-kappa B motif abolishes transcription from the human p53 promoter in HeLa, HepG2 and adenovirus type 5 E1-transformed 293 cells, In comparison, mutation of the previously characterized Myc/Max/USF binding site in the human p53 promoter reduces the transcription rate fivefold. The AP-1 motif in the human p53 promoter binds c-Fos and c-Jun and the NF-kappa-B motif binds p50(NF-kappa B1) and p65(RelA). The cooperative nature of transcriptional activation by these factors was documented by repression of c-fos or NF-kappa B1 translation: Pretreatment of the cells,vith a c-fos or p50(NF-kappa B1) antisense oligonucleotide suppresses transcription from the human p53 promoter completely. In addition, we show that (a) the level of endogenous p53 mRNA and (b) transcription from the strictly p53-dependent human mdm2 promoter are reduced in the presence of c-fos, c-jun, p50(NF-kappa B1), p65(RelA) or c-myc antisense oligonucleotides, underscoring the importance of these transcription factors for the expression of functional p53.	Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, D-45122 Essen, Germany	University of Duisburg Essen	Kirch, HC (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Mol Biol Canc Res, Hufelandstr 55, D-45122 Essen, Germany.							ALAM J, 1990, ANAL BIOCHEM, V188, P254; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Balint E, 1996, CANCER RES, V56, P1648; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BRACH MA, 1993, MOL CELL BIOL, V13, P4284, DOI 10.1128/MCB.13.7.4284; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brockmann D, 1996, ONCOGENE, V12, P1715; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FARSHID M, 1992, J MED VIROL, V38, P235, DOI 10.1002/jmv.1890380402; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hagmeyer BM, 1996, ONCOGENE, V12, P1025; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARELBELLAN A, 1988, J IMMUNOL, V140, P2431; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Jiang SS, 1996, CHINESE PHYS LETT, V13, P9, DOI 10.1088/0256-307X/13/1/003; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIRCH HC, 1993, CELL MOL BIOL RES, V39, P705; Kirch HC, 1997, EUR J BIOCHEM, V246, P736, DOI 10.1111/j.1432-1033.1997.00736.x; Kralova J, 1996, ONCOGENE, V12, P2595; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANZA F, 1995, BRIT J HAEMATOL, V90, P8, DOI 10.1111/j.1365-2141.1995.tb03374.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Roy B, 1996, ONCOGENE, V13, P2359; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; SOKOLOSKI JA, 1993, BLOOD, V82, P625; SONOBE MH, 1995, ONCOGENE, V10, P689; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN XG, 1995, MOL CELL BIOL, V15, P4489; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WU HY, 1994, J BIOL CHEM, V269, P20067; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZOIDL G, 1993, GENE, V131, P269, DOI 10.1016/0378-1119(93)90305-M	69	116	118	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2728	2738		10.1038/sj.onc.1202626	http://dx.doi.org/10.1038/sj.onc.1202626			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348347				2022-12-17	WOS:000080124900008
J	Kishida, M; Koyama, S; Kishida, S; Matsubara, K; Nakashima, S; Higano, K; Takada, R; Takada, S; Kikuchi, A				Kishida, M; Koyama, S; Kishida, S; Matsubara, K; Nakashima, S; Higano, K; Takada, R; Takada, S; Kikuchi, A			Axin prevents Wnt-3a-induced accumulation of beta-catenin	ONCOGENE			English	Article						Axin; Wnt; beta-catenin; APC; GSK-3 beta	GLYCOGEN-SYNTHASE KINASE-3; MOUSE FUSED LOCUS; INT-1 PROTOONCOGENE; SIGNALING PATHWAY; XENOPUS EMBRYOS; MAMMALIAN-CELLS; WNT GENES; PROTEIN; COMPLEX; APC	When Axin, a negative regulator of the Wnt signaling pathway, was expressed in COS cells, it coeluted with glycogen synthase kinase-3 beta (GSK-3 beta), beta-catenin, and adenomatous polyposis coli protein (APC) in a high molecular weight fraction on gel filtration column chromatography. In this fraction, GSK-3 beta, beta-catenin, and APC were co-precipitated with Axin. Although beta-catenin was detected in the high molecular weight fraction in L cells on gel filtration column chromatography, addition of conditioned medium expressing Wnt-3a to the cells increased beta-catenin in the low molecular weight fraction. However, Wnt-3a-dependent accumulation of beta-catenin was greatly inhibited in L cells stably expressing Axin, Axin also suppressed Wnt-3a-dependent activation of Tcf-4 which binds to beta-catenin and acts as a transcription factor. These results suggest that Axin forms a complex with GSK-3 beta, beta-catenin, and APC, resulting in the stimulation of the degradation of beta-catenin and that Wnt-3a induces the dissociation of beta-catenin from the Axin complex and accumulates beta-catenin.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Hiroshima University; Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.			kishida, shosei/0000-0003-0405-851X; Takada, Shinji/0000-0003-4125-6056; Takada, Ritsuko/0000-0002-1615-056X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; JACOBSCOHEN RJ, 1984, GENET RES, V43, P43, DOI 10.1017/S0016672300025702; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PARR BA, 1993, DEVELOPMENT, V119, P247; PERRY WL, 1995, GENETICS, V141, P321; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Reed SC, 1937, GENETICS, V22, P1; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SHIBAMOTO S, 1999, IN PRESS GENES CELLS; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YOST C, 1996, GENE DEV, V10, P143; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	47	116	120	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					979	985		10.1038/sj.onc.1202388	http://dx.doi.org/10.1038/sj.onc.1202388			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023673				2022-12-17	WOS:000078510600014
J	Davies, JM; Hawe, N; Kabarowski, J; Huang, QH; Zhu, J; Brand, NJ; Leprince, D; Dhordain, P; Cook, M; Morriss-Kay, G; Zelent, A				Davies, JM; Hawe, N; Kabarowski, J; Huang, QH; Zhu, J; Brand, NJ; Leprince, D; Dhordain, P; Cook, M; Morriss-Kay, G; Zelent, A			Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene	ONCOGENE			English	Article						transcription factor; development; limb; lymphoma; dimerization	ACUTE PROMYELOCYTIC LEUKEMIA; ACID RECEPTOR-ALPHA; B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; TRANSCRIPTIONAL REPRESSION; LAZ3/BCL6 ONCOPROTEIN; MYELOGENOUS LEUKEMIA; 3Q27 TRANSLOCATION; INTERACTION MOTIF; GENE-EXPRESSION	BTB/POZ-domain C2H2 zinc(Zn)-finger proteins are encoded by a subfamily of genes related to the Drosophila gap gene kruppel. To date, two such proteins, PLZF and LAZ-3/BCL-6, have been implicated in oncogenesis. We have now identified a new member of this gent subfamily which encodes a 62 kDa Zn-finger protein, termed LRF, with a BTB/POZ domain highly similar to that of PLZF, Both human and mouse LRF genes, which localized to syntenic chromosomal regions (19p13.3 and 10B5.3, respectively), were widely expressed in adult tissues and cell lines. At approximately 9.5-10.0 days of embryonic development, the mouse LRF gene was expressed in the limb buds, pharyngeal arches, tail bud, placenta and neural tube. The LRF protein associated in vivo with LAZ-3/BCL-6, but not with PLZF to which it was more related. Although the LRF, or LAZ-3/BCL-6, BTB/POZ domain could readily homodimerize, no heterodimerization was detected in vivo between the LRF and LAZ-3/BCL-6 BTB/POZ domains and interaction between full length LRF and LAZ-3/BCL-6 required the presence of both the BTB/POZ domain and Zn-fingers in each partner protein. As expected from the above results, LRF and LAZ-3/BCL-6 also colocalized with each other in the nucleus. Taken together, our findings suggest that BTB/POZ-domain Zn-finger proteins may function as homo and heterodimeric complexes whose formation, and hence the resultant effect on transcription of their downstream target genes, is determined by the levels and expression domains of a given partner protein.	Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Natl Heart & Lung Inst, Imperial Coll, Sch Med, London SW3 6LY, England; Inst Rech Canc Lille, U124 INSERM, F-59045 Lille, France; Univ Oxford, Dept Human Anat, Oxford OX1 3QX, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oxford	Zelent, A (corresponding author), Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.		Zelent, Arthur/B-3532-2009	Leprince, Dominique/0000-0002-1999-0775; O'Connor, Nicola/0000-0003-1981-3055; Zelent, Arthur/0000-0002-7968-9888	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Bartel PL, 1993, CELLULAR INTERACTION, P153; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN SJ, 1992, ONCOGENE, V7, P1223; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN W, 1995, MOL CELL BIOL, V15, P3424; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5299; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; CONSTANTINOUDELTAS CD, 1992, GENOMICS, V12, P581, DOI 10.1016/0888-7543(92)90451-W; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1995, ONCOGENE, V11, P2689; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; FRIEND C, 1965, NATL CANC I MONO, V22, P505; FUKUDA T, 1995, ONCOGENE, V11, P1657; GALERA P, 1994, P NATL ACAD SCI USA, V91, P9372, DOI 10.1073/pnas.91.20.9372; Gietz R.D., 1994, MOL GENETICS YEAST P, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GODT D, 1993, DEVELOPMENT, V119, P799; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GREENBERGER JS, 1983, CELL BIOL, V60, P2931; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; HARPER JW, 1993, CELL, V75, P805; Hawe N, 1996, BLOOD, V88, P1151; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEIM S, 1987, CANC CYTOGNETICS; Heyworth CM, 1990, GROWTH FACTORS, V2, P197, DOI 10.3109/08977199009071506; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HU S, 1995, GENE DEV, V9, P2936, DOI 10.1101/gad.9.23.2936; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Johnston J.R., 1994, MOL GENETICS YEAST P; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Karin M, 1990, CURR OPIN CELL BIOL, V2, P996, DOI 10.1016/0955-0674(90)90148-8; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KLEIN E, 1968, CANCER RES, V28, P1300; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MINOWADA J, 1978, J NATL CANCER I, V60, P1269, DOI 10.1093/jnci/60.6.1269; MITELMAN F, 1991, CATALOG CHROMOSOME A; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; ONIZUKA T, 1995, BLOOD, V86, P25; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945; RALPH P, 1977, CANCER RES, V37, P546; RALPH P, 1973, J NATL CANCER I, V31, P883; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Sambrook J, 1989, MOL CLONING LAB MANU; Seyfert VL, 1996, ONCOGENE, V12, P2331; SHAKNOVICH R, 1998, IN PRESS MOL CELL BI; Shi YP, 1997, GENOMICS, V45, P42, DOI 10.1006/geno.1997.4904; SHIRASUNA K, 1981, CANCER, V48, P745, DOI 10.1002/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEIMA SM, 1988, DIFFERENTIATION, V38, P203, DOI 10.1111/j.1432-0436.1988.tb00214.x; WEISS A, 1984, J IMMUNOL, V133, P1; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZELENT A, 1997, METHOD MOL BIOL, V89, P307; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	92	116	132	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					365	375		10.1038/sj.onc.1202332	http://dx.doi.org/10.1038/sj.onc.1202332			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927193				2022-12-17	WOS:000078166500009
J	Lee, KK; Murakawa, M; Nishida, E; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S				Lee, KK; Murakawa, M; Nishida, E; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S			Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis	ONCOGENE			English	Article						Fas (Apo-1/CD95); apoptosis; caspase; protein kinase; signal transduction	TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; MONOCLONAL-ANTIBODY; FAS; PROTEASES; CLONING; DOMAIN; INTERACTS; CONTAINS; RECEPTOR	The Fas system has been extensively investigated as a model of apoptosis and the caspase cascade has been shown to be a characteristic mechanism of signaling of apoptosis. We have identified and purified a kinase that was activated after the stimulation of Fas on human thymoma-derived HPB-ALL cells. Partial amino acid sequencing of the purified kinase revealed it to be MST/ Krs, member of the yeast STE20 family of protein kinases. MST/Krs was activated by proteolytic cleavage and proteolytic activation was blocked by the caspase inhibitor, Z-VAD-FK. A mutant MST with Asp-->Asn replacement at a putative caspase cleavage site was resistant to either the proteolytic cleavage or the activation of the kinase activity. These findings suggest that proteolytic activation is one activation mechanism of MST and plays a role in apoptosis.	Kyoto Univ, Inst Virus Res, Kyoto 60601, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 60601, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science; Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 60601, Japan.			Sakamaki, Kazuhiro/0000-0002-7072-9628				Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; CASCIOLA RL, 1995, J EXP MED, V12, P1625; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	35	116	119	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					3029	3037		10.1038/sj.onc.1201840	http://dx.doi.org/10.1038/sj.onc.1201840			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662336				2022-12-17	WOS:000074125300010
J	Zhou, XP; Hoang, JM; Cottu, P; Thomas, G; Hamelin, R				Zhou, XP; Hoang, JM; Cottu, P; Thomas, G; Hamelin, R			Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors	ONCOGENE			English	Article						colon cancer; replication error; microsatellites; mononucleotide repeats	II RECEPTOR GENE; INSTABILITY; CANCER; MUTATIONS; SEQUENCES; COLON; CELLS	We have recently shown that analysis of BAT-26, was sufficient to establish the Replication Error status of colorectal tumors and cell lines without the need for matching normal DNA, BAT-26, a poly(A) tract in the 5th intron of the hMSH2 gene, does not present significant size variation either between the allleles of one individual or between alleles of different individuals, In colorectal tumors without defects in the replication error system (RER- phenotype), BAT-26 is also quasi-monomorphic, On the contrary, in RER+ colorectal tumors, BAT-26 shows unstable shortened alleles, In order to see whether this behaviour was specific for BAT-26, or was a more general phenomenon for mononucleotide repeat microsatellites, we analysed eight other mononucleotide repeats, In control individuals (72 samples) and in RER- colorectal tumors and cell lines (55 samples), these microsatellites were polymorphic, dimorphic, quasi-monomorphic or monomorphic, indicating that the quasi-monomorphic nature of BAT-26 was not a general rule, All of them showed a tendency to be shorter in RER+ colorectal tumors and cell lines (19 samples), but only quasi-monomorphic and monomorphic mononucleotide repeats could be used to determine the RER status of tumors without matching normal DNA, although with a lower efficiency than BAT-26 due to either a smaller range of shortening in RER+ tumors or to a larger number of false negative cases.	INST CURIE,INSERM,U434,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Cottu, Paul/ABC-8595-2020					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; CHEN JS, 1995, CANCER RES, V55, P174; Cottu PH, 1996, ONCOGENE, V13, P2727; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KOLODNER RD, 1995, CANCER RES, V55, P242; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LEFRANCOIS D, 1989, INT J CANCER, V44, P871, DOI 10.1002/ijc.2910440521; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LIU B, 1994, CANCER RES, V54, P4590; MALHOSYAN S, 1996, NATURE, V382, P499; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1995, GENOMICS, V30, P195, DOI 10.1006/geno.1995.9885; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122	20	116	130	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1713	1718		10.1038/sj.onc.1201337	http://dx.doi.org/10.1038/sj.onc.1201337			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349505				2022-12-17	WOS:A1997XY63100011
J	Watanabe, Y; Lee, SW; Detmar, M; Ajioka, I; Dvorak, HF				Watanabe, Y; Lee, SW; Detmar, M; Ajioka, I; Dvorak, HF			Vascular permeability factor vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells	ONCOGENE			English	Article						VPF/VEGF; senescence; cell cycle; endothelial cells	CYCLIN-DEPENDENT KINASES; DNA-BINDING FUNCTION; HUMAN-FIBROBLASTS; CELLULAR SENESCENCE; MUTANT P53; EXPRESSION; TUMOR; INTERLEUKIN-1-ALPHA; INHIBITOR; INVITRO	Like most other normal cells, human endothelial cells possess a limited replicative life span, and, after multiple passages in vitro, develop an arrest in cell division referred to as replicative senescence, For many cell types senescence can be delayed by oncogenes or tumor suppressor genes or prevented altogether by malignant transformation; however, once developed, senescence has been regarded as irreversible, We now report that a cytokine, vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), significantly delays senescence in human dermal microvascular endothelial cells (HDMEC). Typically, VPF/VEGF-treated HDMEC could be cultured for at least 15-20 more population doublings (PD) than control cells, Protection from senescence was reversible in that subsequent withdrawal of VPF/VEGF returned cells to the senescent phenotype, Expression of several cell cycle-related genes (p21, p16 and p27) was significantly reduced in VPF/VEGF-treated cells but p53 expression was not significantly altered, Of particular importance, VPF/VEGF was able to rescue senescent HDMEC, restoring them to proliferation, to a more normal morphology, and to reduced expression of a senescence marker, neutral beta-galactosidase, Taken together, VPF/VEGF delayed the onset of senescence and also reversed senescence in microvascular endothelial cells without inducing cell transformation.	BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT PATHOL,DIV GERONTOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; TOKYO INST TECHNOL,DEPT BIOMOL ENGN,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Tokyo Institute of Technology					NCI NIH HHS [CA-58845, CA-50453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058845, R01CA050453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; COMI P, 1995, EXP CELL RES, V219, P304, DOI 10.1006/excr.1995.1232; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DETMAR M, 1990, J INVEST DERMATOL, V95, pS219, DOI 10.1111/1523-1747.ep12875807; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENGERMAN RL, 1967, LAB INVEST, V17, P738; GARFINKEL S, 1994, P NATL ACAD SCI USA, V91, P1559, DOI 10.1073/pnas.91.4.1559; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1993, CELL, V75, P805; HITRAYA EG, 1995, LAB INVEST, V73, P393; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IMCKE E, 1991, ARCH DERMATOL RES, V283, P149, DOI 10.1007/BF00372054; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIRKLAND JL, 1992, CLIN BIOCHEM, V25, P61, DOI 10.1016/0009-9120(92)80047-K; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RUSZCZAK Z, 1990, J INVEST DERMATOL, V95, P693, DOI 10.1111/1523-1747.ep12514496; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; TAHARA H, 1995, ONCOGENE, V10, P835; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto Y, 1996, CLIN CANCER RES, V2, P821; YEO KT, 1993, CANCER RES, V53, P2912; Zar J., 1994, BIOSTATISTICAL ANAL	46	116	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2025	2032		10.1038/sj.onc.1201033	http://dx.doi.org/10.1038/sj.onc.1201033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160882				2022-12-17	WOS:A1997WW80900004
J	Jiang, Z; Zacksenhaus, E; Gallie, BL; Phillips, RA				Jiang, Z; Zacksenhaus, E; Gallie, BL; Phillips, RA			The retinoblastoma gene family is differentially expressed during embryogenesis	ONCOGENE			English	Article						tumor suppressor genes; pRb; mouse development; in situ hybridization	MOLECULAR-CLONING; CHIMERIC MICE; PROTEIN; MOUSE; CYCLINS; MUTATION; RESCUE; CELLS; P107	We report differential expression of the RBI tumor suppressor gene and the homologous genes p107 and p130 during embryogenesis. Abundant RBI transcripts were detected during neurogenesis, hematopoiesis, myogenesis, lens development and in the ganglion cell layer of the embryonic retina, prior to and during differentiation, The expression pattern of RBI mirrored the defects in RBI mutant mice (RB-/-), In the heart, lung, kidney and intestine, p107, but not RBI, was expressed, In the liver and the central nervous system p107 and RBI were co-expressed, consistent with the accelerated cell death observed in RB-/-; p107(-/-) double knock-out mice, In the central nervous system, p107 expression was restricted to proliferating cells surrounding the ventricles, while RBI was expressed in areas of both proliferating and differentiating cells, In contrast to RBI and p107, expression of p130 was low throughout embryogenesis. In situ hybridization and Western blot analyses showed that the expression of p107 and p130 was not markedly altered in RB-/- embryos compared to control litter-mates, Our results suggest that members of RBI gene family have distinct, but overlapping roles in embryogenesis, with p107 and RBI possibly having redundant functions in the central nervous system and liver.	UNIV TORONTO,HOSP SICK CHILDREN,DEPT MOL & MED GENET,RES INST,DIV IMMUNOL & CANC RES,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DIV HEMATOL & ONCOL,ONCOL RES LABS,BREAST CANC PREVENT PROGRAM,TORONTO,ON M5G 2M1,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Zacksenhaus, Eldad/AAD-3584-2020	Gallie, Brenda/0000-0002-9697-9211				BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	30	116	123	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1789	1797		10.1038/sj.onc.1201014	http://dx.doi.org/10.1038/sj.onc.1201014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150384				2022-12-17	WOS:A1997WW16600004
J	THOMPSON, TC; PARK, SH; TIMME, TL; REN, C; EASTHAM, JA; DONEHOWER, LA; BRADLEY, A; KADMON, D; YANG, G				THOMPSON, TC; PARK, SH; TIMME, TL; REN, C; EASTHAM, JA; DONEHOWER, LA; BRADLEY, A; KADMON, D; YANG, G			LOSS OF P53 FUNCTION LEADS TO METASTASIS IN RAS+MYC-INITIATED MOUSE PROSTATE-CANCER	ONCOGENE			English	Article						P53; METASTASES; PROSTATE CANCER	MESSENGER-RNA LEVELS; WILD-TYPE P53; MOUSE PROSTATE; SV40-TRANSFORMED CELLS; CARCINOMA-CELLS; GENE MUTATION; GROWTH; CANCER; ONCOGENES; MYC	To study the interactions between dominantly acting oncogenes and tumor suppressor genes we used p53 'knockout' mouse urogenital sinus tissue for retroviral transduction of ras and myc in the mouse prostate reconstitution (MPR) model system. Epithelial hyperplasia was observed in all wild-type p53 MPRs with one small focal cancer and no evidence of metastasis. Prostatic cancer was found in 100% of the heterozygous and homozygous p53 mutant MPRs with metastatic deposits in 95% of the mice. The pattern of metastasis was remarkably similar to that in human prostate cancer with gross metastatic deposits in the lung, lymph nodes, bone and liver of many animals. Progression of carcinomas in the ras+myc-initiated heterozygous p53 mutant MPRs was invariably associated with either complete loss, partial deletion or loss of expression of the wild-type p53 allele. Southern blotting analysis of proviral-cellular DNA junction fragments in primary carcinomas and cell lines derived from metastatic deposits revealed that metastases do not necessarily seed out from the most abundant clone in the primary carcinoma.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT RADIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	THOMPSON, TC (corresponding author), BAYLOR COLL MED,DEPT UROL,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839	NCI NIH HHS [P50-CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BODNER SM, 1992, ONCOGENE, V7, P743; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EGAWA S, 1992, MOL CARCINOGEN, V5, P52, DOI 10.1002/mc.2940050110; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREENE DR, 1994, J UROLOGY, V151, P1301, DOI 10.1016/S0022-5347(17)35236-9; GREENE DR, 1991, CANCER RES, V51, P4084; Hart I R, 1982, Cancer Metastasis Rev, V1, P5, DOI 10.1007/BF00049477; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERBEL RS, 1988, CANCER SURV, V7, P597; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T, 1989, DECONTAMINATION DILU; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERZ VW, 1991, MOL ENDOCRINOL, V5, P503, DOI 10.1210/mend-5-4-503; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; PURDIE CA, 1994, ONCOGENE, V9, P603; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAWIN K, 1993, CANCER RES, V53, P4461; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Steeg P S, 1991, Semin Cancer Biol, V2, P105; TAYLOR WR, 1992, ONCOGENE, V7, P1383; THOMPSON TC, 1990, CANCER CELL-MON REV, V2, P345; THOMPSON TC, 1993, MOL CARCINOGEN, V7, P165, DOI 10.1002/mc.2940070307; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TIMME TL, 1994, BIOTECHNIQUES, V17, P460; VAN MEIR EG, 1994, CANCER RES, V54, P649; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	58	116	122	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					869	879						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7534899				2022-12-17	WOS:A1995QL03800008
J	KITAGAWA, M; HIGASHI, H; SUZUKITAKAHASHI, I; SEGAWA, K; HANKS, SK; TAYA, Y; NISHIMURA, S; OKUYAMA, A				KITAGAWA, M; HIGASHI, H; SUZUKITAKAHASHI, I; SEGAWA, K; HANKS, SK; TAYA, Y; NISHIMURA, S; OKUYAMA, A			PHOSPHORYLATION OF E2F-1 BY CYCLIN A-CDK2	ONCOGENE			English	Article						E2F; CYCLIN DEPENDENT KINASE; CELL CYCLE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; BINDING PROTEIN; CDC2 KINASE; DEPENDENT REGULATION; SUSCEPTIBILITY GENE; RB PROTEIN; S-PHASE; CDK2	Transcription factor E2F-1 has a putative consensus sequence for phosphorylation by cyclin dependent kinase (Ser-Pro-X-Lys/Arg). Therefore, we studied the phosphorylation of E2F-1 in vivo and in vitro and its biological functions. E2F-1 was prepared by immunoprecipitation with anti-E2F-1 antibody from IMR32 lysates and was effectively phosphorylated by human cyclin A-cdk2 which was expressed in insect cells using baculovirus system. GST-EZF-1 was phosphorylated by cyclin A-cdk2 more efficiently than by cyclin E-cdk2. Cyclin D1-cdk4 phosphorylated PRE but scarcely phosphorylated GST-E2F-1 or H1 histone. The 60 kd protein precipitated with anti-E2F-1 antibody was phosphorylated in vivo. Phospho-peptide mapping indicated that its cleavage profile was identical with that of E2F-1 phosphorylated by cyclin A-cdk2 in vitro. This 60 kd protein, which is likely to be E2F-1, was not phosphorylated during the GO and early G1 phase, Phosphorylation of E2F-1 began from the S phase while phosphorylation of pRB started nearly at G1/S. The in vivo phosphorylation of E2F-1 was inhibited by butyrolactone I, a cyclin-dependent kinase inhibitor (Kitagawa et al., 1993, Oncogene, 8, 2425-2432). The binding of E2F-1 to E2 promoter was found to be reduced by phosphorylation of E2F-1 by cyclin A-cdk2, suggesting that phosphorylation of E2F-1 may induce shut off of gene expression at the transcriptional level. These results suggest that E2F-1 is phosphorylated by cyclin A-cdkZ in the S phase in vivo as well as in vitro and that its phosphorylation by cyclin A-cdkZ may modulate its activity.	KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJYUKU KU,TOKYO 160,JAPAN; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Keio University; Vanderbilt University; National Cancer Center - Japan	KITAGAWA, M (corresponding author), MERCK RES LABS,BANYU TSUKUBA RES INST COLLABORAT,OKUBO 3,TSUKUBA,IBARAKI 30033,JAPAN.		Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V66, P1217; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; GIRARD F, 1993, CELL, V67, P1169; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUBER HE, 1993, P NATL ACAD SCI USA, V99, P3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORI N, 1990, ONCOGENE, V5, P1713; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARTRIDGE JF, 1991, EMBO J, V10, P3819, DOI 10.1002/j.1460-2075.1991.tb04951.x; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171	53	116	119	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					229	236						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838523				2022-12-17	WOS:A1995QC62400002
J	KITAGAWA, M; HIGASHI, H; TAKAHASHI, IS; OKABE, T; OGINO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A				KITAGAWA, M; HIGASHI, H; TAKAHASHI, IS; OKABE, T; OGINO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A			A CYCLIN-DEPENDENT KINASE INHIBITOR, BUTYROLACTONE-I, INHIBITS PHOSPHORYLATION OF RB PROTEIN AND CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							MATURATION-PROMOTING FACTOR; RETINOBLASTOMA-SUSCEPTIBILITY GENE; FISSION YEAST; CDC2 KINASE; MAMMALIAN FIBROBLASTS; TRANSCRIPTION FACTOR; DNA-REPLICATION; PRODUCT; PHASE; CDK2	Butyrolactone I is a selective inhibitor of the cyclin-dependent kinase (cdk) family. It inhibits both cdk2 and cdc2 kinase, but scarcely affects C-kinase, A-kinase, casein kinases, MAP kinase or EGF receptor-tyrosine kinase (Kitagawa et al., 1993, Oncogene, 8, 2425-2432). We studied the effects of butyrolactone I on the cell cycle as well as on phosphorylation of retinoblastoma protein (pRB). Butyrolactone I inhibited phosphorylation of pRB catalyzed by cyclin A-cdk2 produced by baculovirus in vitro. Furthermore, it inhibited phosphorylation of pRB and cell cycle progression from G1 to S phase in WI38 cell cultures. WI38 cells arrested at the G0 phase by serum starvation progressed in the cell cycle after serum stimulation. pRB was phosphorylated after 10 h serum stimulation. Incorporation of [H-3]thymidine into the cells began to increase after 16 h serum stimulation. These processes were inhibited by butyrolactone I. Flow cytometric analysis showed that exposure to butyrolactone I inhibited progression of the cell cycle from G1 to S phase. These data suggested that initiation of DNA synthesis was inhibited by butyrolactone I and that the cell cycle was arrested in the G1 phase. Butyrolactone I also inhibited H1 histone phosphorylation in human WI38 cells and their G2/M progression, tsFT210 cells, a temperature-sensitive cdc2 mutant cell line, were synchronized at G2/M at a nonpermissive temperature, butyrolactone I inhibited the cell cycle progression of these cells at G2/M at the permissive temperature. Thus butyrolactone I, a cyclin-dependent kinase family inhibitor, which prevented the phosphorylations of the cell cycle-regulating proteins pRB and H1 histone, inhibited the cell cycle at G1/S and G2/M, respectively. These results suggest that the phosphorylations of pRB and H1 histone may play crucial roles in G1/S and G2/M progression, respectively, although it is possible that phosphorylations of other proteins by cdks are involved in G1/S and G2/M progression.	MERCK RES LABS,BANYU TSUKUBA RES INST,TSUKUBA,IBARAKI 30033,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Merck & Company; National Cancer Center - Japan			Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KITAGAWA M, 1993, ONCOGENE, V8, P2425; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATUURA Y, 1987, J GEN VIROL, V68, P1233; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1038; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, New Biologist, V2, P389; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SOMEYA A, 1994, BIOCHEM BIOPH RES CO, V198, P535; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; TAYA Y, 1990, GENETIC BASIS FOR CARCINOGENESIS, P171; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105	56	116	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2549	2557						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058318				2022-12-17	WOS:A1994PC05400014
J	HUSSAIN, SP; AGUILAR, F; AMSTAD, P; CERUTTI, P				HUSSAIN, SP; AGUILAR, F; AMSTAD, P; CERUTTI, P			OXY-RADICAL INDUCED MUTAGENESIS OF HOTSPOT CODON-248 AND CODON-249 OF THE HUMAN P53 GENE	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; OXIDATIVE DNA DAMAGE; HEPATOCELLULAR-CARCINOMA; MAMMALIAN-CELLS; NITRIC-OXIDE; MUTATIONS; 8-HYDROXYGUANINE; CANCER; SPECIFICITY; PROMOTION	Oxidants are suspected to represent important human carcinogens. They are mutagenic and may participate in the activation of proto-oncogenes and the inactivation of tumor suppressor genes. We have studied the capacity of hydrogen peroxide plus ferric chloride (FeCl3) to induce base pair changes in the hotspot codons 248 and 249 of the p53 tumor suppressor gene in human fibroblasts. In codon 248 (CGG) H2O2/FeCl3 only induced the transversion of G to C in the second position and the transition of G to A in the third position. No evidence was obtained for spontaneous or oxidant-induced deamination of 5-methylcytosine in the CpG dinucleotide of codon 248 since neither C to T transitions in the first position nor G to A transitions in the middle position were observed. H2O2/FeCl3, efficiently induced G to T transversions at both G-residues of codon 249 (AGG) and C to A transversions at the first position of codon 250 (CCC). It is evident that H2O2/FeCI3 possesses essentially the same mutagenic specificity for codons 249 and 250 of p53 as bulky carcinogens such as aflatoxin B1, benzo(a)pyrene or heterocyclic amines. In particular, it is not possible to eliminate oxidants from the list of candidate carcinogens which may be responsible for the high incidence of p53 codon 249 AGT mutations in hepatocellular carcinoma from certain areas of the world.	SWISS INST EXPTL CANC RES,DEPT CARCINOGENESIS,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research				Hussain, S. Perwez/0000-0002-2294-522X				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; BOS JL, 1989, CANCER RES, V49, P4682; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHENG KC, 1992, J BIOL CHEM, V267, P166; DAYAGROSJEAN L, 1993, CANCER RES, V53, P1625; DECUYPERDEBERGH D, 1987, EMBO J, V6, P3155, DOI 10.1002/j.1460-2075.1987.tb02626.x; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; HAYWARD N, 1993, NATURE, V352, P764; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSIE AW, 1986, P NATL ACAD SCI USA, V83, P9616, DOI 10.1073/pnas.83.24.9616; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HUSSAIN SP, 1994, ONCOGENE, V9, P13; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KOZUMBO WJ, 1985, CHEM-BIOL INTERACT, V54, P199, DOI 10.1016/S0009-2797(85)80163-0; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; MCBRIDE T, 1991, BIOCHEMISTRY-US, V30, P208; MORAES EC, 1990, CARCINOGENESIS, V11, P283, DOI 10.1093/carcin/11.2.283; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA N, 1993, CANCER RES, V53, P368; REID TM, 1993, P NATL ACAD SCI USA, V90, P3904, DOI 10.1073/pnas.90.9.3904; REID TM, 1992, CANCER RES, V52, P1082; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	35	116	120	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2277	2281						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036011				2022-12-17	WOS:A1994NX62900020
J	PIM, D; STOREY, A; THOMAS, M; MASSIMI, P; BANKS, L				PIM, D; STOREY, A; THOMAS, M; MASSIMI, P; BANKS, L			MUTATIONAL ANALYSIS OF HPV-18 E6 IDENTIFIES DOMAINS REQUIRED FOR P53 DEGRADATION IN-VITRO, ABOLITION OF P53 TRANSACTIVATION IN-VIVO AND IMMORTALIZATION OF PRIMARY BMK CELLS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN KERATINOCYTES; MOUSE CELLS; PROTEIN; ASSOCIATION; EXPRESSION; GENE; E7; TRANSFORMATION; TRANSCRIPTION	The two major transforming proteins of oncogenic human papillomaviruses are encoded by the E6 and E7 oncogenes. Both viral proteins interact specifically with the products of cellular human tumour suppressor genes; E6 with p53 and E7 with Rb. However, the mechanism of action of E6 is still poorly understood in comparison with that of E7. Although extensive in vitro studies have been done with mutant E6 proteins, very little is known about the activities of E6 in vivo. In this study we have analysed the structure-function relationships of HPV-18 E6 in in vitro analyses and we correlate this with in vivo activity. These studies define a number of domains on the E6 molecule which are involved in the ability of E6 to target p53 for degradation in vitro. This analysis demonstrates that domains previously shown to be important in HPV-16 E6 (Crook et al., 1991; Mietz et al., 1992) are also conserved in HPV-18 and also reconciles the differences between these reports. A series of in vivo studies demonstrate that E6 mediated degradation of p53 in vitro is irrelevant both for cell transformation and for the ability of E6 to abolish p53 transcriptional activation. In addition, we show that at least four distinct regions of the E6 protein are involved in the p53 association in vivo.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)				Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; COLE ST, 1987, J MOL BIOL, V193, P599, DOI 10.1016/0022-2836(87)90343-3; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MUNGER K, 1989, J VIROL, V63, P4417; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	28	116	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1869	1876						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208532				2022-12-17	WOS:A1994NR68500009
J	BARBEAU, D; CHARBONNEAU, R; WHALEN, SG; BAYLEY, ST; BRANTON, PE				BARBEAU, D; CHARBONNEAU, R; WHALEN, SG; BAYLEY, ST; BRANTON, PE			FUNCTIONAL INTERACTIONS WITHIN ADENOVIRUS E1A PROTEIN COMPLEXES	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN CYCLIN-A; EARLY REGION-1A POLYPEPTIDES; LARGE T-ANTIGENS; SV40 LARGE-T; CELL-CYCLE; PHOSPHORYLATION SITES; DNA-SYNTHESIS; 1A PROTEINS	The transforming potential of adenovirus E1A oncogene products derives largely from the formation of complexes with cellular proteins, including the p105(Rb) tumor suppressor and a related p107 species, p130 and p300 proteins, and cyclin A (p60(cycA)). Extensive quantitative analyses using E1A deletion mutants identified unique binding patterns for each of these polypeptides within the amino terminus and conserved regions 1 and 2 (CR1 and CR2) of E1A proteins. A novel protein, termed p400, was found by peptide mapping to be related to p300, and, like p300, to require the E1A amino terminus and a portion of CR1 for binding. p130 was shown to be related to p107, and like p107, to associate with p60(cycA). p107, p130 and p105(Rb) all interacted primarily with CR2, however, sequences within CR1 and the amino terminus were capable of weak interactions and appeared to function cooperatively with CR2 to bind these proteins. Protein kinase activity present in E1A complexes probably derives at least in part from p60(cycA)-linked p33(cdk2) associated with p107 and p130. In vitro phosphorylation of complexes purified by immunoprecipitation resulted in labeling of several proteins. p60(cycA) was phosphorylated to about the same extent in cyclin A complexes prepared from either AD5- or mock-infected KB cells, however, that of p130 and p107 was dramatically higher in p60(cycA) complexes from infected cells. p300 was also phosphorylated in complexes prepared using E1A-specific antibodies. Thus one role of E1A proteins in signal transduction and regulation of the cell cycle may be to control the biological activity of p107, p130 and p300 by enhancing their phosphorylation through complex formation.	DEPT BIOCHEM, MONTREAL H3G 1Y6, PQ, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ON, CANADA	McMaster University								BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARBEAU D, 1992, BIOCHEM CELL BIOL, V70, P1123, DOI 10.1139/o92-158; BELLETT AJD, 1989, J VIROL, V63, P303, DOI 10.1128/JVI.63.1.303-310.1989; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUMONT DJ, 1993, J GEN VIROL, V74, P583, DOI 10.1099/0022-1317-74-4-583; DUMONT DJ, 1992, VIROLOGY, V189, P111, DOI 10.1016/0042-6822(92)90686-J; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HALL FL, 1993, ONCOGENE, V8, P1377; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1988, ANTIBODIES LABORATOR; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; MONTELL C, 1982, NATURE, V295, P380, DOI 10.1038/295380a0; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NAKAJIMA T, 1987, MOL CELL BIOL, V7, P3846, DOI 10.1128/MCB.7.10.3846; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROWE DT, 1983, VIROLOGY, V127, P253, DOI 10.1016/0042-6822(83)90142-3; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TREMBLAY ML, 1989, VIROLOGY, V169, P397, DOI 10.1016/0042-6822(89)90165-7; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	94	116	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					359	373						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290250				2022-12-17	WOS:A1994MW24800003
J	PARK, JS; MEISLER, AI; CARTWRIGHT, CA				PARK, JS; MEISLER, AI; CARTWRIGHT, CA			C-YES TYROSINE KINASE-ACTIVITY IN HUMAN COLON-CARCINOMA	ONCOGENE			English	Article								To examine the role of Src-related proteins in human colon carcinoma we measured the tyrosine kinase activity of pp60c-src (Src), p62c-yes (Yes), p56lck (Lck), p59fyn (Fyn), p59hck (Hck), p56lyn (Lyn) and p55c-fgr (Fgr) from colonic cells. Yes activity, similar to that of Src, was 10-20 fold higher in three of five colon carcinoma cell lines and fivefold higher in 10 of 21 primary colon cancers than that in normal colonic cells. Lck activity was present in COLO 205 cells, otherwise Lck, Fyn, Hck, Lyn and Fgr activities were not detected in any of the carcinoma cell lines or cancers tested. Increased Yes activity, like that of Src, was due mostly to increased protein levels and not to an apparent decrease in phosphorylation of Tyr 537, the major mechanisms known to deregulate enzymatic activity. Only those colon carcinoma cell lines with elevated Src and/or Yes tyrosine kinase activity as measured in vitro had elevated levels of three tyrosine-phosphorylated proteins as measured in vivo. Thus, colon carcinoma cells contain active tyrosine kinases and/or inactive tyrosine phosphatases not present in normal colonic cells, and Src and Yes appear to be active kinases in the carcinoma cells. These data, together with those demonstrating decreased Src activity in fully differentiated enterocytes, suggest that down regulation of Src-related tyrosine kinases is important for differentiation, and/or deregulation of the kinases is important for growth and transformation of intestinal epithelial cells.	STANFORD UNIV, MED CTR,SCH MED,DEPT MED,MED SCH LAB SURGE BLDG, P304, STANFORD, CA 94305 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15240 USA	Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NIDDK NIH HHS [R29 DK43743, P30-DK38707] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043743, P30DK038707] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BUCKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FOSS FM, 1989, ONCOGENE RES, V5, P13; GARCIA R, 1991, ONCOGENE, V6, P1983; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAY R, 1992, CATALOGUE CELL LINES, P119; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLEY TR, 1989, ONCOGENE, V4, P265; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629	69	116	117	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2627	2635						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690925				2022-12-17	WOS:A1993LX34300003
J	DALY, MC; XIANG, RH; BUCHHAGEN, D; HENSEL, CH; GARCIA, DK; KILLARY, AM; MINNA, JD; NAYLOR, SL				DALY, MC; XIANG, RH; BUCHHAGEN, D; HENSEL, CH; GARCIA, DK; KILLARY, AM; MINNA, JD; NAYLOR, SL			A HOMOZYGOUS DELETION ON CHROMOSOME-3 IN A SMALL-CELL LUNG-CANCER CELL-LINE CORRELATES WITH A REGION OF TUMOR-SUPPRESSOR ACTIVITY	ONCOGENE			English	Article							SHORT ARM; DNA POLYMORPHISMS; CARCINOMA; GENE; RETINOBLASTOMA; SEQUENCE; 3P; IDENTIFICATION; HETEROZYGOSITY; PROTEIN	Small cell lung cancer (SCLC) tumors frequently display deletions on the short arm of chromosome 3 suggesting the existence of a 'tumor suppressor' gene within that region whose functional inactivation may be involved in tumorigenesis. Recently, a hybrid, HA(3)BB9F, was identified that contains a small fragment of human chromosome 3 of approximately 2 Mb on a mouse (A9) background (Killary et. al., 1992). This hybrid was utilized to define a functional tumor suppressor gene within 3p22-p21 which could suppress the tumorigenic properties of the mouse fibrosarcoma cell line. The existence of a tumor suppressor gene in the region 3p22-p21 is supported by the present report which describes the assessment of 89 SCLC and 32 non-SCLC lung cancer tumors and cell lines for the existence of a homozygous deletion(s) at 43 loci on the short arm of chromosome 3. One of the SCLC cell lines was found to harbor a homozygous deletion involving the loss of five markers on chromosome 3p. All five of the markers map to the region 3p21.3-p21.2 and four of the five markers are located within the chromosome 3 fragment exhibiting properties of tumor suppression in the HA(3)BB9F hybrid. The other tumors analysed all retained at least one copy of each of the markers assessed.	UNIV TEXAS,SW MED CTR,SIMMONS CANC INST,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,HOUSTON,TX 77030; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,MED ONCOL BRANCH,NCI NAVY MED ONCOL BRANCH,BETHESDA,MD 20814	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	DALY, MC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NCI NIH HHS [CA44764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA044764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGERHEIM U, 1989, CANCER RES, V49, P1390; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DELEIJ L, 1985, CANCER RES, V45, P6024; DIDSBURY JR, 1987, FEBS LETT, V211, P160, DOI 10.1016/0014-5793(87)81428-X; DRABKINHA, 1992, GENE CHROMOSOME CANC, V5, P67; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; FALOR WH, 1985, CANCER GENET CYTOGEN, V16, P175, DOI 10.1016/0165-4608(85)90012-3; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARCIA DK, 1991, CYTOGENET CELL GENET, V58, P225; GEIHL D, 1989, CYTOGENET CELL GENET, V51, P1001; GORADIA TM, 1991, GENOMICS, V10, P748, DOI 10.1016/0888-7543(91)90459-R; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEPPELLPARTON AC, 1992, GENE CHROMOSOME CANC, V4, P228, DOI 10.1002/gcc.2870040307; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; JOHNSON BE, 1989, J NATL CANCER I, V81, P1223, DOI 10.1093/jnci/81.16.1223; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1989, CANCER RES, V49, P651; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MULERIS M, 1987, INT J CANCER, V39, P595, DOI 10.1002/ijc.2910390509; NAYLOR S, 1991, CYTOGENET CELL GENET, V58, P170, DOI 10.1159/000133163; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; WATERS JJ, 1988, CANCER GENET CYTOGEN, V6, P119; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; YOKOTA J, 1989, CANCER RES, V49, P3598; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0; ZHANG R, 1989, CANCER RES, V49, P444	40	116	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1721	1729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8390035				2022-12-17	WOS:A1993LG68200002
J	BIANCHI, AB; FISCHER, SM; ROBLES, AI; RINCHIK, EM; CONTI, CJ				BIANCHI, AB; FISCHER, SM; ROBLES, AI; RINCHIK, EM; CONTI, CJ			OVEREXPRESSION OF CYCLIN-D1 IN MOUSE SKIN CARCINOGENESIS	ONCOGENE			English	Article							CELL NUCLEAR ANTIGEN; HARVEY-RAS ONCOGENE; MESSENGER-RNA; CANDIDATE ONCOGENE; PAPILLOMAS; TUMORS; GENE; CARCINOMAS; MICE; HETEROZYGOSITY	Recent studies have provided evidence suggesting that disruption of cyclin function may play a critical role in tumorigenesis. Cyclin D1, a putative G1 cyclin previously isolated in human parathyroid adenomas (designated PRAD1) and mouse macrophages (designated Cyl1), has been implicated in various neoplasias including breast and squamous cell carcinomas (SCC). The role of cyclin altered regulation in the different stages of tumor progression has not been studied in a well defined animal model system. In the study presented here, Cyl1 was mapped to the distal end of mouse chromosome 7 and found to be dramatically overexpressed in skin SCC. In premalignant stages of tumor development, early papillomas showed basal Cyl1 transcript levels, whereas overexpression was observed in most advanced papillomas. These findings suggest that altered expression of cyclin D1 plays a critical role in mouse skin carcinogenesis and may be related to the acquisition of autonomous growth by papillomas. Further studies on the role of cyclin D1 in the mouse model system should prove valuable for understanding the multistep basis of tumor progression.	UNIV TEXAS, MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,DIV RES, SCI PK,POB 389, SMITHVILLE, TX 78957 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Oak Ridge National Laboratory				Robles, Ana/0000-0001-5019-4374	NCI NIH HHS [CA42157, CA53123] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123, R01CA042157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1991, CANCER RES, V51, P1045; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIANCHI AB, 1993, IN PRESS MAMMALIAN G, V4; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BURNS F, 1983, ENVIRON HEALTH PERSP, V50, P309, DOI 10.2307/3429562; BURNS FJ, 1976, CANCER RES, V36, P1422; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FISCHER SM, 1988, CANCER RES, V48, P658; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HENNINGS H, 1985, J NATL CANCER I, V74, P735; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JOHNSON DK, 1989, P NATL ACAD SCI USA, V86, P8862, DOI 10.1073/pnas.86.22.8862; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KIDD VJ, 1992, MOL CARCINOGEN, V5, P95, DOI 10.1002/mc.2940050203; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lew D J, 1992, Trends Cell Biol, V2, P77, DOI 10.1016/0962-8924(92)90076-Y; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY AL, 1987, INT J CANCER, V39, P261, DOI 10.1002/ijc.2910390223; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUGGERI B, 1991, CANCER RES, V51, P6615; SLAGA T J, 1989, P1; STEINERT PM, 1984, P NATL ACAD SCI-BIOL, V81, P5709, DOI 10.1073/pnas.81.18.5709; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; VANDIERENDONCK JH, 1991, AM J PATHOL, V138, P1165; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	47	116	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1127	1133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479737				2022-12-17	WOS:A1993KY32800003
J	WANG, NP; TO, H; LEE, WH; LEE, EYHP				WANG, NP; TO, H; LEE, WH; LEE, EYHP			TUMOR SUPPRESSOR ACTIVITY OF RB AND P53 GENES IN HUMAN BREAST-CARCINOMA CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; WILD-TYPE P53; HUMAN PROSTATE CARCINOMA; MEDIATED FOCUS FORMATION; RECESSIVE MUTATION; PROTO-ONCOGENE; OSTEO-SARCOMA; ALLELE LOSS; SHORT ARM; EXPRESSION	Breast cancer is the most common cancer of women in Western countries. Various genetic alterations have been implicated in its development. Two tumor suppressor genes, the retinsoblastoma susceptibility gene (RB) and the gene encoding the p53 protein, are frequently found to be deleted or mutated in breast cancer cell lines and primary tumor samples. Breast carcinoma cell lines MDA-MB468 and BT549 both harbor partial RB gene deletions as well as point mutations of their p53 genes, thus providing an excellent model system for testing the roles played by these two genes in the oncogenesis of breast cancer. Single copies of wild-type RB or p53 were delivered to these cells by retrovirus-mediated gene transfer. Restoration of RB expression in cells reduced their ability to grow in soft agar and their tumorigenicity in nude mice, although no significant alteration of growth rate in culture could be detected. Introduction of wild-type p53 into these cells exerted a similar effect on the neoplastic phenotypes. This effect occurred even in the presence of their endogenous mutated p53 alleles, which argues for the phenotypical dominance of the wild-type p53 over mutated p53 during human oncogenesis. The ability of RB and p53 genes to suppress the tumorigenicity of breast carcinoma cells provides functional evidence that deletion or mutational inactivation of tumor suppressor genes represents an important step in the genesis of breast cancer.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio								ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN YM, 1991, ONCOGENE, V6, P1799; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; Crawford L V, 1984, Mol Biol Med, V2, P261; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEVILEE P, 1990, CYTOGENET CELL GENET, V53, P52, DOI 10.1159/000132893; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HENSEL CH, 1990, CANCER RES, V50, P3067; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Maniatis T., 1982, MOL CLONING; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MUNCASTER MM, 1992, CANCER RES, V52, P654; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROSSER J, 1990, ONCOGENE, V5, P1573; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1988, ONCOGENE, V3, P87; VARLEY JM, 1989, ONCOGENE, V4, P725; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	72	116	118	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					279	288						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426737				2022-12-17	WOS:A1993KN00600006
J	GILARDIHEBENSTREIT, P; NIETO, MA; FRAIN, M; MATTEI, MG; CHESTIER, A; WILKINSON, DG; CHARNAY, P				GILARDIHEBENSTREIT, P; NIETO, MA; FRAIN, M; MATTEI, MG; CHESTIER, A; WILKINSON, DG; CHARNAY, P			AN EPH-RELATED RECEPTOR PROTEIN TYROSINE KINASE GENE SEGMENTALLY EXPRESSED IN THE DEVELOPING MOUSE HINDBRAIN	ONCOGENE			English	Article							HOMEOBOX-CONTAINING GENES; AUG INITIATOR CODON; CHICK HINDBRAIN; NERVOUS-SYSTEM; MESSENGER-RNA; CDNA CLONING; 2 FORMS; SEQUENCE; IDENTIFICATION; DROSOPHILA	In search of genes possibly involved in the regulation of hindbrain segmentation, we have isolated mouse cDNA clones corresponding to putative protein kinase genes by polymerase chain reaction amplification of cDNA from 9.5-day-old embryo hindbrains. In situ hybridization analysis revealed that one of these genes, Sek, was expressed in an alternating segment-restricted pattern in the developing hindbrain. Isolation and analysis of Sek cDNAs covering the entire coding sequence indicated that Sek encoded a putative receptor protein tyrosine kinase, belonging to the Eph family. These data are consistent with a role of the Sek gene product in a signal transduction process involved in pattern formation in the hindbrain.	ECOLE NORM SUPER,GENET MOLEC LAB,CNRS,URA 1302,46 RUE ULM,F-75230 PARIS 05,FRANCE; HOP ENFANTS LA TIMONE,CTR GENET MED,INSERM,U242,F-13385 MARSEILLE,FRANCE; NATL INST MED RES,MRC,EUKARYOT MOLEC GENET LAB,LONDON NW7 1AA,ENGLAND	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; MRC National Institute for Medical Research			Nieto, M. Angela/A-6531-2008	Nieto, M. Angela/0000-0002-3538-840X; Charnay, Patrick/0000-0002-3847-6042; Wilkinson, David/0000-0001-6757-7080				BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DAVISSON MT, 1990, CYTOGENET CELL GENET, V55, P434, DOI 10.1159/000133026; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; HANKS SK, 1988, SCIENCE, V241, P45; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOGAN B, 1986, MANIPULATING MOUSE E, P126; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1990, PROTEIN DESIGN DEV N, P119; KEYNES R, 1990, NEURON, V2, P1; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Maniatis T., 1982, MOL CLONING; MARU Y, 1990, ONCOGENE, V5, P445; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MURPHY P, 1991, DEVELOPMENT, V111, P61; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAJJADI FG, 1991, NEW BIOL, V3, P769; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILKINSON DG, 1990, SEMINARS DEV BIOL, V1, P127; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	46	116	134	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2499	2506						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281307				2022-12-17	WOS:A1992KA85600015
J	BOULET, I; RALPH, S; STANLEY, E; LOCK, P; DUNN, AR; GREEN, SP; PHILLIPS, WA				BOULET, I; RALPH, S; STANLEY, E; LOCK, P; DUNN, AR; GREEN, SP; PHILLIPS, WA			LIPOPOLYSACCHARIDE-GAMMA-INDUCED AND INTERFERON-GAMMA-INDUCED EXPRESSION OF HCK AND LYN TYROSINE KINASES IN MURINE BONE MARROW-DERIVED MACROPHAGES	ONCOGENE			English	Article							RESPIRATORY BURST; GENE HCK; HUMAN NEUTROPHIL; CELLS; PHOSPHORYLATION; ACTIVATION; PHAGOCYTES; RECEPTOR; OXIDASE; CD4	We have examined the role of tyrosine phosphorylation during the course of macrophage activation. Initial experiments indicated that vanadate, a known phosphotyrosine phosphatase inhibitor, enhanced the phorbol 12-myristate 13-acetate (PMA)-triggered respiratory burst and potentiated the priming effects of bacterial lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma), suggesting that tyrosine phosphorylation may be important in these end cell functions. As src-related kinases have been implicated in the activation of cells of other haemopoietic lineages, we examined the relationship between the activity of two such kinases, hck and lyn, and priming of the respiratory burst. We found that the level of hck and lyn is increased following exposure of bone marrow-derived macrophages (BMM) to LPS or IFN-gamma. The induction of both of these kinases follows similar kinetics with maximal activity occurring at 24-48 h. Interestingly, the kinetics of induction of hck and lyn kinase activity in BMM demonstrated a close temporal relationship with the priming effects of LPS and IFN-gamma on the macrophage respiratory burst. Collectively, these observations raise the possibility that modulation of expression of hck and lyn is involved in the regulation of the respiratory burst.	LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PO ROYAL MELBOURNE HOSP,MELBOURNE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne			Stanley, Ed G/A-2985-2013; Phillips, Wayne A/H-8070-2013	Stanley, Ed G/0000-0002-6389-3665; Phillips, Wayne A/0000-0002-7961-638X; Lock, Peter/0000-0003-4421-3609; Ralph, Stephen/0000-0002-4335-092X				CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CLARK RA, 1990, J INFECT DIS, V161, P1140, DOI 10.1093/infdis/161.6.1140; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; JOHNSTON RB, 1990, PEDIATRIC RES S, V27, P544; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; PHILLIPS WA, 1990, J CELL PHYSIOL, V144, P190, DOI 10.1002/jcp.1041440203; PHILLIPS WA, 1989, J IMMUNOL, V142, P2445; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; ROSSI F, 1986, BIOCHIM BIOPHYS ACTA, V853, P65, DOI 10.1016/0304-4173(86)90005-4; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZIEGLER SF, 1988, J EXP MED, V168, P1801, DOI 10.1084/jem.168.5.1801; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	26	116	116	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					703	710						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1373483				2022-12-17	WOS:A1992HQ68200012
J	WU, JX; CARPENTER, PM; GRESENS, C; KEH, R; NIMAN, H; MORRIS, JWS; MERCOLA, D				WU, JX; CARPENTER, PM; GRESENS, C; KEH, R; NIMAN, H; MORRIS, JWS; MERCOLA, D			THE PROTOONCOGENE C-FOS IS OVER-EXPRESSED IN THE MAJORITY OF HUMAN OSTEOSARCOMAS	ONCOGENE			English	Article									UNIV CALIF SAN DIEGO,DEPT PATHOL,V-151,SAN DIEGO,CA 92161; MEM HOSP LONG BEACH,LONG BEACH,CA 90801; VET ADM MED CTR,SAN DIEGO,CA 92161; PROGENX INC,LA JOLLA,CA 92093	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)			mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [R0-1 CA49963-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049963] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON ED, 1985, EMBO J, V4, P941, DOI 10.1002/j.1460-2075.1985.tb03722.x; ALLEN DC, 1987, J CLIN PATHOL, V40, P157, DOI 10.1136/jcp.40.2.157; BATTIFORA H, 1988, AM J SURG PATHOL, V12, P24; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOGENMANN E, 1987, CANCER RES, V47, P3808; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOSH A, 1986, J CLIN PATHOL, V39, P428; GRAVES DT, 1983, CANCER RES, V43, P83; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HUANG JS, 1988, SCIENCE, V241, P1563; IBA H, 1988, ONCOGENE RES, V2, P121; IKEDA S, 1989, JPN J CANCER RES, V80, P6, DOI 10.1111/j.1349-7006.1989.tb02236.x; Marrack J, 1932, BRIT J EXP PATHOL, V13, P394; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P854; MERCOLA D, 1989, J CELL BIOL, V107, pA41; MILLER AD, 1984, CELL, V36, P51; MIZUKAMI Y, 1988, CANCER, V61, P873, DOI 10.1002/1097-0142(19880301)61:5<873::AID-CNCR2820610504>3.0.CO;2-W; MULLER R, 1983, NATURE, V454, P457; NARDEUX PC, 1987, BIOCHEM BIOPH RES CO, V146, P395, DOI 10.1016/0006-291X(87)90542-0; NIMAN HL, 1985, P NATL ACAD SCI USA, V82, P7924, DOI 10.1073/pnas.82.23.7924; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NOWELL PC, 1986, CANCER RES, V46, P2203; Pauling L, 1944, J AM CHEM SOC, V66, P784, DOI 10.1021/ja01233a039; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHON A, 1986, INT J CANCER, V38, P67, DOI 10.1002/ijc.2910380112; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEINBERGER LA, 1986, IMMUNOCYTOCHEMISTRY, P211; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VARMA VA, 1989, ARCH PATHOL LAB MED, V113, P16; VIOLA M, 1986, NEW ENGL J MED, V6314, P133; WOMER R, 1987, J CELL PHYSL, V132, P66; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	50	116	122	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					989	1000						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2115647				2022-12-17	WOS:A1990DP41500006
J	THEILLET, C; ADNANE, J; SZEPETOWSKI, P; SIMON, MP; JEANTEUR, P; BIRNBAUM, D; GAUDRAY, P				THEILLET, C; ADNANE, J; SZEPETOWSKI, P; SIMON, MP; JEANTEUR, P; BIRNBAUM, D; GAUDRAY, P			BCL-1 PARTICIPATES IN THE 11Q13 AMPLIFICATION FOUND IN BREAST-CANCER	ONCOGENE			English	Note									UER MED & PHARM,LGMCH,F-06034 NICE,FRANCE; INSERM,U119,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	THEILLET, C (corresponding author), CTR PAUL LAMARQUE,CNRS,UNITE 1191,F-34094 MONTPELLIER,FRANCE.		SIMON, Marie-Pierre/B-8017-2012; Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				ADELAIDE J, 1988, ONCOGENE, V2, P413; ADNANE J, 1989, ONCOGENE, V4, P147; ALI IU, 1989, ONCOGENE, V4, P89; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GEBHART E, 1986, BREAST CANCER RES TR, V8, P125, DOI 10.1007/BF01807701; GOSDEN JR, 1986, CYTOGENET CELL GENET, V43, P150, DOI 10.1159/000132313; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; NGUYEN C, 1988, ONCOGENE, V3, P703; RABBITTS PH, 1988, ONCOGENE, V3, P99; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; THEILLET C, 1989, ONCOGENE, V4, P915; TRENT JM, 1987, GROWTH FACTORS ONCOG, P142; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VARLEY JM, 1988, ONCOGENE, V3, P87; WADA A, 1988, BIOCHEM BIOPH RES CO, V157, P828, DOI 10.1016/S0006-291X(88)80324-3; WAHL GM, 1989, CANCER RES, V49, P1333; WILLIAMS BP, 1988, ONCOGENE, V3, P345; ZHOU DJ, 1988, ONCOGENE, V2, P279	24	116	116	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					147	149						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181375				2022-12-17	WOS:A1990CM62000020
J	REISSMANN, PT; SIMON, MA; LEE, WH; SLAMON, DJ				REISSMANN, PT; SIMON, MA; LEE, WH; SLAMON, DJ			STUDIES OF THE RETINOBLASTOMA GENE IN HUMAN SARCOMAS	ONCOGENE			English	Article									UNIV CHICAGO, PRITZKER SCH MED, DEPT SURG, CHICAGO, IL 60637 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT PATHOL, LA JOLLA, CA 92093 USA	University of Chicago; University of California System; University of California San Diego	REISSMANN, PT (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA36827] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; ABRAMSON DH, 1976, T AM ACAD OPHTHALMOL, V81, pP454; BALABAN G, 1982, CANCER GENET CYTOGEN, V6, P213, DOI 10.1016/0165-4608(82)90058-9; BENEDICT WF, 1983, CANCER GENET CYTOGEN, V10, P311, DOI 10.1016/0165-4608(83)90090-0; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHAUM E, 1984, CYTOGENET CELL GENET, V38, P82, DOI 10.1159/000132037; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENNEKING WF, 1975, CANCER-AM CANCER SOC, V36, P2192, DOI 10.1002/cncr.2820360937; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GALLIE BL, 1986, J CELL BIOCHEM, V32, P215, DOI 10.1002/jcb.240320308; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HOVIG E, 1987, CANCER GENET CYTOGEN, V24, P327, DOI 10.1016/0165-4608(87)90115-4; KITCHIN FD, 1974, J MED GENET, V11, P244, DOI 10.1136/jmg.11.3.244; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1976, NEW ENGL J MED, V295, P1120, DOI 10.1056/NEJM197611112952007; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MALAWER MM, 1985, CANCER PRINCIPLES PR, P1293; MANIATIS T, 1982, MOL CLONING LABORATO, P282; MEADOWS AT, 1985, J CLIN ONCOL, V3, P532, DOI 10.1200/JCO.1985.3.4.532; MITELMAN F, 1983, CHROMOSOMES CANCER M, P61; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; Reese A, 1976, TUMORS EYE; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VOGEL F, 1979, HUM GENET, V52, P1; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106	31	116	117	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1989	4	7					839	843						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2755701				2022-12-17	WOS:A1989AE58400004
J	Erpenbeck, L; Schon, MP				Erpenbeck, L.; Schoen, M. P.			Neutrophil extracellular traps: protagonists of cancer progression?	ONCOGENE			English	Review							VON-WILLEBRAND-FACTOR; DEEP-VEIN THROMBOSIS; ELASTASE-MEDIATED DEGRADATION; TUMOR-CELLS; ANGIOGENIC SWITCH; VENOUS THROMBOSIS; LYMPHOCYTE RATIO; LIVER METASTASIS; NADPH OXIDASE; NET FORMATION	Neutrophil extracellular traps (NETs) are a defense mechanism first described to trap and kill bacteria and other pathogens. Increasingly, however, their involvement in the pathogenesis of inflammatory and malignant diseases is being recognized. Several recent studies have suggested important roles of NETs in tumor progression, metastasis and tumor-associated thrombosis. Although systematic studies to address the role of NETs in tumor development are still scarce, we will explore the emerging evidence for NETs as potential protagonists in malignant disease and highlight the mechanisms through which these effects may be exerted. Future questions arising from our current knowledge of direct and indirect interactions between NETs and cancer cells will be outlined and we will explore NETs as candidate pharmaceutical targets in cancer patients.	[Erpenbeck, L.; Schoen, M. P.] Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Robert Koch Str 40, D-37075 Gottingen, Germany	University of Gottingen	Erpenbeck, L (corresponding author), Univ Med Ctr Gottingen, Dept Dermatol Venereol & Allergol, Robert Koch Str 40, D-37075 Gottingen, Germany.	luise.erpenbeck@med.uni-goettingen.de		Erpenbeck, Luise/0000-0002-6561-472X				Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502; Alfaro C, 2016, CLIN CANCER RES, V22, P3924, DOI 10.1158/1078-0432.CCR-15-2463; Ammollo CT, 2011, J THROMB HAEMOST, V9, P1795, DOI 10.1111/j.1538-7836.2011.04422.x; Amschler K, 2014, ACS NANO, V8, P9113, DOI 10.1021/nn502690b; An H, 2015, TUMOR BIOL, V37, P4523; Baj-Krzyworzeka M, 2010, ANTICANCER RES, V30, P3515; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Bauer AT, 2015, BLOOD, V125, P3153, DOI 10.1182/blood-2014-08-595686; Ben-Smith A, 2001, BLOOD, V98, P1448, DOI 10.1182/blood.V98.5.1448; Berger-Achituv S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00048; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bodey B, 1996, ANTICANCER RES, V16, P3439; Brill A, 2012, J THROMB HAEMOST, V10, P136, DOI 10.1111/j.1538-7836.2011.04544.x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Carmona-Rivera C, 2013, SEMIN IMMUNOPATHOL, V35, P455, DOI 10.1007/s00281-013-0375-7; Cedervall J, 2015, CANCER RES, V75, P2653, DOI 10.1158/0008-5472.CAN-14-3299; Chowdhury CS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4579; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Cools-Lartigue J., 2013, J CLIN INVEST, V67484; Cools-Lartigue J, 2014, CELL MOL LIFE SCI, V71, P4179, DOI 10.1007/s00018-014-1683-3; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Demers M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134073; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; Erpenbeck L, 2010, BLOOD, V115, P3427, DOI 10.1182/blood-2009-10-247296; Erpenbeck L, 2010, J INVEST DERMATOL, V130, P576, DOI 10.1038/jid.2009.278; Etulain J, 2015, BLOOD, V126, P242, DOI 10.1182/blood-2015-01-624023; Franchini M, 2013, THROMB RES, V131, P290, DOI 10.1016/j.thromres.2013.01.015; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fuchs TA, 2012, ARTERIOSCL THROM VAS, V32, P1777, DOI 10.1161/ATVBAHA.111.242859; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gaida MM, 2012, EUR J IMMUNOL, V42, P3369, DOI 10.1002/eji.201242628; Garcia-Romo GS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001201; Geddings JE, 2013, BLOOD, V122, P1873, DOI 10.1182/blood-2013-04-460139; Grassle S, 2014, ARTERIOSCL THROM VAS, V34, P1382, DOI 10.1161/ATVBAHA.113.303016; Guglietta S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11037; Gupta AK, 2005, HUM IMMUNOL, V66, P1146, DOI 10.1016/j.humimm.2005.11.003; Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006; Heissig B, 2010, HISTOL HISTOPATHOL, V25, P765, DOI 10.14670/HH-25.765; Ho-Tin-Noe B, 2009, AM J PATHOL, V175, P1699, DOI 10.2353/ajpath.2009.090460; Houghton AM, 2010, CELL CYCLE, V9, P1732, DOI 10.4161/cc.9.9.11297; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Jaillon S, 2007, J EXP MED, V204, P793, DOI 10.1084/jem.20061301; Keshari RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048111; Knight JS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00380; Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673; Kruss S, 2013, ACS NANO, V7, P9984, DOI 10.1021/nn403923h; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Lewis HD, 2015, NAT CHEM BIOL, V11, P189, DOI 10.1038/nchembio.1735; Liang S, 2008, CELL MOL BIOENG, V1, P189, DOI 10.1007/s12195-008-0016-8; Lin AM, 2011, J IMMUNOL, V187, P490, DOI 10.4049/jimmunol.1100123; Ludwig RJ, 2004, CANCER RES, V64, P2743, DOI 10.1158/0008-5472.CAN-03-1054; Martinod K, 2016, J THROMB HAEMOST, V14, P551, DOI 10.1111/jth.13239; Martinod K, 2015, BLOOD, V125, P1948, DOI 10.1182/blood-2014-07-587709; Martinod K, 2013, P NATL ACAD SCI USA, V110, P8674, DOI 10.1073/pnas.1301059110; Massberg S, 2010, NAT MED, V16, P887, DOI 10.1038/nm.2184; McDonald B, 2009, INT J CANCER, V125, P1298, DOI 10.1002/ijc.24409; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Parker H, 2012, J LEUKOCYTE BIOL, V92, P841, DOI 10.1189/jlb.1211601; Perisanidis C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0334-5; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Quan JM, 2001, J PEDIATR-US, V139, P813, DOI 10.1067/mpd.2001.118570; Raftery MJ, 2014, J EXP MED, V211, P1484, DOI 10.1084/jem.20131092; Sangaletti S, 2014, CANCER DISCOV, V4, P110, DOI 10.1158/2159-8290.CD-13-0276; Sangaletti S, 2012, BLOOD, V120, P3007, DOI 10.1182/blood-2012-03-416156; Savchenko AS, 2014, BLOOD, V123, P141, DOI 10.1182/blood-2013-07-514992; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Semeraro F, 2011, BLOOD, V118, P1952, DOI 10.1182/blood-2011-03-343061; SMITH DR, 1994, J EXP MED, V179, P1409, DOI 10.1084/jem.179.5.1409; Spicer JD, 2012, CANCER RES, V72, P3919, DOI 10.1158/0008-5472.CAN-11-2393; Starke RD, 2011, BLOOD, V117, P1071, DOI 10.1182/blood-2010-01-264507; SUGIHARA S, 1993, BRIT J CANCER, V67, P66, DOI 10.1038/bjc.1993.10; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Terraube V, 2007, THROMB RES, V120, pS64, DOI 10.1016/S0049-3848(07)70132-9; Thomas GM, 2015, J THROMB HAEMOST, V13, P1310, DOI 10.1111/jth.13002; Thomas MP, 2014, J IMMUNOL, V192, P5390, DOI 10.4049/jimmunol.1303296; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood-2006-10-053736; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Wada Y, 2007, ONCOL REP, V17, P161; Wang JC, 2015, ONCOTARGET, V6, P42825, DOI 10.18632/oncotarget.5739; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; Wong SL, 2015, NAT MED, V21, P815, DOI 10.1038/nm.3887; Xiao WK, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-117; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Zhao JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033655	91	115	123	6	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2483	2490		10.1038/onc.2016.406	http://dx.doi.org/10.1038/onc.2016.406			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941879				2022-12-17	WOS:000400597300014
J	Peng, DH; Ungewiss, C; Tong, P; Byers, LA; Wang, J; Canales, JR; Villalobos, PA; Uraoka, N; Mino, B; Behrens, C; Wistuba, II; Han, RI; Wanna, CA; Fahrenholtz, M; Grande-Allen, KJ; Creighton, CJ; Gibbons, DL				Peng, D. H.; Ungewiss, C.; Tong, P.; Byers, L. A.; Wang, J.; Canales, J. R.; Villalobos, P. A.; Uraoka, N.; Mino, B.; Behrens, C.; Wistuba, I. I.; Han, R. I.; Wanna, C. A.; Fahrenholtz, M.; Grande-Allen, K. J.; Creighton, C. J.; Gibbons, D. L.			ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LYSYL OXIDASE; THERAPEUTIC TARGET; MIR-200 FAMILY; SECRETED LOXL2; EXPRESSION; EMT; ADENOCARCINOMA; ENZYME; CELLS	Lung cancer is the leading cause of cancer-related deaths, primarily due to distant metastatic disease. Metastatic lung cancer cells can undergo an epithelial-to-mesenchymal transition (EMT) regulated by various transcription factors, including a double-negative feedback loop between the microRNA-200 (miR-200) family and ZEB1, but the precise mechanisms by which ZEB1-dependent EMT promotes malignancy remain largely undefined. Although the cell-intrinsic effects of EMT are important for tumor progression, the reciprocal dynamic crosstalk between mesenchymal cancer cells and the extracellular matrix (ECM) is equally critical in regulating invasion and metastasis. Investigating the collaborative effect of EMT and ECM in the metastatic process reveals increased collagen deposition in metastatic tumor tissues as a direct consequence of amplified collagen gene expression in ZEB1-activated mesenchymal lung cancer cells. In addition, collagen fibers in metastatic lung tumors exhibit greater linearity and organization as a result of collagen crosslinking by the lysyl oxidase (LOX) family of enzymes. Expression of the LOX and LOXL2 isoforms is directly regulated by miR-200 and ZEB1, respectively, and their upregulation in metastatic tumors and mesenchymal cell lines is coordinated to that of collagen. Functionally, LOXL2, as opposed to LOX, is the principal isoform that crosslinks and stabilizes insoluble collagen deposition in tumor tissues. In turn, focal adhesion formation and FAK/SRC signaling is activated in mesenchymal tumor cells by crosslinked collagen in the ECM. Our study is the first to validate direct regulation of LOX and LOXL2 by the miR-200/ZEB1 axis, defines a novel mechanism driving tumor metastasis, delineates collagen as a prognostic marker, and identifies LOXL2 as a potential therapeutic target against tumor progression.	[Peng, D. H.; Ungewiss, C.; Byers, L. A.; Behrens, C.; Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA; [Peng, D. H.; Ungewiss, C.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Tong, P.; Wang, J.; Creighton, C. J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Canales, J. R.; Villalobos, P. A.; Uraoka, N.; Mino, B.; Wistuba, I. I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Han, R. I.; Wanna, C. A.; Fahrenholtz, M.; Grande-Allen, K. J.] Rice Univ, Dept Bioengn, Houston, TX USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Gibbons, D. L.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Rice University; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Gibbons, DL (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thoracic Head & Neck Med Oncol, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA.	dlgibbon@mdanderson.org	Villalobos, Pamela/AAM-2677-2021	Peng, David/0000-0003-0511-1888; Han, Richard I/0000-0002-8332-622X; Fahrenholtz, Monica/0000-0003-4112-8230	NCI [K08 CA151661, RP120713 C2 and NCI grant CA125123]; MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer [RP120713 P2]; CPRIT [RP120713 P2, RP120713 C2]; CPRIT Graduate Scholar Training Grant [RP140106]; Lung SPORE [P50 CA070907]; Cancer Center Support Grant [CCSG CA016672]; Mary K Chapman Foundation; Jeane F Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE [P30CA016672, K08CA151651, P50CA070907] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MD Anderson Cancer Center Physician Scientist Award; Rexanna's Foundation for Fighting Lung Cancer; CPRIT; CPRIT Graduate Scholar Training Grant; Lung SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center Support Grant; Mary K Chapman Foundation; Jeane F Shelby Scholarship Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr G Goodall (University of Adelaide, Australia) for the kind gift of the pTRIPz-miR-200 expression constructs. We thank Dr M Dickinson (Baylor College of Medicine, Houston, TX, USA) for providing access to the multiphoton microscope for SHG analysis. We would like to thank members of the Gibbons lab for their assistance and critical reading of the manuscript. This work was supported by NCI K08 CA151661 (DLG), an MD Anderson Cancer Center Physician Scientist Award (DLG), Rexanna's Foundation for Fighting Lung Cancer (DLG) and CPRIT grant RP120713 P2 (DLG and JG-A). DP was supported by a CPRIT Graduate Scholar Training Grant (RP140106). JW and PT are supported by Lung SPORE (P50 CA070907), Cancer Center Support Grant (CCSG CA016672) and Mary K Chapman Foundation. CJC was supported by CPRIT grant RP120713 C2 and NCI grant CA125123. LAB and DLG are R Lee Clark Fellows of the University of Texas MD Anderson Cancer Center, supported by the Jeane F Shelby Scholarship Fund.	Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Alderton GK, 2013, NAT REV CANCER, V13, P3, DOI 10.1038/nrc3428; Baker AM, 2011, JNCI-J NATL CANCER I, V103, P407, DOI 10.1093/jnci/djq569; Barker HE, 2013, MOL CANCER RES, V11, P1425, DOI 10.1158/1541-7786.MCR-13-0033-T; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Barker HE, 2011, CANCER RES, V71, P1561, DOI 10.1158/0008-5472.CAN-10-2868; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Canesin G, 2015, ONCOGENE, V34, P951, DOI 10.1038/onc.2014.23; CHAUDHURI BB, 1993, PATTERN RECOGN LETT, V14, P147, DOI 10.1016/0167-8655(93)90088-U; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Egeblad M, 2010, CURR OPIN CELL BIOL, V22, P697, DOI 10.1016/j.ceb.2010.08.015; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fong SFT, 2007, GENE CHROMOSOME CANC, V46, P644, DOI 10.1002/gcc.20444; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gibbons DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005401; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Gill BJ, 2012, CANCER RES, V72, P6013, DOI 10.1158/0008-5472.CAN-12-0895; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hollosi P, 2009, INT J CANCER, V125, P318, DOI 10.1002/ijc.24308; Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kundu ST, 2016, ONCOGENE, V35, P173, DOI 10.1038/onc.2015.71; Leight JL, 2012, MOL BIOL CELL, V23, P781, DOI 10.1091/mbc.E11-06-0537; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lucero HA, 2006, CELL MOL LIFE SCI, V63, P2304, DOI 10.1007/s00018-006-6149-9; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; Palamakumbura AH, 2002, ANAL BIOCHEM, V300, P245, DOI 10.1006/abio.2001.5464; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2008, CANCER RES, V68, P4541, DOI 10.1158/0008-5472.CAN-07-6345; Peng L, 2009, CARCINOGENESIS, V30, P1660, DOI 10.1093/carcin/bgp178; Pickup MW, 2013, CANCER RES, V73, P5336, DOI 10.1158/0008-5472.CAN-13-0012; Rossi MA, 1998, CIRCULATION, V97, P934, DOI 10.1161/01.CIR.97.9.934; Roybal JD, 2011, MOL CANCER RES, V9, P25, DOI 10.1158/1541-7786.MCR-10-0497; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Shintani Y, 2008, AM J RESP CELL MOL, V38, P95, DOI 10.1165/rcmb.2007-0071OC; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; STREULI CH, 1991, J CELL BIOL, V115, P1383, DOI 10.1083/jcb.115.5.1383; Ungewiss C, 2016, SCI REP-UK, V6, DOI 10.1038/srep18652; Vadasz Z, 2005, J HEPATOL, V43, P499, DOI 10.1016/j.jhep.2005.02.052; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xiao Dakai, 2010, J Thorac Dis, V2, P154, DOI 10.3978/j.issn.2072-1439.2010.02.03.7; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang YA, 2014, J CLIN INVEST, V124, P2696, DOI 10.1172/JCI72171; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Zhan P, 2012, MED ONCOL, V29, P648, DOI 10.1007/s12032-011-9959-z	58	115	119	0	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1925	1938		10.1038/onc.2016.358	http://dx.doi.org/10.1038/onc.2016.358			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27694892	Green Accepted			2022-12-17	WOS:000398898500004
J	van Beijnum, JR; Nowak-Sliwinska, P; van den Boezem, E; Hautvast, P; Buurman, WA; Griffioen, AW				van Beijnum, J. R.; Nowak-Sliwinska, P.; van den Boezem, E.; Hautvast, P.; Buurman, W. A.; Griffioen, A. W.			Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1	ONCOGENE			English	Article						high-mobility group box 1; tumor angiogenesis; chicken embryo chorioallantoic membrane; VEGF; autocrine	END-PRODUCTS RAGE; ENDOTHELIAL-CELLS; NEURITE OUTGROWTH; GENE-EXPRESSION; IN-VIVO; CARDIOVASCULAR-DISEASES; DEPENDENT MECHANISM; SIGNALING PATHWAYS; HMGB1; PROTEIN	The endothelium plays a pivotal role in the progression of solid tumors and is considered a highly relevant target for therapy. However, it emerges that current clinical angiogenesis inhibitors that act through inhibition of tumor-derived growth factors are prone to inducing drug resistance. Therefore, markers of tumor endothelial cells (ECs) themselves provide attractive novel therapeutic targets. In a screen for markers of tumor angiogenesis, we recently identified high-mobility group box 1 (HMGB1), known to act as proinflamnnatory cytokine and chromatin-binding molecule. Here we report on the role of HMGB1 in angiogenesis by showing that its overexpression is associated with an increased angiogenic potential of ECs. HMGB1 stimulates the expression of players in vascular endothelial growth factor and platelet-derived growth factor signaling, both in vitro and in vivo. Importantly, we show that HMGB1 triggers and helps to sustain this proangiogenic gene expression program in ECs, additionally characterized by increased activity of matrix metalloproteinases, integrins and nuclear factor-kappa B. Moreover, we found that HMGB1 is involved in several autocrine and/or paracrine feedback mechanisms resulting in positive enforcement of HMGB1 expression, and that of its receptors, RAGE (receptor for advanced glycation end products) and Toll-like receptor 4 (TLR4). Interference in HMGB1 expression and/or function using knockdown approaches and antibody-mediated targeting to break this vicious circle resulted in inhibited migration and sprouting of ECs. Using different in vivo models, therapeutic efficacy of HMGB1 targeting was confirmed. First, we demonstrated induction of HMGB1 expression in the chicken embryo chorioallantoic membrane (CAM) neovasculature following both photodynannic therapy and tumor challenge. We subsequently showed that anti-HMGB1 antibodies inhibited vessel density in both models, accompanied by a reduced vascular expression of angiogenic growth factor receptors. Collectively, these data identify HMGB1 as an important modulator of tumor angiogenesis and suggest the feasibility of targeting HMGB1 for multi-level cancer treatment. Oncogene (2013) 32, 363-374; doi:10.1038/onc.2012.49; published online 5 March 2012	[van Beijnum, J. R.; Nowak-Sliwinska, P.; Griffioen, A. W.] Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Angiogenesis Lab, NL-1081 HV Amsterdam, Netherlands; [van den Boezem, E.; Hautvast, P.] Maastricht Univ, Dept Pathol, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands; [Buurman, W. A.] Maastricht Univ, Med Ctr, Dept Surg, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands	Vrije Universiteit Amsterdam; Maastricht University; Maastricht University; Maastricht University Medical Centre (MUMC)	Griffioen, AW (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, Angiogenesis Lab, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	aw.griffioen@vumc.nl	Nowak-Sliwinska, Patrycja/T-7663-2018	Nowak-Sliwinska, Patrycja/0000-0002-8299-0444	transnational University Limburg (tUL); GROW-School for Oncology and Developmental Biology; sixth EU Framework Programme (Integrated Project 'Angiotargeting') [504743]; Center for Translational Molecular Medicine (CTMM) [03O-201 MAMMOTH]; EU Framework Programme Integrated Project 'Angiotargeting' [50474]	transnational University Limburg (tUL); GROW-School for Oncology and Developmental Biology; sixth EU Framework Programme (Integrated Project 'Angiotargeting'); Center for Translational Molecular Medicine (CTMM); EU Framework Programme Integrated Project 'Angiotargeting'	This work was supported by grants of the transnational University Limburg (tUL), GROW-School for Oncology and Developmental Biology, the sixth EU Framework Programme (Integrated Project 'Angiotargeting'; contract no. 504743) in the area of 'Life sciences, genomics and biotechnology for health' and Center for Translational Molecular Medicine (CTMM) '03O-201 MAMMOTH'. We are grateful for financial support from J Jacobi Trust, and technical assistance from Dr Roeland Hanemaaijer, Saskia van der Velden, Iris Schulkens, Rajshri Lalai and Maaike van Berkel.; Transnational University Limburg (tUL); EU Framework Programme Integrated Project 'Angiotargeting'; contract no. 50474; Center for Translational Molecular Medicine (CTMM) '03O-201 MAMMOTH'.	Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0; Andersson U, 2002, J LEUKOCYTE BIOL, V72, P1084; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Biscetti F, 2010, DIABETES, V59, P1496, DOI 10.2337/db09-1507; Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38; Fiuza C, 2003, BLOOD, V101, P2652, DOI 10.1182/blood-2002-05-1300; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Kawahara KI, 2008, CARDIOVASC PATHOL, V17, P129, DOI 10.1016/j.carpath.2007.08.006; Laib AM, 2009, NAT PROTOC, V4, P1202, DOI 10.1038/nprot.2009.96; Li W, 2006, CURR OPIN PHARMACOL, V6, P130, DOI 10.1016/j.coph.2005.10.010; Lim SH, 2010, J MED CHEM, V53, P2865, DOI 10.1021/jm901823u; Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225; Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Mitola S, 2006, J IMMUNOL, V176, P12, DOI 10.4049/jimmunol.176.1.12; Mullins GE, 2004, SCAND J IMMUNOL, V60, P566, DOI 10.1111/j.0300-9475.2004.01518.x; Nowak-Sliwinska P, 2012, J CELL MOL MED, V16, P1553, DOI 10.1111/j.1582-4934.2011.01440.x; Nowak-Sliwinska P, 2011, J MED CHEM, V54, P3895, DOI 10.1021/jm2002074; Nowak-Sliwinska P, 2010, ANGIOGENESIS, V13, P281, DOI 10.1007/s10456-010-9185-x; Nowak-Sliwinska P, 2010, MICROVASC RES, V79, P21, DOI 10.1016/j.mvr.2009.10.004; Oh YJ, 2009, J IMMUNOL, V182, P5800, DOI 10.4049/jimmunol.0801873; Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schlueter C, 2005, AM J PATHOL, V166, P1259, DOI 10.1016/S0002-9440(10)62344-9; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Thijssen VLJL, 2007, CURR PHARM DESIGN, V13, P3576, DOI 10.2174/138161207782794121; Thijssen VLJL, 2004, EXP CELL RES, V299, P286, DOI 10.1016/j.yexcr.2004.06.014; Treutiger CJ, 2003, J INTERN MED, V254, P375, DOI 10.1046/j.1365-2796.2003.01204.x; van Beijnum JR, 2005, BBA-REV CANCER, V1755, P121, DOI 10.1016/j.bbcan.2005.06.001; van Beijnum JR, 2008, NAT PROTOC, V3, P1085, DOI 10.1038/nprot.2008.71; van Beijnum JR, 2008, ANGIOGENESIS, V11, P91, DOI 10.1007/s10456-008-9093-5; van Beijnum JR, 2008, EXP CELL RES, V314, P264, DOI 10.1016/j.yexcr.2007.08.013; van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Youn JH, 2006, J IMMUNOL, V177, P7889, DOI 10.4049/jimmunol.177.11.7889; Zhang CL, 2008, MED HYPOTHESES, V70, P343, DOI 10.1016/j.mehy.2007.05.024	47	115	116	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					363	374		10.1038/onc.2012.49	http://dx.doi.org/10.1038/onc.2012.49			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391561				2022-12-17	WOS:000314736600010
J	Vesuna, F; Lisok, A; Kimble, B; Domek, J; Kato, Y; van der Groep, P; Artemov, D; Kowalski, J; Carraway, H; van Diest, P; Raman, V				Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; van der Groep, P.; Artemov, D.; Kowalski, J.; Carraway, H.; van Diest, P.; Raman, V.			Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha	ONCOGENE			English	Article						breast cancer; hormone resistance; Twist; ER transcriptional regulation; histone deacetylation; methylation	EPITHELIAL-CELL LINES; TRANSCRIPTIONAL REGULATION; CHROMOSOMAL INSTABILITY; AROMATASE INHIBITORS; DNA METHYLATION; EXPRESSION; PROTEIN; MUTATIONS; ANGIOGENESIS; ACTIVATION	The role of estrogen receptor-alpha (ER) in breast cancer development, and as a primary clinical marker for breast cancer prognosis, has been well documented. In this study, we identified the oncogenic protein, TWIST1 (Twist), which is overexpressed in high-grade breast cancers, as a potential negative regulator of ER expression. Functional characterization of ER regulation by Twist was performed using Twist low (MCF-7, T-47D) and Twist high (Hs 578T, MDA-MB-231, MCF-7/Twist) expressing cell lines. All Twist high expressing cell lines exhibited low ER transcript and protein levels. By chromatin immunoprecipitation and promoter assays, we demonstrated that Twist could directly bind to E-boxes in the ER promoter and significantly downregulate ER promoter activity in vitro. Functionally, Twist overexpression caused estrogen-independent proliferation of breast cells, and promoted hormone resistance to the selective estrogen receptor modulator tamoxifen and selective estrogen receptor down-regulator fulvestrant. Importantly, this effect was reversible on downregulating Twist. In addition, orthotopic tumors generated in mice using MCF-7/Twist cells were resistant to tamoxifen. These tumors had high vascular volume and permeability surface area, as determined by magnetic resonance imaging (MRI). Mechanistically, Twist recruited DNA methyltransferase 3B (DNMT3B) to the ER promoter, leading to a significantly higher degree of ER promoter methylation compared with parental cells. Furthermore, we demonstrated by co-immunoprecipitation that Twist interacted with histone deacetylase 1 (HDAC1) at the ER promoter, causing histone deacetylation and chromatin condensation, further reducing ER transcript levels. Functional re-expression of ER was achieved using the demethylating agent, 5-azacytidine, and the HDAC inhibitor, valproic acid. Finally, an inverse relationship was observed between Twist and ER expression in human breast tumors. In summary, the regulation of ER by Twist could be an underlying mechanism for the loss of ER activity observed in breast tumors, and may contribute to the generation of hormone-resistant, ER-negative breast cancer. Oncogene (2012) 31, 3223-3234; doi:10.1038/onc.2011.483; published online 7 November 2011	[Vesuna, F.; Lisok, A.; Kimble, B.; Domek, J.; Kato, Y.; Artemov, D.; Raman, V.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD 21205 USA; [van der Groep, P.; van Diest, P.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Kowalski, J.; Carraway, H.; Raman, V.] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA	Johns Hopkins University; Utrecht University; Utrecht University Medical Center; Johns Hopkins University; Johns Hopkins Medicine	Raman, V (corresponding author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, 340 Traylor,720 Rutland Ave,340 Traylor Bldg, Baltimore, MD 21205 USA.	fvesuna1@jhmi.edu; vraman2@jhmi.edu	Vesuna, Farhad/G-3179-2010; Carraway, Hetty/AAR-4977-2020	Vesuna, Farhad/0000-0002-0356-5096; Carraway, Hetty/0000-0001-5241-3614; Kato, Yoshinori/0000-0002-6218-8710; Kowalski, Jeanne/0000-0003-3458-3024	National Institutes of Health [1RO1CA140226]; NATIONAL CANCER INSTITUTE [R01CA131250, R01CA140226] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the UMC Utrecht Biobank and M van Blokland for their help in obtaining the human breast cancer RNA. We also thank Flonne Wildes and Gary Cromwell for helping with mice, Yelena Mironchik for helping with cell culture, and Mary McAllister, Paul T Winnard Jr, and Balaji Krishnamachary for critically reading the manuscript. We also thank Kayleen Bailey for help with methylation experiments. ER promoter and ERE-luciferase constructs were kindly provided by Professor Nancy Davidson (Johns Hopkins University, MD). Twist mutant constructs were kindly provided by Professor Jacky Bonaventure (INSERM, France). This work was supported by the National Institutes of Health (1RO1CA140226 to VR).	Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Bhujwalla ZM, 2001, NEOPLASIA, V3, P143, DOI 10.1038/sj.neo.7900129; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bikfalvi A, 2002, TRENDS PHARMACOL SCI, V23, P576, DOI 10.1016/S0165-6147(02)02109-0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cho EY, 2006, INT J GYNECOL CANCER, V16, P1000, DOI 10.1111/j.1525-1438.2006.00553.x; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; deGraffenried LA, 2002, J STEROID BIOCHEM, V82, P7, DOI 10.1016/S0960-0760(02)00151-6; El Ghouzzi V, 2000, HUM MOL GENET, V9, P813, DOI 10.1093/hmg/9.5.813; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; FOX MH, 1980, CYTOMETRY, V1, P71, DOI 10.1002/cyto.990010114; Fuqua SAW, 2000, CANCER RES, V60, P4026; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; Herynk MH, 2007, ADV EXP MED BIOL, V608, P130; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; MORISSET M, 1986, ENDOCRINOLOGY, V119, P2773, DOI 10.1210/endo-119-6-2773; Murphy LC, 1997, J STEROID BIOCHEM, V62, P363, DOI 10.1016/S0960-0760(97)00084-8; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; O'Doherty A, 2002, BRIT J CANCER, V86, P282, DOI 10.1038/sj.bjc.6600028; Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344; Osborne C, 2005, ANNU REV MED, V56, P103, DOI 10.1146/annurev.med.56.062804.103324; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Osborne CK, 2005, J STEROID BIOCHEM, V95, P183, DOI 10.1016/j.jsbmb.2005.04.021; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Osborne CK, 2000, J CLIN ONCOL, V18, P3172, DOI 10.1200/JCO.2000.18.17.3172; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pilat MJP, 1998, ANTICANCER RES, V18, P2575; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; Rose CSP, 1997, TRENDS GENET, V13, P384, DOI 10.1016/S0168-9525(97)01296-1; Schiff R, 2005, CANCER CHEMOTH PHARM, V56, pS10, DOI 10.1007/s00280-005-0108-2; Sengupta K, 2003, INT J ONCOL, V22, P609; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; Vesuna F, 2005, ANAL BIOCHEM, V342, P345, DOI 10.1016/j.ab.2005.04.047; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Vesuna F, 2006, CANCER GENET CYTOGEN, V167, P189, DOI 10.1016/j.cancergencyto.2006.01.014; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512	40	115	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3223	3234		10.1038/onc.2011.483	http://dx.doi.org/10.1038/onc.2011.483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22056872	Green Accepted			2022-12-17	WOS:000306113400002
J	Fernandez, A; Squatrito, M; Northcott, P; Awan, A; Holland, EC; Taylor, MD; Nahle, Z; Kenney, AM				Fernandez-L, A.; Squatrito, M.; Northcott, P.; Awan, A.; Holland, E. C.; Taylor, M. D.; Nahle, Z.; Kenney, A. M.			Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation	ONCOGENE			English	Article						medulloblastoma; sonic hedgehog; cerebellum; YAP; IGF; DNA damage	CELL-CYCLE PROGRESSION; SONIC HEDGEHOG; CHECKPOINT ACTIVATION; NEURONAL SURVIVAL; DNA-DAMAGE; N-MYC; GROWTH; PROLIFERATION; PATHWAY; INHIBITION	Radiation therapy remains the standard of care for many cancers, including the malignant pediatric brain tumor medulloblastoma. Radiation leads to long-term side effects, whereas radioresistance contributes to tumor recurrence. Radio-resistant medulloblastoma cells occupy the perivascular niche. They express Yes-associated protein (YAP), a Sonic hedgehog (Shh) target markedly elevated in Shh-driven medulloblastomas. Here we report that YAP accelerates tumor growth and confers radioresistance, promoting ongoing proliferation after radiation. YAP activity enables cells to enter mitosis with un-repaired DNA through driving insulin-like growth factor 2 (IGF2) expression and Akt activation, resulting in ATM/Chk2 inactivation and abrogation of cell cycle checkpoints. Our results establish a central role for YAP in counteracting radiation-based therapies and driving genomic instability, and indicate the YAP/IGF2/Akt axis as a therapeutic target in medulloblastoma. Oncogene (2012) 31, 1923-1937; doi:10.1038/onc.2011.379; published online 29 August 2011	[Awan, A.; Nahle, Z.; Kenney, A. M.] Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37232 USA; [Awan, A.; Nahle, Z.; Kenney, A. M.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Fernandez-L, A.; Squatrito, M.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Northcott, P.; Taylor, M. D.] Univ Toronto, Hosp Sick Children, Program Dev & Stem Cell Biol, Arthur & Sonia Labatt Brain Tumor Res Ctr,Div Neu, Toronto, ON M5G 1X8, Canada	Vanderbilt University; Vanderbilt University; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Kenney, AM (corresponding author), Vanderbilt Univ, Dept Neurosurg, T-4224 MCN, Nashville, TN 37232 USA.	anna.kenney@vanderbilt.edu	Squatrito, Massimo/F-4149-2016; Northcott, Paul A/N-4022-2018	Squatrito, Massimo/0000-0002-4593-3790; Northcott, Paul A/0000-0002-1220-5252; Taylor, Michael/0000-0001-7009-3466; Awan, Aashir/0000-0002-8726-2921	Spanish Ministry of Education; Charles H Revson Foundation; Childhood Brain Tumor Foundation; Alex's Lemonade Stand Foundation; National Brain Tumor Society; James S McDonnell Foundation; NIH [NINDS R01NS061070]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061070] Funding Source: NIH RePORTER	Spanish Ministry of Education(Spanish Government); Charles H Revson Foundation; Childhood Brain Tumor Foundation; Alex's Lemonade Stand Foundation; National Brain Tumor Society; James S McDonnell Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We are grateful to Martine Roussel and her group at St Jude Children's Research Hospital for training and advice on MBC culture and intracranial implantation. AF-L received support from the Spanish Ministry of Education, the Charles H Revson Foundation and the Childhood Brain Tumor Foundation. This work was supported by grants to AMK from the Alex's Lemonade Stand Foundation, National Brain Tumor Society, James S McDonnell Foundation and the NIH (NINDS R01NS061070).	Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Bhatia B, 2011, ONCOGENE, V30, P410, DOI 10.1038/onc.2010.454; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Chrysis DC, 2001, CLIN ENDOCRINOL, V54, P253, DOI 10.1046/j.1365-2265.2001.01198.x; Corcoran RB, 2008, CANCER RES, V68, P8788, DOI 10.1158/0008-5472.CAN-08-2135; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; Eberhart CG, 2008, CANCER CELL, V14, P105, DOI 10.1016/j.ccr.2008.07.011; Fernandez A, 2010, CELL CYCLE, V9, P2292, DOI 10.4161/cc.9.12.11919; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Frappart PO, 2009, P NATL ACAD SCI USA, V106, P1880, DOI 10.1073/pnas.0806882106; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hartmann W, 2005, AM J PATHOL, V166, P1153, DOI 10.1016/S0002-9440(10)62335-8; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hirose Y, 2005, CANCER RES, V65, P4861, DOI 10.1158/0008-5472.CAN-04-2633; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Leonard JM, 2008, J CELL BIOL, V183, P385, DOI 10.1083/jcb.200804042; Mueller S, 2009, NEUROTHERAPEUTICS, V6, P570, DOI 10.1016/j.nurt.2009.04.006; Nahle Z, 2008, J BIOL CHEM, V283, P14317, DOI 10.1074/jbc.M706478200; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Northcott PA, 2009, CANCER RES, V69, P3249, DOI 10.1158/0008-5472.CAN-08-4710; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Parathath SR, 2008, DEVELOPMENT, V135, P3291, DOI 10.1242/dev.022871; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Tanori M, 2008, CARCINOGENESIS, V29, P1911, DOI 10.1093/carcin/bgn174; Tanori M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-53; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Xu NH, 2010, J CELL BIOL, V190, P297, DOI 10.1083/jcb.201003004; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	52	115	118	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1923	1937		10.1038/onc.2011.379	http://dx.doi.org/10.1038/onc.2011.379			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874045	Green Accepted			2022-12-17	WOS:000302809900005
J	Streicher, KL; Zhu, W; Lehmann, KP; Georgantas, RW; Morehouse, CA; Brohawn, P; Carrasco, RA; Xiao, Z; Tice, DA; Higgs, BW; Richman, L; Jallal, B; Ranade, K; Yao, Y				Streicher, K. L.; Zhu, W.; Lehmann, K. P.; Georgantas, R. W.; Morehouse, C. A.; Brohawn, P.; Carrasco, R. A.; Xiao, Z.; Tice, D. A.; Higgs, B. W.; Richman, L.; Jallal, B.; Ranade, K.; Yao, Y.			A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth	ONCOGENE			English	Article						miRNA cluster; melanoma; melanocyte transformation	MICRORNA CLUSTER; SOFT AGAR; EXPRESSION; CANCER; EVOLUTION; CELLS; GENE; OVEREXPRESSION; PROGRESSION; PROFILES	Malignant melanoma is the most aggressive form of skin cancer and its incidence has doubled in the last two decades. It represents only 4% of skin cancer cases per year, but causes as many as 74% of skin cancer deaths. Early detection of malignant melanoma is associated with survival rates of up to 90%, but later detection (stage III to stage IV) is associated with survival rates of only 10%. Dysregulation of microRNA (miRNA) expression has been linked to tumor development and progression by functioning either as a tumor suppressor, an oncogene or a metastasis regulator in multiple cancer types. To understand the role of miRNA in the pathogenesis of malignant melanoma and identify biomarkers of metastasis, miRNA expression profiles in skin punches from 33 metastatic melanoma patients and 14 normal healthy donors were compared. We identified a cluster of 14 miRNAs on the X chromosome, termed the miR-506-514 cluster, which was consistently overexpressed in nearly all melanomas tested (30-60 fold, P < 0.001), regardless of mutations in N-ras or B-raf. Inhibition of the expression of this cluster as a whole, or one of its sub-clusters (Sub-cluster A) consisting of six mature miRNAs, led to significant inhibition of cell growth, induction of apoptosis, decreased invasiveness and decreased colony formation in soft agar across multiple melanoma cell lines. Sub-cluster A of the miR-506-514 cluster was critical for maintaining the cancer phenotype, but the overexpression of the full cluster was necessary for melanocyte transformation. Our results provide new insights into the functional role of this miRNA cluster in melanoma, and suggest new approaches to treat or diagnose this disease. Oncogene (2012) 31, 1558-1570; doi:10.1038/onc.2011.345; published online 22 August 2011	[Streicher, K. L.; Zhu, W.; Lehmann, K. P.; Georgantas, R. W.; Morehouse, C. A.; Brohawn, P.; Higgs, B. W.; Richman, L.; Jallal, B.; Ranade, K.; Yao, Y.] MedImmune LLC, Dept Translat Sci, Gaithersburg, MD USA; [Carrasco, R. A.; Xiao, Z.; Tice, D. A.] MedImmune LLC, Dept Oncol, Gaithersburg, MD USA	AstraZeneca; Medimmune; AstraZeneca; Medimmune	Streicher, KL (corresponding author), Medimmune Inc, 1 MedImmune Way, Gaithersburg, MD 20878 USA.	StreicherK@MedImmune.com; YaoY@MedImmune.com	Xie, Huangming/B-2260-2012	Higgs, Brandon/0000-0002-2951-0245				Ambros Victor, 2004, Methods Mol Biol, V265, P131; Bandarchi B, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/583748; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Hausler SFM, 2010, BRIT J CANCER, V103, P693, DOI 10.1038/sj.bjc.6605833; Hartman ZC, 2011, CANCER RES, V71, P4380, DOI 10.1158/0008-5472.CAN-11-0308; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Kuphal S, 2006, ONCOGENE, V25, P5027, DOI 10.1038/sj.onc.1209508; Landais S, 2007, CANCER RES, V67, P5699, DOI 10.1158/0008-5472.CAN-06-4478; Leidinger P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-262; Li JJ, 2010, MOL BIOL EVOL, V27, P671, DOI 10.1093/molbev/msp284; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; MONTESANO R, 1977, J NATL CANCER I, V59, P1651, DOI 10.1093/jnci/59.6.1651; Mueller DW, 2009, BRIT J CANCER, V101, P551, DOI 10.1038/sj.bjc.6605204; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Nakamura JL, 2008, CANCER RES, V68, P6516, DOI 10.1158/0008-5472.CAN-07-6188; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Osawa M, 2008, J INVEST DERMATOL, V128, P2571, DOI 10.1038/jid.2008.289; Palmieri G, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-86; Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; RHIM JS, 1983, CANCER DETECT PREV, V6, P381; Rigel DS, 2010, CA-CANCER J CLIN, V60, P301, DOI 10.3322/caac.20074; SCHOLZ CC, 1990, EUR J CANCER, V26, P901, DOI 10.1016/0277-5379(90)90196-Z; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Segura MF, 2010, CLIN CANCER RES, V16, P1577, DOI 10.1158/1078-0432.CCR-09-2721; Sotiropoulou G, 2009, RNA, V15, P1443, DOI 10.1261/rna.1534709; Syed M, 2008, CLIN EXP METASTAS, V25, P787, DOI 10.1007/s10585-008-9192-0; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; Zhang R, 2007, GENOME RES, V17, P612, DOI 10.1101/gr.6146507; ZIRVI KA, 1983, INT J CANCER, V32, P45, DOI 10.1002/ijc.2910320108	39	115	127	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1558	1570		10.1038/onc.2011.345	http://dx.doi.org/10.1038/onc.2011.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860416				2022-12-17	WOS:000302132000008
J	Baritaki, S; Chapman, A; Yeung, K; Spandidos, DA; Palladino, M; Bonavida, B				Baritaki, S.; Chapman, A.; Yeung, K.; Spandidos, D. A.; Palladino, M.; Bonavida, B.			Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction	ONCOGENE			English	Article						metastasis; epithelial to mesenchymal transition; proteasome inhibitor; NF-kappa B; Raf-1 kinase inhibitor protein; Snail	NF-KAPPA-B; RAF KINASE; E-CADHERIN; PROTEIN EXPRESSION; TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; TUMOR-CELLS; IN-VITRO; SUPPRESSES	Metastasis is associated with the loss of epithelial features and the acquisition of mesenchymal characteristics and invasive properties by tumor cells, a process known as epithelial to mesenchymal transition (EMT). Snail expression, through nuclear factor (NF)-kappa B activation, is an EMT determinant. The proteasome inhibitor, NPI-0052, induces the metastasis tumor suppressor/immune surveillance cancer gene, Raf kinase inhibitor protein (RKIP), via NF-kappa B inhibition. We hypothesized that NPI-0052 may inhibit Snail expression and, consequently, the metastatic phenotype in DU-145 prostate cancer cells. Cell treatment with NPI-0052 induced E-cadherin and inhibited Snail expression and both tumor cell invasion and migration. Inhibition of Snail inversely correlated with the induction of RKIP. The underlying mechanism of NPI-0052-induced inhibition of the metastatic phenotype was corroborated by: (1) treatment with Snail siRNA in DU-145 inhibited EMT and, in contrast, overexpression of Snail in the nonmetastatic LNCaP cells induced EMT, (2) NPI-0052-induced repression of Snail via inhibition of NF-kappa B was corroborated by the specific NF-kappa B inhibitor DHMEQ and (3) RKIP overexpression mimicked NPI-0052 in the inhibition of Snail and EMT. These findings demonstrate, for the first time, the role of NPI-0052 in the regulation of EMT via inhibition of NF-kappa B and Snail and induction of RKIP. Oncogene (2009) 28, 3573-3585; doi: 10.1038/onc.2009.214; published online 27 July 2009	[Baritaki, S.; Chapman, A.; Bonavida, B.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Yeung, K.] Univ Toledo, Dept Canc Biol & Biochem, Coll Med, Toledo, OH 43606 USA; [Spandidos, D. A.] Univ Crete, Fac Med, Dept Clin Virol, Iraklion, Greece; [Palladino, M.] Nereus Pharmaceut, San Diego, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University System of Ohio; University of Toledo; University of Crete	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Baritaki, Voula/AAA-9544-2021	Spandidos, Demetrios/0000-0002-1146-931X	NIH/NCI [CA107023-02S1, CA057152-13S1]; Bodossaki Foundation postdoctoral fellowship; NATIONAL CANCER INSTITUTE [R01CA057152, R01CA107023] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bodossaki Foundation postdoctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the NIH/NCI research supplements CA107023-02S1, CA057152-13S1 and by Bodossaki Foundation postdoctoral fellowship (SB). We thank Chau Tran, Jose A Rodriguez and Haiming Chen for their help in the migration and invasion assays and the immuno. uorescence microscopy. We also thank Dr Kazuo Umezawa for providing us with the NF-kappa B inhibitor DHMEQ. In addition, we thank Tiffany Chin, Katherine Wu and Erica Keng for helping in the preparation of this article.	Ahn KS, 2007, BLOOD, V110, P2286, DOI 10.1182/blood-2007-04-084996; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Baritaki S, 2008, J IMMUNOL, V180, P6199, DOI 10.4049/jimmunol.180.9.6199; Baritaki S, 2007, J IMMUNOL, V179, P5441, DOI 10.4049/jimmunol.179.8.5441; Beach S, 2008, ONCOGENE, V27, P2243, DOI 10.1038/sj.onc.1210860; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chauhan D, 2006, BRIT J CANCER, V95, P961, DOI 10.1038/sj.bjc.6603406; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cusack JC, 2006, CLIN CANCER RES, V12, P6758, DOI 10.1158/1078-0432.CCR-06-1151; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; DEHERREROS AG, 2001, COMMON MOL DEV CARCI; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Elloul S, 2006, VIRCHOWS ARCH, V449, P520, DOI 10.1007/s00428-006-0274-6; Fenical W, 2009, BIOORGAN MED CHEM, V17, P2175, DOI 10.1016/j.bmc.2008.10.075; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Granovsky AE, 2008, CELL RES, V18, P452, DOI 10.1038/cr.2008.43; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Katsman A, 2007, DRUG RESIST UPDATE, V10, P1, DOI 10.1016/j.drup.2007.01.002; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Miller CP, 2007, BLOOD, V110, P267, DOI 10.1182/blood-2006-03-013128; Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Roccaro AM, 2008, BLOOD, V111, P4752, DOI 10.1182/blood-2007-11-120972; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Ruiz S, 2006, MOL CANCER THER, V5, P1836, DOI 10.1158/1535-7163.MCT-06-0066; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; Sloss CM, 2008, CLIN CANCER RES, V14, P5116, DOI 10.1158/1078-0432.CCR-07-4506; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sterz J, 2008, EXPERT OPIN INV DRUG, V17, P879, DOI [10.1517/13543784.17.6.879, 10.1517/13543784.17.6.879 ]; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; Yang MH, 2007, ONCOGENE, V26, P1459, DOI 10.1038/sj.onc.1209929; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	49	115	124	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3573	3585		10.1038/onc.2009.214	http://dx.doi.org/10.1038/onc.2009.214			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19633685				2022-12-17	WOS:000270851700006
J	Chekenya, M; Krakstad, C; Svendsen, A; Netland, IA; Staalesen, V; Tysnes, BB; Selheim, F; Wang, J; Sakariassen, PO; Sandal, T; Lonning, PE; Flatmark, T; Enger, PO; Bjerkvig, R; Sioud, M; Stallcup, WB				Chekenya, M.; Krakstad, C.; Svendsen, A.; Netland, I. A.; Staalesen, V.; Tysnes, B. B.; Selheim, F.; Wang, J.; Sakariassen, P. O.; Sandal, T.; Lonning, P. E.; Flatmark, T.; Enger, P. O.; Bjerkvig, R.; Sioud, M.; Stallcup, W. B.			The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling	ONCOGENE			English	Article						apoptosis; chemoresistance; integrin; NG2/MPG	CHONDROITIN SULFATE PROTEOGLYCAN; ACUTE MYELOID-LEUKEMIA; PDGF ALPHA-RECEPTOR; NG2 PROTEOGLYCAN; MONOCLONAL-ANTIBODY; GROWTH-FACTOR; HUMAN HOMOLOG; BRAIN-TUMORS; EXPRESSION; PHOSPHORYLATION	Chemoresistance represents a major problem in the treatment of many malignancies. Overcoming this obstacle will require improved understanding of the mechanisms responsible for this phenomenon. The progenitor cell marker NG2/melanoma proteoglycan (MPG) is aberrantly expressed by various tumors, but its role in cell death signaling and its potential as a therapeutic target are largely unexplored. We have assessed cytotoxic drug-induced cell death in glioblastoma spheroids from 15 patients, as well as in five cancer cell lines that differ with respect to NG2/MPG expression. The tumors were treated with doxorubicin, etoposide, carboplatin, temodal, cisplatin and tumor necrosis factor (TNF)alpha. High NG2/MPG expression correlated with multidrug resistance mediated by increased activation of alpha 3 beta 1 integrin/PI3K signaling and their downstream targets, promoting cell survival. NG2/MPG knockdown with shRNAs incorporated into lentiviral vectors attenuated beta 1 integrin signaling revealing potent antitumor effects and further sensitized neoplastic cells to cytotoxic treatment in vitro and in vivo. Thus, as a novel regulator of the antiapoptotic response, NG2/MPG may represent an effective therapeutic target in several cancer subtypes.	[Chekenya, M.; Svendsen, A.; Netland, I. A.; Tysnes, B. B.; Wang, J.; Sakariassen, P. O.; Enger, P. O.; Bjerkvig, R.] Univ Bergen, Dept Biomed, Norlux Neuro Oncol Grp, N-5009 Bergen, Norway; [Staalesen, V.] Univ Bergen, Dept Mol Biol, N-5009 Bergen, Norway; [Lonning, P. E.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Norway; [Flatmark, T.] Univ Bergen, Dept Biomed, Sect Biochem & Mol Biol, N-5009 Bergen, Norway; [Enger, P. O.] Haukeland Hosp, Dept Neurosurg, N-5021 Bergen, Norway; [Bjerkvig, R.] CRP Sante, Norlux Neuro Oncol Grp, Luxembourg, Luxembourg; [Sioud, M.] Norwegian Radium Hosp, Dept Immunol, Mol Med Grp, Oslo, Norway; [Stallcup, W. B.] Tumor Microenvironm Program, Canc Res Ctr, Burnham Med Res Inst, La Jolla, CA USA	University of Bergen; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; Luxembourg Institute of Health; University of Oslo; Sanford Burnham Prebys Medical Discovery Institute	Chekenya, M (corresponding author), Univ Bergen, Dept Biomed, Norlux Neuro Oncol Grp, Jonas Lies Vei 91, N-5009 Bergen, Norway.	martha.chekenya@biomed.uib.no	Krakstad, Camilla/AAB-5138-2020	Krakstad, Camilla/0000-0002-0174-8139; Lonning, Per Eystein/0000-0002-8890-6303; Chekenya, PhD, Dr Philos, Dr. Martha/0000-0001-7241-3451	The Norwegian Cancer Society; The Bergen Translational Research Group; Familien Blix Fond; University of Bergen; National Institutes of Health [RO1 CA95287]; Sixth EU Framework Programme; Helse-Vest; NATIONAL CANCER INSTITUTE [R01CA095287] Funding Source: NIH RePORTER	The Norwegian Cancer Society(Norwegian Cancer SocietyEuropean Commission); The Bergen Translational Research Group; Familien Blix Fond; University of Bergen; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sixth EU Framework Programme(European Commission); Helse-Vest; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by research grants from The Norwegian Cancer Society, The Bergen Translational Research Group, Familien Blix Fond, The University of Bergen, and a RO1 CA95287 grant from the National Institutes of Health. This study was also supported by the Sixth EU Framework Programme and Helse-Vest. We thank Narve Brekka, Tove Johansen, Christine Eriksen, Erna Finsas and Nina Lied Larsen for their technical assistance. We thank Jesus Planaguma for assistance with image analysis.	ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; BEG AA, 1996, SCIENCE, V274, P784; Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Burg MA, 1997, EXP CELL RES, V235, P254, DOI 10.1006/excr.1997.3674; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO;2-0; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chekenya M, 2002, NEUROPATH APPL NEURO, V28, P367, DOI 10.1046/j.1365-2990.2002.00412.x; Chekenya M, 2002, FASEB J, V16, P586, DOI 10.1096/fj.01-0632fje; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Fang XX, 1999, MOL BIOL CELL, V10, P3373, DOI 10.1091/mbc.10.10.3373; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200; Grako KA, 1999, J CELL SCI, V112, P905; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hilden JM, 1997, BLOOD, V89, P3801, DOI 10.1182/blood.V89.10.3801.3801_3801_3805; Joo NE, 2008, CELL DEATH DIFFER, V15, P899, DOI 10.1038/cdd.2008.22; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Li Y, 2003, BRIT J OPHTHALMOL, V87, P629, DOI 10.1136/bjo.87.5.629; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Makagiansar IT, 2007, J CELL BIOL, V178, P155, DOI 10.1083/jcb.200612084; Makagiansar IT, 2004, J BIOL CHEM, V279, P55262, DOI 10.1074/jbc.M411045200; Mauvieux L, 1999, BRIT J HAEMATOL, V107, P674; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.3.CO;2-3; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Pluschke G, 1996, P NATL ACAD SCI USA, V93, P9710, DOI 10.1073/pnas.93.18.9710; Sandal T, 2002, J BIOL CHEM, V277, P20783, DOI 10.1074/jbc.M112248200; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Smith FO, 1996, BLOOD, V87, P1123, DOI 10.1182/blood.V87.3.1123.bloodjournal8731123; Stallcup WB, 2002, J NEUROCYTOL, V31, P423, DOI 10.1023/A:1025731428581; Stallcup WB, 2001, J CELL SCI, V114, P2315; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; TYSNES OB, 1985, THROMB RES, V40, P329, DOI 10.1016/0049-3848(85)90268-3; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wewer UM, 1997, AM J PATHOL, V151, P1191; Yang JB, 2004, J CELL BIOL, V165, P881, DOI 10.1083/jcb.200403174	45	115	120	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5182	5194		10.1038/onc.2008.157	http://dx.doi.org/10.1038/onc.2008.157			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18469852	Green Accepted			2022-12-17	WOS:000258915100002
J	O'Connor, MJ; Martin, NMB; Smith, GCM				O'Connor, M. J.; Martin, N. M. B.; Smith, G. C. M.			Targeted cancer therapies based on the inhibition of DNA strand break repair	ONCOGENE			English	Review						DNA-PK; ATM; PARP; CHK1; CHK2	DEPENDENT PROTEIN-KINASE; HUMAN POLYNUCLEOTIDE KINASE; 3-KINASE RELATED KINASES; SMALL-MOLECULE INHIBITOR; ADP-RIBOSE POLYMERASE; POLY(ADP-RIBOSE) POLYMERASE; RADIOSENSITIZING AGENT; SELECTIVE INHIBITOR; SYNTHETIC LETHALITY; ATM ACTIVATION	Both DNA double- and single-strand break repair are highly coordinated processes utilizing signal transduction cascades and post-translational modifications such as phosphorylation, acetylation and ADP ribosylation. 'Drugable' targets within these networks have been identified that could potentially lead to novel therapeutic approaches within the oncology arena. Key regulators within these signalling cascades, such as DNA-dependent protein kinase, ataxia-telangiectasia mutated, checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2) and poly( ADPribose) polymerase, use either ATP or nicotinamide adenine dinucleotide for their enzymatic functions and are therefore readily accessible to small molecule inhibition at their catalytic sites. A range of highly potent and selective inhibitors of these DNA damage response pathways has now been identified through drug discovery efforts, with candidate molecules either approaching or already in clinical trials. This review will describe the small molecule inhibitors and drug discovery activities that focus on DNA break repair, along with the therapeutic rationale behind chemosensitization and the concept of synthetic lethality. We will also describe the emerging clinical data coming from this exciting new approach to targeted cancer therapy.	KuDOS Pharmaceut Ltd, Cambridge CB4 0PE, England	AstraZeneca	Smith, GCM (corresponding author), KuDOS Pharmaceut Ltd, 410 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0PE, England.	gcmsmith@kudospharma.co.uk						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abrahamsson PA, 2004, EUR UROL SUPPL, V3, P3, DOI 10.1016/j.eursup.2004.09.001; Albertella MR, 2005, CANCER RES, V65, P9799, DOI 10.1158/0008-5472.CAN-05-1095; Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Arienti KL, 2005, J MED CHEM, V48, P1873, DOI 10.1021/jm0495935; Austen B, 2005, BLOOD, V106, P3175, DOI 10.1182/blood-2004-11-4516; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bonicalzi ME, 2005, CELL MOL LIFE SCI, V62, P739, DOI 10.1007/s00018-004-4505-1; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Carlessi L, 2007, MOL CANCER THER, V6, P935, DOI 10.1158/1535-7163.MCT-06-0567; Chalmers A, 2004, INT J RADIAT ONCOL, V58, P410, DOI 10.1016/j.ijrobp.2003.09.053; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Curtin Nicola J., 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S146239940500904X; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; De Soto JA, 2006, INT J BIOL SCI, V2, P179; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fedier A, 2004, INT J ONCOL, V24, P1039; FONG PC, 2006, J CLIN ONCOL, V24, pA3022; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hardcastle IR, 2005, J MED CHEM, V48, P7829, DOI 10.1021/jm050444b; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hay T, 2005, CANCER RES, V65, P10145, DOI 10.1158/0008-5472.CAN-05-1186; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hollick JJ, 2007, J MED CHEM, V50, P1958, DOI 10.1021/jm061121y; Hu HY, 2004, J BIOL CHEM, V279, P39736, DOI 10.1074/jbc.M402842200; Ismail IH, 2004, ONCOGENE, V23, P873, DOI 10.1038/sj.onc.1207303; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Janetka JW, 2007, CURR OPIN DRUG DISC, V10, P473; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karimi-Busheri F, 2007, CANCER RES, V67, P6619, DOI 10.1158/0008-5472.CAN-07-0480; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kennedy RD, 2006, J CLIN ONCOL, V24, P3799, DOI 10.1200/JCO.2005.05.4171; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Krokan HE, 2007, DNA REPAIR, V6, P397, DOI 10.1016/j.dnarep.2006.10.007; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu Lili, 2004, Curr Opin Investig Drugs, V5, P623; LUCCHESI JC, 1968, GENETICS, V59, P37; Lynch HT, 1999, J MED GENET, V36, P801; Madhusudan S, 2005, NUCLEIC ACIDS RES, V33, P4711, DOI 10.1093/nar/gki781; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Miknyoczki SJ, 2003, MOL CANCER THER, V2, P371; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; PLUMMER R, 2006, J CLIN ONCOL, V24, pA8013; PLUMMER R, 2005, J CLIN ONCOL ASCO AN, V23, pA3065; POWELL SN, 1995, CANCER RES, V55, P1643; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496; Shinohara ET, 2005, CANCER RES, V65, P4987, DOI 10.1158/0008-5472.CAN-04-4250; Shiobara M, 2001, J GASTROEN HEPATOL, V16, P338, DOI 10.1046/j.1440-1746.2001.02378.x; Smith G.C.M., 2003, HDB CELL SIGNALING, V1, P557; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Southan GJ, 2003, CURR MED CHEM, V10, P321, DOI 10.2174/0929867033368376; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; TOMODA T, 1991, AM J HEMATOL, V37, P223, DOI 10.1002/ajh.2830370402; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Won JJ, 2006, NAT CHEM BIOL, V2, P369, DOI 10.1038/nchembio800; Yang S, 2005, MOL CANCER THER, V4, P1923, DOI 10.1158/1535-7163.MCT-05-0229; YAP TA, 2007, J CLIN ONCOL ASCO 1, V25, pA3529; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	84	115	122	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7816	7824		10.1038/sj.onc.1210879	http://dx.doi.org/10.1038/sj.onc.1210879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066095				2022-12-17	WOS:000251537900013
J	Bostner, J; Waltersson, MA; Fornander, T; Skoog, L; Nordenskjold, B; Stal, O				Bostner, J.; Waltersson, M. Ahnstrom; Fornander, T.; Skoog, L.; Nordenskjold, B.; Stal, O.			Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer	ONCOGENE			English	Article						cyclin D1; pak1; drug resistance; breast cancer; real-time PCR	COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN D1; ESTROGEN-RECEPTOR; GENE AMPLIFICATION; PROGNOSTIC-SIGNIFICANCE; 11Q13 AMPLIFICATION; P21-ACTIVATED-KINASE-1; CELLS; EXPRESSION; ACTIVATION	The 11q13 region is amplified in approximately 15% of all breast tumors. Situated in this region are the cyclin D1 gene (CCND1) and the p-21-activated kinase 1 (PAK1) gene. Both genes encode proteins shown to activate the estrogen receptor (ER), leading to transcription of CCND1 and other ER-responsive genes. Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene ampli. cation in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment. Amplification of CCND1 and PAK1, assessed by real-time PCR, was observed in 12.5 and 9.3%, respectively. Amplification of PAK1 was seen in 37% of the CCND1-amplified tumors, indicating coamplification (Po0.001). In ER-positive patients, ampli. cation of at least one of the genes indicated a reduced recurrence-free survival (P = 0.025). When response to tamoxifen treatment was analysed, patients with PAK1 ampli. cation showed decreased benefit from the drug (ER+; relative risk ratio (RR) = 1.62; 95% confedence interval (CI), 0.47 -5.55) compared to patients without ampli. cation (ER+; RR = 0.53; 95% CI, 0.32 0.88). This was not evident for CCND1 ampli. cation. We show that PAK1 may be a predictor of tamoxifen resistance and furthermore, we do not discard PAK1 as a potential candidate oncogene in the 11q13 amplicon. In addition, we show that high pak1 protein levels may predict tamoxifen insensitivity.	Linkoping Univ, Fac Hlth Sci, Div Oncol, Dept Biomed & Surg, Linkoping, Sweden; Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden; Karolinska Univ Hosp, Dept Cytol, Stockholm, Sweden	Linkoping University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Waltersson, MA (corresponding author), Univ Hosp, Dept Oncol, SE-58185 Linkoping, Sweden.	marah@ibk.liu.se						Ahnstrom M, 2005, BREAST CANCER RES TR, V91, P145, DOI 10.1007/s10549-004-6457-4; Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Askmalm MS, 2004, ACTA ONCOL, V43, P235, DOI 10.1080/02841860410029474; Balasenthil S, 2004, FEBS LETT, V567, P243, DOI 10.1016/j.febslet.2004.04.071; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; BERNARDS R, 1999, BIOCHIM BIOPHYS ACTA, V1424, P17; Bieche I, 2002, BRIT J CANCER, V86, P580, DOI 10.1038/sj.bjc.6600109; Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P128, DOI 10.1002/gcc.2870120207; Cuny M, 2000, CANCER RES, V60, P1077; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hodges LC, 2003, MOL CANCER RES, V1, P300; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Jirstrom K, 2005, CANCER RES, V65, P8009, DOI 10.1158/0008-5472.CAN-05-0746; Jordan VC, 2006, JNCI-J NATL CANCER I, V98, P657, DOI 10.1093/jnci/djj204; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Kyomoto R, 1997, INT J CANCER, V74, P576, DOI 10.1002/(SICI)1097-0215(19971219)74:6<576::AID-IJC3>3.0.CO;2-R; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Mayr D, 2006, AM J CLIN PATHOL, V126, P101, DOI 10.1309/N6X5MB24BP42KP20; Menard RE, 2005, NEOPLASIA, V7, P638, DOI 10.1593/neo.04736; Miyamoto R, 2003, ORAL ONCOL, V39, P610, DOI 10.1016/S1368-8375(03)00048-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Rayala SK, 2006, CANCER RES, V66, P5985, DOI 10.1158/0008-5472.CAN-06-0978; Rennstam K, 2001, CANCER RES, V61, P1214; Rutqvist LE, 2006, ACTA ONCOL, V45, P517, DOI 10.1080/02841860600702068; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Singh AP, 2005, WORLD J MICROB BIOT, V21, P1, DOI 10.1007/s11274-004-0872-x; Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang DN, 2002, MOL BIOTECHNOL, V21, P1, DOI 10.1385/MB:21:1:001; Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309; Wong LJC, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-111; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	43	115	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	49					6997	7005		10.1038/sj.onc.1210506	http://dx.doi.org/10.1038/sj.onc.1210506			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17486065				2022-12-17	WOS:000250412200005
J	Laiho, P; Kokko, A; Vanharanta, S; Salovaara, R; Sammalkorpi, H; Jarvinen, H; Mecklin, JP; Karttunen, TJ; Tuppurainen, K; Davalos, V; Schwartz, S; Arango, D; Makinen, MJ; Aaltonen, LA				Laiho, P.; Kokko, A.; Vanharanta, S.; Salovaara, R.; Sammalkorpi, H.; Jarvinen, H.; Mecklin, J-P; Karttunen, T. J.; Tuppurainen, K.; Davalos, V.; Schwartz, S., Jr.; Arango, D.; Makinen, M. J.; Aaltonen, L. A.			Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis	ONCOGENE			English	Article						molecular classification; microarray; serrated colorectal cancer; EPHB2	CPG ISLAND METHYLATION; CELL NEVUS SYNDROME; MICROSATELLITE INSTABILITY; GENE-EXPRESSION; HYPERPLASTIC POLYPOSIS; HUMAN HOMOLOG; ADENOMAS; NEOPLASIA; PATHWAYS; HEDGEHOG	Serrated colorectal carcinomas (CRCs) are morphologically different from conventional CRCs and have been proposed to follow a distinct pathway of CRC formation. Despite studies of single molecular events in this tumor type, the diagnosis of serrated CRC relies on morphology and the putative unique biological character of these tumors has not been established. Here we show that the gene expression pro. ling of 37 CRCs separated serrated and conventional CRCs into two distinct branches in unsupervised hierarchical clustering (P-value 7.8 x 10(-7)), and revealed 201 differentially expressed genes representing potential biomarkers for serrated CRC. Immunohistochemistry was utilized to verify the key findings in the 37 CRCs examined by express ion profiling, and a separate validation set of 37 serrated and 86 conventional CRCs was examined to evaluate the candidate biomarkers in an extended sample material. Ephrin receptor B2, hypoxia-inducible factor 1-alpha and patched appeared as proteins important for genesis of serrated CRC. This study establishes serrated CRCs as a biologically distinct subclass of CRC and represents a step forward in the molecular classification of these cancers. The study also provides a platform to understand the molecular basis of serrated CRC and in long term may contribute to the development of specific treatment options for this tumor type.	Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00014 Helsinki, Finland; Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; Univ Oulu, Dept Pathol, Oulu, Finland; Hosp Gen Valle Hebron, Res Inst, CIBBIM, Mol Biol & Biochem Res Ctr, Barcelona, Spain	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital; University of Oulu; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Aaltonen, LA (corresponding author), Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, Room B520A,POB 63, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Arango, Diego/M-5667-2016; Mecklin, Jukka-Pekka/AAB-5378-2020; Schwartz, Simo/H-7776-2012; Arango, Diego/AFW-0125-2022; Aaltonen, Lauri/A-5375-2010; Davalos, Veronica/AAR-8547-2020; Davalos, Veronica/S-1668-2016	Arango, Diego/0000-0003-2953-3284; Mecklin, Jukka-Pekka/0000-0003-4895-2249; Arango, Diego/0000-0003-2953-3284; Aaltonen, Lauri/0000-0001-6839-4286; Davalos, Veronica/0000-0003-4077-5137; Schwartz, Simo/0000-0001-8297-7971; Karttunen, Tuomo/0000-0002-8843-7957; Stefanius, Karoliina/0000-0002-9456-1954				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Higuchi T, 2004, J CLIN PATHOL, V57, P682, DOI 10.1136/jcp.2003.015230; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lazarus R, 2005, AM J CLIN PATHOL, V123, P349, DOI 10.1309/VBAGV3BR96N2EQTR; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; LONGACRE TA, 1990, AM J SURG PATHOL, V14, P524, DOI 10.1097/00000478-199006000-00003; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Narita T, 2000, DEVELOPMENT, V127, P981; Oldak M, 2001, INT J MOL MED, V8, P445; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Sawyer EJ, 2002, GUT, V51, P200, DOI 10.1136/gut.51.2.200; SCHWARTZ RA, 1978, NEW ENGL J MED, V299, P49; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tateyama H, 2002, AM J SURG PATHOL, V26, P249, DOI 10.1097/00000478-200202000-00013; Tuppurainen K, 2005, J PATHOL, V207, P285, DOI 10.1002/path.1850; Yashiro M, 2005, CANCER EPIDEM BIOMAR, V14, P2253, DOI 10.1158/1055-9965.EPI-04-0790; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28; Zhong H, 1999, CANCER RES, V59, P5830	45	115	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					312	320		10.1038/sj.onc.1209778	http://dx.doi.org/10.1038/sj.onc.1209778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819509				2022-12-17	WOS:000243398300016
J	Maeda, T; Desouky, J; Friedl, A				Maeda, T; Desouky, J; Friedl, A			Syndecan-1 expression by stromal. broblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis	ONCOGENE			English	Article						tumor stroma; breast carcinoma; syndecan-1; epithelial-stromal interactions; angiogenesis	HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE PROTEOGLYCAN; EPITHELIAL MESENCHYMAL INTERACTIONS; MULTIPLE-MYELOMA; BINDING; CANCER; RECEPTORS; MATRIX; FGF	The induction of the cell surface heparan sulfate proteoglycan syndecan-1 (Sdc1) in stromal fibroblasts is observed in more than 70% of human breast carcinomas. Using a coculture model, we have recently shown that stromal cell-derived Sdc1 stimulates carcinoma cell proliferation in vitro, and that this activity requires Sdc1 glycanation. In the present study, we investigated the effect of stromal cell Sdc1 on breast carcinoma growth in vivo. MDA-MB-231 human breast carcinoma cells were inoculated into the flanks of athymic nude mice either alone, or as mixed suspensions with Sdc1-transfected or mock-transfected 3T3 mouse fibroblasts. The mixed tumors showed an intimate association between carcinoma cells and stromal fibroblasts and histologically closely resembled poorly differentiated human breast carcinomas. The presence of fibroblasts led to significantly accelerated tumor growth, which was further augmented (88% increase) by forced expression of stromal Sdc1. The hyperemic macroscopic appearance of tumors containing Sdc1-positive stromal cells contrasted with pale tumors developing in the presence of mock-transfected fibroblasts, which prompted us to examine tumor microvessels. Stromal Sdc1 expression was associated with a significantly elevated microvessel density (36% increase) and a larger vessel area (153% increase). To evaluate the relevance of this finding in human breast cancer, the relationship between stromal Sdc1 and tumor vascularity was also examined in a tissue array containing 207 human breast carcinoma samples. Similar to the xenografts, stromal Sdc1 expression correlated with both vessel density (P = 0.013) and total vessel area (P = 0.0026). In conclusion, stromal fibroblast-derived Sdc1 stimulates breast carcinoma growth and angiogenesis in vivo.	Univ Wisconsin, Clin Sci Ctr K4812, Dept Pathol & Lab Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Clin Sci Ctr K4812, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA.	afriedl@wisc.edu			NATIONAL CANCER INSTITUTE [P30CA014520, R01CA107012] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA107012, CA14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Bayer-Garner IB, 2001, MODERN PATHOL, V14, P1052, DOI 10.1038/modpathol.3880435; Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Beauvais DLM, 2004, J CELL BIOL, V167, P171, DOI 10.1083/jcb.200404171; Beauvais DM, 2003, EXP CELL RES, V286, P219, DOI 10.1016/S0014-4827(03)00126-5; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Burbach BJ, 2004, EXP CELL RES, V300, P234, DOI 10.1016/j.yexcr.2004.07.001; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Filla MS, 1998, J CELL PHYSIOL, V174, P310, DOI 10.1002/(SICI)1097-4652(199803)174:3<310::AID-JCP5>3.0.CO;2-R; Friedl A, 2001, Methods Mol Biol, V171, P535; Ito Y, 2003, HISTOPATHOLOGY, V43, P157, DOI 10.1046/j.1365-2559.2003.01656.x; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Mennerich D, 2004, EUR J CANCER, V40, P1373, DOI 10.1016/j.ejca.2004.01.038; Mukunyadzi P, 2003, MODERN PATHOL, V16, P796, DOI 10.1097/01.MP.0000081731.17549.53; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Radisky D, 2002, CANCER INVEST, V20, P139, DOI 10.1081/CNV-120000374; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102; TESSLER S, 1994, J BIOL CHEM, V269, P12456; VAINIO S, 1989, J CELL BIOL, V108, P1945, DOI 10.1083/jcb.108.5.1945; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; Weaver VM, 2004, J CELL SCI, V117, P1287, DOI 10.1242/jcs.01137; Wiksten JP, 2001, INT J CANCER, V95, P1, DOI 10.1002/1097-0215(20010120)95:1<1::AID-IJC1000>3.0.CO;2-5; Yang Y, 2002, BLOOD, V100, P610, DOI 10.1182/blood.V100.2.610	29	115	123	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1408	1412		10.1038/sj.onc.1209168	http://dx.doi.org/10.1038/sj.onc.1209168			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247452				2022-12-17	WOS:000235708200014
J	Schimanski, CC; Schmitz, G; Kashyap, A; Bosserhoff, AK; Bataille, F; Schafer, SC; Lehr, HA; Berger, MR; Galle, PR; Strand, S; Strand, D				Schimanski, CC; Schmitz, G; Kashyap, A; Bosserhoff, AK; Bataille, F; Schafer, SC; Lehr, HA; Berger, MR; Galle, PR; Strand, S; Strand, D			Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer	ONCOGENE			English	Article						lgl; Hugl-1; tumour suppressor; colon cancer	LETHAL-GIANT-LARVAE; CELL POLARITY; PROTEIN; MUTATIONS; COMPLEX; REGION; MAPS; APC; NEOPLASMS; PATHWAYS	The human gene, human giant larvae (Hugl-1/Llg1/Lgl1) has significant homology to the Drosophila tumour suppressor gene lethal( 2) giant larvae (lgl). The lgl gene codes for a cortical cytoskeleton protein, Lgl, that binds Myosin II and is involved in maintaining cell polarity and epithelial integrity. The human protein, Hugl-1 contains several conserved functional domains found in Lgl, suggesting that these proteins may have closely related functions. Whether loss of Hugl expression plays a role in human tumorigenesis has so far not been extensively investigated. Thus, we evaluated tumour tissues from 94 patients undergoing surgery for colorectal cancer (CRC) for loss of Hugl-1 transcription and compared our findings with the clinical data from each of these patients. We found that Hugl-1 was lost in 75% of tumour samples and these losses were associated with advanced stage and particularly with lymph node metastases. Reduced Hugl-1 expression during the adenoma-carcinoma sequence occurring as early as in colorectal adenomas was detected by both immunohistochemical and reverse transcription polymerase chain reaction analysis. Functional assays with ecdysone-inducible cell lines revealed that Hugl-1 expression increased cell adhesion and decreased cell migration. Our studies thus indicate that downregulation of Hugl-1 contributes to CRC progression.	Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55131 Mainz, Germany; German Canc Res Ctr, Unit Toxicol & Chemotherapy, D-69120 Heidelberg, Germany	Johannes Gutenberg University of Mainz; University of Regensburg; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ)	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	dstrand@uni-mainz.de	Bosserhoff, Anja/GNH-4801-2022; Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Bosserhoff, Anja/0000-0001-8147-394X				AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Boulay JL, 2001, GENE CHROMOSOME CANC, V31, P240, DOI 10.1002/gcc.1140; CHEN KS, 1995, AM J HUM GENET, V56, P175; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Guanti G, 2000, Acta Chir Iugosl, V47, P23; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kagami M, 1998, GENETICS, V149, P1717; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Koyama K, 1996, CYTOGENET CELL GENET, V72, P78, DOI 10.1159/000134167; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Larsson K, 1998, J BIOL CHEM, V273, P33610, DOI 10.1074/jbc.273.50.33610; Leslie A, 2003, CANCER RES, V63, P4656; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Micheli A, 2002, ANN ONCOL, V13, P840, DOI 10.1093/annonc/mdf127; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PARKIN DM, 1993, INT J CANCER, V54, P594; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Roth S, 2000, J MED GENET, V37, P298, DOI 10.1136/jmg.37.4.298; Scheurlen WG, 1999, GENE CHROMOSOME CANC, V25, P230, DOI 10.1002/(SICI)1098-2264(199907)25:3<230::AID-GCC5>3.0.CO;2-E; Scheurlen WG, 1997, GENE CHROMOSOME CANC, V18, P50, DOI 10.1002/(SICI)1098-2264(199701)18:1<50::AID-GCC6>3.0.CO;2-0; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1995, ONCOGENE, V11, P291; STRAND D, 1998, MOL B INT U, V3, P61; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; WOODHOUSE E, 1994, CELL GROWTH DIFFER, V5, P151; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Yam JWP, 2001, ONCOGENE, V20, P58, DOI 10.1038/sj.onc.1203982; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	42	115	123	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3100	3109		10.1038/sj.onc.1208520	http://dx.doi.org/10.1038/sj.onc.1208520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735678				2022-12-17	WOS:000228728100004
J	Reis, EM; Nakaya, HI; Louro, R; Canavez, FC; Flatschart, AVF; Almeida, GT; Egidio, CM; Paquola, AC; Machado, AA; Festa, F; Yamamoto, D; Alvarenga, R; da Silva, CC; Brito, GC; Simon, SD; Moreira, CA; Leite, KR; Camara-Lopes, LH; Campos, FS; Gimba, E; Vignal, GM; El-Dorry, H; Sogayar, MC; Barcinski, MA; da Silva, AM; Verjovski-Almeida, S				Reis, EM; Nakaya, HI; Louro, R; Canavez, FC; Flatschart, AVF; Almeida, GT; Egidio, CM; Paquola, AC; Machado, AA; Festa, F; Yamamoto, D; Alvarenga, R; da Silva, CC; Brito, GC; Simon, SD; Moreira, CA; Leite, KR; Camara-Lopes, LH; Campos, FS; Gimba, E; Vignal, GM; El-Dorry, H; Sogayar, MC; Barcinski, MA; da Silva, AM; Verjovski-Almeida, S			Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer	ONCOGENE			English	Article						prostate cancer; Gleason score; intronic transcripts; antisense RNA; microarray	GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVITY; SEQUENCE; HUMAN-CHROMOSOME-21; SITES	A large fraction of transcripts are expressed antisense to introns of known genes in the human genome. Here we show the construction and use of a cDNA microarray platform enriched in intronic transcripts to assess their biological relevance in pathological conditions. To validate the approach, prostate cancer was used as a model, and 27 patient tumor samples with Gleason scores ranging from 5 to 10 were analyzed. We find that a considerably higher fraction (6.6%,[23/346]) of intronic transcripts are significantly correlated (Pless than or equal to0.001) to the degree of prostate tumor differentiation ( Gleason score) when compared to transcripts from unannotated genomic regions (1%,[6/539]) or from exons of known genes (2%,[27/1369]). Among the top twelve transcripts most correlated to tumor differentiation, six are antisense intronic messages as shown by orientation-specific RTPCR or Northern blot analysis with strand-specific riboprobe. Orientation-specific real-time RT-PCR with six tumor samples, confirmed the correlation ( P = 0.024) between the low/high degrees of tumor differentiation and antisense intronic RASSF1 transcript levels. The need to use intron arrays to reveal the transcriptome profile of antisense intronic RNA in cancer has clearly emerged.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Lab Bioinformat, BR-05508900 Sao Paulo, Brazil; Hosp Israelita Albert Einstein, Div Oncol, BR-05651901 Sao Paulo, Brazil; Hosp Sirio Libanes, Lab Patol Cirurg & Mol, BR-01308050 Sao Paulo, Brazil; Inst Nacl Canc MS, BR-20230130 Rio De Janeiro, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; Hospital Sirio Libanes	Verjovski-Almeida, S (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil.	verjo@iq.usp.br	Tesaarin e Almeida, Giulliana/F-5936-2013; da Silva, Aline Maria/C-3649-2012; Gimba, Etel/B-4473-2016; Sogayar, Mari C/B-3980-2017; LEITE, KATIA RM/C-2055-2008; moreira-filho, carlos alberto/J-2551-2014; Gimba, Etel/H-7195-2012; Verjovski-Almeida, Sergio/E-4082-2012; Nakaya, Helder I/A-1397-2010; Reis, Eduardo Moraes Rego/AAF-3553-2020; Nakaya, Helder/AAF-1738-2020; Reis, Eduardo M/H-2008-2011; Brito, Glauber/C-4415-2013	da Silva, Aline Maria/0000-0001-9249-4922; Sogayar, Mari C/0000-0003-4805-4609; LEITE, KATIA RM/0000-0002-2615-7730; moreira-filho, carlos alberto/0000-0003-3433-4714; Verjovski-Almeida, Sergio/0000-0002-6356-2401; Nakaya, Helder I/0000-0001-5297-9108; Nakaya, Helder/0000-0001-5297-9108; Reis, Eduardo M/0000-0002-9556-3070; Brito, Glauber/0000-0002-9887-3939; Festa, Fernanda/0000-0002-2822-823X				Best CJM, 2003, DIAGN MOL PATHOL, V12, P63, DOI 10.1097/00019606-200306000-00001; Brentani H, 2003, P NATL ACAD SCI USA, V100, P13418, DOI 10.1073/pnas.1233632100; Brunschwig EB, 2003, CANCER RES, V63, P1568; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Camargo AA, 2001, P NATL ACAD SCI USA, V98, P12103, DOI 10.1073/pnas.201182798; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Iseli C, 1999, Proc Int Conf Intell Syst Mol Biol, P138; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; Kiyosawa H, 2003, GENOME RES, V13, P1324, DOI 10.1101/gr.982903; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Liu YL, 1996, GENOMICS, V31, P58, DOI 10.1006/geno.1996.0009; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; Neto ED, 2000, P NATL ACAD SCI USA, V97, P3491; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Sanchez-Carbayo M, 2002, CANCER RES, V62, P6973; Shendure J, 2002, GENOME BIOL, V3; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Sorek R, 2003, NUCLEIC ACIDS RES, V31, P1067, DOI 10.1093/nar/gkg170; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; Tufarelli C, 2003, NAT GENET, V34, P157, DOI 10.1038/ng1157; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	37	115	141	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6684	6692		10.1038/sj.onc.1207880	http://dx.doi.org/10.1038/sj.onc.1207880			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221013				2022-12-17	WOS:000223530800017
J	Hall, EJ; Hei, TK				Hall, EJ; Hei, TK			Genomic instability and bystander effects induced by high-LET radiation	ONCOGENE			English	Article						alpha-particles; microbeam; bystander effects; gene amplification; allelic imbalance	BRONCHIAL EPITHELIAL-CELLS; ALPHA-PARTICLES; GENE AMPLIFICATION; MAMMALIAN-CELLS; LOW FLUENCES; IONIZING-RADIATION; IN-VITRO; TRANSFORMATION; MICROBEAM; CORRELATE	An understanding of the radiobiological effects of high-linear energy transfer (LET) radiation is essential for radiation protection and human risk assessment. Ever since the discovery of X-rays was made by Rontgen more than a century ago, it has always been accepted that the deleterious effects of ionizing radiation, such as mutation and carcinogenesis, are due mainly to direct damage to DNA. With the availability of a precision single-particle microbeam, it is possible to demonstrate, unequivocally, the presence of a bystander effect with many biological end points. These studies provide clear evidence that irradiated cells can induce a bystander mutagenic response in neighboring cells not directly traversed by alpha-particles, and that cell-cell communication processes play a critical role in mediating the bystander phenomenon. Following exposure to high-LET radiation, immortalized human bronchial (BEP2D) and breast (MCF-10F) cells have been shown to undergo malignant transformation through a series of successive steps, before becoming tumorigenic in nude mice. There is a progressive increase in genomic instability, determined either by gene amplification or allelic imbalance, with the highest incidence observed among established tumor cell lines, relative to transformed, nontumorigenic and control cell lines.	Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University	Hall, EJ (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.	ejh1@Columbia.edu			NCI NIH HHS [CA 49062] Funding Source: Medline; NCRR NIH HHS [RR 11623] Funding Source: Medline; NIEHS NIH HHS [ES 07890, ES 10349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007890, P42ES010349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Cheng TL, 1999, BRIT J CANCER, V79, P1378, DOI 10.1038/sj.bjc.6690221; Cohen BL, 2002, AM J ROENTGENOL, V179, P1137, DOI 10.2214/ajr.179.5.1791137; Dale Walter M., 1943, BRIT JOUR RADIOL, V16, P171; Dale Walter M., 1942, BIOCHEM JOUR, V36, P80; Dale WM, 1940, BIOCHEM J, V34, P1367, DOI 10.1042/bj0341367; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINENDEGEN LE, 1998, PHYS SOC, V27, P4; Hall E, 2000, RAD BIOL RADIOLOGIST; HEI TK, 1996, ADV SPACE RES-SERIES, V18, P137, DOI 10.1016/0273-1177(95)00800-T; Hei TK, 2001, ADV SPACE RES-SERIES, V27, P411, DOI 10.1016/S0273-1177(01)00009-6; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; Hei TK, 1997, P NATL ACAD SCI USA, V94, P3765, DOI 10.1073/pnas.94.8.3765; HEI TK, 1996, RADIAT ONCOL INVEST, V3, P398; International Commission on Radiological Protection, 1991, 60 ICRP 60 ICRP; KOTVAL JP, 1947, J GENET, V48, P135, DOI 10.1007/BF02989375; Lea D., 1944, PARASITOLOGY, V36, P110, DOI 10.1017/S003118200001204X; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MITCHELL SA, 2003, MICR PROB CELL RAD R; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Nagar S, 2003, CANCER RES, V63, P324; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Nagasawa H, 2002, MUTAT RES-FUND MOL M, V508, P121, DOI 10.1016/S0027-5107(02)00193-8; NAGASAWA H, 1992, CANCER RES, V52, P6394; NCRP 116. National Council on Radiation Protection and Measurements, 1993, 116 NCRP; Piao CQ, 2001, RADIAT RES, V155, P263, DOI 10.1667/0033-7587(2001)155[0263:GAAMII]2.0.CO;2; Piao CQ, 1999, CARCINOGENESIS, V20, P1529, DOI 10.1093/carcin/20.8.1529; Prise KM, 2002, ADV SPACE RES, V30, P871, DOI 10.1016/S0273-1177(02)00408-8; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Roy D, 2001, MOL CARCINOGEN, V31, P192, DOI 10.1002/mc.1054; Roy D, 2001, CARCINOGENESIS, V22, P1685, DOI 10.1093/carcin/22.10.1685; Sawant SG, 2002, RADIAT RES, V157, P361, DOI 10.1667/0033-7587(2002)157[0361:TRIBEF]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; SOULE HD, 1990, CANCER RES, V50, P6075; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; Weaver DA, 1997, CARCINOGENESIS, V18, P1251, DOI 10.1093/carcin/18.6.1251; Weaver DA, 2000, CARCINOGENESIS, V21, P205, DOI 10.1093/carcin/21.2.205; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798	47	115	126	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7034	7042		10.1038/sj.onc.1206900	http://dx.doi.org/10.1038/sj.onc.1206900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557808				2022-12-17	WOS:000185903900008
J	Tsou, AP; Yang, CW; Huang, CYF; Yu, RCT; Lee, YCG; Chang, CW; Chen, BR; Chung, YF; Fann, MJ; Chi, CW; Chiu, JH; Chou, CK				Tsou, AP; Yang, CW; Huang, CYF; Yu, RCT; Lee, YCG; Chang, CW; Chen, BR; Chung, YF; Fann, MJ; Chi, CW; Chiu, JH; Chou, CK			Identification of a novel cell cycle regulated gene, HURP, overexpressed in human hepatocellular carcinoma	ONCOGENE			English	Article						HURP; heptocellular carcinoma; liver regeneration; cell cycle regulator; bioinformatics	MITOTIC CHECKPOINT GENES; LIVER-REGENERATION; HUMAN CANCERS; HEPATITIS-B; EXPRESSION; KINASE; PROGRESSION; PATHOGENESIS; MUTATIONS; HOMOLOG	An analytic strategy was followed to identify putative regulatory genes during the development of human hepatocellular carcinoma (HCC). This strategy employed a bioinformatics analysis that used a database search to identify genes, which are differentially expressed in human HCC and are also under cell cycle regulation. A novel cell cycle regulated gene (HURP) that is overexpressed in HCC was identified. Full-length cDNAs encoding the human and mouse HURP genes were isolated. They share 72 and 61% identity at the nucleotide level and amino-acid level, respectively. Endogenous levels of HURP mRNA were found to be tightly regulated during cell cycle progression as illustrated by its elevated expression in the G(2)/M phase of synchronized HeLa cells and in regenerating mouse liver after partial hepatectomy. Immunofluorescence studies revealed that hepatoma up-regulated protein (HURP) localizes to the spindle poles during mitosis. Overexpression of HURP in 293T cells resulted in an enhanced cell growth at low serum levels and at polyhema-based, anchorage-independent growth assay. Taken together, these results strongly suggest that HURP is a potential novel cell cycle regulator that may play a role in the carcinogenesis of human cancer cells.	Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Tradit Med, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chou, CK (corresponding author), Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.		Huang, Chi-Ying/AFL-7729-2022; Huang, Chi-Ying/AAG-7672-2022	Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Boyer N, 2000, J HEPATOL, V32, P98, DOI 10.1016/S0168-8278(00)80419-5; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Ferea TL, 1999, CURR OPIN GENET DEV, V9, P715, DOI 10.1016/S0959-437X(99)00033-7; Hansen LK, 1999, J CELL SCI, V112, P2971; Higgins GM, 1931, ARCH PATHOL, V12, P186; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kawada M, 1997, BIOCHEM BIOPH RES CO, V231, P735, DOI 10.1006/bbrc.1997.6179; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Menjo M, 1998, J GASTROEN HEPATOL, V13, pS100; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Nelsen CJ, 2001, ONCOGENE, V20, P1825, DOI 10.1038/sj.onc.1204248; Okabe H, 2001, CANCER RES, V61, P2129; Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6; Pfleger CM, 2000, GENE DEV, V14, P655; SU Q, 1994, HEPATOLOGY, V20, P788, DOI 10.1002/hep.1840200404; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	29	115	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					298	307		10.1038/sj.onc.1206129	http://dx.doi.org/10.1038/sj.onc.1206129			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527899				2022-12-17	WOS:000180322400015
J	Benhar, M; Engelberg, D; Levitzki, A				Benhar, M; Engelberg, D; Levitzki, A			Cisplatin-induced activation of the EGF receptor	ONCOGENE			English	Article						cisplatin; EGF receptor; Src; glioblastoma; DNA damage	GROWTH-FACTOR RECEPTOR; N-TERMINAL KINASE; BCL-X-L; C-SRC; INDUCED APOPTOSIS; TYROSINE KINASES; PROTEIN-KINASE; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; PHOSPHORYLATION	Cisplatin (CDDP) is an efficient DNA-damaging antitumor agent employed for the treatment of various human cancers. CDDP activates nuclear as well as cytoplasmatic signaling pathways involved in regulation of the cell cycle, damage repair and programmed cell death. Here we report that CDDP also activates a membrane-integrated protein, the epidermal growth factor receptor (EGFR). We show that EGFR is activated in response to CDDP in various types of cells that overexpress the receptor, including transformed human glioma cells and human breast tumor cells. CDDP-induced EGFR activation requires its kinase activity, as it can be blocked by an EGFR kinase inhibitor or by expression of a kinase dead receptor. We also show that CDDP-induced EGFR activation is independent of receptor ligand. CDDP induces the activation of c-Src, and EGFR activation is blocked by Src-family inhibitor PP1, suggesting that Src kinases mediate CDDP-induced EGFR activation. We propose that EGFR activation in response to CDDP is a survival response, since inhibition of EGFR activation enhances CDDP-induced death. These findings show that signals generated by DNA damage can modulate EGFR activity, and argue that interfering with CDDP-induced EGFR activation in tumor cells might be a useful approach to sensitize these cells to genotoxic agents.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il	Benhar, Moran/AAV-5764-2020	Benhar, Moran/0000-0002-7094-3456				Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Gebauer G, 2000, INT J ONCOL, V16, P321; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KITAGAWA D, 2001, J BIOL CHEM, V2, P2; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Miyajima A, 1997, BRIT J CANCER, V76, P206, DOI 10.1038/bjc.1997.363; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Persons DL, 1999, CLIN CANCER RES, V5, P1007; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	43	115	120	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8723	8731		10.1038/sj.onc.1205980	http://dx.doi.org/10.1038/sj.onc.1205980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483525				2022-12-17	WOS:000179734400006
J	Segawa, T; Nau, ME; Xu, LL; Chilukuri, RN; Makarem, M; Zhang, W; Petrovics, G; Sesterhenn, IA; McLeod, DG; Moul, JW; Vahey, M; Srivastava, S				Segawa, T; Nau, ME; Xu, LL; Chilukuri, RN; Makarem, M; Zhang, W; Petrovics, G; Sesterhenn, IA; McLeod, DG; Moul, JW; Vahey, M; Srivastava, S			Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen regulated genes; gene chip; endoplasmic reticulum stress response	UNFOLDED PROTEIN RESPONSE; FATTY-ACID SYNTHASE; RECEPTOR GENE; ORNITHINE DECARBOXYLASE; POLYAMINE LEVELS; CARCINOMA-CELLS; GROWTH-FACTOR; IN-VIVO; PROGRESSION; MODEL	Evaluations of androgen regulated gene (ARG) repertoire provide new insights into the androgen receptor (AR) mediated signaling at the transcriptional level. Definition of ARGs having critical functions in the biology of normal and malignant prostate should aid in identifying new bio-markers and therapeutic targets for prostate cancer (CaP). Using Affymetrix HuGene FL oligonucleotide arrays, temporal expression profiles of ARGs in widely used hormone responsive LNCaP cells, were analysed by hierarchical clustering methods and functional classification. ARGs in response to different androgen concentrations showed temporal co-regulation of genes involved in specific biochemical pathways. This study focuses on our new observations of the coordinated androgen induction of genes (NDRG1, PDIR, HERPUD1, ORP150) involved in the endoplasmic reticulum (ER) stress response pathway. Expression analysis of the two selected ER stress responsive genes, NDRG1 and HERPUD1 in primary CaPs revealed a significantly reduced tumor associated expression. Intriguing linkage of the androgen signaling to ER stress responsive genes, a protective response to protein unfolding or protein damage resulting from cellular stress signals, suggests that androgens may induce such stress signals in CaP cells. Decreased CaP associated expression of two ER stress responsive genes also suggests that possible abrogation of this pathway in prostate tumorigenesis.	Uniformed Serv Univ Hlth Sci, Ctr Prostrate Dis Res, Dept Surg, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Urol Serv, Washington, DC 20307 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20307 USA; Walter Reed Army Inst Res, Div Retrovirol, Affymetrix Gene Array Lab, Rockville, MD 20850 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Srivastava, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostrate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	ssrivastava@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X				Amler LC, 2000, CANCER RES, V60, P6134; Augustus M, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P321; Bettuzzi S, 2000, CANCER RES, V60, P1472; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; COFFEY DS, 1992, CAMPBELLS UROLOGY, V1, P221; CROZAT A, 1992, ENDOCRINOLOGY, V130, P1131, DOI 10.1210/en.130.3.1131; CULIG Z, 1994, CANCER RES, V54, P5474; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FJOSNE HE, 1990, PROSTATE, V17, P1, DOI 10.1002/pros.2990170102; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Greeve I, 2000, J NEUROSCI, V20, P7345; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Guang RJ, 2000, CANCER RES, V60, P749; Hakimi JM, 1996, WORLD J UROL, V14, P329; Hardy DO, 1996, J CLIN ENDOCR METAB, V81, P4400, DOI 10.1210/jc.81.12.4400; Heemers H, 2001, MOL ENDOCRINOL, V15, P1817, DOI 10.1210/me.15.10.1817; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huggins C, 1941, CANCER RES, V1, P293; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kanai S, 1998, J MOL EVOL, V47, P200, DOI 10.1007/PL00006377; Koike C, 1999, CANCER RES, V59, P6109; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lin BY, 2000, CANCER RES, V60, P858; Lin BY, 2001, CANCER RES, V61, P1611; Messing EM, 1999, J NATL CANCER I, V91, P1416, DOI 10.1093/jnci/91.16.1416; Mohan RR, 1999, CLIN CANCER RES, V5, P143; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mousses S, 2002, CANCER RES, V62, P1256; Myers RB, 2001, J UROLOGY, V165, P1027, DOI 10.1016/S0022-5347(05)66596-2; Nagabhushan M, 1996, CANCER RES, V56, P3042; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; NOBLE RL, 1977, CANCER RES, V37, P1929; Ozawa K, 1999, J BIOL CHEM, V274, P6397, DOI 10.1074/jbc.274.10.6397; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Pollard M, 1998, PROSTATE, V37, P1, DOI 10.1002/(SICI)1097-0045(19980915)37:1<1::AID-PROS1>3.0.CO;2-L; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; ROSS R, 1986, JNCI-J NATL CANCER I, V76, P45; Segawa T, 1998, CANCER RES, V58, P2282; Simoneau AR, 2001, JNCI-J NATL CANCER I, V93, P57, DOI 10.1093/jnci/93.1.57; SMITH RC, 1995, NAT MED, V1, P1040, DOI 10.1038/nm1095-1040; Stanford JL, 1997, CANCER RES, V57, P1194; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; Vaarala MH, 2000, LAB INVEST, V80, P1259, DOI 10.1038/labinvest.3780134; van Laar T, 2000, FEBS LETT, V469, P123, DOI 10.1016/S0014-5793(00)01253-9; vanBelzen N, 1997, LAB INVEST, V77, P85; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Xu LL, 2000, CANCER RES, V60, P6568; Xu LL, 2001, INT J CANCER, V92, P322, DOI 10.1002/ijc.1196	59	115	116	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8749	8758		10.1038/sj.onc.1205992	http://dx.doi.org/10.1038/sj.onc.1205992			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483528				2022-12-17	WOS:000179734400009
J	Wistuba, II; Mao, L; Gazdar, AF				Wistuba, II; Mao, L; Gazdar, AF			Smoking molecular damage in bronchial epithelium	ONCOGENE			English	Article						smoking; preneoplasia; lung cancer	CELL LUNG CANCERS; ABERRANT PROMOTER METHYLATION; BRONCHOALVEOLAR LAVAGE FLUID; FORMER SMOKERS; RESPIRATORY EPITHELIUM; ONCOGENE MUTATIONS; GENE-EXPRESSION; P53 MUTATION; EARLY-STAGE; PATHOGENESIS	Our understanding of the molecular pathology of lung cancer is advancing rapidly with several specific genes and chromosomal regions being identified. Lung cancer appears to require many mutations in both dominant and recessive oncogenes to possess malignant phenotypes. Several genetic and epigenetic changes are common to all lung cancer histologic types, while others appear to be cell type specific. However, specific roles of the genes undergoing mutations and the order of cumulative molecular changes that lead to the development of each lung tumor histologic type remain to be fully elucidated. Recent findings of molecular abnormalities in normal appearing and preneoplastic bronchial epithelium from patients with lung cancer and chronic smokers suggest that genetic changes may serve as biomarkers for early diagnosis, risk assessment and monitoring response to chemoprevention.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Pontificia Univ Catolica Chile, Dept Anat Pathol, Santiago, Chile; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pontificia Universidad Catolica de Chile; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, NB8-106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358				Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Betticher DC, 1997, BRIT J CANCER, V75, P1761, DOI 10.1038/bjc.1997.300; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Colby T V, 1998, Adv Anat Pathol, V5, P205, DOI 10.1097/00125480-199807000-00001; Esteller M, 2001, CANCER RES, V61, P3225; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; Girard L, 2000, CANCER RES, V60, P4894; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hanahan D, 2000, NATURE, V406, P573, DOI 10.1038/35020662; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hittelman WN, 1999, MOLECULAR PATHOLOGY OF EARLY CANCER, P385; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; KISHIMOTO Y, 1995, JNCI-J NATL CANCER I, V87, P1224, DOI 10.1093/jnci/87.16.1224; Kitamura H, 1999, AM J CLIN PATHOL, V111, P610; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; Lam S, 1999, JNCI-J NATL CANCER I, V91, P691, DOI 10.1093/jnci/91.8.691; Lang S M, 2000, Eur J Med Res, V5, P341; Lee JJ, 2001, J NATL CANCER I, V93, P1081, DOI 10.1093/jnci/93.14.1081; MAO L, 1994, CANCER RES, V54, P1634; Mao L, 1997, J NATL CANCER I, V89, P857, DOI 10.1093/jnci/89.12.857; MILLS NE, 1995, J NATL CANCER I, V87, P1056, DOI 10.1093/jnci/87.14.1056; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NUORVA K, 1993, AM J PATHOL, V142, P725; Palmisano WA, 2000, CANCER RES, V60, P5954; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Peto R, 2000, BRIT MED J, V321, P323, DOI 10.1136/bmj.321.7257.323; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Smith AL, 1996, BRIT J CANCER, V73, P203, DOI 10.1038/bjc.1996.36; Soria JC, 2002, CANCER RES, V62, P351; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Toyooka S, 2001, MOL CANCER THER, V1, P61; Viallet J, 1996, J CELL BIOCHEM, P228; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Wistuba II, 1999, ONCOGENE, V18, P643, DOI 10.1038/sj.onc.1202349; Wistuba II, 1999, CANCER RES, V59, P1973; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366; Yashima K, 1997, CANCER RES, V57, P2373; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	49	115	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	2002	21	48					7298	7306		10.1038/sj.onc.1205806	http://dx.doi.org/10.1038/sj.onc.1205806			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JW	12379874				2022-12-17	WOS:000178618000004
J	Channavajhala, P; Seldin, DC				Channavajhala, P; Seldin, DC			Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis	ONCOGENE			English	Article						casein kinase II; protein kinase CK2; c-myc; lymphoma; proteasome	II-ALPHA; COMPETITIVE INHIBITOR; PHOSPHORYLATION SITES; EPITHELIAL-CELLS; CASEIN KINASE-2; EXPRESSION; MICE; PROTEASOME; ACTIVATION; SUBUNIT	Protein kinase CK2 (formerly casein kinase II) is frequently upregulated in human cancers, and transgenic expression of CK2alpha in lymphocytes is oncogenic. Lymphomagenesis is dramatically acclerated by coexpression of a c-myc transgene, suggestive of a synergistic interaction between the kinase and the transcription factor. Since c-myc can be phosphorylated by CK2, we hypothesized that the synergy between CK2 and c-myc might be due to a functional interaction of the two molecules. Pharmacologic inhibition of CK2 activity in cell lines established from CK2alpha transgenic T cell lymphomas reduces their proliferation and concomitantly with this, the steady state levels of c-myc protein decline. This is caused by acclerated c-myc protein turnover, which occurs in a proteasome-dependent manner. Transfection of cells with sense or anti-sense CK2 constructs modulates c-myc protein levels in concert with the alteration in CK2 activity, validating the findings obtained using the kinase inhibitors. Thus, CK2 is a critical regulator of c-myc protein stability and of the proliferation of these T cell lymphomas.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Seldin, DC (corresponding author), 650 Albany St, Boston, MA 02118 USA.	dseldin@medicine.bu.edu		Seldin, David C/0000-0003-0168-2333	NCI NIH HHS [R01 CA71796] Funding Source: Medline; NHLBI NIH HHS [T32 HL07501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Battistutta R, 2000, J BIOL CHEM, V275, P29618, DOI 10.1074/jbc.M004257200; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BOLDYREFF B, 1993, BIOCHIM BIOPHYS ACTA, V1173, P32, DOI 10.1016/0167-4781(93)90239-A; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Critchfield JW, 1997, P NATL ACAD SCI USA, V94, P6110, DOI 10.1073/pnas.94.12.6110; Critchfield JW, 1996, AIDS RES HUM RETROV, V12, P39, DOI 10.1089/aid.1996.12.39; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; Dobrowolska G, 1999, MOL CELL BIOCHEM, V191, P3, DOI 10.1023/A:1006882910351; Dumont FJ, 1998, J IMMUNOL, V160, P2579; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; Faust RA, 1999, INT J BIOCHEM CELL B, V31, P941, DOI 10.1016/S1357-2725(99)00050-3; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; GAPANY M, 1995, MOL MED, V1, P659, DOI 10.1007/BF03401606; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; Guerra B, 1999, PHARMACOL THERAPEUT, V82, P303, DOI 10.1016/S0163-7258(98)00064-3; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Kamei H, 1998, CANCER BIOTHER RADIO, V13, P185, DOI 10.1089/cbr.1998.13.185; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lin JK, 1997, J CELL BIOCHEM, P39; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; Penn L J, 1990, Semin Cancer Biol, V1, P69; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1994, CELL MOL BIOL RES, V40, P383; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; Reddy KB, 1999, INT J CANCER, V82, P268, DOI 10.1002/(SICI)1097-0215(19990719)82:2<268::AID-IJC18>3.3.CO;2-W; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SNELL V, 1994, EMBO J, V13, P2066, DOI 10.1002/j.1460-2075.1994.tb06481.x; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; Trochon V, 2000, INT J CANCER, V85, P691, DOI 10.1002/(SICI)1097-0215(20000301)85:5&lt;691::AID-IJC15&gt;3.0.CO;2-Q; VONDEIMLING A, 1990, VERH DEUT G, V74, P432; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yim H, 1999, PLANTA MED, V65, P9, DOI 10.1055/s-1999-13953; Yin F, 1999, ANTICANCER RES, V19, P4297	54	115	123	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2002	21	34					5280	5288		10.1038/sj.onc.1205640	http://dx.doi.org/10.1038/sj.onc.1205640			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149649	Bronze			2022-12-17	WOS:000177193900009
J	Gallimore, PH; Turnell, AS				Gallimore, PH; Turnell, AS			Adenovirus E1A: remodelling the host cell, a life or death experience	ONCOGENE			English	Review						adenovirus; E1A; transformation; transcription; tumour suppressors	EARLY REGION 1A; NATURAL-KILLER-CELLS; HIGHLY ONCOGENIC ADENOVIRUS-12; RETINOBLASTOMA GENE-PRODUCT; TRANSFORMED RAT-CELLS; LARGE TUMOR-ANTIGEN; C-TERMINAL REGION; CLASS-I ENHANCER; NF-KAPPA-B; HISTONE DEACETYLASE		Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Gallimore, PH (corresponding author), Univ Birmingham, Sch Med, CRC Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	P.H.Gallimore@bham.ac.uk; A.S.Turnell@bham.ac.uk						Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALLISON AC, 1967, NATURE, V215, P185, DOI 10.1038/215185a0; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BARBEAU D, 1994, ONCOGENE, V9, P359; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERNARDS R, 1983, VIROLOGY, V127, P45, DOI 10.1016/0042-6822(83)90369-0; BOS JL, 1983, VIROLOGY, V131, P30; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREIDING DE, 1988, VIROLOGY, V164, P390, DOI 10.1016/0042-6822(88)90552-1; BROWN DT, 1975, J VIROL, V16, P366, DOI 10.1128/JVI.16.2.366-387.1975; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; BYRD PJ, 1988, VIROLOGY, V163, P155, DOI 10.1016/0042-6822(88)90242-5; BYRD PJ, 1988, ONCOGENE, V2, P477; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHATTERJEE PK, 1986, EMBO J, V5, P1633, DOI 10.1002/j.1460-2075.1986.tb04406.x; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERY CV, 1985, J GEN VIROL, V66, P2671, DOI 10.1099/0022-1317-66-12-2671; DIJKEMA R, 1982, GENE, V18, P143, DOI 10.1016/0378-1119(82)90112-3; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DUMONT DJ, 1989, J VIROL, V63, P987, DOI 10.1128/JVI.63.2.987-991.1989; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fax P, 2001, VIROLOGY, V285, P30, DOI 10.1006/viro.2001.0926; Fax P, 2000, J BIOL CHEM, V275, P40554, DOI 10.1074/jbc.M004626200; Fax P, 2000, J BIOL CHEM, V275, P8911, DOI 10.1074/jbc.275.12.8911; FLINT SJ, 1975, J MOL BIOL, V96, P47, DOI 10.1016/0022-2836(75)90181-3; Fraser RA, 1997, J BIOL CHEM, V272, P7122, DOI 10.1074/jbc.272.11.7122; FREEMAN AE, 1967, P NATL ACAD SCI USA, V58, P1205, DOI 10.1073/pnas.58.3.1205; FROST E, 1978, VIROLOGY, V91, P39, DOI 10.1016/0042-6822(78)90353-7; FUCHS M, 2001, IN PRESS CELL; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; FUJINAGA K, 1970, Proceedings of the National Academy of Sciences of the United States of America, V65, P375; FUJINAGA K, 1979, COLD SPRING HARB SYM, V44, P383; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; GALLIMORE PH, 1982, VIROLOGY, V120, P146, DOI 10.1016/0042-6822(82)90013-7; GALLIMORE PH, 1977, CELL, V10, P669, DOI 10.1016/0092-8674(77)90100-3; GALLIMORE PH, 1972, J GEN VIROL, V16, P99, DOI 10.1099/0022-1317-16-1-99; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GALLIMORE PH, 1985, CANCER RES, V45, P2670; Gallimore PH, 1984, VIRUSES CANCER, P125; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; GIRARDI AJ, 1964, P SOC EXP BIOL MED, V115, P1141, DOI 10.3181/00379727-115-29138; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRAHAM FL, 1978, VIROLOGY, V86, P10, DOI 10.1016/0042-6822(78)90003-X; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 2001, VIRUSES CELL TRANSFO, P43; GROSS L, 1996, ONCOGENIC VIRUSES, P784; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HALBERT DN, 1979, J VIROL, V31, P621, DOI 10.1128/JVI.31.3.621-629.1979; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARTER ML, 1978, J VIROL, V26, P736, DOI 10.1128/JVI.26.3.736-749.1978; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUEBNER RJ, 1962, P NATL ACAD SCI USA, V48, P2051, DOI 10.1073/pnas.48.12.2051; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JOCHEMSEN AG, 1986, J VIROL, V59, P684, DOI 10.1128/JVI.59.3.684-691.1986; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; JONES N, 1978, CELL, V13, P181, DOI 10.1016/0092-8674(78)90148-4; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KITCHINGMAN GR, 1977, P NATL ACAD SCI USA, V74, P4392, DOI 10.1073/pnas.74.10.4392; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; Kushner DB, 1996, ONCOGENE, V12, P143; Kushner DB, 1999, MOL CELL BIOL, V19, P2169; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lei M, 2001, J CELL SCI, V114, P1447; LEWIS JB, 1976, CELL, V7, P141, DOI 10.1016/0092-8674(76)90264-6; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; MATSUMOTO K, 1995, J BIOL CHEM, V270, P9645, DOI 10.1074/jbc.270.16.9645; MCBRIDE WD, 1964, P SOC EXP BIOL MED, V115, P870, DOI 10.3181/00379727-115-29060; Melhuish TA, 2000, J BIOL CHEM, V275, P39762, DOI 10.1074/jbc.C000416200; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Molloy DP, 1999, J BIOL CHEM, V274, P3503, DOI 10.1074/jbc.274.6.3503; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; Nemunaitis J, 2001, GENE THER, V8, P746, DOI 10.1038/sj.gt.3301424; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PEREIRA MS, 1965, LANCET, V1, P21; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; PETTERSSON U, 1973, J MOL BIOL, V73, P125, DOI 10.1016/0022-2836(73)90164-2; PHILPOTT N, 2001, VIRUSES CELL TRANSFO, P413; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Proffitt JA, 1997, FEBS LETT, V400, P141, DOI 10.1016/S0014-5793(96)01375-0; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RASKA K, 1982, VIROLOGY, V123, P8, DOI 10.1016/0042-6822(82)90290-2; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSSELL WC, 1971, J GEN VIROL, V11, P35, DOI 10.1099/0022-1317-11-1-35; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHARP PA, 1974, COLD SPRING HARB SYM, V39, P457, DOI 10.1101/SQB.1974.039.01.058; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, FIELDS VIROLOGY, P2111; Smirnov DA, 2001, VIROLOGY, V284, P13, DOI 10.1006/viro.2001.0913; Smirnov DA, 2000, VIROLOGY, V268, P319, DOI 10.1006/viro.1999.0181; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; SUGISAKI H, 1980, CELL, V20, P777, DOI 10.1016/0092-8674(80)90324-4; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; TREMBLAY ML, 1988, J BIOL CHEM, V263, P6375; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; TRENTIN JJ, 1968, P SOC EXP BIOL MED, V127, P683, DOI 10.3181/00379727-127-32773; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Turnell AS, 1999, J VIROL, V73, P2074, DOI 10.1128/JVI.73.3.2074-2083.1999; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; VANORMONDT H, 1980, GENE, V11, P299, DOI 10.1016/0378-1119(80)90070-0; VANORMONDT H, 1978, GENE, V4, P309, DOI 10.1016/0378-1119(78)90048-3; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Whalen SG, 1996, J VIROL, V70, P5373, DOI 10.1128/JVI.70.8.5373-5383.1996; White E, 1998, SEMIN VIROL, V8, P505, DOI 10.1006/smvy.1998.0155; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; YABE Y, 1962, P SOC EXP BIOL MED, V111, P343, DOI 10.3181/00379727-111-27786; YABE Y, 1964, SCIENCE, V143, P46, DOI 10.1126/science.143.3601.46; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOHN DS, 1965, J NATL CANCER I, V35, P617; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699	181	115	119	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7824	7835		10.1038/sj.onc.1204913	http://dx.doi.org/10.1038/sj.onc.1204913			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753665				2022-12-17	WOS:000172336500002
J	Kimura, SH; Ikawa, M; Ito, A; Okabe, M; Nojima, H				Kimura, SH; Ikawa, M; Ito, A; Okabe, M; Nojima, H			Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery	ONCOGENE			English	Article						cyclin G1; cyclin G1-disrupted mouse; p53; G2/M arrest	CELL-CYCLE; CHROMOSOMAL LOCALIZATION; P53-MEDIATED APOPTOSIS; GENOMIC INTEGRITY; GENE-TRANSFER; P53; EXPRESSION; PROTEIN; RNA; MICE	Cyclin G1 is one of the target genes of the transcription factor p53, and is induced in a p53-dependent manner in response to DNA damage. Although cyclin G1 has been implicated in a range of biological phenomena, its precise function remains unclear. Here we present an analysis of the physiological role of cyclin Ct using mice homozygous for a targeted disruption of the cyclin G1 gene. In order to clarify the role of cyclin G1 in the p53 pathway, downstream events such as apoptosis, cell growth and cell cycle checkpoint control were analysed in thymocytes and embryonic fibroblasts derived from cyclin G1-disrupted mice. No difference was detected in induction of apoptosis between mouse embryo fibroblasts (MEFs) derived from cyclin G1(+/+) and cyclin G1(-/-) mice. Following irradiation, cyclin G1(-/-) MEFs proliferated more slowly and reached lower cell densities in culture dishes than cyclin G1(+/+) MEFs, Analysis of cell survival showed that cyclin G1(-/-) MEFs were about twice as sensitive as cyclin G1(+/+) MEFs to gamma radiation or UV radiation. Cyclin G1(-/-) mice were more sensitive to gamma radiation than wild-type mice. Flow cytometeric analysis revealed that the number of cyclin G1(-/-) MEFs in G2/M phase after irradiation was reduced by 50% relative to cyclin G1(+/+) MEFs, Our results demonstrate that cyclin ct plays roles in G2/M arrest, damage recovery and growth promotion after cellular stress.	Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Nojima, H (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Mol Genet, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Asahina H, 1999, MUTAT RES-DNA REPAIR, V435, P255, DOI 10.1016/S0921-8777(99)00051-8; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bates S, 1996, ONCOGENE, V13, P1103; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; FANTES P, 1993, CELL CYCLE PRACTICAL, P6; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; Hunt T, 1991, Semin Cell Biol, V2, P213; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kimura SH, 1997, GENOMICS, V46, P483, DOI 10.1006/geno.1997.5034; Kimura SH, 1997, GENOMICS, V44, P179, DOI 10.1006/geno.1997.4873; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MIYASHITA T, 1995, CELL, V80, P293; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morita N, 1996, J NEUROSCI, V16, P5961; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PINES J, 1991, CELL GROWTH DIFFER, V2, P305; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Robertson E, 1987, TERATOCARCINOMAS EMB; ROSSI CC, 1998, TOXICOL LETT, V102, P491; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sambrook J, 1989, MOL CLONING LAB MANU; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SKOTZKO M, 1995, CANCER RES, V55, P5493; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; TAMURA K, 1993, ONCOGENE, V8, P2113; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	53	115	125	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3290	3300		10.1038/sj.onc.1204270	http://dx.doi.org/10.1038/sj.onc.1204270			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423978				2022-12-17	WOS:000169163500012
J	Michieli, P; Basilico, C; Pennacchietti, S; Maffe, A; Tamagnone, L; Giordano, S; Bardelli, A; Comoglio, PM				Michieli, P; Basilico, C; Pennacchietti, S; Maffe, A; Tamagnone, L; Giordano, S; Bardelli, A; Comoglio, PM			Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists	ONCOGENE			English	Article						growth factors; invasive growth; oncogenes; transformation; tyrosine kinases	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; RECEPTOR TYROSINE KINASE; CONSTITUTIVELY ACTIVATING MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; PAPILLARY RENAL CARCINOMAS; C-MET; CELL-LINE; PROTOONCOGENE PRODUCT; FACTOR/SCATTER FACTOR	Mutations in the genes encoding for Met, Ret and Kit receptor tyrosine kinases invariably result in increased kinase activity and in the acquisition of transforming potential. However, the requirement of receptor ligands for the transformation process is still unclear. We have investigated the role of hepatocyte growth factor (HGF), the high-affinity ligand for Met, in mutant Met-mediated cell transformation. We provide evidence that the transforming potential displayed by mutant forms of Met found in human cancer is not only sensitive but entirely dependent on the presence of HGF, by showing that mutant Met transforms NIH3T3 fibroblasts, which produce endogenous HGF, but is not able to transform epithelial cells, unless exogenous HGF is supplied. Accordingly, mutant Met-induced transformation of NIH3T3 cells can be inhibited by HGF antagonists and increased by HGF stimulation, We also show that an engineered Met receptor which contains an oncogenic mutation but is impaired in its ability to bind HGF completely loses its transforming activity, which can be rescued by causing receptor dimerization using a monoclonal antibody. These results indicate that point mutations resulting in Met kinase activation are necessary but not sufficient to cause cell transformation, the latter being dependent on ligand-induced receptor dimerization, They also suggest that mutant Met-driven tumour growth depends on the availability and tissue distribution of active HGF, and provide proof-of-concept for the treatment of mutant-Met related pathologies by HGF-antagonizing drugs.	Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment,Dept Mol Oncol, I-10060 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Michieli, P (corresponding author), Univ Turin, Sch Med, IRCC, Inst Canc Res & Treatment,Dept Mol Oncol, Str Provinciale 142,Km 3-95, I-10060 Turin, Italy.		Basilico, Cristina/A-3253-2011; Michieli, Paolo/A-2588-2011; Tamagnone, Luca/J-8948-2018; Pennacchietti, Selma/A-3252-2011; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	Michieli, Paolo/0000-0002-3093-8871; Tamagnone, Luca/0000-0002-2884-7946; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; BARDELLI A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P41; Birchmeier W, 1997, CIBA F SYMP, V212, P230; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Borrello MG, 1995, ONCOGENE, V11, P2419; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1998, FEBS LETT, V430, P126, DOI 10.1016/S0014-5793(98)00558-4; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Giordano S, 1992, Eur J Cancer Prev, V1 Suppl 3, P45, DOI 10.1097/00008469-199210003-00007; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kitayama H, 1996, BLOOD, V88, P995; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARK MR, 1992, J BIOL CHEM, V267, P26166; MASUMOTO K, 1993, HEPATOCYTE GROWTH FA, P225; MICHIELI P, 1996, ONCOGENE, V12, P755; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moriyama Y, 1996, J BIOL CHEM, V271, P3347; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; NISHINO T, 1995, BLOOD, V85, P3093, DOI 10.1182/blood.V85.11.3093.bloodjournal85113093; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; VANDEWOUDE J, 1997, CIBA FDN S, V212, P119; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHEN Z, 1994, ONCOGENE, V9, P1691; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	71	115	121	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5221	5231		10.1038/sj.onc.1202899	http://dx.doi.org/10.1038/sj.onc.1202899			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498872				2022-12-17	WOS:000082555700011
J	Russell, A; Thompson, MA; Hendley, J; Trute, L; Armes, J; Germain, D				Russell, A; Thompson, MA; Hendley, J; Trute, L; Armes, J; Germain, D			Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer	ONCOGENE			English	Article						D-type cyclin; breast cancer; proteolysis; SCF	CELL-CYCLE; ESTROGEN-RECEPTOR; EXPRESSION; GENE; DEGRADATION; PROTEIN; D2; DIFFERENTIATION; UBIQUITINATION; AMPLIFICATION	D-type cyclins are important cell cycle regulators that promote cellular proliferation in response to growth factors by inactivation of the retinoblastoma protein (Rb), Cyclin D1 has been shown to be overexpressed in several cancer types and to act as an oncogene in breast cancers. As D-type cyclins are rate limiting for progression into S phase, the level at which they accumulate must be carefully regulated. Several mechanisms leading to overexpression of cyclin D1 have been reported including amplification, translocation and stabilization of the mRNA, Here, we present data showing elevated cyclin D1 protein in breast cancer samples in the absence of elevated mRNA level. Further, we found that in these cases, cyclin D3 protein also accumulates and that the coordinate increase in cyclin D1 and D3 occurs in 15% (7/47) of breast cancers. In addition we show that blocking the activity of the 26S proteosome results in the accumulation of cyclin D1 and D3, that both D-type cyclins are abiquitinated and associate with Cul-1, a component of the SCF ubiquitin Ligase complex. Finally, we show that the coordinated elevation of cyclin D1 and D3 is also observed in the breast cell line MCF-7 and demonstrate that the degradation of cyclin D1 and D3 is deficient in this cell line. These results indicate that cyclin D1 and cyclin D3 share a common mechanism of degradation and we propose that the coordinate increase of D-type cyclins observed in primary breast cancers reflects a defect in their proteolysis.	Peter MacCallum Canc Inst, Trescowthick Res Lab, Melbourne, Vic 3000, Australia	Peter Maccallum Cancer Center	Germain, D (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Lab, Locked Bag 1,Abeckett St, Melbourne, Vic 3000, Australia.		Armes, Jane/D-6396-2012	Armes, Jane/0000-0002-2215-0347				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; GILLETT C, 1994, CANCER RES, V54, P1812; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HERBER B, 1994, ONCOGENE, V9, P1295; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welcker M, 1996, ONCOGENE, V13, P419; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	41	115	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1983	1991		10.1038/sj.onc.1202511	http://dx.doi.org/10.1038/sj.onc.1202511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208420				2022-12-17	WOS:000079191300008
J	Laudet, V; Hanni, C; Stehelin, D; Duterque-Coquillaud, M				Laudet, V; Hanni, C; Stehelin, D; Duterque-Coquillaud, M			Molecular phylogeny of the ETS gene family	ONCOGENE			English	Article						phylogeny; ETS family; transcription factors; DNA binding domains	EWINGS-SARCOMA TRANSLOCATION; DNA-BINDING SPECIFICITIES; TRANSCRIPTION FACTOR PU.1; C-FOS; CHROMOSOMAL TRANSLOCATION; DOMAIN PROTEIN; FACTORS ELK-1; MURINE ETS-1; HOX GENES; EWS GENE	We have constructed a molecular phylogeny of the ETS gene family, By distance and parsimony analysis of the ETS conserved domains we show that the family containing so far 29 different genes in vertebrates can be divided into 13 groups of genes namely ETS, ER71, GABP, PEA3, ERG, ERF, ELK, DETS4, ELF, ESE, TEL, YAN, SPI, Since the three dimensional structure of the ETS domain has revealed a similarity with the winged-helix - turn- helix proteins, we used two of them (CAP and HSF) to root the tree. This allowed us to show that the family can be divided into five subfamilies: ETS, DETS4, ELF, TEL and SPI, The ETS subfamily comprises the ETS, ER71, GABP, PEA3, ERG, ERF and the ELK groups which appear more related to each other than to any other ETS family members. The fact that some members of these subfamilies were identified in early metazoans such as diploblasts and sponges suggests that the diversification of ETS family genes predates the diversification of metazoans. By the combined analysis of both the ETS and the PNT domains, which are conserved in some members of the family, we showed that the GABP group, and not the ERG group, is the one most closely related to the ETS group. We also observed that the speed of accumulation of mutations in the various genes of the family is highly variable, Noticeably, paralogous members of the ELK group exhibit strikingly different evolutionary speed suggesting that the evolutionary pressure they support is very different.	Ecole Normale Super Lyon, UMR 49 CNRS, F-69364 Lyon 07, France; Inst Biol Lille, CNRS UMR 319, F-59021 Lille, France; Univ Lyon 1, CGMC, UMR CNRS 5534, F-69962 Villeurbanne, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Laudet, V (corresponding author), Ecole Normale Super Lyon, UMR 49 CNRS, 46 Allee Italie, F-69364 Lyon 07, France.			Duterque-Coquillaud, Martine/0000-0003-3943-5629				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Averof M, 1997, CURR BIOL, V7, pR634, DOI 10.1016/S0960-9822(06)00321-6; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Buttice G, 1996, ONCOGENE, V13, P2297; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Escriva H, 1997, P NATL ACAD SCI USA, V94, P6803, DOI 10.1073/pnas.94.13.6803; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; JEON IS, 1995, ONCOGENE, V10, P1229; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kasahara M, 1996, P NATL ACAD SCI USA, V93, P9096, DOI 10.1073/pnas.93.17.9096; Katsanis N, 1996, GENOMICS, V35, P101, DOI 10.1006/geno.1996.0328; Kherrouche Z, 1998, ONCOGENE, V16, P1357, DOI 10.1038/sj.onc.1201650; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LANDSMAN D, 1995, TRENDS BIOCHEM SCI, V20, P225, DOI 10.1016/S0968-0004(00)89021-0; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; Ohno S., 1970, EVOLUTION GENE DUPLI; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; PHILIPPE H, 1994, DEVELOPMENT, P15; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SETH A, 1990, ONCOGENE, V5, P1761; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; VERNIER P, 1995, TRENDS PHARMACOL SCI, V16, P375, DOI 10.1016/S0165-6147(00)89078-1; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	69	115	118	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1351	1359		10.1038/sj.onc.1202444	http://dx.doi.org/10.1038/sj.onc.1202444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022817				2022-12-17	WOS:000078510900011
J	Yin, XY; Grove, L; Datta, NS; Long, MW; Prochownik, EV				Yin, XY; Grove, L; Datta, NS; Long, MW; Prochownik, EV			C-myc overexpression and p53 loss cooperate to promote genomic instability	ONCOGENE			English	Article						c-myc; p53; tetraploidy; genomic instability	HUMAN-PAPILLOMAVIRUS TYPE-16; LYMPHOMA CELL-LINES; WILD-TYPE P53; NORMAL HUMAN FIBROBLASTS; DNA-DAMAGE; S-PHASE; GROWTH-FACTOR; CYCLE CONTROL; EMBRYO FIBROBLASTS; EPITHELIAL-CELLS	p53 monitors genomic integrity at the G1 and G2/M cell cycle checkpoints. Cells lacking p53 may show gene amplification as well as the polyploidy or aneuploidy typical of many tumors. The pathways through which this develops, however, are not well defined. We demonstrate here that the combination of p53 inactivation and c-myc overexpression in diploid cells markedly accelerates the spontaneous development of tetraploidy. This is not seen with either N-myc or L-myc. Tetraploidy is accompanied by significantly higher levels of cyclin B and its associated cdc2 kinase activity, Mitotic spindle poisons accelerate the appearance of tetraploidy in cells either lacking functional p53 or overexpressing c-myc whereas the combination is additive. Restoration of p53 function in cells overexpressing c-myc causing rapid apoptosis, indicating that cells yet to become tetraploid have nonetheless suffered irreversible genomic and/or mitotic spindle damage. In the face of normal p53 function, such damage would either be repaired or trigger apoptotis. We propose that loss of p53 and overexpression of c-myc permits the emergence and survival of cells with increasingly severe damage and the eventual development of tetraploidy.	Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Michigan, Med Ctr, Dept Pediat, Hematol Oncol Sect, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA; Univ Pittsburgh, Pittsburgh Canc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Hematol Oncol Sect, Pittsburgh, PA 15213 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33741] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BALLERINI P, 1993, BLOOD, V81, P166; BANKS L, 1990, ONCOGENE, V5, P833; Barbosa MS, 1996, CRIT REV ONCOGENESIS, V7, P1; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BLANDINO G, 1995, ONCOGENE, V10, P731; BLOUNT PL, 1994, CANCER RES, V54, P2292; CARDER P, 1993, ONCOGENE, V8, P1397; Coursen JD, 1997, EXP CELL RES, V235, P245, DOI 10.1006/excr.1997.3670; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, ONCOGENE, V8, P2457; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUIBREGTSE JM, 1994, COLD SPRING HARB SYM, V59, P237, DOI 10.1101/SQB.1994.059.01.028; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1991, CANCER RES, V51, P6304; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MA A, 1993, ONCOGENE, V8, P1093; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nesbit CE, 1998, BLOOD, V92, P1003; NESBIT CE, 1998, IN PRESS CELL GROWTH; OCONNOR PM, 1993, CANCER RES, V53, P4776; Oda D, 1996, CARCINOGENESIS, V17, P2003, DOI 10.1093/carcin/17.9.2003; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; PURDIE CA, 1994, ONCOGENE, V9, P603; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WALKER DH, 1995, CELL GROWTH DIFFER, V6, P1053; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WIMAN KG, 1991, ONCOGENE, V6, P1633; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	66	115	121	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1177	1184		10.1038/sj.onc.1202410	http://dx.doi.org/10.1038/sj.onc.1202410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022123				2022-12-17	WOS:000078510700006
J	Stewart, C; Parente, F; Piehl, F; Farnebo, F; Quincey, D; Silins, G; Bergman, L; Carle, GF; Lemmens, I; Grimmond, S; Xian, CZ; Khodei, S; Teh, BT; Lagercrantz, J; Siggers, P; Calender, A; Van de Vem, V; Kas, K; Weber, G; Hayward, N; Gaudray, P; Larsson, C				Stewart, C; Parente, F; Piehl, F; Farnebo, F; Quincey, D; Silins, G; Bergman, L; Carle, GF; Lemmens, I; Grimmond, S; Xian, CZ; Khodei, S; Teh, BT; Lagercrantz, J; Siggers, P; Calender, A; Van de Vem, V; Kas, K; Weber, G; Hayward, N; Gaudray, P; Larsson, C			Characterization of the mouse Men1 gene and its expression during development	ONCOGENE			English	Article						menin; multiple endocrine neoplasia type 1; mouse RNA in situ hybridization	ENDOCRINE NEOPLASIA TYPE-1; SPORADIC GASTRINOMAS; PARATHYROID TUMORS; MULTIPLE; MUTATIONS; IDENTIFICATION; CHROMOSOME-11; PROTEINS	The gene responsible for multiple endocrine neoplasia type 1 (MEN1), a heritable predisposition to endocrine tumours in man, has recently been identified. Here we have characterized the murine homologue with regard to cDNA sequence, genomic structure, expression pattern and chromosomal localisation, The murine Men1 gene spans approximately 6.7 kb of genomic DNA and is comprised of 10 exons with similar genomic structure to the human locus. It was mapped to the pericentromeric region of mouse chromosome 19, which is conserved with the human 11q13 band where MEN1 is located. The predicted protein is 611 amino acids in length and overall is 97% homologous to the human orthologue. The 45 reported MEN1 mutations which alter or delete a single amino acid in human all occur at conserved residues, thereby supporting their functional significance. Two transcripts of approximately 3.2 and 2.8 kb were detected in both embryonal and adult murine tissues, resulting from alternative splicing of intron 1, By RNA in situ hybridization and Northern analysis the spatiotemporal expression pattern of Men1 was determined during mouse development. Men1 gene activity was detected already at gestational day 7, At embryonic day 14 expression was generally high throughout the embryo, while at day 17 the thymus, skeletal muscle, and CNS showed the strongest signal. In selected tissues from postnatal mouse Men1 was detected in all tissues analysed and was expressed at high levels in cerebral cortex, hippocampus, testis, and thymus. In brain the menin protein was detected mainly in nerve cell nuclei, whereas in testis it appeared perinuclear in spermatogonia, These results show that Men1 expression is not confined to organs affected in MEN1, suggesting that Men1 has a significant function in many different cell types including the CNS and testis.	Karolinska Hosp, CMM, Dept Mol Med, S-17176 Stockholm, Sweden; PO Royal Brisbane Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Herston, Qld 4029, Australia; UNSA, CNRS, UMR 6549, F-06107 Nice, France; Karolinska Hosp, CMM, Dept Neurosci, S-17176 Stockholm, Sweden; Karolinska Hosp, CMM, Dept Surg, S-17176 Stockholm, Sweden; Katholieke Univ Leuven, Mol Oncol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Human Genet, B-3000 Louvain, Belgium; MRC, Didcot OX11 0RD, Oxon, England; Med Univ Claude Bernard Lyon 1, UMR 5641, CNRS, Lab Genet & Canc, Lyon, France	Karolinska Institutet; Karolinska University Hospital; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; MRC Harwell; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Larsson, C (corresponding author), Karolinska Hosp, CMM, Dept Mol Med, S-17176 Stockholm, Sweden.		Carle, Georges/GWC-5240-2022; hayward, nick/AAV-8802-2020; Grimmond, Sean M/J-5304-2016; Grimmond, Sean/K-3246-2019; Piehl, Fredrik/E-3451-2013; hayward, nicholas k/C-1367-2015; Weber, Günther/F-3410-2016	Grimmond, Sean M/0000-0002-8102-7998; Grimmond, Sean/0000-0002-8102-7998; hayward, nicholas k/0000-0003-4760-1033; Zhang, Chang Xian/0000-0002-5443-8951; Weber, Gunther/0000-0002-3861-808X; Bergman, Lee/0000-0002-0111-411X; Carle, Georges/0000-0002-3901-1052; Teh, Bin Tean/0000-0003-1514-1124				Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARON B, 1984, EXP CELL RES, V152, P220, DOI 10.1016/0014-4827(84)90247-7; Bassett JHD, 1998, AM J HUM GENET, V62, P232, DOI 10.1086/301729; BRANDI ML, 1993, AM J HUM GENET, V53, P1167; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courseaux A, 1996, GENOMICS, V37, P354, DOI 10.1006/geno.1996.0570; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Debelenko LV, 1997, CANCER RES, V57, P2238; Debelenko LV, 1997, HUM MOL GENET, V6, P2285, DOI 10.1093/hmg/6.13.2285; Farnebo F, 1998, J CLIN ENDOCR METAB, V83, P2627, DOI 10.1210/jc.83.8.2627; FRIEDMAN E, 1989, NEW ENGL J MED, V321, P213, DOI 10.1056/NEJM198907273210402; FRIEDMAN E, 1994, PARATHYROIDS BASIC C, V38, P647; GU W, 1995, J BIOL CHEM, V270, P236, DOI 10.1074/jbc.270.1.236; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; LINK DC, 1992, ONCOGENE, V7, P877; SAWICKI MP, 1992, HUM GENET, V89, P445; Shows TB, 1996, CYTOGENET CELL GENET, V74, P2; Teh BT, 1998, J CLIN ENDOCR METAB, V83, P2621, DOI 10.1210/jc.83.8.2621; THAKKER RV, 1989, NEW ENGL J MED, V318, P658; Toliat MR, 1997, LANCET, V350, P1223, DOI 10.1016/S0140-6736(05)63453-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Zhuang ZP, 1997, CANCER RES, V57, P4682; Zhuang ZP, 1997, CANCER RES, V57, P5446	30	115	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	1998	17	19					2485	2493		10.1038/sj.onc.1202164	http://dx.doi.org/10.1038/sj.onc.1202164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824159				2022-12-17	WOS:000076927300008
J	Geurts, JMW; Schoenmakers, EFPM; Roijer, E; Astrom, AK; Stenman, G; van de Ven, WJM				Geurts, JMW; Schoenmakers, EFPM; Roijer, E; Astrom, AK; Stenman, G; van de Ven, WJM			Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas	ONCOGENE			English	Article						NFIB; pleomorphic adenoma of the salivary glands; HMGIC	NUCLEAR FACTOR-I; SALIVARY-GLAND TUMORS; DNA-BINDING; PROTEINS; TRANSCRIPTION; PROMOTER; BREAKPOINT; CARCINOMA; CLONING; LIPOMAS	Approximately 12% of all pleomorphic adenomas of the salivary glands are characterized by chromosome aberrations involving the chromosome segment 12q13-15. Several chromosomes have been found as translocation partners of chromosome 12, and some of these recurrently. Recently, the HMGIC gene was identified as the target gene affected by the 12q13-15 aberrations. Here, me report the identification and characterization of a new translocation partner gene of HMGIC in pleomorphic adenomas, 3'-RACE analysis of a primary adenoma with an apparently normal karyotype revealed an HMGIC fusion transcript containing ectopic sequences derived from the human NFIB gene, previously mapped to chromosome band 9p24.1. The HMGIC NFIB fusion transcript was also confirmed by RT-PCR, Since the chromosome segment 9p12-24 is repeatedly involved as translocation partner of chromosome 12q13-15 in pleomorphic adenomas, we tested whether NFIB might be a recurrent partner of HMGIC, RT-PCR analysis of a second adenoma with an ins(9;12)(p23;q12q15) as the sole anomaly, revealed that also in this tumor an HMGIC/NFIB hybrid transcript was present, The reciprocal NFIB/HMGIC fusion transcript, however, could not be detected in any of these tumors, Nucleotide sequence analysis of the fusion transcripts indicated that the genetic aberration in both tumors resulted in the replacement of a carboxy-terminal segment of HMGIC by the last five amino acids of NFIB. In conclusion, our results reveal the recurrent involvement of the NFIB gene as translocation partner gene of HMGIC in pleomorphic adenomas.	Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Mol Oncol Lab, B-3000 Louvain, Belgium; Gothenburg Univ, Sahlgrens Hosp, Canc Genet Lab, S-41345 Gothenburg, Sweden	KU Leuven; Sahlgrenska University Hospital; University of Gothenburg	van de Ven, WJM (corresponding author), Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium.							APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; ASHAR HR, 1995, CELL, V82, P57; BULLERDIEK J, 1993, CANCER GENET CYTOGEN, V65, P27, DOI 10.1016/0165-4608(93)90054-P; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Fejzo MS, 1996, GENE CHROMOSOME CANC, V17, P1, DOI 10.1002/(SICI)1098-2264(199609)17:1<1::AID-GCC1>3.0.CO;2-0; Geurts JMW, 1997, CANCER RES, V57, P13; Geurts JMW, 1997, CANCER GENET CYTOGEN, V95, P198, DOI 10.1016/S0165-4608(96)00411-6; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; INOUE T, 1990, J BIOL CHEM, V265, P19065; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NORDKVIST A, 1994, GENE CHROMOSOME CANC, V10, P115, DOI 10.1002/gcc.2870100206; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; QIAN F, 1995, GENOMICS, V28, P66, DOI 10.1006/geno.1995.1107; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Roijer E, 1996, GENE CHROMOSOME CANC, V17, P166; ROULET E, 1995, MOL CELL BIOL, V15, P5552; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SHAH JP, 1990, CURR PROB SURG, V27, P779, DOI 10.1016/0011-3840(90)90032-Z; STENMAN G, 1994, CHROMOSOME 12 ABERRA, P3; TIJAN R, 1994, CELL, V77, P5; Tkachenko A, 1997, CANCER RES, V57, P2276; Waldron CA., 1991, SURG PATHOLOGY SALIV, P165; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0; ZORBAS H, 1992, J BIOL CHEM, V267, P8478	36	115	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					865	872		10.1038/sj.onc.1201609	http://dx.doi.org/10.1038/sj.onc.1201609			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484777				2022-12-17	WOS:000072053200005
J	Tahara, H; Tokutake, Y; Maeda, S; Kataoka, H; Watanabe, T; Satoh, M; Matsumoto, T; Sugawara, M; Ide, T; Goto, M; Furuichi, Y; Sugimoto, M				Tahara, H; Tokutake, Y; Maeda, S; Kataoka, H; Watanabe, T; Satoh, M; Matsumoto, T; Sugawara, M; Ide, T; Goto, M; Furuichi, Y; Sugimoto, M			Abnormal telomere dynamics of B-lymphoblastoid cell strains from Werner's syndrome patients transformed by Epstein-Barr virus	ONCOGENE			English	Article						Werner's syndrome; B-lymphoblastoid cells; telomere; telomerase; EBT	LINES; LYMPHOCYTES; ELONGATION	The characteristics of B-lymphoblastoid cell strains transformed by Epstein-Barr virus (EBV) from normal individuals and Werner's syndrome (WRN) patients were compared, We continuously passaged cell strains from 28 WRN patients and 20 normal individuals for about 2 years corresponding to over 160 population doubling levels (PDLs), First, the WRN mutation significantly suppressed the immortalization: all the 28 cell strains from WRN patients, as well as 15 out of 20 cell strains from normal individuals, died out before 160 PDLs mostly without developing a significant telomerase activity, The remaining five cell strains from normal individuals became moderately/strongly telomerase-positive and, three of them were apparently immortalized with an infinitively proliferating activity, Second, the monitoring of the telomere length of both normal and WRN cell strains during;the culture period suggests that the WRN gene mutation causes abnormal dynamics of the telomere: (1) a significant proportion of WRN cell strains showed drastic shortening or lengthening of telomere lengths during cell passages compared with normal cell strains, and (2) WRN cell strains terminated their life-span at a wide range of telomere length (between 3.5 and 18.5 Kbp), whereas normal cell strains terminated within a narrow telomere length range (between 5.5 and 9 Kbp), The chromosomal aberration characteristic of WRN cells, including translocation was confirmed in our experiment, We discussed the correlation between the chromosomal instability, abnormal telomere dynamics and inability of immortalization of the WRN B-lymphobloastoid cell strains.	AGENE,RES INST,KAMAKURA,KANAGAWA 247,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOL BIOL,MINAMI KU,HIROSHIMA 734,JAPAN; TOKYO METROPOLITAN OTSUKA HOSP,DEPT RHEUMATOL,TOSHIMA KU,TOKYO 170,JAPAN	Hiroshima University								Avilion AA, 1996, CANCER RES, V56, P645; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; BRYAN TM, 1997, IN PRESS EUR J CAN; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P175; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GOSDEN J, 1994, HUM MOL GENET, V3, P931, DOI 10.1093/hmg/3.6.931; Goto M, 1997, HUM GENET, V99, P191, DOI 10.1007/s004390050336; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; GOTO M, 1981, CLIN GENET, V19, P8; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HIROSE M, 1997, IN PRESS J CANC RES; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; MILLER G, 1990, VIROLOGY, P1921; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Norrback KF, 1996, BLOOD, V88, P222; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1985, ADV EXP MED BIOL, V190, P541; SALK D, 1985, ADV EXP MED BIOL, P305; SCHELLENBERG GD, 1992, LANCET, V339, P1002, DOI 10.1016/0140-6736(92)91590-5; Schulz VP, 1996, HUM GENET, V97, P750; Strahl C, 1996, MOL CELL BIOL, V16, P53; Sugihara S, 1996, HUM GENET, V97, P1; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	115	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1911	1920		10.1038/sj.onc.1201377	http://dx.doi.org/10.1038/sj.onc.1201377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365237				2022-12-17	WOS:A1997YA87200005
J	Whitesell, L; Sutphin, P; An, WG; Schulte, T; Blagosklonny, MV; Neckers, L				Whitesell, L; Sutphin, P; An, WG; Schulte, T; Blagosklonny, MV; Neckers, L			Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo	ONCOGENE			English	Article						ubiquitin; lactacystin; benzoquinone ansamycins; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE; MULTICATALYTIC PROTEINASE; ACTIVATING MUTATIONS; PROTEOLYTIC SYSTEM; TRANSFORMED-CELLS; E6 ONCOPROTEIN; MUTANT P53; DEGRADATION; COMPLEX	Mutation of the tumor suppressor gene p53 is the most common genetic abnormality detected in human cancers, Wild type p53 is a short-lived protein with very low basal intracellular levels, Most mutated forms of the protein, however, display markedly increased intracellular levels as an essential feature of their positive transforming activity, In this report, we have used selective inhibitors of the 20S proteasome to demonstrate that processing of p53 by ubiquitination and proteasome-mediated degradation is impaired by commonly occurring mutations of the protein, We found that this impairment of p53 turnover can be reversed by treatment of tumor cells with the benzoquinone ansamycin, geldanamycin, leading to a marked reduction in intracellular p53 levels. Finally, using cells which over-express a mutant p53 protein, we were able to demonstrate that restoration of proteasome-mediated degradation by geldanamycin is accompanied by p53 polyubiquitination, Although much remains to be learned about the mechanisms involved, our data demonstrate that selective de-stabilization of mutant transforming proteins such as p53 can be achieved pharmacologically with agents such as geldanamycin which modify the function of molecular chaperone proteins within tumor cells.	UNIV ARIZONA,DEPT PEDIAT,STEELE MEM CHILDRENS RES CTR,TUCSON,AZ 85724; NCI,CLIN PHARMACOL BRANCH,NIH,BETHESDA,MD 20892	University of Arizona; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [R29 CA-69537-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HADARI T, 1992, J BIOL CHEM, V267, P719; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; Maki CG, 1996, CANCER RES, V56, P2649; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHKEDY D, 1994, FEBS LETT, V348, P126, DOI 10.1016/0014-5793(94)00582-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	36	115	117	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2809	2816		10.1038/sj.onc.1201120	http://dx.doi.org/10.1038/sj.onc.1201120			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190897				2022-12-17	WOS:A1997XD64300009
J	Bol, DK; Kiguchi, K; GimenezConti, I; Rupp, T; DiGiovanni, J				Bol, DK; Kiguchi, K; GimenezConti, I; Rupp, T; DiGiovanni, J			Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice	ONCOGENE			English	Article						insulin-like growth factor-1; skin; tumor promotion; hyperplasia	FACTOR-I RECEPTOR; FACTOR-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; SKIN TUMORIGENESIS; MOUSE SKIN; PAPILLOMAS; EPIDERMIS; INDUCTION; CELLS	Transgenic animals were developed to assess the role of insulin-like growth factor 1 (IGF-1) in skin growth, differentiation and organization, as well as its importance in tumor formation. Expression of a human IGF-1 cDNA was targeted to the interfollicular epidermis of transgenic mice using a human keratin 1 promoter construct (HK1). Transgenic animals (HK1.IGF-1 mice) could be identified at birth by early ear unfolding and excessive ear and skin growth compared to nontransgenic littermates. Further examination of the skin from these mice showed epidermal hyperplasia and hyperkeratosis, marked thickening of the dermis and hypodermis, and early hair follicle generation in newborns. The severity of this phenotype correlated with transgene expression both of which subsided,vith age. Adult HK1.IGF-1 mice developed spontaneous tumors following treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) alone and exhibited an exaggerated epidermal proliferative response following treatment with the tumor promoter compared to non transgenic littermates. Additionally, HK1.IGF-1 transgenic mice developed papillomas faster and in markedly greater numbers compared to non-transgenic littermates in standard initiation-promotion experiments. The data presented suggest an important role for IGF-I in the process of multistage carcinogenesis in mouse skin.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV CARCINOGENESIS,DIV RES,SMITHVILLE,TX 78957	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672, R01CA037111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA37111, CA16672] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDO Y, 1993, J INVEST DERMATOL, V100, P633, DOI 10.1111/1523-1747.ep12472297; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASERGA R, 1995, CANCER RES, V55, P249; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAWSON TP, 1995, CANCER RES, V55, P915; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; ELDRIDGE SR, 1990, CARCINOGENESIS, V11, P2245, DOI 10.1093/carcin/11.12.2245; EWING MW, 1988, CANCER RES, V48, P7048; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GREENHALGH D, 1994, KERATINOCYTE HDB, P471; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; JANSEN M, 1983, NATURE, V306, P609, DOI 10.1038/306609a0; JHAPPAN C, 1994, CELL GROWTH DIFFER, V5, P385; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KIGUCHI K, 1995, MOL CARCINOGEN, V12, P225, DOI 10.1002/mc.2940120407; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MATTHEWS L S, 1988, Endocrinology, V123, P2827; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINUTO F, 1986, CANCER RES, V46, P985; NAITO M, 1987, CARCINOGENESIS, V8, P1807, DOI 10.1093/carcin/8.12.1807; QUAIFE CJ, 1989, ENDOCRINOLOGY, V124, P40, DOI 10.1210/endo-124-1-40; RECHLER MM, 1992, GROWTH REGULAT, V2, P55; RESNICOFF M, 1995, CANCER RES, V55, P3739; Rho O, 1996, MOL CARCINOGEN, V17, P62, DOI 10.1002/(SICI)1098-2744(199610)17:2<62::AID-MC2>3.0.CO;2-V; ROGLER CE, 1994, J BIOL CHEM, V269, P1379; ROOP DR, 1984, J BIOL CHEM, V259, P8037; ROSENTHAL DS, 1991, CELL GROWTH DIFFER, V2, P107; ROTHNAGEL JA, 1990, J INVEST DERMATOL, V94, P573; ROTWEIN P, 1993, MOL REPROD DEV, V35, P358, DOI 10.1002/mrd.1080350407; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; TAVAKKOL A, 1992, J INVEST DERMATOL, V99, P343, DOI 10.1111/1523-1747.ep12616668; TRICOLI JV, 1986, CANCER RES, V46, P6169; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WARD A, 1994, P NATL ACAD SCI USA, V91, P10365, DOI 10.1073/pnas.91.22.10365; XIAN WJ, 1995, CELL GROWTH DIFFER, V6, P1447; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509	46	115	122	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1725	1734		10.1038/sj.onc.1201011	http://dx.doi.org/10.1038/sj.onc.1201011			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135074				2022-12-17	WOS:A1997WR89300011
J	Kazmierczak, B; Rosigkeit, J; Wanschura, S; MeyerBolte, K; VandeVen, WJM; Kayser, K; Krieghoff, B; Kastendiek, H; Bartnitzke, S; Bullerdiek, J				Kazmierczak, B; Rosigkeit, J; Wanschura, S; MeyerBolte, K; VandeVen, WJM; Kayser, K; Krieghoff, B; Kastendiek, H; Bartnitzke, S; Bullerdiek, J			HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: A survey of 30 tumors	ONCOGENE			English	Article						chondroid hamartomas of the lung, 12q14-15; HMGI-C gene	DNA-BINDING DOMAIN; INSITU HYBRIDIZATION; PROTEIN	Pulmonary chondroid hamartomas (PCH) are benign tumors of the lung characterized by a more or less high degree of mesenchymal metaplasia, In our series we investigated 30 PCH by a combination of cytogenetic and molecular methods, 18 tumors (60%) had cytogenetically detectable aberrations involving either 12q14-15 or 6p21 with a clear predominance of chromosomal abnormalities involving 12q14-15 (15 tumors), As in subgroups of pleomorphic adenomas of the salivary glands, leiomyomas of the uterus, and lipomas with 12q14-15 abnormalities the HMGI-C gene is frequently rearranged we tested PCH with either 12q14-15 abnormalities or normal karyotype by FISH and 3' RACE experiments for rearrangements of HMGI-C, Rearrangements were found in all cases with chromosomal 12q14-15 abnormalities and further six cases with an apparently normal karyotype, By the combination of cytogenetics with molecular techniques the percentage of cases with intragenic rearrangements of HMGI-C or rearrangements of its immediate surrounding was thus increased to 70% (21/30 cases), Considering all types of aberrations within this series 80% (24/30) of all PCH were aberrant, This is the first report on a combined molecular and cytogenetic analysis of a large series of pulmonary chondroid hamartomas indicating that rearrangements of HMGI-C, a member of the high mobility group protein gene family, are the;leading molecular events in the genesis of PCH.	UNIV BREMEN,CTR HUMAN GENET & GENET COUNSELLING,ZHG,D-28359 BREMEN,GERMANY; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; LVA BODEN,HOSP PULM DIS,DEPT PATHOL,D-69126 HEIDELBERG,GERMANY; URBAN HOSP ST GEORGE,DEPT PATHOL,D-04129 LEIPZIG,GERMANY; PUBL HOSP HARBURG,DEPT PATHOL,D-21041 HAMBURG,GERMANY	University of Bremen; KU Leuven								ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BULLERDIEK J, 1987, CYTOGENET CELL GENET, V45, P187, DOI 10.1159/000132452; DALCIN P, 1993, GENE CHROMOSOME CANC, V8, P131; FLETCHER AJ, 1995, GENE CHROMOSOME CANC, V12, P220; FLETCHER JA, 1992, CANCER RES, V52, P6224; FLETCHER JA, 1991, AM J PATHOL, V138, P1199; JOHANSSON M, 1992, CANCER GENET CYTOGEN, V60, P219, DOI 10.1016/0165-4608(92)90026-5; JOHANSSON M, 1993, BRIT J CANCER, V67, P1236, DOI 10.1038/bjc.1993.231; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; KAZMIERCZAK B, 1995, AM J PATHOL, V147, P580; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; KOOLS PFJ, 1995, CANCER GENET CYTOGEN, V79, P1, DOI 10.1016/0165-4608(94)00137-Z; Koss MN, 1990, SURGICAL PATHOLOGY L, P418; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROMMEL B, 1988, CYTOMETRY, V9, P504, DOI 10.1002/cyto.990090517; SCHOENMAKERS EFPM, 1994, GENE CHROMOSOME CANC, V11, P106, DOI 10.1002/gcc.2870110207; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296	24	115	116	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637707				2022-12-17	WOS:A1996TV59700007
J	Dhordain, P; Albagli, O; Ansieau, S; Koken, MHM; Deweindt, C; Quief, S; Lantoine, D; Leutz, A; Kerckaert, JP; Leprince, D				Dhordain, P; Albagli, O; Ansieau, S; Koken, MHM; Deweindt, C; Quief, S; Lantoine, D; Leutz, A; Kerckaert, JP; Leprince, D			The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo	ONCOGENE			English	Article						LAZ3/BCL6; lymphoma; BTB/POZ domain; Kruppel-like Zinc finger; nuclear dots; two-hybrid system	POSITION-EFFECT VARIEGATION; FINGER ENCODING GENE; CONSERVED DOMAIN; PROTEIN; EXPRESSION; DROSOPHILA; TRANSLOCATIONS; SEGMENTATION; LOCALIZATION; ENHANCER	The LAZ3/BCL6 gene was identified by its disruption in 3q27 translocations associated with diffuse large cell lymphomas, It is predicted to be a transcription factor as it contains six Kruppel-like Zinc finger motifs and a N-terminal BTB/POZ domain, a protein/protein interaction interface that is widely conserved in Metazoans, Using two antisera raised against non overlapping regions of the predicted ORF, we demonstrate that the LAZ3/BCL6 protein appears as a close ca, 79 kDa doublet in B lymphoid cell lines with either a rearranged or a non rearranged LAZ3/BCL6 locus, By immunofluorescence experiments on transiently transfected COS-1 or NTH3T3 cells, we show that the LAZ3/BCL6 protein displays a punctuated nuclear localisation. This appears to rely on LAZ3/BCL6 proper folding and/or activities as it is impaired in a hormone reversible-fashion through fusion of LAZ3/BCL6 to the ligand-binding domain of the oestrogen receptor, Moreover, deletion of its BTB/POZ domain leads to the disappearance of the nuclear dots although the protein remains nuclear, In addition, by using the yeast two-hybrid system, we show that the LAZ3/BCL6 BTB/POZ domain homomerises in vivo, Thus, the LAZ3/BCL6 BTB/POZ domain has the capability to self-interact and target the protein to discrete nuclear substructures.	IRCL,U124 INSERM,F-59045 LILLE,FRANCE; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY; HOP ST LOUIS,CTR HAYEM,U43 CNRS,F-75475 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Leutz, Achim/K-9643-2013; koken, marcel/N-1349-2019; Ansieau, Stephane/I-6195-2016; koken, marcel/J-8154-2012	Leutz, Achim/0000-0001-8259-927X; koken, marcel/0000-0002-0839-0125; ANSIEAU, Stephane/0000-0003-0989-2108; Leprince, Dominique/0000-0002-1999-0775				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; BROWN JL, 1993, DEVELOPMENT, V117, P45; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; DANIEL MT, 1993, BLOOD, V82, P1858; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GODT D, 1993, DEVELOPMENT, V119, P799; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOBAYASHI H, 1993, BLOOD, V81, P3027; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; MIKI T, 1994, BLOOD, V83, P26; Miller J.H., 1972, EXPT MOL GENETICS; NACHEVA E, 1993, BLOOD, V82, P231, DOI 10.1182/blood.V82.1.231.bloodjournal821231; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	44	115	119	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2689	2697						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545127				2022-12-17	WOS:A1995TP18800026
J	LEE, JM; ABRAHAMSON, JLA; KANDEL, R; DONEHOWER, LA; BERNSTEIN, A				LEE, JM; ABRAHAMSON, JLA; KANDEL, R; DONEHOWER, LA; BERNSTEIN, A			SUSCEPTIBILITY TO RADIATION CARCINOGENESIS AND ACCUMULATION OF CHROMOSOMAL BREAKAGE IN P53 DEFICIENT MICE	ONCOGENE			English	Article							WILD-TYPE P53; CELL-CYCLE ARREST; IONIZING-RADIATION; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; DNA DAMAGE; APOPTOSIS; CANCER; INDUCTION; PROTEIN	The p53 tumour suppressor gene is an important participant in the cellular response to ionizing radiation and other DNA damaging agents. Cells which lack p53 are unable to arrest cell cycle or enter into apoptotic cell death following irradiation. Moreover, these p53 deficient cells exhibit an increased resistance to DNA damaging agents, including radiation. The significance of this radiation-resistance and its relationship to the role that p53 plays in tumour suppression and the cellular radiation response has not yet been determined. In this report we have analyzed p53 deficient mice, expressing either a mutant p53 transgene or having a targeted p53 null allele, in order to investigate the role that p53 plays in governing susceptibility to radiation-carcinogenesis and in controlling the in vivo accumulation of chromosomal abnormalities. We show that wild-type p53 plays a critical role in controlling susceptibility to gamma-radiation-induced tumorigenesis, and sarcomas and lymphomas rapidly appear in irradiated p53 transgenic mice. Moreover, this susceptibility to radiation-carcinogenesis is associated with a two-fold increase in the in vivo accumulation of radiation-induced double stranded chromosomal breaks relative to that observed in wild-type animals. Taken together, these observations suggest that p53 acts to suppress tumour formation in vivo by preventing the accumulation of cells that have sustained radiation-induced DNA damage.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Baylor College of Medicine			Kandel, Rita/E-2149-2017; Kandel, Rita/AAU-9908-2021	Kandel, Rita/0000-0003-4047-3913; Kandel, Rita/0000-0003-4047-3913	NATIONAL CANCER INSTITUTE [R01CA054897] Funding Source: NIH RePORTER; NCI NIH HHS [CA54897] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDBERG EC, 1979, ADV RADIAT BIOL, V8, P85; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P5413; Haran-Ghera N, 1979, Adv Cancer Res, V30, P45, DOI 10.1016/S0065-230X(08)60894-5; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2456; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HUTCHINSON F, 1993, SEMIN CANCER BIOL, V4, P85; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERSEY JH, 1973, INT J CANCER, V12, P333, DOI 10.1002/ijc.2910120204; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEE JM, 1994, MUTAT RES, V307, P573, DOI 10.1016/0027-5107(94)90267-4; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKUMOTO M, 1990, CANCER RES, V50, P3848; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOMETSKO AM, 1992, MUTAT RES, V292, P145; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	115	117	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3731	3736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970733				2022-12-17	WOS:A1994PT39200039
J	KORHONEN, J; POLVI, A; PARTANEN, J; ALITALO, K				KORHONEN, J; POLVI, A; PARTANEN, J; ALITALO, K			THE MOUSE TIE RECEPTOR TYROSINE KINASE GENE - EXPRESSION DURING EMBRYONIC ANGIOGENESIS	ONCOGENE			English	Article							CAPILLARY ENDOTHELIAL-CELLS; GROWTH-FACTOR; LIGAND-BINDING; CHICK-EMBRYO; IDENTIFICATION; VASCULOGENESIS; DOMAINS; FEATURES; INVITRO; TISSUES	Angiogenesis, the process by which new blood vessels are formed, is essential in reproduction, development, wound repair and oncogenesis. Endothelial receptor tyrosine kinases are Likely to play key roles in the intercellular signalling controlling angiogenesis. We have here analysed the expression of the endothelial receptor tyrosine kinase tie during the earliest stages of vascular development. The mouse tie cDNA was isolated and sequenced and the exon structure of the coding region was determined. The part of the tie gene encoding the extracellular domain was found to be organized in exons specifying the characteristic domains of the Tie polypeptide. Early postimplantation mouse tissues were analysed for tie expression by in situ hybridization. No tie mRNA was detected in 7.5 day mouse embryos. In 8.5 day embryos, tie expression was observed in differentiating angioblasts of the head mesenchyme, in the splanchnopleure and dorsal aorta as well as in migrating endothelial cells of the developing heart. A weak tie signal was also obtained from angioblasts in the blood islands of the yolk sac. Furthermore, tie mRNA was prominent in the endocardium of the embryo and in the endothelial cells forming the lung vasculature. Expression of tie persisted in the lung capillaries of adult mice, but was decreased in the endocardium. These results suggest that the tie receptor tyrosine kinase is involved in angiogenesis and/or maintenance of endothelial cell functions.			KORHONEN, J (corresponding author), UNIV HELSINKI,DEPT PATHOL,MOLEC CANC BIOL LAB,POB 21,SF-00014 HELSINKI,FINLAND.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902				APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1993, IN PRESS LEUKEMIA; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; COFFIN JD, 1988, DEVELOPMENT, V102, P735; CORMIER F, 1988, DEVELOPMENT, V102, P279; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1993, ONCOGENE, V8, P1293; FLAMME I, 1992, DEVELOPMENT, V116, P435; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1992, Semin Cancer Biol, V3, P65; GALLAND F, 1993, ONCOGENE, V8, P1233; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GONZALEZCRUSSI F, 1971, AM J ANAT, V130, P441, DOI 10.1002/aja.1001300406; GROSS JL, 1983, P NATL ACAD SCI-BIOL, V80, P2623, DOI 10.1073/pnas.80.9.2623; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOBSON B, 1984, BRIT J CANCER, V49, P405, DOI 10.1038/bjc.1984.66; HORITA K, 1992, BIOCHEM BIOPH RES CO, V189, P1747, DOI 10.1016/0006-291X(92)90280-X; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; Johnson Daniel E., 1993, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KORHONEN J, 1992, BLOOD, V80, P2548; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MILLAUER B, 1993, CELL, V72, P1; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; NODEN DM, 1990, EMBRYONIC ORIGINS DE, P236; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARDANAUD L, 1987, DEVELOPMENT, V100, P339; PARTANEN J, 1992, Progress in Growth Factor Research, V4, P69, DOI 10.1016/0955-2235(92)90005-3; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARZANI R, 1992, BIOCHEM BIOPH RES CO, V186, P706, DOI 10.1016/0006-291X(92)90804-T; SATO TN, 1993, IN PRESS P NATL ACAD; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SMITH RA, 1992, DEV COMP IMMUNOL, V6, P359; STEVENS A, 1992, HISTOLOGIE, P103; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZETTER BR, 1980, NATURE, V285, P41, DOI 10.1038/285041a0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	45	115	123	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					395	403						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507228				2022-12-17	WOS:A1994MW24800006
J	YU, DH; HUNG, MC				YU, DH; HUNG, MC			EXPRESSION OF ACTIVATED RAT NEU ONCOGENE IS SUFFICIENT TO INDUCE EXPERIMENTAL METASTASIS IN 3T3 CELLS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; TUMOR EFFECTS INVIVO; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; POINT MUTATION; PROTO-ONCOGENE; INVITRO ASSAY; GENE; PHENOTYPE; AMPLIFICATION	Amplification or overexpression of the human neu oncogene has been shown to correlate with the number of lymph node metastases in breast cancer patients, suggesting that expression of the neu oncogene may be associated with increased metastatic potential. However, there has been no systematic study on the role of the neu oncogene in metastasis to support this correlation. In our study, mouse embryo fibroblast 3T3 cells transformed by the mutation-activated rat neu oncogene exhibited metastatic properties both in vitro and in vivo, while parental 3T3 cells did not. Monoclonal antibodies capable of inducing down-regulation of the neu-encoded p185 protein reduced the metastatic potential induced by neu. These data provide strong experimental evidence that neu oncogene expression is sufficient for the induction of metastasis in the 3T3 cell system and supply a molecular basis supporting the correlations found in clinical observation. The results also suggest that neu-specific monoclonal antibodies may have preventative or therapeutic potential for neu-induced metastasis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045265] Funding Source: NIH RePORTER; NCI NIH HHS [R03 CAS4989-01, CA-16672, CA-45265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBINI A, 1987, CANCER RES, V47, P3239; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BELLONI PN, 1988, J CELL PHYSIOL, V136, P398, DOI 10.1002/jcp.1041360303; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; HART IR, 1989, BIOCHIM BIOPHYS ACTA, V989, P65, DOI 10.1016/0304-419X(89)90035-8; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; INOKUCHI J, 1990, CANCER RES, V50, P6731; LEMOINE NR, 1990, ONCOGENE, V5, P237; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MATIN A, 1990, ONCOGENE, V5, P111; MENSING H, 1983, EUR J CELL BIOL, V29, P268; NICOLSON GL, 1982, BIOCHIM BIOPHYS ACTA, V695, P113, DOI 10.1016/0304-419X(82)90020-8; NICOLSON GL, 1987, CANCER RES, V47, P1473; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; REPESH LA, 1989, INVAS METAST, V9, P192; SAYA H, 1990, MOL CARCINOGEN, V3, P198, DOI 10.1002/mc.2940030406; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; Tressler R J, 1989, Cancer Commun, V1, P55; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAN DH, 1991, ONCOGENE, V6, P343; YAN DH, 1991, MOL CELL BIOL, V11, P1875, DOI 10.1128/MCB.11.4.1875; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YUSA K, 1990, J NATL CANCER I, V82, P1633, DOI 10.1093/jnci/82.20.1633; ZHANG X, 1989, ONCOGENE, V4, P985	46	115	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1991	1996						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1682865				2022-12-17	WOS:A1991GX11900008
J	MORI, N; YOKOTA, J; AKIYAMA, T; SAMESHIMA, Y; OKAMOTO, A; MIZOGUCHI, H; TOYOSHIMA, K; SUGIMURA, T; TERADA, M				MORI, N; YOKOTA, J; AKIYAMA, T; SAMESHIMA, Y; OKAMOTO, A; MIZOGUCHI, H; TOYOSHIMA, K; SUGIMURA, T; TERADA, M			VARIABLE MUTATIONS OF THE RB GENE IN SMALL-CELL LUNG-CARCINOMA	ONCOGENE			English	Article									TOKYO WOMENS MED COLL,DEPT MED,SHINJUKU KU,TOKYO 162,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	Tokyo Women's Medical University; University of Tokyo	YOKOTA, J (corresponding author), NATL CANC CTR,RES INST,STUDIES METASTASIS SECT,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN.							AKIYAMA T, 1990, ONCOGENE, V5, P179; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; WEIL D, 1989, EMBO J, V8, P1705, DOI 10.1002/j.1460-2075.1989.tb03562.x; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1659; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	24	115	116	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1713	1717						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2176283				2022-12-17	WOS:A1990EL40100015
J	LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			COMPLEXITY OF THE IMMEDIATE EARLY RESPONSE OF MYELOID CELLS TO TERMINAL DIFFERENTIATION AND GROWTH ARREST INCLUDES ICAM-1, JUN-B AND HISTONE VARIANTS	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					NCRR NIH HHS [SO7-RR-05415-27] Funding Source: Medline; NICHD NIH HHS [3T32HD07152] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007152] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005415] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; BRADSHAW RA, 1987, ONCOGENES GROWTH FAC; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHIU CP, 1989, J IMMUNOL, V142, P1909; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS SJ, 1987, BLOOD, V70, P1233; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; DUSTIN ML, 1988, IMMUNOL TODAY, V9, P213, DOI 10.1016/0167-5699(88)91216-9; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOLDE DW, 1988, SCI AM, V259, P62, DOI 10.1038/scientificamerican0788-62; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMANLIEBERMANN B, 1978, CELL, V14, P825, DOI 10.1016/0092-8674(78)90338-0; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUANG HS, 1989, SCIENCE, V242, P1563; IRVING SG, 1989, MOL CELL BIOL, V9, P1034, DOI 10.1128/MCB.9.3.1034; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; LANDSCHULTZ WH, 1988, SCIENCE, V240, P1769; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LIEBERMANN D, 1982, INT J CANCER, V29, P159, DOI 10.1002/ijc.2910290208; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; METCALF D, 1984, HEMOPOIETIC COLONY S, P315; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; ROCHE J, 1985, NATURE, V314, P197, DOI 10.1038/314197a0; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHABO Y, 1988, BLOOD, V72, P1543; SHABO Y, 1988, BLOOD, V72, P2070; SITTMAN DB, 1983, NUCLEIC ACIDS RES, V11, P6679, DOI 10.1093/nar/11.19.6679; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAYLORPAPADIMIT.J, 1980, INTERFERON 1980, V2, P13; TRIONE F, 1989, P NATL ACAD SCI USA, V86, P2088; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; WELLS D, 1985, P NATL ACAD SCI USA, V82, P2834, DOI 10.1073/pnas.82.9.2834; WINTROBE MM, 1981, CLIN HEMATOLOGY, P35; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; WUNSCH AM, 1987, DEV BIOL, V119, P94, DOI 10.1016/0012-1606(87)90210-7	56	115	121	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					387	396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690380				2022-12-17	WOS:A1990CW41500017
J	Bao, LL; You, B; Shi, S; Shan, Y; Zhang, QC; Yue, HJ; Zhang, J; Zhang, W; Shi, YW; Liu, YF; Wang, X; Liu, D; You, YW				Bao, Lili; You, Bo; Shi, Si; Shan, Ying; Zhang, Qicheng; Yue, Huijun; Zhang, Jie; Zhang, Wei; Shi, Yunwei; Liu, Yifei; Wang, Xin; Liu, Dong; You, Yiwen			Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; EXPRESSION; CANCER; MICRORNAS; CHEMOTHERAPY; OVEREXPRESSION; RADIOTHERAPY; METAANALYSIS; VESICLES; GROWTH	Benefiting from more precise imaging and radiotherapy, patients with locoregionally nasopharyngeal carcinoma (NPC) have a significantly higher survival rate. Nonetheless, distant metastasis is still the predominant mode of failure. Advances in cancer research have highlighted that pathological angiogenesis is necessary for tumor metastasis by offering oxygen, nutrients, or cell metastatic conduits. MicroRNAs (miRNAs), a class of small noncoding RNAs, are increasingly implicated in modulation of angiogenesis in physiological and pathological conditions. Currently, we detected that miR-23a was highly enriched in NPC tissues at the metastatic or premetastatic stage, and its levels in NPC were associated with microvessel density. Subsequently, we proved that alteration of miR-23a expression modulated the growth, migration, and tube formation of HUVECs in vitro and affected the blood vessel outgrowth in the zebrafish model. Considering the possibility that extracellular miR-23a was horizontally transferred from CNE2 cells to HUVECs, we analyzed miR-23a encapsulated in exosomes, showing that overexpression of exosomal miR-23a in NPC promoted angiogenesis both in vitro and in vivo. Moreover, we provided evidences that miR-23a regulated angiogenesis by directly targeting testis-specific gene antigen (TSGA10). Taken together, our findings revealed that metastasis-associated miR-23a from NPC-derived exosomes plays an important role in mediating angiogenesis by targeting TSGA10.	[Bao, Lili; You, Bo; Shi, Si; Shan, Ying; Zhang, Qicheng; Yue, Huijun; Zhang, Jie; Zhang, Wei; You, Yiwen] Nantong Univ, Dept Otorhinolaryngol Head & Neck Surg, Affiliated Hosp, Xisi Rd 20, Nantong 226001, Peoples R China; [Shi, Yunwei; Wang, Xin; Liu, Dong] Nantong Univ, Coinnovat Ctr Neuroregenerat, Jiangsu Key Lab Neuroregenerat, Qixiu Rd 19, Nantong 226001, Peoples R China; [Liu, Yifei] Nantong Univ, Dept Pathol, Affiliated Hosp, Xisi Rd 20, Nantong 226001, Peoples R China	Nantong University; Nantong University; Nantong University	You, YW (corresponding author), Nantong Univ, Dept Otorhinolaryngol Head & Neck Surg, Affiliated Hosp, Xisi Rd 20, Nantong 226001, Peoples R China.; Liu, D (corresponding author), Nantong Univ, Coinnovat Ctr Neuroregenerat, Jiangsu Key Lab Neuroregenerat, Qixiu Rd 19, Nantong 226001, Peoples R China.	liudongtom@gmail.com; docyouyiwen@163.com	Liu, Dong/O-1271-2013	Liu, Dong/0000-0002-2764-6544	National Natural Science Foundation of China [81672682, 81602385]; Provincial Natural Science Foundation of Jiangsu, China [SBK2015022581]; innovative research project for postgraduate students of Jiangsu province [SJLX15_0645]; innovative research project for Nantong University postgraduate students [YKC15093]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Provincial Natural Science Foundation of Jiangsu, China(National Natural Science Foundation of China (NSFC)); innovative research project for postgraduate students of Jiangsu province; innovative research project for Nantong University postgraduate students	This work was supported by grants from the National Natural Science Foundation of China (No. 81672682 to YY, and No. 81602385 to BY), the Provincial Natural Science Foundation of Jiangsu, China (No. SBK2015022581 to YY), the innovative research project for postgraduate students of Jiangsu province (No. SJLX15_0645 to LB), and the innovative research project for Nantong University postgraduate students (No. YKC15093 to LB).	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Balaj L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1180; Bao LL, 2016, TUMOR BIOL, V37, P15043, DOI 10.1007/s13277-016-5400-8; Baujat B, 2006, INT J RADIAT ONCOL, V64, P47, DOI 10.1016/j.ijrobp.2005.06.037; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chan ATC, 2010, ANN ONCOL, V21, P308, DOI 10.1093/annonc/mdq277; Demircioglu F, 2016, CURR OPIN CELL BIOL, V42, P121, DOI 10.1016/j.ceb.2016.07.008; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Graner MW, 2009, FASEB J, V23, P1541, DOI 10.1096/fj.08-122184; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Hatzl S, 2016, CANCER RES, V76, P3644, DOI 10.1158/0008-5472.CAN-15-3049; Honegger A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004712; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain Rakesh K, 2005, Oncology (Williston Park), V19, P7; Kahlert C, 2014, J BIOL CHEM, V289, P3869, DOI 10.1074/jbc.C113.532267; Kalluri R, 2016, J CLIN INVEST, V126, P1208, DOI 10.1172/JCI81135; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113; Langendijk JA, 2004, J CLIN ONCOL, V22, P4604, DOI 10.1200/JCO.2004.10.074; Lee AWM, 2005, INT J RADIAT ONCOL, V61, P1107, DOI 10.1016/j.ijrobp.2004.07.702; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li ZL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1044712; Lin JC, 2003, BRIT J CANCER, V88, P187, DOI 10.1038/sj.bjc.6600716; Liu YF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027472; Mansouri K, 2016, HUM MOL GENET, V25, P233, DOI 10.1093/hmg/ddv461; NIELSEN NH, 1977, ACTA PATH MICRO IM A, V85, P850; Rana S, 2013, NEOPLASIA, V15, P281, DOI 10.1593/neo.122010; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Ruan W, 2012, CARDIOVASC RES, V93, P623, DOI 10.1093/cvr/cvr290; Shi S, 2015, J CANCER, V6, P1245, DOI 10.7150/jca.12825; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smyth LA, 2013, EUR J IMMUNOL, V43, P2430, DOI 10.1002/eji.201242909; Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Umezu T, 2013, ONCOGENE, V32, P2747, DOI 10.1038/onc.2012.295; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vickers KC, 2012, CURR OPIN LIPIDOL, V23, P91, DOI 10.1097/MOL.0b013e328350a425; Wang X, 2016, CARDIOVASC RES, V110, P140, DOI 10.1093/cvr/cvw023; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yang Z, 2016, BRIT J CANCER, V115, P731, DOI 10.1038/bjc.2016.244; You B, 2016, ONCOTARGET, V7, P12505, DOI 10.18632/oncotarget.7274; Yuan X, 2013, INT J CLIN EXP PATHO, V6, P2651; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zheng LS, 2017, CANCER RES, V77, P579, DOI 10.1158/0008-5472.CAN-16-1281; Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhuo XL, 2015, INT J CLIN EXP MED, V8, P1265	52	114	121	3	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2873	2889		10.1038/s41388-018-0183-6	http://dx.doi.org/10.1038/s41388-018-0183-6			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29520105	Green Published, hybrid			2022-12-17	WOS:000432929800009
J	Tong, J; Tan, S; Zou, F; Yu, J; Zhang, L				Tong, J.; Tan, S.; Zou, F.; Yu, J.; Zhang, L.			FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation	ONCOGENE			English	Article							UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; MULTIKINASE INHIBITOR; APOPTOTIC RESPONSE; DOWN-REGULATION; REGORAFENIB; SORAFENIB; SURVIVAL; PATHWAY; CELLS	Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of FBW7, an E3 ubiquitin ligase and a tumor suppressor frequently mutated in CRCs, contribute to resistance to targeted therapies. CRC cells containing FBW7-inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib. In contrast, sensitivity to these agents is not affected by oncogenic mutations in KRAS, BRAF, PIK3CA or p53. These cells are defective in apoptosis owing to blocked degradation of Mcl-1, a pro-survival Bcl-2 family protein. Deleting FBW7 in FBW7-wild-type CRC cells abolishes Mcl-1 degradation and recapitulates the in vitro and in vivo drug-resistance phenotypes of FBW7-mutant cells. CRC cells selected for regorafenib resistance have progressive enrichment of pre-existing FBW7 hotspot mutations, and are cross-resistant to other targeted drugs that induce Mcl-1 degradation. Furthermore, a selective Mcl-1 inhibitor restores regorafenib sensitivity in CRC cells with intrinsic or acquired resistance. Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies, and Mcl-1 as an attractive therapeutic target.	[Tong, J.; Tan, S.; Zhang, L.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Tan, S.; Zou, F.] Sichuan Univ, Col Life Sci, Chengdu, Peoples R China; [Yu, J.] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Sichuan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Dept Pharmacol & Chem Biol, UPCI Res Pavil,Room 2-42a,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Tong, Jingshan/0000-0003-1640-5769; Zou, Fangdong/0000-0002-2133-4320	U.S. National Institute of Health [CA106348, CA172136, CA203028, U01DK085570, AI068021]; American Cancer Society grant [RGS-10-124-01-CCE];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA172136, R01CA106348, R01CA203028, P30CA047904] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society grant(American Cancer Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank our lab members for critical reading. This work is supported by U.S. National Institute of Health grants (CA106348, CA172136 and CA203028 to LZ; U01DK085570 and AI068021 to JY) and American Cancer Society grant (RGS-10-124-01-CCE to JY). This project used the UPCI shared facilities that were supported in part by award P30CA047904.	Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Chan SL, 2014, EXPERT OPIN DRUG MET, V10, P1607, DOI 10.1517/17425255.2014.970169; Chen DS, 2014, ONCOTARGET, V5, P8107, DOI 10.18632/oncotarget.2440; Chen DS, 2014, CLIN CANCER RES, V20, P3472, DOI 10.1158/1078-0432.CCR-13-2944; Choudhary GS, 2015, ONCOTARGET, V6, P16912, DOI 10.18632/oncotarget.4857; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; He L, 2013, CANCER DISCOV, V3, P324, DOI 10.1158/2159-8290.CD-12-0417; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Lerner M, 2011, CELL CYCLE, V10, P2172, DOI 10.4161/cc.10.13.16248; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Mojsa B, 2014, CELLS-BASEL, V3, P418, DOI 10.3390/cells3020418; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Peng R, 2013, CELL DEATH DIFFER, V20, P744, DOI 10.1038/cdd.2013.4; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Schulein-Volk C, 2014, CELL REP, V9, P1099, DOI 10.1016/j.celrep.2014.09.057; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Varadarajan S, 2013, CELL DEATH DIFFER, V20, P1475, DOI 10.1038/cdd.2013.79; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	47	114	116	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					787	796		10.1038/onc.2016.247	http://dx.doi.org/10.1038/onc.2016.247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399335	Green Accepted			2022-12-17	WOS:000394168200006
J	Huang, JM; Nagatomo, I; Suzuki, E; Mizuno, T; Kumagai, T; Berezov, A; Zhang, H; Karlan, B; Greene, MI; Wang, Q				Huang, J-M; Nagatomo, I.; Suzuki, E.; Mizuno, T.; Kumagai, T.; Berezov, A.; Zhang, H.; Karlan, B.; Greene, M. I.; Wang, Q.			YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14	ONCOGENE			English	Article						ovarian cancer; YAP; PTPN14; EGFR; survivin; erlotinib	YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; WW DOMAIN; HIPPO PATHWAY; TRANSCRIPTIONAL COACTIVATOR; SIZE-CONTROL; ORGAN SIZE; TGF-BETA; GROWTH; TAZ	The Yes-associated protein (YAP) is a transcriptional factor involved in tissue development and tumorigenesis. Although YAP has been recognized as a key element of the Hippo signaling pathway, the mechanisms that regulate YAP activities remain to be fully characterized. In this study, we demonstrate that the non-receptor type protein tyrosine phosphatase 14 (PTPN14) functions as a negative regulator of YAP. We show that YAP forms a protein complex with PTPN14 through the WW domains of YAP and the PPXY motifs of PTPN14. In addition, PTPN14 inhibits YAP-mediated transcriptional activities. Knockdown of YAP sensitizes cancer cells to various anti-cancer agents, such as cisplatin, the EGFR tyrosine kinase inhibitor erlotinib and the small-molecule antagonist of survivin, S12. YAP-targeted modalities may be used in combination with other cancer drugs to achieve maximal therapeutic effects. Oncogene (2013) 32, 2220-2229; doi:10.1038/onc.2012.231; published online 11 June 2012	[Huang, J-M; Karlan, B.; Wang, Q.] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Womens Canc Program, Los Angeles, CA USA; [Nagatomo, I.; Kumagai, T.; Zhang, H.; Greene, M. I.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Suzuki, E.; Mizuno, T.; Berezov, A.; Greene, M. I.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of Pennsylvania; Pennsylvania Medicine; Cedars Sinai Medical Center	Greene, MI (corresponding author), Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, 36th Hamilton Walk,252 John Morgan Bldg, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu; qiang.wang@cshs.org	Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute of the Cedars-Sinai Medical Center; Donna and Jesse Garber Award for Cancer Research; National Cancer Institute [R01CA089481, R01 CA055306]; Breast Cancer Research Foundation; Abramson Family Cancer Research Institute at the University of Pennsylvania; Abramson Cancer Center [P30CA016520]; CEET [ES013508-04]; NATIONAL CANCER INSTITUTE [P30CA016520, R01CA055306, R01CA089481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER	Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute of the Cedars-Sinai Medical Center; Donna and Jesse Garber Award for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Abramson Family Cancer Research Institute at the University of Pennsylvania; Abramson Cancer Center; CEET; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work has been supported by funds from the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute of the Cedars-Sinai Medical Center (QW), the Donna and Jesse Garber Award for Cancer Research (QW), R01CA089481 and R01 CA055306 from the National Cancer Institute (MIG), the Breast Cancer Research Foundation, and the Abramson Family Cancer Research Institute at the University of Pennsylvania (MIG). We thank these investigators for providing plasmids Masato Ogata (murine PTPN14/ PEZ), Joan Brugge (YAP), Kunliang Guan (Gal4- TEAD4) and Marius Sudol (LATS1). We thank Dr Chao-Xing Yuan for performing proteomics analysis at the proteomics core facility at the University of Pennsylvania. The Proteomics Core was supported by grant P30CA016520 (Abramson Cancer Center) and by grant ES013508-04 (CEET). We also thank the members of the Women's Cancer Program (Cedars-Sinai) and the Greene laboratory (UPenn) for helpful discussion.	Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Andersen J, 2010, DANCING TIMES, V100, P55; Barr AJ, 2006, PROTEINS, V63, P1132, DOI 10.1002/prot.20958; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Berezov A, 2012, ONCOGENE, V31, P1938, DOI 10.1038/onc.2011.377; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cao XW, 2008, GENE DEV, V22, P3320, DOI 10.1101/gad.1726608; Carlucci A, 2008, J BIOL CHEM, V283, P10919, DOI 10.1074/jbc.M707248200; Carlucci A, 2010, J BIOL CHEM, V285, P39260, DOI 10.1074/jbc.M110.174706; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; Fernandez LA, 2011, ONCOGENE, P29; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Laczmanska I, 2011, ACTA BIOCHIM POL, V58, P467; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Niedergethmann M, 2007, BRIT J CANCER, V97, P1432, DOI 10.1038/sj.bjc.6604031; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Ogata M, 1999, J BIOL CHEM, V274, P20717, DOI 10.1074/jbc.274.29.20717; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Poernbacher I, 2012, CURR BIOL, V22, P389, DOI 10.1016/j.cub.2012.01.019; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wadham C, 2000, J CELL SCI, V113, P3117; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Webb C, 2011, BIOCHEMISTRY-US, V50, P3300, DOI 10.1021/bi2001888; Wu ZZ, 2010, BIOCHEM PHARMACOL, V80, P262, DOI 10.1016/j.bcp.2010.03.029; Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yoneda T, 2006, DNA CELL BIOL, V25, P530, DOI 10.1089/dna.2006.25.530; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	64	114	119	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2220	2229		10.1038/onc.2012.231	http://dx.doi.org/10.1038/onc.2012.231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22689061	Green Accepted			2022-12-17	WOS:000318062800011
J	Zhang, J; Sun, Q; Zhang, Z; Ge, S; Han, ZG; Chen, WT				Zhang, J.; Sun, Q.; Zhang, Z.; Ge, S.; Han, Z-G; Chen, W-T			Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop	ONCOGENE			English	Article						microRNA; miRNA-143/145; MDM2; p53; epithelial maligancies	MIR-143/145 CLUSTER; ANTI-ONCOMIRS; C-MYC; P53; EXPRESSION; ONCOPROTEIN; ACTIVATION; INDUCTION; MICRORNAS; ONCOGENE	Dysregulated microRNAs (miRNAs) have an important role in many malignant tumors. However, elucidating the roles of miRNAs in cancer biology, especially in epithelial cancers, remains an ongoing process. In this study, we show that both miR-143 and miR-145, which belong to the same miRNA cluster, can negatively modulate expression of their target gene, MDM2. The miR-143 and miR-145 is posttranscriptionally activated by upregulated p53, thereby generating a short miRNAs-MDM2-p53 feedback loop. Re-expression of these miRNAs suppresses cellular growth and triggers the apoptosis of epithelial cancer, in vitro and in vivo, by enhancing p53 activity via MDM2 turnover. Moreover, the miRNA-dependent MDM2 turnover contributes to the equilibrium of repeated p53 pulses in response to DNA damage stress. These findings suggest that MDM2 dysregulation caused by downregulation of miR-143 and miR-145 contributes to epithelial cancer development and has a key role in regulating cellular proliferation and apoptosis. Re-expression of miR-143 and miR-145 may be a reasonable strategy for treatment of epithelial cancers. Oncogene (2013) 32, 61-69; doi:10.1038/onc.2012.28; published online 13 February 2012	[Zhang, J.; Zhang, Z.; Chen, W-T] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Oral & Maxillofacial Surg,Peoples Hosp 9, Shanghai 200011, Peoples R China; [Han, Z-G] Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Dis & Hlth Genom, Shanghai, Peoples R China	Shanghai Jiao Tong University	Chen, WT (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Stomatol, Dept Oral & Maxillofacial Surg,Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.	chenwantao2002@hotmail.com	建军, 张/R-3679-2019		National Natural Science Foundation of China [30973343, 81101515]; Shanghai Science and Technology Committee [08JC1414400, 11DZ2291800, 10DZ1951300, 10XD1402500]; Shanghai Leading Academic Discipline Project [S30206]; Shanghai Municipal Education Commission [12YZ052, shjdy027]; National Basic Research Program of China [2010CB529204]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Committee(Shanghai Science & Technology Committee); Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC)); National Basic Research Program of China(National Basic Research Program of China)	This study was supported by the National Natural Science Foundation of China (Grant No. 30973343 and 81101515), Projects of the Shanghai Science and Technology Committee (Grant No. 08JC1414400, 11DZ2291800, 10DZ1951300 and 10XD1402500), the Shanghai Leading Academic Discipline Project (S30206), the Program of Shanghai Municipal Education Commission (12YZ052 and shjdy027) and National Basic Research Program of China (2010CB529204).	Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Arva NC, 2008, ETHN DIS S2, V18, pS2; Asslaber D, 2010, BLOOD, V115, P4191, DOI 10.1182/blood-2009-07-234823; Boucher JM, 2011, J BIOL CHEM, V286, P28312, DOI 10.1074/jbc.M111.221945; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Brown BD, 2009, NAT REV GENET, V10, P578, DOI 10.1038/nrg2628; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chen LH, 2010, J ONCOL, V2010, DOI 10.1155/2010/135632; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Dai YM, 2011, HEAD NECK-J SCI SPEC, V33, P786, DOI 10.1002/hed.21540; Fan Chun-Yang, 2004, Curr Oncol Rep, V6, P152, DOI 10.1007/s11912-004-0027-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kitade Y, 2010, J PHARMACOL SCI, V114, P276, DOI 10.1254/jphs.10R12FM; Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liu G, 2005, CANCER CELL, V7, P113, DOI 10.1016/j.ccr.2005.01.019; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Phelps M, 2003, CANCER RES, V63, P2616; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Saha MN, 2010, CANCER BIOL THER, V9, P936, DOI 10.4161/cbt.9.11.11882; Soriano ME, 2011, CELL, V145, P15, DOI 10.1016/j.cell.2011.03.025; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Vassilev LT, 2004, CELL CYCLE, V3, P419; Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522; Zhang JJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-211	37	114	120	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2013	32	1					61	69		10.1038/onc.2012.28	http://dx.doi.org/10.1038/onc.2012.28			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063VG	22330136	Bronze			2022-12-17	WOS:000313029500006
J	Li, Y; Cai, L; Wang, H; Wu, P; Gu, W; Chen, Y; Hao, H; Tang, K; Yi, P; Liu, M; Miao, S; Ye, D				Li, Y.; Cai, L.; Wang, H.; Wu, P.; Gu, W.; Chen, Y.; Hao, H.; Tang, K.; Yi, P.; Liu, M.; Miao, S.; Ye, D.			Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2	ONCOGENE			English	Article						formyl peptide receptor-2; macrophage colony-stimulating factor; monocyte chemoattractant protein-1; macrophages; tumorigenesis	TUMOR-ASSOCIATED MACROPHAGES; NF-KAPPA-B; IN-VIVO; SIGNAL TRANSDUCER; LIPID MEDIATORS; A(4) RECEPTOR; CANCER-CELLS; INFLAMMATION; ACTIVATION; RESOLUTION	Cancer cells recruit monocytes, macrophages and other inflammatory cells by producing abundant chemo-attractants and growth factors, such as macrophage colony-stimulating factor (M-CSF/CSF-1) and monocyte chemoattractant protein-1 (MCP-1/CCL2), to promote tumor growth and dissemination. An understanding of the mechanisms that target cancer cells and regulate tumor microenvironment is essential in designing anticancer therapies. Here, we showed that serum amyloid-A (SAA) and cathelicidin (LL-37) stimulated M-CSF and MCP-1 expression with or without lipopolysaccharide (LPS) administration; conversely, lipoxin-A(4) (LXA(4)) and annexin-A1 (ANXA1) inhibited LPS-induced M-CSF and MCP-1 production by human (HepG2) and mouse (H22) hepatocellular carcinoma cells (HCCs). The effects of LXA(4), ANXA1, SAA and LL-37 were dependent on the activation of their mutual cell-surface receptor formyl peptide receptor-2 (FPR2) and subsequent ROS-MAPK-NF-kB signalings. Furthermore, our results indicated that LPS switched macrophages into an IL-10(low)IL-12(high) M1 profile, whereas M-CSF + MCP-1 and FPR2 agonists skewed them into M2 (IL-10(high)IL-12(low)). In that respect, through modulating the phosphorylation of signal transducer and activator of transcription-3 (STAT3), LXA(4) and ANXA1 induced monocyte differentiation into M2a + M2c-like cells and showed antitumorigenetic activities, whereas SAA, LL-37 and M-CSF + MCP-1 led to M2b- or M2d-like polarization, which exacerbated HCC invasion in vitro and in vivo, respectively. Our results suggest that FPR2 has an appreciable pleiotropic regulator role in tumor immunoediting. Oncogene (2011) 30, 3887-3899; doi:10.1038/onc.2011.112; published online 18 April 2011	[Li, Y.; Cai, L.; Wu, P.; Gu, W.; Hao, H.; Tang, K.; Yi, P.; Liu, M.; Miao, S.; Ye, D.] Huazhong Univ Sci & Technol, Dept Pathophysiol, Tongji Med Coll, Wuhan 430030, Peoples R China; [Li, Y.] Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol, Boston, MA 02115 USA; [Wang, H.] Harvard Univ, Sch Med, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Chen, Y.] Univ Aizu, Grad Sch Comp Sci & Engn, Biomed Informat Technol Lab, Aizu Wakamatsu, Japan	Huazhong University of Science & Technology; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Aizu	Li, Y (corresponding author), Huazhong Univ Sci & Technol, Dept Pathophysiol, Tongji Med Coll, Wuhan 430030, Peoples R China.	yli@zeus.bwh.harvard.edu; yedy@mails.tjmu.edu.cn		Li, Yongsheng/0000-0003-2175-9449	China Scholarship Council [2009616073]; National Natural Science Foundation of China [30570726, 30772154]	China Scholarship Council(China Scholarship Council); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Professor Charles N Serhan for helpful comments about FPR2. We also appreciate all anonymous reviewers for helpful suggestions on quality improvement of the paper. This work was supported by China Scholarship Council Fellowship No. 2009616073 and National Natural Science Foundation of China Grants 30570726 and 30772154.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; Cocco E, 2010, CANCER-AM CANCER SOC, V116, P843, DOI 10.1002/cncr.24838; Coimbra M, 2009, CURR PHARM DESIGN, V15, P1825, DOI 10.2174/138161209788453220; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Craig M, 2008, J CELL BIOCHEM, V103, P1, DOI 10.1002/jcb.21379; Duff MD, 2007, J SURG RES, V142, P119, DOI 10.1016/j.jss.2006.12.542; Duluc D, 2007, BLOOD, V110, P4319, DOI 10.1182/blood-2007-02-072587; Duluc D, 2009, INT J CANCER, V125, P367, DOI 10.1002/ijc.24401; El Kebir D, 2008, J LEUKOCYTE BIOL, V84, P600, DOI 10.1189/jlb.1107765; EMOTO M, 1992, J EXP MED, V176, P363, DOI 10.1084/jem.176.2.363; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; FIORE S, 1992, J BIOL CHEM, V267, P16168; Fujimoto H, 2009, INT J CANCER, V125, P1276, DOI 10.1002/ijc.24378; GAO JL, 1993, J BIOL CHEM, V268, P25395; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kuninaka S, 2000, CYTOKINE, V12, P8, DOI 10.1006/cyto.1998.0504; Lawrence T, 2007, TRENDS PHARMACOL SCI, V28, P162, DOI 10.1016/j.tips.2007.02.003; Li Y, 2010, CURR CANCER DRUG TAR, V10, P782, DOI 10.2174/156800910793605857; Li YS, 2008, ARCH BIOCHEM BIOPHYS, V478, P110, DOI 10.1016/j.abb.2008.07.002; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; McMahon B, 2000, J BIOL CHEM, V275, P27566; Miao T, 2006, J NEUROSCI, V26, P9512, DOI 10.1523/JNEUROSCI.2160-06.2006; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Panzer U, 2009, AM J PHYSIOL-RENAL, V297, pF429, DOI 10.1152/ajprenal.90435.2008; Peng J, 2010, CELL RES, V20, P62, DOI 10.1038/cr.2009.128; PEPINSKY RB, 1986, J BIOL CHEM, V261, P4239; Perretti M, 2002, J IMMUNOL, V169, P2085, DOI 10.4049/jimmunol.169.4.2085; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Sandri S, 2008, J LEUKOCYTE BIOL, V83, P1174, DOI 10.1189/jlb.0407203; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; Sironi M, 2006, J LEUKOCYTE BIOL, V80, P342, DOI 10.1189/jlb.1005586; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Teng MWL, 2010, P NATL ACAD SCI USA, V107, P8328, DOI 10.1073/pnas.1003251107; Varney ML, 2002, IN VIVO, V16, P471; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Ye RD, 2009, PHARMACOL REV, V61, P119, DOI 10.1124/pr.109.001578; Zhang L, 2007, CHINESE MED J-PEKING, V120, P981, DOI 10.1097/00029330-200706010-00008; Zhang T, 2010, CANCER IMMUNOL IMMUN, V59, P1097, DOI 10.1007/s00262-010-0836-y; Zhang ZQ, 2010, CANCER RES, V70, P2379, DOI 10.1158/0008-5472.CAN-09-4204	49	114	123	3	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	36					3887	3899		10.1038/onc.2011.112	http://dx.doi.org/10.1038/onc.2011.112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	817PV	21499310				2022-12-17	WOS:000294687200006
J	Normant, E; Paez, G; West, KA; Lim, AR; Slocum, KL; Tunkey, C; McDougall, J; Wylie, AA; Robison, K; Caliri, K; Palombella, VJ; Fritz, CC				Normant, E.; Paez, G.; West, K. A.; Lim, A. R.; Slocum, K. L.; Tunkey, C.; McDougall, J.; Wylie, A. A.; Robison, K.; Caliri, K.; Palombella, V. J.; Fritz, C. C.			The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models	ONCOGENE			English	Article						Hsp90; EML4-ALK; IPI-504; NSCLC; ALK inhibitor	PROTEIN 90 INHIBITOR; GASTROINTESTINAL STROMAL TUMOR; CELL LUNG-CANCER; KINASE INHIBITOR; BREAST-CANCER; HEAT-SHOCK-PROTEIN-90 INHIBITION; FUSION GENE; CHAPERONE; SURVIVAL; IDENTIFICATION	Heat shock protein 90 (Hsp90) is an emerging target for cancer therapy due to its important role in maintaining the activity and stability of key oncogenic signaling proteins. We show here that the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein, presumed to be the oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC), is associated with Hsp90 in cells and is rapidly degraded upon exposure of cells to IPI-504. We find EML4-ALK to be more sensitive to Hsp90 inhibition than either HER2 or mutant epidermal growth factor receptor (EGFR) with an inhibitory concentration (IC)(50) for protein degradation in the low nanomolar range. This degradation leads to a potent inhibition of downstream signaling pathways and to the induction of growth arrest and apoptosis in cells carrying the EML4-ALK fusion. To generate a causative link between the expression of EML4-ALK and sensitivity to IPI-504, we introduced an EML4-ALK cDNA into HEK293 cells and show that the expression of the fusion protein sensitizes cells to IPI-504 both in vitro and in vivo. In a xenograft model of a human NSCLC cell line containing the ALK rearrangement, we observe tumor regression at clinically relevant doses of IPI-504. Finally, cells that have been selected for resistance to ALK kinase inhibitors retain their sensitivity to IPI-504. We have recently observed partial responses to administration of IPI-504 as a single agent in a phase 2 clinical trial in patients with NSCLC, specifically in patients that carry an ALK rearrangement. This study provides a molecular explanation for these clinical observations. Oncogene (2011) 30, 2581-2586; doi:10.1038/onc.2010.625; published online 24 January 2011	[Normant, E.; Paez, G.; West, K. A.; Lim, A. R.; Slocum, K. L.; Tunkey, C.; McDougall, J.; Wylie, A. A.; Robison, K.; Caliri, K.; Palombella, V. J.; Fritz, C. C.] Infin Pharmaceut, Cambridge, MA 02139 USA		Normant, E (corresponding author), Infin Pharmaceut, 780 Mem Dr, Cambridge, MA 02139 USA.	emmanuel.normant@infi.com						An WG, 2000, CELL GROWTH DIFFER, V11, P355; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Choi YL, 2008, CANCER RES, V68, P4971, DOI 10.1158/0008-5472.CAN-07-6158; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dewaele B, 2008, CLIN CANCER RES, V14, P5749, DOI 10.1158/1078-0432.CCR-08-0533; Fumo G, 2004, BLOOD, V103, P1078, DOI 10.1182/blood-2003-07-2477; Ge J, 2006, J MED CHEM, V49, P4606, DOI 10.1021/jm0603116; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038; Li CF, 2008, CLIN CANCER RES, V14, P7822, DOI 10.1158/1078-0432.CCR-08-1369; McCarthy MM, 2008, ANN ONCOL, V19, P590, DOI 10.1093/annonc/mdm545; Modi S, 2007, J CLIN ONCOL, V25, P5410, DOI 10.1200/JCO.2007.11.7960; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y; PARK J, 2008, AACR M; Pearl LH, 2006, ANNU REV BIOCHEM, V75, P271, DOI 10.1146/annurev.biochem.75.103004.142738; Peng C, 2007, BLOOD, V110, P678, DOI 10.1182/blood-2006-10-054098; Pick E, 2007, CANCER RES, V67, P2932, DOI 10.1158/0008-5472.CAN-06-4511; Ruiz MIG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001722; Sequist LV, 2010, J CLIN ONCOL, V28, P4953, DOI 10.1200/JCO.2010.30.8338; Sequist LV, 2010, J CLIN ONCOL, V28; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; Shimamura T, 2008, CANCER RES, V68, P5827, DOI 10.1158/0008-5472.CAN-07-5428; Shimamura T, 2008, J THORAC ONCOL, V3, pS152, DOI 10.1097/JTO.0b013e318174ea3a; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Song D, 2008, MOL CANCER THER, V7, P3275, DOI 10.1158/1535-7163.MCT-08-0508; Sydor JR, 2006, P NATL ACAD SCI USA, V103, P17408, DOI 10.1073/pnas.0608372103; Takeuchi K, 2009, CLIN CANCER RES, V15, P3143, DOI 10.1158/1078-0432.CCR-08-3248; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Tillotson B, 2010, J BIOL CHEM, V285, P39835, DOI 10.1074/jbc.M110.141580; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	31	114	122	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	22					2581	2586		10.1038/onc.2010.625	http://dx.doi.org/10.1038/onc.2010.625			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258415				2022-12-17	WOS:000291198400009
J	Lee, SH; Kim, J; Kim, WH; Lee, YM				Lee, S. H.; Kim, J.; Kim, W-H; Lee, Y. M.			Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells	ONCOGENE			English	Article						hypoxia; RUNX3; histone methylation; histone deacetylation; G9a; HDAC1	HELICOBACTER-PYLORI; DNA METHYLATION; GENE-EXPRESSION; E-CADHERIN; GROWTH; HYPERMETHYLATION; DEACETYLASE; REPRESSION; METHYLTRANSFERASE; UBIQUITINATION	RUNX3 is a tumor suppressor that is silenced in cancer following hypermethylation of its promoter. The effects of hypoxia in tumor suppressor gene (TSG) transcription are largely unknown. Here, we investigated hypoxia-induced silencing mechanisms of RUNX3. The expression of RUNX3 was downregulated in response to hypoxia in human gastric cancer cells at the transcriptional level. This downregulation was abolished following treatment with the histone deacetylase ( HDAC) inhibitor trichostatin A (TSA) and cytosine methylation inhibitor 5-aza-2-deoxycytidine (5-Aza), suggesting that an epigenetic regulatory mechanism may be involved in RUNX3 silencing by hypoxia. DNA methylation PCR and bisulfite-sequencing data revealed that hypoxia did not affect the methylation of RUNX3 promoter. A chromatin immunoprecipitation (ChIP) assay revealed increased histone H3-lysine 9 dimethylation and decreased H3 acetylation in the RUNX3 promoter following hypoxia. Hypoxia resulted in the upregulation of G9a histone methyltransferase (HMT) and HDAC1; additionally, overexpression of G9a and HDAC1 attenuated RUNX3 expression. The overexpression of G9a and HDAC1, but not their mutants, inhibited the nuclear localization and expression of RUNX3. Diminished mRNA expression and nuclear localization of RUNX3 during hypoxia was abolished by siRNA-mediated knockdown of G9a and HDAC1. This study suggests that hypoxia silences RUNX3 by epigenetic histone regulation during the progression of gastric cancer.	[Lee, S. H.; Lee, Y. M.] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Dept Nat Sci, Taegu 702701, South Korea; [Kim, J.; Kim, W-H] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; [Kim, J.; Kim, W-H] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	Kyungpook National University; Seoul National University (SNU); Seoul National University (SNU)	Lee, YM (corresponding author), Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Dept Nat Sci, Taegu 702701, South Korea.	lym@knu.ac.kr	Kim, Wooho/G-3703-2011		National R&D Program for Cancer Control, Ministry of Health and Welfare [0520120-1]; Korea Science and Engineering Foundation (KOSEF) [MOST; R01-2006-000-11046-0]	National R&D Program for Cancer Control, Ministry of Health and Welfare(Ministry of Health & Welfare (MOHW), Republic of Korea); Korea Science and Engineering Foundation (KOSEF)(Korea Science and Engineering Foundation)	Expression vectors of full-length HDAC1 and HDAC1 mutants were kindly provided by Dr Kyu-Won Kim (Seoul National University), GFP-tagged human G9a expression vector, pEGFP-hG9a, and its SET domain deletion mutant, pEGFP-hG9a (Delta SET) were by Martin Walsh (Mount Sinai School of Medicine, New York, NY, USA) and myc-tagged RUNX3 plasmids in pCS4 was by Dr Suk-Chul Bae (Chungbuk National University, Korea). This work was supported by National R&D Program for Cancer Control, Ministry of Health and Welfare (0520120-1) and the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MOST; R01-2006-000-11046-0).	Anderson C, 2006, MOL DIAGN THER, V10, P345, DOI 10.1007/BF03256211; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Box AH, 2004, CARCINOGENESIS, V25, P2325, DOI 10.1093/carcin/bgh274; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chan AOO, 2003, AM J PATHOL, V163, P370, DOI 10.1016/S0002-9440(10)63663-2; Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Fahrner JA, 2002, CANCER RES, V62, P7213; Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang CH, 2007, BIOCHEM PHARMACOL, V73, P990, DOI 10.1016/j.bcp.2006.12.013; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ivanov SV, 2007, ONCOGENE, V26, P802, DOI 10.1038/sj.onc.1209842; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Meng AX, 2005, RADIOTHER ONCOL, V76, P168, DOI 10.1016/j.radonc.2005.06.025; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nguyen CT, 2002, CANCER RES, V62, P6456; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Takebayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P921, DOI 10.1006/bbrc.2001.5863; Tamaru H, 2003, MOL CELL BIOL, V23, P2379, DOI 10.1128/MCB.23.7.2379-2394.2003; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125	47	114	122	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					184	194		10.1038/onc.2008.377	http://dx.doi.org/10.1038/onc.2008.377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850007				2022-12-17	WOS:000262501100003
J	Liu, P; Kao, TP; Huang, H				Liu, P.; Kao, T. P.; Huang, H.			CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor	ONCOGENE			English	Article						FOXO1; CDK1; phosphorylation; cell cycle; apoptosis; prostate cancer	PROSTATE-CANCER CELLS; PROTEIN-KINASE-B; CYCLIN-DEPENDENT KINASES; FACTOR FKHR; TUMOR SUPPRESSION; PROTEASOMAL DEGRADATION; INCREASED EXPRESSION; NUCLEAR EXCLUSION; BCL-2 EXPRESSION; DOWN-REGULATION	The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by regulating expression of genes involved in apoptosis, cell cycle arrest and oxidative detoxification. Here, we demonstrate that cyclin-dependent kinase 1 (CDK1) specifically phosphorylates FOXO1 at serine 249 (S249) in vitro and in vivo. Coimmunoprecipitation assays demonstrate that both endogenous CDK1 and ectopically expressed CDK1 form a protein complex with FOXO1 in prostate cancer (PCa) cells. In vitro protein binding assays reveal that CDK1 interacts directly with FOXO1. Accordingly, overexpression of CDK1 inhibits the transcriptional activity of FOXO1 in PCa cells through S249 phosphorylation on FOXO1. Consistent with the roles of FOXO3a and FOXO4 (two other members of the FOXO family) in cell cycle regulation, forced expression of FOXO1 causes a delay in the transition from G2 to M phase. This effect is blocked completely by overexpression of CDK1 and cyclin B1. Ectopic expression of constitutively active CDK1 also inhibits FOXO1-induced apoptosis in PCa cells. Moreover, we demonstrate that the inhibitory effect of FOXO1 on Ras oncogene-induced colony formation in fibroblasts is diminished by overexpression of CDK1. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, our findings suggest that aberrant activation of CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival via phosphorylation and inhibition of FOXO1.	[Liu, P.; Kao, T. P.; Huang, H.] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; [Liu, P.; Kao, T. P.; Huang, H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Huang, H (corresponding author), Univ Minnesota, Ctr Canc, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	huang253@umn.edu						Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Kallakury BV, 1998, J CLIN ONCOL, V16, P1302, DOI 10.1200/JCO.1998.16.4.1302; Kallakury BVS, 1997, CANCER-AM CANCER SOC, V80, P753, DOI 10.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-S; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341; Mashal RD, 1996, CANCER RES, V56, P4159; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pinkston JM, 2006, SCIENCE, V313, P971, DOI 10.1126/science.1121908; Pinkston-Gosse J, 2007, NAT GENET, V39, P1403, DOI 10.1038/ng.2007.1; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Soria JC, 2000, CANCER RES, V60, P4000; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu XL, 2006, HUM MUTAT, V27, P742, DOI 10.1002/humu.20321; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	57	114	120	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4733	4744		10.1038/onc.2008.104	http://dx.doi.org/10.1038/onc.2008.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408765	Bronze			2022-12-17	WOS:000258236300011
J	Lee, J; Sung, YH; Cheong, C; Choi, YS; Jeon, HK; Sun, W; Hahn, WC; Ishikawa, F; Lee, HW				Lee, J.; Sung, Y. H.; Cheong, C.; Choi, Y. S.; Jeon, H. K.; Sun, W.; Hahn, W. C.; Ishikawa, F.; Lee, H-W			TERT promotes cellular and organismal survival independently of telomerase activity	ONCOGENE			English	Article						telomerase; telomerase activity; TERT; cell death; cellular protection	REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; MOUSE TELOMERASE; INDUCED-APOPTOSIS; NEURONAL DEATH; CANCER-CELLS; IN-VITRO; HTERT; MICE; INHIBITION	The expression level of the telomerase catalytic subunit (telomerase reverse transcriptase, TERT) positively correlates with cell survival after exposure to several lethal stresses. However, whether the protective role of TERT is independent of telomerase activity has not yet been clearly explored. Here, we genetically evaluated the protective roles of both TERT and telomerase activity against cell death induced by staurosporine (STS) and N-methyl-D-aspartic acid (NMDA). First generation (G1) TERT-deficient mouse embryonic fibroblasts (MEFs) displayed an increased sensitivity to STS, while TERT transgenic MEFs were more resistant to STS-induced apoptosis than wildtype. Deletion of the telomerase RNA component (TERC) failed to alter the sensitivity of TERT transgenic MEFs to STS treatment. Similarly, NMDA-induced excitotoxic cell death of primary neurons was suppressed by TERT, but not by TERC both in vitro and in vivo. Specifically, NMDA accelerated death of TERT-deficient mice, while TERT transgenic mice showed enhanced survival when compared with wild-type littermates after administration of NMDA. In addition, the transgenic expression of TERT protected motor neurons from apoptosis induced by sciatic nerve axotomy. These results indicate that telomerase activity is not essential for the protective function of TERT. This telomerase activity-independent TERT function may contribute to cancer development and aging independently of telomere lengthening.	[Sung, Y. H.; Choi, Y. S.; Jeon, H. K.; Lee, H-W] Yonsei Univ, Dept Biochem, Brain Korea Program 21, Seoul 120749, South Korea; [Lee, J.; Cheong, C.] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon, South Korea; [Sun, W.] Korea Univ, Coll Med, Brain Korea Program 21, Dept Anat, Seoul 136705, South Korea; [Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Hahn, W. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Ishikawa, F.] Kyoto Univ, Dept Gene Mech, Kyoto, Japan	Yonsei University; Sungkyunkwan University (SKKU); Korea University; Korea University Medicine (KU Medicine); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kyoto University	Lee, HW (corresponding author), Yonsei Univ, Dept Biochem, Brain Korea Program 21, 134 Sinchon Dong, Seoul 120749, South Korea.	hwl@yonsei.ac.kr	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305; sun, woong/0000-0003-1792-4894	NATIONAL INSTITUTE ON AGING [R01AG023145] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG23145] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Autexier C, 1996, EMBO J, V15, P5928, DOI 10.1002/j.1460-2075.1996.tb00979.x; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boklan J, 2002, CANCER RES, V62, P2104; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Cerezo A, 2002, J CELL SCI, V115, P1305; Chen JL, 2003, GENE DEV, V17, P2747, DOI 10.1101/gad.1140303; Chung HK, 2005, CURR MOL MED, V5, P233, DOI 10.2174/1566524053586635; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Djebaili M, 2000, NEUROREPORT, V11, P2973, DOI 10.1097/00001756-200009110-00029; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; Erdmann N, 2004, P NATL ACAD SCI USA, V101, P6080, DOI 10.1073/pnas.0401580101; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Folini M, 2005, EUR J CANCER, V41, P624, DOI 10.1016/j.ejca.2004.12.002; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Massard C, 2006, ONCOGENE, V25, P4505, DOI 10.1038/sj.onc.1209487; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Middleman EJ, 2006, MOL CELL BIOL, V26, P2146, DOI 10.1128/MCB.26.6.2146-2159.2006; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Perez-Navarro E, 2005, J NEUROCHEM, V92, P678, DOI 10.1111/j.1471-4159.2004.02904.x; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Seleznev K, 2006, J BIOL CHEM, V281, P22275, DOI 10.1074/jbc.M604330200; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; SOFIA RD, 1994, PHARMACOL RES, V29, P139, DOI 10.1016/1043-6618(94)80037-5; Sun W, 2003, J NEUROSCI, V23, P7298, DOI 10.1523/jneurosci.23-19-07298.2003; Sung YH, 2005, MOL CELLS, V19, P303; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wu YL, 2006, J CELL SCI, V119, P2797, DOI 10.1242/jcs.03001; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zhang PS, 2003, FASEB J, V17, P767, DOI 10.1096/fj.02-0603fje	49	114	119	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3754	3760		10.1038/sj.onc.1211037	http://dx.doi.org/10.1038/sj.onc.1211037			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18223679				2022-12-17	WOS:000256659300013
J	Lee, DY; Sugden, B				Lee, D. Y.; Sugden, B.			The latent membrane protein 1 oncogene modifies B-cell physiology by regulating autophagy	ONCOGENE			English	Article						autophagy; EBV; LMP1	EPSTEIN-BARR-VIRUS; MEMBRANE-PROTEIN 1; LATENT MEMBRANE-PROTEIN-1; GROWTH TRANSFORMATION; NUCLEAR ANTIGEN; LMP1; PROLIFERATION; ASSOCIATION; RECEPTOR; CD40	Epstein-Barr virus (EBV) is a herpes virus that is associated with several human cancers. Infection of B cells by EBV leads to their induction and maintenance of proliferation and requires the oncogene, latent membrane protein 1 (LMP1). LMP1 signals in a ligand-independent manner and is expressed at widely different levels in cells of a single clone. It is this unusual distribution that allows LMP1 to stimulate multiple, distinct pathways. Average levels of LMP1 induce proliferation while high levels induce cytostasis and inhibition of protein synthesis. These inhibitory pathways are induced by the six transmembrane domains of LMP1. We uncovered a novel function encoded by transmembrane domains 3-6 of LMP1; they induce autophagy in a dose-dependent manner and thus, modify the physiology of their host. Cells that express low levels of LMP1 display early stages of autophagy, autophagosomes; those that express high levels of this oncogene display late stages of autophagy, autolysosomes. Inhibition of autophagy in EBV-positive cells leads to an accumulation of LMP1 and a decreased ability to form colonies. These results indicate that LMP1's induction of autophagy contributes to its own regulation and that of its host cell.	[Lee, D. Y.; Sugden, B.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sugden, B (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	sugden@oncology.wisc.edu			NCI NIH HHS [P30 CA014520, CA070723] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Dirmeier U, 2005, ONCOGENE, V24, P1711, DOI 10.1038/sj.onc.1208367; Dirmeier U, 2003, CANCER RES, V63, P2982; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kaykas A, 2002, J VIROL, V76, P11551, DOI 10.1128/JVI.76.22.11551-11560.2002; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Lam N, 2004, J VIROL, V78, P1657, DOI 10.1128/JVI.78.4.1657-1664.2004; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Lee J, 2007, J VIROL, V81, P9121, DOI 10.1128/JVI.00136-07; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Neuhierl B, 2002, P NATL ACAD SCI USA, V99, P15036, DOI 10.1073/pnas.232381299; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; Tassa A, 2003, BIOCHEM J, V376, P577, DOI 10.1042/BJ20030826; Taylor GS, 2006, J IMMUNOL, V177, P3746, DOI 10.4049/jimmunol.177.6.3746; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	36	114	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2833	2842		10.1038/sj.onc.1210946	http://dx.doi.org/10.1038/sj.onc.1210946			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037963				2022-12-17	WOS:000255502500004
J	Raabe, EH; Laudenslager, M; Winter, C; Wasserman, N; Cole, K; LaQuaglia, M; Maris, DJ; Mosse, YP; Maris, JM				Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.			Prevalence and functional consequence of PHOX2B mutations in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; PHOX2B; MYCN; neural crest; tumor suppressor gene	CENTRAL-HYPOVENTILATION-SYNDROME; HOMEOBOX GENE PHOX2B; HEREDITARY NEUROBLASTOMA; TRANSCRIPTION; PHENOTYPE; SHOWS	PHOX2B is a homeodomain-containing protein that is involved in the development of the peripheral nervous system and is the major disease gene for the rare congenital breathing disorder congenital central hypoventilation syndrome (CCHS). Germline PHOX2B alterations were also recently discovered in neuroblastoma cases with CCHS and/or Hirschsprung disease, but a comprehensive survey for mutational frequency and functional consequence has not been performed. We therefore studied a large panel of hereditary neuroblastomas to understand the frequency and functional effects of PHOX2B mutations. Three of 47 individuals with presumed genetic predisposition to neuroblastoma showed a germline PHOX2B mutation (6.4%). Mutations were also discovered in 2 of 30 human neuroblastoma-derived cell lines, but none of 86 primary tumors from patients with sporadically occurring neuroblastoma. The vast majority of primary tumors showed abundant PHOX2B mRNA expression relative to the remainder of the transcriptome. Consistent with its role as an important neurodevelopmental gene, forced overexpression of wild-type PHOX2B in neuroblastoma cell lines suppressed cell proliferation and synergized with all-trans retinoic acid to promote differentiation. Patient-derived mutant PHOX2B constructs retained the ability to suppress cellular proliferation, but were not able to promote differentiation or activate expression of a known PHOX2B target gene in vitro. These findings show that PHOX2B alterations are a rare cause of hereditary neuroblastoma, but disruption of this neurodevelopmental pathway can interfere with transcription-dependent terminal differentiation. These data also suggest that the genetics of neuroblastoma initiation are complex, and highlight genes involved in normal noradrenergic development as candidate predisposition genes.	[Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Raabe, E. H.; Laudenslager, M.; Winter, C.; Wasserman, N.; Cole, K.; LaQuaglia, M.; Maris, D. J.; Mosse, Y. P.; Maris, J. M.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Maris, J. M.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Maris, JM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, ARC902A,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	maris@chop.edu		Raabe, Eric/0000-0002-9368-7037	NATIONAL CANCER INSTITUTE [R01CA087847, U10CA098543, R01CA078545] Funding Source: NIH RePORTER; NCI NIH HHS [U10-CA98543, R01-CA87847, R01-CA78545] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Atienza JM, 2006, J BIOMOL SCREEN, V11, P634, DOI 10.1177/1087057106289334; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Beiske K, 2005, CANCER LETT, V228, P229, DOI 10.1016/j.canlet.2005.02.053; DINGWALL C, 1991, BIOESSAYS, V13, P213, DOI 10.1002/bies.950130503; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; GAETANO C, 1991, CELL GROWTH DIFFER, V2, P487; Maris JM, 2002, CANCER RES, V62, P6651; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; McConville C, 2006, AM J MED GENET A, V140A, P1297, DOI 10.1002/ajmg.a.31278; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	18	114	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					469	476		10.1038/sj.onc.1210659	http://dx.doi.org/10.1038/sj.onc.1210659			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637745				2022-12-17	WOS:000252426100007
J	Whitmarsh, AJ; Davis, RJ				Whitmarsh, A. J.; Davis, R. J.			Role of mitogen-activated protein kinase kinase 4 in cancer	ONCOGENE			English	Review						MAP kinase; MKK4; JNK; p38; tumor suppressor	JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; METASTASIS-SUPPRESSOR GENE; EMBRYONIC STEM-CELLS; SIGNAL-TRANSDUCTION PATHWAY; BAX-DEPENDENT APOPTOSIS; HUMAN OVARIAN-CARCINOMA; PROLYL ISOMERASE PIN1; RETINOID-X-RECEPTOR; C-JUN	Mitogen-activated protein (MAP) kinase kinase 4 (MKK4) is a component of stress activated MAP kinase signaling modules. It directly phosphorylates and activates the c-Jun N-terminal kinase (JNK) and p38 families of MAP kinases in response to environmental stress, proinflammatory cytokines and developmental cues. MKK4 is ubiquitously expressed and the targeted deletion of the Mkk4 gene in mice results in early embryonic lethality. Further studies in mice have indicated a role for MKK4 in liver formation, the immune system and cardiac hypertrophy. In humans, it is reported that loss of function mutations in the MKK4 gene are found in approximately 5% of tumors from a variety of tissues, suggesting it may have a tumor suppression function. Further more, MKK4 has been identified as a suppressor of metastasis of prostate and ovarian cancers. However, the role of MKK4 in cancer development appears complex as other studies support a pro-oncogenic role for MKK4 and JNK. Here we review the biochemical and functional properties of MKK4 and discuss the likely mechanisms by which it may regulate the steps leading to the formation of cancers.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Fac Life Sci, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.	roger.davis@umassmed.edu		Davis, Roger/0000-0002-0130-1652; Whitmarsh, Alan/0000-0003-1184-6610				Adam-Stitah S, 1999, J BIOL CHEM, V274, P18932, DOI 10.1074/jbc.274.27.18932; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 2001, ONCOGENE, V20, P7425, DOI 10.1038/sj.onc.1204924; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Carboni L, 1997, NEUROSCIENCE, V80, P147, DOI 10.1016/S0306-4522(97)00005-5; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Cazillis M, 2004, ONCOGENE, V23, P4735, DOI 10.1038/sj.onc.1207619; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen NY, 2001, CANCER RES, V61, P3908; Choi BY, 2005, NAT STRUCT MOL BIOL, V12, P699, DOI 10.1038/nsmb960; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Coffey ET, 2000, J NEUROSCI, V20, P7602; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Cunningham SC, 2006, CANCER RES, V66, P5560, DOI 10.1158/0008-5472.CAN-06-0555; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEMIDOV ON, 2006, IN PRESS ONCOGENE; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Gao YF, 2005, J IMMUNOL, V175, P5783, DOI 10.4049/jimmunol.175.9.5783; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Griend DJV, 2005, CANCER RES, V65, P10984, DOI 10.1158/0008-5472.CAN-05-2382; Ha HY, 2005, DEV BIOL, V277, P184, DOI 10.1016/j.ydbio.2004.09.019; Han ZQS, 1998, MOL CELL BIOL, V18, P3527, DOI 10.1128/MCB.18.6.3527; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hickson JA, 2006, CANCER RES, V66, P2264, DOI 10.1158/0008-5472.CAN-05-3676; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jaeschke A, 2006, MOL CELL, V23, P899, DOI 10.1016/j.molcel.2006.07.028; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kelkar N, 2003, P NATL ACAD SCI USA, V100, P9843, DOI 10.1073/pnas.1733944100; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; KHATLANI TS, 2006, IN PRESS ONCOGENE; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim GH, 2005, DEV BIOL, V286, P256, DOI 10.1016/j.ydbio.2005.07.033; Kim HL, 2001, CANCER RES, V61, P2833; Kishimoto H, 2003, J BIOL CHEM, V278, P16595, DOI 10.1074/jbc.M213182200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lawler S, 1997, FEBS LETT, V414, P153, DOI 10.1016/S0014-5793(97)00990-3; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; Lee HY, 2005, CLIN CANCER RES, V11, P6065, DOI 10.1158/1078-0432.CCR-05-0009; Lee JK, 1999, MOL BRAIN RES, V66, P133, DOI 10.1016/S0169-328X(99)00035-2; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Lopez-Aviles S, 2005, MOL CELL, V17, P49, DOI 10.1016/j.molcel.2004.11.043; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Mann KK, 2005, J CLIN INVEST, V115, P2924, DOI 10.1172/JCI23628; Matsuo Y, 2006, J BIOL CHEM, V281, P36767, DOI 10.1074/jbc.M604371200; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mori S, 2004, ONCOGENE, V23, P7416, DOI 10.1038/sj.onc.1207981; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakayama K, 2006, CANCER BIOL THER, V5, P630, DOI 10.4161/cbt.5.6.2675; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; She QB, 2002, CANCER RES, V62, P1343; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Srinivas H, 2005, MOL CELL BIOL, V25, P1054, DOI 10.1128/MCB.25.3.1054-1069.2005; Stark AM, 2005, J CANCER RES CLIN, V131, P191, DOI 10.1007/s00432-004-0629-9; Su GH, 1998, CANCER RES, V58, P2339; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Swat W, 1998, IMMUNITY, V8, P625, DOI 10.1016/S1074-7613(00)80567-1; Takekawa M, 2005, MOL CELL, V18, P295, DOI 10.1016/j.molcel.2005.04.001; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Teng DHF, 1997, CANCER RES, V57, P4177; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Ventura JJ, 2004, MOL CELL, V15, P269, DOI 10.1016/j.molcel.2004.06.007; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xiao L, 2000, CANCER RES, V60, P400; Xin W, 2004, CLIN CANCER RES, V10, P8516, DOI 10.1158/1078-0432.CCR-04-0885; Xiu M, 2003, MOL CELL BIOL, V23, P8890, DOI 10.1128/MCB.23.23.8890-8901.2003; Xu P, 2003, J BIOL CHEM, V278, P48422, DOI 10.1074/jbc.M307888200; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yamada SD, 2002, CANCER RES, V62, P6717; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang YM, 2003, CLIN CANCER RES, V9, P391; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; Yoshida BA, 1999, CANCER RES, V59, P5483; Yoshida S, 2001, J HUM GENET, V46, P182, DOI 10.1007/s100380170086; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	132	114	128	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3172	3184		10.1038/sj.onc.1210410	http://dx.doi.org/10.1038/sj.onc.1210410			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496914				2022-12-17	WOS:000246603600007
J	Tremblay, PL; Auger, FA; Huot, J				Tremblay, P-L; Auger, F. A.; Huot, J.			Regulation of transendothelial migration of colon cancer cells by E-selectin-mediated activation of p38 and ERK MAP kinases	ONCOGENE			English	Article						E-selectin; MAP kinases; transendothelial migration; colon cancer	VASCULAR ENDOTHELIAL-CELLS; ACTIN REORGANIZATION; LEUKOCYTE ADHESION; BARRIER DYSFUNCTION; OXIDATIVE STRESS; LIVER METASTASIS; CARCINOMA CELLS; TUMOR-CELLS; PERMEABILITY; PHOSPHORYLATION	The invasive properties of cancer cells depend on their intrinsic motile potential and on their ability to breach the endothelial barrier. In the present work, we investigated the mechanisms by which adhesion of colon cancer cells to E-selectin expressed by endothelial cells regulates the barrier function of these cells and modulates transmigration of cancer cells. We found that the stimulation of E-selectin by activating antibodies or the adhesion of HT-29 cells results in an increase in the activity of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinases. In turn, the activation of p38 and ERK enhances transendothelial permeability and migration of HT-29 cells. We also obtained evidence suggesting that p38-mediated increase in transendothelial migration of cancer cells depends on a myosin light chain phosphorylation-mediated formation of stress fibres. On the other hand, the activation of ERK by E-selectin modulates the opening of interendothelial spaces by initiating the activation of Src kinase activities and the dissociation of the VE-cadherin/beta-catenin complex. We conclude that activation of E-selectin by adhering cancer cells is an important process that regulates the extravasation of colon cancer cells by initiating p38- and ERK-dependent mechanisms that both contribute to regulate the integrity of the endothelial layer.	Univ Laval, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Quebec, Ctr Hosp, Lab Organogenese Expt, Ste Foy, PQ G1S 4L8, Canada	Laval University; Laval University; University of Quebec	Huot, J (corresponding author), Univ Laval, Ctr Rech Cancerol, 9,Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Baldwin AL, 2001, CRIT REV BIOMED ENG, V29, P247, DOI 10.1615/CritRevBiomedEng.v29.i2.20; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Bogatcheva NV, 2002, VASC PHARMACOL, V39, P201, DOI 10.1016/S1537-1891(03)00009-0; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Criscuoli ML, 2005, BLOOD, V105, P1508, DOI 10.1182/blood-2004-06-2246; DEJANA E, 1992, LAB INVEST, V66, P324; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Dejana E, 1999, EXP CELL RES, V252, P13, DOI 10.1006/excr.1999.4601; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Haier J, 2001, DIS COLON RECTUM, V44, P876, DOI 10.1007/BF02234713; Hale KK, 1999, J IMMUNOL, V162, P4246; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; Hu YY, 2000, J IMMUNOL, V165, P2142, DOI 10.4049/jimmunol.165.4.2142; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ionescu CV, 2003, MICROCIRCULATION, V10, P205, DOI 10.1038/sj.mn.7800185; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kevil CG, 2001, ENDOTHELIUM-J ENDOTH, V8, P107, DOI 10.3109/10623320109165320; Khatib AM, 2002, CANCER RES, V62, P5393; Khatib AM, 1999, CANCER RES, V59, P1356; Kobayashi K, 2000, CANCER RES, V60, P3978; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Laferriere J, 2002, ANN NY ACAD SCI, V973, P562, DOI 10.1111/j.1749-6632.2002.tb04702.x; Lafferriere J, 2004, CLIN EXP METASTAS, V21, P257, DOI 10.1023/B:CLIN.0000037708.09420.9a; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Mehta D, 1999, J PHYSIOL-LONDON, V519, P829, DOI 10.1111/j.1469-7793.1999.0829n.x; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Peng HH, 2005, FRONT BIOSCI-LANDMRK, V10, P1597, DOI 10.2741/1643; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Saito H, 1998, J IMMUNOL, V161, P1533; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCHNITTLER HJ, 1990, J PHYSIOL-LONDON, V431, P379, DOI 10.1113/jphysiol.1990.sp018335; Shaw L, 2003, J VASC RES, V40, P1, DOI 10.1159/000068940; Tinsley JH, 1999, J BIOL CHEM, V274, P24930, DOI 10.1074/jbc.274.35.24930; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; YAMADA N, 1995, DIGEST DIS SCI, V40, P1005, DOI 10.1007/BF02064189; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yoshida M, 2003, ARTERIOSCL THROM VAS, V23, P783, DOI 10.1161/01.ATV.0000067427.40133.59; Yoshida M, 1996, J CELL BIOL, V133, P445, DOI 10.1083/jcb.133.2.445; Yuan SY, 2002, VASC PHARMACOL, V39, P213, DOI 10.1016/S1537-1891(03)00010-7; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539	54	114	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6563	6573		10.1038/sj.onc.1209664	http://dx.doi.org/10.1038/sj.onc.1209664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715142				2022-12-17	WOS:000241569700001
J	Roccio, M; Bos, JL; Zwartkruis, FJT				Roccio, M; Bos, JL; Zwartkruis, FJT			Regulation of the small GTPase Rheb by amino acids	ONCOGENE			English	Article						Rheb; mTOR; S6 kinase	TUBEROUS SCLEROSIS COMPLEX-1; TUMOR-SUPPRESSOR PROTEINS; TOP MESSENGER-RNAS; P70 S6 KINASE; CELL-GROWTH; MAMMALIAN TARGET; GENE-PRODUCTS; RPS6 PHOSPHORYLATION; RAPAMYCIN; MTOR	The mTOR/S6K/4E-BP1 pathway integrates extracellular signals derived from growth factors, and intracellular signals, determined by the availability of nutrients like amino acids and glucose. Activation of this pathway requires inhibition of the tumor suppressor complex TSC1/2. TSC2 is a GTPase-activating protein for the small GTPase Ras homologue enriched in brain ( Rheb), GTP loading of which activates mTOR by a yet unidentified mechanism. The level at which this pathway senses the availability of amino acids is unknown but is suggested to be at the level of TSC2. Here, we show that amino-acid depletion completely blocks insulin- and TPA-induced Rheb activation. This indicates that amino-acid sensing occurs upstream of Rheb. Despite this, amino-acid depletion can still inhibit mTOR/S6 kinase signaling in TSC2(-/-). broblasts. Since under these conditions Rheb-GTP levels remain high, a second level of amino-acid sensing exists, affecting mTOR activity in a Rhebin-dependent fashion.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University	Zwartkruis, FJT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	g.j.t.zwartkruis@med.uu.nl		Roccio, Marta/0000-0001-7568-9429				Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grammer TC, 1996, CANCER SURV, V27, P271; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Iiboshi Y, 1999, J BIOL CHEM, V274, P1092, DOI 10.1074/jbc.274.2.1092; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richardson CJ, 2004, CURR BIOL, V14, P1540, DOI 10.1016/j.cub.2004.08.061; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang RJ, 2000, MOL CELL BIOL, V20, P2706, DOI 10.1128/MCB.20.8.2706-2717.2000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	39	114	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					657	664		10.1038/sj.onc.1209106	http://dx.doi.org/10.1038/sj.onc.1209106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16170341				2022-12-17	WOS:000235068800001
J	Kurisu, S; Suetsugu, S; Yamazaki, D; Yamaguchi, H; Takenawa, T				Kurisu, S; Suetsugu, S; Yamazaki, D; Yamaguchi, H; Takenawa, T			Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of murine melanoma cells	ONCOGENE			English	Article						WAVE; Rac; WASP family; invasion; metastasis; actin cytoskeleton	ACTIN-DEPOLYMERIZING PROTEIN; MATRIX-METALLOPROTEINASE; PLASMINOGEN-ACTIVATOR; N-WASP; RAC; WAVE; RHO; MIGRATION; CYTOSKELETON; INHIBITION	WAVEs (WASP-family verprolin-homologous proteins) regulate the actin cytoskeleton through activation of Arp2/3 complex. As cell motility is regulated by actin cytoskeleton rearrangement and is required for tumor invasion and metastasis, blocking actin polymerization may be an effective strategy to prevent tumor dissemination. We show that WAVEs, especially WAVE2, are essential for invasion and metastasis of melanoma cells. Malignant B16F10 mouse melanoma cells expressed more WAVE1 and WAVE2 proteins and showed higher Rac activity than B16 parental cells, which are neither invasive nor metastatic. The effect of WAVE2 silencing by RNA interference (RNAi) on the highly invasive nature of B16F10 cells was more dramatic than that of WAVE1 RNAi. Membrane ruffling, cell motility, invasion into the extracellular matrix, and pulmonary metastasis of B16F10 cells were suppressed by WAVE2 RNAi. WAVE2 RNAi also had a profound effect on invasion induced by a constitutively active form of Rac (RacCA). In addition, ectopic expression of both RacCA and WAVE2 in B16 cells resulted in further increase in the invasiveness than that observed in B16 cells expressing only RacCA. Thus, WAVE2 acts as the primary effector downstream of Rae to achieve invasion and metastasis, suggesting that suppression of WAVE2 activity holds a promise for preventing cancer invasion and metastasis.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Canc Genet, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	takenawa@ims.u-tokyo.ac.jp	Yamaguchi, Hideki/AAP-1767-2021; Kurisu, Shusaku/AAB-1799-2022; Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020; Suetsugu, Shiro/B-3300-2010	Yamaguchi, Hideki/0000-0003-2125-9655; Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628; Kurisu, Shusaku/0000-0002-4876-4419				Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Connolly JO, 2002, MOL BIOL CELL, V13, P2474, DOI 10.1091/mbc.E02-01-0006; De Corte V, 2002, EMBO J, V21, P6781, DOI 10.1093/emboj/cdf680; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Giavazzi R, 2001, Methods Mol Med, V58, P223, DOI 10.1385/1-59259-137-X:223; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Joyce PL, 2003, CANCER RES, V63, P7959; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Li YS, 2001, CANCER RES, V61, P6906; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Menna PL, 2003, CANCER RES, V63, P2284; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Nozumi M, 2003, J CELL SCI, V116, P239, DOI 10.1242/jcs.00233; Ortega A, 2003, J BIOL CHEM, V278, P39591, DOI 10.1074/jbc.M303753200; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Suetsugu S, 2003, DEV CELL, V5, P595, DOI 10.1016/S1534-5807(03)00297-1; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Suetsugu S, 2002, CELL MOTIL CYTOSKEL, V51, P113, DOI 10.1002/cm.10020; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Takenawa T, 2001, J CELL SCI, V114, P1801; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Voura EB, 1998, CELL TISSUE RES, V293, P375, DOI 10.1007/s004410051129; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Yamazaki D, 2003, NATURE, V424, P452, DOI 10.1038/nature01770; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; YU H, 1990, CANCER RES, V50, P7623; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	46	114	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1309	1319		10.1038/sj.onc.1208177	http://dx.doi.org/10.1038/sj.onc.1208177			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608687				2022-12-17	WOS:000227092600001
J	Kimura, A; Ohmichi, M; Kawagoe, J; Kyo, S; Mabuchi, S; Takahashi, T; Ohshima, C; Arimoto-Ishida, E; Nishio, Y; Inoue, M; Kurachi, H; Tasaka, K; Murata, Y				Kimura, A; Ohmichi, M; Kawagoe, J; Kyo, S; Mabuchi, S; Takahashi, T; Ohshima, C; Arimoto-Ishida, E; Nishio, Y; Inoue, M; Kurachi, H; Tasaka, K; Murata, Y			Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines	ONCOGENE			English	Article						estrogen; telomerase; Akt; ovarian cancer	TELOMERASE REVERSE-TRANSCRIPTASE; NF-KAPPA-B; REGULATED PROTEIN-KINASE; CATALYTIC SUBUNIT GENE; NITRIC-OXIDE SYNTHASE; CRITICAL DETERMINANT; MESSENGER-RNA; ACTIVATION; INHIBITION; RECEPTOR	We examined the mechanism by which estrogen regulates telomerase activity in Caov-3 human ovarian cancer cell lines, which express ER, to determine whether the regulation affects the expression and/or phosphorylation of the telomerase catalytic subunit (hTERT). 17beta-Estradiol (E-2) induced telomerase activity and hTERT expression. Transient expression assays using luciferase reporter plasmids containing various fragments of hTERT promoter showed that the estrogen-responsive element appeared to be partially responsible for the E-2-induced activation of the hTERT promoter. Either pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, or transfection with a dominant-negative Akt attenuated the E-2-induced activation of the hTERT promoter. In addition, estrogen induced the phosphorylation Of IkappaB inhibitor protein via the Akt cascade, and cotransfection with a dominant-negative subunit of NFkappaB attenuated the response of the ERE-deleted hTERT promoter to E-2-Moreover, E2 induced the phosphorylation of hTERT, the association of 14-3-3 protein and NFkappaB with hTERT, and nuclear accumulation of hTERT in an Akt-dependent manner. These results indicate that E-2 induces telomerase activity not only by transcriptional regulation of hTERT via an ERE-dependent mechanism and a PI3K/Akt/NFkappaB cascade, but also by post-transcriptional regulation via Akt-dependent phosphorylation of hTERT. Thus, the phosphorylation of Akt is a key event in the induction of telomeras activity by E-2 in human ovarian cancer cells.	Osaka Univ, Sch Med, Dept Obstet & Gynecol, Suita, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Obstet & Gynecol, Yamagata 9909585, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 920, Japan; Yamagata Univ, Sch Med, Div Nursing, Yamagata 9909585, Japan	Osaka University; Yamagata University; Kanazawa University; Yamagata University	Ohmichi, M (corresponding author), Osaka Univ, Sch Med, Dept Obstet & Gynecol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	masa@gyne.med.osaka-u.ac.jp	Mabuchi, Seiji/AAX-1986-2020					Akalin A, 2001, CANCER RES, V61, P4791; Akiyama M, 2003, CANCER RES, V63, P18; Akiyama M, 2002, CANCER RES, V62, P3876; Alfonso-De Matte MY, 2002, CANCER RES, V62, P4575; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Boldrini L, 2002, INT J ONCOL, V21, P493; Bourgarel-Rey V, 2001, MOL PHARMACOL, V59, P1165, DOI 10.1124/mol.59.5.1165; Breitschopf K, 2001, FEBS LETT, V493, P21, DOI 10.1016/S0014-5793(01)02272-4; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chow SN, 1996, INT SURG, V81, P152; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Hayakawa J, 2000, CANCER RES, V60, P5988; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Kawagoe J, 2003, J BIOL CHEM, V278, P43363, DOI 10.1074/jbc.M304363200; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kraemer K, 2003, CLIN CANCER RES, V9, P3794; Kyo S, 1999, INT J CANCER, V80, P804; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Kyo S, 1999, CANCER RES, V59, P5917; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Murakami J, 1997, CANCER, V80, P1085; Nakano K, 1998, AM J PATHOL, V153, P857, DOI 10.1016/S0002-9440(10)65627-1; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Ozes ON, 1999, NATURE, V401, P82; Park TW, 1999, INT J CANCER, V84, P426, DOI 10.1002/(SICI)1097-0215(19990820)84:4<426::AID-IJC17>3.3.CO;2-T; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Takakura M, 1998, CANCER RES, V58, P1558; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Teng LS, 2003, J CLIN ENDOCR METAB, V88, P1362, DOI 10.1210/jc.2002-021222; Wang Z, 2000, CANCER RES, V60, P5376; Wang ZO, 2002, ONCOGENE, V21, P3517, DOI 10.1038/sj.onc.1205463; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	61	114	123	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4505	4515		10.1038/sj.onc.1207582	http://dx.doi.org/10.1038/sj.onc.1207582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15048073				2022-12-17	WOS:000221799000001
J	Gilmore, TD; Kalaitzidis, D; Liang, MC; Starczynowski, DT				Gilmore, TD; Kalaitzidis, D; Liang, MC; Starczynowski, DT			The c-Rel transcription factor and B-cell proliferation: a deal with the devil	ONCOGENE			English	Review						c-Rel; Rel; NF-kappa B; B cell; lymphoma; gene amplification	NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION; BRUTONS TYROSINE KINASE; CHICKEN SPLEEN-CELLS; V-REL; GENE-EXPRESSION; MICE LACKING; MARGINAL ZONE; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE	Activation of the Rel/NF-kappaB signal transduction pathway has been associated with a variety of animal and human malignancies. However, among the Rel/NF-kappaB family members, only c-Rel has been consistently shown to be able to malignantly transform cells in culture. In addition, c-rel has been activated by a retroviral promoter insertion in an avian B-cell lymphoma, and amplifications of REL (human c-rel) are frequently seen in Hodgkin's lymphomas and diffuse large B-cell lymphomas, and in some follicular and mediastinal B-cell lymphomas. Phenotypic analysis of c-rel knockout mice demonstrates that c-Rel has a normal role in B-cell proliferation and survival; moreover, c-Rel nuclear activity is required for B-cell development. Few mammalian model systems are available to study the role of c-Rel in oncogenesis, and it is still not clear what features of c-Rel endow it with its unique oncogenic activity among the Rel/NF-kappaB family. In any event, REL may provide an appropriate therapeutic target for certain human lymphoid cell malignancies.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu		Liang, Mei-Chih/0000-0002-7389-2455				Agresti A, 2002, MOL IMMUNOL, V38, P849, DOI 10.1016/S0161-5890(01)00121-3; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; AvetLoiseau H, 1997, BRIT J HAEMATOL, V97, P119, DOI 10.1046/j.1365-2141.1997.d01-2140.x; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bentz M, 1996, BLOOD, V88, P1437, DOI 10.1182/blood.V88.4.1437.bloodjournal8841437; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cabatingan MS, 2002, J IMMUNOL, V169, P6795, DOI 10.4049/jimmunol.169.12.6795; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Cheng SH, 2003, ONCOGENE, V22, P8472, DOI 10.1038/sj.onc.1206917; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Doerre S, 1999, J IMMUNOL, V163, P269; Donnelly GB, 2001, BLOOD, V98, p302A; Dyer MJS, 2003, INT J HEMATOL, V77, P315, DOI 10.1007/BF02982637; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; FAN Y, 2003, IN PRESS ONCOGENE; Fields ER, 2000, J IMMUNOL, V164, P4762, DOI 10.4049/jimmunol.164.9.4762; Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2003, VIROLOGY, V316, P9, DOI 10.1016/S0042-6822(03)00562-2; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; GILMORE TD, 2003, REL NF KAPPA B TRANS; Glineur C, 2000, BIOCHEM J, V352, P583, DOI 10.1042/0264-6021:3520583; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Harling-McNabb L, 1999, INT IMMUNOL, V11, P1431, DOI 10.1093/intimm/11.9.1431; Harnett M, 1996, IMMUNOL TODAY, V17, P4, DOI 10.1016/0167-5699(96)80558-5; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Houldsworth J, 1996, BLOOD, V87, P25; HOULDSWORTH J, 2003, IN PRESS BLOOD; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Hu CJ, 2001, IMMUNITY, V15, P545, DOI 10.1016/S1074-7613(01)00219-9; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kaku H, 2002, INT IMMUNOL, V14, P1055, DOI 10.1093/intimm/dxf072; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kim HG, 2002, EXP CELL RES, V272, P199, DOI 10.1006/excr.2001.5420; Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100; Kistler B, 1998, J IMMUNOL, V160, P2308; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Liou HC, 2003, BIOESSAYS, V25, P767, DOI 10.1002/bies.10306; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; LU D, 1991, ONCOGENE, V6, P1235; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mao X, 2003, GENE CHROMOSOME CANC, V37, P176, DOI 10.1002/gcc.10184; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Martinez-Climent JA, 2003, BLOOD, V101, P3109, DOI 10.1182/blood-2002-07-2119; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; NEUMANN M, 1992, ONCOGENE, V7, P2095; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; Popescu NC, 2002, J CELL MOL MED, V6, P151, DOI 10.1111/j.1582-4934.2002.tb00183.x; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Schmidt CS, 2003, J EXP MED, V197, P51, DOI 10.1084/jem.20020617; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Suzuki H, 2003, NAT IMMUNOL, V4, P280, DOI 10.1038/ni890; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; Tamura A, 2001, CANCER GENET CYTOGEN, V129, P1, DOI 10.1016/S0165-4608(01)00436-8; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; Tolnay M, 2002, J IMMUNOL, V169, P6236, DOI 10.4049/jimmunol.169.11.6236; Tsuboi K, 2000, LEUKEMIA, V14, P449, DOI 10.1038/sj.leu.2401696; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; WEIH F, 1994, ONCOGENE, V9, P3289; Werner CA, 1997, AM J PATHOL, V151, P335; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297; White DW, 1996, ONCOGENE, V13, P891; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Yamazaki T, 2003, NAT IMMUNOL, V4, P780, DOI 10.1038/ni949; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	151	114	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2275	2286		10.1038/sj.onc.1207410	http://dx.doi.org/10.1038/sj.onc.1207410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14755244				2022-12-17	WOS:000220427700001
J	Stoner, M; Wormke, M; Saville, B; Samudio, I; Qin, CH; Abdelrahim, M; Safe, S				Stoner, M; Wormke, M; Saville, B; Samudio, I; Qin, CH; Abdelrahim, M; Safe, S			Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins	ONCOGENE			English	Article						estrogen; VEGF; transactivation; ER alpha/Sp1; ER alpha/Sp3	PERMEABILITY FACTOR EXPRESSION; NECROSIS-FACTOR-ALPHA; CATHEPSIN-D GENE; TRANSCRIPTIONAL ACTIVATION; FACTOR VEGF; PROGESTERONE-RECEPTOR; HORMONAL-REGULATION; RESPONSIVE ELEMENT; GLIOMA-CELLS; TUMOR-GROWTH	Vascular endothelial growth factor (VEGF) is expressed in multiple hormone-dependent cancer cells/tumors. Treatment of ZR-75 breast cancer cells with 17beta-estradiol (E2) induced a greater than fourfold increase of VEGF mRNA levels. ZR-75 breast cancer cells were transfected with pVEGF1, a construct containing a -2018 to +50 VEGF prom oter insert, and E2 induced reporter gene (luciferase) activity. Deletion and mutation analysis of the VEGF gene promoter identified a GC-rich region (-66 to -47) which was required for E2-induced transactivation of pVEGF5, a construct containing the minimal promoter (-66 to +54) that exhibited E2-responsiveness. Interactions of nuclear proteins from ZR-75 cells with the proximal GC-rich region of the VEGF gene promoter were investigated by electrophoretic mobility shift and chromatin immunoprecipitation assays. The results demonstrate that both Sp1 and Sp3 proteins bound the GC-rich motif (-66 to +47), and estrogen receptor alpha (ERalpha) interactions were confirmed by chromatin immunoprecipitation. Moreover, E2-dependent activation of constructs containing proximal and distal GC/GT-rich regions of the VEGF promoter was inhibited in ZR-75 cells transfected with small inhibitory RNAs for Sp1 and Sp3. These results were consistent with a mechanism of hormone activation of VEGF through ERalpha/Sp1 and ERalpha/Sp3 interactions with GC-rich motifs.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NCI NIH HHS [CA076636] Funding Source: Medline; NIEHS NIH HHS [ES04176, ES09106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004176, P30ES009106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bogin L, 2002, CANCER RES, V62, P1948; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brekken RA, 2000, CANCER RES, V60, P5117; BROWN LF, 1993, AM J PATHOL, V143, P1255; Buteau-Lozano H, 2002, CANCER RES, V62, P4977; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; Classen-Linke I, 2000, STEROIDS, V65, P763, DOI 10.1016/S0039-128X(00)00180-X; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harborth J, 2001, J CELL SCI, V114, P4557; Hyder SM, 1997, CANCER LETT, V120, P165, DOI 10.1016/S0304-3835(97)00306-6; Hyder SM, 1998, CANCER RES, V58, P392; Hyder SM, 1996, CANCER RES, V56, P3954; Hyder SM, 2000, CANCER RES, V60, P3183; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KLOTZ DM, 1995, BIOCHEM BIOPH RES CO, V210, P609, DOI 10.1006/bbrc.1995.1702; Laitinen M, 1997, ENDOCRINOLOGY, V138, P4748, DOI 10.1210/en.138.11.4748; Linderholm BK, 2001, CANCER RES, V61, P2256; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; Nakamura J, 1996, ENDOCRINOLOGY, V137, P5589, DOI 10.1210/en.137.12.5589; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Scheidegger KJ, 2000, J BIOL CHEM, V275, P38921, DOI 10.1074/jbc.M004691200; Schlaeppi JM, 1999, CANCER METAST REV, V18, P473, DOI 10.1023/A:1006358220123; Shi Q, 2001, CANCER RES, V61, P4143; Simmen RCM, 1999, ENDOCRINOLOGY, V140, P2517, DOI 10.1210/en.140.6.2517; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshiji H, 1997, CANCER RES, V57, P3924; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	63	114	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1052	1063		10.1038/sj.onc.1207201	http://dx.doi.org/10.1038/sj.onc.1207201			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647449				2022-12-17	WOS:000188749900004
J	Nassif, NT; Lobo, GP; Wu, XJ; Henderson, CJA; Morrison, CD; Eng, C; Jalaludin, B; Segelov, E				Nassif, NT; Lobo, GP; Wu, XJ; Henderson, CJA; Morrison, CD; Eng, C; Jalaludin, B; Segelov, E			PTEN mutations are common in sporadic microsatellite stable colorectal cancer	ONCOGENE			English	Article						PTEN; sporadic colorectal cancer; mutation; microsatellite instability; loss of heterozygosity; immunohistochemistry	TUMOR-SUPPRESSOR GENE; PTEN/MMAC1 GENE; COWDEN-DISEASE; SOMATIC MUTATIONS; ADJUVANT CHEMOTHERAPY; PHOSPHATASE-ACTIVITY; GERMLINE MUTATIONS; INSTABILITY; ENDOMETRIAL; EXPRESSION	The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a dual-specificity phosphatase that negatively regulates the phosphatidylinositol 3'-kinase (PI3K)/Akt-dependent cellular survival pathway. PTEN is frequently inactivated in many tumour types including glioblastoma, prostate and endometrial cancers. While initial studies reported that PTEN gene mutations were rare in colorectal cancer, more recent reports have shown an approximate 18% incidence of somatic PTEN mutations in colorectal tumours exhibiting microsatellite instability (MSI+). To verify the role of this gene in colorectal tumorigenesis, we analysed paired normal and tumour DNA from 41 unselected primary sporadic colorectal cancers for PTEN inactivation by mutation and/or allelic loss. We now report PTEN gene mutations in 19.5% (8/41) of tumours and allele loss, including all or part of the PTEN gene, in a further 17% (7/41) of the cases. Both PTEN alleles were affected in over half (9/15) of these cases showing PTEN genetic abnormalities. Using immunohistochemistry, we have further shown that all tumours harbouring PTEN alterations have either reduced or absent PTEN expression and this correlated strongly with later clinical stage of tumour at presentation (P=0.02). In contrast to previous reports, all but one of the tumours with PTEN gene mutations were microsatellite stable (MSI-), suggesting that PTEN is involved in a distinct pathway of colorectal tumorigenesis that is separate from the pathway of mismatch repair deficiency. This work therefore establishes the importance of PTEN in primary sporadic colorectal cancer.	Univ New S Wales, Liverpool Hosp, SW Sydney Clin Sch, Canc Res Labs, Liverpool, NSW 2170, Australia; Liverpool Hosp, Dept Anat Pathol, SW Area Pathol Serv, Liverpool, NSW 2170, Australia; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA; Univ Cambridge, Canc Res UK Human Canc Genet Res Grp, Cambridge CB2 2XZ, England; Univ New S Wales, Liverpool Hosp, Sch Publ Hlth & Community Med, Epidemiol Unit, Liverpool, NSW 2170, Australia	Liverpool Hospital; University of New South Wales Sydney; Liverpool Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Cambridge; Liverpool Hospital; University of New South Wales Sydney	Nassif, NT (corresponding author), Univ Technol Sydney, Dept Cell & Mol Biol, St Leonards Campus,Cnr Pacific Hwy & Westbourne S, Gore Hill, NSW 2065, Australia.	Najah.Nassif@uts.edu.au; e.segelov@unsw.edu.au	Segelov, Eva/Q-7611-2019; Nassif, Najah T/G-6214-2012; Lobo, Glenn P./AAI-9736-2020	Segelov, Eva/0000-0002-4410-6144; Nassif, Najah T/0000-0003-2675-8322; Eng, Charis/0000-0002-3693-5145				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; BEAHRS OH, 1997, AM JOINT COMMITTEE C, P83; Biesecker LG, 2001, LANCET, V358, P2079, DOI 10.1016/S0140-6736(01)07109-4; Boland CR, 1998, CANCER RES, V58, P5248; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Cairns P, 1997, CANCER RES, V57, P4997; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dicuonzo G, 2001, CLIN CANCER RES, V7, P4049; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Elsaleh H, 2000, ONCOLOGY-BASEL, V58, P52, DOI 10.1159/000012079; Elsaleh H, 2001, GASTROENTEROLOGY, V121, P230, DOI 10.1053/gast.2001.26044; Elsaleh H, 2001, CLIN CANCER RES, V7, P1343; Elsaleh H, 2001, GASTROENTEROLOGY, V120, P1309; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Frayling IM, 1997, CANCER GENET CYTOGEN, V97, P64, DOI 10.1016/S0165-4608(97)00011-3; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Giraud S, 1997, J CLIN ENDOCR METAB, V82, P3487, DOI 10.1210/jc.82.10.3487; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Guldberg P, 1997, CANCER RES, V57, P3660; Han SY, 2000, CANCER RES, V60, P3147; Hansen L, 2001, DIABETOLOGIA, V44, P237, DOI 10.1007/s001250051605; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kahnoski K, 2003, J MED GENET, V40, P511, DOI 10.1136/jmg.40.7.511; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kurose K, 1998, JPN J CANCER RES, V89, P842, DOI 10.1111/j.1349-7006.1998.tb00638.x; Kurose K, 2000, GENE CHROMOSOME CANC, V29, P166, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1025>3.3.CO;2-D; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin WM, 1998, CLIN CANCER RES, V4, P2577; Liu Q, 1994, PCR Methods Appl, V4, P97; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Maxwell GL, 2000, CLIN CANCER RES, V6, P2999; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Mutter GL, 2001, CANCER RES, V61, P4311; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Negoro K, 2000, DIS COLON RECTUM, V43, pS29, DOI 10.1007/BF02237223; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Okami K, 1998, CANCER RES, V58, P509; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rhei E, 1997, CANCER RES, V57, P3657; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Taniyama K, 2001, J PATHOL, V194, P341, DOI 10.1002/path.908; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Wang SI, 1997, CANCER RES, V57, P4183; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhou XP, 1999, INT J CANCER, V84, P150, DOI 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445	77	114	125	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					617	628		10.1038/sj.onc.1207059	http://dx.doi.org/10.1038/sj.onc.1207059			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724591	Green Submitted			2022-12-17	WOS:000188098300034
J	Oliveira, C; Pinto, M; Duval, A; Brennetot, C; Domingo, E; Espin, E; Armengol, M; Yamamoto, H; Hamelin, R; Seruca, R; Schwartz, S				Oliveira, C; Pinto, M; Duval, A; Brennetot, C; Domingo, E; Espin, E; Armengol, M; Yamamoto, H; Hamelin, R; Seruca, R; Schwartz, S			BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency	ONCOGENE			English	Article						genomic instability; BRAF; K-Ras; DNA mismatch repair; mutator phenotype; gastrointestinal cancer	MICROSATELLITE MUTATOR PHENOTYPE; TARGET GENES; GASTROINTESTINAL CANCER; SOMATIC MUTATIONS; COLORECTAL-CANCER; INSTABILITY; SEQUENCES; FEATURES	Genes from the RAF family are Ras-regulated kinases involved in growth cellular responses. Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR). Additionally, BRAF mutations were described only in K-Ras-negative colon carcinomas, suggesting that BRAF/K-Ras activating mutations might be alternative genetic events in colon cancer. We have addressed to what extent the tumorigenic-positive selection exerted by BRAF mutations seen in colorectal MMR-deficient tumors was also involved in the tumorigenesis of gastric cancer. Accordingly, BRAF mutations were detected in 34% (25/74) of colorectal MMR-deficient tumors and in 5% (7/142) of MMR-proficient colorectal cases (P = 0.0001). All mutations found in the MSI cases corresponded to the previously reported hotspot V599E. Two D593K and a K600E additional mutations were also detected in three MSS cases. However, only one mutation of BRAF was found within 124 MSS gastric tumors and none in 37 MSI gastric tumors, clearly suggesting that BRAF mutations are not involved in gastric tumorigenesis. Nonetheless, a high incidence of mutations of K-Ras was found within the MSI gastric group of tumors (P = 0.0005), suggesting that the activation of K-Ras-dependent pathways contributes to the tumorigenesis of gastric cancers with MMR deficiency. Accordingly, our results show evidences that BRAF mutations characterize colon but not gastric tumors with MMR deficiency and are not involved in the tumorigenesis of gastric cancer of the mutator phenotype pathway.	Ctr Invest Bioquim & Biol Mol CIBBIM, Mol Pathol Program, Barcelona 08035, Spain; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Porto, Inst Patol & Imunol Mol, P-4200465 Oporto, Portugal	Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade do Porto	Schwartz, S (corresponding author), Ctr Invest Bioquim & Biol Mol CIBBIM, Mol Pathol Program, Passeig Vall hebron 119-129, Barcelona 08035, Spain.		Oliveira, Carla/F-8188-2011; Domingo, Enric/A-9099-2018; seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012	Oliveira, Carla/0000-0001-8340-2264; Domingo, Enric/0000-0003-4390-8767; LOUIS, Caroline/0000-0002-4952-3828; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Espin-Basany, Eloy/0000-0002-9139-4548; Pinto, Mafalda/0000-0003-4684-4797; Armengol, Manuel/0000-0002-3211-3195				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; BRENNETOT C, IN PRESS GASTROENTER; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Duval A, 2002, CANCER RES, V62, P2447; Fukushima H, 2001, J EXP CLIN CANC RES, V20, P553; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Oliveira C, 1998, AM J PATHOL, V153, P1211, DOI 10.1016/S0002-9440(10)65665-9; Perucho M, 1996, BIOL CHEM, V377, P675; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Schwartz S, 1999, CANCER RES, V59, P2995; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yamamoto H, 1999, GASTROENTEROLOGY, V116, P1348, DOI 10.1016/S0016-5085(99)70499-3; Yamamoto H, 1997, CANCER RES, V57, P4420; Yuen ST, 2002, CANCER RES, V62, P6451	17	114	121	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9192	9196		10.1038/sj.onc.1207061	http://dx.doi.org/10.1038/sj.onc.1207061			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668801				2022-12-17	WOS:000187149100010
J	Tognon, M; Corallini, A; Martini, F; Negrini, M; Barbanti-Brodano, G				Tognon, M; Corallini, A; Martini, F; Negrini, M; Barbanti-Brodano, G			Oncogenic transformation by BK virus and association with human tumors	ONCOGENE			English	Review						BK virus; T antigen; transformation; oncogenesis; human tumors	LARGE-T-ANTIGEN; HARVEY-RAS ONCOGENE; HUMAN-BRAIN-TUMORS; HUMAN POLYOMAVIRUS-BK; HUMAN PAPOVA-VIRUS; POLYMERASE CHAIN-REACTION; ENDOTHELIAL GROWTH-FACTOR; EMBRYONIC KIDNEY-CELLS; JC VIRUS; EARLY REGION	BK virus (BKV), a human polyomavirus closely related to JC virus and Simian Virus 40, is ubiquitous in human populations worldwide. After primary infection, BKV establishes a lifelong latent infection in many organs. BKV transforms rodent cells to the neoplastic phenotype and is highly oncogenic in rodents. This review considers the oncogenic potential of BKV in humans and its possible involvement in human tumors. BKV sequences and T antigen (Tag) are detected in several types of human neoplasms, although the viral load is generally low, with less than one copy of the viral genome per cell. The possible causative role of BKV in human oncogenesis rests on the ability of BKV Tag to inactivate the functions of tumor suppressor proteins p53 and pRB family as well as on its ability to induce chromosomal aberrations in human cells. A 'hit and run' mechanism and secretion of paracrine growth factors by BKV Tag-positive cells, recruiting into proliferation neighboring and distant cells, are discussed as possible BKV pathogenic elements in human oncogenesis.	Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, I-44100 Ferrara, Italy; Univ Ferrara, Dept Morphol & Embryol, Sect Histol & Embryol, I-44100 Ferrara, Italy; Univ Ferrara, Interdept Ctr Canc Res, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara; University of Ferrara	Barbanti-Brodano, G (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920				ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; AZZI A, 1994, BONE MARROW TRANSPL, V14, P235; Barbanti-Brodano G, 1987, Antibiot Chemother (1971), V38, P113; Barbanti-Brodano G, 1998, ADV VIRUS RES, V50, P69, DOI 10.1016/S0065-3527(08)60806-4; BARBANTIBRODANO G, 1988, AIDS ASS CANC AFRICA, P175; Baysal BE, 1998, GENE, V217, P107, DOI 10.1016/S0378-1119(98)00350-3; BECK GR, 1998, HUMAN TUMOR VIRUSES, P51; Bofill-Mas S, 2001, J VIROL, V75, P10290, DOI 10.1128/JVI.75.21.10290-10299.2001; BOUCK N, 1978, P NATL ACAD SCI USA, V75, P2473, DOI 10.1073/pnas.75.5.2473; Bratt G, 1999, AIDS, V13, P1071, DOI 10.1097/00002030-199906180-00010; BROWN P, 1975, AM J EPIDEMIOL, V102, P331, DOI 10.1093/oxfordjournals.aje.a112169; Cacciotti P, 2002, AM J RESP CELL MOL, V26, P189, DOI 10.1165/ajrcmb.26.2.4673; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CALOS MP, 1980, CELL, V20, P579, DOI 10.1016/0092-8674(80)90305-0; CAPUTO A, 1983, J MED VIROL, V12, P37, DOI 10.1002/jmv.1890120105; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; CHENCINER N, 1980, P NATL ACAD SCI-BIOL, V77, P975, DOI 10.1073/pnas.77.2.975; CHOO KB, 1993, VIROLOGY, V193, P1042; CORALLINI A, 1991, CANCER J - FRANCE, V4, P24; CORALLINI A, 1982, ARCH VIROL, V73, P243, DOI 10.1007/BF01318078; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; CORALLINI A, 1988, J GEN VIROL, V69, P2671, DOI 10.1099/0022-1317-69-10-2671; CORALLINI A, 1987, CANCER RES, V47, P6671; CORALLINI A, 1977, J NATL CANCER I, V59, P1561, DOI 10.1093/jnci/59.5.1561; CORALLINI A, 1978, J NATL CANCER I, V61, P875; Corallini A, 2001, HUMAN POLYOMAVIRUSES, P431; COSTA T, 1976, J NATL CANCER I, V56, P863; Cubukcu-Dimopulo O, 2000, AM J SURG PATHOL, V24, P145, DOI 10.1097/00000478-200001000-00019; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEMATTEI M, 1994, J INFECT DIS, V169, P1175; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; Dolei A, 2000, J GEN VIROL, V81, P1967, DOI 10.1099/0022-1317-81-8-1967; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DOUGHERTY RM, 1976, J NATL CANCER I, V57, P395, DOI 10.1093/jnci/57.2.395; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ELSNER C, 1992, VIROLOGY, V191, P72, DOI 10.1016/0042-6822(92)90167-N; FIORI M, 1976, P NATL ACAD SCI USA, V73, P4662, DOI 10.1073/pnas.73.12.4662; Flaegstad T, 1999, CANCER RES, V59, P1160; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; Geetha D, 2002, TRANSPLANTATION, V73, P1933, DOI 10.1097/00007890-200206270-00015; GOUDSMIT J, 1982, J MED VIROL, V10, P91, DOI 10.1002/jmv.1890100203; GROSSI MP, 1981, INTERVIROLOGY, V15, P10, DOI 10.1159/000149209; GROSSI MP, 1982, J GEN VIROL, V63, P369; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; HAUKLAND HH, 1992, INT J CANCER, V51, P79, DOI 10.1002/ijc.2910510116; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; Imperiale MJ, 2001, ONCOGENE, V20, P7917, DOI 10.1038/sj.onc.1204916; ISRAEL MA, 1978, VIROLOGY, V90, P187, DOI 10.1016/0042-6822(78)90302-1; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; Kim JYH, 2002, NEURO-ONCOLOGY, V4, P165, DOI 10.1093/neuonc/4.3.165; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lednicky JA, 1999, FRONT BIOSCI, V4, P153; LEE YY, 1994, ONCOGENE, V9, P1655; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; LOEKEN MR, 1992, J VIROL, V66, P2551, DOI 10.1128/JVI.66.4.2551-2555.1992; MacKenzie J, 1999, BRIT J CANCER, V81, P898, DOI 10.1038/sj.bjc.6690783; MARTIN RG, 1979, CELL, V17, P635, DOI 10.1016/0092-8674(79)90271-X; Martini F, 1996, CANCER RES, V56, P4820; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MONINI P, 1995, DNA TUMOR VIRUSES ON, P51; NAKASHATRI H, 1988, J VIROL, V62, P4613; NEGRINI M, 1990, J GEN VIROL, V71, P2731, DOI 10.1099/0022-1317-71-11-2731; Nickeleit V, 2000, NEW ENGL J MED, V342, P1309, DOI 10.1056/NEJM200005043421802; NOSS G, 1984, ARCH VIROL, V81, P41, DOI 10.1007/BF01309295; NOSS G, 1981, ARCH VIROL, V69, P239, DOI 10.1007/BF01317339; OCONNELL K, 1991, AM J PATHOL, V139, P743; PADGETT BL, 1976, PROG MED VIROL, V22, P1; PAGNANI M, 1988, INT J CANCER, V42, P405, DOI 10.1002/ijc.2910420317; PAGNANI M, 1986, J VIROL, V59, P500, DOI 10.1128/JVI.59.2.500-505.1986; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PATER MM, 1980, VIRUSES NATURALLY OC, P329; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; Pietropaolo V, 1998, J MED VIROL, V56, P372, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;372::AID-JMV14&gt;3.0.CO;2-4; PORTOLANI M, 1985, MICROBIOLOGICA, V8, P59; PORTOLANI M, 1978, J GEN VIROL, V38, P369, DOI 10.1099/0022-1317-38-2-369; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Reploeg MD, 2001, CLIN INFECT DIS, V33, P191, DOI 10.1086/321813; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RUNDELL K, 1981, J VIROL, V37, P1090, DOI 10.1128/JVI.37.3.1090-1093.1981; SHAH KV, 1976, P SOC EXP BIOL MED, V153, P180, DOI 10.3181/00379727-153-39506; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; Shivakumar CV, 1996, ONCOGENE, V13, P323; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stoner GL, 2002, AM J KIDNEY DIS, V39, P1102, DOI 10.1053/ajkd.2002.32795; TAKEMOTO KK, 1979, J VIROL, V29, P1177, DOI 10.1128/JVI.29.3.1177-1185.1979; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; UCHIDA S, 1979, J NATL CANCER I, V63, P119; VANDERNOORDAA J, 1986, J GEN VIROL, V67, P1485, DOI 10.1099/0022-1317-67-7-1485; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; Vastag B, 2002, JAMA-J AM MED ASSOC, V288, P1337, DOI 10.1001/jama.288.11.1337; Volter C, 1997, VIROLOGY, V237, P389, DOI 10.1006/viro.1997.8772; Waheed I, 1999, CANCER RES, V59, P6068; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; WATANABE S, 1979, J VIROL, V32, P934, DOI 10.1128/JVI.32.3.934-942.1979; WATANABE S, 1982, INT J CANCER, V29, P583, DOI 10.1002/ijc.2910290515; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; WOLD WSM, 1978, P NATL ACAD SCI USA, V75, P454, DOI 10.1073/pnas.75.1.454; Zambrano A, 2002, ONCOGENE, V21, P5725, DOI 10.1038/sj.onc.1205692; zur Hausen H, 1994, Curr Top Microbiol Immunol, V186, P131; Zur Hausen H, 2001, ONCOGENE, V20, P7820, DOI 10.1038/sj.onc.1204958	114	114	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5192	5200		10.1038/sj.onc.1206550	http://dx.doi.org/10.1038/sj.onc.1206550			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910256				2022-12-17	WOS:000184615100010
J	Nicolas, FJ; Hill, CS				Nicolas, FJ; Hill, CS			Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest	ONCOGENE			English	Article						TGF-beta; Smad; signal duration; pancreatic tumor cells; cell cycle arrest	PLASMINOGEN-ACTIVATOR INHIBITOR; TRANSCRIPTIONAL ACTIVATION; ACTIVIN RECEPTOR; CDK INHIBITORS; CYCLE ARREST; CANCER CELLS; C-MYC; REPRESSION; EXPRESSION; GENE	We have investigated the mechanism whereby tumor cells become resistant to the antiproliferative effects of transforming growth factor (TGF)-beta, while maintaining other responses that can lead to increased malignancy and invasiveness. TGF-beta signaling results in nuclear accumulation of active Smad complexes which regulate transcription of target genes. Here we show that in two pancreatic carcinoma cell lines, PT45 and Panc-1, that are resistant to TGF-beta-induced growth arrest, the TGF-beta-Smad signaling pathway is attenuated compared with epithelial cells that are sensitive to the antiproliferative effects of TGF-beta (HaCaT and Colo-357). In PT45 and Panc-1 cells, active Smad complexes remain nuclear for only 1-2 It compared with more than 6 h in HaCaT and Colo-357 cells. The attenuated pathway in PT45 and Panc-1 cells correlates with low levels of TGF-beta type I receptor and results in an altered expression profile of TGF-beta-inducible genes required for cell cycle arrest. Most significantly, expression of the CDK inhibitor, p21(Cip1/WAF1), which is required for TGF-beta-induced growth arrest in these cells, is not maintained. Moreover, we show that artificially attenuating the TGF-beta-Smad signaling pathway in HaCaT cells is sufficient to prevent TGF-beta-induced growth arrest. Our results demonstrate that the duration of TGF-beta-Smad signaling is a critical determinant of the specificity of the TGF-beta response.	Canc Res UK, London Res Inst, Lab Dev Signalling, London WC2A 3PX, England	Cancer Research UK	Hill, CS (corresponding author), Canc Res UK, London Res Inst, Lab Dev Signalling, 44 Lincolns Inn Fields, London WC2A 3PX, England.	caroline.hill@cancer.org.uk	Nicolás, Francisco José/H-9422-2019	Nicolás, Francisco José/0000-0002-3969-1430; Hill, Caroline/0000-0002-8632-0480				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; Faure S, 2000, DEVELOPMENT, V127, P2917; Fink SP, 2001, CANCER RES, V61, P256; Florenes VA, 1996, ONCOGENE, V13, P2447; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Goggins M, 1998, CANCER RES, V58, P5329; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hay ED, 1995, ACTA ANAT, V154, P8; Hill CS, 2001, CURR OPIN GENET DEV, V11, P533, DOI 10.1016/S0959-437X(00)00229-X; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; Hua XX, 2000, J BIOL CHEM, V275, P33205, DOI 10.1074/jbc.C000568200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Iavarone A, 1997, NATURE, V387, P417; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jonson T, 2001, INT J ONCOL, V19, P71; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; LAVARONE A, 1999, MOL CELL BIOL, V19, P916; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu K, 1999, P NATL ACAD SCI USA, V96, P6791, DOI 10.1073/pnas.96.12.6791; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Sirivatanauksorn V, 2001, INT J CANCER, V91, P350, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.3.CO;2-3; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wells RG, 1997, J BIOL CHEM, V272, P11444; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Wong C, 1999, MOL CELL BIOL, V19, P1821	67	114	126	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3698	3711		10.1038/sj.onc.1206420	http://dx.doi.org/10.1038/sj.onc.1206420			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802277				2022-12-17	WOS:000183551000004
J	Macaluso, M; Cinti, C; Russo, G; Russo, A; Giordano, A				Macaluso, M; Cinti, C; Russo, G; Russo, A; Giordano, A			PRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer	ONCOGENE			English	Article						pRb2/p130; chromatin-modifying enzymes; estrogen receptor-alpha; breast carcinoma	HISTONE DEACETYLASE INHIBITION; CHROMATIN-REMODELING COMPLEXES; CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; REPRESSES TRANSCRIPTION; GENE-EXPRESSION; DNA METHYLATION; METHYLTRANSFERASE; RECRUITMENT; ACETYLATION	The estrogen receptor-alpha (ER) plays a crucial role in normal breast development and is also linked to development and progression of mammary carcinoma. The transcriptional repression of ER-alpha gene in breast cancer is an area of active investigation with potential clinical significance. However, the molecular mechanisms that regulate the ER-alpha gene expression are not fully understood. Here we show a new molecular mechanism of ER-alpha gene inactivation mediated by pRb2/p130 in ER-negative breast cancer cells. We investigated in vivo occupancy of ER-alpha promoter by pRb2/p130-E2F4/5-HDAC1-SUV39 H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 complexes, and provided a link between pRb2/p130 and chromatin-modifying enzymes in the regulation of ER-alpha transcription in a physiological setting. These findings suggest that pRb2/p130-multimolecular complexes can be key elements in the regulation of ER-alpha gene expression and may be viewed as promising targets for the development of novel therapeutic strategies in the treatment of breast cancer, especially for those tumors that are ER negative.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Palermo, Dept Oncol, Sect Mol Oncol, Reg Reference Ctr Biomol Characterizat Neoplasms, Palermo, Italy; CNR, ITOI, Inst Normal & Pathol Cytomorphol, I-40126 Bologna, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Palermo; Consiglio Nazionale delle Ricerche (CNR); University of Siena	Macaluso, M (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cinti, Caterina/0000-0001-8049-0369				Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Davis T, 2000, CLIN CANCER RES, V6, P4334; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Hortobagyi GN, 1998, NEW ENGL J MED, V339, P974, DOI 10.1056/NEJM199810013391407; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Keller C, 2002, J BIOL CHEM, V277, P31430, DOI 10.1074/jbc.M202165200; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lapidus RG, 1998, CANCER RES, V58, P2515; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Parl F.F., 2000, ESTROGENS ESTROGEN R; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Stiegler P, 1998, CANCER RES, V58, P5049; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WEIGEL RJ, 1993, CANCER RES, V53, P3472; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890	34	114	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3511	3517		10.1038/sj.onc.1206578	http://dx.doi.org/10.1038/sj.onc.1206578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789259				2022-12-17	WOS:000183399200001
J	Tyagi, A; Agarwal, R; Agarwal, C				Tyagi, A; Agarwal, R; Agarwal, C			Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis	ONCOGENE			English	Article						prostate cancer; MAPK; AP1; apoptosis; grape seed extract	EPIDERMAL GROWTH-FACTOR; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; CANCER CELLS; C-JUN; MAP KINASES; STRESS; TRANSDUCTION; RECEPTORS; DEATH	A loss of functional androgen receptor and an enhanced expression of growth factor receptors and associated ligands are causal genetic events in prostate cancer (PCA) progression. These genetic alterations lead to an epigenetic mechanism where a feedback autocrine loop between membrane receptor and ligand (e.g. EGFR-TGFalpha) results in a constitutive activation of MAPK-Elk1-AP1-mediated mitogenic signaling in human PCA at an advanced and androgen-independent stage. We rationalized that inhibiting these epigenetic events could be useful in controlling advanced PCA growth. Recently, we found that grape seed extract (GSE), a dietary supplement rich in flavonoid procyanidins, inhibits advanced and androgen-independent human PCA DU145 cell growth in culture and nude mice. Here, we performed detailed mechanistic studies to define the effect of GSE on EGFR-Shc-MAPK-Elk1-AP1-mediated mitogenic signaling in DU145 cells. Pretreatment of serum-starved cells with GSE resulted in 70% to almost complete inhibition of EGF-induced EGFR activation and 50% to complete inhibition of She activation, which corroborated with a comparable decrease in EGF-induced Shc binding to EGFR. Conversely, EGF-induced ERK1/2 phosphorylation was inhibited only by lower doses of GSE; in fact, higher doses showed an increase. Additional studies showed that GSE alone causes a dose- and time-dependent increase in ERK1/2 phosphorylation in starved DU145 cells that is inhibited by an MEK1 inhibitor PD98059. Independent of this increase in ERK1/2 phosphorylation, GSE showed a strong inhibition of ERK1/2 kinase activity to Elk1 in both cellular and cell-free systems. GSE treatment of cells also inhibited both EGF-induced and constitutively active Elk1 phosphorylation and AP1 activation. GSE treatment also showed DNA synthesis inhibition in starved and EGF-stimulated cells as well as loss of cell viability and apoptotic death that was further increased by adding MEK1 inhibitor. Since GSE strongly induced apoptosis independent of its affect on an increase in phospho-ERK1/2, we hypothesized that apoptotic effect of GSE could be by other mechanism(s) including its effect on stress-associated MAPK, the JNK. Indeed, GSE-treated cells showed a strong and sustained increase in phospho-JNK1/JNK2 levels, JNK activity and phospho-cJun levels. An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response. Together, these results suggest that anticancer effects of GSE in PCA be mediated via impairment of EGFR-ERK1/2-Elk1-AP1-mediated mitogenic signaling and activation of JNK causing growth inhibition and apoptosis, respectively.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, C (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Chapia.Agarwal@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA083741, R29CA064514, R01CA064514] Funding Source: NIH RePORTER; NCI NIH HHS [CA83741, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2000, MOL CARCINOGEN, V28, P129, DOI 10.1002/1098-2744(200007)28:3&lt;129::AID-MC1&gt;3.0.CO;2-0; Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Bartolome B, 1996, J CHROMATOGR A, V723, P19, DOI 10.1016/0021-9673(95)00839-X; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bhatia N, 2001, PROSTATE, V46, P98; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CONNOLLY JM, 1989, PROSTATE, V15, P177, DOI 10.1002/pros.2990150211; DAI TN, 1995, ONCOGENE, V10, P849; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dragsted L O, 1998, Arch Toxicol Suppl, V20, P209; ESCRIBANOBAILON T, 1992, J AGR FOOD CHEM, V40, P1794, DOI 10.1021/jf00022a013; Gioeli D, 1999, CANCER RES, V59, P279; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Harris KA, 2001, DRUGS, V61, P2177, DOI 10.2165/00003495-200161150-00003; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin JQ, 1999, CANCER RES, V59, P2891; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Putz T, 1999, CANCER RES, V59, P227; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sato M, 2001, FREE RADICAL BIO MED, V31, P729, DOI 10.1016/S0891-5849(01)00626-8; Segawa N, 2001, CANCER RES, V61, P6060; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; TILLOTSON JK, 1991, CANCER LETT, V60, P109, DOI 10.1016/0304-3835(91)90216-5; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wattenberg LW, 1997, P SOC EXP BIOL MED, V216, P133; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu R, 2000, CANCER RES, V60, P2384; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhao J, 1999, CARCINOGENESIS, V20, P1737, DOI 10.1093/carcin/20.9.1737; Zi XL, 2000, CANCER RES, V60, P5617; Zi XL, 1998, CANCER RES, V58, P1920; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	58	114	120	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2003	22	9					1302	1316		10.1038/sj.onc.1206265	http://dx.doi.org/10.1038/sj.onc.1206265			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618755				2022-12-17	WOS:000181360900004
J	Masuda, A; Takahashi, T				Masuda, A; Takahashi, T			Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis	ONCOGENE			English	Review						chromosome instability; cell cycle checkpoint; DNA double-strand break; telomere; lung cancer	STRAND BREAK REPAIR; COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN-PAPILLOMAVIRUS TYPE-16; MOLECULAR CYTOGENETIC ANALYSIS; SPINDLE ASSEMBLY CHECKPOINT; FLOW CYTOMETRIC ANALYSIS; CYCLIN-E OVEREXPRESSION; SMALL-CELL-CARCINOMA; END-JOINING PATHWAY; DNA-LIGASE-IV	Chromosomal abnormality is one of the hallmarks of neoplastic cells, and the persistent presence of chromosome instability (CIN) has been demonstrated in human cancers, including lung cancer. Recent progress in molecular and cellular biology as well as cytogenetics has shed light on the underlying mechanisms and the biological and clinical significance of chromosome abnormalities and the CIN phenotype. Chromosome abnormalities can be classified broadly into numerical (i.e., aneuploidy) and structural alterations (e.g., deletion, translocation, homogenously staining region (HSR), double minutes (DMs)). However, both alterations usually occur in the same cells, suggesting some overlap in their underlying mechanisms. Missegregation of chromosomes may result from various causes, including defects of mitotic spindle checkpoint, abnormal centrosome formation and failure of cytokinesis, while structural alterations of chromosomes may be caused especially by failure in the repair of DNA double-strand breaks (DSBs) due to the impairment of DNA damage checkpoints and/or DSB repair systems. Recent studies also suggest that telomere erosion may be involved. The consequential acquisition of the CIN phenotype would give lung cancer cells an excellent opportunity to efficiently alter their characteristics so as to be more malignant and suitable to their microenvironment, thereby gaining a selective growth advantage.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bieche I, 2000, CLIN CANCER RES, V6, P452; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Boveri T, 1914, FRAGE ENTSTEHUNG MAL; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Brown R, 1999, FRACTALS, V7, P277, DOI 10.1142/S0218348X99000281; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney JP, 1999, CURR OPIN IMMUNOL, V11, P443, DOI 10.1016/S0952-7915(99)80074-0; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Choma D, 2001, BRIT J CANCER, V85, P14, DOI 10.1054/bjoc.2001.1892; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Dennis TR, 1999, CANCER GENET CYTOGEN, V113, P134, DOI 10.1016/S0165-4608(99)00023-0; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dobashi Y, 1998, AM J PATHOL, V153, P963, DOI 10.1016/S0002-9440(10)65638-6; DOHNER H, 1992, GENE CHROMOSOME CANC, V5, P392, DOI 10.1002/gcc.2870050415; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; FAN SJ, 1995, CANCER RES, V55, P1649; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukuda T, 2001, CANCER RES, V61, P23; Fukuse T, 2000, CANCER RES, V60, P242; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gemma A, 2000, GENE CHROMOSOME CANC, V29, P213, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1027>3.0.CO;2-G; Girard L, 2000, CANCER RES, V60, P4894; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HAGAG N, 1990, ONCOGENE, V5, P1481; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Harley CB, 1997, CANCER SURV, V29, P263; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haruki N, 2000, CANCER RES, V60, P4689; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; HEIM S, 1989, ADV CANCER RES, V52, P1; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Higashiyama M, 1997, BRIT J CANCER, V75, P1302, DOI 10.1038/bjc.1997.221; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; HIRANO T, 1994, AM J PATHOL, V144, P296; HIYAMA K, 1995, ONCOGENE, V10, P937; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; JACKSONYORK GL, 1991, CANCER, V68, P374, DOI 10.1002/1097-0142(19910715)68:2<374::AID-CNCR2820680227>3.0.CO;2-2; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Katayama H, 1999, J NATL CANCER I, V91, P1160, DOI 10.1093/jnci/91.13.1160; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; Khan SH, 1998, CANCER RES, V58, P396; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2000, JNCI-J NATL CANCER I, V92, P795, DOI 10.1093/jnci/92.10.795; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Konishi H, 2002, CANCER RES, V62, P271; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Latil A, 2000, INT J CANCER, V89, P172; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; LEVIN NA, 1994, CANCER RES, V54, P5086; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsuoka S, 2001, CANCER RES, V61, P5362; Matzke MA, 1999, BIOESSAYS, V21, P761, DOI 10.1002/(SICI)1521-1878(199909)21:9&lt;761::AID-BIES7&gt;3.0.CO;2-C; McClintock B, 1938, GENETICS, V23, P315; McClintock B, 1941, GENETICS, V26, P234; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Michelland S, 1999, CANCER GENET CYTOGEN, V114, P22, DOI 10.1016/S0165-4608(99)00035-7; Mishina T, 2000, CLIN CANCER RES, V6, P11; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigro S, 1996, INT J CANCER, V67, P871; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; NUORVA K, 1993, AM J PATHOL, V142, P725; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh ST, 2001, J VIROL, V75, P5559, DOI 10.1128/JVI.75.12.5559-5566.2001; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; OUD PS, 1989, CANCER, V64, P1304, DOI 10.1002/1097-0142(19890915)64:6<1304::AID-CNCR2820640623>3.0.CO;2-K; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Petersen I, 1997, CANCER RES, V57, P2331; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 1998, CANCER RES, V58, P3974; POWELL SN, 1995, CANCER RES, V55, P1643; Rashid A, 1999, BRIT J CANCER, V80, P59, DOI 10.1038/sj.bjc.6690321; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Sagawa Y, 2001, CANCER LETT, V168, P45, DOI 10.1016/S0304-3835(01)00501-8; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shivapurkar N, 1999, CANCER RES, V59, P3576; SHU HB, 1995, J CELL BIOL, V130, P1137, DOI 10.1083/jcb.130.5.1137; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; Suzuki H, 2000, CANCER RES, V60, P4353; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TESTA JR, 1992, CANCER RES, V52, pS2702; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; Ullmann R, 2001, HUM PATHOL, V32, P1059, DOI 10.1053/hupa.2001.28248; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Veldman T, 1997, NAT GENET, V15, P406, DOI 10.1038/ng0497-406; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Viren MMT, 1997, MED ONCOL, V14, P35, DOI 10.1007/BF02990943; Volm M, 1997, BRIT J CANCER, V75, P1774, DOI 10.1038/bjc.1997.302; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu WG, 1998, CANCER RES, V58, P4082; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yamaguchi T, 2001, CANCER RES, V61, P8256; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	192	114	122	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6884	6897		10.1038/sj.onc.1205566	http://dx.doi.org/10.1038/sj.onc.1205566			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362271				2022-12-17	WOS:000178640200004
J	Johnsen, SA; Subramaniam, M; Janknecht, R; Spelsberg, TC				Johnsen, SA; Subramaniam, M; Janknecht, R; Spelsberg, TC			TGF beta inducible early gene enhances TGF beta/Smad-dependent transcriptional responses	ONCOGENE			English	Article						Smad; TGF beta; TIEG; transcription; zinc-finger	GROWTH-FACTOR-BETA; N-TERMINAL KINASE; TUMOR-SUPPRESSOR GENE; PANCREATIC-CANCER; EPITHELIAL-CELLS; FAMILY MEMBERS; DPC4 GENE; SMAD7; PROTEIN; TIEG	TGFbeta inducible early gene (TIEG) encodes a three zinc-finger Kruppel-like transcription factor whose overexpression has been shown to mimic the effects of TGFbeta in human osteosarcoma and pancreatic carcinoma cells. In order to investigate a potential role of TIEG in the TGFbeta signal transduction pathway, we studied its impact on a Smad binding element (SBE) reporter which is known to be regulated by TGFbeta through the R-Smad proteins. We demonstrate that TIEG overexpression enhances TGFbeta induction of SBE reporter activity. TIEG overexpression also enhances induction of the endogenous TGFbeta regulated genes p21 and PAI-1. The ability of TIEG to enhance TGFbeta actions is Smad dependent since TIEG has no effect on SBE transcription in the absence of Smad4 expression or when an inhibitory Smad protein, Smad7, is overexpressed. Furthermore, TIEG overexpression enhances TGFbeta induced Smad2 phosphorylation. Lastly, TIEG appears to function by binding to and thereby repressing a specific element in the proximal promoter of the inhibitory Smad7 gene. In conclusion, these results describe a novel mechanism for the potentiation of TGFbeta/Smad signaling via repression of the inhibitory Smad7 gene by TIEG.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Spelsberg, TC (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Johnsen, Steven/AAX-2322-2020	Johnsen, Steven/0000-0003-1198-5805; Janknecht, Ralf/0000-0003-1741-1562	NIDCR NIH HHS [1R01 DE14036-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014036] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BLOK LJ, 1995, MOL ENDOCRINOL, V9, P1610, DOI 10.1210/me.9.11.1610; BOYER PL, 1993, ONCOGENE, V8, P457; Chalaux E, 1999, FEBS LETT, V457, P478, DOI 10.1016/S0014-5793(99)01051-0; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fautsch MP, 1998, GENOMICS, V51, P408, DOI 10.1006/geno.1998.5388; Fautsch MP, 1998, MAMM GENOME, V9, P838, DOI 10.1007/s003359900878; Frey RS, 1997, CANCER RES, V57, P628; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hefferan TE, 2000, J BIOL CHEM, V275, P20255, DOI 10.1074/jbc.C000135200; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Imai K, 1999, FEBS LETT, V456, P375, DOI 10.1016/S0014-5793(99)00988-6; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim SK, 1996, CANCER RES, V56, P2519; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schutte M, 1996, CANCER RES, V56, P2527; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Subramaniam M, 1998, J CELL BIOCHEM, V68, P226, DOI 10.1002/(SICI)1097-4644(19980201)68:2<226::AID-JCB9>3.0.CO;2-X; Subramaniam M, 1995, NUCLEIC ACIDS RES, V23, P4907, DOI 10.1093/nar/23.23.4907; Tachibana I, 1997, J CLIN INVEST, V99, P2365, DOI 10.1172/JCI119418; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yajima S, 1997, J NEUROSCI, V17, P8657; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	46	114	125	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 22	2002	21	37					5783	5790		10.1038/sj.onc.1205681	http://dx.doi.org/10.1038/sj.onc.1205681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173049				2022-12-17	WOS:000177463400014
J	Hoo, LS; Zhang, JYY; Chan, EKL				Hoo, LS; Zhang, JYY; Chan, EKL			Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer	ONCOGENE			English	Article						auto-antigen; auto-antibody; tumor associated antigen; tumor auto-immunity	RNA-BINDING-PROTEINS; CHRONIC LIVER-DISEASE; HEPATITIS-C VIRUS; HEPATOCELLULAR-CARCINOMA; ANTINUCLEAR ANTIBODIES; RISK-FACTORS; SS-A/RO; KH-DOMAIN; AUTOANTIBODIES; AUTOANTIGEN	Recently our laboratory identified a cytoplasmic RNA-binding protein p62 which binds to and regulates the expression of IGF II mRNA. p62 was initially shown to be recognized by auto-antibodies in hepatocellular carcinoma (HCC) but now anti-p62 has been described in diverse malignancies. p62 is uniformly expressed in fetal liver and prominently in 33% of HCC nodules, but not detectable in adult liver or normal tissue adjacent to HCC nodules. In this study, a 90 kDa protein (p90), auto-antibodies to which were found associated with anti-p62 responses in the same HCC patient group, was identified by cDNA expression cloning. Indirect immunofluorescence showed that, like p62, p90 localized to the cytoplasm in cultured cells and mouse fetal, but not adult liver. Among 11 human gastric cancer tissues examined, p90 was overexpressed in six (55%). Together with other cancer associated auto-antibodies such as anti-p53, anti-p62, anti-Koc, and anti-CENP-F, auto-antibodies to p90 represent a new marker for tumors such as HCC and gastric cancer. Our data support the working hypothesis that auto-antibody production in cancer may be directly linked to aberrant auto-antigen expression.	Scripps Res Inst, Dept Mol & Expt Med, WM Keck Autoimmune Dis Ctr, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, DNA Core Lab Struct Anal, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Chan, EKL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, WM Keck Autoimmune Dis Ctr, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	echan@scripps.edu	Chan, Edward K. L./B-5671-2009; Zhang, Jianying/F-3798-2010	Chan, Edward K. L./0000-0003-3938-9503; 	NATIONAL CANCER INSTITUTE [R01CA056956] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039645] Funding Source: NIH RePORTER; NCI NIH HHS [CA56956] Funding Source: Medline; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI39645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; Chan EKL, 1994, MANUAL BIOL MARKERS, P1; CHANDLER N, 1998, P 19 ANN C CAN NUCL, V1, P1; Covini G, 1997, J HEPATOL, V26, P1255, DOI 10.1016/S0168-8278(97)80460-6; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; Doyle GAR, 1998, NUCLEIC ACIDS RES, V26, P5036, DOI 10.1093/nar/26.22.5036; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fritzler MJ, 2000, J INVEST MED, V48, P28; HARDIN JA, 1986, ARTHRITIS RHEUM, V29, P457, DOI 10.1002/art.1780290401; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; IMAI H, 1993, CANCER-AM CANCER SOC, V71, P26, DOI 10.1002/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N; Kikuno R, 2000, NUCLEIC ACIDS RES, V28, P331, DOI 10.1093/nar/28.1.331; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lu ML, 2001, AM J PATHOL, V159, P945, DOI 10.1016/S0002-9440(10)61770-1; Lupas A, 1997, CURR OPIN STRUC BIOL, V7, P388, DOI 10.1016/S0959-440X(97)80056-5; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nagase T, 2000, DNA RES, V7, P143, DOI 10.1093/dnares/7.2.143; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Ochs RL, 1996, MOL BIOL CELL, V7, P1015, DOI 10.1091/mbc.7.7.1015; Rattner JB, 1997, CLIN INVEST MED, V20, P308; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Selak S, 1999, J INVEST MED, V47, P311; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMONETTI RG, 1991, DIGEST DIS SCI, V36, P962, DOI 10.1007/BF01297149; Soussi T, 2000, CANCER RES, V60, P1777; Tan E.M., 1989, ADV IMMUNOL, V44, P151, DOI [10.1016/S0065-2776(08)60641-0, DOI 10.1016/S0065-2776(08)60641-0]; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; Tan EM, 2001, J CLIN INVEST, V108, P1411, DOI 10.1172/JCI200114451; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Wang DR, 1996, J INVEST DERMATOL, V107, P610, DOI 10.1111/1523-1747.ep12584194; Zhang JY, 1998, AM J TROP MED HYG, V59, P947, DOI 10.4269/ajtmh.1998.59.947; Zhang JY, 1998, INT J EPIDEMIOL, V27, P574, DOI 10.1093/ije/27.4.574; Zhang JY, 1999, J EXP MED, V189, P1101, DOI 10.1084/jem.189.7.1101; Zhang JY, 2001, CLIN IMMUNOL, V100, P149, DOI 10.1006/clim.2001.5048; Zhang JY, 2001, CLIN EXP IMMUNOL, V125, P3, DOI 10.1046/j.1365-2249.2001.01585.x	39	114	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					5006	5015		10.1038/sj.onc.1205625	http://dx.doi.org/10.1038/sj.onc.1205625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118381				2022-12-17	WOS:000176874800017
J	Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Ellis, E; Fisher, PB; Dent, P				Park, JS; Qiao, L; Su, ZZ; Hinman, D; Willoughby, K; McKinstry, R; Yacoub, A; Duigou, GJ; Young, CSH; Grant, S; Hagan, MP; Ellis, E; Fisher, PB; Dent, P			Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways	ONCOGENE			English	Article						ionizing radiation; MAPK; JNK; AP-1; VEGF; PEG-3; apoptosis	SQUAMOUS CARCINOMA-CELLS; BREAST-CANCER CELLS; FACTOR-ALPHA; GLIOBLASTOMA-MULTIFORME; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; GENE-EXPRESSION; A431 CELLS; FACTOR-I; INHIBITION	We investigated the role of radiation-induced mitogen activated protein kinase (MAPK) pathway activity in the regulation of proliferation, cell survival and vascular endothelial growth factor (VEGF) production in primary astrocytes and in To and RT2 glioblastoma cells derived from Fisher 344 rats, In these cells, ionizing radiation (2 Gy) caused activation of the MAPK pathway which was blocked by specific inhibitor drugs, Blunting of radiation-induced MAPK activity weakly enhanced radiation-induced apoptosis 24 h after exposure in RT2 cells, Furthermore, blunting of MAPK activation weakly enhanced the ability of radiation to reduce RT2 cell growth in clonogenic growth assays, These findings argue that inhibition of MAPK signaling reduces proliferation and enhances cell killing by ionizing radiation in transformed astrocytes, Proliferation and survival of cancer cells has been linked in vivo to enhanced expression of angiogenic growth factors, Recently we demonstrated that the gene product of a novel rodent radiation-responsive gene, progression elevated gene 3 (PEG-3), could enhance vascular endothelial growth factor (VEGF) promoter activity in rodent fibroblasts, leading to increased VEGF protein levels and tumorigenic behavior in vivo. Thus PEG-3 and VEGF expression could be expected to directly correlate with the oncogenic potential of transformed cells, RT2 cells expressed more PEG-3 and VEGF protein than To cells, and were more tumorigenic in vivo than To cells, Radiation activated the PEG-3 promoter via MAPK signaling and ectopic over-expression of PEG-3 enhanced both basal MARK activity and basal VEGF promoter activity, Basal MAPK activity partially correlated with basal VEGF promoter activity and VEGF protein levels in primary astrocytes, T9 and RT2 cells, Radiation increased the activity of the VEGF promoter and VEGF protein levels in primary astrocytes, T9 and RT2 cells which were dependent upon MAPK function, Furthermore, inhibition of AP-1 transcription factor signaling by dominant negative c-Jun (TAM67) also significantly reduced basal, and to a lesser extent radiation-induced, VEGF promoter function in RT2 cells, Collectively, our data demonstrate that radiation-induced MAPK signaling can both protect cells: from radiation-induced cell death as well as enhance protein levels of pro-angiogenic factors such as VEGF, Enhanced VEGF expression in RT2 cells may be mediated via MAPK and JNK pathway signaling which converges upon the AP-1 transcription factor complex.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Dept Urol & Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Columbia University; Columbia University	Dent, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, 401 Coll St, Richmond, VA 23298 USA.				NCI NIH HHS [CA35675] Funding Source: Medline; NIDDK NIH HHS [DK52875] Funding Source: Medline; NIGMS NIH HHS [GM31452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031452] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Barth RF, 1998, J NEURO-ONCOL, V36, P91, DOI 10.1023/A:1005805203044; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Cartee L, 2000, INT J ONCOL, V16, P413; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chmura SJ, 1997, CANCER RES, V57, P4340; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hossain MA, 2000, J BIOL CHEM, V275, P27874; Huhn SL, 1999, CLIN CANCER RES, V5, P1435; Kang DC, 1998, P NATL ACAD SCI USA, V95, P13788, DOI 10.1073/pnas.95.23.13788; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kraus JA, 2000, J NEUROL, V247, P455, DOI 10.1007/s004150070175; Levenson AS, 1998, BRIT J CANCER, V77, P1812, DOI 10.1038/bjc.1998.301; Li ZG, 2000, INT J ONCOL, V17, P453; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 1999, BIOCHEM BIOPH RES CO, V261, P534, DOI 10.1006/bbrc.1999.0995; Pages G, 2000, ANN NY ACAD SCI, V902, P187; Park JS, 1999, MOL BIOL CELL, V10, P4231, DOI 10.1091/mbc.10.12.4231; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Putz T, 1999, CANCER RES, V59, P227; Rak J, 2000, CANCER RES, V60, P490; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHMIDTULLRICH RK, 1992, INT J RADIAT BIOL, V61, P405, DOI 10.1080/09553009214551101; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Slevin M, 2000, NEUROREPORT, V11, P2759, DOI 10.1097/00001756-200008210-00030; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2000, ONCOGENE, V19, P3411, DOI 10.1038/sj.onc.1203666; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zundel W, 2000, GENE DEV, V14, P391	46	114	122	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2001	20	25					3266	3280		10.1038/sj.onc.1204258	http://dx.doi.org/10.1038/sj.onc.1204258			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423976				2022-12-17	WOS:000169163500010
J	Ren, FG; Zhang, SB; Mitchell, SH; Butler, R; Young, CYF				Ren, FG; Zhang, SB; Mitchell, SH; Butler, R; Young, CYF			Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells	ONCOGENE			English	Article						tea polyphenols; androgen receptor; theaflavins; prostate specific antigen; human glandular kallikrein; Sp1	THERAPY FAILURE; MESSENGER-RNA; ANTIGEN GENE; CARCINOMA; INDUCTION; PROTEIN; PHOSPHORYLATION; ADENOCARCINOMA; PROMOTER; LINE	Androgens via their cognate receptor may be involved in the development and progression of prostate cancer. The aim of this study was to determine whether tea polyphenols have inhibitory effects on androgen action in an androgen-responsive, prostate cancer cell line, LNCaP, The tea polyphenol, EGCG, inhibited LNCaP cell growth and the expression of androgen regulated PSA and hK2 genes. Moreover, EGCG had a significant inhibitory effect on the androgenic inducibility of the PSA promoter. Immunoblotting detected a decrease in androgen receptor protein with treatments of the tea polyphenols EGCG, GCG and theaflavins, Northern blot analysis showed decreased levels of androgen receptor mRNA by EGCG, Transient transfections demonstrated that EGCG and theaflavins could repress the transcriptional activities of the androgen receptor promoter region. An Spl binding site in the androgen receptor gene promoter is an important regulatory component for its expression. This study suggests Spl is the target for the tea polyphenols because treatments of EGCG decreased the expression, DNA binding activity and transactivation activity of Spl protein. In conclusion, we have described a new property of tea polyphenols that inhibits androgen action by repressing the transcription of the androgen receptor gene.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Young, CYF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.				NCI NIH HHS [CA 70982] Funding Source: Medline; NIDDK NIH HHS [DK 41995] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Alroy I, 1999, MOL CELL BIOL, V19, P1961; ANDREWS PE, 1992, CANCER RES, V52, P1525; Blok LJ, 1998, BIOCHEMISTRY-US, V37, P3850, DOI 10.1021/bi9724422; Blok LJ, 1996, ENDOCR RES, V22, P197, DOI 10.3109/07435809609030508; Blot WJ, 1996, EUR J CANCER PREV, V5, P425; BRAWER MK, 1995, CANCER-AM CANCER SOC, V75, P1783, DOI 10.1002/1097-0142(19950401)75:7+<1783::AID-CNCR2820751606>3.0.CO;2-U; Charlesworth MC, 1997, UROLOGY, V49, P487; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; Darson MF, 1997, UROLOGY, V49, P857, DOI 10.1016/S0090-4295(97)00108-8; Dorgan JF, 1996, AM J CLIN NUTR, V64, P850, DOI 10.1093/ajcn/64.6.850; FEIGL P, 1995, CONTROL CLIN TRIALS, V16, P150, DOI 10.1016/0197-2456(94)00XXX-M; FLESHNER NE, 1995, J UROLOGY, V154, P1646; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gregory CW, 1998, CANCER RES, V58, P5718; Gupta S, 1999, CANCER RES, V59, P2115; HAMALAINEN E, 1984, J STEROID BIOCHEM, V20, P459, DOI 10.1016/0022-4731(84)90254-1; Hsieh ML, 1997, CANCER RES, V57, P2651; Huggins C, 1941, CANCER RES, V1, P293; KAISARY AV, 1995, EUR UROL, V28, P215; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1996, UROLOGY, V48, P157, DOI 10.1016/S0090-4295(96)00117-3; Koivisto P, 1997, CANCER RES, V57, P314; Koivisto P, 1998, AM J PATHOL, V152, P1; KRONGRAD A, 1991, MOL CELL ENDOCRINOL, V76, P79, DOI 10.1016/0303-7207(91)90262-Q; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LIAO SS, 1995, BIOCHEM BIOPH RES CO, V214, P833, DOI 10.1006/bbrc.1995.2362; LIAO SS, 1995, CANCER LETT, V96, P239, DOI 10.1016/0304-3835(95)03948-V; LINDZEY J, 1994, VITAM HORM, V49, P383; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; Paschka AG, 1998, CANCER LETT, V130, P1, DOI 10.1016/S0304-3835(98)00084-6; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SOLOWAY MS, 1993, CANCER, V71, P1083, DOI 10.1002/1097-0142(19930201)71:3+<1083::AID-CNCR2820711430>3.0.CO;2-1; Spitzweg C, 1999, CANCER RES, V59, P2136; STONER GD, 1995, J CELL BIOCHEM, P169; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THOMPSON L, 1995, IMPORTAN ADV ONCOLOG, P57; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Zhang JY, 1997, NUCLEIC ACIDS RES, V25, P3143, DOI 10.1093/nar/25.15.3143; Zhang SB, 1997, BIOCHEM BIOPH RES CO, V231, P784, DOI 10.1006/bbrc.1997.6197; Zhang SB, 1999, ENDOCRINOLOGY, V140, P1665, DOI 10.1210/en.140.4.1665; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	50	114	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1924	1932		10.1038/sj.onc.1203511	http://dx.doi.org/10.1038/sj.onc.1203511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773882				2022-12-17	WOS:000086424300008
J	de Rozieres, S; Maya, R; Oren, M; Lozano, G				de Rozieres, S; Maya, R; Oren, M; Lozano, G			The loss of mdm2 induces p53 mediated apoptosis	ONCOGENE			English	Article						apoptosis; temperature sensitive p53; mdm2; mouse embryo fibroblasts	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; TUMOR-SUPPRESSOR P53; CELL-CYCLE CONTROL; GROWTH ARREST; DNA-DAMAGE; HEMATOPOIETIC-CELLS; MICE DEFICIENT; BAX GENE; IN-VIVO	The p53 tumor suppressor gene product is negatively regulated by the product of its downstream target, mdm2. The deletion of mdm2 in the mouse results in embryonic lethality at 5.5 days post coitum (d.p.c.) which can be overcome by simultaneous loss of the p53 tumor suppressor, substantiating the importance of the negative regulatory function of MDM2 on p53 function ill rho. Hence, the loss of MDM2 allowed the unregulated p53 protein to continuously exert its growth-suppressing activity, which either led to a complete G1 arrest or induced the p53-dependent apoptotic pathway, resulting in the death of the mdm2-/- embryos. To determine which of these possibilities is occurring, mouse embryo fibroblasts (MEFs) from p53 null and p53/mdm2 double null embryos were transfected with a retroviral vector carrying a temperature-sensitive p53 (tsp53) cDNA. Shifting of single-cell clonal populations to the permissive temperature caused the p53-/-mdr2-/- fibroblasts expressing tsp53 to undergo apoptosis in a dose-dependent manner. This phenotype was not observed in the tsp53 expressing p53-/- clones nor the parental cell lines. Thus, our data indicate that the simple loss of mdm2 can induce the p53-dependent apoptotic pathway in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	University of Texas System; UTMD Anderson Cancer Center; Weizmann Institute of Science	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Oren, Moshe/0000-0003-4311-7172	NCI NIH HHS [CA40099, CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047296, R37CA040099, R01CA047296, R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Caron De Fromentel Claude, 1992, Genes Chromosomes and Cancer, V4, P1; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1994, CANCER RES, V54, P794; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; DEOCALUNA R, 1995, NATURE, V0378; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Mayo LD, 1997, CANCER RES, V57, P5013; McMasters KM, 1996, ONCOGENE, V13, P1731; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHEIKH MS, 1993, CANCER RES, V53, P3226; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TAMURA T, 1995, ONCOGENE, V11, P1939; TISHLER RB, 1993, CANCER RES, V53, P2212; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	71	114	116	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1691	1697		10.1038/sj.onc.1203468	http://dx.doi.org/10.1038/sj.onc.1203468			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763826				2022-12-17	WOS:000086083800009
J	Ducray, C; Pommier, JP; Martins, L; Boussin, FD; Sabatier, L				Ducray, C; Pommier, JP; Martins, L; Boussin, FD; Sabatier, L			Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process	ONCOGENE			English	Article						telomere; chromosomal instability; telamerase	CELLULAR SENESCENCE; TERMINAL TRANSFERASE; LIFE-SPAN; CELLS; LENGTH; TRF2; INSTABILITY; TETRAHYMENA; PROTEINS; CANCER	Loss of telomeric repeats during cell proliferation could play a role in senescence, It has been generally assumed that activation of telomerase prevents further telomere shortening and is essential for cell immortalization, In this study, we performed a detailed cytogenetic and molecular characterization of four SV40 transformed human fibroblastic cell lines by regularly monitoring the size distribution of terminal restriction fragments, telomerase activity and the associated chromosomal instability throughout immortalization, The mean TRF lengths progressively decreased in pre-crisis cells during the lifespan of the cultures, At crisis, telomeres reached a critical size, different among the cell lines, contributing to the peak of dicentric chromosomes, which resulted mostly from telomeric associations. We observed a direct correlation between short telomere length at crisis and chromosomal instability. In two immortal cell lines, although telomerase was detected, mean telomere length still continued to decrease whereas the number of dicentric chromosomes associated was stabilized. Thus telomerase could protect specifically telomeres which have reached a critical size against end-to-end dicentrics, while long telomeres continue to decrease, although at a slower rate as before crisis. This suggests a balance between elongation by telomerase and telomere shortening, towards a stabilized 'optimal' length.	CEA, DSV, DRR, Lab Radiobiol & Oncol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Sabatier, L (corresponding author), CEA, DSV, DRR, Lab Radiobiol & Oncol, BP6, F-92265 Fontenay Aux Roses, France.			Sabatier, Laure/0000-0003-0552-6549; Boussin, francois/0000-0003-3778-4403				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BENN PA, 1976, AM J HUM GENET, V28, P465; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dutrillaux B, 1981, PRATIQUE ANAL CHROMO; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Filatov L, 1998, ONCOGENE, V16, P1825, DOI 10.1038/sj.onc.1201711; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 1998, EXP CELL RES, V240, P333, DOI 10.1006/excr.1998.3944; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; OERTER KE, 1990, ANAL BIOCHEM, V189, P235, DOI 10.1016/0003-2697(90)90114-O; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; RHYU MS, 1995, J NATL CANCER I, V87, P884, DOI 10.1093/jnci/87.12.884; Rubin H, 1998, NAT BIOTECHNOL, V16, P396, DOI 10.1038/nbt0598-396; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; SPRUNG CN, 1998, IN PRESS EXP CELL RE; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wan TSK, 1999, GENE CHROMOSOME CANC, V24, P83, DOI 10.1002/(SICI)1098-2264(199901)24:1<83::AID-GCC12>3.0.CO;2-C; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	44	114	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4211	4223		10.1038/sj.onc.1202797	http://dx.doi.org/10.1038/sj.onc.1202797			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435634				2022-12-17	WOS:000081542400005
J	Fazili, Z; Sun, WP; Mittelstaedt, S; Cohen, C; Xu, XX				Fazili, Z; Sun, WP; Mittelstaedt, S; Cohen, C; Xu, XX			Disabled-2 inactivation is an early step in ovarian tumorigenicity	ONCOGENE			English	Article						ovarian cancer; breast cancer; Disabled-2 (Dab2); immunohistology; expression	ABL TYROSINE KINASE; DROSOPHILA-ABL; SIGNAL-TRANSDUCTION; HUMAN CANCER; SH3 DOMAIN; BREAST; GENE; PROTEINS; MOUSE; GRB2	Disabled-2 (Dab2) functions in mitogenic signal transduction pathway, and is frequently activated by homozygous gene deletion in tumors, suggesting that Dab2 is a candidate tumor suppressor. Here, we surveyed the expression of Dab2 and report that Dab2 is expressed in a variety of tissues, and the level of expression is particularly high in ovary and breast. Dab2 expression was also detected in immortalized breast and ovarian epithelial cells. However, in more than a dozen established tumor cell lines derived from breast and ovarian epithelial tumors examined by Western blotting, Dab2 expression was undetectable in 90% of these cell lines. Histological staining of human ovarian tissues with specific anti-Dab2 antibodies indicated that Dab2 is highly expressed in the surface epithelial layer, In an immunohistological study of 26 ovarian carcinomas, 22 (85%) of the tumors were found to lose the expression of Dab2 in the tumor cells, which are epithelial origin. Loss of Dab2 expression is not correlated with tumor grade, suggesting that Dab2 is lost in an early stage of tumorigenicity. indeed, loss of Dab2 correlates closely with morphological transformation of the surface epithelial cells. Additionally, loss of Dab2 protein occurs in hyperproliferative, but histological benign ovarian epithelium, suggesting that loss of Dab2 occurs in premalignant lesions. Thus, this study indicates that the loss of Dab2 expression is correlated with tumorigenicity of the cells disregarding the grade of the tumors, and loss of Dab2 expression is an early event in ovarian malignancies.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Xu, XX (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.				NATIONAL CANCER INSTITUTE [R01CA075389, R55CA070783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA75389, R55 CA70783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertsen HM, 1996, GENOMICS, V33, P207, DOI 10.1006/geno.1996.0185; BAST RC, 1993, CANCER, V71, P1597, DOI 10.1002/cncr.2820710426; BELL DA, 1991, HUM PATHOL, V22, P750, DOI 10.1016/0046-8177(91)90205-4; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1995, ONCOGENE, V11, P1327; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DArcangelo G, 1997, J NEUROSCI, V17, P23, DOI 10.1523/JNEUROSCI.17-01-00023.1997; FAZILI Z, 1998, UNPUB DISABLED 2 GEN; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GODWIN AK, 1993, CANCER-AM CANCER SOC, V71, P530; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STENBACK F, 1985, EUR J OBSTET GYN R B, V20, P357, DOI 10.1016/0028-2243(85)90059-0; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; WONG KK, 1993, INT J ONCOL, V3, P13; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; ZHENG J, 1995, J NATL CANCER I, V15, P1146; ZHOU DJ, 1988, CANCER, V62, P1573, DOI 10.1002/1097-0142(19881015)62:8<1573::AID-CNCR2820620819>3.0.CO;2-M	37	114	118	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3104	3113		10.1038/sj.onc.1202649	http://dx.doi.org/10.1038/sj.onc.1202649			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340382				2022-12-17	WOS:000080388000006
J	Fulda, S; Lutz, W; Schwab, M; Debatin, KM				Fulda, S; Lutz, W; Schwab, M; Debatin, KM			MycN sensitizes neuroblastoma cells for drug-induced apoptosis	ONCOGENE			English	Article						MycN; apoptosis; CD95; drugs; neuroblastoma	APO-1/FAS RECEPTOR/LIGAND SYSTEM; CHEMOTHERAPY-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; C-MYC; TRANSGENIC MICE; CELLULAR-SUSCEPTIBILITY; CANCER-THERAPY; LEUKEMIA-CELLS; WILD-TYPE; DEATH	Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN, Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis, Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bar protein expression, while Bcl-2 and Bcl-X-L protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; German Canc Res Ctr, Dept Cytogenet, D-69120 Heidelberg, Germany	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ)	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.		Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BERTHOLD F, 1990, OVERVIEW BIOL NEUROB, P1; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Dong JA, 1997, ONCOGENE, V15, P639, DOI 10.1038/sj.onc.1201237; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Faris M, 1998, J IMMUNOL, V160, P134; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; FULDA S, 1998, IN PRESS CELL DEATH; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; OEHM A, 1992, J BIOL CHEM, V267, P10709; Packham G, 1996, ONCOGENE, V13, P461; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Villunger A, 1997, CANCER RES, V57, P3331; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu K, 1997, CELL GROWTH DIFFER, V8, P731; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORNIG M, 1995, ONCOGENE, V11, P2165; ZORNIG M, 1995, ONCOGENE, V10, P2397	50	114	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1479	1486		10.1038/sj.onc.1202435	http://dx.doi.org/10.1038/sj.onc.1202435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050884				2022-12-17	WOS:000078651600009
J	Gimm, O; Neuberg, DS; Marsh, DJ; Dahia, PLM; Cuong, HV; Raue, F; Hinze, R; Dralle, H; Eng, C				Gimm, O; Neuberg, DS; Marsh, DJ; Dahia, PLM; Cuong, HV; Raue, F; Hinze, R; Dralle, H; Eng, C			Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation	ONCOGENE			English	Article						tyrosine kinase; polymorphism; germline mutation; somatic mutation; medullary thyroid cancer	MULTIPLE-ENDOCRINE-NEOPLASIA; TYROSINE KINASE DOMAIN; POINT MUTATION; MESSENGER-RNA; PROTOONCOGENE; POLYMORPHISM; FMTC; GENE; ACTIVATION; DISEASE	The aetiology of sporadic medullary thyroid carcinoma is unknown, About 50% harbour a somatic mutation at codon 918 of RET (M918T). To investigate whether other RET sequence variants may be associated with or predispose to the development of sporadic medullary thyroid carcinoma, we analysed genomic DNA from the germline and corresponding tumour from 50 patients to identify RET sequence variants. In one patient, tumour DNA showed a novel somatic 12 bp in-frame deletion in exon 15. More interestingly, we found that the rare polymorphism at codon 836 (c.2439C > T; S836S) occurred at a significantly higher frequency than that in control individuals without sporadic medullary thyroid carcinoma (Fisher's exact test, P = 0.03), Further, among the nine evaluable cases with germline c.2439C/T, eight also had the somatic M918T mutation in MTC DNA which was more frequent than in patients with the more common c.2439C/C (89% vs 40%, respectively; Fisher's exact test, P = 0.01), These findings suggest that the rare sequence variant at codon 836 may somehow play a role in the genesis of sporadic medullary thyroid carcinoma.	Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Halle Wittenberg, Klin Allgemeinchirurg, D-06097 Halle, Germany; Endokrinol Gemeinschaftspraxis, D-69120 Heidelberg, Germany; Univ Halle Wittenberg, Inst Pathol, D-06097 Halle, Germany; Univ Cambridge, Canc Res Campaign, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Dana-Farber Cancer Institute; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; CRUK Cambridge Institute; University of Cambridge	Eng, C (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, 420 W 12th Ave,690 MRF, Columbus, OH 43210 USA.		Marsh, Deborah J/I-1491-2014; Raue, Friedhelm/ABD-6150-2021; Dralle, Henning/ABD-4454-2020	Marsh, Deborah J/0000-0001-5899-4931; Raue, Friedhelm/0000-0002-7700-1648; Eng, Charis/0000-0002-3693-5145				BERGHOLM U, 1990, ACTA ONCOL, V29, P9, DOI 10.3109/02841869009089985; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; CARLSON KM, 1994, AM J HUM GENET, V55, P1076; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Ceccherini I, 1997, ONCOGENE, V14, P2609, DOI 10.1038/sj.onc.1201079; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Leviev I, 1997, ARTERIOSCL THROM VAS, V17, P2935, DOI 10.1161/01.ATV.17.11.2935; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIGTENBERG MJL, 1991, NUCLEIC ACIDS RES, V19, P297, DOI 10.1093/nar/19.2.297; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Platten M, 1997, J NEUROPATH EXP NEUR, V56, P806; RAUE F, 1993, CLIN INVESTIGATOR, V71, P7, DOI 10.1007/BF00210956; Rodien P, 1997, HORM RES, V47, P263, DOI 10.1159/000185474; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; StallingsMann ML, 1996, P NATL ACAD SCI USA, V93, P12394, DOI 10.1073/pnas.93.22.12394	31	114	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1369	1373		10.1038/sj.onc.1202418	http://dx.doi.org/10.1038/sj.onc.1202418			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022819				2022-12-17	WOS:000078510900013
J	Pesche, S; Latil, A; Muzeau, F; Cussenot, O; Fournier, G; Longy, M; Eng, C; Lidereau, R				Pesche, S; Latil, A; Muzeau, F; Cussenot, O; Fournier, G; Longy, M; Eng, C; Lidereau, R			PTEN/MMAC1/TEP1 involvement in primary prostate cancers	ONCOGENE			English	Article						prostate cancer; chromosome arm 10q; LOH; PTEN	ALLELIC LOSS; MICROSATELLITE INSTABILITY; DISTINCT REGIONS; CHROMOSOME-10; HETEROZYGOSITY; DELETION; LOCI; GENE; PROGRESSION; ADENOCARCINOMA	The PTEN/MMAC1/TEP1 gene, located at 10q23.3, is a tumor suppressor gene responsible for the familial cancer syndromes Cowden disease and Bannayan-Zonana syndrome, and is commonly somatically mutated in several types of cancers. Mutations of the PTEN gene have been found in prostate cancer cell lines and LOH at 10q22-24 in prostate tumors have also been described with a high frequency. To determine the role of this gene in prostate tumorigenesis, we therefore analysed 22 primary tumors for loss of heterozygosity (LOH) within the 10q22-23 region such that tumors hemizygous at those loci may be examined for somatic PTEN mutations. Losses of heterozygosity of at least one locus was found in 12 (55%) of the 22 tumors DNAs. Among these, six tumors exhibited allele loss in the interval between D10S1765 and D10S541 wherein lies the PTEN gene. We searched the entire coding region of PTEN for somatic mutations in these six tumors. One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in ode tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; CHU St Louis, Dept Urol, F-75010 Paris, France; Hop Cavale Blanche, Dept Urol, F-29609 Brest, France; Ctr Reg Lutte Canc, Inst Bergonie, F-33076 Bordeaux, France; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England	Rene Huguenin Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Brest; Universite de Bretagne Occidentale; UNICANCER; Institut Bergonie; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Cambridge	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, 9 Rue Gaston Latouche, F-92211 St Cloud, France.			Eng, Charis/0000-0002-3693-5145; cussenot, olivier/0000-0002-9912-0533				ALBRECHT S, 1992, CANCER-AM CANCER SOC, V70, P869, DOI 10.1002/1097-0142(19920815)70:4<869::AID-CNCR2820700424>3.0.CO;2-E; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOVA GS, 1993, CANCER RES, V53, P3869; CAIRNS P, 1994, CANCER RES, V54, P1422; Cairns P, 1997, CANCER RES, V57, P4997; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cooney KA, 1996, CANCER RES, V56, P1142; DAHIA PLM, IN PRESS CANC RES; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; GAO X, 1995, CANCER RES, V55, P1002; GRAY IC, 1995, CANCER RES, V55, P4800; Guldberg P, 1997, CANCER RES, V57, P3660; HERBST RA, 1994, CANCER RES, V54, P3111; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; Ittmann M, 1996, CANCER RES, V56, P2143; KARLBOM AE, 1993, HUM GENET, V92, P169; Komiya A, 1996, GENE CHROMOSOME CANC, V17, P245; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Lacombe L, 1996, INT J CANCER, V69, P110, DOI 10.1002/(SICI)1097-0215(19960422)69:2<110::AID-IJC7>3.0.CO;2-3; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; Marsh DJ, 1997, CANCER RES, V57, P500; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; MELLINGER GT, 1967, J UROLOGY, V97, P331, DOI 10.1016/S0022-5347(17)63039-8; MORITA R, 1991, CANCER RES, V51, P5817; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PEIFFER SL, 1995, CANCER RES, V55, P1922; PHILLIPS SMA, 1994, BRIT J UROL, V73, P390, DOI 10.1111/j.1464-410X.1994.tb07602.x; REMPEL SA, 1993, CANCER RES, V53, P2386; Rhei E, 1997, CANCER RES, V57, P3657; SCHRODER FH, 1992, PROSTATE, P129; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki H, 1998, CANCER RES, V58, P204; Tashiro H, 1997, CANCER RES, V57, P3935; Trybus TM, 1996, CANCER RES, V56, P2263; WATANABE M, 1995, BRIT J CANCER, V72, P562, DOI 10.1038/bjc.1995.374; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370	46	114	121	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	1998	16	22					2879	2883		10.1038/sj.onc.1202081	http://dx.doi.org/10.1038/sj.onc.1202081			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZR544	9671408	Bronze			2022-12-17	WOS:000073988200006
J	Vande Pol, SB; Brown, MC; Turner, CE				Vande Pol, SB; Brown, MC; Turner, CE			Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif	ONCOGENE			English	Article						integrin; transformation; cytoskeleton; phosphotyrosine	TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; BINDING PROTEIN; CELLS; IDENTIFICATION; KINASE; EXPRESSION; VINCULIN; SYSTEM; GENE	We have found that the E6 oncoprotein of Bovine Papillomavirus Type 1 (BE6) as well as the E6 protein of the cancer associated HPV-16 (16E6) interact with the focal adhesion protein paxillin. Mutational analysis of paxillin revealed that BE6 binds paxillin through small protein interaction motifs called LD motifs that have been previously identified as important in regulating association of paxillin with vinculin and focal adhesion kinase (FAK), and that BE6 can interact with at least two separate binding sites on paxillin. The LD motifs of paxillin that bind BE6 share homology with the E6 binding site of E6-AP, a ubiquitin ligase that together with 16E6 targets the degradation of the p53 tumor suppressor. Paxillin binding to BE6 excludes simultaneous binding to E6-AP. Mutational analysis of BE6 can distinguish the interaction of BE6 with E6-AP compared to paxillin and revealed that the interaction of BE6 with paxillin may be necessary for the induction of anchorage independent growth of cells by BE6.	Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA; SUNY Syracuse, Dept Anat & Cell Biol, Syracuse, NY USA	Case Western Reserve University; State University of New York (SUNY) System	Vande Pol, SB (corresponding author), Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA.		Pol, Scott Vande/AAO-1068-2020	Pol, Scott Vande/0000-0002-0587-4802	NATIONAL CANCER INSTITUTE [R29CA069292, R01CA069292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047607, R29GM047607] Funding Source: NIH RePORTER; NCI NIH HHS [CA69292, R29 CA069292] Funding Source: Medline; NIGMS NIH HHS [GM47607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HARLOW E, 1990, CIBA F SYMP, V150, P262; HELLERHARRISON RA, 1989, BIOCHEMISTRY-US, V28, P9053, DOI 10.1021/bi00449a014; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Howley P M, 1991, Princess Takamatsu Symp, V22, P239; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MEYERS C, 1992, J VIROL, V66, P1655, DOI 10.1128/JVI.66.3.1655-1664.1992; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Moore DD, 1995, GLOB MOB SURV; Ned R, 1997, J VIROL, V71, P4866, DOI 10.1128/JVI.71.6.4866-4870.1997; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SIKORSKI RS, 1989, GENETICS, V122, P19; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TEMPLETON DJ, 1992, MOL CELL BIOL, V12, P435, DOI 10.1128/MCB.12.2.435; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Trujillo JM, 1996, VIROLOGY, V220, P1, DOI 10.1006/viro.1996.0279; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VANDEPOL SB, 1995, J VIROL, V69, P395, DOI 10.1128/JVI.69.1.395-402.1995; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709; YAN MH, 1994, J BIOL CHEM, V269, P19067; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	54	114	117	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	1998	16	1					43	52		10.1038/sj.onc.1201504	http://dx.doi.org/10.1038/sj.onc.1201504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467941				2022-12-17	WOS:000071236800005
J	MacGrogan, D; Pegram, M; Slamon, D; Bookstein, R				MacGrogan, D; Pegram, M; Slamon, D; Bookstein, R			Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas	ONCOGENE			English	Article						tumor suppressor gene; DPC4; mutation; prostate cancer; colorectal cancer	COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-FACTOR-BETA; ALLELIC IMBALANCE; CANCER; GENE; DCC; LOCI; P53	Allelic deletions of chromosome 18q are reported to be common in prostate and colorectal cancers, suggesting that one or more tumor suppressor genes on 18q are involved in the genesis of these neoplasms, The DPC4 gene, a recently identified candidate tumor suppressor in 18q21, was examined for evidence of inactivation in prostatic carcinomas, and results compared to those of a parallel analysis of colorectal carcinomas, for which DPC4 mutation has been reported in similar to 10% of cases, In this study, only three (10%) of 29 informative primary prostate cancers showed allelic loss of chromosome 18q21 markers, and no point mutations or deletions of DPC4 were detected in the complete set of 45 primary or metastatic cases, In contrast, five (56%) of nine primary colorectal tumors displayed allelic loss of 18q markers and in one of these a somatically acquired G-->T missense mutation was found in exon 1. Of twelve colorectal tumor cell lines, one showed a G-->C missense mutation in exon 8 and two had partial homozygous deletions that would likely abrogate gene function, These data suggest that DPC4 is rarely if ever mutated during prostatic oncogenesis, whereas inactivation of this gene may contribute to the genesis of a subset of colorectal carcinomas.	CANJI INC,DEPT BIOL MOL,SAN DIEGO,CA 92121; UNIV CALIF LOS ANGELES,SCH MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422	NCI NIH HHS [1K12 CA01714, 1R01 CA 60358] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001714, R01CA060358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BREWSTER SF, 1994, J UROLOGY, V151, P1073, DOI 10.1016/S0022-5347(17)35186-8; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; Cher ML, 1996, CANCER RES, V56, P3091; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Cunningham JM, 1996, CANCER RES, V56, P4475; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GAO X, 1993, CANCER RES, V53, P2723; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; JOOS S, 1995, GENE CHROMOSOME CANC, V14, P267, DOI 10.1002/gcc.2870140405; Kim SK, 1996, CANCER RES, V56, P2519; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nagatake M, 1996, CANCER RES, V56, P2718; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sambrook J, 1989, MOL CLONING LAB MANU; Schutte M, 1996, CANCER RES, V56, P2527; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VISAKORPI T, 1995, CANCER RES, V55, P342; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WILDING G, 1989, MOL CELL ENDOCRINOL, V62, P79, DOI 10.1016/0303-7207(89)90115-9; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	114	121	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1111	1114		10.1038/sj.onc.1201232	http://dx.doi.org/10.1038/sj.onc.1201232			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285566				2022-12-17	WOS:A1997XT16100013
J	Yao, R; Cooper, GM				Yao, R; Cooper, GM			Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70(S6K) activity	ONCOGENE			English	Article						apoptosis; PI 3-kinase; S6 kinase	PROGRAMMED CELL-DEATH; PROTEIN-KINASE-C; S6 KINASE; DNA-SYNTHESIS; MAMMALIAN PROTEIN; ACTIVATION; RAPAMYCIN; INSULIN; WORTMANNIN; APOPTOSIS	A variety of mammalian cells undergo apoptosis when deprived of growth factors, but the intracellular signaling pathways responsible for cell survival remain to be characterized. In the present study, we have investigated the role of PI 3-kinase and pp70(S6K) in growth factor-dependent survival of rodent fibroblasts. As previously reported for PC12 pheochromocytoma cells, Rat-1 and REF52 cells underwent apoptosis following either serum-deprivation or treatment with the PI 3-kinase inhibitors wortmannin and LY294002. In contrast, NIH3T3 and BALB 3T3 cells were resistant to apoptosis induced by either serum-deprivation or PI 3-kinase inhibition. It thus appears that PI 3-kinase is specifically required to prevent apoptosis of fibroblast that are dependent upon growth factors survival. Consistent with this role of PI 3-kinase, serum and growth factors maintained steady state levels of PI 3-kinase activity that rapidly decreased following serum-deprivation. Serum and growth factors similarly maintained a steady state level of pp70(S6K), which is thought to be activated downstream of PI 3-kinase. However, inhibition of pp70(S6K) activation by rapamycin failed to induce apoptosis in either Rat-1 or PC12 cells. Cell survival thus appears to require a PI 3-kinase signaling pathway that is independent of pp70(S6K) activation.	DANA FARBER CANC INST,DIV MOL GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	42	114	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					343	351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710373				2022-12-17	WOS:A1996VA25200013
J	Rutberg, SE; Saez, E; Glick, A; Dlugosz, AA; Spiegelman, BM; Yuspa, SH				Rutberg, SE; Saez, E; Glick, A; Dlugosz, AA; Spiegelman, BM; Yuspa, SH			Differentiation of mouse keratinocytes is accompanied by PKC-dependent changes in AP-1 proteins	ONCOGENE			English	Article						AP-1; keratinocytes; protein kinase C; mouse skin; differentiation; c-fos	TISSUE-SPECIFIC EXPRESSION; KINASE-C-DELTA; EPIDERMAL DIFFERENTIATION; SELECTIVE INHIBITOR; SKIN CARCINOGENESIS; BINDING-PROTEINS; GENE-EXPRESSION; PHORBOL ESTER; CYCLIC-AMP; FOS	The conversion of cultured basal keratinocytes to the spinous and granular cell phenotypes seen in the skin can be stimulated by raising the levels of extracellular calcium, Here me show that AP-1 DNA binding activity is very low in primary cultures of basal keratinocytes, but that this activity is induced 24-48 h after increasing the concentration of extracellular calcium from 0.05 to 0.12 mM. As such, the induction of AP-1 DNA binding activity correlates with events occurring during the terminal stages of keratinocyte differentiation, Calcium-induced AP-1 DNA binding complexes consist of Pra-1, Fra-2, c-Jun, JunB and JunD and are independent of c-Fos, since the induction of DNA binding activity and the composition of the AP-1 binding complexes are identical in differentiating keratinocytes derived from c-fos null and wild type mice, The formation of calcium-induced AP-1 binding complexes is regulated by protein kinase C (PKC) and requires a functional PKC alpha isozyme, as determined through pharmacological down-modulation of specific PKC isozymes in differentiating keratinocytes, Moreover, PKC activation is required for the increased expression of Fra-2, JunB and JunD in the nucleus of differentiating cells in vitro. This observation provides a link between the obligate activation of PKC during keratinocyte differentiation and the nuclear response required to alter gene expression, In vivo expression patterns suggest that the predominant AP-1 heterodimer in the granular layer consists of Fra-2 and JunB while a JunD and Fra-1 complex predominates the spinous layer of mouse epidermis, These findings suggest distinct functions for different AP-1 proteins in the regulation of events related to keratinocyte maturation.	NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA; NCI, TUMOR VIRUS BIOL LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; Bernerd Francoise, 1993, Gene Expression, V3, P187; CARRASCO D, 1995, ONCOGENE, V10, P1069; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; FISHER C, 1991, DEVELOPMENT, V111, P253; FRANZA BR, 1987, ONCOGENE, V1, P213; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GILLARDON F, 1994, ONCOGENE, V9, P3219; GRUDA MC, 1994, ONCOGENE, V9, P2537; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUFF CA, 1991, J INVEST DERMATOL, V96; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; LU B, 1994, J BIOL CHEM, V269, P7443; MALMQVIST KG, 1984, NUCL INSTRUM METH B, V3, P611, DOI 10.1016/0168-583X(84)90447-6; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PETTIT GR, 1991, CAN J CHEM, V69, P856, DOI 10.1139/v91-126; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RODDEY PK, 1994, J INVEST DERMATOL, V102, P296, DOI 10.1111/1523-1747.ep12371785; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAKO T, 1987, CANCER RES, V47, P5445; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SONOBE MH, 1995, ONCOGENE, V10, P689; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Takahashi S., 1994, Journal of Dermatological Science, V7, P54, DOI 10.1016/0923-1811(94)90022-1; TANGUAY DA, 1994, CELL IMMUNOL, V158, P281, DOI 10.1006/cimm.1994.1276; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	67	114	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					167	176						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700543				2022-12-17	WOS:A1996UX31900019
J	SCHOTT, AF; APEL, IJ; NUNEZ, G; CLARKE, MF				SCHOTT, AF; APEL, IJ; NUNEZ, G; CLARKE, MF			BCL-X(L) PROTECTS CANCER-CELLS FROM P53-MEDIATED APOPTOSIS	ONCOGENE			English	Article						BCL-X(L); P53; BREAST CANCER	BCL-2 PROTEIN; DEATH; GENE; MYC; P53; EXPRESSION; SURVIVAL; LINE	Oncogenesis is a process resulting from genetic events which cause loss of growth control or inhibition of appropriate cell death. The Bcl-x(L) protein is a recently discovered member of the bcl-2 family which has been shown to protect cells from some forms of programmed cell death, but has not yet been implicated in the genesis of human carcinomas. In this report we explore the role of Bcl-x(L) overexpression in protecting cancer cells from p53-mediated apoptosis. Increased levels of Bcl-x(L) were found in a subset of primary human breast carcinomas, as well as in the breast cancer line, T47D. T47D cells were then transfected with a temperature-sensitive mutant of the tumor suppressor p53 (p53ts). Although many tumor cell lines undergo apoptosis when p53 is expressed, the T47D transfectants remained viable at temperatures permitting wild-type p53 phenotype. This suggested that endogenous Bcl-x(L) could protect cancer cells from p53-mediated apoptosis. To test this hypothesis, murine erythroleukemia cells were transfected with bcl-x(L) and p53ts. While cell lines expressing p53 alone rapidly died, those cells co-expressing Bcl-x(L) survived. These results demonstrate that Bcl-x(L) is capable of protecting cells from p53-mediated apoptosis, and suggest a possible mechanism by which tumors expressing Bcl-x(L) are able to partly overcome the tumor suppressor functions of p53.	UNIV MICHIGAN,DEPT HEMATOL ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT PATHOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Nuñez, Gabriel/A-7160-2014; Schott, Anne/AAD-1902-2019		NCI NIH HHS [CA-46657] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046657] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BHARGAVA V, 1994, AM J PATHOL, V145, P535; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DOGLIONI C, 1994, VIRCHOWS ARCH, V424, P47; FUKUNAGAJOHNSON N, 1995, IN PRESS CARCINOGENE; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1994, CANCER RES, V54, P2095; IKEGAKI N, 1994, CANCER RES, V54, P6; JOENSUU H, 1994, AM J PATHOL, V145, P1191; KORSMEYER SJ, 1992, BLOOD, V880, P879; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; PIENTENPOL JA, 1993, NATURE, V365, P17; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZUTTER M, 1991, BLOOD, V78, P1062	34	114	117	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1389	1394						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478561				2022-12-17	WOS:A1995RY96700021
J	DALLERY, E; GALIEGUEZOUITINA, S; COLLYNDHOOGHE, M; QUIEF, S; DENIS, C; HILDEBRAND, MP; LANTOINE, D; DEWEINDT, C; TILLY, H; BASTARD, C; KERCKAERT, JP				DALLERY, E; GALIEGUEZOUITINA, S; COLLYNDHOOGHE, M; QUIEF, S; DENIS, C; HILDEBRAND, MP; LANTOINE, D; DEWEINDT, C; TILLY, H; BASTARD, C; KERCKAERT, JP			TTF, A GENE ENCODING A NOVEL SMALL G-PROTEIN, FUSES TO THE LYMPHOMA-ASSOCIATED LAZ3 GENE BY T(3-4) CHROMOSOMAL TRANSLOCATION	ONCOGENE			English	Article						LAZ3 BCL6 GENE; LYMPHOMA; TRANSLOCATION (3-4); SMALL G PROTEIN; LAZ3 FUSION GENE	GTP-BINDING-PROTEIN; NON-HODGKINS-LYMPHOMA; RAS GENE; BURKITTS-LYMPHOMA; FAMILY; EXPRESSION; CLONING; CDNAS; PURIFICATION; BREAKPOINT	We have previously shown that the LAZ3/BCL6 gene encoding a potential transcription factor, is disrupted in B-diffuse large cell non-Hodgkin's lymphomas (NHL) with 3q27 chromosomal abnormalities involving the immunoglobulin (IG) genes. However, LAZ3 rearrangement also occurs in NHL bearing 3q27 translocations without involvement of the IG genes: for example the VAL cell line exhibits t(3;4)(q27;p11). In the present work we have used a RT-PCR method to detect and to sequence the LAZ3 mRNA products from the VAL cell line. We report that the consequence of the t(3;4) is the expression of a chimeric transcript of LAZ3 with a new gene encoding a small G-like protein, termed TTF (Translocation Three Four). Nucleotide sequence analysis of a 1.4 kb cDNA predicts that the TTF gene encodes a protein of 191 amino-acids similar to members of the RAS superfamily including HRAS (27% identical), RAB1A (30% identical) and RHO proteins: the human RAC1, RHOB and CDC42Hs proteins (respectively 43, 44 and 45% identical) and the yeast RHO2 protein (44% identical). Unlike most other small G proteins which are expressed ubiquitously, TTF was transcribed only in hemopoietic cells as a 2.2 kb transcript. TTF may define a new subgroup of RHO-like proteins.	INST RECH CANC LILLE, INSERM, U124, F-59045 LILLE, FRANCE; CTR HENRI BECQUEREL, F-76038 ROUEN, FRANCE; CTR REG TRANSFUS SANGUINE, DEPT CYTOGENET, F-76232 BOIS GUILLAUME, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASTARD C, 1992, BLOOD, V79, P2527; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHARDIN P, 1993, HDB EXPT PHARM, V108, P159; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FUKUHARA S, 1979, CANCER RES, V39, P3119; HEIN J, 1990, METHOD ENZYMOL, V183, P626; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MANOLOVA Y, 1979, HEREDITAS, V90, P5; MIKI T, 1994, BLOOD, V83, P26; OLOFSSON B, 1988, ONCOGENE, V3, P231; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TERRYN N, 1993, PLANT MOL BIOL, V22, P143, DOI 10.1007/BF00039002; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	42	114	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2171	2178						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784061				2022-12-17	WOS:A1995RB70300012
J	COX, AD; BRTVA, TR; LOWE, DG; DER, CJ				COX, AD; BRTVA, TR; LOWE, DG; DER, CJ			R-RAS INDUCES MALIGNANT, BUT NOT MORPHOLOGIC, TRANSFORMATION OF NIH3T3 CELLS	ONCOGENE			English	Article							C-MYC; PROTEIN-KINASE; EXPRESSION; ONCOGENES; GROWTH; BCL-2; GENE; ACTIVATION; PRODUCT; GTPASES	Although previous studies have not identified transforming properties of the Ras-related protein R-Ras, two recent observations have prompted our further evaluation of R-Ras function. First, we observed that mutant forms of the closely related R-Ras2/TC21 protein (similar to 70% identity) exhibited the same potent transforming activity as oncogenic Ras proteins. Second, R-Ras association with Bcl-2 suggested a possible role for R-Ras in apoptotic growth control. Therefore, we have performed a detailed analysis of R-Ras transforming potential in NIH3T3 cells. Whereas expression of a mutant R-Ras protein (38V; analogous to the 12V activating Ras mutation) did not induce morphologic transformation of NIH3T3 cells, R-Ras(38V)-expressing cells proliferated in low serum, formed colonies in soft agar, and formed progressive tumors in nude mice. Like Ras-transformed cells, R-Ras(38V)-transformed cells exhibited constitutively activated mitogen activated protein kinases. Furthermore, R-Ras(38V) stimulated transcriptional activation of Ras-responsive promoter elements, and this activity (and transformation) was blocked by Raf dominant negative proteins, Finally, whereas co-expression of Bcl-2 did not cause significant alteration in wild type or mutant R-Ras transforming activity, coexpression of v-Myc and R-Ras(38V) induced a striking morphologic transformation of NIH3T3 cells. Taken together, these observations suggest that aberrant R-Ras function may stimulate malignant transformation, in the absence of morphologic transformation, via up-regulation of part of the Ras signal transduction pathway.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Roche Holding; Genentech	COX, AD (corresponding author), UNIV N CAROLINA,SCH MED,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA61951, CA52070, CA42978] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R29CA061951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COX AD, 1994, METHOD ENZYMOL, V238, P277; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PERONA R, 1993, ONCOGENE, V8, P1285; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SELF AJ, 1993, ONCOGENE, V8, P655; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	36	114	117	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3281	3288						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936652				2022-12-17	WOS:A1994PM65800021
J	MIGLIACCIO, A; PAGANO, M; AURICCHIO, F				MIGLIACCIO, A; PAGANO, M; AURICCHIO, F			IMMEDIATE AND TRANSIENT STIMULATION OF PROTEIN-TYROSINE PHOSPHORYLATION BY ESTRADIOL IN MCF-7 CELLS	ONCOGENE			English	Article							HUMAN-BREAST-CANCER; PHOSPHOTYROSINE-CONTAINING PROTEINS; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; ESTROGEN-RECEPTOR; HORMONE BINDING; OWN RECEPTOR; STEROID-HORMONES; CELLULAR PROTEIN; ONCOGENE PRODUCT	Estradiol stimulates protein phosphorylation on tyrosine in human breast cancer MCF-7 cells under conditions of estradiol-stimulated cell growth. The stimulatory effect of estradiol has been observed by P-32-labeling of cells followed by purification of proteins using antiphosphotyrosine antibody coupled to agarose and confirmed by immunoblotting analysis with antiphosphotyrosine antibody. This stimulation is immediate (maximal in 10 s) and transient. In addition, it is receptor-mediated since estradiol stimulation is prevented by two well-known antiestrogens, OH-Tamoxifen and ICI 164 384. Estradiol fails to stimulate tyrosine protein phosphorylation of Cos cells which do not express the estradiol receptor. Two substrates of the estrogen stimulated phosphorylation on tyrosine with approximate mol wt of 55 and 60 kDa interact with a polyclonal antibody raised against amino acids 527-533 of pp60c-src (anti-cst.1 antibody). Tyrosine kinase activity of immunoprecipitates made using either anti cst.1 antibody or the monoclonal 327 antibody specific for pp60c-src shows that kinase(s) strongly related to pp60c-src are immediately and transiently stimulated by estradiol treatment of cells. The present findings provide the first demonstration that a steroid hormone rapidly stimulates tyrosine phosphorylation of target cells and induces functional modifications of substrates of this phosphorylation. These modifications might initiate the estradiol action on cell growth.	UNIV NAPOLI 2, FAC MED & CHIRURG,IST PATOL GEN & ONCOL, CATTEDRA PATOL GEN 2,VIA S ANDREA DAME 2, I-80138 NAPLES, ITALY	Universita della Campania Vanvitelli			Migliaccio, Antimo/AAB-3376-2019	Migliaccio, Antimo/0000-0002-4197-2055				AURICCHIO F, 1989, J STEROID BIOCHEM, V32, P613, DOI 10.1016/0022-4731(89)90397-X; AURICCHIO F, 1987, EMBO J, V6, P2923, DOI 10.1002/j.1460-2075.1987.tb02596.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BISWAS R, 1987, CANCER RES, V47, P3509; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; BRESSION D, 1986, ENDOCRINOLOGY, V119, P1048, DOI 10.1210/endo-119-3-1048; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COOPER JA, 1990, PEPTIDES PROTEIN PHO; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; EK B, 1982, J BIOL CHEM, V257, P486; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HARLOW E, 1988, ANTIBODIES LABORATOR; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBERHERR M, 1989, J BIOL CHEM, V264, P20403; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MIGLIACCIO A, 1989, MOL ENDOCRINOL, V3, P1061, DOI 10.1210/mend-3-7-1061; MIGLIACCIO A, 1991, J STEROID BIOCHEM, V38, P407, DOI 10.1016/0960-0760(91)90328-3; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; MIGLIACCIO A, 1986, EMBO J, V5, P2867, DOI 10.1002/j.1460-2075.1986.tb04581.x; MULDOON TG, 1988, J STEROID BIOCHEM, V30, P23, DOI 10.1016/0022-4731(88)90072-6; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARIKH I, 1980, J BIOL CHEM, V255, P266; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PRATT WB, 1988, J BIOL CHEM, V263, P267; REDDY KB, 1992, CANCER RES, V52, P3636; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; STERN DF, 1991, METHOD ENZYMOL, V198, P494; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WONG TW, 1984, J BIOL CHEM, V259, P8505; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZICK Y, 1983, J BIOL CHEM, V258, P3431	52	114	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2183	2191						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	7687761				2022-12-17	WOS:A1993LP17100019
J	HU, YL; RAMSAY, RG; KANEIISHII, C; ISHII, S; GONDA, TJ				HU, YL; RAMSAY, RG; KANEIISHII, C; ISHII, S; GONDA, TJ			TRANSFORMATION BY CARBOXYL-DELETED MYB REFLECTS INCREASED TRANSACTIVATING CAPACITY AND DISRUPTION OF A NEGATIVE REGULATORY DOMAIN	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; GENE V-MYB; C-MYB; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL DOMAINS; PROTO-ONCOGENE; CELLULAR PROGENITOR; FOS PROTEIN; EXPRESSION; SEQUENCE	Carboxyl-truncated forms of the product of the c-myb proto-oncogene (Myb) are encoded by the v-myb oncogene, the rearranged c-myb genes of certain murine cell lines and a transforming recombinant c-myb retrovirus. We report here an examination of the abilities of a series of carboxyl deletions of Myb to transform hemopoietic cells. Increasing degrees of truncation resulted in increasing transforming capacity until the deletions removed the region responsible for transactivation by Myb. Because the effects of these deletions on transformation paralleled their previously described effects on the transactivating capacity of Myb but did not correlate with their ability to repress transcription, our results imply that removal of a domain which negatively regulates transactivation is responsible for oncogenic activation of carboxyl-truncated forms of Myb. Moreover, these data support the view that activated forms of myb transform by increasing and/or deregulating the expression of other genes.	ROYAL MELBOURNE HOSP,MELBOURNE TUMOUR BIOL BRANCH,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; RIKEN			Gonda, Thomas J/A-3620-2012; Ishii, Shunsuke/A-5271-2016; Hu, Yinling/G-5682-2015; Ramsay, Robert G/C-3291-2015	Ishii, Shunsuke/0000-0002-6530-2478; Hu, Yinling/0000-0002-4795-8537; Ramsay, Robert G/0000-0001-5003-0433				ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; DUDEK H, 1989, ONCOGENE, V4, P1489; DURBAN EM, 1981, P NATL ACAD SCI-BIOL, V78, P3600, DOI 10.1073/pnas.78.6.3600; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frykberg L, 1988, Oncogene Res, V3, P313; GELINAS C, 1988, ONCOGENE, V3, P349; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MILLER AD, 1984, CELL, V36, P51; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1991, IN PRESS ONCOGENE; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	114	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1549	1553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923521				2022-12-17	WOS:A1991GX27400008
J	XU, HJ; HU, SX; BENEDICT, WF				XU, HJ; HU, SX; BENEDICT, WF			LACK OF NUCLEAR RB PROTEIN STAINING IN G0 MIDDLE G1 CELLS - CORRELATION TO CHANGES IN TOTAL RB PROTEIN LEVEL	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; SV40 LARGE-T; OSTEO-SARCOMA; HUMAN CANCER; PRODUCT; EXPRESSION; CYCLE; PHOSPHORYLATION; CARCINOMA; INACTIVATION	Functional loss of the retinoblastoma (RB) gene has been implicated in a diverse group of human malignancies. The potential clinical importance of such loss demands a reproducible RB cell staining method to distinguish RB+ from RB- tumors. We report that normal and known RB+ tumor cells either in culture or in vivo display a mosaic RB staining pattern with variable proportions of cells having unstained nuclei which are indistinguishable from truly RB- tumor cells. We also show that the apparent lack of nuclear staining corresponds to RB+ cells which are in the G0 or middle G1 phase, where as much as 10-fold decrease in total cellular RB protein occurs compared to their G2/M phase counterparts. These findings not only provide new clues to RB protein function in cell growth and differentiation, but also need to be considered when evaluating the RB status in primary malignancies for its role in tumor initiation/progression or as a prognostic parameter.			XU, HJ (corresponding author), BAYLOR COLL MED,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.				NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER; NEI NIH HHS [EYO 2715, EYO 6195] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GRAND RJA, 1989, ONCOGENE, V4, P1291; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1988, ANTIBODIES LABORATOR; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; KNUDSON AG, 1985, CANCER RES, V45, P1437; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1988, ONCOGENE, V3, P471	35	114	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1139	1146						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861863				2022-12-17	WOS:A1991GV26000007
J	SAFRAN, A; AVIVI, A; ORRURTEREGER, A; NEUFELD, G; LONAI, P; GIVOL, D; YARDEN, Y				SAFRAN, A; AVIVI, A; ORRURTEREGER, A; NEUFELD, G; LONAI, P; GIVOL, D; YARDEN, Y			THE MURINE FLG GENE ENCODES A RECEPTOR FOR FIBROBLAST GROWTH-FACTOR	ONCOGENE			English	Article									WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; TECHNION ISRAEL INST TECHNOL, DEPT BIOL, IL-32000 HAIFA, ISRAEL	Weizmann Institute of Science; Technion Israel Institute of Technology			Neufeld, Gera/F-1524-2019; YARDEN, YOSEF/K-1467-2012	Orr-Urtreger, Avi/0000-0001-9305-6203				ARMELIN HA, 1973, P NATL ACAD SCI USA, V70, P2702, DOI 10.1073/pnas.70.9.2702; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1986, J BIOL CHEM, V261, P7581; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GOSPODAROWICZ D, 1974, NATURE, V249, P123, DOI 10.1038/249123a0; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; Hogan B., 1986, MANIPULATING MOUSE E; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; JAYE M, 1985, SCIENCE, V228, P882, DOI 10.1126/science.3890179; KAN M, 1988, J BIOL CHEM, V263, P11306; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARUYAMA T, 1986, NUCLEIC ACIDS RES, V14, pR151, DOI 10.1093/nar/14.suppl.r151; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SMITH JC, 1989, DEVELOPMENT, V105, P665; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALICKE PA, 1989, J BIOL CHEM, V264, P4120; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	54	114	121	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1990	5	5					635	643						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2161096				2022-12-17	WOS:A1990DG37400002
J	CAPOBIANCO, AJ; SIMMONS, DL; GILMORE, TD				CAPOBIANCO, AJ; SIMMONS, DL; GILMORE, TD			CLONING AND EXPRESSION OF A CHICKEN C-REL CDNA - UNLIKE P59V-REL, P68C-REL IS A CYTOPLASMIC PROTEIN IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article									BOSTON UNIV,DEPT BIOL,2 CUMMINGTON ST,BOSTON,MA 02215; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Boston University; Harvard University				Capobianco, Anthony/0000-0002-3706-6797	NCI NIH HHS [CA42580, CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763, R35CA042580] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BROWNELL E, 1989, ONCOGENE, V4, P935; CHEN HR, 1986, NUCLEIC ACIDS RES, V14, P3977, DOI 10.1093/nar/14.9.3977; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P971; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1989, ONCOGENE, V4, P845; MORRISON LE, 1989, ONCOGENE, V4, P677; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; THIELEN GH, 1966, J NATL CANCER I, V37, P747; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	36	114	115	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					257	265						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2179815				2022-12-17	WOS:A1990CW41500002
J	GUERIN, M; SHENG, ZM; ANDRIEU, N; RIOU, G				GUERIN, M; SHENG, ZM; ANDRIEU, N; RIOU, G			STRONG ASSOCIATION BETWEEN C-MYB AND ESTROGEN-RECEPTOR EXPRESSION IN HUMAN BREAST-CANCER	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,PHARMACOL CLIN & MOLEC LAB,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT STAT MED,F-94800 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy			ANDRIEU, Nadine/H-4255-2014					ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; CHU AM, 1980, CANCER, V45, P2730, DOI 10.1002/1097-0142(19800601)45:11<2730::AID-CNCR2820451106>3.0.CO;2-C; CLARK GM, 1983, NEW ENGL J MED, V309, P1343, DOI 10.1056/NEJM198312013092240; CONTESSO G, 1987, J CLIN ONCOL, V5, P1378, DOI 10.1200/JCO.1987.5.9.1378; CRAIG RW, 1984, CANCER RES, V44, P442; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DELARUE JC, 1988, BREAST CANCER RES TR, V11, P173, DOI 10.1007/BF01805841; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; DUBIK D, 1987, CANCER RES, V47, P6517; GRIFFIN CA, 1985, CANCER RES, V45, P272; GUERIN M, 1985, CR ACAD SCI III-VIE, V301, P833; GUERIN M, 1988, CR ACAD SCI III-VIE, V307, P855; GUERIN M, 1989, INT J CANCER, V43, P201, DOI 10.1002/ijc.2910430205; GUERIN M, 1988, ONCOGENE RES, V3, P21; JAKOWLEW SB, 1984, NUCLEIC ACIDS RES, V12, P2861, DOI 10.1093/nar/12.6.2861; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; Maniatis T., 1982, MOL CLONING; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; MORISSET M, 1986, BIOCHEM BIOPH RES CO, V138, P102, DOI 10.1016/0006-291X(86)90252-4; MOURALI N, 1982, BRIT J CANCER, V45, P367, DOI 10.1038/bjc.1982.63; MULLER R, 1988, CELLULAR ONCOGENE AC, P1; MURPHY C, 1988, BAILLIERES CLIN ONCO, V2, P117; RIO MC, 1987, P NATL ACAD SCI USA, V84, P9243, DOI 10.1073/pnas.84.24.9243; ROCHEFORT H, 1988, BREAST CANCER CELLUL, P207; ROUESSE J, 1986, J CLIN ONCOL, V4, P1765, DOI 10.1200/JCO.1986.4.12.1765; SAEZ RA, 1988, BAILLIERES CLIN ONCO, V2, P103; SAINSBURY JRC, 1985, LANCET, V1, P364; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TORELLI G, 1987, CANCER RES, V47, P5266; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; WILDING G, 1988, CANCER RES, V48, P802	38	114	115	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					131	135						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181374				2022-12-17	WOS:A1990CM62000018
J	Battistelli, C; Cicchini, C; Santangelo, L; Tramontano, A; Grassi, L; Gonzalez, FJ; de Nonno, V; Grassi, G; Amicone, L; Tripodi, M				Battistelli, C.; Cicchini, C.; Santangelo, L.; Tramontano, A.; Grassi, L.; Gonzalez, F. J.; de Nonno, V.; Grassi, G.; Amicone, L.; Tripodi, M.			The Snail repressor recruits EZH2 to specific genomic sites through the enrollment of the lncRNA HOTAIR in epithelial-to-mesenchymal transition	ONCOGENE			English	Article							LONG NONCODING RNA; NUCLEAR FACTOR 4-ALPHA; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTORS; COMPLEX 2; CHROMATIN MODIFICATION; CARCINOMA PROGRESSION; MOLECULAR-MECHANISMS; EMT/MET DYNAMICS; GENE-EXPRESSION	The transcription factor Snail is a master regulator of cellular identity and epithelial-to-mesenchymal transition (EMT) directly repressing a broad repertoire of epithelial genes. How chromatin modifiers instrumental to its activity are recruited to Snail-specific binding sites is unclear. Here we report that the long non-coding RNA (lncRNA) HOTAIR (for HOX Transcript Antisense Intergenic RNA) mediates a physical interaction between Snail and enhancer of zeste homolog 2 (EZH2), an enzymatic subunit of the polycomb-repressive complex 2 and the main writer of chromatin-repressive marks. The Snail-repressive activity, here monitored on genes with a pivotal function in epithelial and hepatic morphogenesis, differentiation and cell-type identity, depends on the formation of a tripartite Snail/HOTAIR/EZH2 complex. These results demonstrate an lncRNA-mediated mechanism by which a transcriptional factor conveys a general chromatin modifier to specific genes, thereby allowing the execution of hepatocyte transdifferentiation; moreover, they highlight HOTAIR as a crucial player in the Snail-mediated EMT.	[Battistelli, C.; Cicchini, C.; Santangelo, L.; de Nonno, V.; Amicone, L.; Tripodi, M.] Sapienza Univ Rome, Ist Pasteur Italia Fdn Cenci Bolognetti, Dept Cellular Biotechnol & Haematol, Sez Genet Mol, Rome, Italy; [Tramontano, A.] Sapienza Univ Rome, Ist Pasteur Italia Fdn Cenci Bolognetti, Dept Phys, Rome, Italy; [Grassi, L.] Sapienza Univ Rome, Dept Phys, Rome, Italy; [Gonzalez, F. J.] NCI, Ctr Canc Res, Lab Metab, NIH, Bethesda, MD 20892 USA; [Grassi, G.; Tripodi, M.] IRCCS, Natl Inst Infect Dis L Spallanzani, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Sapienza University Rome; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Lazzaro Spallanzani	Cicchini, C; Tripodi, M (corresponding author), Sapienza Univ Rome, Fdn Cenci Bolognetti, Ist Pasteur Italia, Dipartimento Biotecnol Cellulari & Ematol,Sez Gen, Viale Regina Elena 324, I-00161 Rome, Italy.	cicchini@bce.uniroma1.it; tripodi@bce.uniroma1.it	Tripodi, Marco/F-1143-2011; Battistelli, Cecilia/AFD-8694-2022; Grassi, Luigi/E-5877-2011; Tripodi, Marco/ABO-1160-2022	Tripodi, Marco/0000-0001-6135-971X; Battistelli, Cecilia/0000-0002-5611-7377; Tripodi, Marco/0000-0001-6135-971X; Grassi, Luigi/0000-0002-6308-7540; Grassi, Germana/0000-0001-8168-8721	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 14114]; Ministero della Salute; Ministero Universita e Ricerca Scientifica [PRIN 20108XYHJS]; Epigenomics Flagship Project-EPIGEN; NATIONAL CANCER INSTITUTE [ZIABC005562] Funding Source: NIH RePORTER	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Ministero Universita e Ricerca Scientifica(Ministry of Education, Universities and Research (MIUR)); Epigenomics Flagship Project-EPIGEN; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank I Bozzoni and SA Ciafre for suggestions and critical revision of the manuscript. This was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) IG 14114; Ministero della Salute; Ministero Universita e Ricerca Scientifica PRIN 20108XYHJS; Epigenomics Flagship Project-EPIGEN.	Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Arnold P, 2013, GENOME RES, V23, P60, DOI 10.1101/gr.142661.112; Battistelli C, 2014, J CELL SCI, V127, P3757, DOI 10.1242/jcs.149427; Bolotin E, 2010, HEPATOLOGY, V51, P642, DOI 10.1002/hep.23357; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181; Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668; Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027; Cicchini C, 2008, EXP CELL RES, V314, P143, DOI 10.1016/j.yexcr.2007.09.005; Cicchini C, 2006, J CELL PHYSIOL, V209, P230, DOI 10.1002/jcp.20730; Cicchini C, 2015, BBA-GENE REGUL MECH, V1849, P919, DOI 10.1016/j.bbagrm.2015.05.005; Cicchini C, 2015, LIVER INT, V35, P302, DOI 10.1111/liv.12577; Cifuentes-Rojas C, 2014, MOL CELL, V55, P171, DOI 10.1016/j.molcel.2014.05.009; Colletti M, 2009, GASTROENTEROLOGY, V137, P660, DOI 10.1053/j.gastro.2009.05.038; Courel M, 2008, DEV DYNAM, V237, P1232, DOI 10.1002/dvdy.21516; Dahm GM, 2012, JOVE-J VIS EXP, DOI 10.3791/3851; Davidovich C, 2013, NAT STRUCT MOL BIOL, V20, P1250, DOI 10.1038/nsmb.2679; Deb G, 2014, MOL CANCER RES, V12, P639, DOI 10.1158/1541-7786.MCR-13-0546; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175; Geng YJ, 2011, J INT MED RES, V39, P2119, DOI 10.1177/147323001103900608; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Huang RYJ, 2012, J CELL SCI, V125, P4417, DOI 10.1242/jcs.099697; Javaid S, 2013, CELL REP, V5, P1679, DOI 10.1016/j.celrep.2013.11.034; Kaneko S, 2013, NAT STRUCT MOL BIOL, V20, P1258, DOI 10.1038/nsmb.2700; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021; Kretz M, 2014, MOL CELL, V55, P157, DOI 10.1016/j.molcel.2014.07.002; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Li LJ, 2013, CELL REP, V5, P3, DOI 10.1016/j.celrep.2013.09.003; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; McHugh CA, 2015, NATURE, V521, P232, DOI 10.1038/nature14443; Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nolan KD, 2015, J BIOL CHEM, V290, P8271, DOI 10.1074/jbc.M115.637496; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rodriguez M, 2008, CANCER RES, V68, P7872, DOI 10.1158/0008-5472.CAN-08-0301; Santangelo L, 2011, HEPATOLOGY, V53, P2063, DOI 10.1002/hep.24280; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tien CL, 2015, DEVELOPMENT, V142, P722, DOI 10.1242/dev.111997; Tong ZT, 2012, ONCOGENE, V31, P583, DOI 10.1038/onc.2011.254; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Wongtrakoongate P, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005615; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y; Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017; Yu M, 2012, MOL CELL, V45, P330, DOI 10.1016/j.molcel.2011.11.032; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	57	113	117	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					942	955		10.1038/onc.2016.260	http://dx.doi.org/10.1038/onc.2016.260			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452518	Green Published, hybrid			2022-12-17	WOS:000394169100007
J	Wen, SY; Lin, Y; Yu, YQ; Cao, SJ; Zhang, R; Yang, XM; Li, J; Zhang, YL; Wang, YH; Ma, MZ; Sun, WW; Lou, XL; Wang, JH; Teng, YC; Zhang, ZG				Wen, S-Y; Lin, Y.; Yu, Y-Q; Cao, S-J; Zhang, R.; Yang, X-M; Li, J.; Zhang, Y-L; Wang, Y-H; Ma, M-Z; Sun, W-W; Lou, X-L; Wang, J-H; Teng, Y-C; Zhang, Z-G			miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer	ONCOGENE			English	Article							REGULATORY NETWORK; SONIC HEDGEHOG; UP-REGULATION; EXPRESSION; CELLS; DIFFERENTIATION; MICRORNAS	Although significant advances have recently been made in the diagnosis and treatment of cervical carcinoma, the long-term survival rate for advanced cervical cancer remains low. Therefore, an urgent need exists to both uncover the molecular mechanisms and identify potential therapeutic targets for the treatment of cervical cancer. MicroRNAs (miRNAs) have important roles in cancer progression and could be used as either potential therapeutic agents or targets. miR-506 is a component of an X chromosome-linked miRNA cluster. The biological functions of miR-506 have not been well established. In this study, we found that miR-506 expression was downregulated in approximately 80% of the cervical cancer samples examined and inversely correlated with the expression of Ki-67, a marker of cell proliferation. Gain-of-function and loss-of-function studies in human cervical cancer, Caski and SiHa cells, demonstrated that miR-506 acts as a tumor suppressor by inhibiting cervical cancer growth in vitro and in vivo. Further studies showed that miR-506 induced cell cycle arrest at the G1/S transition, and enhanced apoptosis and chemosensitivity of cervical cancer cell. We subsequently identified Gli3, a hedgehog pathway transcription factor, as a direct target of miR-506 in cervical cancer. Furthermore, Gli3 silencing recapitulated the effects of miR-506, and reintroduction of Gli3 abrogated miR-506-induced cell growth arrest and apoptosis. Taken together, we conclude that miR-506 exerts its anti-proliferative function by directly targeting Gli3. This newly identified miR-506/Gli3 axis provides further insight into the pathogenesis of cervical cancer and indicates a potential novel therapeutic agent for the treatment of cervical cancer.	[Wen, S-Y; Teng, Y-C] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, Shanghai 200233, Peoples R China; [Wen, S-Y; Lin, Y.] Shanghai Jiao Tong Univ, Sch Med, China Welf Inst, Dept Obstet & Gynecol,Int Peace Matern & Child Hl, Shanghai 200233, Peoples R China; [Wen, S-Y; Yang, X-M; Li, J.; Zhang, Y-L; Wang, Y-H; Ma, M-Z; Zhang, Z-G] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, State Key Lab Oncogenes & Related Genes,Shanghai, Shanghai 200233, Peoples R China; [Yu, Y-Q] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang 110001, Peoples R China; [Cao, S-J; Sun, W-W] Shanghai Songjiang Dist Cent Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Zhang, R.] Shanghai Fengxian Dist Cent Hosp, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Wang, J-H] Southern Med Univ, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; China Medical University; Southern Medical University - China	Teng, YC (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Obstet & Gynecol, 600 Yisan Rd, Shanghai 200233, Peoples R China.	teng_yc@126.com; zzhang@shsci.org	Ma, Ming-Ze/ABC-4612-2021	Zhang, Yan-Li/0000-0002-8942-5325; Zhang, Zhi-gang/0000-0001-8965-223X	National Science Foundation of China [81071738, 81101600, 81201624]; Songjiang district of Science and Technology Commission of Shanghai Municipality [10SJGG26]; Shanghai Songjiang District Central Hospital [BY10A07]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Songjiang district of Science and Technology Commission of Shanghai Municipality; Shanghai Songjiang District Central Hospital	We are most grateful for Dr Lei-Zhu, Bo-Shi Wang, Ming-Xuan Feng and Doctor XingLin Yang of Medical and Biological Engineering Technology Co. Ltd of Heyuan of Shanghai. This work was supported by the National Science Foundation of China (no. 81071738; no. 81101600; no. 81201624), Songjiang district of Science and Technology Commission of Shanghai Municipality (no. 10SJGG26), and Shanghai Songjiang District Central Hospital (no. BY10A07).	Ambros Victor, 2004, Methods Mol Biol, V265, P131; Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Castro RE, 2012, CLIN RES HEPATOL GAS, V36, P402, DOI 10.1016/j.clinre.2012.05.019; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Iwasaki H, 2013, CANCER SCI, V104, P328, DOI 10.1111/cas.12073; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kang HN, 2012, EXP CELL RES, V318, P539, DOI 10.1016/j.yexcr.2011.12.010; Kim KH, 2009, PATHOL INT, V59, P279, DOI 10.1111/j.1440-1827.2009.02366.x; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Li KKW, 2009, HUM PATHOL, V40, P1234, DOI 10.1016/j.humpath.2009.02.003; Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275; Liu KJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/867537; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Pierson J, 2008, J NEURO-ONCOL, V90, P1, DOI 10.1007/s11060-008-9624-3; Renault MA, 2009, CIRC RES, V105, P818, DOI 10.1161/CIRCRESAHA.109.206706; Roy SS, 2014, ONCOGENE, V33, P3707, DOI 10.1038/onc.2013.332; Scherr M, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm971; Sengupta A, 2007, LEUKEMIA, V21, P949, DOI 10.1038/sj.leu.2404657; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Steg A, 2010, CANCER BIOL THER, V10, P897, DOI 10.4161/cbt.10.9.13252; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Sun MM, 2014, ONCOGENE, V33, P2075, DOI 10.1038/onc.2013.165; Tong JL, 2011, FEBS LETT, V585, P3560, DOI 10.1016/j.febslet.2011.10.021; Vale C, 2008, J CLIN ONCOL, V26, P5802, DOI 10.1200/JCO.2008.16.4368; Wang P, 2014, ONCOGENE, V33, P514, DOI 10.1038/onc.2012.598; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhao Y, 2011, TOXICOL LETT, V205, P320, DOI 10.1016/j.toxlet.2011.06.022	32	113	117	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					717	725		10.1038/onc.2014.9	http://dx.doi.org/10.1038/onc.2014.9			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24608427				2022-12-17	WOS:000348853800005
J	Grayson, AR; Walsh, EM; Cameron, MJ; Godec, J; Ashworth, T; Ambrose, JM; Aserlind, AB; Wang, H; Evan, GI; Kluk, MJ; Bradner, JE; Aster, JC; French, CA				Grayson, A. R.; Walsh, E. M.; Cameron, M. J.; Godec, J.; Ashworth, T.; Ambrose, J. M.; Aserlind, A. B.; Wang, H.; Evan, G. I.; Kluk, M. J.; Bradner, J. E.; Aster, J. C.; French, C. A.			MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma	ONCOGENE			English	Article						BRD4; NUT; MYC; epigenetic; differentiation; fusion oncogene	SQUAMOUS-CELL CARCINOMA; SET ENRICHMENT ANALYSIS; C-MYC; POOR-PROGNOSIS; IN-VIVO; INDUCED APOPTOSIS; BET BROMODOMAINS; STEM-CELLS; GENE; REARRANGEMENT	NUT midline carcinoma (NMC) is an aggressive type of squamous cell carcinoma that is defined by the presence of BRD-NUT fusion oncogenes, which encode chimeric proteins that block differentiation and maintain tumor growth. BRD-NUT oncoproteins contain two bromodomains whose binding to acetylated histones is required for the blockade of differentiation in NMC, but the mechanisms by which BRD-NUT act remain uncertain. Here, we provide evidence that MYC is a key downstream target of BRD4-NUT. Expression profiling of NMCs shows that the set of genes whose expression is maintained by BRD4-NUT is highly enriched for MYC upregulated genes, and MYC and BRD4-NUT protein expression is strongly correlated in primary NMCs. More directly, we find that BRD4-NUT associates with the MYC promoter and is required to maintain MYC expression in NMC cell lines. Moreover, both siRNA knockdown of MYC and a dominant-negative form of MYC, omomyc, induce differentiation of NMC cells. Conversely, differentiation of NMC cells induced by knockdown of BRD4-NUT is abrogated by enforced expression of MYC. Together, these findings suggest that MYC is a downstream target of BRD4-NUT that is required for maintenance of NMC cells in an undifferentiated, proliferative state. Our findings support a model in which dysregulation of MYC by BRD-NUT fusion proteins has a central role in the pathogenesis of NMC.	[Grayson, A. R.; Walsh, E. M.; Cameron, M. J.; Ashworth, T.; Ambrose, J. M.; Aserlind, A. B.; Wang, H.; Kluk, M. J.; Aster, J. C.; French, C. A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Grayson, A. R.; Walsh, E. M.; Cameron, M. J.; Ashworth, T.; Ambrose, J. M.; Aserlind, A. B.; Wang, H.; Kluk, M. J.; Bradner, J. E.; Aster, J. C.; French, C. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Godec, J.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA; [Godec, J.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Evan, G. I.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Bradner, J. E.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Cambridge; Harvard University; Dana-Farber Cancer Institute	French, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	cfrench@partners.org			Samuel Waxman Cancer Research Foundation; US National Institutes of Health [1R01CA124633]; Adolescent and Young Adult Gap Fund; American Association for Cancer Research [10-20-03-FREN]; NATIONAL CANCER INSTITUTE [R01CA124633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER	Samuel Waxman Cancer Research Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Adolescent and Young Adult Gap Fund; American Association for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Samuel Waxman Cancer Research Foundation (CAF and JEB), the US National Institutes of Health grant 1R01CA124633 (CAF), the Adolescent and Young Adult Gap Fund (CAF and JEB), and the American Association for Cancer Research grant 10-20-03-FREN. We would like to thank Dr Nicholas Haining for assistance with GSEA. Many thanks to Dr Paola Dal Cin for providing fluorescent in situ hybridization probes, and to Mr Dan Shea for his assistance with fluorescent in situ hybridization photomicrographs. High-throughput siRNA assays were performed at the Institute of Chemistry and Cell Biology, Longwood Campus (ICCB-L, http://iccb.med.harvard.edu/).	AbouElella A, 1996, MODERN PATHOL, V9, P95; Acosta JC, 2008, MOL CELL BIOL, V28, P7286, DOI 10.1128/MCB.00752-08; Akervall J, 2003, CLIN CANCER RES, V9, P1750; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; FIELD JK, 1989, ONCOGENE, V4, P1463; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flores I, 2004, ONCOGENE, V23, P5923, DOI 10.1038/sj.onc.1207796; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2003, CANCER RES, V63, P304; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gomez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Kluk MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033813; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Lin YJ, 2008, PROTEIN SCI, V17, P2174, DOI 10.1110/ps.037580.108; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mossafa H, 2006, LEUKEMIA LYMPHOMA, V47, P1885, DOI 10.1080/10428190600687547; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Senapedis WT, 2011, MOL BIOL CELL, V22, P1791, DOI 10.1091/mbc.E10-10-0854; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Varlakhanova NV, 2010, DIFFERENTIATION, V80, P9, DOI 10.1016/j.diff.2010.05.001; Varlakhanova NV, 2009, CANCER RES, V69, P7487, DOI 10.1158/0008-5472.CAN-08-4832; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; YOUNG J, 1994, ONCOGENE, V9, P1053; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	45	113	116	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1736	1742		10.1038/onc.2013.126	http://dx.doi.org/10.1038/onc.2013.126			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604113	Green Accepted			2022-12-17	WOS:000334344700013
J	Yan, W; Liu, S; Xu, E; Zhang, J; Zhang, Y; Chen, X; Chen, X				Yan, W.; Liu, S.; Xu, E.; Zhang, J.; Zhang, Y.; Chen, X.; Chen, X.			Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8	ONCOGENE			English	Article						p53; mutant p53; HDAC8; HDAC inhibitor; HoxA5; transcription	CLINICAL-IMPLICATIONS; HDAC INHIBITORS; CANCER; EXPRESSION; APOPTOSIS; ACTIVATION; CELLS; GENE; IDENTIFICATION; ACETYLATION	Mutation of the p53 gene is the most common genetic alteration in human cancer and contributes to malignant process by enhancing transformed properties of cells and resistance to anticancer therapy. Mutant p53 is often highly expressed in tumor cells at least, in part, due to its increased half-life. However, whether mutant p53 expression is regulated by other mechanisms in tumors is unclear. Here we found that histone deacetylase (HDAC) inhibitors suppress both wild-type and mutant p53 transcription in time- and dose-dependent manners. Consistent with this, the levels of wild-type and mutant p53 proteins are decreased upon treatment with HDAC inhibitors. Importantly, we found that upon knockdown of each class I HDAC, only HDAC8 knockdown leads to decreased expression of wild-type and mutant p53 proteins and transcripts. Conversely, we found that ectopic expression of wild-type, but not mutant HDAC8, leads to increased transcription of p53. Furthermore, we found that knockdown of HDAC8 results in reduced expression of HoxA5 and consequently, attenuated ability of HoxA5 to activate p53 transcription, which can be rescued by ectopic expression of HoxA5. Because of the fact that HDAC8 is required for expression of both wild-type and mutant p53, we found that targeted disruption of HDAC8 expression remarkably triggers proliferative defect in cells with a mutant but not wild-type, p53. Together, our data uncover a regulatory mechanism of mutant p53 transcription via HDAC8 and suggest that HDAC inhibitors and especially HDAC8-targeting agents might be explored as an adjuvant for tumors carrying a mutant p53. Oncogene (2013) 32, 599-609; doi:10.1038/onc.2012.81; published online 5 March 2012	[Yan, W.; Liu, S.; Xu, E.; Zhang, J.; Zhang, Y.; Chen, X.; Chen, X.] Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA	University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Comparat Oncol Lab, Davis, CA 95616 USA.	xbchen@ucdavis.edu	qiao, zhixin/I-3408-2012; liu, shou/C-5406-2015	Zhang, Yi/0000-0002-2789-0811	National Institutes of Health [R01 CA121137]; NATIONAL CANCER INSTITUTE [R01CA076069, R01CA121137] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by National Institutes of Health Grant R01 CA121137. We thank S Townson (Merck Pharmaceuticals) for SAHA.	Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9; Bertrand P, 2010, EUR J MED CHEM, V45, P2095, DOI 10.1016/j.ejmech.2010.02.030; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chen HX, 2005, J BIOL CHEM, V280, P19373, DOI 10.1074/jbc.M413528200; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; Dong GE, 2010, AM J PHYSIOL-RENAL, V298, pF293, DOI 10.1152/ajprenal.00410.2009; Dowling DP, 2008, BIOCHEMISTRY-US, V47, P13554, DOI 10.1021/bi801610c; Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111; Glaser KB, 2003, MOL CANCER THER, V2, P151; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022; Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kirschbaum M, 2011, J CLIN ONCOL, V29, P1198, DOI 10.1200/JCO.2010.32.1398; KrennHrubec K, 2007, BIOORG MED CHEM LETT, V17, P2874, DOI 10.1016/j.bmcl.2007.02.064; Lee H, 2004, MOL CELL BIOL, V24, P765, DOI 10.1128/MCB.24.2.765-773.2004; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185; McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Noureen N, 2010, CANCER CHEMOTH PHARM, V66, P625, DOI 10.1007/s00280-010-1324-y; Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Peart MJ, 2003, CANCER RES, V63, P4460; Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sasakawa Y, 2005, BIOCHEM PHARMACOL, V69, P603, DOI 10.1016/j.bcp.2004.11.008; Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179; Somoza JR, 2004, STRUCTURE, V12, P1325, DOI 10.1016/j.str.2004.04.012; Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Yan WS, 2009, J BIOL CHEM, V284, P12178, DOI 10.1074/jbc.M900994200; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001	54	113	119	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					599	609		10.1038/onc.2012.81	http://dx.doi.org/10.1038/onc.2012.81			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22391568	Green Accepted			2022-12-17	WOS:000316164700007
J	Kalvik, TV; Arnesen, T				Kalvik, T. V.; Arnesen, T.			Protein N-terminal acetyltransferases in cancer	ONCOGENE			English	Review						N-terminal acetylation; NAT; Naa10p; oncoprotein; tumor suppressor	ARF-LIKE GTPASE; SACCHAROMYCES-CEREVISIAE; ALPHA-ACETYLATION; IDENTIFICATION; EXPRESSION; HYPOXIA; YEAST; COMPLEX; HARD1; REQUIRES	The human N-terminal acetyltransferases (NATs) catalyze the transfer of acetyl moieties to the N-termini of 80-90% of all human proteins. Six NAT types are present in humans, NatA-NatF, each is composed of specific subunits and each acetylates a set of substrates defined by the N-terminal amino-acid sequence. NATs have been suggested to act as oncoproteins as well as tumor suppressors in human cancers, and NAT expression may be both elevated and decreased in cancer versus non-cancer tissues. Manipulation of NATs in cancer cells induced cell-cycle arrest, apoptosis or autophagy, implying that these enzymes target a variety of pathways. Of particular interest is hNaa10p (human ARD1), the catalytic subunit of the NatA complex, which was coupled to a number of signaling molecules including hypoxia inducible factor-1 alpha, beta-catenin/cyclin D1, TSC2/mammalian target of rapamycin, myosin light chain kinase, DNA methyltransferase1/E-cadherin and p21-activated kinase-interacting exchange factors (PIX)/Cdc42/Rac1. The variety of mechanistic links where hNaa10p acts as a NAT, a lysine acetyltransferase or displaying a non-catalytic role, provide insights to how hNaa10p may act as both a tumor suppressor and oncoprotein. Oncogene (2013) 32, 269-276; doi:10.1038/onc.2012.82; published online 5 March 2012	[Kalvik, T. V.; Arnesen, T.] Univ Bergen, Dept Mol Biol, N-5020 Bergen, Hordaland, Norway; [Arnesen, T.] Haukeland Hosp, Dept Surg, N-5021 Bergen, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Arnesen, T (corresponding author), Univ Bergen, Dept Mol Biol, N-5020 Bergen, Hordaland, Norway.	Thomas.Arnesen@mbi.uib.no	Arnesen, Thomas/J-7139-2017; Arnesen, Thomas/Q-8117-2019	Arnesen, Thomas/0000-0002-3005-147X; Arnesen, Thomas/0000-0002-3005-147X				Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; Ametzazurra A, 2008, ONCOGENE, V27, P7296, DOI 10.1038/onc.2008.332; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Arnesen T, 2006, ONCOGENE, V25, P4350, DOI 10.1038/sj.onc.1209469; Arnesen T, 2006, GENE, V371, P291, DOI 10.1016/j.gene.2005.12.008; Arnesen T, 2005, THYROID, V15, P1131, DOI 10.1089/thy.2005.15.1131; Arnesen T, 2005, BIOCHEM J, V386, P433, DOI 10.1042/BJ20041071; Arnesen T, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001074; Arnesen T, 2010, MOL CELL BIOL, V30, P1898, DOI 10.1128/MCB.01199-09; Arnesen T, 2009, P NATL ACAD SCI USA, V106, P8157, DOI 10.1073/pnas.0901931106; Arnesen Thomas, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-13; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Behnia R, 2004, NAT CELL BIOL, V6, P405, DOI 10.1038/ncb1120; Behnia R, 2007, J CELL BIOL, V176, P255, DOI 10.1083/jcb.200607151; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; BROWN JL, 1976, J BIOL CHEM, V251, P1009; Caesar R, 2004, J BIOL CHEM, V279, P38532, DOI 10.1074/jbc.M402939200; Coulton AT, 2010, J CELL SCI, V123, P3235, DOI 10.1242/jcs.069971; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; Evjenth R, 2009, J BIOL CHEM, V284, P31122, DOI 10.1074/jbc.M109.001347; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Fluge O, 2002, ONCOGENE, V21, P5056, DOI 10.1038/sj.onc.1205687; Forte GMA, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001073; Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Gromyko D, 2010, INT J CANCER, V127, P2777, DOI 10.1002/ijc.25275; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Helbig AO, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-685; Helsens K, 2011, J PROTEOME RES, V10, P3578, DOI 10.1021/pr2002325; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; Hofmann I, 2006, J CELL SCI, V119, P1494, DOI 10.1242/jcs.02958; Hole K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024713; Hopfl G, 2004, AM J PHYSIOL-REG I, V286, pR608, DOI 10.1152/ajpregu.00538.2003; Hou FJ, 2007, J CELL BIOL, V177, P587, DOI 10.1083/jcb.200701043; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hua KT, 2011, CANCER CELL, V19, P218, DOI 10.1016/j.ccr.2010.11.010; Huang GL, 2010, WORLD J GASTROENTERO, V16, P2046, DOI 10.3748/wjg.v16.i16.2046; Hwang CS, 2010, SCIENCE, V327, P973, DOI 10.1126/science.1183147; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kuo HP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000590; Lee CF, 2010, J CLIN INVEST, V120, P2920, DOI 10.1172/JCI42275; Lim JH, 2008, CANCER RES, V68, P5177, DOI 10.1158/0008-5472.CAN-07-6234; Lim JH, 2006, CANCER RES, V66, P10677, DOI 10.1158/0008-5472.CAN-06-3171; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Liu Z, 2009, INT J BIOCHEM CELL B, V41, P2528, DOI 10.1016/j.biocel.2009.08.009; Marmorstein R, 2004, METHOD ENZYMOL, V376, P106; Martin DT, 2007, CLIN CANCER RES, V13, P1480, DOI 10.1158/1078-0432.CCR-06-1716; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; Murray-Rust TA, 2006, FEBS LETT, V580, P1911, DOI 10.1016/j.febslet.2006.02.012; Murthi A, 2005, GENETICS, V170, P1553, DOI 10.1534/genetics.105.043620; Pimenta-Marques A, 2008, DEV BIOL, V323, P197, DOI 10.1016/j.ydbio.2008.08.021; Plasman K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.003301; Poellinger L, 2004, CURR OPIN GENET DEV, V14, P81, DOI 10.1016/j.gde.2003.12.006; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Polevoda B, 2003, J MOL BIOL, V325, P595, DOI 10.1016/S0022-2836(02)01269-X; Polevoda B, 1999, EMBO J, V18, P6155, DOI 10.1093/emboj/18.21.6155; Polevoda B, 2008, J CELL BIOCHEM, V103, P492, DOI 10.1002/jcb.21418; Polevoda Bogdan, 2009, BMC Proc, V3 Suppl 6, pS2, DOI 10.1186/1753-6561-3-S6-S2; Ren TT, 2008, CANCER LETT, V264, P83, DOI 10.1016/j.canlet.2008.01.028; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Rope AF, 2011, AM J HUM GENET, V89, P28, DOI 10.1016/j.ajhg.2011.05.017; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott DC, 2011, SCIENCE, V334, P674, DOI 10.1126/science.1209307; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Seo JH, 2010, CANCER RES, V70, P4422, DOI 10.1158/0008-5472.CAN-09-3258; Setty SRG, 2004, NAT CELL BIOL, V6, P414, DOI 10.1038/ncb1121; Shin DH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007451; Song OK, 2003, J BIOL CHEM, V278, P38109, DOI 10.1074/jbc.C300355200; Starheim KK, 2008, BIOCHEM J, V415, P325, DOI 10.1042/BJ20080658; Starheim Kristian K, 2009, BMC Proc, V3 Suppl 6, pS3, DOI 10.1186/1753-6561-3-S6-S3; Starheim KK, 2009, MOL CELL BIOL, V29, P3569, DOI 10.1128/MCB.01909-08; Sugiura N, 2003, J BIOL CHEM, V278, P40113, DOI 10.1074/jbc.M301218200; Van Damme P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002169; Varshavsky A, 2011, PROTEIN SCI, V20, P1298, DOI 10.1002/pro.666; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Williams BC, 2003, CURR BIOL, V13, P2025, DOI 10.1016/j.cub.2003.11.018; Yi CH, 2007, J CELL BIOL, V179, P619, DOI 10.1083/jcb.200708090; Yi CH, 2011, CELL, V146, P607, DOI 10.1016/j.cell.2011.06.050; Yu M, 2009, CANCER INVEST, V27, P978, DOI 10.3109/07357900902769723; Yu M, 2009, ONCOL REP, V21, P909, DOI 10.3892/or_00000303; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028	88	113	119	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					269	276		10.1038/onc.2012.82	http://dx.doi.org/10.1038/onc.2012.82			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391571				2022-12-17	WOS:000314736600001
J	Zhou, AD; Diao, LT; Xu, H; Xiao, ZD; Li, JH; Zhou, H; Qu, LH				Zhou, A-D; Diao, L-T; Xu, H.; Xiao, Z-D; Li, J-H; Zhou, H.; Qu, L-H			beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway	ONCOGENE			English	Article						miR-372&373; Wnt/beta-catenin; LEF1; DKK1; feedback loop	EMBRYONIC STEM-CELLS; COLORECTAL-CANCER; BETA-CATENIN; EPIGENETIC INACTIVATION; NEGATIVE REGULATOR; COLON-CANCER; C-MYC; GENE; MICRORNAS; TARGET	The microRNA-371-373 (miR-371-373) cluster is specifically expressed in human embryonic stem cells (ESCs) and is thought to be involved in stem cell maintenance. Recently, microRNAs (miRNAs) of this cluster were shown to be frequently upregulated in several human tumors. However, the regulatory mechanism for the involvement of the miR-371-373 cluster in human ESCs or cancer cells remains unclear. In this study, we explored the relationship between this miRNA cluster and the Wnt/beta-catenin-signaling pathway, which has been shown to be involved in both stem cell maintenance and tumorigenesis. We show that miR-371-373 expression is induced by lithium chloride and is positively correlated with Wnt/beta-catenin-signaling activity in several human cancer cell lines. Mechanistically, three TCF/LEF1-binding elements (TBEs) were identified in the promoter region and shown to be required for Wnt-dependent activation of miR-371-373. Interestingly, we also found that miR-372&373, in turn, activate Wnt/beta-catenin signaling. In addition, four protein genes related to the Wnt/beta-catenin-signaling pathway were identified as direct targets of miR-372&373, including Dickkopf-1 (DKK1), a well-known inhibitor of Wnt/beta-catenin signaling. Using a lentiviral system, we showed that overexpression of miR-372 or miR-373 promotes cell growth and the invasive activity of tumor cells as knockdown of DKK1. Taken together, our study demonstrates a novel beta-catenin/LEF1-miR-372&373-DKK1 regulatory feedback loop, which may have a critical role in regulating the activity of Wnt/beta-catenin signaling in human cancer cells.	[Zhou, A-D; Diao, L-T; Xu, H.; Xiao, Z-D; Li, J-H; Zhou, H.; Qu, L-H] Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn, Minist Educ, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Qu, LH (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Key Lab Gene Engn, Minist Educ, 135 Xingangxi Rd, Guangzhou 510275, Guangdong, Peoples R China.	lssqlh@mail.sysu.edu.cn	Li, Junhao/AAI-2570-2019	Li, Junhao/0000-0001-6784-3780; Zhou, Hui/0000-0001-9157-3792; Zhou, Aidong/0000-0001-8389-9522; Xu, Hui/0000-0003-3424-1219	National Natural Science Foundation of China [30830066, 81070589, 30870530]; Ministry of Science and Technology of China [2011CB811300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Professor Mitsuyasu Kato at the University of Tsukuba for providing the pCAGGS-HA-LEF1 plasmid and Professor Mengfeng Li at the Second Affiliated Hospital of Sun Yat-Sen University for providing the Topflash/Fopflash plasmids. This work was supported by grants from the National Natural Science Foundation of China (30830066, 81070589 and 30870530) and the National Basic Research Program from the Ministry of Science and Technology of China (2011CB811300).	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Avvisato CL, 2007, J CELL SCI, V120, P2672, DOI 10.1242/jcs.03476; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005-0034; Eulalio A, 2008, CELL, V132, P9, DOI 10.1016/j.cell.2007.12.024; Falk S, 2008, CELL STEM CELL, V2, P472, DOI 10.1016/j.stem.2008.03.006; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirata H, 2011, INT J CANCER, V128, P1793, DOI 10.1002/ijc.25507; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Judson RL, 2009, NAT BIOTECHNOL, V27, P459, DOI 10.1038/nbt.1535; Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137; Kennell JA, 2008, P NATL ACAD SCI USA, V105, P15417, DOI 10.1073/pnas.0807763105; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Lluis F, 2008, CELL STEM CELL, V3, P493, DOI 10.1016/j.stem.2008.08.017; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Palmer RD, 2010, CANCER RES, V70, P2911, DOI 10.1158/0008-5472.CAN-09-3301; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Silver SJ, 2007, P NATL ACAD SCI USA, V104, P18151, DOI 10.1073/pnas.0706673104; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Xu H, 2010, HEPATOLOGY, V52, P1431, DOI 10.1002/hep.23818	39	113	124	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2968	2978		10.1038/onc.2011.461	http://dx.doi.org/10.1038/onc.2011.461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22020335				2022-12-17	WOS:000305388400006
J	Chao, A; Lin, CY; Lee, YS; Tsai, CL; Wei, PC; Hsueh, S; Wu, TI; Tsai, CN; Wang, CJ; Chao, AS; Wang, TH; Lai, CH				Chao, A.; Lin, C-Y; Lee, Y-S; Tsai, C-L; Wei, P-C; Hsueh, S.; Wu, T-I; Tsai, C-N; Wang, C-J; Chao, A-S; Wang, T-H; Lai, C-H			Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2	ONCOGENE			English	Article						microRNA; miR-187; Dab2; epithelial-mesenchymal transition (EMT)	MESENCHYMAL TRANSITION; STEM-CELLS; EXPRESSION; CARCINOMA; EMT; GENE; OVEREXPRESSION; RESISTANCE; SIGNATURES; PROGNOSIS	MicroRNAs (miRNAs) play important roles in tumorigenesis by regulating oncogenes and tumor-suppressor genes. In this study, miR-187 and miR-200a were found to be expressed at higher levels in ovarian cancers than in benign tumors. In patients with ovarian cancer, however, higher levels of miR-187 and miR-200a expression were paradoxically associated with better OS and recurrence-free survival. Further, multivariate analysis showed that miR-187 served as an independent prognostic factor for patients with ovarian cancer (n = 176). Computational prediction and microarray results indicated that miR-187 directly targeted Disabled homolog-2 (Dab2), and luciferase reporter assays confirmed that the target site of miR-187 was located at the 3'-UTR of the Dab2 gene. Generally considered as a tumor-suppressor gene, Dab2 may actually promote tumor progression in advanced cancers through epithelial-to-mesenchymal transition (EMT). Ectopic expression of miR-187 in cancer cells promoted cell proliferation, but continued overexpression of miR-187 suppressed Dab2 and inhibited migration. Suppression of miR-187 upregulated Dab2, which, by inhibiting E-cadherin levels while stimulating vimentin and phospho-FAK levels, promoted EMT. Reduced ovarian cancer Dab2 histoscores correlated with high miR-187 levels and improved outcomes of patients. Collectively, these results demonstrate distinct dual roles of Dab2 in cell proliferation and tumor progression. In the initial steps of tumorigenesis, upregulated miR-187 suppresses Dab2, promoting cell proliferation. During the later stages, however, continued increased levels of miR-187 inhibits the Dab2-dependent EMT that is associated with tumor invasiveness, which is presumed to be the reason why cancers with high miR-187 levels were associated with better survivals. Oncogene (2012) 31, 764-775; doi:10.1038/onc.2011.269; published online 4 July 2011	[Chao, A.; Lin, C-Y; Tsai, C-L; Wei, P-C; Wu, T-I; Wang, C-J; Chao, A-S; Wang, T-H; Lai, C-H] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Tao Yuan 333, Taiwan; [Chao, A.; Lin, C-Y; Tsai, C-L; Wei, P-C; Hsueh, S.; Wu, T-I; Wang, C-J; Chao, A-S; Wang, T-H; Lai, C-H] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Lee, Y-S; Wang, T-H] Chang Gung Mem Hosp, Genom Med Res Core Lab, Gwei Shan, Taiwan; [Lee, Y-S] Ming Chuan Univ, Dept Biotechnol, Tao Yuan, Taiwan; [Wei, P-C; Wang, T-H] Chang Gung Univ, Grad Inst Biomed Sci, Gwei Shan, Taiwan; [Hsueh, S.] Chang Gung Mem Hosp, Dept Clin Pathol, Tao Yuan 333, Taiwan; [Tsai, C-N] Chang Gung Univ, Grad Inst Clin Med Sci, Gwei Shan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Ming Chuan University; Chang Gung Memorial Hospital	Wang, TH (corresponding author), Chang Gung Mem Hosp, Dept Obstet & Gynecol, 5 Fu Hsing St, Tao Yuan 333, Taiwan.	knoxtn@cgmh.org.tw; sh46erry@ms6.hinet.net	Lai, Chyong-Huey/AAE-5731-2022; Tsai, Chi-Neu/AAZ-2558-2020; Tsai, Chi neu/C-3373-2011	Tsai, Chi-Neu/0000-0002-5940-0696; Tsai, Chi neu/0000-0002-5940-0696; Lai, Chyong-Huey/0000-0002-9977-9645	National Science Council [NSC99-2314-B-182A-087-MY3]; National Research Program for Genomic Medicine [NSC97-3112-B-001-020]; Chang Gung Medical Foundation [CMRPG360953/4, 391451, 95-1364B, 97-1444C, 99-2072C, 99-2411C]; Department of Health [DOH99-TD-B-111-005, DOH99-TD-C-111-006]	National Science Council(Ministry of Science and Technology, Taiwan); National Research Program for Genomic Medicine(Ministry of Science and Technology, Taiwan); Chang Gung Medical Foundation; Department of Health	We thank Ching-Ling Wang, Jung-Erh Yang and Ying-Yu Lin for technical assistance; the Division of Gynecologic Oncology of Chang Gung Memorial Hospital for clinical data retrieval; Shih-Yee Mimi Wang (University of Illinois College of Medicine, Rockford) for language editing and Professor Ching-Ping Tseng (Chang Gung University) for discussion and advices. This study was supported by grants from the National Science Council (NSC99-2314-B-182A-087-MY3 to AC), the National Research Program for Genomic Medicine (NSC97-3112-B-001-020 to Y-SL), the Chang Gung Medical Foundation (CMRPG360953/4, 391451 to AC; IRB No. 95-1364B, 97-1444C, 99-2072C, 99-2411C) and the Department of Health (DOH99-TD-B-111-005 to C-HL; DOH99-TD-C-111-006 to AC and T-HW).	[Anonymous], 2007, PRED MICRORNA TARG; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Berek JS, 2010, BEREK HACKERS GYNECO, P444; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Chao A, 2006, INT J CANCER, V119, P91, DOI 10.1002/ijc.21813; Chao A, 2010, CANCER LETT, V291, P99, DOI 10.1016/j.canlet.2009.10.005; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Choi JH, 2006, ENDOCR-RELAT CANCER, V13, P641, DOI 10.1677/erc.1.01057; Chung CM, 2005, MOL CARCINOGEN, V43, P165, DOI 10.1002/mc.20098; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; Hu XX, 2009, GYNECOL ONCOL, V114, P457, DOI 10.1016/j.ygyno.2009.05.022; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Lee YS, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp168; Liao CJ, 2011, GYNECOL ONCOL, V120, P135, DOI 10.1016/j.ygyno.2010.10.005; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai MS, 2007, STEM CELLS, V25, P2511, DOI 10.1634/stemcells.2007-0023; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang WL, 2004, CANCER RES, V64, P1534, DOI 10.1158/0008-5472.CAN-03-2928	40	113	121	3	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					764	775		10.1038/onc.2011.269	http://dx.doi.org/10.1038/onc.2011.269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725366				2022-12-17	WOS:000300222100009
J	Kwak, HJ; Kim, YJ; Chun, KR; Woo, YM; Park, SJ; Jeong, JA; Jo, SH; Kim, TH; Min, HS; Chae, JS; Choi, EJ; Kim, G; Shin, SH; Gwak, HS; Kim, SK; Hong, EK; Lee, GK; Choi, KH; Kim, JH; Yoo, H; Park, JB; Lee, SH				Kwak, H-J; Kim, Y-J; Chun, K-R; Woo, Y. M.; Park, S-J; Jeong, J-A; Jo, S. H.; Kim, T. H.; Min, H. S.; Chae, J. S.; Choi, E-J; Kim, G.; Shin, S-H; Gwak, H-S; Kim, S-K; Hong, E-K; Lee, G-K; Choi, K-H; Kim, J. H.; Yoo, H.; Park, J. B.; Lee, S-H			Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas	ONCOGENE			English	Article						glioma; invasion; hyaluronan; miR-21; spry2; PTEN	INVASION; GLIOBLASTOMA; MICRORNA-21; HYALURONAN; ADHESION; TARGETS; SPROUTY	Gliomas are associated with high mortality because of their exceedingly invasive character. As these tumors acquire their invasiveness from low-grade tumors, it is very important to understand the detailed molecular mechanisms of invasion onset. Recent evidences suggest the significant role of microRNAs in tumor invasion. Thus, we hypothesized that deregulation of microRNAs may be important for the malignant progression of gliomas. We found that the aberrant expression of miR-21 is responsible for glioma invasion by disrupting the negative feedback circuit of Ras/MAPK signaling, which is mediated by Spry2. Upregulation of miR-21 was triggered by tumor microenvironmental factors such as hyaluronan and growth factors in glioma cells lacking functional phosphatase and tensin homolog (PTEN), but not harboring wild-type PTEN. Consistently with these in vitro results, Spry2 protein levels were significantly decreased in 79.7% of invasive WHO grade II-IV human glioma tissues, but not in non-invasive grade I and normal tissues. The Spry2 protein levels were not correlated with their mRNA levels, but inversely correlated with miR-21 levels. Taken together, these results suggest that the post-transcriptional regulation of Spry2 by miR-21 has an essential role on the malignant progression of human gliomas. Thus, Spry2 may be a novel therapeutic target for treating gliomas. Oncogene (2011) 30, 2433-2442; doi:10.1038/onc.2010.620; published online 31 January 2011	[Kwak, H-J; Kim, Y-J; Chun, K-R; Woo, Y. M.; Park, S-J; Jeong, J-A; Jo, S. H.; Kim, T. H.; Kim, G.; Choi, K-H; Park, J. B.] Natl Canc Ctr, Res Inst Hosp, Specif Organs Canc Branch, Goyang 411769, Gyeonggi, South Korea; [Kim, Y-J] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; [Min, H. S.; Hong, E-K; Lee, G-K] Natl Canc Ctr, Res Inst Hosp, Dept Pathol, Goyang 411769, Gyeonggi, South Korea; [Chae, J. S.; Choi, E-J] Korea Univ, Sch Life Sci & Biotechnol, Lab Cell Death & Human Dis, Seoul, South Korea; [Shin, S-H; Gwak, H-S; Yoo, H.; Lee, S-H] Natl Canc Ctr, Res Inst Hosp, Neurooncol Clin, Goyang 411769, Gyeonggi, South Korea; [Kim, S-K] Seoul Natl Univ, Coll Med, Seoul Natl Univ Childrens Hosp, Div Pediat Neurosurg, Seoul, South Korea; [Kim, J. H.] Natl Canc Ctr, Res Inst Hosp, Carcinogenesis Branch, Goyang 411769, Gyeonggi, South Korea	National Cancer Center - Korea (NCC); Korea Advanced Institute of Science & Technology (KAIST); National Cancer Center - Korea (NCC); Korea University; National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University Hospital; National Cancer Center - Korea (NCC)	Park, JB (corresponding author), Natl Canc Ctr, Res Inst Hosp, Specif Organs Canc Branch, 323 Ilsan Ro, Goyang 411769, Gyeonggi, South Korea.	jbp@ncc.re.kr; nslsh@ncc.re.kr	Kim, Seung-Ki/J-2742-2012; Choi, Kyungho/J-5685-2012	Choi, Kyungho/0000-0003-1635-173X	National Cancer Center [1010171, 1010172, 1110120, 1110110]; National Research Foundation [2010-0016811, 2010-0016704]	National Cancer Center; National Research Foundation	This work was supported by the National Cancer Center Grants (1010171, 1010172, and 1110120) and the National Research Foundation Grant (2010-0016811). JHK was supported by the National Cancer Center Grant (1110110) and the National Research Foundation Grant (2010-0016704).	Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934; Kim MS, 2008, MOL CANCER RES, V6, P1657, DOI 10.1158/1541-7786.MCR-08-0034; Kim MS, 2005, INT J ONCOL, V27, P839; Kim VN, 2006, TRENDS GENET, V22, P165, DOI 10.1016/j.tig.2006.01.003; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; MERZAK A, 1994, CANCER RES, V54, P3988; Negrini M, 2009, CURR OPIN CELL BIOL, V21, P470, DOI 10.1016/j.ceb.2009.03.002; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Park MJ, 2002, CANCER RES, V62, P6318; Roversi G, 2006, ONCOGENE, V25, P1571, DOI 10.1038/sj.onc.1209177; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; Shaw AT, 2007, GENE DEV, V21, P694, DOI 10.1101/gad.1526207; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391	24	113	118	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2433	2442		10.1038/onc.2010.620	http://dx.doi.org/10.1038/onc.2010.620			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21278789				2022-12-17	WOS:000291008000005
J	Shimizu, T; Ishikawa, T; Sugihara, E; Kuninaka, S; Miyamoto, T; Mabuchi, Y; Matsuzaki, Y; Tsunoda, T; Miya, F; Morioka, H; Nakayama, R; Kobayashi, E; Toyama, Y; Kawai, A; Ichikawa, H; Hasegawa, T; Okada, S; Ito, T; Ikeda, Y; Suda, T; Saya, H				Shimizu, T.; Ishikawa, T.; Sugihara, E.; Kuninaka, S.; Miyamoto, T.; Mabuchi, Y.; Matsuzaki, Y.; Tsunoda, T.; Miya, F.; Morioka, H.; Nakayama, R.; Kobayashi, E.; Toyama, Y.; Kawai, A.; Ichikawa, H.; Hasegawa, T.; Okada, S.; Ito, T.; Ikeda, Y.; Suda, T.; Saya, H.			c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis	ONCOGENE			English	Article						osteosarcoma; differentiation; animal model; PPAR gamma	MESENCHYMAL STEM-CELLS; TRANSCRIPTIONAL REGULATION; OSTEOBLAST LINEAGE; EXPRESSION; DIFFERENTIATION; PROTEIN; CANCER; GENE; MICE; PATHOGENESIS	The development of cancer is due to the growth and proliferation of transformed normal cells. Recent evidence suggests that the nature of oncogenic stress and the state of the cell of origin critically affect both tumorigenic activity and tumor histological type. However, this mechanistic relationship in mesenchymal tumors is currently largely unexplored. To clarify these issues, we established a mouse osteosarcoma (OS) model through overexpression of c-MYC in bone marrow stromal cells (BMSCs) derived from Ink4a/Arf (-/-) mice. Single-cell cloning revealed that c-MYC-expressing BMSCs are composed of two distinctly different clones: highly tumorigenic cells, similar to bipotent-committed osteo-chondral progenitor cells, and low-tumorigenic tripotent cells, similar to mesenchymal stem cells (MSCs). It is noteworthy that both bipotent and tripotent cells were capable of generating histologically similar, lethal OS, suggesting that both committed progenitor cells and MSCs can become OS cells of origin. Shifting mesenchymal differentiation by depleting PPAR gamma in tripotent MSC-like cells and overexpressing PPAR gamma in bipotent cells affected cell proliferation and tumorigenic activity. Our findings indicate that differentiation potential has a key role in OS tumorigenic activity, and that the suppression of adipogenic ability is a critical factor for the development of OS. Oncogene (2010) 29, 5687-5699; doi:10.1038/onc.2010.312; published online 2 August 2010	[Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo 1608582, Japan; [Shimizu, T.; Sugihara, E.; Saya, H.] Japan Sci & Technol Agcy, CREST, Tokyo, Japan; [Ishikawa, T.] Daiichi Sankyo Co Ltd, Kasai R& Ctr, Tokyo, Japan; [Miyamoto, T.; Morioka, H.; Nakayama, R.; Kobayashi, E.; Toyama, Y.] Keio Univ, Dept Orthoped Surg, Tokyo 1608582, Japan; [Miyamoto, T.] Japan Sci & Technol Agcy, Saitama, Japan; [Mabuchi, Y.; Matsuzaki, Y.] Keio Univ, Dept Physiol, Tokyo 1608582, Japan; [Tsunoda, T.; Miya, F.] RIKEN, Ctr Genom Med, Yokohama, Kanagawa, Japan; [Kawai, A.] Natl Canc Ctr, Orthoped Div, Tokyo, Japan; [Ichikawa, H.] Natl Canc Ctr, Res Inst, Canc Transcriptome Project, Tokyo 104, Japan; [Hasegawa, T.] Sapporo Med Univ, Sch Med, Dept Surg Pathol, Sapporo, Hokkaido, Japan; [Okada, S.] Kumamoto Univ, Grad Sch Med Sci, Ctr AIDS Res, Div Hemopoiesis, Kumamoto, Japan; [Ito, T.] Kumamoto Univ, Grad Sch Med Sci, Dept Pathol & Expt Med, Kumamoto, Japan; [Ikeda, Y.] Keio Univ, Dept Internal Med, Tokyo 1608582, Japan; [Suda, T.] Keio Univ, Sakaguchi Lab, Dept Cell Differentiat, Tokyo 1608582, Japan	Keio University; Japan Science & Technology Agency (JST); Daiichi Sankyo Company Limited; Keio University; Japan Science & Technology Agency (JST); Keio University; RIKEN; National Cancer Center - Japan; National Cancer Center - Japan; Sapporo Medical University; Kumamoto University; Kumamoto University; Keio University; Keio University	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Okada, Seiji/F-5785-2013; Toyama, Yoshiaki/K-5743-2013; Tsunoda, Tatsuhiko/K-2061-2014; Mabuchi, Yo/L-1535-2013; Saya, Hideyuki/J-4325-2013; Kuninaka, Shinji/J-7158-2013; Suda, Toshio/H-6761-2013; Sugihara, Eiji/J-8058-2013	Tsunoda, Tatsuhiko/0000-0002-5439-7918; Mabuchi, Yo/0000-0001-8008-3966; Suda, Toshio/0000-0001-7540-1771; Saya, Hideyuki/0000-0001-6610-1902; Miya, Fuyuki/0000-0001-6758-2015; Sugihara, Eiji/0000-0002-3233-1045	Ministry of Education, Science, Sports, and Culture of Japan; National Institute of Biomedical Innovation, Japan	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); National Institute of Biomedical Innovation, Japan(National Institute of Biomedical Innovation)	We are grateful to I Ishimatsu and N Suzuki for technical assistance. We thank K Arai for secretarial assistance. This work was partly supported by grants from the Ministry of Education, Science, Sports, and Culture of Japan (TS and HS) and a grant from the National Institute of Biomedical Innovation, Japan (HS).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; BARRIOS C, 1994, AM J CLIN ONCOL-CANC, V17, P273, DOI 10.1097/00000421-199406000-00019; Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Corless CL, 2004, J CLIN ONCOL, V22, P3813, DOI 10.1200/JCO.2004.05.140; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585-006-9046-6; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712; Fletcher C.D.M, 2002, OSTEOGENIC TUMOURS W; Fujino RS, 2006, MOL ENDOCRINOL, V20, P904, DOI 10.1210/me.2005-0423; Gamberi G, 1998, ONCOLOGY-BASEL, V55, P556, DOI 10.1159/000011912; Gregory CA, 2005, EXP CELL RES, V306, P330, DOI 10.1016/j.yexcr.2005.03.018; Haydon RC, 2002, CLIN CANCER RES, V8, P1288; Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Li H, 2008, DEV BIOL, V316, P458, DOI 10.1016/j.ydbio.2008.01.001; Li N, 2009, CANCER-AM CANCER SOC, V115, P4795, DOI 10.1002/cncr.24519; Lopez-Guerrero JA, 2004, DIAGN MOL PATHOL, V13, P81; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Mandal D, 2007, GENE, V386, P131, DOI 10.1016/j.gene.2006.08.030; Miller SFC, 2007, GENE EXPR PATTERNS, V7, P635, DOI 10.1016/j.modgep.2006.12.002; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Parker LH, 2004, NATURE, V428, P754, DOI 10.1038/nature02416; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; PONTEN J, 1967, INT J CANCER, V2, P434, DOI 10.1002/ijc.2910020505; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Riggi N, 2006, CANCER RES, V66, P7016, DOI 10.1158/0008-5472.CAN-05-3979; Rosen ED, 2000, GENE DEV, V14, P1293; Shibata KR, 2007, STEM CELLS, V25, P2371, DOI 10.1634/stemcells.2007-0225; Thomas G, 2003, J BIOL CHEM, V278, P50563, DOI 10.1074/jbc.M307310200; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Zang X, 2007, P NATL ACAD SCI USA, V104, P19458, DOI 10.1073/pnas.0709802104	50	113	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5687	5699		10.1038/onc.2010.312	http://dx.doi.org/10.1038/onc.2010.312			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676132				2022-12-17	WOS:000283262500005
J	Xiong, J; Du, Q; Liang, Z				Xiong, J.; Du, Q.; Liang, Z.			Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein	ONCOGENE			English	Article						microRNA; c-Myc binding protein; MYCBP; miR-22; cancer; cell growth	CELL-PROLIFERATION; AMY-1; IDENTIFICATION; EXPRESSION; REPRESSION; S-AKAP84; SUBUNIT; NETWORK; COMPLEX; KINASE	Oncogenic c-Myc has been described to modulate the expression of a subset of microRNAs (miRNAs), which include miR-22; however, the mechanism through which a miRNA controls c-Myc activity remains unclear. Here we report a novel anti-c-Myc function mediated by miR-22. Ectopically expressed miR-22 inhibited cell proliferation and anchorage-independent growth of human cancer cell lines. Microarray screening and western analyses revealed that miR-22 repressed the c-Myc-binding protein MYCBP, a positive regulator of c-Myc. Consistent with this, reporter assays showed that miR-22-mediated MYCBP gene suppression largely depends on the conserved miR-22 target site within the MYCBP 3'-untranslational region (3'UTR), implying that MYCBP mRNA is a direct miR-22 target. Depletion of MYCBP using small interfering RNA (siRNA) recapitulated the miR-22-induced anti-growth effect on tumor cells, whereas ectopically expressed MYCBP rescued cells from the growth suppression mediated by miR-22. Moreover, repression of MYCBP by miR-22 downregulated a panel of E-box-containing c-Myc target genes. Our results suggest that miR-22 acts as a tumor suppressor through direct repression of MYCBP expression and subsequent reduction of oncogenic c-Myc activities. As c-Myc inhibits the expression of miR-22, we propose a novel positive feedback loop formed by oncogenic c-Myc to accelerate cell proliferation by suppressing miR-22, a potent inhibitor of MYCBP. Oncogene (2010) 29, 4980-4988; doi: 10.1038/onc.2010.241; published online 21 June 2010	[Liang, Z.] Peking Univ, Inst Mol Med, Lab Nucle Acid Technol, Beijing 100871, Peoples R China	Peking University	Liang, Z (corresponding author), Peking Univ, Inst Mol Med, Lab Nucle Acid Technol, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.	liangz@pku.edu.cn	Liang, Zicai/A-2646-2013; Xiong, Jianhua/D-6099-2015	Xiong, Jianhua/0000-0002-2740-4027	National High-tech R&D Program of China [2007AA02Z165, 2008DFA30770]; National Basic Research Program of China [2007CB512100]; National Natural Science Foundation of China [30873187, 30771085, 30871385]; Department of Education of China [20070001011, 200800010019]	National High-tech R&D Program of China(National High Technology Research and Development Program of China); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Department of Education of China	We thank Tianjing Cai for excellent technical assistance, and Dr Iain C Bruce for critical reading of the paper. This work was supported by the National High-tech R&D Program of China (2007AA02Z165, 2008DFA30770), the National Basic Research Program of China (2007CB512100), the National Natural Science Foundation of China (30873187, 30771085 and 30871385) and by grants from the Department of Education of China (20070001011 and 200800010019).	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dews M, 2006, NAT GENET, V38, P1060, DOI 10.1038/ng1855; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Furusawa M, 2002, J BIOL CHEM, V277, P50885, DOI 10.1074/jbc.M206387200; Furusawa M, 2001, J BIOL CHEM, V276, P36647, DOI 10.1074/jbc.M103885200; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Ishizaki R, 2006, GENES CELLS, V11, P949, DOI 10.1111/j.1365-2443.2006.00991.x; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lei CX, 2009, HUM REPROD, V24, P2879, DOI 10.1093/humrep/dep250; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Neely LA, 2006, NAT METHODS, V3, P41, DOI 10.1038/NMETH825; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Taira T, 1998, GENES CELLS, V3, P549, DOI 10.1046/j.1365-2443.1998.00206.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yukitake H, 2002, J BIOL CHEM, V277, P45480, DOI 10.1074/jbc.M206201200	37	113	118	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	35					4980	4988		10.1038/onc.2010.241	http://dx.doi.org/10.1038/onc.2010.241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562918				2022-12-17	WOS:000281578700012
J	Macurek, L; Lindqvist, A; Voets, O; Kool, J; Vos, HR; Medema, RH				Macurek, L.; Lindqvist, A.; Voets, O.; Kool, J.; Vos, H. R.; Medema, R. H.			Wip1 phosphatase is associated with chromatin and dephosphorylates gamma H2AX to promote checkpoint inhibition	ONCOGENE			English	Article						DNA damage; checkpoint inhibition; phosphatase; cancer	DOUBLE-STRAND BREAKS; DNA-DAMAGE CHECKPOINT; HISTONE H2AX PHOSPHORYLATION; ACTIVATION IN-VIVO; PROTEIN PHOSPHATASE; ATM ACTIVATION; RADIOSENSITIZING AGENT; IONIZING-RADIATION; SIGNALING PATHWAYS; REPAIR PROTEINS	DNA double-stranded breaks (DSBs) elicit a checkpoint response that causes a delay in cell cycle progression. Early in the checkpoint response, histone H2AX is phosphorylated in the chromatin region flanking the DSB by ATM/ATR and DNA-PK kinases. The resulting foci of phosphorylated H2AX (gamma-H2AX) serve as a platform for recruitment and retention of additional components of the checkpoint-signaling cascade that enhance checkpoint signaling and DSB repair. Upon repair, both the assembled protein complexes and the chromatin modifications are removed to quench the checkpoint signal. In this study, we show that the DNA damage-responsive Wip1 phosphatase is bound to chromatin. Moreover, Wip1 directly dephosphorylates gamma-H2AX and cells depleted of Wip1 fail to dephosphorylate gamma-H2AX during checkpoint recovery. Conversely, premature activation of Wip1 leads to displacement of MDC1 from damage foci and prevents activation of the checkpoint. Taken together, our data show that Wip1 has an essential role in dephosphorylation of gamma-H2AX to silence the checkpoint and restore chromatin structure once DNA damage is repaired. Oncogene (2010) 29, 2281-2291; doi: 10.1038/onc.2009.501; published online 25 January 2010	[Macurek, L.; Lindqvist, A.; Voets, O.; Kool, J.; Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3584 CG Utrecht, Netherlands; [Macurek, L.; Lindqvist, A.; Voets, O.; Kool, J.; Vos, H. R.; Medema, R. H.] Univ Med Ctr Utrecht, Canc Genom Ctr, NL-3584 CG Utrecht, Netherlands; [Macurek, L.] Acad Sci Czech Republic, Inst Mol Genet, Dept Genome Integr, Vvi, Prague, Czech Republic; [Vos, H. R.] Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, Univ Sweg 100,Str 2-118, NL-3584 CG Utrecht, Netherlands.	r.h.medema@umcutrecht.nl	Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013; Lindqvist, Arne/B-6792-2008; Macurek, Libor/C-7865-2014	Macurek, Libor/0000-0002-0987-1238; Lindqvist, Arne/0000-0002-0141-1579; Medema, Rene/0000-0002-6754-0381; Vos, Harmjan/0000-0002-4696-6068	Netherlands Genomics Initiative of NWO; Dutch Cancer Society [UU2006-3579]; Grant Agency of the Czech Republic [P305/10/P420]; Wenner-Gren foundation; Netherlands Organization for Scientific Research (NWO) [ZonMw 916.86.083]; Center for Translational Molecular Medicine (CTMM)	Netherlands Genomics Initiative of NWO; Dutch Cancer Society(KWF Kankerbestrijding); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Wenner-Gren foundation; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Center for Translational Molecular Medicine (CTMM)	We are thankful to Dr Lukas for providing MDC-EGFP plasmid, Dr Donehower for Wip1-FLAG, Dr Dansen and P Charitou for providing reagents, Livio Kleij for maintenance of the microscopes and Monica Alvarez for critical reading of the article. RHM and LM were funded by the Netherlands Genomics Initiative of NWO and the Dutch Cancer Society (UU2006-3579), LM by Grant Agency of the Czech Republic (P305/10/P420), AL by the Wenner-Gren foundation and by the Netherlands Organization for Scientific Research (NWO) (ZonMw 916.86.083) and HV by the Center for Translational Molecular Medicine (CTMM).	Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Block WD, 2004, NUCLEIC ACIDS RES, V32, P1967, DOI 10.1093/nar/gkh508; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Chowdhury D, 2008, MOL CELL, V31, P33, DOI 10.1016/j.molcel.2008.05.016; Chuman Y, 2009, J BIOCHEM, V145, P1, DOI 10.1093/jb/mvn135; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; Dinant C, 2007, J CELL SCI, V120, P2731, DOI 10.1242/jcs.004523; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Foster ER, 2005, FEBS J, V272, P3231, DOI 10.1111/j.1742-4658.2005.04741.x; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Heo K, 2008, MOL CELL, V30, P86, DOI 10.1016/j.molcel.2008.02.029; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Keogh MC, 2006, NATURE, V439, P497, DOI 10.1038/nature04384; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lindqvist A, 2007, PLOS BIOL, V5, P1127, DOI 10.1371/journal.pbio.0050123; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Nakada S, 2008, EMBO REP, V9, P1019, DOI 10.1038/embor.2008.162; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Svetlova M, 2007, BIOCHEM BIOPH RES CO, V358, P650, DOI 10.1016/j.bbrc.2007.04.188; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s	59	113	116	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2281	2291		10.1038/onc.2009.501	http://dx.doi.org/10.1038/onc.2009.501			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101220				2022-12-17	WOS:000276685200013
J	Thoennissen, NH; O'Kelly, J; Lu, D; Iwanski, GB; La, DT; Abbassi, S; Leiter, A; Karlan, B; Mehta, R; Koeffler, HP				Thoennissen, N. H.; O'Kelly, J.; Lu, D.; Iwanski, G. B.; La, D. T.; Abbassi, S.; Leiter, A.; Karlan, B.; Mehta, R.; Koeffler, H. P.			Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway	ONCOGENE			English	Article						capsaicin; EGFR/HER-2 pathway; cell-cycle arrest; apoptosis	ACTIVATED PROTEIN-KINASE; RECEPTOR-GAMMA; GROWTH; INDUCTION; RESISTANCE; HER2; PHOSPHORYLATION; DEGRADATION; ANTAGONISTS; INHIBITORS	Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is an ingredient of chili peppers with inhibitory effects against cancer cells of different origin. We examined the activity of capsaicin on breast cancer cells in vitro and in vivo. The drug potently inhibited growth of ER-positive (MCF-7, T47D, BT-474) and ER-negative (SKBR-3, MDA-MB231) breast cancer cell lines, which was associated with G(0)/G(1) cell-cycle arrest, increased levels of apoptosis and reduced protein expression of human epidermal growth factor receptor (EGFR), HER-2, activated extracellular-regulated kinase (ERK) and cyclin D1. In contrast, cell-cycle regulator p27(KIP1), caspase activity as well as poly-ADP ribose polymerase (PARP) cleavage were increased. Notably, capsaicin blocked breast cancer cell migration in vitro and decreased by 50% the size of MDA-MB231 breast cancer tumors growing orthotopically in immunodeficient mice without noticeable drug side effects. in vivo activation of ERK was clearly decreased, as well as expression of HER-2 and cyclin D1, whereas caspase activity and PARP cleavage products were increased in tumors of drug-treated mice. Besides, capsaicin potently inhibited the development of preneoplastic breast lesions by up to 80% without evidence of toxicity. Our data indicate that capsaicin is a novel modulator of the EGFR/HER-2 pathway in both ER-positive and-negative breast cancer cells with a potential role in the treatment and prevention of human breast cancer. Oncogene (2010) 29, 285-296; doi:10.1038/onc.2009.335; published online 26 October 2009	[Thoennissen, N. H.; O'Kelly, J.; Lu, D.; Iwanski, G. B.; La, D. T.; Abbassi, S.; Leiter, A.; Koeffler, H. P.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA; [Karlan, B.] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA; [Mehta, R.] IIT, Res Inst, Div Carcinogenesis & Chemoprevent, Chicago, IL 60616 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Illinois Institute of Technology	Thoennissen, NH (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, 8700 Beverly Blvd,AC 1069, Los Angeles, CA 90048 USA.	Nils.Thoennissen@cshs.org	Abbassi, Sam/AAF-7646-2021		Deutsche Forschungsgemeinschaft, Bonn, Germany [TH 1438/1-1]; Woman Cancer Institute of Cedars-Sinai Medical Center, Los Angeles, CA, USA; Jung-Stiftung fur Wissenschaft und Forschung, Hamburg, Germany	Deutsche Forschungsgemeinschaft, Bonn, Germany(German Research Foundation (DFG)); Woman Cancer Institute of Cedars-Sinai Medical Center, Los Angeles, CA, USA; Jung-Stiftung fur Wissenschaft und Forschung, Hamburg, Germany	NH Thoennissen's work was supported by the Deutsche Forschungsgemeinschaft, Bonn, Germany (TH 1438/1-1); B Karlan by the Woman Cancer Institute of Cedars-Sinai Medical Center, Los Angeles, CA, USA and GB Iwanski by the Jung-Stiftung fur Wissenschaft und Forschung, Hamburg, Germany. HP Koeffler is the holder of the Mark Goodson endowed Chair in Oncology Research and is a member of the Jonsson Cancer and Molecular Biology Institute, UCLA, Los Angeles, CA, USA.	Athanasiou A, 2007, BIOCHEM BIOPH RES CO, V354, P50, DOI 10.1016/j.bbrc.2006.12.179; Carraway KL, 2006, CANCER CELL, V10, P93, DOI 10.1016/j.ccr.2006.07.015; Chen FL, 2008, CLIN CANCER RES, V14, P6730, DOI 10.1158/1078-0432.CCR-08-0581; *COUNC EUR, 2001, 48 M STRASB 2 6 APR; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Fukazawa H, 2002, MOL CANCER THER, V1, P303; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Johnson W, 2007, INT J TOXICOL, V26, P3, DOI 10.1080/10915810601163939; Jung MY, 2001, CANCER LETT, V165, P139, DOI 10.1016/S0304-3835(01)00426-8; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kim CS, 2004, J MED FOOD, V7, P267, DOI 10.1089/jmf.2004.7.267; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lo YC, 2005, WORLD J GASTROENTERO, V11, P6254, DOI 10.3748/wjg.v11.i40.6254; Magkou C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2103; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Mehta RG, 2001, J NATL CANCER I, V93, P1103, DOI 10.1093/jnci/93.14.1103; Menard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MONSEREENUSORN Y, 1982, CRC CR REV TOXICOL, V10, P321, DOI 10.3109/10408448209003371; Montgomery RB, 2005, CANCER RES, V65, P650; Mori A, 2006, CANCER RES, V66, P3222, DOI 10.1158/0008-5472.CAN-05-0087; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; Morris GJ, 2008, J NATL MED ASSOC, V100, P698, DOI 10.1016/S0027-9684(15)31344-4; Rock E, 2003, J NUTR, V133, p3785S, DOI 10.1093/jn/133.11.3785S; Sanchez AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554; Schafer JM, 2002, J STEROID BIOCHEM, V83, P75, DOI 10.1016/S0960-0760(02)00251-0; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Solit DB, 2002, CLIN CANCER RES, V8, P986; TAIKKOO Y, 1999, ANN NY ACAD SCI, V889, P157, DOI DOI 10.1111/J.1749-6632.1999.TB08734.X; Tuoya, 2006, LIFE SCI, V78, P1515, DOI 10.1016/j.lfs.2005.07.019	37	113	125	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					285	296		10.1038/onc.2009.335	http://dx.doi.org/10.1038/onc.2009.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19855437				2022-12-17	WOS:000273650000011
J	Wang, Q; Williamson, M; Bott, S; Brookman-Amissah, N; Freeman, A; Nariculam, J; Hubank, MJF; Ahmed, A; Masters, JR				Wang, Q.; Williamson, M.; Bott, S.; Brookman-Amissah, N.; Freeman, A.; Nariculam, J.; Hubank, M. J. F.; Ahmed, A.; Masters, J. R.			Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer	ONCOGENE			English	Article						cancer; epigenetics; prostate; WNT5A; S100P; CRIP1	TRANSCRIPTION FACTOR AP-2; C-MYB; ABERRANT EXPRESSION; OVARIAN-CARCINOMA; GENE-EXPRESSION; UP-REGULATION; CELL-LINES; ALPHA GENE; V-MYB; METHYLATION	Oligoarray analysis of a matched pair of prostate cancer and normal cell lines derived from the same radical prostatectomy specimen identified 113 candidate hypo-methylated genes that were overexpressed in the cancer cells and contained CpG islands. Hypomethylation of wingless-related MMTV integration site 5A (WNT5A), S100 calcium-binding protein P (S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the cancer cells by bisulfate sequencing. Treatment of the corresponding normal prostate epithelial cells 1542-NPTX with the DNA methyltransferase inhibitor 5-Aza-2 '-deoxycytidine (5-aza-CdR) induced higher levels of mRNA expression and partial loss of methylation on these genes. Primary prostate cancers were tested using methylation-specific polymerase chain reaction. WNT5A was hypomethylated in 11/17 (65%) tumors, S100P in 8/16 (50%) and CRIP1 in 13/20 ( 65%). Bisulfate sequencing of a section of the 50 untranslated region (UTR) of WNT5A revealed that three CpG sites ( 15, 24 and 35) were consistently methylated (93%) in the normal cell line and normal tissues, but not in the prostate cancer cell line and eight primary prostate cancers. Multiple putative binding sites for the transcription factors SP1 and AP-2 were found adjacent to CpG sites 15 and 24. A putative c-Myb binding site was located within the CpG site 35. Anti-c-Myb antibody co-precipitation with WNT5A was methylation- sensitive in 1542-NPTX cells. It is likely that an epigenetic mechanism regulates WNT5A expression in prostate cancer.	UCL, Prostate Canc Res Ctr, Inst Urol & Nephrol, London W1W 7EJ, England; UCL Hosp Trust, Dept Histopathol, London, England; UCL, Gene Microarray Ctr, Inst Child Hlth, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Masters, JR (corresponding author), UCL, Prostate Canc Res Ctr, Inst Urol & Nephrol, 3rd Floor,67 Riding House St, London W1W 7EJ, England.	j.masters@ucl.ac.uk	Hubank, Michael JF/C-1837-2008; Masters, John R/C-5694-2011	Hubank, Michael JF/0000-0002-2901-0742; Williamson, Magali/0000-0002-7183-7495; Ahmed, Aamir/0000-0001-7405-5336	Medical Research Council [G0100116] Funding Source: Medline; MRC [G0100116] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Bright RK, 1997, CANCER RES, V57, P995; Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004; Cho M, 2001, BRIT J CANCER, V85, P563, DOI 10.1054/bjoc.2001.1951; Esteller M, 2001, CANCER RES, V61, P3225; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gibadulinova A, 2005, ONCOL REP, V14, P575; Gupta A, 2003, CANCER RES, V63, P664; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; IOZZO RV, 1995, CANCER RES, V55, P3495; Ishii Y, 2005, BBA-MOL CELL RES, V1745, P156, DOI 10.1016/j.bbamcr.2005.01.005; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KLEMPNAUER KH, 1993, ONCOGENE, V8, P111; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; LEVENSON CW, 1993, P NATL ACAD SCI USA, V90, P712, DOI 10.1073/pnas.90.2.712; Li LC, 2004, BBA-REV CANCER, V1704, P87, DOI 10.1016/j.bbcan.2004.06.001; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mousses S, 2002, CURR OPIN CHEM BIOL, V6, P97, DOI 10.1016/S1367-5931(01)00283-6; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Ogishima T, 2005, CLIN CANCER RES, V11, P1028; Ording E, 1996, ONCOGENE, V13, P1043; Oshimo Y, 2003, INT J ONCOL, V23, P1663; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Sato N, 2003, CANCER RES, V63, P4158; Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	41	113	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	45					6560	6565		10.1038/sj.onc.1210472	http://dx.doi.org/10.1038/sj.onc.1210472			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17486081				2022-12-17	WOS:000249919800009
J	Kim, D; Rath, O; Kolch, W; Cho, KH				Kim, D.; Rath, O.; Kolch, W.; Cho, K-H			A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways	ONCOGENE			English	Article						signaling pathways; crosstalk; positive feed-back loop; Wnt pathway; ERK pathway; colorectal cancer	BETA-CATENIN; SIGNALING PATHWAYS; NEGATIVE FEEDBACK; UP-REGULATION; OKADAIC ACID; EXPRESSION; MUTATIONS; TRANSACTIVATION; OVEREXPRESSION; APOPTOSIS	The Wnt and the extracellular signal regulated-kinase (ERK) pathways are both involved in the pathogenesis of various kinds of cancers. Recently, the existence of crosstalk between Wnt and ERK pathways was reported. Gathering all reported results, we have discovered a positive feedback loop embedded in the crosstalk between the Wnt and ERK pathways. We have developed a plausible model that represents the role of this hidden positive feedback loop in the Wnt/ERK pathway crosstalk based on the integration of experimental reports and employing established basic mathematical models of each pathway. Our analysis shows that the positive feedback loop can generate bistability in both the Wnt and ERK signaling pathways, and this prediction was further validated by experiments. In particular, using the commonly accepted assumption that mutations in signaling proteins contribute to cancerogenesis, we have found two conditions through which mutations could evoke an irreversible response leading to a sustained activation of both pathways. One condition is enhanced production of beta-catenin, the other is a reduction of the velocity of MAP kinase phosphatase(s). This enables that high activities of Wnt and ERK pathways are maintained even without a persistent extracellular signal. Thus, our study adds a novel aspect to the molecular mechanisms of carcinogenesis by showing that mutational changes in individual proteins can cause fundamental functional changes well beyond the pathway they function in by a positive feedback loop embedded in crosstalk. Thus, crosstalk between signaling pathways provides a vehicle through which mutations of individual components can affect properties of the system at a larger scale.	Seoul Natl Univ, Bio MAX Inst, Seoul 151818, South Korea; Seoul Natl Univ, Coll Med, Seoul, South Korea; Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Seoul National University (SNU); Seoul National University (SNU); Beatson Institute; University of Glasgow	Cho, KH (corresponding author), Seoul Natl Univ, Bio MAX Inst, 3rd Floor,IVI,San 4-8,Bongcheon 7 Dong, Seoul 151818, South Korea.	w.kolch@beatson.gla.ac.uk; ckh-sb@snu.ac.kr	Cho, Kwang-Hyun/C-1684-2011; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Rath, Oliver/D-6523-2018	Rath, Oliver/0000-0001-7986-591X; Kolch, Walter/0000-0001-5777-5016				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; Aust DE, 2005, INT J CANCER, V115, P673, DOI 10.1002/ijc.20925; Behrens J, 2005, BIOCHEM SOC T, V33, P672, DOI 10.1042/BST0330672; Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; Cho KH, 2003, LECT NOTES COMPUT SC, V2602, P127; Cho KH, 2006, FEBS LETT, V580, P3665, DOI 10.1016/j.febslet.2006.05.053; Civenni G, 2003, EMBO REP, V4, P166, DOI 10.1038/sj.embor.embor735; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Kim CJ, 2005, WORLD J GASTROENTERO, V11, P5006, DOI 10.3748/wjg.v11.i32.5006; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolch W, 2005, FEBS LETT, V579, P1891, DOI 10.1016/j.febslet.2005.02.002; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kolch Walter, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004386; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Loda M, 1996, AM J PATHOL, V149, P1553; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rottinger E, 2004, DEVELOPMENT, V131, P1075, DOI 10.1242/dev.01000; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; TAKATA K, 2000, BREED RES, V2, P11; Wolkenhauer O, 2005, BIOCHEM SOC T, V33, P507, DOI 10.1042/BST0330507; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601	36	113	120	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4571	4579		10.1038/sj.onc.1210230	http://dx.doi.org/10.1038/sj.onc.1210230			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237813				2022-12-17	WOS:000247836100011
J	Galizia, G; Lieto, E; De Vita, F; Orditura, M; Castellano, P; Troiani, T; Imperatore, V; Ciardiello, F				Galizia, G.; Lieto, E.; De Vita, F.; Orditura, M.; Castellano, P.; Troiani, T.; Imperatore, V.; Ciardiello, F.			Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer	ONCOGENE			English	Review						colorectal cancer; EGFR-targeted therapy; monoclonal antibodies; cetuximab; combination therapies	ANTITUMOR-ACTIVITY; G(1) ARREST; PHASE-I; C225; COMBINATION; EXPRESSION; RADIATION; BLOCKADE; THERAPY; IRINOTECAN	The recent successful development of monoclonal antibodies that target key components of biological pathways has expanded the armamentarium of treatment options for patients with colorectal cancer (CRC). In particular, the epidermal growth factor receptor (EGFR), a tyrosine kinase growth factor receptor involved in CRC development and progression, is exploited by the newest monoclonal antibody that is available for use in CRC patients. Cetuximab, the first chimeric monoclonal antibody, which has been generated against the EGFR, is currently registered in USA, Europe and worldwide, in combination with irinotecan in the treatment of metastatic CRC patients who have progressed on irinotecan containing chemotherapy. Cetuximab is well tolerated and does not exacerbate the toxicity of concomitant chemotherapy. Furthermore, a series of phase III clinical trials are currently evaluating the combination of cetuximab with standard chemotherapy regimens in the first-line treatment chemotherapy-naive patients with metastatic CRC.	Univ Naples 2, Sch Med, Policlin 2,F Magrassi A Lanzara,Dept Clin & Expt, Div Surg,PhD Degree Program Med & Surg Oncol & Cl, I-80131 Naples, Italy; Univ Naples 2, Sch Med, F Magrassi A Lanzara Dept Clin & Expt Med & Surg, Div Med Oncol,PhD Degree Program Med & Surg Oncol, Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Galizia, G (corresponding author), Univ Naples 2, Sch Med, Policlin 2,F Magrassi A Lanzara,Dept Clin & Expt, Div Surg,PhD Degree Program Med & Surg Oncol & Cl, Edificio 17,Via Pansini 5, I-80131 Naples, Italy.	gennaro.galizia@unina2.it	Galizia, Gennaro/A-3924-2010	troiani, teresa/0000-0002-0646-4901; GALIZIA, Gennaro/0000-0002-6897-0391; Ciardiello, Fortunato/0000-0002-3369-4841; ORDITURA, Michele/0000-0001-9105-8563				Abubakr Y, 2006, J CLIN ONCOL, V24, p160S; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; BADARINATH SME, 2004, 2004 AM SOC CLIN ONC; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Bianco C, 2000, CLIN CANCER RES, V6, P4343; Braun AH, 2004, CANCER-AM CANCER SOC, V100, P1558, DOI 10.1002/cncr.20154; Bruns CJ, 2000, CLIN CANCER RES, V6, P1936; Busam KJ, 2001, BRIT J DERMATOL, V144, P1169, DOI 10.1046/j.1365-2133.2001.04226.x; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2002, EXPERT OPIN INV DRUG, V11, P755; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; COHEN RB, 2000, P AM SOC CLIN ONCOL, V19; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; DEBALDO C, 2003, EUR J CANC S, V1; Folprecht G, 2006, ANN ONCOL, V17, P450, DOI 10.1093/annonc/mdj084; Galizia G, 2006, ANN SURG ONCOL, V13, P823, DOI 10.1245/ASO.2006.05.052; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Herbst RS, 2002, CANCER-AM CANCER SOC, V94, P1593, DOI 10.1002/cncr.10372; HOHLER T, 2004, EUR SOC MED ONC C VI; Hollywood Ellen, 2002, Semin Oncol Nurs, V18, P30, DOI 10.1053/sonu.2002.33070; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; Humblet Y, 2004, EXPERT OPIN PHARMACO, V5, P1621, DOI 10.1517/14656566.5.7.1621; Inoue K, 2000, CLIN CANCER RES, V6, P4874; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; LEE E, 2004, J CLIN ONCOL, V22, P1177; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; Milas L, 2000, CLIN CANCER RES, V6, P701; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Peng D, 1996, CANCER RES, V56, P3666; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; ROSEMBERG AH, 2002, P AM SOC CLIN ONCOL; Saleh MN, 1999, CANCER BIOTHER RADIO, V14, P451, DOI 10.1089/cbr.1999.14.451; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALOMON DS, 2001, SIGNAL, V2, P4; SALTZ L, 2005, AM SOC CLIN ONC GAST; SALTZ L, 2003, P AM SOC CLIN ONCOL, V22; Saltz L., 2001, P AM SOC CLIN ONCOL, V20, p3a; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; Wu XP, 1996, ONCOGENE, V12, P1397; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	51	113	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3654	3660		10.1038/sj.onc.1210381	http://dx.doi.org/10.1038/sj.onc.1210381			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530019	Bronze			2022-12-17	WOS:000246816100008
J	Fantin, VR; Leder, P				Fantin, V. R.; Leder, P.			Mitochondriotoxic compounds for cancer therapy	ONCOGENE			English	Review						mitochondria; cancer; therapy; cell death; peptide; conjugate	PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; PERIPHERAL BENZODIAZEPINE-RECEPTORS; DIAZEPAM-BINDING INHIBITOR; SMALL-MOLECULE INHIBITORS; CELL-CYCLE ARREST; BCL-X-L; TUMOR-CELLS; IN-VIVO; CARCINOMA-CELLS	One of the hallmarks of cancer cells is their increased resistance to apoptosis induction. Alterations in many apoptosis regulators belonging to the intrinsic pathway confer emerging neoplastic cells with a selective growth advantage in the hostile tumor microenvironment. The realization that those same defects contribute to resistance to radiation and chemotherapeutic agents have prompted the unrelenting search for mitochondria-targeted compounds for the treatment of cancer. Mitochondria play a central role in the process of cell death. They serve as integrators of upstream effector mechanisms. Most importantly, mitochondrial outer membrane permeabilization becomes a commitment point during cell death. Thus, strategies aimed at directly triggering this event by either blocking the activity of antiapoptotic factors or by interfering with vital mitochondrial functions may help to overcome resistance to standard cancer therapy.	Merck & Co Inc, Boston, MA USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Merck & Company; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Fantin, VR (corresponding author), Merck & Co Inc, Boston, MA USA.	valeria_fantin@merck.com						ANDERSON WM, 1989, BIOCHEM INT, V19, P673; Andre N, 2002, FEBS LETT, V532, P256, DOI 10.1016/S0014-5793(02)03691-8; Beinlich A, 2000, BIOCHEM PHARMACOL, V60, P397, DOI 10.1016/S0006-2952(00)00325-7; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; BENZ CC, 1990, MOL PHARMACOL, V37, P840; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brewis ND, 2003, MOL THER, V7, P262, DOI 10.1016/S1525-0016(02)00054-0; Britten CD, 2000, CLIN CANCER RES, V6, P42; Bulet P, 2004, IMMUNOL REV, V198, P169, DOI 10.1111/j.0105-2896.2004.0124.x; Chahboune N, 2006, BIOORGAN MED CHEM, V14, P1089, DOI 10.1016/j.bmc.2005.09.036; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5; Chiba Y, 1998, ANTICANCER RES, V18, P1047; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Decaudin D, 2002, CANCER RES, V62, P1388; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dharap SS, 2003, PHARMACEUT RES, V20, P889, DOI 10.1023/A:1023839319950; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Eiznhamer DA, 2004, IDRUGS, V7, P359; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Fantin VR, 2005, CANCER RES, V65, P6891, DOI 10.1158/0008-5472.CAN-05-0395; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Forte M, 2005, J BIOENERG BIOMEMBR, V37, P121, DOI 10.1007/s10863-005-6565-9; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Geschwind JFH, 2002, CANCER RES, V62, P3909; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo PG, 2001, CANCER CHEMOTH PHARM, V48, P169, DOI 10.1007/s002800100284; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Jameel JKA, 2004, BREAST, V13, P452, DOI 10.1016/j.breast.2004.08.004; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kandela IK, 2003, BIOTECH HISTOCHEM, V78, P157, DOI 10.1080/10520290310001597050; Kang DC, 2005, CURR MED CHEM, V12, P429, DOI 10.2174/0929867053363081; KATZ Y, 1990, CLIN SCI, V78, P155, DOI 10.1042/cs0780155; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 2002, BIOCHIMIE, V84, P103, DOI 10.1016/S0300-9084(02)01382-2; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lacerda SHD, 2005, PHOTOCHEM PHOTOBIOL, V81, P1430, DOI 10.1562/2005-08-05-RA-639; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; Liu H, 2001, BIOCHEMISTRY-US, V40, P5542, DOI 10.1021/bi002426w; Lo S, 2005, INT J ONCOL, V27, P337; Maaser K, 2001, BRIT J CANCER, V85, P1771, DOI 10.1054/bjoc.2001.2181; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Marchetti P, 1999, CANCER RES, V59, P6257; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; MIETTINEN H, 1995, CANCER RES, V55, P2691; MIYASHITA T, 1993, BLOOD, V81, P151; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; Moretti JL, 2005, EUR J NUCL MED MOL I, V32, P836, DOI 10.1007/s00259-005-1840-x; NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Propper DJ, 1999, ANN ONCOL, V10, P923, DOI 10.1023/A:1008336904585; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, CANCER RES, V50, P6565; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SINGH G, 1992, PHARMACOL THERAPEUT, V54, P217, DOI 10.1016/0163-7258(92)90033-V; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292; Sutter AP, 2002, INT J CANCER, V102, P318, DOI 10.1002/ijc.10724; TEICHER BA, 1986, BIOCHEM PHARMACOL, V35, P3365, DOI 10.1016/0006-2952(86)90437-5; Trapp S, 2005, EUR BIOPHYS J BIOPHY, V34, P959, DOI 10.1007/s00249-005-0472-1; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Venturini I, 1999, LIFE SCI, V65, P2223, DOI 10.1016/S0024-3205(99)00487-7; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walter RB, 2005, BLOOD, V106, P3584, DOI 10.1182/blood-2005-02-0711; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Weissig V, 2004, MITOCHONDRION, V3, P229, DOI 10.1016/j.mito.2003.11.002; Xu L, 2005, MOL CANCER THER, V4, P197; Yamada Y, 2005, INT J PHARMACEUT, V303, P1, DOI 10.1016/j.ijpharm.2005.06.009; Yin H, 2005, J AM CHEM SOC, V127, P10191, DOI 10.1021/ja050122x; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	117	113	116	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4787	4797		10.1038/sj.onc.1209599	http://dx.doi.org/10.1038/sj.onc.1209599			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892091				2022-12-17	WOS:000239687000015
J	Sheth, SS; Bodnar, JS; Ghazalpour, A; Thipphavong, CK; Tsutsumi, S; Tward, AD; Demant, P; Kodama, T; Aburatani, H; Lusis, AJ				Sheth, S. S.; Bodnar, J. S.; Ghazalpour, A.; Thipphavong, C. K.; Tsutsumi, S.; Tward, A. D.; Demant, P.; Kodama, T.; Aburatani, H.; Lusis, A. J.			Hepatocellular carcinoma in Txnip-deficient mice	ONCOGENE			English	Article						hepatocellular carcinoma; mouse model; Txnip; thioredoxin	THIOREDOXIN-INTERACTING PROTEIN; DIFFERENTIALLY EXPRESSED GENES; MESSENGER-RNA; 1,25-DIHYDROXYVITAMIN D-3; COMBINED HYPERLIPIDEMIA; PLASMINOGEN-ACTIVATOR; LIVER-REGENERATION; UP-REGULATION; E-CADHERIN; IN-VITRO	The molecular pathogenesis and the genetic aberrations that lead to the progression of hepato cellular carcinoma (HCC) are largely unknown. Here, we demonstrate that the thioredoxin interacting protein (Txnip) gene is a candidate tumor suppressor gene in vivo. We previously showed that the recombinant inbred congenic strain HcB-19 has a spontaneous mutation of the Txnip gene, and we now show that the strain has dramatically increased incidence of HCC, and that the HCC cosegregates with the Txnip mutation. Approximately 40% of the Txnip deficient mice developed hepatic tumors with an increased prevalence in male mice. Visible tumors develop as early as 8 months of age. Histological analysis confirmed the morphology of HCC in the Txnip-deficient mice. Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of Txnip-deficient mice. The upregulation of p53 preceded tumor development; however, bromodeoxyuridine (BrdU) labeling of normal hepatic tissue of Txnip-deficient mice did not reveal increased cell proliferation. Finally, microarray analyses of tumor, non-tumor adjacent, and normal tissue of Txnip-deficient mice highlighted the genetic differences leading to the predisposition and onset of HCC. Our findings suggest that Txnip de. ciency is sufficient to initiate HCC and suggest novel mechanisms in hepatocarcinogenesis.	Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 47 123, Dept Human Genet,Mol Biol Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Beckman Coulter Inc, Biomed Res Div, Fullerton, CA USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo, Japan; Univ Calif San Francisco, Dept Microbiol & Immunol, George Williams Hooper Fdn, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Meguro Ku, Tokyo, Japan; Univ Calif Los Angeles, Johnson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Beckman Coulter Inc.; University of Tokyo; University of California System; University of California San Francisco; Roswell Park Cancer Institute; University of Tokyo; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Lusis, AJ (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci 47 123, Dept Human Genet,Mol Biol Inst, Los Angeles, CA 90095 USA.	jlusis@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28481] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bechard D, 2001, J BIOL CHEM, V276, P48341, DOI 10.1074/jbc.M108395200; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Capiati DA, 2004, J CELL BIOCHEM, V93, P384, DOI 10.1002/jcb.20165; Castellani LW, 1998, NAT GENET, V18, P374, DOI 10.1038/ng0498-374; Chen F, 2004, CANCER RES, V64, P5425, DOI 10.1158/0008-5472.CAN-04-0806; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DRAGANI TA, 1989, MOL CARCINOGEN, V2, P355, DOI 10.1002/mc.2940020610; Dudoit S, 2002, GENOME BIOL, V3; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Escrich E, 2004, MOL CARCINOGEN, V40, P73, DOI 10.1002/mc.20028; Faith DA, 2004, PROSTATE, V61, P215, DOI 10.1002/pros.20095; Feitelson MA, 1997, AM J PATHOL, V150, P1141; Feng SLY, 2000, AM J PATHOL, V156, P1253, DOI 10.1016/S0002-9440(10)64996-6; Furutani M, 1996, HEPATOLOGY, V24, P1441, DOI 10.1053/jhep.1996.v24.pm0008938178; Goldberg SF, 2003, CANCER RES, V63, P432; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Han SH, 2003, ONCOGENE, V22, P4035, DOI 10.1038/sj.onc.1206610; Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073; HSU HC, 1993, CANCER RES, V53, P4691; Ikarashi M, 2002, ANTICANCER RES, V22, P4045; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Jiang F, 2004, J BIOL CHEM, V279, P53213, DOI 10.1074/jbc.M410395200; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Koteish A, 2002, ALCOHOL CLIN EXP RES, V26, P1710, DOI 10.1097/01.ALC.0000036923.77613.59; Lee KN, 2005, IMMUNITY, V22, P195, DOI 10.1016/j.immuni.2004.12.012; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; MARONPOT RR, 1995, TOXICOLOGY, V101, P125, DOI 10.1016/0300-483X(95)03112-S; Minn AH, 2005, ENDOCRINOLOGY, V146, P2397, DOI 10.1210/en.2004-1378; Miyaguchi S, 2000, HEPATO-GASTROENTEROL, V47, P468; Pajukanta P, 2001, MAMM GENOME, V12, P238, DOI 10.1007/s003350010265; Pourgholami MH, 2000, CANCER LETT, V151, P97, DOI 10.1016/S0304-3835(99)00416-4; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Saitoh T, 2001, J NEUROCHEM, V78, P1267, DOI 10.1046/j.1471-4159.2001.00505.x; Scherpereel A, 2003, CANCER RES, V63, P6084; Sergeev IN, 2004, J STEROID BIOCHEM, V89-90, P419, DOI 10.1016/j.jsbmb.2004.03.010; Sheth SS, 2005, J LIPID RES, V46, P123, DOI 10.1194/jlr.M400341-JLR200; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Solmi R, 2004, INT J ONCOL, V25, P1049; Tackels-Horne D, 2001, CANCER-AM CANCER SOC, V92, P395, DOI 10.1002/1097-0142(20010715)92:2<395::AID-CNCR1335>3.0.CO;2-U; Takahashi Y, 2002, ONCOL REP, V9, P75; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Yamada Y, 1999, LAB INVEST, V79, P1059; Yang XQ, 1998, BREAST CANCER RES TR, V48, P33, DOI 10.1023/A:1005929714900; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	50	113	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3528	3536		10.1038/sj.onc.1209394	http://dx.doi.org/10.1038/sj.onc.1209394			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16607285				2022-12-17	WOS:000238448200005
J	Siddique, M; Sabapathy, K				Siddique, M.; Sabapathy, K.			Trp53-dependent DNA-repair is affected by the codon 72 polymorphism	ONCOGENE			English	Article						Trp53; codon 72; polymorphism; DNA-repair; target genes	STRAND BREAK REPAIR; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE CHECKPOINT; WILD-TYPE; IN-VITRO; P53 POLYMORPHISM; LACKING P53; EXPRESSION; RADIATION; CANCER	Trp53 is arguably the most critical tumour suppressor gene product that inhibits malignant transformation. Besides mutations that inactivate Trp53 functions, genetic polymorphisms have been suggested to be risk factors for cancer. A polymorphic site at codon 72 in exon 4 encodes either an arginine amino acid (Trp53(72R)) or a proline residue (Trp53(72P)). Previous studies have shown that the Trp53(72R) form is more efficient in apoptosis induction, whereas the Trp53(72P) form was suggested to induce G1 arrest better. Here we report that Trp53(72P) is more efficient than Trp53(72P) in specifically activating several Trp53-dependent DNA-repair target genes in several cellular systems. Moreover, using isogenic cell lines and several DNA-repair assays, we show that Trp53(72P) cells have a significantly higher DNA-repair capacity than the Trp53(72R) cells. Furthermore, Trp53(72P)-expressing cells exhibit reduced micronuclei formation compared to Trp53(72R)-expressing cells, suggesting that genomic instability is reduced in these cells. Together, the data highlight the functional differences between the Trp53 polymorphic variants, and suggest that their expression status may influence cancer risk.	Natl Canc Ctr, Lab Mol Carcinogenesis, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Lab Mol Carcinogenesis, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dahm-Daphi J, 2005, ONCOGENE, V24, P1663, DOI 10.1038/sj.onc.1208396; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Ghebranious N, 1998, ONCOGENE, V17, P3385, DOI 10.1038/sj.onc.1202573; Hanawalt PC, 2003, MUTAT RES-REV MUTAT, V544, P107, DOI 10.1016/j.mrrev.2003.06.002; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lahav G, 2004, SCI STKE, V264, P55; Langerod A, 2002, CANCER EPIDEM BIOMAR, V11, P1684; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Mallya SM, 1998, INT J RADIAT BIOL, V74, P231, DOI 10.1080/095530098141618; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MATSUOKA A, 1992, MUTAT RES, V272, P223, DOI 10.1016/0165-1161(92)91535-Y; McGregor JM, 2002, J INVEST DERMATOL, V119, P84, DOI 10.1046/j.1523-1747.2002.01655.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Olivier Magali, 2004, IARC Sci Publ, P247; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; RAUTH S, 1994, ANTICANCER RES, V14, P2457; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schwarz A, 2002, NAT CELL BIOL, V4, P26, DOI 10.1038/ncb717; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Siddique MM, 2005, CANCER EPIDEM BIOMAR, V14, P2245, DOI 10.1158/1055-9965.EPI-05-0153; Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stopper H, 1997, Recent Results Cancer Res, V143, P183; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; THODAY JM, 1951, BRIT J RADIOL, V24, P572, DOI 10.1259/0007-1285-24-286-572; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Toh WH, 2005, J BIOL CHEM, V280, P17329, DOI 10.1074/jbc.M500044200; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wani MA, 2002, CARCINOGENESIS, V23, P403, DOI 10.1093/carcin/23.3.403; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yang WL, 1998, BIOCHEM BIOPH RES CO, V250, P593, DOI 10.1006/bbrc.1998.9366; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	61	113	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3489	3500		10.1038/sj.onc.1209405	http://dx.doi.org/10.1038/sj.onc.1209405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16462765				2022-12-17	WOS:000238448200001
J	Muraoka-Cook, RS; Shin, I; Yi, JY; Easterly, E; Barcellos-Hoff, MH; Yingling, JM; Zent, R; Arteaga, CL				Muraoka-Cook, R. S.; Shin, I.; Yi, J. Y.; Easterly, E.; Barcellos-Hoff, M. H.; Yingling, J. M.; Zent, R.; Arteaga, C. L.			Activated type I TGF beta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression	ONCOGENE			English	Article						TGF beta; mammary cancer; transgenic mice; PI-3 kinase; involution; oncogenes	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1 TRANSGENE; SIGNAL-TRANSDUCTION; GLAND INVOLUTION; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; TGF-BETA-1 EXPRESSION; CANCER-CELLS; MICE	We have examined the effects of transforming growth factor-beta (TGF beta) signaling on mammary epithelial cell survival. Transgenic mice expressing an active mutant of Alk5 in the mammary gland (MMTV-Alk5(T204D)) exhibited reduced apoptosis in terminal endbuds and during postlactational involution. Transgene-expressing mammary cells contained lower Smad2/3 and higher c-myc levels than controls, high ligand-independent phosphatidylinositol-3 kinase (PI3K) and Akt activities, and were insensitive to TGF beta-mediated growth arrest. Treatment with a proteasome inhibitor increased Smad2/3 levels and ligand-independent Smad transcriptional reporter activity, as well as reduced both c-myc protein and basal cell proliferation. Treatment with an Alk5 kinase small-molecule inhibitor upregulated Smad2/3 levels, reduced PI3K activity, P-Akt, and c-myc, and inhibited cell survival. Although Alk5(T204D)-expressing mice did not develop mammary tumors, bigenic MMTV-Alk(T204D) x Neu mice developed cancers that were more metastatic than those occurring in MMTV-Neu transgenics. These data suggest that (1) TGF beta can signal to PI3K/Akt and enhance mammary epithelial cell survival in vivo before cytological or histological evidence of transformation, and (2) TGF beta signaling can provide epithelial cells with a 'gain-of-function' effect that synergizes with oncogene-induced transformation.	Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Vet Affairs Hosp, Dept Med Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA; Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea	Vanderbilt University; Vanderbilt University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Eli Lilly; Vanderbilt University; Hanyang University	Arteaga, CL (corresponding author), Vanderbilt Univ, Sch Med, Div Oncol, Dept Canc Biol, 2220 Pierce Ave,777 Preston Res Bldg, Nashville, TN 37232 USA.	carlos.arteaga@vanderbilt.edu	Yin, Ji-Ye/AAE-6794-2020		NCI NIH HHS [P50 CA98131, R01 CA80195, R010 CA62212, P30 CA68485] Funding Source: Medline; NIA NIH HHS [R01 AG022413] Funding Source: Medline; NIDDK NIH HHS [R01 DK069921] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA098131, P30CA068485, R01CA062212, R01CA080195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022413] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bottinger EP, 1997, CANCER RES, V57, P5564; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; Engle SJ, 1999, CANCER RES, V59, P3379; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Glick AB, 1996, CANCER RES, V56, P3645; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; Gotzmann J, 2002, J CELL SCI, V115, P1189; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Higaki M, 1999, ARTERIOSCL THROM VAS, V19, P2127, DOI 10.1161/01.ATV.19.9.2127; Horowitz JC, 2004, J BIOL CHEM, V279, P1359, DOI 10.1074/jbc.M306248200; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nguyen AV, 2000, DEVELOPMENT, V127, P3107; Peng SB, 2005, BIOCHEMISTRY-US, V44, P2293, DOI 10.1021/bi048851x; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stambolic V, 2000, CANCER RES, V60, P3605; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yang YA, 2002, CELL GROWTH DIFFER, V13, P123; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200	58	113	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3408	3423		10.1038/sj.onc.1208964	http://dx.doi.org/10.1038/sj.onc.1208964			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16186809				2022-12-17	WOS:000238448100006
J	Patil, MA; Chua, MS; Pan, KH; Lin, R; Lih, CJ; Cheung, ST; Ho, C; Li, R; Fan, ST; Cohen, SN; Chen, X; So, S				Patil, MA; Chua, MS; Pan, KH; Lin, R; Lih, CJ; Cheung, ST; Ho, C; Li, R; Fan, ST; Cohen, SN; Chen, X; So, S			An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma	ONCOGENE			English	Article						HCC; microarrays; gene expression; tumor markers	GENOME-WIDE ANALYSIS; IDENTIFICATION; CANCER; LIVER; GLYPICAN-3; PATTERNS; MARKERS	Hepatocellular carcinoma (HCC) is one of the major causes of cancer deaths worldwide. New diagnostic and therapeutic options are needed for more effective and early detection and treatment of this malignancy. We identified 703 genes that are highly expressed in HCC using DNA microarrays, and further characterized them in order to uncover novel tumor markers, oncogenes, and therapeutic targets for HCC. Using Gene Ontology annotations, genes with functions related to cell proliferation and cell cycle, chromatin, repair, and transcription were found to be significantly enriched in this list of highly expressed genes. We also identified a set of genes that encode secreted ( e. g. GPC3, LCN2, and DKK1) or membrane-bound proteins ( e. g. GPC3, IGSF1, and PSK-1), which may be attractive candidates for the diagnosis of HCC. A significant enrichment of genes highly expressed in HCC was found on chromosomes 1q, 6p, 8q, and 20q, and we also identified chromosomal clusters of genes highly expressed in HCC. The microarray analyses were validated by RT-PCR and PCR. This approach of integrating other biological information with gene expression in the analysis helps select aberrantly expressed genes in HCC that may be further studied for their diagnostic or therapeutic utility.	Stanford Univ, Dept Surg, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Stanford Univ, Asian Liver Ctr, Stanford, CA 94305 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Ctr Study Liver Dis, Hong Kong, Hong Kong, Peoples R China; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; Stanford University; University of Hong Kong; University of Hong Kong; University of California System; University of California San Francisco	Chen, X (corresponding author), Stanford Univ, Dept Surg, 300 Pasteur Dr,H3680, Stanford, CA 94305 USA.	xinchen@itsa.ucsf.edu; samso@stanford.edu	Cheung, Siu-Tim/C-4238-2009; Fan, Sheung Tat/C-4138-2009	Cheung, Siu-Tim/0000-0003-2147-315X; Chua, Mei-Sze/0000-0002-3282-4894	NCI NIH HHS [K01 CA096774] Funding Source: Medline; NIDDK NIH HHS [DK26743-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA096774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Chen X, 2004, MODERN PATHOL, V17, P1198, DOI 10.1038/modpathol.3800167; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung ST, 2002, CANCER RES, V62, P4711; Crawley JJ, 2002, GENOME BIOL, V3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; Helton WS, 2003, J GASTROINTEST SURG, V7, P401, DOI 10.1016/S1091-255X(02)00161-0; Hippo Y, 2004, CANCER RES, V64, P2418, DOI 10.1158/0008-5472.CAN-03-2191; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Lafaro KJ, 2015, SURG ONCOL CLIN N AM, V24, P1, DOI 10.1016/j.soc.2014.09.001; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; LIN TY, 1987, BRIT J SURG, V74, P839, DOI 10.1002/bjs.1800740931; Mor E, 1998, ANN INTERN MED, V129, P643, DOI 10.7326/0003-4819-129-8-199810150-00013; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Nguyen MH, 2002, J CLIN GASTROENTEROL, V35, pS86, DOI 10.1097/00004836-200211002-00004; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Nishida N, 2003, HISTOL HISTOPATHOL, V18, P897, DOI 10.14670/HH-18.897; Okabe H, 2001, CANCER RES, V61, P2129; Pan KH, 2002, P NATL ACAD SCI USA, V99, P2118, DOI 10.1073/pnas.251687398; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith MW, 2003, CANCER RES, V63, P859; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Zhang H, 2003, P NATL ACAD SCI USA, V100, P3251, DOI 10.1073/pnas.2627983100	36	113	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3737	3747		10.1038/sj.onc.1208479	http://dx.doi.org/10.1038/sj.onc.1208479			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15735714				2022-12-17	WOS:000229346300005
J	Subramanian, S; West, RB; Corless, CL; Ou, WB; Rubin, BP; Chu, KM; Leung, SY; Yuen, ST; Zhu, S; Hernandez-Boussard, T; Montgomery, K; Nielsen, TO; Patel, RM; Goldblum, JR; Heinrich, MC; Fletcher, JA; van de Rijn, M				Subramanian, S; West, RB; Corless, CL; Ou, WB; Rubin, BP; Chu, KM; Leung, SY; Yuen, ST; Zhu, S; Hernandez-Boussard, T; Montgomery, K; Nielsen, TO; Patel, RM; Goldblum, JR; Heinrich, MC; Fletcher, JA; van de Rijn, M			Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles	ONCOGENE			English	Article						GIST; KIT; PDGFRA; mutations; microarray; gene expression	OF-FUNCTION MUTATIONS; SIGNAL-TRANSDUCTION; C-KIT; ERM PROTEINS; CANCER; IMATINIB; SITE; MICROARRAYS; MODULATION; APOPTOSIS	Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Pathol, Portland, OR 97201 USA; Portland VA Med Ctr, Portland, OR USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Med Ctr, Dept Anat Pathol, Seattle, WA 98195 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Med, Portland, OR 97201 USA	Stanford University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; University of Hong Kong; University of Hong Kong; Stanford University; University of British Columbia; University of British Columbia; Cleveland Clinic Foundation; Oregon Health & Science University	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	mrijn@stanford.edu	Leung, Suet Yi/C-4340-2009; Ou, Wen-Bin/J-1142-2019; Chu, Kent/C-4251-2009; Heinrich, Michael/AAC-6745-2019; PATEL, Rajiv Michael/AAI-9424-2021; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	PATEL, Rajiv Michael/0000-0002-1521-4947; West, Robert/0000-0002-8330-8283; Subramanian, Subbaya/0000-0002-2544-480X; , Wenbin/0000-0002-6311-9442; Heinrich, Michael/0000-0003-3790-0478; Leung, Suet Yi/0000-0001-8614-4619; van de Rijn, Matt/0000-0002-1909-9739	NCI NIH HHS [CA85129] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonescu CR, 2003, CLIN CANCER RES, V9, P3329; Antonescu CR, 2004, CLIN CANCER RES, V10, P3282, DOI 10.1158/1078-0432.CCR-03-0715; BESMER P, 1997, MOL CELL BIOL, P369; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Breiner JA, 2000, CANCER GENET CYTOGEN, V120, P111, DOI 10.1016/S0165-4608(00)00212-0; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Debiec-Rychter M, 2004, J PATHOL, V202, P430, DOI 10.1002/path.1546; Debiec-Rychter M, 2004, EUR J CANCER, V40, P689, DOI 10.1016/j.ejca.2003.11.025; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gunawan B, 2004, J PATHOL, V202, P421, DOI 10.1002/path.1537; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kinoshita K, 2003, J GASTROEN HEPATOL, V18, P147, DOI 10.1046/j.1440-1746.2003.02911.x; Kohno T, 1999, CANCER RES, V59, P4170; Koon N, 2004, GUT, V53, P235, DOI 10.1136/gut.2003.021238; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plo I, 2001, ONCOGENE, V20, P6752, DOI 10.1038/sj.onc.1204877; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rubin BP, 2001, CANCER RES, V61, P8118; Sanders KM, 1999, NEUROGASTROENT MOTIL, V11, P311; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	47	113	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7780	7790		10.1038/sj.onc.1208056	http://dx.doi.org/10.1038/sj.onc.1208056			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15326474				2022-12-17	WOS:000224331600004
J	Burgess, A; Ruefli, A; Beamish, H; Warrener, R; Saunders, N; Johnstone, R; Gabrielli, B				Burgess, A; Ruefli, A; Beamish, H; Warrener, R; Saunders, N; Johnstone, R; Gabrielli, B			Histone deacetylase inhibitors specifically kill nonproliferating tumour cells	ONCOGENE			English	Article						histone deacetylase inhibitors; quiescent; apoptosis; chemotherapy; cell cycle	SUBEROYLANILIDE HYDROXAMIC ACID; HUMAN LEUKEMIA-CELLS; SODIUM-BUTYRATE; P21(WAF1) EXPRESSION; APOPTOSIS; CHEMOTHERAPY; SAHA; CYTOTOXICITY; ACETYLATION; PROTECTION	Conventional chemotherapeutic drugs target proliferating cells, relying on often small differences in drug sensitivity of tumour cells compared to normal tissue to deliver a therapeutic benefit. Consequently, they have significant limiting toxicities and greatly reduced efficacy against nonproliferating compared to rapidly proliferating tumour cells. This lack of selectivity and inability to kill nonproliferating cells that exist in tumours with a low mitotic index are major failings of these drugs. A relatively new class of anticancer drugs, the histone deacetylase inhibitors (HDI), are selectively cytotoxic, killing tumour and immortalized cells but normal tissue appears resistant. Treatment of tumour cells with these drugs causes both G1 phase cell cycle arrest correlated with increase p21 expression, and cell death, but even the G1 arrested cells died although the onset of death was delayed. We have extended these observations using cells that were stably arrested by either serum starvation or expression of the cyclin-dependent kinase inhibitor p16(ink4a). We report that histone deacetylase inhibitors have similar cytotoxicity towards both proliferating and arrested tumour and immortalized cells, although the onset of apoptosis is delayed by 24 h in the arrested cells. Both proliferating and arrested normal cells are unaffected by HDI treatment. Thus, the histone deacetylase inhibitors are a class of anticancer drugs that have the desirable features of being tumour-selective cytotoxic drugs that are equally effective in killing proliferating and nonproliferating tumour cells and immortalized cells. These drugs have enormous potential for the treatment of not only rapidly proliferating tumours, but tumours with a low mitotic index.	Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	University of Queensland; Peter Maccallum Cancer Center	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Johnstone, Ricky w/H-3748-2014; saunders, nicholas/AAJ-6101-2020; Burgess, Andrew/C-7952-2009; McTaggart, Jill/G-4696-2010; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019	Johnstone, Ricky w/0000-0001-7053-9237; saunders, nicholas/0000-0002-2478-3420; Burgess, Andrew/0000-0003-4536-9226; McTaggart, Jill/0000-0002-9000-8529; Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Chittenden T, 2002, CANCER CELL, V2, P165, DOI 10.1016/S1535-6108(02)00128-9; DREWINKO B, 1981, CANCER RES, V41, P2328; Fueyo J, 1998, INT J ONCOL, V12, P665; Gabrielli BG, 2002, CURR CANCER DRUG TAR, V2, P337, DOI 10.2174/1568009023333818; Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200; Ju R, 2003, CANCER RES, V63, P2891; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; Parsons PG, 1997, BIOCHEM PHARMACOL, V53, P1719, DOI 10.1016/S0006-2952(97)00016-6; Peart MJ, 2003, CANCER RES, V63, P4460; Prabhu NS, 1999, INT J ONCOL, V15, P209; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Rahmani M, 2003, CANCER RES, V63, P8420; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rosato RR, 2001, INT J ONCOL, V19, P181; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Schmidt M, 2001, ONCOGENE, V20, P6164, DOI 10.1038/sj.onc.1204814; Stone S, 1996, CANCER RES, V56, P3199; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Vrana JA, 1999, ONCOGENE, V18, P7016, DOI 10.1038/sj.onc.1203176; Wang XQ, 1996, CANCER RES, V56, P2510; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje	30	113	120	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6693	6701		10.1038/sj.onc.1207893	http://dx.doi.org/10.1038/sj.onc.1207893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15235588				2022-12-17	WOS:000223653600001
J	Punj, V; Bhattacharyya, S; Saint-Dic, D; Vasu, C; Cunningham, EA; Graves, J; Yamada, T; Constantinou, AI; Christov, K; White, B; Li, G; Majumdar, D; Chakrabarty, AM; Das Gupta, TK				Punj, V; Bhattacharyya, S; Saint-Dic, D; Vasu, C; Cunningham, EA; Graves, J; Yamada, T; Constantinou, AI; Christov, K; White, B; Li, G; Majumdar, D; Chakrabarty, AM; Das Gupta, TK			Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer	ONCOGENE			English	Article						cupredoxin azurin; breast cancer; apoptosis	SUPPRESSOR PROTEIN P53; CELL-CYCLE ARREST; MCF7 CELLS; CASPASE 3; TUMOR; ACTIVATION; DEATH; BAX; DNA; MITOCHONDRIA	Azurin, a copper-containing redox protein released by the pathogenic bacterium Pseudomonas aeruginosa, is highly cytotoxic to the human breast cancer cell line MCF-7, but is less cytotoxic toward p53-negative (MDA-MB-157) or nonfunctional p53 cell lines like MDD2 and MDA-MB-231. The purpose of this study was to investigate the underlying mechanism of the action of bacterial cupredoxin azurin in the regression of breast cancer and its potential chemotherapeutic efficacy. Azurin enters into the cytosol of MCF-7 cells and travels to the nucleus, enhancing the intracellular levels of p53 and Bax, thereby triggering the release of mitochondrial cytochrome c into the cytosol. This process activates the caspase cascade (including caspase-9 and caspase-7), thereby initiating the apoptotic process. Our results indicate that azurin-induced cell death stimuli are amplified in the presence of p53. In vivo injection of azurin in immunodeficient mice harboring xenografted human breast cancer cells in the mammary fat pad leads to statistically significant regression (85%, P = 0.0179, Kruskal-Wallis Test) of the tumor. In conclusion, azurin blocks breast cancer cell proliferation and induces apoptosis through the mitochondrial pathway both in vitro and in vivo, thereby suggesting a potential chemotherapeutic application of this bacterial cupredoxin for the treatment of breast cancer.	Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Surg, Chicago, IL 60612 USA; Univ Illinois, Dept Math Stat & Comp Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Das Gupta, TK (corresponding author), Univ Illinois, Dept Surg Oncol, 840 S Wood St,M-C 820, Chicago, IL 60612 USA.	tkdg@uic.edu	White, Bethany E. Perez/AAF-7256-2020; Li, Gang/AAD-4952-2021; Johnson, Michael D. L./B-4352-2012; Bhattacharyya, Suchita/V-5390-2019	Bhattacharyya, Suchita/0000-0002-6775-630X; Constantinou, Andreas/0000-0003-0365-1821; vasu, chenthamarakshan/0000-0002-1772-6508; Perez White, Bethany/0000-0002-5594-0599	NCI NIH HHS [CA09432, CA95712, CA96517] Funding Source: Medline; NIEHS NIH HHS [ES04050-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA095712, R01CA096517, T32CA009432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexandroff AB, 1999, LANCET, V353, P1689, DOI 10.1016/S0140-6736(98)07422-4; ALTMANN KH, 2000, BIOCHIM BIOPHYS ACTA, V1470, P78; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Blanc C, 2000, CANCER RES, V60, P4386; Budhram-Mahadeo V, 1999, J BIOL CHEM, V274, P15237, DOI 10.1074/jbc.274.21.15237; Chakrabarty AM, 2003, J BACTERIOL, V185, P2683, DOI 10.1128/JB.185.9.2683-2686.2003; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chou TC, 1998, P NATL ACAD SCI USA, V95, P9642, DOI 10.1073/pnas.95.16.9642; Coley WB, 1911, SURG GYNECOL OBSTET, V13, P174; Cowan CM, 2001, J NEUROSCI, V21, P7099, DOI 10.1523/JNEUROSCI.21-18-07099.2001; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Eilon GF, 2000, CANCER CHEMOTH PHARM, V45, P183; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Goto M, 2003, MOL MICROBIOL, V47, P549, DOI 10.1046/j.1365-2958.2003.03317.x; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; He ZW, 2003, CANCER RES, V63, P4396; Heerdt BG, 1999, CANCER RES, V59, P1584; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; Hu CCA, 2001, FEBS LETT, V503, P65, DOI 10.1016/S0014-5793(01)02691-6; Hu HB, 2002, INT J CANCER, V102, P250, DOI 10.1002/ijc.10707; Hunter CA, 2001, J IMMUNOL, V166, P5878, DOI 10.4049/jimmunol.166.10.5878; Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; LAMOUREUX G, 1976, BCG CANC IMMUNOTHERA; Le XF, 2001, ONCOGENE, V20, P8258, DOI 10.1038/sj.onc.1205039; Lee ATC, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-16; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Marcelli M, 1998, CANCER RES, V58, P76; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mc Gee MM, 2002, FEBS LETT, V515, P66, DOI 10.1016/S0014-5793(02)02440-7; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mooney LM, 2002, BRIT J CANCER, V87, P909, DOI 10.1038/sj.bjc.6600541; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Onuki R, 2003, ANTISENSE NUCLEIC A, V13, P75, DOI 10.1089/108729003321629629; Paglia P, 1998, CANCER IMMUNOL IMMUN, V46, P88, DOI 10.1007/s002620050466; Pawelek JM, 1997, CANCER RES, V57, P4537; Punj V, 2003, CELL MICROBIOL, V5, P225, DOI 10.1046/j.1462-5822.2003.00269.x; Punj V, 2003, BIOCHEM BIOPH RES CO, V312, P109, DOI 10.1016/j.bbrc.2003.09.217; Raffo AJ, 2000, ONCOGENE, V19, P6216, DOI 10.1038/sj.onc.1203995; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RUNNEBAUM IB, 1994, ANTICANCER RES, V14, P1137; Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X; Salti GI, 2000, EUR J CANCER, V36, P796, DOI 10.1016/S0959-8049(00)00017-4; Saunders PA, 2000, ANAL BIOCHEM, V284, P114, DOI 10.1006/abio.2000.4690; Schiffman K, 2002, BREAST CANCER RES TR, V74, P17, DOI 10.1023/A:1016009317796; Sinha G, 2003, NAT MED, V9, P1229, DOI 10.1038/nm1003-1229a; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sznol M, 2000, J CLIN INVEST, V105, P1027, DOI 10.1172/JCI9818; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tangri S, 2001, J EXP MED, V194, P833, DOI 10.1084/jem.194.6.833; Tong WG, 2002, MOL CANCER THER, V1, P929; Torchilin VP, 2003, DRUG DISCOV TODAY, V8, P259, DOI 10.1016/S1359-6446(03)02623-0; Wojciechowski J, 2003, INT J CANCER, V106, P486, DOI 10.1002/ijc.11290; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yamada T, 2002, P NATL ACAD SCI USA, V99, P14098, DOI 10.1073/pnas.222539699; Yamada T, 2002, INFECT IMMUN, V70, P7054, DOI 10.1128/IAI.70.12.7054-7062.2002; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	66	113	144	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2367	2378		10.1038/sj.onc.1207376	http://dx.doi.org/10.1038/sj.onc.1207376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14981543				2022-12-17	WOS:000220427700011
J	McKenna, WG; Muschel, RJ; Gupta, AK; Hahn, SM; Bernhard, EJ				McKenna, WG; Muschel, RJ; Gupta, AK; Hahn, SM; Bernhard, EJ			The RAS signal transduction pathway and its role in radiation sensitivity	ONCOGENE			English	Article						RAS; EGFR; AKT; signal transduction; radiation sensitivity	MAP KINASE ACTIVATION; TUMOR-CELL LINES; H-RAS; FARNESYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC RADIOSENSITIVITY; CERVICAL-CARCINOMA; SMALL GTPASES; CANCER CELLS; NECK-CANCER	RAS has been shown to increase radiation resistance. Upstream and downstream pathways from RAS could thus be targets for manipulation of radiosensitivity. EGFR expression and AKT phosphorylation are also associated with the response to radiation. A retrospective study evaluating EGFR and AKT in patients treated with multimodality therapy found a significant association between P-AKT and treatment failure. Moreover, these data are strengthened by in vitro studies showing that inhibition of EGFR, RAS, PI3K, and AKT radiosensitized cancer cell lines. We have previously shown that PI3K is a mediator of RAS-induced radiation resistance. We now suggest that EGFR, which is upstream of PI3K, may also mediate resistance through a common pathway. In addition to EGFR and RAS, PTEN can also regulate the PI3K pathway. Identifying a common signal for EGFR, RAS, or PTEN that results in radiation resistance may uncover targets for developing molecular-based radiosensitization protocols for tumors resistant to radiation and thus improve local control.	Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19103 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19103 USA	University of Pennsylvania; University of Pennsylvania	McKenna, WG (corresponding author), Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19103 USA.	mckenna@xrt.upenn.edu			NCI NIH HHS [P01 CA 75138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ader I, 2002, ONCOGENE, V21, P5998, DOI 10.1038/sj.onc.1205746; Arase Y, 2000, BIOCHEM BIOPH RES CO, V267, P33, DOI 10.1006/bbrc.1999.1857; Barabasi A.-L., 2002, LINKED NEW SCI NETWO, P256; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bernhard EJ, 2000, CANCER RES, V60, P6597; BERNHARD EJ, 2000, PRENYLTRANSFERASE IN; Bonner JA, 2000, J CLIN ONCOL, V18, p47S; Brognard J, 2001, CANCER RES, V61, P3986; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Cataldi A, 2001, CELL SIGNAL, V13, P369, DOI 10.1016/S0898-6568(01)00147-4; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; Delmas C, 2002, INT J CANCER, V100, P43, DOI 10.1002/ijc.10439; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Edwards E, 2002, CANCER RES, V62, P4671; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; GIRINSKY T, 1993, INT J RADIAT ONCOL, V25, P3, DOI 10.1016/0360-3016(93)90137-K; Gokhale PC, 1999, ANTISENSE NUCLEIC A, V9, P191, DOI 10.1089/oli.1.1999.9.191; Grana TM, 2002, CANCER RES, V62, P4142; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Gupta AK, 2001, METHOD ENZYMOL, V333, P284; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hahn SM, 2002, CLIN CANCER RES, V8, P1065; HAHN SMK, 2000, CLIN CANCER RES, V8, P1065; Harari PM, 2002, SEMIN RADIAT ONCOL, V12, P21, DOI 10.1053/srao.2002.34865; Harari PM, 2001, INT J RADIAT ONCOL, V49, P427, DOI 10.1016/S0360-3016(00)01488-7; HENDERSON L, 2002, DISAPPOINTING IRESSA; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; Klapper LN, 2000, ADV CANCER RES, V77, P25; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; MCKENNA WG, 1990, CANCER RES, V50, P97; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; McKenna WG, 2002, SEMIN RADIAT ONCOL, V12, P27, DOI 10.1053/srao.2002.34866; Milas L, 2000, CLIN CANCER RES, V6, P701; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Pastan Ira, 2002, Curr Opin Investig Drugs, V3, P1089; Prior IA, 2001, J CELL SCI, V114, P1603; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rait A, 2000, BIOCONJUGATE CHEM, V11, P153, DOI 10.1021/bc990106n; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Russell JS, 2002, CANCER RES, V62, P2318; Russell JS, 1999, CANCER RES, V59, P5239; Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO;2-8; Sheridan M T, 1997, Radiat Oncol Investig, V5, P180, DOI 10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.3.CO;2-Z; SHIN DM, 1994, CANCER RES, V54, P3153; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thomssen C, 2001, ANTI-CANCER DRUG, V12, pS19, DOI 10.1097/00001813-200112004-00004; van Meer G, 2002, SCIENCE, V296, P855, DOI 10.1126/science.1071491; WEST CML, 1991, LANCET, V338, P818, DOI 10.1016/0140-6736(91)90700-Y; WEST CML, 1995, INT J RADIAT ONCOL, V31, P841, DOI 10.1016/0360-3016(94)00508-7; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Workman P, 2001, CURR CANCER DRUG TAR, V1, P33, DOI 10.2174/1568009013334269; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	83	113	121	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5866	5875		10.1038/sj.onc.1206699	http://dx.doi.org/10.1038/sj.onc.1206699			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947393				2022-12-17	WOS:000185086100013
J	Roussigne, M; Cayrol, C; Clouaire, T; Amalric, F; Girard, JP				Roussigne, M; Cayrol, C; Clouaire, T; Amalric, F; Girard, JP			THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies	ONCOGENE			English	Article						PML nuclear bodies; Par-4; apoptosis; nuclear proteins; protein interaction	BINDING-PROTEIN; DOWN-REGULATION; DLK/ZIP KINASE; EXPRESSION; DAXX; APOPTOSIS; LOCALIZATION; PATHWAY; REPRESSOR; ISOFORMS	Promyelocytic leukemia (PML) nuclear bodies (PML NBs) are discrete subnuclear domains organized by the promyelocytic leukemia protein PML, a tumor suppressor essential for multiple apoptotic pathways. We have recently described a novel family of cellular factors, the THAP proteins, characterized by the presence at their amino-terminus of an evolutionary conserved putative DNA-binding motif, designated THAP domain. Here, we report that THAP1 is a novel nuclear proapoptotic factor associated with PML NBs, which potentiates both serum withdrawal- and TNFalpha-induced apoptosis, and interacts with prostate-apoptosis-response-4 (Par-4), a well characterized proapoptotic factor, previously linked to prostate cancer and neurodegenerative diseases. We show that endogenous Par-4 colocatizes with ectopic THAP1 within PML NBs in primary endothelial cells and fibroblasts. In addition, we found that Par-4 is a component of PML NBs in blood vessels, a major site of PML expression in vivo. Finally, we investigated the role of the THAP domain in THAP1 activities and found that this putative DNA-binding domain is not required for Par-4 binding and localization within PML NBs, but is essential for THAP1 proapoptotic activity. Together, our results provide an unexpected link between a nuclear factor of the THAP family, the proapoptotic protein Par-4 and PML nuclear bodies.	CNRS, UMR 5089, Inst Pharmacol & Biol Struct, Lab Biol Vasc, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Girard, JP (corresponding author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, Lab Biol Vasc, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	GIRARD, Jean-Philippe/F-5229-2010; CAYROL, Corinne/C-2106-2011; CLOUAIRE, THOMAS/L-7396-2017	GIRARD, Jean-Philippe/0000-0002-9154-1691; CAYROL, Corinne/0000-0002-7813-4397; CLOUAIRE, THOMAS/0000-0003-3238-1496; Roussigne, Myriam/0000-0002-4240-4105				Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Besset S, 2000, FASEB J, V14, P345, DOI 10.1096/fasebj.14.2.345; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Ferbeyre G, 2000, GENE DEV, V14, P2015; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gale M, 1998, MOL CELL BIOL, V18, P859, DOI 10.1128/MCB.18.2.859; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Hofmann T.G., 2001, NAT CELL BIOL, V10, P10; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lee CC, 1998, EMBO J, V17, P4166, DOI 10.1093/emboj/17.14.4166; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Mattson MP, 1999, J MOL NEUROSCI, V13, P17, DOI 10.1385/JMN:13:1-2:17; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; ROUSSIGNE M, 2003, IN PRESS TRENDS BIOC; Ruggero D, 2000, BIOESSAYS, V22, P827, DOI 10.1002/1521-1878(200009)22:9<827::AID-BIES8>3.3.CO;2-T; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	49	113	122	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2003	22	16					2432	2442		10.1038/sj.onc.1206271	http://dx.doi.org/10.1038/sj.onc.1206271			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717420				2022-12-17	WOS:000182383500006
J	Robles, AI; Linke, SP; Harris, CC				Robles, AI; Linke, SP; Harris, CC			The p53 network in lung carcinogenesis	ONCOGENE			English	Review						p73; p14(ARF); mutational spectrum; mutational hotspots; tobacco smoke	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; POLYCYCLIC AROMATIC-HYDROCARBONS; CANCER MUTATIONAL HOTSPOTS; TUMOR-SUPPRESSOR P53; KINASE C-ABL; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; MAMMALIAN-CELLS; TRANSCRIPTIONAL TARGET; FUNCTIONAL INTERACTION	The p53 tumor suppressor gene lies at the crossroads of multiple cellular response pathways that control a cell's fate in response to endogenous or exogenous stresses. Positive and negative regulatory loops both upstream and downstream of p53 cooperate to finely tune its functions as a transcription factor, a DNA damage sensor, and possibly, a protein-assembly scaffold. Through this plethora of activities, p53 is a major determinant of cell survival and a safeguard against genetic instability. Functional inactivation of p53 pathways through genetic and epigenetic events affecting the p53 gene itself and/or its interacting partners occur with a high frequency in lung cancer. The p53 mutational spectrum provides molecular evidence of the etiology of lung cancer and supports abundant epidemiological data indicating the role of tobacco smoke in the causation of this disease.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harris, CC (corresponding author), 37 Convent Dr,Bldg 37,Room 2C05, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov		Robles, Ana/0000-0001-5019-4374; Linke, Steven/0000-0001-8584-4947				Agami R, 1999, NATURE, V399, P809; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BENNETT WP, 1993, CANCER RES, V53, P4817; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DeMarini DM, 2001, CANCER RES, V61, P6679; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fan R, 2000, CANCER EPIDEM BIOMAR, V9, P1037; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Gazzeri S, 1998, CANCER RES, V58, P3926; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Goldman R, 2001, CANCER RES, V61, P6367; Gong JG, 1999, NATURE, V399, P806; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hagiwara K, 1999, CANCER RES, V59, P4165; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1974, NATURE, V252, P68, DOI 10.1038/252068a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hernandez-Boussard TM, 1998, ENVIRON HEALTH PERSP, V106, P385, DOI 10.2307/3434065; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1998, CANCER RES, V58, P4023; Hussain SP, 2001, CANCER RES, V61, P6350; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; IIZASA T, 1993, CARCINOGENESIS, V14, P1789, DOI 10.1093/carcin/14.9.1789; International Agency for Research on Cancer Tobacco smoking IARC, 1986, IARC MON EV CARC RIS, V38; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY AM, 1977, NATURE, V269, P348, DOI 10.1038/269348a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu G, 2001, CANCER RES, V61, P8718; Mai M, 1998, CANCER RES, V58, P2347; MARCHETTI A, 1995, DIAGN MOL PATHOL, V4, P93, DOI 10.1097/00019606-199506000-00004; Mariatos G, 2000, MUTAT RES-FUND MOL M, V456, P59, DOI 10.1016/S0027-5107(00)00110-X; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nicholson SA, 2001, CANCER RES, V61, P5636; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nigro JM, 1997, CANCER RES, V57, P3635; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Robles AI, 2001, ACTA ONCOL, V40, P696; Robles AI, 2001, CANCER RES, V61, P6660; Rodin SN, 2000, P NATL ACAD SCI USA, V97, P12244, DOI 10.1073/pnas.180320897; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sigal A, 2000, CANCER RES, V60, P6788; Smith LE, 2000, JNCI-J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SOZZI G, 1992, CANCER RES, V52, P6079; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKESHIMA Y, 1993, LANCET, V342, P1520, DOI 10.1016/S0140-6736(05)80087-X; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; Vahakangas KH, 2001, CANCER RES, V61, P4350; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WESTON A, 1993, ENVIRON HEALTH PERSP, V99, P257, DOI 10.2307/3431495; WESTON A, 1992, CANCER EPIDEM BIOMAR, V1, P481; Wiencke JK, 1999, J NATL CANCER I, V91, P614, DOI 10.1093/jnci/91.7.614; Wiesmuller L, 1996, J VIROL, V70, P737; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wolf P, 2001, CANCER RES, V61, P8113; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yoon JH, 2001, CANCER RES, V61, P7110; Yoshikawa H, 1999, ONCOGENE, V18, P3415, DOI 10.1038/sj.onc.1202677; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	119	113	116	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2002	21	45					6898	6907		10.1038/sj.onc.1205563	http://dx.doi.org/10.1038/sj.onc.1205563			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362272				2022-12-17	WOS:000178640200005
J	Bacus, SS; Altomare, DA; Lyass, L; Chin, DM; Farrell, MP; Gurova, K; Gudkov, A; Testa, JR				Bacus, SS; Altomare, DA; Lyass, L; Chin, DM; Farrell, MP; Gurova, K; Gudkov, A; Testa, JR			AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival	ONCOGENE			English	Article						AKT; HER-2/neu; overexpression; breast tumors; apoptosis; hypoxia	FACTOR-INDUCED APOPTOSIS; AKT/PROTEIN KINASE-B; KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MONOCLONAL-ANTIBODY; RECEPTOR; HEREGULIN; PHOSPHORYLATION; OVEREXPRESSION	Amplification or overexpression of the HER-2/neu gene in breast cancers is associated with aggressive behavior and resistance to therapeutic regimens. The molecular mechanisms that contribute to therapeutic resistance/survival of HER-2/neu-overexpressing tumor cells have not been well defined. To determine if phosphatidylinositol 3-kinase/AKT signaling contributes to cell survival in HER-2/neu-positive breast cancers, we performed immunohistochemical analyses to evaluate expression of HER-2/neu and AKT in a series of 52 breast carcinomas. Elevated expression of HER-2/neu was found to correlate with overexpression of AKT2 protein and activation of AKT kinase. HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells. These observations suggest that AKT signaling augments resistance to stress-induced apoptosis in breast cancer cells over-expressing HER-2/neu.	Ventana Med Syst Inc, QDL, Westmont, IL 60559 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Cleveland Clin Fdn, Dept Mol Biol, Cleveland, OH 44195 USA	Roche Holding; Ventana Medical Systems, Inc.; Fox Chase Cancer Center; Cleveland Clinic Foundation	Bacus, SS (corresponding author), Ventana Med Syst Inc, QDL, 610 Oakmont Lane, Westmont, IL 60559 USA.	sbacus@ventanamed.com; D_Altomare@fccc.edu		Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA077429] Funding Source: NIH RePORTER; NCI NIH HHS [CA77429, P30 CA006927, R01 CA077429, CA06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alaoui-Jamali MA, 1997, BIOCHEM CELL BIOL, V75, P315, DOI 10.1139/bcb-75-4-315; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bacus S, 1997, ANAL QUANT CYTOL, V19, P316; Bacus S S, 2000, Breast Dis, V11, P63; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BACUS SS, 1992, CANCER RES, V52, P2580; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; BACUS SS, 1993, PATHOL ANNU, V28, P179; BACUS SS, 1994, COMPENDIUM COMPUTERI, P143; BACUS SS, 1996, MOL CARCINOG, V3, P350; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brognard J, 2001, CANCER RES, V61, P3986; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CARPENTER G, 1979, J CELL PHYSIOL, V99, P101, DOI 10.1002/jcp.1040990112; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; HANCOCK MC, 1991, CANCER RES, V51, P4575; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Huang Y, 2000, CANCER RES, V60, P4426; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Shak S, 1999, SEMIN ONCOL, V26, P71; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stal O, 2000, ANN ONCOL, V11, P1545, DOI 10.1023/A:1008313310474; Sun M, 2001, CANCER RES, V61, P5985; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WRIGHT C, 1992, BRIT J CANCER, V65, P118, DOI 10.1038/bjc.1992.22; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	57	113	120	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3532	3540		10.1038/sj.onc.1205438	http://dx.doi.org/10.1038/sj.onc.1205438			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032855				2022-12-17	WOS:000175793700004
J	Burns, TF; Bernhard, EJ; El-Deiry, WS				Burns, TF; Bernhard, EJ; El-Deiry, WS			Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo	ONCOGENE			English	Article						p53; apoptosis; gamma irradiation; KILLER/DR5; c-FLIP-s; real-time RT-PCR	RADIATION-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; DEFICIENT MICE; CYTOCHROME-C; DEATH; ACTIVATION; INHIBITION; PROTEIN; TRAIL; CELLS	The p53 tumor suppressor plays a key role in the cell's response to genotoxic stress and loss of this 'guardian of the genome' is an important step in carcinogenesis. The ability of p53 to induce apoptosis through transactivation of its target genes is critical for its function as tumor suppressor. We have found that overexpression of p53 in human cancer cell lines resulted in apoptosis as measured by PARP cleavage. Furthermore we observed cleavage of both caspase 9 and caspase 8 after overexpression of p53 and found that p53-dependent apoptosis was inhibited by either cellular (c-Flip-s, BCI-X-L) or pharmacological inhibitors of caspase 8 or caspase 9 respectively. These results indicate that p53 is mediating apoptosis through both the mitochondrial and death receptor pathways. To elucidate the relevant p53 target genes and examine the caspase pathways utilized in vivo, we treated p53+/+ and age matched p53-/- mice with 5 Gy ionizing radiation or 0.5 mg/animal dexamethasone and harvested tissues at 0, 6 and 24 h. We examined the mRNA expression of p21, bax, KILLER/DR5, FAS/APO1 and EI24/PIG8 using TaqMan real time quantitative RT-PCR in the spleen, thymus and small intestine. Although the basal mRNA levels of these genes did not depend on the presence of p53, we observed a p53-dependent induction of all these targets in response to gamma -radiation and a p53-independent regulation for p21 and KILLER/DR5 in response to dexamethasone. Furthermore, we have demonstrated that the relative induction of these p53 target genes is tissue specific. Despite observing otherwise similar levels of death in these tissues, our findings suggest that in some cases apoptosis mediated through p53 occurs by redundant pathways or by a 'group effect' while in other tissues one or few targets may play a key role in p53-dependent apoptosis. Surprisingly, KILLER/DR5 is the dominantly induced transcript in both the spleen and small intestine suggesting a potentially important role for this p53 target gene in vivo.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA 75454, CA 75138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075454, P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Fuchs EJ, 1997, CANCER RES, V57, P2550; Gu ZM, 2000, MOL CELL BIOL, V20, P233, DOI 10.1128/MCB.20.1.233-241.2000; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lee SH, 1999, CANCER RES, V59, P5683; Lehar SM, 1996, ONCOGENE, V12, P1181; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 1998, CLIN CANCER RES, V4, P251; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Ozoren N, 2000, CANCER RES, V60, P6259; Pai SI, 1998, CANCER RES, V58, P3513; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu GS, 1999, CANCER RES, V59, P2770; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhao RB, 2000, GENE DEV, V14, P981; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	113	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4601	4612		10.1038/sj.onc.1204484	http://dx.doi.org/10.1038/sj.onc.1204484			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498783				2022-12-17	WOS:000170208600001
J	Matroule, JY; Carthy, CM; Granville, DJ; Jolois, O; Hunt, DWC; Piette, J				Matroule, JY; Carthy, CM; Granville, DJ; Jolois, O; Hunt, DWC; Piette, J			Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization	ONCOGENE			English	Article						photosensitization; photodynamic therapy; pyropheophorbide; apoptosis; caspase; NF-kappa B	NF-KAPPA-B; CYTOCHROME-C RELEASE; MITOCHONDRIAL PERMEABILITY TRANSITION; ACTIVATED PROTEIN-KINASE; PHOTODYNAMIC THERAPY; CASPASE ACTIVATION; SINGLET OXYGEN; HELA-CELLS; INDUCTION; NECROSIS	Pyropheophorbide-a methylester (PPME) is a second generation of photosensitizers used in photodynamic therapy (PDT), We demonstrated that PPME photosensitization triggered apoptosis of colon cancer cells as measured by using several classical parameters such as DNA laddering, PARP cleavage, caspase activation and mitochondrial release of cytochrome c, Preincubation of cells with N-acetyl cysteine (NAC) or pyrolidine dithiocarbamate (PDTC) protected against apoptosis mediated by PPME photosensitization showing that reactive oxygen species (ROS) are involved as second messengers. On the other hand, photosensitization carried out in the presence of deuterium oxide (D2O) which enhances singlet oxygen (O-1(2)) lifetime only increases necrosis without affecting apoptosis, Since PPME was localized in the endoplasmic reticulum (ER)/Golgi system and lysosomes, other messengers than ROS were tested such as calcium, Bid, Bap31, phosphorylated Bcl-2 and caspase-12 but none was clearly identified as being involved in triggering cytochrome c release from mitochondria, On the other hand, we demonstrated that the transduction pathways leading to NF-kappaB activation and apoptosis were clearly independent although NF-kappaB was shown to counteract apoptosis mediated by PPME photosensitization.	Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium; Univ Liege, Lab Human Histol, B-4000 Liege, Belgium; QLT Inc, Vancouver, BC V5T 4T5, Canada	University of Liege; University of Liege	Piette, J (corresponding author), Univ Liege, Inst Pathol B23, Lab Virol & Immunol, B-4000 Liege, Belgium.	jpiette@ulg.ac.be						Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; BELLNIER DA, 1993, J PHOTOCH PHOTOBIO B, V20, P55, DOI 10.1016/1011-1344(93)80131-R; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Granville D J, 2000, Curr Opin Drug Discov Devel, V3, P232; Granville DJ, 1998, FEBS LETT, V437, P5, DOI 10.1016/S0014-5793(98)01193-4; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Henderson BW, 1997, CANCER RES, V57, P4000; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Katschinski DM, 2000, J BIOL CHEM, V275, P21094, DOI 10.1074/jbc.M001629200; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; LEE C, 1995, CANCER RES, V55, P2063; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lin CP, 2000, EXP CELL RES, V259, P351, DOI 10.1006/excr.2000.4979; MacDonald IJ, 1999, PHOTOCHEM PHOTOBIOL, V70, P789, DOI 10.1111/j.1751-1097.1999.tb08284.x; Matroule JY, 1999, PHOTOCHEM PHOTOBIOL, V70, P540, DOI 10.1111/j.1751-1097.1999.tb08249.x; Matroule JY, 1999, J BIOL CHEM, V274, P2988, DOI 10.1074/jbc.274.5.2988; MILLER GG, 1995, PHOTOCHEM PHOTOBIOL, V61, P632, DOI 10.1111/j.1751-1097.1995.tb09880.x; Monney L, 1998, EUR J BIOCHEM, V251, P295, DOI 10.1046/j.1432-1327.1998.2510295.x; Morgan J, 2000, PHOTOCHEM PHOTOBIOL, V71, P747, DOI 10.1562/0031-8655(2000)071<0747:COPTIA>2.0.CO;2; Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; Pandey RK, 1996, PHOTOCHEM PHOTOBIOL, V64, P194, DOI 10.1111/j.1751-1097.1996.tb02442.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; Payne JT, 1996, LASER SURG MED, V18, P406, DOI 10.1002/(SICI)1096-9101(1996)18:4<406::AID-LSM10>3.3.CO;2-7; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; Ruck A, 2000, PHOTOCHEM PHOTOBIOL, V72, P210, DOI 10.1562/0031-8655(2000)072<0210:LIAIAD>2.0.CO;2; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimura M, 2000, J LEUKOCYTE BIOL, V68, P87; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tajiri H, 1998, CANCER LETT, V128, P205, DOI 10.1016/S0304-3835(98)00066-4; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	65	113	124	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2001	20	30					4070	4084		10.1038/sj.onc.1204546	http://dx.doi.org/10.1038/sj.onc.1204546			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494135				2022-12-17	WOS:000169681500015
J	Wagner, EF				Wagner, EF			AP-1 - Introductory remarks	ONCOGENE			English	Editorial Material						AP-1; Fos; Jun; oncogene; signal transduction; transcription factor		This issue attempts to give a 'state of the art' overview of the AP-1 transcription factor family, a fundamental class of transcriptional regulators. The AP-1 family consists of several bZIP (basic region leucine zipper) domain proteins, the Jun, the Fos, and the ATF subfamilies, which all have to dimerize before they can bind to their DNA target sites, AP-1 has been a paradigm for transcription factors that regulate many aspects of cell physiology in response to environmental changes such as stress, radiation, or to growth factor signals thereby acting like an environmental biosensor, Although we have come a long way from discovering its major components, the heterodimer between c-Fos and c-Jun, it is daunting to realize that we still lack a detailed molecular knowledge of how these factors interact with DNA to activate or repress genes in the nucleus, It is also not clear how the response of AP-1 to growth factor signaling from the cell surface to the nucleus a interpreted at the molecular level and whether AP-1 is relevant for human disease.	Res Inst Mol Pathol, IMP, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, IMP, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Wagner, Erwin F/0000-0001-7872-0196					0	113	115	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	2001	20	19					2334	2335		10.1038/sj.onc.1204416	http://dx.doi.org/10.1038/sj.onc.1204416			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402330				2022-12-17	WOS:000168568700001
J	Fillippovich, I; Sorokina, N; Gatei, M; Haupt, Y; Hobson, K; Moallem, E; Spring, K; Mould, M; McGuckin, MA; Lavin, MF; Khanna, KK				Fillippovich, I; Sorokina, N; Gatei, M; Haupt, Y; Hobson, K; Moallem, E; Spring, K; Mould, M; McGuckin, MA; Lavin, MF; Khanna, KK			Transactivation-deficient p73 alpha (p73 Delta exon2) inhibits apoptosis and competes with p53	ONCOGENE			English	Article						p53; p73; apoptosis; breast cancer; transactivation	APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; KINASE C-ABL; P73 GENE; MEDIATED APOPTOSIS; DNA-DAMAGE; PROTEIN; ACTIVATION; EXPRESSION; INDUCTION	p73 has recently been identified as a structural and functional homolog of the tumor suppressor protein p53. Overexpression of p53 activates transcription of p53 effector genes, causes growth inhibition and induced apoptosis. We describe here the effects of a tumor-derived truncated transcript of p73 alpha (p73 Delta exon2) on p53 function and on cell death. This transcript, which lacks the acidic N-terminus corresponding to the transactivation domain of p53, was initially detected in a neuroblastoma cell line. Overexpression of p73 Delta exon2 partially protects lymphoblastoid cells against apoptosis induced by anti-Fas antibody or cisplatin. By cotransfecting p73 Delta exon2 with wild-type p53 in the p53 null line Saos 2, we found that this truncated transcript reduces the ability of wild-type p53 to promote apoptosis. This anti-apoptotic effect was also observed when p73 Delta exon2 was co-transfected with full-length p73 (p73 alpha). This was further substantiated by suppression of p53 transactivation of the effector gene p21-Waf1 in p73 Delta exon2 transfected cells and by inhibition of expression of a reporter gene under the control of the p53 promoter. Thus, this truncated form of p73 can act as a dominant-negative agent towards transactivation by p53 and p73 alpha, highlighting the potential implications of these findings for p53 signaling pathway. Furthermore, we demonstrate the existence of a p73 Delta exon2 transcript in a very significant proportion (46%) of breast cancer cell lines. However, a large spectrum of normal and malignant tissues need to be surveyed to determine whether this transdominant p73 variant occurs in a tumor-specific manner.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Russian Minist Hlth, Inst Biophys, Lab Mol Radiobiol, Moscow 123182, Russia; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Mater Med Res Inst, Brisbane, Qld 4101, Australia; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ministry of Health of the Russian Federation; Hebrew University of Jerusalem; Mater Research; Royal Brisbane & Women's Hospital; University of Queensland	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Hobson, Keith/Q-9306-2019; Lavin, Martin F/F-5961-2014; McGuckin, Michael/G-2310-2010	Lavin, Martin F/0000-0002-5940-4769; McGuckin, Michael/0000-0002-8375-2675; Spring, Kevin/0000-0003-0601-924X; Khanna, Kum Kum/0000-0001-8650-5381				ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Casciano I, 1999, CELL DEATH DIFFER, V6, P391, DOI 10.1038/sj.cdd.4400522; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gong JG, 1999, NATURE, V399, P806; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1996, CELL DEATH DIFFER, V3, P315; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Miyake H, 1998, INT J ONCOL, V12, P469; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nomoto S, 1998, CANCER RES, V58, P1380; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POZNIAK CD, 2000, NATURE, V289, P304; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; TAMURA T, 1995, ONCOGENE, V11, P1939; VOUSDEN KH, 1993, J GEN VIROL, V74, P803, DOI 10.1099/0022-1317-74-5-803; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 1998, P NATL ACAD SCI USA, V95, P6681, DOI 10.1073/pnas.95.12.6681; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	43	113	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2001	20	4					514	522		10.1038/sj.onc.1204118	http://dx.doi.org/10.1038/sj.onc.1204118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313982				2022-12-17	WOS:000166562500011
J	Johnston, AM; Naselli, G; Gonez, LJ; Martin, RM; Harrison, LC; DeAizpurua, HJ				Johnston, AM; Naselli, G; Gonez, LJ; Martin, RM; Harrison, LC; DeAizpurua, HJ			SPAK, a STE20/SPS1-related kinase that activates the p38 pathway	ONCOGENE			English	Article						SPAK; STE20; SPS1; kinase; p38	STE20-LIKE PROTEIN-KINASE; GERMINAL CENTER KINASE; N-TERMINAL KINASE; SACCHAROMYCES-CEREVISIAE; APOPTOSIS; CLONING; LYMPHOCYTES; DOWNSTREAM; COMPONENTS; PROTEASES	We have cloned a member of the STE20/SPS1 protein kinase family from a transformed rat pancreatic beta cell line. SPAK (STE20/SPS1-related, proline alanine-rich kinase) belongs to the SPS1 subfamily of STE20 kinases and is highly conserved between species. SPAK is expressed ubiquitously, although preferentially in brain and pancreas. Biochemical characterization of SPAK catalytic activity demonstrates that is a serine/threonine kinase that can phosphorylate itself and an exogenous substrate in vitro. SPAK is immunoprecipitated from transfected mammalian cells as a complex with another, as yet uncharacterized, serine/threonine kinase which is capable of phosphorylating catalytically-inactive SPAK and myelin basic protein in an in vitro kinase assay. SPAK specifically activates the p38 pathway in cotransfection assays. Like MST1 and MST2, SPAK contains a putative caspase cleavage site at the junction of the catalytic domain and the C-terminal region. Full-length SPAK is expressed in the cytoplasm in transfected cells, while a mutant corresponding to caspase-cleaved SPAK is expressed predominantly in the nucleus. The similarity of SPAK to other SPS1 family members, its ability to activate the p38 pathway, in addition to its putative caspase cleavage site, provide evidence that SPAK may act as a novel mediator of stress-activated signals.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, PO, Melbourne, Vic 3050, Australia; Commonwealth Serum Labs, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Johnston, AM (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, PO, Melbourne, Vic 3050, Australia.							Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Cahill MA, 1996, ONCOGENE, V13, P2087; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; DeAizpurua HJ, 1997, J BIOL CHEM, V272, P16364, DOI 10.1074/jbc.272.26.16364; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; FRANK G, 1974, EUR J BIOCHEM, V44, P317; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HATZ P, 1994, J BIOL CHEM, V269, P16802; HEJTMANCIK JF, 1986, J BIOL CHEM, V261, P982; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MASSON D, 1993, J CELL BIOL, V123, P357, DOI 10.1083/jcb.123.2.357; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Ushiro H, 1998, ARCH BIOCHEM BIOPHYS, V355, P233, DOI 10.1006/abbi.1998.0736; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	113	119	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4290	4297		10.1038/sj.onc.1203784	http://dx.doi.org/10.1038/sj.onc.1203784			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980603				2022-12-17	WOS:000089032900012
J	da Costa, LT; He, TC; Yu, J; Sparks, AB; Morin, PJ; Polyak, K; Laken, S; Vogelstein, B; Kinzler, KW				da Costa, LT; He, TC; Yu, J; Sparks, AB; Morin, PJ; Polyak, K; Laken, S; Vogelstein, B; Kinzler, KW			CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling	ONCOGENE			English	Article						CDX2; APC; colorectal cancer; mutation; regulation	TUMOR-SUPPRESSOR PROTEIN; APC GENE-PRODUCT; BETA-CATENIN; COLON-CARCINOMA; TUMORIGENESIS; ASSOCIATION; EXPRESSION; ACTIVATION; POLYPOSIS; MUTATIONS	The majority of human colorectal cancers have elevated beta-catenin/TCF regulated transcription due to either inactivating mutations of the APC tumor suppressor gene or activating mutations of beta-catenin, Surprisingly, one commonly used colorectal cancer cell line was found to have intact APC and beta-catenin and no demonstrable beta-catenin/TCF regulated transcription. However, this line did possess a truncating mutation in one allele of CDX2, a gene whose inactivation has recently been shown to cause colon tumorigenesis in mice. Expression of CDX2 was found to be induced by restoring expression of wild type APC in a colorectal cancer cell line. These findings raise the intriguing possibility that CDX2 contributes to APC's tumor suppressive effects.	Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Program Human Genet & Mol Biol, Baltimore, MD 21231 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 20815 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Howard Hughes Medical Institute; Johns Hopkins University	Kinzler, KW (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.		Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000	NATIONAL CANCER INSTITUTE [R01CA057345, R37CA057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER; NCI NIH HHS [CA57345] Funding Source: Medline; NIGMS NIH HHS [GM07814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; EE HC, 1995, AM J PATHOL, V147, P586; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; He TC, 1997, BIOESSAYS, V19, P551, DOI 10.1002/bies.950190705; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Sparks AB, 1998, CANCER RES, V58, P1130; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Wicking C, 1998, ONCOGENE, V17, P657, DOI 10.1038/sj.onc.1201971	27	113	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					5010	5014		10.1038/sj.onc.1202872	http://dx.doi.org/10.1038/sj.onc.1202872			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490837				2022-12-17	WOS:000082321700015
J	Sun, SY; Yue, P; Wu, GS; El-Deiry, WS; Shroot, B; Hong, WK; Lotan, R				Sun, SY; Yue, P; Wu, GS; El-Deiry, WS; Shroot, B; Hong, WK; Lotan, R			Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells	ONCOGENE			English	Article						retinoids; CD437; lung cancer; p53; apoptosis	P53 GENE-MUTATIONS; GROWTH ARREST; IN-VIVO; CANCER; DEATH; ACID; INDUCTION; LINES; PATHWAY; IDENTIFICATION	The novel synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) has been shown to induce apoptosis in various tumor cell lines including human non-small cell lung carcinoma (NSCLC) cells, which are resistant to the natural all-trans retinoic acid and to many synthetic receptor-selective retinoids, Although the mechanism of this effect was not elucidated, it was found to be independent of nuclear retinoid receptors, In the present study, we analysed the mechanisms by which CD437 induces apoptosis in two human NSCLC cell lines: H460 with wild-type p53 and H1792 with mutant p53. Both cell lines underwent apoptosis after exposure to CD437, although the cell line with wild-type p53 (H460) was more sensitive to the induction of apoptosis, CD437 increased the activity of caspase in both cell lines, however, the effect was much more pronounced in the H460 cells, The caspase inhibitors (Z-DEVD-FMK and Z-VAD-FMK) suppressed CD437-induced CPP32-like caspase activation and apoptosis in both cell lines, CD437 induced the expression of the p53 gene and its target genes, p21, Bas, and Killer/DR5, only in the H460 cells. These results suggest that CD437-induced apoptosis is more extensive in NSCLC cells that express wild-type p53, possibly due to the involvement of the p53 regulated genes Killer/DR5, and Bar although CD437 can also induce apoptosis by means of a p53-independent mechanism. Both pathways of CD437-induced apoptosis appear to involve activation of CPP32-like caspase.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Galderma Res & Dev, Sophia Antipolis, France	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; University of Pennsylvania; Galderma R&D SNC	Sun, SY (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NATIONAL CANCER INSTITUTE [U19CA068437] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA68437] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Benner S E, 1995, Oncology (Williston Park), V9, P205; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN YQ, 1995, CANCER RES, V55, P4536; DE LUCA LM, 1991, FASEB J, V5, P2924; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FAN SJ, 1994, CANCER RES, V54, P5824; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; HARPER JW, 1993, CELL, V75, P805; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEHMANN JM, 1991, CANCER RES, V51, P4804; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU S, 1994, P AM ASSOC CANC RES, V35, pA1517; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; MICHIELI P, 1994, CANCER RES, V54, P3391; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1995, CELL, V80, P293; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Shimamura A, 1996, CLIN CANCER RES, V2, P435; Sun SY, 1997, J CELL PHYSIOL, V173, P279, DOI 10.1002/(SICI)1097-4652(199711)173:2<279::AID-JCP36>3.0.CO;2-8; Sun SY, 1997, CANCER RES, V57, P4931; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zou CP, 1998, CLIN CANCER RES, V4, P1345	39	113	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2357	2365		10.1038/sj.onc.1202543	http://dx.doi.org/10.1038/sj.onc.1202543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327056				2022-12-17	WOS:000079595500008
J	Wood, KM; Roff, M; Hay, RT				Wood, KM; Roff, M; Hay, RT			Defective I kappa B alpha in Hodgkin cell lines with constitutively active NF-kappa B	ONCOGENE			English	Article						Hodgkin's lymphoma; NF-kappa B; I kappa B alpha	REED-STERNBERG CELLS; UBIQUITIN-PROTEASOME PATHWAY; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; INDUCIBLE DEGRADATION; TERMINAL SEQUENCES; INDUCED APOPTOSIS; SIGNAL; EXPRESSION; DISEASE	The molecular mechanisms underlying Hodgkin's disease remain obscure, but it has been recognized that the neoplastic cells display high levels of constitutively active nuclear NF-kappa B. Here me demonstrate that although nuclear NF-kappa B is transcriptionally active, the Hodgkin cells fail to activate NF-KB dependent transcription in response to CD40 ligand, In three Hodgkin cell lines examined each had abnormalities in expression of I kappa B alpha which could account for the deregulated NF-kappa B. Although all three cell lines had greater than normal levels of I kappa B alpha mRNA no I kappa B alpha protein could be detected in the KM-H2 cells, while the L428 cell line contains a C-terminally truncated I kappa B alpha species that fails to associate with NF-kappa B. The HDLM-2 cell line contains a more slowly migrating form of I kappa B alpha that can associate with NF-kappa B, but increasing the level of this protein within the cell fails to inhibit nuclear NF-kappa B. Addition of recombinant I kappa B alpha to nuclear extracts from all three cell lines resulted in complete inhibition of NF-kappa B DNA binding activity and introduction of a plasmid expressing I kappa B alpha into the cells inhibited the transcriptional activity of an NF-kappa B dependent reporter plasmid, Thus the constitutive expression of NF-kappa B in Hodgkin cells is a direct consequence of the abnormal expression of I kappa B alpha rather than changes in NF-kappa B that render it refractory to inhibition by I kappa B proteins. These changes could, at least in part, account for the characteristic activated phenotype of Hodgkin cells and their pattern of cytokine secretion, which determine the pathological appearance and clinical manifestations of Hodgkin's disease.	Univ St Andrews, Sch Biol & Med Sci, St Andrews KY16 9AL, Fife, Scotland; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of St Andrews; Newcastle University - UK	Hay, RT (corresponding author), Univ St Andrews, Sch Biol & Med Sci, Irvine Bldg, St Andrews KY16 9AL, Fife, Scotland.		Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CARBONE A, 1995, BLOOD, V85, P780, DOI 10.1182/blood.V85.3.780.bloodjournal853780; CARBONE A, 1995, AM J PATHOL, V146, P780; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GLAVAC D, 1994, HUM GENET, V93, P694, DOI 10.1007/BF00201573; GORSCHLUTER M, 1995, ANN ONCOL, V6, P477, DOI 10.1093/oxfordjournals.annonc.a059218; GRUSS HJ, 1994, BLOOD, V84, P2305; GRUSS HJ, 1995, EUR J IMMUNOL, V25, P2083, DOI 10.1002/eji.1830250742; Gruss HJ, 1997, IMMUNOL TODAY, V18, P156, DOI 10.1016/S0167-5699(97)84661-0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Kadin Marshall E., 1994, Current Opinion in Oncology, V6, P456, DOI 10.1097/00001622-199409000-00002; KODURU PRK, 1993, AM J HEMATOL, V44, P117, DOI 10.1002/ajh.2830440209; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MASON DY, 1994, AM J SURG PATHOL, V18, P526, DOI 10.1097/00000478-199405000-00014; MATTHEWS JR, 1995, INT J BIOCHEM CELL B, V27, P865, DOI 10.1016/1357-2725(95)00071-V; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; OGRADY JT, 1994, AM J PATHOL, V144, P21; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAZZAGLI M, 1992, ANAL BIOCHEM, V204, P315, DOI 10.1016/0003-2697(92)90245-3; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rodriguez MS, 1996, ONCOGENE, V12, P2425; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Stein H, 1993, Leuk Lymphoma, V10 Suppl, P99, DOI 10.3109/10428199309149120; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339	62	113	115	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2131	2139		10.1038/sj.onc.1201735	http://dx.doi.org/10.1038/sj.onc.1201735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572494				2022-12-17	WOS:000073177200011
J	Kerkhoff, E; Houben, R; Loffler, S; Troppmair, J; Rapp, UR				Kerkhoff, E; Houben, R; Loffler, S; Troppmair, J; Rapp, UR			Regulation of c-myc expression by Ras/Raf signalling	ONCOGENE			English	Article						raf; signal transduction; myc	NIH 3T3 CELLS; RAF; ACTIVATION; PROTEIN; GROWTH; FOS; TRANSFORMATION; ONCOGENES; KINASE; GENE	The c-myc gene is induced upon growth factor stimulation of arrested cells, The interaction of a mitogen with a transmembrane receptor triggers a variety of parallel signal transduction cascades. In order to analyse the role of the Ras/Raf cascade in the regulation of c-myc expression we have established fibroblast cell lines harboring conditional systems activating or inhibiting this pathway, Fusion of the c-Raf-1 kinase domain with the hormone binding domain of the estrogen receptor (c-Raf-1-BxB-ER(TM)) provides a 4-hydroxytamoxifen regulated form of the oncogenic c-Raf-1 kinase, We have generated NIH3T3 cells stably expressing the chimeric Raf protein (N-BxB-ER(TM)). 4-hydroxytamoxifen mediated activation of the fusion protein in serum starved N-BxB-ER(TM) induces the expression of the c-myc gene within 2-6 h, Deletion of the c-Raf-1 kinase domain generates a mutant c-Raf-1 protein (c-Raf-1-C4B), which can directly interact with the effector domain of the Ras protein and thereby block Ras mediated signalling, We have established a NIH3T3 based cell line expressing the c-Raf-1-C4B protein under the control of a tetracycline responsive promoter (N-C4B-tet), Serum starved cells expressing the c-Raf-1-C4B protein exhibit a significantly reduced induction of c-myc expression following serum stimulation compared to the same cells not expressing the Ras inhibitor, The induction of c-myc mRNA following the activation of the isolated Raf/Mek/Erk cascade in addition to the partial inhibition of serum mediated induction of c-myc expression in the presence of the Ras inactivating c-Raf-1-C4B mutant strongly indicates an involvement of the Ras/Raf pathway in the regulation of c-myc expression.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany	University of Wurzburg	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, Verbacher Str 5, D-97078 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837; Houben, Roland/0000-0003-4538-2324				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BORTNER DM, 1992, INT J ONCOL, V1, P221; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cooper G.M., 1995, ONCOGENES; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Markowitz D G, 1988, Trans Assoc Am Physicians, V101, P212; MCCHARTY SA, 1997, MOL CELL BIOL, V17, P2401; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORSE HC, 1988, CELLULAR ONCOGENE AC, P335; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; RAPP UR, 1994, ONCOGENE, V9, P3493; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WATERS CM, 1991, ONCOGENE, V6, P797; Yang BS, 1996, MOL CELL BIOL, V16, P538	34	113	115	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					211	216		10.1038/sj.onc.1201520	http://dx.doi.org/10.1038/sj.onc.1201520			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464539				2022-12-17	WOS:000071427100008
J	Sheikh, MS; Chen, YQ; Smith, ML; Fornace, AJ				Sheikh, MS; Chen, YQ; Smith, ML; Fornace, AJ			Role of p21(Waf1/Cip1/Sd1) in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells	ONCOGENE			English	Article						excision repair; cell death; adriamycin; uv-irradiation; p53 deficient cells	NUCLEOTIDE EXCISION-REPAIR; P53-MEDIATED G(1) ARREST; CYCLIN-DEPENDENT KINASES; HUMAN BREAST-CARCINOMA; TUMOR SUPPRESSION; GENE-EXPRESSION; GROWTH ARREST; CANCER-CELLS; P21; INDUCTION	Postulated roles for p21(Waf1/Cip1/Sdi1) (p21) in DNA repair and apoptosis remain controversial. Studies suggest both stimulatory and inhibitory effects of p21 in DNA repair. p21 has also been implicated in induction or protection from apoptosis. Using the tetracycline inducible expression system, we studied the role of p21 in DNA repair and apoptosis in wild-type p53 deficient DLD1 colorectal carcinoma cells. These cells displayed marked heterogeneity in their ability to tolerate higher levels of exogenous p21, The majority of the p21 overexpressing cells grew slower and did not exhibit apoptotic phenotype, some cells underwent apoptotic death within 5-8 days following p21 induction while other became giant cells prior to undergoing cell death. Induction of p21 transgene neither sensitized to nor protected from adriamycin-induced acute cell death. p21 also did not alter the clonogenic survival following adriamycin treatment. Clonogenic survival u.v.-irradiation was, however, increased when p21 expression was transiently induced a few hours before and after u.v.-irradiation. Consistent with its effect on clonogenic survival, p21 also enhanced the cellular capacity to repair three different exogenously introduced u.v.-damaged reporter plasmids. Taken together our results demonstrate that p21 may modulate the nucleotide excision repair process to facilitate the repair of u.v.-type DNA damage even in the absence of wild-type p53.	WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48201 USA	Wayne State University	Sheikh, MS (corresponding author), NCI, MOL PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA.		Chen, Yong Q/AAI-9864-2021; Fornace, Albert J/A-7407-2008	Chen, Yong Q/0000-0003-4747-4708; Fornace, Albert J/0000-0001-9695-085X				Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; CHEN YQ, 1995, CANCER RES, V55, P4536; DIGIUSEPPE JA, 1995, AM J PATHOL, V147, P884; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDBERG EC, 1995, DNA REPAIR; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARPER JW, 1993, CELL, V75, P805; HUANG YL, UNPUB; Isaacs John T., 1994, Current Opinion in Oncology, V6, P82, DOI 10.1097/00001622-199401000-00012; Johnson E. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P569; JUNG JM, 1995, ONCOGENE, V11, P2021; KLOCKER H, 1986, EUR J CELL BIOL, V39, P346; Kobayashi T, 1995, ONCOGENE, V11, P2311; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin J. K., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P29; McDonald E, 1996, CANCER RES, V56, P2250; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; REED SI, 1994, J CELL SCI, P69; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SHAO ZM, 1995, ONCOGENE, V11, P493; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1996, IN PRESS ONCOGENE; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang J.-L., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P593; ZHANG W, 1995, CANCER RES, V55, P668; Zhang W., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P5	42	113	122	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	1997	14	15					1875	1882		10.1038/sj.onc.1201004	http://dx.doi.org/10.1038/sj.onc.1201004			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150394				2022-12-17	WOS:A1997WW16600014
J	Barrett, MT; Galipeau, PC; Sanchez, CA; Emond, MJ; Reid, BJ				Barrett, MT; Galipeau, PC; Sanchez, CA; Emond, MJ; Reid, BJ			Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms	ONCOGENE			English	Article						allelotype; esophageal adenocarcinoma; polymorphisms	BARRETTS-ESOPHAGUS; GENETIC ALTERATIONS; ALLELOTYPE; CANCERS; PROGRESSION; DYSPLASIA	It is well established that the progression to human cancer is characterized by the evolution of clones of cells with accumulated genetic abnormalities. However, technical difficulties limit the ability to study this process in some premalignant and malignant conditions. For example, the progression to esophageal adenocarcinoma in the premalignant condition Barrett's esophagus is characterized by the evolution of genetic and cell cycle abnormalities, but it has been difficult to characterize this process completely because of the small size of biopsies and the relative abundance of genetically normal stromal cells in some esophageal adenocarcinomas and premalignant mucosa. We have combined how cytometric cell sorting to obtain purified populations of neoplastic cells with whole genome amplification and analysis of microsatellite polymorphisms to determine the frequency of allelic loss on every nonacrocentric autosomal arm in 20 esophageal adenocarcinomas and two high-grade dysplasias. DNA samples of purified how-sorted aneuploid and corresponding normal tissue were amplified with a degenerate 15mer primer. Aliquots of these reactions were then screened with forty-three highly polymorphic simple sequence repeat markers in PCR-based assays. Allelic losses were observed at polymorphic loci in 38 of the 40 chromosome arms that were analysed and the median fractional allelic loss (FAL) observed in the samples was 0.28. The background allelic loss frequency was estimated at 0.23 with the highest rates of loss observed at 17p (100%), 5q (80%), 9P (64%), 13q (43%), 18q (43%) acid Ip (41%). These data represent the first comprehensive allelotype of esophageal adenocarcinoma and show the feasibility of multiloci analyses with small highly purified human biopsy material.	UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [R0 1 CA61202, 5 PO 1 CA42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042792, R01CA061202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT MT, 1995, NUC ACIDS RES, V23, P3368; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; BOYNTON RF, 1991, CANCER RES, V51, P5766; FULTS D, 1990, CANCER RES, V50, P5784; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HIROHASHI S, 1991, CANCER CELL-MON REV, V3, P49; HUANG Y, 1992, CANCER RES, V52, P6525; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MELTZER SJ, 1994, CANCER RES, V54, P3370; NAGAI H, 1995, CANCER RES, V55, P1752; NESHAT K, 1994, COLD SPRING HARB SYM, V59, P577, DOI 10.1101/SQB.1994.059.01.065; PEIFFER SL, 1995, CANCER RES, V55, P1922; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; SATO T, 1990, CANCER RES, V50, P7184; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SNABES MC, 1994, P NATL ACAD SCI USA, V91, P6181, DOI 10.1073/pnas.91.13.6181; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; TARMIN L, 1994, CANCER RES, V54, P6094; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAMAGUCHI T, 1992, CANCER RES, V52, P419; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; ZHOU XL, 1994, ONCOGENE, V9, P3737	32	113	116	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1873	1878						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649847				2022-12-17	WOS:A1996UK49800005
J	Kondo, M; Matsuoka, S; Uchida, K; Osada, H; Nagatake, M; Takagi, K; Harper, JW; Takahashi, T; Elledge, SJ; Takahashi, T				Kondo, M; Matsuoka, S; Uchida, K; Osada, H; Nagatake, M; Takagi, K; Harper, JW; Takahashi, T; Elledge, SJ; Takahashi, T			Selective maternal-allele loss in human lung cancers of the maternally expressed p57(KIP2) gene at 11p15.5	ONCOGENE			English	Article						lung cancer; genomic imprinting; allele loss; p57(KIP2); cyclin dependent kinase inhibitor	SPORADIC WILMS-TUMOR; CHROMOSOME-11; HETEROZYGOSITY; P53; ABNORMALITIES; SUPPRESSION	Genomic imprinting at 11p15 is suggested to play a role in certain pediatric tumors such as Wilms' tumor, based on the findings of selective maternal loss of this chromosomal region, Although the allele loss at 11p15 is also frequent in a number of cancers of adults including lung, breast, and bladder cancers, possible involvement of genomic imprinting in these tumors has not been investigated extensively, p57(KIP2), a newly described member of the p21 cyclin-dependent kinase (CDK) inhibitor family which is thought to negatively regulate the cell cylce at the G(1) checkpoint, has been mapped to 11p15, In the present study, we searched for somatic p57(KIP2) mutations in lung cancer, but failed to find such alterations, Interestingly, however, we found that the p57(KIP2) gene is imprinted with maternal expression and that the maternal alleles had been selectively lost in 11 of 13 (85%) lung cancer cases carrying 11p15 deletions, this being a significant bias (P=0.01), These data provide the first evidence that genomic imprinting may play a role in the oncogenesis of not only rare pediatric tumors but also this common cancer of adults, suggesting that the imprinted p57(KIP2) CDK inhibitor gene is a potential target for maternally biased 11p15 deletions.	AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT HUMAN & MOL GENET,HOUSTON,TX 77030; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Nagoya University			Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; Harper, Jeffrey/0000-0002-6944-7236				DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HIBI K, 1994, ONCOGENE, V9, P611; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; KONDO M, 1994, ONCOGENE, V9, P3063; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOUTLON T, 1994, NAT GENET, V7, P440; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PAL N, 1990, ONCOGENE, V5, P1665; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEY RB, 1990, ONCOGENE, V5, P901; WASHIMI O, 1995, CANCER RES, V55, P514; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099	31	113	126	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1365	1368						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649840				2022-12-17	WOS:A1996UC06700023
J	Zhang, LS; Hung, MC				Zhang, LS; Hung, MC			Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin	ONCOGENE			English	Article						emodin; HER-2/neu; tyrosine kinase; lung cancer; combination therapy	GROWTH-FACTOR-RECEPTOR; NEU ONCOGENE; GENE; EXPRESSION; ADENOCARCINOMA; ACTIVATION; SURVIVAL; P185NEU; ASSAY; LINES	Overexpression of the HER-2/neu proto-oncogene which encodes tyrosine kinase receptor p185(neu), has been observed frequently in many human cancers, including non-small cell lung cancer (NSCLC), and is correlated with poor patient survival in these cancers, In addition, HER-2/neu overexpression in NSCLC is known to induce chemoresistance, Recently, we demonstrated that emodin, a tyrosine kinase inhibitor, suppresses HER-2/neu tyrosine kinase activity in HER-2/neu-overexpressing breast cancer cells and preferentially represses proliferation of these cells, The work described here was carried out to examine (1) whether the tyrosine kinase activity of p185(neu) is required for resistance to chemotherapeutic drugs of HER-2/neu-overexpressing NSCLC cells and (2) whether the tyrosine kinase inhibitor emodin can sensitize these cells to chemotherapeutic drugs. We found that emodin decreased tyrosine phosphorylation of HER-2/neu and preferentially suppressed proliferation of HER-2/neu-overexpressing NSCLC cells. Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells, These results indicate that tyrosine kinase activity is required for the chemoresistant phenotype of HER-2/neu-overexpressing NSCLC cells and that tyrosine kinase inhibitors such as emodin can sensitize these cells to chemotherapeutic drugs, The results may have important implications in chemotherapy for HER-2/neu-overexpressing cancers.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA 60856, CA 16672, CA 58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HATA Y, 1994, ONCOL RES, V6, P19; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; KERN JA, 1990, CANCER RES, V50, P5184; KUPCHAN SM, 1976, LLOYDIA, V39, P223; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Silverberg E., 1988, CA-CANCER J CLIN, V38, P5; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; UDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; WEINER DB, 1990, CANCER RES, V50, P421; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEH SF, 1988, PLANTA MED, P413, DOI 10.1055/s-2006-962484; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG LS, 1995, CANCER RES, V55, P3890	30	113	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					571	576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637714				2022-12-17	WOS:A1996TV59700014
J	GRAHAM, DK; BOWMAN, GW; DAWSON, TL; STANFORD, WL; EARP, HS; SNODGRASS, HR				GRAHAM, DK; BOWMAN, GW; DAWSON, TL; STANFORD, WL; EARP, HS; SNODGRASS, HR			CLONING AND DEVELOPMENTAL EXPRESSION ANALYSIS OF THE MURINE C-MER TYROSINE KINASE	ONCOGENE			English	Article						TYROSINE; KINASE; RECEPTOR; EXPRESSION; ONCOGENE; DEVELOPMENT	EMBRYONIC STEM-CELLS; YOLK-SAC; RECEPTOR; INVITRO; ONCOGENE; CLEAVAGE; CULTURE	We have cloned the putative mouse homologue of the human c-mer receptor tyrosine kinase proto-oncogene. Comparison of the mouse and human c-mer amino acid sequences reveals an overall identity of 88%, Similar to the human, the extracellular region of the murine c-mev protein possesses two amino terminal immunoglobulinlike domains and two membrane proximal fibronectin type III domains, which places it in the Axl family of tyrosine kinases, Our analysis of the Axl family identifies eight different regions of amino acid consensus that have residues characteristic of this and no other tyrosine kinase family; six of the eight are within tyrosine kinase subdomains. The homology within the Axl family is highest between c-mer and c-eyk, the chicken proto-oncogene of the tumor virus gene product v-eyk, Northern analysis of adult tissues suggests that the mouse c-mev, although expressed in many tissues, has an expression pattern unique among Axl family members. In normal adult hematopoietic cells c-mer seems to be expressed predominantly if not exclusively in the monocytic lineage, Mouse c-mer is expressed during most, if not all, stages of embryological development beginning in the morula and blastocyst and progressing through the yolk sac and fetal liver stages. This early and consistent expression of c-mer was confirmed during in vitro differentiation of embryonic stem cells, The embryonic expression profile of c-mer suggests that this tyrosine kinase may play an important function in the developing mouse.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT IMMUNOL & MICROBIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Stanford, William/0000-0002-5813-8016; Dawson, Thomas/0000-0003-3878-1722	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK4351701] Funding Source: Medline; NIGMS NIH HHS [GM07040] Funding Source: Medline; PHS HHS [A107273] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BISHOP JM, 1988, LEUKEMIA, V2, P199; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAI W, 1994, ONCOGENE, V9, P975; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; JIA R, 1994, J BIOL CHEM, V269, P1839; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; KOZAK M, 1986, CELL, V144, P283; KUNG HJ, 1990, DEV BIOLOGICALS, V72, P139; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MAGUIRE HC, 1989, SEMIN ONCOL, V16, P148; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; POLVI A, 1993, GENE, V134, P289, DOI 10.1016/0378-1119(93)90109-G; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SNODGRASS HR, 1992, J CELL BIOCHEM, V49, P225, DOI 10.1002/jcb.240490304; SNODGRASS HR, 1993, PERIPHERAL BLOOD STE, P65; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; TYAN ML, 1968, J IMMUNOL, V101, P446; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILES MV, 1991, DEVELOPMENT, V111, P259; 1991, GCG SOFTWARE PACKAGE	38	113	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2349	2359						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784083				2022-12-17	WOS:A1995RE54300010
J	MORI, M; BARNARD, GF; STANIUNAS, RJ; JESSUP, JM; STEELE, GD; CHEN, LB				MORI, M; BARNARD, GF; STANIUNAS, RJ; JESSUP, JM; STEELE, GD; CHEN, LB			PROTHYMOSIN-ALPHA MESSENGER-RNA EXPRESSION CORRELATES WITH THAT OF C-MYC IN HUMAN COLON-CANCER	ONCOGENE			English	Article							GENE-EXPRESSION; CELL-PROLIFERATION; LYMPHOCYTES-T; AMEX METHOD; ONCOGENE; PROTEIN; MUCOSA; FAMILY; TRANSCRIPTION; AMPLIFICATION	Prothymosin alpha (PT-alpha) is a nuclear protein involved in cell proliferation. Transcription of PT-alpha has been reported to be regulated by the c-myc gene in vitro. We identified PT-alpha as being overexpressed in a human colon cancer minus normal mucosa subtraction cDNA library. Northern blot (messenger RNA) analysis showed that both PT-alpha and c-myc genes were overexpressed in human colorectal cancers compared with adjacent normal tissues. Immunohistochemical studies for PT-alpha and c-myc supported these findings. There was no correlation between PT-alpha or c-myc messenger RNA expression and Dukes' stage of colorectal cancer; or between either of these two and actin messenger RNA expression. There was, however, a significant correlation between the PT-alpha expression and c-myc expression (P <0.001). These findings support the hypothesis that PT-alpha gene transcription may be associated with, and possibly under the control of, the c-myc gene in human colorectal cancers.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,44 BINNEY ST,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DEPT SURG,BOSTON,MA 02215	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [P01CA44704, 1F32CA9001] Funding Source: Medline; NIDDK NIH HHS [T32DK07533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704, F32CA009001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD GF, 1992, CANCER RES, V52, P3067; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLEIBERG H, 1976, CANCER RES, V36, P325; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P62; ERISMAN MD, 1989, P NATL ACAD SCI USA, V86, P4264, DOI 10.1073/pnas.86.11.4264; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FINLEY GG, 1989, ONCOGENE, V4, P963; FRANCO FJ, 1989, IMMUNOLOGY, V67, P263; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANNAPPEL E, 1982, BIOCHEM BIOPH RES CO, V104, P266, DOI 10.1016/0006-291X(82)91969-6; HARITOS A, 1983, P NATL ACAD SCI USA, V80, P1008; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAFUNE K, 1991, ARCH SURG-CHICAGO, V126, P462; MANROW RE, 1991, J BIOL CHEM, V266, P3916; PAVELIC K, 1990, Journal of Experimental Pathology (New York), V5, P143; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; RISIO M, 1991, CANCER RES, V51, P1917; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROYDS JA, 1992, J PATHOL, V166, P225, DOI 10.1002/path.1711660304; SATO Y, 1986, AM J PATHOL, V125, P431; SATO Y, 1992, AM J PATHOL, V140, P775; SBURLATI AR, 1991, P NATL ACAD SCI USA, V88, P253, DOI 10.1073/pnas.88.1.253; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; TERPSTRA OT, 1987, GASTROENTEROLOGY, V92, P704, DOI 10.1016/0016-5085(87)90021-7; TULCHIN N, 1992, AM J PATHOL, V140, P917; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621	41	113	114	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2821	2826						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378090				2022-12-17	WOS:A1993LX34300024
J	FISCH, P; BOEHM, T; LAVENIR, I; LARSON, T; ARNO, J; FORSTER, A; RABBITTS, TH				FISCH, P; BOEHM, T; LAVENIR, I; LARSON, T; ARNO, J; FORSTER, A; RABBITTS, TH			T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA INDUCED IN TRANSGENIC MICE BY THE RBTN1 AND RBTN2 LIM-DOMAIN GENES	ONCOGENE			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING MOTIF; HUMAN CD2 GENE; C-MYC GENE; CHROMOSOMAL TRANSLOCATION; MESSENGER-RNAS; CHAIN GENE; LEUKEMIA; PROTEIN; ONCOGENE	Two members of the RBTN gene family, RBTN1/Ttg-1 and RBTN2/Ttg-2, were found by their association with T-cell tumour-specific chromosomal translocations and are thought to be involved in the aetiology of such T-cell tumours. Here a transgenic mouse model is described in which T-cell tumours are induced by the presence of RBTN1 and RBTN2 transgenes that direct expression in thymus-derived cells. The latency period for lymphoid tumour appearance is variable, and tumours occur in a small proportion of transgenic animals that develop T-cell acute lymphoblastic malignancies. No significant increase in the rate of tumour development was observed in RBTN1 transgenic mice infected with Moloney murine leukaemia virus, nor did tumours arise in mice bearing a construct in which RBTN1 was expressed from the insulin transcriptional promoter. These data, which provide formal proof of the oncogenic activity of these genes, suggest that aberrant expression of transcription factor genes, such as RBTN1 and RBTN2, functions in tumour aetiology by disturbing some aspect of T-cell differentiation.	MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND; ADDENBROOKES HOSP, DEPT HISTOPATHOL, CAMBRIDGE CB2 2QQ, ENGLAND	MRC Laboratory Molecular Biology; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALLEN ND, 1988, NATURE, V333, P852, DOI 10.1038/333852a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BLUESTONE JA, 1987, NATURE, V326, P82, DOI 10.1038/326082a0; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRUGGEMANN M, 1991, EUR J IMMUNOL, V21, P1323, DOI 10.1002/eji.1830210535; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DUBE ID, 1991, BLOOD, V78, P2996; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEIM S, 1991, REC ADV PATH, V3, P37; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; RABBITTS TH, 1985, EMBO J, V4, P2217, DOI 10.1002/j.1460-2075.1985.tb03917.x; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; THICK J, 1992, IN PRESS GENES CHROM, V5; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	51	113	118	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2389	2397						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461647				2022-12-17	WOS:A1992KA85600003
J	LILLY, M; LE, T; HOLLAND, P; HENDRICKSON, SL				LILLY, M; LE, T; HOLLAND, P; HENDRICKSON, SL			SUSTAINED EXPRESSION OF THE PIM-1 KINASE IS SPECIFICALLY INDUCED IN MYELOID CELLS BY CYTOKINES WHOSE RECEPTORS ARE STRUCTURALLY RELATED	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; GM-CSF; PROTEIN-KINASES; LEUKEMIA-CELLS; GROWTH-FACTORS; INTERLEUKIN-3; CLONING; LINES; ACTIVATION	We have examined the effects of myeloid growth factors on expression of the pim-1 kinase protein in human and murine myeloid cells. pim-1 protein was identified in K562 cells by immunoblotting as a 33 kDa protein. In the human factor-dependent myeloid leukemia cell line M07E, pim-1 protein was induced by interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF), with maximum expression by 4 h. Expression continued for the duration of growth factor exposure, but declined rapidly when cytokines were removed. GM-CSF induced pim-1 protein in a dose-dependent manner, with expression being proportional to the proliferative effect of the cytokine. To examine the specificity of pim-1 protein induction, we compared pim-1 protein levels in myeloid cells which demonstrated different GM-CSF response phenotypes. We also examined the effects on pim-1 protein expression of different growth factors which induced similar response phenotypes. GM-CSF induced pim-1 protein in several myeloid cell lines, most of which demonstrated a proliferative response, but did not induce pim-1 protein expression in neutrophils or monocytic cells. In contrast, the murine cell line Mac-11 expressed pim-1 message in response to IL-3 and GM-CSF, but not in response to bryostatin or M-CSF, which were equivalent mitogens. In human U937 myeloid cells sustained expression of pim-1 protein was induced by GM-CSF, G-CSF and IL-6, but not by bryostatin. Expression of the pim-1 kinase protein in response to myeloid cytokines depends on both the nature of the growth factor and the response phenotype. The pim-1 kinase may be an important intermediate in transmembrane signaling or response phenotype induced by IL-3, GM-CSF and other cytokines whose receptors are structurally similar. Its constitutive expression in some myeloid leukemia cell lines suggests activation of signal cascades utilized by myeloid growth factors.	UNIV WASHINGTON, DEPT MED, DIV MED ONCOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	LILLY, M (corresponding author), VET ADM MED CTR, 1660 COLUMBIAN WAY S, SEATTLE, WA 98108 USA.							AMSON R, 1989, P NATL ACAD SCI USA, V86, P8857, DOI 10.1073/pnas.86.22.8857; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DANREA A, 1989, CELL, V57, P277; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DREYFUS F, 1990, LEUKEMIA, V4, P590; EVERSON MP, 1989, BLOOD, V74, P1472; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KRAFT AS, 1990, ONCOGENE, V5, P1243; LILLY M, 1989, BLOOD, V74, pA245; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; MAEKAWA T, 1989, LEUKEMIA, V3, P270; MAEKAWA T, 1990, INT J CANCER, V45, P353, DOI 10.1002/ijc.2910450224; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MEEKER TC, 1987, J CELL BIOCHEM, V35, P105, DOI 10.1002/jcb.240350204; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RHYNER K, 1986, BRIT J HAEMATOL, V64, P601, DOI 10.1111/j.1365-2141.1986.tb02216.x; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SORENSEN PHB, 1989, BLOOD, V73, P406; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; TUCKER KA, 1987, BLOOD, V70, P372; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WING EJ, 1989, BLOOD, V73, P643; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	44	113	115	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					727	732						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314369				2022-12-17	WOS:A1992HQ68200015
J	HERRMANN, CPE; KRAISS, S; MONTENARH, M				HERRMANN, CPE; KRAISS, S; MONTENARH, M			ASSOCIATION OF CASEIN KINASE-II WITH IMMUNOPURIFIED P53	ONCOGENE			English	Article							LARGE-T-ANTIGEN; CELLULAR TUMOR-ANTIGEN; PROTEIN-KINASE; SIMIAN VIRUS-40; TRANSFORMED-CELLS; CYCLE CONTROL; 3T3 CELLS; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS	Viral and cellular oncogene products sometimes activate protein kinases, are protein kinases themselves, or share phosphorylation sequence motifs for different protein kinases. We have recently shown that a protein kinase activity is tightly associated with immunopurified p53. We have now expressed p53 in a baculovirus expression system and characterized this protein kinase activity in more detail. We found that casein could compete with p53 in the kinase reaction. Heparin efficiently inhibited the p53 associated protein kinase whereas the polyamine spermidine stimulated enzymatic activity. A synthetic peptide which was shown to be specifically phosphorylated by casein kinase II blocked the in vitro phosphorylation of p53, whereas a synthetic peptide with a potential phosphorylation site on human p53 at ser 315 was ineffective in blocking the phosphorylation of p53. GTP as well as ATP can be used as a phosphate donor in the in vitro kinase reaction. An antibody directed against casein kinase II coprecipitated p53 from insect cells as well as from mammalian cells. These data strongly indicate that casein kinase II is associated with immunopurified p53 and contributes to the phosphorylation of p53. A mutant p53 with a ser 389 to ala exchange was not phosphorylated in vitro by the p53 associated protein kinase.	UNIV ULM, DEPT BIOCHEM, PARKSTR 11, W-7900 ULM, GERMANY	Ulm University	MONTENARH, M (corresponding author), UNIV ULM, DEPT BIOCHEM, PARKSTR 11, W-7900 ULM, GERMANY.		Montenarh, Mathias/AAB-6689-2020					Anderson CW., 1986, CANC CELLS, V4, P395; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; COCHET C, 1980, ENDOCRINOLOGY, V106, P750, DOI 10.1210/endo-106-3-750; COX RF, 1973, EUR J BIOCHEM, V39, P49, DOI 10.1111/j.1432-1033.1973.tb03102.x; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLANAGAN JF, 1967, J CELL PHYSIOL, V69, P117, DOI 10.1002/jcp.1040690114; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HAYLES J, 1986, J CELL SCI, P155; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KRAISS S, 1990, ONCOGENE, V5, P845; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KRAISS S, 1990, LEUKEMIA RES, V14, P1041, DOI 10.1016/0145-2126(90)90118-S; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAENPAA PH, 1977, BIOCHIM BIOPHYS ACTA, V498, P294, DOI 10.1016/0304-4165(77)90267-7; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILLER DW, 1986, GENETIC ENG, V8; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; OLIVECRONA T, 1977, FED PROC, V36, P60; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHNEIDER HR, 1988, BIOCHEM BIOPH RES CO, V156, P1390, DOI 10.1016/S0006-291X(88)80786-1; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	67	113	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1991	6	5					877	884						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052362				2022-12-17	WOS:A1991GT82500027
J	WADEY, RB; PAL, N; BUCKLE, B; YEOMANS, E; PRITCHARD, J; COWELL, JK				WADEY, RB; PAL, N; BUCKLE, B; YEOMANS, E; PRITCHARD, J; COWELL, JK			LOSS OF HETEROZYGOSITY IN WILMS-TUMOR INVOLVES 2 DISTINCT REGIONS OF CHROMOSOME-11	ONCOGENE			English	Article									INST CHILD HLTH,DEPT HEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND; HOSP SICK CHILDREN,DEPT HAEMATOL & ONCOL,LONDON WC1N 3JH,ENGLAND	Cancer Research UK; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Cowell, John/0000-0002-2079-5950				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; ALLISON J, 1981, BIOCHEM J, V199, P725, DOI 10.1042/bj1990725; ANTONARAKIS SE, 1983, P NATL ACAD SCI-BIOL, V80, P6615, DOI 10.1073/pnas.80.21.6615; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOEHM T, 1988, ONCOGENE, V3, P691; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DAO DD, 1987, AM J HUM GENET, V41, P202; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; ECCLES MR, 1984, HUM GENET, V67, P190, DOI 10.1007/BF00272999; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GREEN AR, 1988, BRIT J CANCER, V58, P115, DOI 10.1038/bjc.1988.176; GRUNDY P, 1988, NATURE, V336, P375; HAYWARD NK, 1988, CANCER GENET CYTOGEN, V30, P127, DOI 10.1016/0165-4608(88)90100-8; HEIGHWAY J, 1986, BRIT J CANCER, V53, P453, DOI 10.1038/bjc.1986.72; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOPPENER JWM, 1985, HUM GENET, V70, P259; HUFF V, 1987, NUCLEIC ACIDS RES, V15, P7651, DOI 10.1093/nar/15.18.7651; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUFF V, 1989, IN PRESS HUMAN GENET; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; JUNIEN C, 1989, CYTOGENET CELL GENET, V51, P226, DOI 10.1159/000132793; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; LITTLE MH, 1988, HUM GENET, V79, P186, DOI 10.1007/BF00280564; LUNDBERG C, 1987, P NATL ACAD SCI USA, V84, P2372, DOI 10.1073/pnas.84.8.2372; MACKAY J, 1988, BRIT J CANCER, V58, P710, DOI 10.1038/bjc.1988.295; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUNAGA E, 1981, HUM GENET, V57, P231; MILLER RW, 1964, NEW ENGL J MED, V270, P922, DOI 10.1056/NEJM196404302701802; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PING AJ, 1989, AM J HUM GENET, V44, P720; QUAN F, 1985, NUCLEIC ACIDS RES, V13, P8288, DOI 10.1093/nar/13.22.8288; RAIZIS AM, 1985, HUM GENET, V70, P344, DOI 10.1007/BF00295375; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOLIS V, 1988, CANCER GENET CYTOGEN, V34, P223, DOI 10.1016/0165-4608(88)90264-6; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THEILLET C, 1986, CANCER RES, V46, P4776; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TURLEAU C, 1984, HUM GENET, V67, P455, DOI 10.1007/BF00291410; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; WADEY RB, 1989, NUCLEIC ACIDS RES, V17, P3332, DOI 10.1093/nar/17.8.3332; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563; YOKATO J, 1987, P NATL ACAD SCI USA, V84, P9252; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	75	113	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					901	907						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2163053				2022-12-17	WOS:A1990DP55300017
J	Weng, CH; Chen, LY; Lin, YC; Shih, JY; Lin, YC; Tseng, RY; Chiu, AC; Yeh, YH; Liu, C; Lin, YT; Fang, JM; Chen, CC				Weng, Chien-Hui; Chen, Li-Yu; Lin, Yu-Chin; Shih, Jin-Yuan; Lin, Yun-Chieh; Tseng, Ruo-Yu; Chiu, An-Chieh; Yeh, Yu-Hsuan; Liu, Chi; Lin, Yi-Ting; Fang, Jim-Min; Chen, Ching-Chow			Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI	ONCOGENE			English	Article							COENZYME-A REDUCTASE; STEM-CELLS; HISTONE DEACETYLASE; VIMENTIN EXPRESSION; DRUG-RESISTANCE; TYROSINE KINASE; CANCER; INHIBITORS; THERAPY; ROLES	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is a major advance in treating NSCLC with EGFR-activating mutations. However, acquired resistance, due partially to secondary mutations limits their use. Here we report that NSCLC cells with acquired resistance to gefitinib or osimertinib (AZD9291) exhibit EMT features, with a decrease in E-cadherin, and increases in vimentin and stemness, without possessing any EGFR secondary mutations. Knockdown of E-cadherin in parental cells increased gefitinib resistance and stemness, while knockdown of vimentin in resistant cells resulted in opposite effects. Src activation and Hakai upregulation were found in gefitinib-resistant cells. Knockdown of Hakai elevated E-cadherin expression, attenuated stemness, and resensitized the cells to gefitinib. Clinical cancer specimens with acquired gefitinib resistance also showed a decrease in E-cadherin and an increase in Hakai expression. The dual HDAC and HMGR inhibitor JMF3086 inhibited the Src/Hakai and Hakai/E-cadherin interaction to reverse E-cadherin expression, and attenuated vimentin and stemness to restore gefitinib sensitivity. The EMT features of AZD9291-resistant H1975 cells were related to the upregulation of Zeb1. Both gefitinib and AZD9291 sensitivity was restored by JMF3086 through reversing EMT. Our study not only revealed a common mechanism of EMT in both gefitinib and AZD9291 resistance beyond EGFR mutations per se, but also provides a new strategy to overcome it.	[Weng, Chien-Hui; Chen, Li-Yu; Lin, Yu-Chin; Lin, Yun-Chieh; Tseng, Ruo-Yu; Chiu, An-Chieh; Yeh, Yu-Hsuan; Liu, Chi; Lin, Yi-Ting; Chen, Ching-Chow] Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei, Taiwan; [Lin, Yu-Chin] Mennonite Christian Hosp, Dept Internal Med, Hualien, Taiwan; [Shih, Jin-Yuan] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Fang, Jim-Min] Natl Taiwan Univ, Dept Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei, Taiwan.	chingchowchen@ntu.edu.tw	LIN, YU-CHIN/T-9092-2019	SHIH, JIN-YUAN/0000-0002-2854-5067	Ministry of Science and Technology [MOST-106-2320-B002-003]; Excellent Translational Medicine Research Projects of National Taiwan University, College of Medicine; National Taiwan University Hospital [106R39012]; National Health Research Institute of Taiwan [NHRI-EX107-10707BI]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Excellent Translational Medicine Research Projects of National Taiwan University, College of Medicine; National Taiwan University Hospital(National Taiwan University); National Health Research Institute of Taiwan(National Health Research Institutes - Taiwan)	This work was supported by grants from the Ministry of Science and Technology (MOST-106-2320-B002-003), Excellent Translational Medicine Research Projects of National Taiwan University, College of Medicine and National Taiwan University Hospital (106R39012), and the National Health Research Institute of Taiwan (NHRI-EX107-10707BI). We thank the technical assistance of the First Core Labs in the National Taiwan University College of Medicine.	Cao ZW, 2011, CANCER RES, V71, P2286, DOI 10.1158/0008-5472.CAN-10-3367; Charafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845; Chen JB, 2013, J MED CHEM, V56, P3645, DOI 10.1021/jm400179b; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dou J, 2014, CELL BIOL INT, V38, P452, DOI 10.1002/cbin.10223; Figueroa A, 2009, MOL BIOL CELL, V20, P3533, DOI 10.1091/mbc.E08-08-0845; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Honke K, 1997, JPN J CANCER RES, V88, P484, DOI 10.1111/j.1349-7006.1997.tb00407.x; Ishiguro T, 2017, CANCER SCI, V108, P283, DOI 10.1111/cas.13155; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Janne PA, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.10.004; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Katz MS, 2005, NAT CLIN PRACT ONCOL, V2, P82, DOI 10.1038/ncponc0097; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807; Lin YC, 2015, CLIN CANCER RES, V21, P428, DOI 10.1158/1078-0432.CCR-14-1150; Liu YN, 2015, ONCOTARGET, V6, P10415, DOI 10.18632/oncotarget.3389; Locke I, 2002, NEW ENGL J MED, V346, P1498; Meidhof S, 2015, EMBO MOL MED, V7, P831, DOI 10.15252/emmm.201404396; Mikami S, 2011, LAB INVEST, V91, P1443, DOI 10.1038/labinvest.2011.111; Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496; Pao W, 2009, CLIN CANCER RES, V15, P5317, DOI 10.1158/1078-0432.CCR-09-0913; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654; Sequist LV, 2007, J CLIN ONCOL, V25, P587, DOI 10.1200/JCO.2006.07.3585; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Wei TT, 2016, EBIOMEDICINE, V10, P124, DOI 10.1016/j.ebiom.2016.07.019; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246	48	112	119	1	40	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					455	468		10.1038/s41388-018-0454-2	http://dx.doi.org/10.1038/s41388-018-0454-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30111817				2022-12-17	WOS:000456589800001
J	Zhang, JP; Zeng, C; Xu, L; Gong, J; Fang, JH; Zhuang, SM				Zhang, J-P; Zeng, C.; Xu, L.; Gong, J.; Fang, J-H; Zhuang, S-M			MicroRNA-148a suppresses the epithelial-mesenchymal transition and metastasis of hepatoma cells by targeting Met/Snail signaling	ONCOGENE			English	Article						miR-148a; epithelial-mesenchymal transition; metastasis; met; hepatocellular carcinoma	HEPATOCELLULAR-CARCINOMA; E-CADHERIN; PROMOTES APOPTOSIS; GASTRIC-CANCER; EXPRESSION; SNAIL; CONTRIBUTES; INVASION; BETA; MET	Metastasis is responsible for the rapid recurrence and poor survival of malignancies. Epithelial-mesenchymal transition (EMT) has a critical role in metastasis. Increasing evidence indicates that EMT can be regulated by microRNAs (miRNAs). miR-148a is a liver-abundant miRNA. However, the role of miR-148a in the development of liver cancer remains largely unknown. In this study, we found that, compared with normal livers, miR-148a was significantly decreased in hepatocellular carcinoma (HCC) tissues, especially in those with the portal vein tumor thrombus. An in vitro transwell assay and an in vivo orthotopic liver xenograft model showed that the restoration of miR-148a expression significantly repressed the migration and pulmonary metastasis of hepatoma cells. Linear regression analysis revealed a positive correlation between the expression of miR-148a and the mRNA level of E-cadherin gene in human HCC tissues. Both gain-and loss-of-function studies disclosed that miR-148a promoted the expression of epithelial marker (E-cadherin) and reduced the levels of mesenchymal markers (N-cadherin, fibronectin or vimentin) in hepatoma cells. These data suggest that miR-148a may suppress EMT and cancer metastasis. Further mechanistic investigations showed that miR-148a directly inhibited Met expression by binding to its 3'-UTR. Moreover, the reintroduction of miR-148a attenuated the downstream signaling of Met, like activated phosphorylation of AKT-Ser473 and inhibitory phosphorylation of GSK-3b-Ser9, and consequently reduced the nuclear accumulation of Snail, a transcription factor that promotes EMT. Taken together, miR-148a may negatively regulate Met/Snail signaling and therefore inhibit the EMT and metastasis of hepatoma cells. These findings highlight the significance of miR-148a downregulation in tumor progression and implicate miR-148a as an attractive candidate for cancer therapy.	[Zhang, J-P; Zeng, C.; Gong, J.; Fang, J-H; Zhuang, S-M] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Key Lab Gene Engn,Minist Educ, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, J-P; Xu, L.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Zhuang, SM (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Xin Gang Xi Rd 135, Guangzhou 510275, Guangdong, Peoples R China.	zhuangshimei@163.com	Fang, Jian-hong/HCH-6747-2022; ZHANG, JINGPING/AAT-8229-2021; zhang, jingping/AAM-2751-2021	zhang, jingping/0000-0003-0090-6710; Fang, Jian-hong/0000-0002-7723-5348; Zhuang, Shi-Mei/0000-0002-2512-3942	Ministry of Science and Technology of China [2010CB912803, 2011CB811305]; Ministry of Health of China [2012ZX10002011]; National Natural Science Foundation of China [81101593, 30925036]; Ministry of Education of China [20110171120043]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Health of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China)	This study was supported by grants from Ministry of Science and Technology of China (2010CB912803, 2011CB811305), Ministry of Health of China (2012ZX10002011), National Natural Science Foundation of China (81101593, 30925036), Ministry of Education of China (20110171120043).	Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; Gailhouste L, 2013, HEPATOLOGY, V58, P1153, DOI 10.1002/hep.26422; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Khew-Goodall Y, 2010, NAT CELL BIOL, V12, P209, DOI 10.1038/ncb0310-209; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Liffers ST, 2011, LAB INVEST, V91, P1472, DOI 10.1038/labinvest.2011.99; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Papadimitriou E, 2012, ONCOGENE, V31, P2862, DOI 10.1038/onc.2011.457; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; Wei Y, 2002, HEPATOLOGY, V36, P692, DOI 10.1053/jhep.2002.35342; Xu Q, 2013, CARCINOGENESIS, V34, P539, DOI 10.1093/carcin/bgs374; Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; You HN, 2011, HEPATOLOGY, V54, P879, DOI 10.1002/hep.24450; Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5; Zhang H, 2011, CELL DEATH DIFFER, V18, P1702, DOI 10.1038/cdd.2011.28; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	34	112	119	1	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4069	4076		10.1038/onc.2013.369	http://dx.doi.org/10.1038/onc.2013.369			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24013226				2022-12-17	WOS:000340595300006
J	Mao, B; Hu, F; Cheng, J; Wang, P; Xu, M; Yuan, F; Meng, S; Wang, Y; Yuan, Z; Bi, W				Mao, B.; Hu, F.; Cheng, J.; Wang, P.; Xu, M.; Yuan, F.; Meng, S.; Wang, Y.; Yuan, Z.; Bi, W.			SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma	ONCOGENE			English	Article						SIRT1; YAP; acetylation; transcription; hepatocellular carcinoma	TRANSCRIPTION FACTORS; GROWTH-CONTROL; DNA-DAMAGE; ACETYLATION; DEACETYLASE; ACTIVATION; YAP; PATHWAY; INACTIVATION; MODULATION	The MST/YAP (mammalian Ste20-like kinase/Yes-associated protein 2) pathway plays an important role in hepatocellular carcinoma (HCC). Although post-translational modification-especially MST/Lats (large tumor suppressor)-mediated phosphorylation and PP1 (protein phosphatase-1)-mediated dephosphorylation-has been found to regulate the activity of YAP2, very little is known about its acetylation. In our experiments, we observed that the expression of SIRT1 is significantly upregulated in the tumor samples of the hepatocarcinoma patients, and SIRT1 mRNA level positively correlates with connective tissue growth factor (CTGF) mRNA level. We then found that SIRT1 deacetylates YAP2 protein in HCC cells and SIRT1-mediated deacetylation increases the YAP2/TEAD4 association, leading to YAP2/TEAD4 transcriptional activation and upregulated cell growth in HCC cells. Moreover, knockdown of SIRT1 blocks the cisplatin (CDDP)-induced nuclear translocation of YAP2 and enhances the chemosensitivity of HCC cells to CDDP treatment. Together, our findings reveal a new regulatory mechanism of YAP2 by the SIRT1-mediated deacetylation that may be involved in HCC tumorigenesis and drug resistance.	[Mao, B.; Cheng, J.; Wang, P.; Yuan, Z.] Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; [Hu, F.] Tianjin Hosp, Dept Orthoped, Tianjin, Peoples R China; [Xu, M.; Yuan, F.; Wang, Y.; Bi, W.] Chinese Peoples Liberat Army Gen Hosp, Clin Div Surg, Dept Orthoped, Beijing 100853, Peoples R China; [Meng, S.] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Dalian, Peoples R China; [Meng, S.; Yuan, Z.] Chinese Hippo Consortium, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese People's Liberation Army General Hospital; Dalian Medical University	Yuan, Z (corresponding author), Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China.	zqyuan@ibp.ac.cn; biwenzhi@sina.com	Yuan, Zengqiang/G-5245-2017		National Science Foundation of China [81172553, 81201564, 81125010, 81030025]; Ministry of Science and Technology of China [973-2009CB918704, 973-2012CB910701]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Dr Depei Liu for the gift of all the SIRT1 plasmids; Dr Lei Zhang for the 3*SD binding site artificial-luciferase reporter plasmid; Dr Zhixiong Xiao for the p73 antibody; Ursula Adams for manuscript editing; and Xudong Zhao and Su Liu of IBP core facility center for technical support. This work was supported by the National Science Foundation of China (81172553, 81201564, 81125010 and 81030025), and the Ministry of Science and Technology of China (973-2009CB918704 and 973-2012CB910701).	Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Hata S, J BIOL CHEM, V287, P22089; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kemper JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Molloy D, 2006, VIROLOGY, V355, P115, DOI 10.1016/j.virol.2006.05.004; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024288; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	32	112	121	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1468	1474		10.1038/onc.2013.88	http://dx.doi.org/10.1038/onc.2013.88			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542177				2022-12-17	WOS:000332943500014
J	Rius, M; Lyko, F				Rius, M.; Lyko, F.			Epigenetic cancer therapy: rationales, targets and drugs	ONCOGENE			English	Review						DNA methylation; chromatin; DNA methyltransferase inhibitors; histone deacetylase inhibitors; metabolic activation; stem cells	DNA METHYLTRANSFERASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; B-CELL LYMPHOMAS; MYELODYSPLASTIC SYNDROME; NUCLEOSIDE ANALOGS; IN-VIVO; CYTOSINE-ARABINOSIDE; SOMATIC MUTATIONS; GENE EZH2	The fundamental role of altered epigenetic modification patterns in tumorigenesis establishes epigenetic regulatory enzymes as important targets for cancer therapy. Over the past few years, several drugs with an epigenetic activity have received approval for the treatment of cancer patients, which has led to a detailed characterization of their modes of action. The results showed that both established drug classes, the histone deacetylase (HDAC) inhibitors and the DNA methyltransferase inhibitors, show substantial limitations in their epigenetic specificity. HDAC inhibitors are highly specific drugs, but the enzymes have a broad substrate specificity and deacetylate numerous proteins that are not associated with epigenetic regulation. Similarly, the induction of global DNA demethylation by non-specific inhibition of DNA methyltransferases shows pleiotropic effects on epigenetic regulation with no apparent tumor-specificity. Second-generation azanucleoside drugs have integrated the knowledge about the cellular uptake and metabolization pathways, but do not show any increased specificity for cancer epigenotypes. As such, the traditional rationale of epigenetic cancer therapy appears to be in need of refinement, as we move from the global inhibition of epigenetic modifications toward the identification and targeting of tumor-specific epigenetic programs. Recent studies have identified epigenetic mechanisms that promote self-renewal and developmental plasticity in cancer cells. Druggable somatic mutations in the corresponding epigenetic regulators are beginning to be identified and should facilitate the development of epigenetic therapy approaches with improved tumor specificity. Oncogene (2012) 31, 4257-4265; doi:10.1038/onc.2011.601; published online 19 December 2011	[Rius, M.; Lyko, F.] German Canc Res Ctr, Div Epigenet, DKFZ ZMBH Alliance, D-6900 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Lyko, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	f.lyko@dkfz.de			Clavis Pharma; Deutsche Forschungsgemeinschaft [RI 2121/1-1]; Deutsche Krebshilfe [109773]	Clavis Pharma; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	Maria Rius declares no conflict of interest. Frank Lyko received a commercial research grant from Clavis Pharma.; We thank Bodo Bruckner for critically reading the manuscript. This work is supported by grants from the Deutsche Forschungsgemeinschaft (RI 2121/1-1) and Deutsche Krebshilfe (grant number 109773).	Aiden AP, 2010, CELL STEM CELL, V6, P591, DOI 10.1016/j.stem.2010.03.016; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bhatla D, 2009, BRIT J HAEMATOL, V144, P388, DOI 10.1111/j.1365-2141.2008.07461.x; Bocker MT, 2011, BLOOD, V117, pE182, DOI 10.1182/blood-2011-01-331926; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Broske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463; Brueckner B, 2010, MOL CANCER THER, V9, P1256, DOI 10.1158/1535-7163.MCT-09-1202; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Choi SH, 2007, BRIT J HAEMATOL, V138, P616, DOI 10.1111/j.1365-2141.2007.06707.x; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172; Chuang JC, 2010, MOL CANCER THER, V9, P1443, DOI 10.1158/1535-7163.MCT-09-1048; Cole SPC, 2006, TRENDS PHARMACOL SCI, V27, P438, DOI 10.1016/j.tips.2006.06.008; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Damaraju VL, 2009, NUCLEOS NUCLEOT NUCL, V28, P450, DOI 10.1080/15257770903044499; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547; FLASSHOVE M, 1994, LEUKEMIA, V8, P780; Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hagemann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017388; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001; Howard G, 2008, ONCOGENE, V27, P404, DOI 10.1038/sj.onc.1210631; Huang Y, 2004, CANCER RES, V64, P4294, DOI 10.1158/0008-5472.CAN-03-3884; Huber-Ruano I, 2009, CURR DRUG METAB, V10, P347, DOI 10.2174/138920009788499030; Issa JPJ, 2009, CLIN CANCER RES, V15, P3938, DOI 10.1158/1078-0432.CCR-08-2783; Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kroep JR, 2002, MOL CANCER THER, V1, P371; Kuck D, 2010, BIOORGAN MED CHEM, V18, P822, DOI 10.1016/j.bmc.2009.11.050; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; LI LH, 1970, CANCER RES, V30, P2760; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Lizardi PM, 2010, ONCOGENE, V29, P5772, DOI 10.1038/onc.2010.372; Maring JG, 2010, EUR J CLIN PHARMACOL, V66, P611, DOI 10.1007/s00228-010-0799-0; Medina-Franco JL, 2011, MOL DIVERS, V15, P293, DOI 10.1007/s11030-010-9262-5; Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Parmar S, 2011, PHARMACOGENOMICS, V12, P503, DOI [10.2217/PGS.10.200, 10.2217/pgs.10.200]; Pastor-Anglada M, 2005, VIRUS RES, V107, P151, DOI 10.1016/j.virusres.2004.11.005; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038; Rius M, 2010, DRUG METAB DISPOS, V38, P1054, DOI 10.1124/dmd.110.032664; Rius M, 2009, MOL CANCER THER, V8, P225, DOI 10.1158/1535-7163.MCT-08-0743; Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576; STEGMANN APA, 1995, LEUKEMIA, V9, P1032; Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821; Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607; Van Rompay AR, 2001, MOL PHARMACOL, V59, P1181, DOI 10.1124/mol.59.5.1181; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Weber B, 2010, ONCOGENE, V29, P5775, DOI 10.1038/onc.2010.227; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yoo CB, 2007, CANCER RES, V67, P6400, DOI 10.1158/0008-5472.CAN-07-0251	80	112	117	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4257	4265		10.1038/onc.2011.601	http://dx.doi.org/10.1038/onc.2011.601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179827	Bronze			2022-12-17	WOS:000309520200001
J	Leber, B; Lin, J; Andrews, DW				Leber, B.; Lin, J.; Andrews, D. W.			Still embedded together binding to membranes regulates Bcl-2 protein interactions	ONCOGENE			English	Review						apoptosis; model; membranes; Bcl-2; Bcl-XL; Bax	CONFORMATIONAL-CHANGE; BAX ACTIVATION; CELL-SURVIVAL; APOPTOSIS; BCL-X(L); BH3; BIM; MITOCHONDRIA; CANCER; FAMILY	The dysregulation of apoptosis is a key step in developing tumours, and mediates resistance to cancer therapy. Many different signals for cell death converge on permeabilization of the outer mitochondrial membrane, which is controlled by the Bcl-2 family of proteins. The importance of this step is becoming increasingly relevant as the first generation of small molecules that inhibit the interaction of Bcl-2 family proteins enters clinical trials as anticancer agents. The Bcl-2 family can be divided into three classes: BH3-only proteins that are activated by various forms of cellular stress, Bax and Bak proteins that mediate mitochondrial membrane permeabilization, and inhibitory proteins such as Bcl-2 and Bcl-XL. The recently proposed embedded together model emphasizes the fact that many of the regulatory interactions between different classes of Bcl-2 family members occur at intracellular membranes, and binding to membranes causes conformational changes in the proteins that dictate functions in a dynamic manner. Within this context, recent results indicate that Bcl-XL functions as a dominant-negative Bax, a concept that resolves the paradox of similar structures but opposite functions of Bcl-XL and Bax. We have also shown that the conformational change that allows Bax to insert into the outer mitochondrial membrane is the rate-limiting step in the multistep process of Bax activation. Nevertheless, investigating the structure of activated Bax or Bak as monomers and as components of the oligomeric structures that mediate membrane permeabilization is the focus of ongoing research (and controversy) at many laboratories worldwide. Oncogene (2010) 29, 5221-5230; doi:10.1038/onc.2010.283; published online 19 July 2010	[Leber, B.; Andrews, D. W.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Leber, B.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Lin, J.] Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	McMaster University; McMaster University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, 1200 Main St W,Room 4H-41, Hamilton, ON L8N 3Z5, Canada.	andrewsd@dwalab.ca		Leber, Brian/0000-0001-5502-1480; Andrews, David/0000-0002-9266-7157	Canadian Institute of Health Research (CIHR) [FRN12517]; Tier-I Canada Research Chair in Membrane Biogenesis; NIH [GM062964]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Tier-I Canada Research Chair in Membrane Biogenesis(Canada Research Chairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Work from our laboratories cited in this review was supported by a Canadian Institute of Health Research (CIHR FRN12517) Grant to DWA and BL, by a Tier-I Canada Research Chair in Membrane Biogenesis to DWA and by NIH Grant GM062964 to JL.	Albeck JG, 2008, PLOS BIOL, V6, P2831, DOI 10.1371/journal.pbio.0060299; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Billen LP, 2008, ONCOGENE, V27, pS93, DOI 10.1038/onc.2009.47; Billen LP, 2008, PLOS BIOL, V6, P1268, DOI 10.1371/journal.pbio.0060147; Brunelle JK, 2009, J CELL BIOL, V187, P429, DOI 10.1083/jcb.200904049; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Chonghaile TN, 2008, ONCOGENE, V27, pS149, DOI 10.1038/onc.2009.52; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Czabotar PE, 2009, CELL DEATH DIFFER, V16, P1187, DOI 10.1038/cdd.2009.83; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Denisov AY, 2007, BIOCHEMISTRY-US, V46, P734, DOI 10.1021/bi062080a; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Dewson G, 2009, MOL CELL, V36, P696, DOI 10.1016/j.molcel.2009.11.008; Dewson G, 2009, J CELL SCI, V122, P2801, DOI 10.1242/jcs.038166; Dlugosz PJ, 2006, EMBO J, V25, P2287, DOI 10.1038/sj.emboj.7601126; Fiebig AA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-213; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; George NM, 2007, GENE DEV, V21, P1937, DOI 10.1101/gad.1553607; Green DR, 2008, NATURE, V455, P1047, DOI 10.1038/4551047a; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hekman M, 2006, J BIOL CHEM, V281, P17321, DOI 10.1074/jbc.M600292200; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Ivashyna O, 2009, J BIOL CHEM, V284, P23935, DOI 10.1074/jbc.M109.023853; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim H, 2009, MOL CELL, V36, P487, DOI 10.1016/j.molcel.2009.09.030; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Leber B, 2007, APOPTOSIS, V12, P897, DOI 10.1007/s10495-007-0746-4; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Merino D, 2009, J CELL BIOL, V186, P355, DOI 10.1083/jcb.200905153; Moldoveanu T, 2006, MOL CELL, V24, P677, DOI 10.1016/j.molcel.2006.10.014; Peng J, 2006, J BIOL CHEM, V281, P35802, DOI 10.1074/jbc.M608303200; Pinon JD, 2008, ONCOGENE, V27, pS41, DOI 10.1038/onc.2009.42; Ploner C, 2008, ONCOGENE, V27, pS84, DOI 10.1038/onc.2009.46; Polzien L, 2009, J BIOL CHEM, V284, P28004, DOI 10.1074/jbc.M109.010702; Roy SS, 2009, MOL CELL, V33, P377, DOI 10.1016/j.molcel.2009.01.018; Schafer B, 2009, MOL BIOL CELL, V20, P2276, DOI 10.1091/mbc.E08-10-1056; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Tan CB, 2006, J BIOL CHEM, V281, P14764, DOI 10.1074/jbc.M602374200; Terrones O, 2008, J BIOL CHEM, V283, P7790, DOI 10.1074/jbc.M708814200; Wang H, 2009, J STRUCT BIOL, V166, P32, DOI 10.1016/j.jsb.2008.12.003; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang Z, 2004, J BIOL CHEM, V279, P43920, DOI 10.1074/jbc.M406412200; Zhang Z, 2010, J BIOL CHEM, V285, P17614, DOI 10.1074/jbc.M110.113456; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	61	112	121	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5221	5230		10.1038/onc.2010.283	http://dx.doi.org/10.1038/onc.2010.283			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20639903	Green Accepted			2022-12-17	WOS:000282089100001
J	Millour, J; Constantinidou, D; Stavropoulou, AV; Wilson, MSC; Myatt, SS; Kwok, JMM; Sivanandan, K; Coombes, RC; Medema, RH; Hartman, J; Lykkesfeldt, AE; Lam, EWF				Millour, J.; Constantinidou, D.; Stavropoulou, A. V.; Wilson, M. S. C.; Myatt, S. S.; Kwok, J. M-M; Sivanandan, K.; Coombes, R. C.; Medema, R. H.; Hartman, J.; Lykkesfeldt, A. E.; Lam, E. W-F			FOXM1 is a transcriptional target of ER alpha and has a critical role in breast cancer endocrine sensitivity and resistance	ONCOGENE			English	Article						breast cancer; forkhead; estrogen receptor; FOXM1; endocrine resistance; transcription	ESTROGEN-RECEPTOR-ALPHA; CYCLIN D1; HEPATOCYTE ENTRY; REGULATED GENES; FACTOR HFH-11B; GROWTH-FACTOR; CELL-LINES; S-PHASE; EXPRESSION; MOUSE	In this study, we investigated the regulation of FOXM1 expression by estrogen receptor alpha (ER alpha) and its role in hormonal therapy and endocrine resistance. FOXM1 protein and mRNA expression was regulated by ER-ligands, including estrogen, tamoxifen (OHT) and fulvestrant (ICI182780; ICI) in breast carcinoma cell lines. Depletion of ER alpha by RNA interference (RNAi) in MCF-7 cells downregulated FOXM1 expression. Reporter gene assays showed that ER alpha activates FOXM1 transcription through an estrogen-response element ( ERE) located within the proximal promoter region. The direct binding of ER alpha to the FOXM1 promoter was confirmed in vitro by mobility shift and DNA pull-down assays and in vivo by chromatin immunoprecipitation (ChIP) analysis. Our data also revealed that upon OHT treatment ER alpha recruits histone deacetylases to the ERE site of the FOXM1 promoter, which is associated with a decrease in histone acetylation and transcription activity. Importantly, silencing of FOXM1 by RNAi abolished estrogen-induced MCF-7 cell proliferation and overcame acquired tamoxifen resistance. Conversely, ectopic expression of FOXM1 abrogated the cell cycle arrest mediated by the antiestrogen OHT. OHT repressed FOXM1 expression in endocrine sensitive but not resistant breast carcinoma cell lines. Furthermore, qRT-PCR analysis of breast cancer patient samples revealed that there was a strong and significant positive correlation between ERa and FOXM1 mRNA expression. Collectively, these results show FOXM1 to be a key mediator of the mitogenic functions of ER alpha and estrogen in breast cancer cells, and also suggest that the deregulation of FOXM1 may contribute to anti-estrogen insensitivity. Oncogene (2010) 29, 2983-2995; doi:10.1038/onc.2010.47; published online 8 March 2010	[Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, CR UK Labs, Dept Surg & Canc, London W12 0NN, England; [Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Hartman, J.] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden; [Lykkesfeldt, A. E.] Danish Canc Soc, Inst Canc Biol, Dept Breast Canc Res, Copenhagen, Denmark	Imperial College London; Utrecht University; Utrecht University Medical Center; Karolinska Institutet; Danish Cancer Society	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, CR UK Labs, Dept Surg & Canc, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Wilson, Miranda/W-1453-2019; Medema, Rene H/E-2981-2013; Hartman, Johan/N-1406-2015; Medema, Rene H/G-5415-2011; Teh, Muy-Teck/B-9284-2016; Lam, Eric W-F/AAW-8566-2020	Wilson, Miranda/0000-0001-7521-4036; Hartman, Johan/0000-0002-6500-8527; Teh, Muy-Teck/0000-0002-7725-8355; Lam, Eric W-F/0000-0003-1274-3576; Coombes, Raoul Charles/0000-0002-4811-1100	Breast Cancer Campaign; Cancer Research UK; Biotechnology and Biological Sciences Research Council; Cancer Research UK [12011] Funding Source: researchfish	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK)	Grant support was given by Breast Cancer Campaign (J Millour and EW-F Lam), Cancer Research UK (SS Myatt, K-K Ho, RC Coombes, EW-F Lam), Biotechnology and Biological Sciences Research Council (MSC Wilson and EW-F Lam).	Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441; BRUNNER N, 1989, CANCER CELL-MON REV, V1, P81; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Carroll JS, 2006, MOL ENDOCRINOL, V20, P1707, DOI 10.1210/me.2005-0334; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cicatiello L, 2004, J MOL ENDOCRINOL, V32, P719, DOI 10.1677/jme.0.0320719; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; DIAZARIAS AA, 1993, DIAGN CYTOPATHOL, V9, P516, DOI 10.1002/dc.2840090509; Elkak AE, 2001, CURR MED RES OPIN, V17, P282, DOI 10.1185/030079901753403180; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Essafi Abdelkader, 2009, V462, P201, DOI 10.1007/978-1-60327-115-8_13; Fellowes VS, 2004, INT J ONCOL, V24, P861; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; GAPINSKI PV, 1980, SURGERY, V88, P386; Goss PE, 2008, CLIN BREAST CANCER, V8, P411, DOI 10.3816/CBC.2008.n.049; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kothari MS, 2003, BRIT J CANCER, V88, P1071, DOI 10.1038/sj.bjc.6600866; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2008, CELL CYCLE, V7, P2720, DOI 10.4161/cc.7.17.6580; Laoukili J, 2008, MOL CELL BIOL, V28, P3076, DOI 10.1128/MCB.01710-07; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150; Luscher-Firzlaff JM, 2006, FEBS LETT, V580, P1716, DOI 10.1016/j.febslet.2006.02.021; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1986, BREAST CANCER RES TR, V7, P83; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Madsen MW, 1997, CANCER RES, V57, P585; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Myatt SS, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-6; OSBORNE CK, 1979, B CANCER, V66, P203; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Schug Jonathan, 2008, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0206s21; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Tashiro E, 2007, CANCER SCI, V98, P629, DOI 10.1111/j.1349-7006.2007.00449.x; WANG XD, 2005, J ORGAN DYSFUNCT, V1, P2; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Wang Y, 2008, CANCER RES, V68, P5628, DOI 10.1158/0008-5472.CAN-07-3170; Wierstra I, 2006, BIOCHEM BIOPH RES CO, V348, P99, DOI 10.1016/j.bbrc.2006.07.008; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; Yamashita H, 2008, INT J CLIN ONCOL, V13, P380, DOI 10.1007/s10147-008-0818-7; Yamashita H, 2009, CANCER SCI, V100, P2028, DOI 10.1111/j.1349-7006.2009.01274.x; Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Zwart W, 2009, MOL ENDOCRINOL, V23, P1335, DOI 10.1210/me.2008-0268	54	112	119	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2983	2995		10.1038/onc.2010.47	http://dx.doi.org/10.1038/onc.2010.47			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208560	Green Accepted, Green Submitted			2022-12-17	WOS:000277890400009
J	Schneider, G; Henrich, A; Greiner, G; Wolf, V; Lovas, A; Wieczorek, M; Wagner, T; Reichardt, S; von Werder, A; Schmid, RM; Weih, F; Heinzel, T; Saur, D; Kramer, OH				Schneider, G.; Henrich, A.; Greiner, G.; Wolf, V.; Lovas, A.; Wieczorek, M.; Wagner, T.; Reichardt, S.; von Werder, A.; Schmid, R. M.; Weih, F.; Heinzel, T.; Saur, D.; Kraemer, O. H.			Cross talk between stimulated NF-kappa B and the tumor suppressor p53	ONCOGENE			English	Article						NF-kappa B; p53; S-phase; hydroxyurea; TNF-alpha; apoptosis	ACID PHENETHYL ESTER; NECROSIS-FACTOR-ALPHA; DNA-DAMAGE; CELL-CYCLE; INDUCED APOPTOSIS; GENE-EXPRESSION; MOUSE MODEL; ACTIVATION; CANCER; PATHWAY	Nuclear factor-kappa B (NF-kappa B) and p53 critically determine cancer development and progression. Defining the cross talk between these transcription factors can expand our knowledge on molecular mechanisms of tumorigenesis. Here, we show that induction of replicational stress activates NF-kappa B p65 and triggers its interaction with p53 in the nucleus. Experiments with knockout cells show that p65 and p53 are both required for enhanced NF-kappa B activity during S-phase checkpoint activation involving ataxiatelangiectasia mutated and checkpoint kinase-1. Accordingly, the pro-inflammatory cytokine tumor necrosis factora alpha (TNF-alpha) also triggers formation of a transcriptionally active complex containing nuclear p65 and p53 on jB response elements. Gene expression analyses revealed that, independent of NF-kappa B activation in the cytosol, TNFinduced NF-kappa B-directed gene expression relies on p53. Hence, p53 is unexpectedly necessary for NF-kappa B-mediated gene expression induced by atypical and classical stimuli. Remarkably, data from gain- and loss-of function approaches argue that anti-apoptotic NF-kappa B p65 activity is constitutively evoked by a p53 hot-spot mutant frequently found in tumors. Our observations suggest explanations for the outstanding question why p53 mutations rather than p53 deletions arise in tumors of various origins. Oncogene (2010) 29, 2795-2806; doi: 10.1038/onc.2010.46; published online 1 March 2010	[Greiner, G.; Wolf, V.; Wieczorek, M.; Wagner, T.; Reichardt, S.; Heinzel, T.; Kraemer, O. H.] Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Dept Biochem, D-07743 Jena, Germany; [Schneider, G.; Henrich, A.; von Werder, A.; Schmid, R. M.; Saur, D.] Tech Univ Munich, Med Klin, Klinikum Rechts Isar 2, Munich, Germany; [Lovas, A.; Weih, F.] Fritz Lipmann Inst, Leibniz Inst Age Res, Jena, Germany	Friedrich Schiller University of Jena; Technical University of Munich; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Kramer, OH (corresponding author), Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Dept Biochem, Hans Knoll Str 2, D-07743 Jena, Germany.	oliver.kraemer@uni-jena.de	Heinzel, Thorsten/B-1013-2015; Krämer, Oliver H/L-9266-2015; Saur, Dieter/G-4629-2011; Saur, Dieter/O-8355-2015	Krämer, Oliver H/0000-0003-3973-045X; Saur, Dieter/0000-0001-5874-0210	DFG [SCHN 959/1-2, SFB456]; Landesprogramm 'ProExzellenz' [PE 123-2-1]; Deutsche Krebshilfe	DFG(German Research Foundation (DFG)); Landesprogramm 'ProExzellenz'; Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Dr B Vogelstein for HCT-116 cells, Dr A Hoffmann for wild-type and Rel A/ MEFs, Dr T Jacks and Dr D Tuveson for LSL-KRAS<SUP>G12D</SUP> and LSL-p53<SUP>R172H</SUP> mice, Dr A Berns for TP53<SUP>lox/lox</SUP> mice, Dr H Nakhai for Ptf1a/p48<SUP>ex1Cre/+</SUP> mice, Dr R Bernards and Dr R Agami for shRNA against p53, M Buchwald for help with electroporation, Dr A Licht for help with EMSAs, Dr Z-Q Wang and Dr W-K Min for wild-type and p53/ MEFs and very helpful discussions and suggestions. This study was supported by DFG (SCHN 959/1-2) and SFB456 grants to GS, Landesprogramm 'ProExzellenz' (PE 123-2-1) to OHK, and a grant from Deutsche Krebshilfe to GS and OHK.	Alsafadi S, 2009, CURR MED CHEM, V16, P4328, DOI 10.2174/092986709789578196; Ansari SA, 2001, EXP CELL RES, V265, P221, DOI 10.1006/excr.2001.5168; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Armstrong MB, 2006, NEOPLASIA, V8, P967, DOI 10.1593/neo.06574; Bar J, 2009, ONCOGENE, V28, P933, DOI 10.1038/onc.2008.445; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Deppert W, 2007, ONCOGENE, V26, P2142, DOI 10.1038/sj.onc.1210276; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Finkel T, 2007, NATURE, V448, P767, DOI 10.1038/nature05985; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Gapuzan MER, 2005, ONCOGENE, V24, P6574, DOI 10.1038/sj.onc.1208809; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Grallert B, 2008, CELL CYCLE, V7, P2315, DOI 10.4161/cc.6389; Ha J, 2009, INT IMMUNOPHARMACOL, V9, P774, DOI 10.1016/j.intimp.2009.03.001; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi T, 2007, J IMMUNOL, V178, P7385, DOI 10.4049/jimmunol.178.11.7385; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Ho CC, 2006, CANCER RES, V66, P2233, DOI 10.1158/0008-5472.CAN-05-1790; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Hung MW, 2003, ANTICANCER RES, V23, P4773; Janssens S, 2006, CELL DEATH DIFFER, V13, P773, DOI 10.1038/sj.cdd.4401843; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Kaustov L, 2006, CELL CYCLE, V5, P489, DOI 10.4161/cc.5.5.2489; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; Kawauchi K, 2008, BIOCHEM BIOPH RES CO, V372, P137, DOI 10.1016/j.bbrc.2008.05.021; Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com; Kramer OH, 2008, ONCOGENE, V27, P732, DOI 10.1038/sj.onc.1210677; Kramer OH, 2009, TRENDS PHARMACOL SCI, V30, P647, DOI 10.1016/j.tips.2009.09.007; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Lee YJ, 2003, BIOCHEM PHARMACOL, V66, P2281, DOI 10.1016/j.bcp.2003.07.014; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Li J, 2007, J CLIN INVEST, V117, P3283, DOI 10.1172/JCI31772; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marusyk A, 2007, CELL CYCLE, V6, P2148, DOI 10.4161/cc.6.17.4732; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Nesic D, 2008, MOL CANCER RES, V6, P1193, DOI 10.1158/1541-7786.MCR-07-2125; O'Brien DI, 2005, EXPERT OPIN THER TAR, V9, P1031, DOI 10.1517/14728222.9.5.1031; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Ravi R, 1998, CANCER RES, V58, P4531; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schafer T, 2003, FASEB J, V17, P660, DOI 10.1096/fj.02-0774com; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schneider G, 2006, EMBO J, V25, P3801, DOI 10.1038/sj.emboj.7601259; Schrell UMH, 1996, LANCET, V348, P888, DOI 10.1016/S0140-6736(05)64757-5; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Seidler B, 2008, P NATL ACAD SCI USA, V105, P10137, DOI 10.1073/pnas.0800487105; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027; Szoltysek K, 2008, ACTA BIOCHIM POL, V55, P741; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023; Tsai CJ, 2009, TRENDS BIOCHEM SCI, V34, P594, DOI 10.1016/j.tibs.2009.07.007; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang W, 2008, CURR OPIN ONCOL, V20, P90, DOI 10.1097/CCO.0b013e3282f31d6f; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425; Wietek C, 2007, TRENDS BIOCHEM SCI, V32, P311, DOI 10.1016/j.tibs.2007.05.003; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127; Yan B, 2006, CANCER RES, V66, P11565, DOI 10.1158/0008-5472.CAN-06-2540; Yazdanpanah B, 2009, NATURE, V460, P1159, DOI 10.1038/nature08206; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yoshida K, 2008, ONCOGENE, V27, P1183, DOI 10.1038/sj.onc.1210722; Zhang XP, 2009, P NATL ACAD SCI USA, V106, P12245, DOI 10.1073/pnas.0813088106	82	112	114	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2795	2806		10.1038/onc.2010.46	http://dx.doi.org/10.1038/onc.2010.46			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190799				2022-12-17	WOS:000277591900005
J	Goel, VK; Ibrahim, N; Jiang, G; Singhal, M; Fee, S; Flotte, T; Westmoreland, S; Haluska, FS; Hinds, PW; Haluska, FG				Goel, V. K.; Ibrahim, N.; Jiang, G.; Singhal, M.; Fee, S.; Flotte, T.; Westmoreland, S.; Haluska, F. S.; Hinds, P. W.; Haluska, F. G.			Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice	ONCOGENE			English	Article						BRAF; p53; CDKN2A; AKT; melanoma; senescence	BRAF MUTATIONS; TUMOR SUPPRESSION; P53; ACTIVATION; SENESCENCE; INK4A; LOCUS; MDM2; INACTIVATION; INHIBITION	BRAF, a cellular oncogene and effector of RAS-mediated signaling, is activated by mutation in similar to 60% of melanomas. Most of these mutations consist of a V600E substitution resulting in constitutive kinase activation. Mutant BRAF thus represents an important therapeutic target in melanoma. In an effort to produce a pre-clinical model of mutant BRAF function in melanoma, we have generated a mouse expressing BRAF V600E targeted to melanocytes. We show that in these transgenic mice, widespread benign melanocytic hyperplasia with histological features of nevi occurs, with biochemical evidence of senescence. Melanocytic hyperplasia progresses to overt melanoma with an incidence dependent on BRAF expression levels. Melanomas show CDKN2A loss, and genetic disruption of the CDKN2A locus greatly enhances melanoma formation, consistent with collaboration between BRAF activation and CDKN2A loss suggested from studies of human melanoma. The development of melanoma also involves activation of the Mapk and Akt signaling pathways and loss of senescence, findings that faithfully recapitulate those seen in human melanomas. This murine model of mutant BRAF-induced melanoma formation thus provides an important tool for identifying further genetic alterations that cooperates with BRAF and that may be useful in enhancing susceptibility to BRAF-targeted therapeutics in melanoma. Oncogene (2009) 28, 2289-2298; doi: 10.1038/onc.2009.95; published online 27 April 2009	[Goel, V. K.; Ibrahim, N.; Jiang, G.; Singhal, M.; Hinds, P. W.; Haluska, F. G.] Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; [Fee, S.; Flotte, T.; Haluska, F. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Westmoreland, S.] Harvard Univ, Sch Med, New England Primate Res Ctr, Boston, MA USA	Tufts Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Goel, VK (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	vkumargoel@gmail.com; frank.haluska@ARIAD.com			NIH [CA095798]; NATIONAL CANCER INSTITUTE [R01CA095798] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA095798 to FGH. We thank Mohammad Miri for technical assistance, Dr Louis Montoliu for the tyrosinase promoter, Dr Lynda Chin for the mouse strains, and Dr Philip Tsichlis, Dr Amit Deshpande and Dr Trevor Pemberton for useful discussions.	Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Chang DLF, 2007, ONCOGENE, V26, P4627, DOI 10.1038/sj.onc.1210254; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Dhawan P, 2002, CANCER RES, V62, P7335; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Eisen T, 2006, BRIT J CANCER, V95, P581, DOI 10.1038/sj.bjc.6603291; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hingorani SR, 2003, CANCER RES, V63, P5198; Laud K, 2006, J MED GENET, V43, P39, DOI 10.1136/jmg.2005.033498; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sharpless NE, 2003, ONCOGENE, V22, P5055, DOI 10.1038/sj.onc.1206809; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; Tonks ID, 2003, GENESIS, V37, P131, DOI 10.1002/gene.10242; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	112	121	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2289	2298		10.1038/onc.2009.95	http://dx.doi.org/10.1038/onc.2009.95			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19398955	Green Accepted			2022-12-17	WOS:000266886300005
J	Akiri, G; Cherian, MM; Vijayakumar, S; Liu, G; Bafico, A; Aaronson, SA				Akiri, G.; Cherian, M. M.; Vijayakumar, S.; Liu, G.; Bafico, A.; Aaronson, S. A.			Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma	ONCOGENE			English	Article						autocrine; lung cancer; wnt	HUMAN CANCER-CELLS; BETA-CATENIN; SIGNALING PATHWAY; STEM-CELLS; EPITHELIAL-CELLS; MUTATIONS; ADENOCARCINOMA; IDENTIFICATION; APC; DIFFERENTIATION	Lung cancer is the most common cause of cancer mortality worldwide. Non-small-cell lung carcinomas (NSCLCs), which represent around 80% of lung tumors, exhibit poor prognosis and are usually refractory to conventional chemotherapy. Elucidating the molecular and cellular mechanisms that are dysregulated in NSCLCs may lead to new possibilities for targeted therapy or enhanced efficacy of current therapies. Here we demonstrate Wnt pathway activation in around 50% of human NSCLC cell lines and primary tumors, through different mechanisms, including autocrine Wnt pathway activation involving upregulation of specific Wnt ligands. Downregulation of activated Wnt signaling inhibited NSCLC proliferation and induced a more differentiated phenotype. Together, our findings establish importance of activated Wnt signaling in human NSCLCs and offer the possibility of targeting upregulated Wnt signaling as a new therapeutic modality for this disease. Oncogene (2009) 28, 2163-2172; doi: 10.1038/onc.2009.82; published online 20 April 2009	[Akiri, G.; Cherian, M. M.; Vijayakumar, S.; Liu, G.; Bafico, A.; Aaronson, S. A.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Aaronson, SA (corresponding author), Mt Sinai Sch Med, Dept Oncol Sci, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.	stuart.aaronson@mssm.edu			National Cancer Institute [5R01CA071672]; New York State Department of Health and American Urological Association; NATIONAL CANCER INSTITUTE [R01CA071672] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); New York State Department of Health and American Urological Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant number 5R01CA071672 from the National Cancer Institute. SV is supported by consecutive post-doctoral fellowships from New York State Department of Health and American Urological Association. We are grateful to Dr J Minna and Dr A Gazdar (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing us with some NSCLC cell lines. We thank Dr Stefano Rivella (Weill Medical College of Cornell University, New York, NY, USA) for the generous gift of the lentiviral vector, pRRL-SIN-cPPT-PGK-GFP. We also thank Dr Robert Hannigan (Mount Sinai School of Medicine, New York, NY, USA) and Professor Roger Tsien (Howard Hughes Medical Institute, University of California, San Diego, CA, USA) for kindly providing us with the cDNA encoding mOrange. We especially thank Randy Arroyave for excellent technical assistance and Martina Kracikova and Ioana Rus for critical reading of this paper.	Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bernasconi NL, 2000, AM J RESP CELL MOL, V23, P560, DOI 10.1165/ajrcmb.23.4.4233; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GUZMAN J, 1994, EUR RESPIR J, V7, P736, DOI 10.1183/09031936.94.07040736; He B, 2004, NEOPLASIA, V6, P7, DOI 10.1016/S1476-5586(04)80048-4; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mucenski ML, 2005, AM J PHYSIOL-LUNG C, V289, pL971, DOI 10.1152/ajplung.00172.2005; Nakamura N, 2006, ONCOGENE, V25, P4245, DOI 10.1038/sj.onc.1209442; Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reynolds SD, 2008, STEM CELLS, V26, P1337, DOI 10.1634/stemcells.2008-0053; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; SCHILLER JH, 1992, IN VITRO CELL DEV-AN, V28A, P461; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; VENEMBRE P, 1994, FEBS LETT, V346, P171, DOI 10.1016/0014-5793(94)80695-0; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zhang Y, 2008, NAT GENET, V40, P862, DOI 10.1038/ng.157	33	112	133	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2163	2172		10.1038/onc.2009.82	http://dx.doi.org/10.1038/onc.2009.82			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19377513	Green Accepted			2022-12-17	WOS:000266451300005
J	Chen, RS; Song, YM; Zhou, ZY; Tong, T; Li, Y; Fu, M; Guo, XL; Dong, LJ; He, X; Qiao, HX; Zhan, QM; Li, W				Chen, R-S; Song, Y-M; Zhou, Z-Y; Tong, T.; Li, Y.; Fu, M.; Guo, X-L; Dong, L-J; He, X.; Qiao, H-X; Zhan, Q-M; Li, W.			Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway	ONCOGENE			English	Article						xCT/SLC7A11; cancer; metastasis; caveolin-1; beta-catenin; oxidative stress	BETA-CATENIN; DOWN-REGULATION; PREMATURE SENESCENCE; TYROSINE KINASES; OXIDATIVE STRESS; PLASMA-MEMBRANE; CYSTINE UPTAKE; E-CADHERIN; CAVEOLIN-1; PROTEIN	xCT, the functional subunit of the cystine/glutamate transporter xc- system, plays a critical role in the maintenance of intracellular glutathione and redox balance. Disruption of xCT significantly inhibits the growth of a variety of carcinomas, including lymphoma, glioma, prostate and breast cancer. However, the role of xCT in tumor metastasis remains largely unknown. In this study, both xCT(+/+) and xCT(-/-) melanocytes were used to evaluate the role of xCT in adhesion. xCT activity was suppressed by an inhibitor, sulfasalazine (SASP), or by xCT siRNA in an esophageal cancer cell line, KYSE150. We found that disruption of xCT enhanced homotypic cell-cell adhesion and attenuated cell-extracellular matrix adhesion. SASP significantly inhibited both cell invasion of KYSE150 in vitro and its experimental metastasis in nude mice. Caveolin-1 was upregulated and beta-catenin was recruited to the plasma membrane when xCT was deficient, which were followed by the inhibition of beta-catenin transcriptional activity. Further study revealed that the upregulation of caveolin-1 and inhibition of tumor cell invasion were mediated by reactive oxygen species-induced p38 MAPK activation. These results first establish the role of xCT in tumor metastasis and implicate a potential target for cancer therapy.	[Chen, R-S; Zhou, Z-Y; Li, Y.; Guo, X-L; He, X.; Qiao, H-X; Li, W.] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Beijing 100101, Peoples R China; [Chen, R-S; Li, Y.; Guo, X-L] Chinese Acad Sci, Grad Univ, Beijing 100101, Peoples R China; [Chen, R-S] Fujian Acad Agr Sci, Ctr Biotechnol, Fuzhou, Fujian, Peoples R China; [Song, Y-M; Tong, T.; Fu, M.; Dong, L-J; Zhan, Q-M] Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Song, Y-M; Tong, T.; Fu, M.; Dong, L-J; Zhan, Q-M] Chinese Acad Med Sci, Beijing 100037, Peoples R China	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Fujian Academy of Agricultural Sciences; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College	Li, W (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol & Dev Biol, Datun Rd, Beijing 100101, Peoples R China.	zhanqimin@pumc.edu.cn; wli@genetics.ac.cn	Guo, Xiaoli/O-3906-2014		National Basic Research Program of China [2006CB504100, 2006CB500700, 2007CB947200]; National Natural Science Foundation of China [30525007, 30730049]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Richard T Swank and Dr Edward K Novak for their invaluable comments on this paper. This study was supported in part by National Basic Research Program of China (2006CB504100, 2006CB500700 and 2007CB947200), grants from National Natural Science Foundation of China (30525007 and 30730049) (to WL or XH).	Chintala S, 2005, P NATL ACAD SCI USA, V102, P10964, DOI 10.1073/pnas.0502856102; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236; Doxsee DW, 2007, PROSTATE, V67, P162, DOI 10.1002/pros.20508; Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gout PW, 2001, LEUKEMIA, V15, P1633, DOI 10.1038/sj.leu.2402238; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Ji J, 2007, ONCOGENE, V26, P6396, DOI 10.1038/sj.onc.1210469; Kim JY, 2001, BBA-BIOMEMBRANES, V1512, P335, DOI 10.1016/S0005-2736(01)00338-8; Lastro M, 2008, CELL SIGNAL, V20, P390, DOI 10.1016/j.cellsig.2007.10.030; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lehrbach Dárcio Matenhauer, 2003, Arq. Gastroenterol., V40, P256, DOI 10.1590/S0004-28032003000400011; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu H, 2007, ONCOGENE, V26, P5900, DOI 10.1038/sj.onc.1210400; Lu ZM, 2004, CELL CYCLE, V3, P571; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Narang VS, 2003, ANTICANCER RES, V23, P4571; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Qiao HX, 2008, BIOCHEM BIOPH RES CO, V370, P584, DOI 10.1016/j.bbrc.2008.03.134; Roberson B, 2006, ECON THEOR, V29, P1, DOI 10.1007/s00199-005-0071-5; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; Shao SJ, 2006, J BIOL CHEM, V281, P28943, DOI 10.1074/jbc.M600235200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Stoner GD, 2001, CARCINOGENESIS, V22, P1737, DOI 10.1093/carcin/22.11.1737; Tominaga J, 2008, GENES CELLS, V13, P67, DOI 10.1111/j.1365-2443.2007.01149.x; Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X	44	112	120	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					599	609		10.1038/onc.2008.414	http://dx.doi.org/10.1038/onc.2008.414			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	19015640				2022-12-17	WOS:000262866500013
J	Scavelli, C; Nico, B; Cirulli, T; Ria, R; Di Pietro, G; Mangieri, D; Bacigalupo, A; Mangialardi, G; Coluccia, AML; Caravita, T; Molica, S; Ribatti, D; Dammacco, F; Vacca, A				Scavelli, C.; Nico, B.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangieri, D.; Bacigalupo, A.; Mangialardi, G.; Coluccia, A. M. L.; Caravita, T.; Molica, S.; Ribatti, D.; Dammacco, F.; Vacca, A.			Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma	ONCOGENE			English	Article						basic fibroblast growth factor; macrophages; multiple myeloma; vascular endothelial growth factor; vasculogenesis	ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; PROGENITOR CELLS; PERIPHERAL-BLOOD; HUMAN MONOCYTES; FACTOR VEGF; STEM-CELLS; ANGIOGENESIS; EXPRESSION; NEOVASCULARIZATION	Bone marrow macrophages of patients with active and nonactive multiple myeloma (MM), monoclonal gammopathies of undetermined significance (MGUS) and benign anemia (controls) were stimulated for 7 days with vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and analysed for the expression of endothelial cell (EC) markers by reverse transcription (RT) - PCR, real- time RT - PCR, western blot and immunofluorescence. Their vasculogenic ability was investigated in vitro in a Matrigel assay and in vivo on bone marrow biopsies through dual immunofluorescence and confocal laser microscopy. Active MM macrophages exposed to VEGF and bFGF acquired EC markers and formed capillary-like structures mimicking paired bone marrow ECs (multiple myeloma patient-derived endothelial cells, MMECs), with major responsiveness compared to macrophages from nonactive MM, MGUS or controls. Bone marrow biopsies of active MM harbored 'mosaic' vessels, being formed by MMECs, EC-like macrophages and macrophages themselves. These figures were rare in nonactive MM and absent in MGUS or controls. Our data indicate that macrophages contribute to build neovessels in active MM through vasculogenic mimicry, and this ability proceeds parallel to progression of the plasma cell tumors. Macrophages may be a target for the MM antivascular treatment.	[Scavelli, C.; Cirulli, T.; Ria, R.; Di Pietro, G.; Mangialardi, G.; Coluccia, A. M. L.; Dammacco, F.; Vacca, A.] Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70124 Bari, Italy; [Nico, B.; Mangieri, D.] Univ Bari, Sch Med, Dept Human Anat & Histol, I-70124 Bari, Italy; [Bacigalupo, A.] San Martino Hosp, Dept Hematooncol, Genoa, Italy; [Caravita, T.] Univ Roma Tor Vergata, Sch Med, Dept Hematol, S Eugenio Hosp, Rome, Italy; [Molica, S.] Azienda Osped Pugliese Ciaccio, Dept Med Oncol, Catanzaro, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Genoa; IRCCS AOU San Martino IST; Sant'Eugenio Hospital; University of Rome Tor Vergata	Vacca, A (corresponding author), Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, Piazzi Giulio Cesare 11, I-70124 Bari, Italy.	a.vacca@dimo.uniba.it	Caravita, Tommaso/O-8929-2019; Dammacco, Franco/ABG-5728-2020; Vacca, Angelo/AAC-9558-2022; Ria, Roberto/I-4263-2015	Dammacco, Franco/0000-0003-2149-5471; Vacca, Angelo/0000-0002-4567-8216; Mangieri, Domenica/0000-0001-7350-9383; Ria, Roberto/0000-0002-1515-0090; Mangieri, Domenica/0000-0003-4871-1701	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Anghelina M, 2004, STEM CELLS DEV, V13, P665, DOI 10.1089/scd.2004.13.665; Anghelina M, 2006, AM J PATHOL, V168, P529, DOI 10.2353/ajpath.2006.050255; Anghelina M, 2006, J CELL MOL MED, V10, P708, DOI 10.2755/jcmm010.003.21; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BARONI CD, 1987, HISTOPATHOLOGY, V11, P1029; Bellamy WT, 1999, CANCER RES, V59, P728; Bender AT, 2004, CELL SIGNAL, V16, P365, DOI 10.1016/j.cellsig.2003.08.009; Bender CM, 1998, CANCER RES, V58, P95; Cavallaro U, 2006, EXP CELL RES, V312, P659, DOI 10.1016/j.yexcr.2005.09.019; Conejo-Garcia JR, 2005, BLOOD, V105, P679, DOI 10.1182/blood-2004-05-1906; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; DURIE BGM, 1986, SEMIN ONCOL, V13, P300; Fehrenbach H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-60; Fernandez E, 2000, Gac Sanit, V14, P287; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujiyama S, 2003, CIRC RES, V93, P980, DOI 10.1161/01.RES.0000099245.08637.CE; Gendron RL, 1996, DEV BIOL, V177, P332, DOI 10.1006/dbio.1996.0167; GOTO F, 1993, LAB INVEST, V69, P508; Guidolin D, 2004, MICROVASC RES, V67, P117, DOI 10.1016/j.mvr.2003.11.002; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Kerjaschki D, 2006, NAT MED, V12, P230, DOI 10.1038/nm1340; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Kyle RA, 2003, BRIT J HAEMATOL, V121, P749; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Maruyama K, 2007, AM J PATHOL, V170, P1178, DOI 10.2353/ajpath.2007.060018; Moldovan NI, 2000, CIRC RES, V87, P378; Moldovan NI, 2005, STEM CELLS DEV, V14, P111, DOI 10.1089/scd.2005.14.111; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Rajkumar SV, 1999, LEUKEMIA, V13, P469, DOI 10.1038/sj.leu.2401336; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456; RISAU W, 1988, DEVELOPMENT, V102, P471; Schmeisser A, 2001, CARDIOVASC RES, V49, P671, DOI 10.1016/S0008-6363(00)00270-4; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vacca A, 1999, BLOOD, V93, P3064; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100	45	112	117	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					663	674		10.1038/sj.onc.1210691	http://dx.doi.org/10.1038/sj.onc.1210691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667938				2022-12-17	WOS:000252674900010
J	Dahl, E; Wiesmann, F; Woenckhaus, M; Stoehr, R; Wild, PJ; Veeck, J; Knuechell, R; Klopocki, E; Sauter, G; Simon, R; Wieland, WF; Walter, B; Denzinger, S; Hartmann, A; Hammerschmied, CG				Dahl, E.; Wiesmann, F.; Woenckhaus, M.; Stoehr, R.; Wild, P. J.; Veeck, J.; Knuechell, R.; Klopocki, E.; Sauter, G.; Simon, R.; Wieland, W. F.; Walter, B.; Denzinger, S.; Hartmann, A.; Hammerschmied, C. G.			Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma	ONCOGENE			English	Article						loss of SFRP1 in human tumours; renal cell carcinoma; tumour suppressor gene; Wnt pathway; SFRP1 methylation; tissue microarray	WNT ANTAGONIST SFRP1; BETA-CATENIN; EPIGENETIC INACTIVATION; BREAST-CANCER; GENES; TARGET; IDENTIFICATION; NONPAPILLARY; PROGRESSION; SUPPRESSOR	Oncogenic wingless-related mouse mammary tumour virus (Wnt) signalling, caused by epigenetic inactivation of specific pathway regulators like the putative tumour suppressor secreted frizzled-related protein 1 (SFRP1), may be causally involved in the carcinogenesis of many human solid tumours including breast, colon and kidney cancer. To evaluate the incidence of SFRP1 deficiency in human tumours, we performed a large-scale SFRP1 expression analysis using immunohistochemistry on a comprehensive tissue microarray (TMA) comprising 3448 tumours from 36 organs. This TMA contained 132 different tumour subtypes as well as 26 different normal tissues. Although tumour precursor stages of, for example kidney, colon, endometrium or adrenal gland still exhibited moderate to abundant SFRP1 expression, this expression was frequently lost in the corresponding genuine tumours. We defined nine novel tumour entities with apparent loss of SFRP1 expression, i.e., cancers of the kidney, stomach, small intestine, pancreas, parathyroid, adrenal gland, gall bladder, endometrium and testis. Renal cell carcinoma (RCC) exhibited the highest frequency of SFRP1 loss (89% on mRNA level; 75% on protein level) and was selected for further analysis to investigate the cause of SFRP1 loss in human tumours. We performed expression, mutation and methylation analysis in RCC and their matching normal kidney tissues. SFRP1 promoter methylation was frequently found in RCC (68%, n=38) and was correlated with loss of SFRP1 mRNA expression ( p < 0.05). Although loss of heterozygosity was found in 16% of RCC, structural mutations in the coding or promoter region of the SFRP1 gene were not observed. Our results indicate that loss of SFRP1 expression is a very common event in human cancer, arguing for a fundamental role of aberrant Wnt signalling in the development of solid tumours. In RCC, promoter hypermethylation seems to be the predominant mechanism of SFRP1 gene silencing and may contribute to initiation and progression of this disease.	Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany; Univ Regensburg, Inst Pathol, D-8400 Regensburg, Germany; Univ Regensburg, Dept Urol, D-8400 Regensburg, Germany; Univ Zurich, Inst Pathol, Zurich, Switzerland; Univ Med Berlin, Charite, Inst Med Genet, Berlin, Germany; Univ Hamburg Hosp, Inst Pathol, D-2000 Hamburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; University of Regensburg; University of Regensburg; University of Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Veeck, Jürgen/B-9256-2008; Stoehr, Robert/D-7504-2011; Stoehr, Christine/N-6637-2018; Klopocki, Eva/B-6823-2017	Veeck, Jürgen/0000-0002-2952-6159; Stoehr, Christine/0000-0001-7501-4886; Klopocki, Eva/0000-0003-1438-2081				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bohm M, 1997, UROL RES, V25, P161; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoei-Hansen CE, 2004, MOL HUM REPROD, V10, P423, DOI 10.1093/molehr/gah059; HUGHSON MD, 1993, MODERN PATHOL, V6, P449; Janssens N, 2004, TUMOR BIOL, V25, P161, DOI 10.1159/000081098; Kim YS, 2000, PATHOL INT, V50, P725, DOI 10.1046/j.1440-1827.2000.01111.x; Klopocki E, 2004, INT J ONCOL, V25, P641; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Li CH, 2006, J DENT RES, V85, P374, DOI 10.1177/154405910608500418; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; MANCILLAJIMENEZ R, 1976, CANCER, V38, P2469, DOI 10.1002/1097-0142(197612)38:6<2469::AID-CNCR2820380636>3.0.CO;2-R; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; ORTMANN M, 1991, VIRCHOWS ARCH B, V61, P123; Presti JC, 2002, J UROLOGY, V167, P1464, DOI 10.1016/S0022-5347(05)65346-3; Reutzel D, 2001, CYTOGENET CELL GENET, V93, P221, DOI 10.1159/000056987; SCHLEGEL J, 1995, VIRCHOWS ARCH, V426, P223; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; STORKEL S, 1989, VIRCHOWS ARCH B, V56, P237; Suzuki H, 1997, ONCOLOGY-BASEL, V54, P252; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Vainio SJ, 1999, INT J DEV BIOL, V43, P419; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Watanabe H, 2006, PANCREAS, V32, P382, DOI 10.1097/01.mpa.0000221617.89376.38; Zafrakas M, 2006, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-88; ZANG T, 2000, CHINESE SCI BULL, V45, P1703; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	112	118	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5680	5691		10.1038/sj.onc.1210345	http://dx.doi.org/10.1038/sj.onc.1210345			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353908				2022-12-17	WOS:000248801900015
J	Ehtesham, M; Sarangi, A; Valadez, JG; Chanthaphaychith, S; Becher, MW; Abel, TW; Thompson, RC; Cooper, MK				Ehtesham, M.; Sarangi, A.; Valadez, J. G.; Chanthaphaychith, S.; Becher, M. W.; Abel, T. W.; Thompson, R. C.; Cooper, M. K.			Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells	ONCOGENE			English	Article						brain tumor; glioma; Hedgehog; cancer stem; cell; Olig2; patched	NEURAL STEM-CELLS; SONIC-HEDGEHOG; BRAIN-TUMORS; NERVOUS-SYSTEM; IN-VIVO; GROWTH; CANCER; GLIOBLASTOMA; INHIBITION; DISEASE	The hedgehog (Hh) signaling pathway regulates progenitor cells during embryogenesis and tumorigenesis in multiple organ systems. We have investigated the activity of this pathway in adult gliomas, and demonstrate that the Hh pathway is operational and activated within grade II and III gliomas, but not grade IV de novo glioblastoma multiforme. Furthermore, our studies reveal that pathway activity and responsiveness is confined to progenitor cells within these tumors. Additionally, we demonstrate that Hh signaling in glioma progenitor cells is ligand-dependent and provide evidence documenting the in vivo source of Sonic hedgehog protein. These findings suggest a regulatory role for the Hh pathway in progenitor cells within grade II and III gliomas, and the potential clinical utility of monitoring and targeting this pathway in these primary brain tumors.	Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Cooper, MK (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol, MRBIII,Rm 6140,465 21st Ave S, Nashville, TN 37232 USA.	michael.cooper@vanderbilt.edu			NINDS NIH HHS [R01 NS051557, K08 NS02133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051557, K08NS002133] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; American Cancer Society, 2004, CANC FACTS FIG; Azzarelli B, 2004, J NEUROPATH EXP NEUR, V63, P170, DOI 10.1093/jnen/63.2.170; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Katayama M, 2002, J NEURO-ONCOL, V59, P107, DOI 10.1023/A:1019660421216; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; Mokhtari K, 2005, NEUROPATH APPL NEURO, V31, P62, DOI 10.1111/j.1365-2990.2004.00612.x; Oh S, 2005, DEV DYNAM, V234, P489, DOI 10.1002/dvdy.20422; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493	33	112	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5752	5761		10.1038/sj.onc.1210359	http://dx.doi.org/10.1038/sj.onc.1210359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353902				2022-12-17	WOS:000248885100007
J	Shi, Q; Bao, S; Song, L; Bigner, DD; Hjelmeland, AB; Rich, JN				Shi, Q.; Bao, S.; Song, L.; Bigner, D. D.; Hjelmeland, A. B.; Rich, J. N.			Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases	ONCOGENE			English	Article						SPARC; AKT; glioma; invasion; siRNA	HUMAN-MELANOMA CELLS; BREAST-CANCER; GENE-EXPRESSION; TUMOR-GROWTH; IN-VITRO; PROTEIN; RICH; GLIOBLASTOMA; OSTEONECTIN; METASTASIS	Secreted protein acidic and rich in cysteine (SPARC) is an extracellular glycoprotein expressed in several solid cancers, including malignant gliomas, upon adoption of metastatic or invasive behaviors. SPARC expression in glioma cells promotes invasion and survival under stress, the latter process dependent on SPARC activation of AKT. Here we demonstrate that downregulation of SPARC expression with short interfering RNA (siRNA) in glioma cells decreased tumor cell survival and invasion. SPARC siRNA reduced the activating phosphorylation of AKT and two cytoplasmic kinases, focal adhesion kinase (FAK) and integrin-linked kinase (ILK). We determined the contributions of FAK and ILK to SPARC effects using SPARC protein and cell lines engineered to overexpress SPARC. SPARC activated FAK and ILK in glioma cells previously characterized as responsive to SPARC. Downregulation of either FAK or ILK expression inhibited SPARC-mediated AKT phosphorylation, and targeting both FAK and ILK attenuated AKT activation more potently than targeting either FAK or ILK alone. Decreased SPARC-mediated AKT activation correlated with a reduction in SPARC-dependent invasion and survival upon the downregulation of FAK and/or ILK expression. These data further demonstrate the role of SPARC in glioma tumor progression through the activation of intracellular kinases that may provide novel therapeutic targets for advanced cancers.	Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, POB 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu	Rich, Jeremy/AAM-1445-2021		NCI NIH HHS [CA 116659, CA 108786] Funding Source: Medline; NINDS NIH HHS [NS054276, NS047409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA108786, R01CA116659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS047409, R01NS054276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alvarez MJ, 2005, CANCER RES, V65, P5123, DOI 10.1158/0008-5472.CAN-04-1102; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; CHICOINE MR, 1995, J NEUROSURG, V82, P615, DOI 10.3171/jns.1995.82.4.0615; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gradishar WJ, 2006, EXPERT OPIN PHARMACO, V7, P1041, DOI 10.1517/14656566.7.8.1041; Hecker TP, 2002, CANCER RES, V62, P2699; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; KENNEY J, 1992, MAGNET RESON MED, V27, P68, DOI 10.1002/mrm.1910270108; Koblinski JE, 2005, CANCER RES, V65, P7370, DOI 10.1158/0008-5472.CAN-05-0807; Lal A, 1999, CANCER RES, V59, P5403; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; Obara S, 2004, CANCER LETT, V208, P115, DOI 10.1016/j.canlet.2003.11.020; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rich JN, 2005, CANCER RES, V65, P4051, DOI 10.1158/0008-5472.CAN-04-3936; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Schultz C, 2002, CANCER RES, V62, P6270; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Watkins G, 2005, PROSTAG LEUKOTR ESS, V72, P267, DOI 10.1016/j.plefa.2004.12.003; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	25	112	116	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4084	4094		10.1038/sj.onc.1210181	http://dx.doi.org/10.1038/sj.onc.1210181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17213807				2022-12-17	WOS:000247252700004
J	Chen, CS; Sun, XD; Ran, QM; Wilkinson, KD; Murphy, TJ; Simons, JW; Dong, JT				Chen, CS; Sun, XD; Ran, QM; Wilkinson, KD; Murphy, TJ; Simons, JW; Dong, JT			Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells	ONCOGENE			English	Article						KLF5; degradation; ubiquitin; proteasome; cancer	KRUPPEL-LIKE FACTOR; ELEMENT-BINDING PROTEIN-2; GROWTH FACTOR-A; DEPENDENT DEGRADATION; HUMAN BTEB2; EXPRESSION; SP1; REGULATOR; PHOSPHORYLATION; ACTIVATION	Ubiquitin-mediated proteolysis plays a central role in controlling intracellular levels of essential regulatory molecules such as p53, cyclins, myc, BRCA1, HIF-1 alpha, etc. The Kruppel-like factor 5 (KLF5) transcription factor regulates biological processes involved in carcinogenesis, angiogenesis, and smooth muscle cell differentiation. In carcinogenesis, KLF5's role has been indicated by frequent genetic deletion as well as functional studies. Here we show that KLF5 is an unstable protein with a short half-life. Destruction of KLF5 was prevented by each of the proteasome-specific inhibitors tested but not by an inhibitor for trypsin-like proteases and cysteine proteases or by a lysosome inhibitor in epithelial cells. Furthermore, KLF5 underwent ubiquitination, and deletion of a 56-amino-acid sequence adjacent to a known transactivation domain of KLF5 significantly reduced its ubiquitination and degradation. Interestingly, cancer cells appeared to be more active in KLF5 degradation than untransformed epithelial cells, yet their proteasome activity was not higher. These results suggest that KLF5 protein is degraded at least in part through ubiquitination-proteasome pathway, which may have become hyperactive for KLF5 in cancer cells.	Emory Univ, Sch Med, Winship Canc Ctr, Dept Oncol & Hematol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University; Emory University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Dept Oncol & Hematol, 1365-C Clifton Rd, Atlanta, GA 30322 USA.	jdong2@emory.edu		Dong, Jin-Tang/0000-0003-2349-5782	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bateman NW, 2004, J BIOL CHEM, V279, P12093, DOI 10.1074/jbc.M311532200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2004, GENE, V330, P133, DOI 10.1016/j.gene.2004.01.014; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Johnsen SA, 2002, J BIOL CHEM, V277, P30754, DOI 10.1074/jbc.M204812200; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Kojima S, 1997, J BIOCHEM, V121, P389; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Murphy TJ, 2002, METHOD ENZYMOL, V345, P539; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Ogata T, 2000, J THORAC CARDIOV SUR, V119, P983, DOI 10.1016/S0022-5223(00)70093-6; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Taneyhill Lisa, 2004, BMC Developmental Biology, V4; Usui S, 2004, J BIOL CHEM, V279, P12300, DOI 10.1074/jbc.M305025200; Wada Y, 2001, J HEART LUNG TRANSPL, V20, P590, DOI 10.1016/S1053-2498(00)00210-2; Wada Y, 2000, TRANSPLANT P, V32, P1089, DOI 10.1016/S0041-1345(00)01136-2; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang ZP, 2003, NUCLEIC ACIDS RES, V31, P2196, DOI 10.1093/nar/gkg310; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	39	112	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3319	3327		10.1038/sj.onc.1208497	http://dx.doi.org/10.1038/sj.onc.1208497			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735697				2022-12-17	WOS:000228881800010
J	Gabai, VL; Budagova, KR; Sherman, MY				Gabai, VL; Budagova, KR; Sherman, MY			Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents	ONCOGENE			English	Article						Hsp72; prostate cancer; chemoresistance; apoptosis; signal transduction	NF-KAPPA-B; INDUCED APOPTOSIS; TERMINAL KINASE; ENHANCED RADIOSENSITIVITY; PROTEASOME INHIBITORS; BREAST-CANCER; ACTIVATION; DEATH; PATHWAY; HEAT-SHOCK-PROTEIN-72	The major heat shock protein Hsp72 is expressed at high levels in various types of cancer. Here we attempt to clarify the role of Hsp72 in prostate cancer cells by studying the effects of specific downregulation of this protein using siRNA and antisense RNA approaches. Contrary to previous reports, specific depletion of Hsp72 did not reduce viability of the prostate carcinoma cell lines PC-3 and DU-145. However, even short-term downregulation of Hsp72 in these cells made them more sensitive to hyperthermia, inhibitors of proteasome and Hsp90, and tumor necrosis factor. Interestingly, prolonged downregulation of Hsp72 in PC-3 cells over 3 weeks aggravated these effects, as well as enhanced the sensitivity of cells to oxidative stress, radiation, cis-platinum, vinblastin and taxol. The increased sensitivity to the anticancer agents was due to increased apoptosis, as well as other types of cell death, which resulted in the loss of clonogenic survival. Prolonged downregulation of Hsp72 led to severe suppression of the major survival pathways, ERK and NF-kappa B, which may be responsible for enhanced sensitivity of prostate carcinoma cells to a variety of anticancer treatments, as well as reduction of the cell's capability of forming colonies in soft agar.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Med Radiol Res Ctr, Obninsk 249020, Russia	Boston University	Sherman, MY (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	Sherman@biochem.bumc.bu.edu	Gabai, Vladimir L/I-1650-2013	Gabai, Vladimir L/0000-0003-4505-4718; Sherman, Michael/0000-0003-3345-073X				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Costa MJM, 1997, ONCOL REP, V4, P1113; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gasparian AV, 2002, J CELL SCI, V115, P141; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hostein I, 2001, CANCER RES, V61, P4003; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; Hwang TS, 2003, J GASTROEN HEPATOL, V18, P690, DOI 10.1046/j.1440-1746.2003.03011.x; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Musch MW, 2001, CELL GROWTH DIFFER, V12, P419; Nanbu K, 1998, CANCER DETECT PREV, V22, P549, DOI 10.1046/j.1525-1500.1998.00069.x; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Park HS, 2002, MOL CELL BIOL, V22, P7721, DOI 10.1128/MCB.22.22.7721-7730.2002; Roninson IB, 2003, CANCER RES, V63, P2705; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Volm M, 2002, CLIN EXP METASTAS, V19, P385, DOI 10.1023/A:1016361924216; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374	50	112	114	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3328	3338		10.1038/sj.onc.1208495	http://dx.doi.org/10.1038/sj.onc.1208495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735699				2022-12-17	WOS:000228881800011
J	Zavros, Y; Eaton, KA; Kang, WQ; Rathinavelu, S; Katukuri, V; Kao, JY; Samuelson, LC; Merchant, JL				Zavros, Y; Eaton, KA; Kang, WQ; Rathinavelu, S; Katukuri, V; Kao, JY; Samuelson, LC; Merchant, JL			Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma	ONCOGENE			English	Article						gastric cancer; anchorage-independent assay; atrophy; somatostatin; RUNX3; villin; STAT3; STAT1	INTESTINAL METAPLASIA; MICE LACKING; CANCER; EXPRESSION; RUNX3; PROTEIN; VILLIN; STAT3; DIFFERENTIATION; ACTIVATION	The current study tests the hypothesis that chronic atrophic gastritis from hypochlorhydria in the gastrin-deficient mouse predisposes the stomach to gastric cancer. Gross morphology and histology of 12-month-old wildtype (WT), gastrin-deficient (G-/-) and somatostatin-deficient (SOM-/-) mice were examined. Parietal and G cells, Ki67, TUNEL, villin and MUC2 expression were analysed by immunohistochemistry. RUNX3 and STAT3 expression was analysed by Western blot. Anchorage-independent growth was determined by cell cluster formation in soft agar. Compared to the WT and SOM-/- mice, hypochlorhydric G-/- mice developed parietal cell atrophy, significant antral inflammation and intestinal metaplasia. Areas of metaplasia within the G-/- mouse stomach showed decreased RUNX3 expression with elevated MUC2 and villin expression. Cells isolated from the tumor grew in soft agar. However, the cells isolated from WT, nontransformed G-/- and SOM-/gastric tissue did not form colonies in soft agar. Consistent with elevated antral proliferation, tumor tissue isolated from the G-/- mice showed elevated phosphorylated STAT3 expression. We then examined the mechanism by which STAT3 was constitutively expressed in the tumor tissue of the G-/- mice. We found that IFN gamma expression was also significantly higher in the tumor tissue of G-/- mice compared to WT and SOM-/- animals. To determine whether STAT3 was regulated by IFN gamma, MKN45 cells were cocultured with IFN gamma or gastrin. IFN gamma significantly stimulated phosphorylation of STAT3 in the MKN45 cell line, but not gastrin. Therefore, we show here that in the hypochlorhydric mouse stomach, the chronic gastritis, atrophy, metaplasia, dysplasia paradigm can be recapitulated in mice. Moreover, neoplastic transformation of the antral gastric mucosa does not require gastrin.	Univ Michigan, Dept Gastroenterol, Ann Arbor, MI USA; Univ Michigan, Unit Lab Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Merchant, JL (corresponding author), 1150 W Med Dr,MSRB 1,3510, Ann Arbor, MI 48109 USA.	merchanj@umich.edu	Merchant, Juanita/AAF-8277-2019; Rathinavelu, Sivaprakash/AAT-2526-2021	Merchant, Juanita/0000-0002-6559-8184; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061410, P30DK041301, P01DK062041, P30DK034933, R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK062041, DK45729, DK61410, DK34933, DK41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACCHI CE, 1991, LAB INVEST, V64, P418; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; BARRETT NR, 1957, SURGERY, V41, P881; BLASER MJ, 1994, J CLIN INVEST, V94, P4, DOI 10.1172/JCI117336; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; CORREA P, 1992, CANCER RES, V52, P6735; Cover TL, 2003, CANCER RES, V63, P951; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Eaton KA, 1999, INFECT IMMUN, V67, P4594, DOI 10.1128/IAI.67.9.4594-4602.1999; Fox JG, 1998, GASTROENTEROLOGY, V114, P755, DOI 10.1016/S0016-5085(98)70589-X; Fox JG, 2003, CANCER RES, V63, P942; Friis-Hansen L, 1998, AM J PHYSIOL-GASTR L, V274, pG561, DOI 10.1152/ajpgi.1998.274.3.G561; Harigai M, 2004, ARTHRITIS RHEUM-US, V50, P2167, DOI 10.1002/art.20340; JOHNSON LR, 1977, GASTROENTEROLOGY, V72, P788; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Koh TJ, 1997, GASTROENTEROLOGY, V113, P1015, DOI 10.1016/S0016-5085(97)70199-9; Ku JL, 2004, ONCOGENE, V23, P6736, DOI 10.1038/sj.onc.1207731; Kumble S, 1996, INT J CANCER, V66, P48, DOI 10.1002/(SICI)1097-0215(19960328)66:1<48::AID-IJC9>3.0.CO;2-Z; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; MOORE JH, 1994, INT J CANCER, V56, P487, DOI 10.1002/ijc.2910560406; Mora LB, 2002, CANCER RES, V62, P6659; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Peek RM, 2002, J GASTROENTEROL, V37, P10, DOI 10.1007/BF02990093; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Semino-Mora C, 2003, J INFECT DIS, V187, P1165, DOI 10.1086/368133; Suter J, 2001, BIOL REPROD, V64, P1481, DOI 10.1095/biolreprod64.5.1481; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; Waki T, 2003, CANCER SCI, V94, P360, DOI 10.1111/j.1349-7006.2003.tb01447.x; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zavros Y, 2003, P NATL ACAD SCI USA, V100, P12944, DOI 10.1073/pnas.2135193100; Zavros Y, 2002, GASTROENTEROLOGY, V122, P119, DOI 10.1053/gast.2002.30298; Zavros Y, 2002, AM J PHYSIOL-GASTR L, V282, pG175, DOI 10.1152/ajpgi.00287.2001	44	112	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2354	2366		10.1038/sj.onc.1208407	http://dx.doi.org/10.1038/sj.onc.1208407			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735748				2022-12-17	WOS:000227877400008
J	May, D; Itin, A; Gal, O; Kalinski, H; Feinstein, E; Keshet, E				May, D; Itin, A; Gal, O; Kalinski, H; Feinstein, E; Keshet, E			Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer	ONCOGENE			English	Article						ero1-l alpha; VEGF; HIF1; hypoxia; disulfide bond formation	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; MESSENGER-RNA STABILITY; INDUCIBLE FACTOR-I; ENDOPLASMIC-RETICULUM; HIF-ALPHA; PROTEIN; EXPRESSION; FACTOR-1; GENES	Oxygen is the ultimate source of oxidizing power for disulfide bond formation, suggesting that under limiting oxygen proper protein folding might be compromised. We show that secretion of vascular endothelial growth factor ( VEGF), a protein with multiple disulfide bonds, was indeed impeded under hypoxia and was partially restored by artificial increase of oxidizing equivalents with diamide. Physiologically, the oxireductase endoplasmic reticulum oxidoreductin-1 (Ero1)-Lalpha, but not other proteins in the relay of disulfide formation, was strongly upregulated by hypoxia and independently by hypoglycemia, two known accompaniments of tumors. Further, we provide genetic evidence that induction of Ero1-Lalpha by hypoxia and hypoglycemia is mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1) but is independent of p53. In natural human tumors, Ero1-Lalpha mRNA was specifically induced in hypoxic microenvironments coinciding with that of upregulated VEGF expression. To establish a physiological relevance to modulations in Ero1-Lalpha levels, we showed that even a modest, two- to three-fold reduction in Ero1-Lalpha production via siRNA leads to significant inhibition of VEGF secretion, a compromised proliferation capacity and enhanced apoptosis. Together, these findings demonstrate that hypoxic induction of Ero1-Lalpha is the key adaptive response in a previously unrecognized HIF-1-mediated pathway that operates to improve protein secretion under hypoxia and might be harnessed for inhibiting tumor growth via inhibiting VEGF-driven angiogenesis.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Quark Biotech Inc, QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel	Hebrew University of Jerusalem	Keshet, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel.	keshet@cc.huji.ac.il	Keshet, Eli/GQR-0445-2022					An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; BARASH Y, 2004, BIOINFORMATICS  0928; BENDA P, 1968, SCIENCE, V161, P371; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; CzyzykKrzeska MF, 1997, RESP PHYSIOL, V110, P99, DOI 10.1016/S0034-5687(97)00076-5; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Endoh H, 2004, J CLIN ONCOL, V22, P811, DOI 10.1200/JCO.2004.04.109; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kuwabara K, 1996, J BIOL CHEM, V271, P5025; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Ryan HE, 2000, CANCER RES, V60, P4010; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P845; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Sullivan DC, 2003, J BIOL CHEM, V278, P47079, DOI 10.1074/jbc.M308124200; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Walter DH, 1996, LAB INVEST, V74, P546; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	45	112	121	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1011	1020		10.1038/sj.onc.1208325	http://dx.doi.org/10.1038/sj.onc.1208325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592500				2022-12-17	WOS:000226749200007
J	Reale, A; De Matteis, G; Galleazzi, G; Zampieri, M; Caiafa, P				Reale, A; De Matteis, G; Galleazzi, G; Zampieri, M; Caiafa, P			Modulation of DNMT1 activity by ADP-ribose polymers	ONCOGENE			English	Article						CpG islands; DNA methylation pattern; DNMT1; poly(ADP-ribosyl)ation	DNA METHYLATION; CPG-ISLANDS; DE-NOVO; POLY(ADP-RIBOSE) BINDS; TRANSCRIPTION; METHYLTRANSFERASES; PARP; EXPRESSION; ELEMENTS; DOMAINS	We provided evidence that competitive inhibition of poly(ADP-ribose) polymerases in mammalian cells treated with 3-aminobenzamide causes DNA hypermethylation in the genome and anomalous hypermethylation of CpG islands. The molecular mechanism(s) connecting poly(ADP-ribosyl)ation with DNA methylation is still unknown. Here we show that DNMT1 is able to bind long and branched ADP-ribose polymers in a noncovalent way. Binding of poly ADP-ribose on DNMT1 inhibits DNA methyltransferase activity. Co-immunoprecipitation reactions indicate that PARP1 and DNMT1 are associated in vivo and that in this complex PARP1 is present in its ADP-ribosylated isoform. We suggest that this complex is catalytically inefficient in DNA methylation.	Univ Roma La Sapienza, Sez Biochim Clin, Dept Cellular Biotechnol & Haematol, I-00161 Rome, Italy	Sapienza University Rome	Caiafa, P (corresponding author), Univ Roma La Sapienza, Sez Biochim Clin, Dept Cellular Biotechnol & Haematol, Vle Regina Elena 324, I-00161 Rome, Italy.	caiafa@bce.uniroma1.it	Zampieri, Michele/F-7099-2013; Zampieri, Michele/AGF-5460-2022; Reale, Anna/J-5933-2016; De Matteis, Giovanna/ABD-1479-2020	Zampieri, Michele/0000-0002-6799-2492; Zampieri, Michele/0000-0002-6799-2492; Reale, Anna/0000-0001-8988-2342; De Matteis, Giovanna/0000-0003-2963-3365				ABOULELA N, 1988, ANAL BIOCHEM, V174, P239, DOI 10.1016/0003-2697(88)90541-6; ALTHAUS FR, 1995, BIOCHIMIE, V77, P423, DOI 10.1016/0300-9084(96)88155-7; AME JC, 2000, DNA DAMAGE STRESS SI, P1; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2003, NAT IMMUNOL, V4, P208, DOI 10.1038/ni0303-208; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; De Capoa A, 1999, FASEB J, V13, P89; FAKAN S, 1988, EXP CELL RES, V179, P517, DOI 10.1016/0014-4827(88)90289-3; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Griesenbeck J, 1999, FEBS LETT, V443, P20, DOI 10.1016/S0014-5793(98)01671-8; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Ku MC, 2003, BIOCHEM BIOPH RES CO, V311, P702, DOI 10.1016/j.bbrc.2003.10.053; Kun E, 2002, J BIOL CHEM, V277, P39066, DOI 10.1074/jbc.C200410200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MALANGA M, 1994, J BIOL CHEM, V269, P17691; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PANZETER PL, 1993, J BIOL CHEM, V268, P17662; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rolli V., 2000, DNA DAMAGE STRESS SI, P35; Schmitz AAP, 1998, BIOCHEMISTRY-US, V37, P9520, DOI 10.1021/bi973063b; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	45	112	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					13	19		10.1038/sj.onc.1208005	http://dx.doi.org/10.1038/sj.onc.1208005			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637587				2022-12-17	WOS:000226125800003
J	Vega, MI; Huerta-Yepaz, S; Garban, H; Jazirehi, A; Emmanouilides, C; Bonavida, B				Vega, MI; Huerta-Yepaz, S; Garban, H; Jazirehi, A; Emmanouilides, C; Bonavida, B			Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance	ONCOGENE			English	Article						Rituximab; non-Hodgkin's lymphoma; p38 MAPK; NF-kappa B; chemosensitization	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; NON-HODGKINS-LYMPHOMA; HUMAN INTERLEUKIN-10 PROMOTER; MONOCLONAL-ANTIBODIES; GENE-EXPRESSION; CELL-LINE; TNF-ALPHA; IN-VIVO; INDUCTION	We have recently reported that Rituximab (anti-CD20) sensitizes drug-resistant 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) cell lines to the apoptotic effects of various chemotherapeutic drugs by downregulation of IL-10 and Bcl-2 expression. The mechanism by which Rituximab induces downregulation of IL-10 was examined. We hypothesized that Rituximab may inhibit p38 MAPK activity that regulates IL-10 expression via Sp1. Treatment of 2F7 cells with Rituximab or the p38 inhibitor SB203580 inhibited the constitutive p38 MAPK activity and resulted in the inhibition of Sp1, IL-10, STAT3, and Bcl-2. Inhibition of the Src-family PTKs, Lyn, and Src-family PTKs upstream signaling molecules of the p38MAPK pathway, by PP2, a specific Src-family kinase inhibitor, resulted in the inhibition of p38MAPK and IL-10 expression. In addition to p38 MAPK, Rituximab also inhibited NF-kappaB activity. Inhibition of the Src PTKs, MAPK, and NF-kappaB activities by Rituximab or by specific chemical inhibitors sensitized the cells to CDDP-mediated apoptosis. The above signaling-mediated effects by Rituximab were observed with similar kinetics beginning at 1 h following treatment. Thus, altogether, these results demonstrate that signaling by Rituximab results in the inhibition of the p38MAPK pathway, which in turn inhibits the transcription of IL-10 via Sp1. Inhibition of the IL-10 autocrine/paracrine loop results in the inhibition of STAT3 activity and, consequently, inhibition of Bcl-2 expression and sensitization to drugs-apoptosis. Further, Rituximab-mediated signaling identifies several new intracellular targets in NHL that may be of potential therapeutic interest for the development of new drugs in the treatment of drug-refractory NHL tumor cells.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Bonavida, B (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Vega, Mario I/0000-0002-3932-2483; Garban, Hermes/0000-0001-7754-5357	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alas S, 2001, CLIN CANCER RES, V7, P709; ALAS S, 2001, CAN RES, V6, P1; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Coiffier B, 2003, BLOOD REV, V17, P25, DOI 10.1016/S0268-960X(02)00059-0; Demidem A, 1997, CANCER BIOTHER RADIO, V12, P177, DOI 10.1089/cbr.1997.12.177; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eskdale J, 1997, IMMUNOGENETICS, V46, P120, DOI 10.1007/s002510050250; Foey AD, 1998, J IMMUNOL, V160, P920; Foran JM, 2002, BEST PRACT RES CL HA, V15, P449, DOI 10.1053/beha.2002.0222; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Gan XH, 1999, CELL IMMUNOL, V193, P125, DOI 10.1006/cimm.1999.1457; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hu XT, 2001, CANCER RES, V61, P6290; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; KUBE D, 1995, CYTOKINE, V7, P1, DOI 10.1006/cyto.1995.1001; LEVINE AM, 1992, BLOOD, V80, P8; LIDA M, 1999, LEUKEMIA, V13, P585; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Miki H, 1999, ANTICANCER RES, V19, P5283; Mori N, 1997, EUR J HAEMATOL, V59, P162; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Polyak MJ, 1998, J IMMUNOL, V161, P3242; REFF ME, 1994, BLOOD, V83, P435; Riley LK, 2000, SEMIN ONCOL, V27, P17, DOI 10.1053/sonc.2000.20424; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; Semac I, 2003, CANCER RES, V63, P534; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; STASHENKO P, 1980, J IMMUNOL, V125, P1678; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Thieblemont C, 2002, INT J HEMATOL, V76, P394, DOI 10.1007/BF02982804; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; Voorzanger N, 1996, CANCER RES, V56, P5499; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200	47	112	122	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3530	3540		10.1038/sj.onc.1207336	http://dx.doi.org/10.1038/sj.onc.1207336			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15077178				2022-12-17	WOS:000221101700004
J	Kulaeva, OI; Draghici, S; Tang, L; Kraniak, JM; Land, SJ; Tainsky, MA				Kulaeva, OI; Draghici, S; Tang, L; Kraniak, JM; Land, SJ; Tainsky, MA			Epigenetic silencing of multiple interferon pathway genes after cellular immortalization	ONCOGENE			English	Article						senescence; immortalization; interferon gene silencing; LI-Fraumeni syndrome	LI-FRAUMENI-SYNDROME; INDUCIBLE NEGATIVE REGULATOR; HUMAN-CELLS; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; DNA METHYLATION; EPITHELIAL-CELLS; CPG ISLAND; CANCER; EXPRESSION	Abrogating cellular senescence is a necessary step in the formation of a cancer cell. Promoter hypermethylation is an epigenetic mechanism of gene regulation known to silence gene expression in carcinogenesis. Treatment of spontaneously immortal Li-Fraumeni fibroblasts with 5-aza-2'-deoxycytidine (5AZA-dC), an inhibitor of DNA methyltransferase (DNMT), induces a senescence-like state. We used microarrays containing 12 558 genes to determine the gene expression pro. le associated with cellular immortalization and also regulated by 5AZA-dC. Remarkably, among 85 genes with methylation-dependent downregulation (silencing) after immortalization, 39 (46%) are known to be regulated during interferon signaling, a known growth-suppressive pathway. This work indicates that gene silencing may be associated with an early event in carcinogenesis, cellular immortalization.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Tainsky, MA (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, 110 Warren Ave, Detroit, MI 48201 USA.		Studitskaia, Olga/D-8551-2014; Draghici, Sorin/B-3074-2013	Studitskaia, Olga/0000-0001-5417-9964; Draghici, Sorin/0000-0002-0786-8377; Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P30CA022453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bechter OE, 2002, EXP HEMATOL, V30, P26, DOI 10.1016/S0301-472X(01)00760-3; Bender CM, 1998, CANCER RES, V58, P95; Berube NG, 1998, AM J HUM GENET, V62, P1015, DOI 10.1086/301848; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Dessain SK, 2000, CANCER RES, V60, P537; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duncan EL, 2000, BIOGERONTOLOGY, V1, P103, DOI 10.1023/A:1010000132671; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FAIRWEATHER NF, 1987, INFECT IMMUN, V55, P2541, DOI 10.1128/IAI.55.11.2541-2545.1987; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Harada M, 2001, J IMMUNOTHER, V24, P323, DOI 10.1097/00002371-200107000-00008; HAYFLICK L, 1976, NEW ENGL J MED, V295, P1302, DOI 10.1056/NEJM197612022952308; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jay P, 1997, NAT GENET, V17, P357, DOI 10.1038/ng1197-357; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kerr MK, 2000, J COMPUT BIOL, V7, P819, DOI 10.1089/10665270050514954; Liang G, 2002, CANCER RES, V62, P961; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; Mori Y, 2001, CANCER RES, V61, P6046; Nakada Y, 1998, GENE, V213, P65, DOI 10.1016/S0378-1119(98)00206-6; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Schwarze SR, 2002, J BIOL CHEM, V277, P14877, DOI 10.1074/jbc.M200373200; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Strathdee G, 2002, EXPERT OPIN INV DRUG, V11, P747; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Wen Y, 2001, CANCER RES, V61, P7142; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xin H, 2001, ONCOGENE, V20, P6828, DOI 10.1038/sj.onc.1204844; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	49	112	116	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4118	4127		10.1038/sj.onc.1206594	http://dx.doi.org/10.1038/sj.onc.1206594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821946				2022-12-17	WOS:000183707600015
J	Pratt, RL; Kinch, MS				Pratt, RL; Kinch, MS			Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade	ONCOGENE			English	Article						Eph kinase; Eck; signal transduction	TERNARY COMPLEX FACTORS; MAP KINASE; PROTEIN-KINASE; GROWTH; LIGANDS; TRANSFORMATION; EXPRESSION; RECEPTORS; FAMILY; DOMAIN	Intracellular signaling by receptor tyrosine kinases regulates many different aspects of cell behavior. Recent studies in our laboratory and others have demonstrated that the EphA2 receptor tyrosine kinase critically regulates tumor cell growth, migration and invasiveness. Although the cellular consequences of EphA2 signaling have been the focus of recent attention, the biochemical changes that are triggered by ligand-mediated activation of EphA2 remain largely unknown. Herein, we demonstrate that ligand stimulation of EphA2 promotes the nucleus translocation and phosphorylation of ERK kinases, followed by an increase in nuclear induction of the Elk-1 transcription factor. Ligand-mediated activation allows EphA2 to form a molecular complex with the SHC and GRB2 adaptor proteins. Specifically, we demonstrate that tyrosine phosphorylated EphA2 interacts with the PTB and SH2 domains of SHC. We also show that the interaction of EphA2 with GRB2 is indirect and mediated by SHC and that this complex is necessary for EphA2-mediated activation of ERK kinases. These studies provide a novel mechanism to demonstrate how EphA2 can convey information from the cell exterior to the nucleus.	Medimmune Inc, Gaithersburg, MD 20878 USA; Purdue Univ, Ctr Canc, Dept Basic Med Sci, W Lafayette, IN 47907 USA	AstraZeneca; Medimmune; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kinch, MS (corresponding author), Medimmune Inc, 35 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.	kinchm@medimmune.com		Kinch, Michael/0000-0003-3939-3756				Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Brennan C, 1997, DEVELOPMENT, V124, P655; Brunet Anne, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P43; CARPENTER MK, 1995, J NEUROSCI RES, V42, P199, DOI 10.1002/jnr.490420207; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lu Q, 2002, BIOL REPROD, V66, P29, DOI 10.1095/biolreprod66.1.29; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MCCORMICK BA, 1992, PHARMACOL THERAPEUT, V53, P239, DOI 10.1016/0163-7258(92)90011-N; MCNEIL PL, 1989, METHOD CELL BIOL, V29, P153; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Morris MC, 2000, J BIOL CHEM, V275, P28849, DOI 10.1074/jbc.M002942200; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Schramek H, 1997, J BIOL CHEM, V272, P11426; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Vanhoutte P, 2001, J BIOL CHEM, V276, P5189, DOI 10.1074/jbc.M006678200; Verlhac MH, 2000, EMBO J, V19, P6065, DOI 10.1093/emboj/19.22.6065; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	56	112	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7690	7699		10.1038/sj.onc.1205758	http://dx.doi.org/10.1038/sj.onc.1205758			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400011				2022-12-17	WOS:000178756200008
J	Weaver, Z; Montagna, C; Xu, XL; Howard, T; Gadina, M; Brodie, SG; Deng, CX; Ried, T				Weaver, Z; Montagna, C; Xu, XL; Howard, T; Gadina, M; Brodie, SG; Deng, CX; Ried, T			Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer	ONCOGENE			English	Article						Brca1; mouse models; SKY; genomic imbalances; centrosome	SUPPRESSOR GENE BRCA1; CHROMOSOMAL-ABERRATIONS; COPY NUMBER; CELL-CYCLE; MOUSE; TUMORIGENESIS; CARCINOMAS; CARCINOGENESIS; MORPHOGENESIS; PROGRESSION	BRCA1 mutation carriers have an increased susceptibility to breast and ovarian cancer. Excision of exon 11 of Brca1 in the mouse, using a conditional knockout (Cre-loxP) approach, results in mammary tumor formation after long latency. To characterize the genomic instability observed in these tumors, to establish a comparative map of chromosomal imbalances and to contribute to the validation of this mouse model of breast cancer, we have characterized chromosomal imbalances and aberrations using comparative genomic hybridization (CGH), and spectral karyotyping (SKY). We found that all tumors exhibit chromosome instability as evidenced by structural chromosomal aberrations and aneuploidy, yet they display a pattern of chromosomal gain and loss that is similar to the pattern in human breast carcinomas. Of note, nine of 15 tumors exhibited a gain of distal chromosome 11, a region that is orthologous to human chromosome 17q11-qter, the mapping position of Erbb2. However, our analysis suggests that genes distal to Erbb2 are the main targets of amplification. Four of the tumors also exhibited a copy number loss of proximal chromosome 11 (11A-B), a region orthologous to human 17p. In eight of the tumors we observed whole or partial gain of chromosome 15 centering on 15D2-D3 (orthologous to human chromosome 8q24), the map location of the c-Myc gene, and six of the tumors exhibited copy number loss of whole or partial chromosome 14, including 14D3, the map location of Rb1. We conclude that despite the tremendous shuffling of chromosomes during the course of mammalian evolution, the pattern of genomic imbalances is conserved between BRCA1-associated mammary gland tumors in mice and humans. Western blot analysis showed that while p53 is absent or mutated in some tumors, at least two tumors revealed wild-type protein, suggesting that other genetic events may lead to tumorigenesis. Similar to BRCA1-deficient mouse embryonic fibroblasts, the tumor cells contained supernumerary functional centrosomes with intact centrioles whose presence results in multipolar mitoses and aneuploidy.	NIH, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; NIAMSD, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Ried, T (corresponding author), NIH, Genet Branch, Ctr Canc Res, 50 S Dr,Room 1306, Bethesda, MD 20892 USA.	riedt@mail.nih.gov	deng, chuxia/N-6713-2016; Gadina, Massimo/R-4195-2019	Weaver Ohler, Zoe/0000-0002-6287-2504	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACON CM, 1995, FEBS LETT, V370, P63, DOI 10.1016/0014-5793(95)00796-C; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Deng CX, 2001, SEMIN CANCER BIOL, V11, P387, DOI 10.1006/scbi.2001.0394; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; Phillips JL, 2001, CANCER RES, V61, P8143; Platzer P, 2002, CANCER RES, V62, P1134; Rhei E, 1998, CANCER RES, V58, P3193; RIED T, 1995, CANCER RES, V55, P5415; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Schuyer M, 1999, MOL CELL ENDOCRINOL, V155, P143, DOI 10.1016/S0303-7207(99)00117-3; Schuyer M, 1999, EUR J OBSTET GYN R B, V82, P147, DOI 10.1016/S0301-2115(98)00217-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SPECTOR DL, 1997, CELLS LAB MANUAL; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu GJ, 2000, CANCER RES, V60, P5371; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	35	112	119	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5097	5107		10.1038/sj.onc.1205636	http://dx.doi.org/10.1038/sj.onc.1205636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140760				2022-12-17	WOS:000176975900008
J	Ohyashiki, JH; Sashida, G; Tauchi, T; Ohyashiki, K				Ohyashiki, JH; Sashida, G; Tauchi, T; Ohyashiki, K			Telomeres and telomerase in hematologic neoplasia	ONCOGENE			English	Article						telomere; telomerase; leukemia; lymphoma; hematopoietic stem cell	MALIGNANT HEMATOPOIETIC-CELLS; ACUTE MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; REPEAT AMPLIFICATION PROTOCOL; MYELODYSPLASTIC SYNDROMES; BONE-MARROW; HODGKINS-DISEASE; STEM-CELLS; JUMPING TRANSLOCATION; REVERSE-TRANSCRIPTASE	Normal hematopoietic cells express telomerase activity, however the presence of telomerase does not necessarily imply stable and thus unchanging telomere length. Gradual telomere loss with aging and rapid cycling of hematopoietic stem cells might contribute to immunosenescence, exhausted hematopoiesis, and increased likelihood of malignant transformation. In leukemias and lymphomas, telomere length may reflect the cellular proliferative history, prior to immortalization. The level of telomerase activity is generally influenced by the fraction of cells in the proliferative pool. Shortened telomeres and high telomerase activity almost always correlates with disease severity in hematologic neoplasias such as relapsed leukemia and high-grade lymphomas, indicating that measurement of telomere length and telomerase activity might be useful to monitor disease condition. Since the mode of action of telomerase inhibitors may require telomeric shortening before induction of apoptosis, anti-telomerase therapy might be helpful for adjuvant therapy following conventional chemotherapy, in vitro purging of neoplastic cells in stem cell transplantation, and treating minimal residual disease. Some promising areas of tissue engineering include rejuvenation of hematopoietic stem cells for improving stem cell transplants or enhancing general immunity for older patients.	Tokyo Med & Dent Univ, Med Res Inst, Dept Virol, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med Univ, Dept Internal Med 1, Shinjuku Ku, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical University	Ohyashiki, JH (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Virol, Bunkyo Ku, 4-45,1 Chome, Tokyo 1138510, Japan.		Sashida, Goro/N-5259-2014	Sashida, Goro/0000-0003-2318-5987				Akiyama M, 1998, BONE MARROW TRANSPL, V21, P167, DOI 10.1038/sj.bmt.1701060; Akiyama M, 2000, BONE MARROW TRANSPL, V25, P441, DOI 10.1038/sj.bmt.1702144; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Arai J, 2001, BLOOD, V97, P2903, DOI 10.1182/blood.V97.9.2903; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Bearss DJ, 2000, ONCOGENE, V19, P1114, DOI 10.1038/sj.onc.1203275; Bechter OE, 1998, CANCER RES, V58, P4918; BERGEMANN J, 1995, NUCLEIC ACIDS RES, V23, P4451, DOI 10.1093/nar/23.21.4451; Boultwood J, 1997, AM J HEMATOL, V56, P266; Boultwood J, 2000, BLOOD, V96, P358, DOI 10.1182/blood.V96.1.358.013k16_358_361; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Brousset P, 1997, BLOOD, V89, P26, DOI 10.1182/blood.V89.1.26.26_26_31; Brousset P, 1998, LEUKEMIA LYMPHOMA, V30, P189, DOI 10.3109/10428199809050942; Brummendorf TH, 2000, BLOOD, V95, P1883, DOI 10.1182/blood.V95.6.1883; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; Cuthbert G, 1999, GENE CHROMOSOME CANC, V24, P295, DOI 10.1002/(SICI)1098-2264(199904)24:4<295::AID-GCC1>3.0.CO;2-8; Daibata M, 1999, BLOOD, V94, P1545, DOI 10.1182/blood.V94.5.1545.417a25_1545_1549; Ely SA, 2000, CANCER, V89, P445, DOI 10.1002/1097-0142(20000715)89:2<445::AID-CNCR33>3.0.CO;2-T; Engelhardt M, 2000, CANCER RES, V60, P610; Engelhardt M, 1997, BLOOD, V90, P182; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Harada K, 1999, CANCER, V86, P1050, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1050::AID-CNCR22>3.0.CO;2-K; Hatakeyama S, 1999, ONCOGENE, V18, P2085, DOI 10.1038/sj.onc.1202510; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igarashi H, 1997, BLOOD, V89, P1299, DOI 10.1182/blood.V89.4.1299; Igarashi H, 1996, BIOCHEM BIOPH RES CO, V219, P649, DOI 10.1006/bbrc.1996.0288; Iwama H, 1997, CANCER-AM CANCER SOC, V79, P1552, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1552::AID-CNCR17>3.0.CO;2-X; Iwama H, 1998, HUM GENET, V102, P397, DOI 10.1007/s004390050711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Le Coniat MB, 2000, LEUKEMIA, V14, P1630, DOI 10.1038/sj.leu.2401876; Lee JJ, 1999, BONE MARROW TRANSPL, V24, P411, DOI 10.1038/sj.bmt.1701923; Li BR, 2000, LEUKEMIA LYMPHOMA, V36, P579, DOI 10.3109/10428190009148406; Nakajima A, 2001, LEUKEMIA, V15, P989, DOI 10.1038/sj.leu.2402137; NILSSON P, 1994, ONCOGENE, V9, P3043; Norrback KF, 1998, BLOOD, V92, P567, DOI 10.1182/blood.V92.2.567.414a18_567_573; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Norrback KF, 1996, BLOOD, V88, P222; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; Ohyashiki JH, 1999, CLIN CANCER RES, V5, P1155; Ohyashiki JH, 1996, TRENDS GENET, V12, P395; Ohyashiki JH, 2001, INT J ONCOL, V18, P593; OHYASHIKI JH, 1994, CANCER RES, V54, P3557; Ohyashiki JH, 1997, CLIN CANCER RES, V3, P619; Ohyashiki K, 1997, LEUKEMIA, V11, P190, DOI 10.1038/sj.leu.2400560; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; Remes K, 2000, BRIT J CANCER, V82, P601, DOI 10.1054/bjoc.1999.0970; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Rufer N, 2001, BLOOD, V97, P575, DOI 10.1182/blood.V97.2.575; Sakabe H, 1998, LEUKEMIA, V12, P728, DOI 10.1038/sj.leu.2401001; Shay JW, 1998, LANCET, V351, P153, DOI 10.1016/S0140-6736(05)78218-0; Shay JW, 1996, LEUKEMIA, V10, P1255; Shay JW, 2000, NAT BIOTECHNOL, V18, P22, DOI 10.1038/71872; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; TAKEUCHI K, 1994, JPN J CANCER RES, V85, P127; Tatematsu K, 1996, ONCOGENE, V13, P2265; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Trentin L, 1999, BRIT J HAEMATOL, V106, P662, DOI 10.1046/j.1365-2141.1999.01620.x; VAZIRI H, 1994, P NATL ACAD SCI USA, V91, P9857, DOI 10.1073/pnas.91.21.9857; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Wynn RF, 1998, LANCET, V351, P178, DOI 10.1016/S0140-6736(97)08256-1; Xu D, 1999, BRIT J CANCER, V80, P1156, DOI 10.1038/sj.bjc.6690480; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x; YAMADA O, 1995, J CLIN INVEST, V95, P1117, DOI 10.1172/JCI117759; Yeager TR, 1999, CANCER RES, V59, P4175; Yui J, 1998, BLOOD, V91, P3255, DOI 10.1182/blood.V91.9.3255.3255_3255_3262; Zhang W, 1996, CLIN CANCER RES, V2, P799	72	112	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					680	687		10.1038/sj.onc.1205075	http://dx.doi.org/10.1038/sj.onc.1205075			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850796				2022-12-17	WOS:000173390500023
J	Brabender, J; Usadel, H; Danenberg, KD; Metzger, R; Schneider, PM; Lord, RV; Wickramasinghe, K; Lum, CE; Park, J; Salonga, D; Singer, J; Sidransky, D; Holscher, AH; Meltzer, SJ; Danenberg, PV				Brabender, J; Usadel, H; Danenberg, KD; Metzger, R; Schneider, PM; Lord, RV; Wickramasinghe, K; Lum, CE; Park, J; Salonga, D; Singer, J; Sidransky, D; Holscher, AH; Meltzer, SJ; Danenberg, PV			Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival	ONCOGENE			English	Article						APC; methylation; neoplasia; NSCLC	CHI-SQUARE STATISTICS; DNA; METHYLATION	Methylation of 5 ' CpG islands in promoter and upstream coding regions has been identified as a mechanism for transcriptional inactivation of tumor suppressor genes. The purpose of this study was to determine whether hypermethylation of the adenomatous polyposis coli (APC) gene promoter occurs in primary non-small cell lung cancer (NSCLC), and whether hypermethylated APC has any relationship with survival. APC promoter 1A methylation was determined in normal and corresponding tumor tissue from 91 NSCLC patients and in a control group of 10 patients without cancer, using a quantitative fluorogenic real-time PCR (Taqman((R))) system. APC promoter methylation was detectable in 86 (95%) of 91 tumor samples, but also in 80 (88%) of 91 normal samples of NSCLC patients, and in only two (20%) of 10 normal lung tissues of the control group. The median level of APC promoter methylation was 4.75 in tumor compared to 1.57 in normal lung tissue (P < 0.001), Patients with low methylation status showed significantly longer survival than did patients with high methylation status (P = 0.041), In a multivariate analysis of prognostic factors, APC methylation was a significant independent prognostic factor (P = 0.044), as were pT (P = 0.050) and pN (P < 0.001) classifications. This investigation shows that APC gene promoter methylation occurs in the majority of primary NSCLCs, High APC promoter methylation is significantly associated with inferior survival, showing promise as a biomarker of biologically aggressive disease in NSCLC.	Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA; Univ Cologne, Dept Visual & Vasc Surg, D-50931 Cologne, Germany; Johns Hopkins Univ, Div Head & Neck Canc Res, Baltimore, MD 21231 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Med, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA	University of Southern California; University of Southern California; University of Southern California; University of Cologne; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Brabender, J (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, NOR 5318,1441 Eastlake Ave, Los Angeles, CA 90033 USA.			Lord, Reginald V N/0000-0001-7475-492X	NCI NIH HHS [CA78843, R01 CA71716, CA85069, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717, DK53620] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843, U01CA085069, R01CA071716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053620, R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 1998, ADV CANCER RES, V72, P141; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EGUICHI K, 1997, CANCER RES, V57, P4913; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 1999, CANCER RES, V59, P67; Ginsberg Robert J., 1997, P858; HALPERN J, 1982, BIOMETRICS, V38, P1017, DOI 10.2307/2529882; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; PIKE MC, 1972, J R STAT SOC A, V135, P210; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tsuchiya T, 2000, ONCOGENE, V19, P3642, DOI 10.1038/sj.onc.1203704	19	112	122	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3528	3532		10.1038/sj.onc.1204455	http://dx.doi.org/10.1038/sj.onc.1204455			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429699				2022-12-17	WOS:000169478300008
J	Radhika, V; Dhanasekaran, N				Radhika, V; Dhanasekaran, N			Transforming G proteins	ONCOGENE			English	Article						G protein; oncogene; signal transduction; transformation; Ras; Rac	SERUM RESPONSE FACTOR; MUTANT ALPHA-SUBUNIT; RHO-DEPENDENT ACTIVATION; CELL-CYCLE PROGRESSION; N-TERMINAL KINASE; MAP KINASE; S-PHASE; TYROSINE KINASE; COOPERATIVE TRANSFORMATION; NEOPLASTIC TRANSFORMATION	Heterotrimeric guanine nucleotide binding proteins, commonly known as G proteins form a super-family of signal transduction proteins. They are peripherally associated with the plasma membrane and provide signal coupling to seven transmembrane surface receptors, G proteins are composed of monomers of alpha, beta, and gamma subunits, The beta- and gamma -subunits are tightly associated. The receptors activated by the appropriate 'signal', interact catalytically with specific G-proteins to mediate guanine nucleotide exchange at the GDP/GTP binding site of the G-protein alpha -subunits, thus displacing the bound GDP for GTP, The GTP bound form of the g-protein alpha -subunit and in some cases the free beta gamma -subunits initiate cellular response by altering the activity of specific effector molecules, Recent studies have indicated that the asynchronous activation of these proteins can lead to the oncogenic transformation of different cell types, The mechanism by which G-proteins regulate the various cell functions appear to involve a complex net-working between different signaling pathways. This review summarizes the signaling mechanisms involved in the regulation of cell proliferation by these transforming G proteins.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; Dermott JM, 1999, ONCOGENE, V18, P7185, DOI 10.1038/sj.onc.1203345; DERMOTT JM, 2001, IN PRESS METH ENZYMO; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, CONT ENDOCRINOL, V6, P101; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ham J, 1997, MOL CELL ENDOCRINOL, V127, P41, DOI 10.1016/S0303-7207(96)03987-1; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; HERMOUET S, 1993, CELL SIGNAL, V5, P215, DOI 10.1016/0898-6568(93)90072-T; Hermouet S, 1996, CELL SIGNAL, V8, P159, DOI 10.1016/0898-6568(95)02049-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; HO, 2001, IN PRESS ONCOGENE; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; MUCA C, 1994, ONCOGENE, V9, P3647; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RAM P, 2001, IN PRESS ONCOGENE; REDDY ST, 1994, J BIOL CHEM, V269, P15473; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWINDINGER WF, 2001, IN PRESS ONCOGENE; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Slice LM, 1999, J BIOL CHEM, V274, P27562, DOI 10.1074/jbc.274.39.27562; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; TORDJMAN K, 1993, J CLIN ENDOCR METAB, V77, P765, DOI 10.1210/jc.77.3.765; Vallar L, 1996, CANCER SURV, V27, P325; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1995, ONCOGENE, V10, P1927; WU DQ, 1992, J BIOL CHEM, V267, P1811; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zeiger MA, 1996, ENDOCRINOLOGY, V137, P5392, DOI 10.1210/en.137.12.5392; Zhang YH, 1996, ONCOGENE, V12, P2377; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	96	112	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1607	1614		10.1038/sj.onc.1204274	http://dx.doi.org/10.1038/sj.onc.1204274			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313908	Bronze			2022-12-17	WOS:000168089800011
J	Lee-Fruman, KK; Kuo, CJ; Lippincott, J; Terada, N; Blenis, J				Lee-Fruman, KK; Kuo, CJ; Lippincott, J; Terada, N; Blenis, J			Characterization of S6K2, a novel kinase homologous to S6K1	ONCOGENE			English	Article						p70(S6k); S6K1; S6K2; rapamycin; wortmannin; PDK1	PROTEIN-SYNTHESIS; RAPAMYCIN; ACTIVATION; PHOSPHORYLATION; TRANSLATION; P70(S6K); CELLS; LOCALIZATION; REQUIREMENT; EXPRESSION	Rapamycin is an immunosuppressant which antagonizes cellular proliferation by inhibiting the function of mTOR. The mTOR:FKBP12:rapamycin complex blocks G1/S transition by inhibiting downstream targets essential for cell cycle progression. One such target is p70(S6k1) (S6K1), a serine/threonine kinase which is inactivated by the mTOR:FKBP12: rapamycin complex, and which has been linked to translational control by virtue of its ability to phosphorylate the ribosomal protein S6. In the current work, me describe cloning and characterization of a novel S6K1 homolog, p54 S6 kinase 2 (p54(S6k2)/S6K2). Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin. Differences between activation of S6K1 and S6K2 by PDK1 were observed, suggesting potential differences in the regulation of these homologs. Strikingly, S6K2 activity and S6 phosphorylation were both intact in S6K1(-/-)ES cell, indicating a possible role for S6K2 in in vivo S6 phosphorylation. Interestingly, we found two isoforms of S6K2 which are localized to distinct cellular compartments; the smaller form resides in the detergent-soluble fraction, whereas the larger form is found in the particulate fraction. Our findings demonstrate the existence of a family of rapamycin-sensitive protein kinases potentially involved in S6 phosphorylation, translational control, and transduction of mTOR signals.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; National Jewish Health	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P426; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Gout I, 1998, J BIOL CHEM, V273, P30061, DOI 10.1074/jbc.273.46.30061; GRAMMER TC, 1996, CANC SURVEYS; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; KOH H, 1999, BRIT J PHARMACOL, V36, P5115; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saitoh M, 1998, BIOCHEM BIOPH RES CO, V253, P470, DOI 10.1006/bbrc.1998.9784; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	33	112	118	1	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5108	5114		10.1038/sj.onc.1202894	http://dx.doi.org/10.1038/sj.onc.1202894			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490847				2022-12-17	WOS:000082497100010
J	Ariumi, Y; Masutani, M; Copeland, TD; Mimori, T; Sugimura, T; Shimotohno, K; Ueda, K; Hatanaka, M; Noda, M				Ariumi, Y; Masutani, M; Copeland, TD; Mimori, T; Sugimura, T; Shimotohno, K; Ueda, K; Hatanaka, M; Noda, M			Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro	ONCOGENE			English	Article						DNA-PK; PARP; Ku; poly(ADP-ribosyl)ation; dsDNA break	HUMAN-IMMUNODEFICIENCY-VIRUS; ABL TYROSINE KINASE; C-ABL; V(D)J RECOMBINATION; DAMAGE; REPAIR; CELLS; P53; ACTIVATION; ANTIGEN	It has been suggested that DNA-dependent protein kinase (DNA-PK) is a central component of DNA double-strand-break repair. The mechanism of DNA-PK action, however, has not been fully understood. Poly(ADP-ribose) polymerase (PARP) is another nuclear enzyme which has high affinity to DNA ends. In this study, we analysed the interaction between these tao enzymes. First, DNA-PK was found to suppress the PARP activity and alters the pattern of poly(ADP-ribosyl)ation. Although DNA-PK phosphorylates PARP in a DNA-dependent manner, this modification is unlikely to be responsible for the suppression of PARP activity, since this suppression occurs even in the absence of ATP. Conversely, PARP was found to ADP-ribosylate DNA-PK in vitro. However, the autophosphorylation activity of DNA-PK was not influenced by this modification. In a competitive electrophoretic mobility shift assay, Ku 70/80 complex, the DNA binding component of DNA-PK, was found to have higher affinity to a short fragment of DNA than does PARP. Furthermore, co-immunoprecipitation analysis suggested direct or close association between Ku and PARP. Thus, DNA-PK suppresses PARP activity, probably through direct binding and/or sequestration of DNA-ends which serve as an important stimulator for both enzymes.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Natl Canc Ctr, Res Inst, Div Biochem, Tokyo 1040045, Japan; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Keio Univ, Sch Med, Tokyo 1600016, Japan; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Kyoto 6068501, Japan	Kyoto University; National Cancer Center - Japan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Keio University; Kyoto University; Kyoto University	Ariumi, Y (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.		Ariumi, Yasuo/F-5804-2013					Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; Ariumi Y, 1998, FEBS LETT, V423, P25, DOI 10.1016/S0014-5793(98)00051-9; Ariumi Yasuo, 1997, Leukemia (Basingstoke), V11, P29; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; DARBY MK, 1985, EMBO J, V4, P2129, DOI 10.1002/j.1460-2075.1985.tb03903.x; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; IKEJIMA M, 1989, BIOCHEM BIOPH RES CO, V163, P739, DOI 10.1016/0006-291X(89)92285-7; IKEJIMA M, 1990, J BIOL CHEM, V265, P21907; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; KAWAGUCHI H, 1989, NUCLEIC ACIDS RES, V17, P6229, DOI 10.1093/nar/17.15.6229; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; NOSAKA T, 1993, NUCLEIC ACIDS RES, V21, P5124, DOI 10.1093/nar/21.22.5124; OHTSUKI M, 1984, FEBS LETT, V168, P275, DOI 10.1016/0014-5793(84)80261-6; REEVES WH, 1989, J BIOL CHEM, V264, P5047; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TANIGUCHI T, 1988, BIOCHEM BIOPH RES CO, V154, P1034, DOI 10.1016/0006-291X(88)90244-6; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; UEDA K, 1975, P NATL ACAD SCI USA, V72, P205, DOI 10.1073/pnas.72.1.205; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; YAMAGOE S, 1991, MOL CELL BIOL, V11, P3522, DOI 10.1128/MCB.11.7.3522; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	112	115	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4616	4625		10.1038/sj.onc.1202823	http://dx.doi.org/10.1038/sj.onc.1202823			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467406				2022-12-17	WOS:000082018600011
J	Xie, W; Chow, LT; Paterson, AJ; Chin, E; Kudlow, JE				Xie, W; Chow, LT; Paterson, AJ; Chin, E; Kudlow, JE			Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGF alpha expression in transgenic mice	ONCOGENE			English	Article						tetracycline; skin; hair follicle	GROWTH-FACTOR RECEPTOR; HAIR FOLLICLE DEVELOPMENT; CANCER CELL-LINE; NEU-ONCOGENE; EGF RECEPTOR; TARGETED EXPRESSION; KERATIN PROMOTER; EPIDERMAL EXPRESSION; GENE-EXPRESSION; OWN RECEPTOR	The ErbB2 receptor tyrosine kinase (RTK) is expressed in basal cells of squamous epithelia and the outer root sheath of hair follicles. We previously showed that constitutive expression of activated ErbB2 directed to these sites in the skin by the keratin 14 (K14) promoter produces prominent hair follicle abnormalities and striking skin hyperplasia in transgenic mice. However, perinatal lethality precluded the establishment of a transgenic line for analysis of ErbB2 function in adult animals. To investigate the significance of ErbB2 signaling in epithelial tissues during and post development, we developed a K14-rtTA/TetRE-ErbB2 'Tet-On' bitransgenic mouse system. These mice were normal until the ErbB2 transgene mas induced by exposure to doxycycline (Dox). Prenatal induction resulted in perinatal death. Postnatally, ErbB2 transgene expression was observed at 4 h after the initiation of Dox, and reached a plateau at 24 h. Skin hyperplasia followed after 2 days and these changes reverted to normal upon Dox withdrawal. In adults, as in the neonates, prolonged ErbB2 induction caused prominent skin and hair follicle hyperplasias. Severe hyperplasias in the cornea, eye lids, tongue and esophagus mere also observed. ErbB2 transgene induction was accompanied by increased expression of TGF alpha, a ligand of epidermal growth factor receptor (EGFR), and to a lesser extent, EGFR, further enhancing RTK signal transduction. We conclude that ErbB2 plays important roles in both development and maintenance of hair follicles and diverse squamous epithelia and that this ligand-inducible and tissue-specific 'Tet-On' transgenic mouse system provides a means to study transgenes with perinatal toxicity.	Univ Alabama, Dept Med Endocrinol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med Endocrinol, 1808 7th Ave S,Room 756, Birmingham, AL 35294 USA.		Xie, Wen/M-1768-2016		NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652, R01DK048882] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200] Funding Source: Medline; NIDDK NIH HHS [DK48882, DK43652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DAVIS BM, 1993, NEUROSCIENCE, V56, P789, DOI 10.1016/0306-4522(93)90127-2; DOUGALL WC, 1994, ONCOGENE, V9, P2109; EARP HS, 1986, J BIOL CHEM, V261, P4777; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KUDLOW JE, 1986, J BIOL CHEM, V261, P4134; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PRESS MF, 1990, ONCOGENE, V5, P953; SAITOU M, 1995, NATURE, V374, P159, DOI 10.1038/374159a0; SHIH C, 1981, NATURE, V290, P621; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Tanaka S, 1997, CANCER RES, V57, P28; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219; WILLIAMS IR, 1994, P NATL ACAD SCI USA, V91, P9710, DOI 10.1073/pnas.91.21.9710; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; Xie W, 1998, CELL GROWTH DIFFER, V9, P313; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Xie W, 1997, ANTICANCER RES, V17, P2627; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	46	112	115	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	1999	18	24					3593	3607		10.1038/sj.onc.1202673	http://dx.doi.org/10.1038/sj.onc.1202673			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	206QZ	10380881				2022-12-17	WOS:000080891700005
J	Ugolini, F; Adelaide, J; Charafe-Jauffret, E; Nguyen, C; Jacquemier, J; Jordan, B; Birnbaum, D; Pebusque, MJ				Ugolini, F; Adelaide, J; Charafe-Jauffret, E; Nguyen, C; Jacquemier, J; Jordan, B; Birnbaum, D; Pebusque, MJ			Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes	ONCOGENE			English	Article						amplification; breast cancer; tumor suppressor gene; oncogene; FGFR1; FRP1/FRZB; cDNA array; gene expression; chromosome 8	HUMAN GENOME; SUSCEPTIBILITY GENE; DNA AMPLIFICATION; FACTOR HEREGULIN; LINKAGE ANALYSIS; SEQUENCE TAGS; MAP; FAMILY; CELLS; HETEROZYGOSITY	Deletions and amplifications are frequent alterations of the short arm of chromosome 8 associated with various types of cancers, including breast cancers. This indicates the likely presence of tumor suppressor genes and oncogenes, In the present study, we have used the expressed sequence tag (EST) map of 8p11-21 to assemble a set of available cDNAs representing genes from this region. DNA arrays were prepared for expression analysis and search for genes potentially involved in breast cancer, Underexpresion in tumoral breast cells (versus normal breast) was observed for 15 transcripts, Among these, the Frizzled-related gene FRP1/FRZB, was turned off in 78% of breast carcinomas, suggesting that the lack of its product may be associated with malignant transformation, Overexpression in tumoral breast cells was observed for 13 genes. The FGFR1 gene, that encodes a tyrosine kinase receptor for members of the fibroblast growth factor family, was identified as a good candidate for one amplification unit, Taken together, our results demonstrate that such a strategy can rapidly identify genes with an altered pattern of expression and provide candidate genes for malignancies.	INSERM U119, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Anatomopathol, F-13009 Marseille, France; Ctr Immunol Marseille Luminy, TAGC, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Pebusque, MJ (corresponding author), INSERM U119, Oncol Mol Lab, 27 Bd Lei Roure, F-13009 Marseille, France.		ADELAIDE, José JA/O-4390-2017; Nguyen, Catherine/M-4119-2016; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Nguyen, Catherine/0000-0001-9376-6360; Birnbaum, Daniel/0000-0001-7920-9883; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Anbazhagan R, 1998, AM J PATHOL, V152, P815; Bacus SS, 1996, ONCOGENE, V12, P2535; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courjal F, 1997, CANCER RES, V57, P4360; Dale TC, 1996, CANCER RES, V56, P4320; DIB A, 1995, ONCOGENE, V10, P995; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Granjeaud S, 1996, GENET ANAL-BIOMOL E, V12, P151, DOI 10.1016/1050-3862(95)00128-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jordan BR, 1998, J BIOCHEM-TOKYO, V124, P251, DOI 10.1093/oxfordjournals.jbchem.a022104; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lyne JC, 1997, CANCER J SCI AM, V3, P21; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller G, 1997, GENOME RES, V7, P1027, DOI 10.1101/gr.7.10.1027; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Pennisi E, 1998, SCIENCE, V279, P1445; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; POPOVICI C, 1999, IN PRESS BLOOD; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rocha D, 1997, IMMUNOGENETICS, V46, P142, DOI 10.1007/s002510050253; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Tanner MM, 1996, CANCER RES, V56, P3441; Theillet C, 1998, NAT MED, V4, P767, DOI 10.1038/nm0798-767; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WILLIAMSON AR, 1995, J NIH RES, V7, P61; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	54	112	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1903	1910		10.1038/sj.onc.1202739	http://dx.doi.org/10.1038/sj.onc.1202739			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086345				2022-12-17	WOS:000079090000014
J	Lim, FL; Soulez, M; Koczan, D; Thiesen, HJ; Knight, JC				Lim, FL; Soulez, M; Koczan, D; Thiesen, HJ; Knight, JC			A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas	ONCOGENE			English	Article						sarcoma; SSX; KRAB; transcription	ZINC-FINGER PROTEINS; KRUPPEL-ASSOCIATED BOX; HUMAN SYNOVIAL SARCOMA; SYT; TRANSLOCATION; FUSION; FAMILY; CHROMOSOME; ACTIVATOR; MEMBERS	SSX genes show extensive nucleotide sequence conservation but little is known of their function. Disruption of SSX1 or SSX2, by chromosome translocation and 'in-frame' fusion to SYT, is a consistent feature of synovial sarcomas, The resulting SYT-SSX1/SSX2 proteins are activators of transcription; transactivation function is located in SYT, Unrearranged SSX1 can repress transcription, and this has been attributed to a putative Kruppel associated box (KRAB) repression domain at the N-terminus. Here we isolated SSX-KRAB domains to specifically measure repression activity, using a previously characterized KOX1-KRAB domain as a control. In our repressor assay SSX1- and SSX2-KRAB domains down-modulated the transactivation of reporter gene by threefold, compared with 83-fold repression achieved by KOX1-KRAB in the assay. Yeast two-hybrid analysis showed that SSX1-KRAB, unlike KOX1-KRAB, fails to interact with the KRAB co-repressor TIF1 beta. These results raise questions about the evolutionary and functional relationship of SSX-KRAB and typical KRAB domains of Kruppel zinc finger genes. We found that full-length SSX1 showed potent (74-fold) repression in our repressor assay, indicating the existence of a repression domain distinct from SSX-KRAB. By assaying deletion constructs of SSX1 we localized repression activity to 33 amino acids at the C-terminus. This novel domain is conserved between SSX family members, and, unlike the KRAB-related domain, is retained on fusion with SYT, This has important implications in understanding the mechanism by which the SYT-SSX fusion protein could contribute to neoplasia.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0HS, England; Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Mol Oncol Unit, London W12 0HS, England; Univ Rostock, Inst Immunol, D-18055 Rostock, Germany	Imperial College London; Cancer Research UK; Imperial College London; University of Rostock	Knight, JC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Campus, London W12 0HS, England.			Lim, Fei Ling/0000-0002-7744-4836				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bridge JA, 1994, CYTOGENETICS BONE SO; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; THIESEN H-J, 1990, New Biologist, V2, P363; Thiesen Hans-Juergen, 1997, P315; Tureci O, 1996, CANCER RES, V56, P4766; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	26	112	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					2013	2018		10.1038/sj.onc.1202122	http://dx.doi.org/10.1038/sj.onc.1202122			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788446				2022-12-17	WOS:000076423500016
J	Sawa, H; Ohshima, TA; Ukita, H; Murakami, H; Chiba, Y; Kamada, H; Hara, M; Saito, I				Sawa, H; Ohshima, TA; Ukita, H; Murakami, H; Chiba, Y; Kamada, H; Hara, M; Saito, I			Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner	ONCOGENE			English	Article						cyclin D1; cell cycle regulation; transfection; FACS; Ki-67 antigen; alternative splicing	DEPENDENT KINASE-4 CDK4; DNA-REPLICATION; RETINOBLASTOMA-PROTEIN; DIPLOID FIBROBLASTS; GENE AMPLIFICATION; GROWTH ARREST; BREAST-CANCER; S-PHASE; EXPRESSION; OVEREXPRESSION	Alternative splicing of cyclin D1 gene mRNA has recently been demonstrated, The novel transcript shows no splicing at the downstream exon 3 boundary and encodes a protein with an altered carboxyl-terminal domain that is a cyclin D1 variant; exon 5 is not included in the coding sequence which terminates downstream of exon 4, We here produced cells that exogenously express each form of cyclin D1 and analysed their cell cycle regulation. We found that (1) alternative splicing forms of cyclin D1 modulated entry into the cell cycle in an inverse manner; (2) both splicing forms suppressed cell growth; and (3) cells overexpressing form [a] were inhibited from entry into and completion of the S phase, although form [b]-expressing cells shelved no reduction of G1- to S transition. We also found that overexpression of either cyclin D1 form up-regulated Rb gene products, suggesting that this up-regulation may be one of the causes of growth suppression in cyclin D1 overexpressing cells.	Kyorin Univ, Sch Med, Dept Neurosurg, Tokyo, Japan; Kyorin Univ, Sch Med, Dept Biochem 2, Tokyo, Japan; Hokuto Hosp, Obihiro, Hokkaido, Japan	Kyorin University; Kyorin University	Sawa, H (corresponding author), Kyorin Univ, Sch Med, Dept Neurosurg, Tokyo, Japan.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Asano K, 1995, BIOCHEM BIOPH RES CO, V217, P1169, DOI 10.1006/bbrc.1995.2892; ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; BARTKOVA J, 1995, ONCOGENE, V10, P775; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CELLAPPAN SP, 1991, CELL, V65, P1053; CHEN XB, 1995, CANCER RES, V55, P4257; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; DelSal G, 1996, ONCOGENE, V12, P177; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EBLEN ST, 1995, CELL GROWTH DIFFER, V6, P915; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GILLETT C, 1994, CANCER RES, V54, P1812; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HAN EKH, 1995, ONCOGENE, V10, P953; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KEY G, 1993, LAB INVEST, V68, P629; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Liu Y, 1996, CANCER RES, V56, P31; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MICHALIDES R, 1995, CANCER RES, V55, P973; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P761; PELLICCIARI C, 1995, CYTOMETRY, V21, P329, DOI 10.1002/cyto.990210404; Pusch O, 1996, FEBS LETT, V385, P143, DOI 10.1016/0014-5793(96)00369-9; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9639; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; TENAN M, 1995, BIOCHEM BIOPH RES CO, V217, P195, DOI 10.1006/bbrc.1995.2763; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhou P, 1996, CANCER RES, V56, P36; ZWIJSEN RML, 1995, MOL CELL BIOL, V15, P2554	66	112	114	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1701	1712		10.1038/sj.onc.1201691	http://dx.doi.org/10.1038/sj.onc.1201691			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582018				2022-12-17	WOS:000072807600008
J	Hiyama, H; Iavarone, A; Reeves, SA				Hiyama, H; Iavarone, A; Reeves, SA			Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F	ONCOGENE			English	Article						E2F; p21; cell cycle; transcription	PROTEIN FAMILY MEMBERS; RETINOBLASTOMA PROTEIN; IN-VIVO; C-MYC; P53-INDEPENDENT EXPRESSION; FUNCTIONAL INTERACTION; PROMOTER; BINDING; ARREST; GROWTH	The control of cell cycle progression is orchestrated by an extraordinary diverse and dynamic in function group of proteins. Critical in the progression are the actions of the E2F family of transcription factors which regulate the expression of genes necessary for the G(1)/S transition and the WAF/CIP/KIP family of cdk inhibitors which can inhibit cell cycle progression. In this report, we have identified E2F binding sites in both the human and mouse p21 promoters that bind E2F protein complexes from nuclear extracts in a cell cycle-dependent manner. In ectopic expression experiments we determined that E2F1, but not E2F4, can strongly transactivate the human p21 gene through these E2F binding sites which are located in the -215/+1 region of the p21 gene. The transactivation of the p21 gene through regulatory elements within the -215/+1 region of the promoter was correlated with increased levels of endogenous E2F1 and p21 proteins at the G(1)/S boundary. The significance of transactivation of the p21 gene by E2F is that p21 function is important in cell cycle progression as well as for cell cycle arrest. Indeed, E2F- induced levels of p21 protein during the G(1)/S transition is consistent with the recent findings demonstrating that p21 acts as an assembly factor for kinase active cyclin/cdk/p21 complexes.	Massachusetts Gen Hosp, Ctr Neurosci, Neurosurg Serv, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Mem Sloan Kettering Canc Ctr, Cell Biol & Genet Program, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Reeves, SA (corresponding author), Massachusetts Gen Hosp, Ctr Neurosci, Neurosurg Serv, Boston, MA 02129 USA.							BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Botz J, 1996, MOL CELL BIOL, V16, P3401; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hiyama H, 1997, ONCOGENE, V14, P2533, DOI 10.1038/sj.onc.1201080; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JUNG JM, 1995, ONCOGENE, V11, P2021; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LAU LF, 1991, GENES INDUCED SERUM, P165; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu Y, 1996, CANCER RES, V56, P31; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Magae J, 1996, J CELL SCI, V109, P1717; Marchetti A, 1996, ONCOGENE, V12, P1319; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAYOL X, 1995, ONCOGENE, V11, P801; MICHIELI P, 1994, CANCER RES, V54, P3391; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOLNAR G, 1994, MOL CELL BIOL, V14, P5254; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	59	112	112	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1513	1523		10.1038/sj.onc.1201667	http://dx.doi.org/10.1038/sj.onc.1201667			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569018				2022-12-17	WOS:000072743200001
J	Miyake, H; Hanada, N; Nakamura, H; Kagawa, S; Fujiwara, T; Hara, I; Eto, H; Gohji, K; Arakawa, S; Kamidono, S; Saya, H				Miyake, H; Hanada, N; Nakamura, H; Kagawa, S; Fujiwara, T; Hara, I; Eto, H; Gohji, K; Arakawa, S; Kamidono, S; Saya, H			Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer	ONCOGENE			English	Article						Bcl-2; cisplatin; adenoviral-mediated p53 gene transfer; apoptosis; bladder cancer	WILD-TYPE P53; IN-VIVO; LUNG-CANCER; P53-DEPENDENT APOPTOSIS; RECOMBINANT ADENOVIRUS; DNA-BINDING; CARCINOMA; EXPRESSION; THERAPY; RESISTANCE	To investigate the effects of the expression of Bcl-2 protein in bladder cancer on the apoptosis induced by cisplatin or adenoviral-mediated p53 gene (Ad5CMV-p53) transfer, we transfected the bcl-2 gene into KoTCC-1, a human bladder cancer cell line that does not express the Bcl-2 protein. The Bcl-2-transfected KoTCC-1 (KoTCC-1/B) exhibited significantly higher resistance to both cisplatin and Ad5CMV-p53 transfer than did either the parental KoTCC-1 (KoTCC-1/P) or the vector-only transfected cell line (KoTCC-1/C). The flow cytometric analysis of the propidium iodide-stained nuclei and DNA fragmentation analysis after cisplatin or Ad5CMV-p53 treatment revealed DNA degradation in both KoTCC-1/P and KoTCC-1/C, whereas KoTCC1/B showed a marked inhibition of DNA degradation. Following the treatment with cisplatin or Ad5CMV-p53, the accumulation of p53 protein was highly detectable for a long period in KoTCC-1/B compared to that in KoTTC-1/P and KoTCC-1/C. Furthermore, the cisplatin and Ad5CMV-p53 treatments each reduced the volume of the subcutaneous tumors established in nude mice formed by KoTCC-1/P or KoTCC-1/C; in contrast, their reductive effects on the tumors formed by KoTCC-1/B were significantly suppressed. The intraperitoneal tumor cell implantation model revealed that the prognoses of mice injected with KoTCC-1/B were significantly inferior to those of the mice injected with either KoTCC-1/P or KoTCC-1/C after treatment with cisplatin or Ad5CMV-p53. These findings suggest that the expression of Bcl-2 in bladder cancer cells interferes with the therapeutic effects of cisplatin and Ad5CMV-p53 through the inhibition of the apoptotic pathway.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kobe Univ, Sch Med, Dept Urol, Kobe, Hyogo 650, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 700, Japan	Kumamoto University; Kobe University; Okayama University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Kagawa, Shunsuke/B-2189-2011; Saya, Hideyuki/J-4325-2013	Kagawa, Shunsuke/0000-0002-3610-8211				ARMSTRONG DK, 1992, CANCER RES, V52, P3418; Bilim V, 1996, J NATL CANCER I, V88, P686, DOI 10.1093/jnci/88.10.686-a; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHU G, 1994, J BIOL CHEM, V269, P787; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUJIWARA T, 1994, CANCER RES, V54, P2287; Gallo O, 1996, CLIN CANCER RES, V2, P261; GomezManzano C, 1996, CANCER RES, V56, P694; Graham FL, 1991, METHOD MOL BIOL, P109; Hamada K, 1996, CANCER RES, V56, P3047; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIM YH, 1992, J IMMUNOL, V149, P17; King ED, 1996, J UROLOGY, V155, P316, DOI 10.1016/S0022-5347(01)66652-7; KYO E, 1993, INT J ONCOL, V3, P265; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIU TJ, 1995, CANCER RES, V55, P3117; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Miyake H, 1997, J UROLOGY, V157, P2351, DOI 10.1016/S0022-5347(01)64779-7; Mujoo K, 1996, ONCOGENE, V12, P1617; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; PARK JG, 1987, CANCER RES, V47, P5875; Parker S. L., 1996, CA CANC J CLIN, V65, P5; RAFFO AJ, 1995, CANCER RES, V55, P4438; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROUSCULP MD, 1992, HUM GENE THER, V3, P471, DOI 10.1089/hum.1992.3.5-471; STERNBERG CN, 1993, CANCER, V72, P1975, DOI 10.1002/1097-0142(19930915)72:6<1975::AID-CNCR2820720631>3.0.CO;2-I; THRASHER JB, 1993, J UROLOGY, V149, P957, DOI 10.1016/S0022-5347(17)36270-5; Tomita Y, 1996, INT J CANCER, V66, P322, DOI 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG YS, 1993, ONCOGENE, V8, P3427; WELSH MJ, 1994, HUM GENE THER, V5, P209, DOI 10.1089/hum.1994.5.2-209; Werthman PE, 1996, J UROLOGY, V155, P753, DOI 10.1016/S0022-5347(01)66515-7; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	44	112	113	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					933	943		10.1038/sj.onc.1201602	http://dx.doi.org/10.1038/sj.onc.1201602			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484785				2022-12-17	WOS:000072053200013
J	Watabe, M; Ito, K; Masuda, Y; Nakajo, S; Nakaya, K				Watabe, M; Ito, K; Masuda, Y; Nakajo, S; Nakaya, K			Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells	ONCOGENE			English	Article						apoptosis; AP-1; JNK; leukemia cells; MAP kinase	MAP KINASE KINASE; PROTEIN-KINASES; JUN; PHOSPHORYLATION; MEK1; TRANSFORMATION; FIBROBLASTS; DOMAIN; FAMILY; AGENTS	In a previous study, we demonstrated that bufalin caused apoptosis in human leukemia U937 cells by the anomalous activation of mitogen-activated protein kinase (MAPK) via a signaling pathway that included Ras, Raf-1 and MAPK kinase-l, We report here the effect of bufalin on c-Jun N-terminal protein kinase (JNK), a member of the MAPK family, and on the signaling pathway downstream of MAPKs in U937 cells, When U937 cells were treated with 10(-8) M bufalin, the activity of JNK1 was markedly elevated 3 h after the start of treatment and remained so for 9 h, This activation of JNK and the induction of apoptosis by bufalin were suppressed by expression of antisense mRNA for MAPK kinase-l, c-Jun was translocated from the cytoplasm to the nucleus after treatment of U937 cells with bufalin. The transcriptional activity of AP-1 was transiently enhanced by the treatment with bufalin and this activation was suppressed by the expression of antisense mRNA for MAPK kinase-l, Both curcumin (1,7-bis[4-hydroxy-3-methoxy-phenyl]-1,6-heptadiene-3,5-dione), an inhibitor of the biosynthesis of AP-1, and the expression of dominant negative c-Jun inhibited the activation of AP-1 and the induction of apoptosis by. bufalin, Expression of a constitutively active mutant form of MAPK kinase-l induced the activation of AP-1 and subsequent apoptosis in U937 cells. These results suggest that the activation of AP-1 via a MAPK cascade that includes JNK is required for the induction of apoptosis by bufalin in U937 cells,.	Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, Tokyo 142, Japan	Showa University	Nakaya, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Biol Chem Lab, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.							BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Franklin CC, 1995, ONCOGENE, V11, P2365; GOTOH Y, 1994, ONCOGENE, V9, P1891; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOSHI M, 1988, J BIOL CHEM, V263, P5396; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watabe M, 1996, J BIOL CHEM, V271, P14067, DOI 10.1074/jbc.271.24.14067; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu R, 1996, CANCER RES, V56, P2954; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	29	112	123	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					779	787		10.1038/sj.onc.1201592	http://dx.doi.org/10.1038/sj.onc.1201592			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488042				2022-12-17	WOS:000071931800010
J	Zhao, Y; Hague, S; Manek, S; Zhang, L; Bicknell, R; Rees, MCP				Zhao, Y; Hague, S; Manek, S; Zhang, L; Bicknell, R; Rees, MCP			PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium	ONCOGENE			English	Article						tamoxifen; adenomedullin; differential PCR display; endometrium; angiogenesis	BREAST-CANCER PATIENTS; GROWTH-FACTOR; POSTMENOPAUSAL WOMEN; HYPOTENSIVE PEPTIDE; CELL-PROLIFERATION; PROMOTER-CONTEXT; POTENTIAL ROLE; EXPRESSION; PREVENTION; PHEOCHROMOCYTOMA	Tamoxifen is currently the most widely used drug for the treatment of breast cancer, but there now exists considerable evidence that tamoxifen can also induce endometrial hyperplasia in pre menopausal women. We have used PCR differential display on primary human endometrial isolates in an attempt to identify genes induced by but not estrogen. Eight such tamoxifen differentially expressed bands were cloned and sequenced, one of which was found to be the peptide adrenomedullin. We have shown that adrenomedullin is a novel growth factor for endothelial cells and is angiogenic in vivo in the chick chorioallantoic membrane assay. Immunohistochemical analysis of endometrial sections have shown that while macrophages in the endometrium express adrenomedullin at a low level, endometrial macrophages of women receiving tamoxifen strongly express adrenomedullin (P=0.008). We postulate that endometrial induction of the angiogenic factor adrenomedullin by tamoxifen is part of the mechanism by which tamoxifen results in endometrial hyperplasia.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Oxford OX3 9DU, England; Univ Oxford, Inst Mol Med, Imperial Canc Res Fund, Mol Angiogenesis Grp, Oxford OX3 9DU, England; Univ Oxford, John Radcliffe Hosp, Dept Histopathol, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford	Rees, MCP (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynecol, Oxford OX3 9DU, England.		zhao, yuan/E-2435-2013	Bicknell, Roy/0000-0002-0941-8919	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Barakat RR, 1996, CLIN OBSTET GYNECOL, V39, P629, DOI 10.1097/00003081-199609000-00012; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BUTTA A, 1992, CANCER RES, V52, P4261; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; GAL D, 1991, GYNECOL ONCOL, V42, P120, DOI 10.1016/0090-8258(91)90330-8; HARPER MJK, 1967, J REPROD FERTIL, V13, P101; HUYNH H, 1994, CANCER RES, V54, P3115; ICHIKI Y, 1994, FEBS LETT, V338, P6, DOI 10.1016/0014-5793(94)80106-1; Ishihara T, 1997, LIFE SCI, V60, P1763, DOI 10.1016/S0024-3205(97)00136-7; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; ISMAIL SM, 1994, J CLIN PATHOL, V47, P827, DOI 10.1136/jcp.47.9.827; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jones RK, 1996, FERTIL STERIL, V66, P81, DOI 10.1016/S0015-0282(16)58391-5; JORDAN VC, 1991, ANN NY ACAD SCI, V622, P439; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; LAHTI E, 1993, OBSTET GYNECOL, V81, P660; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Macri CJ, 1996, AM J OBSTET GYNECOL, V175, P906, DOI 10.1016/S0002-9378(96)80023-8; MARTINEZ A, 1995, ENDOCRINOLOGY, V136, P4099, DOI 10.1210/en.136.9.4099; Miller MJ, 1996, J BIOL CHEM, V271, P23345; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; Nephew KP, 1996, ENDOCRINOLOGY, V137, P219, DOI 10.1210/en.137.1.219; PEEK MJ, 1988, EXP PATHOL-JENA, V34, P35, DOI 10.1016/S0232-1513(88)80020-3; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; SAKAKIBARA K, 1992, AM J OBSTET GYNECOL, V166, P206, DOI 10.1016/0002-9378(92)91860-D; Sambrook J., 1982, MOL CLONING; SARTOR BM, 1995, REPROD TOXICOL, V9, P225, DOI 10.1016/0890-6238(95)00003-S; SATOH F, 1995, J CLIN ENDOCR METAB, V80, P1750, DOI 10.1210/jc.80.5.1750; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VU N, 1984, P ANN C RES MED ED, V23, P383; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Withers DJ, 1996, FEBS LETT, V378, P83, DOI 10.1016/0014-5793(95)01427-6; ZHANG L, 1995, J CELL SCI, V108, P323	38	112	120	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	1998	16	3					409	415		10.1038/sj.onc.1201768	http://dx.doi.org/10.1038/sj.onc.1201768			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467966				2022-12-17	WOS:000071582100013
J	Pirollo, KF; Hao, ZM; Rait, A; Jang, YJ; Fee, WE; Ryan, P; Chiang, YW; Chang, EH				Pirollo, KF; Hao, ZM; Rait, A; Jang, YJ; Fee, WE; Ryan, P; Chiang, YW; Chang, EH			p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy	ONCOGENE			English	Article						p53; adenovirus; head and neck; cancer; radiosensitization	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; IN-VIVO; RECOMBINANT ADENOVIRUS; RADIATION-RESISTANT; IONIZING-RADIATION; CANCER-THERAPY; APOPTOSIS; EXPRESSION; GROWTH	Radiation resistant squamous cell carcinoma of the head and neck cell line JSQ-3 carries a mutant form of tumor suppressor gene p53. Treatment of these cells with an adenoviral vector containing wild-type p53 (Av1p53) was able to inhibit their growth in vitro and in vivo while having no effect on normal cells. More significantly, introduction of wtp53 also reduced the radiation-resistance level of this cell line in vitro, in a viral dose-dependent manner, Furthermore, this radiosensitization also carried over to the in vivo situation where the response of JSQ-3 cell-induced mouse xenografts to radiotherapy was markedly enhanced after treatment with Av1p53, Complete, long-term regression of the tumors for up to 162 days was observed when a single dose of Av1p53 was administered in combination with ionizing radiation, demonstrating the effectiveness of this combination of gene therapy and conventional radiotherapy, This sensitization of tumors to radiation therapy by replacement of wtp53 could significantly decrease the rate of recurrence after radiation treatment. Since radiation is one of the most prevalent forms of adjunctive therapy for a variety of cancers, these results have great relevance in moving toward an improved cancer therapy.	STANFORD UNIV,DEPT SURG,DIV OTOLARYNGOL,STANFORD,CA 94305; GENET THERAPY INC,NOVARTIS,GAITHERSBURG,MD 20878	Stanford University; Novartis					NCI NIH HHS [R01 CA45158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; *AM CANC SOC, 1993, PUB AM CANC SOC; *AM JOINT COMM CAN, 1983, MAN STAG CANC, P25; AWAN AM, 1991, HEMATOL ONCOL CLIN N, V5, P635, DOI 10.1016/S0889-8588(18)30406-4; BLAU HM, 1995, NEW ENGL J MED, V333, P1204, DOI 10.1056/NEJM199511023331808; BRACHMAN DG, 1994, SEMIN ONCOL, V21, P320; BRAMSON JL, 1995, CURR OPIN BIOTECH, V6, P590, DOI 10.1016/0958-1669(95)80097-2; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLAYMAN GL, 1995, CANCER RES, V55, P1; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DIMERY IW, 1993, JNCI-J NATL CANCER I, V85, P95, DOI 10.1093/jnci/85.2.95; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELSTNER E, 1995, CANCER RES, V55, P2822; FIELD JK, 1993, ARCH OTOLARYNGOL, V119, P1118; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, CANCER RES, V54, P2287; HALLAHAN DE, 1995, NAT MED, V1, P786, DOI 10.1038/nm0895-786; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; Janat M. Fouad, 1994, Molecular and Cellular Differentiation, V2, P241; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG M, 1992, CANCER RES, V52, P6390; KASID U, 1993, ADV CANCER RES, V61, P195, DOI 10.1016/S0065-230X(08)60959-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KOECHLI OR, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90447-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, COLD SPRING HARB SYM, V59, P419, DOI 10.1101/SQB.1994.059.01.047; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MITTEREDER N, 1994, HUM GENE THER, V5, P717, DOI 10.1089/hum.1994.5.6-717; NABEYA Y, 1995, INT J CANCER, V64, P37, DOI 10.1002/ijc.2910640109; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; OCONNOR PM, 1993, CANCER RES, V53, P4776; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PITTS JD, 1994, MOL CARCINOGEN, V11, P127, DOI 10.1002/mc.2940110302; POWELL SN, 1995, CANCER RES, V55, P1643; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SEACHRIST L, 1994, J NATL CANCER I, V86, P82, DOI 10.1093/jnci/86.2.82; SETOGUCHI Y, 1994, J RESPIR CELL MOL BI, V10, P369; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shin DM, 1996, J NATL CANCER I, V88, P519, DOI 10.1093/jnci/88.8.519; SILBER R, 1994, BLOOD, V84, P3440; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1995, UROLOGY, V46, P843, DOI 10.1016/S0090-4295(99)80355-0; STEWART FM, 1995, J CELL BIOCHEM, V58, P416, DOI 10.1002/jcb.240580404; STEWART N, 1995, ONCOGENE, V10, P109; TRAPNELL BC, 1993, ADV DRUG DELIVER REV, V12, P185, DOI 10.1016/0169-409X(93)90059-D; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WEICHSELBAUM RR, 1986, P NATL ACAD SCI USA, V83, P2684, DOI 10.1073/pnas.83.8.2684; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; WU SG, 1996, NAT MED, V2, P255; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG CL, 1995, CANCER RES, V55, P4210; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	69	112	133	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1735	1746		10.1038/sj.onc.1201116	http://dx.doi.org/10.1038/sj.onc.1201116			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135075				2022-12-17	WOS:A1997WR89300012
J	Moretti, F; Farsetti, A; Soddu, S; Misiti, S; Crescenzi, M; Filetti, S; Andreoli, M; Sacchi, A; Pontecorvi, A				Moretti, F; Farsetti, A; Soddu, S; Misiti, S; Crescenzi, M; Filetti, S; Andreoli, M; Sacchi, A; Pontecorvi, A			p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells	ONCOGENE			English	Article						p53; tumor suppressor gene; differentiation; thyroid carcinoma	WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; G(1) ARREST; MUTANT P53; MUTATIONS; GROWTH; PROTEIN; TRANSFORMATION; THYROTROPIN; INDUCTION	Alterations of the tumor suppressor gene p53 are uncommon in differentiated thyroid neoplasia but are detected at high frequency in anaplastic thyroid carcinoma suggesting that impaired p53 function may contribute to the undifferentiated and highly aggressive phenotype of these tumors, Effects of wild type p53 (wt-p53) re-expression were investigated in a human anaplastic thyroid carcinoma cell line (ARO) expressing a mutated p53, ARO cells were stably transfected with the temperature-sensitive p53 Val(135) gene (ts-p53) which exhibits wild type-like activity at 32 degrees C, Exogenous wt-p53 function in ARO-tsp53 clones was assessed by evaluating its transcriptional activity on a CAT reporter vector containing p53 binding sites, At 32 degrees C, a significant reduction in the proliferation rate (congruent to 50%) was observed, with accumulation of cells in the G(0)/G(1) phase of the cell cycle, This effect was accompanied by induction of the expression of the growth inhibitor p21/Waf1 gene, At 32 degrees C, ARO-tsp53 clones also showed a marked impairment of their tumorigenic potential, Furthermore, transfected clones re-acquired the ability to respond to thyrotropin (TSH) stimulation showing an increased expression of thyroid-specific genes (thyroglobulin, thyroperoxidase and TSH receptor), In conclusion, re-expression of wt-p53 activity in ARO cells, inhibits cell proliferation and restores responsiveness to physiological stimuli.	REGINA ELENA INST CANC RES,MOL ONCOGENESIS LAB,ROME,ITALY; CNR,INST EXPT MED,ROME,ITALY; UNIV ROMA LA SAPIENZA,CHAIR ENDOCRINOL 2,ROME,ITALY; UNIV CATANZARO,CHAIR ENDOCRINOL,CATANZARO,ITALY; CATHOLIC UNIV ROME,INST MED PATHOL,ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Magna Graecia University of Catanzaro; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Crescenzi, Marco/J-3603-2018; Soddu, Silvia/K-2467-2018; Farsetti, Antonella/I-8710-2018; Soddu, Silvia/ABH-6774-2020; Moretti, Fabiola/I-5647-2013	Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Farsetti, Antonella/0000-0002-8603-7925; Soddu, Silvia/0000-0001-8526-0044; Moretti, Fabiola/0000-0002-2691-1254				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BATTISTA S, 1995, ONCOGENE, V11, P2029; BRENNER L, 1993, CELL GROWTH DIFFER, V4, P993; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Fagin JA, 1996, CANCER RES, V56, P765; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FAGIN JA, 1994, THYROID TODAY, V17, P1; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUBER GK, 1992, ENDOCRINOLOGY, V130, P2858, DOI 10.1210/en.130.5.2858; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INGBAR S H, 1985, P682; ITO T, 1992, CANCER RES, V52, P1369; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P4279; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIMURA H, 1992, EXP CELL RES, V203, P402, DOI 10.1016/0014-4827(92)90014-Y; LAMPARIELLO F, 1991, CYTOMETRY, V12, P343, DOI 10.1002/cyto.990120409; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; NAKAMURA T, 1992, JPN J CANCER RES, V83, P1293, DOI 10.1111/j.1349-7006.1992.tb02761.x; NAMBA H, 1992, ENDOCRINOLOGY, V132, P839; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PROKOCIMER M, 1994, BLOOD, V84, P2391; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1991, CANCER RES, V51, P5232; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WRIGHT PA, 1991, ONCOGENE, V6, P1693; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [No title captured]	51	112	115	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					729	740		10.1038/sj.onc.1200887	http://dx.doi.org/10.1038/sj.onc.1200887			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038381	Green Published, Bronze			2022-12-17	WOS:A1997WG43000012
J	Cottu, PH; Muzeau, F; Estreicher, A; Flejou, JF; Iggo, R; Thomas, G; Hamelin, R				Cottu, PH; Muzeau, F; Estreicher, A; Flejou, JF; Iggo, R; Thomas, G; Hamelin, R			Inverse correlation between RER(+) status and p53 mutation in colorectal cancer cell lines	ONCOGENE			English	Article						colon cancer; p53 mutations; mismatch repair	NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; REPEATED SEQUENCES; MISMATCH REPAIR; HOMOLOG; TUMORIGENESIS; GENE; RECEPTOR; TUMORS	The high point mutation rate of replication error-prone (RER(+)) cells could theoretically lead to inactivation of the p53 gene by polyclonal mutations, which might explain the conflicting results that have been published on the p53 status of RER(+) colon cancers, To address this issue, we tested the p53 status of 21 human colorectal cancer cell lines, including four showing microsatellite instability (RER(+) phenotype). Denaturing gradient gel electrophoresis (DGGE) followed by sequencing showed that all four RER(+) cell lines were mild type for p53 while 15 of the 17 RER(-) cell lines contained p53 mutations (P=0.001), Eight cell lines (four RER(+) and four RER(-)) were analysed using three complementary methods to test more rigorously the polyclonal mutation hypothesis, (i) Of 87 single-cell clones (seven to 14 per cell line) examined by DGGE, only those derived from known p53 mutant cell lines showed altered profiles, (ii) Antibody DO-7 stained more than 80% of nuclei from the p53 mutant cell lines, but only 15% of nuclei from the RER(+) cell lines, (iii) A yeast functional assay which can simultaneously detect polyclonal mutations at over 500 different sites in the p53 cDNA scored all four RER(+) cell lines as containing only transcriptionally active p53, These data thus do not support the polyclonal mutation hypothesis and instead suggest that mismatch repair deficiency provides a p53-independent pathway for development of colorectal cancers.	INST CURIE,INSERM U434,F-75005 PARIS,FRANCE; FAC XAVIER BICHAT,INSERM U410,PARIS,FRANCE; SWISS INST EXPT CANC RES,CH-1066 EPALINGES,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Swiss Institute Experimental Cancer Research			Iggo, Richard/G-3546-2014; Cottu, Paul/ABC-8595-2020	Estreicher, Anne/0000-0001-6828-2508				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; HAMELIN R, 1993, ONCOGENE, V8, P2213; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	21	112	113	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2727	2730						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000147				2022-12-17	WOS:A1996VZ65400023
J	Ferracini, R; Olivero, M; DiRenzo, MF; Martano, M; DeGiovanni, C; Nanni, P; Basso, G; Scotlandi, K; Lollini, PL; Comoglio, PM				Ferracini, R; Olivero, M; DiRenzo, MF; Martano, M; DeGiovanni, C; Nanni, P; Basso, G; Scotlandi, K; Lollini, PL; Comoglio, PM			Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas	ONCOGENE			English	Article						rhabdomyosarcoma; hepatocyte growth factor; proto-oncogenes; tyrosine kinase receptors	HEPATOCYTE GROWTH-FACTOR; TUMOR ALVEOLAR RHABDOMYOSARCOMA; RECEPTOR TYROSINE KINASE; FACTOR SCATTER FACTOR; N-MYC ONCOGENE; C-MET; EPITHELIAL-CELLS; MOLECULAR-CLONING; METASTATIC ABILITY; SEQUENCE-ANALYSIS	The MET oncogene encodes the receptor for HGF/Scatter Factor, known to control cell motility and invasion in epithelial cells, We report that the Met/HGF receptor, absent in differentiated adult skeletal muscles, is aberrantly expressed in clinical samples and in established cell lines of human rhabdomyosarcomas. In both the embryonal and alveolar histotypes the oncogene is overexpressed and, in some cases, amplified, The Met receptor is exposed at the cell surface and is functionally active in response to HGF/Scatter Factor, Accordingly, rhabdomyosarcoma cells exhibit an invasive phenotype in vitro in response to exogenous HGF/Scatter factor, As the factor is known to be produced by connective tissues, a paracrine stimulation of rhabdomyosarcoma invasiveness in vivo is hypothesized, Two alveolar rhabdomyosarcomas were found to co-express the 'two-kringle' alternatively-spliced HGF/Scatter Factor variant, which has been previously shown to stimulate cell motility and matrix invasion in vitro, These cells displayed the invasive phenotype in the absence of exogenous HGF/Scatter Factor, suggesting an autocrine mechanism in vivo, These data indicate that aberrant expression of the MET proto-oncogene provides rhabdomyosarcoma cells with the same property as embryonal myoblasts to migrate into the surrounding connective tissues.	UNIV TURIN,SCH MED,INST CANC RES,TURIN,ITALY; UNIV BOLOGNA,RIZZOLI ORTHOPAED INST,INST CANC RES,BOLOGNA,ITALY; UNIV BOLOGNA,RIZZOLI ORTHOPAED INST,ONCOL LAB,BOLOGNA,ITALY	University of Turin; IRCCS Istituto Ortopedico Rizzoli; University of Bologna; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	Ferracini, R (corresponding author), SAVIGLIANO GEN HOSP,ORTHOPAED DIV,VIA OSPEDALI 14,I-121028 SAVIGLIANO,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; Ferracini, Riccardo/AAL-4622-2020; De Giovanni, Carla/B-1312-2009; olivero, martina/J-4811-2018; Scotlandi, Katia/J-9009-2016; Lollini, Pier Luigi/A-7644-2008	DI RENZO, Maria Flavia/0000-0002-5093-3373; olivero, martina/0000-0002-6815-3498; Scotlandi, Katia/0000-0001-6114-9499; Lollini, Pier Luigi/0000-0003-1702-4108; Comoglio, Paolo/0000-0002-7056-5328; BASSO, GIUSEPPE/0000-0002-2634-9302; Nanni, Patrizia/0000-0001-5319-0803				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ASMAR L, 1994, CANCER, V74, P2579, DOI 10.1002/1097-0142(19941101)74:9<2579::AID-CNCR2820740928>3.0.CO;2-A; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V254, P1382; Braun AC, 1975, CANCER COMPREHENSIVE, V3, P3; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAM AML, 1991, SCIENCE, V254, P1382; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFER A, 1991, BIOCHEM J, V278, P35, DOI 10.1042/bj2780035; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEFRANCES MC, 1992, DEVELOPMENT, V116, P387; DEGIOVANNI C, 1989, ANTICANCER RES, V9, P1943; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EBERT M, 1994, CANCER RES, V54, P5775; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1995, ONCOGENE, V10, P739; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GARSON JA, 1986, LANCET, V1, P1496; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ITAKURA Y, 1994, CANCER LETT, V83, P235, DOI 10.1016/0304-3835(94)90325-5; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KOBAYASHI H, 1992, CANCER RES, V52, P3610; KOSCIELNIAK E, 1992, MED PEDIATR ONCOL, V20, P209, DOI 10.1002/mpo.2950200305; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LOLLINI PL, 1991, INVAS METAST, V11, P116; LONGATI P, 1994, ONCOGENE, V9, P49; MCCUSKER RH, 1989, J BIOL CHEM, V264, P7795; MEDICO E, 1996, MOL BIOL CELL, V7; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1985, CELL, V42, P460; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NANNI P, 1989, INVAS METAST, P231; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PARHAM DM, 1994, SEMIN DIAGN PATHOL, V11, P39; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1990, INVAS METAST, V10, P49; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SEKI T, 1990, BIOCHEM BIOPH RES CO, V172, P321, DOI 10.1016/S0006-291X(05)80212-8; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUBLETT JE, 1995, ONCOGENE, V11, P545; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; TSOKOS M, 1994, SEMIN DIAGN PATHOL, V11, P26; Uriel J., 1975, CANCER COMPREHENSIVE, V3, P21; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WEIDNER KM, 1990, J CELL BIOL, V111, P2907	88	112	114	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1697	1705						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622890				2022-12-17	WOS:A1996UG45800012
J	RUSSO, D; ARTURI, F; SCHLUMBERGER, M; CAILLOU, B; MONIER, R; FILETTI, S; SUAREZ, HG				RUSSO, D; ARTURI, F; SCHLUMBERGER, M; CAILLOU, B; MONIER, R; FILETTI, S; SUAREZ, HG			ACTIVATING MUTATIONS OF THE TSH RECEPTOR IN DIFFERENTIATED THYROID CARCINOMAS	ONCOGENE			English	Note						THYROTROPIN RECEPTOR; HYPERFUNCTIONING; ADENYLYL CYCLASE; CYCLIC AMP RAS ONCOGENE; GSP ONCOGENE	HUMAN THYROTROPIN RECEPTOR; HUMAN ENDOCRINE TUMORS; ALPHA-SUBUNIT; EXPRESSION; ONCOGENE; ADENOMAS; CLONING; GENE; RAS	A series of 14 thyroid carcinomas, characterized for their basal adenyl cyclase activity (ACA), was examined for the presence of activating point mutations in the TSH receptor (TSHR) gene, Sequencing of the carboxyl-part of this gene revealed the presence of a somatic and heterozygotic point mutation in codon 623 in three out of six tumors showing a constitutively enhanced ACA and a poor response to TSH stimulation. The mutation determines the substitution of a serine for an alanine in the third intracellular loop of the receptor, in a region critical for signal transduction. One tumor bearing a TSHR mutation presented also a N-ras point mutation. Both mutations were detected also in a lung metastasis of this tumor, Our data represent the first report of alterations in the TSHR gene in thyroid malign neoplasia, TSHR mutations may indeed participate, as web as the G alpha(s) protein (gsp oncogene), in the oncogenesis of some differentiated thyroid carcinomas presenting increased basal levels of cAMP and a poor response to TSH.	INST RECH SCI CANC,IFC 01,GENET MOLEC LAB,CNRS,UPR 42,F-94801 VILLEJUIF,FRANCE; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,CATTEDRA ENDOCRINOL,I-88100 CATANZARO,ITALY; UNIV REGGIO CALABRIA,FAC FARM,CATTEDRA FARMACOL,I-88100 CATANZARO,ITALY; INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universita Mediterranea di Reggio Calabria; Universita Mediterranea di Reggio Calabria; UNICANCER; Gustave Roussy				ARTURI, Franco/0000-0002-1660-1228				AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; CHAZENBALK GD, 1991, MOL ENDOCRINOL, V5, P1523, DOI 10.1210/mend-5-10-1523; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; DEVRIES MV, 1986, GENE, V50, P313; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUMONT JE, 1989, METABOLIC BASIS INHE; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LIEBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MATSUO K, 1993, J CLIN ENDOCR METAB, V76, P1446, DOI 10.1210/jc.76.6.1446; MAZZAFERRI EL, 1993, AM J MED, V97, P1446; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMASMORVAN C, 1982, ACTA ENDOCRINOL-COP, V101, P25, DOI 10.1530/acta.0.1010025; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; YOSHIMOTO K, 1993, CANCER, V72, P1386, DOI 10.1002/1097-0142(19930815)72:4<1386::AID-CNCR2820720439>3.0.CO;2-J	30	112	119	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1907	1911						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478621				2022-12-17	WOS:A1995TD09400028
J	STONE, S; DAYANANTH, P; JIANG, P; WEAVERFELDHAUS, JM; TAVTIGIAN, SV; CANNONALBRIGHT, L; KAMB, A				STONE, S; DAYANANTH, P; JIANG, P; WEAVERFELDHAUS, JM; TAVTIGIAN, SV; CANNONALBRIGHT, L; KAMB, A			GENOMIC STRUCTURE, EXPRESSION AND MUTATIONAL ANALYSIS OF THE P15 (MTS2) GENE	ONCOGENE			English	Note						TUMORGENESIS; CDK INHIBITOR; CELL CYCLE	INHIBITION; KINASES; P21	The P15 gene (MTS2) encodes a cyclin-dependent kinase (CDK) inhibitor with considerable sequence identity and biochemical similarity to the CDK inhibitor p16. It is closely linked to the Pld gene (MTS1) and is homozygously deleted in many tumor cell lines. These features suggest that p15 may be a tumor suppressor. We have determined the genomic structure of P15 and examined its pattern of mRNA expression. In addition, we have shown that ectopic expression of p15 inhibits growth of tumor-derived cell lines. We have also searched for P15 mutations in tumor cell lines and in 9p21-linked melanoma kindreds. Other than the previously described homozygous deletions, no mutations of P15 were found. Collectively, these observations suggest a role for p15 in growth regulation, but a limited role for p15 in tumor progression.	MYRIAD GENET INC, SALT LAKE CITY, UT 84018 USA; UNIV UTAH, MED CTR, DEPT INTERNAL MED, SALT LAKE CITY, UT 84132 USA	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah				albright, lisa/0000-0003-2602-3668				CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1995, GENE DEV, V8, P6078; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HORI T, 1987, BLOOD, V70, P1069; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAMB A, 1994, CSH S QUANT BIOL, V59, P38; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LIU Q, 1995, ONCOGENE, V10, P1061; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sambrook J., 1989, MOL CLONING LAB MANU; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, IN PRESS CANCER RES; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	34	112	124	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					987	991						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675459				2022-12-17	WOS:A1995RU79800021
J	FUJIWARA, Y; OHATA, H; KUROKI, T; KOYAMA, K; TSUCHIYA, E; MONDEN, M; NAKAMURA, Y				FUJIWARA, Y; OHATA, H; KUROKI, T; KOYAMA, K; TSUCHIYA, E; MONDEN, M; NAKAMURA, Y			ISOLATION OF A CANDIDATE TUMOR-SUPPRESSOR GENE ON CHROMOSOME 8P21.3-P22 THAT IS HOMOLOGOUS TO AN EXTRACELLULAR DOMAIN OF THE PDGF RECEPTOR-BETA GENE	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; PDGF RECEPTOR BETA; COLORECTAL CANCER; HEPATOCELLULAR CARCINOMA	GROWTH-FACTOR PDGF; CELL-LINES; IDENTIFICATION; DELETION; MUTATIONS; CANCER; FAMILY; LOCUS; CARCINOMAS; EXPRESSION	We have isolated a candidate tumor suppressor gene from a 600-kb region on chromosome 8p21.3-p22 that is commonly deleted in sporadic hepatocellular carcinomas (HCC), colorectal cancers (CRC), and non-small cell lung cancers (NSCLC). As this gene encodes a protein of 375 amino acids that bears significant sequence similarity to the extracellular (ligand-binding domain of platelet-derived growth factor receptor beta, we have designated it PRLTS (PDGF-receptor beta-like tumor suppressor). Structural rearrangement involving this gene was found in a sporadic NSCLC. In addition, somatic missense and frame-shift mutations were found in two HCCs and one CRC. These findings indicate that inactivation of the PRLTS gene may play a significant role in development of some carcinomas.	CANC INST,DEPT BIOCHEM,TOKYO 170,JAPAN; CANC INST,DEPT PATHOL,TOKYO 170,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Osaka University								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BERGQVIST MHJ, 1992, PHYTOCHEM ANALYSIS, V3, P215, DOI 10.1002/pca.2800030503; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KAMP A, 1994, SCIENCE, V264, P436; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; RASKIND WH, 1991, AM J HUM GENET, V49, P1355; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SHIBUYA M, 1988, CANCER RES, V48, P1930; SMITS A, 1992, AM J PATHOL, V140, P639; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; YAMAKAWA K, 1991, GENOMICS, V9, P536, DOI 10.1016/0888-7543(91)90421-A; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	34	112	123	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					891	895						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898930				2022-12-17	WOS:A1995QL03800010
J	Zhang, H; Pu, J; Qi, T; Qi, M; Yang, C; Li, S; Huang, K; Zheng, L; Tong, Q				Zhang, H.; Pu, J.; Qi, T.; Qi, M.; Yang, C.; Li, S.; Huang, K.; Zheng, L.; Tong, Q.			MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha	ONCOGENE			English	Article						neuroblastoma; microRNA-145; hypoxia-inducible factor 2 alpha	TUMOR-SUPPRESSOR MIR-145; CANCER-CELLS; EXPRESSION; HIF-2-ALPHA; CARCINOMA; FACTOR-1-ALPHA; INVASIVENESS; HIF-1-ALPHA; HEPARANASE; ABOLISHES	Recent evidence shows that hypoxia-inducible factor 2 alpha (HIF-2 alpha) may have critical roles in the growth and progression of neuroblastoma (NB) under non-hypoxic conditions. However, the underlying mechanisms and clinical potentials of normoxic HIF-2 alpha expression in NB still remain largely unknown. In this study, HIF-2 alpha immunostaining was identified in 26/42 NB tissues, which was correlated with clinicopathological features. In subtotal 20 NB cases, microRNA-145 (miR-145) was downregulated and inversely correlated with HIF-2 alpha expression. Bioinformatics analysis revealed a putative miR-145 binding site in the 3'-untranslated region (3'-UTR) of HIF-2 alpha messenger RNA (mRNA). Overexpression or knockdown of miR-145 responsively altered both the mRNA and protein levels of HIF-2 alpha and its downstream genes, cyclin D1, matrix metalloproteinase 14 and vascular endothelial growth factor, in normoxically cultured NB cell lines SH-SY5Y and SK-N-SH. In a luciferase reporter system, miR-145 downregulated the luciferase activity of HIF-2 alpha 3'-UTR, and these effects were abolished by a mutation in the putative miR-145-binding site. Overexpression of miR-145 suppressed the growth, invasion, metastasis and angiogenesis of SH-SY5Y and SK-N-SH cells in vitro and in vivo, while restoration of HIF-2 alpha expression rescued the tumor cells from miR-145-mediated defects in these biological features. Furthermore, anti-miR-145 inhibitor rescued the HIF-2 alpha knockdown-mediated repression on the growth, migration, invasion and angiogenesis of NB cells. These data indicate that miR-145 suppresses HIF-2 alpha expression via the binding site in the 3'-UTR under normoxic conditions, thus inhibiting the aggressiveness and angiogenesis of NB.	[Zhang, H.; Pu, J.; Qi, T.; Qi, M.; Yang, C.; Li, S.; Tong, Q.] Huazhong Univ Sci & Technol, Dept Pediat Surg, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Huang, K.; Zheng, L.; Tong, Q.] Huazhong Univ Sci & Technol, Clin Ctr Human Genom Res, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Dept Cardiol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Zheng, L.] Huazhong Univ Sci & Technol, Dept Pathol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zheng, L (corresponding author), Huazhong Univ Sci & Technol, Dept Pathol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014	Tong, Qiangsong/0000-0002-2615-6404	National Natural Science Foundation of China [30600278, 30772359, 81071997, 81072073, 81272779]; Program for New Century Excellent Talents in University [NCET-06-0641]; Scientific Research Foundation for the Returned Overseas Chinese Scholars [2008-889]; Fundamental Research Funds for the Central Universities [2012QN224]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Scientific Research Foundation for the Returned Overseas Chinese Scholars(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (Nos. 30600278, 30772359, 81071997, 81072073, 81272779), Program for New Century Excellent Talents in University (NCET-06-0641), Scientific Research Foundation for the Returned Overseas Chinese Scholars (2008-889) and Fundamental Research Funds for the Central Universities (2012QN224).	Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Aplin AC, 2009, AM J PHYSIOL-CELL PH, V297, pC471, DOI 10.1152/ajpcell.00019.2009; Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374; Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Borel C, 2008, MAMM GENOME, V19, P503, DOI 10.1007/s00335-008-9137-6; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chae KS, 2011, ONCOGENE, V30, P1213, DOI 10.1038/onc.2010.498; Chiyomaru T, 2011, PROSTATE, DOI [10.1002/pros.21372, DOI 10.1002/PR0S.21372)]; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Fischer L, 2011, NEURO-ONCOLOGY, V13, P1090, DOI 10.1093/neuonc/nor107; Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Koo S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-143; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lei Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007629; Liu HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005436; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Michael MZ, 2003, MOL CANCER RES, V1, P882; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Speranza MC, 2012, ONCOTARGET, V3, P724; Stallings RL, 2009, CURR PHARM DESIGN, V15, P456, DOI 10.2174/138161209787315837; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730; Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522; Zheng LD, 2009, WORLD J PEDIATR, V5, P206, DOI 10.1007/s12519-009-0039-9; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33; Zou C, 2012, CELL CYCLE, V11, P2137, DOI 10.4161/cc.20598	40	111	115	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					387	397		10.1038/onc.2012.574	http://dx.doi.org/10.1038/onc.2012.574			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23222716				2022-12-17	WOS:000330214000013
J	Kappelmann, M; Kuphal, S; Meister, G; Vardimon, L; Bosserhoff, AK				Kappelmann, M.; Kuphal, S.; Meister, G.; Vardimon, L.; Bosserhoff, A-K			MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression	ONCOGENE			English	Article						malignant melanoma; miRNA; c-Jun; migration; post-transcriptionally; protein expression	CELL INVASION; TRANSCRIPTION FACTORS; MALIGNANT-MELANOMA; MESSENGER-RNAS; PROLIFERATION; GENE; AP-1; MELANOCYTES; MECHANISMS; REGIONS	A fundamental event in the development and progression of malignant melanoma is the deregulation of cancer-relevant transcription factors. We recently showed that c-Jun is a main regulator of tumor progression in melanoma and thus the most important member of the AP-1 transcription factor family for this disease. Interestingly, we revealed that c-Jun expression was regulated on the post-transcriptional level and therefore speculated that miRNAs could be involved in c-Jun regulation. We determined seed sequences for miR-125b and miR-527 in the coding region of c-Jun mRNA that hints at the direct involvement of miRNA-dependent regulation on the protein level. We found that the expression of miR-125b was significantly reduced in malignant melanoma cell lines and tissue samples compared with melanocytes, whereas miR-527 remained unchanged. In further functional experiments, treatment of melanoma cells with pre-miR-125b resulted in strong suppression of cellular proliferation and migration, supporting the role of miR-125b in melanoma. In addition, transfection of pre-miR-125b led to strong downregulation of c-Jun protein but not mRNA expression in melanoma cells. Luciferase assays using reporter plasmids containing the miR-125b seed sequence in the luciferase coding region confirmed the direct interaction with miR-125b. Furthermore, immunoprecipitation of Ago-2 revealed that c-Jun mRNA accumulated in the RNA-induced silencing complex after pre-miR-125b transfection in melanoma cells. In summary, we identified an important role for miR-125b in malignant melanoma. Moreover, we demonstrated post-transcriptional regulation of c-Jun by this miRNA and showed that c-Jun is a main mediator of the effects of miR-125b on melanoma cells.	[Kappelmann, M.; Kuphal, S.; Bosserhoff, A-K] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany; [Meister, G.] Univ Regensburg, Inst Biochem, D-93053 Regensburg, Germany; [Vardimon, L.] Tel Aviv Univ, Dept Biochem & Mol Biol, IL-69978 Tel Aviv, Israel	University of Regensburg; University of Regensburg; Tel Aviv University	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X; Kappelmann-Fenzl, Melanie/0000-0003-0312-1687	Melanoma Research Network of the Deutsche Krebshilfe e.V. (German Cancer Aid); DFG; Bavarian Ministry for education and science (BayGene); European Union; Bundesministerium fur Bildung und Forschung (BMBF, NGFN+)	Melanoma Research Network of the Deutsche Krebshilfe e.V. (German Cancer Aid)(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); Bavarian Ministry for education and science (BayGene); European Union(European Commission); Bundesministerium fur Bildung und Forschung (BMBF, NGFN+)(Federal Ministry of Education & Research (BMBF))	We would like to thank Lisa Ellmann for continuous assistance in cultivation. This work was supported by Melanoma Research Network of the Deutsche Krebshilfe e.V. (German Cancer Aid) and the DFG. GM is supported by grants from the Bavarian Ministry for education and science (BayGene), the European Union (ERC starting grant 'sRNAs', FP7 project 'ONCOMIRs') and the Bundesministerium fur Bildung und Forschung (BMBF, NGFN+).	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Braig S, 2013, ONCOGENE, V32, P837, DOI 10.1038/onc.2012.115; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; Deng Y, 2011, INT J BIOL SCI, V7, P133, DOI 10.7150/ijbs.7.133; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ender C, 2010, J CELL SCI, V123, P1819, DOI 10.1242/jcs.055210; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang YX, 2012, HEPATOLOGY, V55, P1852, DOI 10.1002/hep.25576; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Glud M, 2011, MELANOMA RES, V21, P253, DOI 10.1097/CMR.0b013e328345333b; Glud M, 2010, MELANOMA RES, V20, P479, DOI 10.1097/CMR.0b013e32833e32a1; Howell PM, 2010, OCHSNER J, V10, P83; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Janga SC, 2011, ADV EXP MED BIOL, V722, P59, DOI 10.1007/978-1-4614-0332-6_4; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Katiyar S, 2010, MOL BIOL CELL, V21, P4264, DOI 10.1091/mbc.E10-08-0705; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Le XF, 2010, CANCER MICROENVIRON, V3, P137, DOI 10.1007/s12307-010-0037-4; Libermann TA, 2006, CURR GENE THER, V6, P17, DOI 10.2174/156652306775515501; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mueller DW, 2009, BRIT J CANCER, V101, P551, DOI 10.1038/sj.bjc.6605204; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Papaconstantinou I, 2012, EUR J GASTROEN HEPAT, V24, P223, DOI 10.1097/MEG.0b013e3283505063; Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512; Polak P, 2006, ONCOGENE, V25, P665, DOI 10.1038/sj.onc.1209114; Poser I, 2004, ONCOGENE, V23, P6115, DOI 10.1038/sj.onc.1207797; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Rigoutsos I, 2009, CANCER RES, V69, P3245, DOI 10.1158/0008-5472.CAN-09-0352; Rothhammer T, 2005, CANCER RES, V65, P448; Russo AE, 2009, INT J ONCOL, V34, P1481, DOI 10.3892/ijo_00000277; Schmid R, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.78; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shoo BA, 2009, SEMIN CUTAN MED SURG, V28, P96, DOI 10.1016/j.sder.2009.04.005; Spangler B, 2011, PIGM CELL MELANOMA R, V24, P148, DOI 10.1111/j.1755-148X.2010.00787.x; Spangler B, 2012, INT J CANCER, V130, P2801, DOI 10.1002/ijc.26277; Vasudevan S, 2012, WIRES RNA, V3, P311, DOI 10.1002/wrna.121; Weiss C, 2004, CELL CYCLE, V3, P111; Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	45	111	111	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2984	2991		10.1038/onc.2012.307	http://dx.doi.org/10.1038/onc.2012.307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797068				2022-12-17	WOS:000320369700008
J	Skrypek, N; Duchene, B; Hebbar, M; Leteurtre, E; van Seuningen, I; Jonckheere, N				Skrypek, N.; Duchene, B.; Hebbar, M.; Leteurtre, E.; van Seuningen, I.; Jonckheere, N.			The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family	ONCOGENE			English	Article						MUC4; mucin; pancreatic cancer; gemcitabine; hCNT1; NF-kappa B	KAPPA-B; ADJUVANT GEMCITABINE; TRANSCRIPTION FACTOR; ANTITUMOR-ACTIVITY; ORTHOTOPIC MODEL; BILE-ACIDS; GENE; EXPRESSION; SURVIVAL; PROTEIN	The fluorinated analog of deoxycytidine, Gemcitabine (Gemzar), is the main chemotherapeutic drug in pancreatic cancer, but survival remains weak mainly because of the high resistance of tumors to the drug. Recent works have shown that the mucin MUC4 may confer an advantage to pancreatic tumor cells by modifying their susceptibility to drugs. However, the cellular mechanism(s) responsible for this MUC4-mediated resistance is unknown. The aim of this work was to identify the cellular mechanisms responsible for gemcitabine resistance linked to MUC4 expression. CAPAN-2 and CAPAN-1 adenocarcinomatous pancreatic cancer (PC) cell lines were used to establish stable MUC4-deficient clones (MUC4-KD) by shRNA interference. Measurement of the IC50 index using tetrazolium salt test indicated that MUC4-deficient cells were more sensitive to gemcitabine. This was correlated with increased Bax/Bcl(XL) ratio and apoptotic cell number. Expression of Equilibrative/Concentrative Nucleoside Transporter (hENT1, hCNT1/3), deoxycytidine kinase (dCK), ribonucleotide reductase (RRM1/2) and Multidrug-Resistance Protein (MRP3/4/5) was evaluated by quantitative RT-PCR (qRT-PCR) and western blotting. Alteration of MRP3, MRP4, hCNT1 and hCNT3 expression was observed in MUC4-KD cells, but only hCNT1 alteration was correlated to MUC4 expression and sensitivity to gemcitabine. Decreased activation of MAPK, JNK and NF-kappa B pathways was observed in MUC4-deficient cells, in which the NF-kappa B pathway was found to have an important role in both sensitivity to gemcitabine and hCNT1 regulation. Finally, and in accordance with our in vitro data, we found that MUC4 expression was conversely correlated to that of hCNT1 in tissues from patients with pancreatic adenocarcinoma. This work describes a new mechanism of PC cell resistance to gemcitabine, in which the MUC4 mucin negatively regulates the hCNT1 transporter expression via the NF-kappa B pathway. Altogether, these data point out to MUC4 and hCNT1 as potential targets to ameliorate the response of pancreatic tumors to gemcitabine treatment. Oncogene (2013) 32, 1714-1723; doi:10.1038/onc.2012.179; published online 14 May 2012	[Skrypek, N.; Duchene, B.; Hebbar, M.; Leteurtre, E.; van Seuningen, I.; Jonckheere, N.] INSERM, JPARC, UMR837, F-59045 Lille, France; [Skrypek, N.; Duchene, B.; Hebbar, M.; Leteurtre, E.; van Seuningen, I.; Jonckheere, N.] Univ Lille Nord France, Lille, France; [Skrypek, N.; Duchene, B.; van Seuningen, I.; Jonckheere, N.] Ctr Hosp Reg & Univ Lille, Lille, France; [Hebbar, M.] Ctr Hosp Reg & Univ Lille, Dept Med Oncol, Lille, France; [Leteurtre, E.] Ctr Hosp Reg & Univ Lille, Ctr Biol Pathol, Dept Pathol, Lille, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille	Jonckheere, N (corresponding author), INSERM, JPARC, UMR837, Rue Polonovski, F-59045 Lille, France.	nicolas.jonckheere@inserm.fr	Jonckheere, Nicolas/J-6028-2013; VAN SEUNINGEN, Isabelle/N-6176-2016	Jonckheere, Nicolas/0000-0002-0496-0661; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Duchene, Belinda/0000-0002-4810-4680	PhD fellowship of Centre Hospitalier Regional et Universitaire (CHRU) de Lille; Region Nord-Pas de Calais; Institut National du Cancer (INCa); Ligue Nationale contre le Cancer (LNCC); la Ligue Nationale contre le Cancer (Equipe Labellisee Ligue, IVS); 'Contrat Hospitalier de Recherche Translationnelle'/CHRT, AVIESAN	PhD fellowship of Centre Hospitalier Regional et Universitaire (CHRU) de Lille; Region Nord-Pas de Calais(Region Hauts-de-FranceEuropean Commission); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer (LNCC)(Ligue nationale contre le cancer); la Ligue Nationale contre le Cancer (Equipe Labellisee Ligue, IVS); 'Contrat Hospitalier de Recherche Translationnelle'/CHRT, AVIESAN	We thank MH Gevaert and R Siminsky (Department of Histology, Faculty of Medicine, University of Lille 2) and the technical platform IFR114/IMPRT for flow cytometry (Dr N Jouy) and luciferase (AS Drucbert) analyses. Gemcitabine and oxaliplatin are a kind gift from Dr A Lansiaux (Centre Oscar Lambret, Universite Lille Nord de France, Inserm UMR837, team 4, Lille, France). Cytarabine/aracytin ARA-C is a kind gift from Pr B Quesnel (Oncohaematology department, Centre Hospitalier Regional et Universitaire de Lille, Inserm UMR837, team 3, Lille, France). We thank Dr JL Desseyn (Inserm U995) for his help in designing MUC4 shRNA. Nicolas Skrypek is a recipient of a PhD fellowship of Centre Hospitalier Regional et Universitaire (CHRU) de Lille and Region Nord-Pas de Calais. Dr Nicolas Jonckheere is a recipient of postdoctoral fellowship from the Institut National du Cancer (INCa) and Ligue Nationale contre le Cancer (LNCC). This work is supported by a grant from la Ligue Nationale contre le Cancer (Equipe Labellisee Ligue 2010, IVS). Isabelle Van Seuningen is the recipient of a 'Contrat Hospitalier de Recherche Translationnelle'/CHRT 2010, AVIESAN. The funders had no role in study design, data collection and analysis, decision to publish or in preparation of the paper.	Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bafna S, 2009, BRIT J CANCER, V101, P1155, DOI 10.1038/sj.bjc.6605285; Banerjee S, 2005, CANCER RES, V65, P9064, DOI 10.1158/0008-5472.CAN-05-1330; Bhutia YD, 2011, CANCER RES, V71, P1825, DOI 10.1158/0008-5472.CAN-10-2736; Blackstock AW, 2001, CLIN CANCER RES, V7, P3263; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; Farrell JJ, 2009, GASTROENTEROLOGY, V136, P187, DOI 10.1053/j.gastro.2008.09.067; Garcia-Manteiga J, 2003, CLIN CANCER RES, V9, P5000; Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203; Hagmann W, 2010, NEOPLASIA, V12, P740, DOI 10.1593/neo.10576; Hu YP, 2003, BIOCHEM PHARMACOL, V65, P1419, DOI 10.1016/S0006-2952(03)00086-8; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769; Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190; Jonckheere N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032232; Jonckheere Nicolas, 2010, Cancers (Basel), V2, P1794, DOI 10.3390/cancers2041794; Jordheim LP, 2011, LANCET ONCOL, V12, P693, DOI 10.1016/S1470-2045(10)70244-8; Kalra AV, 2007, BRIT J CANCER, V97, P910, DOI 10.1038/sj.bjc.6603972; Kalra AV, 2009, EUR J CANCER, V45, P164, DOI 10.1016/j.ejca.2008.10.008; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Kong R, 2010, CANCER LETT, V291, P90, DOI 10.1016/j.canlet.2009.10.001; Konig J, 2005, INT J CANCER, V115, P359, DOI 10.1002/ijc.20831; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; Mackey TJ, 1998, UROLOGY, V52, P1085, DOI 10.1016/S0090-4295(98)00360-4; Marechal R, 2010, CANCER-AM CANCER SOC, V116, P5200, DOI 10.1002/cncr.25303; Marechal R, 2009, CLIN CANCER RES, V15, P2913, DOI 10.1158/1078-0432.CCR-08-2080; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; O'Reilly Eileen M, 2009, Gastrointest Cancer Res, V3, pS11; Oguri T, 2001, INT J CANCER, V93, P584, DOI 10.1002/ijc.1369; Ohishi Y, 2002, CLIN CANCER RES, V8, P3767; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Theile D, 2009, BIOCHEM PHARMACOL, V78, P1366, DOI 10.1016/j.bcp.2009.07.006; Tian Q, 2005, PHARM RES-DORDR, V22, P1837, DOI 10.1007/s11095-005-7595-z; van der Sluis M, 2004, BIOCHEM BIOPH RES CO, V325, P952, DOI 10.1016/j.bbrc.2004.10.108; Van Seuningen I, 2000, BIOCHEM J, V348, P675; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wang SJ, 2010, CANCER LETT, V293, P99, DOI 10.1016/j.canlet.2010.01.001; Wang WX, 1999, CLIN CANCER RES, V5, P119; Workman HC, 2009, CANCER RES, V69, P2845, DOI 10.1158/0008-5472.CAN-08-2089	49	111	112	2	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1714	1723		10.1038/onc.2012.179	http://dx.doi.org/10.1038/onc.2012.179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22580602	Green Accepted, Green Submitted			2022-12-17	WOS:000316855800011
J	Ponnusamy, MP; Lakshmanan, I; Jain, M; Das, S; Chakraborty, S; Dey, P; Batra, SK				Ponnusamy, M. P.; Lakshmanan, I.; Jain, M.; Das, S.; Chakraborty, S.; Dey, P.; Batra, S. K.			MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells	ONCOGENE			English	Article						MUC4; EMT; E-cadherin; N-cadherin; metastasis and ovarian cancer	N-CADHERIN; DIAGNOSTIC-SIGNIFICANCE; SURFACE EPITHELIUM; TUMOR PROGRESSION; GENE-EXPRESSION; ADHESION; GROWTH; REQUIREMENT; CARCINOMA; MOTILITY	The acquisition of invasiveness in ovarian cancer (OC) is accompanied by the process of epithelial-to-mesenchymal transition (EMT). The MUC4 mucin is overexpressed in ovarian tumors and has a role in the invasiveness of OC cells. The present study was aimed at evaluating the potential involvement of MUC4 in the metastasis of OC cells by inducing EMT. Ectopic overexpression of MUC4 in OC cells (SKOV3-MUC4) resulted in morphological alterations along with a decreased expression of epithelial markers (E-cadherin and cytokeratin (CK)-18) and an increased expression of mesenchymal markers (N-cadherin and vimentin) compared with the control cells (SKOV3-vector). Also, pro-EMT transcription factors TWIST1, TWIST2 and SNAIL showed an upregulation in SKOV3-MUC4 cells. We further investigated the pathways upstream of N-cadherin, such as focal adhesion kinase (FAK), MKK7, JNK1/2 and c-Jun, which were also activated in the SKOV3-MUC4 cells compared with SKOV3-vector cells. Inhibition of phospho-FAK (pFAK) and pJNK1/2 decreased N-cadherin expression in the MUC4-overexpressing cells, which further led to a significant decrease in cellular motility. Knockdown of N-cadherin decreased the activation of extracellular signal-regulated kinase-1/2 (ERK1/2), AKT and matrix metalloproteinase 9 (MMP9), and inhibited the motility in the SKOV3-MUC4 cells. Upon in vivo tumorigenesis and metastasis analysis, the SKOV3-MUC4 cells produced significantly larger tumors and demonstrated a higher incidence of metastasis to distance organs (peritoneal wall, colon, intestine, stomach, lymph nodes, liver and diaphragm). Taken together, our study reveals a novel role for MUC4 in inducing EMT through the upregulation of N-cadherin and promoting metastasis of OC cells. Oncogene (2010) 29, 5741-5754; doi:10.1038/onc.2010.309; published online 9 August 2010	[Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	chakraborty, subhankar/B-6550-2012	lakshmanan, Imayavaramban/0000-0003-1733-2223; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	National Institutes of Health [CA78590, CA111294, CA127297, CA133774, CA131944]; Department of Defense [BC074639]; Susan G Komen Foundation [KG070826]; NATIONAL CANCER INSTITUTE [U01CA111294, R01CA131944, P50CA127297, R01CA133774, R01CA078590] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work are supported by the grants from the National Institutes of Health (CA78590, CA111294, CA127297, CA133774 and CA131944), Department of Defense (BC074639) and the Susan G Komen Foundation (KG070826). We thank Ms Kristi L Berger for editing the paper. The authors acknowledge the invaluable technical support from Mr Erik Moore and Mrs Kavita Mallya. We also thank Janice A Tayor and James R Talaska of the confocal laser scanning microscope core facility at the UNMC for their support.	Ahmed N, 2007, J CELL PHYSIOL, V213, P581, DOI 10.1002/jcp.21240; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; BEHRENS J, 1994, ACTA ANAT, V149, P165; Boman F, 2001, J PATHOL, V193, P339, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH798>3.0.CO;2-9; Carraway KL, 2001, J MAMMARY GLAND BIOL, V6, P323, DOI 10.1023/A:1011327708973; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646; Chen HY, 1997, J CELL SCI, V110, P345; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; Giuntoli RL, 1998, CANCER RES, V58, P5546; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Horn G, 2009, EXP CELL RES, V315, P1490, DOI 10.1016/j.yexcr.2009.02.011; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kolosionek E, 2009, MOL BIOL CELL, V20, P4751, DOI 10.1091/mbc.E09-01-0019; Kondo K, 1998, CANCER RES, V58, P2014; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Lopez-Ferrer A, 2001, HUM PATHOL, V32, P1197, DOI 10.1053/hupa.2001.28938; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Moniaux N, 2007, BRIT J CANCER, V97, P345, DOI 10.1038/sj.bjc.6603868; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Shintani Y, 2008, J CELL BIOL, V180, P1277, DOI 10.1083/jcb.200708137; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Sommers CL, 1996, J MAMMARY GLAND BIOL, V1, P219, DOI 10.1007/BF02013645; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011	38	111	117	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5741	5754		10.1038/onc.2010.309	http://dx.doi.org/10.1038/onc.2010.309			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20697346	Green Accepted			2022-12-17	WOS:000283262500010
J	Heublein, S; Kazi, S; Ogmundsdottir, MH; Attwood, EV; Kala, S; Boyd, CAR; Wilson, C; Goberdhan, DCI				Heublein, S.; Kazi, S.; Oegmundsdottir, M. H.; Attwood, E. V.; Kala, S.; Boyd, C. A. R.; Wilson, C.; Goberdhan, D. C. I.			Proton-assisted amino-acid transporters are conserved regulators of proliferation and amino-acid-dependent mTORC1 activation	ONCOGENE			English	Article						SLC36; PAT; mTORC1; amino-acid sensing; transporter; transceptor	XENOPUS-LAEVIS OOCYTES; PI3K PATHWAY; RAG GTPASES; CANCER; GROWTH; RAPAMYCIN; KINASE; TARGET; LOCALIZATION; METABOLISM	The phosphoinositide3-kinase (PI3K)/Akt and downstream mammalian target of rapamycin complex 1 (mTORC1) signalling cascades promote normal growth and are frequently hyperactivated in tumour cells. mTORC1 is also regulated by local nutrients, particularly amino acids, but the mechanisms involved are poorly understood. Unexpectedly, members of the proton-assisted amino-acid transporter (PAT or SLC36) family emerged from in vivo genetic screens in Drosophila as transporters with uniquely potent effects on mTORC1-mediated growth. In this study, we show the two human PATs that are widely expressed in normal tissues and cancer cell lines, namely PAT1 and PAT4, behave similarly to fly PATs when expressed in Drosophila. Small interfering RNA knockdown shows that these molecules are required for the activation of mTORC1 targets and for proliferation in human MCF-7 breast cancer and HEK-293 embryonic kidney cell lines. Furthermore, activation of mTORC1 in starved HEK-293 cells stimulated by amino acids requires PAT1 and PAT4, and is elevated in PAT1-overexpressing cells. Importantly, in HEK-293 cells, PAT1 is highly concentrated in intracellular compartments, including endosomes, wherein mTOR shuttles upon amino-acid stimulation. Therefore our data are consistent with a model in which PATs modulate the activity of mTORC1 not by transporting amino acids into the cell but by modulating the intracellular response to amino acids. Oncogene (2010) 29, 4068-4079; doi:10.1038/onc.2010.177; published online 24 May 2010	[Heublein, S.; Kazi, S.; Oegmundsdottir, M. H.; Attwood, E. V.; Kala, S.; Boyd, C. A. R.; Wilson, C.; Goberdhan, D. C. I.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England	University of Oxford	Goberdhan, DCI (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Le Gros Clark Bldg,S Parks Rd, Oxford OX1 3QX, England.	deborah.goberdhan@dpag.ox.ac.uk			Cancer Research-UK [C19591/A9093, C191591/A6181, C7713/A6174]; Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; University of Oxford; Newton Abraham Studentship and Overseas Research	Cancer Research-UK(Cancer Research UK); Studienstiftung des deutschen Volkes; Max Weber Programm Bayern; University of Oxford; Newton Abraham Studentship and Overseas Research	We thank Toshiro Aigaki, Hugo Bellen and the Bloomington Stock Centre for fly strains, Robert Edwards (UCSF) for generously providing the PAT1 antisera and Vuk Stambolic (Toronto) for the GFP-Rheb construct. We are grateful to Dr David Meredith (Oxford Brookes University) for helpful discussion and to Bass Hassan and Claudia Buehnemann for comments on the paper. This work was supported by Cancer Research-UK grants (C19591/A9093, C191591/A6181 and C7713/A6174), funding from the Studienstiftung des deutschen Volkes and the Max Weber Programm Bayern to SH and a University of Oxford, Newton Abraham Studentship and Overseas Research Student Award to MHO.	Atkins MB, 2009, NAT REV DRUG DISCOV, V8, P535, DOI 10.1038/nrd2924; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Bermingham JR, 2004, MAMM GENOME, V15, P114, DOI 10.1007/s00335-003-2319-3; Beugnet A, 2003, BIOCHEM J, V372, P555, DOI 10.1042/BJ20021266; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Chang YY, 2009, BIOCHEM SOC T, V37, P232, DOI 10.1042/BST0370232; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; Cohen A, 2009, CELL, V136, P399, DOI 10.1016/j.cell.2009.01.021; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Findlay GM, 2007, BIOCHEM J, V403, P13, DOI 10.1042/BJ20061881; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Gao MG, 2006, NAT CELL BIOL, V8, P657, DOI 10.1038/ncb1419; Goberdhan DCI, 2005, DEVELOPMENT, V132, P2365, DOI 10.1242/dev.01821; Goberdhan DCI, 2003, DIFFERENTIATION, V71, P375, DOI 10.1046/j.1432-0436.2003.7107001.x; Goberdhan DCI, 2009, BIOCHEM SOC T, V37, P248, DOI 10.1042/BST0370248; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hafen E, 2004, SWISS MED WKLY, V134, P711; Hietakangas V, 2009, ANNU REV GENET, V43, P389, DOI 10.1146/annurev-genet-102108-134815; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Hundal HS, 2009, AM J PHYSIOL-ENDOC M, V296, pE603, DOI 10.1152/ajpendo.91002.2008; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Kim RH, 2006, BRIT J CANCER, V94, P620, DOI 10.1038/sj.bjc.6602994; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Nishimura Masuhiro, 2005, Drug Metab Pharmacokinet, V20, P452, DOI 10.2133/dmpk.20.452; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Panitsas KE, 2006, PFLUG ARCH EUR J PHY, V452, P53, DOI 10.1007/s00424-005-0002-0; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Reynolds B, 2007, BIOCHEM SOC T, V35, P1215, DOI 10.1042/BST0351215; Rubio-Aliaga I, 2004, J BIOL CHEM, V279, P2754, DOI 10.1074/jbc.M305556200; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Toivonen JM, 2009, MOL CELL ENDOCRINOL, V299, P39, DOI 10.1016/j.mce.2008.07.005; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zinzalla V, 2008, NATURE, V454, P287, DOI 10.1038/454287a	48	111	116	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4068	4079		10.1038/onc.2010.177	http://dx.doi.org/10.1038/onc.2010.177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20498635	Green Accepted			2022-12-17	WOS:000279892400007
J	Li, J; Yang, L; Song, L; Xiong, H; Wang, L; Yan, X; Yuan, J; Wu, J; Li, M				Li, J.; Yang, L.; Song, L.; Xiong, H.; Wang, L.; Yan, X.; Yuan, J.; Wu, J.; Li, M.			Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1	ONCOGENE			English	Article						AEG-1; FOXO1; p27(Kip1); p21(Cip1); Akt; breast cancer	TUMOR PROGRESSION; PROSTATE-CANCER; CELL-SURVIVAL; BCCIP-ALPHA; PROTEIN; METASTASIS; DEGRADATION; INTEGRATION; ACTIVATION; EXPRESSION	We have previously reported that astrocyte elevated gene-1 (AEG-1) was upregulated in human breast cancer. However, the biological function of AEG-1 in the development and progression of breast cancer remains to be clarified. In this study, we examined the effect of AEG-1 on cell proliferation and found that AEG-1 upregulation was significantly linked to increased Ki67 (P < 0.001). Ectopic expression of AEG-1 in MCF-7 and MDA-MB-435 breast cancer cells dramatically enhanced cell proliferation and their ability of anchorage-independent growth, whereas silencing endogenous AEG-1 with shRNAs inhibited cell proliferation and colony-forming ability of the cells on soft agar. Furthermore, these proliferative effects were significantly associated with decreases of p27(Kip1) and p21(Cip1) two key cell-cycle inhibitors. Moreover, we further demonstrated that AEG-1 could downregulate the transcriptional activity of FOXO1 by inducing its phosphorylation through the PI3K/Akt signaling pathway. These observations were further confirmed in clinical human primary breast cancer specimens, in which high-level expression of AEG-1 was inversely correlated with the expression of FOXO1. Taken together, our results provide the first demonstration of a novel mechanism by which AEG-1 induces proliferation of breast cancer cell, and our findings suggest that AEG-1 might play an important role in tumorigenesis of breast cancer. Oncogene (2009) 28, 3188-3196; doi: 10.1038/onc.2009.171; published online 27 July 2009	[Yang, L.; Xiong, H.; Wang, L.; Wu, J.; Li, M.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, Guangzhou 510080, Guangdong, Peoples R China; [Li, J.; Yan, X.; Yuan, J.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou 510080, Guangdong, Peoples R China; [Li, J.; Yang, L.; Xiong, H.; Wang, L.; Yan, X.; Yuan, J.; Wu, J.; Li, M.] Sun Yat Sen Univ, Key Lab Trop Dis Control, Minist Educ, Guangzhou 510080, Guangdong, Peoples R China; [Song, L.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, M (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Microbiol, 74 Zhongshan Rd 2,Her Mu Bldg 9th Floor, Guangzhou 510080, Guangdong, Peoples R China.	limf@mail.sysu.edu.cn	Song, LB/AAL-1968-2020		Ministry of Science and Technology of China [2005CB724605]; Foundation of Ministry of Science and Technology of China [30670803, 30770836, 30771110, 30870963, 30831160517, 30872930]; Program for New Century Excellent Talents in University [NCET-07-0877]; Science and Technology Department of Guangdong Province, China [07001503, 8251008901000006, 2008A030201006]; Foundation of Ministry of Education [(2008) 890, 200805580047]; Science and Technology Department of Guangdong Province, Zhuhai City [PC20071076]; Guangdong Provincial Natural Science Foundation [2006Z3-E4081]; 985-II project	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Foundation of Ministry of Science and Technology of China; Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Science and Technology Department of Guangdong Province, China; Foundation of Ministry of Education; Science and Technology Department of Guangdong Province, Zhuhai City; Guangdong Provincial Natural Science Foundation(National Natural Science Foundation of Guangdong Province); 985-II project	This study was supported by grants from the Ministry of Science and Technology of China (Grant (973) 2005CB724605); the Foundation of Ministry of Science and Technology of China (No. 30670803, 30770836, 30771110, 30870963, 30831160517, 30872930); Program for New Century Excellent Talents in University (Grant No. NCET-07-0877); the Science and Technology Department of Guangdong Province, China (No. 07001503, 8251008901000006, 2008A030201006); Foundation of Ministry of Education (No. (2008) 890 and No. 200805580047); the Science and Technology Department of Guangdong Province, Zhuhai City (PC20071076); Guangdong Provincial Natural Science Foundation (Grant 2006Z3-E4081) and a key grant from the 985-II project.	Arden KC, 2007, CELL, V128, P235, DOI 10.1016/j.cell.2007.01.009; Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Doerfler W, 2001, ANN NY ACAD SCI, V945, P276; Dong XY, 2006, CANCER RES, V66, P6998, DOI 10.1158/0008-5472.CAN-06-0411; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Greene FL PDL, 2002, BREAST CANC AJCC CAN, P255; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Meng X, 2007, ONCOGENE, V26, P6253, DOI 10.1038/sj.onc.1210460; Meng XB, 2004, CELL CYCLE, V3, P1457, DOI 10.4161/cc.3.11.1213; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Roeb W, 2007, P NATL ACAD SCI USA, V104, P18085, DOI 10.1073/pnas.0708910104; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TRENT RJ, 2006, MOL MED, P93; Ward EC, 2008, ENDOCRINOLOGY, V149, P1942, DOI 10.1210/en.2007-0756	29	111	127	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3188	3196		10.1038/onc.2009.171	http://dx.doi.org/10.1038/onc.2009.171			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19633686				2022-12-17	WOS:000269673400002
J	Lallet-Daher, H; Roudbaraki, M; Bavencoffe, A; Mariot, P; Gackiere, F; Bidaux, G; Urbain, R; Gosset, P; Delcourt, P; Fleurisse, L; Slomianny, C; Dewailly, E; Mauroy, B; Bonnal, JL; Skryma, R; Prevarskaya, N				Lallet-Daher, H.; Roudbaraki, M.; Bavencoffe, A.; Mariot, P.; Gackiere, F.; Bidaux, G.; Urbain, R.; Gosset, P.; Delcourt, P.; Fleurisse, L.; Slomianny, C.; Dewailly, E.; Mauroy, B.; Bonnal, J. L.; Skryma, R.; Prevarskaya, N.			Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry	ONCOGENE			English	Article						intermediate-conductance potassium channels; TRPV6; prostate cancer; proliferation; capacitative calcium entry; patch clamp	OPERATED CA2+ CURRENT; POTASSIUM CHANNELS; EPITHELIAL-CELLS; UP-REGULATION; EXPRESSION; GROWTH; CYCLE; INVOLVEMENT; PROGRESSION; ACTIVATION	Accumulating data point to K+ channels as relevant players in controlling cell cycle progression and proliferation of human cancer cells, including prostate cancer (PCa) cells. However, the mechanism(s) by which K+ channels control PCa cell proliferation remain illusive. In this study, using the techniques of molecular biology, biochemistry, electrophysiology and calcium imaging, we studied the expression and functionality of intermediate-conductance calcium-activated potassium channels (IKCa1) in human PCa as well as their involvement in cell proliferation. We showed that IKCa1 mRNA and protein were preferentially expressed in human PCa tissues, and inhibition of the IKCa1 potassium channel suppressed PCa cell proliferation. The activation of IKCa1 hyperpolarizes membrane potential and, by promoting the driving force for calcium, induces calcium entry through TRPV6, a cation channel of the TRP (Transient Receptor Potential) family. Thus, the overexpression of the IKCa1 channel is likely to promote carcinogenesis in human prostate tissue.	[Roudbaraki, M.] USTL, Lab Physiol Cellulaire, INSERM U800, Equipe Labellisee Ligue Natl Contre Canc, F-59655 Villeneuve Dascq, Nord, France; [Lallet-Daher, H.; Roudbaraki, M.; Bavencoffe, A.; Mariot, P.; Gackiere, F.; Bidaux, G.; Delcourt, P.; Slomianny, C.; Dewailly, E.; Skryma, R.; Prevarskaya, N.] Univ Sci & Technol Lille, Villeneuve Dascq, France; [Urbain, R.] Inst Rech Pierre Fabre, Paris, France; [Gosset, P.; Fleurisse, L.] Groupement Hosp Inst Catholique Lille, Lab Anat & Cytol Pathol, Fac Libre Med, Lille, France; [Mauroy, B.; Bonnal, J. L.] Hosp St Philibert, Serv Urol, Lomme Les Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Universite Catholique de Lille	Roudbaraki, M (corresponding author), USTL, Lab Physiol Cellulaire, INSERM U800, Equipe Labellisee Ligue Natl Contre Canc, Batiment SN3,2E Etage, F-59655 Villeneuve Dascq, Nord, France.	morad.roudbaraki@univ-lille1.fr; natacha.prevarskaya@univ-lille1.fr	Slomianny, Christian/L-8285-2018; Bonnal, Jean-Louis JLB/U-9025-2018; Bidaux, Gabriel/F-1294-2016	Prevarskaya, natacha/0000-0003-0316-197X; Morad, Roudbaraki/0000-0001-5751-3323; Bidaux, Gabriel/0000-0002-6162-3223; Bavencoffe, Alexis Guillaume/0000-0001-5659-5988; Mariot, Pascal/0000-0001-7226-9162	INSERM; Ministere de l'Education Nationale de l'Enseignement Supe'rieur et de la Recherche; La Ligue Nationale Contre le Cancer; Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministere de l'Education Nationale de l'Enseignement Supe'rieur et de la Recherche; La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)	We thank Dr Y Shuba (Bogomoletz Institute of Physiology, Kiev, Ukraine) for helpful discussions. This study was supported by grants from INSERM, the Ministere de l'Education Nationale de l'Enseignement Supe'rieur et de la Recherche, La Ligue Nationale Contre le Cancer. H LalletDaher was supported by the Association pour la Recherche sur les Tumeurs de la Prostate (ARTP). We also thank Dr Mao Xiang Chen ( Laboratory of Gene Expression and Protein Biochemistry, GlaxoSmithKline R&D, UK) for the generous gift of the IK<INF>Ca1</INF> antibodies.	AYUB M, 1990, BIOCHEM PHARMACOL, V40, P1569, DOI 10.1016/0006-2952(90)90456-U; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bidaux G, 2005, ENDOCR-RELAT CANCER, V12, P367, DOI 10.1677/erc.1.00969; Bloch M, 2007, ONCOGENE, V26, P2525, DOI 10.1038/sj.onc.1210036; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Ducret T, 2002, GLIA, V38, P200, DOI 10.1002/glia.10056; Enomoto N, 1998, J HEPATOL, V28, P221, DOI 10.1016/0168-8278(88)80009-6; Gackiere F, 2006, CELL CALCIUM, V39, P357, DOI 10.1016/j.ceca.2005.12.003; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Ghiani CA, 1999, DEVELOPMENT, V126, P1077; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Gut A, 1998, J BIOL CHEM, V273, P29381, DOI 10.1074/jbc.273.45.29381; HAZELTON B, 1979, J CELL BIOL, V83, P487, DOI 10.1083/jcb.83.2.487; Hemmerlein B, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-41; ISAACS JT, 1994, VITAM HORM, V49, P433; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kunzelmann K, 2005, J MEMBRANE BIOL, V205, P159, DOI 10.1007/s00232-005-0781-4; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; MagnierGaubil C, 1996, J BIOL CHEM, V271, P27788, DOI 10.1074/jbc.271.44.27788; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; MAURICE M, 1992, FASEB J, V6, P752, DOI 10.1096/fasebj.6.2.1371482; NILIUS B, 1993, AM J PHYSIOL, V265, pC1501, DOI 10.1152/ajpcell.1993.265.6.C1501; Ouadid-Ahidouch H, 2004, BIOCHEM BIOPH RES CO, V316, P244, DOI 10.1016/j.bbrc.2004.02.041; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2005, J MEMBRANE BIOL, V205, P115, DOI 10.1007/s00232-005-0776-1; Pardo LM, 2005, MUTAT RES-FUND MOL M, V592, P89, DOI 10.1016/j.mrfmmm.2005.06.006; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pedersen KA, 1999, BBA-BIOMEMBRANES, V1420, P231, DOI 10.1016/S0005-2736(99)00110-8; Pena TL, 2000, J BIOL CHEM, V275, P13677, DOI 10.1074/jbc.275.18.13677; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; Roudbaraki M, 1999, ENDOCRINOLOGY, V140, P4874, DOI 10.1210/en.140.10.4874; Sherbet GV, 1998, ANTICANCER RES, V18, P2415; Si H, 2006, BRIT J PHARMACOL, V148, P909, DOI 10.1038/sj.bjp.0706793; Skryma R, 1999, RECEPTOR CHANNEL, V6, P241; Skryma R, 2000, J PHYSIOL-LONDON, V527, P71, DOI 10.1111/j.1469-7793.2000.00071.x; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Spitzner M, 2007, FASEB J, V21, P35, DOI 10.1096/fj.06-6200com; Thebault S, 2006, CANCER RES, V66, P2038, DOI 10.1158/0008-5472.CAN-05-0376; Thebault S, 2003, J CLIN INVEST, V111, P1691, DOI 10.1172/JCI200316293; TOMITA M, 1987, ENDOCRINOL JAPON, V34, P313; TUPPER JT, 1980, J CELL PHYSIOL, V104, P97, DOI 10.1002/jcp.1041040113; Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943; van de Graaf SFJ, 2006, AM J PHYSIOL-RENAL, V290, pF1295, DOI 10.1152/ajprenal.00443.2005; Vanden Abeele F, 2003, J BIOL CHEM, V278, P15381, DOI 10.1074/jbc.M212106200; Vanoverberghe K, 2004, CELL DEATH DIFFER, V11, P321, DOI 10.1038/sj.cdd.4401375; Vanoverberghe K, 2003, CELL CALCIUM, V34, P75, DOI 10.1016/S0143-4160(03)00024-1; von Hahn T, 2001, CELL PHYSIOL BIOCHEM, V11, P219, DOI 10.1159/000051936; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; WOOLF SH, 1995, NEW ENGL J MED, V333, P1401, DOI 10.1056/NEJM199511233332107; Wulff H, 2004, J IMMUNOL, V173, P776, DOI 10.4049/jimmunol.173.2.776	61	111	120	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1792	1806		10.1038/onc.2009.25	http://dx.doi.org/10.1038/onc.2009.25			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19270724	Green Published			2022-12-17	WOS:000265640400006
J	McElhinny, AS; Li, JL; Wu, L				McElhinny, A. S.; Li, J-L; Wu, L.			Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways	ONCOGENE			English	Review						Mastermind-like co-activator; Notch; MEF2C; p53; Wnt/beta-catenin	NEUROGENIC LOCUS MASTERMIND; DROSOPHILA MASTERMIND; GENETIC CIRCUITRY; NOTCH COACTIVATOR; B-CELLS; PROTEIN; MAML1; CSL; ACTIVATOR; COMPLEX	A family of Mastermind-like (MAML) genes encodes critical transcriptional co-activators for Notch signaling, an evolutionarily conserved pathway with numerous roles in both development and human diseases. Notch receptors are cleaved upon ligand engagement and the intracellular domain of Notch shuttles to the nucleus. MAMLs form a functional DNA-binding complex with the cleaved Notch receptor and the transcription factor CSL, thereby regulating transcriptional events that are specific to the Notch pathway. Here, we review recent studies that have utilized molecular, cellular and physiological model system strategies to reveal the pivotal roles of the MAML proteins in Notch signaling. Unexpectedly, however, emerging evidence implicate MAML proteins as exciting key transcriptional co-activators in other signal transduction pathways including: muscle differentiation and myopathies (MEF2C), tumor suppressor pathway (p53) and colon carcinoma survival (beta-catenin). Thus, the MAML family appears to function in transcriptional co-activation in a multitude of cellular processes. It is hypothesized that MAML proteins mediate cross-talk among the various signaling pathways and the diverse activities of the MAML proteins converge to impact normal biological processes and human diseases, including cancers.	[Wu, L.] Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Li, J-L] Univ Florida, Interdisciplinary Ctr Biotechnol Res, Gainesville, FL 32610 USA; [McElhinny, A. S.] Ventana Med Syst Inc, Tucson, AZ USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Roche Holding; Ventana Medical Systems, Inc.	Wu, L (corresponding author), Univ Florida, Shands Canc Ctr, Dept Mol Genet & Microbiol, 1376 Mowry Rd, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X	NIH [R01 CA097148]; Muscular Dystrophy Association (MDA); NATIONAL CANCER INSTITUTE [R01CA097148] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Muscular Dystrophy Association (MDA)(Muscular Dystrophy Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH (R01 CA097148) and Muscular Dystrophy Association (MDA).	Alves-Guerra MC, 2007, CANCER RES, V67, P8690, DOI 10.1158/0008-5472.CAN-07-1720; Anderson LM, 2007, J CLIN INVEST, V117, P299, DOI 10.1172/JCI31288; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Bettler D, 1996, GENETICS, V143, P859; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brennan K, 2002, BIOESSAYS, V24, P405, DOI 10.1002/bies.10089; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Go MJ, 1998, GENETICS, V150, P211; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Helms W, 1999, DEV BIOL, V215, P358, DOI 10.1006/dbio.1999.9477; High FA, 2007, J CLIN INVEST, V117, P353, DOI 10.1172/JCI30070; Hozumi K, 2004, NAT IMMUNOL, V5, P638, DOI 10.1038/ni1075; Ilagan Maria Xenia G, 2007, Cell, V128, P1246; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; Kankel MW, 2007, GENETICS, V177, P2493, DOI 10.1534/genetics.107.080994; Katada T, 2003, INT J DEV BIOL, V47, P397; Katada T, 2006, MECH DEVELOP, V123, P851, DOI 10.1016/j.mod.2006.08.001; Kitagawa M, 2001, MOL CELL BIOL, V21, P4337, DOI 10.1128/MCB.21.13.4337-4346.2001; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kovall RA, 2007, CURR OPIN STRUC BIOL, V17, P117, DOI 10.1016/j.sbi.2006.11.004; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Lasky JL, 2005, PEDIATR RES, V57, p104R, DOI 10.1203/01.PDR.0000159632.70510.3D; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Luo D, 2005, SEMIN CELL DEV BIOL, V16, P612, DOI 10.1016/j.semcdb.2005.07.002; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Oyama T, 2007, P NATL ACAD SCI USA, V104, P9764, DOI 10.1073/pnas.0700240104; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Pires-daSilva A, 2003, NAT REV GENET, V4, P39, DOI 10.1038/nrg977; Proweller A, 2007, P NATL ACAD SCI USA, V104, P16275, DOI 10.1073/pnas.0707950104; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001; Saito T, 2003, IMMUNITY, V18, P675, DOI 10.1016/S1074-7613(03)00111-0; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; Tanigakik K, 2002, NAT IMMUNOL, V3, P443, DOI 10.1038/ni793; Tu LL, 2005, J EXP MED, V202, P1037, DOI 10.1084/jem.20050923; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu L, 2007, BLOOD, V110, P3618, DOI 10.1182/blood-2007-06-097030; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI 10.1016/j.semcancer.2004.04.014; Wu LZ, 2004, GENE, V328, P153, DOI 10.1016/j.gene.2003.12.007; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; XU T, 1990, GENETICS, V126, P665; YEDVOBNICK B, 1988, GENETICS, V118, P483; Yu ST, 2007, BBA-MOL CELL BIOL L, V1771, P936, DOI 10.1016/j.bbalip.2007.01.008; Zhao YT, 2007, J BIOL CHEM, V282, P11969, DOI 10.1074/jbc.M608974200	62	111	114	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5138	5147		10.1038/onc.2008.228	http://dx.doi.org/10.1038/onc.2008.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758483				2022-12-17	WOS:000258914900008
J	Glaros, S; Cirrincione, GM; Muchardt, C; Kleer, CG; Michael, CW; Reisman, D				Glaros, S.; Cirrincione, G. M.; Muchardt, C.; Kleer, C. G.; Michael, C. W.; Reisman, D.			The reversible epigenetic silencing of BRM: implications for clinical targeted therapy	ONCOGENE			English	Article						Brahma; Brahma-related gene 1; BRG1/BRM-associated factor; tumor suppressor; lung cancer; SWI/SNF complex	CHROMATIN REMODELING FACTORS; HUMAN LUNG-CANCER; TUMOR-CELL LINES; SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; CD44 EXPRESSION; GROWTH; BRG1; TRANSCRIPTION	The SWI/SNF chromatin- remodeling complex serves as a master switch that directs and limits the execution of specific cellular programs, such as differentiation and growth control. SWI/SNF function requires one of two paralogous ATPase subunits, Brahma (BRM) or BRMrelated gene 1 (BRG1), which we previously found are lost together in cancer cell lines and primary lung cancers. Although BRG1 has been found to be mutated in cancer cell lines, the mechanisms underlying BRM silencing are not known. To address this question, we sequenced BRM in 10 BRM/BRG10 deficient cancer cell lines and found that BRM was devoid of abrogating mutations. Moreover, histone deacetylase (HDAC) inhibitors restored BRM expression in each of these BRG1/BRM-defficient cancer cell lines, indicating that epigenetic silencing is a major mechanism underlying the loss of BRM expression. Despite their ability restore BRM expression, these HDAC inhibitors also blocked BRM function when present. However, after their removal, we observed that BRM expression remained elevated for several days, and during this period, BRM activity was detected. We also found that the suppression of BRM occurs in a broad range of human tumor types and that loss of one or both BRM alleles potentiated tumor development in mice. Thus, BRG1 and BRM are silenced by different mechanisms, and it may be possible to clinically target and reexpress BRM in a number of tumor types, potentially impacting tumor development.	Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48103 USA; Inst Pasteur, Dept Dev Biol, CNRS, URA1644, Paris, France; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Michigan System; University of Michigan	Reisman, D (corresponding author), Univ Michigan, Div Hematol Oncol, Dept Internal Med, MRSB2,B570B, Ann Arbor, MI 48103 USA.	dreisman@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P60DK020572] Funding Source: NIH RePORTER; NCI NIH HHS [CA092149-03, 5-P30-CA46592] Funding Source: Medline; NIDDK NIH HHS [DK20572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Coisy-Quivy M, 2006, CANCER RES, V66, P5069, DOI 10.1158/0008-5472.CAN-05-0596; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Machida Y, 2001, J BIOCHEM, V129, P43, DOI 10.1093/oxfordjournals.jbchem.a002834; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; STROBECK MW, 2002, J BIOL CHEM, V21, P21; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Trotter KW, 2004, MOL CELL BIOL, V24, P3347, DOI 10.1128/MCB.24.8.3347-3358.2004; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716	20	111	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2007	26	49					7058	7066		10.1038/sj.onc.1210514	http://dx.doi.org/10.1038/sj.onc.1210514			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223YN	17546055				2022-12-17	WOS:000250412200011
J	Taubert, H; Greither, T; Kaushal, D; Wurl, P; Bache, M; Bartel, F; Kehlen, A; Lautenschlager, C; Harris, L; Kraemer, K; Meye, A; Kappler, M; Schmidt, H; Holzhausen, HJ; Hauptmann, S				Taubert, H.; Greither, T.; Kaushal, D.; Wuerl, P.; Bache, M.; Bartel, F.; Kehlen, A.; Lautenschlaeger, C.; Harris, L.; Kraemer, K.; Meye, A.; Kappler, M.; Schmidt, H.; Holzhausen, H-J; Hauptmann, S.			Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma	ONCOGENE			English	Article						Hiwi; stem cell self-renewal; soft-tissue sarcoma; prognosis; Piwi domain; mRNA expression	PIWI; PROTEINS; RECOGNITION; HOMOLOG; CANCER	Self-renewal is considered as a common property of stem cells. Dysregulation of stem cell self-renewal is likely a requirement for the development of cancer. Hiwi, the human Piwi gene, encodes a protein responsible for stem cell self-renewal. In this study, we investigated the expression of Hiwi at the RNA level by real-time quantitative PCR in 65 primary soft-tissue sarcomas (STS) and ascertained its impact on prognosis for STS patients. In a multivariate Cox's proportional hazards regression model, we found that an increased expression of Hiwi mRNA is a significant negative prognostic factor for patients with STS (P=0.017; relative risk 4.6, 95% confidence interval (CI) 1.3 - 16.1) compared to medium expression of Hiwi transcript. However, a low expression of Hiwi transcript is correlated with a 2.4- fold ( CI 0.7-8.0) increased risk, but this effect was not significant (P=0.17). Altogether, high-level expression of Hiwi mRNA identifies STS patients at high risk of tumour-related death. This is the first report showing a correlation between expression of a gene involved in stem cell self-renewal and prognosis of cancer patients.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle, Germany; St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Ulm, Clin Gen & Transplantat Surg, D-89069 Ulm, Germany; Univ Halle Wittenberg, Dept Radiotherapy, D-4010 Halle, Germany; Probiodrug AG, Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, Halle, Germany; St Jude Childrens Hosp, Memphis, TN 38105 USA; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany; Univ Halle Wittenberg, Inst Pathol, Jr Res Grp, Halle, Germany	Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Ulm University; Martin Luther University Halle Wittenberg; Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Technische Universitat Dresden; Martin Luther University Halle Wittenberg	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle, Germany.	helge.taubert@medizin.uni-halle.de	Greither, Thomas/M-5334-2019; Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271				Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cox DN, 2000, DEVELOPMENT, V127, P503; Fetzer CP, 2002, NUCLEIC ACIDS RES, V30, P4380, DOI 10.1093/nar/gkf579; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010; Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Soltysova A, 2005, NEOPLASMA, V52, P435; VANUNNIK JAM, 1995, HEMATOL ONCOL CLIN N, V9, P677, DOI 10.1016/S0889-8588(18)30091-1; WITTEKIND C, 1997, UICC TNM KLASSIFIKAT; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4	14	111	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1098	1100		10.1038/sj.onc.1209880	http://dx.doi.org/10.1038/sj.onc.1209880			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16953229				2022-12-17	WOS:000244245400016
J	Macaluso, M; Montanari, M; Giordano, A				Macaluso, M.; Montanari, M.; Giordano, A.			Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes	ONCOGENE			English	Review						pocket proteins; pRb1/p105; pRb2/p130; p107; gene transcription; E2Fs; chromatin remodeling nzymes	DEPENDENT TRANSCRIPTIONAL REPRESSION; S-PHASE ENTRY; CELL-CYCLE; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; E2F FAMILY; POCKET PROTEINS; G(1) CONTROL; DNA-REPAIR	The pRb family proteins (pRb1/105, p107, pRb2/p130), collectively referred to as pocket proteins, are believed to function primarily as regulators of the mammalian cell cycle progression, and suppressors of cellular growth and proliferation. In addition, different studies suggest that these pocket proteins are also involved in development and differentiation of various tissues. Several lines of evidence indicate that generally pRb-family proteins function through their effect on the transcription of E2F-regulated genes. In fact, each of Rb family proteins binds to distinct members of the E2F transcription factors, which regulate the expression of genes whose protein products are necessary for cell proliferation and to drive cell-cycle progression. Nevertheless, pocket proteins can affect the G1/S transition through E2F-independent mechanisms. More recently, a broad range of evidences indicate that pRb-family proteins associate with a wide variety of transcription factors and chromatin remodeling enzymes forming transcriptional repressor complexes that control gene expression. This review focuses on the complex regulatory mechanisms by which pRb-family proteins tell genes when to switch on and off.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Univ Palermo, Dept Oncol, Sect Oncol, Palermo, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University of Palermo	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Black EP, 2003, CANCER RES, V63, P3716; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 1996, CANCER RES, V56, P2003; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang WZ, 2002, ONCOGENE, V21, P5557, DOI 10.1038/sj.onc.1205666; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Gallo G, 2005, J CELL PHYSIOL, V205, P176, DOI 10.1002/jcp.20451; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Iavarone A, 1999, MOL CELL BIOL, V19, P916; ISHIDA S, 2001, MOL CELL BIOL, V16, P47; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; KATO J, 1993, GENE DEV, V7, P331; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lee KY, 1999, MOL CELL BIOL, V19, P7724; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Macaluso M, 2005, ANN ONCOL, V16, P20, DOI 10.1093/annonc/mdi903; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MACALUSO M, 2006, CELL DEATH DIFF 0106; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paggi MG, 2001, CANCER RES, V61, P4651; Parakati R, 2005, J BIOL CHEM, V280, P21284, DOI 10.1074/jbc.M410744200; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Spencer C, 2005, GENE EXPR PATTERNS, V5, P687, DOI 10.1016/j.modgep.2005.02.003; Stiegler P, 1998, CANCER RES, V58, P5049; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TAMARU H, 2003, NAT GENET, V12, P177; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Tsantoulis PK, 2005, EUR J CANCER, V41, P2403, DOI 10.1016/j.ejca.2005.08.005; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	84	111	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5263	5267		10.1038/sj.onc.1209680	http://dx.doi.org/10.1038/sj.onc.1209680			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936746				2022-12-17	WOS:000240064100011
J	Bigelow, RLH; Cardelli, JA				Bigelow, RLH; Cardelli, JA			The green tea catechins, (-)-epigallocatechin-3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells	ONCOGENE			English	Article						green tea; EGCG; HGF; Met; breast cancer	COLON-CARCINOMA CELLS; MET EXPRESSION; SCATTER-FACTOR; IN-VIVO; GROWTH; CANCER; POLYPHENOLS; PHOSPHORYLATION; RECEPTOR; ACTIVATION	The hepatocyte growth factor (HGF) receptor, Met, is a strong prognostic indicator of breast cancer patient outcome and survival, suggesting that therapies targeting Met may have beneficial outcomes in the clinic. (-)Epigallocatechin- 3-gallate ( EGCG), a catechin found in green tea, has been recognized as a potential therapeutic agent. We assessed the ability of EGCG to inhibit HGF signaling in the immortalized, nontumorigenic breast cell line, MCF10A, and the invasive breast carcinoma cell line, MDA-MB-231. HGF treatment in both cell lines induced rapid, sustained activation of Met, ERK and AKT. Pretreatment of cells with concentrations of EGCG as low as 0.3 mu M inhibited HGF-induced Met phosphorylation and downstream activation of AKT and ERK. Treatment with 5.0 mu M EGCG blocked the ability of HGF to induce cell motility and invasion. We assessed the ability of alternative green tea catechins to inhibit HGF induced signaling and motility. (-)-Epicatechin-3-gallate ( ECG) functioned similar to EGCG by completely blocking HGF-induced signaling as low as 0.6 mu M and motility at 5 mu M in MCF10A cells; whereas, (-)- epicatechin (EC) was unable to inhibit HGF-induced events at any concentration tested. (-)- Epigallocatechin ( EGC), however, completely repressed HGF-induced AKT and ERK phosphorylation at concentrations of 10 and 20 mu M, but was incapable of blocking Met activation. Despite these observations, EGC did inhibit HGF-induced motility in MCF10A cells at 10 mu M. These observations suggest that the R1 galloyl and the R2 hydroxyl groups are important in mediating the green tea catechins' inhibitory effect towards HGF/Met signaling. These combined in vitro studies reveal the possible benefits of green tea polyphenols as cancer therapeutic agents to inhibit Met signaling and potentially block invasive cancer growth.	Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Cardelli, JA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Feist Weiller Canc Ctr, 1501 Kings Highway, Shreveport, LA 71130 USA.	jcarde@lsuhsc.edu			NATIONAL CANCER INSTITUTE [R01CA104242] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA104242-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Berger SJ, 2001, BIOCHEM BIOPH RES CO, V288, P101, DOI 10.1006/bbrc.2001.5736; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S; Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x; Fang MZ, 2003, CANCER RES, V63, P7563; Fujimura Y, 2004, FEBS LETT, V556, P204, DOI 10.1016/S0014-5793(03)01432-7; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Jung YD, 2001, BRIT J CANCER, V84, P844, DOI 10.1054/bjoc.2000.1691; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Masuda M, 2003, CLIN CANCER RES, V9, P3486; Nakachi K, 1998, JPN J CANCER RES, V89, P254, DOI 10.1111/j.1349-7006.1998.tb00556.x; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Ocal IT, 2003, CANCER-AM CANCER SOC, V97, P1841, DOI 10.1002/cncr.11335; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; Sah JF, 2004, J BIOL CHEM, V279, P12755, DOI 10.1074/jbc.M312333200; Su LJ, 2002, PUBLIC HEALTH NUTR, V5, P419, DOI 10.1079/PHN2001314; Sun CL, 2002, CARCINOGENESIS, V23, P1497, DOI 10.1093/carcin/23.9.1497; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035	31	111	117	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1922	1930		10.1038/sj.onc.1209227	http://dx.doi.org/10.1038/sj.onc.1209227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16449979				2022-12-17	WOS:000236224800009
J	Du, KY; Tsichlis, PN				Du, KY; Tsichlis, PN			Regulation of the Akt kinase by interacting proteins	ONCOGENE			English	Review						Akt; PKB; protein-protein interaction; phosphoinositide 3-kinase	T-CELL PROLIFERATIONS; SIGNAL-TRANSDUCTION; AKT/PKB ACTIVATION; NEGATIVE REGULATOR; MOLECULAR-CLONING; DOCKING SITE; HSP90; TCL1; PHOSPHORYLATION; IDENTIFICATION	Ten years ago, it was observed that the Akt kinase is activated by phosphorylation via a phosphoinositide 3-kinase (PI-3K)-dependent process. This discovery generated enormous interest because it provided a link between PI-3K, an enzyme known to play a critical role in cellular physiology, and its downstream targets. Subsequently, it was shown that the activity of the core components of the 'PI-3K/Akt pathway' is modulated by a complex network of regulatory proteins and pathways. Some of the Akt-binding partners modulate its activation by external signals by interacting with different domains of the Akt protein. This review focuses on the Akt interacting proteins and the mechanisms by which they regulate Akt activation.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Tufts Medical Center	Tsichlis, PN (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	ptsichlis@tufts-nemc.org			NATIONAL CANCER INSTITUTE [R01CA057436] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200; Bagatell R, 2004, MOL CANCER THER, V3, P1021; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barnouin Karin, 2004, Methods Mol Biol, V261, P479; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Cestra G, 2005, P NATL ACAD SCI USA, V102, P1731, DOI 10.1073/pnas.0409376102; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chan TO, 2002, CANCER CELL, V1, P181, DOI 10.1016/S1535-6108(02)00033-8; Chang-Liao KS, 2001, ELEC SOC S, V2001, P1; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fowler Amy M, 2004, Sci STKE, V2004, ptr11, DOI 10.1126/stke.2622004tr11; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; French SW, 2002, BIOCHEMISTRY-US, V41, P6376, DOI 10.1021/bi016068o; Fukushima K, 2003, BIOL REPROD, V68, P1771, DOI 10.1095/biolreprod.102.010314; Glazer RI, 1998, CURR PHARM DESIGN, V4, P277; Goh CS, 2004, CURR OPIN STRUC BIOL, V14, P104, DOI 10.1016/j.sbi.2004.01.005; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gritti C, 1997, ONCOGENE, V15, P1329, DOI 10.1038/sj.onc.1201303; Gritti C, 1998, BLOOD, V92, P368, DOI 10.1182/blood.V92.2.368.414k39_368_373; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Hiromura M, 2004, J BIOL CHEM, V279, P53407, DOI 10.1074/jbc.M403775200; Huang X, 2003, STRUCTURE, V11, P21, DOI 10.1016/S0969-2126(02)00937-1; Ingley E, 2000, FEBS LETT, V478, P253, DOI 10.1016/S0014-5793(00)01866-4; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; Klingenspor M, 1999, J BIOL CHEM, V274, P23078, DOI 10.1074/jbc.274.33.23078; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Lim MA, 2004, FRONT BIOSCI-LANDMRK, V9, P387, DOI 10.2741/1226; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Madani A, 1996, BLOOD, V87, P1923; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Miller John, 2004, Methods Mol Biol, V261, P247; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Neckers Len, 2003, Current Opinion in Oncology, V15, P419, DOI 10.1097/00001622-200311000-00003; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Pearl LH, 2005, CURR OPIN GENET DEV, V15, P55, DOI 10.1016/j.gde.2004.12.011; Pekarsky Y, 2004, HEMATOL ONCOL CLIN N, V18, P863, DOI 10.1016/j.hoc.2004.04.007; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Petock John M, 2002, ScientificWorldJournal, V2, P1876; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Rorth P, 2000, MOL CELL, V6, P23; Saka Y, 2004, DEV BIOL, V273, P210, DOI 10.1016/j.ydbio.2004.05.032; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; Siegel DH, 2002, CURR OPIN PEDIATR, V14, P419, DOI 10.1097/00008480-200208000-00011; Simpson F, 2005, TRAFFIC, V6, P442, DOI 10.1111/j.1600-0854.2005.00289.x; Song JJ, 2005, J BIOL CHEM, V280, P26845, DOI 10.1074/jbc.M502318200; Stagljar Igor, 2003, Sci STKE, V2003, ppe56; Sun LG, 2004, J CELL SCI, V117, P3021, DOI 10.1242/jcs.01142; Tanaka M, 1999, BIOCHEM BIOPH RES CO, V255, P169, DOI 10.1006/bbrc.1999.0162; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Vilenchik M, 2004, CHEM BIOL, V11, P787, DOI 10.1016/j.chembiol.2004.04.008; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Xi W, 2005, BIOCHEM BIOPH RES CO, V332, P200, DOI 10.1016/j.bbrc.2005.04.111; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yang L, 2003, J BIOL CHEM, V278, P16820, DOI 10.1074/jbc.M213163200; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yuan ZQ, 2005, J BIOL CHEM, V280, P21483, DOI 10.1074/jbc.M500097200; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200	103	111	121	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2005	24	50					7401	7409		10.1038/sj.onc.1209099	http://dx.doi.org/10.1038/sj.onc.1209099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982ZW	16288287				2022-12-17	WOS:000233201900003
J	Kirk, GD; Lesi, OA; Mendy, M; Szymanska, K; Whittle, H; Goedert, JJ; Hainaut, P; Montesano, R				Kirk, GD; Lesi, OA; Mendy, M; Szymanska, K; Whittle, H; Goedert, JJ; Hainaut, P; Montesano, R			249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; aflatoxin; hepatitis B virus; TP53 gene; plasma DNA	AFLATOXIN-ALBUMIN ADDUCTS; CIRCULATING NUCLEIC-ACIDS; LIVER-CANCER RISK; REPUBLIC-OF-CHINA; WEST-AFRICA; P53 GENE; MOLECULAR PATHOGENESIS; VIRUS-INFECTION; STEM-CELLS; E-ANTIGEN	Hepatocellular carcinoma (HCC) from regions with high dietary exposure to aflatoxins and endemic for hepatitis B virus (HBV) often contain a specific mutation at codon 249 in TP53 (249(ser); AGG to AGT, Arg to Ser). This mutation is also detectable in circulating cell-free DNA from the plasma of HCC patients and healthy subjects in these regions. We have examined the joint effect of plasma 249(ser) and HBV infection in a case-control study design involving 348 control, 98 cirrhotic, and 186 HCC participants from The Gambia, West Africa, an area of high HCC incidence. The 249(ser) mutation was detected in 3.5% of controls, 15.3% of cirrhotics, and 39.8% of HCC cases (adjusted odds ratios (OR): 4.83, (95% confidence interval (CI): 1.71-13.7) for cirrhosis and 20.3 (8.19-50.0) for HCC). HBsAg positivity along with plasma 249(ser) was observed in 45/183 (24.6%) HCC cases compared to only one (0.3%) control. Risk for HCC was associated with markers of HBV alone (OR: 10.0, 95% CI: 5.16-19.6), 249(ser) alone (OR: 13.2, 95% CI: 4.99-35.0), and both markers present (OR: 399, 95% CI: 48.6-3270). These results suggest a multiplicative effect on HCC risk resulting from the mutational effect of aflatoxin on TP53, as monitored by detection of plasma 249(ser), with concomitant chronic infection with HBV.	Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, Baltimore, MD 21205 USA; Gambia Hepatitis Intervent Study, Banjul, Gambia; NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; MRC Labs, Banjul, Gambia; Int Agcy Res Canc, F-69372 Lyon, France	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); MRC Laboratory Molecular Biology; World Health Organization; International Agency for Research on Cancer (IARC)	Kirk, GD (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Infect Dis Epidemiol Program, Dept Epidemiol, 615 N Wolfe St,E-6533, Baltimore, MD 21205 USA.	gkirk@jhsph.edu	Kirk, Gregory/A-8484-2009; Hainaut, Pierre/B-6018-2012; Mendy, Maimuna/ABD-5038-2021	Hainaut, Pierre/0000-0002-1303-1610; LESI, Olufunmilayo/0000-0002-6958-1531	NATIONAL CANCER INSTITUTE [Z01CP010176, ZIACP010176] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Anker P, 2003, INT J CANCER, V103, P149, DOI 10.1002/ijc.10791; AUTRUP H, 1987, CANCER RES, V47, P3430; Bah E, 2001, BRIT J CANCER, V84, P1207, DOI 10.1054/bjoc.2001.1730; BANNASCH P, 1995, CANCER RES, V55, P3318; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Chen CJ, 1996, HEPATOLOGY, V24, P38, DOI 10.1002/hep.510240108; COURSAGET P, 1993, BRIT J CANCER, V67, P1395, DOI 10.1038/bjc.1993.258; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Groopman JD, 1996, PROG CLIN BIOL RES, V395, P211; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hudson Geoffrey J., 1992, Natural Toxins, V1, P100, DOI 10.1002/nt.2620010208; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; IARC, 2002, MON EV CARC RISKS HU, V82; IARC, 1994, MON EV CARC RISKS HU; Jackson PE, 2003, CARCINOGENESIS, V24, P1657, DOI 10.1093/carcin/bgg101; Jackson PE, 1999, BEST PRACT RES CL GA, V13, P545, DOI 10.1053/bega.1999.0047; Jackson PE, 2001, CANCER RES, V61, P33; Kirk GD, 2004, HEPATOLOGY, V39, P211, DOI 10.1002/hep.20027; Kirk GD, 2000, JNCI-J NATL CANCER I, V92, P148, DOI 10.1093/jnci/92.2.148; Liang TJ, 2002, NEW ENGL J MED, V347, P208, DOI 10.1056/NEJMe020060; LIN DY, 1993, J CLIN ULTRASOUND, V21, P303, DOI 10.1002/jcu.1870210502; Liu MC, 2002, SEMIN ONCOL, V29, P246, DOI 10.1053/sonc.2002.32900; Mandishona E, 1998, HEPATOLOGY, V27, P1563, DOI 10.1002/hep.510270614; Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34; MENDY ME, 1998, BRIT J BIOMED SCI, V55, P92; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Olubuyide I O, 1993, Afr J Med Med Sci, V22, P89; Omer RE, 2001, CANCER CAUSE CONTROL, V12, P23, DOI 10.1023/A:1008943200826; Omer RE, 1998, NUTR CANCER, V32, P174, DOI 10.1080/01635589809514737; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Payne RJH, 1996, P NATL ACAD SCI USA, V93, P6542, DOI 10.1073/pnas.93.13.6542; Pisani P, 1997, CANCER EPIDEM BIOMAR, V6, P387; PONCHEL F, 1994, CANCER RES, V54, P2064; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; SELL S, 1993, INT J DEV BIOL, V37, P189; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Stern MC, 2001, CANCER EPIDEM BIOMAR, V10, P617; Strain AJ, 2000, GUT, V46, P743, DOI 10.1136/gut.46.6.743; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Szymanska K, 2004, INT J CANCER, V110, P374, DOI 10.1002/ijc.20103; Taback B, 2004, CURR OPIN MOL THER, V6, P273; Thorgeirsson S S, 1995, Princess Takamatsu Symp, V25, P163; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Turner PC, 2000, TROP MED INT HEALTH, V5, P837, DOI 10.1046/j.1365-3156.2000.00664.x; Vall Mayans M., 1990, Lancet, V336, P1107; van Rensburg S J, 1990, J Environ Pathol Toxicol Oncol, V10, P11; Wang LY, 1996, INT J CANCER, V67, P620, DOI 10.1002/(SICI)1097-0215(19960904)67:5&lt;620::AID-IJC5&gt;3.0.CO;2-W; Wang XW, 2002, TOXICOLOGY, V181, P43, DOI 10.1016/S0300-483X(02)00253-6; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112; Wild CP, 1996, CANCER EPIDEM BIOMAR, V5, P179; Wild CP, 2000, INT J CANCER, V86, P1, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;1::AID-IJC1&gt;3.0.CO;2-I; WILD CP, 1990, CARCINOGENESIS, V11, P2271, DOI 10.1093/carcin/11.12.2271; WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229; WILD CP, 1987, INT J CANCER, V40, P328, DOI 10.1002/ijc.2910400308; WILD CP, 1992, TOXICOL LETT, V64-5, P455, DOI 10.1016/0378-4274(92)90219-A; Wogan GN, 2000, SEMIN CANCER BIOL, V10, P201, DOI 10.1006/scbi.2000.0320; Wu TL, 2002, CLIN CHIM ACTA, V321, P77, DOI 10.1016/S0009-8981(02)00091-8; Yan R Q, 1989, Zhonghua Bing Li Xue Za Zhi, V18, P19; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215	64	111	118	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2005	24	38					5858	5867		10.1038/sj.onc.1208732	http://dx.doi.org/10.1038/sj.onc.1208732			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007211				2022-12-17	WOS:000231590400008
J	Lilly, MA; Duronio, RJ				Lilly, MA; Duronio, RJ			New insights into cell cycle control from the Drosophila endocycle	ONCOGENE			English	Review						endocycle; Drosophila; cyclin E; DNA replication; E2F; notch	DEPENDENT KINASE INHIBITOR; MINICHROMOSOME MAINTENANCE PROTEINS; TROPHOBLAST GIANT-CELLS; DNA-REPLICATION; S-PHASE; FOLLICLE CELLS; POLYTENE CHROMOSOMES; ENDOREDUPLICATION CYCLES; TRANSCRIPTION FACTOR; DISTINCT ROLES	During metazoan development, the organization of the cell cycle is often modified in response to developmental signals. The endocycle provides a dramatic example of this phenomenon. In the endocycle, also referred to as the endoreplicative cycle, cells undergo successive rounds of DNA replication without an intervening mitosis. Often the endocycle is used to expand the genome of a group of specialized cells that are highly biosynthetically active. In these circumstances, large polyploid cells are produced in organisms that are primarily comprised of diploid cells. However, many organisms achieve growth by increasing cell size, rather than cell number. This strategy is more generally exploited in insects and plants. For instance, in the insect Drosophila melanogaster, the majority of the larval tissues, as well as many adult tissues, enter the endocycle and become polyploid. Therefore, Drosophila has been a rich source for studies on endocycle regulation. Recent work from Drosophila is beginning to reveal how developmental signals promote the transition from the mitotic cycle to the endocycle, as well as what drives endocycle progression. In addition, studies on the endocycle have provided insight into the regulatory principles underlying the once per cell cycle replication of the genome, as well as the relationship between S phase and mitosis.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lilly, MA (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	mlilly@helix.nih.gov; duronio@med.unc.edu		Lilly, Mary/0000-0003-1564-619X; Duronio, Robert/0000-0001-6469-6965	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001613] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001613] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BALLS M, 1973, BRIT SOC DEV BIOL S; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Belyaeva ES, 1998, P NATL ACAD SCI USA, V95, P7532, DOI 10.1073/pnas.95.13.7532; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Britton JS, 1998, DEVELOPMENT, V125, P2149; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Caldwell MC, 1998, MECH DEVELOP, V79, P121, DOI 10.1016/S0925-4773(98)00178-6; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; de Cuevas M, 1997, ANNU REV GENET, V31, P405, DOI 10.1146/annurev.genet.31.1.405; de Nooij JC, 2000, MECH DEVELOP, V97, P73, DOI 10.1016/S0925-4773(00)00435-4; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; Dej KJ, 1999, DEVELOPMENT, V126, P293; Deng WM, 2001, DEVELOPMENT, V128, P4737; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Diffley JFX, 2000, COLD SPRING HARB SYM, V65, P333, DOI 10.1101/sqb.2000.65.333; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Emmerich J, 2004, GENETICS, V168, P867, DOI 10.1534/genetics.104.027417; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; GALL JG, 1971, CHROMOSOMA, V33, P319; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Grewal SS, 2004, DEV CELL, V7, P148, DOI 10.1016/j.devcel.2004.07.014; Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086; HAMMOND MP, 1985, CHROMOSOMA, V91, P267, DOI 10.1007/BF00328222; HAMMOND MP, 1985, CHROMOSOMA, V91, P279, DOI 10.1007/BF00328223; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hattori N, 2000, MOL BIOL CELL, V11, P1037, DOI 10.1091/mbc.11.3.1037; Hayashi S, 1996, DEVELOPMENT, V122, P1051; Hong A, 2003, DEVELOPMENT, V130, P1235, DOI 10.1242/dev.00352; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Jacobs HW, 2002, CURR BIOL, V12, P1435, DOI 10.1016/S0960-9822(02)01074-6; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kashevsky H, 2002, P NATL ACAD SCI USA, V99, P11217, DOI 10.1073/pnas.172391099; Kawamura K, 1999, DEVELOPMENT, V126, P211; KING RC, 1959, SCIENCE, V129, P1674, DOI 10.1126/science.129.3364.1674; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lane ME, 2000, GENETICS, V155, P233; Leach TJ, 2000, MOL CELL BIOL, V20, P6308, DOI 10.1128/MCB.20.17.6308-6316.2000; Lee LA, 2003, ANNU REV GENET, V37, P545, DOI 10.1146/annurev.genet.37.110801.143149; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; Lopez-Schier H, 2001, GENE DEV, V15, P1393, DOI 10.1101/gad.200901; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Makunin IV, 2002, GENETICS, V160, P1023; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; Meyer CA, 2002, CURR BIOL, V12, P661, DOI 10.1016/S0960-9822(02)00770-4; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Park Y, 2003, DEV BIOL, V253, P247, DOI 10.1016/S0012-1606(02)00019-2; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Reed BH, 1997, DEVELOPMENT, V124, P3543; Royzman I, 2002, MECH DEVELOP, V119, P225, DOI 10.1016/S0925-4773(02)00388-X; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schaeffer V, 2004, CURR BIOL, V14, P630, DOI 10.1016/j.cub.2004.03.040; Shcherbata HR, 2004, DEVELOPMENT, V131, P3169, DOI 10.1242/dev.01172; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; SMITH AV, 1991, DEVELOPMENT, V112, P997; STERN B, 1993, DEVELOPMENT, V117, P219; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Su TT, 1997, J CELL BIOL, V139, P13, DOI 10.1083/jcb.139.1.13; Swanhart Lisa, 2004, V296, P69; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Traas J, 1998, CURR OPIN PLANT BIOL, V1, P498, DOI 10.1016/S1369-5266(98)80042-3; Vidwans SJ, 2002, CURR BIOL, V12, P829, DOI 10.1016/S0960-9822(02)00845-X; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weiss A, 1998, CURR BIOL, V8, P239, DOI 10.1016/S0960-9822(98)70090-9; Weng L, 2003, EMBO J, V22, P3865, DOI 10.1093/emboj/cdg373; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xin SJ, 2002, DEVELOPMENT, V129, P1345; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zybina EV, 1996, INT REV CYTOL, V165, P53, DOI 10.1016/S0074-7696(08)62220-2	105	111	115	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2765	2775		10.1038/sj.onc.1208610	http://dx.doi.org/10.1038/sj.onc.1208610			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838513				2022-12-17	WOS:000228465800003
J	Dirmeier, U; Hoffmann, R; Kilger, E; Schultheiss, U; Briseno, C; Gires, O; Kieser, A; Eick, D; Sugden, B; Hammerschmidt, W				Dirmeier, U; Hoffmann, R; Kilger, E; Schultheiss, U; Briseno, C; Gires, O; Kieser, A; Eick, D; Sugden, B; Hammerschmidt, W			Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis	ONCOGENE			English	Article						Epstein-Barr virus; B cell proliferation; latent membrane protein; target genes; c-myc; p53	MEMBRANE-PROTEIN 1; NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; DOMAIN PROTEIN; CELL-LINE; LMP1; PATHWAY	Latent membrane protein 1 (LMP1), an oncoprotein encoded by Epstein-Barr virus (EBV), is an integral membrane protein, which acts like a constitutively active receptor. LMP1 is critical for some facet of EBV's induction and maintenance of proliferation of infected B cells. It, in part, mimics signaling by the CD40 receptor and has been implicated in regulating proliferation, survival, or both properties of EBV-infected cells. We established a conditional LMP1 allele in the context of the intact EBV genome to de. ne the immediate-early cellular target genes regulated by LMP1 in order to assess its contributions to infected human B cells. The functional analysis of this conditional system indicated that LMP1 specifically induces mitogenic B-cell activation through c-myc and Jun/AP1 family members and confirms its direct role in upregulating expression of multiple genes with opposing activities involved in cell survival. LMP1's signals were found to be essential for the G(1)/S transition in human B cells; cells lacking LMP1's signals are cell cycle arrested and survive quiescently. LMP1's activities are therefore not required to maintain survival in nonproliferating cells. LMP1 does induce both pro- and antiapoptotic genes whose balance seems to permit survival during LMP1's induction and maintenance of proliferation.	GSF Munich, Natl Res Ctr Environm & Hlth, Dept Gene Vectors, D-81377 Munich, Germany; Max Von Pettenkofer Inst, Dept Bacteriol, D-80336 Munich, Germany; Univ Munich, Dept Otorhinolaryngol, D-81377 Munich, Germany; Inst Clin Mol Biol & Tumour Genet, D-81377 Munich, Germany; Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; University of Munich; University of Wisconsin System; University of Wisconsin Madison	Hammerschmidt, W (corresponding author), GSF Munich, Natl Res Ctr Environm & Hlth, Dept Gene Vectors, Marchioninstr 25, D-81377 Munich, Germany.	hammerschmidt@gsf.de	Kieser, Arnd/M-4616-2014; Hoffmann, Reinhard/I-8748-2018; Hammerschmidt, Wolfgang/ABG-3921-2021; Gires, Olivier/V-2689-2017	Kieser, Arnd/0000-0003-0783-1950; Hoffmann, Reinhard/0000-0003-1514-1183; Hammerschmidt, Wolfgang/0000-0002-4659-0427; Gires, Olivier/0000-0002-2292-7064	NCI NIH HHS [CA22443, CA70723, P30CA14529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; [Anonymous], 1997, EPSTEIN BARR VIRUS K; Ardila-Osorio H, 1999, INT J CANCER, V81, P645, DOI 10.1002/(SICI)1097-0215(19990517)81:4<645::AID-IJC22>3.0.CO;2-0; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen HL, 2003, J VIROL, V77, P4139, DOI 10.1128/JVI.77.7.4139-4148.2003; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dadgostar H, 2002, P NATL ACAD SCI USA, V99, P1497, DOI 10.1073/pnas.032665099; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; Dirmeier U, 2003, CANCER RES, V63, P2982; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hammerschmidt W, 2004, TRENDS MOL MED, V10, P331, DOI 10.1016/j.molmed.2004.05.006; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2002, J VIROL, V76, P11551, DOI 10.1128/JVI.76.22.11551-11560.2002; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kieff E, 2001, FIELDS VIROLOGY, V2, P2511; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lam N, 2003, CELL SIGNAL, V15, P9, DOI 10.1016/S0898-6568(02)00083-9; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Uchida J, 1999, SCIENCE, V286, P300, DOI 10.1126/science.286.5438.300; Wan J, 2004, MOL CELL BIOL, V24, P192, DOI 10.1128/MCB.24.1.192-199.2004; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Zhao RB, 2000, GENE DEV, V14, P981	52	111	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1711	1717		10.1038/sj.onc.1208367	http://dx.doi.org/10.1038/sj.onc.1208367			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674340				2022-12-17	WOS:000227345100007
J	Lee, CC; Putnam, AJ; Miranti, CK; Gustafson, M; Wang, LM; Woude, GFV; Gao, CF				Lee, CC; Putnam, AJ; Miranti, CK; Gustafson, M; Wang, LM; Woude, GFV; Gao, CF			Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis	ONCOGENE			English	Article						sprouty; hepatocyte growth factor/scatter factor; met; signaling; invasion; migration	DROSOPHILA-SPROUTY; DOWN-REGULATION; MET; RECEPTOR; EXPRESSION; PATHWAY; FGF; METASTASIS; ANTAGONIST; ACTIVATION	A strict regulation of hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling is essential for its appropriate function. Several negative regulators of Met signaling have been identified. Here we report that human Spry2 is induced by HGF/SF and negatively regulates HGF/SF-Met signaling. We show that overexpression of Spry2 inhibits cell proliferation, anchorage-independent cell growth, and migration in wound-healing and in vitro invasion assays. Measured in an electric cell-substrate impedance sensing biosensor, cell movement is restricted, because Spry2 dramatically facilitates cell attachment and spreading by enhancing focal adhesions and increasing stress fibers. An analysis of cell cycle distribution shows, unexpectedly, that Spry2-GFP cells are polyploid. Thus, as with FGF and EGF receptors, Spry2-GFP tempers downstream Met signaling in addition to its pronounced effect on cell adhesion, and it has properties suitable to be considered a tumor-suppressor protein.	Van Andel Res Inst, Grand Rapids, MI 49503 USA	Van Andel Institute	Woude, GFV (corresponding author), Van Andel Res Inst, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	george.vandewoude@vai.org	Miranti, Cindy/AAJ-3783-2020; Putnam, Andrew J./E-8643-2010	Putnam, Andrew J./0000-0002-1262-4377				Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hammond DE, 2003, MOL BIOL CELL, V14, P1346, DOI 10.1091/mbc.E02-09-0578; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kramer S, 1999, DEVELOPMENT, V126, P2515; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Minowada G, 1999, DEVELOPMENT, V126, P4465; Miranti CK, 2002, METHOD CELL BIOL, V69, P359, DOI 10.1016/S0091-679X(02)69023-5; Ozaki K, 2001, BIOCHEM BIOPH RES CO, V285, P1084, DOI 10.1006/bbrc.2001.5295; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Reich A, 1999, DEVELOPMENT, V126, P4139; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang SB, 2001, MECH DEVELOP, V109, P367, DOI 10.1016/S0925-4773(01)00526-3	35	111	117	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5193	5202		10.1038/sj.onc.1207646	http://dx.doi.org/10.1038/sj.onc.1207646			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122328				2022-12-17	WOS:000222382500009
J	Krasilnikov, M; Ivanov, VN; Dong, J; Ronai, Z				Krasilnikov, M; Ivanov, VN; Dong, J; Ronai, Z			ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis	ONCOGENE			English	Article						ERK; PI3K; STAT; melanoma; apoptosis	PERIPHERAL-BLOOD CELLS; KAPPA-B ACTIVATION; CONSTITUTIVE ACTIVATION; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SERINE PHOSPHORYLATION; MAP KINASE; C-JUN; INHIBITION; INTERFERON	Signal transducers and activators of transcription (STAT) proteins nuclear translocation and transcriptional activity are regulated by diverse protein kinases in response to extracellular stimuli by cytokines, growth factors and stress. Using two melanoma-derived cell lines that exhibit marked differences in basal activities of MAPKs and PI3K-AKT, we studied changes both in STAT activities and in their sensitization to apoptosis. Activating mutations of B-RAF (T1796A) and impaired expression of PTEN are detected in LU1205, but not in FEMX melanoma cells, and are reflected in high basal levels of expression and activities of MAPKs and PI3K-AKT. Treatment with either PD98059 (PD) or LY294002 (LY), the pharmacological inhibitors of MEK-ERK and PI3K, respectively, markedly increased GAS-Luc activity in LU1205, but not in FEMX cells. Tyrosine phosphorylation of STAT3/5 and of JAK2 also increased upon treatment of LU1205 cells with either PD or LY, suggesting that constitutive active MAPK and PI3K signals inhibit tyrosine phosphorylation of JAK/STATs. Treatment of FEMX and LU1205 with PD sensitized the cells to apoptosis, albeit by TNFalpha and TRAIL death cascades, respectively, indicating that additional yet distinct targets are affected by each signaling pathway. Indeed, the combination of LY and PD treatment synergistically increased the apoptosis of LU1205 and FEMX cells. Overall, whereas PI3K and MAPK downregulate JAK-STAT signaling, additional targets are affected by these kinases and sensitizes melanoma to apoptosis via distinct death cascades.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; NN Blochin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.	zeev.ronai@mssm.edu	Krasil'nikov, Mikhail/R-6938-2019; Ivanov, Vladimir N/A-3081-2008	Krasil'nikov, Mikhail/0000-0002-5902-7633; Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brose MS, 2002, CANCER RES, V62, P6997; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chai SK, 1997, J IMMUNOL, V159, P4720; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Czerniecki BJ, 1997, J IMMUNOL, V159, P3823; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Edwards E, 2002, CANCER RES, V62, P4671; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kim HJ, 1999, MOL CELL BIOL, V19, P6323; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Krasilnikov M, 1999, MOL CARCINOGEN, V24, P64, DOI 10.1002/(SICI)1098-2744(199901)24:1<64::AID-MC9>3.0.CO;2-2; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Ozes ON, 1999, NATURE, V401, P82; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Sengupta TK, 1996, P NATL ACAD SCI USA, V93, P9499, DOI 10.1073/pnas.93.18.9499; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; TakahashiTezuka M, 1997, ONCOGENE, V14, P2273, DOI 10.1038/sj.onc.1201071; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; WeberNordt RM, 1996, BLOOD, V88, P809; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719	49	111	112	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2003	22	26					4092	4101		10.1038/sj.onc.1206598	http://dx.doi.org/10.1038/sj.onc.1206598			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821943	Green Published			2022-12-17	WOS:000183707600012
J	Lacour, S; Micheau, O; Hammann, A; Drouineaud, V; Tschopp, J; Solary, E; Dimanche-Boitrel, MT				Lacour, S; Micheau, O; Hammann, A; Drouineaud, V; Tschopp, J; Solary, E; Dimanche-Boitrel, MT			Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells	ONCOGENE			English	Article							TUMOR-NECROSIS-FACTOR; TRAIL-INDUCED APOPTOSIS; FADD-DEPENDENT APOPTOSIS; UP-REGULATION; APO-2 LIGAND; FAS LIGAND; DEATH; RECEPTOR; EXPRESSION; CASPASE-8	Cytokines such as Fas-ligand (Fas-L) and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) can induce human colon cancer cell apoptosis through engagement of their death domain receptors. All the cancer cells are not sensitive to these cytokines. We have shown recently that low doses of cytotoxic drugs could restore TRAIL-induced cell death in resistant colon cancer cell lines. The present work further explores the death pathway triggered by the cytotoxic drug/TRAIL combination in HT-29 colon cancer cells (www.alexiscorp.com). Clinically relevant concentrations of cisplatin, doxorubicin and 5-fluorouracil synergize with TRAIL to trigger HT-29 cell death. Activation of this pathway leads to apoptosis that involves both caspases and the mitochondria. An increased recruitment of Fas-associated death domain (FADD) and procaspase-8 to the TRAIL-induced death-inducing signaling complex (DISC) was shown in cells exposed to anticancer drugs. Following caspase-8 activation at the DISC level, the mitochondria-dependent death pathway is activated, as demonstrated by the cleavage of Bid, the dissipation of DeltaPsi(m), the release of mitochondrial proteins in the cytosol and the inhibitory effect of Bcl-2 expression. Importantly, besides mitochondrial potentiation, we show here that cytotoxic drugs sensitize HT-29 colon cancer cells to TRAIL-induced cell death by enhancing FADD and procaspase-8 recruitment to the DISC, a novel mechanism whose efficacy could depend partly on Bcl-2 expression level.	Fac Med & Pharm Dijon, INSERM, IFR 100, U517, F-21033 Dijon, France; Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; University of Lausanne	Dimanche-Boitrel, MT (corresponding author), Fac Med & Pharm Dijon, INSERM, IFR 100, U517, 7 Blvd Jeanne Arc, F-21033 Dijon, France.	marie-therese.boitrel@rennes.inserm.fr	Dimanche-Boitrel, Marie-Therese M/I-4642-2015; micheau, olivier/C-3574-2011	micheau, olivier/0000-0001-8499-7984; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Solary, Eric/0000-0002-8629-1341				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BISIAU H, 1995, NOUV REV FR HEMATOL, V37, P241; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Burns TF, 2001, J BIOL CHEM, V276, P37879; CHAPMAN PB, 1987, J CLIN ONCOL, V5, P1942, DOI 10.1200/JCO.1987.5.12.1942; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; Gorlick R, 1999, SEMIN ONCOL, V26, P606; Gottlieb RA, 2001, BIOL SIGNAL RECEPT, V10, P147; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Keane MM, 1999, CANCER RES, V59, P734; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacour S, 2001, CANCER RES, V61, P1645; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mizutani Y, 1999, CLIN CANCER RES, V5, P2605; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Seol DW, 2001, CANCER RES, V61, P1138; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Tanaka M, 1997, J IMMUNOL, V158, P2303; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang XD, 1999, CANCER RES, V59, P2747	46	111	118	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1807	1816		10.1038/sj.onc.1206127	http://dx.doi.org/10.1038/sj.onc.1206127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660816				2022-12-17	WOS:000181678200007
J	Miyamoto, K; Asada, K; Fukutomi, T; Okochi, E; Yagi, Y; Hasegawa, T; Asahara, T; Sugimura, T; Ushijima, T				Miyamoto, K; Asada, K; Fukutomi, T; Okochi, E; Yagi, Y; Hasegawa, T; Asahara, T; Sugimura, T; Ushijima, T			Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers	ONCOGENE			English	Article						DNA methylation; silencing; 3-OST-2; breast cancer	REPRESENTATIONAL DIFFERENCE ANALYSIS; DNA METHYLATION; EXPRESSION; GENE; PLASMA; HYPERMETHYLATION; IDENTIFICATION; PATTERNS; ASSAY	Aberrant CpG methylations play important roles in cancer development and progression. In this study, aberrant methylations in human breast cancer were searched for using methylation-sensitive representational difference analysis (MS-RDA). A CpG island (CGI) in the 5' region of the heparan sulfate D-glucosaminyl 3-O-suffiotransferase-2 (3-OST-2) gene was found to be hypermethylated, while its exon 2 was hypomethylated. In seven breast cancer cell lines, hypermethylation of the 5' region and loss of 3-OST-2 expression were observed. Treatment with a demethylating agent, 5-aza-2'-deoxycyfidine, removed the methylation of the CGI in the 5' region and restored its expression, demonstrating silencing of the 3-OST-2 gene. Methylation-specific PCR (MSP) analysis in 85 primary breast cancers showed that the hypermethylation of the CGI in the 5' region was present in 75 (88%) of them. Quantitative reverse transcriptase-PCR (RTPCR) analysis in 37 primary breast cancers showed that the average expression level was decreased in them. Further, MSP analysis in primary colon, lung and pancreatic cancers showed that hypermethylation of the CGI in the 5' region was present in the colon (8/10, 80%), lung (7/10, 70%) and pancreatic (10/10, 100%) cancers. These results showed that silencing of 3-OST-2 was present in a wide range of human cancers. The 3-OST-2 gene encodes an enzyme involved in the final modification step of heparan sulfate proteoglycans (HSPGs), and its silencing is expected to result in abnormal modification of HSPGs and abnormal signal transduction. From the high incidence, silencing of the 3-OST-2 gene is expected to have high diagnostic, and potentially therapeutic, values.	Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Dept Surg, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; Hiroshima University	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Carcinogenesis, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Asada, Kiyoshi/AFL-8696-2022; Ushijima, Toshikazu/AAP-5742-2021; Asada, Kiyoshi/GPW-7758-2022	Asada, Kiyoshi/0000-0002-4515-6047; Ushijima, Toshikazu/0000-0003-3405-7817; 				ASADA K, IN PRESS ONCOLOGY; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P3225; Feinberg AP, 2001, NAT GENET, V27, P9, DOI 10.1038/83825; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; KANEDA A, IN PRESS CANC RES; Kawakami K, 2000, J NATL CANCER I, V92, P1805, DOI 10.1093/jnci/92.22.1805; Kelsey G, 1999, GENOMICS, V62, P129, DOI 10.1006/geno.1999.6022; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Matsuda K, 2001, CANCER RES, V61, P5562; Muller K, 2001, J BIOL CHEM, V276, P14271; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; SAMBROOK J, 1989, MOL CLONING, V2, P1914; SHAPIRO B, 1983, CANCER, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495; Stanley MJ, 1999, AM J CLIN PATHOL, V112, P377; STROUN M, 1989, ONCOLOGY, V46, P318; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284	35	111	119	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					274	280		10.1038/sj.onc.1206146	http://dx.doi.org/10.1038/sj.onc.1206146			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527896				2022-12-17	WOS:000180322400012
J	Qian, H; Wang, T; Naumovski, L; Lopez, CD; Brachmann, RK				Qian, H; Wang, T; Naumovski, L; Lopez, CD; Brachmann, RK			Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites	ONCOGENE			English	Article						apoptosis; cell cycle; DNA binding site; DNA repair; p53	TUMOR-SUPPRESSOR P53; BAX PROMOTER; GROWTH; APOPTOSIS; PROTEIN; CANCER; DEATH; TRANSACTIVATION; PROTOONCOGENE; MUTATIONS	The tumor suppressor protein p53, once activated, can cause either cell cycle arrest or apoptosis through transactivation of target genes with p53 DNA binding sites (DBS). To investigate the role of p53 DBS in the regulation of this profound, yet poorly understood decision of life versus death, we systematically studied all known and potential p53 DBS. We analysed the DBS separated from surrounding promoter regions in yeast and mammalian assays with and without DNA damage. p53 efficiently utilized the DBS of MDM2 and of genes connected to cell cycle arrest, DNA repair and the death receptor pathway of apoptosis. However, p53 was unable to utilize two-thirds of the isolated DBS, a subset that included almost all DBS of apoptosis-related genes. Neither ASPP2, a p53-interacting protein reported to specifically stimulate p53 transcriptional activity on apoptosis-related promoters, nor DNA damage resulted in p53 utilization of isolated DBS of apoptosis-related genes. Thus, a major regulation of p53 activity occurs at the level of p53 DBS themselves by posing additional requirements for the successful utilization of apoptosis-related DBS.	Washington Univ, Sch Med, Div Oncol, Dept Med, St Louis, MO 63110 USA; Stanford Univ, Div Hematol Oncol & Stem Cell Transplantat, Stanford, CA 94305 USA; Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA	Washington University (WUSTL); Stanford University; Oregon Health & Science University	Brachmann, RK (corresponding author), Washington Univ, Sch Med, Div Oncol, Dept Med, 660 S Euclid Ave,Box 8069, St Louis, MO 63110 USA.				NCI NIH HHS [CA81511, CA76316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081511, R01CA076316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1998, ONCOGENE, V16, P2527; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MIYASHITA T, 1995, CELL, V80, P293; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SIKORSKI RS, 1989, GENETICS, V122, P19; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7	42	111	116	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 7	2002	21	51					7901	7911		10.1038/sj.onc.1205974	http://dx.doi.org/10.1038/sj.onc.1205974			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420228				2022-12-17	WOS:000178946000016
J	Xie, SH; Lin, H; Sun, T; Arlinghaus, RB				Xie, SH; Lin, H; Sun, T; Arlinghaus, RB			Jak2 is involved in c-Myc induction by Bcr-Abl	ONCOGENE			English	Article						Philadelphia chromosome leukemia; Bcr-Abl oncoprotein; Jak2 tyrosine kinase; c-Myc induction	NF-KAPPA-B; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCER; STAT5 ACTIVATION; FACTOR-RECEPTOR; KINASE-ACTIVITY; FUSION PROTEIN; MYELOID CELLS	We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. We are searching for downstream targets of Jak2 in Bcr-Abl positive cells. It is known that c-Myc expression is required for the oncogenic effects of Bcr-Abl, and that over-expression of c-Myc complements the transformation defect of the Bcr-Abl SH2 deletion mutant. Moreover, the Bcr-Abl SH2 deletion mutant and an Abl C-terminal deletion mutant are deficient in activating c-Myc expression. Since the Jak2 binds to the C-terminal domain of Bcr-Abl and optimal Jak2 activation requires the SH2 domain, we tested whether Jak2 was involved in c-Myc protein induction by Bcr-Abl. We treated the 32Dp210 Bcr-Abl cells with the Jak2 specific tyrosine kinase inhibitor, AG490, and found that this drug, like the Abl tyrosine kinase inhibitor STI-571, inhibited c-Myc protein induction by Bcr-Abl. Treatment of 32Dp210 Bcr-Abl cells with AG490 also inhibited c-MYC RNA expression. It is also known that c-Myc protein is a labile protein that is increased in amounts in response to various growth factors by a mechanism not involving new Myc protein formation. Treatment of 32Dp210 Bcr-Abl cells with both the proteasome inhibitor MG132 and AG490 blocked the reduction of the c-Myc protein observed by AG490 alone. An adaptor protein SH2-Bbeta is involved in the enhancement of the tyrosine kinase activity of Jak2 following ligand/receptor interaction. In this regard we showed that the Jak2/Bcr-Abl complex contains SH2-Bbeta. Expression of the SH2-Bbeta R555E mutant in 32Dp210 Bcr-Abl cells reduced c-Myc expression about 40% compared to a vector control. Interestingly, we found the reduction of the c-Myc protein in several clones of dominant-negative (DN) Jak2 expressing K562 cells correlated very well with the reduction of tumor growth of these cells in nude mice as compared to vector transfected K562 cells. Both STI-571 and AG490 also induced apoptosis in 32Dp210 cells. Of interest, IL-3 containing medium reversed the STI-571 induced apoptosis of 32Dp210 cells but did not reverse the induction of apoptosis by AG490, which strongly supports the specificity of the inhibitory effects of AG490 on the Jak2 tyrosine kinase. In summary, our findings indicate that Jak2 mediates the increase in c-Myc expression that is induced by Bcr-Abl. Our results indicate that activated Jak2 not only mediates an increase of c-MYC RNA expression but also interferes with proteasome-dependent degradation of c-Myc protein.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672, CA 49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GUO JQ, 1993, HEMATOL PATHOL, V7, P91; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Miyamoto N, 2001, LEUKEMIA, V15, P1758, DOI 10.1038/sj.leu.2402260; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Okuda K, 1998, BLOOD, V92, P3848, DOI 10.1182/blood.V92.10.3848.422k44_3848_3856; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sambrook J., 1989, MOL CLONING; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHUI K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WilsonRawls J, 1996, CANCER RES, V56, P3426; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	44	111	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7137	7146		10.1038/sj.onc.1205942	http://dx.doi.org/10.1038/sj.onc.1205942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370803				2022-12-17	WOS:000178504600001
J	Kaye, FJ				Kaye, FJ			RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer	ONCOGENE			English	Article						retinoblastoma; cyclin dependent kinase; pl6INK4; p27Kipl; lung cancer; neuroendocrine	RETINOBLASTOMA SUSCEPTIBILITY GENE; SMALL-CELL CARCINOMA; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; RAS ONCOGENE MUTATIONS; N-MYC GENE; P16(INK4) PROTEIN; IN-VIVO; EXPRESSION; LINES	The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.	Natl Naval Med Res Inst, NCI Navy Oncol, Bethesda, MD 20889 USA; NCI, Genet Branch, Canc Res Ctr, NIH, Bethesda, MD 20889 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaye, FJ (corresponding author), Natl Naval Med Res Inst, NCI Navy Oncol, Bldg 8,Room 5101, Bethesda, MD 20889 USA.	fkaye@helix.nih.gov	kaye, frederic/E-2437-2011					Abramson DH, 2001, OPHTHALMOLOGY, V108, P1868, DOI 10.1016/S0161-6420(01)00713-8; Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bockhorn M, 2000, EXP CLIN ENDOCR DIAB, V108, P49; Cagle PT, 1997, AM J PATHOL, V150, P393; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Capella G, 1996, DIAGN MOL PATHOL, V5, P45, DOI 10.1097/00019606-199603000-00008; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 2000, CANCER RES, V60, P372; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Easton J, 1998, CANCER RES, V58, P2624; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1995, MOL GENETICS CANC, P1; GAZDAR AF, 1985, SCIENCE, V229, P679, DOI 10.1126/science.2992083; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gray SG, 2001, CANCER RES, V61, P5950; Grimison B, 2000, CELL GROWTH DIFFER, V11, P507; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARVEY M, 1995, CANCER RES, V55, P1146; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HERMAN JG, 1995, CANCER RES, V55, P4525; Hirsch FR, 2002, SEMIN ONCOL, V29, P51, DOI 10.1053/sonc.2002.31523; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; JOHNSON BE, 1988, CANCER RES, V48, P5163; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kaye F, 2001, MOL GENETICS CANC, P387; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Kleinerman RA, 2000, JNCI-J NATL CANCER I, V92, P2037, DOI 10.1093/jnci/92.24.2037; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Modi S, 2000, ONCOGENE, V19, P4632, DOI 10.1038/sj.onc.1203815; Momparler RL, 2001, LUNG CANCER, V34, pS111; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; OOKAWA K, 1993, ONCOGENE, V8, P2175; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIMIZU E, 1994, ONCOGENE, V9, P2441; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUGIO K, 1994, CANCER RES, V54, P5811; Tomizawa Y, 1998, JPN J CLIN ONCOL, V28, P192, DOI 10.1093/jjco/28.3.192; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	90	111	117	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2002	21	45					6908	6914		10.1038/sj.onc.1205834	http://dx.doi.org/10.1038/sj.onc.1205834			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604UV	12362273				2022-12-17	WOS:000178640200006
J	Sekhar, KR; Yan, XX; Freeman, ML				Sekhar, KR; Yan, XX; Freeman, ML			Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2	ONCOGENE			English	Article						Nrf2; INrf2; ubiquitin; proteasome	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAPHTHOFLAVONE-INDUCED EXPRESSION; ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; SUBUNIT GENE; INDUCIBLE EXPRESSION; CATALYTIC SUBUNIT; GLUTATHIONE; PROTEIN; DOMAIN	INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine if tethering affected Nrf2 degradation. Data is presented showing that Nrf2 is degraded by the ubiquitin-proteasome pathway. Nrf2 co-immunoprecipitated with a HA tagged ubiquitin polymer and accumulated in cells expressing inactive ubiquitin activating enzyme El. Inhibition of proteasome activity resulted in accumulation of Nrf2. The rate of Nrf2 degradation, measured under conditions where the majority of Nrf2 was not tethered, exhibited a T-1/2 of approximately 3 h. Over-expression of human INrf2, KIAA0132, blocked Nrf2 conjugation to the ubiquitin polymer and blocked Nrf2 degradation. These results suggest that association of Nrf2 with INrf2 inhibits ubiquitin-proteasome degradation of Nrf2. Maintaining the majority of Nrf2 in a tethered form, resistant to ubiquitin-proteasome dependent degradation, allows a pool of Nrf2 to be available for rapid Nrf2/ARE-dependent gene transcription following stress mediated release from INrf2. Further, the observation that free Nrf2 is degraded by the ubiquitin proteasome pathway provides a potential mechanism by which ARE-dependent gene transcription is attenuated after induction.	Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA	Vanderbilt University	Freeman, ML (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 221 Kirkland Hall, Nashville, TN 37232 USA.			Freeman, Michael/0000-0003-1881-366X; Konjeti, Sekhar/0000-0003-2930-0739	NATIONAL CANCER INSTITUTE [R01CA038079, R55CA038079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA038079, CA-38079] Funding Source: Medline; NIEHS NIH HHS [P30ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; McMahon M, 2001, CANCER RES, V61, P3299; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Wolf CR, 2001, P NATL ACAD SCI USA, V98, P2941, DOI 10.1073/pnas.071042698; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497	26	111	113	13	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6829	6834		10.1038/sj.onc.1205905	http://dx.doi.org/10.1038/sj.onc.1205905			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360409				2022-12-17	WOS:000178315800013
J	Hollander, MC; Fornace, AJ				Hollander, MC; Fornace, AJ			Genomic instability, centrosome amplification, cell cycle checkpoints and Gadd45a	ONCOGENE			English	Review						Gadd45a; centrosome amplification; p53(-/-)	DOUBLE-STRAND BREAKS; DNA-DAMAGING AGENTS; C-MYC GENE; ATAXIA-TELANGIECTASIA; SACCHAROMYCES-CEREVISIAE; ANAPHASE INHIBITOR; KINASE-ACTIVITY; DEFICIENT MICE; PROTEIN-KINASE; S-PHASE	Genomic instability has been a recognized feature of many human tumors for decades. Until recently, however, there was little insight into potential mechanisms for this phenomenon. Recent work has shown first, that increased centrosome numbers (also referred to as centrosome amplification) often accompany genomic instability and second, that when centrosome numbers are increased, cells become genetically unstable. Deletion of Gadd45a leads to centrosome amplification and consequent abnormal mitosis and aneuploidy. Gadd45a is known to be involved in a G2 checkpoint and may be involved in the normal progression from G2 to M and its coordination with S phase events. Whether these functions contribute to prevention of centrosome amplification is being investigated. However, potential mechanisms can be proposed based on known protein associations with Gadd45a, as well as proteins that regulate Gadd45a transcription and are also required for efficient coordination of centrosome duplication and DNA synthesis.	NCI, Gene Response Sect, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hollander, MC (corresponding author), NCI, Gene Response Sect, CCR, NIH, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Amundson SA, 2000, CANCER RES, V60, P6101; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Baumer M, 2000, J BIOL CHEM, V275, P38929, DOI 10.1074/jbc.M007925200; Bertwistle D, 1999, Breast Cancer Res, V1, P41, DOI 10.1186/bcr12; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Clarke DJ, 1999, CURR BIOL, V9, P365, DOI 10.1016/S0960-9822(99)80163-8; Clarke DJ, 2001, NAT CELL BIOL, V3, P619, DOI 10.1038/35083009; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; Deng CX, 2002, ENVIRON MOL MUTAGEN, V39, P171, DOI 10.1002/em.10069; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Law W, 2001, ONCOGENE, V20, P1118, DOI 10.1038/sj.onc.1204226; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Leung CH, 2001, BIOCHEM BIOPH RES CO, V285, P283, DOI 10.1006/bbrc.2001.5164; Li Q, 1999, MOL CELL BIOL, V19, P5339; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Lu YY, 1996, BIOCHEM J, V317, P321, DOI 10.1042/bj3170321; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; Mai S, 1996, ONCOGENE, V12, P277; Mallory JC, 2000, P NATL ACAD SCI USA, V97, P13749, DOI 10.1073/pnas.250475697; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Nicolaidis P, 1998, HUM REPROD, V13, P313, DOI 10.1093/humrep/13.2.313; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Pihan GA, 1998, CANCER RES, V58, P3974; RODILLA V, 1993, MUTAT RES, V300, P281, DOI 10.1016/0165-1218(93)90062-I; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shiloh Y, 2001, BIOCHEM SOC T, V29, P661, DOI 10.1042/0300-5127:0290661; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stumm M, 2001, CYTOGENET CELL GENET, V92, P186, DOI 10.1159/000056900; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TISTY TD, 1990, P NATL ACAD SCI USA, V87, P3132; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yin XY, 2001, CANCER RES, V61, P6487; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	67	111	120	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6228	6233		10.1038/sj.onc.1205774	http://dx.doi.org/10.1038/sj.onc.1205774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214253				2022-12-17	WOS:000177840500012
J	Yuan, XJ; Whang, YE				Yuan, XJ; Whang, YE			PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway	ONCOGENE			English	Article						PTEN; apoptosis; FADD; death receptors	NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; CYTOCHROME-C RELEASE; PHOSPHATASE-ACTIVITY; PTEN/MMAC1; ACTIVATION; PHOSPHORYLATION; PROTEIN; DOMAIN; MICE	The PTEN tumor suppressor is frequently mutated in human tumors. Loss of PTEN function is associated with constitutive survival signaling through the phosphatidylinositol-3 kinase/Akt pathway. Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. Adenovirus-mediated expression of PTEN completely suppressed constitutive Akt activation in LNCaP prostate cancer cells and enhanced apoptosis induced by a broad range of apoptotic stimuli. PTEN expression sensitized cells to death receptor-mediated apoptosis induced by tumor necrosis factor, anti-Fas antibody, and TRAIL. PTEN also sensitized cells to non-receptor mediated apoptosis induced by a kinase inhibitor staurosporine and chemotherapeutic agents mitoxantrone and etoposide. PTEN-mediated apoptosis was accompanied by caspase-3 and caspase-8 activation and was inhibited by a broad specificity caspase inhibitor Z-VAD-fmk. Bcl-2 overexpression also blocked PTEN-mediated apoptosis. Lipid phosphatase activity of PTEN is required for apoptosis as the PTEN G129E mutant selectively deficient in lipid phosphatase activity was unable to sensitize cells to apoptosis. PTEN-mediated apoptosis involves a FADD-dependent pathway for both death receptor-mediated and drug-induced apoptosis as coexpression of a dominant negative FADD mutant blocked PTEN-mediated apoptosis. Since in death receptor signaling, FADD mediates activation of caspase-8, which in turn cleaves BID, and since caspase-8 is activated in PTEN-mediated apoptosis, we examined BID cleavage in PTEN-mediated apoptosis. PTEN facilitated BID cleavage after treatment with low doses of staurosporine and mitoxantrone. BID cleavage was inhibited by dominant negative FADD. Taken together, these data are consistent with the hypothesis that PTEN promotes drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage through a FADD-dependent pathway.	Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Whang, YE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA.		Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NATIONAL CANCER INSTITUTE [K08CA085772] Funding Source: NIH RePORTER; NCI NIH HHS [CA85772] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kulik G, 2001, CANCER RES, V61, P2713; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Marcelli M, 1999, CANCER RES, V59, P382; McMenamin ME, 1999, CANCER RES, V59, P4291; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1998, CANCER RES, V58, P204; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	52	111	114	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					319	327		10.1038/sj/onc/1205054	http://dx.doi.org/10.1038/sj/onc/1205054			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803475				2022-12-17	WOS:000173026200016
J	Danial, NN; Rothman, P				Danial, NN; Rothman, P			JAK-STAT signaling activated by Abl oncogenes	ONCOGENE			English	Article						JAK; STAT; v-Abl; BCR-Abl	LYMPHOID-CELL TRANSFORMATION; CHRONIC MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD CELLS; DNA-BINDING ACTIVITY; PRE-B CELLS; BCR-ABL; C-ABL; TYROSINE KINASE; V-ABL; CONSTITUTIVE ACTIVATION	The Abl oncoproteins v-Abl and BCR-Abl can activate member of the signal transducers and activators of transcription (STAT) family of signaling proteins. The mechanisms by which these oncoproteins activate STATs appear to differ, In cells transformed by v-Abl, Janus kinase (JAK) tyrosine kinases are constitutively activated. Tn these cells, the v-Abl oncoprotein and the JAK kinases physically associate. Mapping of the JAK interaction domain in v-Abl demonstrates that amino acids within the carboxyl terminal region of v-Abl bind JAKs through a direct interaction. A mutant of v-Abl lacking this region does not bind or activate JAK 1 in vivo, fails to activate STAT proteins, does not induce cellular proliferation, and is less efficient in cellular transformation. Kinase inactive mutants of JAK 1 inhibit the ability of v-Abl to activate STATs, to induce cytokine-independent proliferation, and to transform bone marrow cells. Interestingly, these effects correlate with defects in the activation of several pathways by v-AbI including Akt, PI3-kinase, STATs, and Ras, These data suggest that Jak kinases may play an important role in v-Abl induced transformation.	Columbia Univ Coll Phys & Surg, Dept Microbiol, Integrated Program Mol Cellular & Biophys Studies, New York, NY 10032 USA	Columbia University	Rothman, P (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, Integrated Program Mol Cellular & Biophys Studies, 630 168th St, New York, NY 10032 USA.							Banerjee A, 1998, J IMMUNOL, V161, P4611; Berchtold S, 1998, MOL ENDOCRINOL, V12, P556, DOI 10.1210/me.12.4.556; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DORSCH M, 1996, P NATL ACAD SCI, V93; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FISHER AG, 1993, LEUKEMIA, V7, pS66; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GOGA A, 1995, ONCOGENE, V11, P791; Golub TR, 1996, BBA-REV CANCER, V1288, pM7, DOI 10.1016/0304-419X(96)00015-7; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Henderson YC, 1997, CLIN CANCER RES, V3, P145; HEVEZI P, 1993, ONCOGENE, V8, P2413; Hilbert DM, 1998, ONCOGENE, V17, P2125, DOI 10.1038/sj.onc.1202134; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kanwar VS, 1996, BLOOD, V87, P4911, DOI 10.1182/blood.V87.11.4911.bloodjournal87114911; Ke SA, 1999, PROG BIOPHYS MOL BIO, V71, P405, DOI 10.1016/S0079-6107(98)00051-0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; ODA T, 1994, J BIOL CHEM, V269, P22925; Ota J, 1998, BIOCHEM BIOPH RES CO, V252, P779, DOI 10.1006/bbrc.1998.9445; OVERELL RW, 1991, MOL CELL BIOL, V11, P1590, DOI 10.1128/MCB.11.3.1590; Ozaki K, 1998, BLOOD, V92, P4652; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROSENBERG N, 1994, SEMIN CANCER BIOL, V5, P95; ROSENBERG N, 1998, ADV VIRUS RES, V35, P39; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG JYJ, 1984, CELL, V36, P349; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; WeberNordt RM, 1996, BLOOD, V88, P809; WilsonRawls J, 1996, CANCER RES, V56, P3426; YASUNAGA M, 1995, J EXP MED, V182, P315, DOI 10.1084/jem.182.2.315; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; YOUNG JC, 1991, MOL CELL BIOL, V11, P854, DOI 10.1128/MCB.11.2.854; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	80	111	114	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2000	19	21					2523	2531		10.1038/sj.onc.1203484	http://dx.doi.org/10.1038/sj.onc.1203484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851051				2022-12-17	WOS:000087459400008
J	Ito, K; Okamoto, I; Araki, N; Kawano, Y; Nakao, M; Fujiyama, S; Tomita, K; Mimori, T; Saya, H				Ito, K; Okamoto, I; Araki, N; Kawano, Y; Nakao, M; Fujiyama, S; Tomita, K; Mimori, T; Saya, H			Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts	ONCOGENE			English	Article						metalloprotease; mechanical stimulation; calcium ionophore; E-cadherin; beta-catenin	BREAST-CARCINOMA CELLS; SOLUBLE E-CADHERIN; CANCER-PATIENTS; ADHESION; RECEPTORS; CLEAVAGE; TISSUE; GROWTH; METALLOPROTEINASES; IDENTIFICATION	Cadherins are major cell-cell adhesion molecules in both tumor and normal tissues. Although serum levels of soluble E-cadherin have been shown to be higher in the cancer patients than in healthy volunteers, the detail mechanism regulating release of soluble E-cadherin remains to be elucidated. Here we show that the ectodomain of E-cadherin is proteolytically cleaved from some cancer cells by a membrane-bound metalloprotease to yield soluble form, and the residual membrane-tethered cleavage product is subsequently degraded by intracellular proteolytic pathway. Futhermore, we show that extracellular calcium influx, that is induced by mechanical scraping of cells or ionomycin treatment, enhances the metalloprotease-mediated E-cadherin cleavage and the subsequent degradation of the cytoplasmic domain. Immunocytochemical analysis demonstrates that the sequential proteolysis of E-cadherin triggered by the calcium influx results in translocation of beta-catenin from the cell-cell contacts to cytoplasm. Our data suggest that calcium influx-induced proteolysis of E-cadherin not only disrupts the cell-cell adhesion but also activates beta-catenin-mediated intracellular signaling pathway, potentially leading to alterations in motility and proliferation activity of cells.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Internal Med 3, Kumamoto 8600811, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					ABERLE H, 1994, J CELL SCI, V107, P3655; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Codony-Servat J, 1999, CANCER RES, V59, P1196; COOMBER BL, 1990, ARTERIOSCLEROSIS, V10, P215, DOI 10.1161/01.ATV.10.2.215; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; Dethlefsen SM, 1998, J CELL BIOCHEM, V69, P143, DOI 10.1002/(SICI)1097-4644(19980501)69:2<143::AID-JCB5>3.0.CO;2-S; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; Gofuku J, 1998, BRIT J CANCER, V78, P1095, DOI 10.1038/bjc.1998.634; GORDON MY, 1991, CANCER CELL-MON REV, V3, P127; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; LIN YZJ, 1991, ONCOGENE, V6, P639; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lombard MA, 1998, CANCER RES, V58, P4001; Murphy Andrew J. M., 1992, Methods (Orlando), V4, P111, DOI 10.1016/1046-2023(92)90044-9; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; REIDY MA, 1990, TOXICOL PATHOL, V18, P547; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SATO H, 1992, ONCOGENE, V7, P77; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; Tran POT, 1999, EXP CELL RES, V246, P319, DOI 10.1006/excr.1998.4239; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	39	111	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7080	7090		10.1038/sj.onc.1203191	http://dx.doi.org/10.1038/sj.onc.1203191			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597309				2022-12-17	WOS:000083901900015
J	Reardon, DB; Contessa, JN; Mikkelsen, RB; Valerie, K; Amir, C; Dent, P; Schmidt-Ullrich, RK				Reardon, DB; Contessa, JN; Mikkelsen, RB; Valerie, K; Amir, C; Dent, P; Schmidt-Ullrich, RK			Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells	ONCOGENE			English	Article						EGFR; EGFR-CD533, dominant-negative; MAPK; JNK1; ionizing radiation; mammary carcinoma cells	EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; RAS-DEPENDENT ACTIVATION; FACTOR RECEPTOR MUTANTS; BREAST-CANCER CELLS; PROTEIN-KINASE; C-JUN; INDUCED APOPTOSIS; IONIZING-RADIATION; SOS PHOSPHORYLATION	Exposure of MDA-MB-231 human mammary carcinoma cells to an ionizing radiation dose of 2 Gy results in immediate activation and Tyr phosphorylation of the epidermal growth factor receptor (EGFR), Doxycycline induced expression of a dominant negative EGFR-CD533 mutant, lacking the COOH-terminal 533 amino acids, in MDA-TR15-EGFR-CD533 cells was used to characterize intracellular signaling responses following irradiation. Within 10 min, radiation exposure caused an immediate, transient activation of mitogen activated protein kinase (MAPK) which was completely blocked by expression of EGFR-CD533, The same radiation treatment also induced an immediate activation of the c-Jun-NH2-terminal kinase 1 (JNK1) pathway that was followed by an extended rise in kinase activity after 30 min. Expression of EGFR-CD533 did not block the immediate JNK1 response but completely inhibited the later activation. Treatment of MDA-TR15-ECFR-CD533 cells with the MEK1/2 inhibitor, PD98059, resulted in similar to 70% inhibition of radiation-induced MAPK activity, and potentiated the radiation-induced increase of immediate JNK1 activation twofold. Inhibition of Ras farnesylation with a concomitant inhibition of Res function completely blocked radiation-induced MAPK( and JNK1 activation, Modulation of EGFR and MAPK functions also altered overall cellular responses of growth and apoptosis, Induction of EGFR-CD533 or treatment with PD98059 caused a 3-5-fold increase in radiation toxicity in a novel repeated radiation exposure growth assay by interfering with cell proliferation and potentiating apoptosis, In summary, this data demonstrates that both MAPK and JNK1 activation in response to radiation occur through EGFR-dependent and -independent mechanisms, and are mediated by signaling through Ras, Furthermore, we have demonstrated that radiation-induced activation of EGFR results in downstream activation of MAPK which may affect the radiosensitivity of carcinoma cells.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Med Coll Virginia Campus, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA65896, CA72955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065896, P01CA072955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; BENTZEN SM, 1991, RADIOTHER ONCOL, V22, P161, DOI 10.1016/0167-8140(91)90019-D; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARMICHAEL J, 1987, CANCER RES, V47, P943; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chelliah J, 1997, BIOCHEM PHARMACOL, V54, P563, DOI 10.1016/S0006-2952(97)00212-8; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chmura SJ, 1997, CANCER RES, V57, P1270; Contessa JN, 1999, CLIN CANCER RES, V5, P405; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; GORCZYCA W, 1993, CANCER RES, V53, P1945; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HEERDT BG, 1994, CANCER RES, V54, P3288; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; JARVIS M, 1997, MOL PHARMACOL, V2, P935; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; KWOK TT, 1991, BRIT J CANCER, V64, P251, DOI 10.1038/bjc.1991.286; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LADEROUTE KR, 1994, CANCER RES, V54, P1407; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lee HS, 1997, INT J RADIAT ONCOL, V38, P1079, DOI 10.1016/S0360-3016(97)00073-4; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MANNE V, 1995, ONCOGENE, V10, P1763; Michael JM, 1997, CANCER RES, V57, P3600; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; Suy S, 1997, ONCOGENE, V15, P53, DOI 10.1038/sj.onc.1201165; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TODD DG, 1999, IN PRESS J RECEPT SI; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	66	111	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4756	4766		10.1038/sj.onc.1202849	http://dx.doi.org/10.1038/sj.onc.1202849			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467423				2022-12-17	WOS:000082154400013
J	Claassen, GF; Hann, SR				Claassen, GF; Hann, SR			Myc-mediated transformation: the repression connection	ONCOGENE			English	Review						Myc; transformation; transrepression	LUNG-CANCER CELLS; HUMAN C-MYC; ADENOVIRUS E1A; GROWTH ARREST; DNA-BINDING; NEGATIVE AUTOREGULATION; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; NEOPLASTIC TRANSFORMATION; TUMORIGENIC CONVERSION	Myc is an important regulator of many cellular processes, including growth promotion, differentiation, and apoptosis. The mechanisms underlying Myc biological activity, however, remain elusive. For many years, research in the field has focused on the idea of Myc as a transactivator of gene expression. More recently, alternative mechanisms of Myc function have been proposed, including gene repression. In this review we present several lines of evidence to support a connection between Myc-mediated transformation and transcriptional repression.	Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University	Hann, SR (corresponding author), Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Barr LF, 1998, CANCER RES, V58, P5537; Barr LF, 1996, CELL GROWTH DIFFER, V7, P1149; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chen CH, 1996, ONCOGENE, V13, P1659; Cleveland J L, 1988, Oncogene Res, V3, P357; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Crouch DH, 1996, NUCLEIC ACIDS RES, V24, P3216, DOI 10.1093/nar/24.16.3216; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Griffioen M, 1998, MOL IMMUNOL, V35, P829, DOI 10.1016/S0161-5890(98)00074-1; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee LA, 1997, CURR TOP MICROBIOL, V224, P131; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1997, ONCOGENE, V14, P967, DOI 10.1038/sj.onc.1200920; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSHIER JA, 1993, CANCER RES, V53, P2618; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; PAGANIN C, 1994, INT J CLIN LAB RES, V24, P29, DOI 10.1007/BF02592406; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PULVERER BJ, 1994, ONCOGENE, V9, P59; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHENK T, 1991, ADV CANCER RES, V57, P47; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; White E, 1995, Curr Top Microbiol Immunol, V199 ( Pt 3), P34; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	103	111	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2925	2933		10.1038/sj.onc.1202747	http://dx.doi.org/10.1038/sj.onc.1202747			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378689				2022-12-17	WOS:000080387800003
J	Wasylyk, C; Salvi, R; Argentini, M; Dureuil, C; Delumeau, I; Abecassis, J; Debussche, L; Wasylyk, B				Wasylyk, C; Salvi, R; Argentini, M; Dureuil, C; Delumeau, I; Abecassis, J; Debussche, L; Wasylyk, B			p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53	ONCOGENE			English	Article						p21(WAF1/CIP1); E2F; E6; cell cycle; apoptosis; antisense	WILD-TYPE P53; HUMAN TUMOR-CELLS; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; DNA-DAMAGE; P53-MEDIATED APOPTOSIS; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2	The p53 tumour suppressor is frequently inactivated in human tumours, One form of inactivation results from overexpression of MDM2, that normally forms a negative auto-regulatory loop with p53 and inhibits its activity through complex formation, We have investigated whether disrupting the MDM2-p53 complex in cells that overexpress MDM2 is sufficient to trigger p53 mediated cell death. We find that expression of a peptide homologue of p53 that binds to MDM2 leads to increased p53 levels and transcriptional activity. The consequences are increased expression of the downstream effecters MDM2 and p21(WAF1/CIP1), inhibition of colony formation, cell cycle arrest and cell death. There is also a decrease in E2F activity, that might have been due to the known physical and functional interactions of MDM2 with E2F1/DP1, However, this decrease is p53 dependent, as are also colony formation, cell cycle arrest and cell death, These results show that a peptide homologue of p53 is sufficient to induce p53 dependent cell death in cells overexpressing MDM2, and support the notion that disruption of the p53-MDM2 complex is a target for the development of therapeutic agents.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, Dept Oncol, F-94403 Vitry, France; Lab Biol Tumorale, F-67085 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ALKHALAF M, 1998, IN PRESS ONCOGENE; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340; CASEY G, 1991, ONCOGENE, V6, P1791; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; CORDONCARDO C, 1994, CANCER RES, V54, P794; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; Kondo S, 1996, ONCOGENE, V13, P1773; KONDO S, 1995, ONCOGENE, V10, P2001; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Leveillard T, 1998, MECH DEVELOP, V74, P189, DOI 10.1016/S0925-4773(98)00074-4; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1996, ONCOGENE, V12, P2279; Momand J, 1997, J CELL BIOCHEM, V64, P343; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Picksley SM, 1996, ACTA ONCOL, V35, P429, DOI 10.3109/02841869609109917; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SAKAI E, 1992, ONCOGENE, V7, P927; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Teoh G, 1997, BLOOD, V90, P1982, DOI 10.1182/blood.V90.5.1982; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wubah JA, 1996, CURR BIOL, V6, P60, DOI 10.1016/S0960-9822(02)00422-0; Wurl P, 1998, ONCOGENE, V16, P1183, DOI 10.1038/sj.onc.1201646; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YAGINUMA Y, 1991, CANCER RES, V51, P6506; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	96	111	119	1	15	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1921	1934		10.1038/sj.onc.1202528	http://dx.doi.org/10.1038/sj.onc.1202528			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208414				2022-12-17	WOS:000079191300002
J	Fedele, M; Berlingieri, MT; Scala, S; Chiariotti, L; Viglietto, G; Rippel, V; Bullerdiek, J; Santoro, M; Fusco, A				Fedele, M; Berlingieri, MT; Scala, S; Chiariotti, L; Viglietto, G; Rippel, V; Bullerdiek, J; Santoro, M; Fusco, A			Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts	ONCOGENE			English	Article						lipoma; chromatin; oncogene; tumor	NUCLEAR PROTEINS; THYROID-CELLS; CDNA CLONING; Y PROTEINS; BETA GENE; EXPRESSION; BINDING; PHOSPHOPROTEIN; ORGANIZATION; ELEMENTS	Overexpression of the high mobility group I (HMGI) proteins is often associated with the malignant phenotype. Moreover, many benign human tumors, mainly of mesenchymal origin, are characterized by rearrangements of the HMGI-C gene. In most cases, HMGI-C alterations involve breaks within the third intron of the gene resulting in aberrant transcripts carrying exons from 1-3, which encode the three DNA binding domains, fused to ectopic sequences. Here, we show that the expression of a truncated form of HMGI-C protein carrying only the three DNA-binding domains, or of a fusion protein carrying the three DNA-binding domains of HMGI-C and the LIM domains of the lipoma preferred partner gene (LPP) protein, causes malignant transformation of NIH3T3 cells. The unrearranged wildtype HMGI-C cDNA did not exert any transforming activity. These findings indicate that rearranged forms of HMGI-C play a role in cell transformation.	Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Ist Nazl Tumori, Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg Napoli, CNR,Ctr Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Bremen, Ctr Human Genet & Genet, Bremen, Germany	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Bremen	Fusco, A (corresponding author), Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, Via Tommaso Campanella, I-88100 Catanzaro, Italy.		Viglietto, Giuseppe/AAC-2852-2019; Scala, Stefania/K-1380-2016; Fedele, Monica/C-1417-2015; Chiariotti, Lorenzo/AAC-5262-2022	Viglietto, Giuseppe/0000-0003-2327-7515; Scala, Stefania/0000-0001-9524-2616; Fedele, Monica/0000-0002-9171-1312; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; Fusco, Alfredo/0000-0003-3332-5197				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Bol S, 1996, CANCER GENET CYTOGEN, V90, P88, DOI 10.1016/0165-4608(96)00062-3; CHAN KY, 1995, NUCLEIC ACIDS RES, V21, P4262; Chiappetta G, 1996, ONCOGENE, V13, P2439; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DU W, 1994, PNAS, V91, P113; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894; Fedele M, 1996, CANCER RES, V56, P1896; FERRANTI P, 1992, J BIOL CHEM, V267, P22486; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kazmierczak B, 1996, ONCOGENE, V12, P515; LEWIS H, 1994, MOL CELL BIOL, V15, P3738; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; Petit MMR, 1996, GENOMICS, V36, P118, DOI 10.1006/geno.1996.0432; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Staats B, 1996, BREAST CANCER RES TR, V38, P299, DOI 10.1007/BF01806149; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	36	111	114	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					413	418		10.1038/sj.onc.1201952	http://dx.doi.org/10.1038/sj.onc.1201952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696033				2022-12-17	WOS:000075043000002
J	Bellanger, JM; Lazaro, JB; Diriong, S; Fernandez, A; Lamb, N; Debant, A				Bellanger, JM; Lazaro, JB; Diriong, S; Fernandez, A; Lamb, N; Debant, A			The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo	ONCOGENE			English	Article						Trio; GDP/GTP exchange factor; actin; MAP kinases	ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; CDC42 GTPASES; ACTIVATION; KINASE; RAS; ONCOGENE; TRANSFORMATION; FAMILY	Trio contains two functional guanine nucleotide exchange factors (GEF) domains for the Rho-like GTPases and a serine/threonine kinase domain. In vitro, GEF domain 1(GEFD1) is specifically active on Rac1, while GEF domain 2 (GEFD2) targets RhoA. To determine whether Trio could activate Rad and RhoA in vivo, we measured the effect of Trio on Mitogen Activated Protein Kinase (MAPK) pathways and cytoskeletal rearrangments events mediated by the two GTPases. We show that: (i) the GEFD1 domain of Trio triggers the MAPK pathway leading to Jun kinase (JNK) activation and the production of membrane ruffles; (ii) co-expression of the TrioGEFD1 domain with a dominant-negative form of Rac blocked JNK induction, whereas a dominant-negative form of Cdc42 did not; (iii) a deletion mutant of TrioGEFD1 lacking a region important for exchange activity could not stimulate JNK activity; (iv) in contrast, the TrioGEFD2 domain does not stimulate JNK activity and induces the formation of stress fibers, as does activated RhoA; (v) furthermore, co-expression of both GEF domains induces simultaneously the formation of ruffles and stress fibers. Trio, therefore represents a unique member of the Rho-GEFs family possessing two functional domains of distinct specificities, that allow it to link Rho and Rac signaling pathway in vivo.	CNRS, CRBM, ERS155, F-34033 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Debant, A (corresponding author), CNRS, CRBM, ERS155, 1919 Route Mende,BP5051, F-34033 Montpellier 01, France.		Bellanger, Jean-Michel/D-1579-2017; Bellanger, Jean-Michel/S-2103-2019	Bellanger, Jean-Michel/0000-0001-9289-2349				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CERIONE RA, 1996, CURR OPIN CELL BIOL, V6, P216; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Lamb NJC, 1997, METHOD ENZYMOL, V283, P72; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Leung T, 1996, MOL CELL BIOL, V16, P5313; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TOMINAGA T, 1993, J CELL BIOL, V120, P1523; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZHENG Y, 1996, J BIOL CHEM, V271, P33269	32	111	112	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					147	152		10.1038/sj.onc.1201532	http://dx.doi.org/10.1038/sj.onc.1201532			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464532				2022-12-17	WOS:000071427100001
J	Craig, C; Kim, M; Ohri, E; Wersto, R; Katayose, D; Li, ZW; Choi, YH; Mudahar, B; Srivastava, S; Seth, P; Cowan, K				Craig, C; Kim, M; Ohri, E; Wersto, R; Katayose, D; Li, ZW; Choi, YH; Mudahar, B; Srivastava, S; Seth, P; Cowan, K			Effects of adenovirus-mediated p16(INK4A) expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells	ONCOGENE			English	Article						adenovirus; gene therapy; breast cancer; p16; cyclin dependent kinase inhibitors	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR GENE; CDK INHIBITORS; POTENTIAL MEDIATOR; GROWTH SUPPRESSION; PRODUCT PRB; PROTEIN; P21; PHOSPHORYLATION	We constructed an adenoviral vector containing human p16 cDNA in order to evaluate the cytotoxic effects of exogenous p16 expression on cancer cell proliferation and to explore the potential use of p16 in cancer gene therapy, Following infection of human breast (MCF-7, MDA-MB-231, and BT549), osteosarcoma (U-2 OS and Saos-2), cervical (C33a), and lung cancer (H358) cell lines with the recombinant adenovirus Adp16, high levels of p16 expression were observed in all cell lines. Cancer cell lines which were mutant or null for p16 but wild-type for the retinoblastoma gene product (pRb) (MCF-7, MDA-MB-231, BT549 and U-2 OS) were 7-22-fold more sensitive to the cytotoxic effects of Adp16 than to a control virus, In contrast, cancer cell lines which were wild-type for p16 but mutant or null for pRb (Saos-2, C33a and H358) were <threefold more sensitive to Adp16 when compared to a control virus, Analysis of 5-bromodeoxyuridine incorporation into DNA following infection with Adp16 showed a loss of S phase in those cell lines which were null or mutant for p16 but expressed a functional pRb. This cell cycle arrest was associated with binding of the p16 protein to cyclin-dependent kinase 4 and dephosphorylation of pRb. In contrast, human cancer cell lines expressing a wild-type p16 and a mutant pRb or no pRb showed no substantial loss of S phase following Adp16 infection. Based on these studies, we conclude that p16-mediated cytotoxicity is tightly associated with the presence of functional pRb in human cancer cells, and that tumor cells which are mutant or null for p16 are candidates for Adp16 mediated cancer gene therapy.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA; NCI, Pathol Branch, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Surg Branch, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA	Seth, P (corresponding author), NCI, Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.							AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; ARAP W, 1995, CANCER RES, V55, P1351; BARTEK J, 1992, ONCOGENE, V7, P101; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Costello JF, 1996, CANCER RES, V56, P2405; CRAIG C, 1997, ONCOGENE, V11, P110; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fueyo J, 1996, ONCOGENE, V12, P103; Geradts J, 1996, AM J PATHOL, V149, P15; GINSBERG HS, 1988, VIROLOGY, P147; GOTTESMAN MM, 1994, J NATL CANCER I, V86, P1277, DOI 10.1093/jnci/86.17.1277; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERMAN JG, 1995, P AM ASSOC CANC RES, V36, P20; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIN XM, 1995, CANCER RES, V55, P3250; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose D, 1995, CLIN CANCER RES, V1, P889; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SCHUTTE B, 1987, CYTOMETRY, V8, P372, DOI 10.1002/cyto.990080405; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Seth P, 1996, CANCER RES, V56, P1346; SETH P, 1986, VIRUS ATTACHMENT ENT, P191; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; Spillare EA, 1996, MOL CARCINOGEN, V16, P53, DOI 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	58	111	120	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					265	272		10.1038/sj.onc.1201493	http://dx.doi.org/10.1038/sj.onc.1201493			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464545				2022-12-17	WOS:000071427100014
J	Nathan, CA; Carter, P; Liu, L; Li, BD; Abreo, F; Tudor, A; Zimmer, SG; DeBenedetti, A				Nathan, CA; Carter, P; Liu, L; Li, BD; Abreo, F; Tudor, A; Zimmer, SG; DeBenedetti, A			Elevated expression of eIT4E and FGF-2 isoforms during vascularization of breast carcinomas	ONCOGENE			English	Article						eIF4E oncogene; FGF-2 isoforms; tumor vascularization; translation initiation; breast cancer progression; immunohistology	FIBROBLAST GROWTH-FACTOR; RAT EMBRYO FIBROBLASTS; MESSENGER-RNA; INITIATION FACTOR-4E; TRANSLATION; CELLS; TRANSFORMATION; AMPLIFICATION; CANCER	The translation initiation factor eIF4E is a novel protooncogene found over expressed in most breast carcinomas (Kerekatte et al., 1995), but the pathology where this elevation is initially manifested and its possible role in cancer progression are unknown, We report that eIF4E is markedly increased in vascularized malignant ductules of invasive carcinomas, whereas necrotic and avascular ductal carcinomas lit situ display significantly lower levels, eIF4E facilitates the synthesis of FGF-2, a powerful tumor angiogenic factor, Conversely, reducing eIF4E with antisense RNA in MDA-435 cells suppresses their tumorigenic and angiogenic properties, consistent with loss of FGF-2 synthesis, These findings suggest a causal role for eIF4E in tumor vascularization.	LOUISIANA STATE UNIV, MED CTR, DEPT BIOCHEM, SHREVEPORT, LA 71105 USA; LOUISIANA STATE UNIV, MED CTR, DEPT OTOLARYNGOL, SHREVEPORT, LA USA; LOUISIANA STATE UNIV, MED CTR, DEPT SURG, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, SHREVEPORT, LA 71130 USA; UNIV KENTUCKY, MED CTR, LUCILLE P MARKEY CANC CTR, LEXINGTON, KY 40536 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Kentucky				de benedetti, arrigo/0000-0002-4198-8647	NATIONAL CANCER INSTITUTE [R29CA069148] Funding Source: NIH RePORTER; NCI NIH HHS [CA69148-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; Anthony B, 1996, INT J CANCER, V65, P858, DOI 10.1002/(SICI)1097-0215(19960315)65:6<858::AID-IJC25>3.0.CO;2-Z; ASCHER NL, 1979, TRANSPLANTATION, V27, P254, DOI 10.1097/00007890-197904000-00010; CHAMPEME MH, 1994, MODERN PATHOL, V7, P900; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; EDGINGTON TS, 1995, FASEB J, V9, P841, DOI 10.1096/fasebj.9.10.7615153; FOLKMAN J, 1986, CANCER RES, V46, P467; FRYKBERG ER, 1994, WORLD J SURG, V18, P45, DOI 10.1007/BF00348191; GABRA N, 1994, BIOCHEM BIOPH RES CO, V205, P1423, DOI 10.1006/bbrc.1994.2824; GRAFF JR, 1995, INT J CANCER, V60, P255; HALABAN R, 1988, ONCOGENE RES, V3, P177; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P403; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; LI BDL, 1997, IN PRESS CANCER; LIPPMAN M, 1996, 19 ANN SAN ANT BREAS, V41, P191; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MORRISON RS, 1990, CANCER RES, V50, P2524; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Souttou B, 1996, INT J CANCER, V68, P675, DOI 10.1002/(SICI)1097-0215(19961127)68:5<675::AID-IJC19>3.0.CO;2-0; SU ZZ, 1993, ONCOGENE, V8, P1211; TAKEI Y, 1993, J CLIN BIOCHEM NUTR, V15, P57; THEILLET C, 1989, ONCOGENE, V4, P915; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VISSCHER DW, 1995, MODERN PATHOL, V8, P665; WELLSTEIN A, 1991, MOL F ONCOLOGY, P403; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	38	111	114	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	1997	15	9					1087	1094		10.1038/sj.onc.1201272	http://dx.doi.org/10.1038/sj.onc.1201272			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285563				2022-12-17	WOS:A1997XT16100010
J	Lorenzo, MJ; Gish, GD; Houghton, C; Stonehouse, TJ; Pawson, T; Ponder, BAJ; Smith, DP				Lorenzo, MJ; Gish, GD; Houghton, C; Stonehouse, TJ; Pawson, T; Ponder, BAJ; Smith, DP			RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2	ONCOGENE			English	Article						RET; multiple endocrine neoplasia type 2; Hirschsprung disease; Shc; Grb2	MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; SIGNAL-TRANSDUCTION; HIRSCHSPRUNG DISEASE; NUCLEOTIDE EXCHANGE; POINT MUTATION; PROTOONCOGENE; RECEPTOR; PROTEIN	Activating germline mutations of the RET receptor tyrosine kinase are found in the majority of cases of inherited cancer syndrome MEN 2, and inactivating mutations in some cases of dominantly inherited Hirschsprung disease. Using RET activated by a MEN 2 mutation, we show that both the SH2 and PTB domains of the adaptor protein Shc interact with RET, and we identify the PTB domain interaction site. Interaction with both the SH2 and PTB domains of She contributes to the transcriptional activation of a serum response element. RET alternate splicing affects the strength of interaction with both the She SH2 and PTB domains. In addition, a splice isoform-specific HSCR missense mutation, which does not inactivate the RET kinase activity, decreases the strength of the PTB domain interaction and the level of RET-dependent She phosphorylation.	UNIV CAMBRIDGE, ADDENBROOKES HOSP,DEPT PATHOL,CRC, HUMAN CANC GENET RES GRP, CAMBRIDGE CB2 1TN, ENGLAND; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, PROGRAM MOL BIOL & CANC, TORONTO, ON M5G 1X5, CANADA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Gish, Gerald D/C-7228-2017; Pawson, Tony J/E-4578-2013	Lorenzo, Maria Jesus/0000-0003-4416-0615				ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CROWE AJ, 1994, ONCOGENE, V9, P537; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gotoh N, 1995, ONCOGENE, V11, P2525; GUITON M, 1994, J BIOL CHEM, V269, P30370; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JOHANSEN FE, 1996, BIOCHIM BIOPHYS ACTA, V1242, P1; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1995, J INTERN MED, V238, P343, DOI 10.1111/j.1365-2796.1995.tb01208.x; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MYERS SM, 1995, ONCOGENE, V11, P2039; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; PONDER BAJ, 1996, IN PRESS ADV CAN RES; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	111	112	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					763	771		10.1038/sj.onc.1200894	http://dx.doi.org/10.1038/sj.onc.1200894			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047383	Bronze			2022-12-17	WOS:A1997WJ11200002
J	Parker, GA; Crook, T; Bain, M; Sara, EA; Farrell, PJ; Allday, MJ				Parker, GA; Crook, T; Bain, M; Sara, EA; Farrell, PJ; Allday, MJ			Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus EIA and papillomavirus E7	ONCOGENE			English	Article						growth transformation; EBV; EBNA3C; pRb; p16(INK4A)	CELL-CYCLE REGULATION; B-MYB TRANSCRIPTION; TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; BINDING PROTEIN; DNA-DAMAGE; P53; TRANSFORMATION; EXPRESSION	Epstein-Barr virus (EBV) requires six genes to efficiently immortalize human B cells, We have shown that one of these, EBNA3C, can cooperate with activated (Ha-)ras in co-transfection assays to immortalize and transform rat embryo fibroblasts (REFs), EBNA3C also augmented transformation by (Ha-)ras and a mutant p53 to a similar extent as human papilloma virus E7, As with E7 this effect was not inhibited by cotransfection with the cyclin-dependent kinase inhibitor (CDKI), a p16(INK4A), which can normally activate the retinoblastoma protein (pRb) and induce growth arrest, Also like E7/ras and E1A/ras transformed cells the EBNA3C/ras transformants are very susceptible to apoptotic cell death. In vitro EBNA3C binds to pRb in a manner which is dependent on the integrity of the pocket domain; this suggests that EBNA3C, even though it lacks the LXCXE pRb binding motif found in E7 and E1A, may interact with pRb in vivo. We conclude that EBNA3C functions as an oncoprotein which directs cell cycle progression through the G(1) phase restriction point when conditions might signal arrest. For the first time this demonstrates that EBV encodes a protein, functionally but not necessarily mechanistically, similar to the pRb-neutralizing nuclear antigens encoded by the 'small' DNA tumor viruses.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DEPT MED MICROBIOL, LONDON W2 1PG, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; INST CANC RES, HADDOW LABS, SUTTON SM2 5NG, SURREY, ENGLAND	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; Institute of Cancer Research - UK			Fraser, Elizabeth/M-7049-2015	Fraser, Elizabeth/0000-0001-8420-3208; Farrell, Paul/0000-0002-6754-9351	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLDAY MJ, 1988, NUCLEIC ACIDS RES, V16, P4353, DOI 10.1093/nar/16.10.4353; ALLDAY MJ, 1994, J VIROL, V68, P3491, DOI 10.1128/JVI.68.6.3491-3498.1994; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUTHU A, 1992, ONCOGENE, V7, P2161; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; KIEFF E, 1996, FIELDS VIROLOGY; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER G, 1990, VIROLOGY; NEVINS JR, 1992, SCIENCE, V258, P424; Nevins JR, 1996, FIELDS VIROLOGY, P301; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; ROBERTSON ES, 1995, J VIROL, V69, P3108, DOI 10.1128/JVI.69.5.3108-3116.1995; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; THOMAS JA, 1991, ADV CANCER RES, V57, P329; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0	39	111	117	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2541	2549						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000128				2022-12-17	WOS:A1996VZ65400004
J	Shibata, T; Ochiai, A; Kanai, Y; Akimoto, S; Gotoh, M; Yasui, N; Machinami, R; Hirohashi, S				Shibata, T; Ochiai, A; Kanai, Y; Akimoto, S; Gotoh, M; Yasui, N; Machinami, R; Hirohashi, S			Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells	ONCOGENE			English	Article						beta-catenin; c-erbB-2; protein-protein interaction; metastasis	EPIDERMAL GROWTH-FACTOR; ADHESION MOLECULE UVOMORULIN; HUMAN CARCINOMA-CELLS; HUMAN-BREAST-CANCER; E-CADHERIN; TYROSINE PHOSPHORYLATION; GENE-PRODUCT; EPITHELIAL-CELLS; FACTOR RECEPTOR; CYTOPLASMIC DOMAIN	tyrosine phosphorylation of beta-catenin inactivates the E-cadherin-mediated cell adhesion and invasion suppressor system in cancer cells, Elucidation of the association between beta-catenin and c-erbB-2 protein prompted us to investigate whether interference with this interaction can change the invasive phenotype, In a human gastric cancer cell line, TMK-1, N-terminally deleted beta-catenin, which binds to c-erbB-2 but not to cadherin, inhibited the association between endogenous beta-catenin and c-erbB-2 protein, and suppressed the tyrosine phosphorylation of beta-catenin. Cells expressing truncated beta-catenin exhibited markedly reduced invasiveness in vitro and peritoneal metastasis in vivo, and developed an epithelial morphology, These results suggest that tyrosine phosphorylation of beta-catenin regulated by c-erbB-2 protein may play an important role in the invasion, metastasis and morphogenesis of cancer cells and that inhibition of the aberrant tyrosine phosphorylation of beta-catenin effectively prevents invasion and metastasis of cancer cells.	NATL CANC CTR,RES INST,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT PATHOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								ABERLE H, 1994, J CELL SCI, V107, P3655; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BORG A, 1991, ONCOGENE, V6, P137; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; OYAMA T, 1994, CANCER RES, V54, P6268; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIGUCHI S, 1989, CANCER RES, V49, P6738; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YU DH, 1992, ONCOGENE, V7, P2263	43	111	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					883	889						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806677				2022-12-17	WOS:A1996VG76600001
J	Dehbi, M; Ghahremani, M; Lechner, M; Dressler, G; Pelletier, J				Dehbi, M; Ghahremani, M; Lechner, M; Dressler, G; Pelletier, J			The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1)	ONCOGENE			English	Article						Wilms' tumor; WT1; Pax-2; kidney development; cancer genetics	FACTOR-A-CHAIN; ALVEOLAR RHABDOMYOSARCOMA; PROMOTER ACTIVITY; POINT MUTATIONS; PRODUCT; REPRESSION; PROTEIN; KIDNEY; BINDING; RECOGNITION	The Wilms' tumor suppressor gene, wt1, encodes a zinc finger protein which functions as a transcriptional regulator. Expression of the wt1 gene is developmentally regulated and restricted to a small set of tissues which include the fetal urogenital system, mesothelium, and spleen. In the developing kidney, induction of neprohogenesis by the ureter is accompanied by an increase in expression levels of the Pax-2 gene, a developmentally and spatially regulated paired-box member. This is followed by an increase in wt1 expression as mesenchymal cells condense and differentiate. In this report, we demonstrate that PAX2 isoforms are capable of transactivating the wt1 promoter. Deletion mutagenesis of the wt1 promoter identified an element responsible for mediating PAX2 responsiveness, located between nucleotides -33 and -71 relative to the first wt1 transcription start site. Consistent with its identity as a PAX responsive element, multimerization of this mofit upstream of a heterologous minimal promoter enhanced reporter activity when co-transfected with a Pax-2 expression vector. Finally, we demonstrate that PAX2 can stimulate expression of the endogenous wt1 gene. These results suggest that a role for mesenchyme-to-epithelium transition in ment is to induce wt1 expression.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA	McGill University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1988, DEVELOPMENT, V104, P181; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1995, AM J PATHOL, V146, P40; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GNARRA JR, 1995, CANCER RES, V55, P4092; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOFMANN W, 1993, ONCOGENE, V8, P3123; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SHAPIRO DN, 1993, CANCER RES, V53, P5108; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TAGGE EP, 1994, J PEDIATR SURG, V29, P134, DOI 10.1016/0022-3468(94)90308-5; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	49	111	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					447	453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760285				2022-12-17	WOS:A1996VB32800001
J	DoucRasy, S; Barrois, M; Fogel, S; Ahomadegbe, JC; Stehelin, D; Coll, J; Riou, G				DoucRasy, S; Barrois, M; Fogel, S; Ahomadegbe, JC; Stehelin, D; Coll, J; Riou, G			High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19	ONCOGENE			English	Article						cervical cancer; H19; IGF2; loss of imprinting; allele switch; methylation	GROWTH FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; HUMAN CANCER; METHYLATION; RELAXATION; ALLELES; RNA	The few imprinted genes characterized so far include the insulin-like growth factor-2 gene (IGF2) coding for a foetal growth factor and the H19 gene whose normal function is unknown but which is likely to act as an RNA with an antitumour effect, IGF2 is expressed by the paternal allele and H19 by the maternal allele. This reciprocal expression is quite interesting because both H19 and IGF2 genes are located close to each other on chromosome 11p15.5 in a region subject to loss of heterozygosity (LOH), Moreover, loss of imprinting (LOI) or biallelic expression has been proposed as an epigenetic mechanism for tumorigenesis in a variety of human cancers including Wilms' tumour, In this study we report the LOH, LOI and methylation status of H19 and IGF2 genes in 29 invasive cervical carcinomas of different clinical stages, Fourteen (48%) and 13 (45%) tumours were heterozygous for H19 and IGF2 respectively, LOH for H19 and IGF2 genes were found in 2 of 14 (14%) and 3 of 13 (23%) informative tumours, respectively, LOI of H19 and IGF2 was detected in 2 of 12 (17%) and 5 of 10 (50%) tumours with no LOH, respectively, More interestingly, monoallelic expression of the otherwise silent H19 allele (allele switch) was observed in 2 of 12 (17%) tumours and biallelic expression of IGF2 was detected in one specimen of normal cervix adjacent to the tumour, The expressing H19 allele, and to a lower degree also the silent allele, were hypomethylated in tumours suggesting that demethylation of both H19 alleles may be associated with an early step of imprinting alteration. In cervical cancer H19 and IGF2 expressions could be independently regulated, In conclusion, our data suggest that H19 and IGF2 genes, via deletions and/or abnormal imprinting, could play a crucial role in a large proportion (58%) of cervical cancers where they may be associated with disease progression.	INST GUSTAVE ROUSSY,LAB PHARMACOL CLIN & MOLEC,F-94800 VILLEJUIF,FRANCE; INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; DOUCRASY S, 1993, INT J ONCOL, V2, P753; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; KONDO M, 1995, ONCOGENE, V10, P1193; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI XR, 1995, ONCOGENE, V11, P221; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RANIER S, 1995, CANCER RES, V55, P1836; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1985, PAPILLOMAVIRUSES MOL, V32, P47; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1994, CURR OPIN CELL BIOL, V6, P390, DOI 10.1016/0955-0674(94)90031-0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	41	111	119	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					423	430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570220				2022-12-17	WOS:A1996TR53800022
J	KUPRASH, DV; UDALOVA, IA; TURETSKAYA, RL; RICE, NR; NEDOSPASOV, SA				KUPRASH, DV; UDALOVA, IA; TURETSKAYA, RL; RICE, NR; NEDOSPASOV, SA			CONSERVED KAPPA-B ELEMENT LOCATED DOWNSTREAM OF THE TUMOR-NECROSIS-FACTOR-ALPHA GENE - DISTINCT NF-KAPPA-B BINDING PATTERN AND ENHANCER ACTIVITY IN LPS ACTIVATED MURINE MACROPHAGES	ONCOGENE			English	Article						NF-KAPPA-B; TUMOR NECROSIS FACTOR; TRANSCRIPTION	C-REL; NUCLEAR FACTOR; DNA-BINDING; V-REL; TRANSCRIPTIONAL ACTIVATION; P65 SUBUNIT; TNF LOCUS; PREFERENTIALLY INTERACTS; PROTEIN; MOTIFS	Transcriptional activation of various genes by lipopolysaccharide (LPS) is known to be mediated, at least in part, by the NF-kappa B/Rel family of transcription factors. We have identified a novel kappa B element located immediately downstream of the TNF-alpha gene that is conserved together with its flanking sequences across species lines and can act as an LPS-responsive enhancer for reporter gene constructs driven by the minimal TNF promoter. In extracts from activated murine macrophages and macrophage cell lines this element binds several non-canonical NF-kappa B/Rel complexes, in addition to p50 (NFKB1) homodimer and p50-p65 (NKFB1-RelA) heterodimer. Combination of high-resolution electrophoretic mobility shift assays (EMSA) with monospecific antibodies and u.v.-cross-linking indicates that the prominent slow migrating complex III contain p65 homodimer and c-Rel. The appearance of complex III in EMSA parallels the translocation of p65 and c-Rel into the nucleus and occurs shortly after LPS induction. Transfection experiments with reporter constructs driven by this kappa B element indicate strong inducibility by LPS and p65, moderate inducibility by c-Rel and repression by p50. Functional activity of sandwich TNF-CAT-TNF constructs further suggests that LPS-inducible transcriptional activation of the TNF gene in murine macrophages may be partly mediated by a downstream enhancer.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,MOLEC IMMUNOREGULAT LAB,FREDERICK,MD 21702; RUSSIAN ACAD SCI,VA ENGELHARDT MOLEC BIOL INST,CYTOKINE MOLEC BIOL LAB,MOSCOW,RUSSIA; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Kuprash, Dmitry/O-4899-2015; Nedospasov, Sergei/Q-7319-2016	Kuprash, Dmitry/0000-0002-1488-4148; Udalova, Irina/0000-0002-6716-2528	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; BIRAGYN A, 1995, IN PRESS J IMMUNOL, V155; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DROUET C, 1991, J IMMUNOL, V147, P1694; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GIROIR BP, 1992, P NATL ACAD SCI USA, V89, P4864, DOI 10.1073/pnas.89.11.4864; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRILLI M, 1993, INT REV CYTOL, V143, P1; HAN J, 1991, J IMMUNOL, V146, P1843; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JONGENEEL CV, 1989, EUR J IMMUNOL, V19, P549; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P561; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KOCHEL T, 1992, ONCOGENE, V7, P567; KUHNERT P, 1991, GENE, V102, P171, DOI 10.1016/0378-1119(91)90075-M; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUPRASH D, 1993, TUMOR NECROSIS FACTOR : MOLECULAR AND CELLULAR BIOLOGY AND CLINICAL RELEVANCE, P19; KUPRASH DV, 1994, P ACAD SCI USSR DOKL, V337, P658; LATTION AL, 1992, MOL CELL BIOL, V12, P5217, DOI 10.1128/MCB.12.11.5217; LAWTON P, 1995, J IMMUNOL, V154, P239; LAYBOURN PJ, 1994, SCIENCE, V257, P1682; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; OHMORI Y, 1994, J BIOL CHEM, V269, P17684; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEMON D, 1987, NUCLEIC ACIDS RES, V15, P9083, DOI 10.1093/nar/15.21.9083; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TURETSKAYA RL, 1992, TUMOR NECROSIS FACTO, P35; WIRTH T, 1988, EMBO J, V7, P3109, DOI 10.1002/j.1460-2075.1988.tb03177.x	67	111	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					97	106						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624137				2022-12-17	WOS:A1995RJ29500012
J	FELLER, SM; KNUDSEN, B; HANAFUSA, H				FELLER, SM; KNUDSEN, B; HANAFUSA, H			CELLULAR PROTEINS BINDING TO THE FIRST SRC HOMOLOGY-3 (SH3) DOMAIN OF THE PROTOONCOGENE PRODUCT C-CRK INDICATE CRK-SPECIFIC SIGNALING PATHWAYS	ONCOGENE			English	Article						CRK; SH3; SIGNAL TRANSDUCTION; CRKL; BLOT ASSAY	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; PHOSPHOTYROSINE-CONTAINING PROTEINS; ADAPTER PROTEIN; CYTOPLASMIC PROTEIN; SARCOMA-VIRUS; V-CRK; RAS; GRB2; IDENTIFICATION	The widely expressed c-Crk protein, composed of one SH2 and two SH3 domains, lacks an apparent catalytic domain, suggesting that it functions through the formation of specific complexes with other proteins. Bacterially expressed c-Crk formed in vitro highly stable complexes via the first SH3 domain [SH3(N)]. Most prominent were a 185 kDa protein of unknown identity (p185), Sos- immunoreactive bands of 170 kDa (p170) and 145 to 155 kDa bands, corresponding to the recently cloned C3G protein. p170 also bound to Ash/Grb2 and Nck while p185 and C3G bound only to Crk, Additional Crk binding proteins were found in hematopoietic cells, particularly the myeloid-monocytic lineage. The protein binding properties of Crk were subsequently compared to CRKL, the product of a homologous but distinct gene, and found to be very similar. The binding of two guanine nucleotide exchange factors, Sos and C3G, to Crk and CRKL indicates that Ras or related proteins likely play a role in signaling through Crk family proteins.			FELLER, SM (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.							ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, IN PRESS J BIOL CHEM; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1992, BIOCHEMISTRY-US, V31, P3044, DOI 10.1021/bi00127a003; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, IN PRESS METH ENZYMO; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, STRUCT BIOL, V1, P221; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SECHLER JMG, 1989, J IMMUNOL METHODS, V119, P277, DOI 10.1016/0022-1759(89)90407-9; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SUDOL M, 1994, ONCOGENE, V9, P2145; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TSUCHIE H, 1989, ONCOGENE, V4, P1281; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	70	111	113	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1465	1473						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731701				2022-12-17	WOS:A1995QU68100001
J	EDELHOFF, S; AYER, DE; ZERVOS, AS; STEINGRIMSSON, E; JENKINS, NA; COPELAND, NG; EISENMAN, RN; BRENT, R; DISTECHE, CM				EDELHOFF, S; AYER, DE; ZERVOS, AS; STEINGRIMSSON, E; JENKINS, NA; COPELAND, NG; EISENMAN, RN; BRENT, R; DISTECHE, CM			MAPPING OF 2 GENES ENCODING MEMBERS OF A DISTINCT SUBFAMILY OF MAX INTERACTING PROTEINS - MAD TO HUMAN-CHROMOSOME-2 AND MOUSE CHROMOSOME-6, AND MXI1 TO HUMAN-CHROMOSOME-10 AND MOUSE CHROMOSOME-19	ONCOGENE			English	Note							INSITU HYBRIDIZATION; DNA-SEQUENCES; LEUKEMIA; MYC; BINDING	Both the MAD and the MXI1 genes encode basic-helix-loop-helix-leucine zipper (bHLH-Zip) transcription factors which bind Max in vitro, forming a sequence-specific DNA-binding complex similar to the Myc-Max heterodimer. Mad and Myc compete for binding to Max. In addition, Mad has been shown to act as a transcriptional repressor while Myc appears to function as an activator. Mxi1 also appears to lack a transcriptional activation domain. Therefore, Mxi1 and Mad might antagonize Myc function and are candidate tumor suppressor genes. We report here the mapping of the MAD and MXI1 genes in human and mouse by fluorescence in situ hybridization (FISH) and by recombination mapping. The MAD gene was mapped to human chromosome 2 at band p13 by FISH and to mouse chromosome 6 by meiotic mapping. The MXI1 gene was mapped to human chromosome 10 at band q25 and on mouse chromosome 19 at region D by FISH. There was a second site of hybridization on mouse chromosome 2 at region C, which may represent a pseudogene or a related sequence. The mapping results confirm regions of conservation between human chromosome 2p13 and mouse chromosome 6 and between chromosome 10q25 and mouse chromosome 19D. Human chromosomes 2p13 and 10q25 have been involved in specific tumors where the role of Mad and Mxi1 can now he investigated.	UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Steingrimsson, Eirikur/0000-0001-5826-7486; Ayer, Donald/0000-0002-5595-3269	NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, IN PRESS GENES DEV; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; GILLADOGA AD, 1992, ONCOGENE, V7, P1249; Green EL, 1981, GENETICS PROBABILITY, P77; INABA T, 1991, LEUKEMIA, V5, P719; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KRETZNER L, 1992, NATURE, V359, P423; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MARTH JD, 1986, P NATL ACAD SCI USA, V83, P7841; MERTENS F, 1989, CANCER GENET CYTOGEN, V39, P227, DOI 10.1016/0165-4608(89)90189-1; MOORE KJ, 1992, GENOMICS, V12, P388, DOI 10.1016/0888-7543(92)90389-A; MOYZIS RK, 1987, CHROMOSOMA, V95, P375, DOI 10.1007/BF00333988; NADEAU JH, 1992, MAMM GENOME, V3, P480, DOI 10.1007/BF00778825; NEUMANN HPH, 1988, CANCER GENET CYTOGEN, V31, P41, DOI 10.1016/0165-4608(88)90009-X; OCHI H, 1988, JPN J CANCER RES, V79, P1024, DOI 10.1111/j.1349-7006.1988.tb00069.x; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RICHARDSON AL, 1992, ONCOGENE, V7, P961; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; 1990, CYTOGENET CELL GENET, V55, P1	26	111	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					665	668						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290278				2022-12-17	WOS:A1994MW24800036
J	KOVAR, H; AUINGER, A; JUG, G; ARYEE, D; ZOUBEK, A; SALZERKUNTSCHIK, M; GADNER, H				KOVAR, H; AUINGER, A; JUG, G; ARYEE, D; ZOUBEK, A; SALZERKUNTSCHIK, M; GADNER, H			NARROW SPECTRUM OF INFREQUENT P53 MUTATIONS AND ABSENCE OF MDM2 AMPLIFICATION IN EWING TUMORS	ONCOGENE			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; POLYMERASE CHAIN-REACTION; MURINE LEUKEMIA-VIRUS; RAS GENE-MUTATIONS; HUMAN BRAIN-TUMORS; MONOCLONAL-ANTIBODIES; REACTION PRODUCTS; MULTIPLE-MYELOMA; POINT MUTATIONS; HUMAN SARCOMAS	The p53 and MDM2 genes are part of a physiological pathway frequently impaired in human cancer. With the exception of tumours occasionally associated with hereditary predisposition, childhood malignancies have not been studied in detail vet. This is the first report on the analysis of p53 and MDM2 in a group of non-hereditary paediatric neoplasms referred to as the Ewing tumours (ETs). Thirty-seven primary tumours and cell lines from 19 patients were screened for the presence of p53 mutations. Only 5% of the primary tumour specimens were found to carry an alteration within this gene. However, p53 mutations were 10-fold enriched in ET cell lines, thus indicating a selective growth advantage in vitro. Strikingly, five out of nine alterations detected were missense mutations within codon 273, which were previously reported to impair only partially the normal p53 function. Two single-base substitutions occurred at codons 277 and 176, and two alterations were loss-of-function mutations. Investigation of the MDM2 gene revealed neither gene amplification in the primary tumours and cell lines nor significant overexpression in any of the cell lines. Our data therefore suggest that impairment of cellular mechanisms involving p53 is rare in a distinct group of childhood malignancies.	ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; UNIV VIENNA,INST PATHOL ANAT,VIENNA BONE TUMOR REGISTRY,A-1090 VIENNA,AUSTRIA	Saint Anna Children's Hospital; University of Vienna				Kovar, Heinrich/0000-0001-6873-9109				AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FELIX CA, 1992, CANCER RES, V52, P2243; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREBOURG T, 1992, CANCER RES, V52, P1; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JURGENS H, 1988, CANCER, V61, P23, DOI 10.1002/1097-0142(19880101)61:1<23::AID-CNCR2820610106>3.0.CO;2-M; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KOVAR H, 1990, ONCOGENE, V5, P1067; KOVAR H, 1991, NUCLEIC ACIDS RES, V19, P3507, DOI 10.1093/nar/19.13.3507; KOVAR H, 1992, ONCOGENE, V7, P2169; KOVAR H, 1993, IN PRESS CLIN CHEM E; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; LIPINSKI M, 1987, CANCER RES, V47, P183; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MEDCALF EA, 1992, ONCOGENE, V7, P71; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILLER CW, 1990, CANCER RES, V50, P7950; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUJOO K, 1987, CANCER RES, V47, P1098; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NERI A, 1991, HAEMATOLOGICA S4, V76, P31; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHGAKI H, 1991, CANCER RES, V51, P6202; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PORTIER M, 1992, ONCOGENE, V7, P2539; PREUDHOMME C, 1992, BRIT J HAEMATOL, V81, P440, DOI 10.1111/j.1365-2141.1992.tb08253.x; SAYLORS RL, 1991, CANCER RES, V51, P4721; SELS FT, 1992, ONCOGENE, V7, P643; SPINARDI L, 1991, NUCLEIC ACIDS RES, V19, P4009, DOI 10.1093/nar/19.14.4009; SPRUCK CH, 1992, CANCER RES, V52, P4787; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A	61	111	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2683	2690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378080				2022-12-17	WOS:A1993LX34300009
J	WRIGHT, PA; LEMOINE, NR; GORETZKI, PE; WYLLIE, FS; BOND, J; HUGHES, C; ROHER, HD; WILLIAMS, ED; WYNFORDTHOMAS, D				WRIGHT, PA; LEMOINE, NR; GORETZKI, PE; WYLLIE, FS; BOND, J; HUGHES, C; ROHER, HD; WILLIAMS, ED; WYNFORDTHOMAS, D			MUTATION OF THE P53-GENE IN A DIFFERENTIATED HUMAN THYROID-CARCINOMA CELL-LINE, BUT NOT IN PRIMARY THYROID-TUMORS	ONCOGENE			English	Note							P53 GENE; ENZYMATIC AMPLIFICATION; RAS ONCOGENE; LUNG-CANCER; CDNA CLONE; TRANSFORMATION; ANTIGEN; DNA; PROTEIN; GROWTH	The p53 gene has been implicated as a tumour suppressor, with mutations occurring in many carcinomas, such as colon, breast and lung. We have sequenced exons 5, 7 and 8 containing conserved gene regions in the only available differentiated thyroid follicular carcinoma cell line and found a mutation at position 273, Arg --> His, with no normal allele present. The same mutation was also present in DNA from the tumour of origin. However immunohistochemical analysis of 129 human thyroid tumours using a panel of p53 antibodies was unequivocally negative. Southern blotting in 20 cases failed to demonstrate any deletion or rearrangement, and direct genomic sequencing of 20 carcinomas showed normal DNA sequence for exons 5, 7 and 8. Thus p53 abnormalities may not be important in human thyroid carcinogenesis, in contrast to colon, breast and lung. However, the FTC 133 cell line was only established after 132 unsuccessful attempts with other differentiated thyroid follicular tumours. Since this line and the corresponding tumour of origin have a p53 mutation, we propose that p53 mutation may confer on thyroid follicular tumour cells the ability to grow in culture. This has potential applications for the future development of thyroid carcinoma cell lines.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL UNIT,LONDON W12 0HS,ENGLAND; UNIV DUSSELDORF,DEPT SURG,W-4000 DUSSELDORF 1,GERMANY	Cancer Research UK; Imperial College London; Heinrich Heine University Dusseldorf	WRIGHT, PA (corresponding author), UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOUR BIOL RES GRP,HEATH PK,CARDIFF CF4 4XN,S GLAM,WALES.							ALLISON J, 1981, BIOCHEM J, V199, P725, DOI 10.1042/bj1990725; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BENDAVID Y, 1988, ONCOGENE, V3, P179; Boenisch T, 1989, HDB IMMUNOCHEMICAL S, P13; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORETZKI PE, 1989, ANN ENDOCRINOL, V50, P145; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROSSER J, 1990, ONCOGENE, V5, P1573; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; WRIGHT PA, 1990, J PATHOL, V162, P99, DOI 10.1002/path.1711620203; WYNFORDTHOMAS D, 1985, EXP CELL RES, V159, P191, DOI 10.1016/S0014-4827(85)80048-3; WYNFORDTHOMAS D, 1990, MOL CELL BIOL, V10, P5365, DOI 10.1128/MCB.10.10.5365	32	111	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1693	1697						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923534				2022-12-17	WOS:A1991GX27400028
J	MORRIS, JDH; PRICE, B; LLOYD, AC; SELF, AJ; MARSHALL, CJ; HALL, A				MORRIS, JDH; PRICE, B; LLOYD, AC; SELF, AJ; MARSHALL, CJ; HALL, A			SCRAPE-LOADING OF SWISS 3T3 CELLS WITH RAS PROTEIN RAPIDLY ACTIVATES PROTEIN KINASE-C IN THE ABSENCE OF PHOSPHOINOSITIDE HYDROLYSIS	ONCOGENE			English	Article											MORRIS, JDH (corresponding author), ROYAL CANC HOSP,INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND.							ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1988, ONCOGENE, V3, P187; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; MAHADEVAN LC, 1987, EMBO J, V6, P921, DOI 10.1002/j.1460-2075.1987.tb04839.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; PENNINGTON SR, 1988, FEBS LETT, V227, P203, DOI 10.1016/0014-5793(88)80899-8; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P556; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	39	111	112	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					27	31						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2536916				2022-12-17	WOS:A1989U567400004
J	VANDEVIJVER, MJ; MOOI, WJ; WISMAN, P; PETERSE, JL; NUSSE, R				VANDEVIJVER, MJ; MOOI, WJ; WISMAN, P; PETERSE, JL; NUSSE, R			IMMUNOHISTOCHEMICAL DETECTION OF THE NEU PROTEIN IN TISSUE-SECTIONS OF HUMAN-BREAST TUMORS WITH AMPLIFIED NEU DNA	ONCOGENE			English	Article									NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DEPT PATHOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute				van de Vijver, Marc/0000-0002-0385-4787				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HAUSTEIN D, 1975, BIOCHEMISTRY-US, V14, P1826, DOI 10.1021/bi00680a004; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765	14	111	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					175	178						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285295				2022-12-17	WOS:A1988M086000011
J	Wang, SX; Jia, MM; He, ZK; Liu, XS				Wang, Shixiang; Jia, Mingming; He, Zaoke; Liu, Xue-Song			APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer	ONCOGENE			English	Article							MULTIPLE HUMAN CANCERS; PD-1 BLOCKADE; BREAST-CANCER; EXPRESSION PROFILES; ADVANCED MELANOMA; ADENOCARCINOMA; MUTAGENESIS; TUMORS; HYPERMUTATION; INFILTRATION	Non-small cell lung cancer (NSCLC) is known to carry heavy mutation load. Besides smoking, cytidine deaminase APOBEC3B plays a key role in the mutation process of NSCLC. APOBEC3B is also reported to be upregulated and predicts bad prognosis in NSCLC. However, targeting APOBEC3B high NSCLC is still a big challenge. Here we show that APOBEC3B upregulation is significantly associated with immune gene expression, and APOBEC3B expression positively correlates with known immunotherapy response biomarkers, including: PD-L1 expression and T-cell infiltration in NSCLC. Importantly, APOBEC mutational signature is specifically enriched in NSCLC patients with durable clinical benefit after immunotherapy and APOBEC mutation count can be better than total mutation in predicting immunotherapy response. In together, this work provides evidence that APOBEC3B upregulation and APOBEC mutation count can be used as novel predictive markers in guiding NSCLC checkpoint blockade immunotherapy.	[Wang, Shixiang; Jia, Mingming; He, Zaoke; Liu, Xue-Song] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China; [Wang, Shixiang; Jia, Mingming; He, Zaoke] Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai, Peoples R China; [Wang, Shixiang; Jia, Mingming; He, Zaoke] Univ Chinese Acad Sci, Beijing, Peoples R China	ShanghaiTech University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Liu, XS (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China.	liuxs@shanghaitech.edu.cn	Liu, Xue-Song/ADF-2183-2022; Wang, Shixiang/ABF-1926-2021	Liu, Xue-Song/0000-0002-7736-0077; Wang, Shixiang/0000-0001-9855-7357; He, Zaoke/0000-0002-5756-3862; Jia, Mingming/0000-0002-8757-5856	Shanghai Pujiang Program [16PJ1407400]; National Natural Science Foundation of China [31771373]; ShanghaiTech University.	Shanghai Pujiang Program(Shanghai Pujiang Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ShanghaiTech University.	We are grateful to the TCGA research network (http://cancergenome.nih.gov/), and the Broad-Novartis Cancer Cell Line Encyclopedia (http://www.broadinstitute.org/ccle/home) for providing the data analyzed in this manuscript. We thank Raymond Shuter for editing the text. We also thank Pengfei Lv of ShanghaiTech for the critical discussions. This work was supported in part by the Shanghai Pujiang Program (16PJ1407400), the National Natural Science Foundation of China (31771373) and startup funding from ShanghaiTech University.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Boichard A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284719; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Cescon DW, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1069-y; Chan K, 2015, NAT GENET, V47, P1067, DOI 10.1038/ng.3378; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Danaher P, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0215-8; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Dong ZY, 2016, TUMOR BIOL, V37, P4251, DOI 10.1007/s13277-016-4812-9; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Leonard B, 2015, CANCER RES, V75, P4538, DOI 10.1158/0008-5472.CAN-15-2171-T; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Maruyama W, 2016, BIOCHEM BIOPH RES CO, V478, P1466, DOI 10.1016/j.bbrc.2016.08.148; Middlebrooks CD, 2016, NAT GENET, V48, P1330, DOI 10.1038/ng.3670; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Refsland EW, 2013, CURR TOP MICROBIOL, V371, P1, DOI 10.1007/978-3-642-37765-5_1; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2; Roberts SA, 2014, NAT REV CANCER, V14, P786, DOI 10.1038/nrc3816; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Saini N, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006385; Sasaki H, 2014, BIOMED REP, V2, P392, DOI 10.3892/br.2014.256; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Shi JX, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002162; Shukuya T, 2016, J THORAC ONCOL, V11, P976, DOI 10.1016/j.jtho.2016.02.015; Smid M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12910; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Starrett GJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12918; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swanton C, 2015, CANCER DISCOV, V5, P704, DOI 10.1158/2159-8290.CD-15-0344; Tang HD, 2016, CANCER CELL, V29, P285, DOI 10.1016/j.ccell.2016.02.004; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Ulloa-Montoya F, 2013, J CLIN ONCOL, V31, P2388, DOI 10.1200/JCO.2012.44.3762; Wang E, 2013, J CLIN ONCOL, V31, P2369, DOI 10.1200/JCO.2013.49.2157; Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369; Yan SM, 2016, J CANCER, V7, P618, DOI 10.7150/jca.14030	51	110	111	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3924	3936		10.1038/s41388-018-0245-9	http://dx.doi.org/10.1038/s41388-018-0245-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29695832	Green Published, hybrid			2022-12-17	WOS:000439101300002
J	Lim, SY; Yuzhalin, AE; Gordon-Weeks, AN; Muschel, RJ				Lim, S. Y.; Yuzhalin, A. E.; Gordon-Weeks, A. N.; Muschel, R. J.			Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells	ONCOGENE			English	Article							CALCIUM-BINDING PROTEINS; MYELOID CELLS; MATRIX METALLOPROTEINASES; OXIDATIVE MODIFICATIONS; ROLES; METASTASIS; DIFFERENTIATION; INFLAMMATION; RECRUITMENT; PROGRESSION	Myeloid cells promote the development of distant metastases, but little is known about the molecular mechanisms underlying this process. Here we have begun to uncover the effects of myeloid cells on cancer cells in a mouse model of liver metastasis. Monocytes/macrophages, but not granulocytes, isolated from experimental liver metastases stimulated migration and invasion of MC38 colon and Lewis lung carcinoma cells. In response to conditioned media from tumor-infiltrating monocytes/macrophages, cancer cells upregulated S100a8 and S100a9 messenger RNA expression through an extracellular signal-related kinase-dependent mechanism. Suppression of S100A8 and S100A9 in cancer cells using short hairpin RNA significantly diminished migration and invasion in culture. Downregulation of S100A8 and S100A9 had no effect on subcutaneous tumor growth. However, colony size was greatly reduced in liver metastases with decreased invasion into adjacent tissue. In tissue culture and in the liver colonies derived from cancer cells with knockdown of S100A8 and S100A9, MMP2 and MMP9 expression was decreased, consistent with the reduction in migration and invasion. Our findings demonstrate that monocytes/macrophages in the metastatic liver microenvironment induce S100A8 and S100A9 in cancer cells, and that these proteins are essential for tumor cell migration and invasion. S100A8 and S100A9, however, are not responsible for stimulation of proliferation. This study implicates S100A8 and S100A9 as important mediators of tumor cell aggressiveness, and highlights the therapeutic potential of S100A8 and S100A9 for interference of metastasis.	[Lim, S. Y.; Yuzhalin, A. E.; Gordon-Weeks, A. N.; Muschel, R. J.] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Oxford, England	University of Oxford	Muschel, RJ (corresponding author), Univ Oxford, Dept Oncol, Old Rd Campus,Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.	ruth.muschel@oncology.ox.ac.uk	Yuzhalin, Arseniy E./J-3951-2013; Gordon-Weeks, Alex/L-1831-2019	Yuzhalin, Arseniy E./0000-0001-7454-6653; Gordon-Weeks, Alex/0000-0003-2997-4194; Lim, Su Yin/0000-0001-9576-5441; Muschel, Ruth/0000-0002-5656-5970	CRUK; CRUK Oxford Cancer Centre; Cancer Research UK [20407] Funding Source: researchfish	CRUK(Cancer Research UK); CRUK Oxford Cancer Centre; Cancer Research UK(Cancer Research UK)	This study was supported by CRUK funding to the Oxford Institute for Radiation Oncology and Biology and by the CRUK Oxford Cancer Centre.	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x; Arai K, 2008, CURR CANCER DRUG TAR, V8, P243, DOI 10.2174/156800908784533445; Bozzuto G, 2010, ANN I SUPER SANITA, V46, P66, DOI 10.4415/ANN_10_01_09; Souto JC, 2011, MED RES REV, V31, P311, DOI 10.1002/med.20185; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheng PY, 2008, J EXP MED, V205, P2235, DOI 10.1084/jem.20080132; Cross SS, 2005, HISTOPATHOLOGY, V46, P256, DOI 10.1111/j.1365-2559.2005.02097.x; DeNardo D, 2010, CANCER METAST REV, V29, P309, DOI 10.1007/s10555-010-9223-6; Duan L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062092; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; Hermani A, 2005, CLIN CANCER RES, V11, P5146, DOI 10.1158/1078-0432.CCR-05-0352; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; KOHN EC, 1994, J BIOL CHEM, V269, P21505; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Leukert N, 2006, J MOL BIOL, V359, P961, DOI 10.1016/j.jmb.2006.04.009; Lim SY, 2008, J IMMUNOL, V181, P5627, DOI 10.4049/jimmunol.181.8.5627; Lim SY, 2015, HEPATOLOGY, V62, P521, DOI 10.1002/hep.27838; Lim SY, 2011, ANTIOXID REDOX SIGN, V15, P2235, DOI 10.1089/ars.2010.3641; Lim SY, 2010, J BIOL CHEM, V285, P14377, DOI 10.1074/jbc.M109.075242; Lim SY, 2009, J LEUKOCYTE BIOL, V86, P577, DOI 10.1189/jlb.1008608; LOHI J, 1995, J BIOL CHEM, V270, P17602, DOI 10.1074/jbc.270.29.17602; Luschen S, 2005, EXP CELL RES, V310, P33, DOI 10.1016/j.yexcr.2005.07.022; Moon A, 2008, MOL CANCER RES, V6, P1544, DOI 10.1158/1541-7786.MCR-08-0189; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Raymond E, 2014, CANCER CHEMOTH PHARM, V73, P1, DOI 10.1007/s00280-013-2321-8; Ryckman C, 2003, J IMMUNOL, V170, P3233, DOI 10.4049/jimmunol.170.6.3233; Srikrishna G, 2012, J INNATE IMMUN, V4, P31, DOI 10.1159/000330095; Strupat K, 2000, J AM SOC MASS SPECTR, V11, P780, DOI 10.1016/S1044-0305(00)00150-1; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wu CY, 2009, GLIA, V57, P1775, DOI 10.1002/glia.20890; Yong HY, 2007, ARCH PHARM RES, V30, P75, DOI 10.1007/BF02977781; Zhao L, 2013, HEPATOLOGY, V57, P829, DOI 10.1002/hep.26094	44	110	114	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5735	5745		10.1038/onc.2016.107	http://dx.doi.org/10.1038/onc.2016.107			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27086923	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000386998400005
J	Yang, J; Zhang, Z; Chen, C; Liu, Y; Si, Q; Chuang, TH; Li, N; Gomez-Cabrero, A; Reisfeld, RA; Xiang, R; Luo, Y				Yang, J.; Zhang, Z.; Chen, C.; Liu, Y.; Si, Q.; Chuang, T-H; Li, N.; Gomez-Cabrero, A.; Reisfeld, R. A.; Xiang, R.; Luo, Y.			MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene	ONCOGENE			English	Article						tumor-associated macrophages; tumor microenvironment; Fra-1; miR-19a-3p	TUMOR; INVASION; MIGRATION; CELLS; INVASIVENESS; DIAGNOSTICS; PROGNOSIS; PROMOTES; IL-6; FOS	One of the hallmarks of malignancy is the polarization of tumor-associated macrophages (TAMs) from a pro-immune (M1-like) phenotype to an immune-suppressive (M2-like) phenotype. However, the molecular basis of the process is still unclear. MicroRNA (miRNA) comprises a group of small, non-coding RNAs that are broadly expressed by a variety of organisms and are involved in cell behaviors such as suppression or promotion of tumorigenesis. Here, we demonstrate that miR-19a-3p, broadly conserved among vertebrates, was downregulated in RAW264.7 macrophage cells of the M2 phenotype in conditoned medium of 4T1 mouse breast tumor cells. This downregulation correlated with an increased expression of the Fra-1 gene, which was reported to act as a pro-oncogene by supporting the invasion and progression of breast tumors. We found significant upregulation of miR-19a-3p in RAW264.7 macrophages after transfection with a miR-19a-3p mimic that resulted in a significant suppression of the expression of this gene. In addition, we could measure the activity of binding between miR-19a-3p and Fra-1 with a psiCHECK luciferase reporter system. Further, transfection of RAW264.7 macrophage cells with the miR-19a-3p mimic decreased the expression of the Fra-1 downstream genes VEGF, STAT3 and pSTAT3. Most importantly, the capacity of 4T1 breast tumor cells to migrate and invade was impaired in vivo by the intratumoral injection of miR-19a-3p. Taken together, these findings indicate that miR-19a-3p is capable of downregulating the M2 phenotype in M2 macrophages and that the low expression of this miRNA has an important role in the upregulation of Fra-1 expression and induction of M2 macrophage polarization.	[Yang, J.; Chen, C.; Liu, Y.; Si, Q.; Luo, Y.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Beijing 100730, Peoples R China; [Yang, J.; Chen, C.; Liu, Y.; Si, Q.; Luo, Y.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Yang, J.; Zhang, Z.; Li, N.; Xiang, R.] Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China; [Chuang, T-H] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Gomez-Cabrero, A.; Reisfeld, R. A.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nankai University; National Health Research Institutes - Taiwan; Scripps Research Institute	Xiang, R (corresponding author), Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China.	rxiang@nankai.edu.cn; yunpingluo@hotmail.com	Chuang, Tsung-Hsien/F-9679-2010; Yang, Jian/E-1051-2015		Major State Basic Research Development Program of China (973 program) [2013CB967202]; National Science Foundation of China (NSFC) [91029734, 81071711]; Department of Defense grant [BC097723];  [30830096];  [09ZCZDSF04000]	Major State Basic Research Development Program of China (973 program)(National Basic Research Program of China); National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Department of Defense grant(United States Department of Defense); ; 	This work was supported by grants from the Major State Basic Research Development Program of China (973 program): grant no. 2013CB967202 (to YL); the National Science Foundation of China (NSFC): grant no. 91029734 and 81071711 (to YL); grant nos 30830096 and 09ZCZDSF04000 (to RX); and Department of Defense grant, grant no. BC097723 (to RAR).	Babykutty S, 2012, CLIN EXP METASTAS, V29, P471, DOI 10.1007/s10585-012-9464-6; Bluml S, 2011, ARTHRITIS RHEUM-US, V63, P1281, DOI 10.1002/art.30281; Chandrasekar B, 2006, J BIOL CHEM, V281, P15099, DOI 10.1074/jbc.M600200200; Cubillos-Ruiz JR, 2012, ONCOIMMUNOLOGY, V1, P968, DOI 10.4161/onci.20020; De Vito C, 2012, CANCER CELL, V21, P807, DOI 10.1016/j.ccr.2012.04.023; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Eulalio A, 2012, RNA BIOL, V9, P742, DOI 10.4161/rna.20018; Garzon R, 2012, CURR OPIN ONCOL, V24, P655, DOI 10.1097/CCO.0b013e328358522c; Giordano S, 2013, HEPATOLOGY, V57, P840, DOI 10.1002/hep.26095; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Kesari S, 2011, CANCER BIOL THER, V11, P307, DOI 10.4161/cbt.11.3.14718; Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Liu DF, 2012, J CLIN INVEST, V122, P2221, DOI 10.1172/JCI59535; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Mizoguchi F, 2010, J CELL BIOCHEM, V109, P866, DOI 10.1002/jcb.22228; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Setoyama Tetsuro, 2011, Keio Journal of Medicine, V60, P106; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Singh PK, 2012, NAT REV GASTRO HEPAT, V9, P334, DOI 10.1038/nrgastro.2012.63; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood-2010-10-311415; Tai SK, 2012, J IMMUNOL, V188, P2464, DOI 10.4049/jimmunol.1101101; Thomas RM, 2012, CLIN CANCER RES, V18, P4482, DOI 10.1158/1078-0432.CCR-12-2089; Usui A, 2012, CANCER-AM CANCER SOC, V118, P3387, DOI 10.1002/cncr.26652; Valleron W, 2012, BLOOD, V120, P3997, DOI 10.1182/blood-2012-06-438135; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yang M, 2012, ARTERIOSCL THROM VAS, V32, P1675, DOI 10.1161/ATVBAHA.112.248732; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Yang WW, 2012, J BIOL CHEM, V287, P40140, DOI 10.1074/jbc.M112.348763	39	110	119	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3014	3023		10.1038/onc.2013.258	http://dx.doi.org/10.1038/onc.2013.258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23831570				2022-12-17	WOS:000337232200008
J	Vereide, DT; Seto, E; Chiu, YF; Hayes, M; Tagawa, T; Grundhoff, A; Hammerschmidt, W; Sugden, B				Vereide, D. T.; Seto, E.; Chiu, Y-F; Hayes, M.; Tagawa, T.; Grundhoff, A.; Hammerschmidt, W.; Sugden, B.			Epstein-Barr virus maintains lymphomas via its miRNAs	ONCOGENE			English	Article						EBV; BART miRNAs; apoptosis; RISC-IP; Burkitt's lymphoma	HUMAN GAMMA-HERPESVIRUSES; MICRORNA TARGETS; DOWN-REGULATION; LMP1 ONCOGENE; PROTEIN; EBV; EXPRESSION; APOPTOSIS; CELLS; BIM	Epstein-Barr virus (EBV) has evolved exquisite controls over its host cells, human B lymphocytes, not only directing these cells during latency to proliferate and thereby expand the pool of infected cells, but also to survive and thereby persist for the lifetime of the infected individual. Although these activities ensure the virus is successful, they also make the virus oncogenic, particularly when infected people are immunosuppressed. Here we show, strikingly, that one set of EBVs microRNAs (miRNAs) both sustain Burkitt's lymphoma (BL) cells in the absence of other viral oncogenes and promote the transformation of primary B lymphocytes. BL cells were engineered to lose EBV and found to die by apoptosis and could be rescued by constitutively expressing viral miRNAs in them. Two of these EBV miRNAs were found to target caspase 3 to inhibit apoptosis at physiological concentrations.	[Vereide, D. T.; Chiu, Y-F; Hayes, M.; Sugden, B.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; [Seto, E.; Tagawa, T.; Hammerschmidt, W.] DZIF German Ctr Infect Res, Res Unit Gene Vectors, Munich, Germany; [Seto, E.; Tagawa, T.; Hammerschmidt, W.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Munich, Germany; [Grundhoff, A.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany	University of Wisconsin System; University of Wisconsin Madison; German Center for Infection Research; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Heinrich Pette Institute	Sugden, B (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Room 814,1400 Univ Ave, Madison, WI 53706 USA.	sugden@oncology.wisc.edu	Hammerschmidt, Wolfgang/ABG-3921-2021; Tagawa, Takanobu/AAZ-2351-2021; Chiu, Ya-Fang/AAS-7536-2020	Hammerschmidt, Wolfgang/0000-0002-4659-0427; Tagawa, Takanobu/0000-0001-8637-2996; Chiu, Ya-Fang/0000-0002-7506-9032; Grundhoff, Adam/0000-0003-0940-7045	National Cancer Institute, National Institutes of Health [P01 CA022443, R01 CA133027, R01 CA070723]; Deutsche Forschungsgemeinschaft [SFB455, SEBTR5]; National Cancer Center; DAAD, German Academic Exchange Service; NATIONAL CANCER INSTITUTE [P01CA022443, R01CA133027, P30CA014520, T32CA009135, R01CA070723] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Cancer Center; DAAD, German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alan Rickinson for kindly providing the early passage BL cell lines and Dagmar Pich for her invaluable support This work was funded by grants from the National Cancer Institute, National Institutes of Health (grant P01 CA022443, grants R01 CA133027 and R01 CA070723) and Deutsche Forschungsgemeinschaft (grants SFB455 and SEBTR5). David Vereide was supported by a predoctoral fellowship from the National Cancer Center. Takanobu Tagawa is supported by a predoctoral grant of DAAD, German Academic Exchange Service, Bill Sugden is an American Cancer Society Research Professor,	Altmann M, 2005, PLOS BIOL, V3, P2148, DOI 10.1371/journal.pbio.0030404; Anderton E, 2008, ONCOGENE, V27, P421, DOI 10.1038/sj.onc.1210668; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Dolken L, 2010, CELL HOST MICROBE, V7, P324, DOI 10.1016/j.chom.2010.03.008; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; Kuzembayeva M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047409; Lee DY, 2008, BLOOD, V111, P2280, DOI 10.1182/blood-2007-07-100032; Nanbo A, 2007, EMBO J, V26, P4252, DOI 10.1038/sj.emboj.7601853; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oliver PM, 2006, J EXP MED, V203, P731, DOI 10.1084/jem.20051407; Paschos K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000492; Pratt ZL, 2012, J VIROL, V86, P4380, DOI 10.1128/JVI.06966-11; Pratt ZL, 2009, VIROLOGY, V386, P387, DOI 10.1016/j.virol.2009.01.006; Pruitt KD, 2009, NUCLEIC ACIDS RES, V37, pD32, DOI 10.1093/nar/gkn721; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; Schafer A, 2007, VIROLOGY, V364, P21, DOI 10.1016/j.virol.2007.03.029; Seto E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001063; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Suffert G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002405; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vereide D, 2010, ADV CANCER RES, V108, P1, DOI 10.1016/S0065.230X(10)08004.8; Vereide DT, 2011, BLOOD, V117, P1977, DOI 10.1182/blood-2010-05-285791; Walz N, 2010, J VIROL, V84, P716, DOI 10.1128/JVI.01302-09	30	110	119	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1258	1264		10.1038/onc.2013.71	http://dx.doi.org/10.1038/onc.2013.71			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503461	Green Accepted			2022-12-17	WOS:000332631100006
J	Zhou, X; Hao, Q; Liao, J; Zhang, Q; Lu, H				Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.			Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress	ONCOGENE			English	Article						RPS14; p53; MDM2; RPS19; ribosomal stress	DIAMOND-BLACKFAN ANEMIA; N-TERMINAL DOMAIN; P53 ACTIVATION; NUCLEOLAR PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; CELL-PROLIFERATION; ONCOPROTEIN MDM2; UBIQUITIN LIGASE; C-TERMINUS	The MDM2-p53 feedback loop is crucially important for restricting p53 level and activity during normal cell growth and proliferation, and is thus subjected to dynamic regulation in order for cells to activate p53 upon various stress signals. Several ribosomal proteins, such as RPL11, RPL5, RPL23, RPL26 or RPS7, have been shown to have a role in regulation of this feedback loop in response to ribosomal stress. Here, we identify another ribosomal protein S14, which is highly associated with 5q-syndrome, as a novel activator of p53 by inhibiting MDM2 activity. We found that RPS14, but not RPS19, binds to the central acidic domain of MDM2, similar to RPL5 and RPL23, and inhibits its E3 ubiquitin ligase activity toward p53. This RPS14-MDM2 binding was induced upon ribosomal stress caused by actinomycin D or mycophenolic acid. Overexpression of RPS14, but not RPS19, elevated p53 level and activity, leading to G1 or G2 arrest. Conversely, knockdown of RPS14 alleviated p53 induction by these two reagents. Interestingly, knockdown of either RPS14 or RPS19 caused a ribosomal stress that led to p53 activation, which was impaired by further knocking down the level of RPL11 or RPL5. Together, our results demonstrate that RPS14 and RPS19 have distinct roles in regulating the MDM2-p53 feedback loop in response to ribosomal stress. Oncogene (2013) 32, 388-396; doi:10.1038/onc.2012.63; published online 5 March 2012	[Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Indiana Univ Sch Med, Ctr Canc, Indianapolis, IN USA; [Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H.] Tulane Univ, Sch Med, Ctr Canc, New Orleans, LA 70112 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Tulane University; Tulane University	Lu, H (corresponding author), Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA.	hlu2@tulane.edu	Zhou, Xiang/J-5046-2017	Zhou, Xiang/0000-0002-1172-7948	NIH-NCI [CA095441, CA 079721, CA129828]; NATIONAL CANCER INSTITUTE [R01CA079721, R01CA095441, R01CA129828] Funding Source: NIH RePORTER	NIH-NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Steven Ellis for reagents and discussion. This work was supported in part by NIH-NCI Grants CA095441, CA 079721 and CA129828 to HL.	Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Cmejla R, 2009, HUM MUTAT, V30, P321, DOI 10.1002/humu.20874; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holzel M, 2010, J BIOL CHEM, V285, P6364, DOI 10.1074/jbc.M109.054734; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Llanos S, 2010, CELL CYCLE, V9, P4005, DOI 10.4161/cc.9.19.13299; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Poyurovsky MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465; Poyurovsky MV, 2010, NAT STRUCT MOL BIOL, V17, P982, DOI 10.1038/nsmb.1872; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Yu WS, 2011, NUCLEIC ACIDS RES, V39, P2234, DOI 10.1093/nar/gkq1117; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	60	110	113	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2013	32	3					388	396		10.1038/onc.2012.63	http://dx.doi.org/10.1038/onc.2012.63			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22391559	Green Accepted			2022-12-17	WOS:000314736600012
J	Bulut, G; Hong, SH; Chen, K; Beauchamp, EM; Rahim, S; Kosturko, GW; Glasgow, E; Dakshanamurthy, S; Lee, HS; Daar, I; Toretsky, JA; Khanna, C; Uren, A				Bulut, G.; Hong, S-H; Chen, K.; Beauchamp, E. M.; Rahim, S.; Kosturko, G. W.; Glasgow, E.; Dakshanamurthy, S.; Lee, H-S; Daar, I.; Toretsky, J. A.; Khanna, C.; Ueren, A.			Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells	ONCOGENE			English	Article						ezrin; osteosarcoma; metastasis; small molecule screening; drug discovery	ERM PROTEINS; OSTEOGENIC-SARCOMA; PLASMA-MEMBRANE; BINDING-SITE; LINKER EZRIN; METASTASIS; EXPRESSION; SURVIVAL; IDENTIFICATION; CHEMOTHERAPY	Ezrin is a multifunctional protein that connects the actin cytoskeleton to the extracellular matrix through transmembrane proteins. High ezrin expression is associated with lung metastasis and poor survival in cancer. We screened small molecule libraries for compounds that directly interact with ezrin protein using surface plasmon resonance to identify lead compounds. The secondary functional assays used for lead compound selection included ezrin phosphorylation as measured by immunoprecipitation and in vitro kinase assays, actin binding, chemotaxis, invasion into an endothelial cell monolayer, zebrafish and Xenopus embryonic development, mouse lung organ culture and an in vivo lung metastasis model. Two molecules, NSC305787 and NSC668394, that directly bind to ezrin with low micromolar affinity were selected based on inhibition of ezrin function in multiple assays. They inhibited ezrin phosphorylation, ezrin-actin interaction and ezrin-mediated motility of osteosarcoma (OS) cells in culture. NSC305787 mimicked the ezrin morpholino phenotype, and NSC668394 caused a unique developmental defect consistent with reduced cell motility in zebrafish. Following tail vein injection of OS cells into mice, both molecules inhibited lung metastasis of ezrinsensitive cells, but not ezrin-resistant cells. The small molecule inhibitors NSC305787 and NSC668394 demonstrate a novel targeted therapy that directly inhibits ezrin protein as an approach to prevent tumor metastasis. Oncogene (2012) 31, 269-281; doi:10.1038/onc.2011.245; published online 27 June 2011	[Ueren, A.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, NRB, Washington, DC 20057 USA; [Hong, S-H; Khanna, C.] NCI, Tumor & Metastasis Biol Sect, Ctr Canc Res, Bethesda, MD 20892 USA; [Lee, H-S; Daar, I.] NCI, Lab Cell & Dev Signaling, Frederick, MD 21701 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Uren, A (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, NRB, 3970 Reservoir Rd NW,Room E312, Washington, DC 20057 USA.	au26@georgetown.edu	Lee, Hyun-Shik/G-3555-2011; , sivanesan/CAF-4258-2022; BULUT, GULAY/J-3180-2012	, sivanesan/0000-0003-3681-4121; Glasgow, Eric/0000-0001-7729-3954; Daar, Ira/0000-0003-2657-526X	Children's Cancer Foundation of Baltimore; US Department of Defense [W81XWH-10-1-0137]; Brandon Carrington Lee Foundation; Go4theGoal; Dani's Foundation; Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Burroughs Wellcome Clinical Scientist Award in Translational Research; NIH [R01CA133662, R01CA138212]; Cancer Center [P30 CA051008]; NATIONAL CANCER INSTITUTE [ZIABC010006, T32CA009686, ZIABC010566, ZIABC010958, ZIABC011024, R01CA138212, P30CA051008, R01CA133662] Funding Source: NIH RePORTER	Children's Cancer Foundation of Baltimore; US Department of Defense(United States Department of Defense); Brandon Carrington Lee Foundation; Go4theGoal; Dani's Foundation; Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Burroughs Wellcome Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for our work came from the Children's Cancer Foundation of Baltimore (AU), US Department of Defense (W81XWH-10-1-0137, AU), Brandon Carrington Lee Foundation (G.K., AU), Go4theGoal, Dani's Foundation, Alex's Lemonade Stand Foundation, Liddy Shriver Sarcoma Initiative, Burroughs Wellcome Clinical Scientist Award in Translational Research (JT), and the NIH R01CA133662 (JT), R01CA138212 (JT) and Cancer Center Support Grant P30 CA051008 for use of Biacore Molecular Interaction Shared Resource. We would like to thank to Dr Anthony Bretscher (Cornell University) for providing the WT Ezrin construct, Developmental Therapeutics Program, NCI for providing the small molecule libraries.	Bacci G, 2006, CANCER-AM CANCER SOC, V106, P2701, DOI 10.1002/cncr.21937; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BOGER DL, 1987, J MED CHEM, V30, P1918, DOI 10.1021/jm00393a040; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CASE DA, 2004, AMBER 8; Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595; DUNN D, 1977, CANCER-AM CANCER SOC, V40, P3054, DOI 10.1002/1097-0142(197712)40:6<3054::AID-CNCR2820400644>3.0.CO;2-A; Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006; Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Ferrari S, 2007, CURR OPIN ONCOL, V19, P341, DOI 10.1097/CCO.0b013e328122d73f; Fievet B, 2007, BBA-MOL CELL RES, V1773, P653, DOI 10.1016/j.bbamcr.2006.06.013; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Link V, 2006, J CELL SCI, V119, P2073, DOI 10.1242/jcs.02928; Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0; Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; Malmqvist M, 1999, BIOCHEM SOC T, V27, P335, DOI 10.1042/bst0270335; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Mendoza A, 2010, J CLIN INVEST, V120, P2979, DOI 10.1172/JCI40252; OHNMACHT CJ, 1971, J MED CHEM, V14, P926; Pang ST, 2004, UROLOGY, V63, P609, DOI 10.1016/j.urology.2003.09.068; Park HR, 2006, PATHOL RES PRACT, V202, P509, DOI 10.1016/j.prp.2006.01.015; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; ROSEN G, 1982, CANCER-AM CANCER SOC, V49, P1221, DOI 10.1002/1097-0142(19820315)49:6<1221::AID-CNCR2820490625>3.0.CO;2-E; ten Klooster JP, 2009, DEV CELL, V16, P551, DOI 10.1016/j.devcel.2009.01.016; Wan X, 2009, ONCOGENE, V28, P3401, DOI 10.1038/onc.2009.206; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Weng WH, 2005, CLIN CANCER RES, V11, P6198, DOI 10.1158/1078-0432.CCR-05-0548; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078-0432.CCR-07-1992	44	110	119	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	3					269	281		10.1038/onc.2011.245	http://dx.doi.org/10.1038/onc.2011.245			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21706056	Green Accepted, Bronze			2022-12-17	WOS:000299542100001
J	Park, SY; Jeong, KJ; Panupinthu, N; Yu, S; Lee, J; Han, JW; Kim, JM; Lee, JS; Kang, J; Park, CG; Mills, GB; Lee, HY				Park, S. Y.; Jeong, K. J.; Panupinthu, N.; Yu, S.; Lee, J.; Han, J. W.; Kim, J. M.; Lee, J-S; Kang, J.; Park, C. G.; Mills, G. B.; Lee, H. Y.			Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression	ONCOGENE			English	Article						lysophosphatidic acid; human hepatocellular carcinoma cells; invasion; LPA1; matrix metalloproteinase-9	CANCER; ACTIVATION; MIGRATION; AUTOTAXIN; SECRETION; MOTILITY; GENE	Lysophosphatidic acid (LPA), produced extracellularly by autotaxin (ATX), has diverse biological activities implicated in tumor initiation and progression, including increasing cell survival, angiogenesis, invasion and metastasis. ATX, LPA and the matrix metalloproteinase (MMP)-9 have all been implicated in hepatocellular carcinoma (HCC) invasion and metastasis. We, thus sought to determine whether ATX with subsequent LPA production and action, including induction of MMP-9 could provide a unifying mechanism. ATX transcripts and LPA receptor type 1 (LPA1) protein are elevated in HCC compared with normal tissues. Silencing or pharmacological inhibition of LPA1 significantly attenuated LPA-induced MMP-9 expression and HCC cell invasion. Further, reducing MMP-9 activity or expression significantly inhibits LPA-induced HCC cell invasion, demonstrating that MMP-9 is downstream of LPA1. Inhibition of phosphoinositide-3 kinase (PI3K) signaling or dominant-negative mutants of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK) abrogated LPA-induced MMP-9 expression and subsequent invasion. We thus demonstrate a mechanistic cascade of ATX-producing LPA with LPA activating LPA1 and inducing MMP-9 through coordinate activation of the PI3K and the p38 MPAK signaling cascades, providing novel biomarkers and potential therapeutic targets for HCC. Oncogene (2011) 30, 1351-1359; doi: 10.1038/onc.2010.517; published online 22 November 2010	[Park, S. Y.; Jeong, K. J.; Kang, J.; Park, C. G.; Lee, H. Y.] Konyang Univ, Dept Pharmacol, Coll Med, Taejon 302718, South Korea; [Panupinthu, N.; Yu, S.; Lee, J-S; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Lee, J.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Han, J. W.] Sungkyunkwan Univ, Dept Biochem & Mol Biol, Sch Pharm, Suwon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Canc Res Inst, Reg Canc Ctr, Taejon, South Korea; [Kim, J. M.] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon, South Korea	Konyang University; Konyang University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sungkyunkwan University (SKKU); Chungnam National University; Chungnam National University	Lee, HY (corresponding author), Konyang Univ, Dept Pharmacol, Coll Med, 821 Med Sci Bldg,681 Gasuwon Dong, Taejon 302718, South Korea.	hoi@konyang.ac.kr	Kang, Jaeku/D-4933-2011; Jeong, Kangjin/HGT-9268-2022	Kang, Jaeku/0000-0002-8660-7940; KIM, JIN MAN/0000-0003-0905-9730	Cancer Metastasis Research Center at Yonsei University; Ministry of Education, Science and Technology [2010-0022216]; Korean Institute of Environmental Science and Technology; Korea Science & Engineering Foundation through the Infection Signaling Network Research Center at Chungnam National University [R13-2007-020-01000-0]; Breast Cancer Research foundation; NCI [RO1CA092160]; NATIONAL CANCER INSTITUTE [R01CA092160] Funding Source: NIH RePORTER	Cancer Metastasis Research Center at Yonsei University; Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Institute of Environmental Science and Technology; Korea Science & Engineering Foundation through the Infection Signaling Network Research Center at Chungnam National University; Breast Cancer Research foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by the Korea Science and the Engineering Fund through the Cancer Metastasis Research Center at Yonsei University (HYL), by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0022216, HYL) and by the Korean Institute of Environmental Science and Technology and the Korea Science & Engineering Foundation through the Infection Signaling Network Research Center (R13-2007-020-01000-0) at Chungnam National University (JMK). GBM and NP are supported by a grant from the Breast Cancer Research foundation and NCI RO1CA092160.	Arii S, 1996, HEPATOLOGY, V24, P316; Boucharaba A, 2006, P NATL ACAD SCI USA, V103, P9643, DOI 10.1073/pnas.0600979103; Brinkmann V, 2007, PHARMACOL THERAPEUT, V115, P84, DOI 10.1016/j.pharmthera.2007.04.006; Byun HS, 2008, EXP MOL MED, V40, P186, DOI 10.3858/emm.2008.40.2.186; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hayasaka A, 1996, HEPATOLOGY, V24, P1058; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Jiang YF, 2000, WORLD J GASTROENTERO, V6, P61, DOI 10.3748/wjg.v6.i1.61; Kim JH, 2008, CHEM-BIOL INTERACT, V171, P133, DOI 10.1016/j.cbi.2007.07.008; Lee J, 2006, CLIN CANCER RES, V12, P6351, DOI 10.1158/1078-0432.CCR-06-1252; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; McKenna GJ, 2002, AM J SURG, V183, P588, DOI 10.1016/S0002-9610(02)00833-4; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Murph MM, 2008, BBA-MOL CELL BIOL L, V1781, P547, DOI 10.1016/j.bbalip.2008.04.007; Murph MM, 2003, J CELL SCI, V116, P1969, DOI 10.1242/jcs.00397; Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Seo EH, 2008, J MICROBIOL BIOTECHN, V18, P1606; Shida D, 2003, CANCER RES, V63, P1706; Simon C, 1998, CANCER RES, V58, P1135; SKILL NJ, 2009, J SURG RES IN PRESS; Wang DS, 2004, WORLD J GASTROENTERO, V10, P299; Woo JH, 2004, ONCOGENE, V23, P1845, DOI 10.1038/sj.onc.1207307; Wu JM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-71; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Zhang GX, 1999, CHINESE MED J-PEKING, V112, P330; Zhao Z, 1999, Zhonghua Gan Zang Bing Za Zhi, V7, P140; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	34	110	122	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1351	1359		10.1038/onc.2010.517	http://dx.doi.org/10.1038/onc.2010.517			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21102517				2022-12-17	WOS:000288492100009
J	Wiman, KG				Wiman, K. G.			Pharmacological reactivation of mutant p53: from protein structure to the cancer patient	ONCOGENE			English	Review						mutant p53; drug discovery; reactivation; apoptosis; cancer therapy	TUMOR-SUPPRESSOR; LEUKEMIA CELLS; RESCUE; RESTORATION; ACTIVATION; APOPTOSIS; MUTATIONS; CP-31398; PRIMA-1; GROWTH	The p53 tumor suppressor pathway blocks tumor development by triggering apoptosis or cellular senescence in response to oncogenic stress. A large fraction of human tumors carry p53 mutations that disrupt DNA binding of p53 and transcriptional regulation of target genes. Reconstitution of wild-type p53 in vivo triggers rapid elimination of tumors. Therefore, pharmacological reactivation of mutant p53 is a promising strategy for novel cancer therapy. Several approaches for identification of small molecules that target mutant p53 have been applied, including rational design and screening of chemical libraries. The compound PhiKan083 binds with high affinity to a crevice created by the Y220C mutation in p53 and stabilizes the mutant protein. The compound PRIMA-1 (p53 reactivation and induction of massive apoptosis) restores wild-type conformation to mutant p53 by binding to the core and induces apoptosis in human tumor cells. The PRIMA-1 analog APR-246 is currently tested in a clinical trial. Successful development of mutant p53-reactivating anticancer drugs should have a major impact on the treatment of cancer. Oncogene (2010) 29, 4245-4252; doi: 10.1038/onc.2010.188; published online 24 May 2010	Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X	Swedish Cancer Society; Swedish Medical Research Council; Cancer Society of Stockholm; EU	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Cancer Society of Stockholm; EU(European Commission)	I thank the Swedish Cancer Society (Cancerfonden), the Swedish Medical Research Council (VR), the Cancer Society of Stockholm (Cancerforeningen) and the EU 6th Framework Program for generous support. I am cofounder and shareholder of Aprea AB, a company that develops p53-based cancer therapy, and member of its board.	Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Bykov VJN, 2009, CELL CYCLE, V8, P2509, DOI 10.4161/cc.8.16.9382; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Donehower LA, 2009, NAT REV CANCER, V9, P830, DOI 10.1038/nrc2731; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Huang C, 2009, CANCER BIOL THER, V8, P2185, DOI 10.4161/cbt.8.22.10446; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nahi H, 2006, BRIT J HAEMATOL, V132, P230, DOI 10.1111/j.1365-2141.2005.05851.x; Nahi H, 2004, BRIT J HAEMATOL, V127, P285, DOI 10.1111/j.1365-2141.2004.05210.x; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029; Olivier M, 2005, 25 YEARS OF P53 RESEARCH, P321, DOI 10.1007/1-4020-2922-5_14; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shi LM, 1998, MOL PHARMACOL, V53, P241, DOI 10.1124/mol.53.2.241; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Weinmann L, 2008, CELL DEATH DIFFER, V15, P718, DOI 10.1038/sj.cdd.4402301; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zache N, 2008, CELL ONCOL, V30, P411, DOI 10.3233/CLO-2008-0440; Zache N, 2008, MOL ONCOL, V2, P70, DOI 10.1016/j.molonc.2008.02.004	55	110	116	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4245	4252		10.1038/onc.2010.188	http://dx.doi.org/10.1038/onc.2010.188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20498645				2022-12-17	WOS:000280547900001
J	Chuang, LSH; Ito, Y				Chuang, L. S. H.; Ito, Y.			RUNX3 is multifunctional in carcinogenesis of multiple solid tumors	ONCOGENE			English	Review						RUNX3; tumor suppressor; solid tumors; functional inactivation; TGF-beta; Wnt	ONCOGENE-INDUCED SENESCENCE; PIM-1 KINASE PHOSPHORYLATES; FOXO TRANSCRIPTION FACTORS; GASTRIC EPITHELIAL-CELLS; PROMOTER HYPERMETHYLATION; GENE-EXPRESSION; PROTEIN MISLOCALIZATION; CONFERS RESISTANCE; INSERTION LOCUS; DOWN-REGULATION	The study of RUNX3 in tumor pathogenesis is a rapidly expanding area of cancer research. Functional inactivation of RUNX3-through mutation, epigenetic silencing, or cytoplasmic mislocalization-is frequently observed in solid tumors of diverse origins. This alone indicates that RUNX3 inactivation is a major risk factor in tumorigenesis and that it occurs early during progression to malignancy. Conversely, RUNX3 has also been described to have an oncogenic function in a subset of tumors. Although the mechanism of how RUNX3 switches from tumor suppressive to oncogenic activity is unclear, this is of clinical relevance with implications for cancer detection and prognosis. Recent developments have significantly contributed to our understanding of the pleiotropic tumor suppressive properties of RUNX3 that regulate major signaling pathways. This review summarizes the important findings that link RUNX3 to tumor suppression. Oncogene (2010) 29, 2605-2615; doi:10.1038/onc.2010.88; published online 29 March 2010	[Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Canc Sci Inst, Singapore 138673, Singapore; [Chuang, L. S. H.; Ito, Y.] Natl Univ Singapore, Canc Biol Program, Canc Sci Inst Singapore, Singapore 138673, Singapore; [Ito, Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore	Ito, Y (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Canc Sci Inst, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg			Ministry of Education (MOE); National Research Foundation (NRF), Singapore	Ministry of Education (MOE)(Ministry of Education, Singapore); National Research Foundation (NRF), Singapore(National Research Foundation, Singapore)	This work was funded by the Ministry of Education (MOE) and National Research Foundation (NRF), Singapore. We give special thanks to Dr Kazuyoshi Kohu for his contribution of Figure 2.	Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Aho TL, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-21; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bae SC, 2003, EMBO REP, V4, P538, DOI 10.1038/sj.embor.embor875; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Brady G, 2009, J CELL PHYSIOL, V221, P283, DOI 10.1002/jcp.21880; Brady G, 2009, J VIROL, V83, P6909, DOI 10.1128/JVI.00216-09; Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cameron ER, 2004, ONCOGENE, V23, P4308, DOI 10.1038/sj.onc.1207130; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chen PC, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000092; Chen W, 2007, GENE CHROMOSOME CANC, V46, P288, DOI 10.1002/gcc.20411; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Fukushima-Nakase Y, 2005, BLOOD, V105, P4298, DOI 10.1182/blood-2004-08-3372; Gao F, 2009, J CANCER RES CLIN, V135, P739, DOI 10.1007/s00432-008-0508-x; Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Inoue KI, 2007, J BIOL CHEM, V282, P24175, DOI 10.1074/jbc.M703746200; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2009, ONCOGENE, V28, P1379, DOI 10.1038/onc.2008.496; Ito T, 2008, ASIAN ECON POLICY R, V3, P237, DOI 10.1111/j.1748-3131.2008.00107.x; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katayama Y, 2009, BIOCHEM BIOPH RES CO, V388, P496, DOI 10.1016/j.bbrc.2009.08.003; Kilbey A, 2008, CELL CYCLE, V7, P2333; Kilbey A, 2007, CANCER RES, V67, P11263, DOI 10.1158/0008-5472.CAN-07-3016; Kim HR, 2008, J CELL BIOCHEM, V105, P1048, DOI 10.1002/jcb.21906; Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Levanon D, 2009, BLOOD CELL MOL DIS, V43, P1, DOI 10.1016/j.bcmd.2009.01.009; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Miething C, 2007, P NATL ACAD SCI USA, V104, P4594, DOI 10.1073/pnas.0604716104; Motoda L, 2007, STEM CELLS, V25, P2976, DOI 10.1634/stemcells.2007-0061; Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805; Nevadunsky NS, 2009, GYNECOL ONCOL, V112, P325, DOI 10.1016/j.ygyno.2008.09.006; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Pande S, 2009, J CELL PHYSIOL, V218, P473, DOI 10.1002/jcp.21630; Pockwinse SM, 2006, J CELL PHYSIOL, V206, P354, DOI 10.1002/jcp.20469; Rahrmann EP, 2009, CANCER RES, V69, P4388, DOI 10.1158/0008-5472.CAN-08-3901; Sakakura C, 2007, ONCOGENE, V26, P5927, DOI 10.1038/sj.onc.1210403; Salto-Tellez M, 2006, ONCOGENE, V25, P7646, DOI 10.1038/sj.onc.1209739; Sato K, 2006, ONCOL REP, V15, P129; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Shi MJ, 1998, J IMMUNOL, V161, P6751; Snoeks L, 2009, LAB INVEST, V89, P1053, DOI 10.1038/labinvest.2009.66; Soong R, 2009, BRIT J CANCER, V100, P676, DOI 10.1038/sj.bjc.6604899; Spender LC, 2005, ONCOGENE, V24, P1873, DOI 10.1038/sj.onc.1208404; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; Subramaniam MM, 2009, AM J GASTROENTEROL, V104, P426, DOI 10.1038/ajg.2008.141; Tanaka Y, 2007, EXP CELL RES, V313, P3251, DOI 10.1016/j.yexcr.2007.06.012; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tsai WB, 2008, NAT CELL BIOL, V10, P460, DOI 10.1038/ncb1709; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wada M, 2004, ONCOGENE, V23, P2401, DOI 10.1038/sj.onc.1207395; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wolff EM, 2008, CANCER RES, V68, P6208, DOI 10.1158/0008-5472.CAN-07-6616; Wotton S, 2008, ONCOGENE, V27, P5856, DOI 10.1038/onc.2008.195; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yanada M, 2005, ONCOL REP, V14, P817; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang ZZ, 2008, CARCINOGENESIS, V29, P1973, DOI 10.1093/carcin/bgn183; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2009, CANCER RES, V69, P1089, DOI 10.1158/0008-5472.CAN-08-2997; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	102	110	125	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2010	29	18					2605	2615		10.1038/onc.2010.88	http://dx.doi.org/10.1038/onc.2010.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20348954				2022-12-17	WOS:000277354600001
J	Boily, G; He, XH; Pearce, B; Jardine, K; McBurney, MW				Boily, G.; He, X. H.; Pearce, B.; Jardine, K.; McBurney, M. W.			SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol	ONCOGENE			English	Article						oncogenesis; sirtuins; resveratrol	NF-KAPPA-B; PANCREATIC BETA-CELLS; COLON-CANCER GROWTH; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; REGULATES SIRT1; MOUSE SKIN; CELLULAR SENESCENCE; INSULIN-SECRETION	The function of the class III histone deacetylase, Sir2, in promoting lifespan extension is well established in small model organisms. By analogy, SirT1, the mammalian orthologue of Sir2, is a candidate gene to slow down aging and forestall the onset of age-associated diseases. We have used SirT1-null mice to study the function of SirT1 in susceptibility to tumorigenesis. The number of intestinal polyps induced in mice carrying the Apc(min) mutation was unaffected by the SirT1 genotype although the average polyp size was slightly smaller in the SirT1-null animals. Similarly, the presence or absence of SirT1 had no effect on incidence and tumor load of skin papillomas induced by the classical two-stage carcinogenesis protocol. We found that resveratrol topically applied to the skin profoundly reduced tumorigenesis. This chemoprotective effect was significantly reduced but not ablated in SirT1-null mice, suggesting that part of the protection afforded by resveratrol requires the SirT1-encoded protein. Thus, our results suggest that SirT1 does not behave like a classical tumor-suppressor gene but the antitumor activity of resveratrol is mediated at least in part by SirT1. Oncogene (2009) 28, 2882-2893; doi:10.1038/onc.2009.147; published online 8 June 2009	[McBurney, M. W.] Ottawa Hlth Res Inst, Ctr Canc Therapeut, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	McBurney, MW (corresponding author), Ottawa Hlth Res Inst, Ctr Canc Therapeut, Box 926,3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	mmcburney@ohri.ca			Canadian Institutes of Health Research; Fonds de Recherche en Sante du Quebec (FRSQ)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec)	We thank Christine Pratt for allowing us to use some of her chemicals. The projects were funded by the Canadian Institutes of Health Research. GB is a recipient of fellowship from the Fonds de Recherche en Sante du Quebec (FRSQ).	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cucciolla V, 2007, CELL CYCLE, V6, P2495, DOI 10.4161/cc.6.20.4815; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Duan CM, 2005, GEN COMP ENDOCR, V142, P44, DOI 10.1016/j.ygcen.2004.12.022; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001710; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kundu JK, 2006, BIOCHEM PHARMACOL, V72, P1506, DOI 10.1016/j.bcp.2006.08.005; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Moynihan KA, 2005, CELL METAB, V2, P105, DOI 10.1016/j.cmet.2005.07.001; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; ONO M, 1991, CELL GROWTH DIFFER, V2, P317; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107; Qin WP, 2006, J BIOL CHEM, V281, P21745, DOI 10.1074/jbc.M602909200; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Tiano HF, 2002, CANCER RES, V62, P3395; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van der Veer E, 2007, J BIOL CHEM, V282, P10841, DOI 10.1074/jbc.C700018200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; [王福 WANG Fu], 2008, [扬州大学学报. 自然科学版, Journal of Yangzhou University], V11, P20; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu YP, 2002, CANCER RES, V62, P1030; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang QJ, 2008, CARDIOVASC RES, V80, P191, DOI 10.1093/cvr/cvn224	60	110	112	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2009	28	32					2882	2893		10.1038/onc.2009.147	http://dx.doi.org/10.1038/onc.2009.147			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482VJ	19503100				2022-12-17	WOS:000268917100004
J	Rice, KL; Hormaeche, I; Licht, JD				Rice, K. L.; Hormaeche, I.; Licht, J. D.			Epigenetic regulation of normal and malignant hematopoiesis	ONCOGENE			English	Review						hematopoiesis; epigenetics; histone code; methylation; leukemia; acetylation	ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOID-LEUKEMIA; HISTONE ACETYLTRANSFERASE ACTIVITY; POLYCOMB GROUP PROTEINS; DOMAIN-CONTAINING GENE; T-CELL LYMPHOMA; PML-RAR-ALPHA; DNA METHYLATION; ARGININE METHYLATION	The molecular processes governing hematopoiesis involve the interplay between lineage- specific transcription factors and a series of epigenetic tags, including DNA methylation and covalent histone tail modifications, such as acetylation, methylation, phosphorylation, SUMOylation and ubiquitylation. These post- translational modifications, which collectively constitute the 'histone code', are capable of affecting chromatin structure and gene transcription and are catalysed by opposing families of enzymes, allowing the developmental potential of hematopoietic stem cells to be dynamically regulated. The essential role of these enzymes in regulating normal blood development is highlighted by the finding that members from all families of chromatin regulators are targets for dysregulation in many hematological malignancies, and that patterns of histone modification are globally affected in cancer as well as the regulatory regions of specific oncogenes and tumor suppressors. The discovery that these epigenetic marks can be reversed by compounds targeting aberrant transcription factor/ co- activator/ co- repressor interactions and histone- modifying activities, provides the basis for an exciting field in which the epigenome of cancer cells may be manipulated with potential therapeutic benefits.	Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Licht, JD (corresponding author), Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, Lurie 5-123,303 E Super St, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Licht, Jonathan/AAL-9184-2020; Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; 	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aagaard L, 1999, EMBO J, V18, P1923, DOI 10.1093/emboj/18.7.1923; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ahluwalia A, 2001, GYNECOL ONCOL, V82, P299, DOI 10.1006/gyno.2001.6284; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; ALLIS CD, 1980, CELL, V20, P55; Ambros V, 2007, DEVELOPMENT, V134, P1635, DOI 10.1242/dev.002006; Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Balint BL, 2005, IMMUNOBIOLOGY, V210, P141, DOI 10.1016/j.imbio.2005.05.009; Balint BL, 2005, MOL CELL BIOL, V25, P5648, DOI 10.1128/MCB.25.13.5648-5663.2005; Bao N, 2004, DEV CELL, V7, P653, DOI 10.1016/j.devcel.2004.10.003; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Belinsky SA, 2003, CANCER RES, V63, P7089; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Blobel GA, 2002, J LEUKOCYTE BIOL, V71, P545; Bottardi S, 2007, CELL CYCLE, V6, P1035, DOI 10.4161/cc.6.9.4208; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160; Bruserud O, 2006, EXPERT OPIN THER TAR, V10, P51, DOI 10.1517/14728222.10.1.51; Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Canote R, 2002, ONCOL REP, V9, P57; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375; Chen HM, 2004, SER REMOTE SENS, V3, P3, DOI 10.1142/9789812702630_0001; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Cowger JJM, 2007, ONCOGENE, V26, P3378, DOI 10.1038/sj.onc.1210126; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Douglas J, 2005, EUR J HUM GENET, V13, P150, DOI 10.1038/sj.ejhg.5201298; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; Ernst P, 2001, MOL CELL BIOL, V21, P2249, DOI 10.1128/MCB.21.7.2249-2258.2001; Esteller M, 2003, CLIN IMMUNOL, V109, P80, DOI 10.1016/S1521-6616(03)00208-0; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099; Fazi F, 2005, ONCOGENE, V24, P1820, DOI 10.1038/sj.onc.1208286; Forneris F, 2006, J BIOL CHEM, V281, P35289, DOI 10.1074/jbc.M607411200; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Gray SG, 2005, J BIOL CHEM, V280, P28507, DOI 10.1074/jbc.M413687200; Grewal SIS, 2007, NATURE, V447, P399, DOI 10.1038/nature05914; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Huang SM, 1999, ONCOGENE, V18, P4958, DOI 10.1038/sj.onc.1202889; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Huo XF, 2005, J CELL MOL MED, V9, P103, DOI 10.1111/j.1582-4934.2005.tb00340.x; Ikegami K, 2007, GENES CELLS, V12, P1, DOI 10.1111/j.1365-2443.2006.01029.x; Ivascu C, 2007, INT J BIOCHEM CELL B, V39, P1523, DOI 10.1016/j.biocel.2007.02.006; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kapoor A, 2005, FEBS LETT, V579, P5889, DOI 10.1016/j.febslet.2005.08.039; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kim DY, 2005, LEUKEMIA LYMPHOMA, V46, P1061, DOI 10.1080/10428190500102589; Kim KC, 2003, CANCER RES, V63, P7619; Kishigami S, 2006, DEV BIOL, V289, P195, DOI 10.1016/j.ydbio.2005.10.026; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Langst G, 2001, MOL CELL, V8, P1085, DOI 10.1016/S1097-2765(01)00397-5; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004; Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Letting DL, 2003, MOL CELL BIOL, V23, P1334, DOI 10.1128/MCB.23.4.1334-1340.2003; Levings PP, 2002, EUR J BIOCHEM, V269, P1589, DOI 10.1046/j.1432-1327.2002.02797.x; Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahadevan D, 2005, MOL CANCER THER, V4, P1867, DOI 10.1158/1535-7163.MCT-05-0146; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; OSTLER KR, IN PRESS ONCOGENE; Ouaissi M, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/13474; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Panagopoulos I, 2001, HUM MOL GENET, V10, P395, DOI 10.1093/hmg/10.4.395; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Qian C, 2006, CELL MOL LIFE SCI, V63, P2755, DOI 10.1007/s00018-006-6274-5; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reed-Inderbitzin E, 2006, ONCOGENE, V25, P5777, DOI 10.1038/sj.onc.1209591; Richie ER, 2002, ONCOGENE, V21, P299, DOI 10.1038/sj.onc.1205051; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rozman M, 2004, GENE CHROMOSOME CANC, V40, P140, DOI 10.1002/gcc.20022; Sanchez C, 2007, MOL CELL PROTEOMICS, V6, P820, DOI 10.1074/mcp.M600275-MCP200; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Santillan DA, 2006, CANCER RES, V66, P10032, DOI 10.1158/0008-5472.CAN-06-2597; Saunthararajah Y, 2004, SEMIN HEMATOL, V41, P11, DOI 10.1053/j.seminhematol.2004.08.003; Schaefer CB, 2007, SCIENCE, V316, P398, DOI 10.1126/science.1137544; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Singh M, 2007, EXP HEMATOL, V35, P48, DOI 10.1016/j.exphem.2006.09.001; Sirulnik A, 2003, BEST PRACT RES CL HA, V16, P387, DOI 10.1016/S1521-6926(03)00062-8; Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807; Spannhoff A, 2007, J MED CHEM, V50, P2319, DOI 10.1021/jm061250e; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Steele JC, 2006, BRIT J CANCER, V95, P1202, DOI 10.1038/sj.bjc.6603369; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Stopka T, 2005, EMBO J, V24, P3712, DOI 10.1038/sj.emboj.7600834; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tan CP, 2006, MOL CELL BIOL, V26, P7224, DOI 10.1128/MCB.00473-06; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353; van Haelst MM, 2005, AM J MED GENET A, V139A, P40, DOI 10.1002/ajmg.a.30973; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Verdone Loredana, 2006, Briefings in Functional Genomics & Proteomics, V5, P209, DOI 10.1093/bfgp/ell028; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Vitoux D, 2007, INT J BIOCHEM CELL B, V39, P1063, DOI 10.1016/j.biocel.2007.01.028; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yang MJ, 2006, MOL CELL, V23, P377, DOI 10.1016/j.molcel.2006.07.012; Yang MJ, 2007, BIOCHEMISTRY-US, V46, P8058, DOI 10.1021/bi700664y; Yoon YS, 2007, MOL CELL BIOL, V27, P3499, DOI 10.1128/MCB.02170-06; Zayed A, 2007, LEUKEMIA LYMPHOMA, V48, P489, DOI 10.1080/10428190601136163; Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou J, 2006, P NATL ACAD SCI USA, V103, P9238, DOI 10.1073/pnas.0603324103; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	177	110	112	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6697	6714		10.1038/sj.onc.1210755	http://dx.doi.org/10.1038/sj.onc.1210755			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934479				2022-12-17	WOS:000250147000003
J	Wu, D; Zhau, HE; Huang, WC; Iqbal, S; Habib, FK; Sartor, O; Cvitanovic, L; Marshall, FF; Xu, Z; Chung, LWK				Wu, D.; Zhau, H. E.; Huang, W-C; Iqbal, S.; Habib, F. K.; Sartor, O.; Cvitanovic, L.; Marshall, F. F.; Xu, Z.; Chung, L. W. K.			cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis	ONCOGENE			English	Article						prostate cancer; bone metastasis; EMT; CREB; VEGF; HIF	EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTOR-1; GENOME-WIDE ANALYSIS; TRANSCRIPTIONAL REGULATION; TUMOR PROGRESSION; CELLS; CREB; ACTIVATION; GENE; VEGF	Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP- responsive element- binding protein (CREB) and VEGF levels were significantly elevated in patient bone metastatic PCa specimens. A PCa ARCaP progression model demonstrating epithelial- to-mesenchymal transition exhibited increased CREB phosphorylation and VEGF expression as ARCaP cells became progressively more mesenchymal and bone- metastatic. Activation of CREB induced, whereas inhibition of CREB blocked, VEGF expression in ARCaP cells. CREB may regulate VEGF transcription via a hypoxia- inducible factor- dependent mechanism in normoxic conditions. Activation of CREB signaling is involved in the coordinated regulation of VEGF and may pre- dispose to PCa bone metastasis.	Emory Univ, Sch Med, Mol Urol & Therapeut Program, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Western Gen Hosp, Sch Mol & Clin Med, Div Oncol, Prostate Res Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; LSU, Ctr Hlth Sci, Stanley Scott Canc Ctr, New Orleans, LA USA	Emory University; Emory University; University of Edinburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Wu, D (corresponding author), Emory Univ, Sch Med, Mol Urol & Therapeut Program, Dept Urol, 1365-B Clifton Rd,Suite 5100, Atlanta, GA 30322 USA.	dwu2@emory.edu; lwchung@emory.edu		, Shareen/0000-0002-9489-7781; Huang, William/0000-0001-5261-0650; Huang, Wen-Chin/0000-0003-2342-9099	NATIONAL CANCER INSTITUTE [R01CA108468, P01CA098912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072069] Funding Source: NIH RePORTER; NCI NIH HHS [PC040260, 1 R01 CA108468, 1 P01 CA098912, PC060566] Funding Source: Medline; NIGMS NIH HHS [5 P20 GM072069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitch R, 2004, CANCER RES, V64, P1338, DOI 10.1158/0008-5472.CAN-03-2089; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arcinas M, 2001, CANCER RES, V61, P5202; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739; Chen TS, 1999, CANCER RES, V59, P213; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG LWK, 1991, CANCER SURV, V11, P91; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; George DJ, 2001, CLIN CANCER RES, V7, P1932; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Huang WC, 2006, CANCER RES, V66, P9108, DOI 10.1158/0008-5472.CAN-06-1996; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang YM, 1996, ONCOGENE, V12, P2223; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	38	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5070	5077		10.1038/sj.onc.1210316	http://dx.doi.org/10.1038/sj.onc.1210316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310988				2022-12-17	WOS:000248487400005
J	Ayllon, V; O'Connor, R				Ayllon, V.; O'Connor, R.			TOPK promotes tumour cell proliferation through p38MAPK activity and regulation of the DNA damage response	ONCOGENE			English	Article						IGF-IR; p38; PBK; H2AX; tumour growth	INSULIN-LIKE-GROWTH; IGF-I RECEPTOR; PDZ-BINDING KINASE; NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; PROTEIN-KINASE; MICROARRAY ANALYSIS; IONIZING-RADIATION; GENE-EXPRESSION	The contribution of the insulin-like growth-factor-I receptor (IGF-IR) to tumour progression is well documented. To identify new mediators of IGF-IR function in cancer, we recently isolated genes differentially expressed in cells overexpressing the IGF-IR. Among these was the serine/threonine kinase PBK/TOPK (PDZ-binding kinase/T-LAK cell-originated protein kinase), previously associated with highly proliferative cells and tissues. Here, we show that PBK is expressed at high levels in tumour cell lines compared with non-transformed cells. IGF-I could induce PBK expression only in transformed cells, whereas epidermal growth factor could induce PBK in non-transformed MCF-10A breast epithelial cells. Suppression of PBK expression using small interfering RNA did not prevent progression through the cell cycle, but caused decreased proliferation over time in culture, and reduced clonogenic growth in soft agarose. PBK knockdown impaired p38 activation after long-term stimulation with different growth factors and reduced DU145 cells motility. Suppressed PBK expression also resulted in an impaired response to DNA damage that was evident by the decreased generation of gamma-H2AX, increased DNA damage and decreased cell survival. Taken together, the data indicate that PBK is necessary for appropriate activation and function of the p38 pathway by growth factors. Thus, enhanced expression of PBK may facilitate tumour growth by mediating p38 activation and by helping cells to overcome DNA damage.	Natl Univ Ireland, BioSci Inst, Cell Biol Lab, Dept Biochem, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland, BioSci Inst, Cell Biol Lab, Dept Biochem, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	Ayllon, Veronica/L-7069-2014; O'Connor, Rosemary/B-7902-2014	Ayllon, Veronica/0000-0002-7322-9282; O'Connor, Rosemary/0000-0002-0687-3422				Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Bartucci M, 2001, CANCER RES, V61, P6747; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; Dougherty JD, 2005, J NEUROSCI, V25, P10773, DOI 10.1523/JNEUROSCI.3207-05.2005; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Friedmann B, 2004, CLIN CANCER RES, V10, P6476, DOI 10.1158/1078-0432.CCR-04-0586; Fujibuchi T, 2005, DEV GROWTH DIFFER, V47, P637, DOI 10.1111/j.1440-169X.2005.00834.x; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Hofmann F, 2005, DRUG DISCOV TODAY, V10, P1041, DOI 10.1016/S1359-6446(05)03512-9; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Kiely PA, 2005, J BIOL CHEM, V280, P7624, DOI 10.1074/jbc.M412889200; Kim MS, 2003, CANCER RES, V63, P5454; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Madhusudan S, 2005, TRENDS MOL MED, V11, P503, DOI 10.1016/j.molmed.2005.09.004; Maldonado C, 2005, BIOCHEM BIOPH RES CO, V336, P1112, DOI 10.1016/j.bbrc.2005.08.245; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Mauro L, 2004, J MOL HISTOL, V35, P247; Mikhailov A, 2005, CELL CYCLE, V4, P57, DOI 10.4161/cc.4.1.1357; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011; O'Connor R, 2003, HORM METAB RES, V35, P771; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Risinger MA, 2004, CANCER CELL, V6, P539, DOI 10.1016/j.ccr.2004.12.001; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Sartor CI, 2004, NAT CLIN PRACT ONCOL, V1, P80, DOI 10.1038/ncponc0048; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shen WH, 2004, J BIOL CHEM, V279, P7438, DOI 10.1074/jbc.M310264200; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Speit G, 1999, METH MOL B, V113, P203; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Wang WD, 2005, CLIN CANCER RES, V11, P5140, DOI 10.1158/1078-0432.CCR-04-2548; Yacoub A, 2003, RADIAT RES, V159, P439, DOI 10.1667/0033-7587(2003)159[0439:EGFAIR]2.0.CO;2; Yang S, 2005, AM J PHYSIOL-RENAL, V289, pF1144, DOI 10.1152/ajprenal.00094.2005	49	110	117	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3451	3461		10.1038/sj.onc.1210142	http://dx.doi.org/10.1038/sj.onc.1210142			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160018				2022-12-17	WOS:000246799200001
J	Han, YH; Cao, X; Lin, B; Lin, F; Kolluri, SK; Stebbins, J; Reed, JC; Dawson, MI; Zhang, XK				Han, Y-H; Cao, X.; Lin, B.; Lin, F.; Kolluri, S. K.; Stebbins, J.; Reed, J. C.; Dawson, M. I.; Zhang, X-k			Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt	ONCOGENE			English	Article						apoptosis; Nur77; JNK; Akt; AHPN; CD437	SYNTHETIC RETINOID CD437; CANCER-CELL-LINES; BREAST-CARCINOMA CELLS; ORPHAN RECEPTOR TR3; NGFI-B; PROSTATE-CANCER; APOPTOSIS INDUCTION; SIGNALING PATHWAY; BINDING DOMAIN; LEUKEMIA-CELLS	Proapoptotic nuclear receptor family member Nur77 translocates from the nucleus to the mitochondria, where it interacts with Bcl-2 to trigger apoptosis. Nur77 translocation is induced by certain apoptotic stimuli, including the synthetic retinoid-related 6-[3-(1-adamantyl)-4hydroxyphenyl]-2- naphthalenecarboxylic acid (AHPN)/CD437 class. In this study, we investigated the molecular mechanism by which AHPN/CD437 analog (E)-4-[3(1-adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic acid (3- Cl- AHPC) induces Nur77 nuclear export. Our results demonstrate that 3- Cl- AHPC effectively activated Jun N-terminal kinase (JNK), which phosphorylates Nur77. Inhibition of JNK activation by a JNK inhibitor suppressed 3-Cl-AHPC-induced Nur77 nuclear export and apoptosis. In addition, several JNK upstream activators, including the phorbol ester TPA, anisomycin and MAPK kinase kinase-1 (MEKK1), phosphorylated Nur77 and induced itsnuclear export. However, Nur77 phosphorylation by JNK, although essential, was not sufficient for inducing Nur77 nuclear export. Induction of Nur77 nuclear export by MEKK1 required a prolonged MEKK1 activation and was attenuated by Akt activation. Expression of constitutively active Akt prevented MEKK1-induced Nur77 nuclear export. Conversely, transfection of dominant-negative Akt or treatment with a phosphatidylinositol 3- kinase (PI3-K) inhibitor accelerated MEKK1-induced Nur77 nuclear export. Furthermore, mutation of an Akt phosphorylation residue Ser351 in Nur77 abolished the effect of Akt or the PI3-K inhibitor. Together, our results demonstrate that both activation of JNK and inhibition of Akt play a role in translocation of Nur77 from the nucleus to the cytoplasm.	Burke Med Res Inst, Ctr Canc, La Jolla, CA 92037 USA		Zhang, XK (corresponding author), Burke Med Res Inst, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	xzhang@burnham.org			NATIONAL CANCER INSTITUTE [R01CA087000, R01CA109345] Funding Source: NIH RePORTER; NCI NIH HHS [CA109345, CA87000] Funding Source: Medline; NIGMS NIH HHS [GM60544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi H, 1998, AM J RESP CELL MOL, V18, P323, DOI 10.1165/ajrcmb.18.3.2974; Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Boisvieux-Ulrich E, 2005, EXP CELL RES, V307, P76, DOI 10.1016/j.yexcr.2005.02.005; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Dawson MI, 1998, CANCER LETT, V133, P1, DOI 10.1016/S0304-3835(98)00147-5; Dawson MI, 2001, CANCER RES, V61, P4723; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Farhana L, 2004, ONCOGENE, V23, P1874, DOI 10.1038/sj.onc.1207311; Flaig R, 2005, J BIOL CHEM, V280, P19250, DOI 10.1074/jbc.M413175200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Garattini E, 2004, BLOOD, V103, P194, DOI 10.1182/blood-2003-05-1577; Gianni M, 1999, LEUKEMIA, V13, P739, DOI 10.1038/sj.leu.2401419; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Hsu CKA, 1997, EXP CELL RES, V232, P17, DOI 10.1006/excr.1997.3509; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jeong JH, 2003, ANN NY ACAD SCI, V1010, P171, DOI 10.1196/annals.1299.029; Kanda H, 2004, J BIOCHEM, V136, P1, DOI 10.1093/jb/mvh098; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li XS, 1996, CANCER RES, V56, P5055; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liang JY, 1999, PROSTATE, V38, P228; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schadendorf D, 1995, Recent Results Cancer Res, V139, P183; SHAO ZM, 1995, ONCOGENE, V11, P493; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Wan XL, 2001, ANTICANCER RES, V21, P2657; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Widschwendter M, 1997, INT J CANCER, V71, P497; Wilson AJ, 2003, CANCER RES, V63, P5401; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WINGATE AD, 2005, BIOCH J         1013; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhang YX, 2003, BLOOD, V102, P3743, DOI 10.1182/blood-2003-01-0108; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	74	110	116	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					2974	2986		10.1038/sj.onc.1209358	http://dx.doi.org/10.1038/sj.onc.1209358			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16434970				2022-12-17	WOS:000237950800002
J	Herman, JF; Mangala, LS; Mehta, K				Herman, J. F.; Mangala, L. S.; Mehta, K.			Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells	ONCOGENE			English	Article						tissue transglutaminase; apoptosis; integrins; chemoresistance	FOCAL ADHESION KINASE; INDUCED APOPTOSIS; BINDING DOMAIN; HUMAN TUMOR; INTEGRIN; FIBRONECTIN; LINE; OVEREXPRESSION; ALPHA-4-BETA-1; ACTIVATION	The development of resistance to chemotherapeutic drugs is a major obstacle to the successful treatment of breast cancer. Ways to block or overcome this resistance are objects of intense research. We have previously shown that cancer cells selected for resistance against chemotherapeutic drugs or isolated from metastatic tumor sites have high levels of a calcium-dependent protein crosslinking enzyme, tissue transglutaminase (TG2) but no direct link between TG2 and resistance was established. As TG2 can associate with the ss members of the integrin family of proteins, we hypothesized that TG2 promotes cell survival signaling pathways by activating integrins on the surface of these cells. To test this hypothesis, we studied the expression of TG2 and its interaction with various integrins in drug-resistant MCF-7 breast cancer cells. TG2 closely associated with ss 1 and ss 5 integrins on the surface of drug-resistant MCF-7 (MCF-7/Dox and MCF-7/RT) cells. The incubation of TG2-expressing drug-resistant MCF-7 cells on fibronectin(Fn)-coated surfaces strongly activated focal adhesion kinase, an event that leads to the activation of several downstream signaling pathways and, in turn, can confer apoptosis-resistant phenotype to cancer cells. The role of TG2 in Fn-mediated cell attachment, cell growth, and cell survival functions was further analysed by small interfering RNA ( siRNA) approach. Inhibition of TG2 by siRNA-inhibited Fn-mediated cell attachment and cell survival functions in drug-resistant MCF-7 cells. We conclude that the expression of TG2 in breast cancer cells contributes to the development of the drug-resistance phenotype by promoting interaction between integrins and Fn.	UT MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Mehta, K (corresponding author), UT MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 326,Room Y6-5318,1515 Holcombe Blvd, Houston, TX 77030 USA.	kmehta@mdanderson.org						Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; ANTONYAK M, 2001, J BIOL CHEM, V279, P8715; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Autuori F, 1998, Adv Biochem Eng Biotechnol, V62, P129, DOI 10.1007/BFb0102308; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Cary LA, 1996, J CELL SCI, V109, P1787; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen JSK, 2004, J CELL PHYSIOL, V200, P223, DOI 10.1002/jcp.20014; Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403; Cordes N, 2003, INT J RADIAT BIOL, V79, P709, DOI 10.1080/09553000310001610240; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DAVIES PJ, 1994, MOL CELL BIOL, V14, P6584; de la Fuente MT, 2002, J LEUKOCYTE BIOL, V71, P495; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Devarajan E, 2002, INT J ONCOL, V20, P913; FESUS L, 1991, EUR J CELL BIOL, V56, P170; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; ILLC D, 1995, NATURE, V377, P539; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Longtin R, 2004, J NATL CANCER I, V96, P6, DOI 10.1093/jnci/96.1.6; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mangala LS, 2005, PROG EXP TUMOR RES, V38, P125; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Mehta K, 2002, J NATL CANCER I, V94, P1652; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nista A, 1997, INT J CANCER, V72, P133, DOI 10.1002/(SICI)1097-0215(19970703)72:1<133::AID-IJC19>3.0.CO;2-K; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	44	110	115	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3049	3058		10.1038/sj.onc.1209324	http://dx.doi.org/10.1038/sj.onc.1209324			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16449978				2022-12-17	WOS:000237950800009
J	Bektas, M; Jolly, PS; Muller, C; Eberle, R; Spiegel, S; Geilen, CC				Bektas, M; Jolly, PS; Muller, C; Eberle, R; Spiegel, S; Geilen, CC			Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression	ONCOGENE			English	Article						melanoma; bcl-2; sphingosine; apoptosis	ACTIVATED PROTEIN-KINASES; MALIGNANT-MELANOMA; INHIBITS APOPTOSIS; NUDE-MICE; KAPPA-B; GROWTH; 1-PHOSPHATE; RESISTANCE; LINES; SPHINGOSINE-1-PHOSPHATE	While most of the pharmacological therapies for melanoma utilize the apoptotic machinery of the cells, the available therapeutic options are limited due to the ability of melanoma cells to resist programmed cell death. Human melanoma cell lines A-375 and M186 are sensitive to ceramide- and Fas-induced cell death, while Mel-2a and M221 are resistant. We have now found that Mel-2a and M221 cells have a significantly higher ceramide/sphingosine-1-phosphate (S1P) ratio than A-375 and M186 cells. As sphingosine kinase (SphK) type 1 plays a critical role in determining the dynamic balance between the proapoptotic sphingolipid metabolite ceramide and the prosurvival S1P, we examined its role in apoptosis of melanoma cells. Increasing SphK1 expression reduced the sensitivity of A-375 melanoma cells to Fas- and ceramide- mediated apoptosis. Conversely, downregulation of SphK1 with small interfering RNA decreased the resistance of Mel-2a cells to apoptosis. Importantly, overexpression of the prosurvival protein Bcl-2 in A-375 cells markedly stimulated SphK1 expression and activity, while downregulation of Bcl-2 reduced SphK1 expression. This link between Bcl-2 and SphK1 might be an additional clue to chemotherapy resistance of malignant melanoma.	Charite Univ Med Berlin, Dept Dermatol, D-14195 Berlin, Germany; Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Virginia Commonwealth University; Georgetown University	Geilen, CC (corresponding author), Charite Univ Med Berlin, Dept Dermatol, Campus Benjamin Franklin,Fabeckstr 60-62, D-14195 Berlin, Germany.	ccgeilen@zedat.fu-berlin.de		Bektas, Meryem/0000-0001-8080-7557; Eberle, Jurgen/0000-0001-8533-1519	NCI NIH HHS [P30CA16059, R01CA61774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774, P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; BRUGGEN J, 1981, J CANCER RES CLIN, V102, P141, DOI 10.1007/BF00410665; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; Edsall L, 2000, METHOD ENZYMOL, V312, P9; Edsall LC, 1997, J NEUROSCI, V17, P6952; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; ENDO K, 1991, CANCER RES, V51, P1613; French KJ, 2003, CANCER RES, V63, P5962; Geilen CC, 2001, SKIN PHARMACOL APPL, V14, P261, DOI 10.1159/000056356; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Govindarajan B, 2003, J BIOL CHEM, V278, P9790, DOI 10.1074/jbc.M212929200; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jayadev S, 1996, J LIPID MEDIAT CELL, V14, P295, DOI 10.1016/0929-7855(96)00538-X; Jendiroba DB, 2002, LEUKEMIA RES, V26, P301, DOI 10.1016/S0145-2126(01)00129-1; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kortylewski M, 2001, BIOCHEM J, V357, P297, DOI 10.1042/0264-6021:3570297; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; LOCKSHIN A, 1985, CANCER RES, V45, P345; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Olivera A, 1998, Methods Mol Biol, V105, P233; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; Satyamoorthy K, 2001, TRENDS MOL MED, V7, P191, DOI 10.1016/S1471-4914(01)02013-5; Serrone L, 1999, MELANOMA RES, V9, P51, DOI 10.1097/00008390-199902000-00007; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Tang LR, 1998, CLIN CANCER RES, V4, P1865; Thomas WD, 1998, J IMMUNOL, V161, P2195; Toman RE, 2002, J NEUROSCI RES, V68, P323, DOI 10.1002/jnr.10190; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	55	110	115	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					178	187		10.1038/sj.onc.1208019	http://dx.doi.org/10.1038/sj.onc.1208019			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637591				2022-12-17	WOS:000226125800020
J	Abulrob, A; Giuseppin, S; Andrade, MF; McDermid, A; Moreno, M; Stanimirovic, D				Abulrob, A; Giuseppin, S; Andrade, MF; McDermid, A; Moreno, M; Stanimirovic, D			Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae	ONCOGENE			English	Article						caveolin-1; glioblastoma; epidermal growth factor receptor; tyrosine phosphorylation	GROWTH-FACTOR RECEPTOR; PLASMA-MEMBRANE; KINASE-ACTIVITY; DOWN-REGULATION; IN-VITRO; EXPRESSION; PROTEIN; CHOLESTEROL; METASTASIS; ACTIVATION	Epidermal growth factor receptor (EGFR) amplification and type III mutation ( EGFRvIII), associated with constitutive tyrosine kinase activation and high malignancy, are commonly observed in glioblastoma tumors. The association of EGFR and EGFRvIII with caveolins was investigated in human glioblastoma cell lines, U87MG and U87MG-EGFRvIII. Caveolin-1 expression, determined by RT-PCR, real-time quantitative PCR and Western blot, was upregulated in glioblastoma cell lines (two-fold) and tumors (20-300-fold) compared to primary human astrocytes and nonmalignant brain tissue, respectively. U87MG-EGFRvIII expressed higher levels of caveolin-1 than U87MG. In contrast, the expression of caveolin-2 and -3 were downregulated in glioblastoma cells compared to astrocytes. A colocalization of EGFR, but not of EGFRvIII, with lipid rafts and caveolin-1 was observed by immunocytochemistry. Association of EGFR and EGFRvIII with caveolae, assessed in vitro by binding to caveolin scaffolding domain peptides and in vivo by immunocolocalization studies in cells and caveolae-enriched cellular fraction, was phosphorylation-dependent: ligand-induced phosphorylation of EGFR resulted in dissociation of EGFR from caveolae. In contrast, inhibition of the EGFRvIII constitutive tyrosine phosphorylation by AG1478 increased association of EGFRvIII with caveolin-1. AG1478 also increased caveolin-1 expression and reduced glioblastoma cell growth in a semi-solid agar. The evidence suggests that the phosphorylation-regulated sequestration of EGFR in caveolae may be involved in arresting constitutive or ligand-induced signaling through EGFR responsible for glial cell transformation.	Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, D (corresponding author), Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, 1200 Montreal Rd,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	Danica.Stanimirovic@nrc.ca		Freitas-Andrade, Moises/0000-0002-5649-9053				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bender FC, 2000, CANCER RES, V60, P5870; Cameron PL, 2002, GLIA, V37, P275, DOI 10.1002/glia.10036; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Emrich JG, 2002, AM J CLIN ONCOL-CANC, V25, P541, DOI 10.1097/00000421-200212000-00001; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Ge GX, 2001, BIOCHEM BIOPH RES CO, V282, P511, DOI 10.1006/bbrc.2001.4600; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Han YC, 1996, CANCER RES, V56, P3859; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Jakobisiak M, 2003, INT J ONCOL, V23, P1055; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jungbluth AA, 2003, P NATL ACAD SCI USA, V100, P639, DOI 10.1073/pnas.232686499; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Mamot C, 2003, CANCER RES, V63, P3154; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mischel PS, 2003, BRAIN PATHOL, V13, P52; NAGANE M, 2001, CANC LETT, V162, P17; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Ringerike T, 2002, J CELL SCI, V115, P1331; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Schlegel A, 2000, FRONT BIOSCI-LANDMRK, V5, pD929, DOI 10.2741/schlegel; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Thompson TC, 1998, CANCER METAST REV, V17, P439, DOI 10.1023/A:1006110326366; Voldborg BR, 1997, ANN ONCOL, V8, P1197, DOI 10.1023/A:1008209720526; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Worm K, 1999, HUM PATHOL, V30, P222, DOI 10.1016/S0046-8177(99)90280-0; Yang G, 1998, CLIN CANCER RES, V4, P1873; YONG VW, 1992, J NEUROL SCI, V111, P92; Zhang RL, 2003, GLIA, V42, P194, DOI 10.1002/glia.10222	49	110	116	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6967	6979		10.1038/sj.onc.1207911	http://dx.doi.org/10.1038/sj.onc.1207911			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273741				2022-12-17	WOS:000223750700013
J	Wagner, KW; Sapinoso, LM; El-Rifai, W; Frierson, HF; Butz, N; Mestan, J; Hofmann, F; Deveraux, QL; Hampton, GM				Wagner, KW; Sapinoso, LM; El-Rifai, W; Frierson, HF; Butz, N; Mestan, J; Hofmann, F; Deveraux, QL; Hampton, GM			Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin	ONCOGENE			English	Article						UbcH10; gene expression; DNA amplification; RNA interference; TRAIL/DR5; apoptosis	ANAPHASE-PROMOTING COMPLEX; INDUCED APOPTOSIS; CANCER-TREATMENT; PROSTATE-CANCER; EXPRESSION; PROTEOLYSIS; CELLS; MITOSIS; TARGETS; MARKERS	Gene expression pro. ling of anatomically diverse carcinomas and their corresponding normal tissues was used to identify genes with cancer-associated expression. We show here that the ubiquitin conjugase, UbcH10, is significantly overexpressed in many different types of cancers and is associated with the degree of tumor differentiation in carcinomas of the breast, lung, ovary and bladder, as well as in glioblastomas. We also show that UbcH10 overexpression in gastro-esophageal, and probably other carcinomas may be a direct consequence of chromosomal amplification at the UbcH10 locus, 20q13.1, a region known to be amplified in diverse tumors. To evaluate whether inhibition of UbcH10 function may be therapeutically relevant in cancer, we used small interfering RNAs (siRNAs) to silence UbcH10 transcription selectively. Diminution of UbcH10 expression significantly inhibited both tumor and normal cell proliferation without inducing cell death. However, when combined with agonists of the DR5/TRAIL receptor, siRNAs directed against the UbcH10 transcript dramatically enhanced killing of cancer cells, but not of proliferating primary human epithelial cells or fibroblasts. Together, these data demonstrate that UbcH10 plays an important role in tumor development and that its inhibition in combination with agonists of the TRAIL receptor may provide an enhanced therapeutic index.	Novartis Res Fdn, Gen Inst, San Diego, CA 92121 USA; Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA USA; Novartis Pharma AG, Novartis Inst BioMed Res, Basel, Switzerland	Novartis; University of Virginia; University of Virginia; Novartis	Hampton, GM (corresponding author), Novartis Res Fdn, Gen Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	hampton@gnf.org						Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; Borkhardt A, 2002, CANCER CELL, V2, P167, DOI 10.1016/S1535-6108(02)00129-0; Boye J, 2003, ANN ONCOL, V14, P520, DOI 10.1093/annonc/mdg175; Cuthill S, 1999, GENE CHROMOSOME CANC, V26, P304, DOI 10.1002/(SICI)1098-2264(199912)26:4<304::AID-GCC4>3.0.CO;2-1; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; El-Rifai W, 2001, GASTROENTEROLOGY, V121, P592, DOI 10.1053/gast.2001.27215; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Grunwald V, 2003, JNCI-J NATL CANCER I, V95, P851, DOI 10.1093/jnci/95.12.851; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Jazaeri AA, 2003, MOL CARCINOGEN, V36, P53, DOI 10.1002/mc.10098; Jin ZY, 2002, CELL CYCLE, V1, P82, DOI 10.4161/cc.1.1.104; LaTulippe E, 2002, CANCER RES, V62, P4499; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Mayer RJ, 2000, NAT REV MOL CELL BIO, V1, P145; O'Dwyer M E, 2000, Lancet Oncol, V1, P207, DOI 10.1016/S1470-2045(00)00149-2; Okamoto Y, 2003, CANCER RES, V63, P4167; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Stennicke H R, 2000, Symp Soc Exp Biol, V52, P13; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Watanabe T, 2002, JPN J CANCER RES, V93, P1114, DOI 10.1111/j.1349-7006.2002.tb01213.x; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamanaka A, 2000, MOL BIOL CELL, V11, P2821, DOI 10.1091/mbc.11.8.2821	30	110	124	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6621	6629		10.1038/sj.onc.1207861	http://dx.doi.org/10.1038/sj.onc.1207861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208666				2022-12-17	WOS:000223530800009
J	Tomida, S; Koshikawa, K; Yatabe, Y; Harano, T; Ogura, N; Mitsudomi, T; Some, M; Yanagisawa, K; Takahashi, T; Osada, H; Takahashi, T				Tomida, S; Koshikawa, K; Yatabe, Y; Harano, T; Ogura, N; Mitsudomi, T; Some, M; Yanagisawa, K; Takahashi, T; Osada, H; Takahashi, T			Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients	ONCOGENE			English	Article						lung cancer; gene expression profile; microarray; prognosis	SQUAMOUS DIFFERENTIATION MARKER; PROGNOSTIC-SIGNIFICANCE; CELL-LINES; ADENOCARCINOMA; CLASSIFICATION; TUMORS; METASTASIS; TRANSFORMATION; PROGRESSION; CARCINOMAS	Individualized outcome prediction classifiers were successfully constructed through expression pro. ling of a total of 8644 genes in 50 non-small-cell lung cancer (NSCLC) cases, which had been consecutively operated on within a defined short period of time and followed up for more than 5 years. The resultant classifier of NSCLCs yielded 82% accuracy for forecasting survival or death 5 years after surgery of a given patient. In addition, since two major histologic classes may differ in terms of outcome-related expression signatures, histologic-type-specific outcome classifiers were also constructed. The resultant highly predictive classifiers, designed specifically for nonsquamous cell carcinomas, showed a prediction accuracy of more than 90% independent of disease stage. In addition to the presence of heterogeneities in adenocarcinomas, our unsupervised hierarchical clustering analysis revealed for the first time the existence of clinicopathologically relevant subclasses of squamous cell carcinomas with marked differences in their invasive growth and prognosis. This finding clearly suggests that NSCLCs comprise distinct subclasses with considerable heterogeneities even within one histologic type. Overall, these findings should advance not only our understanding of the biology of lung cancer but also our ability to individualize postoperative therapies based on the predicted outcome.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan; Fuji Photo Film Co Ltd, Miyanodai Technol Dev Ctr, Kanagawa 2588538, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center; Fujifilm Corporation; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; YATABE, Yasushi/J-6461-2014; Yanagisawa, Kiyoshi/I-7263-2014	Takahashi, Takashi/0000-0003-0615-7001; YATABE, Yasushi/0000-0003-1788-559X; Mitsudomi, Tetsuya/0000-0001-9860-8505				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Craig SW, 2003, CURR BIOL, V13, pR236, DOI 10.1016/S0960-9822(03)00160-X; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HORIO Y, 1993, CANCER RES, V53, P1; Hu R, 1998, LUNG CANCER, V20, P25, DOI 10.1016/S0169-5002(97)00097-4; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MINNA JD, 1997, MOL BIOL LUNG CANC, P849; Mitsudomi T, 2000, CLIN CANCER RES, V6, P4055; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Patterson T, 2001, ONCOGENE, V20, P634, DOI 10.1038/sj.onc.1204134; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Robert C, 1999, CLIN CANCER RES, V5, P2094; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Vuong H, 2002, AM J PHYSIOL-LUNG C, V282, pL215, DOI 10.1152/ajplung.00125.2001; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Willett CG, 1998, AM J RESP CELL MOL, V18, P489, DOI 10.1165/ajrcmb.18.4.2978; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	37	110	116	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5360	5370		10.1038/sj.onc.1207697	http://dx.doi.org/10.1038/sj.onc.1207697			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15064725				2022-12-17	WOS:000222491600011
J	McBride, WH; Iwamoto, KS; Syljuasen, R; Pervan, M; Pajonk, F				McBride, WH; Iwamoto, KS; Syljuasen, R; Pervan, M; Pajonk, F			The role of the ubiquitin/proteasome system in cellular responses to radiation	ONCOGENE			English	Review						proteasome; ubiquitin; DNA repair; cell cycle arrest; apoptosis	NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; MULTICATALYTIC PROTEINASE COMPLEX; DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; ANAPHASE-PROMOTING COMPLEX; NUCLEOTIDE EXCISION-REPAIR; CEREBELLAR GRANULE NEURONS; HUMAN ENDOTHELIAL-CELLS; MULTIPLE-MYELOMA CELLS	In the last few years, the ubiquitin(Ub)/proteasome system has become increasingly recognized as a controller of numerous physiological processes, including signal transduction, DNA repair, chromosome maintenance, transcriptional activation, cell cycle progression, cell survival, and certain immune cell functions. This is in addition to its more established roles in the removal of misfolded, damaged, and effete proteins. This review examines the role of the Ub/proteasome system in processes underlying the classical effects of irradiation on cells, such as radiation-induced gene expression, DNA repair and chromosome instability, oxidative damage, cell cycle arrest, and cell death. Furthermore, recent evidence suggests that the proteasome is a redox-sensitive target for ionizing radiation and other oxidative stress signals. In other words, the Ub/proteasome system may not simply be a passive player in radiation-induced responses, but may modulate them. The extent of the modulation will be influenced by the functional and structural diversity that is expressed by the system. Cell types vary in the Ub/proteasome structures they possess and the level at which they function, and this changes as they go from the normal to the cancerous condition. Cancer-related functional changes within the Ub/proteasome system may therefore present unique targets for cancer therapy, especially when targeting agents are used in combination with radio- or chemotherapy. The peptide boronic acid compound PS-341, which was designed to inhibit proteasome chymotryptic activity, is in clinical trials for the treatment of solid and hematogenous tumors. It has shown some efficacy on its own and in combination with chemotherapy. Preclinical studies have shown that PS-341 will also potentiate the cytotoxic effects of radiation therapy. In addition, other drugs in common clinical use have been shown to affect proteasome function, and their activities may be valuably reconsidered from this perspective.	Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Radiol Univ Clin, Dept Radiat Oncol, D-79098 Freiburg, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Danish Cancer Society; University of Freiburg	McBride, WH (corresponding author), Univ Calif Los Angeles, Dept Radiat Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA.	mcbride@radonc.ucla.edu	Pajonk, Frank/E-4247-2010		NCI NIH HHS [CA-87887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEYAMA K, 1995, FEBS LETT, V364, P298, DOI 10.1016/0014-5793(95)00412-3; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Arnold J, 2002, BIOESSAYS, V24, P1060, DOI 10.1002/bies.10179; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; Bastians H, 1999, MOL BIOL CELL, V10, P3927, DOI 10.1091/mbc.10.11.3927; Beetz A, 1997, INT J RADIAT BIOL, V72, P33, DOI 10.1080/095530097143518; BEHRENDS U, 1994, 42ND ANN M RAD RES S, P164; Bennett CB, 2001, NAT GENET, V29, P426, DOI 10.1038/ng778; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bobba A, 2002, FEBS LETT, V515, P8, DOI 10.1016/S0014-5793(02)02231-7; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; BROSKI AP, 1994, TRANSPLANTATION, V57, P582; Bulteau AL, 2002, FREE RADICAL BIO MED, V32, P1157, DOI 10.1016/S0891-5849(02)00816-X; Bush KT, 1997, J BIOL CHEM, V272, P9086; Bussell K, 2001, NAT REV MOL CELL BIO, V2, P875, DOI 10.1038/35103057; Canu N, 2000, J NEUROSCI, V20, P589, DOI 10.1523/JNEUROSCI.20-02-00589.2000; Cao ZA, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-11; Carrard G, 2002, INT J BIOCHEM CELL B, V34, P1461, DOI 10.1016/S1357-2725(02)00085-7; Carthew RW, 2000, CURR BIOL, V10, pR532, DOI 10.1016/S0960-9822(00)00587-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Chendil D, 2002, CANCER BIOL THER, V1, P152, DOI 10.4161/cbt.61; Cheson BD, 2002, SEMIN ONCOL, V29, P33, DOI 10.1053/sonc.2002.34878; CHIANG CS, 1993, RADIOTHER ONCOL, V29, P60, DOI 10.1016/0167-8140(93)90174-7; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cohen S, 2001, J BIOL CHEM, V276, P26769, DOI 10.1074/jbc.M102448200; CohenFix O, 1997, CURR OPIN CELL BIOL, V9, P800, DOI 10.1016/S0955-0674(97)80080-4; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Costelli P, 2002, CYTOKINE, V19, P1, DOI 10.1006/cyto.2002.1036; Coux Olivier, 2002, Prog Mol Subcell Biol, V29, P85; Daino K, 2002, RADIAT RES, V157, P478, DOI 10.1667/0033-7587(2002)157[0478:EIOCPA]2.0.CO;2; Dallaporta B, 2000, CELL DEATH DIFFER, V7, P368, DOI 10.1038/sj.cdd.4400661; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; Delic J, 1998, BRIT J CANCER, V77, P1103, DOI 10.1038/bjc.1998.183; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; DEWEY WC, 1971, RADIAT RES, V47, P672, DOI 10.2307/3573359; DEWEY WC, 1972, RADIAT RES, V52, P373, DOI 10.2307/3573575; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Ding QX, 2001, J NEUROCHEM, V77, P1010, DOI 10.1046/j.1471-4159.2001.00302.x; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Eisen V, 1977, Agents Actions Suppl, V2, P99; EKJKOVA E, 2002, EMBO REP, V3, P219; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Finkielstein CV, 2002, J BIOL CHEM, V277, P38476, DOI 10.1074/jbc.M206184200; Fittkau M, 2001, J CANCER RES CLIN, V127, P96, DOI 10.1007/s004320000174; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FONTANA A, 1982, J IMMUNOL, V129, P2413; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; FUJIWARA T, 1990, J BIOL CHEM, V265, P16604; Fukuchi K, 2002, BIOCHEM BIOPH RES CO, V293, P120, DOI 10.1016/S0006-291X(02)00198-5; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; Garber K, 2002, J NATL CANCER I, V94, P550; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gaugler MH, 1997, INT J RADIAT BIOL, V72, P201, DOI 10.1080/095530097143428; GILLETTE EL, 1970, RADIOLOGY, V96, P639, DOI 10.1148/96.3.639; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; Gorski DH, 1999, CANCER RES, V59, P3374; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 2000, BIOGERONTOLOGY, V1, P31, DOI 10.1023/A:1010037908060; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; Hayashi T, 2000, J BIOL CHEM, V275, P5238, DOI 10.1074/jbc.275.7.5238; Heckmann M, 1998, EXP CELL RES, V238, P148, DOI 10.1006/excr.1997.3826; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hildebrandt G, 1998, STRAHLENTHER ONKOL, V174, P580, DOI 10.1007/BF03038296; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hoffmann C, 2001, AIDS, V15, P2119, DOI 10.1097/00002030-200111090-00007; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hong JH, 1997, MOL BRAIN RES, V48, P223, DOI 10.1016/S0169-328X(97)00095-8; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; HONG JH, 1994, INT J RADIAT ONCOL, V30, pS315; Hosoi Y, 2001, INT J CANCER, V96, P270, DOI 10.1002/ijc.1030; Hu J, 2002, EUR J NEUROSCI, V16, P1409, DOI 10.1046/j.1460-9568.2002.02218.x; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; ICHIHARA A, 1993, ADV ENZYME REGUL, V33, P173; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Ishii K, 1997, NEUROSCI LETT, V228, P17, DOI 10.1016/S0304-3940(97)00347-9; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; IWAMOTO KS, 1992, RAD RES, V118; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jaster R, 1999, BBA-GENE STRUCT EXPR, V1446, P308, DOI 10.1016/S0167-4781(99)00095-0; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Johnston CJ, 2002, RADIAT RES, V157, P256, DOI 10.1667/0033-7587(2002)157[0256:RIPFEO]2.0.CO;2; Joiner MC, 2001, INT J RADIAT ONCOL, V49, P379, DOI 10.1016/S0360-3016(00)01471-1; Joiner MC, 1999, CR ACAD SCI III-VIE, V322, P167, DOI 10.1016/S0764-4469(99)80040-7; Jung M, 2001, SEMIN RADIAT ONCOL, V11, P346, DOI 10.1053/srao.2001.26034; KANAYAMA H, 1991, CANCER RES, V51, P6677; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuckelkorn U, 2000, BIOL CHEM, V381, P1017, DOI 10.1515/BC.2000.125; KUMATORI A, 1990, P NATL ACAD SCI USA, V87, P7071, DOI 10.1073/pnas.87.18.7071; Kumeda SI, 1999, ANTICANCER RES, V19, P3961; L'Allemain G, 2002, B CANCER, V89, P29; Ladner KJ, 2003, J BIOL CHEM, V278, P2294, DOI 10.1074/jbc.M207129200; Laroia G, 2002, P NATL ACAD SCI USA, V99, P1842, DOI 10.1073/pnas.042575699; Lebbe C, 1998, AIDS, V12, pF45, DOI 10.1097/00002030-199807000-00002; Lee MH, 2001, J NEUROCHEM, V78, P32, DOI 10.1046/j.1471-4159.2001.00416.x; Lee RT, 2001, CIRC RES, V88, P262, DOI 10.1161/01.RES.88.3.262; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li WH, 2000, NUCLEIC ACIDS RES, V28, P1145, DOI 10.1093/nar/28.5.1145; Liao Yu-Pei, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P480; Liu QH, 2000, GENE DEV, V14, P1448; Locke JE, 2002, INT J RADIAT BIOL, V78, P493, DOI [10.1080/095530002317577312, 10.1080/09553000110120355]; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; Lu XH, 2001, ARCH BIOCHEM BIOPHYS, V387, P163, DOI 10.1006/abbi.2001.2270; LuHesselmann J, 1997, RADIAT RES, V148, P531, DOI 10.2307/3579728; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Luo GJ, 2000, AM J PHYSIOL-REG I, V278, pR749, DOI 10.1152/ajpregu.2000.278.3.R749; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; Macagno A, 2001, EUR J IMMUNOL, V31, P3271, DOI 10.1002/1521-4141(200111)31:11<3271::AID-IMMU3271>3.0.CO;2-2; Machiels BM, 1997, CYTOMETRY, V28, P243; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Martin JMC, 1999, CANCER RES, V59, P1134; Masuda T, 2002, CANCER RES, V62, P3819; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; McBride William H, 2002, Mil Med, V167, P66; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Mimnaugh EG, 2000, BIOCHEM PHARMACOL, V60, P1343, DOI 10.1016/S0006-2952(00)00455-X; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morel S, 2000, IMMUNITY, V12, P107, DOI 10.1016/S1074-7613(00)80163-6; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORTH RJ, 1984, ADV IMMUNOL, V35, P89, DOI 10.1016/S0065-2776(08)60575-1; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Ottosen S, 2002, SCIENCE, V296, P479, DOI 10.1126/science.1071270; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pajonk F, 2001, RADIAT RES, V156, P447, DOI 10.1667/0033-7587(2001)156[0447:TPICBA]2.0.CO;2; Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956; Pajonk F, 2000, INT J RADIAT ONCOL, V47, P1025, DOI 10.1016/S0360-3016(00)00516-2; Pajonk F, 2002, AIDS, V16, P1195, DOI 10.1097/00002030-200205240-00020; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Pajonk F, 2000, INT J RADIAT BIOL, V76, P1691; Pajonk F, 2001, RADIOTHER ONCOL, V59, P203, DOI 10.1016/S0167-8140(01)00311-5; Pajonk F, 2002, CANCER RES, V62, P5230; PAJONK F, 2001, RADIOTHER ONCOL, P191; Pallares-Trujillo J, 2000, MED HYPOTHESES, V54, P565, DOI 10.1054/mehy.1999.0895; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; Patel S, 1998, ACTA ONCOL, V37, P475, DOI 10.1080/028418698430430; Pervan M, 2001, AM J CLIN ONCOL-CANC, V24, P481, DOI 10.1097/00000421-200110000-00013; Pervan Milena, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P666; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Piccinini M, 2001, BIOCHEM J, V356, P835, DOI 10.1042/0264-6021:3560835; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Ponnappan U, 1999, CELL IMMUNOL, V192, P167, DOI 10.1006/cimm.1998.1418; Poon RYC, 1997, CANCER RES, V57, P5168; Pritts T, 2002, AM J SURG, V183, P372, DOI 10.1016/S0002-9610(02)00812-7; Raju U, 1998, INT J RADIAT BIOL, V74, P617, DOI 10.1080/095530098141195; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rock KL, 2002, ADV IMMUNOL, V80, P1, DOI 10.1016/S0065-2776(02)80012-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roedel F, 2002, INT J RADIAT BIOL, V78, P711, DOI 10.1080/09553000210137671; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Sadekova S, 1997, INT J RADIAT BIOL, V72, P653, DOI 10.1080/095530097142807; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sawada H, 2002, P NATL ACAD SCI USA, V99, P1223, DOI 10.1073/pnas.032389499; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schultz ES, 2002, J EXP MED, V195, P391, DOI 10.1084/jem.20011974; Scully R, 2001, EXP CELL RES, V264, P67, DOI 10.1006/excr.2000.5132; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shah SA, 2002, SURGERY, V131, P595, DOI 10.1067/msy.2002.121890; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; SIERRARIVERA E, 1993, RADIAT RES, V135, P40, DOI 10.2307/3578394; Sijts A, 2002, MOL IMMUNOL, V39, P165, DOI 10.1016/S0161-5890(02)00099-8; Sijts AJAM, 2000, J IMMUNOL, V164, P4500, DOI 10.4049/jimmunol.164.9.4500; Soldatenkov VA, 1997, CANCER RES, V57, P3881; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Spruck CH, 2002, CELL CYCLE, V1, P248, DOI 10.4161/cc.1.4.132; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sun Y, 2002, CANCER RES, V62, P2875; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Trott KR, 1999, RADIOTHER ONCOL, V51, P197, DOI 10.1016/S0167-8140(99)00066-3; Ueda T, 2001, FEBS LETT, V491, P40, DOI 10.1016/S0014-5793(01)02145-7; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vodermaier HC, 2001, CURR BIOL, V11, pR834, DOI 10.1016/S0960-9822(01)00498-5; Vugmeyster Y, 2002, MOL IMMUNOL, V39, P431, DOI 10.1016/S0161-5890(02)00123-2; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wojcik C, 1996, EUR J CELL BIOL, V70, P172; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; Wu HM, 2002, AM J RESP CELL MOL, V27, P234, DOI 10.1165/ajrcmb.27.2.4792; Wu HM, 2002, FEBS LETT, V526, P101, DOI 10.1016/S0014-5793(02)03151-4; Wu LW, 1999, BLOOD CELL MOL DIS, V25, P20, DOI 10.1006/bcmd.1999.0223; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yamaguchi R, 2000, EXP CELL RES, V261, P271, DOI 10.1006/excr.2000.5053; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zaiss DMW, 2002, P NATL ACAD SCI USA, V99, P14344, DOI 10.1073/pnas.212257299; Zhang F, 2002, EXP CELL RES, V281, P190, DOI 10.1006/excr.2002.5670; ZHANG JS, 1994, CHINESE MED J-PEKING, V107, P653; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou XY, 2002, CANCER RES, V62, P1598	282	110	117	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2003	22	37					5755	5773		10.1038/sj.onc.1206676	http://dx.doi.org/10.1038/sj.onc.1206676			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	717JV	12947384				2022-12-17	WOS:000185086100004
